<SEC-DOCUMENT>0001104659-23-029687.txt : 20230308
<SEC-HEADER>0001104659-23-029687.hdr.sgml : 20230308
<ACCEPTANCE-DATETIME>20230307190017
ACCESSION NUMBER:		0001104659-23-029687
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20230307
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Changes in Registrant's Certifying Accountant
ITEM INFORMATION:		Changes in Control of Registrant
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230308
DATE AS OF CHANGE:		20230307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		23714357

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm238578d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:CARM="http://carismatx.com/20230307">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_CARM_carismatx.com_20230307 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20230307_20230307 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0001485003 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\DocumentInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:EntityCentralIndexKey">0001485003</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="carm-20230307.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-03-07to2023-03-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-07</xbrli:startDate>
        <xbrli:endDate>2023-03-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-072023-03-07_dei_FormerAddressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-07</xbrli:startDate>
        <xbrli:endDate>2023-03-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt"></p>

<p style="margin: 0pt">&#160;</p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_908_edei--DocumentType_c20230307__20230307_zU2eKlIbqtF5"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_908_edei--DocumentPeriodEndDate_c20230307__20230307_zKE6lejMcPl3"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 7, 2023</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityRegistrantName_c20230307__20230307_zYpDglEEdRfe"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:EntityRegistrantName">Carisma Therapeutics Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified in its
Charter)</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20230307__20230307_zoSdIw8B034a"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityFileNumber_c20230307__20230307_zFsN8wuYugSj"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:EntityFileNumber">001-36296</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20230307__20230307_zMvYahxVBzwl"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:EntityTaxIdentificationNumber">26-2025616</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top"><b>(State or other jurisdiction<br /> of incorporation)</b></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top"><b>(Commission<br /> File Number)</b></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top"><b>(IRS Employer<br /> Identification No.)</b></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20230307__20230307_zFLyJzU66uN4"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:EntityAddressAddressLine1">3675 Market Street</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20230307__20230307_zPpw86rM8kog"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:EntityAddressAddressLine2">Suite&#160;200</ix:nonNumeric></span><br /> <span id="xdx_904_edei--EntityAddressCityOrTown_c20230307__20230307_znwPEJ0uisuj"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:EntityAddressCityOrTown">Philadelphia</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20230307__20230307_zWAeBikr3jLl"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric> </span></b></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20230307__20230307_zY649vI3b47"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:EntityAddressPostalZipCode">19104</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of Principal Executive Offices)</b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>( Zip Code)</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: (<span id="xdx_904_edei--CityAreaCode_c20230307__20230307_zYlCsR3gFApl"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:CityAreaCode">267</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20230307__20230307_zJfb2DAj0kzl"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:LocalPhoneNumber">491-6422</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20230307__20230307__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zhpdWrrMJ5Q4"><ix:nonNumeric contextRef="From2023-03-072023-03-07_dei_FormerAddressMember" name="dei:EntityAddressAddressLine1">Sesen Bio,&#160;Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine2_c20230307__20230307__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zbX5hKpPh2Qf"><ix:nonNumeric contextRef="From2023-03-072023-03-07_dei_FormerAddressMember" name="dei:EntityAddressAddressLine2">245 First Street</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine3_c20230307__20230307__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zsVV4sELvgKj"><ix:nonNumeric contextRef="From2023-03-072023-03-07_dei_FormerAddressMember" name="dei:EntityAddressAddressLine3">Suite&#160;1800</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20230307__20230307__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zFPIGuYAk3Kf"><ix:nonNumeric contextRef="From2023-03-072023-03-07_dei_FormerAddressMember" name="dei:EntityAddressCityOrTown">Cambridge</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20230307__20230307__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zithK5wpmR98"><ix:nonNumeric contextRef="From2023-03-072023-03-07_dei_FormerAddressMember" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20230307__20230307__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zy9pphUStR0c"><ix:nonNumeric contextRef="From2023-03-072023-03-07_dei_FormerAddressMember" name="dei:EntityAddressPostalZipCode">02142</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since
Last Report)</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction
A.2 below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90C_edei--WrittenCommunications_c20230307__20230307_z7ayrUKwcQD8"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="width: 93%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--SolicitingMaterial_c20230307__20230307_zGWQ1Y4MJOC"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20230307__20230307_zxnFF19P8GM4"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20230307__20230307_z6U6G5IU6p4h"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 45%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 24%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 29%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading<br /> Symbol(s)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Name of exchange<br /> on which registered</b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--Security12bTitle_c20230307__20230307_zyS4xOqAsJT7"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:Security12bTitle">Common Stock, $0.001 par value</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--TradingSymbol_c20230307__20230307_z74hCxWkxzdk"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" name="dei:TradingSymbol">CARM</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--SecurityExchangeName_c20230307__20230307_zBN0AIJJhGM5"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Emerging growth company&#160;</span><span style="font-family: Wingdings"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20230307__20230307_zpFXjnVrksT4"><ix:nonNumeric contextRef="From2023-03-07to2023-03-07" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Introductory Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March&#160;7, 2023, Carisma Therapeutics Inc. (formerly Sesen Bio,&#160;Inc.)
(the &#8220;<b>Company</b>&#8221;) completed its business combination in accordance with the terms of the Agreement and Plan of Merger
and Reorganization, dated as of September&#160;20, 2022, as amended by the First Amendment thereto dated as of December&#160;29, 2022
and the Second Amendment thereto dated as of February&#160;13, 2023 (as amended, the &#8220;<b>Merger Agreement</b>&#8221;), by and among
the Company, CTx Operations,&#160;Inc. (formerly CARISMA Therapeutics Inc.) (&#8220;<b>Carisma</b>&#8221;) and Seahawk Merger Sub,&#160;Inc.,
a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;<b>Merger Sub</b>&#8221;), pursuant to which, among other
matters, Merger Sub merged with and into Carisma, with Carisma continuing as a wholly owned subsidiary of the Company and the surviving
corporation of the merger (the &#8220;<b>Merger</b>&#8221;). Pursuant to the Merger Agreement, the Company changed its name from &#8220;Sesen
Bio,&#160;Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; Following the completion of the Merger, the business conducted by the
Company became primarily the business conducted by Carisma, which is a biopharmaceutical company dedicated to developing a differentiated
and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive
immune response.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 1.01.</b></td><td><b>Entry into a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Prior Carisma Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Merger, the following agreements of Carisma effectively
became agreements of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="text-decoration: underline">Moderna Collaboration Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January&#160;2022, Carisma entered into a Collaboration and License
Agreement (the &#8220;<b>Moderna Collaboration Agreement</b>&#8221;) with ModernaTX, Inc. (&#8220;<b>Moderna</b>&#8221;) providing for
a broad strategic partnership to discover, develop and commercialize in vivo engineered CAR-M therapeutics for up to 12 oncology programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In collaboration with Moderna, Carisma has established an approach
that uses Moderna&#8217;s LNP/mRNA technology, together with Carisma&#8217;s CAR-M platform technology,
to create novel in vivo oncology medications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Moderna Collaboration Agreement, the parties initiate research
programs during a research term, focused on the discovery and research of products directed to biological targets. Either party may nominate
a target for inclusion in a research program, subject to certain exclusions. Targets included in a research program pursuant to designated
procedures are referred to as a &#8220;research target&#8221;. Moderna may replace research targets pursuant to designated procedures.
The first four research targets have been nominated and all programs are currently in the discovery phase at Carisma. Moderna funds the
cost of Carisma&#8217;s activities in accordance with an agreed research budget.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moderna has the right to designate up to 12 research targets as development
targets during a specified development target nomination period upon payment of a development target designation milestone payment. Moderna
can replace development targets with research targets during a specified period of time. If Moderna exercises its right to designate a
development target, Moderna will have a worldwide, exclusive license under patents and know-how controlled by Carisma to develop and commercialize
products directed to the applicable development target, subject to certain diligence obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Commencing a specified time after the effective date of the Moderna
Collaboration Agreement, Moderna will have the right to nominate targets relating to diseases outside the field of oncology for inclusion
in research programs in specified circumstances. Such right is subject to the same exclusions as Moderna&#8217;s right to nominate other
targets for inclusion in research programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the term of the Moderna Collaboration Agreement, Carisma and
its affiliates are subject to various exclusivity obligations under which Carisma is not permitted to research, develop or commercialize
particular products outside of the collaboration, including products for use as in vivo therapies in the field of oncology, products directed
to any target included in the collaboration, or products containing a polypeptide provided by Carisma to Moderna in connection with a
research program that are directed to any development target.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Moderna Collaboration Agreement, Carisma received
a $45.0 million up-front cash payment. Assuming Moderna develops and commercializes 12 products, each directed to a different development
target, Carisma is also eligible to receive up to between $247.0 million and $253.0 million per product in development target designation,
development, regulatory and commercial milestone payments. In addition, Carisma is eligible to receive mid to high single digit tiered
royalties on net sales of any products that are commercialized under the agreement, which may be subject to reductions. Moderna has also
agreed to cover the cost of certain milestone payments and royalties Carisma owes to a licensor under one of its intellectual property
in-license agreements that Carisma is sublicensing to Moderna under the Moderna Collaboration Agreement, which royalties Moderna may deduct
in part from any royalties owed to Carisma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless earlier terminated, the Moderna Collaboration Agreement will
expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Moderna Collaboration
Agreement will expire on a country-by-country basis upon the later of (1)&#160;the expiration of the last-to-expire valid patent claim
of specified patents, (2)&#160;the expiration of regulatory-based exclusivity for such product in such country or (3)&#160;ten years after
the first commercial sale with respect to such product in such country. Moderna has the right to terminate the Moderna Collaboration Agreement
for convenience in its entirety or with respect to a specific product or target on ninety days&#8217; prior notice. Either Carisma or
Moderna may terminate the Moderna Collaboration Agreement in its entirety if the other party is in material breach and such breach is
not cured within the specified cure period, except in the case of Moderna&#8217;s breach of its diligence obligations, termination by
Carisma is limited to the applicable target and product. In addition, either Carisma or Moderna may terminate the Moderna Collaboration
Agreement in the event of specified insolvency events involving the other party. As an alternative to termination in the event of Carisma&#8217;s
uncured material breach of certain sections of the agreement, Moderna has the option to continue the collaboration under the agreement
with reduced payment obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Moderna Collaboration Agreement does
not purport to be complete and is qualified in its entirety by the full text of the Moderna Collaboration Agreement, which is filed herewith
as Exhibit&#160;10.1 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="text-decoration: underline">University of Pennsylvania License Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In November&#160;2017, Carisma entered into a license agreement (as
amended, the &#8220;<b>Penn License Agreement</b>&#8221;) with the Trustees of the University of Pennsylvania (&#8220;<b>Penn</b>&#8221;),
which was amended in February&#160;2018, January&#160;2019, March&#160;2020 and June&#160;2021. Pursuant to the Penn License Agreement,
Penn granted Carisma (1)&#160;an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s interest in specified
patents related to CAR-M, (2)&#160;an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s interest in
specified patents related to CAR-M directed to mesothelin, and (3)&#160;a nonexclusive, worldwide license under Penn&#8217;s interest
in specified know-how related to CAR-M, with limited rights to sublicense only in combination with specified products or patents. These
licensed patents and know-how arose primarily from research conducted by Dr.&#160;Saar Gill and Dr.&#160;Michael Klichinsky at the University
of Pennsylvania, co-founders of Carisma. The foregoing licenses are subject to rights retained by Penn for specified non-commercial uses
and rights retained by the United States government. Under the Penn License Agreement, Carisma is obligated to use commercially reasonable
efforts to pursue development and commercialization of at least one CAR-M product in oncology and non-oncology fields.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma is responsible for paying Penn an annual license maintenance
fee in the low tens of thousands of dollars, payable until Carisma&#8217;s first payment of a royalty. Carisma is required to pay Penn
up to $10.9 million per product in development and regulatory milestone payments, up to $30.0 million per product in commercial milestone
payments, and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to
mesothelin. While the agreement remains in effect, Carisma is required to pay Penn low to mid-single digit percentage tiered royalties
on annual net sales of licensed products, which may be subject to reductions. Penn is guaranteed a minimum royalty payment amount in the
low hundreds of thousands of dollars for each year after the first commercial sale of a licensed product. Carisma must also pay Penn a
percentage in the mid-single digits to low double digits of certain types of income Carisma receives from sublicensees. In addition, Carisma
is required to pay Penn an annual alliance management fee in the low tens of thousands of dollars, ending after several years, unless
Carisma provides funding to Penn for research and development activities that extend beyond a specified date, in which case Carisma will
continue to owe the alliance management fee for each year in which Carisma continues to fund such activities. Carisma also paid Penn an
upfront fee in the low hundreds of thousands of dollars for the license to the patents related to the mesothelin binder that is incorporated
into the CAR design for Carisma&#8217;s mesothelin product candidate. Carisma is responsible for a pro rata share of costs relating to
the prosecution and maintenance of the licensed patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The royalty period for each licensed product will expire on a product-by-product
basis upon the later of (1)&#160;the expiration of the last-to-expire valid patent claim of the licensed patents covering such product
in the country of sale or in the country of manufacture, or (2)&#160;the expiration of regulatory-based exclusivity for such product in
the country of sale. The license agreement remains in effect until the later of (1)&#160;expiration or abandonment of the last licensed
patent or (2)&#160;loss of regulatory exclusivity. Carisma may terminate the agreement for convenience upon thirty days&#8217; prior notice.
Penn may terminate the agreement for Carisma&#8217;s material breach, subject to a specified cure period, except for certain breaches
for which Penn may terminate immediately. Penn may also terminate if Carisma becomes the subject of a specified insolvency event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Penn License Agreement does not purport
to be complete and is qualified in its entirety by the full text of the Penn License Agreement, which is filed herewith as Exhibit&#160;10.2
and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="text-decoration: underline">New York University License Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July&#160;2020, Carisma entered into a license agreement (the &#8220;<b>NYU
License Agreement</b>&#8221;) with New York University (&#8220;<b>NYU</b>&#8221;). NYU granted Carisma (1)&#160;an exclusive, worldwide
license, with specified rights to sublicense, under NYU&#8217;s interest in specified patents related to the Vpx-LV and (2)&#160;a nonexclusive,
worldwide license, with specified rights to sublicense, under NYU&#8217;s interest in specified know-how related to the Vpx-LV, in each
case to develop, manufacture, use and sell products developed using the Vpx-LV (together, the &#8220;<b>NYU Licensed Products</b>&#8221;).
The foregoing licenses are subject to rights retained by NYU to use, and to permit other non-commercial entities to use, the licensed
patents and licensed know-how for educational and research purposes, as well as rights retained by the United States government. Under
the NYU License Agreement, Carisma is obligated to use reasonable diligence to carry out a specified development plan and to obtain regulatory
approval for NYU Licensed Products in the U.S. and each of the other countries in which Carisma or its sublicensees intend to produce,
use, and/or sell NYU Licensed Products, as well as to begin the regular commercial production, use, and sale of the NYU Licensed Products
in good faith in accordance with the development plan and to continue diligently thereafter to commercialize the NYU Licensed Products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma is required to pay NYU an annual license maintenance fee in
the mid tens of thousands of dollars; up to $1,685,000 per NYU Licensed Product in development and regulatory milestone payments; and
low single digit percentage tiered royalties on annual net sales of NYU Licensed Products on a country-by-country basis until the later
of (1)&#160;12 years after first commercial sale of an NYU Licensed Product in such country or (2)&#160;expiration of the last to expire
licensed patent. Carisma must also pay NYU a percentage in the low single digits to low double digits of certain types of income Carisma
receives from sublicensees or assignees of the agreement. Carisma is also responsible for all costs relating to the prosecution, maintenance,
and defense of the licensed patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The NYU License Agreement remains in effect until the expiration of
all royalty terms in all countries. Either party may terminate the NYU License Agreement for the other party&#8217;s uncured material
breach or insolvency or bankruptcy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the NYU License Agreement does not purport
to be complete and is qualified in its entirety by the full text of the NYU License Agreement, which is filed herewith as Exhibit&#160;10.3
and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="text-decoration: underline">Registration Rights Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March&#160;7, 2023, immediately prior to the effective time of the
Merger and in connection with the consummation of the pre-closing financing pursuant to which certain former stockholders of Carisma (the
 &#8220;<b>Carisma Investors</b>&#8221;) purchased 1,964,101 shares of Carisma common stock at an aggregate purchase price of approximately
$30.6 million, Carisma and the Carisma Investors entered into a Registration Rights Agreement (the &#8220;<b>Registration Rights Agreement</b>&#8221;),
pursuant to which Carisma (i)&#160;agreed to register for resale the shares purchased by the Carisma Investors in the pre-closing financing
(the &#8220;<b>Registrable Subscription Securities</b>&#8221;), and (ii)&#160;provided the Carisma Investors (A)&#160;the right to require
the Company to register additional shares held by such Carisma Investors (the &#8220;<b>Registrable Existing Securities</b>&#8221;) under
specified circumstances and (B)&#160;the right to participate in future registrations of securities by the Company under specified circumstances.
All of the shares of Carisma common stock held by the Carisma Investors immediately prior to the effective time of the Merger, including
shares of Carisma common stock issued in connection with the pre-closing financing, were exchanged into shares of the Company&#8217;s
common stock at the effective time of the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mandatory
Registration Rights</i></span>. As promptly as reasonably practicable and in any event within 60 days after the date of the Registration
Rights Agreement, the Company is required to file a Registration Statement on Form&#160;S-3 with the Securities and Exchange Commission
(the &#8220;<b>SEC</b>&#8221;) to register all of the Registration Subscription Securities under the Securities Act of 1933, as amended
(the &#8220;<b>Securities Act</b>&#8221;), subject to certain limitations. Following such filing, the Company will use its reasonable
best efforts to have the Registration Statement on Form&#160;S-3 declared effective by the SEC and maintain such effectiveness continuously
for a period up to the earlier of (i)&#160;three years from the date of the Registration Rights Agreement and (ii)&#160;the date that
all Registrable Subscription Securities covered by such Registration Statement on Form&#160;S-3 have been sold or can be sold without
restriction pursuant to Rule&#160;144 promulgated by the SEC under the Securities Act (&#8220;<b>SEC Rule&#160;144</b>&#8221;) or another
similar exemption under the Securities Act and without the requirement to be in compliance with subsection (c)(1)&#160;of SEC Rule&#160;144
(or any successor thereto).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Demand
Registration Rights. </i></span>Under the Registration Rights Agreement, and subject to specified limitations set forth therein, the Carisma
Investors have rights to certain customary demand and piggyback registration rights with respect to the Registrable Existing Securities.
Such registration rights will terminate upon the earliest to occur of (i)&#160;such time as SEC Rule&#160;144 or another similar exemption
under the Securities Act is available for the sale of all of such Carisma Investor&#8217;s Registrable Existing Securities and without
the requirement to be in compliance with subsection (c)(1)&#160;of SEC Rule&#160;144 (or any successor thereto) and (ii)&#160;the third
anniversary of the date of the Registration Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expenses
and Indemnification.</i></span> Pursuant to the Registration Rights Agreement, the Company is required to pay all registration expenses
(excluding underwriting discounts, selling commissions and stock transfer taxes). The Registration Rights Agreement contains customary
cross-indemnification provisions, pursuant to which the Company is obligated to indemnify the Carisma Investors in the event of material
misstatements or omissions attributable to the Company or certain violation or alleged violation by the Company under applicable securities
laws, and the Company is not obligated to indemnify the Carisma Investors for material misstatements or omissions attributable to the
Carisma Investors or violations or alleged violations by the Carisma Investors under applicable securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Registration Rights Agreement does
not purport to be complete and is qualified in its entirety by the full text of the Registration Rights Agreement, which is filed herewith
as Exhibit&#160;10.4 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contingent Value Rights Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On March&#160;7, 2023, the Company entered
into a Contingent Value Rights Agreement (the &#8220;<b>CVR Agreement</b>&#8221;) with a rights agent (&#8220;<b>Rights Agent</b>&#8221;)
pursuant to which the Company&#8217;s pre-Merger stockholders of record as of March&#160;7, 2023 received one contingent value right in
the form of a dividend (each, a &#8220;<b>CVR</b>&#8221;) for each outstanding share of Company common stock held by such stockholders
on such date. Each CVR represents the contractual right to receive contingent cash payments upon the receipt by the Company of (i)&#160;certain
proceeds payable by Roche (as defined below), if any, pursuant to the Asset Purchase Agreement by and among the Company and F. Hoffmann-La
Roche Ltd and Hoffman-La Roche Inc. (collectively &#8220;<b>Roche</b>&#8221;), dated July&#160;15, 2022 (the &#8220;<b>Asset Purchase
Agreement</b>&#8221;), upon the achievement by Roche of a specified milestone set forth in the Asset Purchase Agreement, and (ii)&#160;the
proceeds from any sale of the Company&#8217;s pre-Merger non-cash assets, including Vicineum, in each case subject to certain customary
deductions, including for expenses and taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The contingent payments under the CVR Agreement,
if they become due, will be payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such
proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that
any cash payment will be made or that any holders of CVRs will receive any amounts with respect thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The right to the contingent payments contemplated
by the CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the CVR
Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will
not have any voting or dividend rights and will not represent any equity or ownership interest in the Company or any of its affiliates.
No interest will accrue on any amounts payable in respect of the CVRs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The foregoing description of the CVR Agreement
does not purport to be complete and is qualified in its entirety by the full text of the CVR Agreement, which is filed herewith as Exhibit&#160;10.5
and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Indemnification Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Merger, on March&#160;7, 2023, the Company entered
into indemnification agreements with each of its directors and executive officers. Each indemnification agreement provides for indemnification
and advancements by the Company of certain expenses and costs relating to claims, suits or proceedings arising from each individual&#8217;s
service to the Company as an officer or director, as applicable, to the maximum extent permitted by applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the indemnification agreements is qualified
in its entirety by the full text of the form of indemnification agreement, which is filed herewith as Exhibit&#160;10.6 and incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 2.01.</b></td><td><b>Completion of Acquisition or Disposition of Assets.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March&#160;7, 2023, the Company completed its business combination
with Carisma in accordance with the terms of the Merger Agreement. Effective at 5:01 p.m.&#160;Eastern Time on March&#160;7, 2023, the
Company effected a 1-for-20 reverse stock split of its common stock (the &#8220;<b>Reverse Stock Split</b>&#8221;) and implemented a reduction
in the number of authorized shares of common stock to 100,000,000 (the &#8220;<b>Common Stock Reduction</b>&#8221;), effective at 5:02
p.m.&#160;Eastern Time, the Company completed the Merger, and effective at 5:03 p.m.&#160;Eastern Time, the Company amended and restated
the Company&#8217;s Restated Certificate of Incorporation to change the Company&#8217;s name to &#8220;Carisma Therapeutics Inc.&#8221;
and to restate and integrate all prior amendments (the &#8220;<b>Restated Certificate of Incorporation</b>&#8221;). Unless noted otherwise,
all references to share and per share amounts in this Current Report on Form&#160;8-K reflect the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the closing of the Merger, after taking into account shares of Carisma
common stock purchased in connection with the pre-closing financing and the conversion of Carisma&#8217;s $35.0 million outstanding convertible
note, the Company issued an aggregate of approximately 29,880,400 shares of its common stock to Carisma stockholders (including 5,059,338
shares issued to the holder of the convertible note in accordance with the Convertible Note Conversion Agreement, dated as of September&#160;20,
2022), based on an exchange ratio set forth in the Merger Agreement, resulting in approximately 40,254,672 shares of the Company&#8217;s
common stock being issued and outstanding immediately following the effective time of the Merger. The exchange ratio was determined in
accordance with the Merger Agreement and was calculated using a formula intended to allocate the Company&#8217;s pre-Merger stockholders
and Carisma stockholders a percentage of the combined company. The Company also assumed all of the outstanding and unexercised stock options
to purchase shares of Carisma common stock. The assumed options continue to be governed by the terms of the CARISMA Therapeutics Inc.
2017 Stock Incentive Plan, as amended (the &#8220;<b>Carisma 2017 Plan</b>&#8221;). Upon the closing of the Merger, the Company also assumed
the Carisma 2017 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of shares of the Company&#8217;s common stock to former
stockholders of Carisma (other than shares of the Company&#8217;s common stock issued in exchange for shares of Carisma common stock sold
in the pre-closing financing) and upon conversion of Carisma&#8217;s $35.0 million convertible note, was registered with the SEC on the
Company&#8217;s Registration Statement on Form&#160;S-4, as amended (File No.&#160;333-267891) (the &#8220;<b>Registration Statement</b>&#8221;).
The shares of the Company&#8217;s common stock issued in exchange for shares of Carisma common stock sold in the pre-closing financing
were issued in a transaction exempt from registration under the Securities Act in reliance on Section&#160;4(a)(2)&#160;of the Securities
Act and the rules&#160;promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The shares of the Company&#8217;s common stock listed on The
Nasdaq Stock Market, previously trading on The Nasdaq Capital Market through the close of business on Tuesday, March&#160;7, 2023
under the ticker symbol &#8220;SESN,&#8221; will commence trading on The Nasdaq Global Market, on a post-Reverse Stock Split
adjusted basis, under the ticker symbol &#8220;CARM,&#8221; on March&#160;8, 2023. The Company&#8217;s common stock is represented
by a new CUSIP number: 14216R 101.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by the full text of the
Merger Agreement, which was filed as <a href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000135/exhibit21-projectseahawkxm.htm">Exhibit&#160;2.1</a></span>
on the <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500322000135/sesn-20220920.htm">Current Report on Form&#160;8-K
filed    with the SEC on September&#160;21, 2022</a> and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 3.02.</b></td><td><b>Unregistered Sales of Equity Securities.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required by Item 3.02 of Form&#160;8-K, the information
set forth in Items 1.01 and 2.01 of this Current Report on Form&#160;8-K regarding the issuance of shares with respect to the shares of
the Company&#8217;s common stock issued in exchange for shares of Carisma common stock sold in the pre-closing financing is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 3.03</b></td><td><b>Material Modification to Rights of Security Holders.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information set forth in Items 2.01, 5.01 and 5.03 of this Current
Report on Form&#160;8-K is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed on the Company&#8217;s <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500323000096/sesn-20230302.htm">Current
Report on Form&#160;8-K filed with   the SEC on March&#160;2, 2023</a></span> (the &#8220;<b>Reverse Stock Split
Form&#160;8-K</b>&#8221;), effective at 5:01 p.m.&#160;Eastern Time on March&#160;7, 2023, the Company effected the Reverse Stock
Split and implemented the Common Stock Reduction. The disclosure set forth in the Reverse Stock Split Form&#160;8-K under
&#8220;Item 3.03. Material Modification to Rights of Security Holders,&#8221; including Exhibit&#160;3.1 incorporated by reference
therein, is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 4.01.</b></td><td><b>Changes in Registrant&#8217;s Certifying Accountant.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&#160;Prior to the completion of the Merger, Ernst&#160;&amp; Young
LLP served as the independent registered public accounting firm of Sesen Bio, Inc. On March&#160;6, 2023, the Audit Committee (the &#8220;<b>Audit Committee</b>&#8221;) of the
Board of Directors of Sesen Bio, Inc. dismissed Ernst&#160;&amp; Young LLP as its independent registered public accounting firm, effective
as of the effective time of the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The reports of Ernst&#160;&amp; Young LLP on Sesen Bio, Inc.'s consolidated
financial statements for the past two fiscal years did not contain an adverse opinion or disclaimer of opinion, nor were they qualified
or modified as to uncertainty, audit scope, or accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the audits of Sesen Bio, Inc.&#8217;s consolidated financial
statements for the fiscal years ended December&#160;31, 2022 and 2021, and in the subsequent interim period through March&#160;7, 2023,
there were no: (1)&#160;disagreements with Ernst&#160;&amp; Young LLP on any matters of accounting principles or practices, financial
statement disclosure, or auditing scope and procedures, which disagreements if not resolved to the satisfaction of Ernst&#160;&amp; Young
LLP, would have caused Ernst&#160;&amp; Young LLP to make reference to the matter in its report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company delivered a copy of this Current Report on Form&#160;8-K
to Ernst&#160;&amp; Young LLP and requested  a letter addressed to the SEC stating whether it agrees with the above statements. A
copy of that letter, dated March&#160;7, 2023 is filed as Exhibit&#160;16.1 to this Form&#160;8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&#160;On March&#160;7, 2023, the Audit Committee approved the engagement
of KPMG LLP as the Company&#8217;s independent registered public accounting firm for the year ended December&#160;31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the years ended December&#160;31, 2022 and 2021, neither the
Company, Carisma, nor anyone on their behalf, consulted with KPMG LLP, regarding either (i)&#160;the application of accounting principles
to a specific transaction, completed or proposed, or the type of audit opinion that might be rendered on Carisma&#8217;s financial statements,
and neither a written report nor oral advice was provided to Carisma that KPMG LLP concluded was an important factor considered by Carisma
in reaching a decision as to any accounting, auditing or financial reporting issue or (ii)&#160;any matter that was either the subject
of a disagreement (as defined in Item 304(a)(1)(iv)&#160;of Regulation S-K and the related instructions) or a reportable event (as described
in Item 304(a)(1)(v)&#160;of Regulation S-K).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 5.01.</b></td><td><b>Changes in Control of Registrant.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information set forth in Item 2.01 of this Current Report on Form&#160;8-K
regarding the Merger and the information set forth in Item 5.02 of this Current Report on Form&#160;8-K regarding the Board of Directors
(the &#8220;<b>Board</b>&#8221;) and executive officers following the Merger are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 5.02.</b></td><td><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b><i>Directors</i></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with the Merger Agreement, effective as of the closing
of the Merger, Thomas R. Cannell, Jay S. Duker, M.D., Peter K Honig, M.D., Michael A.S. Jewett, M.D., Jason A. Keyes and Carrie L. Bourdow
resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements
with the Company relating to the Company&#8217;s operations, policies or practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with the Merger Agreement, effective as of the effective
time of the Merger, the size of the Board was increased to seven members and the Board and its committees were reconstituted, consisting
of six directors designated by Carisma, who are Steven Kelly, Regina Hodits, Ph.D., Briggs Morrison, M.D., Bj&#246;rn Odlander, M.D.,
Ph.D., Chidozie Ugwumba and Sanford Zweifach, and one director designated by the Company, who is Michael Torok.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regina Hodits, Ph.D. and Bj&#246;rn Odlander, M.D., Ph.D. were appointed
as Class&#160;III directors, whose terms expire at the Company&#8217;s 2023 annual meeting, Michael Torok and Chidozie Ugwumba were appointed
as Class&#160;I directors, whose terms expire at the Company&#8217;s 2024 annual meeting, and Steven Kelly, Briggs Morrison, M.D. and
Sanford Zweifach were appointed as Class&#160;II directors, whose terms expire at the Company&#8217;s 2025 annual meeting. Sanford Zweifach
was appointed as the Chair of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, Chidozie Ugwumba, Regina Hodits, Ph.D., and Sanford Zweifach
were appointed to the Audit Committee, and Chidozie Ugwumba was appointed the Chair of the Audit Committee. Briggs Morrison, M.D., and
Sanford Zweifach were appointed to the Compensation Committee of the Board (the &#8220;<b>Compensation Committee</b>&#8221;), and Briggs
Morrison was appointed the Chair of the Compensation Committee. Bj&#246;rn Odlander, M.D., Ph.D. and Sanford Zweifach were appointed to
the Nominating and Corporate Governance Committee of the Board (the &#8220;<b>NCG Committee</b>&#8221;), and Bj&#246;rn Odlander, M.D.,
Ph.D. was appointed the Chair of the NCG Committee. Regina Hodits, Ph.D. and Briggs Morrison, M.D. were appointed to the Science Committee
of the Board (the &#8220;<b>Science Committee</b>&#8221;), and Regina Hodits, Ph.D. was appointed the Chair of the Science Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the execution of the Second Amendment to the Merger
Agreement, which amendment included Michael Torok as the Company&#8217;s designee to the Board in place of Dr.&#160;Thomas R. Cannell,
D.V.M., on February&#160;13, 2023, the Company and Carisma entered into a voting and support agreement (the &#8220;<b>Voting and Support
Agreement</b>&#8221;) with Bradley L. Radoff and Michael Torok (together with their affiliates, the &#8220;<b>Investor Group</b>&#8221;),
pursuant to which the Investor Group agreed to vote their shares of Company common stock in favor of the adoption and approval of the
Merger Agreement and the transactions contemplated thereby and all related proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other than pursuant to the Merger Agreement and the Voting and Support
Agreement, there were no arrangements or understandings between the Company&#8217;s newly appointed directors and any person pursuant
to which they were elected. None of the Company&#8217;s newly appointed directors has a direct or indirect material interest in any transaction
required to be disclosed pursuant to Item 404(a)&#160;of Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Biographical information for each of the above named directors is set
forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Steven
Kelly</b></span>, age 57, served as Carisma&#8217;s President and Chief Executive Officer and as a member of the Carisma board of directors
since February&#160;2018. Prior to joining Carisma, Mr.&#160;Kelly served as Chief Executive Officer of Pinteon Therapeutics, a biotechnology
company, from April&#160;2014 to July&#160;2015 and as the Chief Executive Officer of Theracrine,&#160;Inc., a biopharmaceutical company,
from June&#160;2011 to August&#160;2012. Mr.&#160;Kelly currently serves on the board of directors of Artelo Biosciences,&#160;Inc. (Nasdaq:
ARTL). Mr.&#160;Kelly received a B.S. from the University of Oregon and an M.B.A. from Cornell University. The Company believes Mr.&#160;Kelly
is qualified to serve as a member of the Board because of his extensive knowledge of the Company based on his current role as its President
and Chief Executive Officer, as well as his significant biopharmaceutical industry and management experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regina
Hodits, Ph.D.</b></span> served as a member of the Carisma board of directors since June&#160;2018. Dr.&#160;Hodits has served as a Managing
Partner at Wellington Partners, a venture capital firm investing in companies mainly in areas of technology, life sciences and digital
media, since 2010. Prior to that, Dr.&#160;Hodits served as Partner of Atlas Ventures from 2004 to 2010. She currently serves on the board
of directors of Onward Medical. Dr.&#160;Hodits received a Master&#8217;s degree in Chemical Engineering and a Ph.D. in biochemistry from
Technical University of Vienna, Austria. The Company believes Dr.&#160;Hodits is qualified to serve as a member of the Board because of
her scientific background and training in biochemistry, extensive experience with biopharmaceutical companies and service on the boards
of other biopharmaceutical companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Briggs
Morrison, M.D.</b></span> served as a member of the Carisma board of directors since July&#160;2020. Dr.&#160;Morrison has served as President,
Head of Research and Development of Syndax Pharmaceuticals Inc., a biopharmaceutical company, since February&#160;2022; he was previously
Chief Executive Officer of Syndax Pharmaceuticals Inc. from June&#160;2015. Dr.&#160;Morrison currently serves on the boards of directors
of Repare Therapeutics Inc. (Nasdaq: RPTX), Werewolf Therapeutics Inc. (Nasdaq: HOWL), Arvinas,&#160;Inc. (Nasdaq: ARVN) and Syndax Pharmaceuticals
Inc. (Nasdaq: SNDX). Dr.&#160;Morrison received an M.D. from the University of Connecticut and a B.S. in Biology from Georgetown University.
The Company believes Dr.&#160;Morrison is qualified to serve as a member of the Board due to his extensive executive leadership experience,
medical background and training, and extensive service on the boards of other public and private biopharmaceutical companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bj&#246;rn
Odlander, M.D., Ph.D.</b></span> served as a member of the Carisma board of directors since February&#160;2022. Dr.&#160;Odlander is a
co-founder of HealthCap, a family of venture capital funds investing globally in life sciences, where he has been a Managing Partner since
1996. Dr.&#160;Odlander received a M.D. and Ph.D. from Karolinska Institute. The Company believes Dr.&#160;Odlander is qualified to serve
as a member of the Board with his medical background and training, industry background and extensive experience of investments in the
life-science sector.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michael
Torok </b></span>currently serves as the co-founder and managing director of JEC Capital Partners, LLC, an investment company with offices
in the United States and Germany, since 2008, and Manager of JEC II Associates, LLC, an investment company, since 2008. Prior to that,
he served as Chief Financial Officer for Integrated Dynamics Engineering Inc, a semiconductor equipment technology company that was acquired
by Aalberts Industries (AMS: AALB). Earlier in his career, Mr.&#160;Torok served in various positions for PricewaterhouseCoopers LLP,
a multinational professional services network of firms. Mr.&#160;Torok currently serves on the board of directors of Liberated Syndication,&#160;Inc.
(formerly NASDAQ: LSYN), a podcasting platform for creators and advertisers, since December&#160;2022. He previously served on the board
of directors of Photon Control Inc. (formerly TSX: PHO), which designs, manufactures and distributes a wide range of optical sensors and
systems to measure temperature and position, from 2016 to May&#160;2018, and Symbility Solutions Inc., a software company focused on the
insurance industry, from 2015 to January&#160;2018. Mr.&#160;Torok received a B.S. in Finance and a Master in Finance from Boston College.
The Company believes that Mr.&#160;Torok is qualified to serve as a member of the Board due to his executive leadership experience and
extensive service on the boards of other public and private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chidozie
Ugwumba</b></span> served as a member of the Carisma board of directors since December&#160;2020. Mr.&#160;Ugwumba has served as Managing
Partner of SymBiosis, a venture capital firm focused on investments in biotherapeutics, since August&#160;2021. Prior to SymBiosis, Mr.&#160;Ugwumba
served as a Managing Director and the Co-Head of the Direct and Impact Investment Group of WIT, LLC, an investment management entity affiliated
with Walton Enterprises, from 2018 to 2021 and on the Private Credit and Infrastructure teams at Partners Group, a global private investment
manager, from 2015 to 2018. Mr.&#160;Ugwumba currently serves on the board of directors of Clene,&#160;Inc. (Nasdaq: CLNN). Mr.&#160;Ugwumba
received an M.B.A. from Cornell University and a B.A. in Political Science from Amherst College. The Company believes Mr.&#160;Ugwumba
is qualified to serve as a member of the Board because of his significant experience and expertise in biopharmaceutical investments and
his overall industry knowledge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sanford
Zweifach</b></span> served as a member and Chair of the Carisma board of directors since November&#160;2021. Mr.&#160;Zweifach has served
as the Founder and President of Pelican Consulting Group, a biotechnology consulting firm, since December&#160;2019. Mr.&#160;Zweifach
founded and served as Chief Executive Officer of Nuvelution Pharma,&#160;Inc., a pharmaceutical company, from June&#160;2015 to November&#160;2019.
Mr.&#160;Zweifach currently serves on the boards of directors of Essa Pharma Inc. (Nasdaq: EPIX) and Compugen Ltd. (Nasdaq: CGEN). Mr.&#160;Zweifach
received a B.A. in Biology from University of California San Diego and a M.S. in Human Physiology from University of California Davis.
The Company believes Mr.&#160;Zweifach is qualified to serve as Chair of the Board because of his extensive experience in the biopharmaceutical
industry and service on the boards of other public and private biopharmaceutical companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><b><i>Executive Officers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of the effective time of the Merger, the Board appointed
Steven Kelly as the Company&#8217;s President and Chief Executive Officer and principal executive officer, Richard Morris as the Company&#8217;s
Chief Financial Officer, Chief Compliance Officer and Treasurer, principal financial officer and principal accounting officer and Michael
Klichinsky, Pharm.D., Ph.D. as Chief Scientific Officer, each to serve at the discretion of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are no family relationships among any of the Company&#8217;s
newly appointed principal officers. None of the Company&#8217;s newly appointed principal officers has a direct or indirect material interest
in any transaction required to be disclosed pursuant to Item 404(a)&#160;of Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Biographical information for each of the above-named officers is set
forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Steven
Kelly&#8217;s</b></span> biographical information is disclosed in the section above under the heading &#8220;Directors.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into an employment agreement with Mr.&#160;Kelly (the &#8220;<b>Kelly Employment Agreement</b>&#8221;), effective
as of March&#160;7, 2023, pursuant to which Mr.&#160;Kelly will serve as the Company&#8217;s President and Chief Executive Officer. The
employment agreement provides for Mr.&#160;Kelly&#8217;s at-will employment and an annual base salary of $560,000, an annual bonus with
a target amount equal to 55% of his base salary, as well as his ability to participate in the Company&#8217;s employee benefit plans generally
on the same basis as other similarly-situated employees. The Kelly Employment Agreement also provides that if his employment is terminated
either (i)&#160;by the Company without Cause or (ii)&#160;by him with Good Reason (each as defined in the Kelly Employment Agreement),
in either case within the period beginning three months before and ending twelve months after a Change in Control (as defined in the Kelly
Employment Agreement) (the &#8220;<b>Change in Control Period</b>&#8221;), then Mr.&#160;Kelly will be entitled to receive, subject to
his execution and nonrevocation of a release of claims in favor of the Company and compliance with all post-employment obligations under
law or any restrictive covenant agreement with the Company, (a)&#160;a lump sum payment of (x)&#160;eighteen months of base salary and
(y)&#160;an amount equal to 150% of his target bonus for the year of termination (or, if higher, his target bonus immediately prior to
the Change in Control), (b)&#160;a lump sum payment equal to 100% of his target bonus for the year of termination (or, if higher, based
on the target bonus immediately prior to the Change in Control) pro-rated based on the number of days he was employed during the calendar
year in which his termination occurs</span><span style="font-size: 10pt">,</span> (c)&#160;COBRA health continuation for up to eighteen
months and (d)&#160;100% acceleration of all outstanding and unvested stock-based awards subject to time-based vesting. The Kelly Employment
Agreement also provides that if his employment is terminated either (i)&#160;by the Company without Cause or (ii)&#160;by him with Good
Reason, in either case outside the Change in Control Period, then Mr.&#160;Kelly will be entitled to receive, subject to his execution
and nonrevocation of a release of claims in favor of the Company and compliance with all post-employment obligations under law or any
restrictive covenant agreement with the Company, (a)&#160;twelve months of base salary payable over a period of twelve months following
such termination, (b)&#160;a lump sum payment equal to 100% of his target bonus for the year of termination, pro-rated based on the number
of days he was employed during the calendar year in which his termination occurs, and (c)&#160;COBRA health continuation for up to twelve
months. The Kelly Employment Agreement contains a Section&#160;280G limited cutback, in which Mr.&#160;Kelly is entitled to receive the
greater of (a)&#160;the best net after-tax amount of any payments that are subject to the excise tax imposed by Section&#160;4999 of the
Internal Revenue Code of 1986, as amended (the &#8220;<b>Code</b>&#8221;), calculated in a manner consistent with Section&#160;280G of
the Code, and (b)&#160;the amount of parachute payments he would be entitled to receive if they were reduced to an amount equal to one
dollar less than the amount at which Mr.&#160;Kelly becomes subject to excise tax imposed by Section&#160;4999 of the Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Richard
Morris</b></span>, age 49, served as Carisma&#8217;s Chief Financial Officer since June&#160;2021. Prior to joining Carisma, Mr.&#160;Morris
served as Chief Financial Officer of Passage Bio,&#160;Inc., a genetic medicines company, from October&#160;2019 to May&#160;2021 and
as Executive Vice President and Chief Financial Officer of Context Therapeutics, LLC, a biopharmaceutical company, or Context, from November&#160;2017
to July&#160;2019. Prior to Context, Mr.&#160;Morris served as Chief Financial Officer of Vitae Pharmaceuticals Incorporated, a biopharmaceutical
company, from 2014 to October&#160;2016, and held several senior financial roles over 12 years at ViroPharma Incorporated, a biopharmaceutical
company, including Chief Accounting Officer and Vice President, Financial and Strategic Planning. Mr.&#160;Morris received a B.S. in Accounting
from Saint Joseph&#8217;s University and has been a CPA since 1999.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Mr.&#160;Morris (the &#8220;<b>Morris Employment Agreement</b>&#8221;), effective as
of March&#160;7, 2023, pursuant to which Mr.&#160;Morris will serve as the Company&#8217;s Chief Financial Officer. The employment agreement
provides for Mr.&#160;Morris&#8217; at-will employment and an annual base salary of $467,000, an annual bonus with a target amount equal
to 40% of his base salary, as well as his ability to participate in the Company&#8217;s employee benefit plans generally on the same basis
as other similarly-situated employees. The Morris Employment Agreement also provides that if his employment is terminated either (i)&#160;by
the Company without Cause or (ii)&#160;by him with Good Reason (each as defined in the Morris Employment Agreement), in either case within
Change in Control Period, then Mr.&#160;Morris will be entitled to receive, subject to his execution and nonrevocation of a release of
claims in favor of the Company and compliance with all post-employment obligations under law or any restrictive covenant agreement with
the Company, (a)&#160;a lump sum payment of (x)&#160;twelve months of base salary and (y)&#160;an amount equal to 100% of his target bonus
for the year of termination (or, if higher, his target bonus immediately prior to the Change in Control), (b)&#160;a lump sum payment
equal to 100% of his target bonus for the year of termination (or, if higher, based on the target bonus immediately prior to the Change
in Control) pro-rated based on the number of days he was employed during the calendar year in which his termination occurs</span><span style="font-size: 10pt">,</span>
(c)&#160;COBRA health continuation for up to twelve months and (d)&#160;100% acceleration of all outstanding and unvested stock-based
awards subject to time-based vesting. The Morris Employment Agreement also provides that if his employment is terminated either (i)&#160;by
the Company without Cause or (ii)&#160;by him with Good Reason, in either case outside the Change in Control Period, then Mr.&#160;Morris
will be entitled to receive, subject to his execution and nonrevocation of a release of claims in favor of the Company and compliance
with all post-employment obligations under law or any restrictive covenant agreement with the Company, (a)&#160;twelve months of base
salary payable over a period of twelve months following such termination, (b)&#160;a lump sum payment equal to 100% of his target bonus
for the year of termination, pro-rated based on the number of days he was employed during the calendar year in which his termination occurs,
and (c)&#160;COBRA health continuation for up to twelve months. The Morris Employment Agreement contains a Section&#160;280G limited cutback,
in which Mr.&#160;Morris is entitled to receive the greater of (a)&#160;the best net after-tax amount of any payments that are subject
to the excise tax imposed by Section&#160;4999 of the Code, calculated in a manner consistent with Section&#160;280G of the Code, and
(b)&#160;the amount of parachute payments he would be entitled to receive if they were reduced to an amount equal to one dollar less than
the amount at which Mr.&#160;Morris becomes subject to excise tax imposed by Section&#160;4999 of the Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michael
Klichinsky, Pharm.D., Ph.D.</b></span>, age 33, served as Carisma&#8217;s Chief Scientific Officer since April&#160;2022. He co-founded
Carisma in 2016 and served as Vice President of Discovery of Carisma from October&#160;2018 to April&#160;2021 and as Senior Vice President
of Research of Carisma from April&#160;2021 to April&#160;2022. Dr.&#160;Klichinsky received a Doctor of Pharmacy from the University
of Sciences in Philadelphia and a Ph.D. in Pharmacology from the University of Pennsylvania.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Mr.&#160;Klichinsky (the &#8220;<b>Klichinsky Employment Agreement</b>&#8221;), effective
as of March&#160;7, 2023, pursuant to which Mr.&#160;Klichinsky will serve as the Company&#8217;s Chief Scientific Officer. The employment
agreement provides for Mr.&#160;Klichinsky&#8217;s at-will employment and an annual base salary of $420,000, an annual bonus with a target
amount equal to 40% of his base salary, as well as his ability to participate in the Company&#8217;s employee benefit plans generally
on the same basis as other similarly-situated employees. The Klichinsky Employment Agreement also provides that if his employment is terminated
either (i)&#160;by the Company without Cause or (ii)&#160;by him with Good Reason (each as defined in the Klichinsky Employment Agreement),
in either case within the Change in Control Period, then Mr.&#160;Klichinsky will be entitled to receive, subject to his execution and
nonrevocation of a release of claims in favor of the Company and compliance with all post-employment obligations under law or any restrictive
covenant agreement with the Company, (a)&#160;a lump sum payment of (x)&#160;twelve months of base salary and (y)&#160;an amount equal
to 100% of his target bonus for the year of termination (or, if higher, his target bonus immediately prior to the Change in Control),
(b)&#160;a lump sum payment equal to 100% of his target bonus for the year of termination (or, if higher, based on the target bonus immediately
prior to the Change in Control) pro-rated based on the number of days he was employed during the calendar year in which his termination
occurs</span><span style="font-size: 10pt">,</span> (c)&#160;COBRA health continuation for up to twelve months and (d)&#160;100% acceleration
of all outstanding and unvested stock-based awards subject to time-based vesting. The Klichinsky Employment Agreement also provides that
if his employment is terminated either (i)&#160;by the Company without Cause or (ii)&#160;by him with Good Reason, in either case outside
the Change in Control Period, then Mr.&#160;Klichinsky will be entitled to receive, subject to his execution and nonrevocation of a release
of claims in favor of the Company and compliance with all post-employment obligations under law or any restrictive covenant agreement
with the Company, (a)&#160;twelve months of base salary payable over a period of twelve months following such termination, (b)&#160;a
lump sum payment equal to 100% of his target bonus for the year of termination, pro-rated based on the number of days he was employed
during the calendar year in which his termination occurs, and (c)&#160;COBRA health continuation for up to twelve months. The Klichinsky
Employment Agreement contains a Section&#160;280G limited cutback, in which Mr.&#160;Klichinsky is entitled to receive the greater of
(a)&#160;the best net after-tax amount of any payments that are subject to the excise tax imposed by Section&#160;4999 of the Code, calculated
in a manner consistent with Section&#160;280G of the Code, and (b)&#160;the amount of parachute payments he would be entitled to receive
if they were reduced to an amount equal to one dollar less than the amount at which Mr.&#160;Klichinsky becomes subject to excise tax
imposed by Section&#160;4999 of the Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing descriptions of the Kelly Employment Agreement, Morris
Employment Agreement and Klichinsky Employment Agreement do not purport to be complete and are qualified in their entirety by the full
text of the Kelly Employment Agreement, Morris Employment Agreement and Klichinsky Employment Agreement, which are filed herewith as Exhibits
10.7, 10.8 and 10.9, respectively, and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Compensatory Plans</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the effective time of the Merger and in accordance with the Merger
Agreement, the Company assumed the Carisma 2017 Plan and each Carisma option outstanding thereunder in accordance with the terms of the
Carisma 2017 Plan and the terms of the nonstatutory stock option agreement or incentive stock option agreement by which such Carisma option
is evidenced (the &#8220;<b>2017 Plan Award Agreements</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective immediately after the effective time of the Merger, the Company
(i)&#160;amended and restated the Sesen Bio,&#160;Inc. Amended and Restated 2014 Stock Incentive Plan to change the name of the plan to
the &#8220;Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan&#8221; and to reflect the effect of the Reverse Stock
Split (the &#8220;<b>A&amp;R 2014 Plan</b>&#8221;), (ii)&#160;adopted a new form of Stock Option Agreement and a new form of Restricted
Stock Unit Agreement for the grant of options and restricted stock units under the A&amp;R 2014 Plan from and after the effective time
of the Merger (together, the &#8220;<b>2014 Plan Award Agreements</b>&#8221;), and (iii)&#160;amended and restated the Sesen Bio,&#160;Inc.
2014 Employee Stock Purchase Plan, as amended, to change the name of the plan to the &#8220;Carisma Therapeutics Inc. 2014 Employee Stock
Purchase Plan&#8221; and to restate and integrate all prior amendments thereto (as amended, the &#8220;<b>ESPP</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing descriptions of the Carisma 2017 Plan, the forms of
2017 Plan Award Agreements, the A&amp;R 2014 Plan, the forms of 2014 Plan Award Agreements and the ESPP do not purport to be
complete and are qualified in their entirety by the full text of the Carisma 2017 Plan, the forms of 2017 Plan Award Agreements, the
A&amp;R 2014 Plan, the forms of 2014 Plan Award Agreements and the ESPP, which are filed herewith as Exhibits 10.10, 10.11, 10.12,
10.13, 10.14, 10.15 and 10.16, respectively, and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Departure of Officers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March&#160;7, 2023, effective as of the effective time of the Merger,
Thomas R. Cannell, D.V.M., the Company&#8217;s President and Chief Executive Officer Monica Forbes, the Company&#8217;s Chief Financial
Officer and Treasurer, and Mark Sullivan, the Company&#8217;s General Counsel, Chief Compliance Officer and Corporate Secretary, resigned
as officers of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with their termination of employment, Dr.&#160;Cannell, Ms.&#160;Forbes and Mr.&#160;Sullivan are entitled to certain severance
payments and benefits, in each case, as described in their respective employment agreements. For additional information regarding these
payments and benefits, please refer to the Company&#8217;s <a href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923005017/tm2227887-17_424b3.htm">proxy
statement/prospectus dated January&#160;19, 2023</a></span>, <a href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923022869/tm236507-3_424b3.htm">as
supplemented on February&#160;16, 2023</a>, which is incorporated by reference in all respects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with the Merger Agreement, prior to the effective time
of the Merger, the Board adopted appropriate resolutions and took all other actions necessary and appropriate to (i)&#160;provide that
each outstanding restricted stock unit and option, to the extent unvested, was accelerated in full and (ii)&#160;provide that the outstanding
non-qualified stock options (the &#8220;<b>NQSOs</b>&#8221;) held by the directors and officers, including Dr.&#160;Cannell, Ms.&#160;Forbes
and Mr.&#160;Sullivan, were amended to extend the post-termination exercise period of each such NQSO to up to 210 days following such
individual&#8217;s termination of employment or other service relationship with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 5.03.</b></td><td><b>Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Restated Certificate of Incorporation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required by Item 5.03 of Form&#160;8-K, the information
contained in Item 2.01 and Item 3.03 of this Current Report on Form&#160;8-K is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>By-Laws</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of immediately after the effective time of the Merger,
the Company amended and restated its Amended and Restated By-Laws (the &#8220;<b>Amended and Restated By-Laws</b>&#8221;). The Amended
and Restated By-Laws, among other things, (i)&#160;amend references to the Company&#8217;s name, (ii)&#160;reflect certain updates to
the Delaware General Corporation Law, (iii)&#160;clarify and enhance the procedural mechanics and disclosure requirements of the Company&#8217;s
advance notice procedures for stockholder-requested special meetings, stockholder proposals and stockholder-nominated director candidates,
and (iv)&#160;make conforming changes and other clarifying updates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing descriptions of the Restated Certificate of Incorporation
and the Amended and Restated By-Laws do not purport to be complete and are qualified in their entirety by reference to the full text of
the Restated Certificate of Incorporation and the Amended and Restated By-Laws, copies of which are filed herewith as Exhibits 3.1 and
3.2, respectively, and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 5.05.</b></td><td><b>Amendments to the Registrant&#8217;s Code of Ethics, or Waiver of a Provision of the Code of Ethics.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Merger, the Board adopted a new code of business
conduct and ethics (the &#8220;<b>Code of Conduct</b>&#8221;) effective as of the effective time of the Merger. The Code of Conduct superseded
the Company&#8217;s existing code of business conduct and ethics previously adopted by the Board. The Code of Conduct applies to all directors,
officers and employees of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The existing code was refreshed and updated in connection with the
Merger to conform the Code of Conduct to reflect current best practices and enhance the Company personnel&#8217;s understanding of the
Company&#8217;s standards of ethical business practices, promote awareness of ethical issues that may be encountered in carrying out an
employee&#8217;s or director&#8217;s responsibilities, and improve its clarity as to how to address ethical issues that may arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The newly adopted Code of Conduct did not result in any explicit or
implicit waiver of any provision of the Company&#8217;s code of business conduct and ethics in effect prior to the adoption of the Code
of Conduct. The foregoing description of the Code of Conduct does not purport to be complete and is qualified in its entirety by reference
to the full text of the Code of Conduct, a copy of which is filed herewith as Exhibit&#160;14.1 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Code of Conduct will also be posted on the Company&#8217;s website
at www.carismatx.com. The Company also anticipates filing any future amendment or waiver of the Code of Conduct on the Company&#8217;s
website within four business days of the date thereof. The contents of the Company&#8217;s website are not incorporated by reference in
this Current Report on Form&#160;8-K or made a part hereof for any purpose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 7.01.</b></td><td><b>Regulation FD Disclosure.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March&#160;7, 2023, the Company issued a press release announcing
the closing of the Merger. A copy of the press release is furnished herewith as Exhibit&#160;99.1 hereto and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this Item 7.01 of this Form&#160;8-K (including
Exhibit&#160;99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as
amended (the &#8220;<b>Exchange Act</b>&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a
filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 8.01.</b></td><td><b>Other Events.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s Business Section&#160;and the Company&#8217;s Risk
Factors Section&#160;are filed herewith as Exhibits 99.2 and 99.3, respectively, and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form&#160;8-K and the exhibits attached hereto
contain forward-looking statements within the meaning of the Private Securities Litigation Reform of 1995 that involve substantial risks
and uncertainties. All statements, other than statements of historical fact, contained in this Current Report on Form&#160;8-K and the
exhibits attached hereto, including statements regarding the Company&#8217;s strategy, future operations, future financial position, future
revenues, projected costs, prospectus, plans, objectives of management and expected market growth, are forward-looking statements. The
words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221;
 &#8220;expect,&#8221; &#8220;goals,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;outlook,&#8221; &#8220;plan,&#8221;
 &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221;
 &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; and the negative version of these words and other similar expressions
are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For
example, statements concerning the Company&#8217;s business, strategy, future operations, cash runway, the advancement of the Company&#8217;s
product candidates and product pipeline, and the clinical development of the Company&#8217;s product candidates, including expectations
regarding timing of initiation and results of clinical trials are forward-looking statements. Actual results may differ materially from
those indicated by such forward-looking statements as a result of various important factors, including, without limitation: (i)&#160;risks
associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect to future financial
and operating results; (ii)&#160;the effect of the completion of the Merger on the Company&#8217;s business relationships, operating results
and business generally; (iii)&#160;the outcome of any litigation related to the Merger Agreement or the transactions contemplated thereby;
(iv)&#160;competitive responses to the Merger and changes in expected or existing competition; (v)&#160;the ability of the Company to
obtain, maintain and protect its intellectual property rights related to its product candidates; (vi)&#160;the Company&#8217;s ability
to advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; (vii)&#160;the
Company&#8217;s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials
of its product candidates; (viii)&#160;the Company&#8217;s ability to realize the anticipated benefits of its research and development
programs, strategic partnerships, research and licensing programs and academic and other collaborations; (ix)&#160;regulatory requirements
or developments and the Company&#8217;s ability to obtain and maintain necessary approvals from the U.S. Food and Drug Administration
and other regulatory authorities; (x)&#160;changes to clinical trial designs and regulatory pathways; (xi)&#160;risks associated with
the Company&#8217;s ability to manage expenses; (xii)&#160;changes in capital resource requirements; (xiii)&#160;risks related to the
inability of the Company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs;
and (xiv)&#160;legislative, regulatory, political and economic developments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company may not actually achieve the plans, intentions or expectations
disclosed in the Company&#8217;s forward-looking statements, and you should not place undue reliance on the Company&#8217;s forward-looking
statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking
statements the Company makes. The Company has included important factors in the cautionary statements included in the Risk Factors Section&#160;filed
as Exhibit&#160;99.3 to this Current Report on Form&#160;8-K, that the Company believes could cause actual results or events to differ
materially from the forward-looking statements that made in this Current Report on Form&#160;8-K and the exhibits attached hereto. Such
forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint
ventures or investments the Company may make or enter into. You should read this Current Report on Form&#160;8-K and the documents filed
as exhibits hereto completely and with the understanding that the Company&#8217;s actual future results may be materially different from
what the Company expects. The forward-looking statements contained in this Current Report on Form&#160;8-K are made as of the date of
this report, and the Company does not assume any obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.5in; text-align: left">(a)</td><td style="text-align: justify">Financial Statements of Businesses Acquired.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unaudited historical financial information for Carisma as of and for
the nine months ended September&#160;30, 2022 and September&#160;30, 2021, and audited historical information for Carisma as of and for
the twelve months ended December&#160;31, 2021 and December&#160;31, 2020 are included in the Registration Statement, which was declared
effective by the SEC on January&#160;19, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company intends to file the financial statements of Carisma required
by Item 9.01(a)&#160;as part of an amendment to this Current Report on Form&#160;8-K not later than 71 calendar days after the date this
Current Report on Form&#160;8-K is required to be filed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.5in; text-align: left">(b)</td><td style="text-align: justify">Pro Forma Financial Information.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company intends to file the pro forma financial information required
by Item 9.01(b)&#160;as part of an amendment to this Current Report on Form&#160;8-K not later than 71 calendar days after the date this
Current Report on Form&#160;8-K is required to be filed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.5in; text-align: left">(d)</td><td style="text-align: justify">Exhibits</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: bottom; width: 4%">&#160;</td>
    <td style="width: 88%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">Exhibit</span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">Number</span></b></p></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Description</span></b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restated Certificate of Incorporation of Carisma Therapeutics Inc., dated March&#160;7, 2023.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex3-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex3-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated By-Laws of Carisma Therapeutics Inc., dated March&#160;7, 2023.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d32.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d32.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration and License Agreement, dated January&#160;7, 2022, by and between Carisma and ModernaTX, Inc. (incorporated by reference to Exhibit&#160;10.32 to the Registrant&#8217;s Registration Statement on Form&#160;S-4/A (File No.&#160;333-267891), filed on January&#160;18, 2023)</span>.</a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d33.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d33.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement, dated as of November&#160;10, 2017, by and between Carisma and the Trustees of the University of Pennsylvania, as amended (incorporated by reference to Exhibit&#160;10.33 to the Registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-267891), filed on October&#160;14, 2022)</span>.</a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d34.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d34.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement, dated as of July&#160;24, 2020, by and between Carisma and New York University (incorporated by reference to Exhibit&#160;10.34 to the Registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-267891), filed on October&#160;14, 2022)</span>.</a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement, dated March&#160;7, 2023.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent Value Rights Agreement, dated March&#160;7, 2023.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-6.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-6.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Indemnification Agreement for Directors and Officers of Carisma Therapeutics Inc. </span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated March&#160;7, 2023, by and between Carisma Therapeutics Inc. and Steven Kelly.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-8.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-8.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated March&#160;7, 2023, by and between Carisma Therapeutics Inc. and Richard Morris.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-9.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-9.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated March&#160;7, 2023, by and between Carisma Therapeutics Inc. and Michael Klichinsky.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-10.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-10.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CARISMA Therapeutics Inc. 2017 Stock Incentive Plan.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-11.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-11.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Nonstatutory Stock Option Agreement under the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-12.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-12.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Incentive Stock Option Agreement under the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-13.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-13.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carisma Therapeutics Inc. Amended and Restated 2014 Stock Incentive Plan.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-14.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-14.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Stock Option Agreement under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-15.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-15.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Restricted Stock Unit Agreement under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex10-16.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex10-16.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex14-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex14-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics of Carisma Therapeutics Inc.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex16-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex16-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter from Ernst&#160;&amp; Young LLP, dated March&#160;7, 2023.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued on March&#160;7, 2023.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Section&#160;of Carisma Therapeutics Inc.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm238578d1_ex99-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm238578d1_ex99-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors of Carisma Therapeutics Inc.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">&#160;&#160;</span>*
Portions of this exhibit have been omitted pursuant to Item&#160;601(b)(10)(iv)&#160;of&#160;Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CARISMA THERAPEUTICS INC.</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom">/s/ Steven Kelly</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </span>March&#160;7, 2023</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Kelly</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5Fk0qUuifFhWxihQRf4NdJdhmyyateiRvaWwRl4VlmXkzQozEmlamQobzosjhiHVTaY9Q4BUZ7QWDI9tsUwi3wJtxnrX1/fsDMwoMBmY2VokOQm/tjMMyBTmdyGQST0GqVCUw34noq2dkr6ZE642uQNsSDkwNG/SaX0PCUT/JUv3qq07IzpBNQY3lIL8hliqGPXX6QXx3kOeZiEb9RGLN1DbfmtZ5qmFZYR263ID+N/oAEX1JPQ== -->

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tm238578d1_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RESTATED CERTIFICATE OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SESEN BIO,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(to be renamed Carisma Therapeutics Inc.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(originally incorporated on February&nbsp;25, 2008)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sesen Bio,&nbsp;Inc. (the &#8220;Corporation&#8221;),
a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the
 &#8220;General Corporation Law&#8221;), does hereby certify as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
current name of the Corporation is Sesen Bio,&nbsp;Inc. The original Certificate of Incorporation was filed with the Secretary of State
of the State of Delaware on February&nbsp;25, 2008 under the name Newco LS14,&nbsp;Inc. The Certificate of Incorporation was mostly recently
amended and restated on February&nbsp;11, 2014 (as further amended, including most recently on March&nbsp;7, 2023, the &#8220;Prior Certificate
of Incorporation&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Restated Certificate of Incorporation has been duly adopted by the Board of Directors of the Corporation pursuant to Sections 242 and
245 of the General Corporation Law of the State of Delaware to change the name of the Corporation to Carisma Therapeutics Inc. and to
restate and integrate all amendments to the Prior Certificate of Incorporation and does not further amend (except as permitted under Sections
242(a)(1), 242(a)(7)&nbsp;and 242(b)(1)&nbsp;of the General Corporation Law of the State of Delaware) the provisions of the Prior Certificate
of Incorporation as theretofore amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Restated Certificate of Incorporation shall become effective as of 5:03 p.m.&nbsp;Eastern Standard Time on March&nbsp;7, 2023 (the &#8220;Effective
Time&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, as of the Effective Time, the Prior
Certificate of Incorporation of the Corporation, as theretofore amended, is hereby amended, integrated and restated in its entirety to
read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">First:
</FONT>The name of the Corporation is Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Second:
</FONT>The address of the Corporation&#8217;s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street,
in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at that address is The Corporation Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Third:
</FONT>The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity
for which corporations may be organized under the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Fourth:
</FONT>The total number of shares of all classes of stock which the Corporation shall have authority to issue is 105,000,000 shares, consisting
of (i)&nbsp;100,000,000 shares of Common Stock, $0.001 par value per share (&#8220;Common Stock&#8221;), and (ii)&nbsp;5,000,000 shares
of Preferred Stock, $0.001 par value per share (&#8220;Preferred Stock&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is a statement of the designations
and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital
stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>COMMON
STOCK</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>.
The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of the holders
of the Preferred Stock of any series as may be designated by the Board of Directors upon any issuance of the Preferred Stock of any series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting</U>.
The holders of the Common Stock shall have voting rights at all meetings of stockholders, each such holder being entitled to one vote
for each share thereof held by such holder; <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common
Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (which, as used herein, shall mean the certificate
of incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series
of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected
series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant
to this Certificate of Incorporation. There shall be no cumulative voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The number of authorized shares of Common Stock
may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of
a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2)&nbsp;of the General
Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Dividends</U>.
Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board of Directors
and subject to any preferential dividend or other rights of any then outstanding Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidation</U>.
Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to
receive all assets of the Corporation available for distribution to its stockholders, subject to any preferential or other rights of any
then outstanding Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>PREFERRED
STOCK</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Preferred Stock may be issued from time to time
in one or more series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing
for the issue of such series adopted by the Board of Directors of the Corporation as hereinafter provided. Any shares of Preferred Stock
which may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Authority is hereby expressly granted to the Board
of Directors from time to time to issue the Preferred Stock in one or more series, and in connection with the creation of any such series,
by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating
thereto in accordance with the General Corporation Law of the State of Delaware, to determine and fix the number of shares of such series
and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional
or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights,
conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such resolutions, all to the
full extent now or hereafter permitted by the General Corporation Law of the State of Delaware. Without limiting the generality of the
foregoing, the resolutions providing for issuance of any series of Preferred Stock may provide that such series shall be superior or rank
equally or be junior to any other series of Preferred Stock to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The number of authorized shares of Preferred Stock
may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority
of the voting power of the capital stock of the Corporation entitled to vote thereon, voting as a single class, irrespective of the provisions
of Section&nbsp;242(b)(2)&nbsp;of the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Fifth:
</FONT>Except as otherwise provided herein, the Corporation reserves the right to amend, alter, change or repeal any provision contained
in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and
all rights conferred upon stockholders herein are granted subject to this reservation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Sixth:
</FONT>In furtherance and not in limitation of the powers conferred upon it by the General Corporation Law of the State of Delaware, and
subject to the terms of any series of Preferred Stock, the Board of Directors shall have the power to adopt, amend, alter or repeal the
By-laws of the Corporation by the affirmative vote of a majority of the directors present at any regular or special meeting of the Board
of Directors at which a quorum is present. The stockholders may not adopt, amend, alter or repeal the By-laws of the Corporation, or adopt
any provision inconsistent therewith, unless such action is approved, in addition to any other vote required by this Certificate of Incorporation,
by the affirmative vote of the holders of at least seventy-five percent (75%) of the votes that all the stockholders would be entitled
to cast in any annual election of directors or class of directors. Notwithstanding any other provisions of law, this Certificate of Incorporation
or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote
of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual
election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article&nbsp;SIXTH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Seventh:
</FONT>Except to the extent that the General Corporation Law of the State of Delaware prohibits the elimination or limitation of liability
of directors for breaches of fiduciary duty, no director of the Corporation shall be personally liable to the Corporation or its stockholders
for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability. No
amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the
Corporation for or with respect to any acts or omissions of such director occurring prior to such amendment or repeal. If the General
Corporation Law of the State of Delaware is amended to permit further elimination or limitation of the personal liability of directors,
then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation
Law of the State of Delaware as so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Eighth:
</FONT>The Corporation shall provide indemnification as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Actions,
Suits and Proceedings Other than by or in the Right of the Corporation</U>. The Corporation shall indemnify each person who was or is
a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he or she is or
was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request of
the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership,
joint venture, trust or other enterprise (including any employee benefit plan) (all such persons being referred to hereafter as an &#8220;Indemnitee&#8221;),
or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees),
liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act
of 1974), and amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action,
suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to
be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe his or her conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction
or upon a plea of <U>nolo contendere</U> or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in
good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and,
with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Actions
or Suits by or in the Right of the Corporation</U>. The Corporation shall indemnify any Indemnitee who was or is a party to or
threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to
procure a judgment in its favor by reason of the fact that Indemnitee is or was, or has agreed to become, a director or officer of
the Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner,
employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise
(including any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against
all expenses (including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and
reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if
Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests
of the Corporation, except that no indemnification shall be made under this Section&nbsp;2 in respect of any claim, issue or matter
as to which Indemnitee shall have been adjudged to be liable to the Corporation, unless, and only to the extent, that the Court of
Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the
adjudication of such liability but in view of all the circumstances of the case,&nbsp;Indemnitee is fairly and reasonably entitled
to indemnity for such expenses (including attorneys&#8217; fees) which the Court of Chancery of Delaware or such other court shall
deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
for Expenses of Successful Party</U>. Notwithstanding any other provisions of this Article&nbsp;EIGHTH, to the extent that an Indemnitee
has been successful, on the merits or otherwise, in defense of any action, suit or proceeding referred to in Sections 1 and 2 of this
Article&nbsp;EIGHTH, or in defense of any claim, issue or matter therein, or on appeal from any such action, suit or proceeding,&nbsp;Indemnitee
shall be indemnified against all expenses (including attorneys&#8217; fees) actually and reasonably incurred by or on behalf of Indemnitee
in connection therewith. Without limiting the foregoing, if any action, suit or proceeding is disposed of, on the merits or otherwise
(including a disposition without prejudice), without (i)&nbsp;the disposition being adverse to Indemnitee, (ii)&nbsp;an adjudication that
Indemnitee was liable to the Corporation, (iii)&nbsp;a plea of guilty or <U>nolo contendere</U> by Indemnitee, (iv)&nbsp;an adjudication
that Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests
of the Corporation, and (v)&nbsp;with respect to any criminal proceeding, an adjudication that Indemnitee had reasonable cause to believe
his or her conduct was unlawful,&nbsp;Indemnitee shall be considered for the purposes hereof to have been wholly successful with respect
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notification
and Defense of Claim</U>. As a condition precedent to an Indemnitee&#8217;s right to be indemnified, such Indemnitee must notify the Corporation
in writing as soon as practicable of any action, suit, proceeding or investigation involving such Indemnitee for which indemnity will
or could be sought. With respect to any action, suit, proceeding or investigation of which the Corporation is so notified, the Corporation
will be entitled to participate therein at its own expense and/or to assume the defense thereof at its own expense, with legal counsel
reasonably acceptable to Indemnitee. After notice from the Corporation to Indemnitee of its election so to assume such defense, the Corporation
shall not be liable to Indemnitee for any legal or other expenses subsequently incurred by Indemnitee in connection with such action,
suit, proceeding or investigation, other than as provided below in this Section&nbsp;4. Indemnitee shall have the right to employ his
or her own counsel in connection with such action, suit, proceeding or investigation, but the fees and expenses of such counsel incurred
after notice from the Corporation of its assumption of the defense thereof shall be at the expense of Indemnitee unless (i)&nbsp;the employment
of counsel by Indemnitee has been authorized by the Corporation, (ii)&nbsp;counsel to Indemnitee shall have reasonably concluded that
there may be a conflict of interest or position on any significant issue between the Corporation and Indemnitee in the conduct of the
defense of such action, suit, proceeding or investigation or (iii)&nbsp;the Corporation shall not in fact have employed counsel to assume
the defense of such action, suit, proceeding or investigation, in each of which cases the fees and expenses of counsel for Indemnitee
shall be at the expense of the Corporation, except as otherwise expressly provided by this Article&nbsp;EIGHTH. The Corporation shall
not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Corporation or
as to which counsel for Indemnitee shall have reasonably made the conclusion provided for in clause (ii)&nbsp;above. The Corporation shall
not be required to indemnify Indemnitee under this Article&nbsp;EIGHTH for any amounts paid in settlement of any action, suit, proceeding
or investigation effected without its written consent. The Corporation shall not settle any action, suit, proceeding or investigation
in any manner which would impose any penalty or limitation on Indemnitee without Indemnitee&#8217;s written consent. Neither the Corporation
nor Indemnitee will unreasonably withhold or delay its consent to any proposed settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Advancement
of Expenses</U>. Subject to the provisions of Section&nbsp;6 of this Article&nbsp;EIGHTH, in the event of any threatened or pending action,
suit, proceeding or investigation of which the Corporation receives notice under this Article&nbsp;EIGHTH, any expenses (including attorneys&#8217;
fees) incurred by or on behalf of Indemnitee in defending an action, suit, proceeding or investigation or any appeal therefrom shall be
paid by the Corporation in advance of the final disposition of such matter; <U>provided</U>, <U>however</U>, that the payment of such
expenses incurred by or on behalf of Indemnitee in advance of the final disposition of such matter shall be made only upon receipt of
an undertaking by or on behalf of Indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final
judicial decision from which there is no further right to appeal that Indemnitee is not entitled to be indemnified by the Corporation
as authorized in this Article&nbsp;EIGHTH; and <U>provided further</U> that no such advancement of expenses shall be made under this Article&nbsp;EIGHTH
if it is determined (in the manner described in Section&nbsp;6) that (i)&nbsp;Indemnitee did not act in good faith and in a manner he
or she reasonably believed to be in, or not opposed to, the best interests of the Corporation, or (ii)&nbsp;with respect to any criminal
action or proceeding,&nbsp;Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such undertaking shall be accepted
without reference to the financial ability of Indemnitee to make such repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure
for Indemnification and Advancement of Expenses</U>. In order to obtain indemnification or advancement of expenses pursuant to Section&nbsp;1,
2, 3 or 5 of this Article&nbsp;EIGHTH, an Indemnitee shall submit to the Corporation a written request. Any such advancement of expenses
shall be made promptly, and in any event within 60 days after receipt by the Corporation of the written request of Indemnitee, unless
(i)&nbsp;the Corporation has assumed the defense pursuant to Section&nbsp;4 of this Article&nbsp;EIGHTH (and none of the circumstances
described in Section&nbsp;4 of this Article&nbsp;EIGHTH that would nonetheless entitle the Indemnitee to indemnification for the fees
and expenses of separate counsel have occurred) or (ii)&nbsp;the Corporation determines within such 60-day period that Indemnitee did
not meet the applicable standard of conduct set forth in Section&nbsp;1, 2 or 5 of this Article&nbsp;EIGHTH, as the case may be. Any such
indemnification, unless ordered by a court, shall be made with respect to requests under Section&nbsp;1 or 2 only as authorized in the
specific case upon a determination by the Corporation that the indemnification of Indemnitee is proper because Indemnitee has met the
applicable standard of conduct set forth in Section&nbsp;1 or 2, as the case may be. Such determination shall be made in each instance
(a)&nbsp;by a majority vote of the directors of the Corporation consisting of persons who are not at that time parties to the action,
suit or proceeding in question (&#8220;disinterested directors&#8221;), whether or not a quorum, (b)&nbsp;by a committee of disinterested
directors designated by majority vote of disinterested directors, whether or not a quorum, (c)&nbsp;if there are no disinterested directors,
or if the disinterested directors so direct, by independent legal counsel (who may, to the extent permitted by law, be regular legal counsel
to the Corporation) in a written opinion, or (d)&nbsp;by the stockholders of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
The right to indemnification or advancement of expenses as granted by this Article&nbsp;EIGHTH shall be enforceable by Indemnitee in any
court of competent jurisdiction. Neither the failure of the Corporation to have made a determination prior to the commencement of such
action that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual
determination by the Corporation pursuant to Section&nbsp;6 of this Article&nbsp;EIGHTH that Indemnitee has not met such applicable standard
of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. In
any suit brought by Indemnitee to enforce a right to indemnification, or brought by the Corporation to recover an advancement of expenses
pursuant to the terms of an undertaking, the Corporation shall have the burden of proving that Indemnitee is not entitled to be indemnified,
or to such advancement of expenses, under this Article&nbsp;EIGHTH. Indemnitee&#8217;s expenses (including attorneys&#8217; fees) reasonably
incurred in connection with successfully establishing Indemnitee&#8217;s right to indemnification, in whole or in part, in any such proceeding
shall also be indemnified by the Corporation. Notwithstanding the foregoing, in any suit brought by Indemnitee to enforce a right to indemnification
hereunder it shall be a defense that the Indemnitee has not met any applicable standard for indemnification set forth in the General Corporation
Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitations</U>.
Notwithstanding anything to the contrary in this Article&nbsp;EIGHTH, except as set forth in Section&nbsp;7 of this Article&nbsp;EIGHTH,
the Corporation shall not indemnify an Indemnitee pursuant to this Article&nbsp;EIGHTH in connection with a proceeding (or part thereof)
initiated by such Indemnitee unless the initiation thereof was approved by the Board of Directors of the Corporation. Notwithstanding
anything to the contrary in this Article&nbsp;EIGHTH, the Corporation shall not indemnify an Indemnitee to the extent such Indemnitee
is reimbursed from the proceeds of insurance, and in the event the Corporation makes any indemnification payments to an Indemnitee and
such Indemnitee is subsequently reimbursed from the proceeds of insurance, such Indemnitee shall promptly refund indemnification payments
to the Corporation to the extent of such insurance reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Amendment</U>. No amendment, termination or repeal of this Article&nbsp;EIGHTH or of the relevant provisions of the General Corporation
Law of the State of Delaware or any other applicable laws shall adversely affect or diminish in any way the rights of any Indemnitee to
indemnification under the provisions hereof with respect to any action, suit, proceeding or investigation arising out of or relating to
any actions, transactions or facts occurring prior to the final adoption of such amendment, termination or repeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Rights</U>. The indemnification and advancement of expenses provided by this Article&nbsp;EIGHTH shall not be deemed exclusive of any
other rights to which an Indemnitee seeking indemnification or advancement of expenses may be entitled under any law (common or statutory),
agreement or vote of stockholders or disinterested directors or otherwise, both as to action in Indemnitee&#8217;s official capacity and
as to action in any other capacity while holding office for the Corporation, and shall continue as to an Indemnitee who has ceased to
be a director or officer, and shall inure to the benefit of the estate, heirs, executors and administrators of Indemnitee. Nothing contained
in this Article&nbsp;EIGHTH shall be deemed to prohibit, and the Corporation is specifically authorized to enter into, agreements with
officers and directors providing indemnification rights and procedures different from those set forth in this Article&nbsp;EIGHTH. In
addition, the Corporation may, to the extent authorized from time to time by its Board of Directors, grant indemnification rights to other
employees or agents of the Corporation or other persons serving the Corporation and such rights may be equivalent to, or greater or less
than, those set forth in this Article&nbsp;EIGHTH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Partial
Indemnification</U>. If an Indemnitee is entitled under any provision of this Article&nbsp;EIGHTH to indemnification by the Corporation
for some or a portion of the expenses (including attorneys&#8217; fees), liabilities, losses, judgments, fines (including excise taxes
and penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid in settlement actually and reasonably
incurred by or on behalf of Indemnitee in connection with any action, suit, proceeding or investigation and any appeal therefrom but not,
however, for the total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion of such expenses (including
attorneys&#8217; fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement
Income Security Act of 1974) or amounts paid in settlement to which Indemnitee is entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Corporation may purchase and maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of
the Corporation or another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) against
any expense, liability or loss incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not
the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law
of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Savings
Clause</U>. If this Article&nbsp;EIGHTH or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction,
then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses (including attorneys&#8217; fees), liabilities, losses,
judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) and amounts
paid in settlement in connection with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including
an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article&nbsp;EIGHTH
that shall not have been invalidated and to the fullest extent permitted by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
Terms used herein and defined in Section&nbsp;145(h)&nbsp;and Section&nbsp;145(i)&nbsp;of the General Corporation Law of the State of
Delaware shall have the respective meanings assigned to such terms in such Section&nbsp;145(h)&nbsp;and Section&nbsp;145(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Ninth:
</FONT>This Article&nbsp;NINTH is inserted for the management of the business and for the conduct of the affairs of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Powers</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Number
of Directors; Election of Directors</U>. Subject to the rights of holders of any series of Preferred Stock to elect directors, the number
of directors of the Corporation shall be established by the Board of Directors. Election of directors need not be by written ballot, except
as and to the extent provided in the By-laws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Classes
of Directors</U>. Subject to the rights of holders of any series of Preferred Stock to elect directors, the Board of Directors shall be
and is divided into three classes, designated Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Each class shall consist, as nearly as may
be possible, of one-third of the total number of directors constituting the entire Board of Directors. The Board of Directors is authorized
to assign members of the Board of Directors already in office to Class&nbsp;I, Class&nbsp;II or Class&nbsp;III at the time such classification
becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms
of Office</U>. Subject to the rights of holders of any series of Preferred Stock to elect directors, each director shall serve for a term
ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director was
elected; <U>provided</U> that the term of each director shall continue until the election and qualification of his or her successor and
be subject to his or her earlier death, resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum</U>.
The greater of (a)&nbsp;a majority of the directors at any time in office and (b)&nbsp;one-third of the number of directors fixed pursuant
to Section&nbsp;2 of this Article&nbsp;NINTH shall constitute a quorum of the Board of Directors. If at any meeting of the Board of Directors
there shall be less than such a quorum, a majority of the directors present may adjourn the meeting from time to time without further
notice other than announcement at the meeting, until a quorum shall be present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Action
at Meeting</U>. Every act or decision done or made by a majority of the directors present at a meeting duly held at which a quorum is
present shall be regarded as the act of the Board of Directors unless a greater number is required by law or by this Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal</U>.
Subject to the rights of holders of any series of Preferred Stock, directors of the Corporation may be removed only for cause and only
by the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled
to cast in any annual election of directors or class of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies</U>.
Subject to the rights of holders of any series of Preferred Stock, any vacancy or newly created directorship in the Board of Directors,
however occurring, shall be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole
remaining director and shall not be filled by the stockholders. A director elected to fill a vacancy shall hold office until the next
election of the class for which such director shall have been chosen, subject to the election and qualification of a successor and to
such director&#8217;s earlier death, resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder
Nominations and Introduction of Business, Etc</U>. Advance notice of stockholder nominations for election of directors and other business
to be brought by stockholders before a meeting of stockholders shall be given in the manner provided by the By-laws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments
to Article</U>. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and
notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five
percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors
shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article&nbsp;NINTH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Tenth:
</FONT>Stockholders of the Corporation may not take any action by written consent in lieu of a meeting. Notwithstanding any other provisions
of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may
be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders
would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt
any provision inconsistent with, this Article&nbsp;TENTH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Eleventh:
</FONT>Special meetings of stockholders for any purpose or purposes may be called at any time by only the Board of Directors, the Chairman
of the Board or the Chief Executive Officer, and may not be called by any other person or persons. Business transacted at any special
meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting. Notwithstanding
any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a
lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which
all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or
repeal, or to adopt any provision inconsistent with, this Article&nbsp;ELEVENTH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, this Restated Certificate of
Incorporation has been executed by a duly authorized officer of the Corporation on this seventh day of March, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 5%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ Steven Kelly</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>Steven Kelly</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>President and Chief
Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>tm238578d1_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED BY-LAWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CARISMA THERAPEUTICS INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Page</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 95%">ARTICLE&nbsp;I STOCKHOLDERS</TD>
  <TD STYLE="text-align: right; width: 5%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1</TD><TD>Place of Meetings&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">1</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2</TD><TD>Annual Meeting&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">1</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.3</TD><TD>Special Meetings&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">1</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.4</TD><TD>Record Date for Stockholder Meetings&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">1</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.5</TD><TD>Notice of Meetings&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">1</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.6</TD><TD>Voting List&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.7</TD><TD>Quorum&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.8</TD><TD>Adjournments&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.9</TD><TD>Voting and Proxies&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.10</TD><TD>Action at Meeting&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.11</TD><TD>Nomination of Directors&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">3</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.12</TD><TD>Notice of Business at Annual Meetings&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">5</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.13</TD><TD>Conduct of Meetings&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">7</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.14</TD><TD>No Action by Consent in Lieu of a Meeting&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">8</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 95%">ARTICLE&nbsp;II DIRECTORS</TD>
  <TD STYLE="text-align: right; width: 5%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1</TD><TD>General Powers&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">8</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2</TD><TD>Number, Election and Qualification&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">8</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.3</TD><TD>Chairman of the Board; Vice Chairman of the Board&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">8</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.4</TD><TD>Terms of Office&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">8</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.5</TD><TD>Quorum&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">8</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.6</TD><TD>Action at Meeting&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.7</TD><TD>Removal&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.8</TD><TD>Vacancies&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.9</TD><TD>Resignation&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.10</TD><TD>Regular Meetings&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.11</TD><TD>Special Meetings&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.12</TD><TD>Notice of Special Meetings&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.13</TD><TD>Meetings by Conference Communications Equipment&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.14</TD><TD>Action by Consent&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.15</TD><TD>Committees&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">9</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.16</TD><TD>Emergency by-laws&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">10</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 95%">ARTICLE&nbsp;III OFFICERS</TD>
  <TD STYLE="text-align: right; width: 5%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.1</TD><TD>Titles&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">10</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.2</TD><TD>Election&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">10</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.3</TD><TD>Qualification&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">10</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.4</TD><TD>Tenure&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">10</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.5</TD><TD>Resignation and Removal&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">10</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.6</TD><TD>Vacancies&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">11</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.7</TD><TD>President; Chief Executive Officer&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">11</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.8</TD><TD>Vice Presidents&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">11</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.9</TD><TD>Secretary and Assistant Secretaries&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">11</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.10</TD><TD>Treasurer and Assistant Treasurers&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">11</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.11</TD><TD>Salaries&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">12</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.12</TD><TD>Delegation of Authority&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 5%">12</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 95%">ARTICLE&nbsp;IV CAPITAL STOCK</TD>
  <TD STYLE="text-align: right; width: 5%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.1</TD><TD>Issuance of Stock&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">12</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2</TD><TD>Stock Certificates; Uncertificated Shares&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">12</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.3</TD><TD>Transfers&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">12</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.4</TD><TD>Lost, Stolen or Destroyed Certificates&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">13</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.5</TD><TD>Regulations&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">13</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 95%">ARTICLE&nbsp;V GENERAL PROVISIONS</TD>
  <TD STYLE="text-align: right; width: 5%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.1</TD><TD>Fiscal Year&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">13</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.2</TD><TD>Corporate Seal&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">13</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.3</TD><TD>Record Date for Purposes Other Than Stockholder Meetings&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">13</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.4</TD><TD>Waiver of Notice</TD>
                                                               <TD STYLE="text-align: right; width: 5%">&#9;13</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.5</TD><TD>Voting of Securities&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">13</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.6</TD><TD>Evidence of Authority&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">14</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.7</TD><TD>Certificate of Incorporation</TD>
                                                               <TD STYLE="text-align: right; width: 5%">&#9;14</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.8</TD><TD>Severability&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">14</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.9</TD><TD>Pronouns&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 5%">14</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 95%">ARTICLE&nbsp;VI AMENDMENTS</TD>
  <TD STYLE="text-align: right; width: 5%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Place
of Meetings</U>. All meetings of stockholders shall be held at such place, if any, as may be designated from time to time by the Board
of Directors, the Chairman of the Board or the Chief Executive Officer or, if not so designated, at the principal executive office of
the corporation. The Board of Directors may, in its sole discretion, determine that a meeting shall not be held at any place, but shall
instead be held solely by means of remote communication in a manner consistent with the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Annual
Meeting</U>. The annual meeting of stockholders for the election of directors to succeed those whose terms expire and for the
transaction of such other business as may properly be brought before the meeting shall be held on a date and at an hour designated
by the Board of Directors, the Chairman of the Board or the Chief Executive Officer. The corporation may postpone, reschedule or
cancel any previously scheduled annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Special
Meetings</U>. Special meetings of stockholders for any purpose or purposes may be called at any time only by the Board of Directors, and
may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall be limited to matters
relating to the purpose or purposes stated in the notice of meeting. The corporation may postpone, reschedule or cancel any previously
scheduled special meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Record
Date for Stockholder Meetings</U>. In order that the corporation may determine the stockholders entitled to notice of any meeting of stockholders
or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the
resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than
10 days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining
the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that
a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board
of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at
the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on
the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of and to vote
at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new
record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record
date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders
entitled to vote in accordance herewith at the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notice
of Meetings</U>. Except as otherwise provided by law, the Certificate of Incorporation or these by-laws, notice of each meeting of stockholders,
whether annual or special, shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled
to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting. Without limiting the
manner by which notice otherwise may be given to stockholders, any notice shall be effective if given in accordance with Section&nbsp;232
of the General Corporation Law of the State of Delaware. The notices of all meetings shall state the place, if any, date and hour of the
meeting, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and
vote at such meeting, and the record date for determining stockholders entitled to vote at the meeting, if such date is different from
the record date for determining stockholders entitled to notice of the meeting. The notice of a special meeting shall state, in addition,
the purpose or purposes for which the meeting is called.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Voting
List</U>. The corporation shall prepare, no later than the tenth day before each meeting of stockholders, a complete list of the stockholders
entitled to vote at the meeting (provided, however, if the record date for determining the stockholders entitled to vote is less than
10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth day before the meeting), arranged
in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder.
Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of 10 days ending on
the day before the meeting date: (a)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain
access to such list is provided with the notice of the meeting, or (b)&nbsp;during ordinary business hours, at the principal place of
business of the corporation. Except as otherwise provided by law, the stock ledger shall be the only evidence as to who are the stockholders
entitled to examine the list of stockholders required by this Section&nbsp;1.6 or to vote in person or by proxy at any meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Quorum</U>.
Except as otherwise provided by law, the Certificate of Incorporation or these by-laws, the holders of a majority in voting power of the
shares of the capital stock of the corporation issued and outstanding and entitled to vote at the meeting, present in person, present
by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy,
shall constitute a quorum for the transaction of business; provided, however, that where a separate vote by a class or classes or series
of capital stock is required by law or the Certificate of Incorporation, the holders of a majority in voting power of the shares of such
class or classes or series of the capital stock of the corporation issued and outstanding and entitled to vote on such matter, present
in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole discretion,
or represented by proxy, shall constitute a quorum entitled to take action with respect to the vote on such matter. A quorum, once established
at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Adjournments</U>.
Any meeting of stockholders may be adjourned from time to time to reconvene at any other time and to any other place at which a meeting
of stockholders may be held under these by-laws by the chairman of the meeting. When a meeting is adjourned to another time or place (including
an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given
of the adjourned meeting if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and
proxy holders may be deemed to be present in person and vote at such adjourned meeting are (i)&nbsp;announced at the meeting at which
the adjournment is taken, (ii)&nbsp;displayed, during the time scheduled for the meeting, on the same electronic network used to enable
stockholders and proxy holders to participate in the meeting by means of remote communication or (iii)&nbsp;set forth in the notice of
meeting given in accordance with Section&nbsp;1.5 hereof. At the adjourned meeting, the corporation may transact any business that might
have been transacted at the original meeting. If the adjournment is for more than 30 days, a notice of the adjourned meeting shall be
given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for determination of stockholders
entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for determining stockholders entitled
to notice of such adjourned meeting that is the same or an earlier date as that fixed for determination of stockholders entitled to vote
at such adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned
meeting as of the record date fixed for notice of such adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Voting
and Proxies</U>. Each stockholder shall have one vote upon the matter in question for each share of stock entitled to vote held of
record by such stockholder and a proportionate vote for each fractional share so held, unless otherwise provided by law or the
Certificate of Incorporation. Each stockholder of record entitled to vote at a meeting of stockholders may vote in person (including
by means of remote communications, if any, by which stockholders may be deemed to be present in person and vote at such meeting) or
may authorize another person or persons to vote for such stockholder by a proxy executed or transmitted in a manner permitted by the
General Corporation Law of the State of Delaware by the stockholder or such stockholder&#8217;s authorized officer, director,
employee or agent and delivered (including by electronic transmission) to the Secretary of the corporation. No such proxy shall be
voted upon after three years from the date of its execution, unless the proxy expressly provides for a longer period. Any person
directly or indirectly soliciting proxies from stockholders of the corporation must use a proxy card color other than white, the
color white being reserved for the exclusive use of the Board of Directors of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Action
at Meeting</U>. When a quorum is present at any meeting, any matter other than the election of directors to be voted upon by the stockholders
at such meeting shall be decided by the vote of the holders of shares of stock having a majority in voting power of the votes cast by
the holders of all of the shares of stock present or represented at the meeting and voting affirmatively or negatively on such matter
(or if there are two or more classes or series of stock entitled to vote as separate classes, then in the case of each such class or series,
the holders of a majority in voting power of the shares of stock of that class or series present or represented at the meeting and voting
affirmatively or negatively on such matter), except when a different vote is required by law, the Certificate of Incorporation or these
by-laws. When a quorum is present at any meeting, any election by stockholders of directors shall be determined by a plurality of the
votes cast by the stockholders entitled to vote on the election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Nomination
of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except
for any directors entitled to be elected by the holders of preferred stock, only persons who are nominated in accordance with the procedures
in this Section&nbsp;1.11 shall be eligible for election as directors at any meeting of stockholders. Nomination for election to the Board
of Directors at a meeting of stockholders may be made only (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any
stockholder of the corporation who (x)&nbsp;has given timely notice thereof in writing to the Secretary in accordance with the procedures
in, and otherwise complies with, Section&nbsp;1.11(b), (y)&nbsp;is a stockholder of record who is entitled to vote for the election of
such nominee on the date of the giving of such notice and on the record date for the determination of stockholders entitled to vote at
such meeting and (z)&nbsp;is entitled to vote at such meeting. Notwithstanding the foregoing or anything herein to the contrary, a stockholder
of the corporation may make nominations for election to the Board of Directors at a special meeting of stockholders pursuant to the foregoing
clause (ii)&nbsp;only if the Board of Directors has determined, in accordance with Section&nbsp;1.3, that directors shall be elected at
such special meeting and at such time that the stockholders are not prohibited from filling vacancies or newly created directorships on
the Board of Directors. The number of nominees a stockholder may nominate for election at a meeting (or in the case of a stockholder giving
the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the meeting on behalf of
such beneficial owner) shall not exceed the number of directors to be elected at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>To
be timely, a stockholder&#8217;s notice must be received in writing by the Secretary at the principal executive office of the corporation
as follows: (1)&nbsp;in the case of an election of directors at an annual meeting of stockholders, not less than 90 days nor more than
120 days prior to the first anniversary of the preceding year&#8217;s annual meeting; provided, however, that in the event that the date
of the annual meeting is advanced by more than 30 days, or delayed by more than 60 days, from the first anniversary of the preceding year&#8217;s
annual meeting, or if no annual meeting was held or deemed to have been held in the preceding year, a stockholder&#8217;s notice must
be so received not earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of (A)&nbsp;the
90th day prior to such annual meeting and (B)&nbsp;the tenth day following the day on which notice of the date of such annual meeting
was given or public disclosure of the date of such annual meeting was made, whichever first occurs; or (2)&nbsp;in the case of an election
of directors at a special meeting of stockholders, provided that the Board of Directors has determined, in accordance with Section&nbsp;1.3,
that directors shall be elected at such special meeting and the stockholders are not then prohibited from filling vacancies or newly created
directorships on the Board of Directors, and provided further that the nomination made by the stockholder is for one of the director positions
that the Board of Directors has determined will be filled at such special meeting, not earlier than the 120th day prior to such special
meeting and not later than the close of business on the later of (x)&nbsp;the 90th day prior to such special meeting and (y)&nbsp;the
tenth day following the day on which notice of the date of such special meeting was given or public disclosure of the date of such special
meeting was made, whichever first occurs. In no event shall the adjournment or postponement of a meeting (or the public disclosure thereof)
commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The stockholder&#8217;s notice to the
Secretary shall set forth: (A)&nbsp;as to each proposed nominee (1)&nbsp;such person&#8217;s name, age, business address and, if
known, residence address, (2)&nbsp;such person&#8217;s principal occupation or employment, (3)&nbsp;the class and series and number
of shares of stock of the corporation that are, directly or indirectly, owned, beneficially or of record, by such person, (4)&nbsp;a
description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during
the past three years, and any other material relationships, between or among (x)&nbsp;the stockholder, the beneficial owner, if any,
on whose behalf the nomination is being made and the respective affiliates and associates of, or others acting in concert with, such
stockholder and such beneficial owner (each, a &#8220;Stockholder Associated Person&#8221;), on the one hand, and (y)&nbsp;each
proposed nominee, and his or her respective affiliates and associates, or others acting in concert with such nominee(s), on the
other hand, including all information that would be required to be disclosed pursuant to Item 404 of Regulation S-K if the
stockholder making the nomination and any beneficial owner on whose behalf the nomination is made or any Stockholder Associated
Person were the &#8220;registrant&#8221; for purposes of such Item and the proposed nominee were a director or executive officer of
such registrant, and (5)&nbsp;any other information concerning such person that must be disclosed as to nominees in proxy
solicitations pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;); and
(B)&nbsp;as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is being made
(1)&nbsp;the name and address of such stockholder, as they appear on the corporation&#8217;s books, and of such beneficial owner,
(2)&nbsp;the class and series and number of shares of stock of the corporation that are, directly or indirectly, owned, beneficially
or of record, by such stockholder and such beneficial owner, (3)&nbsp;a description of any material interest related to the
nomination of such stockholder, such beneficial owner and/or any Stockholder Associated Person, (4)&nbsp;a description of any
agreement, arrangement or understanding between or among such stockholder, such beneficial owner and/or any Stockholder Associated
Person and each proposed nominee and any other person or persons (including their names) pursuant to which the
nomination(s)&nbsp;are being made or who may participate in the solicitation of proxies or votes in favor of electing such
nominee(s), (5)&nbsp;a description of any agreement, arrangement or understanding (including any derivative or short positions,
swaps, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and
borrowed or loaned shares) that has been entered into by, or on behalf of, such stockholder, such beneficial owner and/or any
Stockholder Associated Person, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes
for, or increase or decrease the voting power of, such stockholder, such beneficial owner and/or any Stockholder Associated Person
with respect to shares of stock of the corporation, (6)&nbsp;any other information relating to such stockholder, such beneficial
owner and/or any Stockholder Associated Person that would be required to be disclosed in a proxy statement or other filings required
to be made in connection with solicitations of proxies for the election of directors in a contested election pursuant to
Section&nbsp;14 of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder, (7)&nbsp;a representation that such
stockholder intends to appear in person or by proxy at the meeting to nominate the person(s)&nbsp;named in its notice, (8)&nbsp;a
representation that such stockholder, such beneficial owner and/or any Stockholder Associated Person has complied, and will comply,
with all applicable requirements of state law and the Exchange Act with respect to matters set forth in this Section&nbsp;1.11, and
(9)&nbsp;a representation whether such stockholder, such beneficial owner and/or any Stockholder Associated Person intends or is
part of a group that intends (x)&nbsp;to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the
corporation&#8217;s outstanding capital stock reasonably believed by such stockholder or such beneficial owner to be sufficient to
elect the nominee (and such representation shall be included in any such proxy statement and form of proxy) and/or
(y)&nbsp;otherwise to solicit proxies or votes from stockholders in support of such nomination (and such representation shall be
included in any such solicitation materials). Not later than 10 days after the record date for the meeting, the information required
by Items (A)(1)-(5)&nbsp;and (B)(1)-(6)&nbsp;of the prior sentence shall be supplemented by the stockholder giving the notice to
provide updated information as of the record date. In addition, to be effective, the stockholder&#8217;s notice must also be
accompanied by the written consent of the proposed nominee to being named in the corporation&#8217;s proxy statement and
accompanying proxy card as a nominee and to serve as a director if elected. The corporation may require any proposed nominee to
furnish such other information as the corporation may reasonably require to determine, among other things, the eligibility of such
proposed nominee to serve as a director of the corporation or whether such nominee would be independent under applicable Securities
and Exchange Commission and stock exchange rules&nbsp;and the corporation&#8217;s publicly disclosed corporate governance
guidelines. Notwithstanding anything herein to the contrary, a stockholder shall not have complied with this
Section&nbsp;1.11(b)&nbsp;if the stockholder, beneficial owner and/or any Stockholder Associated Person solicits or does not
solicit, as the case may be, proxies or votes in support of such stockholder&#8217;s nominee in contravention of the representations
with respect thereto required by this Section&nbsp;1.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Such notice must also be accompanied by a representation
as to whether or not such stockholder, beneficial owner and/or any Stockholder Associated Person intends to solicit proxies in support
of any director nominees other than the corporation&#8217;s nominees in accordance with Rule&nbsp;14a-19 under the Exchange Act, and,
where such stockholder, beneficial owner and/or Stockholder Associated Person intends to so solicit proxies, the notice and information
required by Rule&nbsp;14a-19(b)&nbsp;under the Exchange Act. Notwithstanding anything to the contrary in these by-laws, unless otherwise
required by law, if any stockholder, beneficial owner and/or Stockholder Associated Person (i)&nbsp;provides notice pursuant to Rule&nbsp;14a-19(b)&nbsp;under
the Exchange Act and (ii)&nbsp;subsequently fails to comply with the requirements of Rule&nbsp;14a-19(a)(2)&nbsp;and Rule&nbsp;14a-19(a)(3)&nbsp;under
the Exchange Act (or fails to timely provide reasonable evidence sufficient to satisfy the corporation that such stockholder, beneficial
owner and/or Stockholder Associated Person has met the requirements of Rule&nbsp;14a-19(a)(3)&nbsp;promulgated under the Exchange Act
in accordance with the following sentence), then the nomination of each of the director nominees proposed by such stockholder, beneficial
owner and/or Stockholder Associated Person shall be disregarded, notwithstanding that proxies or votes in respect of the election of such
proposed nominees may have been received by the corporation (which proxies and votes shall be disregarded). Upon request by the corporation,
if any stockholder, beneficial owner and/or Stockholder Associated Person provides notice pursuant to Rule&nbsp;14a-19(b)&nbsp;under the
Exchange Act, such stockholder, beneficial owner and/or Stockholder Associated Person shall deliver to the corporation, no later than
five business days prior to the applicable meeting, reasonable evidence that it has met the requirements of Rule&nbsp;14a-19(a)(3)&nbsp;under
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
chairman of any meeting (and, in advance of any meeting, the Board of Directors) shall have the power and duty to determine whether a
nomination was made in accordance with the provisions of this Section&nbsp;1.11 (including whether the stockholder, beneficial owner and/or
any Stockholder Associated Person did, or did not so solicit, as the case may be, proxies or votes in support of such stockholder&#8217;s
nominee in compliance with the representations with respect thereto required by this Section&nbsp;1.11), and if the chairman (or the Board
of Directors) should determine that a nomination was not made in accordance with the provisions of this Section&nbsp;1.11, the chairman
shall so declare to the meeting and such nomination shall not be brought before the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except
as otherwise required by law (including Rule&nbsp;14a-19 under the Exchange Act), nothing in this Section&nbsp;1.11 shall obligate the
corporation or the Board of Directors to include in any proxy statement, proxy card or other stockholder communication distributed on
behalf of the corporation or the Board of Directors the name of or other information with respect to any nominee for director submitted
by a stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding
the foregoing provisions of this Section&nbsp;1.11, unless otherwise required by law, if the stockholder (or a qualified representative
of the stockholder) does not appear at the meeting to present a nomination, such nomination shall not be brought before the meeting, notwithstanding
that proxies in respect of such nominee may have been received by the corporation. For purposes of this Section&nbsp;1.11, to be considered
a &#8220;qualified representative of the stockholder&#8221;, a person must be a duly authorized officer, manager or partner of such stockholder
or must be authorized by a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder
to act for such stockholder as proxy at the meeting of stockholders and such person must produce such written instrument or electronic
transmission, or a reliable reproduction of the written instrument or electronic transmission, at the meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For
purposes of this Section&nbsp;1.11, &#8220;public disclosure&#8221; shall include disclosure in a press release reported by the Dow Jones
News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities
and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d)&nbsp;of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Unless
the corporation elects otherwise, a stockholder&#8217;s notice to the corporation of nominations shall be in writing exclusively
(and not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier
service) or by certified or registered mail, return receipt requested, and the corporation shall not be required to accept delivery
of any document not in such written form or so delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notice
of Business at Annual Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At
any annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting.
To be properly brought before an annual meeting, business must be (1)&nbsp;specified in the notice of meeting (or any supplement thereto)
given by or at the direction of the Board of Directors, (2)&nbsp;otherwise properly brought before the meeting by or at the direction
of the Board of Directors, or (3)&nbsp;properly brought before the meeting by a stockholder. For business to be properly brought before
an annual meeting by a stockholder, (i)&nbsp;if such business relates to the nomination of a person for election as a director of the
corporation, the procedures in Section&nbsp;1.11 must be complied with and (ii)&nbsp;if such business relates to any other matter, the
business must constitute a proper matter under Delaware law for stockholder action and the stockholder must (x)&nbsp;have given timely
notice thereof in writing to the Secretary in accordance with the procedures in, and otherwise complied with, Section&nbsp;1.12(b), (y)&nbsp;be
a stockholder of record who is entitled to vote on such business on the date of the giving of such notice and on the record date for the
determination of stockholders entitled to vote at such annual meeting and (z)&nbsp;be entitled to vote at such annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>To
be timely, a stockholder&#8217;s notice must be received in writing by the Secretary at the principal executive office of the corporation
not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year&#8217;s annual meeting; provided, however,
that in the event that the date of the annual meeting is advanced by more than 30 days, or delayed by more than 60 days, from the first
anniversary of the preceding year&#8217;s annual meeting, or if no annual meeting was held or deemed to have been held in the preceding
year, a stockholder&#8217;s notice must be so received not earlier than the 120th day prior to such annual meeting and not later than
the close of business on the later of (x)&nbsp;the 90th day prior to such annual meeting and (y)&nbsp;the tenth day following the day
on which notice of the date of such annual meeting was given or public disclosure of the date of such annual meeting was made, whichever
first occurs. In no event shall the adjournment or postponement of an annual meeting (or the public disclosure thereof) commence a new
time period (or extend any time period) for the giving of a stockholder&#8217;s notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The stockholder&#8217;s notice to the Secretary
shall set forth: (A)&nbsp;as to each matter the stockholder proposes to bring before the annual meeting (1)&nbsp;a brief description of
the business desired to be brought before the annual meeting, (2)&nbsp;the text of the proposal (including the exact text of any resolutions
proposed for consideration and, in the event that such business includes a proposal to amend the by-laws, the exact text of the proposed
amendment), and (3)&nbsp;the reasons for conducting such business at the annual meeting, and (B)&nbsp;as to the stockholder giving the
notice and the beneficial owner, if any, on whose behalf the proposal is being made (1)&nbsp;the name and address of such stockholder,
as they appear on the corporation&#8217;s books, and of such beneficial owner, (2)&nbsp;the class and series and number of shares of stock
of the corporation that are, directly or indirectly, owned, beneficially or of record, by such stockholder and such beneficial owner,
(3)&nbsp;a description of any material interest of such stockholder, such beneficial owner and/or any Stockholder Associated Person in
the business proposed to be brought before the annual meeting, (4)&nbsp;a description of any agreement, arrangement or understanding between
or among such stockholder, such beneficial owner, any Stockholder Associated Person and any other person or persons (including their names)
in connection with the proposal of such business or who may participate in the solicitation of proxies in favor of such proposal, (5)&nbsp;a
description of any agreement, arrangement or understanding (including any derivative or short positions, swaps, profit interests, options,
warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has
been entered into by, or on behalf of, such stockholder, such beneficial owner and/or any Stockholder Associated Person, the effect or
intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of,
such stockholder, such beneficial owner and/or any Stockholder Associated Person with respect to shares of stock of the corporation, (6)&nbsp;any
other information relating to such stockholder, such beneficial owner and/or any Stockholder Associated Person that would be required
to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for the business
proposed pursuant to Section&nbsp;14 of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder, (7)&nbsp;a representation
that such stockholder intends to appear in person or by proxy at the annual meeting to bring such business before the meeting, (8)&nbsp;a
representation that such stockholder, such beneficial owner and/or any Stockholder Associated Person has complied, and will comply, with
all applicable requirements of state law and the Exchange Act with respect to matters set forth in this Section&nbsp;1.12, and (9)&nbsp;a
representation whether such stockholder, such beneficial owner and/or any Stockholder Associated Person intends or is part of a group
that intends (x)&nbsp;to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the corporation&#8217;s
outstanding capital stock required to approve or adopt the proposal (and such representation shall be included in any such proxy statement
and form of proxy) and/or (y)&nbsp;otherwise to solicit proxies or votes from stockholders in support of such proposal (and such representation
shall be included in any such solicitation materials). Not later than 10 days after the record date for the meeting, the information required
by Items (A)(3)&nbsp;and (B)(1)-(6)&nbsp;of the prior sentence shall be supplemented by the stockholder giving the notice to provide updated
information as of the record date. Notwithstanding anything in these by-laws to the contrary, no business shall be conducted at any annual
meeting of stockholders except in accordance with the procedures in this Section&nbsp;1.12; provided that any stockholder proposal that
complies with Rule&nbsp;14a-8 of the proxy rules&nbsp;(or any successor provision) promulgated under the Exchange Act and is to be included
in the corporation&#8217;s proxy statement for an annual meeting of stockholders shall be deemed to comply with the notice requirements
of this Section&nbsp;1.12. Notwithstanding anything herein to the contrary, a stockholder shall not have complied with this Section&nbsp;1.12(b)&nbsp;if
the stockholder, beneficial owner and/or any Stockholder Associated Person solicits or does not solicit, as the case may be, proxies or
votes in support of such stockholder&#8217;s proposal in contravention of the representations with respect thereto required by this Section&nbsp;1.12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
chairman of any annual meeting (and, in advance of any annual meeting, the Board of Directors) shall have the power and duty to determine
whether business was properly brought before the annual meeting in accordance with the provisions of this Section&nbsp;1.12 (including
whether the stockholder, beneficial owner and/or any Stockholder Associated Person did or did not so solicit, as the case may be, proxies
or votes in support of such stockholder&#8217;s proposal in compliance with the representation with respect thereto required by this Section&nbsp;1.12),
and if the chairman (or the Board of Directors) should determine that business was not properly brought before the annual meeting in accordance
with the provisions of this Section&nbsp;1.12, the chairman shall so declare to the meeting and such business shall not be brought before
the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except
as otherwise required by law, nothing in this Section&nbsp;1.12 shall obligate the corporation or the Board of Directors to include in
any proxy statement or other stockholder communication distributed on behalf of the corporation or the Board of Directors information
with respect to any proposal submitted by a stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding
the foregoing provisions of this Section&nbsp;1.12, unless otherwise required by law, if the stockholder (or a qualified representative
of the stockholder) does not appear at the annual meeting to present business, such business shall not be considered, notwithstanding
that proxies in respect of such business may have been received by the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For
purposes of this Section&nbsp;1.12, the terms &#8220;qualified representative of the stockholder&#8221; and &#8220;public disclosure&#8221;
shall have the same meaning as in Section&nbsp;1.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Unless
the corporation elects otherwise, a stockholder&#8217;s notice to the corporation of other business shall be in writing exclusively (and
not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier service)
or by certified or registered mail, return receipt requested, and the corporation shall not be required to accept delivery of any document
not in such written form or so delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Conduct
of Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Unless
otherwise provided by the Board of Directors, meetings of stockholders shall be presided over by the Chairman of the Board, if any, or
in the Chairman&#8217;s absence by the Vice Chairman of the Board, if any, or in the Vice Chairman&#8217;s absence by the Chief Executive
Officer, or in the Chief Executive Officer&#8217;s absence, by the President, or in the President&#8217;s absence by a Vice President,
or in the absence of all of the foregoing persons by a chairman designated by the Board of Directors. The Secretary shall act as secretary
of the meeting, but in the Secretary&#8217;s absence the chairman of the meeting may appoint any person to act as secretary of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Board of Directors may adopt by resolution such rules, regulations and procedures for the conduct of any meeting of stockholders of the
corporation as it shall deem appropriate including, without limitation, such guidelines and procedures as it may deem appropriate regarding
the participation by means of remote communication of stockholders and proxyholders not physically present at a meeting. Except to the
extent inconsistent with such rules, regulations and procedures as adopted by the Board of Directors, the chairman of any meeting of stockholders
shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting and prescribe such rules,
regulations and procedures and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the
meeting. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the chairman of the meeting,
may include, without limitation, the following: (i)&nbsp;the establishment of an agenda or order of business for the meeting; (ii)&nbsp;rules&nbsp;and
procedures for maintaining order at the meeting and the safety of those present; (iii)&nbsp;limitations on attendance at or participation
in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted proxies or such other persons as
shall be determined by the Board of Directors or the chairman of any meeting; (iv)&nbsp;restrictions on entry to the meeting after the
time fixed for the commencement thereof; and (v)&nbsp;limitations on the time allotted to questions or comments by participants. Unless
and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required
to be held in accordance with the rules&nbsp;of parliamentary procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
chairman of the meeting shall announce at the meeting when the polls for each matter to be voted upon at the meeting will be opened and
closed. After the polls close, no ballots, proxies or votes or any revocations or changes thereto may be accepted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In
advance of any meeting of stockholders, the corporation shall appoint one or more inspectors of election to act at the meeting and make
a written report thereof. One or more other persons may be designated as alternate inspectors to replace any inspector who fails to act.
If no inspector or alternate is present, ready and willing to act at a meeting of stockholders, the chairman of the meeting shall appoint
one or more inspectors to act at the meeting. Unless otherwise required by law, inspectors may be officers, employees or agents of the
corporation. Each inspector, before entering upon the discharge of such inspector&#8217;s duties, shall take and sign an oath faithfully
to execute the duties of inspector with strict impartiality and according to the best of such inspector&#8217;s ability. The inspector
shall have the duties prescribed by law and, when the vote is completed, shall make a certificate of the result of the vote taken and
of such other facts as may be required by law. Every vote taken by ballots shall be counted by a duly appointed inspector or duly appointed
inspectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Action by Consent in Lieu of a Meeting</U>. Except as otherwise provided by the Certificate of Incorporation, stockholders of the corporation
may not take any action by consent in lieu of a meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>General
Powers</U>. The business and affairs of the corporation shall be managed by or under the direction of a Board of Directors, who may exercise
all of the powers of the corporation except as otherwise provided by law or the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Number,
Election and Qualification</U>. The number of directors of the corporation shall be the number fixed by, or determined in the manner provided
in, the Certificate of Incorporation. Election of directors need not be by written ballot. Directors need not be stockholders of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Chairman
of the Board; Vice Chairman of the Board</U>. The Board of Directors may appoint from its members a Chairman of the Board and a Vice
Chairman of the Board, neither of whom need be an employee or officer of the corporation. If the Board of Directors appoints a
Chairman of the Board, such Chairman shall perform such duties and possess such powers as are assigned by the Board of Directors
and, if the Chairman of the Board is also designated as the corporation&#8217;s Chief Executive Officer, shall have the powers and
duties of the Chief Executive Officer prescribed in Section&nbsp;3.7 of these by-laws. If the Board of Directors appoints a Vice
Chairman of the Board, such Vice Chairman shall perform such duties and possess such powers as are assigned by the Board of
Directors or the Chairman of the Board. Unless otherwise provided by the Board of Directors, the Chairman of the Board or, in the
Chairman&#8217;s absence, the Vice Chairman of the Board, if any, shall preside at all meetings of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Terms
of Office</U>. Directors shall be elected for such terms and in the manner provided by the Certificate of Incorporation and applicable
law. Accordingly, subject to the rights of holders of any series of Preferred Stock to elect directors, the Board of Directors shall be
and is divided into three classes: Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Each class shall consist, as nearly as may be possible,
of one-third of the total number of directors constituting the entire Board of Directors. The allocation of directors among classes shall
be determined by resolution of the Board of Directors. The term of each director shall continue until the election and qualification of
his or her successor and be subject to his or her earlier death, resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Quorum</U>.
The greater of (a)&nbsp;a majority of the directors at any time in office and (b)&nbsp;one-third of the number of directors established
by the Board of Directors pursuant to the Certificate of Incorporation shall constitute a quorum of the Board of Directors. If at any
meeting of the Board of Directors there shall be less than such a quorum, a majority of the directors present may adjourn the meeting
from time to time without further notice other than announcement at the meeting, until a quorum shall be present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Action
at Meeting</U>. Every act or decision done or made by a majority of the directors present at a meeting duly held at which a quorum is
present shall be regarded as the act of the Board of Directors, unless a greater number is required by law or by the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Removal</U>.
Directors of the corporation may be removed in the manner specified by the Certificate of Incorporation and applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vacancies</U>.
Any vacancy or newly-created directorship on the Board of Directors, however occurring, shall be filled in the manner specified by the
Certificate of Incorporation and applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Resignation</U>.
Any director may resign by delivering a resignation in writing or by electronic transmission to the corporation at its principal executive
office or to the Chairman of the Board, the Chief Executive Officer, the President or the Secretary. Such resignation shall be effective
upon receipt unless it is specified to be effective at some later time or upon the happening of some later event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Regular
Meetings</U>. Regular meetings of the Board of Directors may be held without notice at such time and place as shall be determined from
time to time by the Board of Directors; provided that any director who is absent when such a determination is made shall be given notice
of the determination. A regular meeting of the Board of Directors may be held without notice immediately after and at the same place as
the annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Special
Meetings</U>. Special meetings of the Board of Directors may be held at any time and place designated in a call by the Chairman of the
Board, the Chief Executive Officer, the President, two or more directors, or by one director in the event that there is only a single
director in office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notice
of Special Meetings</U>. Notice of the time and place of any special meeting of directors shall be given to each director by the Secretary
or by the officer or one of the directors calling the meeting. Notice shall be duly given to each director (a)&nbsp;in person, by telephone
or by electronic transmission at least 24&nbsp;hours in advance of the meeting, (b)&nbsp;by delivering written notice by hand, to such
director&#8217;s last known business or home address at least 48&nbsp;hours in advance of the meeting, or (c)&nbsp;by sending written
notice by first-class mail to such director&#8217;s last known business or home address at least 72&nbsp;hours in advance of the meeting.
A notice or waiver of notice of a meeting of the Board of Directors need not specify the purposes of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Meetings
by Conference Communications Equipment</U>. Directors may participate in meetings of the Board of Directors or any committee thereof by
means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each
other, and participation by such means shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Action
by Consent</U>. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may
be taken without a meeting if all members of the Board of Directors or committee, as the case may be, consent to the action in writing
or by electronic transmission. After an action is taken, the consent or consents relating thereto shall be filed with the minutes of proceedings
of the Board of Directors or committee in the same paper or electronic form as the minutes are maintained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Committees</U>.
The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the
corporation with such lawfully delegable powers and duties as the Board of Directors thereby confers, to serve at the pleasure of
the Board of Directors. The Board of Directors may designate one or more directors as alternate members of any committee, who may
replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a
committee, the member or members of the committee present at any meeting and not disqualified from voting, whether or not such
member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the
place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board of
Directors and subject to the provisions of law, shall have and may exercise all the powers and authority of the Board of Directors
in the management of the business and affairs of the corporation and may authorize the seal of the corporation to be affixed to all
papers that may require it. Each such committee shall keep minutes and make such reports as the Board of Directors may from time to
time request. Except as the Board of Directors may otherwise determine, any committee may make rules&nbsp;for the conduct of its
business, but unless otherwise provided by the directors or in such rules, its business shall be conducted as nearly as possible in
the same manner as is provided in these by-laws for the Board of Directors. Except as otherwise provided in the Certificate of
Incorporation, these by-laws, or the resolution of the Board of Directors designating the committee, a committee may create one or
more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all
of the powers and authority of the committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Emergency
by-laws</U>. In the event of any emergency, disaster, catastrophe or other similar emergency condition of a type described in Section&nbsp;110(a)&nbsp;of
the General Corporation Law of the State of Delaware (an &#8220;Emergency&#8221;), notwithstanding any different or conflicting provisions
in the General Corporation Law of the State of Delaware, the Certificate of Incorporation or these by-laws, during such Emergency:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notice</U>.
A meeting of the Board of Directors or a committee thereof may be called by any director, the Chairman of the Board, the Chief Executive
Officer, the President or the Secretary by such means as, in the judgment of the person calling the meeting, may be feasible at the time,
and notice of any such meeting of the Board of Directors or any committee may be given, in the judgment of the person calling the meeting,
only to such directors as it may be feasible to reach at the time and by such means as may be feasible at the time. Such notice shall
be given at such time in advance of the meeting as, in the judgment of the person calling the meeting, circumstances permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Quorum</U>.
The director or directors in attendance at a meeting called in accordance with Section&nbsp;2.16(a)&nbsp;shall constitute a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Liability</U>.
No officer, director or employee acting in accordance with this Section&nbsp;2.16 shall be liable except for willful misconduct. No amendment,
repeal or change to this Section&nbsp;2.16 shall modify the prior sentence with regard to actions taken prior to the time of such amendment,
repeal or change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Titles</U>.
The officers of the corporation shall consist of a Chief Executive Officer, a President, a Secretary, a Treasurer and such other officers
with such other titles as the Board of Directors shall determine, including one or more Vice Presidents, Assistant Treasurers and Assistant
Secretaries. The Board of Directors may appoint such other officers as it may deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Election</U>.
The Chief Executive Officer, President, Treasurer and Secretary shall be elected annually by the Board of Directors at its first meeting
following the annual meeting of stockholders. Other officers may be appointed by the Board of Directors at such meeting or at any other
meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Qualification</U>.
No officer need be a stockholder. Any two or more offices may be held by the same person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Tenure</U>.
Except as otherwise provided by law, the Certificate of Incorporation or these by-laws, each officer shall hold office until such officer&#8217;s
successor is elected and qualified, unless a different term is specified in the resolution electing or appointing such officer, or until
such officer&#8217;s earlier death, resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Resignation
and Removal</U>. Any officer may resign by delivering a resignation in writing or by electronic transmission to the corporation at its
principal executive office or to the Chief Executive Officer, the President or the Secretary. Such resignation shall be effective upon
receipt unless it is specified to be effective at some later time or upon the happening of some later event. Any officer may be removed
at any time, with or without cause, by the Board of Directors. Except as the Board of Directors may otherwise determine, no officer who
resigns or is removed shall have any right to any compensation as an officer for any period following such officer&#8217;s resignation
or removal, or any right to damages on account of such removal, whether such officer&#8217;s compensation be by the month or by the year
or otherwise, unless such compensation is expressly provided for in a duly authorized written agreement with the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vacancies</U>.
The Board of Directors may fill any vacancy occurring in any office for any reason and may, in its discretion, leave unfilled for such
period as it may determine any offices. Each such successor shall hold office for the unexpired term of such officer&#8217;s predecessor
and until a successor is elected and qualified, or until such officer&#8217;s earlier death, resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>President;
Chief Executive Officer</U>. Unless the Board of Directors has designated another person as the corporation&#8217;s Chief Executive Officer,
the President shall be the Chief Executive Officer of the corporation. The Chief Executive Officer shall have general charge and supervision
of the business of the corporation subject to the direction of the Board of Directors, and shall perform all duties and have all powers
that are commonly incident to the office of the chief executive or that are delegated to such officer by the Board of Directors. The President
shall perform such other duties and shall have such other powers as the Board of Directors or the Chief Executive Officer (if the President
is not the Chief Executive Officer) may from time to time prescribe. In the event of the absence, inability or refusal to act of the Chief
Executive Officer or the President (if the President is not the Chief Executive Officer), the Vice President (or if there shall be more
than one, the Vice Presidents in the order determined by the Board of Directors) shall perform the duties of the Chief Executive Officer
and when so performing such duties shall have all the powers of and be subject to all the restrictions upon the Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vice
Presidents</U>. Each Vice President shall perform such duties and possess such powers as the Board of Directors or the Chief Executive
Officer may from time to time prescribe. The Board of Directors may assign to any Vice President the title of Executive Vice President,
Senior Vice President or any other title selected by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Secretary
and Assistant Secretaries</U>. The Secretary shall perform such duties and shall have such powers as the Board of Directors or the Chief
Executive Officer may from time to time prescribe. In addition, the Secretary shall perform such duties and have such powers as are incident
to the office of the secretary, including without limitation the duty and power to give notices of all meetings of stockholders and special
meetings of the Board of Directors, to attend all meetings of stockholders and the Board of Directors and keep a record of the proceedings,
to maintain a stock ledger and prepare lists of stockholders and their addresses as required, to be custodian of corporate records and
the corporate seal and to affix and attest to the same on documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any Assistant Secretary shall perform such duties
and possess such powers as the Board of Directors, the Chief Executive Officer or the Secretary may from time to time prescribe. In the
event of the absence, inability or refusal to act of the Secretary, the Assistant Secretary (or if there shall be more than one, the Assistant
Secretaries in the order determined by the Board of Directors) shall perform the duties and exercise the powers of the Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the absence of the Secretary or any Assistant
Secretary at any meeting of stockholders or directors, the chairman of the meeting shall designate a temporary secretary to keep a record
of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Treasurer
and Assistant Treasurers</U>. The Treasurer shall perform such duties and shall have such powers as may from time to time be assigned
by the Board of Directors or the Chief Executive Officer. In addition, the Treasurer shall perform such duties and have such powers as
are incident to the office of treasurer, including without limitation the duty and power to keep and be responsible for all funds and
securities of the corporation, to deposit funds of the corporation in depositories selected in accordance with these by-laws, to disburse
such funds as ordered by the Board of Directors, to make proper accounts of such funds, and to render as required by the Board of Directors
statements of all such transactions and of the financial condition of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Assistant Treasurers shall perform such duties
and possess such powers as the Board of Directors, the Chief Executive Officer or the Treasurer may from time to time prescribe. In the
event of the absence, inability or refusal to act of the Treasurer, the Assistant Treasurer (or if there shall be more than one, the Assistant
Treasurers in the order determined by the Board of Directors) shall perform the duties and exercise the powers of the Treasurer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Salaries</U>.
Officers of the corporation shall be entitled to such salaries, compensation or reimbursement as shall be fixed or allowed from time to
time by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delegation
of Authority</U>. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent,
notwithstanding any provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Issuance
of Stock</U>. Subject to the provisions of the Certificate of Incorporation, the whole or any part of any unissued balance of the authorized
capital stock of the corporation or the whole or any part of any shares of the authorized capital stock of the corporation held in the
corporation&#8217;s treasury may be issued, sold, transferred or otherwise disposed of by vote of the Board of Directors in such manner,
for such lawful consideration and on such terms as the Board of Directors may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Stock
Certificates; Uncertificated Shares</U>. The shares of the corporation shall be represented by certificates, provided that the Board of
Directors may provide by resolution or resolutions that some or all of any or all classes or series of the corporation&#8217;s stock shall
be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered
to the corporation. Every holder of stock of the corporation represented by certificates shall be entitled to have a certificate, in such
form as may be prescribed by law and by the Board of Directors, representing the number of shares held by such holder registered in certificate
form. Each such certificate shall be signed in a manner that complies with Section&nbsp;158 of the General Corporation Law of the State
of Delaware by or in the name of any two officers of the corporation, each of whom is an authorized officer for this purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each certificate representing shares of stock that
are subject to any restriction on transfer pursuant to the Certificate of Incorporation, these by-laws, applicable securities laws or
any agreement among any number of stockholders or among such holders and the corporation shall have conspicuously noted on the face or
back of the certificate either the full text of the restriction or a statement of the existence of such restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the corporation shall be authorized to issue
more than one class of stock or more than one series of any class, the powers, designations, preferences and relative, participating,
optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such
preferences and/or rights shall be set forth in full or summarized on the face or back of each certificate representing shares of such
class or series of stock, provided that in lieu of the foregoing requirements there may be set forth on the face or back of each certificate
representing shares of such class or series of stock a statement that the corporation will furnish without charge to each stockholder
who so requests a copy of the full text of the powers, designations, preferences and relative, participating, optional or other special
rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Within a reasonable time after the issuance or
transfer of uncertificated shares, the registered owner thereof shall be given a notice, in writing or by electronic transmission, containing
the information required to be set forth or stated on certificates pursuant to Sections 151, 156, 202(a)&nbsp;or 218(a)&nbsp;of the General
Corporation Law of the State of Delaware or, with respect to Section&nbsp;151 of the General Corporation Law of the State of Delaware,
a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences
and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations
or restrictions of such preferences and/or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Transfers</U>.
Shares of stock of the corporation shall be transferable in the manner prescribed by law and in these by-laws. Transfers of shares
of stock of the corporation shall be made only on the books of the corporation or by transfer agents designated to transfer shares
of stock of the corporation. Subject to applicable law, shares of stock represented by certificates shall be transferred only on the
books of the corporation by the surrender to the corporation or its transfer agent of the certificate representing such shares
properly endorsed or accompanied by a written assignment or power of attorney properly executed, and with such proof of authority or
the authenticity of signature as the corporation or its transfer agent may reasonably require. Uncertificated shares may be
transferred by delivery of a written assignment or power of attorney properly executed, and with such proof of authority or the
authenticity of signature as the corporation or its transfer agent may reasonably require. Except as may be otherwise required by
law, the Certificate of Incorporation or these by-laws, the corporation shall be entitled to treat the record holder of stock as
shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with
respect to such stock, regardless of any transfer, pledge or other disposition of such stock until the shares have been transferred
on the books of the corporation in accordance with the requirements of these by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Lost,
Stolen or Destroyed Certificates</U>. The corporation may issue a new certificate of stock or uncertificated shares in place of any previously
issued certificate alleged to have been lost, stolen or destroyed, upon such terms and conditions as the corporation may prescribe, including
the presentation of reasonable evidence of such loss, theft or destruction and the giving of such indemnity and posting of such bond as
the corporation may require for the protection of the corporation or any transfer agent or registrar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Regulations</U>.
The issue, transfer, conversion and registration of shares of stock of the corporation shall be governed by such other regulations as
the Board of Directors may establish.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;V</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENERAL PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Fiscal
Year</U>. Except as from time to time otherwise designated by the Board of Directors, the fiscal year of the corporation shall begin on
the first day of January&nbsp;of each year and end on the last day of December&nbsp;in each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Corporate
Seal</U>. The corporate seal shall be in such form as shall be approved by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Record
Date for Purposes Other Than Stockholder Meetings</U>. In order that the corporation may determine the stockholders entitled to receive
payment of any dividend or other distribution or allotment of any rights, entitled to exercise any rights in respect of any change, conversion
or exchange of stock, or for the purpose of any other lawful action (other than with respect to determining stockholders entitled to notice
of and/or to vote at a meeting of stockholders, which is addressed in Section&nbsp;1.4 of these by-laws), the Board of Directors may fix
a record date, which shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall
not be more than 60 days prior to such action. If no such record date is fixed, the record date for determining stockholders for any such
purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Waiver
of Notice</U>. Whenever notice is required to be given by law, the Certificate of Incorporation or these by-laws, a written waiver signed
by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether provided before, at
or after the time of the event for which notice is to be given, shall be deemed equivalent to notice required to be given to such person.
Neither the business nor the purpose of any meeting need be specified in any such waiver. Attendance of a person at a meeting shall constitute
a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of
the meeting, to the transaction of any business because the meeting is not lawfully called or convened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Voting
of Securities</U>. Except as the Board of Directors may otherwise designate, the Chief Executive Officer, the President, the Secretary
or the Treasurer may waive notice of, vote, or appoint any person or persons to vote, on behalf of the corporation at, and act as, or
appoint any person or persons to act as, proxy or attorney-in-fact for this corporation (with or without power of substitution) at, any
meeting of stockholders or securityholders of any other entity, the securities of which may be held by this corporation, or with respect
to the execution of any written or electronic consent in the name of the corporation as a holder of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Evidence
of Authority</U>. A certificate by the Secretary, or an Assistant Secretary, or a temporary Secretary, as to any action taken by the stockholders,
directors, a committee or any officer or representative of the corporation shall as to all persons who rely on the certificate in good
faith be conclusive evidence of such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certificate
of Incorporation</U>. All references in these by-laws to the Certificate of Incorporation shall be deemed to refer to the Certificate
of Incorporation of the corporation, as amended and/or restated and in effect from time to time, including the terms of any certificate
of designations of any series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>.
Any determination that any provision of these by-laws is for any reason inapplicable, illegal or ineffective shall not affect or invalidate
any other provision of these by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Pronouns</U>.
All pronouns used in these by-laws shall be deemed to refer to the masculine, feminine or neuter, singular or plural, as the identity
of the person or persons may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENTS</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These by-laws may be altered, amended or repealed,
in whole or in part, or new by-laws may be adopted by the Board of Directors or by the stockholders as provided in the Certificate of
Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>tm238578d1_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">THIS REGISTRATION RIGHTS AGREEMENT
(this &#8220;<B>Agreement</B>&#8221;), is made as of the 7<SUP>th </SUP>day of March, 2023, by and among CARISMA Therapeutics Inc., a
Delaware corporation (&#8220;<B>Carisma</B>&#8221;), and each of the investors listed on <U>Schedule A</U> hereto, each of which is referred
to in this Agreement as an &#8220;<B>Investor</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
Carisma is party to that certain Agreement and Plan of Merger and Reorganization, by and among Carisma, Sesen Bio,&nbsp;Inc. (&#8220;<B>Sesen
Bio</B>&#8221;) and Seahawk Merger Sub,&nbsp;Inc. (&#8220;<B>Merger Sub</B>&#8221;), dated as of September&nbsp;20, 2022 (the &#8220;<B>Merger
Agreement</B>&#8221;), pursuant to which Merger Sub will merge with and into Carisma, with Carisma surviving as a wholly-owned subsidiary
of Sesen Bio (the &#8220;<B>Merger</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
following the Merger, Sesen Bio will change its name to Carisma Therapeutics Inc. (&#8220;<B>PubCo</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
Carisma and the Investors are parties to a Subscription Agreement, dated as of September&nbsp;20, 2022 (the &#8220;<B>Subscription Agreement</B>&#8221;),
pursuant to which the Investors, severally and not jointly, are purchasing shares of common stock of Carisma (the &#8220;<B>Shares</B>&#8221;)
immediately prior to the closing of the Merger and subject to the satisfaction or waiver of all conditions to the closing of the Merger
set forth in the Merger Agreement (other than the Closing under the Subscription Agreement and other than those conditions which, by
their nature, are to be satisfied at the closing of the transactions contemplated by the Merger Agreement), which Shares will, upon closing
of the Merger, be exchanged for shares of PubCo&#8217;s common stock, par value $0.001 per share (the &#8220;<B>Common Stock</B>&#8221;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
in connection with the consummation of the transactions contemplated by the Subscription Agreement, and subject to the terms of the Subscription
Agreement, the Parties desire to enter into this Agreement in order to grant certain rights to the Investors as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE,</B></FONT> the parties to this Agreement further agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
For purposes of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Affiliate</B>&#8221;
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common
control with such Person, including without limitation any general partner, managing member, limited partner, officer, director or trustee
of such Person, or any venture capital fund or other investment fund now or hereafter existing that is controlled by one or more general
partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Board
of Directors</B>&#8221; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Company</B>&#8221;
means CARISMA Therapeutics Inc. for all periods prior to closing of the Merger and PubCo for all periods after closing of the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Damages</B>&#8221;
means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the
Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises
out of or is based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any registration statement
of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto;
(ii)&nbsp;an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements
therein not misleading; or (iii)&nbsp;any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates)
of the Securities Act, the Exchange Act, any state securities law, or any rule&nbsp;or regulation promulgated under the Securities Act,
the Exchange Act, or any state securities law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Exchange
Act</B>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Excluded
Registration</B>&#8221; means (i)&nbsp;a registration relating to the sale or grant of securities to employees of the Company or a subsidiary
pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii)&nbsp;a registration relating to an SEC Rule&nbsp;145
transaction; (iii)&nbsp;a registration on any form that does not include substantially the same information as would be required to be
included in a registration statement covering the sale of the Registrable Securities; or (iv)&nbsp;a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Form&nbsp;S&#45;3</B>&#8221;
means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently
adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company
with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Holder</B>&#8221;
means any holder of Registrable Securities who is a party to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Immediate
Family Member</B>&#8221; means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, life partner or similar statutorily-recognized
domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive
relationships, of a natural person referred to herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Initiating
Holders</B>&#8221; means, collectively, Holders who properly initiate a registration request under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Mandatory
Registration Statement</B>&#8221; means a registration statement on Form&nbsp;S-3 (unless the Company is not then eligible to register
for resale the Common Stock on such registration statement, in which case registration shall be on another appropriate form for such
purpose) in satisfaction of the requirements set forth in <U>Subsection 2.1</U> and covering the resale of the Registrable Subscription
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12</FONT>&nbsp;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Permitted
Transferee</B>&#8221; means, with respect to an Investor, an Affiliate of such Investor or any other investment fund or account managed
or advised by the investment manager who acts on behalf of such Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Person</B>&#8221;
means any individual, corporation, partnership, trust, limited liability company, association or other entity<FONT STYLE="color: blue">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Preferred
Stock</B>&#8221; means, collectively, (i)&nbsp;the Series&nbsp;A Preferred Stock, $0.0001 par value per share, of Carisma, (ii)&nbsp;the
Special Voting Preferred Stock, $0.0001 par value per share, of Carisma, (iii)&nbsp;the Series&nbsp;B Preferred Stock, $0.0001 par value
per share, of Carisma, (iv)&nbsp;the Series&nbsp;B Special Voting Preferred Stock, $0.0001 par value per share, of Carisma and (v)&nbsp;for
the avoidance of doubt, any of the Preferred Stock referenced in clauses (i)&nbsp;or (iii)&nbsp;issued upon the exchange of the Class&nbsp;B
Shares, with a nominal value of one tenth of one eurocent (EUR 0.001), or the Class&nbsp;B-1 Shares, with a nominal value of one tenth
of one eurocent (EUR 0.001), of CARISMA Therapeutics S.&agrave; r.l., a soci&eacute;t&eacute; &agrave; responsabilit&eacute; limit&eacute;e.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Registrable
Securities</B>&#8221; means the Registrable Existing Securities and the Registrable Subscription Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Registrable
Existing Securities</B>&#8221; means (i)&nbsp;any shares of Common Stock issued to an Investor in exchange for such Investor&#8217;s
shares of Preferred Stock upon closing of the Merger and (ii)&nbsp;any Common Stock issued as (or issuable upon the conversion or exercise
of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in
replacement of, the shares referenced in clause (i)&nbsp;above; excluding in all cases, however, (a)&nbsp;any Registrable Securities
sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to <U>Subsection 8.1
</U>and (b)&nbsp;any shares for which registration rights have terminated pursuant to <U>Subsection 3.6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Registrable
Subscription Securities</B>&#8221; means (i)&nbsp;any shares of Common Stock issued to an Investor in exchange for the Shares upon closing
of the Merger and (ii)&nbsp;any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security
that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in
clause (i)&nbsp;above; excluding in all cases, however, (a)&nbsp;any Registrable Securities sold or transferred pursuant to a Mandatory
Registration Statement, (b)&nbsp;any Registrable Securities that have been sold or can be sold without restriction pursuant to SEC Rule&nbsp;144
or another similar exemption under the Securities Act and without the requirement to be in compliance with subsection (c)(1)&nbsp;of
SEC Rule&nbsp;144 (or any successor thereto), (c)&nbsp;any Registrable Securities sold by a Person in a transaction in which the applicable
rights under this Agreement are not assigned pursuant to <U>Subsection 8.1</U>, and (d)&nbsp;for the avoidance of doubt, any Shares that
are registered on a Form&nbsp;S-4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Registrable
Securities then outstanding</B>&#8221; means the number of shares of outstanding Common Stock that are Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>SEC</B>&#8221;
means the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>SEC
Rule&nbsp;144</B>&#8221; means Rule&nbsp;144 promulgated by the SEC under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>SEC
Rule&nbsp;145</B>&#8221; means Rule&nbsp;145 promulgated by the SEC under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Securities
Act</B>&#8221; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Selling
Expenses</B>&#8221; means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable
Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel
borne and paid by the Company as provided in <U>Section&nbsp;5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Selling
Securityholder Questionnaire</B>&#8221; means a form of selling securityholder questionnaire as may be reasonably requested by the Company
from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Mandatory
Registration Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Mandatory
Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Statement</U>. The Company shall use its reasonable best efforts to file a Mandatory Registration Statement with the SEC as promptly
as reasonably practicable and in any event within sixty (60) days after the date of this Agreement (the &#8220;<B>Filing Date</B>&#8221;)
to register all of the Registrable Subscription Securities under the Securities Act. The Company shall use its reasonable best efforts
to cause such Mandatory Registration Statement to be declared effective within ninety (90) days following the Filing Date (or, in the
event the staff of the SEC reviews and has written comments to the Mandatory Registration Statement, within one hundred twenty (120)
days following the Filing Date), such efforts to include, without limiting the generality of the foregoing, preparing and filing with
the SEC any financial statements or other information that is required to be filed prior to the effectiveness of such Mandatory Registration
Statement. Such Mandatory Registration Statement shall not include any shares of Common Stock or other securities for the account of
any other holder without the prior written consent of a majority of the Registrable Subscription Securities then held by the Holders
or Permitted Transferees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Filing;
Effectiveness</U>. The Company shall use its reasonable best efforts to keep the Mandatory Registration Statement continuously effective
under the Securities Act for a period up to the earlier of (i)&nbsp;three (3)&nbsp;years from the date of this Agreement and (ii)&nbsp;the
date that all Registrable Subscription Securities covered by such Mandatory Registration Statement have been sold or can be sold without
restriction pursuant to SEC Rule&nbsp;144 or another similar exemption under the Securities Act and without the requirement to be in
compliance with subsection (c)(1)&nbsp;of SEC Rule&nbsp;144 (or any successor thereto) (the &#8220;<B>Effectiveness Period</B>&#8221;).
The Company shall notify the Holders in writing as promptly as reasonably practicable and in any event within three (3)&nbsp;business
days after receiving notification from the SEC that a Mandatory Registration Statement has been declared effective or that a prospectus
used in connection with such Mandatory Registration Statement has been filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rule&nbsp;415;
Cutback</U>. If at any time the SEC takes the position that the offering of some or all of the Registrable Subscription Securities in
the Mandatory Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule&nbsp;415
under the Securities Act (&#8220;<B>Rule&nbsp;415</B>&#8221;) or requires any Holder to be named as an &#8220;underwriter,&#8221; the
Company shall use commercially reasonable efforts to persuade the SEC that the offering contemplated by such Mandatory Registration Statement
is a valid secondary offering and not an offering &#8220;by or on behalf of the issuer&#8221; as defined in Rule&nbsp;415 and that none
of the Holders is an &#8220;underwriter.&#8221; In the event that, despite the Company&#8217;s commercially reasonable efforts and compliance
with the terms of this <U>Subsection&nbsp;2.1(c)</U>, the SEC does not alter its position, the Company shall (i)&nbsp;remove from such
Mandatory Registration Statement such portion of the Registrable Subscription Securities (the &#8220;<B>Cut Back Shares</B>&#8221;) and/or
(ii)&nbsp;agree to such restrictions and limitations on the registration and resale of the Registrable Subscription Securities as the
SEC may require to assure the Company&#8217;s compliance with the requirements of Rule&nbsp;415 (collectively, the &#8220;<B>SEC Restrictions</B>&#8221;);
<U>provided</U>, <U>however</U>, that the Company shall not agree to name any Holder as an &#8220;underwriter&#8221; in such Mandatory
Registration Statement without the prior written consent of such Holder. Any cut-back imposed on the Holders pursuant to this <U>Subsection&nbsp;2.1(c)</U>&nbsp;shall
be allocated among the Holders of Registrable Subscription Securities in proportion (as nearly as practicable) to the number of Registrable
Subscription Securities owned by each Holder or in such proportion as shall be mutually agreed to by all such selling Holders, unless
the SEC Restrictions require or provide otherwise. From and after such date as the Company is able to effect the registration of such
Cut Back Shares, the Company shall use commercially reasonable efforts to file a Mandatory Registration Statement relating to such Cut
Back Shares and to have such Mandatory Registration Statement declared effective by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, it is understood and agreed that a registration statement under the Securities Act may expire pursuant to the rules&nbsp;and
regulations of the SEC after a specified date (currently, in the case of a shelf registration statement pursuant to Rule&nbsp;415 under
the Securities Act, three (3)&nbsp;years following the date it is declared effective by the SEC). It is agreed that any expiration of
a registration statement pursuant to the rules&nbsp;and regulations of the SEC shall not represent a violation or breach of any of the
Company&#8217;s obligations under this <U>Section&nbsp;2</U>; <U>provided</U> that in such case, prior to such expiration time, during
the Effectiveness Period, the Company agrees to use its reasonable best efforts to prepare, file and cause to be declared effective a
replacement Mandatory Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Removal
of Legends</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
connection with any sale, assignment, transfer or other disposition of the Registrable Subscription Securities by a Holder pursuant to
SEC Rule&nbsp;144 or pursuant to any other exemption under the Securities Act such that such Holder acquires freely tradable shares and
upon compliance by the Holder with the requirements of this Agreement, if requested by the Holder, the Company shall cause the transfer
agent for the Common Stock (the &#8220;<B>Transfer Agent</B>&#8221;) to remove any restrictive legends related to the book entry account
holding such Registrable Subscription Securities and make a new, unlegended entry for such book entry Registrable Subscription Securities
sold or disposed of without restrictive legends within two (2)&nbsp;business days of any such request therefor from such Holder, <U>provided
</U>that the Company has timely received from the Holder customary representations and other documentation reasonably acceptable to the
Company in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to receipt from the Holder by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable
to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Registrable Subscription Securities
(i)&nbsp;have been sold or transferred pursuant to an effective registration statement or (ii)&nbsp;have been sold or can be sold without
restriction pursuant to SEC Rule&nbsp;144 or another similar exemption under the Securities Act and without the requirement to be in
compliance with subsection (c)(1)&nbsp;of SEC Rule&nbsp;144 (or any successor thereto) (such earliest date, the &#8220;<B>Effective Date</B>&#8221;),
the Company shall, in accordance with the provisions of this <U>Subsection 2.2</U> and within two (2)&nbsp;business days of any request
therefor from a Holder accompanied by such customary and reasonably acceptable documentation referred to above, (A)&nbsp;deliver to the
Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Registrable Subscription
Securities, and (B)&nbsp;cause its counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such
legends in such circumstances may be effected under the Securities Act if required by the Transfer Agent to effect the removal of such
legend in accordance with the provisions of this Agreement. The Company agrees that following the Effective Date or at such time as such
legend is no longer required under this <U>Subsection 2.2</U>, it will, within two (2)&nbsp;business days of the delivery by a Holder
to the Company or the Transfer Agent of a certificate representing shares issued with a restrictive legend and receipt from the Holder
by the Company and the Transfer Agent of the customary representations and other documentation reasonably acceptable to the Company and
the Transfer Agent in connection therewith that is referred to above, deliver or cause to be delivered to such Holder a certificate representing
such Registrable Subscription Securities (or uncertificated interest therein) that is free from all restrictive and other legends. Registrable
Subscription Securities subject to legend removal hereunder may be transmitted by the Transfer Agent to the Holder by crediting the account
of the Holder&#8217;s prime broker with The Depository Trust Company as directed by such Holder. The Company shall be responsible for
the fees of its Transfer Agent and all fees of The Depository Trust Company associated with such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Demand
Registration Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Demand
Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Form&nbsp;S-3
Demand</U>. If at any time after one hundred eighty (180) days after the effective date of the Merger and if at such time the Company
is eligible to use a Form&nbsp;S-3 registration statement, the Company receives a request from Holders of at least ten percent (10%)
of the Registrable Existing Securities then outstanding that the Company file a Form&nbsp;S-3 registration statement with respect to
outstanding Registrable Existing Securities of such Holders having an anticipated aggregate offering price of at least $5,000,000, then
the Company shall (i)&nbsp;within five (5)&nbsp;days after the date such request is given, give notice thereof (the &#8220;<B>Demand
Notice</B>&#8221;) to all Holders other than the Initiating Holders; and (ii)&nbsp;as promptly as reasonably practicable and in any event
within sixty (60) days after the date such request is given by the Initiating Holders, file a Form&nbsp;S-3 registration statement under
the Securities Act covering all Registrable Existing Securities requested to be included in such registration by any other Holders, as
specified by notice given by each such Holder to the </FONT>Company within twenty (20) days of the date the Demand Notice is given, and
in each case, subject to the limitations of <U>Subsection<FONT STYLE="font-size: 10pt">s 3.1(b)</FONT></U><FONT STYLE="font-size: 10pt">&nbsp;and
<U>3.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this <U>Subsection 3.1</U> a certificate
signed by the Company&#8217;s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially
detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as
long as such registration statement otherwise would be required to remain effective, because such action would (i)&nbsp;materially interfere
with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii)&nbsp;require premature
disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii)&nbsp;render
the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer
taking action with respect to such filing for a period of not more than ninety (90) days after the request of the Initiating Holders
is given; <U>provided</U>, <U>however</U>, that the Company may not invoke this right more than once in any twelve (12) month period;
and <U>provided further</U> that the Company shall not register any securities for its own account or that of any other stockholder during
such ninety (90) day period other than an Excluded Registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Subsection 3.1(a)</U>&nbsp;(i)&nbsp;during
the period that is thirty (30) days before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that
is ninety (90) days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company is actively employing
in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii)&nbsp;if the Company has
effected two (2)&nbsp;registrations pursuant to <U>Subsection 3.1(a)</U>&nbsp;within the twelve (12) month period immediately preceding
the date of such request. A registration shall not be counted as &#8220;effected&#8221; for purposes of this <U>Subsection 3.1(c)</U>&nbsp;until
such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their
request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration
statement pursuant to <U>Section&nbsp;5</U>, in which case such withdrawn registration statement shall be counted as &#8220;effected&#8221;
for purposes of this <U>Subsection 3.1(c)</U>; <U>provided</U> that if such withdrawal is during a period the Company has deferred taking
action pursuant to <U>Subsection 3.1(b)</U>, then the Initiating Holders may withdraw their request for registration and such registration
will not be counted as &#8220;effected&#8221; for purposes of this <U>Subsection 3.1(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Company
Registration</U>. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders
other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely
for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration.
Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to
the provisions of <U>Subsection 3.3</U>, cause to be registered all of the Registrable Existing Securities that each such Holder has
requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by
it under this <U>Subsection 3.2</U> before the effective date of such registration, whether or not any Holder has elected to include
Registrable Existing Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall
be borne by the Company in accordance with <U>Section&nbsp;5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Underwriting
Requirements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If,
pursuant to <U>Subsection 3.1</U>, the Initiating Holders intend to distribute the Registrable Existing Securities covered by their request
by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to <U>Subsection 3.1</U>, and
the Company shall include such information in the Demand Notice. The underwriter(s)&nbsp;will be selected by the Company and shall be
reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder&#8217;s
Registrable Existing Securities in such registration shall be conditioned upon such Holder&#8217;s participation in such underwriting
and the inclusion of such Holder&#8217;s Registrable Existing Securities in the underwriting to the extent provided herein. All Holders
proposing to distribute their securities through such underwriting shall (together with the Company as provided in <U>Subsection 4.1(g)</U>)
enter into an underwriting agreement in customary form with the underwriter(s)&nbsp;selected for such underwriting. Notwithstanding any
other provision of this <U>Subsection 3.3</U>, if the underwriter(s)&nbsp;advise(s)&nbsp;the Initiating Holders in writing that marketing
factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable
Existing Securities that otherwise would be underwritten pursuant hereto, and the </FONT>number of Registrable Existing Securities that
may be included in the underwriting shall be allocated among <FONT STYLE="font-size: 10pt">such Holders of Registrable Existing Securities,
including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Existing Securities owned by
each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; <U>provided</U>, <U>however</U>,
that the number of Registrable Existing Securities held by the Holders to be included in such underwriting shall not be reduced unless
all other securities are first entirely excluded from the underwriting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
connection with any offering involving an underwriting of shares of the Company&#8217;s capital stock pursuant to <U>Subsection 3.2</U>,
the Company shall not be required to include any of the Holders&#8217; Registrable Existing Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity
as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number
of securities, including Registrable Existing Securities, requested by stockholders to be included in such offering exceeds the number
of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with
the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including
Registrable Existing Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Existing Securities requested to be registered can
be included in such offering, then the Registrable Existing Securities that are included in such offering shall be allocated among the
selling Holders in proportion (as nearly as practicable to) the number of Registrable Existing Securities owned by each selling Holder
or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall
(i)&nbsp;the number of Registrable Existing Securities included in the offering be reduced unless all other securities (other than securities
to be sold by the Company) are first entirely excluded from the offering, or (ii)&nbsp;the number of Registrable Existing Securities
included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering. For purposes
of the provision in this <U>Subsection 3.3(b)</U>&nbsp;concerning apportionment, for any selling Holder that is a partnership, limited
liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder,
or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the
benefit of any of the foregoing Persons, shall be deemed to be a single &#8220;selling Holder,&#8221; and any pro rata reduction with
respect to such &#8220;selling Holder&#8221; shall be based upon the aggregate number of Registrable Existing Securities owned by all
Persons included in such &#8220;selling Holder,&#8221; as defined in this sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
purposes of <U>Subsection 3.1</U>, a registration shall not be counted as &#8220;effected&#8221; if, as a result of an exercise of the
underwriter&#8217;s cutback provisions in <U>Subsection 3.3(a)</U>, fewer than fifty percent (50%) of the total number of Registrable
Existing Securities that Holders have requested to be included in such registration statement are actually included.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delay
of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of
this <U>Section&nbsp;3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitations
on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company shall not, without the prior written consent
of the Holders representing a majority of the voting power of the Registrable Existing Securities enter into any agreement with any holder
or prospective holder of any securities of the Company that would (i)&nbsp;provide to such holder or prospective holder the right to
include securities in any registration on other than either a pro rata basis with respect to the Registrable Existing Securities or on
a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable
Existing Securities that they wish to so include or (ii)&nbsp;allow such holder or prospective holder to initiate a demand for registration
of any securities held by such holder or prospective holder; <U>provided</U> that this limitation shall not apply to Registrable Existing
Securities held by any investor of the Company that was a party to that certain Amended and Restated Investors&#8217; Rights Agreement,
dated as of December&nbsp;22, 2020, by and among the Company and the other parties named therein, but is not a party to this Agreement
(each, a &#8220;<B>Series&nbsp;B Investor</B>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination
of Demand Registration Rights</U>. The right of any Holder to request registration or inclusion of Registrable Existing Securities in
any registration pursuant to <U>Section&nbsp;3</U> shall terminate upon the earliest to occur of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">such
time after the date of this Agreement as SEC Rule&nbsp;144 or another similar exemption under the Securities Act is available for the
sale of all of such Holder&#8217;s shares and without the requirement to be in compliance with subsection (c)(1)&nbsp;of SEC Rule&nbsp;144
(or any successor thereto); or</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
third (3rd) anniversary of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Obligations
of the Parties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Obligations
of the Company</U>. Whenever required under this Agreement to effect the registration of any Registrable Securities, the Company shall,
as expeditiously and as reasonably possible:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its reasonable, diligent efforts to
cause such registration statement to become effective and (i)&nbsp;in the case of a Mandatory Registration Statement, keep such Mandatory
Registration Statement effective from the Filing Date to the expiration of the Effectiveness Period, and (ii)&nbsp;in the case of a registration
statement under <U>Section&nbsp;3</U>, upon the request of the Holders of a majority of the Registrable Securities registered thereunder,
keep such registration statement effective for a period of up to one hundred eighty (180) days or, if earlier, until the distribution
contemplated in the registration statement has been completed; <U>provided</U>, <U>however</U>, that in the case of clause (ii)&nbsp;such
one hundred eighty (180) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of
an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">prepare
and file with the SEC such amendments, including post-effective amendments, and supplements to such registration statement, and the prospectus
used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition
of all securities covered by such registration statement and keep such registration statement effective for the period required pursuant
to <U>Subsection 4.1(a)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">promptly
notify the applicable Holders, at any time during which a registration statement is required to be effective pursuant to <U>Subsection
4.1(a)</U>, upon discovery that, or upon the happening of any event as a result of which, the prospectus used in connection with such
registration statement includes an untrue statement of a material fact or omits to state any material fact required to be stated therein
or necessary to make the statements therein not misleading in light of the circumstances then existing, and use reasonable best efforts
to prepare, file with the SEC and furnish to such Holders as promptly as reasonably practicable a supplement to or an amendment of such
prospectus as may be necessary so that the prospectus used in connection with such registration statement shall not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein
not misleading in light of the circumstances then existing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">use
commercially reasonable efforts to (i)&nbsp;prevent the issuance of any stop order or other suspension of effectiveness of any registration
statement and, (ii)&nbsp;if such order is issued, obtain the withdrawal of any such order at the earliest practical moment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">furnish
to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act,
and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities
or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U> that the Company shall
not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless
the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">in
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the underwriter(s)&nbsp;of such offering;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a
national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued
by the Company are then listed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">provide
a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all
such Registrable Securities, in each case not later than the effective date of such registration;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">promptly
make available for inspection by the selling Holders, any underwriter(s)&nbsp;participating in any disposition pursuant to such registration
statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial
and other records, pertinent corporate documents, and properties of the Company, and cause the Company&#8217;s officers, directors, employees,
and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or
agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct
appropriate due diligence in connection therewith;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">promptly
notify each selling Holder, after the Company receives notice thereof, of the time when such registration statement has been declared
effective or a supplement to any prospectus forming a part of such registration statement has been filed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">after
such registration statement becomes effective, promptly notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">promptly
notify the applicable Holders in writing, if at any time during which a registration statement is required to be effective pursuant to
<U>Subsection 4.1(a)</U>, the Company does not satisfy the conditions specified in Rule&nbsp;172 under the Securities Act and, as a result
thereof, such Holders are required to make available a prospectus in connection with any disposition of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In addition, the Company shall ensure that, at all
times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become
effective, its insider trading policy shall provide that the Company&#8217;s directors may implement a trading program under Rule&nbsp;10b5-1
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Obligations
of the Holders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">It
shall be a condition precedent to the obligations of the Company to take any action pursuant to this Agreement with respect to the Registrable
Securities of any selling Holder that such Holder shall furnish in writing to the Company (i)&nbsp;a Selling Securityholder Questionnaire
and (ii)&nbsp;any other information regarding itself, the Registrable Securities held by it, and the intended method of disposition of
such Registrable Securities as is reasonably required to effect the registration of such Holder&#8217;s Registrable Securities. Such
Holder shall execute such documents in connection with such registration as the Company may reasonably request. At least ten (10)&nbsp;business
days prior to the first anticipated filing date of Mandatory Registration Statement, the Company shall notify each Holder of Registrable
Subscription Securities of the information the Company requires from such Holder. Such Holder shall provide such information to the Company
at least two (2)&nbsp;business days prior to the first anticipated filing date of such Mandatory Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Holder agrees to cooperate with the Company, promptly furnish information to the Company and complete and execute such documents in connection
with the preparation and filing of a registration statement hereunder, unless such Holder has notified the Company in writing of its
election to exclude all of its Registrable Securities from such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Holder agrees that, upon receipt of any notice from the Company of the happening of an event pursuant to <U>Section&nbsp;4.1(c)</U>,
such Holder will promptly discontinue disposition of Registrable Securities pursuant to any registration statement covering such Registrable
Securities, until the Holder is advised by the Company that such dispositions may again be made. Each Holder further agrees that it shall
sell its Registrable Securities in accordance with the Plan of Distribution set forth in the applicable prospectus. The Company may provide
appropriate stop orders to enforce the provisions of this paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Expenses
of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications
pursuant to <U>Section&nbsp;2</U> or <U>Section&nbsp;3</U>, including all registration, filing, and qualification fees; printers&#8217;
and accounting fees; fees and disbursements of counsel for the Company; and, in the case of <U>Section&nbsp;3</U>, the reasonable fees
and disbursements, not to exceed $50,000, of one counsel for the selling Holders (&#8220;<B>Selling Holder Counsel</B>&#8221;), shall
be borne and paid by the Company; <U>provided</U>, <U>however</U>, that the Company shall not be required to pay for any expenses of
any registration proceeding begun pursuant to <U>Section&nbsp;3</U> if the registration request is subsequently withdrawn at the request
of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses
pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders
of a </FONT>majority of the Registrable Securities agree to forfeit their right to one registration pursuant to <U>Subsection 3.1(a)</U><FONT STYLE="font-size: 10pt">,
as the case may be; <U>provided further</U> that if, at the time of such withdrawal, the Holders shall have learned of a material adverse
change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn
the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses
and shall not forfeit their right to one registration pursuant to <U>Subsection 3.1(a)</U>. All Selling Expenses relating to Registrable
Securities registered pursuant to <U>Section&nbsp;2</U> or <U>Section&nbsp;3</U> shall be borne and paid by the Holders pro rata on the
basis of the number of Registrable Securities registered on their behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reports
Under Exchange Act</U>. With a view to making available to the Holders the benefits of SEC Rule&nbsp;144 and any other rule&nbsp;or regulation
of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a
registration on Form&nbsp;S&#45;3, the Company shall: (i)&nbsp;make and keep available adequate current public information, as those
terms are understood and defined in SEC Rule&nbsp;144; (ii)&nbsp;use commercially reasonable efforts to file with the SEC in a timely
manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and (iii)&nbsp;furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (a)&nbsp;to the extent accurate, a written
statement by the Company that it has complied with the reporting requirements of SEC Rule&nbsp;144, the Securities Act, and the Exchange,
or that it qualifies as a registrant whose securities may be resold pursuant to Form&nbsp;S&#45;3 (at any time the Company so qualifies);
and (b)&nbsp;such other information as may be reasonably requested in availing any Holder of any rule&nbsp;or regulation of the SEC that
permits the selling of any such securities without registration or pursuant to Form&nbsp;S&#45;3 (at any time the Company so qualifies
to use such form).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification</U>.
If any Registrable Securities are included in a registration statement under this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
by Company</U>. To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members,
officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined
in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the
Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person,
or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement
contained in this <U>Subsection 7.1</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement
is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for
any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with
written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly
for use in connection with such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
by Holders</U>. To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the
Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls
the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the
Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter
or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions
made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in
connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal
or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages
may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this <U>Subsection 7.2</U> shall
not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder,
which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder
by way of indemnity or contribution under <U>Subsections 7.2</U> and <U>7.4</U> exceed the proceeds from the offering received by such
Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Action
against Parties; Notification</U>. Promptly after receipt by an indemnified party under this <U>Section&nbsp;7</U> of notice of the commencement
of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party
will, if a claim in respect thereof is to be made against any indemnifying party under this <U>Section&nbsp;7</U>, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent
the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume
the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all
other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel,
with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained
by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any
other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time
of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this <U>Section&nbsp;</U>7,
to the extent that such failure materially prejudices the indemnifying party&#8217;s ability to defend such action. The failure to give
notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under
this <U>Section&nbsp;</U>7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Contribution</U>.
To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i)&nbsp;any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Section&nbsp;7</U> but it
is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time
to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the
fact that this <U>Section&nbsp;</U>7 provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act may
be required on the part of any party hereto for which indemnification is provided under this <U>Section&nbsp;7</U>, then, and in each
such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject
(after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party
and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability,
or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified
party and the parties&#8217; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement
or omission; provided, however, that, in any such case (x)&nbsp;no Holder will be required to contribute any amount in excess of the
public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and
(y)&nbsp;no Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) will
be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no
event shall a Holder&#8217;s liability pursuant to this <U>Subsection 7.4</U>, when combined with the amounts paid or payable by such
Holder pursuant to <U>Subsection 7.2</U>, exceed the proceeds from the offering received by such Holder (net of any Selling Expenses
paid by such Holder), except in the case of willful misconduct or fraud by such Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.
Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement
entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this <U>Section&nbsp;7</U> shall survive the completion of any offering of Registrable Securities in
a registration under this Agreement, and otherwise shall survive the termination of this Agreement or any provision(s)&nbsp;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a Permitted Transferee;
<U>provided</U>, <U>however</U>, that (x)&nbsp;the Company is, within a reasonable time after such transfer, furnished with written notice
of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and
(y)&nbsp;such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions
of this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors
and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and </FONT>permitted assignees any rights, remedies, obligations or liabilities under
or by reason of this Agreement, except as expressly provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict of law principles
that would result in the application of any law other than the law of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records
Act or other applicable law, <I>e.g.</I>, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed
to have been duly and validly delivered and be valid and effective for all purposes<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Titles
and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or (i)&nbsp;personal delivery to the party to be notified; (ii)&nbsp;when sent, if sent by electronic
mail or facsimile during the recipient&#8217;s normal business hours, and if not sent during normal business hours, then on the recipient&#8217;s
next business day; (iii)&nbsp;five (5)&nbsp;days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv)&nbsp;one (1)&nbsp;business day after the business day of deposit with a nationally recognized overnight courier, freight
prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties
at their address as set forth on the signature page&nbsp;or <U>Schedule A</U> hereto, or to the principal office of the Company and to
the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number or address as subsequently
modified by written notice given in accordance with this <U>Subsection 8.5</U>. If notice is given to the Company, a copy (which shall
not constitute notice) shall also be sent to Wilmer Cutler Pickering Hale and Dorr LLP, 7 World Trade Center, 250 Greenwich Street, New
York, NY 10007, Attention: Brian A. Johnson,&nbsp;Esq., and if notice is given to Stockholders, a copy shall also be given to (i)&nbsp;Stinson
LLP, 1201 Walnut Street, Suite&nbsp;2900, Kansas City, MO 64106, Attention: Jack Bowling, (ii)&nbsp;Fenwick&nbsp;&amp; West LLP, 902
Broadway, New York, NY 10010, Attention: Ian Goldstein, Esq, and (iii)&nbsp;Orrick Herrington&nbsp;&amp; Sutcliffe LLP, 51 West 52nd
Street, New York, NY 10019-6142, Attention: Stephen Thau,&nbsp;Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendments
and Waivers</U>. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may
be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of
(a)&nbsp;the Company, (b)&nbsp;the holders of a majority of the Registrable Securities then outstanding; <U>provided</U> that (i)&nbsp;no
provision of <U>Section&nbsp;2</U> may be amended, modified or terminated or the observance of any term waived without the written consent
of the holders of a majority of the Registrable Subscription Securities and (ii)&nbsp;no provision of <U>Section&nbsp;3</U> may be amended,
modified or terminated or the observance of any term waived without the written consent of the holders of a majority of the Registrable
Existing Securities; <U>provided further</U> that any provision hereof may be waived by any waiving party on such party&#8217;s own behalf,
without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended, modified or terminated and
the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless
such amendment, modification, termination, or waiver applies to all Investors in the same fashion. Notwithstanding the foregoing, <U>Schedule
A</U> hereto may be amended by the Company from time to time (i)&nbsp;to add Permitted Transferees of any Registrable Securities in compliance
with the terms of this Agreement without the consent of the other parties and (ii)&nbsp;to add any Series&nbsp;B Investor who becomes
a party to this Agreement and is deemed to be an &#8220;Investor&#8221; for all purposes hereunder in accordance with <U>Section&nbsp;8.9
</U>without the consent of the other parties. The Company shall give prompt notice of any amendment, modification or termination hereof
or waiver hereunder to any applicable party hereto that did not consent in writing to such amendment, modification, termination, or waiver.
Any amendment, modification, termination, or waiver effected in accordance with this <U>Subsection 8.6</U> shall be binding on all parties
hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision
of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term,
condition, or provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid,
illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent
permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Aggregation
of Stock</U>. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining
the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any
manner they deem appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Additional
Investors</U>. Notwithstanding anything to the contrary contained herein, at the option of the Company, any Series&nbsp;B Investor may
become a party to this Agreement by executing and delivering an additional counterpart signature page&nbsp;to this Agreement, and thereafter
shall be deemed an &#8220;Investor&#8221; for all purposes hereunder. No action or consent by the Investors shall be required for such
joinder to this Agreement by such Series&nbsp;B Investor, so long as such Series&nbsp;B Investor has agreed in writing to be bound by
all of the obligations as an &#8220;Investor&#8221; hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement
among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof
existing between the parties is expressly canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Dispute
Resolution</U>. The parties (a)&nbsp;hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of the State
of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action
or other proceeding arising out of or based upon this Agreement, (b)&nbsp;agree not to commence any suit, action or other proceeding
arising out of or based upon this Agreement except in the state courts of the State of Delaware or the United States District Court for
the District of Delaware, and (c)&nbsp;hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such
suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property
is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue
of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">Waiver
of Jury Trial</FONT>: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF
THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS
INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY&nbsp;BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF
THIS TRANSACTION,&nbsp;INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND
ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION&nbsp;HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS
WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER
WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL
COUNSEL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delays
or Omissions</U>. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach
or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting
party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default
thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of Page&nbsp;Intentionally Left Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>CARISMA THERAPEUTICS INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ Steven Kelly</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>Steven Kelly</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Chief Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>Pictet Thematic Private Equity, SICAV-RAIF &#8211;<BR>
  Pictet Thematic Private Equity &#8211; Health Fund I</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Christophe Vasselin</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Christophe Vasselin</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Assistant Vice-President</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Julia Jeliazkov</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>Julia Jeliazkov</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Head of Indirect Investment Services</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>HEALTHCAP VII LP</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">by its general partner HealthCap VII GP SA</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Dag Richter</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Dag Richter</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Fabrice Bernhard</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>Fabrice Bernhard</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>General Manager</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>ABBVIE BIOTECHNOLOGY LTD.</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Arthur C. Price</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Arthur C. Price</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>WELLINGTON PARTNERS LIFE SCIENCES V GMBH&nbsp;&amp; CO. KG</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">c/o Wellington Partners Life Sciences Venture<BR>
  Capital Management GmbH</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Dr.&nbsp;Regina Hodits</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Dr.&nbsp;Regina Hodits</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Managing Partner</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>SYMBIOSIS II, LLC</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Chidozie Ugwumba</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Chidozie Ugwumba</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Managing Partner</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ John S. Swartley</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">John S. Swartley</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Associate Vice Provost for Research and Managing Director for the Penn Center for Innovation</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>MRL VENTURES FUND, LLC</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Peter Dudek</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Peter Dudek</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Partner</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>AJU LIFE SCIENCE 3.0 VENTURE FUND</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Ji-won Kim</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Ji-won Kim</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>LIVZON INTERNATIONAL VENTURES I</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Yanggang Tang</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Yanggang Tang</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>b-to-v Partners S.&agrave; r.l.</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Florian Schweitzer</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Florian Schweitzer</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Managing Director</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/  Christian Schuetz</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>Dr.&nbsp;Christian Schuetz</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Managing Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>AGENT CAPITAL FUND I LP</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">By: Agent Capital Fund I GP, LLC, its General Partner</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Geeta Vemuri</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Dr.&nbsp;Geeta Vemuri</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Managing Member</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>TPG BIOTECHNOLOGY PARTNERS V, L.P.</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Ken Murphy</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Ken Murphy</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Chief Operating Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>4BIO VENTURES FUND II LP</B></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">Represented by its general partner <BR>
  4BIO Ventures II GP Limited, <BR>
  itself represented by its Director</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Andrew Kozlov</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%"></TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Andrew Kozlov</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD></TD>
  <TD>Title:</TD>
  <TD>Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Investors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>tm238578d1_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONTINGENT
VALUE RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS CONTINGENT VALUE RIGHTS
AGREEMENT, dated as of March&nbsp;7, 2023 (this &ldquo;<B><I>Agreement</I></B>&rdquo;), is entered into by and among Sesen Bio,&nbsp;Inc.,
a Delaware corporation (&ldquo;<B><I>Parent</I></B>&rdquo;), and Computershare Inc. (&ldquo;<B><I>Computershare</I></B>&rdquo;) and its
affiliate, Computershare Trust Company, N.A., together, as the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Parent, Seahawk
Merger Sub,&nbsp;Inc., a Delaware corporation (&ldquo;<B><I>Merger Sub</I></B>&rdquo;), and CARISMA Therapeutics Inc., a Delaware corporation
(the &ldquo;<B><I>Company</I></B>&rdquo;), have entered into an Agreement and Plan of Merger and Reorganization, dated as of September&nbsp;20,
2022 (as it may be amended or supplemented from time to time pursuant to the terms thereof, the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;),
pursuant to which Merger Sub will merge with and into the Company, with the Company surviving the Merger as a subsidiary of Parent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to the
Merger Agreement, Parent has agreed to provide to the holders of record of Parent&rsquo;s common stock, par value $0.001 per share (&ldquo;<B><I>Parent
Common Stock</I></B>&rdquo;), immediately prior to the Effective Time, the right to receive certain contingent cash payments, on the
terms and subject to the conditions hereinafter described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the consummation of the transactions referred to above, Parent and the Rights Agent agree, for the proportionate
benefit of all Holders (as hereinafter defined), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>DEFINITIONS;
CERTAIN RULES OF CONSTRUCTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>1.1</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Definitions</U>.
Capitalized terms used but not otherwise defined herein will have the meanings ascribed to them in the Merger Agreement, unless expressly
set forth otherwise herein. As used in this Agreement, the following terms will have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Acquiror</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Acquisition</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Acting Holders</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.3(d)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Affiliate</I></B>&rdquo;
of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such Person. The term &ldquo;control&rdquo; (including the terms &ldquo;controlled by&rdquo; and &ldquo;under
common control with&rdquo;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Agreement</I></B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Asset Disposition
Proceeds</I></B>&rdquo; means, without duplication, any and all consideration of any kind that is paid to Parent, or is received by,
Parent or any of its Affiliates during the CVR Term in respect of an Asset Disposition, if any. The value of any securities (whether
debt or equity) or other non-cash property constituting Asset Disposition Proceeds shall be determined as follows: (A)&nbsp;the value
of securities for which there is an established public market shall be equal to the volume weighted average of their closing market prices
for the five (5)&nbsp;trading days ending the day prior to the date of payment to, or receipt by, Parent or its relevant Affiliate, and
(B)&nbsp;the value of securities that have no established public market and the value of consideration that consists of other non-cash
property, shall be the fair market value thereof as of the date of payment to, or receipt by, Parent or its relevant Affiliate. Asset
Disposition Proceeds shall be deemed to not include proceeds arising out of a Parent Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B><I>Assignee</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Board of Directors</I></B>&rdquo;
means the board of directors of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Board Resolution</I></B>&rdquo;
means a copy of the resolution(s)&nbsp;certified by the secretary or an assistant secretary (or other comparable officer) of Parent that
have been duly adopted by the Board of Directors and are in full force and effect on the date of such approval, and delivered to the
Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Business Day</I></B>&rdquo;
means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be
closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Company</I></B>&rdquo;
has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Computershare</I></B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Payment</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Payment
Amount</I></B>&rdquo; means, with respect to each Holder, an amount equal to (a)&nbsp;(i)&nbsp;the applicable Total Payment Amount, less
(ii)&nbsp;applicable accrued and documented Permitted Deductions, as calculated in accordance with GAAP, divided by (b)&nbsp;the total
number of CVRs and then multiplied by the total number of CVRs held by such Holder as reflected on the CVR Register (rounded down to
the nearest whole cent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Register</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Sale Assets</I></B>&rdquo;
means any and all assets, tangible and intangible, including, without limitation, patents, patent applications, know-how, trade secrets
and other intellectual property rights, data, documentation, agreements and licenses, inventory related to Vicineum<SUP>TM</SUP>, also
known as VB4-845, which Parent or any of its subsidiaries owned or had rights to, as of immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVR Term</I></B>&rdquo;
means the period beginning on the date hereof and ending on the earlier of (a)&nbsp;the final CVR Payment with respect to any Roche Payment
Amount and Asset Disposition Proceeds, as applicable, being delivered to each Holder in accordance with <U>Section&nbsp;2.4 </U>of this
Agreement or (b)&nbsp;March&nbsp;31, 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>CVRs</I></B>&rdquo;
means the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Disposition</I></B>&rdquo;
means the sale, license, transfer, disposition or other monetizing event of any CVR Sale Assets, in each case (i)&nbsp;during the CVR
Term and (ii)&nbsp;in a transaction identified by Parent&rsquo;s financial advisor who was engaged as of the Effective Time for the purpose
of identifying and proposing a potential Disposition transaction to Parent. For clarity, a Disposition constitutes an Asset Disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>DTC</I></B>&rdquo;
means The Depository Trust Company or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Funds</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Holder</I></B>&rdquo;
means a Person in whose name a CVR is registered in the CVR Register at the applicable time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Merger Agreement</I></B>&rdquo;
has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Merger Sub</I></B>&rdquo;
has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Officer&rsquo;s
Certificate</I></B>&rdquo; means a certificate signed by the chief executive officer, president, chief financial officer, any vice president,
the controller, the treasurer or the secretary, in each case of Parent, in his or her capacity as such an officer, and delivered to the
Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Parent</I></B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Parent Change
of Control</I></B>&rdquo; means a merger, consolidation, business combination or other similar transaction involving Parent or its subsidiaries
or a sale of all or substantially all of the assets or a majority of the equity securities of Parent; provided that Parent Change of
Control shall not include such a transaction if at the time of such transaction the only remaining non-cash assets held by Parent are
the Potentially Transferable Assets. For clarity, the term Asset Disposition as used in this Agreement shall be deemed to not include
any Parent Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Parent Common
Stock</I></B>&rdquo; has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Permitted Deductions</I></B>&rdquo;
means the following costs or expenses, without duplication (as approved by the Board of Directors, including, if applicable, the Parent
Designee (as defined in the Merger Agreement)):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
applicable Tax (including any unreimbursed applicable value added or sales tax) imposed on the Total Payment Amount and payable by Parent
or any of its Affiliates to any tax authority and, without duplication, any income or other similar Taxes payable by Parent or any of
its Affiliates that would not have been incurred by Parent or any of its Affiliates but for the Total Payment Amount; provided that,
for purposes of calculating income Taxes incurred by Parent and its Affiliates in respect of the Total Payment Amount, any such income
Taxes shall be computed after reduction for any net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent
or its subsidiaries (owned prior to the Merger) as of the Closing Date that are available to the maximum extent permitted by law to offset
such gain after taking into account any limits on the usability of such attributes, including under Section&nbsp;382 of the Code, in
each case, as reasonably determined by a nationally recognized tax advisor (and for the sake of clarity such income taxes shall be calculated
without taking into account any net operating losses or other Tax attributes generated by Parent or its subsidiaries after the Closing
Date or any Tax attributes of the Company, whether generated before or after the Closing Date), assuming for this purpose that (i)&nbsp;the
only item of gross income of Parent and its subsidiaries is the Total Payment Amount (for the avoidance of doubt, assuming that the Total
Payment Amount is taxable in the hands of Parent or its subsidiaries no later than the taxable year that includes the corresponding CVR
Payment), and (ii)&nbsp;the net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries
shall only include any net operating loss carryforwards or other Tax attributes (including Tax credits) of Parent or its subsidiaries
(owned prior to the Merger) existing as of immediately prior to the Merger for U.S. federal income tax purposes and applicable state
and local income tax purposes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
reasonable and documented out-of-pocket expenses incurred by Parent or any of its Affiliates in respect of its performance of this Agreement
following the Effective Time, losses incurred and paid by Parent or any of its Affiliates following the Effective Time arising out of
any Legal Proceeding relating to or in connection with (i)&nbsp;an Asset Disposition, (ii)&nbsp;Parent&rsquo;s, Roche&rsquo;s or any
of their respective Affiliates&rsquo; obligations under the Roche Agreement or (iii)&nbsp;otherwise with respect to the Total Payment
Amount; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liabilities that were ascertainable prior to or at the Effective Time which Parent reasonably and in good faith determines should have
been, but were not, deducted from &ldquo;Net Cash&rdquo; (as defined in the Merger Agreement), in connection with the Closing of the
Merger, to the extent that deduction of such Liabilities would have resulted in a change in the Exchange Ratio under the Merger Agreement
were such amounts properly deducted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that no Permitted Deductions shall be
deducted to the extent they were otherwise deducted from the calculation of Net Cash (as defined in the Merger Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Permitted Transfer</I></B>&rdquo;
means a transfer of CVRs: (a)&nbsp;on death of a Holder by will or intestacy; (b)&nbsp;by instrument to an inter vivos or testamentary
trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (c)&nbsp;pursuant to a court order; (d)&nbsp;made
by operation of law (including a consolidation or merger) or without consideration in connection with the dissolution, liquidation or
termination of any corporation, limited liability company, partnership or other entity; (e)&nbsp;in the case of CVRs held in book-entry
or other similar nominee form, from a nominee to a beneficial owner (through an intermediary if applicable) or from a nominee to another
nominee for the same beneficial owner, to the extent allowable by DTC; (f)&nbsp;a transfer from a participant&rsquo;s account in a tax-qualified
employee benefit plan to the participant or to such participant&rsquo;s account in a different tax-qualified employee benefit plan or
to a tax-qualified individual retirement account for the benefit of such participant; (g)&nbsp;to Parent or its Affiliates for any or
no consideration; or (h)&nbsp;as provided in <U>Section&nbsp;2.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Person</I></B>&rdquo;
means any natural person, corporation, limited liability company, trust, unincorporated association, partnership, joint venture or other
entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Record Time</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.3(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Rights Agent</I></B>&rdquo;
means the Rights Agent named in the Preamble, until a successor Rights Agent will have become such pursuant to the applicable provisions
of this Agreement, and thereafter &ldquo;Rights Agent&rdquo; will mean such successor Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Roche</I></B>&rdquo;
means the collective reference to F. Hoffman-La Roche Ltd and Hoffmann La Roche Inc. or its successors or any of its or their respective
Affiliates; provided, that neither Chugai Pharmaceutical Co., Ltd, a Japanese corporation (&ldquo;<B><I>Chugai</I></B>&rdquo;) nor its
subsidiaries (if any) shall be deemed as Affiliates of Roche unless Roche provides written notice to Parent of its desire to include
Chugai or its respective subsidiaries (as applicable) as Affiliate(s)&nbsp;of Roche.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Roche Agreement</I></B>&rdquo;
means that certain Asset Purchase Agreement, dated as of July&nbsp;15, 2022, by and among F. Hoffman-La Roche Ltd, Hoffmann La Roche
Inc. and Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Roche Payment
Amount</I></B>&rdquo; means the thirty million dollar ($30,000,000) milestone payment to be made by Roche to Parent upon the initiation
of a phase III clinical study in diabetic macular disorder with the compound known as &ldquo;EBI-031&rdquo; during the CVR Term, as set
forth in Section&nbsp;11.1 of the Roche Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Third Party</I></B>&rdquo;
means any Person other than Parent, Rights Agent or their respective Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Total Payment
Amount</I></B>&rdquo; means, as of any applicable time of determination, any Asset Disposition Proceeds plus any Roche Payment Amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>1.2</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rules&nbsp;of
Construction</U>. Except as otherwise explicitly specified to the contrary, (a)&nbsp;whenever the context requires, the singular number
shall include the plural, and vice versa; (b)&nbsp;the masculine gender shall include the feminine gender and neuter genders, the feminine
gender shall include the masculine and neuter genders, and the neuter genders shall include masculine and feminine genders; (c)&nbsp;the
word &ldquo;extent&rdquo; in the phrase &ldquo;to the extent&rdquo; means the degree to which a subject or other thing extends, and does
not simply mean &ldquo;if&rdquo;; (d)&nbsp;the word &ldquo;including&rdquo; (in its various forms) means &ldquo;including without limitation&rdquo;;
(e)&nbsp;references to a &ldquo;Section&rdquo; means a Section&nbsp;of this Agreement unless another agreement is specified; (f)&nbsp;references
to a particular statute or regulation include all rules&nbsp;and regulations thereunder and any predecessor or successor statute, rules&nbsp;or
regulation, in each case as amended or otherwise modified from time to time; (g)&nbsp;words in the singular or plural form include the
plural and singular form, respectively; (h)&nbsp;references to a particular Person include such Person&rsquo;s successors and assigns
to the extent not prohibited by this Agreement; (i)&nbsp;the word &ldquo;or&rdquo; shall not be exclusive (i.e., &ldquo;or&rdquo; shall
be deemed to mean &ldquo;and/or&rdquo;) unless the subject of the conjunction are mutually exclusive; and (j)&nbsp;all references to
dollars or &ldquo;$&rdquo; refer to United States dollars. For clarity, the parties agree that the phrase &ldquo;materially adverse&rdquo;
when used in this Agreement with respect to the Holders includes any amendment or other action, as applicable, that does or would be
reasonably expected to reduce, eliminate, or materially delay the Roche Payment Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>CONTINGENT
VALUE RIGHTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>2.1</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>CVRs;
Appointment of Rights Agent.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Holder is entitled to one CVR in the form of a dividend for each share of Parent Common Stock held by such Holder as of the Record Time.
The CVRs represent the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement. The
initial Holders will be the holders of Parent Common Stock as of immediately prior to the Effective Time, and a list of the initial Holders
shall be furnished to the Rights Agent by or on behalf of Parent in accordance with <U>Section&nbsp;4.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
hereby appoints the Rights Agent to act as rights agent for Parent as contemplated hereby in accordance with the express terms and conditions
set forth in this Agreement (and no implied terms or conditions), and the Rights Agent hereby accepts such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
intends to treat the issuance of the CVRs as a distribution of property by Parent to the holders of Parent Common Stock for U.S. federal
income tax purposes. Consistent with such intended tax treatment, Parent will timely send Forms 1099-DIV to all Holders notifying them
of the portion of the CVR value that is a nondividend distribution (or a dividend to the extent of Parent&rsquo;s earnings and profits)
for U.S. federal income tax purposes, and take all necessary steps to file its tax returns and any information statements consistent
with such tax treatment. Parent will determine, in consultation with and with the consent of the Parent Designee, the fair market value
of the CVRs in connection with the issuance and Parent will utilize such fair market value for purposes of all tax reporting (including
on Forms 1099-DIV) with respect to the CVR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2.2</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Nontransferable</U>.
The CVRs shall not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or
in part, other than through a Permitted Transfer. Any attempted sale, assignment, transfer, pledge, encumbrance, transfer or disposition,
in whole or in part, that is not a Permitted Transfer will be void <I>ab initio </I>and of no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2.3</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Certificate; Registration; Registration of Transfer; Change of Address</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
CVRs will not be evidenced by a certificate or other instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Rights Agent will create and keep a register (the &ldquo;<B><I>CVR Register</I></B>&rdquo;) for the purpose of identifying the Holders
and registering CVRs and transfers of CVRs as permitted herein. The CVR Register will be created, and CVRs will be distributed, pursuant
to written instructions to the Rights Agent from Parent. The CVR Register will initially show one position for Cede&nbsp;&amp; Co. representing
all the CVRs provided to the holders of shares of Parent Common Stock held as of immediately prior to the Effective Time. The Rights
Agent will have no responsibility whatsoever directly to the street name holders or DTC participants with respect to transfers of CVRs
unless and until such CVRs are transferred into the name of such street name holders or DTC participants in accordance with <U>Section&nbsp;2.2
</U>of this Agreement. With respect to any payments to be made under <U>Section&nbsp;2.4(a)</U>&nbsp;below, the Rights Agent will accomplish
the payment to any former street name holders of shares of Parent Common Stock by sending one lump-sum payment to DTC. The Rights Agent
will have no responsibilities whatsoever with regard to the distribution of payments by DTC to such street name holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the restrictions on transferability set forth in <U>Section&nbsp;2.2</U>, every request made to transfer a CVR must be in writing
and accompanied by a written instrument of transfer and other reasonably requested documentation in form reasonably satisfactory to the
Rights Agent, duly executed by the Holder thereof or the Holder&rsquo;s attorney duly authorized in writing, personal representative
or survivor and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the
Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form, notify Parent that it has
received such written notice. Upon receipt of such notice from the Rights Agent, Parent shall determine whether the transfer otherwise
complies with the other terms and conditions of this Agreement (including the provisions of <U>Section&nbsp;2.2</U>), and if it determines
that it does so comply, Parent shall instruct the Rights Agent in writing to register the transfer of the CVRs in the CVR Register and
notify Parent of the same. No service charge shall be made for any registration of transfer of a CVR; however Parent and the Rights Agent
may require payment of a sum sufficient to cover any stamp or other tax or governmental charge that is imposed in connection with any
such registration of transfer. The Rights Agent shall have no duty or obligation to take any action under any section of this Agreement
that requires the payment by a Holder of applicable taxes or charges unless and until the Rights Agent is satisfied that all such taxes
or charges have been paid or will be paid. All duly transferred CVRs registered in the CVR Register will be the valid obligations of
Parent and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer
by the transferor. No transfer of a CVR will be valid until registered in the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>A
Holder may make a written request to the Rights Agent to change such Holder&rsquo;s address of record in the CVR Register. The written
request must be duly executed by the Holder. Upon receipt of such written request, the Rights Agent is hereby authorized to promptly
record the change of address in the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
will provide written instructions to the Rights Agent for the distribution of CVRs to holders of Parent Common Stock as of immediately
prior to the Effective Time (the &ldquo;<B><I>Record Time</I></B>&rdquo;). Subject to the terms and conditions of this Agreement and
Parent&rsquo;s prompt confirmation of the Effective Time, the Rights Agent shall effect the distribution of the CVRs, less any applicable
tax withholding, to each holder of Parent Common Stock as of the Record Time by the mailing of a statement of holding reflecting such
CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2.4</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment
Procedures</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Within
thirty (30) days after the receipt of any portion of the Total Payment Amount, Parent shall (i)&nbsp;deliver to the Rights Agent a certificate
certifying to and specifying in reasonable detail (A)&nbsp;the amount of the applicable Total Payment Amount received by Parent or its
Affiliates, (B)&nbsp;a calculation of the CVR Payment Amount and CVR Payment, and (C)&nbsp;the Permitted Deductions reflected in such
CVR Payment Amount, (ii)&nbsp;deliver to the Rights Agent an amount equal to the aggregate CVR Payment Amount in immediately available
funds (each, a &ldquo;<B><I>CVR Payment</I></B>&rdquo;) and (iii)&nbsp;instruct the Rights Agent to deliver the CVR Payment to the Holders.
The Rights Agent will promptly, and in any event within ten (10)&nbsp;Business Days after receipt of each applicable CVR Payment, pay
to each Holder, by check mailed to the address of each Holder as reflected in the CVR Register as of the close of business on the date
of the receipt of the CVR Payment statement, such Holder&rsquo;s CVR Payment Amount less any applicable tax withholding. Until such certificate,
CVR Payment and instructions are received by the Rights Agent, the Rights Agent may presume conclusively for all purposes that such portion
of the Total Payment Amount has not been received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
payments by Parent to the Rights Agent under this Agreement shall be made in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
shall be entitled to deduct or withhold, or cause the Rights Agent to deduct or withhold from any CVR Payment Amount otherwise payable
or otherwise deliverable pursuant to this Agreement, in each case directly or through an authorized payroll agent, such amounts as are
reasonably determined to be required to be deducted or withheld therefrom under the Code or any other provision of any applicable federal,
state, local or non-U.S. Tax Law as may be determined by Parent. To the extent such amounts are so deducted or withheld and paid over
or deposited with the relevant Tax authority, such amounts shall be treated for all purposes under this Agreement as having been paid
to the Holder(s)&nbsp;to whom such amounts would otherwise have been paid or delivered. Prior to making any such Tax withholdings or
causing any such Tax withholdings to be made with respect to any Holder, Parent shall instruct the Rights Agent, to the extent practicable,
to provide notice to the Holder of such potential withholding and a reasonable opportunity for the Holder to provide any necessary Tax
forms (including an IRS Form&nbsp;W-9 or an applicable IRS Form&nbsp;W-8) in order to avoid or reduce such withholding amounts; provided,
that the time period for payment of a CVR Payment Amount by the Rights Agent set forth in <U>Section&nbsp;2.4(a)</U>&nbsp;shall be extended
by a period equal to any delay caused by the Holder providing such forms; provided, further, that in no event shall such period be extended
for more than ten (10)&nbsp;Business Days, unless otherwise requested by the Holder for the purpose of delivering such forms and agreed
to by the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
portion of any CVR Payment that remains undistributed to any Holder six (6)&nbsp;months after such CVR Payment is received by the Rights
Agent from Parent, provided, that the Rights Agent has fully complied with <U>Section&nbsp;2.4(a)</U>, will be delivered by the Rights
Agent to Parent, upon demand, and such Holder will thereafter look only to Parent for payment of its share of such returned CVR Payment,
without interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor the Rights Agent will be liable to any person in respect of any CVR Payment Amount delivered to a public official pursuant
to any applicable abandoned property, escheat or similar Law. If, despite Parent&rsquo;s and/or the Rights Agent&rsquo;s commercially
reasonable efforts to deliver a CVR Payment Amount to the applicable Holder, such CVR Payment Amount has not been paid immediately prior
to the date on which such CVR Payment Amount would otherwise escheat to or become the property of any Governmental Body, any such CVR
Payment Amount will, to the extent permitted by applicable Law, become the property of Parent, free and clear of all claims or interest
of any person previously entitled thereto. In addition to and not in limitation of any other indemnity obligation herein, Parent agrees
to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or
be subject to in connection with transferring such property to Parent and such indemnification obligation shall survive the termination
of this Agreement, the resignation, replacement or removal of the Rights Agent, and the payment, termination and the expiration of the
CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2.5</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Voting, Dividends or Interest; No Equity or Ownership Interest in Parent</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable on the CVRs to any Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
CVRs will not represent any equity or ownership interest in Parent or in any constituent company to the Merger. The sole right of the
Holders to receive property hereunder is the right to receive the CVR Payment in accordance with the terms hereof. It is hereby acknowledged
and agreed that a CVR shall not constitute a security of Parent or any constituent company to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Holder acknowledges and agrees that such Holder will not challenge or contest any action, inaction, determination or decision of Parent
or the Rights Agent, except via written action of the Acting Holders, and will not threaten, bring, commence, institute, maintain, prosecute
or voluntarily aid any action, which challenges the validity of or seeks to enjoin the operation of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2.6</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Ability
to Abandon CVR</U>. A Holder may at any time, at such Holder&rsquo;s option, abandon all of such Holder&rsquo;s remaining rights in a
CVR by transferring such CVR to Parent without consideration therefor, and such rights will be cancelled, with the Rights Agent being
promptly notified in writing by Parent of such transfer and cancellation. Nothing in this Agreement is intended to prohibit Parent from
offering to acquire CVRs, in a private transaction or otherwise, for consideration in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>THE
RIGHTS AGENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>3.1</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Duties and Responsibilities</U>. The Rights Agent will be authorized and protected and will not have any liability for or in respect
of any actions taken, suffered or omitted to be taken by it in connection with its acceptance and administration of this Agreement and
the exercise and performance of its duties hereunder, except to the extent of its own willful misconduct, bad faith or gross negligence
(each as determined by a final non-appealable judgment of a court of competent jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>3.2</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Rights of the Rights Agent</U>. The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth
in this Agreement, and no implied duties, covenants or obligations will be read into this Agreement against the Rights Agent. The Rights
Agent shall not assume any obligations or relationship of agency or trust with any Holder. In addition:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Rights Agent may rely and will be protected by Parent in acting or refraining from acting upon any resolution, certificate, statement,
instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in the absence of bad
faith to be genuine and to have been signed or presented by the proper party or parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>whenever
the Rights Agent will deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder,
the Rights Agent may request and rely upon an Officer&rsquo;s Certificate with respect to such matter, which certificate shall be full
authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of gross negligence, bad faith or willful
or intentional misconduct (each as determined by a final non appealable judgment of a court of competent jurisdiction) on its part, incur
no liability and be held harmless by Parent for or in respect of any action taken, suffered or omitted to be taken by it in the absence
of bad faith under the provisions of this Agreement in reliance upon such certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
the event the Rights Agent believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or
other communication, paper or document received by the Rights Agent hereunder, the Rights Agent, may, in its sole discretion, refrain
from taking any action, and shall be fully protected and shall not be liable in any way to Parent, any Holder or any other person or
entity for refraining from taking such action, unless the Rights Agent receives written instructions from the Parent which eliminates
such ambiguity or uncertainty to the satisfaction of the Rights Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Rights Agent may engage and consult with counsel of its selection (who may be legal counsel for the Rights Agent or the Parent or an
employee of the Rights Agent) and the written advice of such counsel or any opinion of counsel will be full and complete authorization
and protection to the Rights Agent and the Rights Agent shall be held harmless by Parent and shall incur no liability for or in respect
of any action taken, suffered or omitted by it hereunder in the absence of bad faith and in reliance thereon;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
permissive rights of the Rights Agent to do things enumerated in this Agreement will not be construed as a duty;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Rights Agent will not be required to give any note or surety in respect of the execution of such powers or otherwise in respect of the
premises;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Rights Agent shall not be liable for or by reason of, and shall be held harmless by Parent with respect to any of the statements of fact
or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed
to have been made by the Parent only and the Rights Agent will have no liability and shall be held harmless by Parent in respect of the
validity of this Agreement or the execution and delivery hereof (except the due execution and delivery hereof by the Rights Agent), nor
shall the Rights Agent be responsible for any breach by Parent of any covenant or condition contained in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability, damage, judgment, fine, penalty,
settlement, claim, demands, suits, cost or expense (including without limitation, the reasonable and documented fees and expenses of
legal counsel) for any action taken, suffered or omitted to be taken by the Rights Agent or arising out of or in connection with the
Rights Agent&rsquo;s duties under this Agreement, including the reasonable and documented out-of-pocket costs and expenses of defending
the Rights Agent against any claims, charges, demands, suits or loss arising therefrom, directly or indirectly, or enforcement of its
rights hereunder, unless such loss has been determined by a final non-appealable judgment of a court of competent jurisdiction to be
a result of the Rights Agent&rsquo;s gross negligence, bad faith or willful or intentional misconduct;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>anything
to the contrary notwithstanding, (i)&nbsp;any liability of the Rights Agent under this Agreement will be limited to the aggregate amount
of the annual fees (but not reimbursed expenses) paid by Parent to the Rights Agent under this Agreement during the twelve months immediately
preceding the event for which recovery is sought, and (ii)&nbsp;in no event shall the Rights Agent be liable for any special, punitive,
indirect, consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits) arising out of
any action taken, suffered or omitted to be taken by it, even if the Rights Agent has been advised of the likelihood of such loss or
damage and regardless of the form of action;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
agrees (i)&nbsp;to pay the fees and expenses of the Rights Agent in connection with the Rights Agent&rsquo;s duties under this Agreement
as agreed upon in writing by the Rights Agent and Parent on or prior to the date hereof, and (ii)&nbsp;to reimburse the Rights Agent
for all taxes and governmental charges, reasonable and documented out-of-pocket expenses and other charges of any kind and nature incurred
by the Rights Agent in the preparation, delivery, amendment and execution of this Agreement and the exercise and performance of its duties
hereunder (other than taxes imposed on or measured by the Rights Agent&rsquo;s net income and franchise or similar taxes imposed on it
(in lieu of net income taxes)). The Rights Agent will also be entitled to reimbursement from Parent for all reasonable and documented
out-of-pocket expenses paid or incurred by it in connection with the administration by the Rights Agent of its duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Rights Agent shall not be deemed to have knowledge of any event of which it was supposed to receive notice thereof hereunder, and the
Rights Agent shall be fully protected and shall incur no liability for failing to take action in connection therewith, unless and until
it has received such notice in writing from the Parent and all notices or other instruments required by this Agreement to be delivered
to the Rights Agent must, in order to be effective, be received by the Rights Agent as specified herein, and in the absence of such notice
so delivered the Rights Agent may conclusively assume no such event or condition exists;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Rights Agent and any shareholder, affiliate, director, officer or employee of the Rights Agent may buy, sell or deal in any securities
of the Parent or become peculiarly interested in any transaction in which the Parent may be interested, or contract with or lend money
to the Parent or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement. Nothing herein shall
preclude the Rights Agent from acting in any other capacity for the Parent or for any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or
by or through its attorneys or agents, and the Rights Agent shall not be liable, answerable or accountable for any act, omission, default,
neglect or misconduct of any such attorneys or agents or for any loss to the Parent, any Holder or any other person or entity resulting
from any such act, omission, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined
by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no
provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability
in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing
that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect
to any action or default by the Parent or its Affiliates, including, without limiting the generality of the foregoing, any duty or responsibility
to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Rights Agent shall neither be responsible for, nor chargeable with, knowledge of, nor have any requirements to comply with, the terms
and conditions of any other agreement, instrument or document, including, without limitation, the Merger Agreement, nor shall the Rights
Agent be required to determine if any person or entity has complied with any such agreements, instruments or documents, nor shall any
additional obligations of the Rights Agent be inferred from the terms of such agreements, instruments or documents even though reference
thereto may be made in this Agreement. In the event of any conflict between the terms and provisions of this Agreement and those of any
other agreement, instrument or document, including but not limited to the Merger Agreement, the terms and conditions of this Agreement
shall control as they relate to the Rights Agent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
provisions of <U>Section&nbsp;3.1</U> and this <U>Section&nbsp;3.2</U> shall survive the termination of this Agreement, the resignation,
replacement or removal of the Rights Agent, and the payment, termination and the expiration of the CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>3.3</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Resignation
and Removal; Appointment of Successor</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Rights Agent may resign at any time by giving written notice thereof to Parent specifying a date when such resignation will take effect,
which notice will be sent at least thirty (30) days prior to the date so specified, and such resignation will become effective on the
earlier of (i)&nbsp;the date so specified and (ii)&nbsp;the appointment of a successor Rights Agent. Parent has the right to remove the
Rights Agent at any time by a Board Resolution specifying a date when such removal will take effect (or, if earlier, the appointment
of the successor Rights Agent). Notice of such removal will be given by Parent to the Rights Agent, which notice will be sent at least
thirty (30) days prior to the date so specified. Notwithstanding anything to the contrary contained herein, such replacement or removal
of the Rights Agent shall not affect any of the provisions of this Agreement that expressly survive the termination of this Agreement,
or the resignation, replacement or removal of the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
the Rights Agent provides notice of its intent to resign, is removed or becomes incapable of acting, Parent, by a Board Resolution, will
as soon as is reasonably possible appoint a qualified successor Rights Agent, who shall be a stock transfer agent or national reputation
or the corporate trust department of a commercial bank. The successor Rights Agent so appointed will, forthwith upon its acceptance of
such appointment in accordance with <U>Section&nbsp;3.4</U>, become the successor Rights Agent. Notwithstanding the foregoing, if Parent
shall fail to make such appointment within a period of thirty (30) days after giving notice of such removal or after it has been notified
in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply
to any court of competent jurisdiction for the appointment of a new Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
will give notice to each Holder of each resignation and each removal of a Rights Agent and each appointment of a successor Rights Agent
by delivering a written notice of such event to the Holders as their names and addresses appear in the CVR Register in accordance with
<U>Section&nbsp;7.1</U>. Each notice will include the name and address of the successor Rights Agent. If Parent fails to send such notice
within ten (10)&nbsp;Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause
the notice to be mailed at the expense of Parent. Failure to give any notice provided for in this <U>Section&nbsp;3.3</U>, however, and
any defect therein, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of
the successor Rights Agent, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
anything to the contrary in this <U>Section&nbsp;3.3</U>, unless consented to in writing by, at the applicable time of determination,
Holders of at least 33% of the then outstanding CVRs, as set forth in the CVR Register (the &ldquo;<B><I>Acting Holders</I></B>&rdquo;),
Parent will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate
trust department of a commercial bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Rights Agent will reasonably cooperate with Parent and any successor Rights Agent in connection with the transition of the duties and
responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register,
to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any
additional liability in connection with the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>3.4</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Acceptance
of Appointment by Successor</U>. Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge
and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement,
and thereupon such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers,
trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring Rights Agent will execute
and deliver an instrument transferring to the successor Rights Agent all the rights (except such rights of the predecessor Rights Agent
which survive pursuant to <U>Section&nbsp;3.3</U> of this Agreement), powers and trusts of the retiring Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>COVENANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>4.1</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>List
of Holders</U>. Parent will furnish or cause to be furnished to the Rights Agent in such form as Parent receives from Parent&rsquo;s
transfer agent (or other agent performing similar services for Parent), the names and addresses of the Holders within ten (10)&nbsp;Business
Days of the Effective Time. Until such initial list of Holders is furnished to the Rights Agent, the Rights Agent shall have no duties,
responsibilities or obligations with respect to such Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>4.2</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment
of CVR Payment Amounts</U>. If a CVR Payment is due under <U>Section&nbsp;2.4(a)</U>, Parent will deposit the CVR Payment with the Rights
Agent for payment to the Holders in accordance with <U>Section&nbsp;2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>4.3</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Roche
Agreements</U>. Without the prior written consent of the Acting Holders, neither Parent nor any of its Affiliates shall (a)&nbsp;amend,
restate, supplement, terminate or otherwise modify the Roche Agreement in a manner materially adversely affecting the Holders&rsquo;
rights under this Agreement, (b)&nbsp;in the event that Roche fails to make a payment of a Roche Payment at the time rightfully due and
payable, take action with respect to, or unreasonably waive or fail to enforce, the right to receive the applicable payments which are
rightfully due and payable under the Roche Agreement, in a manner materially adversely affecting the Holders&rsquo; rights under this
Agreement or (c)&nbsp;agree to any of the foregoing. Without limiting the foregoing, Parent and its Affiliates shall pursue their rights
under the Roche Agreement in good faith, and not take any action (or fail to take any action) with the intention of avoiding, reducing
or materially delaying any payment to the Holders hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>4.4</U></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Records</U>.
Parent shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to enable the Holders
and their consultants or professional advisors to confirm (a)&nbsp;whether the Roche Payment Amount or the Asset Disposition Proceeds
have been received by Parent or its successors or Affiliates and (b)&nbsp;the applicable CVR Payment Amount payable to each Holder hereunder
in accordance with the terms specified in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="text-transform: uppercase">Disposition</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>5.1</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U></U></FONT>During
the period beginning on the date hereof and ending on December&nbsp;31, 2023, Parent will, and will cause its subsidiaries to, use commercially
reasonable efforts to effectuate a Disposition, including the negotiation and execution of a Sale Agreement and completion of the transactions
contemplated thereby. Further, Parent will not take any actions for the primary purpose of frustrating the payment of CVR Payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>5.2</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Holders acknowledge and agree that, except as expressly set forth in the foregoing Section&nbsp;5.1, (a)&nbsp;Parent has a fiduciary
obligation to operate its business in the best interests of its stockholders, and any potential obligation to pay any potential CVR Payments
will not create any express or implied obligation to operate its business in any particular manner in order to maximize any such CVR
Payments, (b)&nbsp;the Holders are not relying on any representation of Parent or any other Person with regard to any Asset Disposition
or other action involving Potentially Transferable Assets, including CVR Sale Assets, following the Closing, and neither Parent nor any
other Person has provided, or can provide, any assurance to the Holders that any potential CVR Payments will in fact be earned and paid,
and (c)&nbsp;none of Parent or any of its Subsidiaries, officers or directors shall have any obligation or liability whatsoever to any
Person relating to or in connection with any action, or failure to act, with respect to the sale of Potentially Transferrable Assets,
including CVR Sale Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>AMENDMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>6.1</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendments
without Consent of Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Without
the consent of any Holders, Parent, when authorized by a Board Resolution, at any time and from time to time, and the Rights Agent may
enter into one or more amendments hereto, solely to evidence any successor to or permitted Assignee of Parent and the assumption by any
such successor or permitted Assignee of the covenants of Parent herein as provided in <U>Section&nbsp;7.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Without
the consent of any Holders, Parent, when authorized by a Board Resolution, may, with the consent of the Rights Agent, which consent shall
not be unreasonably withheld, conditioned or delayed, at any time and from time to time, enter into one or more amendments hereto, solely
for any of the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
evidence the succession of another Person as a successor Rights Agent in accordance with <U>Section&nbsp;3</U> and the assumption by
any successor of the covenants and obligations of the Rights Agent herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
add to the covenants of Parent such further covenants, restrictions, conditions or provisions as Parent shall consider to be for the
protection of the Holders; provided, that, in each case, such provisions do not adversely affect the interests of the Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision herein,
or to make any other provisions with respect to matters or questions arising under this Agreement; provided, that, in each case, such
provisions do not adversely affect the interests of the Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange Act
or any applicable state securities or &ldquo;blue sky&rdquo; laws; provided, that, in each case, such provisions do not adversely affect
the interests of the Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
cancel any CVRs (A)&nbsp;in the event that any Holder has abandoned its rights in accordance with <U>Section&nbsp;2.6</U>, or (B)&nbsp;following
a transfer of such CVRs to Parent or its Affiliates in accordance with <U>Section&nbsp;2.2</U> or <U>Section&nbsp;2.3</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
other amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition, elimination
or change is adverse to the interests of the Holders; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
may be necessary or appropriate to ensure that Parent complies with applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Promptly
after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this <U>Section&nbsp;6.1</U>, Parent
will transmit a notice thereof in accordance with <U>Section&nbsp;7.1</U> to the Holders at their addresses as they appear on the CVR
Register, setting forth in general terms the substance of such amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>6.2</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendments
with Consent of Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to <U>Section&nbsp;6.1</U> (which amendments pursuant to <U>Section&nbsp;6.1</U> may be made without the consent of the Holders), with
the consent of the Acting Holders, whether evidenced in writing or taken at a meeting of such Holders, Parent, when authorized by a Board
Resolution, and the Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any
provisions of this Agreement, even if such addition, elimination or change is materially adverse to the interest of the Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Promptly
after the execution by Parent, and the Rights Agent of any amendment pursuant to the provisions of this <U>Section&nbsp;6.2</U>, Parent
will transmit (or cause the Rights Agent to transmit) a notice thereof in accordance with <U>Section&nbsp;7.1</U> to the Holders at their
addresses as they appear on the CVR Register, setting forth in general terms the substance of such amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>6.3</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Execution
of Amendments</U>. In executing any amendment permitted by this <U>Section&nbsp;6</U>, the Rights Agent will be entitled to receive,
and will be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of such amendment is
authorized or permitted by this Agreement. Notwithstanding anything contained herein, the Rights Agent may, but is not obligated to,
enter into any such amendment that affects the Rights Agent&rsquo;s own rights, privileges, covenants or duties under this Agreement
or otherwise. No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>6.4</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Effect
of Amendments</U>. Upon the execution of any amendment under this <U>Section&nbsp;6</U>, this Agreement will be modified in accordance
therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>OTHER
PROVISIONS OF GENERAL APPLICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.1</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices
to Rights Agent and Parent</U>. Any notice or other communication required or permitted hereunder shall be in writing and shall be deemed
given when delivered and received hereunder (a)&nbsp;one Business Day after being sent for next Business Day delivery, fee prepared,
via a reputable international overnight courier service, (b)&nbsp;upon delivery in the case of delivery by hand, or (c)&nbsp;on the date
delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 5:00 p.m.&nbsp;New
York time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Rights Agent, to it at:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computershare
    Inc. and Computershare Trust Company, N.A.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150
    Royall Street, 2nd Floor</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canton,
    MA 02021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Relationship Manager</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to Parent, to it at:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sesen
    Bio,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">[ * * * ]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Sullivan</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy to:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hogan
    Lovells US LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve.abrams@hoganlovells.com;
    Jessica.bisignano@hoganlovells.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
    Abrams; Jessica Bisignano</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Rights Agent or Parent may specify
a different address, email address by giving notice to each other in accordance with this <U>Section&nbsp;7.1 </U>and to the Holders
in accordance with <U>Section&nbsp;7.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.2</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
to Holders</U>. Where this Agreement provides for notice to Holders, such notice will be sufficiently given (unless otherwise herein
expressly provided) if in writing and mailed, first-class postage prepaid or, if applicable, transmitted through the facilities of DTC
in accordance with DTC&rsquo;s procedures, to each Holder affected by such event, at the Holder&rsquo;s address as it appears in the
CVR Register, not later than the latest date, and not earlier than the earliest date, if any, prescribed for the giving of such notice.
In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed,
to any particular Holder will affect the sufficiency of such notice with respect to other Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.3</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Parent
Successors and Assigns</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
may not assign this Agreement without the prior written consent of the Acting Holders. Notwithstanding the foregoing (i)&nbsp;Parent
may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder
to one or more direct or indirect wholly-owned subsidiaries of Parent for so long as they remain wholly-owned subsidiaries of Parent
(each, an &ldquo;<B><I>Assignee</I></B>&rdquo;) and the Assignee agrees to assume and be bound by all of the terms of this Agreement;
provided, however, that in connection with any assignment to an Assignee, Parent shall, and shall agree to, remain liable for the performance
by such Assignee of all obligations of Parent hereunder, with such Assignee substituted for Parent under this Agreement, and (ii)&nbsp;Parent
may assign this Agreement in its entirety without the consent of any other party to its successor in interest in connection with the
sale of all or substantially all of its assets or of its stock, or in connection with a merger, acquisition or similar transaction (such
successor in interest, the &ldquo;<B><I>Acquiror</I></B>&rdquo;, and such transaction, the &ldquo;<B><I>Acquisition</I></B>&rdquo;).
This Agreement will be binding upon, inure to the benefit of and be enforceable by Parent&rsquo;s successors, acquirers and each Assignee.
Each reference to &ldquo;<B><I>Parent</I></B>&rdquo; in this Agreement shall be deemed to include Parent&rsquo;s successors, acquirers
and all Assignees. Each of Parent&rsquo;s successors, acquirers and assigns shall expressly assume by an instrument supplemental hereto,
executed and delivered to the Rights Agent, the due and punctual payment of the CVR Payments and the due and punctual performance and
observance of all of the covenants and obligations of this Agreement to be performed or observed by Parent. Notwithstanding anything
to the contrary contained herein, no assignment pursuant to this <U>Section&nbsp;7.3</U> shall relieve Parent of its obligations and
liabilities to the Rights Agent hereunder, unless specifically agreed to in writing by the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or any Person resulting
from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to
the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to
the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties
hereto; provided, that such Person would be eligible for appointment as a successor Rights Agent under the provisions of this Agreement.
The purchase of all or substantially all of the Rights Agent&rsquo;s assets employed in the performance of transfer agent activities
shall be deemed a merger or consolidation for purposes of this <U>Section&nbsp;7.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.4</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Benefits
of Agreement; Action by Acting Holders</U>. The holders shall be intended third-party beneficiaries hereof and shall be entitled to,
solely by action by the written consent of the Acting Holders, specifically enforce the terms hereof; <U>provided</U> that under no circumstances
shall the rights of Holders as third-party beneficiaries pursuant to this <U>Section&nbsp;7.4 </U>be enforceable by such Holders or any
other Person acting for or on their behalf other than through the action of the Acting Holders, which Acting Holders shall have the sole
power and authority to act on behalf of the Holders in enforcing any of their rights hereunder. Nothing in this Agreement, express or
implied, will give to any Person (other than the Rights Agent, Parent, Parent&rsquo;s successors and permitted assignees, and the Holders
and their respective successors and permitted assignees) any benefit or any legal or equitable right, remedy or claim under this Agreement
or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the Rights Agent,
Parent, Parent&rsquo;s successors and permitted Assignees, and the Holders and their respective successors and permitted assignees. The
rights of Holders are limited to those expressly provided in this Agreement and the Merger Agreement. Except for the rights of the Rights
Agent set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of
this Agreement, to institute any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder or
other group of Holders will be entitled to exercise such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.5</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. This Agreement, the CVRs and all claims and causes of action based upon, arising out of or in connection herewith shall be governed
by, and construed in accordance with, the Laws of the State of Delaware, without regard to Laws that may be applicable under conflicts
of laws principles (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction
other than the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In any Legal Proceeding between
any of the parties arising out of our relating to this Agreement, each of the parties hereby (i)&nbsp;irrevocably and unconditionally
consent and submits, for itself and its property, to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware,
New Castle County, or, if such court does not have jurisdiction, the United States District Court for the District of Delaware or, to
the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware, (ii)&nbsp;agrees that
any claim in respect of any such Legal Proceeding shall be heard and determined exclusively in accordance with clause (i)&nbsp;of this
<U>Section&nbsp;7.5</U>, (iii)&nbsp;waives, to the fullest extent it may legally and effectively do so, any objection which it may now
or hereafter have to the laying of venue of any such Legal Proceeding in any such court, (iv)&nbsp;waives, to the fullest extent permitted
by Law, any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, and (v)&nbsp;agrees that
service of process upon such party in any such Legal Proceeding shall be effective if notice is given in accordance with <U>Section&nbsp;7.1
</U>of this Agreement. Nothing in this <U>Section&nbsp;7.5</U>, however, shall affect the right of any Person to serve legal process
in any manner permitted by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.6</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or
provision in any other situation or in any other jurisdiction. If any term or other provision of this Agreement is determined by a final
judgement of a court of competent jurisdiction to be invalid or unenforceable, the parties agree that the court making such determination
shall have the power to limit such term or provisions, to delete specific words or phrases or to replace such term or provision with
a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable
term or provision, and this Agreement shall be valid and enforceable as so modified. Notwithstanding anything to the contrary herein,
if any such excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights
Agent shall be entitled to resign immediately upon written notice to Parent. In the event such court does not exercise the power granted
to it in the prior sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable
term or provision that will achieve, to the extent possible, the economic, business or other purposes of such invalid or unenforceable
term or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.7</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts
and Signature</U>. This Agreement may be signed in any number of counterparts, including by electronic transmission, each of which shall
be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.8</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.
This Agreement will expire and be of no force or effect, the parties hereto will have no liability hereunder (other than with respect
to monies due and owing by Parent to the Rights Agent or any other rights of the Rights Agent which expressly survive the termination
of this Agreement), and no additional payments will be required to be made, upon the later of (i)&nbsp;the conclusion of the CVR Term,
and (ii)&nbsp;the payment of the full amount of all CVR Payments made to Parent on or prior to the end of the applicable CVR Term to
the Rights Agent and the payment of the full amount of all CVR Payment Amounts to the Holders by the mailing by the Rights Agent of each
applicable CVR Payment Amount to each Holder at the address reflected in the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.9</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Funds</U></FONT>.
All funds received by the Rights Agent under this Agreement that are to be distributed or applied by Computershare in the performance
of services hereunder (the &ldquo;<B><I>Funds</I></B>&rdquo;) shall be held by Computershare as agent for Parent and deposited in one
or more bank accounts to be maintained by Computershare in its name as agent for Parent. Until paid pursuant to the terms of this Agreement,
Computershare will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1 billion
or with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&rsquo;s (Long Term Rating) and Fitch
Ratings,&nbsp;Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall have no responsibility
or liability for any diminution of the Funds that may result from any deposit made by the Rights Agent in accordance with this paragraph,
including any losses resulting from a default by any bank, financial institution or other Third Party. The Rights Agent may from time
to time receive interest, dividends or other earnings in connection with such deposits. The Rights Agent shall not be obligated to pay
such interest, dividends or earnings to Parent, any Holder or any other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.10</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U></U></FONT><U>Entire
Agreement</U>. As between Parent and the Holders, this Agreement and the Merger Agreement (including the schedules, annexes and exhibits
thereto, the documents and instruments referred to therein and the documents delivered pursuant thereto) constitute the entire agreement
of Parent and the Holders and supersede all prior agreements and undertakings, both written and oral, among Parent and the Holders, or
any of them, with respect to the subject matter hereof and, except as otherwise expressly provided herein or therein, are not intended
to confer upon any other Person any rights or remedies hereunder or thereunder. As between Parent and the Rights Agent, this Agreement
(including the documents and instruments referred to herein (other than the Merger Agreement) and the documents delivered pursuant thereto)
contains the entire understanding of the parties with reference to the transactions and matters contemplated hereby and thereby and supersedes
all prior agreements, written or oral, among the parties with respect thereto. If and to the extent that any provision of this Agreement
is inconsistent or conflicts with the Merger Agreement, this Agreement will govern and control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7.11</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Waiver
of Jury Trial</U>. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND,
ACTION, OR CAUSE OF ACTION (i)&nbsp;ARISING UNDER THIS AGREEMENT OR (ii)&nbsp;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE
DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY,&nbsp;IN EACH CASE WHETHER
NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY
SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT
MAY&nbsp;FILE AN ORIGINAL COUNTERPART&nbsp;OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES
HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of page&nbsp;intentionally left
blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, each
of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above
written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SESEN BIO,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Thomas Cannell</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;Thomas Cannell, D.V.M.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;President and Chief Executive
    Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMPUTERSHARE INC. and COMPUTERSHARE TRUST</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMPANY, N.A., jointly as RIGHTS AGENT</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Collin
    Ekeogu</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;Collin Ekeogu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Manager, Corporate Actions</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>6
<FILENAME>tm238578d1_ex10-6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.6</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INDEMNIFICATION AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Indemnification Agreement
(&#8220;Agreement&#8221;) is made as of   [&nbsp; ], 20[ ] by and between Carisma Therapeutics Inc., a Delaware corporation (the &#8220;Company&#8221;),
and [ ] (&#8220;Indemnitee&#8221;). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee
covering the subject matter of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, the Board of Directors
of the Company (the &#8220;Board&#8221;) believes that highly competent persons have become more reluctant to serve publicly-held corporations
as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification
against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, the Board has determined
that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense,
liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such
insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company
believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums
and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises
are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally
would have been brought only against the Company or business enterprise itself. The Certificate of Incorporation of the Company (as the
same may be amended from time to time, the &#8220;Certificate of Incorporation&#8221;) requires indemnification of the officers and directors
of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the
 &#8220;DGCL&#8221;). The Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein
are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the Board, officers and
other persons with respect to indemnification;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, the uncertainties
relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, the Board has determined
that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders
and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, it is reasonable,
prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons
to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that
they will not be so indemnified;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">WHEREAS,
this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and any resolutions adopted pursuant thereto,
</FONT>as well as any rights of Indemnitee under any directors&#8217; and officers&#8217; liability insurance policy, and this Agreement
shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; [and]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS,&nbsp;Indemnitee does
not regard the protection available under the Certificate of Incorporation and insurance as adequate in the present circumstances, and
may not be willing to serve or continue to serve as an officer or director without adequate protection, and the Company desires Indemnitee
to serve or continue to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for
or on behalf of the Company on the condition that Indemnitee be so indemnified[; and][.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">[WHEREAS,&nbsp;Indemnitee
is a representative of [ ] [and its affiliated investment funds] (the &#8220;Fund&#8221;), and has certain rights to indemnification and/or
insurance provided by the Fund which Indemnitee and the Fund intend to be secondary to the primary obligation of the Company to indemnify
Indemnitee as provided herein, with the Company&#8217;s acknowledgement and agreement to the foregoing being a material condition to Indemnitee&#8217;s
willingness to serve on the Board.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Services
to the Company</U>. Indemnitee agrees to serve as a[n] [director] [officer] of the Company. Indemnitee may at any time and for any reason
resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event
the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed
an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges
that Indemnitee&#8217;s employment with the Company (or any of its subsidiaries or any Enterprise), if any, is at will, and Indemnitee
may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract
between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted
by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation, the Bylaws of
the Company (the &#8220;Bylaws&#8221;), and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee
has ceased to serve as a[n] [director] [officer] of the Company, as provided in Section&nbsp;16 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
As used in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">References
to &#8220;agent&#8221; shall mean any person who is or was a director, officer, or employee of the Company or a subsidiary of the Company
or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer,
employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other enterprise
at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">A
 &#8220;Change in Control&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following
events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Acquisition
of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly,
of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company&#8217;s then outstanding
securities unless the change in relative Beneficial Ownership of the Company&#8217;s securities by any Person results solely from a reduction
in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Change
in Board of Directors. During any period of two (2)&nbsp;consecutive years (not including any period prior to the execution of this Agreement),
individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person
who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii)&nbsp;or 2(b)(iv))
whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds
of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election
was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Corporate
Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to
represent (either by remaining outstanding or by being converted into voting securities of the Surviving Entity) more than fifty-one percent
(51%) of the combined voting power of the voting securities of the Surviving Entity outstanding immediately after such merger or consolidation
and with the power to elect at least a majority of the board of directors or other governing body of such Surviving Entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Liquidation
or Sale of Assets. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale
or disposition by the Company of all or substantially all of the Company&#8217;s assets; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Other
Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e)&nbsp;of Schedule 14A of
Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below),
whether or not the Company is then subject to such reporting requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this Section&nbsp;2(b), the following terms shall have
the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;Exchange
Act&#8221; shall mean the Securities Exchange Act of 1934, as amended from time to time.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;Person&#8221;
shall have the meaning as set forth in Sections 13(d)&nbsp;and 14(d)&nbsp;of the Exchange Act; provided, however, that Person shall exclude
(i)&nbsp;the Company, (ii)&nbsp;any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii)&nbsp;any
entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;Beneficial
Owner&#8221; shall have the meaning given to such term in Rule&nbsp;13d-3 under the Exchange Act; provided, however, that Beneficial Owner
shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the
Company with another entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;Surviving
Entity&#8221; shall mean the surviving entity in a merger or consolidation or any entity that controls, directly or indirectly, such surviving
entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;Corporate
Status&#8221; describes the status of a person who is or was a director, trustee, partner, managing member, officer, employee, agent or
fiduciary of the Company or of any other corporation, limited liability company, partnership or joint venture, trust or other enterprise
which such person is or was serving at the request of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;Disinterested
Director&#8221; shall mean a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification
is sought by Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;Enterprise&#8221;
shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust or other enterprise of
which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, employee,
agent or fiduciary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;Expenses&#8221;
shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees and other costs of experts and other
professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service
fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under
this Agreement, ERISA excise taxes and penalties, and all other disbursements, obligations or expenses of the types customarily incurred
in connection with, or as a result of, prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to
be a deponent or witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i)&nbsp;Expenses incurred in connection
with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any
cost bond, supersedeas bond, or other appeal bond or its equivalent, (ii)&nbsp;expenses incurred in connection with recovery under any
directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, regardless of whether Indemnitee is ultimately
determined to be entitled to such indemnification, advancement or Expenses or insurance recovery, as the case may be, and (iii)&nbsp;for
purposes of Section&nbsp;14(d)&nbsp;only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense
of Indemnitee&#8217;s rights under this Agreement, the Certificate of Incorporation, the Bylaws or under any directors&#8217; and officers&#8217;
liability insurance policies maintained by the Company, by litigation or otherwise. The parties agree that for the purposes of any advancement
of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such
demand that are certified by affidavit of Indemnitee&#8217;s counsel as being reasonable in the good faith judgment of such counsel shall
be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount
of judgments or fines against Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;Independent
Counsel&#8221; shall mean a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither
presently is, nor in the past five years has been, retained to represent: (i)&nbsp;the Company or Indemnitee in any matter material
to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under
similar indemnification agreements), or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification
hereunder. Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the
applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company
or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement. The Company agrees to pay the reasonable
fees and expenses of the Independent Counsel referred to above and to </FONT>fully indemnify such counsel against any and all
Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
term &#8220;Proceeding&#8221; shall include any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration,
mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed
proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, regulatory
or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party,
potential party, non-party witness or otherwise by reason of Indemnitee&#8217;s Corporate Status, by reason of any action taken by Indemnitee
(or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee&#8217;s part while acting pursuant to Indemnitee&#8217;s
Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification,
reimbursement, or advancement of Expenses can be provided under this Agreement. If Indemnitee believes in good faith that a given situation
may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Reference
to &#8220;other enterprise&#8221; shall include employee benefit plans; references to &#8220;fines&#8221; shall include any excise tax
assessed with respect to any employee benefit plan; references to &#8220;serving at the request of the Company&#8221; shall include any
service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer,
employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and
in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan
shall be deemed to have acted in a manner &#8220;not opposed to the best interests of the Company&#8221; as referred to in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnity
in Third-Party Proceedings.</U> The Company shall indemnify Indemnitee in accordance with the provisions of this Section&nbsp;3 if Indemnitee
is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company
to procure a judgment in its favor. Pursuant to this Section&nbsp;3,&nbsp;Indemnitee shall be indemnified to the fullest extent permitted
by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other
charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and
reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or any claim, issue or matter therein,
if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the
Company and, in the case of a criminal Proceeding had no reasonable cause to believe that Indemnitee&#8217;s conduct was unlawful. The
parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly
permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation, the Bylaws, vote
of the Company&#8217;s stockholders or disinterested directors or applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnity
in Proceedings by or in the Right of the Company.</U> The Company shall indemnify Indemnitee in accordance with the provisions of this
Section&nbsp;4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the
Company to procure a judgment in its favor. Pursuant to this Section&nbsp;4,&nbsp;Indemnitee shall be indemnified to the fullest extent
permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection
with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed
to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section&nbsp;4
in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company,
unless and only to the extent that the Court of Chancery of the State of Delaware (the &#8220;Delaware Court&#8221;) or any court in which
the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances
of the case,&nbsp;Indemnitee is fairly and reasonably entitled to indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
for Expenses of a Party Who is Wholly or Partly Successful.</U> Notwithstanding any other provisions of this Agreement, to the
fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful,
on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company
shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on behalf of Indemnitee in
connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to
one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all
Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s </FONT>behalf in connection with or related to each
successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section&nbsp;and without
limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be
deemed to be a successful result as to such claim, issue or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
For Expenses of a Witness.</U> Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law
and to the extent that Indemnitee is, by reason of Indemnitee&#8217;s Corporate Status, a witness, is or was made (or asked) to respond
to discovery requests in any Proceeding, or otherwise asked to participate in any Proceeding to which Indemnitee is not a party,&nbsp;Indemnitee
shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection
therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Partial
Indemnification.</U> If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion
of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof
to which Indemnitee is entitled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Additional
Indemnification.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee
is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company
to procure a judgment in its favor) by reason of Indemnitee&#8217;s Corporate Status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
purposes of Section&nbsp;8(a), the meaning of the phrase &#8220;to the fullest extent permitted by applicable law&#8221; shall include,
but not be limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">to
the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or
the corresponding provision of any amendment to or replacement of the DGCL, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">to
the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that
increase the extent to which a corporation may indemnify its officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exclusions.</U>
Notwithstanding any provision in this Agreement [but subject to Section&nbsp;15(e), however], the Company shall not be obligated under
this Agreement to make any indemnification payment in connection with any claim involving Indemnitee:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">for
which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with
respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">for
(i)&nbsp;an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within
the meaning of Section&nbsp;16(b)&nbsp;of the Exchange Act (as defined in Section&nbsp;2(b)&nbsp;hereof) or similar provisions of state
statutory law or common law, (ii)&nbsp;any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based
compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Exchange
Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section&nbsp;304 of the Sarbanes-Oxley
Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee
of securities in violation of Section&nbsp;306 of the Sarbanes-Oxley Act) or (iii)&nbsp;any reimbursement of the Company by Indemnitee
of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of the
Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing Section&nbsp;10D
of the Exchange Act; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">except
as provided in Section&nbsp;14(d)&nbsp;of this Agreement, in connection with any Proceeding (or any part of any Proceeding)
initiated by Indemnitee, including any Proceeding (or any part of any </FONT>Proceeding) initiated by Indemnitee against the Company
or its directors, officers, employees or other indemnitees, unless (i)&nbsp;the Board authorized the Proceeding (or any part of any
Proceeding) prior to its initiation, (ii)&nbsp;<FONT STYLE="font-size: 10pt">such payment arises in connection with any mandatory
counterclaim or cross claim brought or raised by Indemnitee in any Proceeding (or any part of any Proceeding), or (iii)&nbsp;the
Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Advances
of Expenses.</U> Notwithstanding any provision of this Agreement to the contrary (other than Section&nbsp;14(d)), the Company shall advance,
to the extent not prohibited by law, the Expenses incurred by Indemnitee or on behalf of Indemnitee in connection with any Proceeding
(or any part of any Proceeding) (x)&nbsp;not initiated by Indemnitee (other than in connection with any mandatory counterclaim or cross
claim brought or raised by Indemnitee therein as provided in Section&nbsp;9(c)), or (y)&nbsp;initiated by Indemnitee with the prior approval
of the Board as provided in Section&nbsp;9(c), and such advancement shall be made within thirty (30) days after the receipt by the Company
of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding.
Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee&#8217;s ability to repay the Expenses
and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement. In accordance
with Section&nbsp;14(d), advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement,
including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. Indemnitee shall qualify
for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that Indemnitee
undertakes to repay the amounts advanced (without interest) by the Company pursuant to this Section&nbsp;10, if and only to the extent
that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall
be required other than the execution of this Agreement. This Section&nbsp;10 shall not apply to any claim made by Indemnitee for which
indemnity is excluded pursuant to Section&nbsp;9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Procedure
for Notification and Defense of Claim.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Indemnitee
shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses
hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to
the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification
under this Agreement,&nbsp;Indemnitee shall submit to the Company a written request, including therein or therewith such documentation
and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee
is entitled to indemnification following the final disposition of such Proceeding. The omission by Indemnitee to notify the Company hereunder
will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and
any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of
the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested
indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company will be entitled to participate in the Proceeding at its own expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company shall not settle any Proceeding (in whole or in part) if such settlement would impose any Expense, judgment, liability, fine,
penalty or limitation on Indemnitee in respect of which Indemnitee is not entitled to be indemnified hereunder without Indemnitee&#8217;s
prior written consent, which shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;12.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Procedure
Upon Application for Indemnification.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Upon
written request by Indemnitee for indemnification pursuant to Section&nbsp;11(a), a determination, if required by applicable law,
with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case: (i)&nbsp;if a Change in Control shall
have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or
(ii)&nbsp;if a Change in Control shall not have occurred, (A)&nbsp;by a majority vote of the Disinterested Directors, even though
less than a quorum of the Board, (B)&nbsp;by a committee of Disinterested Directors designated by a majority vote of the
Disinterested Directors, even though less than a quorum of the Board, (C)&nbsp;if there are no such Disinterested Directors or, if
such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered
to Indemnitee or (D)&nbsp;if so directed by the Board, by the stockholders of the Company; and, if it is so determined that
Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10)&nbsp;days after such determination.
Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&#8217;s
entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any
documentation or information which is not privileged or otherwise protected from </FONT>disclosure and which is reasonably available
to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys&#8217; fees and
disbursements) incurred by Indemnitee or on behalf of Indemnitee in so cooperating with the person, persons or entity making such
determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to
indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly will
advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a
description of any reason or basis for which indemnification has been denied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;12(a)&nbsp;hereof,
the Independent Counsel shall be selected as provided in this Section&nbsp;12(b). If a Change in Control shall not have occurred, the
Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising Indemnitee of the
identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected
by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply),
and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either
event,&nbsp;Indemnitee or the Company, as the case may be, may, within ten (10)&nbsp;days after such written notice of selection shall
have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; <U>provided</U>,
<U>however</U>, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements
of &#8220;Independent Counsel&#8221; as defined in Section&nbsp;2 of this Agreement, and the objection shall set forth with particularity
the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If
such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and
until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days
after the later of submission by Indemnitee of a written request for indemnification pursuant to Section&nbsp;11(a)&nbsp;hereof and the
final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee
may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other&#8217;s
selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by such court or by such other
person as such court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall
act as Independent Counsel under Section&nbsp;12(a)&nbsp;hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant
to Section&nbsp;14(a)&nbsp;of this Agreement,&nbsp;Independent Counsel shall be discharged and relieved of any further responsibility
in such capacity (subject to the applicable standards of professional conduct then prevailing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
the Company disputes a portion of the amounts for which indemnification is requested, the undisputed portion shall be paid and only the
disputed portion withheld pending resolution of any such dispute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Presumptions
and Effect of Certain Proceedings.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination
shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee
has submitted a request for indemnification in accordance with Section&nbsp;11(a)&nbsp;of this Agreement, and the Company shall, to the
fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person,
persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or
Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification
is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company
(including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense
to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to Section&nbsp;14(e), if the person, persons or entity empowered or selected under Section&nbsp;12 of this Agreement to determine
whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the
Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not
prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i)&nbsp;a
misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not
materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under
applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty
(30) days, if the person, persons or entity making the determination with respect to entitlement </FONT>to indemnification in good
faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and
provided, further, that the foregoing provisions of this Section&nbsp;13(b)&nbsp;shall not apply (i)&nbsp;if the determination of
entitlement to indemnification is to be made by the stockholders pursuant to Section&nbsp;12(a)&nbsp;of this Agreement and if
(A)&nbsp;within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to
submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five
(75) days after such receipt and such determination is made thereat, or (B)&nbsp;a special meeting of stockholders is called within
fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within
sixty (60) days after having been so called and such determination is made thereat, or (ii)&nbsp;if the determination of entitlement
to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;12(a)&nbsp;of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of
<U>nolo contendere</U> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect
the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee
had reasonable cause to believe that Indemnitee&#8217;s conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
purposes of any determination of good faith,&nbsp;Indemnitee shall be deemed to have acted in good faith if Indemnitee&#8217;s action
is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee
by the directors or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or
on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser, financial
advisor or other expert selected with reasonable care by or on behalf of the Enterprise. The provisions of this Section&nbsp;13(d)&nbsp;shall
not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable
standard of conduct set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
knowledge and/or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or employee
of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;14.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies
of Indemnitee.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to Section&nbsp;14(e), in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;12 of this Agreement that Indemnitee
is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to Section&nbsp;10
of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have been made pursuant to Section&nbsp;12(a)&nbsp;of
this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv)&nbsp;payment of indemnification
is not made pursuant to Section&nbsp;5, 6 or 7 or the second to last sentence of Section&nbsp;12(a)&nbsp;of this Agreement within ten
(10)&nbsp;days after receipt by the Company of a written request therefor, (v)&nbsp;payment of indemnification pursuant to Section&nbsp;3,
4 or 8 of this Agreement is not made within ten (10)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification,
or (vi)&nbsp;the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or
institutes any litigation or other action or Proceeding designed to deny, or to recover from,&nbsp;Indemnitee the benefits provided or
intended to be provided to Indemnitee hereunder,&nbsp;Indemnitee shall be entitled to an adjudication by a court of Indemnitee&#8217;s
entitlement to such indemnification or advancement of Expenses. Alternatively,&nbsp;Indemnitee, at Indemnitee&#8217;s option, may seek
an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules&nbsp;of the American Arbitration
Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the
date on which Indemnitee first has the right to commence such proceeding pursuant to this Section&nbsp;14(a). The Company shall not oppose
Indemnitee&#8217;s right to seek any such adjudication or award in arbitration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the event that a determination shall have been made pursuant to Section&nbsp;12(a)&nbsp;of this Agreement that Indemnitee is not
entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14 shall be conducted in
all respects as a <U>de novo</U> trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that
adverse determination. In any judicial proceeding or </FONT>arbitration commenced pursuant to this Section&nbsp;14, the Company
shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
a determination shall have been made pursuant to Section&nbsp;12(a)&nbsp;of this Agreement that Indemnitee is entitled to indemnification,
the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14,
absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s
statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification
under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced
pursuant to this Section&nbsp;14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall
stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the
intent of the Company that, to the fullest extent permitted by law,&nbsp;Indemnitee not be required to incur legal fees or other Expenses
associated with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement by litigation or otherwise
because the cost and expense thereof would substantially detract from the benefits intended to be extended to Indemnitee hereunder. The
Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee,
shall (within ten (10)&nbsp;days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by
law, such Expenses to Indemnitee, which are incurred by Indemnitee or on behalf of Indemnitee in connection with any action brought by
Indemnitee for indemnification or advancement of Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217;
liability insurance policies maintained by the Company if, in the case of indemnification,&nbsp;Indemnitee is wholly successful on the
underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only to the extent
Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall
be required to be made prior to the final disposition of the Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;15.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Non-exclusivity;
Survival of Rights; Insurance; Subrogation.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
rights of indemnification and to receive advancement of Expenses as provided by this Agreement (i)&nbsp;shall not be deemed exclusive
of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws,
any agreement, a vote of stockholders or a resolution of directors, or otherwise and (ii)&nbsp;shall be interpreted independently of,
and without reference to, any other such rights to which Indemnitee may at any time be entitled. No amendment, alteration or repeal of
this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action
taken or omitted by Indemnitee in Indemnitee&#8217;s Corporate Status prior to such amendment, alteration or repeal. To the extent that
a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would
be afforded currently under the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee
shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive
of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given
hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder,
or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">To
the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees,
or agents of the Enterprise,&nbsp;Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the
maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time
of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect,
the Company shall give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance
with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause
such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such
policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the event of any payment made by the Company under this Agreement, the Company shall be subrogated to the extent of such payment to
all of the rights of recovery of Indemnitee [(other than any rights of recovery of Indemnitee from a Fund Indemnitor (as defined
below) or under any insurance provided by </FONT>the Fund or its affiliates)], who shall execute all papers required and take all
action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit
to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">[Except
as provided for under Section&nbsp;15(e)&nbsp;of this Agreement, the] The Company shall not be liable under this Agreement to make any
payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee
has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">[The
Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided by
the Fund and certain of its affiliates (collectively, the &#8220;Fund Indemnitors&#8221;). The Company hereby agrees (i)&nbsp;that it
is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance
expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii)&nbsp;that it shall
be required to advance the full amount of Expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments,
penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the Certificate of Incorporation or
Bylaws (or any agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors,
and, (iii)&nbsp;that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors
for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or
payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from
the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent
of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that
the Fund Indemnitors are express third party beneficiaries of the terms hereof.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"></FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">[Except
as provided in paragraph (e)&nbsp;above,] [T]he Company&#8217;s obligation to indemnify or advance Expenses hereunder to Indemnitee who
is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, fiduciary, employee or agent
of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall
be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited
liability company, partnership, joint venture, trust or other enterprise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;16.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Duration
of Agreement.</U> This Agreement shall continue until and terminate upon the later of: (a)&nbsp;ten (10)&nbsp;years after the date that
Indemnitee shall have ceased to serve as a [director] [officer] of the Company or (b)&nbsp;one (1)&nbsp;year after the final termination
of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder
and of any proceeding (including any appeal thereof) commenced by Indemnitee pursuant to Section&nbsp;14 of this Agreement [or by a Fund
Indemnitor pursuant to Section&nbsp;15(e)&nbsp;of this Agreement, in either case,] relating thereto. The indemnification and advancement
of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and
their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to
all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director,
officer, employee or agent of the Company or of any other Enterprise, and shall inure to the benefit of Indemnitee and Indemnitee&#8217;s
spouse, assigns, heirs, devisees, executors and administrators and other legal representatives. The Company shall require and shall cause
any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business
or assets of the Company to, by written agreement, expressly assume and agree to perform this Agreement in the same manner and to the
same extent that the Company would be required to perform if no such succession had taken place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;17.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability.</U> Nothing
in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of
applicable law. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any
reason whatsoever: (a)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including
without limitation, each portion of any Section&nbsp;of this Agreement containing any such provision held to be invalid, illegal or
unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall
remain enforceable to the fullest extent permitted by law; (b)&nbsp;such provision or provisions shall </FONT>be deemed reformed to
the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and
(c)&nbsp;to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any
Section&nbsp;of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself
invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;18.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Enforcement.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order
to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this
Agreement in serving or continuing to serve as a director or officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes and replaces
all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof,
including any agreement covering the subject matter of this Agreement previously entered into between the Company and Indemnitee; provided,
however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the Bylaws, any directors&#8217;
and officers&#8217; insurance maintained by the Company and applicable law, and shall not be deemed a substitute therefor, nor to diminish
or abrogate any rights of Indemnitee thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;19.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Modification
and Waiver.</U> No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties
hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this
Agreement nor shall any waiver constitute a continuing waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;20.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
by Indemnitee.</U> Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena,
complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement
of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which
it may have to Indemnitee under this Agreement or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;21.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices.</U>
All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly
given if (a)&nbsp;delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed,
(b)&nbsp;mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed,
(c)&nbsp;mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been
directed or (d)&nbsp;sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
to Indemnitee, at the address indicated on the signature page&nbsp;of this Agreement, or such other address as Indemnitee shall provide
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
to the Company, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">CARISMA
Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3675 Market Street, Suite&nbsp;200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Philadelphia,
PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">or to any other address as may have been furnished to Indemnitee by
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;22.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Contribution. </U>To
the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to
Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by
Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in
connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and
reasonable in light of all of the circumstances of such Proceeding in order to reflect (i)&nbsp;the relative benefits received by
the Company, on the one hand, and Indemnitee, on the other hand, as a result of the event(s)&nbsp;and/or transaction(s)&nbsp;giving
cause to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and </FONT>its other directors, officers, employees
and agents), on the one hand, and Indemnitee, on the other hand, in connection with such event(s)&nbsp;and/or transaction(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;23.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Applicable
Law and Consent to Jurisdiction.</U> This Agreement and the legal relations among the parties shall be governed by, and construed and
enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any
arbitration commenced by Indemnitee pursuant to Section&nbsp;14(a)&nbsp;of this Agreement, the Company and Indemnitee hereby irrevocably
and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought
only in the Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country,
(ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of
or in connection with this Agreement, (iii)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Delaware
Court, and (iv)&nbsp;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court
has been brought in an improper or inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;24.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Identical
Counterparts.</U> This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an
original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against
whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;25.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous.</U>
Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of this Agreement
are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>The remainder of this page&nbsp;is intentionally
left blank.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the day and year first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">CARISMA THERAPEUTICS Inc.</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INDEMNITEE</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 7%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>7
<FILENAME>tm238578d1_ex10-7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYMENT AGREEMENT
(the &ldquo;Agreement&rdquo;), is made as of March 7, 2023 (the &ldquo;Effective Date&rdquo;), by and between Carisma Therapeutics
Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and Steven Kelly (the &ldquo;Executive&rdquo;) (together, the &ldquo;Parties&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive has
been employed by CTx Operations,&nbsp;Inc. (f/k/a CARISMA Therapeutics Inc.) (the &ldquo;Carisma Sub&rdquo;) pursuant to that certain
letter agreement dated February&nbsp;12, 2018 detailing the terms and conditions of Executive&rsquo;s employment with the Carisma Sub
(the &ldquo;Prior Agreement&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to that
certain Agreement and Plan of Merger and Reorganization dated September&nbsp;20, 2022 and amended on December&nbsp;29, 2022 and February&nbsp;13,
2023 (the &ldquo;Merger Agreement&rdquo;), by and among the Company (f/k/a Sesen Bio,&nbsp;Inc.), Seahawk Merger Sub,&nbsp;Inc., a Delaware
corporation and wholly-owned subsidiary of the Company (&ldquo;Merger Sub&rdquo;), and the Carisma Sub, Merger Sub merged with and into
Carisma Sub, with Carisma Sub continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the
 &ldquo;Merger&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Parties desire
to enter into an agreement whereby the Executive will be employed as President and Chief Executive Officer of the Company on the terms
contained in this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive has
agreed to accept such employment with the Company on the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and of the respective covenants and agreements of the Parties herein contained, the Parties hereto agree to the following
terms, which shall govern the Executive&rsquo;s employment from and after the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <I>Agreement</I>. This Agreement shall be effective
as of the Effective Date. The Executive&rsquo;s employment on the terms contained in this Agreement shall commence on the Effective Date
and shall continue until such employment relationship is terminated in accordance with Section&nbsp;7 hereof (the &ldquo;Term of Employment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <I>Position</I>. During the Term of Employment,
the Executive shall serve as the President and Chief Executive Officer of the Company and shall serve on the Company&rsquo;s board of
directors (the &ldquo;Board&rdquo;), subject to his reelection thereto from time to time by the Company&rsquo;s stockholders, working
out of the Company&rsquo;s office in Philadelphia, Pennsylvania, and travelling as reasonably required by the Executive&rsquo;s job duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <I>Scope of Employment</I>. During the Term
of Employment, the Executive shall be responsible for the performance of those duties consistent with the Executive&rsquo;s position as
President and Chief Executive Officer. The Executive shall report to the Board. The Executive agrees to devote the Executive&rsquo;s full
business time, best efforts, skill, knowledge, attention, and energies to the advancement of the Company's business and interests and
to the performance of the Executive&rsquo;s duties and responsibilities as an employee of the Company and not to engage in any other business
activities (whether as an employee, consultant, board member, advisor or in any other capacity) without prior approval from the Company,
except (a)&nbsp;as set forth on <U>Schedule 1</U> attached hereto and (b)&nbsp;the Executive may engage in charitable or civic activities
and/or serve as an executor, trustee, or other similar fiduciary capacity, provided, however, that in no event may any activity be undertaken
or continued if it would (i)&nbsp;be in violation of any provision of this Agreement or other agreement between the Executive and the
Company, (ii)&nbsp;interfere with the performance of the Executive&rsquo;s duties for the Company, or (iii)&nbsp;present a conflict of
interest with the Company&rsquo;s business interests. As an employee of the Company, the Executive will be required to comply with all
Company policies and procedures. Violations of the Company's policies may lead to immediate termination of the Executive&rsquo;s employment,
provided, however, that nothing in the foregoing shall alter any rights the Executive may have as set forth in Section&nbsp;8 below. Further,
the Company's premises, including all workspaces, furniture, documents, and other tangible materials, and all information technology resources
of the Company (including computers, data and other electronic files, and all internet and email) are subject to oversight and inspection
by the Company at any time. Company employees should have no expectation of privacy with regard to any Company premises, materials, resources,
or information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <I>Compensation</I>. As full compensation for
all services rendered by the Executive to the Company and any affiliate thereof, during the Term of Employment, the Company will provide
to the Executive the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<I>Base Salary</I>.
The Executive shall receive a base salary, effective as of January&nbsp;1, 2023, at the annualized rate of $560,000 (the &ldquo;Base Salary&rdquo;).
For the avoidance of doubt, to the extent Executive is entitled to additional base salary for the period between January&nbsp;1, 2023
and the Effective Date after taking into account any payments of base salary made by Carisma Sub to the Executive prior to the Effective
Date, such payments will be made in the first payroll following the Effective Date. Otherwise, the Executive&rsquo;s Base Salary shall
be paid in equal installments in accordance with the Company&rsquo;s regularly established payroll procedures. The Executive&rsquo;s Base
Salary will be reviewed on an annual or more frequent basis by the Board and is subject to change in the discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<I>Annual Discretionary
Bonus</I>. The Executive will be eligible to receive an annual discretionary performance bonus of 55% of the Executive&rsquo;s Base Salary
(the &ldquo;Target Bonus&rdquo;), based on the Board&rsquo;s assessment of the Executive&rsquo;s performance and the Company&rsquo;s attainment
of targeted goals to be set by the Board in its sole discretion. Following the close of each calendar year, the Board will determine whether
the Executive has earned a performance bonus, and the amount of any performance bonus, based on the set criteria. No amount of the performance
bonus is guaranteed, and the Executive must be an active employee of the Company on the date the bonus is distributed in order to be eligible
for and to earn any bonus award, as it also serves as an incentive for the Executive to remain employed by the Company. The Executive&rsquo;s
bonus eligibility will be reviewed on an annual or more frequent basis by the Board and is subject to change in the discretion of the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<I>Equity Award</I>.
The Executive will be eligible to receive equity awards, if any, at such times and on such terms and conditions as the Board shall, in
its sole discretion, determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<I>&nbsp;Paid Time Off</I>.
The Executive will be eligible for a maximum of twenty-five (25) days of paid time off (&ldquo;PTO&rdquo;) per calendar year to be taken
at such times as may be approved by the Company. The number of PTO days for which the Executive is eligible shall accrue at the rate of
2.083 days per month that the Executive is employed during such calendar year. Any unused PTO time will be forfeited at the end of each
calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<I>Benefits</I>.
Subject to eligibility requirements and the Company&rsquo;s polices, the Executive shall have the right, on the same basis as other similarly-situated
employees of the Company, to participate in, and to receive benefits under, all employee health, disability, insurance, fringe, welfare
benefit and retirement plans, arrangements, practices and programs the Company provides to its senior executives in accordance with the
terms thereof as in effect from time to time. The Company reserves the right to modify, amend and/or terminate any and all of its benefits
plans at is discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<I>Withholdings</I>.
All compensation payable to the Executive shall be subject to applicable taxes and withholdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <I>Expenses</I>. The Executive will be reimbursed
for the Executive&rsquo;s actual, necessary and reasonable business expenses pursuant to Company policy, subject to the provisions of
Section&nbsp;3 of <U>Exhibit&nbsp;A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.
<I>Restrictive Covenants Agreements</I>. The Executive hereby acknowledges that each of the Invention and Non-Disclosure Agreement and
the Non-Competition and Non-Solicitation Agreement that the Executive previously executed in connection with the Executive&rsquo;s employment
with the Carisma Sub (together, the &ldquo;Restrictive Covenant Agreements&rdquo;) remain in full force and effect, with the terms thereof
hereby deemed incorporated herein; provided, however, that the references therein to &ldquo;Company&rdquo; shall be deemed hereinafter
to mean the Company, as well as the Carisma Sub.&nbsp; The Executive further acknowledges that the Executive&rsquo;s employment with the
Company is conditioned on the Executive&rsquo;s continued compliance with the Restrictive Covenant Agreements</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <I>Employment Termination</I>. This Agreement
and the employment of the Executive shall terminate upon the occurrence of any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;Upon the death of
the Executive or at the election of the Company due to the Executive&rsquo;s &ldquo;Disability&rdquo;. As used in this Agreement, the
term &ldquo;Disability&rdquo; shall mean a physical or mental illness or disability that prevents the Executive from performing the duties
of the Executive&rsquo;s position for a period of more than any three (3)&nbsp;consecutive months or for periods aggregating more than
twenty-six (26) weeks. The Company shall determine in good faith and in its sole discretion whether the Executive is unable to perform
the services provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;At the election of
the Company, with or without &ldquo;Cause&rdquo; (as defined below), immediately upon written notice by the Company to the Executive.
As used in this Agreement, &ldquo;Cause&rdquo; shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s engagement in any conduct that has materially and adversely affected, or is reasonably likely to materially and adversely
affect, the business interests or reputation of the Company (for avoidance of doubt, &ldquo;conduct&rdquo; in this subsection does not
mean poor performance or failure to meet Company objectives);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
breach by the Executive of the Restrictive Covenant Agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s willful and repeated failure to perform in any material respect, the Executive&rsquo;s duties to the Company under this
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s fraud or embezzlement, or the Executive&rsquo;s willful misconduct with respect to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s material breach of this Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s conviction of, or plea of guilty or <I>nolo contendere </I>to, a misdemeanor relating to the Company, any crime involving
dishonesty or moral turpitude, or any felony;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided however, that with respect to subsections
(i), (ii)&nbsp;(iii)&nbsp;and (v)&nbsp;hereof, the Executive was given thirty (30) calendar days&rsquo; written notice of such conduct,
breach, or deficiencies and an opportunity to cure such conduct, breach or deficiencies but the Executive failed to do so within such
period (provided that the Executive is eligible for no more than two &ldquo;cure&rdquo; opportunities during the Executive&rsquo;s employment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;At the election of
the Executive, with or without &ldquo;Good Reason&rdquo; (as defined below), upon written notice by the Executive to the Company (subject,
if it is with Good Reason, to the timing provisions set forth in the definition of Good Reason). As used in this Agreement, &ldquo;Good
Reason&rdquo; shall mean the occurrence (without the Executive&rsquo;s prior written consent), of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
material reduction in the Executive&rsquo;s authority, duties, or responsibilities or a material reduction in the authority, duties or
responsibilities of the person to whom the Executive reports;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
relocation of the principal place at which the Executive provides services to the Company by at least fifty (50) miles and to a location
such that the Executive&rsquo;s daily commuting distance is increased;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
material reduction of the Executive&rsquo;s Base Salary; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
material breach by the Company of its obligations under this letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">No termination will
be treated as a termination by the Executive for Good Reason unless (x)&nbsp;the Executive has given written notice to the Company of
the Executive&rsquo;s intention to terminate the Executive&rsquo;s employment for Good Reason, describing the grounds for such action,
no later than ninety (90) days after the first occurrence of such circumstances, (y)&nbsp;the Executive has provided the Company with
at least thirty (30) days in which to cure the circumstances, and (z)&nbsp;if the Company is not successful in curing the circumstances,
the Executive ends the Executive&rsquo;s employment within thirty (30) calendar days following the cure period in (y).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. <I>Effect of Termination</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<I>&nbsp; All Terminations
Other Than by the Company Without Cause or by the Executive With Good Reason</I>. If the Executive&rsquo;s employment is terminated under
any circumstances other than a termination by the Company without Cause or a termination by the Executive with Good Reason (including
a voluntary termination by the Executive without Good Reason or a termination by the Company for Cause or due to the Executive&rsquo;s
death or Disability), the Company&rsquo;s obligations under this Agreement shall immediately cease and the Executive shall only be entitled
to receive (i)&nbsp;the Base Salary that has accrued and to which the Executive is entitled as of the effective date of such termination,
to be paid in accordance with the Company&rsquo;s established payroll procedure and applicable law but no later than the next regularly
scheduled pay period, (ii)&nbsp;unreimbursed business expenses for which expenses the Executive has timely submitted appropriate documentation
in accordance with Section&nbsp;5 hereof, (iii)&nbsp;any amounts or benefits to which the Executive is then entitled under the terms of
the benefit plans then-sponsored by the Company in accordance with their terms (and not accelerated to the extent acceleration does not
satisfy Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, (the &ldquo;Code&rdquo;)), and (iv)&nbsp;any accrued but unused
vacation time through the date of termination, to be paid in accordance with Company policy and applicable law (the payments described
in this sentence, the &ldquo;Accrued Obligations&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;</FONT><I>Termination
by the Company Without Cause or by the Executive With Good Reason More Than Three Months Prior to or More Than Twelve Months Following
a Change in Control.</I>&nbsp;If the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with
Good Reason more than three (3)&nbsp;months prior to, or more than twelve (12)&nbsp;months following, a Change in Control (as defined
below), the Executive shall be entitled to the Accrued Obligations. In addition, and subject to&nbsp;<U>Exhibit&nbsp;A</U>&nbsp;and the
conditions of Section&nbsp;8(d), the Company shall: (i)&nbsp;continue to pay to the Executive, in accordance with the Company&rsquo;s
regularly established payroll procedures, the Executive&rsquo;s Base Salary for a period of twelve (12)&nbsp;months; (ii)&nbsp;pay to
the Executive, in a single lump sum on the Payment Date (as defined below) an amount equal to one hundred percent (100%) of the Executive&rsquo;s
Target Bonus for the year in which termination occurs, prorated based on a fraction, the numerator of which is the number of days during
the calendar year in which the Executive&rsquo;s termination date occurs that the Executive remained employed by the Company and the denominator
of which is 365 (such amount, the &ldquo;Pro Rata Bonus&rdquo;); and (iii)&nbsp;provided the Executive is eligible for and timely elects
to continue receiving group medical insurance pursuant to the &ldquo;COBRA&rdquo; law, continue to pay for twelve (12)&nbsp;months following
the Executive&rsquo;s termination date or until the Executive has secured other employment or is no longer eligible for coverage under
COBRA, whichever occurs first, the share of the premium for health coverage that is paid by the Company for active and similarly-situated
employees who receive the same type of coverage, unless the Company&rsquo;s provision of such COBRA payments will violate the nondiscrimination
requirements of applicable law, in which case this benefit will not apply (collectively, the &ldquo;Severance Benefits&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<FONT STYLE="background-color: white"><I>Termination
by the Company Without Cause or by the Executive With Good Reason Within Three Months Prior to or Twelve Months Following a Change in
Control.</I>&nbsp;If the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with Good Reason
within the period that begins three (3)&nbsp;months prior to and ends twelve (12)&nbsp;months following a Change in Control, then the
Executive shall be entitled to the Accrued Obligations. In addition, and subject to&nbsp;<U>Exhibit&nbsp;A</U>&nbsp;and the conditions
of Section&nbsp;8(d), the Company shall: (i)&nbsp;pay to the Executive, in a single lump sum on the Payment Date, an amount equal to the
sum of (x)&nbsp;eighteen (18) months of the Executive&rsquo;s Base Salary, and (y)&nbsp;one hundred fifty percent (150%) of the Executive&rsquo;s
Target Bonus for the year in which termination occurs or, if higher, the Executive&rsquo;s Target Bonus immediately prior to the Change
in Control, (ii)&nbsp;pay to the Executive, in a single lump sum on the Payment Date, the Pro Rata Bonus which Pro Rata Bonus, shall,
for the avoidance of doubt, be determined by reference to the Executive&rsquo;s Target Bonus for the year in which termination occurs,
or, if higher, the Executive&rsquo;s Target Bonus immediately prior to the Change in Control, (iii)&nbsp;provided the Executive is eligible
for and timely elects to continue receiving group medical insurance pursuant to the &ldquo;COBRA&rdquo; law, continue to pay for eighteen
(18) months following the Executive&rsquo;s termination date or until the Executive has secured other employment or is no longer eligible
for coverage under COBRA, whichever occurs first, the share of the premium for health coverage that is paid by the Company for active
and similarly-situated employees who receive the same type of coverage, unless the Company&rsquo;s provision of such COBRA payments will
violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply, and (iv)&nbsp;provide that the
vesting of the Executive&rsquo;s then-unvested equity awards that vest based solely on the passage of time shall be accelerated, such
that all such then-unvested time-based equity awards shall vest and become fully exercisable or&nbsp;non-forfeitable&nbsp;as of the later
of the date of the Change in Control and the Executive&rsquo;s termination date (collectively, the &ldquo;Change in Control Severance
Benefits&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<I>Release</I>.
As a condition of the Executive&rsquo;s receipt of the Severance Benefits or the Change in Control Severance Benefits, as applicable,
the Executive must execute and deliver to the Company a separation and release of claims agreement in substantially the form attached
hereto as <U>Exhibit&nbsp;B</U> (the &ldquo;Release&rdquo;), which Release must become irrevocable within sixty (60) days following the
date of the Executive&rsquo;s termination of employment (or such shorter period as may be directed by the Company). The Severance Benefits
or the Change in Control Severance Benefits, as applicable, will be paid or commence to be paid in the first regular payroll beginning
after the Release becomes effective, provided that if the foregoing sixty (60) day period would end in a calendar year subsequent to the
year in which the Executive&rsquo;s employment ends, the Severance Benefits or Change in Control Severance Benefits, as applicable, will
not be paid or begin to be paid before the first payroll of the subsequent calendar year (the date the Severance Benefits or Change in
Control Severance Benefits, as applicable, are paid or commence pursuant to this sentence, the &ldquo;Payment Date&rdquo;). The Executive
must continue to comply with all post-employment obligations under law or in any agreement between the Executive and the Company, including
the Restrictive Covenant Agreements, any similar agreement with the Company and as set forth in the Release in order to be eligible to
receive or continue receiving the Severance Benefits or Change in Control Severance Benefits, as applicable. </FONT><FONT STYLE="background-color: white">For
the avoidance of doubt, if the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with Good Reason
prior to a Change in Control, (i)&nbsp;any then-outstanding and unvested time-based equity awards held by the Executive shall remain outstanding
(but any vesting shall be suspended) for up to (but no longer than) three (3)&nbsp;months following the date of termination so that, if
it is later determined that such termination occurred during the three (3)-month period prior to the closing of a Change in Control and
the Executive is entitled to Change in Control acceleration and/or Change in Control Severance Benefits rather than Severance Benefits,
the vesting of such awards may be accelerated, in accordance with Section&nbsp;8(c), immediately prior to the closing of the Change in
Control and (ii)&nbsp;any Change in Control Severance Benefits shall be reduced by any Severance Benefits previously paid to the Executive,
if it is later determined that the termination occurred during the three (3)-month period prior to the closing of a Change in Control
and that the Executive is entitled to Change in Control Severance Benefits rather than Severance Benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<I>Change in Control
Definition</I>. For purposes of this Agreement, &ldquo;Change in Control&rdquo; shall mean the occurrence of any of the following events,
provided that such event or occurrence constitutes a change in the ownership or effective control of the Company, or a change in the ownership
of a substantial portion of the assets of the Company, as defined in Treasury Regulation &sect;&sect; 1.409A-3(i)(5)(v), (vi)&nbsp;and
(vii): (i)&nbsp;the acquisition by an individual, entity or group (within the meaning of Section&nbsp;13(d)(3)&nbsp;or 14(d)(2)&nbsp;of
the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;)) (a &ldquo;Person&rdquo;) of beneficial ownership of any capital
stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule&nbsp;13d-3 under the Exchange
Act) fifty percent (50%) or more of either (x)&nbsp;the then-outstanding shares of common stock of the Company (the &ldquo;Outstanding
Company Common Stock&rdquo;) or (y)&nbsp;the combined voting power of the then-outstanding securities of the Company entitled to vote
generally in the election of directors (the &ldquo;Outstanding Company Voting Securities&rdquo;); provided, however, that for purposes
of this subsection (i), the following acquisitions shall not constitute a Change in Control: (1)&nbsp;any acquisition directly from the
Company or (2)&nbsp;any acquisition by any entity pursuant to a Business Combination (as defined below) which complies with clauses (x)&nbsp;and
(y)&nbsp;of subsection (iii)&nbsp;of this definition; or (ii)&nbsp;a change in the composition of the Board that results in the Continuing
Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of a successor
corporation to the Company), where the term &ldquo;Continuing Director&rdquo; means at any date a member of the Board (x)&nbsp;who was
a member of the Board on the Effective Date or (y)&nbsp;who was nominated or elected subsequent to such date by at least a majority of
the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended
or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided,
however, that there shall be excluded from this clause (y)&nbsp;any individual whose initial assumption of office occurred as a result
of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation
of proxies or consents, by or on behalf of a person other than the Board; or (iii)&nbsp;the consummation of a merger, consolidation, reorganization,
recapitalization or share exchange involving the Company, or a sale or other disposition of all or substantially all of the assets of
the Company (a &ldquo;Business Combination&rdquo;), unless, immediately following such Business Combination, each of the following two
(2)&nbsp;conditions is satisfied: (x)&nbsp;all or substantially all of the individuals and entities who were the beneficial owners of
the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially
own, directly or indirectly, more than fifty percent (50%) of the then-outstanding shares of common stock and the combined voting power
of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring
corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction
owns the Company or substantially all of the Company&rsquo;s assets either directly or through one (1)&nbsp;or more subsidiaries) (such
resulting or acquiring corporation is referred to herein as the &ldquo;Acquiring Corporation&rdquo;) in substantially the same proportions
as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior
to such Business Combination and (y)&nbsp;no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by
the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, fifty percent (50%) or more of the then-outstanding
shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation
entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination);
or (iv)&nbsp;the liquidation or dissolution of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<I>Resignation from
other Positions</I>. If, as of the date that the Executive&rsquo;s employment terminates for any reason, the Executive is a member of
the Board (or the board of directors of any entity affiliated with the Company), or hold any other offices or positions with the Company
(or any entity affiliated with the Company), the Executive shall, unless otherwise requested by the Company, immediately relinquish and/or
resign from any such board memberships, offices and positions as of the date the Executive&rsquo;s employment terminates. The Executive
agrees to execute such documents and take such other actions as the Company may request to reflect such relinquishments and/or resignation(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. <I>Absence of Restrictions</I>. The Executive
represents and warrants that the Executive is not bound by any employment contracts, restrictive covenants or other restrictions that
prevent (or purports to prevent) the Executive from carrying out the Executive&rsquo;s responsibilities for the Company, or which are
in any way inconsistent with any of the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. <I>Notice</I>. Any notice delivered under
this Agreement shall be deemed duly delivered three (3)&nbsp;business days after it is sent by registered or certified mail, return receipt
requested, postage prepaid, one (1)&nbsp;business day after it is sent for next-business day delivery via a reputable nationwide overnight
courier service, or immediately upon hand delivery, in each case to the address of the recipient set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the address set forth in
the Executive&rsquo;s personnel file</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma Therapeutics Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3675 Market Street, Suite&nbsp;200&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Philadelphia, Pennsylvania
19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Either Party may change the address to which notices
are to be delivered by giving notice of such change to the other Party in the manner set forth in this Section&nbsp;10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. <I>Applicable Law and Forum</I>. This Agreement
shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania (without reference to the conflict
of laws provisions thereof). Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall
be commenced only in a court of the Commonwealth of Pennsylvania (or, if appropriate, a federal court located within the Commonwealth
of Pennsylvania), and the Company and the Executive each consent to the exclusive jurisdiction of such a court. The Company and the Executive
each hereby irrevocably waives any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to
any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12. <I>Successors and Assigns</I>. This Agreement
shall be binding upon and inure to the benefit of both Parties and their respective successors and assigns, including any corporation
with which or into which the Company may be merged or which may succeed to its assets or business; provided, however, that the obligations
of the Executive are personal and shall not be assigned by the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13. <I>At-Will Employment</I>. This Agreement
shall not be construed as an agreement, either expressed or implied, to employ the Executive for any stated term, and shall in no way
alter the Company&rsquo;s policy of employment at will, under which both the Executive and the Company remain free to terminate the employment
relationship, with or without cause, at any time, with or without notice. Although the Executive&rsquo;s job duties, title, compensation
and benefits, as well as the Company's personnel policies and procedures, may change from time to time, the &ldquo;at-will&rdquo; nature
of the Executive&rsquo;s employment may only be changed by a written agreement signed by the Executive and a duly authorized representative
of the Company, which written agreement expressly states the intention to modify the at-will nature of the Executive&rsquo;s employment,
provided, however, that nothing in the foregoing shall alter any rights the Executive may have as set forth in Section&nbsp;8 above. Similarly,
nothing in this Agreement shall be construed as an agreement, either express or implied, to pay the Executive any compensation or grant
the Executive any benefit beyond the end of the Executive&rsquo;s employment with the Company, except as explicitly set forth in Section&nbsp;8
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. <I>Acknowledgment</I>. The Executive states
and represents that the Executive has had an opportunity to fully discuss and review the terms of this Agreement with an attorney. The
Executive further states and represents that the Executive has carefully read this Agreement, understands the contents herein, freely
and voluntarily assents to all of the terms and conditions hereof, and signs the Executive&rsquo;s name of the Executive&rsquo;s own free
act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15. <I>No Oral Modification, Waiver, Cancellation
or Discharge</I>. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.
No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right.
A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a
bar to or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16. <I>Captions and Pronouns</I>. The captions
of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of
any section of this Agreement. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17. <I>Interpretation</I>. The Parties agree that
this Agreement will be construed without regard to any presumption or rule&nbsp;requiring construction or interpretation against the drafting
Party. References in this Agreement to &ldquo;include&rdquo; or &ldquo;including&rdquo; should be read as though they said &ldquo;without
limitation&rdquo; or equivalent forms. Except where the context requires otherwise, references in this Agreement to the &ldquo;Board&rdquo;
shall include any authorized committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">18. <I>Severability</I>. Each provision of this
Agreement must be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement
is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition
or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. Moreover, if a court
of competent jurisdiction determines any of the provisions contained in this Agreement to be unenforceable because the provision is excessively
broad in scope, whether as to duration, activity, geographic application, subject or otherwise, it will be construed, by limiting or reducing
it to the extent legally permitted, so as to be enforceable to the extent compatible with then applicable law to achieve the intent of
the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">19. <I>Modified Section&nbsp;280G Cutback</I>.
Notwithstanding any other provision of this Agreement, except as set forth in Section&nbsp;19(b), in the event that the Company undergoes
a &ldquo;Change in Ownership or Control&rdquo; (as defined below), the following provisions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The Company shall
not be obligated to provide to the Executive any portion of any &ldquo;Contingent Compensation Payments&rdquo; (as defined below) that
the Executive would otherwise be entitled to receive to the extent necessary to eliminate any &ldquo;excess parachute payments&rdquo;
(as defined in Section&nbsp;280G(b)(1)&nbsp;of the Code) for the Executive. For purposes of this Section&nbsp;19, the Contingent Compensation
Payments so eliminated shall be referred to as the &ldquo;Eliminated Payments&rdquo; and the aggregate amount (determined in accordance
with Treasury Regulation Section&nbsp;1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated
shall be referred to as the &ldquo;Eliminated Amount.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;Notwithstanding the
provisions of Section&nbsp;19(a), no such reduction in Contingent Compensation Payments shall be made if (1)&nbsp;the Eliminated Amount
(computed without regard to this sentence) exceeds (2)&nbsp;one hundred percent (100%) of the aggregate present value (determined in accordance
with Treasury Regulation Section&nbsp;1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional taxes that
would be incurred by the Executive if the Eliminated Payments (determined without regard to this sentence) were paid to the Executive
(including state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section&nbsp;4999 of the Code payable
with respect to all of the Contingent Compensation Payments in excess of the Executive&rsquo;s &ldquo;base amount&rdquo; (as defined in
Section&nbsp;280G(b)(3)&nbsp;of the Code), and any withholding taxes). The override of such reduction in Contingent Compensation Payments
pursuant to this Section&nbsp;19(b)&nbsp;shall be referred to as a &ldquo;Section&nbsp;19(b)&nbsp;Override.&rdquo; For purpose of this
paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes
shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;For purposes of this
Section&nbsp;19 the following terms shall have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&nbsp;&ldquo;Change in Ownership
or Control&rdquo; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion
of the assets of the Company determined in accordance with Section&nbsp;280G(b)(2)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii)&nbsp;&ldquo;Contingent Compensation
Payment&rdquo; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement
or otherwise) to or for the benefit of a &ldquo;disqualified individual&rdquo; (as defined in Section&nbsp;280G(c)&nbsp;of the Code) and
that is contingent (within the meaning of Section&nbsp;280G(b)(2)(A)(i)&nbsp;of the Code) on a Change in Ownership or Control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;Any payments or other
benefits otherwise due to the Executive following a Change in Ownership or Control that could reasonably be characterized (as determined
by the Company) as Contingent Compensation Payments (the &ldquo;Potential Payments&rdquo;) shall not be made until the dates provided
for in this Section&nbsp;19(d). Within thirty (30) days after each date on which the Executive first becomes entitled to receive (whether
or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify
the Executive (with reasonable detail regarding the basis for its determinations) (1)&nbsp;which Potential Payments constitute Contingent
Compensation Payments, (2)&nbsp;the Eliminated Amount and (3)&nbsp;whether the Section&nbsp;19(b)&nbsp;Override is applicable. Within
thirty (30) days after delivery of such notice to the Executive, the Executive shall deliver a response to the Company (the &ldquo;Executive
Response&rdquo;) stating either (A)&nbsp;that the Executive agrees with the Company&rsquo;s determination pursuant to the preceding sentence
or (B)&nbsp;that the Executive disagrees with such determination, in which case the Executive shall set forth (x)&nbsp;which Potential
Payments should be characterized as Contingent Compensation Payments, (y)&nbsp;the Eliminated Amount, and (z)&nbsp;whether the Section&nbsp;19(b)&nbsp;Override
is applicable. In the event that the Executive fails to deliver an Executive Response on or before the required date, the Company&rsquo;s
initial determination shall be final. If and to the extent that any Contingent Compensation Payments are required to be treated as Eliminated
Payments pursuant to this Section&nbsp;19, then the payments shall be reduced or eliminated, as determined by the Company, in the following
order: (i)&nbsp;any cash payments, (ii)&nbsp;any taxable benefits, (iii)&nbsp;any nontaxable benefits, and (iv)&nbsp;any vesting of equity
awards in each case in reverse order beginning with payments or benefits that are to be paid the farthest in time from the date that triggers
the applicability of the excise tax, to the extent necessary to maximize the Eliminated Payments. If the Executive states in the Executive
Response that the Executive agrees with the Company&rsquo;s determination, the Company shall make the Potential Payments to the Executive
within three (3)&nbsp;business days following delivery to the Company of the Executive Response (except for any Potential Payments which
are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due). If the Executive
states in the Executive Response that the Executive disagrees with the Company&rsquo;s determination, then, for a period of sixty (60)
days following delivery of the Executive Response, the Executive and the Company shall use good faith efforts to resolve such dispute.
If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration as provided in Section&nbsp;11
of this Agreement. The Company shall, within three (3)&nbsp;business days following delivery to the Company of the Executive Response,
make to the Executive those Potential Payments as to which there is no dispute between the Company and the Executive regarding whether
they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments
shall be made on the date on which they are due). The balance of the Potential Payments shall be made within three (3)&nbsp;business days
following the resolution of such dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of this Section&nbsp;19
are intended to apply to any and all payments or benefits available to the Executive under this Agreement or any other agreement or plan
under which the Executive may receive Contingent Compensation Payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">20. <I>Entire Agreement</I>. Except as expressly
provided in the Merger Agreement and any other agreements to which the Executive is or will be party in connection with the Transaction,
this Agreement constitutes the entire agreement between the Parties and supersedes and replaces all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement, including, without limitation, the Prior Agreement; provided,
however, and for the avoidance of doubt, nothing herein shall be deemed to supersede the Restrictive Covenant Agreements, which remain
in full force and effect as set forth in Section&nbsp;6 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the Parties hereto have executed
this Agreement as of the day and year set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 3%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 3%">By:</TD>
                                                                                   <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">/s/ Richard Morris</TD>
                                                                                   <TD STYLE="text-align: justify; width: 47%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 3%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 5%">Name:</TD>
                                                                                   <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%">Richard Morris</TD>
                                                                                   <TD STYLE="text-align: justify; width: 47%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 3%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 4%">Title:</TD>
                                                                                   <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 46%">Chief Financial Officer</TD>
                                                                                   <TD STYLE="text-align: justify; width: 47%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXECUTIVE:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%">/s/ Steven Kelly</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Steven Kelly</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service as a non-employee member on the board
of directors of Artelo Biosciences,&nbsp;Inc. in a non-operating capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Payments Subject to Section&nbsp;409A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to this <U>Exhibit&nbsp;A</U>, any severance payments or benefits that may be due under the Agreement shall begin only upon the date of
the Executive&rsquo;s &ldquo;separation from service&rdquo; (determined as set forth below) which occurs on or after the termination of
the Executive&rsquo;s employment. The following rules&nbsp;shall apply with respect to distribution of the severance payments or benefits,
if any, to be provided to the Executive under the Agreement, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is intended that each installment of the severance payments or benefits provided under the Agreement shall be treated as a separate &ldquo;payment&rdquo;
for purposes of Section&nbsp;409A of the Internal Revenue Code (&ldquo;Section&nbsp;409A&rdquo;). Neither the Company nor the Executive
shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted
or required by Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
as of the date of the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company, the Executive is not a &ldquo;specified
employee&rdquo; (within the meaning of Section&nbsp;409A), then each installment of the severance payments or benefits shall be made on
the dates and terms set forth in the letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
as of the date of the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company, the Executive is a &ldquo;specified employee&rdquo;
(within the meaning of Section&nbsp;409A), then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Each installment of the severance payments or benefits due under the Agreement that, in accordance with
the dates and terms set forth herein, will in all circumstances, regardless of when the Executive&rsquo;s separation from service occurs,
be paid within the short-term deferral period (as defined under Section&nbsp;409A) shall be treated as a short-term deferral within the
meaning of Treasury Regulation Section&nbsp;1.409A-1(b)(4)&nbsp;to the maximum extent permissible under Section&nbsp;409A and shall be
paid on the dates and terms set forth in the Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">Each installment of the severance payments or benefits due under the Agreement that is not described in
this <U>Exhibit&nbsp;A</U>, Section&nbsp;1(c)(i)&nbsp;and that would, absent this subsection, be paid within the six (6)-month period
following the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company shall not be paid until the date that is six (6)&nbsp;months
and one day after such separation from service (or, if earlier, the Executive&rsquo;s death), with any such installments that are required
to be delayed being accumulated during the six (6)-month period and paid in a lump sum on the date that is six months and one day following
the Executive&rsquo;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms
set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of payments or
benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide
for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii)&nbsp;(relating to separation pay
upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section&nbsp;1.409A-1(b)(9)(iii)&nbsp;must
be paid no later than the last day of the Executive&rsquo;s second taxable year following the taxable year in which the separation from
service occurs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
determination of whether and when the Executive&rsquo;s separation from service from the Company has occurred shall be made and in a manner
consistent with, and based on the presumptions set forth in, Treasury Regulation Section&nbsp;1.409A-1(h). Solely for purposes of Section&nbsp;2
of this <U>Exhibit&nbsp;A</U>, &ldquo;Company&rdquo; shall include all persons with whom the Company would be considered a single employer
under Section&nbsp;414(b)&nbsp;and 414(c)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
reimbursements and in-kind benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A
to the extent that such reimbursements or in-kind benefits are subject to Section&nbsp;409A, including, where applicable, the requirements
that (i)&nbsp;any reimbursement is for expenses incurred during the Executive&rsquo;s lifetime (or during a shorter period of time specified
in the Agreement), (ii)&nbsp;the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible
for reimbursement in any other calendar year, (iii)&nbsp;the reimbursement of an eligible expense will be made on or before the last day
of the calendar year following the year in which the expense is incurred and (iv)&nbsp;the right to reimbursement is not subject to set
off or liquidation or exchange for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company makes no representation or warranty and shall have no liability to the Executive or to any other person if any of the provisions
of the Agreement (including this <U>Exhibit&nbsp;A</U>) are determined to constitute deferred compensation subject to Section&nbsp;409A
but that do not satisfy an exemption from, or the conditions of, that section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Agreement is intended to comply with, or be exempt from, Section&nbsp;409A and shall be interpreted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of page&nbsp;intentionally left blank.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B<SUP>1</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sample Separation and Release Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[Insert Date]</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[Insert Name]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear <B>[Insert Name]</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the termination
of your employment with [Carisma Therapeutics Inc.] (the &ldquo;Company&rdquo;) on <B>[Separation Date]</B>, you are eligible to receive
[Severance Benefits] [Change in Control Severance Benefits] as described in Section&nbsp;8 of the employment agreement executed between
you and the Company dated _______ (the &ldquo;Employment Agreement&rdquo;) if you sign and return this letter agreement to me by <B>[Return
Date &ndash;7/21/45 days from date of receipt of this letter agreement] [and it becomes binding between you and the Company</B>]. By
signing and returning this letter agreement [<B>and not revoking your acceptance]</B>, you will be agreeing to the terms and conditions
set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 2. Therefore, you are advised to consult
with an attorney before signing this letter agreement and you have been given at least [<B>seven/twenty-one (21)/forty-five (45)]<SUP>2
</SUP></B>days to do so. [<B>If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7)&nbsp;day
period after you have signed it (the &ldquo;Revocation Period&rdquo;) by notifying me in writing. If you do not so revoke, this letter
agreement will become a binding agreement between you and the Company upon the expiration of the Revocation Period.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although your receipt of the
[Severance Benefits] [Change in Control Severance Benefits] is expressly conditioned on your entering into this letter agreement, the
following will apply regardless of whether or not you do so:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">As of the Separation Date, all salary payments from the Company will cease and any benefits you had as
of the Separation Date under Company-provided benefit plans, programs, or practices will terminate, except as required by federal or state
law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">You will receive payment for your final wages and any unused vacation time accrued through the Separation
Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">You may, if eligible and at your own cost, elect to continue receiving group medical insurance pursuant
to applicable &ldquo;COBRA&rdquo; law. Please consult the COBRA materials to be provided under separate cover for details regarding these
benefits.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">You are obligated to keep confidential and not to use or disclose any and all non-public information concerning
the Company that you acquired during the course of your employment with the Company, including any non-public information concerning the
Company&rsquo;s business affairs, business prospects, and financial condition, except as otherwise permitted by paragraph 9 below. Further,
you remain subject to any and all continuing confidentiality, non-competition and/or non-solicitation obligations that you may have pursuant
to any previous agreement with the Company, including, as may be applicable and without limitation, the Employment Agreement and the Invention
and Non-Disclosure Agreement and Non-Competition and Non-Solicitation Agreement (the &ldquo;Restrictive Covenant Agreements&rdquo;) referenced
therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">You must return to the Company no later than the Separation Date all Company property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> Note: The Company may revise this release agreement in
its sole discretion to reflect changes in law, additional statutes or claims, benefits, or employee&rsquo;s circumstances, so that the
Company receives the benefit of the most complete release of claims that is legally permissible (without releasing employee&rsquo;s right
to receive the Severance Benefits), and the Company may also change the timing, if required to obtain such release. This footnote and
the other footnotes herein are part of the form of release and are to be removed only when the Company finalizes the letter agreement
for execution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP> Consideration period depends upon circumstances of separation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you elect to timely sign
and return this letter agreement, comply with all of your obligations hereunder, and do not revoke your acceptance in writing within the
Revocation Period, the following numbered paragraphs set forth the terms and conditions that will also apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><B><U>Severance Benefits</U></B> The Company will provide you with the [as may be applicable [Severance
Benefits] or [Change in Control Severance Benefits]] set forth in Section&nbsp;8 of the Employment Agreement (the [&ldquo;Severance Benefits&rdquo;]
[&ldquo;Change in Control Severance Benefits&rdquo;]), <B>s</B>ubject to and in accordance with the terms and conditions thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><B><U>Release</U></B> &ndash; In consideration of the [Severance Benefits] [Change in Control Severance
Benefits], which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally
release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their
respective past and present officers, directors, stockholders, partners, members, managers, employees, agents, representatives, plan administrators,
attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &ldquo;Released Parties&rdquo;)
from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts,
reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses
(including attorneys&rsquo; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released
Parties, whether known or unknown, including, but not limited to, any and all claims arising out of or relating to your employment with
and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C.
 &sect; 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. &sect; 12101 et seq., <B>[the Age Discrimination in Employment
Act, 29 U.S.C. &sect; 621 et seq.,] </B>the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &sect; 2000ff et seq., the Family
and Medical Leave Act, 29 U.S.C. &sect; 2601 et seq., the Worker Adjustment and Retraining Notification Act (&ldquo;WARN&rdquo;), 29 U.S.C.
 &sect; 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C. &sect; 701 et seq., Executive Order 11246, Executive Order 11141, the Fair
Credit Reporting Act, 15 U.S.C. &sect; 1681 et seq., and the Employee Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;), 29
U.S.C. &sect; 1001 et seq., all as amended; all claims arising out of the Pennsylvania Human Relations Act, 43 Pa. Stat. &sect; 951 et
seq., the Pennsylvania Equal Pay Law, 43 Pa. Stat. &sect; 336.1 et seq., the Pennsylvania Wage Payment and Collection Law, 43 Pa. Stat.
 &sect; 251 et seq., and the Pennsylvania Whistleblower Law, 43 Pa. Stat. &sect; 1421 et seq., all as amended; <B>[Insert any other applicable
federal, state and local citations at the time of termination;] </B>all common law claims including, but not limited to, actions in defamation,
intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without
limitation, all claims arising out of or relating to the Employment Agreement); all claims to any ownership interest in the Company, contractual
or otherwise; all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of
your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal,
state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this letter agreement: (i)&nbsp;prevents
you from filing a charge with, cooperating with, or participating in any investigation or proceeding before, the Equal Employment Opportunity
Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in
connection with any such charge, investigation, or proceeding, and you further waive any rights or claims to any payment, benefit, attorneys&rsquo;
fees or other remedial relief in connection with any such charge, investigation or proceeding), (ii)&nbsp;deprives you of any accrued
benefits to which you have acquired a vested right under any employee benefit plan or policy, stock plan or deferred compensation arrangement,
any health care continuation to the extent required by applicable law or any agreement, or any right to severance benefits or any other
benefits due to you upon termination of employment that you may have under the Employment Agreement; or (iii)&nbsp;deprives you of any
rights you may have to be indemnified by the Company as provided in any agreement between the Company and you, or pursuant to the Company&rsquo;s
Certificate of Incorporation or by-laws (recognizing that such indemnification is not guaranteed by this letter agreement and shall be
governed by the instrument, if any, providing for such indemnification).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><B><U>Continuing Obligations</U></B> &ndash; You acknowledge and reaffirm your confidentiality and
                                                                                                                                                 nondisclosure obligations discussed above, as well
as any and all confidentiality, non-competition, nonsolicitation obligations and/or assignment of inventions set forth in any previous
agreement you may have with the Company (including without limitation the Employment Agreement and the Restrictive Covenants Agreements
referenced therein), which survive your separation from employment with the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><B><U>Non-Disparagement</U></B> &ndash; You understand and agree that, to the extent permitted by law
and except as otherwise permitted by paragraph 9 below, you will not, in public or private, make any false, disparaging, derogatory or
defamatory statements, online (including, without limitation, on any social media, networking, or employer review site) or otherwise,
to any person or entity, including, but not limited to, any media outlet, industry group, financial institution or current or former employee,
board member, consultant, client or customer of the Company, regarding the Company or any of the other Released Parties, or regarding
the Company&rsquo;s business affairs, business prospects, or financial condition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><B><U>Cooperation</U></B> &ndash; You agree that, to the extent permitted by law, you shall cooperate
fully with the Company in: (i)&nbsp;any internal investigation; (ii)&nbsp;any investigation, defense or prosecution of any claims or actions
which already have been brought, are currently pending, or which may be brought in the future against the Company by a third party or
by or on behalf of the Company against any third party, whether before a state or federal court, any state or federal government agency,
or a mediator or arbitrator; or (iii)&nbsp;any other administrative, regulatory, or judicial inquiry, investigation, proceeding or arbitration.&nbsp;
Your full cooperation hereunder shall include, but not be limited to, making yourself available to the Company upon reasonable notice
for interviews and factual investigations; appearing at the Company&rsquo;s request to give testimony without requiring service of a subpoena
or other legal process; volunteering to the Company pertinent information; and turning over all relevant documents which are in or may
come into your possession.&nbsp; The term &ldquo;cooperation&rdquo; does not mean that you must provide information that is favorable
to the Company; it means only that you will provide truthful information within your knowledge and possession upon request of the Company.
 &nbsp;The Company will reimburse you for all reasonable and documented out-of-pocket expenses that you incur at the Company&rsquo;s request
to comply with this paragraph. You further agree that, to the extent permitted by law, you will notify the Company promptly in the event
that you are served with a subpoena (other than a subpoena issued by a government agency), or in the event that you are asked to provide
a third party (other than a government agency) with information concerning any actual or potential complaint or claim against the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><B><U>Return of Company Property</U></B> &ndash; You confirm that you have returned to the Company all
keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software, printers, flash drives
and other storage devices, wireless handheld devices, cellular phones, tablets,&nbsp;etc.), Company identification, and any other Company
owned property in your possession or control, and that you have left intact all, and have otherwise not destroyed, deleted, or made inaccessible
to the Company any, electronic Company documents, including, but not limited to, those that you developed or helped to develop during
your employment, and that you have not (a)&nbsp;retained any copies in any form or media; (b)&nbsp;maintained access to any copies in
any form, media, or location; (c)&nbsp;stored any copies in any physical or electronic locations that are not readily accessible or not
known to the Company or that remain accessible to you; or (d)&nbsp;sent, given, or made accessible any copies to any persons or entities
that the Company has not authorized to receive such electronic or hard copies. You further confirm that you have cancelled all accounts
for your benefit, if any, in the Company&rsquo;s name, including but not limited to, credit cards, telephone charge cards, cellular phone
accounts, and computer accounts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><B><U>Business Expenses and Final Compensation</U></B> &ndash; You acknowledge that you have been reimbursed
by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements
are owed to you. You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment
by the Company, including payment for all wages, bonuses, and accrued, unused vacation time, and that no other compensation is owed to
you except as provided herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><B><U>Confidentiality</U></B> &ndash; You understand and agree that, to the extent permitted by law and
except as otherwise permitted by paragraph 9 below, the terms and contents of this letter agreement, and the contents of the negotiations
and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and representatives and
shall not be disclosed except as otherwise agreed to in writing by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><B><U>Scope of Disclosure Restrictions</U></B> &ndash; Nothing in this letter agreement or elsewhere prohibits
you from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information
to government agencies, filing a complaint with government agencies, or participating in government agency investigations or proceedings.
You are not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure
of information you obtained through a communication that was subject to the attorney-client privilege. Further, notwithstanding your confidentiality
and nondisclosure obligations, you are hereby advised as follows pursuant to the Defend Trade Secrets Act: &ldquo;An individual shall
not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A)&nbsp;is
made (i)&nbsp;in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii)&nbsp;solely
for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document filed
in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer
for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information
in the court proceeding, if the individual (A)&nbsp;files any document containing the trade secret under seal; and (B)&nbsp;does not disclose
the trade secret, except pursuant to court order.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><B><U>Amendment and Waiver</U></B> &ndash; This letter agreement shall be binding upon the parties and
may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives
of the parties hereto. This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents,
assigns, heirs, executors, successors and administrators. No delay or omission by the Company in exercising any right under this letter
agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be
effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="text-align: justify"><B><U>Validity</U></B> &ndash; Should any provision of this letter agreement be declared or be determined
by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be
affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="text-align: justify"><B><U>Nature of Agreement</U> &ndash; </B>You understand and agree that this letter agreement is a severance
agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD><TD STYLE="text-align: justify"><B><U>Acknowledgments</U> &ndash; </B>You acknowledge that you have been given at least <B>[seven (7)&nbsp;/
twenty-one (21) / forty-five (45)] </B>days to consider this letter agreement, and that the Company is hereby advising you to consult
with an attorney of your own choosing prior to signing this letter agreement. <B>[You understand that you may revoke this letter agreement
during the Revocation Period by notifying me in writing, and the letter agreement shall not be effective or enforceable until the expiration
of the Revocation Period. You understand and agree that by entering into this letter agreement, you are waiving any and all rights or
claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that
you have received consideration beyond that to which you were previously entitled.]</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD><TD STYLE="text-align: justify"><B>[<U>Eligibility for Severance Program</U> &ndash; Attached to this letter agreement as Attachment A
is a description of (i)&nbsp;any class, unit or group of individuals covered by the program of severance benefits which the Company has
offered to you, and any applicable time limits regarding such severance benefit program; and (ii)&nbsp;the job title and ages of all individuals
eligible or selected for such severance benefit program, and the ages of all individuals in the same job classification or organizational
unit who are not eligible or who were not selected for such severance benefit program.]</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD><TD STYLE="text-align: justify"><B><U>Voluntary Assent</U></B> &ndash; You affirm that no other promises or agreements of any kind have
been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand
the meaning and intent of this letter agreement. You state and represent that you have had an opportunity to fully discuss and review
the terms of this letter agreement with an attorney. You further state and represent that you have carefully read this letter agreement,
understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own
free act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD><TD STYLE="text-align: justify"><B><U>Applicable Law</U></B> &ndash; This letter agreement shall be interpreted and construed by the laws
of the Commonwealth of Pennsylvania, without regard to conflict of laws provisions. You hereby irrevocably submit to and acknowledge and
recognize the jurisdiction of the courts of the Commonwealth of Pennsylvania, or if appropriate, a federal court located in the Commonwealth
of Pennsylvania (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action
or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof. You hereby irrevocably
waive any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this letter
agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD><TD STYLE="text-align: justify"><B><U>Entire Agreement</U></B> &ndash; This letter agreement contains and constitutes the entire understanding
and agreement between the parties hereto with respect to your severance benefits and the settlement of claims against the Company and
cancels all previous oral and written negotiations, agreements, and commitments in connection therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD><TD STYLE="text-align: justify"><B><U>Tax Acknowledgement</U></B> &ndash; In connection with the [Severance Benefits] [Change in Control
Severance Benefits], the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall
be responsible for all applicable taxes with respect to such [Severance Benefits] [Change in Control Severance Benefits] under applicable
law. You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of the
[Severance Benefits] [Change in Control Severance Benefits].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page&nbsp;Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you have any questions about the matters covered
in this letter agreement, please call me.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">[Name]&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">[Title]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby agree to the terms and conditions set
forth above. <B>[I have been given at least [twenty-one (21) / forty-five (45)] days to consider this letter agreement and I have chosen
to execute this on the date below. I intend that this letter agreement will become a binding agreement between me and the Company if I
do not revoke my acceptance during the Revocation Period.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">[Insert Name]</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To be returned in a timely manner as set forth
on the first page&nbsp;of this letter agreement, but not to be signed before the close of business on your last day of employment.<SUP>3</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP> Note: All footnotes will be removed from the final execution
version of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>8
<FILENAME>tm238578d1_ex10-8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EMPLOYMENT
AGREEMENT</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
EMPLOYMENT AGREEMENT (the &ldquo;Agreement&rdquo;), is made as of March 7, 2023 (the &ldquo;Effective Date&rdquo;), by and between
Carisma Therapeutics Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and Richard Morris (the &ldquo;Executive&rdquo;) (together,
the &ldquo;Parties&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECITALS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Executive has been employed by CTx Operations,&nbsp;Inc. (f/k/a CARISMA Therapeutics Inc.) (the &ldquo;Carisma Sub&rdquo;) pursuant
to that certain letter agreement dated March&nbsp;15, 2021 detailing the terms and conditions of Executive&rsquo;s employment with the
Carisma Sub (the &ldquo;Prior Agreement&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
pursuant to that certain Agreement and Plan of Merger and Reorganization dated September&nbsp;20, 2022 and amended on December&nbsp;29,
2022 and February&nbsp;13, 2023 (the &ldquo;Merger Agreement&rdquo;), by and among the Company (f/k/a Sesen Bio,&nbsp;Inc.), Seahawk
Merger Sub,&nbsp;Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&ldquo;Merger Sub&rdquo;), and the Carisma
Sub, Merger Sub merged with and into Carisma Sub, with Carisma Sub continuing as a wholly-owned subsidiary of the Company and the surviving
corporation of the merger (the &ldquo;Merger&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Parties desire to enter into an agreement whereby the Executive will be employed as Chief Financial Officer of the Company on the
terms contained in this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Executive has agreed to accept such employment with the Company on the terms and conditions set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the foregoing and of the respective covenants and agreements of the Parties herein contained, the Parties
hereto agree to the following terms, which shall govern the Executive&rsquo;s employment from and after the Effective Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<I>Agreement</I>. This Agreement shall be effective as of the Effective Date. The Executive&rsquo;s employment on the terms contained
in this Agreement shall commence on the Effective Date and shall continue until such employment relationship is terminated in accordance
with Section&nbsp;7 hereof (the &ldquo;Term of Employment&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<I>Position</I>. During the Term of Employment, the Executive shall serve as the Chief Financial Officer of the Company, working out
of the Company&rsquo;s office in Philadelphia, Pennsylvania, and travelling as reasonably required by the Executive&rsquo;s job duties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<I>Scope of Employment</I>. During the Term of Employment, the Executive shall be responsible for the performance of those duties consistent
with the Executive&rsquo;s position as Chief Financial Officer. The Executive shall report to the Chief Executive Officer of the Company
or his/her designee. The Executive agrees to devote the Executive&rsquo;s full business time, best efforts, skill, knowledge, attention,
and energies to the advancement of the Company's business and interests and to the performance of the Executive&rsquo;s duties and responsibilities
as an employee of the Company and not to engage in any other business activities (whether as an employee, consultant, board member, advisor
or in any other capacity) without prior approval from the Company, except the Executive may engage in charitable or civic activities
and/or serve as an executor, trustee, or other similar fiduciary capacity, provided, however, that in no event may any activity be undertaken
or continued if it would (i)&nbsp;be in violation of any provision of this Agreement or other agreement between the Executive and the
Company, (ii)&nbsp;interfere with the performance of the Executive&rsquo;s duties for the Company, or (iii)&nbsp;present a conflict of
interest with the Company&rsquo;s business interests. As an employee of the Company, the Executive will be required to comply with all
Company policies and procedures. Violations of the Company's policies may lead to immediate termination of the Executive&rsquo;s employment,
provided, however, that nothing in the foregoing shall alter any rights the Executive may have as set forth in Section&nbsp;8 below.
Further, the Company's premises, including all workspaces, furniture, documents, and other tangible materials, and all information technology
resources of the Company (including computers, data and other electronic files, and all internet and email) are subject to oversight
and inspection by the Company at any time. Company employees should have no expectation of privacy with regard to any Company premises,
materials, resources, or information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<I>Compensation</I>. As full compensation for all services rendered by the Executive to the Company and any affiliate thereof, during
the Term of Employment, the Company will provide to the Executive the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<I>Base
Salary</I>. The Executive shall receive a base salary, effective as of January&nbsp;1, 2023, at the annualized rate of $467,000 (the
 &ldquo;Base Salary&rdquo;). For the avoidance of doubt, to the extent Executive is entitled to additional base salary for the period
between January&nbsp;1, 2023 and the Effective Date after taking into account any payments of base salary made by Carisma Sub to the
Executive prior to the Effective Date, such payments will be made in the first payroll following the Effective Date. Otherwise, the Executive&rsquo;s
Base Salary shall be paid in equal installments in accordance with the Company&rsquo;s regularly established payroll procedures. The
Executive&rsquo;s Base Salary will be reviewed on an annual or more frequent basis by the Company&rsquo;s board of directors (the &ldquo;Board&rdquo;)
and is subject to change in the discretion of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<I>Annual
Discretionary Bonus</I>. The Executive will be eligible to receive an annual discretionary performance bonus of 40% of the Executive&rsquo;s
Base Salary (the &ldquo;Target Bonus&rdquo;), based on the Board&rsquo;s assessment of the Executive&rsquo;s performance and the Company&rsquo;s
attainment of targeted goals to be set by the Board in its sole discretion. Following the close of each calendar year, the Board will
determine whether the Executive has earned a performance bonus, and the amount of any performance bonus, based on the set criteria. No
amount of the performance bonus is guaranteed, and the Executive must be an active employee of the Company on the date the bonus is distributed
in order to be eligible for and to earn any bonus award, as it also serves as an incentive for the Executive to remain employed by the
Company. The Executive&rsquo;s bonus eligibility will be reviewed on an annual or more frequent basis by the Board and is subject to
change in the discretion of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;<I>Equity
Award</I>. The Executive will be eligible to receive equity awards, if any, at such times and on such terms and conditions as the Board
shall, in its sole discretion, determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)<I>&nbsp;Paid
Time Off</I>. The Executive will be eligible for a maximum of twenty-five (25) days of paid time off (&ldquo;PTO&rdquo;) per calendar
year to be taken at such times as may be approved by the Company. The number of PTO days for which the Executive is eligible shall accrue
at the rate of 2.083 days per month that the Executive is employed during such calendar year. Any unused PTO time will be forfeited at
the end of each calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;<I>Benefits</I>.
Subject to eligibility requirements and the Company&rsquo;s polices, the Executive shall have the right, on the same basis as other similarly-situated
employees of the Company, to participate in, and to receive benefits under, all employee health, disability, insurance, fringe, welfare
benefit and retirement plans, arrangements, practices and programs the Company provides to its senior executives in accordance with the
terms thereof as in effect from time to time. The Company reserves the right to modify, amend and/or terminate any and all of its benefits
plans at is discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;<I>Withholdings</I>.
All compensation payable to the Executive shall be subject to applicable taxes and withholdings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<I>Expenses</I>. The Executive will be reimbursed for the Executive&rsquo;s actual, necessary and reasonable business expenses pursuant
to Company policy, subject to the provisions of Section&nbsp;3 of <U>Exhibit&nbsp;A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<I>Restrictive Covenants Agreements</I>. The Executive hereby acknowledges that each of the Invention and Non-Disclosure Agreement and
the Non-Competition and Non-Solicitation Agreement that the Executive previously executed in connection with the Executive&rsquo;s employment
with the Carisma Sub (together, the &ldquo;Restrictive Covenant Agreements&rdquo;) remain in full force and effect, with the terms thereof
hereby deemed incorporated herein; provided, however, that the references therein to &ldquo;Company&rdquo; shall be deemed hereinafter
to mean the Company, as well as the Carisma Sub.&nbsp; The Executive further acknowledges that the Executive&rsquo;s employment with
the Company is conditioned on the Executive&rsquo;s continued compliance with the Restrictive Covenant Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<I>Employment Termination</I>. This Agreement and the employment of the Executive shall terminate upon the occurrence of any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;Upon
the death of the Executive or at the election of the Company due to the Executive&rsquo;s &ldquo;Disability&rdquo;. As used in this Agreement,
the term &ldquo;Disability&rdquo; shall mean a physical or mental illness or disability that prevents the Executive from performing the
duties of the Executive&rsquo;s position for a period of more than any three (3)&nbsp;consecutive months or for periods aggregating more
than twenty-six (26) weeks. The Company shall determine in good faith and in its sole discretion whether the Executive is unable to perform
the services provided for herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;At
the election of the Company, with or without &ldquo;Cause&rdquo; (as defined below), immediately upon written notice by the Company to
the Executive. As used in this Agreement, &ldquo;Cause&rdquo; shall mean:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s engagement in any conduct that has materially and adversely affected, or is reasonably likely to materially and adversely
affect, the business interests or reputation of the Company (for avoidance of doubt, &ldquo;conduct&rdquo; in this subsection does not
mean poor performance or failure to meet Company objectives);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
breach by the Executive of the Restrictive Covenant Agreements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s willful and repeated failure to perform in any material respect, the Executive&rsquo;s duties to the Company under
this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s fraud or embezzlement, or the Executive&rsquo;s willful misconduct with respect to the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s material breach of this Agreement; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Executive&rsquo;s conviction of, or plea of guilty or <I>nolo contendere </I>to, a misdemeanor relating to the Company, any crime involving
dishonesty or moral turpitude, or any felony;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
however, that with respect to subsections (i), (ii)&nbsp;(iii)&nbsp;and (v)&nbsp;hereof, the Executive was given thirty (30) calendar
days&rsquo; written notice of such conduct, breach, or deficiencies and an opportunity to cure such conduct, breach or deficiencies but
the Executive failed to do so within such period (provided that the Executive is eligible for no more than two &ldquo;cure&rdquo; opportunities
during the Executive&rsquo;s employment).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Execution Copy</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;At
the election of the Executive, with or without &ldquo;Good Reason&rdquo; (as defined below), upon written notice by the Executive to
the Company (subject, if it is with Good Reason, to the timing provisions set forth in the definition of Good Reason). As used in this
Agreement, &ldquo;Good Reason&rdquo; shall mean the occurrence (without the Executive&rsquo;s prior written consent), of any of the following
events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
material reduction in the Executive&rsquo;s authority, duties, or responsibilities or a material reduction in the authority, duties or
responsibilities of the person to whom the Executive reports;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
relocation of the principal place at which the Executive provides services to the Company by at least fifty (50) miles and to a location
such that the Executive&rsquo;s daily commuting distance is increased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
material reduction of the Executive&rsquo;s Base Salary; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
material breach by the Company of its obligations under this letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
termination will be treated as a termination by the Executive for Good Reason unless (x)&nbsp;the Executive has given written notice
to the Company of the Executive&rsquo;s intention to terminate the Executive&rsquo;s employment for Good Reason, describing the grounds
for such action, no later than ninety (90) days after the first occurrence of such circumstances, (y)&nbsp;the Executive has provided
the Company with at least thirty (30) days in which to cure the circumstances, and (z)&nbsp;if the Company is not successful in curing
the circumstances, the Executive ends the Executive&rsquo;s employment within thirty (30) calendar days following the cure period in
(y).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<I>Effect of Termination</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)<I>&nbsp;
All Terminations Other Than by the Company Without Cause or by the Executive With Good Reason</I>. If the Executive&rsquo;s employment
is terminated under any circumstances other than a termination by the Company without Cause or a termination by the Executive with Good
Reason (including a voluntary termination by the Executive without Good Reason or a termination by the Company for Cause or due to the
Executive&rsquo;s death or Disability), the Company&rsquo;s obligations under this Agreement shall immediately cease and the Executive
shall only be entitled to receive (i)&nbsp;the Base Salary that has accrued and to which the Executive is entitled as of the effective
date of such termination, to be paid in accordance with the Company&rsquo;s established payroll procedure and applicable law but no later
than the next regularly scheduled pay period, (ii)&nbsp;unreimbursed business expenses for which expenses the Executive has timely submitted
appropriate documentation in accordance with Section&nbsp;5 hereof, (iii)&nbsp;any amounts or benefits to which the Executive is then
entitled under the terms of the benefit plans then-sponsored by the Company in accordance with their terms (and not accelerated to the
extent acceleration does not satisfy Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, (the &ldquo;Code&rdquo;)), and
(iv)&nbsp;any accrued but unused vacation time through the date of termination, to be paid in accordance with Company policy and applicable
law (the payments described in this sentence, the &ldquo;Accrued Obligations&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<I>Termination
by the Company Without Cause or by the Executive With Good Reason More Than Three Months Prior to or More Than Twelve Months Following
a Change in Control.</I>&nbsp;If the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with
Good Reason more than three (3)&nbsp;months prior to, or more than twelve (12)&nbsp;months following, a Change in Control (as defined
below), the Executive shall be entitled to the Accrued Obligations. In addition, and subject to&nbsp;<U>Exhibit&nbsp;A</U>&nbsp;and the
conditions of Section&nbsp;8(d), the Company shall: (i)&nbsp;continue to pay to the Executive, in accordance with the Company&rsquo;s
regularly established payroll procedures, the Executive&rsquo;s Base Salary for a period of twelve (12)&nbsp;months; (ii)&nbsp;pay to
the Executive, in a single lump sum on the Payment Date (as defined below) an amount equal to one hundred percent (100%) of the Executive&rsquo;s
Target Bonus for the year in which termination occurs, prorated based on a fraction, the numerator of which is the number of days during
the calendar year in which the Executive&rsquo;s termination date occurs that the Executive remained employed by the Company and the
denominator of which is 365 (such amount, the &ldquo;Pro Rata Bonus&rdquo;); and (iii)&nbsp;provided the Executive is eligible for and
timely elects to continue receiving group medical insurance pursuant to the &ldquo;COBRA&rdquo; law, continue to pay for twelve (12)&nbsp;months
following the Executive&rsquo;s termination date or until the Executive has secured other employment or is no longer eligible for coverage
under COBRA, whichever occurs first, the share of the premium for health coverage that is paid by the Company for active and similarly-situated
employees who receive the same type of coverage, unless the Company&rsquo;s provision of such COBRA payments will violate the nondiscrimination
requirements of applicable law, in which case this benefit will not apply (collectively, the &ldquo;Severance Benefits&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;<I>Termination
by the Company Without Cause or by the Executive With Good Reason Within Three Months Prior to or Twelve Months Following a Change in
Control.</I>&nbsp;If the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with Good Reason
within the period that begins three (3)&nbsp;months prior to and ends twelve (12)&nbsp;months following a Change in Control, then the
Executive shall be entitled to the Accrued Obligations. In addition, and subject to&nbsp;<U>Exhibit&nbsp;A</U>&nbsp;and the conditions
of Section&nbsp;8(d), the Company shall: (i)&nbsp;pay to the Executive, in a single lump sum on the Payment Date, an amount equal to
the sum of (x)&nbsp; twelve (12) months of the Executive&rsquo;s Base Salary, and (y)&nbsp;one hundred percent (100%) of the Executive&rsquo;s
Target Bonus for the year in which termination occurs or, if higher, the Executive&rsquo;s Target Bonus immediately prior to the Change
in Control, (ii)&nbsp;pay to the Executive, in a single lump sum on the Payment Date, the Pro Rata Bonus which Pro Rata Bonus, shall,
for the avoidance of doubt, be determined by reference to the Executive&rsquo;s Target Bonus for the year in which termination occurs,
or, if higher, the Executive&rsquo;s Target Bonus immediately prior to the Change in Control, (iii)&nbsp;provided the Executive is eligible
for and timely elects to continue receiving group medical insurance pursuant to the &ldquo;COBRA&rdquo; law, continue to pay for twelve
(12) months following the Executive&rsquo;s termination date or until the Executive has secured other employment or is no longer eligible
for coverage under COBRA, whichever occurs first, the share of the premium for health coverage that is paid by the Company for active
and similarly-situated employees who receive the same type of coverage, unless the Company&rsquo;s provision of such COBRA payments will
violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply, and (iv)&nbsp;provide that the
vesting of the Executive&rsquo;s then-unvested equity awards that vest based solely on the passage of time shall be accelerated, such
that all such then-unvested time-based equity awards shall vest and become fully exercisable or&nbsp;non-forfeitable&nbsp;as of the later
of the date of the Change in Control and the Executive&rsquo;s termination date (collectively, the &ldquo;Change in Control Severance
Benefits&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<I>Release</I>.
As a condition of the Executive&rsquo;s receipt of the Severance Benefits or the Change in Control Severance Benefits, as applicable,
the Executive must execute and deliver to the Company a separation and release of claims agreement in substantially the form attached
hereto as <U>Exhibit&nbsp;B</U> (the &ldquo;Release&rdquo;), which Release must become irrevocable within sixty (60) days following the
date of the Executive&rsquo;s termination of employment (or such shorter period as may be directed by the Company). The Severance Benefits
or the Change in Control Severance Benefits, as applicable, will be paid or commence to be paid in the first regular payroll beginning
after the Release becomes effective, provided that if the foregoing sixty (60) day period would end in a calendar year subsequent to
the year in which the Executive&rsquo;s employment ends, the Severance Benefits or Change in Control Severance Benefits, as applicable,
will not be paid or begin to be paid before the first payroll of the subsequent calendar year (the date the Severance Benefits or Change
in Control Severance Benefits, as applicable, are paid or commence pursuant to this sentence, the &ldquo;Payment Date&rdquo;). The Executive
must continue to comply with all post-employment obligations under law or in any agreement between the Executive and the Company, including
the Restrictive Covenant Agreements, any similar agreement with the Company and as set forth in the Release in order to be eligible to
receive or continue receiving the Severance Benefits or Change in Control Severance Benefits, as applicable. For the avoidance of doubt,
if the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with Good Reason prior to a Change
in Control, (i)&nbsp;any then-outstanding and unvested time-based equity awards held by the Executive shall remain outstanding (but any
vesting shall be suspended) for up to (but no longer than) three (3)&nbsp;months following the date of termination so that, if it is
later determined that such termination occurred during the three (3)-month period prior to the closing of a Change in Control and the
Executive is entitled to Change in Control acceleration and/or Change in Control Severance Benefits rather than Severance Benefits, the
vesting of such awards may be accelerated, in accordance with Section&nbsp;8(c), immediately prior to the closing of the Change in Control
and (ii)&nbsp;any Change in Control Severance Benefits shall be reduced by any Severance Benefits previously paid to the Executive, if
it is later determined that the termination occurred during the three (3)-month period prior to the closing of a Change in Control and
that the Executive is entitled to Change in Control Severance Benefits rather than Severance Benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;<I>Change
in Control Definition</I>. For purposes of this Agreement, &ldquo;Change in Control&rdquo; shall mean the occurrence of any of the following
events, provided that such event or occurrence constitutes a change in the ownership or effective control of the Company, or a change
in the ownership of a substantial portion of the assets of the Company, as defined in Treasury Regulation &sect;&sect; 1.409A-3(i)(5)(v),
(vi)&nbsp;and (vii): (i)&nbsp;the acquisition by an individual, entity or group (within the meaning of Section&nbsp;13(d)(3)&nbsp;or
14(d)(2)&nbsp;of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;)) (a &ldquo;Person&rdquo;) of beneficial ownership
of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule&nbsp;13d-3
under the Exchange Act) fifty percent (50%) or more of either (x)&nbsp;the then-outstanding shares of common stock of the Company (the
 &ldquo;Outstanding Company Common Stock&rdquo;) or (y)&nbsp;the combined voting power of the then-outstanding securities of the Company
entitled to vote generally in the election of directors (the &ldquo;Outstanding Company Voting Securities&rdquo;); provided, however,
that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control: (1)&nbsp;any acquisition
directly from the Company or (2)&nbsp;any acquisition by any entity pursuant to a Business Combination (as defined below) which complies
with clauses (x)&nbsp;and (y)&nbsp;of subsection (iii)&nbsp;of this definition; or (ii)&nbsp;a change in the composition of the Board
that results in the Continuing Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board
of Directors of a successor corporation to the Company), where the term &ldquo;Continuing Director&rdquo; means at any date a member
of the Board (x)&nbsp;who was a member of the Board on the Effective Date or (y)&nbsp;who was nominated or elected subsequent to such
date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election
to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination
or election; provided, however, that there shall be excluded from this clause (y)&nbsp;any individual whose initial assumption of office
occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual
or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or (iii)&nbsp;the consummation of
a merger, consolidation, reorganization, recapitalization or share exchange involving the Company, or a sale or other disposition of
all or substantially all of the assets of the Company (a &ldquo;Business Combination&rdquo;), unless, immediately following such Business
Combination, each of the following two (2)&nbsp;conditions is satisfied: (x)&nbsp;all or substantially all of the individuals and entities
who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to
such Business Combination beneficially own, directly or indirectly, more than fifty percent (50%) of the then-outstanding shares of common
stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively,
of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which
as a result of such transaction owns the Company or substantially all of the Company&rsquo;s assets either directly or through one (1)&nbsp;or
more subsidiaries) (such resulting or acquiring corporation is referred to herein as the &ldquo;Acquiring Corporation&rdquo;) in substantially
the same proportions as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively,
immediately prior to such Business Combination and (y)&nbsp;no Person (excluding any employee benefit plan (or related trust) maintained
or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, fifty percent (50%) or more of
the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities
of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to
the Business Combination); or (iv)&nbsp;the liquidation or dissolution of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;<I>Resignation
from other Positions</I>. If, as of the date that the Executive&rsquo;s employment terminates for any reason, the Executive is a member
of the Board (or the board of directors of any entity affiliated with the Company), or hold any other offices or positions with the Company
(or any entity affiliated with the Company), the Executive shall, unless otherwise requested by the Company, immediately relinquish and/or
resign from any such board memberships, offices and positions as of the date the Executive&rsquo;s employment terminates. The Executive
agrees to execute such documents and take such other actions as the Company may request to reflect such relinquishments and/or resignation(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<I>Absence of Restrictions</I>. The Executive represents and warrants that the Executive is not bound by any employment contracts, restrictive
covenants or other restrictions that prevent (or purports to prevent) the Executive from carrying out the Executive&rsquo;s responsibilities
for the Company, or which are in any way inconsistent with any of the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<I>Notice</I>. Any notice delivered under this Agreement shall be deemed duly delivered three (3)&nbsp;business days after it is sent
by registered or certified mail, return receipt requested, postage prepaid, one (1)&nbsp;business day after it is sent for next-business
day delivery via a reputable nationwide overnight courier service, or immediately upon hand delivery, in each case to the address of
the recipient set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
Executive:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the address set forth in the Executive&rsquo;s personnel file</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carisma
Therapeutics Inc.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3675
Market Street, Suite&nbsp;200&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia,
Pennsylvania 19104</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may change the address to which notices are to be delivered by giving notice of such change to the other Party in the manner set
forth in this Section&nbsp;10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<I>Applicable Law and Forum</I>. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of
Pennsylvania (without reference to the conflict of laws provisions thereof). Any action, suit or other legal proceeding arising under
or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Pennsylvania (or, if appropriate,
a federal court located within the Commonwealth of Pennsylvania), and the Company and the Executive each consent to the exclusive jurisdiction
of such a court. The Company and the Executive each hereby irrevocably waives any right to a trial by jury in any action, suit or other
legal proceeding arising under or relating to any provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<I>Successors and Assigns</I>. This Agreement shall be binding upon and inure to the benefit of both Parties and their respective successors
and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business;
provided, however, that the obligations of the Executive are personal and shall not be assigned by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<I>At-Will Employment</I>. This Agreement shall not be construed as an agreement, either expressed or implied, to employ the Executive
for any stated term, and shall in no way alter the Company&rsquo;s policy of employment at will, under which both the Executive and the
Company remain free to terminate the employment relationship, with or without cause, at any time, with or without notice. Although the
Executive&rsquo;s job duties, title, compensation and benefits, as well as the Company's personnel policies and procedures, may change
from time to time, the &ldquo;at-will&rdquo; nature of the Executive&rsquo;s employment may only be changed by a written agreement signed
by the Executive and a duly authorized representative of the Company, which written agreement expressly states the intention to modify
the at-will nature of the Executive&rsquo;s employment, provided, however, that nothing in the foregoing shall alter any rights the Executive
may have as set forth in Section&nbsp;8 above. Similarly, nothing in this Agreement shall be construed as an agreement, either express
or implied, to pay the Executive any compensation or grant the Executive any benefit beyond the end of the Executive&rsquo;s employment
with the Company, except as explicitly set forth in Section&nbsp;8 above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<I>Acknowledgment</I>. The Executive states and represents that the Executive has had an opportunity to fully discuss and review the
terms of this Agreement with an attorney. The Executive further states and represents that the Executive has carefully read this Agreement,
understands the contents herein, freely and voluntarily assents to all of the terms and conditions hereof, and signs the Executive&rsquo;s
name of the Executive&rsquo;s own free act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<I>No Oral Modification, Waiver, Cancellation or Discharge</I>. This Agreement may be amended or modified only by a written instrument
executed by both the Company and the Executive. No delay or omission by the Company in exercising any right under this Agreement shall
operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only
in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<I>Captions and Pronouns</I>. The captions of the sections of this Agreement are for convenience of reference only and in no way define,
limit or affect the scope or substance of any section of this Agreement. Whenever the context may require, any pronouns used in this
Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include
the plural, and vice versa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<I>Interpretation</I>. The Parties agree that this Agreement will be construed without regard to any presumption or rule&nbsp;requiring
construction or interpretation against the drafting Party. References in this Agreement to &ldquo;include&rdquo; or &ldquo;including&rdquo;
should be read as though they said &ldquo;without limitation&rdquo; or equivalent forms. Except where the context requires otherwise,
references in this Agreement to the &ldquo;Board&rdquo; shall include any authorized committee thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<I>Severability</I>. Each provision of this Agreement must be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective
only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions
of this Agreement. Moreover, if a court of competent jurisdiction determines any of the provisions contained in this Agreement to be
unenforceable because the provision is excessively broad in scope, whether as to duration, activity, geographic application, subject
or otherwise, it will be construed, by limiting or reducing it to the extent legally permitted, so as to be enforceable to the extent
compatible with then applicable law to achieve the intent of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<I>Modified Section&nbsp;280G Cutback</I>. Notwithstanding any other provision of this Agreement, except as set forth in Section&nbsp;19(b),
in the event that the Company undergoes a &ldquo;Change in Ownership or Control&rdquo; (as defined below), the following provisions shall
apply:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;The
Company shall not be obligated to provide to the Executive any portion of any &ldquo;Contingent Compensation Payments&rdquo; (as defined
below) that the Executive would otherwise be entitled to receive to the extent necessary to eliminate any &ldquo;excess parachute payments&rdquo;
(as defined in Section&nbsp;280G(b)(1)&nbsp;of the Code) for the Executive. For purposes of this Section&nbsp;19, the Contingent Compensation
Payments so eliminated shall be referred to as the &ldquo;Eliminated Payments&rdquo; and the aggregate amount (determined in accordance
with Treasury Regulation Section&nbsp;1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated
shall be referred to as the &ldquo;Eliminated Amount.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;Notwithstanding
the provisions of Section&nbsp;19(a), no such reduction in Contingent Compensation Payments shall be made if (1)&nbsp;the Eliminated
Amount (computed without regard to this sentence) exceeds (2)&nbsp;one hundred percent (100%) of the aggregate present value (determined
in accordance with Treasury Regulation Section&nbsp;1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional
taxes that would be incurred by the Executive if the Eliminated Payments (determined without regard to this sentence) were paid to the
Executive (including state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section&nbsp;4999 of the Code
payable with respect to all of the Contingent Compensation Payments in excess of the Executive&rsquo;s &ldquo;base amount&rdquo; (as
defined in Section&nbsp;280G(b)(3)&nbsp;of the Code), and any withholding taxes). The override of such reduction in Contingent Compensation
Payments pursuant to this Section&nbsp;19(b)&nbsp;shall be referred to as a &ldquo;Section&nbsp;19(b)&nbsp;Override.&rdquo; For purpose
of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of
such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax
rate provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;For
purposes of this Section&nbsp;19 the following terms shall have the following respective meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&ldquo;Change
in Ownership or Control&rdquo; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial
portion of the assets of the Company determined in accordance with Section&nbsp;280G(b)(2)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&ldquo;Contingent
Compensation Payment&rdquo; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this
Agreement or otherwise) to or for the benefit of a &ldquo;disqualified individual&rdquo; (as defined in Section&nbsp;280G(c)&nbsp;of
the Code) and that is contingent (within the meaning of Section&nbsp;280G(b)(2)(A)(i)&nbsp;of the Code) on a Change in Ownership or Control
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;Any
payments or other benefits otherwise due to the Executive following a Change in Ownership or Control that could reasonably be characterized
(as determined by the Company) as Contingent Compensation Payments (the &ldquo;Potential Payments&rdquo;) shall not be made until the
dates provided for in this Section&nbsp;19(d). Within thirty (30) days after each date on which the Executive first becomes entitled
to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall
determine and notify the Executive (with reasonable detail regarding the basis for its determinations) (1)&nbsp;which Potential Payments
constitute Contingent Compensation Payments, (2)&nbsp;the Eliminated Amount and (3)&nbsp;whether the Section&nbsp;19(b)&nbsp;Override
is applicable. Within thirty (30) days after delivery of such notice to the Executive, the Executive shall deliver a response to the
Company (the &ldquo;Executive Response&rdquo;) stating either (A)&nbsp;that the Executive agrees with the Company&rsquo;s determination
pursuant to the preceding sentence or (B)&nbsp;that the Executive disagrees with such determination, in which case the Executive shall
set forth (x)&nbsp;which Potential Payments should be characterized as Contingent Compensation Payments, (y)&nbsp;the Eliminated Amount,
and (z)&nbsp;whether the Section&nbsp;19(b)&nbsp;Override is applicable. In the event that the Executive fails to deliver an Executive
Response on or before the required date, the Company&rsquo;s initial determination shall be final. If and to the extent that any Contingent
Compensation Payments are required to be treated as Eliminated Payments pursuant to this Section&nbsp;19, then the payments shall be
reduced or eliminated, as determined by the Company, in the following order: (i)&nbsp;any cash payments, (ii)&nbsp;any taxable benefits,
(iii)&nbsp;any nontaxable benefits, and (iv)&nbsp;any vesting of equity awards in each case in reverse order beginning with payments
or benefits that are to be paid the farthest in time from the date that triggers the applicability of the excise tax, to the extent necessary
to maximize the Eliminated Payments. If the Executive states in the Executive Response that the Executive agrees with the Company&rsquo;s
determination, the Company shall make the Potential Payments to the Executive within three (3)&nbsp;business days following delivery
to the Company of the Executive Response (except for any Potential Payments which are not due to be made until after such date, which
Potential Payments shall be made on the date on which they are due). If the Executive states in the Executive Response that the Executive
disagrees with the Company&rsquo;s determination, then, for a period of sixty (60) days following delivery of the Executive Response,
the Executive and the Company shall use good faith efforts to resolve such dispute. If such dispute is not resolved within such 60-day
period, such dispute shall be settled exclusively by arbitration as provided in Section&nbsp;11 of this Agreement. The Company shall,
within three (3)&nbsp;business days following delivery to the Company of the Executive Response, make to the Executive those Potential
Payments as to which there is no dispute between the Company and the Executive regarding whether they should be made (except for any
such Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which
they are due). The balance of the Potential Payments shall be made within three (3)&nbsp;business days following the resolution of such
dispute.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of this Section&nbsp;19 are intended to apply to any and all payments or benefits available to the Executive under this Agreement
or any other agreement or plan under which the Executive may receive Contingent Compensation Payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<I>Entire Agreement</I>. Except as expressly provided in the Merger Agreement and any other agreements to which the Executive is or will
be party in connection with the Transaction, this Agreement constitutes the entire agreement between the Parties and supersedes and replaces
all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement, including, without
limitation, the Prior Agreement; provided, however, and for the avoidance of doubt, nothing herein shall be deemed to supersede the Restrictive
Covenant Agreements, which remain in full force and effect as set forth in Section&nbsp;6 above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the day and year set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carisma
Therapeutics Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 99%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Steven Kelly</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
</TABLE><P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 99%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">Steven Kelly</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
</TABLE><P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 99%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4.5%">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45.5%">Chief Executive Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
</TABLE><P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">EXECUTIVE:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Richard Morris</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Richard Morris</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Execution Copy</B></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT&nbsp;A</U></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payments
Subject to Section&nbsp;409A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to this <U>Exhibit&nbsp;A</U>, any severance payments or benefits that may be due under the Agreement shall begin only upon the date
of the Executive&rsquo;s &ldquo;separation from service&rdquo; (determined as set forth below) which occurs on or after the termination
of the Executive&rsquo;s employment. The following rules&nbsp;shall apply with respect to distribution of the severance payments or benefits,
if any, to be provided to the Executive under the Agreement, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is intended that each installment of the severance payments or benefits provided under the Agreement shall be treated as a separate &ldquo;payment&rdquo;
for purposes of Section&nbsp;409A of the Internal Revenue Code (&ldquo;Section&nbsp;409A&rdquo;). Neither the Company nor the Executive
shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted
or required by Section&nbsp;409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
as of the date of the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company, the Executive is not a &ldquo;specified
employee&rdquo; (within the meaning of Section&nbsp;409A), then each installment of the severance payments or benefits shall be made
on the dates and terms set forth in the letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
as of the date of the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company, the Executive is a &ldquo;specified employee&rdquo;
(within the meaning of Section&nbsp;409A), then:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            installment of the severance payments or benefits due under the Agreement that, in accordance
                                            with the dates and terms set forth herein, will in all circumstances, regardless of when
                                            the Executive&rsquo;s separation from service occurs, be paid within the short-term deferral
                                            period (as defined under Section&nbsp;409A) shall be treated as a short-term deferral within
                                            the meaning of Treasury Regulation Section&nbsp;1.409A-1(b)(4)&nbsp;to the maximum extent
                                            permissible under Section&nbsp;409A and shall be paid on the dates and terms set forth in
                                            the Agreement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            installment of the severance payments or benefits due under the Agreement that is not described
                                            in this <U>Exhibit&nbsp;A</U>, Section&nbsp;1(c)(i)&nbsp;and that would, absent this subsection,
                                            be paid within the six (6)-month period following the Executive&rsquo;s &ldquo;separation
                                            from service&rdquo; from the Company shall not be paid until the date that is six (6)&nbsp;months
                                            and one day after such separation from service (or, if earlier, the Executive&rsquo;s death),
                                            with any such installments that are required to be delayed being accumulated during the six
                                            (6)-month period and paid in a lump sum on the date that is six months and one day following
                                            the Executive&rsquo;s separation from service and any subsequent installments, if any, being
                                            paid in accordance with the dates and terms set forth herein; provided, however, that the
                                            preceding provisions of this sentence shall not apply to any installment of payments or benefits
                                            if and to the maximum extent that that such installment is deemed to be paid under a separation
                                            pay plan that does not provide for a deferral of compensation by reason of the application
                                            of Treasury Regulation 1.409A-1(b)(9)(iii)&nbsp;(relating to separation pay upon an involuntary
                                            separation from service). Any installments that qualify for the exception under Treasury
                                            Regulation Section&nbsp;1.409A-1(b)(9)(iii)&nbsp;must be paid no later than the last day
                                            of the Executive&rsquo;s second taxable year following the taxable year in which the separation
                                            from service occurs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
determination of whether and when the Executive&rsquo;s separation from service from the Company has occurred shall be made and in a
manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section&nbsp;1.409A-1(h). Solely for purposes
of Section&nbsp;2 of this <U>Exhibit&nbsp;A</U>, &ldquo;Company&rdquo; shall include all persons with whom the Company would be considered
a single employer under Section&nbsp;414(b)&nbsp;and 414(c)&nbsp;of the Code.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
reimbursements and in-kind benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A
to the extent that such reimbursements or in-kind benefits are subject to Section&nbsp;409A, including, where applicable, the requirements
that (i)&nbsp;any reimbursement is for expenses incurred during the Executive&rsquo;s lifetime (or during a shorter period of time specified
in the Agreement), (ii)&nbsp;the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible
for reimbursement in any other calendar year, (iii)&nbsp;the reimbursement of an eligible expense will be made on or before the last
day of the calendar year following the year in which the expense is incurred and (iv)&nbsp;the right to reimbursement is not subject
to set off or liquidation or exchange for any other benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company makes no representation or warranty and shall have no liability to the Executive or to any other person if any of the provisions
of the Agreement (including this <U>Exhibit&nbsp;A</U>) are determined to constitute deferred compensation subject to Section&nbsp;409A
but that do not satisfy an exemption from, or the conditions of, that section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Agreement is intended to comply with, or be exempt from, Section&nbsp;409A and shall be interpreted accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Remainder
of page&nbsp;intentionally left blank.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT&nbsp;B<SUP>1</SUP></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sample
Separation and Release Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Insert
Date]</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Insert
Name]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
<B>[Insert Name]</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the termination of your employment with [Carisma Therapeutics Inc.] (the &ldquo;Company&rdquo;) on <B>[Separation Date]</B>,
you are eligible to receive [Severance Benefits] [Change in Control Severance Benefits] as described in Section&nbsp;8 of the employment
agreement executed between you and the Company dated _______ (the &ldquo;Employment Agreement&rdquo;) if you sign and return this letter
agreement to me by <B>[Return Date &ndash;7/21/45 days from date of receipt of this letter agreement] [and it becomes binding between
you and the Company</B>]. By signing and returning this letter agreement [<B>and not revoking your acceptance]</B>, you will be agreeing
to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 2. Therefore,
you are advised to consult with an attorney before signing this letter agreement and you have been given at least [<B>seven/twenty-one
(21)/forty-five (45)]<SUP>2</SUP></B> days to do so. [<B>If you sign this letter agreement, you may change your mind and revoke your
agreement during the seven (7)&nbsp;day period after you have signed it (the &ldquo;Revocation Period&rdquo;) by notifying me in writing.
If you do not so revoke, this letter agreement will become a binding agreement between you and the Company upon the expiration of the
Revocation Period.]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
your receipt of the [Severance Benefits] [Change in Control Severance Benefits] is expressly conditioned on your entering into this letter
agreement, the following will apply regardless of whether or not you do so:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of the Separation Date, all salary payments from the Company will cease and any benefits
                                            you had as of the Separation Date under Company-provided benefit plans, programs, or practices
                                            will terminate, except as required by federal or state law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            will receive payment for your final wages and any unused vacation time accrued through the
                                            Separation Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            may, if eligible and at your own cost, elect to continue receiving group medical insurance
                                            pursuant to applicable &ldquo;COBRA&rdquo; law. Please consult the COBRA materials to be
                                            provided under separate cover for details regarding these benefits.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>Note: The Company may revise this release agreement in its sole discretion to reflect changes in law, additional statutes or claims,
benefits, or employee&rsquo;s circumstances, so that the Company receives the benefit of the most complete release of claims that is
legally permissible (without releasing employee&rsquo;s right to receive the Severance Benefits), and the Company may also change the
timing, if required to obtain such release. This footnote and the other footnotes herein are part of the form of release and are to be
removed only when the Company finalizes the letter agreement for execution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP>Consideration period depends upon circumstances of separation.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            are obligated to keep confidential and not to use or disclose any and all non-public information
                                            concerning the Company that you acquired during the course of your employment with the Company,
                                            including any non-public information concerning the Company&rsquo;s business affairs, business
                                            prospects, and financial condition, except as otherwise permitted by paragraph 9 below. Further,
                                            you remain subject to any and all continuing confidentiality, non-competition and/or non-solicitation
                                            obligations that you may have pursuant to any previous agreement with the Company, including,
                                            as may be applicable and without limitation, the Employment Agreement and the Invention and
                                            Non-Disclosure Agreement and Non-Competition and Non-Solicitation Agreement (the &ldquo;Restrictive
                                            Covenant Agreements&rdquo;) referenced therein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            must return to the Company no later than the Separation Date all Company property.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you elect to timely sign and return this letter agreement, comply with all of your obligations hereunder, and do not revoke your acceptance
in writing within the Revocation Period, the following numbered paragraphs set forth the terms and conditions that will also apply:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Severance
                                            Benefits</U></B> The Company will provide you with the [as may be applicable [Severance Benefits]
                                            or [Change in Control Severance Benefits]] set forth in Section&nbsp;8 of the Employment
                                            Agreement (the [&ldquo;Severance Benefits&rdquo;] [&ldquo;Change in Control Severance Benefits&rdquo;]),
                                            <B>s</B>ubject to and in accordance with the terms and conditions thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Release
                                            </U></B>&ndash; In consideration of the [Severance Benefits] [Change in Control Severance
                                            Benefits], which you acknowledge you would not otherwise be entitled to receive, you hereby
                                            fully, forever, irrevocably and unconditionally release, remise and discharge the Company,
                                            its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of
                                            their respective past and present officers, directors, stockholders, partners, members, managers,
                                            employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries
                                            (each in their individual and corporate capacities) (collectively, the &ldquo;Released Parties&rdquo;)
                                            from any and all claims, charges, complaints, demands, actions, causes of action, suits,
                                            rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements,
                                            promises, doings, omissions, damages, executions, obligations, liabilities, and expenses
                                            (including attorneys&rsquo; fees and costs), of every kind and nature that you ever had or
                                            now have against any or all of the Released Parties, whether known or unknown, including,
                                            but not limited to, any and all claims arising out of or relating to your employment with
                                            and/or separation from the Company, including, but not limited to, all claims under Title
                                            VII of the Civil Rights Act of 1964, 42 U.S.C. &sect; 2000e et seq., the Americans With Disabilities
                                            Act of 1990, 42 U.S.C. &sect; 12101 et seq., <B>[the Age Discrimination in Employment Act,
                                            29 U.S.C. &sect; 621 et seq.,] </B>the Genetic Information Nondiscrimination Act of 2008,
                                            42 U.S.C. &sect; 2000ff et seq., the Family and Medical Leave Act, 29 U.S.C. &sect; 2601
                                            et seq., the Worker Adjustment and Retraining Notification Act (&ldquo;WARN&rdquo;), 29 U.S.C.
                                            &sect; 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C. &sect; 701 et seq., Executive
                                            Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &sect; 1681
                                            et seq., and the Employee Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;), 29
                                            U.S.C. &sect; 1001 et seq., all as amended; all claims arising out of the Pennsylvania Human
                                            Relations Act, 43 Pa. Stat. &sect; 951 et seq., the Pennsylvania Equal Pay Law, 43 Pa. Stat.
                                            &sect; 336.1 et seq., the Pennsylvania Wage Payment and Collection Law, 43 Pa. Stat. &sect;
                                            251 et seq., and the Pennsylvania Whistleblower Law, 43 Pa. Stat. &sect; 1421 et seq., all
                                            as amended; <B>[Insert any other applicable federal, state and local citations at the time
                                            of termination;] </B>all common law claims including, but not limited to, actions in defamation,
                                            intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge,
                                            and breach of contract (including, without limitation, all claims arising out of or relating
                                            to the Employment Agreement); all claims to any ownership interest in the Company, contractual
                                            or otherwise; all state and federal whistleblower claims to the maximum extent permitted
                                            by law; and any claim or damage arising out of your employment with and/or separation from
                                            the Company (including a claim for retaliation) under any common law theory or any federal,
                                            state or local statute or ordinance not expressly referenced above; provided, however, that
                                            nothing in this letter agreement: (i)&nbsp;prevents you from filing a charge with, cooperating
                                            with, or participating in any investigation or proceeding before, the Equal Employment Opportunity
                                            Commission or a state fair employment practices agency (except that you acknowledge that
                                            you may not recover any monetary benefits in connection with any such charge, investigation,
                                            or proceeding, and you further waive any rights or claims to any payment, benefit, attorneys&rsquo;
                                            fees or other remedial relief in connection with any such charge, investigation or proceeding),
                                            (ii)&nbsp;deprives you of any accrued benefits to which you have acquired a vested right
                                            under any employee benefit plan or policy, stock plan or deferred compensation arrangement,
                                            any health care continuation to the extent required by applicable law or any agreement, or
                                            any right to severance benefits or any other benefits due to you upon termination of employment
                                            that you may have under the Employment Agreement; or (iii)&nbsp;deprives you of any rights
                                            you may have to be indemnified by the Company as provided in any agreement between the Company
                                            and you, or pursuant to the Company&rsquo;s Certificate of Incorporation or by-laws (recognizing
                                            that such indemnification is not guaranteed by this letter agreement and shall be governed
                                            by the instrument, if any, providing for such indemnification).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Continuing
                                            Obligations</U></B> &ndash; You acknowledge and reaffirm your confidentiality and nondisclosure
                                            obligations discussed above, as well as any and all confidentiality, non-competition, nonsolicitation
                                            obligations and/or assignment of inventions set forth in any previous agreement you may have
                                            with the Company (including without limitation the Employment Agreement and the Restrictive
                                            Covenants Agreements referenced therein), which survive your separation from employment with
                                            the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Non-Disparagement
                                            </U></B>&ndash; You understand and agree that, to the extent permitted by law and except
                                            as otherwise permitted by paragraph 9 below, you will not, in public or private, make any
                                            false, disparaging, derogatory or defamatory statements, online (including, without limitation,
                                            on any social media, networking, or employer review site) or otherwise, to any person or
                                            entity, including, but not limited to, any media outlet, industry group, financial institution
                                            or current or former employee, board member, consultant, client or customer of the Company,
                                            regarding the Company or any of the other Released Parties, or regarding the Company&rsquo;s
                                            business affairs, business prospects, or financial condition.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cooperation
                                            </U></B>&ndash; You agree that, to the extent permitted by law, you shall cooperate fully
                                            with the Company in: (i)&nbsp;any internal investigation; (ii)&nbsp;any investigation, defense
                                            or prosecution of any claims or actions which already have been brought, are currently pending,
                                            or which may be brought in the future against the Company by a third party or by or on behalf
                                            of the Company against any third party, whether before a state or federal court, any state
                                            or federal government agency, or a mediator or arbitrator; or (iii)&nbsp;any other administrative,
                                            regulatory, or judicial inquiry, investigation, proceeding or arbitration.&nbsp; Your full
                                            cooperation hereunder shall include, but not be limited to, making yourself available to
                                            the Company upon reasonable notice for interviews and factual investigations; appearing at
                                            the Company&rsquo;s request to give testimony without requiring service of a subpoena or
                                            other legal process; volunteering to the Company pertinent information; and turning over
                                            all relevant documents which are in or may come into your possession.&nbsp; The term &ldquo;cooperation&rdquo;
                                            does not mean that you must provide information that is favorable to the Company; it means
                                            only that you will provide truthful information within your knowledge and possession upon
                                            request of the Company. &nbsp;The Company will reimburse you for all reasonable and documented
                                            out-of-pocket expenses that you incur at the Company&rsquo;s request to comply with this
                                            paragraph. You further agree that, to the extent permitted by law, you will notify the Company
                                            promptly in the event that you are served with a subpoena (other than a subpoena issued by
                                            a government agency), or in the event that you are asked to provide a third party (other
                                            than a government agency) with information concerning any actual or potential complaint or
                                            claim against the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Return
                                            of Company Property</U></B> &ndash; You confirm that you have returned to the Company all
                                            keys, files, records (and copies thereof), equipment (including, but not limited to, computer
                                            hardware, software, printers, flash drives and other storage devices, wireless handheld devices,
                                            cellular phones, tablets,&nbsp;etc.), Company identification, and any other Company owned
                                            property in your possession or control, and that you have left intact all, and have otherwise
                                            not destroyed, deleted, or made inaccessible to the Company any, electronic Company documents,
                                            including, but not limited to, those that you developed or helped to develop during your
                                            employment, and that you have not (a)&nbsp;retained any copies in any form or media; (b)&nbsp;maintained
                                            access to any copies in any form, media, or location; (c)&nbsp;stored any copies in any physical
                                            or electronic locations that are not readily accessible or not known to the Company or that
                                            remain accessible to you; or (d)&nbsp;sent, given, or made accessible any copies to any persons
                                            or entities that the Company has not authorized to receive such electronic or hard copies.
                                            You further confirm that you have cancelled all accounts for your benefit, if any, in the
                                            Company&rsquo;s name, including but not limited to, credit cards, telephone charge cards,
                                            cellular phone accounts, and computer accounts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Business
                                            Expenses and Final Compensation</U></B> &ndash; You acknowledge that you have been reimbursed
                                            by the Company for all business expenses incurred in conjunction with the performance of
                                            your employment and that no other reimbursements are owed to you. You further acknowledge
                                            that you have received payment in full for all services rendered in conjunction with your
                                            employment by the Company, including payment for all wages, bonuses, and accrued, unused
                                            vacation time, and that no other compensation is owed to you except as provided herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Confidentiality
                                            </U></B>&ndash; You understand and agree that, to the extent permitted by law and except
                                            as otherwise permitted by paragraph 9 below, the terms and contents of this letter agreement,
                                            and the contents of the negotiations and discussions resulting in this letter agreement,
                                            shall be maintained as confidential by you and your agents and representatives and shall
                                            not be disclosed except as otherwise agreed to in writing by the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Scope
                                            of Disclosure Restrictions</U></B> &ndash; Nothing in this letter agreement or elsewhere
                                            prohibits you from communicating with government agencies about possible violations of federal,
                                            state, or local laws or otherwise providing information to government agencies, filing a
                                            complaint with government agencies, or participating in government agency investigations
                                            or proceedings. You are not required to notify the Company of any such communications; provided,
                                            however, that nothing herein authorizes the disclosure of information you obtained through
                                            a communication that was subject to the attorney-client privilege. Further, notwithstanding
                                            your confidentiality and nondisclosure obligations, you are hereby advised as follows pursuant
                                            to the Defend Trade Secrets Act: &ldquo;An individual shall not be held criminally or civilly
                                            liable under any Federal or State trade secret law for the disclosure of a trade secret that
                                            (A)&nbsp;is made (i)&nbsp;in confidence to a Federal, State, or local government official,
                                            either directly or indirectly, or to an attorney; and (ii)&nbsp;solely for the purpose of
                                            reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint
                                            or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
                                            An individual who files a lawsuit for retaliation by an employer for reporting a suspected
                                            violation of law may disclose the trade secret to the attorney of the individual and use
                                            the trade secret information in the court proceeding, if the individual (A)&nbsp;files any
                                            document containing the trade secret under seal; and (B)&nbsp;does not disclose the trade
                                            secret, except pursuant to court order.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amendment
                                            and Waiver</U></B> &ndash; This letter agreement shall be binding upon the parties and may
                                            not be modified in any manner, except by an instrument in writing of concurrent or subsequent
                                            date signed by duly authorized representatives of the parties hereto. This letter agreement
                                            is binding upon and shall inure to the benefit of the parties and their respective agents,
                                            assigns, heirs, executors, successors and administrators. No delay or omission by the Company
                                            in exercising any right under this letter agreement shall operate as a waiver of that or
                                            any other right. A waiver or consent given by the Company on any one occasion shall be effective
                                            only in that instance and shall not be construed as a bar to or waiver of any right on any
                                            other occasion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Validity
                                            </U></B>&ndash; Should any provision of this letter agreement be declared or be determined
                                            by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining
                                            parts, terms or provisions shall not be affected thereby and said illegal or invalid part,
                                            term or provision shall be deemed not to be a part of this letter agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Nature
                                            of Agreement</U> &ndash; </B>You understand and agree that this letter agreement is a severance
                                            agreement and does not constitute an admission of liability or wrongdoing on the part of
                                            the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Acknowledgments
                                            </U>&ndash; </B>You acknowledge that you have been given at least <B>[seven (7)&nbsp;/ twenty-one
                                            (21) / forty-five (45)] </B>days to consider this letter agreement, and that the Company
                                            is hereby advising you to consult with an attorney of your own choosing prior to signing
                                            this letter agreement. <B>[You understand that you may revoke this letter agreement during
                                            the Revocation Period by notifying me in writing, and the letter agreement shall not be effective
                                            or enforceable until the expiration of the Revocation Period. You understand and agree that
                                            by entering into this letter agreement, you are waiving any and all rights or claims you
                                            might have under the Age Discrimination in Employment Act, as amended by the Older Workers
                                            Benefit Protection Act, and that you have received consideration beyond that to which you
                                            were previously entitled.]</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[<U>Eligibility
                                            for Severance Program</U> &ndash; Attached to this letter agreement as Attachment A is a
                                            description of (i)&nbsp;any class, unit or group of individuals covered by the program of
                                            severance benefits which the Company has offered to you, and any applicable time limits regarding
                                            such severance benefit program; and (ii)&nbsp;the job title and ages of all individuals eligible
                                            or selected for such severance benefit program, and the ages of all individuals in the same
                                            job classification or organizational unit who are not eligible or who were not selected for
                                            such severance benefit program.]</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Voluntary
                                            Assent</U></B> &ndash; You affirm that no other promises or agreements of any kind have been
                                            made to or with you by any person or entity whatsoever to cause you to sign this letter agreement,
                                            and that you fully understand the meaning and intent of this letter agreement. You state
                                            and represent that you have had an opportunity to fully discuss and review the terms of this
                                            letter agreement with an attorney. You further state and represent that you have carefully
                                            read this letter agreement, understand the contents herein, freely and voluntarily assent
                                            to all of the terms and conditions hereof, and sign your name of your own free act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Applicable
                                            Law</U></B> &ndash; This letter agreement shall be interpreted and construed by the laws
                                            of the Commonwealth of Pennsylvania, without regard to conflict of laws provisions. You hereby
                                            irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the
                                            Commonwealth of Pennsylvania, or if appropriate, a federal court located in the Commonwealth
                                            of Pennsylvania (which courts, for purposes of this letter agreement, are the only courts
                                            of competent jurisdiction), over any suit, action or other proceeding arising out of, under
                                            or in connection with this letter agreement or the subject matter hereof. You hereby irrevocably
                                            waive any right to a trial by jury in any action, suit or other legal proceeding arising
                                            under or relating to any provision of this letter agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Entire
                                            Agreement</U></B> &ndash; This letter agreement contains and constitutes the entire understanding
                                            and agreement between the parties hereto with respect to your severance benefits and the
                                            settlement of claims against the Company and cancels all previous oral and written negotiations,
                                            agreements, and commitments in connection therewith.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Tax
                                            Acknowledgement</U></B> &ndash; In connection with the [Severance Benefits] [Change in Control
                                            Severance Benefits], the Company shall withhold and remit to the tax authorities the amounts
                                            required under applicable law, and you shall be responsible for all applicable taxes with
                                            respect to such [Severance Benefits] [Change in Control Severance Benefits] under applicable
                                            law. You acknowledge that you are not relying upon the advice or representation of the Company
                                            with respect to the tax treatment of the [Severance Benefits] [Change in Control Severance
                                            Benefits].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page&nbsp;Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Execution
Copy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions about the matters covered in this letter agreement, please call me.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Name]&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Title]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby agree to the terms and conditions set forth above. <B>[I have been given at least [twenty-one (21) / forty-five (45)] days to
consider this letter agreement and I have chosen to execute this on the date below. I intend that this letter agreement will become a
binding agreement between me and the Company if I do not revoke my acceptance during the Revocation Period.]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">[Insert Name]</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be returned in a timely manner as set forth on the first page&nbsp;of this letter agreement, but not to be signed before the close of
business on your last day of employment.<SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
</SUP>Note: All footnotes will be removed from the final execution version of this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>9
<FILENAME>tm238578d1_ex10-9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.9&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYMENT AGREEMENT
(the &ldquo;Agreement&rdquo;), is made as of March 7, 2023 (the &ldquo;Effective Date&rdquo;), by and between Carisma Therapeutics
Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and Michael Klichinsky (the &ldquo;Executive&rdquo;) (together, the &ldquo;Parties&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive has
been employed by CTx Operations,&nbsp;Inc. (f/k/a CARISMA Therapeutics Inc.) (the &ldquo;Carisma Sub&rdquo;) pursuant to that certain
letter agreement dated October&nbsp;18, 2018, as amended detailing the terms and conditions of Executive&rsquo;s employment with the Carisma
Sub (the &ldquo;Prior Agreement&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to that
certain Agreement and Plan of Merger and Reorganization dated September&nbsp;20, 2022 and amended on December&nbsp;29, 2022 and February&nbsp;13,
2023 (the &ldquo;Merger Agreement&rdquo;), by and among the Company (f/k/a Sesen Bio,&nbsp;Inc.), Seahawk Merger Sub,&nbsp;Inc., a Delaware
corporation and wholly-owned subsidiary of the Company (&ldquo;Merger Sub&rdquo;), and the Carisma Sub, Merger Sub merged with and into
Carisma Sub, with Carisma Sub continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the
 &ldquo;Merger&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Parties desire
to enter into an agreement whereby the Executive will be employed as Chief Scientific Officer of the Company on the terms contained in
this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive has
agreed to accept such employment with the Company on the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and of the respective covenants and agreements of the Parties herein contained, the Parties hereto agree to the following
terms, which shall govern the Executive&rsquo;s employment from and after the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <I>Agreement</I>. This Agreement shall be effective
as of the Effective Date. The Executive&rsquo;s employment on the terms contained in this Agreement shall commence on the Effective Date
and shall continue until such employment relationship is terminated in accordance with Section&nbsp;7 hereof (the &ldquo;Term of Employment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <I>Position</I>. During the Term of Employment,
the Executive shall serve as the Chief Scientific Officer of the Company, working out of the Company&rsquo;s office in Philadelphia, Pennsylvania,
and travelling as reasonably required by the Executive&rsquo;s job duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <I>Scope of Employment</I>. During the Term
of Employment, the Executive shall be responsible for the performance of those duties consistent with the Executive&rsquo;s position as
Chief Scientific Officer. The Executive shall report to the Chief Executive Officer of the Company or his/her designee. The Executive
agrees to devote the Executive&rsquo;s full business time, best efforts, skill, knowledge, attention, and energies to the advancement
of the Company's business and interests and to the performance of the Executive&rsquo;s duties and responsibilities as an employee of
the Company and not to engage in any other business activities (whether as an employee, consultant, board member, advisor or in any other
capacity) without prior approval from the Company, except the Executive may engage in charitable or civic activities and/or serve as an
executor, trustee, or other similar fiduciary capacity, provided, however, that in no event may any activity be undertaken or continued
if it would (i)&nbsp;be in violation of any provision of this Agreement or other agreement between the Executive and the Company, (ii)&nbsp;interfere
with the performance of the Executive&rsquo;s duties for the Company, or (iii)&nbsp;present a conflict of interest with the Company&rsquo;s
business interests. As an employee of the Company, the Executive will be required to comply with all Company policies and procedures.
Violations of the Company's policies may lead to immediate termination of the Executive&rsquo;s employment, provided, however, that nothing
in the foregoing shall alter any rights the Executive may have as set forth in Section&nbsp;8 below. Further, the Company's premises,
including all workspaces, furniture, documents, and other tangible materials, and all information technology resources of the Company
(including computers, data and other electronic files, and all internet and email) are subject to oversight and inspection by the Company
at any time. Company employees should have no expectation of privacy with regard to any Company premises, materials, resources, or information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <I>Compensation</I>. As full compensation for
all services rendered by the Executive to the Company and any affiliate thereof, during the Term of Employment, the Company will provide
to the Executive the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<I>Base Salary</I>.
The Executive shall receive a base salary, effective as of January&nbsp;1, 2023, at the annualized rate of $420,000 (the &ldquo;Base Salary&rdquo;).
For the avoidance of doubt, to the extent Executive is entitled to additional base salary for the period between January&nbsp;1, 2023
and the Effective Date after taking into account any payments of base salary made by Carisma Sub to the Executive prior to the Effective
Date, such payments will be made in the first payroll following the Effective Date. Otherwise, the Executive&rsquo;s Base Salary shall
be paid in equal installments in accordance with the Company&rsquo;s regularly established payroll procedures. The Executive&rsquo;s Base
Salary will be reviewed on an annual or more frequent basis by the Company&rsquo;s board of directors (the &ldquo;Board&rdquo;) and is
subject to change in the discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<I>Annual Discretionary
Bonus</I>. The Executive will be eligible to receive an annual discretionary performance bonus of 40% of the Executive&rsquo;s Base Salary
(the &ldquo;Target Bonus&rdquo;), based on the Board&rsquo;s assessment of the Executive&rsquo;s performance and the Company&rsquo;s attainment
of targeted goals to be set by the Board in its sole discretion. Following the close of each calendar year, the Board will determine whether
the Executive has earned a performance bonus, and the amount of any performance bonus, based on the set criteria. No amount of the performance
bonus is guaranteed, and the Executive must be an active employee of the Company on the date the bonus is distributed in order to be eligible
for and to earn any bonus award, as it also serves as an incentive for the Executive to remain employed by the Company. The Executive&rsquo;s
bonus eligibility will be reviewed on an annual or more frequent basis by the Board and is subject to change in the discretion of the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<I>Equity Award</I>.
The Executive will be eligible to receive equity awards, if any, at such times and on such terms and conditions as the Board shall, in
its sole discretion, determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<I>&nbsp;Paid Time Off</I>.
The Executive will be eligible for a maximum of twenty-five (25) days of paid time off (&ldquo;PTO&rdquo;) per calendar year to be taken
at such times as may be approved by the Company. The number of PTO days for which the Executive is eligible shall accrue at the rate of
2.083 days per month that the Executive is employed during such calendar year. Any unused PTO time will be forfeited at the end of each
calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<I>Benefits</I>.
Subject to eligibility requirements and the Company&rsquo;s polices, the Executive shall have the right, on the same basis as other similarly-situated
employees of the Company, to participate in, and to receive benefits under, all employee health, disability, insurance, fringe, welfare
benefit and retirement plans, arrangements, practices and programs the Company provides to its senior executives in accordance with the
terms thereof as in effect from time to time. The Company reserves the right to modify, amend and/or terminate any and all of its benefits
plans at is discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<I>Withholdings</I>.
All compensation payable to the Executive shall be subject to applicable taxes and withholdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <I>Expenses</I>. The Executive will be reimbursed
for the Executive&rsquo;s actual, necessary and reasonable business expenses pursuant to Company policy, subject to the provisions of
Section&nbsp;3 of <U>Exhibit&nbsp;A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.
<I>Restrictive Covenants Agreements</I>. The Executive hereby acknowledges that each of the Invention and Non-Disclosure Agreement and
the Non-Competition and Non-Solicitation Agreement that the Executive previously executed in connection with the Executive&rsquo;s employment
with the Carisma Sub (together, the &ldquo;Restrictive Covenant Agreements&rdquo;) remain in full force and effect, with the terms thereof
hereby deemed incorporated herein; provided, however, that the references therein to &ldquo;Company&rdquo; shall be deemed hereinafter
to mean the Company, as well as the Carisma Sub.&nbsp; The Executive further acknowledges that the Executive&rsquo;s employment with the
Company is conditioned on the Executive&rsquo;s continued compliance with the Restrictive Covenant Agreements</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <I>Employment Termination</I>. This Agreement
and the employment of the Executive shall terminate upon the occurrence of any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;Upon the death of
the Executive or at the election of the Company due to the Executive&rsquo;s &ldquo;Disability&rdquo;. As used in this Agreement, the
term &ldquo;Disability&rdquo; shall mean a physical or mental illness or disability that prevents the Executive from performing the duties
of the Executive&rsquo;s position for a period of more than any three (3)&nbsp;consecutive months or for periods aggregating more than
twenty-six (26) weeks. The Company shall determine in good faith and in its sole discretion whether the Executive is unable to perform
the services provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;At the election of
the Company, with or without &ldquo;Cause&rdquo; (as defined below), immediately upon written notice by the Company to the Executive.
As used in this Agreement, &ldquo;Cause&rdquo; shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Executive&rsquo;s engagement in any conduct that has materially and adversely affected, or is reasonably likely to materially and adversely
affect, the business interests or reputation of the Company (for avoidance of doubt, &ldquo;conduct&rdquo; in this subsection does not
mean poor performance or failure to meet Company objectives);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
breach by the Executive of the Restrictive Covenant Agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Executive&rsquo;s willful and repeated failure to perform in any material respect, the Executive&rsquo;s duties to the Company under this
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Executive&rsquo;s fraud or embezzlement, or the Executive&rsquo;s willful misconduct with respect to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Executive&rsquo;s material breach of this Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Executive&rsquo;s conviction of, or plea of guilty or <I>nolo contendere </I>to, a misdemeanor relating to the Company, any crime involving
dishonesty or moral turpitude, or any felony;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided however, that with respect to subsections
(i), (ii)&nbsp;(iii)&nbsp;and (v)&nbsp;hereof, the Executive was given thirty (30) calendar days&rsquo; written notice of such conduct,
breach, or deficiencies and an opportunity to cure such conduct, breach or deficiencies but the Executive failed to do so within such
period (provided that the Executive is eligible for no more than two &ldquo;cure&rdquo; opportunities during the Executive&rsquo;s employment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;At the election of
the Executive, with or without &ldquo;Good Reason&rdquo; (as defined below), upon written notice by the Executive to the Company (subject,
if it is with Good Reason, to the timing provisions set forth in the definition of Good Reason). As used in this Agreement, &ldquo;Good
Reason&rdquo; shall mean the occurrence (without the Executive&rsquo;s prior written consent), of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
material reduction in the Executive&rsquo;s authority, duties, or responsibilities or a material reduction in the authority, duties or
responsibilities of the person to whom the Executive reports;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
relocation of the principal place at which the Executive provides services to the Company by at least fifty (50) miles and to a location
such that the Executive&rsquo;s daily commuting distance is increased;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
material reduction of the Executive&rsquo;s Base Salary; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
material breach by the Company of its obligations under this letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">No termination will
be treated as a termination by the Executive for Good Reason unless (x)&nbsp;the Executive has given written notice to the Company of
the Executive&rsquo;s intention to terminate the Executive&rsquo;s employment for Good Reason, describing the grounds for such action,
no later than ninety (90) days after the first occurrence of such circumstances, (y)&nbsp;the Executive has provided the Company with
at least thirty (30) days in which to cure the circumstances, and (z)&nbsp;if the Company is not successful in curing the circumstances,
the Executive ends the Executive&rsquo;s employment within thirty (30) calendar days following the cure period in (y).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. <I>Effect of Termination</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<I>&nbsp; All Terminations
Other Than by the Company Without Cause or by the Executive With Good Reason</I>. If the Executive&rsquo;s employment is terminated under
any circumstances other than a termination by the Company without Cause or a termination by the Executive with Good Reason (including
a voluntary termination by the Executive without Good Reason or a termination by the Company for Cause or due to the Executive&rsquo;s
death or Disability), the Company&rsquo;s obligations under this Agreement shall immediately cease and the Executive shall only be entitled
to receive (i)&nbsp;the Base Salary that has accrued and to which the Executive is entitled as of the effective date of such termination,
to be paid in accordance with the Company&rsquo;s established payroll procedure and applicable law but no later than the next regularly
scheduled pay period, (ii)&nbsp;unreimbursed business expenses for which expenses the Executive has timely submitted appropriate documentation
in accordance with Section&nbsp;5 hereof, (iii)&nbsp;any amounts or benefits to which the Executive is then entitled under the terms of
the benefit plans then-sponsored by the Company in accordance with their terms (and not accelerated to the extent acceleration does not
satisfy Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, (the &ldquo;Code&rdquo;)), and (iv)&nbsp;any accrued but unused
vacation time through the date of termination, to be paid in accordance with Company policy and applicable law (the payments described
in this sentence, the &ldquo;Accrued Obligations&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;</FONT><I>Termination
by the Company Without Cause or by the Executive With Good Reason More Than Three Months Prior to or More Than Twelve Months Following
a Change in Control.</I>&nbsp;If the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with
Good Reason more than three (3)&nbsp;months prior to, or more than twelve (12)&nbsp;months following, a Change in Control (as defined
below), the Executive shall be entitled to the Accrued Obligations. In addition, and subject to&nbsp;<U>Exhibit&nbsp;A</U>&nbsp;and the
conditions of Section&nbsp;8(d), the Company shall: (i)&nbsp;continue to pay to the Executive, in accordance with the Company&rsquo;s
regularly established payroll procedures, the Executive&rsquo;s Base Salary for a period of twelve (12)&nbsp;months; (ii)&nbsp;pay to
the Executive, in a single lump sum on the Payment Date (as defined below) an amount equal to one hundred percent (100%) of the Executive&rsquo;s
Target Bonus for the year in which termination occurs, prorated based on a fraction, the numerator of which is the number of days during
the calendar year in which the Executive&rsquo;s termination date occurs that the Executive remained employed by the Company and the denominator
of which is 365 (such amount, the &ldquo;Pro Rata Bonus&rdquo;); and (iii)&nbsp;provided the Executive is eligible for and timely elects
to continue receiving group medical insurance pursuant to the &ldquo;COBRA&rdquo; law, continue to pay for twelve (12)&nbsp;months following
the Executive&rsquo;s termination date or until the Executive has secured other employment or is no longer eligible for coverage under
COBRA, whichever occurs first, the share of the premium for health coverage that is paid by the Company for active and similarly-situated
employees who receive the same type of coverage, unless the Company&rsquo;s provision of such COBRA payments will violate the nondiscrimination
requirements of applicable law, in which case this benefit will not apply (collectively, the &ldquo;Severance Benefits&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<FONT STYLE="background-color: white"><I>Termination
by the Company Without Cause or by the Executive With Good Reason Within Three Months Prior to or Twelve Months Following a Change in
Control.</I>&nbsp;If the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with Good Reason
within the period that begins three (3)&nbsp;months prior to and ends twelve (12)&nbsp;months following a Change in Control, then the
Executive shall be entitled to the Accrued Obligations. In addition, and subject to&nbsp;<U>Exhibit&nbsp;A</U>&nbsp;and the conditions
of Section&nbsp;8(d), the Company shall: (i)&nbsp;pay to the Executive, in a single lump sum on the Payment Date, an amount equal to the
sum of (x)&nbsp; twelve (12) months of the Executive&rsquo;s Base Salary, and (y)&nbsp; one hundred percent (100%) of the Executive&rsquo;s
Target Bonus for the year in which termination occurs or, if higher, the Executive&rsquo;s Target Bonus immediately prior to the Change
in Control, (ii)&nbsp;pay to the Executive, in a single lump sum on the Payment Date, the Pro Rata Bonus which Pro Rata Bonus, shall,
for the avoidance of doubt, be determined by reference to the Executive&rsquo;s Target Bonus for the year in which termination occurs,
or, if higher, the Executive&rsquo;s Target Bonus immediately prior to the Change in Control, (iii)&nbsp;provided the Executive is eligible
for and timely elects to continue receiving group medical insurance pursuant to the &ldquo;COBRA&rdquo; law, continue to pay for twelve
(12) months following the Executive&rsquo;s termination date or until the Executive has secured other employment or is no longer eligible
for coverage under COBRA, whichever occurs first, the share of the premium for health coverage that is paid by the Company for active
and similarly-situated employees who receive the same type of coverage, unless the Company&rsquo;s provision of such COBRA payments will
violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply, and (iv)&nbsp;provide that the
vesting of the Executive&rsquo;s then-unvested equity awards that vest based solely on the passage of time shall be accelerated, such
that all such then-unvested time-based equity awards shall vest and become fully exercisable or&nbsp;non-forfeitable&nbsp;as of the later
of the date of the Change in Control and the Executive&rsquo;s termination date (collectively, the &ldquo;Change in Control Severance
Benefits&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<I>Release</I>.
As a condition of the Executive&rsquo;s receipt of the Severance Benefits or the Change in Control Severance Benefits, as applicable,
the Executive must execute and deliver to the Company a separation and release of claims agreement in substantially the form attached
hereto as <U>Exhibit&nbsp;B</U> (the &ldquo;Release&rdquo;), which Release must become irrevocable within sixty (60) days following the
date of the Executive&rsquo;s termination of employment (or such shorter period as may be directed by the Company). The Severance Benefits
or the Change in Control Severance Benefits, as applicable, will be paid or commence to be paid in the first regular payroll beginning
after the Release becomes effective, provided that if the foregoing sixty (60) day period would end in a calendar year subsequent to the
year in which the Executive&rsquo;s employment ends, the Severance Benefits or Change in Control Severance Benefits, as applicable, will
not be paid or begin to be paid before the first payroll of the subsequent calendar year (the date the Severance Benefits or Change in
Control Severance Benefits, as applicable, are paid or commence pursuant to this sentence, the &ldquo;Payment Date&rdquo;). The Executive
must continue to comply with all post-employment obligations under law or in any agreement between the Executive and the Company, including
the Restrictive Covenant Agreements, any similar agreement with the Company and as set forth in the Release in order to be eligible to
receive or continue receiving the Severance Benefits or Change in Control Severance Benefits, as applicable. </FONT><FONT STYLE="background-color: white">For
the avoidance of doubt, if the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with Good Reason
prior to a Change in Control, (i)&nbsp;any then-outstanding and unvested time-based equity awards held by the Executive shall remain outstanding
(but any vesting shall be suspended) for up to (but no longer than) three (3)&nbsp;months following the date of termination so that, if
it is later determined that such termination occurred during the three (3)-month period prior to the closing of a Change in Control and
the Executive is entitled to Change in Control acceleration and/or Change in Control Severance Benefits rather than Severance Benefits,
the vesting of such awards may be accelerated, in accordance with Section&nbsp;8(c), immediately prior to the closing of the Change in
Control and (ii)&nbsp;any Change in Control Severance Benefits shall be reduced by any Severance Benefits previously paid to the Executive,
if it is later determined that the termination occurred during the three (3)-month period prior to the closing of a Change in Control
and that the Executive is entitled to Change in Control Severance Benefits rather than Severance Benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<I>Change in Control
Definition</I>. For purposes of this Agreement, &ldquo;Change in Control&rdquo; shall mean the occurrence of any of the following events,
provided that such event or occurrence constitutes a change in the ownership or effective control of the Company, or a change in the ownership
of a substantial portion of the assets of the Company, as defined in Treasury Regulation &sect;&sect; 1.409A-3(i)(5)(v), (vi)&nbsp;and
(vii): (i)&nbsp;the acquisition by an individual, entity or group (within the meaning of Section&nbsp;13(d)(3)&nbsp;or 14(d)(2)&nbsp;of
the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;)) (a &ldquo;Person&rdquo;) of beneficial ownership of any capital
stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule&nbsp;13d-3 under the Exchange
Act) fifty percent (50%) or more of either (x)&nbsp;the then-outstanding shares of common stock of the Company (the &ldquo;Outstanding
Company Common Stock&rdquo;) or (y)&nbsp;the combined voting power of the then-outstanding securities of the Company entitled to vote
generally in the election of directors (the &ldquo;Outstanding Company Voting Securities&rdquo;); provided, however, that for purposes
of this subsection (i), the following acquisitions shall not constitute a Change in Control: (1)&nbsp;any acquisition directly from the
Company or (2)&nbsp;any acquisition by any entity pursuant to a Business Combination (as defined below) which complies with clauses (x)&nbsp;and
(y)&nbsp;of subsection (iii)&nbsp;of this definition; or (ii)&nbsp;a change in the composition of the Board that results in the Continuing
Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of a successor
corporation to the Company), where the term &ldquo;Continuing Director&rdquo; means at any date a member of the Board (x)&nbsp;who was
a member of the Board on the Effective Date or (y)&nbsp;who was nominated or elected subsequent to such date by at least a majority of
the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended
or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided,
however, that there shall be excluded from this clause (y)&nbsp;any individual whose initial assumption of office occurred as a result
of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation
of proxies or consents, by or on behalf of a person other than the Board; or (iii)&nbsp;the consummation of a merger, consolidation, reorganization,
recapitalization or share exchange involving the Company, or a sale or other disposition of all or substantially all of the assets of
the Company (a &ldquo;Business Combination&rdquo;), unless, immediately following such Business Combination, each of the following two
(2)&nbsp;conditions is satisfied: (x)&nbsp;all or substantially all of the individuals and entities who were the beneficial owners of
the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially
own, directly or indirectly, more than fifty percent (50%) of the then-outstanding shares of common stock and the combined voting power
of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring
corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction
owns the Company or substantially all of the Company&rsquo;s assets either directly or through one (1)&nbsp;or more subsidiaries) (such
resulting or acquiring corporation is referred to herein as the &ldquo;Acquiring Corporation&rdquo;) in substantially the same proportions
as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior
to such Business Combination and (y)&nbsp;no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by
the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, fifty percent (50%) or more of the then-outstanding
shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation
entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination);
or (iv)&nbsp;the liquidation or dissolution of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<I>Resignation from
other Positions</I>. If, as of the date that the Executive&rsquo;s employment terminates for any reason, the Executive is a member of
the Board (or the board of directors of any entity affiliated with the Company), or hold any other offices or positions with the Company
(or any entity affiliated with the Company), the Executive shall, unless otherwise requested by the Company, immediately relinquish and/or
resign from any such board memberships, offices and positions as of the date the Executive&rsquo;s employment terminates. The Executive
agrees to execute such documents and take such other actions as the Company may request to reflect such relinquishments and/or resignation(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. <I>Absence of Restrictions</I>. The Executive
represents and warrants that the Executive is not bound by any employment contracts, restrictive covenants or other restrictions that
prevent (or purports to prevent) the Executive from carrying out the Executive&rsquo;s responsibilities for the Company, or which are
in any way inconsistent with any of the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. <I>Notice</I>. Any notice delivered under
this Agreement shall be deemed duly delivered three (3)&nbsp;business days after it is sent by registered or certified mail, return receipt
requested, postage prepaid, one (1)&nbsp;business day after it is sent for next-business day delivery via a reputable nationwide overnight
courier service, or immediately upon hand delivery, in each case to the address of the recipient set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the address set forth in
the Executive&rsquo;s personnel file</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma Therapeutics Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3675 Market Street, Suite&nbsp;200&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Philadelphia, Pennsylvania
19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Either Party may change the address to which notices
are to be delivered by giving notice of such change to the other Party in the manner set forth in this Section&nbsp;10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. <I>Applicable Law and Forum</I>. This Agreement
shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania (without reference to the conflict
of laws provisions thereof). Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall
be commenced only in a court of the Commonwealth of Pennsylvania (or, if appropriate, a federal court located within the Commonwealth
of Pennsylvania), and the Company and the Executive each consent to the exclusive jurisdiction of such a court. The Company and the Executive
each hereby irrevocably waives any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to
any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12. <I>Successors and Assigns</I>. This Agreement
shall be binding upon and inure to the benefit of both Parties and their respective successors and assigns, including any corporation
with which or into which the Company may be merged or which may succeed to its assets or business; provided, however, that the obligations
of the Executive are personal and shall not be assigned by the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13. <I>At-Will Employment</I>. This Agreement
shall not be construed as an agreement, either expressed or implied, to employ the Executive for any stated term, and shall in no way
alter the Company&rsquo;s policy of employment at will, under which both the Executive and the Company remain free to terminate the employment
relationship, with or without cause, at any time, with or without notice. Although the Executive&rsquo;s job duties, title, compensation
and benefits, as well as the Company's personnel policies and procedures, may change from time to time, the &ldquo;at-will&rdquo; nature
of the Executive&rsquo;s employment may only be changed by a written agreement signed by the Executive and a duly authorized representative
of the Company, which written agreement expressly states the intention to modify the at-will nature of the Executive&rsquo;s employment,
provided, however, that nothing in the foregoing shall alter any rights the Executive may have as set forth in Section&nbsp;8 above. Similarly,
nothing in this Agreement shall be construed as an agreement, either express or implied, to pay the Executive any compensation or grant
the Executive any benefit beyond the end of the Executive&rsquo;s employment with the Company, except as explicitly set forth in Section&nbsp;8
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. <I>Acknowledgment</I>. The Executive states
and represents that the Executive has had an opportunity to fully discuss and review the terms of this Agreement with an attorney. The
Executive further states and represents that the Executive has carefully read this Agreement, understands the contents herein, freely
and voluntarily assents to all of the terms and conditions hereof, and signs the Executive&rsquo;s name of the Executive&rsquo;s own free
act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15. <I>No Oral Modification, Waiver, Cancellation
or Discharge</I>. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.
No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right.
A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a
bar to or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16. <I>Captions and Pronouns</I>. The captions
of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of
any section of this Agreement. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17. <I>Interpretation</I>. The Parties agree that
this Agreement will be construed without regard to any presumption or rule&nbsp;requiring construction or interpretation against the drafting
Party. References in this Agreement to &ldquo;include&rdquo; or &ldquo;including&rdquo; should be read as though they said &ldquo;without
limitation&rdquo; or equivalent forms. Except where the context requires otherwise, references in this Agreement to the &ldquo;Board&rdquo;
shall include any authorized committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">18. <I>Severability</I>. Each provision of this
Agreement must be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement
is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition
or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. Moreover, if a court
of competent jurisdiction determines any of the provisions contained in this Agreement to be unenforceable because the provision is excessively
broad in scope, whether as to duration, activity, geographic application, subject or otherwise, it will be construed, by limiting or reducing
it to the extent legally permitted, so as to be enforceable to the extent compatible with then applicable law to achieve the intent of
the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">19. <I>Modified Section&nbsp;280G Cutback</I>.
Notwithstanding any other provision of this Agreement, except as set forth in Section&nbsp;19(b), in the event that the Company undergoes
a &ldquo;Change in Ownership or Control&rdquo; (as defined below), the following provisions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The Company shall
not be obligated to provide to the Executive any portion of any &ldquo;Contingent Compensation Payments&rdquo; (as defined below) that
the Executive would otherwise be entitled to receive to the extent necessary to eliminate any &ldquo;excess parachute payments&rdquo;
(as defined in Section&nbsp;280G(b)(1)&nbsp;of the Code) for the Executive. For purposes of this Section&nbsp;19, the Contingent Compensation
Payments so eliminated shall be referred to as the &ldquo;Eliminated Payments&rdquo; and the aggregate amount (determined in accordance
with Treasury Regulation Section&nbsp;1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated
shall be referred to as the &ldquo;Eliminated Amount.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;Notwithstanding the
provisions of Section&nbsp;19(a), no such reduction in Contingent Compensation Payments shall be made if (1)&nbsp;the Eliminated Amount
(computed without regard to this sentence) exceeds (2)&nbsp;one hundred percent (100%) of the aggregate present value (determined in accordance
with Treasury Regulation Section&nbsp;1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional taxes that
would be incurred by the Executive if the Eliminated Payments (determined without regard to this sentence) were paid to the Executive
(including state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section&nbsp;4999 of the Code payable
with respect to all of the Contingent Compensation Payments in excess of the Executive&rsquo;s &ldquo;base amount&rdquo; (as defined in
Section&nbsp;280G(b)(3)&nbsp;of the Code), and any withholding taxes). The override of such reduction in Contingent Compensation Payments
pursuant to this Section&nbsp;19(b)&nbsp;shall be referred to as a &ldquo;Section&nbsp;19(b)&nbsp;Override.&rdquo; For purpose of this
paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes
shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;For purposes of this
Section&nbsp;19 the following terms shall have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&nbsp;&ldquo;Change in Ownership
or Control&rdquo; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion
of the assets of the Company determined in accordance with Section&nbsp;280G(b)(2)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii)&nbsp;&ldquo;Contingent Compensation
Payment&rdquo; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement
or otherwise) to or for the benefit of a &ldquo;disqualified individual&rdquo; (as defined in Section&nbsp;280G(c)&nbsp;of the Code) and
that is contingent (within the meaning of Section&nbsp;280G(b)(2)(A)(i)&nbsp;of the Code) on a Change in Ownership or Control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;Any payments or other
benefits otherwise due to the Executive following a Change in Ownership or Control that could reasonably be characterized (as determined
by the Company) as Contingent Compensation Payments (the &ldquo;Potential Payments&rdquo;) shall not be made until the dates provided
for in this Section&nbsp;19(d). Within thirty (30) days after each date on which the Executive first becomes entitled to receive (whether
or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify
the Executive (with reasonable detail regarding the basis for its determinations) (1)&nbsp;which Potential Payments constitute Contingent
Compensation Payments, (2)&nbsp;the Eliminated Amount and (3)&nbsp;whether the Section&nbsp;19(b)&nbsp;Override is applicable. Within
thirty (30) days after delivery of such notice to the Executive, the Executive shall deliver a response to the Company (the &ldquo;Executive
Response&rdquo;) stating either (A)&nbsp;that the Executive agrees with the Company&rsquo;s determination pursuant to the preceding sentence
or (B)&nbsp;that the Executive disagrees with such determination, in which case the Executive shall set forth (x)&nbsp;which Potential
Payments should be characterized as Contingent Compensation Payments, (y)&nbsp;the Eliminated Amount, and (z)&nbsp;whether the Section&nbsp;19(b)&nbsp;Override
is applicable. In the event that the Executive fails to deliver an Executive Response on or before the required date, the Company&rsquo;s
initial determination shall be final. If and to the extent that any Contingent Compensation Payments are required to be treated as Eliminated
Payments pursuant to this Section&nbsp;19, then the payments shall be reduced or eliminated, as determined by the Company, in the following
order: (i)&nbsp;any cash payments, (ii)&nbsp;any taxable benefits, (iii)&nbsp;any nontaxable benefits, and (iv)&nbsp;any vesting of equity
awards in each case in reverse order beginning with payments or benefits that are to be paid the farthest in time from the date that triggers
the applicability of the excise tax, to the extent necessary to maximize the Eliminated Payments. If the Executive states in the Executive
Response that the Executive agrees with the Company&rsquo;s determination, the Company shall make the Potential Payments to the Executive
within three (3)&nbsp;business days following delivery to the Company of the Executive Response (except for any Potential Payments which
are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due). If the Executive
states in the Executive Response that the Executive disagrees with the Company&rsquo;s determination, then, for a period of sixty (60)
days following delivery of the Executive Response, the Executive and the Company shall use good faith efforts to resolve such dispute.
If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration as provided in Section&nbsp;11
of this Agreement. The Company shall, within three (3)&nbsp;business days following delivery to the Company of the Executive Response,
make to the Executive those Potential Payments as to which there is no dispute between the Company and the Executive regarding whether
they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments
shall be made on the date on which they are due). The balance of the Potential Payments shall be made within three (3)&nbsp;business days
following the resolution of such dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of this Section&nbsp;19
are intended to apply to any and all payments or benefits available to the Executive under this Agreement or any other agreement or plan
under which the Executive may receive Contingent Compensation Payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">20. <I>Entire Agreement</I>. Except as expressly
provided in the Merger Agreement and any other agreements to which the Executive is or will be party in connection with the Transaction,
this Agreement constitutes the entire agreement between the Parties and supersedes and replaces all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement, including, without limitation, the Prior Agreement; provided,
however, and for the avoidance of doubt, nothing herein shall be deemed to supersede the Restrictive Covenant Agreements, which remain
in full force and effect as set forth in Section&nbsp;6 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the Parties hereto have executed
this Agreement as of the day and year set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ Steven Kelly</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">Steven Kelly</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Title:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">Chief Executive Officer</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXECUTIVE:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">/s/ Michael Klichinsky</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Michael Klichinsky</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Payments Subject to Section&nbsp;409A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject to this <U>Exhibit&nbsp;A</U>, any severance payments or benefits that may be due
under the Agreement shall begin only upon the date of the Executive&rsquo;s &ldquo;separation from service&rdquo; (determined as set
forth below) which occurs on or after the termination of the Executive&rsquo;s employment. The following rules&nbsp;shall apply with
respect to distribution of the severance payments or benefits, if any, to be provided to the Executive under the Agreement, as
applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;It
is intended that each installment of the severance payments or benefits provided under the Agreement shall be treated as a separate &ldquo;payment&rdquo;
for purposes of Section&nbsp;409A of the Internal Revenue Code (&ldquo;Section&nbsp;409A&rdquo;). Neither the Company nor the Executive
shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted
or required by Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If,
as of the date of the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company, the Executive is not a &ldquo;specified
employee&rdquo; (within the meaning of Section&nbsp;409A), then each installment of the severance payments or benefits shall be made on
the dates and terms set forth in the letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If,
as of the date of the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company, the Executive is a &ldquo;specified employee&rdquo;
(within the meaning of Section&nbsp;409A), then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Each installment of the severance payments or benefits due under the Agreement that, in accordance with
the dates and terms set forth herein, will in all circumstances, regardless of when the Executive&rsquo;s separation from service occurs,
be paid within the short-term deferral period (as defined under Section&nbsp;409A) shall be treated as a short-term deferral within the
meaning of Treasury Regulation Section&nbsp;1.409A-1(b)(4)&nbsp;to the maximum extent permissible under Section&nbsp;409A and shall be
paid on the dates and terms set forth in the Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">Each installment of the severance payments or benefits due under the Agreement that is not described in
this <U>Exhibit&nbsp;A</U>, Section&nbsp;1(c)(i)&nbsp;and that would, absent this subsection, be paid within the six (6)-month period
following the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company shall not be paid until the date that is six (6)&nbsp;months
and one day after such separation from service (or, if earlier, the Executive&rsquo;s death), with any such installments that are required
to be delayed being accumulated during the six (6)-month period and paid in a lump sum on the date that is six months and one day following
the Executive&rsquo;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms
set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of payments or
benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide
for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii)&nbsp;(relating to separation pay
upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section&nbsp;1.409A-1(b)(9)(iii)&nbsp;must
be paid no later than the last day of the Executive&rsquo;s second taxable year following the taxable year in which the separation from
service occurs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The determination of whether and when the Executive&rsquo;s separation from
service from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in,
Treasury Regulation Section&nbsp;1.409A-1(h). Solely for purposes of Section&nbsp;2 of this <U>Exhibit&nbsp;A</U>,
 &ldquo;Company&rdquo; shall include all persons with whom the Company would be considered a single employer under
Section&nbsp;414(b)&nbsp;and 414(c)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All reimbursements and in-kind benefits provided under the Agreement shall
be made or provided in accordance with the requirements of Section&nbsp;409A to the extent that such reimbursements or in-kind
benefits are subject to Section&nbsp;409A, including, where applicable, the requirements that (i)&nbsp;any reimbursement is for
expenses incurred during the Executive&rsquo;s lifetime (or during a shorter period of time specified in the Agreement),
(ii)&nbsp;the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for
reimbursement in any other calendar year, (iii)&nbsp;the reimbursement of an eligible expense will be made on or before the last day
of the calendar year following the year in which the expense is incurred and (iv)&nbsp;the right to reimbursement is not subject to
set off or liquidation or exchange for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company makes no representation or warranty and shall have no
liability to the Executive or to any other person if any of the provisions of the Agreement (including this <U>Exhibit&nbsp;A</U>)
are determined to constitute deferred compensation subject to Section&nbsp;409A but that do not satisfy an exemption from, or the
conditions of, that section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Agreement is intended to comply with, or be exempt from, Section&nbsp;409A and
shall be interpreted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of page&nbsp;intentionally left blank.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B<SUP>1</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sample Separation and Release Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[Insert Date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[Insert Name]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear <B>[Insert Name]</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the termination
of your employment with [Carisma Therapeutics Inc.] (the &ldquo;Company&rdquo;) on <B>[Separation Date]</B>, you are eligible to receive
[Severance Benefits] [Change in Control Severance Benefits] as described in Section&nbsp;8 of the employment agreement executed between
you and the Company dated _______ (the &ldquo;Employment Agreement&rdquo;) if you sign and return this letter agreement to me by <B>[Return
Date &ndash;7/21/45 days from date of receipt of this letter agreement] [and it becomes binding between you and the Company</B>]. By
signing and returning this letter agreement [<B>and not revoking your acceptance]</B>, you will be agreeing to the terms and conditions
set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 2. Therefore, you are advised to consult
with an attorney before signing this letter agreement and you have been given at least [<B>seven/twenty-one (21)/forty-five (45)]<SUP>2
</SUP></B>days to do so. [<B>If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7)&nbsp;day
period after you have signed it (the &ldquo;Revocation Period&rdquo;) by notifying me in writing. If you do not so revoke, this letter
agreement will become a binding agreement between you and the Company upon the expiration of the Revocation Period.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although your receipt of the
[Severance Benefits] [Change in Control Severance Benefits] is expressly conditioned on your entering into this letter agreement, the
following will apply regardless of whether or not you do so:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</font></FONT></TD><TD STYLE="text-align: justify">As of the Separation Date, all salary payments from the Company will cease and any benefits you had as
of the Separation Date under Company-provided benefit plans, programs, or practices will terminate, except as required by federal or state
law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</font></FONT></TD><TD STYLE="text-align: justify">You will receive payment for your final wages and any unused vacation time accrued through the Separation
Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</font></FONT></TD><TD STYLE="text-align: justify">You may, if eligible and at your own cost, elect to continue receiving group medical insurance pursuant
to applicable &ldquo;COBRA&rdquo; law. Please consult the COBRA materials to be provided under separate cover for details regarding these
benefits.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>1</SUP> Note: The Company may revise this
release agreement in its sole discretion to reflect changes in law, additional statutes or claims, benefits, or employee&rsquo;s circumstances,
so that the Company receives the benefit of the most complete release of claims that is legally permissible (without releasing employee&rsquo;s
right to receive the Severance Benefits), and the Company may also change the timing, if required to obtain such release. This footnote
and the other footnotes herein are part of the form of release and are to be removed only when the Company finalizes the letter agreement
for execution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>2</SUP> Consideration period depends upon
circumstances of separation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</font></FONT></TD><TD STYLE="text-align: justify">You are obligated to keep confidential and not to use or disclose any and all non-public information concerning
the Company that you acquired during the course of your employment with the Company, including any non-public information concerning the
Company&rsquo;s business affairs, business prospects, and financial condition, except as otherwise permitted by paragraph 9 below. Further,
you remain subject to any and all continuing confidentiality, non-competition and/or non-solicitation obligations that you may have pursuant
to any previous agreement with the Company, including, as may be applicable and without limitation, the Employment Agreement and the Invention
and Non-Disclosure Agreement and Non-Competition and Non-Solicitation Agreement (the &ldquo;Restrictive Covenant Agreements&rdquo;) referenced
therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</font></FONT></TD><TD STYLE="text-align: justify">You must return to the Company no later than the Separation Date all Company property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you elect to timely sign
and return this letter agreement, comply with all of your obligations hereunder, and do not revoke your acceptance in writing within the
Revocation Period, the following numbered paragraphs set forth the terms and conditions that will also apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><B><U>Severance Benefits</U></B> The Company will provide you with the [as may be applicable [Severance
Benefits] or [Change in Control Severance Benefits]] set forth in Section&nbsp;8 of the Employment Agreement (the [&ldquo;Severance Benefits&rdquo;]
[&ldquo;Change in Control Severance Benefits&rdquo;]), <B>s</B>ubject to and in accordance with the terms and conditions thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><B><U>Release</U></B> &ndash; In consideration of the [Severance Benefits] [Change in Control Severance
Benefits], which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally
release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their
respective past and present officers, directors, stockholders, partners, members, managers, employees, agents, representatives, plan administrators,
attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &ldquo;Released Parties&rdquo;)
from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts,
reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses
(including attorneys&rsquo; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released
Parties, whether known or unknown, including, but not limited to, any and all claims arising out of or relating to your employment with
and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C.
 &sect; 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. &sect; 12101 et seq., <B>[the Age Discrimination in Employment
Act, 29 U.S.C. &sect; 621 et seq.,] </B>the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &sect; 2000ff et seq., the Family
and Medical Leave Act, 29 U.S.C. &sect; 2601 et seq., the Worker Adjustment and Retraining Notification Act (&ldquo;WARN&rdquo;), 29 U.S.C.
 &sect; 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C. &sect; 701 et seq., Executive Order 11246, Executive Order 11141, the Fair
Credit Reporting Act, 15 U.S.C. &sect; 1681 et seq., and the Employee Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;), 29
U.S.C. &sect; 1001 et seq., all as amended; all claims arising out of the Pennsylvania Human Relations Act, 43 Pa. Stat. &sect; 951 et
seq., the Pennsylvania Equal Pay Law, 43 Pa. Stat. &sect; 336.1 et seq., the Pennsylvania Wage Payment and Collection Law, 43 Pa. Stat.
 &sect; 251 et seq., and the Pennsylvania Whistleblower Law, 43 Pa. Stat. &sect; 1421 et seq., all as amended; <B>[Insert any other applicable
federal, state and local citations at the time of termination;] </B>all common law claims including, but not limited to, actions in defamation,
intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without
limitation, all claims arising out of or relating to the Employment Agreement); all claims to any ownership interest in the Company, contractual
or otherwise; all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of
your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal,
state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this letter agreement: (i)&nbsp;prevents
you from filing a charge with, cooperating with, or participating in any investigation or proceeding before, the Equal Employment Opportunity
Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in
connection with any such charge, investigation, or proceeding, and you further waive any rights or claims to any payment, benefit, attorneys&rsquo;
fees or other remedial relief in connection with any such charge, investigation or proceeding), (ii)&nbsp;deprives you of any accrued
benefits to which you have acquired a vested right under any employee benefit plan or policy, stock plan or deferred compensation arrangement,
any health care continuation to the extent required by applicable law or any agreement, or any right to severance benefits or any other
benefits due to you upon termination of employment that you may have under the Employment Agreement; or (iii)&nbsp;deprives you of any
rights you may have to be indemnified by the Company as provided in any agreement between the Company and you, or pursuant to the Company&rsquo;s
Certificate of Incorporation or by-laws (recognizing that such indemnification is not guaranteed by this letter agreement and shall be
governed by the instrument, if any, providing for such indemnification).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><B><U>Continuing Obligations</U></B> &ndash; You acknowledge and reaffirm your confidentiality and nondisclosure</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">obligations discussed above, as well
as any and all confidentiality, non-competition, nonsolicitation obligations and/or assignment of inventions set forth in any previous
agreement you may have with the Company (including without limitation the Employment Agreement and the Restrictive Covenants Agreements
referenced therein), which survive your separation from employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><B><U>Non-Disparagement</U></B> &ndash; You understand and agree that, to the extent permitted by law
and except as otherwise permitted by paragraph 9 below, you will not, in public or private, make any false, disparaging, derogatory or
defamatory statements, online (including, without limitation, on any social media, networking, or employer review site) or otherwise,
to any person or entity, including, but not limited to, any media outlet, industry group, financial institution or current or former employee,
board member, consultant, client or customer of the Company, regarding the Company or any of the other Released Parties, or regarding
the Company&rsquo;s business affairs, business prospects, or financial condition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><B><U>Cooperation</U></B> &ndash; You agree that, to the extent permitted by law, you shall cooperate
fully with the Company in: (i)&nbsp;any internal investigation; (ii)&nbsp;any investigation, defense or prosecution of any claims or actions
which already have been brought, are currently pending, or which may be brought in the future against the Company by a third party or
by or on behalf of the Company against any third party, whether before a state or federal court, any state or federal government agency,
or a mediator or arbitrator; or (iii)&nbsp;any other administrative, regulatory, or judicial inquiry, investigation, proceeding or arbitration.&nbsp;
Your full cooperation hereunder shall include, but not be limited to, making yourself available to the Company upon reasonable notice
for interviews and factual investigations; appearing at the Company&rsquo;s request to give testimony without requiring service of a subpoena
or other legal process; volunteering to the Company pertinent information; and turning over all relevant documents which are in or may
come into your possession.&nbsp; The term &ldquo;cooperation&rdquo; does not mean that you must provide information that is favorable
to the Company; it means only that you will provide truthful information within your knowledge and possession upon request of the Company.
 &nbsp;The Company will reimburse you for all reasonable and documented out-of-pocket expenses that you incur at the Company&rsquo;s request
to comply with this paragraph. You further agree that, to the extent permitted by law, you will notify the Company promptly in the event
that you are served with a subpoena (other than a subpoena issued by a government agency), or in the event that you are asked to provide
a third party (other than a government agency) with information concerning any actual or potential complaint or claim against the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><B><U>Return of Company Property</U></B> &ndash; You confirm that you have returned to the Company all
keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software, printers, flash drives
and other storage devices, wireless handheld devices, cellular phones, tablets,&nbsp;etc.), Company identification, and any other Company
owned property in your possession or control, and that you have left intact all, and have otherwise not destroyed, deleted, or made inaccessible
to the Company any, electronic Company documents, including, but not limited to, those that you developed or helped to develop during
your employment, and that you have not (a)&nbsp;retained any copies in any form or media; (b)&nbsp;maintained access to any copies in
any form, media, or location; (c)&nbsp;stored any copies in any physical or electronic locations that are not readily accessible or not
known to the Company or that remain accessible to you; or (d)&nbsp;sent, given, or made accessible any copies to any persons or entities
that the Company has not authorized to receive such electronic or hard copies. You further confirm that you have cancelled all accounts
for your benefit, if any, in the Company&rsquo;s name, including but not limited to, credit cards, telephone charge cards, cellular phone
accounts, and computer accounts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><B><U>Business Expenses and Final Compensation</U></B> &ndash; You acknowledge that you have been reimbursed
by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements
are owed to you. You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment
by the Company, including payment for all wages, bonuses, and accrued, unused vacation time, and that no other compensation is owed to
you except as provided herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><B><U>Confidentiality</U></B> &ndash; You understand and agree that, to the extent permitted by law and
except as otherwise permitted by paragraph 9 below, the terms and contents of this letter agreement, and the contents of the negotiations
and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and representatives and
shall not be disclosed except as otherwise agreed to in writing by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><B><U>Scope of Disclosure Restrictions</U></B> &ndash; Nothing in this letter agreement or elsewhere prohibits
you from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information
to government agencies, filing a complaint with government agencies, or participating in government agency investigations or proceedings.
You are not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure
of information you obtained through a communication that was subject to the attorney-client privilege. Further, notwithstanding your confidentiality
and nondisclosure obligations, you are hereby advised as follows pursuant to the Defend Trade Secrets Act: &ldquo;An individual shall
not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A)&nbsp;is
made (i)&nbsp;in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii)&nbsp;solely
for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document filed
in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer
for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information
in the court proceeding, if the individual (A)&nbsp;files any document containing the trade secret under seal; and (B)&nbsp;does not disclose
the trade secret, except pursuant to court order.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><B><U>Amendment and Waiver</U></B> &ndash; This letter agreement shall be binding upon the parties and
may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives
of the parties hereto. This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents,
assigns, heirs, executors, successors and administrators. No delay or omission by the Company in exercising any right under this letter
agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be
effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="text-align: justify"><B><U>Validity</U></B> &ndash; Should any provision of this letter agreement be declared or be determined
by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be
affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="text-align: justify"><B><U>Nature of Agreement</U> &ndash; </B>You understand and agree that this letter agreement is a severance
agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD><TD STYLE="text-align: justify"><B><U>Acknowledgments</U> &ndash; </B>You acknowledge that you have been given at least <B>[seven (7)&nbsp;/
twenty-one (21) / forty-five (45)] </B>days to consider this letter agreement, and that the Company is hereby advising you to consult
with an attorney of your own choosing prior to signing this letter agreement. <B>[You understand that you may revoke this letter agreement
during the Revocation Period by notifying me in writing, and the letter agreement shall not be effective or enforceable until the expiration
of the Revocation Period. You understand and agree that by entering into this letter agreement, you are waiving any and all rights or
claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that
you have received consideration beyond that to which you were previously entitled.]</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD><TD STYLE="text-align: justify"><B>[<U>Eligibility for Severance Program</U> &ndash; Attached to this letter agreement as Attachment A
is a description of (i)&nbsp;any class, unit or group of individuals covered by the program of severance benefits which the Company has
offered to you, and any applicable time limits regarding such severance benefit program; and (ii)&nbsp;the job title and ages of all individuals
eligible or selected for such severance benefit program, and the ages of all individuals in the same job classification or organizational
unit who are not eligible or who were not selected for such severance benefit program.]</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD><TD STYLE="text-align: justify"><B><U>Voluntary Assent</U></B> &ndash; You affirm that no other promises or agreements of any kind have
been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand
the meaning and intent of this letter agreement. You state and represent that you have had an opportunity to fully discuss and review
the terms of this letter agreement with an attorney. You further state and represent that you have carefully read this letter agreement,
understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own
free act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD><TD STYLE="text-align: justify"><B><U>Applicable Law</U></B> &ndash; This letter agreement shall be interpreted and construed by the laws
of the Commonwealth of Pennsylvania, without regard to conflict of laws provisions. You hereby irrevocably submit to and acknowledge and
recognize the jurisdiction of the courts of the Commonwealth of Pennsylvania, or if appropriate, a federal court located in the Commonwealth
of Pennsylvania (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action
or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof. You hereby irrevocably
waive any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this letter
agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD><TD STYLE="text-align: justify"><B><U>Entire Agreement</U></B> &ndash; This letter agreement contains and constitutes the entire understanding
and agreement between the parties hereto with respect to your severance benefits and the settlement of claims against the Company and
cancels all previous oral and written negotiations, agreements, and commitments in connection therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD><TD STYLE="text-align: justify"><B><U>Tax Acknowledgement</U></B> &ndash; In connection with the [Severance Benefits] [Change in Control
Severance Benefits], the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall
be responsible for all applicable taxes with respect to such [Severance Benefits] [Change in Control Severance Benefits] under applicable
law. You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of the
[Severance Benefits] [Change in Control Severance Benefits].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page&nbsp;Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Execution Copy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you have any questions about the matters covered
in this letter agreement, please call me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 5%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>[Name]</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>[Title]</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby agree to the terms and conditions set
forth above. <B>[I have been given at least [twenty-one (21) / forty-five (45)] days to consider this letter agreement and I have chosen
to execute this on the date below. I intend that this letter agreement will become a binding agreement between me and the Company if I
do not revoke my acceptance during the Revocation Period.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><B>[Insert Name]</B></TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Date</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To be returned in a timely manner as set forth
on the first page&nbsp;of this letter agreement, but not to be signed before the close of business on your last day of employment.<SUP>3</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP> Note: All footnotes will be removed from the final execution
version of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>10
<FILENAME>tm238578d1_ex10-10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.10</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2017 <FONT STYLE="font-variant: small-caps">Stock
Incentive Plan</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>CARMA
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Table
of Contents<SUP></SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-variant: small-caps"><B>Page</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purpose</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligibility</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration and Delegation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration by the Board</FONT></TD>
    <TD STYLE="text-align: right; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment of Committees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Available for Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substitute Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Options</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive Stock Options</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duration of Options</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of Options</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment Upon Exercise</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Appreciation Rights</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Measurement Price</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duration of SARs</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of SARs</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock; Restricted Stock Units</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General&#9;</FONT></TD>
    <TD STYLE="padding-left: 9pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms and Conditions for All Restricted Stock Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Provisions Relating to Restricted Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Provisions Relating to Restricted Stock Units</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Stock-Based Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms and Conditions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments for Changes in Common Stock and Certain Other Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in Capitalization</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reorganization Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Control Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Provisions Applicable to Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transferability of Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documentation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Discretion</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination of Status</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment of Award</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions on Delivery of Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"></TD><TD>(h)</TD><TD>Acceleration</TD>
                                                               <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">11.</TD>
<TD COLSPAN="2">Miscellaneous</TD>
                        <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"></TD><TD>(a)</TD><TD>No Right To Employment or Other Status</TD>
                     <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"></TD><TD>(b)</TD><TD>No Rights As Stockholder</TD>
                     <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"></TD><TD>(c)</TD><TD>Effective Date and Term of Plan</TD>
                     <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"></TD><TD>(d)</TD><TD>Amendment of Plan</TD>
                     <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"></TD><TD>(e)</TD><TD>Authorization of Sub-Plans (including Grants to non-U.S. Employees)</TD>
                     <TD STYLE="text-align: right">14</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"></TD><TD>(f)</TD><TD>Compliance with Section&nbsp;409A of the Code</TD>
                     <TD STYLE="text-align: right">14</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"></TD><TD>(g)</TD><TD>Limitations on Liability&#9;</TD>
                     <TD STYLE="text-align: right">14</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"></TD><TD>(h)</TD><TD>Governing Law</TD>
                     <TD STYLE="text-align: right">15</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2017 <FONT STYLE="font-variant: small-caps">Stock
Incentive Plan</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>CARMA
Therapeutics Inc.</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Purpose</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The purpose of this 2017
Stock Incentive Plan (the &#8220;<B>Plan</B>&#8221;) of CARMA Therapeutics Inc., a Delaware corporation (the
 &#8220;<B>Company</B>&#8221;), is to advance the interests of the Company&#8217;s stockholders by enhancing the Company&#8217;s
ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing
such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of
such persons with those of the Company&#8217;s stockholders. Except where the context otherwise requires, the term
 &#8220;<B>Company</B>&#8221; shall include any of the Company&#8217;s present and future parent or subsidiary corporations as
defined in Sections&nbsp;424(e)&nbsp;or (f)&nbsp;of the Internal Revenue Code of 1986, as amended, and any regulations thereunder
(the &#8220;<B>Code</B>&#8221;) and any other business venture (including, without limitation, joint venture or limited liability
company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the
 &#8220;<B>Board</B>&#8221;); <I>provided</I>, <I>however</I>, that such other business ventures shall be limited to entities that,
where required by Section&nbsp;409A of the Code, are eligible issuers of service recipient stock (as defined in Treas. Reg.
Section&nbsp;1.409A-1(b)(5)(iii)(E), or applicable successor regulation).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Eligibility</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">All of the Company&#8217;s
employees, officers and directors, as well as consultants and advisors to the Company (as such terms consultants and advisors are defined
and interpreted for purposes of Rule&nbsp;701 under the Securities Act of 1933, as amended (the &#8220;<B>Securities Act</B>&#8221;) (or
any successor rule)) are eligible to be granted Awards under the Plan. Each person who is granted an Award under the Plan is deemed a
 &#8220;<B>Participant</B>.&#8221; &#8220;<B>Award</B>&#8221; means Options (as defined in Section&nbsp;5), SARs (as defined in Section&nbsp;6),
Restricted Stock (as defined in Section&nbsp;7), Restricted Stock Units (as defined in Section&nbsp;7) and Other Stock-Based Awards (as
defined in Section&nbsp;8).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Administration
and Delegation</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Administration
by the Board</U>. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal
such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret
the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile
any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry the Plan into effect and it
shall be the sole and final judge of such expediency. All actions and decisions by the Board with respect to the Plan and any Awards shall
be made in the Board&#8217;s discretion and shall be final and binding on all Participants and any other persons having or claiming any
interest in the Plan or in any Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Appointment
of Committees</U>. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or
more committees or subcommittees of the Board (each, a &#8220;<B>Committee</B>&#8221;). All references in the Plan to the &#8220;<B>Board</B>&#8221;
shall mean the Board or a Committee to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such
Committee.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Stock
Available for Awards</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Number
of Shares</U>. Subject to adjustment under Section&nbsp;9, Awards may be made under the Plan for up to 244,552 shares of common
stock, $0.0001 par value per share, of the Company (the &#8220;<B>Common Stock</B>&#8221;), any or all of which Awards may be in the
form of Incentive Stock Options (as defined in Section&nbsp;5(b)). If any Award expires or is terminated, surrendered or canceled
without having been fully exercised, is forfeited in whole or in part (including as the result of shares of Common Stock subject to
such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right), or results
in any Common Stock not being issued, the unused Common Stock subject to such Award shall again be available for the grant of Awards
under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award or to satisfy tax
withholding obligations arising with respect to an Award shall be added to the number of shares of Common Stock available for the
grant of Awards under the Plan. However, in the case of Incentive Stock Options, the two immediately preceding sentences shall be
subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued
shares or treasury shares.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Substitute
Awards</U>. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or
stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such entity
or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding
any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section&nbsp;4(a),
except as may be required by reason of Section&nbsp;422 and related provisions of the Code.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Stock
Options</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>General</U>.
The Board may grant options to purchase Common Stock (each, an &#8220;<B>Option</B>&#8221;) and determine the number of shares of Common
Stock to be subject to each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of
each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Incentive
Stock Options</U>. An Option that the Board intends to be an &#8220;incentive stock option&#8221; as defined in Section&nbsp;422 of
the Code (an &#8220;<B>Incentive Stock Option</B>&#8221;) shall only be granted to employees of CARMA Therapeutics Inc., any of
CARMA Therapeutics Inc.&#8217;s present and future parent or subsidiary corporations as defined in Sections 424(e)&nbsp;or
(f)&nbsp;of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code,
and shall be subject to and shall be construed consistently with the requirements of Section&nbsp;422 of the Code. An Option that is
not intended to be an Incentive Stock Option shall be </FONT>designated non-statutory stock option (a &#8220;<B>Nonstatutory Stock
Option)</B>.&#8221; The Company shall have no liability to a Participant, or any other person, if an Option (or any part thereof)
that is intended to be an Incentive Stock Option is not an Incentive Stock Option or if the Company converts an Incentive Stock
Option to a Nonstatutory Stock Option.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable Option agreement.
The exercise price shall be not less than 100% of the Grant Date Fair Market Value (as defined below) of the Common Stock on the date
the Option is granted; provided that if the Board approves the grant of an Option with an exercise price to be determined on a future
date, the exercise price shall not be less than 100% of the Grant Date Fair Market Value on such future date. The &#8220;<B>Grant Date
Fair Market Value</B>&#8221; of a share of Common Stock for purposes of the Plan will be determined as follows:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">if
the Common Stock is not publicly traded, the Board will determine the Fair Market Value for purposes of the Plan using any measure of
value it determines to be appropriate (including, as it considers appropriate, relying on appraisals) in a manner consistent with the
valuation principles under Code Section&nbsp;409A, except as the Board may expressly determine otherwise;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">if
the Common Stock is listed on a national securities exchange, the closing sale price (for the primary trading session) on the date of
grant; or</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">if
the Common Stock is not listed on any such exchange, the average of the closing bid and asked prices as reported by an authorized OTCBB
market data vendor as listed on the OTCBB website (otcbb.com) on the date of grant.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For any date that is not a
trading day, the Grant Date Fair Market Value of a share of Common Stock for such date will be determined by using the closing sale price
or average of the bid and asked prices, as appropriate, for the immediately preceding trading day and with the timing in the formulas
above adjusted accordingly. The Board can substitute a particular time of day or other measure of &#8220;closing sale price&#8221; or
 &#8220;bid and asked prices&#8221; if appropriate because of exchange or market procedures or can, in its discretion, use weighted averages
either on a daily basis or such longer period as complies with Code Section&nbsp;409A.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Board has discretion to
determine the Grant Date Fair Market Value for purposes of the Plan, and all Awards are conditioned on the applicable Participant&#8217;s
agreement that the Board&#8217;s determination is conclusive and binding even though others might make a different determination.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Duration
of Options</U>. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the
applicable option agreement; <I>provided, however</I>, that no Option will be granted with a term in excess of 10 years.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Exercise
of Options</U>. Options may be exercised by delivery to the Company of a notice of exercise in a form of notice (which may be electronic)
approved by the Company, together with payment in full (in the manner specified in Section&nbsp;5(f)) of the exercise price for the number
of shares for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company as soon as
practicable following exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Payment
Upon Exercise.</U> Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">in
cash or by check, payable to the order of the Company;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">when
the Common Stock is registered under the Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;), except as
may otherwise be provided in the applicable Option agreement or approved by the Board, in its discretion, by (i)&nbsp;delivery of an irrevocable
and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and
any required tax withholding or (ii)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions
to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax
withholding;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">when
the Common Stock is registered under the Exchange Act and to the extent provided for in the applicable Option agreement or approved
by the Board, in its discretion, by delivery (either by actual </FONT>delivery or attestation) of shares of Common Stock owned by
the Participant valued at their fair market value (valued in the manner determined by (or in a manner approved by) the Board), <I>provided</I>
(i)&nbsp;such method of payment is then permitted under applicable law, (ii)&nbsp;such Common Stock, if acquired directly from the
Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion
and (iii)&nbsp;such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar
requirements;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">to
the extent provided for in the applicable Nonstatutory Stock Option agreement or approved by the Board in its discretion, by delivery
of a notice of &#8220;net exercise&#8221; to the Company, as a result of which the Participant would receive (i)&nbsp;the number of shares
underlying the portion of the Option being exercised, less (ii)&nbsp;such number of shares as is equal to (A)&nbsp;the aggregate exercise
price for the portion of the Option being exercised divided by (B)&nbsp;the fair market value of the Common Stock (valued in the manner
determined by (or in a manner approved by) the Board) on the date of exercise;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">to
the extent permitted by applicable law and provided for in the applicable Option agreement or approved by the Board, in its discretion,
by (i)&nbsp;delivery of a promissory note of the Participant to the Company on terms determined by the Board, or (ii)&nbsp;payment of
such other lawful consideration as the Board may determine; or</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">by
any combination of the above permitted forms of payment.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Stock
Appreciation Rights</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>General</U>.
The Board may grant Awards consisting of stock appreciation rights (&#8220;<B>SARs</B>&#8221;) entitling the Participant, upon exercise,
to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference
to appreciation, from and after the date of grant, in the fair market value of a share of Common Stock (valued in the manner determined
by (or in a manner approved by) the Board) over the measurement price established pursuant to Section&nbsp;6(b). The date as of which
such appreciation is determined shall be the exercise date.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Measurement
Price</U>. The Board shall establish the measurement price of each SAR and specify it in the applicable SAR agreement. The measurement
price shall not be less than 100% of the Grant Date Fair Market Value of a share of Common Stock on the date the SAR is granted; <I>provided</I>,
that if the Board approves the grant of an SAR effective as of a future date, the measurement price shall not be less than 100% of the
Grant Date Fair Market Value on such future date.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Duration
of SARs</U>. Each SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable
SAR agreement; <I>provided</I>, <I>however</I>, that no SAR will be granted with a term in excess of 10 years.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Exercise
of SARs</U>. SARs may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by
the Company, together with any other documents required by the Board.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Restricted
Stock; Restricted Stock Units</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>General</U>.
The Board may grant Awards entitling Participants to acquire shares of Common Stock (&#8220;<B>Restricted Stock</B>&#8221;), subject to
the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require
forfeiture of such shares if issued at no cost) from the Participant in the event that conditions specified by the Board in the applicable
Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The
Board may also grant Awards entitling the Participant to receive shares of Common Stock or cash to be delivered at the time such Award
vests (&#8220;<B>Restricted Stock Units</B>&#8221;) (Restricted Stock and Restricted Stock Units are each referred to herein as a &#8220;<B>Restricted
Stock Award</B>&#8221;).</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Terms
and Conditions for All Restricted Stock Awards</U>. The Board shall determine the terms and conditions of a Restricted Stock Award, including
the conditions for vesting and repurchase (or forfeiture) and the issue price, if any.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Additional
Provisions Relating to Restricted Stock</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Dividends</U>.
Unless otherwise provided in the applicable Award agreement, any dividends (whether paid in cash, stock or property) declared and
paid by the Company with respect to shares of </FONT>Restricted Stock (&#8220;<B>Accrued Dividends</B>&#8221;) shall be paid to the
Participant only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such
shares. Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to
stockholders of that class of stock or, if later, the 15th day of the third month following the lapsing of the restrictions on
transferability and the forfeitability provisions applicable to the underlying shares of Restricted Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Stock
Certificates</U>. The Company may require that any stock certificates issued in respect of shares of Restricted Stock, as well as dividends
or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power endorsed
in blank, with the Company (or its designee). At the expiration of the applicable restriction periods, the Company (or such designee)
shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to Participant&#8217;s
Designated Beneficiary. &#8220;<B>Designated Beneficiary</B>&#8221; means (i)&nbsp;the beneficiary designated, in a manner determined
by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#8217;s death
or (ii)&nbsp;in the absence of an effective designation by a Participant, &#8220;<B>Designated Beneficiary</B>&#8221; means the Participant&#8217;s
estate.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Additional
Provisions Relating to Restricted Stock Units</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Settlement</U>.
Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted Stock Unit, the Participant
shall be entitled to receive from the Company the number of shares of Common Stock specified in the Award agreement or (if so provided
in the applicable Award agreement or otherwise determined by the Board) an amount of cash equal to the fair market value (valued in the
manner determined by (or in a manner approved by) the Board) of such number of shares of Common Stock or a combination thereof. The Board
may, in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of
the Participant in a manner that complies with Section&nbsp;409A of the Code.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Voting
Rights</U>. A Participant shall have no voting rights with respect to any Restricted Stock Units.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Dividend
Equivalents</U>. The Award agreement for Restricted Stock Units may provide Participants with the right to receive an amount equal to
any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (&#8220;<B>Dividend Equivalents</B>&#8221;).
Dividend Equivalents may be paid currently or credited to an account for the Participants, may be settled in cash and/or shares of Common
Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which paid,
in each case to the extent provided in the applicable Award agreement.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Other
Stock-Based Awards</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>General</U>.
The Board may grant other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are
otherwise based on, shares of Common Stock or other property (&#8220;<B>Other Stock-Based Awards</B>&#8221;). Such Other Stock-Based Awards
shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation
to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall
determine.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Terms
and Conditions</U>. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based
Award, including any purchase price applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Adjustments
for Changes in Common Stock and Certain Other Events</U></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Changes
in Capitalization</U>. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of
shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to
holders of Common Stock other than an ordinary cash dividend, (i)&nbsp;the number and class of securities available under the Plan,
(ii)&nbsp;the number and class of securities and exercise price per share of each outstanding Option, (iii)&nbsp;the share and
per-share provisions and the measurement price of each outstanding SAR, (iv)&nbsp;the number of shares subject to and the repurchase
price per share subject to each outstanding Award of Restricted Stock and (v)&nbsp;the share and per-share-related provisions and
the purchase price, if any, of each outstanding Award of Restricted Stock Unit and each outstanding Other Stock-Based Award, shall
be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner </FONT>determined by the
Board. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a
stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of
the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option
between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date,
the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such
shares were not outstanding as of the close of business on the record date for such stock dividend.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Reorganization
Events</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Definition</U>.
A &#8220;<B>Reorganization Event</B>&#8221; shall mean: (a)&nbsp;any merger or consolidation of the Company with or into another entity
as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or
other property or is cancelled, (b)&nbsp;any transfer or disposition of all of the Common Stock of the Company for cash, securities or
other property pursuant to a share exchange or other transaction or (c)&nbsp;any liquidation or dissolution of the Company.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Consequences
of a Reorganization Event on Awards Other than Restricted Stock</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion of)
outstanding Awards other than Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise
in an applicable Award agreement or another agreement between the Company and the Participant): (i)&nbsp;provide that such Awards shall
be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof),
(ii)&nbsp;upon written notice to a Participant, provide that all of the Participant&#8217;s unexercised and/or unvested Awards will terminate
immediately prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable)
within a specified period following the date of such notice, (iii)&nbsp;provide that outstanding Awards shall become exercisable, realizable,
or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv)&nbsp;in
the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment
for each share surrendered in the Reorganization Event (the &#8220;<B>Acquisition Price</B>&#8221;), make or provide for a cash payment
to Participants with respect to each Award held by a Participant equal to (A)&nbsp;the number of shares of Common Stock subject to the
vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization
Event) multiplied by (B)&nbsp;the excess, if any, of (I)&nbsp;the Acquisition Price over (II)&nbsp;the exercise, measurement or purchase
price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (v)&nbsp;provide that, in connection
with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable,
net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (vi)&nbsp;any combination of the foregoing.
In taking any of the actions permitted under this Section&nbsp;9(b)(2), the Board shall not be obligated by the Plan to treat all Awards,
all Awards held by a Participant, or all Awards of the same type, identically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
the terms of Section&nbsp;9(b)(2)(i), in the case of outstanding Restricted Stock Units that are subject to Section&nbsp;409A of the Code:
(i)&nbsp;if the applicable Restricted Stock Unit agreement provides that the Restricted Stock Units shall be settled upon a &#8220;change
in control event&#8221; within the meaning of Treasury Regulation Section&nbsp;1.409A-3(i)(5)(i), and the Reorganization Event constitutes
such a &#8220;change in control event&#8221;, then no assumption or substitution shall be permitted pursuant to Section&nbsp;9(b)(2)(i)&nbsp;and
the Restricted Stock Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and
(ii)&nbsp;the Board may only undertake the actions set forth in clauses (iii), (iv)&nbsp;or (v)&nbsp;of Section&nbsp;9(b)(2)(i)&nbsp;if
the Reorganization Event constitutes a &#8220;change in control event&#8221; as defined under Treasury Regulation Section&nbsp;1.409A-3(i)(5)(i)&nbsp;and
such action is permitted or required by Section&nbsp;409A of the Code; if the Reorganization Event is not a &#8220;change in control event&#8221;
as so defined or such action is not permitted or required by Section&nbsp;409A of the Code, and the acquiring or succeeding corporation
does not assume or substitute the Restricted Stock Units pursuant to clause (i)&nbsp;of Section&nbsp;9(b)(2)(i), then the unvested Restricted
Stock Units shall terminate immediately prior to the consummation of the Reorganization Event without any payment in exchange therefor.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
purposes of Section&nbsp;9(b)(2)(i), an Award (other than Restricted Stock) shall be considered assumed if, following consummation
of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share
of Common Stock subject to the Award immediately prior to the consummation of the Reorganization Event, the consideration (whether
cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of
Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were </FONT>offered a choice of
consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); <I>provided,
however</I>, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring
or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation,
provide for the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares
of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in
value (as of the date of such determination or another date specified by the Board) to the per share consideration received by
holders of outstanding shares of Common Stock as a result of the Reorganization Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Consequences
of a Reorganization Event on Restricted Stock</U>. Upon the occurrence of a Reorganization Event other than a liquidation or dissolution
of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit
of the Company&#8217;s successor and shall, unless the Board determines otherwise, apply to the cash, securities or other property which
the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as
they applied to such Restricted Stock; <I>provided</I>, <I>however</I>, that the Board may provide for termination or deemed satisfaction
of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a Participant and
the Company, either initially or by amendment, or provide for forfeiture of such Restricted Stock if issued at no cost. Upon the occurrence
of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary
in the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, all restrictions and conditions
on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Change
in Control Events</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Definitions</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">A
 &#8220;<B>Change in Control Event</B>&#8221; shall mean:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">The
acquisition by an individual, entity or group (within the meaning of Section&nbsp;13(d)(3)&nbsp;or 14(d)(2)&nbsp;of the Exchange Act))
(a &quot;<B>Person</B>&quot;) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially
owns (within the meaning of Rule&nbsp;13d-3 promulgated under the Exchange Act) 50% or more of the combined voting power of the then-outstanding
securities of the Company entitled to vote generally in the election of directors (the &quot;<B>Outstanding Company Voting Securities</B>&quot;);
provided, however, that for purposes of this subsection (1), the following acquisitions shall not constitute a Change in Control Event:
(X)&nbsp;any acquisition directly from the Company or (Y)&nbsp;any acquisition by any corporation pursuant to a Business Combination (as
defined below) which complies with clauses (X)&nbsp;and (Y)&nbsp;of subsection (3)&nbsp;of this definition; or</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">such
time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of Directors
of a successor corporation to the Company), where the term &quot;<B>Continuing Director</B>&quot; means at any date a member of the Board
(X)&nbsp;who was a member of the Board on the date of the initial adoption of this Plan by the Board or (Y)&nbsp;who was nominated or
elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or
election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors
at the time of such nomination or election; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">the
consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company or a sale or other disposition
of all or substantially all of the assets of the Company (a &quot;<B>Business Combination</B>&quot;), unless, immediately following such
Business Combination, each of the following two conditions is satisfied: (X)&nbsp;all or substantially all of the individuals and entities
who were the beneficial owners of the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially
own, directly or indirectly, more than 50% of the combined voting power of the then-outstanding securities entitled to vote generally
in the election of directors of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation,
a corporation which as a result of such transaction owns the Company or substantially all of the Company's assets either directly or through
one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the &quot;Acquiring Corporation&quot;) in
substantially the same proportions as their ownership of the Outstanding Company Voting Securities immediately prior to such Business
Combination and (Y)&nbsp;no Person beneficially owns, directly or indirectly, 50% or more of the combined voting power of the then-outstanding
securities of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed
prior to the Business Combination); or</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">the
liquidation or dissolution of the Company.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Good
Reason</B>&#8221; shall mean the occurrence of any of the following without the Participant's prior written consent: (A)&nbsp;material
diminution in the duties, authority or responsibilities of the Participant from and after such Change in Control Event as compared to
those in effect immediately preceding the Change in Control Event; provided, however, that a change in the Participant's title or reporting
relationship solely due to the Company becoming a division, subsidiary or other similar part of a larger organization following a Change
in Control Event shall not by itself constitute Good Reason; (B)&nbsp;any material reduction in the Participant's annual base compensation
from and after such Change in Control Event; (C)&nbsp;the material relocation of the Participant&#8217;s place of employment as compared
to his or her place of employment immediately preceding the Change in Control Event; or (D)&nbsp;the material breach of the Company or
its successor of any Award granted under this plan.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#8220;<B>Cause</B>&#8221;
shall mean the occurrence of any of the following: (A)&nbsp;the Participant's willful failure to perform in any material respect Participant's
material duties or responsibilities for the Company, which is not cured within 30 days of written notice thereof to the Participant from
the Company; (B)&nbsp;repeated unexplained or unjustified absence from the Company inconsistent with the Participant's duties and responsibilities
for the Company, which continues without explanation or justification after written notice thereof to the Participant from the Company;
(C)&nbsp;Participant's willful misconduct that causes material and demonstrable monetary or reputational injury to the Company, including,
but not limited to, misappropriation or conversion of assets of the Company (other than non-material assets); or (D)&nbsp;the conviction
of the Participant of, or the entry of a plea of guilty or <I>nolo contendere </I>by the Participant to, any crime involving moral turpitude
or any felony.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Effect
on Options.</U> Notwithstanding the provisions of Section&nbsp;9(b), except to the extent specifically provided to the contrary in the
instrument evidencing any Option or any other agreement between a Participant and the Company, each Option shall be immediately exercisable
in full if, on or prior to the first anniversary of the date of the consummation of the Change in Control Event, the Participant's employment
with the Company or the acquiring or succeeding corporation is terminated for Good Reason by the Participant or is terminated without
Cause by the Company or the acquiring or succeeding corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Effect
on Restricted Stock Awards</U>. Notwithstanding the provisions of Section&nbsp;9(b), except to the extent specifically provided to the
contrary in the instrument evidencing any Restricted Stock Award or any other agreement between a Participant and the Company, each Restricted
Stock Award shall immediately become free from all conditions or restrictions if, on or prior to the first anniversary of the date of
the consummation of the Change in Control Event, the Participant's employment with the Company or the acquiring or succeeding corporation
is terminated for Good Reason by the Participant or is terminated without Cause by the Company or the acquiring or succeeding corporation.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Effect
on SARs and Other Stock-Based Awards.</U> The Board may specify in an Award at the time of the grant the effect of a Change in Control
Event on any SAR or Other Stock-Based Award.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>General
Provisions Applicable to Awards</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Transferability
of Awards</U>. Awards (or any interest in an Award, including, prior to exercise, any interest in shares of Common Stock issuable upon
exercise of an Option or SAR) shall not be sold, assigned, transferred (including by establishing any short position, put equivalent position
(as defined in Rule&nbsp;16a-1 issued under the Exchange Act) or call equivalent position (as defined in Rule&nbsp;16a-1 issued under
the Exchange Act)), pledged, hypothecated or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation
of law, and, during the life of the Participant, shall be exercisable only by the Participant; except that Awards, other than Awards subject
to Section&nbsp;409A of the Code, may be transferred to family members (as defined in Rule&nbsp;701(c)(3)&nbsp;under the Securities Act)
through gifts or (other than Incentive Stock Options) domestic relations orders or to an executor or guardian upon the death or disability
of the Participant. The Company shall not be required to recognize any such permitted transfer until such time as such permitted transferee
shall deliver to the Company a written instrument, as a condition to such transfer, in form and substance satisfactory to the Company
confirming that such transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent
relevant in the context, shall include references to authorized transferees. For the avoidance of doubt, nothing contained in this Section&nbsp;10(a)&nbsp;shall
be deemed to restrict a transfer to the Company.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Documentation</U>.
Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms
and conditions in addition to those set forth in the Plan.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Board
Discretion</U>. Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award.
The terms of each Award need not be identical, and the Board need not treat Participants uniformly.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Termination
of Status</U>. The Board shall determine the effect on an Award of the disability, death, termination or other cessation of employment,
authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period
during which, the Participant, or the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary, may exercise
rights under the Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Withholding</U>.
The Participant must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations before
the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may elect to
satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold
from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender
to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any
shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price unless
the Company determines otherwise. If provided for in an Award or approved by the Board in its discretion, a Participant may satisfy such
tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Common Stock, including shares
retained from the Award creating the tax obligation, valued at their fair market value (valued in the manner determined by (or in a manner
approved by) the Company); <I>provided, however</I>, except as otherwise provided by the Board, that the total tax withholding where stock
is being used to satisfy such tax obligations cannot exceed the Company&#8217;s minimum statutory withholding obligations (based on minimum
statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable
income), <I>except that</I>, to the extent that the Company is able to retain shares of Common Stock having a fair market value (valued
in the manner determined by (or in a manner approved by) the Company) that exceeds the statutory minimum applicable withholding tax without
financial accounting implications or the Company is withholding in a jurisdiction that does not have a statutory minimum withholding tax,
the Company may retain such number of shares of Common Stock (up to the number of shares having a fair market value (valued in the manner
determined by (or in a manner approved by) the Company) equal to the maximum individual statutory rate of tax) as the Company shall determine
in its discretion to satisfy the tax liability associated with any Award. Shares used to satisfy tax withholding requirements cannot be
subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Amendment
of Award</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">The
Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same
or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option.
The Participant&#8217;s consent to such action shall be required unless (i)&nbsp;the Board determines that the action, taking into account
any related action, does not materially and adversely affect the Participant&#8217;s rights under the Plan or (ii)&nbsp;the change is
permitted under Section&nbsp;9.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">The
Board may, without stockholder approval, amend any outstanding Award granted under the Plan to provide an exercise price per share that
is lower than the then-current exercise price per share of such outstanding Award. The Board may also, without stockholder approval, cancel
any outstanding award (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the
same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price
per share of the cancelled award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Conditions
on Delivery of Stock</U>. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove
restrictions from shares previously issued or delivered under the Plan until (i)&nbsp;all conditions of the Award have been met or
removed to the satisfaction of the Company, (ii)&nbsp;in </FONT>the opinion of the Company&#8217;s counsel, all other legal matters
in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and
regulations and any applicable stock exchange or stock market rules&nbsp;and regulations, and (iii)&nbsp;the Participant has
executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the
requirements of any applicable laws, rules&nbsp;or regulations.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Acceleration</U>.
The Board may at any time provide that any Award shall become immediately exercisable in whole or in part, free of some or all restrictions
or conditions, or otherwise realizable in whole or in part, as the case may be.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>No
Right To Employment or Other Status</U>. No person shall have any claim or right to be granted an Award by virtue of the adoption of the
Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship
with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant
free from any liability or claim under the Plan, except as expressly provided in the applicable Award.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>No
Rights As Stockholder</U>. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any
rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record
holder of such shares.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Effective
Date and Term of Plan</U>. The Plan shall become effective on the date on which it is adopted by the Board. No Awards shall be granted
under the Plan after the expiration of 10 years from the earlier of (i)&nbsp;the date on which the Plan was adopted by the Board or (ii)&nbsp;the
date the Plan was approved by the Company&#8217;s stockholders, but Awards previously granted may extend beyond that date.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Amendment
of Plan</U>. The Board may amend, suspend or terminate the Plan or any portion thereof at any time; <I>provided</I> that if at any time
the approval of the Company&#8217;s stockholders is required as to any modification or amendment under Section&nbsp;422 of the Code or
any successor provision with respect to Incentive Stock Options, the Board may not effect such modification or amendment without such
approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section&nbsp;11(d)&nbsp;shall
apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board
determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of Participants
under the Plan.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Authorization
of Sub-Plans (including Grants to non-U.S. Employees)</U>. The Board may from time to time establish one or more sub-plans under the Plan
for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such sub-plans
by adopting supplements to the Plan containing (i)&nbsp;such limitations on the Board&#8217;s discretion under the Plan as the Board deems
necessary or desirable or (ii)&nbsp;such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem
necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only
to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants
in any jurisdiction which is not the subject of such supplement.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Compliance
with Section&nbsp;409A of the Code</U>. If and to the extent (i)&nbsp;any portion of any payment, compensation or other benefit provided
to a Participant pursuant to the Plan in connection with Participant&#8217;s employment termination constitutes &#8220;nonqualified deferred
compensation&#8221; within the meaning of Section&nbsp;409A of the Code and (ii)&nbsp;the Participant is a specified employee as defined
in Section&nbsp;409A(a)(2)(B)(i)&nbsp;of the Code, in each case as determined by the Company in accordance with its procedures, by which
determinations the Participant (through accepting the Award) agrees that the Participant is bound, such portion of the payment, compensation
or other benefit shall not be paid before the day that is six months plus one day after the date of &#8220;separation from service&#8221;
(as determined under Section&nbsp;409A of the Code) (the &#8220;<B>New Payment Date</B>&#8221;), except as Section&nbsp;409A of the Code
may then permit. The aggregate of any payments that otherwise would have been paid to the Participant during the period between the date
of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining
payments will be paid on their original schedule.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company makes no representations or warranty
and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under
the Plan are determined to constitute nonqualified deferred compensation subject to Section&nbsp;409A of the Code but do not to satisfy
the conditions of that section.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Limitations
on Liability</U>. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other employee, or agent
of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability,
or expense incurred in connection with the Plan, nor will such individual be personally liable with respect to the Plan because of any
contract or other instrument such individual executes in such individual&#8217;s capacity as a director, officer, other employee, or agent
of the Company. The Company will indemnify and hold harmless each director, officer, other employee, or agent of the Company to whom any
duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense
(including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Board&#8217;s approval) arising
out of any act or omission to act concerning the Plan unless arising out of such person&#8217;s own fraud or bad faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of
the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a
jurisdiction other than the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARMA THERAPEUTICS INC.<BR>
2017 STOCK INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALIFORNIA SUPPLEMENT</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to Section&nbsp;11(e)&nbsp;of
the Plan, the Board has adopted this supplement for purposes of satisfying the requirements of Section&nbsp;25102(o)&nbsp;of the California
Law:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any Awards granted under the
Plan to a Participant who is a resident of the State of California on the date of grant (a &#8220;<B>California Participant</B>&#8221;)
shall be subject to the following additional limitations, terms and conditions:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Additional
Limitations on Options</U>.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Maximum
Duration of Options</U>. No Options granted to California Participants shall have a term in excess of 10 years measured from the Option
grant date.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Minimum
Exercise Period Following Termination</U>. Unless a California Participant&#8217;s employment is terminated for cause (as defined by applicable
law, the terms of the Plan or option grant or a contract of employment), in the event of termination of employment of such Participant,
such Participant shall have the right to exercise an Option, to the extent that such Participant is entitled to exercise such Option on
the date employment terminated, until the earlier of: (i)&nbsp;at least six months from the date of termination, if termination was caused
by such Participant&#8217;s death or disability, (ii)&nbsp;at least 30 days from the date of termination, if termination was caused other
than by such Participant&#8217;s death or disability and (iii)&nbsp;the Option expiration date.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Additional
Limitations for Other Stock-Based Awards</U>. The terms of all Awards granted to a California Participant under Section&nbsp;8 of the
Plan shall comply, to the extent applicable, with Section&nbsp; 260.140.46 of the California Code of Regulations.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Additional
Limitations on Timing of Awards</U>. No Award granted to a California Participant shall become exercisable, vested or realizable, as applicable
to such Award, unless the Plan has been approved by the holders of a majority of the Company&#8217;s outstanding voting securities by
the later of (i)&nbsp;within 12 months before or after the date the Plan was adopted by the Board, or (ii)&nbsp;prior to or within 12
months of the granting of any Award to a California Participant.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Additional
Restriction Regarding Recapitalizations, Stock Splits, Etc.</U> For purposes of Section&nbsp;9 of the Plan, in the event of a stock split,
reverse stock split, stock dividend, recapitalization, combination, reclassification or other distribution of the Company's securities
underlying the Award without the receipt of consideration by the Company, the number of securities purchasable, and in the case of Options,
the exercise price of such Options, shall be proportionately adjusted.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>Additional
Limitations on Transferability of Awards.</U> Notwithstanding the provisions of Section&nbsp;10(a)&nbsp;of the Plan, an Award granted
to a California Participant may not be transferred to an executor or guardian upon the disability of the Participant.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARMA THERAPEUTICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT TO 2017 STOCK INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approved by the Board of Directors of CARMA Therapeutics
Inc. on June 22, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approved by the Stockholders of CARMA Therapeutics
Inc. on June 22, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first sentence of Section 4(a) of the 2017
Stock Incentive Plan of CARMA Therapeutics Inc. (the &ldquo;<B>Plan</B>&rdquo;) is hereby deleted in its entirety and the following sentence
is inserted in lieu thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Subject to adjustment under Section
9, Awards may be made under the Plan for up to 1,154,413 shares of common stock, $0.0001 par value per share, of the Company (the &ldquo;<B>Common
Stock</B>&rdquo;), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)).&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as expressly amended herein, the Plan and
all of the provisions contained therein shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARISMA THERAPEUTICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT NO. 2 TO 2017 STOCK INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approved by the Board of Directors of CARISMA
Therapeutics Inc. on December 21, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approved by the Stockholders of CARISMA Therapeutics
Inc. on December 21, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first sentence of Section 4(a) of the 2017
Stock Incentive Plan of CARISMA Therapeutics Inc. (the &ldquo;<B>Plan</B>&rdquo;) is hereby deleted in its entirety and the following
sentence is inserted in lieu thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Subject to adjustment under Section
9, Awards may be made under the Plan for up to 1,784,018 shares of common stock, $0.0001 par value per share, of the Company (the &ldquo;<B>Common
Stock</B>&rdquo;), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)).&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as expressly amended herein, the Plan and
all of the provisions contained therein shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARISMA THERAPEUTICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT NO. 3 TO 2017 STOCK INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approved by the Board of Directors of CARISMA
Therapeutics Inc. on November 9, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approved by the Stockholders of CARISMA Therapeutics
Inc. on November 9, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first sentence of Section 4(a) of the 2017
Stock Incentive Plan, as amended, of CARISMA Therapeutics Inc. (the &ldquo;<B>Plan</B>&rdquo;) is hereby deleted in its entirety and the
following sentence is inserted in lieu thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Subject to adjustment under Section
9, Awards may be made under the Plan for up to 1,984,018 shares of common stock, $0.0001 par value per share, of the Company (the &ldquo;<B>Common
Stock</B>&rdquo;), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)).&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as expressly amended herein, the Plan and
all of the provisions contained therein shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARISMA THERAPEUTICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT NO. 4 TO 2017 STOCK INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approved by the Board of Directors of CARISMA
Therapeutics Inc. on March 22, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approved by the Stockholders of CARISMA Therapeutics
Inc. on April 7, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first sentence of Section 4(a) of the 2017
Stock Incentive Plan, as amended, of CARISMA Therapeutics Inc. (the &ldquo;<B>Plan</B>&rdquo;) is hereby deleted in its entirety and the
following sentence is inserted in lieu thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Subject to adjustment under Section
9, Awards may be made under the Plan for up to 2,664,018 shares of common stock, $0.0001 par value per share, of the Company (the &ldquo;<B>Common
Stock</B>&rdquo;), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)).&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as expressly amended herein, the Plan and
all of the provisions contained therein shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>11
<FILENAME>tm238578d1_ex10-11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>CARISMA
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Nonstatutory
Stock Option Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Granted
Under 2017 Stock Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Grant
of Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Nonstatutory Stock Option
Agreement (the &ldquo;<B>Agreement</B>&rdquo;) evidences the grant by CARISMA Therapeutics Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
on [________ __, 20__] (the &ldquo;<B>Grant Date</B>&rdquo;) to [___________], an employee, consultant or director of the Company (the
 &ldquo;<B>Participant</B>&rdquo;), of an option to purchase, in whole or in part, on the terms provided herein and in the Company&rsquo;s
2017 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;), as amended, a total of [___________] shares (the &ldquo;<B>Shares</B>&rdquo;)
of common stock, $0.0001 par value per share, of the Company (&ldquo;<B>Common Stock</B>&rdquo;) at $[_________] per Share. Unless earlier
terminated, this option shall expire at 5:00 p.m., Eastern time, on [________ __, 20__] [date is ten years minus one day from grant date]
(the &ldquo;<B>Final Exercise Date</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is intended that the option
evidenced by this Agreement shall not be an incentive stock option as defined in Section&nbsp;422 of the Internal Revenue Code of 1986,
as amended, and any regulations promulgated thereunder (the &ldquo;<B>Code</B>&rdquo;). Except as otherwise indicated by the context,
the term &ldquo;<B>Participant</B>&rdquo;, as used in this option, shall be deemed to include any person who acquires the right to exercise
this option validly under its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Vesting
Schedule</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[This option will become
exercisable (&ldquo;<B>vest</B>&rdquo;) as to 25% of the original number of Shares on the first anniversary of the Vesting Commencement
Date (as defined below) and as to an additional 2.0833% of the original number of Shares at the end of each successive month following
the first anniversary of the Vesting Commencement Date until the fourth anniversary of the Vesting Commencement Date. On the fourth anniversary
of the Vesting Commencement Date, this option will be exercisable as to all Shares. For purposes of this Agreement, &ldquo;<B>Vesting
Commencement Date</B>&rdquo; shall mean [__________________].]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The right of exercise shall
be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be
exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the
termination of this option under Section&nbsp;3 hereof or the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
of Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Form&nbsp;of
Exercise</U>. Each election to exercise this option shall be accompanied by a completed Notice of Stock Option Exercise in the form attached
hereto as <U>Exhibit&nbsp;A</U>, signed by the Participant, and received by the Company at its principal office, accompanied by this Agreement,
and payment in full in the manner provided in the Plan. The Participant may purchase less than the number of Shares covered hereby, provided
that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Continuous
Relationship with the Company Required</U>. Except as otherwise provided in this Section&nbsp;3, this option may not be exercised unless
the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, officer
or director of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors
of which are eligible to receive option grants under the Plan (an &ldquo;<B>Eligible Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination
of Relationship with the Company</U>. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided
in paragraphs&nbsp;(d)&nbsp;and (e)&nbsp;below, the right to exercise this option shall terminate three months after such cessation (but
in no event after the Final Exercise Date), <U>provided that</U> this option shall be exercisable only to the extent that the Participant
was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final
Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure
agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon
such violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
Period Upon Death or Disability</U>. If the Participant dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3)&nbsp;of
the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship
for &ldquo;cause&rdquo; as specified in paragraph (e)&nbsp;below, this option shall be exercisable, within the period of one year following
the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), <U>provided
that</U> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or
her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination
for Cause</U>. If, prior to the Final Exercise Date, the Participant&rsquo;s employment or other relationship with the Company is terminated
by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of
such termination of employment or other relationship. If, prior to the Final Exercise Date, the Participant is given notice by the Company
of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment
or other termination is subsequent to the date of the delivery of such notice, the right to exercise this option shall be suspended from
the time of the delivery of such notice until the earlier of (i)&nbsp;such time as it is determined or otherwise agreed that the Participant&rsquo;s
employment or other relationship shall not be terminated for Cause as provided in such notice or (ii)&nbsp;the effective date of such
termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the preceding sentence,
terminate immediately upon the effective date of such termination of employment or other relationship). If the Participant is party to
an employment, consulting or severance agreement with the Company that contains a definition of &ldquo;cause&rdquo; for termination of
employment or other relationship, &ldquo;Cause&rdquo; shall have the meaning ascribed to such term in such agreement. Otherwise, &ldquo;Cause&rdquo;
shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company
(including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition
or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive.
The Participant&rsquo;s employment or other relationship shall be considered to have been terminated for &ldquo;Cause&rdquo; if the Company
determines, within 30 days after the Participant&rsquo;s resignation, that termination for Cause was warranted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#8239;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Company
Right of First Refusal</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
of Proposed Transfer</U>. If the Participant proposes to sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation
of law or otherwise (collectively, &ldquo;transfer&rdquo;) any Shares acquired upon exercise of this option, then the Participant shall
first give written notice of the proposed transfer (the &ldquo;<B>Transfer Notice</B>&rdquo;) to the Company. The Transfer Notice shall
name the proposed transferee and state the number of such Shares the Participant proposes to transfer (the &ldquo;<B>Offered Shares</B>&rdquo;),
the price per share and all other material terms and conditions of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Company
Right to Purchase</U>. For 30 days following its receipt of such Transfer Notice, the Company shall have the option to purchase all or
part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase
all or part of the Offered Shares, it shall give written notice of such election to the Participant within such 30-day period. Within
10 days after his or her receipt of such notice, the Participant shall tender to the Company at its principal offices the certificate
or certificates representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the Participant or with duly
endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company. Promptly following receipt
of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the purchase price for
such Offered Shares; <U>provided that</U> if the terms of payment set forth in the Transfer Notice were other than cash against delivery,
the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice; and <U>provided
further</U> that any delay in making such payment shall not invalidate the Company&rsquo;s exercise of its option to purchase the Offered
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shares
Not Purchased By Company</U>. If the Company does not elect to acquire all of the Offered Shares, the Participant may, within the 30-day
period following the expiration of the option granted to the Company under subsection (b)&nbsp;above, transfer the Offered Shares which
the Company has not elected to acquire to the proposed transferee, <U>provided that</U> such transfer shall not be on terms and conditions
more favorable to the transferee than those contained in the Transfer Notice. Notwithstanding any of the above, all Offered Shares transferred
pursuant to this Section&nbsp;4 shall remain subject to the right of first refusal set forth in this Section&nbsp;4 and such transferee
shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by
all of the terms and conditions of this Section&nbsp;4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Consequences
of Non-Delivery</U>. After the time at which the Offered Shares are required to be delivered to the Company for transfer to the Company
pursuant to subsection (b)&nbsp;above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or
permit the Participant to exercise any of the privileges or rights of a stockholder with respect to such Offered Shares, but shall, insofar
as permitted by law, treat the Company as the owner of such Offered Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#8239;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exempt
Transactions</U>. The following transactions shall be exempt from the provisions of this Section&nbsp;4:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
transfer of Shares to or for the benefit of any spouse, child or grandchild of the Participant, or to a trust for their benefit;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
transfer pursuant to an effective registration statement filed by the Company under the Securities Act of 1933, as amended (the &ldquo;<B>Securities
Act</B>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
sale of all or substantially all of the outstanding shares of capital stock of the Company (including pursuant to a merger or consolidation);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided</U></FONT>,
<U>however</U>, that in the case of a transfer pursuant to clause (1)&nbsp;above, such Shares shall remain subject to the right of first
refusal set forth in this Section&nbsp;4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Assignment
of Company Right</U>. The Company may assign its rights to purchase Offered Shares in any particular transaction under this Section&nbsp;4
to one or more persons or entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination</U>.
The provisions of this Section&nbsp;4 shall terminate upon the earlier of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
closing of the sale of shares of Common Stock in an underwritten public offering pursuant to an effective registration statement filed
by the Company under the Securities Act; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger, consolidation,
sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who
were beneficial owners of the Company&rsquo;s voting securities immediately prior to such transaction beneficially own, directly or indirectly,
more than 75% (determined on an as-converted basis) of the outstanding securities entitled to vote generally in the election of directors
of the resulting, surviving or acquiring corporation in such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Obligation to Recognize Invalid Transfer</U>. The Company shall not be required (1)&nbsp;to transfer on its books any of the Shares which
shall have been sold or transferred in violation of any of the provisions set forth in this Section&nbsp;4, or (2)&nbsp;to treat as owner
of such Shares or to pay dividends to any transferee to whom any such Shares shall have been so sold or transferred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legends</U>.
The certificate representing Shares shall bear a legend substantially in the following form (in addition to, or in combination with, any
legend required by applicable federal and state securities laws and agreements relating to the transfer of the Company securities):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;The shares represented by this
certificate are subject to a right of first refusal in favor of the Company, as provided in a certain stock option agreement with the
Company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#8239;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Agreement
in Connection with Initial Public Offering</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Participant agrees, in
connection with the initial underwritten public offering of the Common Stock pursuant to a registration statement under the Securities
Act, (i)&nbsp;not to (a)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly
or indirectly, any shares of Common Stock or any other securities of the Company or (b)&nbsp;enter into any swap or other agreement that
transfers, in whole or in part, any of the economic consequences of ownership of shares of Common Stock or other securities of the Company,
whether any transaction described in clause (a)&nbsp;or (b)&nbsp;is to be settled by delivery of securities, in cash or otherwise, during
the period beginning on the date of the filing of such registration statement with the Securities and Exchange Commission and ending 180
days after the date of the final prospectus relating to the offering (plus up to an additional 34 days to the extent requested by the
managing underwriters for such offering in order to address NASD Rule&nbsp;2711(f)(4)&nbsp;or NYSE Rule&nbsp;472(f)(4)&nbsp;or any similar
successor provision), and (ii)&nbsp;to execute any agreement reflecting clause (i)&nbsp;above as may be requested by the Company or the
managing underwriters at the time of such offering. The Company may impose stop-transfer instructions with respect to the shares of Common
Stock or other securities subject to the foregoing restriction until the end of the &ldquo;lock-up&rdquo; period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Withholding</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Shares will be issued pursuant
to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for
payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Restrictions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation
of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable
only by the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Participant agrees that he or she will not transfer any Shares issued pursuant to the exercise of this option unless the transferee, as
a condition to such transfer, delivers to the Company a written instrument confirming that such transferee shall be bound by all of the
terms and conditions of Section&nbsp;4 and Section&nbsp;5; provided that such a written confirmation shall not be required with respect
to (1)&nbsp;Section&nbsp;4 after such provision has terminated in accordance with Section&nbsp;4(g)&nbsp;or (2)&nbsp;Section&nbsp;5 after
the completion of the lock-up period in connection with the Company&rsquo;s initial underwritten public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#8239;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<FONT STYLE="font-size: 10pt"><U>Provisions of the Plan</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This option is subject to
the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant
with this option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of Page&nbsp;Intentionally Left Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#8239;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the day and year first above written. The Participant hereby accepts the foregoing option and
agrees to the terms and conditions thereof. The Participant hereby acknowledges receipt of a copy of the Company&rsquo;s 2017 Stock Incentive
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="3" STYLE="text-align: left"><B>COMPANY:</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: left"><B>CARISMA THERAPEUTICS INC.</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">By:</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 3%"></TD><TD STYLE="text-align: justify; width: 5%">Name:</TD>
                                                 <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 42%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"></TD><TD STYLE="text-align: justify">Title:</TD>
                                                 <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left"><B>PARTICIPANT:</B></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">[Name]</TD>
    <TD STYLE="text-align: justify; width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">[<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">]</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[</FONT><U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SPOUSAL CONSENT:
    </B><SUP>1</SUP></FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">[<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">]</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">[<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> If the Participant resides in a
community property state, it is desirable to have the Participant&rsquo;s spouse also accept the option. The following are community
property states: Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, and Washington. Although Wisconsin is not formally
a community property state, it has laws governing the division of marital property similar to community property states and it may be
desirable to have a Wisconsin Participant&rsquo;s spouse accept the option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SIGNATURE PAGE TO NONSTATUTORY
STOCK OPTION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Exhibit&nbsp;A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Notice
of Stock Option Exercise</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[DATE]<SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CARISMA Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3025 Market Street, Ste 140<BR>
Philadelphia, PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sir or Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I am the holder of a Nonstatutory
Stock Option granted to me under the CARISMA Therapeutics Inc. (the &ldquo;<B>Company</B>&rdquo;) 2017 Stock Incentive Plan on [__________]<SUP>2
</SUP>for the purchase of [__________]<SUP>3</SUP> shares of Common Stock of the Company at a purchase price of $[__________]<SUP>4</SUP>
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby exercise my option
to purchase [_________]<SUP>5</SUP> shares of Common Stock (the &ldquo;<B>Shares</B>&rdquo;), for which I have enclosed [__________]<SUP>6
</SUP>in the amount of [________]<SUP>7</SUP>. Please register my stock certificate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 50%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name(s):</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 65%; text-align: right"><SUP>8</SUP></TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>Address:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter
date of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2&#8239;</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter
the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter
the total number of shares of Common Stock for which the option was granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter
the option exercise price per share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter
the number of shares of Common Stock to be purchased upon exercise of all or part of the option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>6&#8239;</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter
 &ldquo;cash&rdquo;, &ldquo;personal check&rdquo; or if permitted by the option or Plan, &ldquo;stock certificates No.&nbsp;XXXX and XXXX&rdquo;.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>7</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter
the dollar amount (price per share of Common Stock times the number of shares of Common Stock to be purchased), or the number of shares
tendered. Fair market value of shares tendered, together with cash or check, must cover the purchase price of the shares issued upon
exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>8</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter
name(s) to appear on stock certificate in one of the following formats: (a) your name only (i.e., John Doe); (b) your name and other
name (i.e., John Doe and Jane Doe, Joint Tenants with Right to Survivorship); or for Nonstatutory Stock Options only, (c) a child&rsquo;s
name, with you as custodian (i.e. Jane Doe, Custodian for Tommy Doe). Note: There may be income and/or gift tax consequences for registering
shares in a child&rsquo;s name.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;I represent, warrant and covenant as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution
of the Shares in violation of the Securities Act of 1933 (the &ldquo;<B>Securities Act</B>&rdquo;), or any rule&nbsp;or regulation under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to
permit me to evaluate the merits and risks of my investment in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of
the Shares and to make an informed investment decision with respect to such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
understand that (i)&nbsp;the Shares have not been registered under the Securities Act and are &ldquo;restricted securities&rdquo; within
the meaning of Rule&nbsp;144 under the Securities Act, (ii)&nbsp;the Shares cannot be sold, transferred or otherwise disposed of unless
they are subsequently registered under the Securities Act or an exemption from registration is then available; (iii)&nbsp;in any event,
the exemption from registration under Rule&nbsp;144 will not be available for at least one year and even then will not be available unless
a public market then exists for the Common Stock, adequate information concerning the Company is then available to the public, and other
terms and conditions of Rule&nbsp;144 are complied with; and (iv)&nbsp;there is now no registration statement on file with the Securities
and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the
Shares under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT>Name</FONT>]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: NewSection Last; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>12
<FILENAME>tm238578d1_ex10-12.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&#8239;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&#8239;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>CARISMA
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Incentive
Stock Option Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Granted
Under 2017 Stock Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Grant
of Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Incentive Stock Option
Agreement (the &ldquo;<B>Agreement</B>&rdquo;) evidences the grant by CARISMA Therapeutics Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
on [________ __, 20__] (the &ldquo;<B>Grant Date</B>&rdquo;) to [___________], an employee of the Company (the &ldquo;<B>Participant</B>&rdquo;),
of an option to purchase, in whole or in part, on the terms provided herein and in the Company&rsquo;s 2017 Stock Incentive Plan (the
 &ldquo;<B>Plan</B>&rdquo;), as amended, a total of [_________] shares (the &ldquo;<B>Shares</B>&rdquo;) of common stock, $0.0001 par
value per share, of the Company (&ldquo;<B>Common Stock</B>&rdquo;) at $[_______<U>]</U> per Share. Unless earlier terminated, this option
shall expire at 5:00 p.m., Eastern time, on [_______ __, 20__] [date is ten years minus one day from grant date] (the &ldquo;<B>Final
Exercise Da</B>te&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is intended that the option
evidenced by this Agreement shall be an incentive stock option as defined in Section&#8239;422 of the Internal Revenue Code of 1986,
as amended, and any regulations promulgated thereunder (the &ldquo;<B>Code</B>&rdquo;). Except as otherwise indicated by the context,
the term &ldquo;<B>Participant</B>&rdquo;, as used in this option, shall be deemed to include any person who acquires the right to exercise
this option validly under its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Vesting
Schedule</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[This option will become
exercisable (&ldquo;<B>vest</B>&rdquo;) as to 25% of the original number of Shares on the first anniversary of the Vesting Commencement
Date (as defined below) and as to an additional 2.0833% of the original number of Shares at the end of each successive month following
the first anniversary of the Vesting Commencement Date until the fourth anniversary of the Vesting Commencement Date. On the fourth anniversary
of the Vesting Commencement Date, this option will be exercisable as to all Shares. For purposes of this Agreement, &ldquo;<B>Vesting
Commencement Date</B>&rdquo; shall mean [__________________].]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The right of exercise shall
be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be
exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the
termination of this option under Section&#8239;3 hereof or the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
of Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Form&#8239;of
Exercise</U>. Each election to exercise this option shall be accompanied by a completed Notice of Stock Option Exercise in the form attached
hereto as <U>Exhibit&#8239;A</U>, signed by the Participant, and received by the Company at its principal office, accompanied by this Agreement,
and payment in full in the manner provided in the Plan. The Participant may purchase less than the number of Shares covered hereby, provided
that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Continuous
Relationship with the Company Required</U>. Except as otherwise provided in this Section&#8239;3, this option may not be exercised unless
the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee or officer
of, or consultant or advisor to, the Company or any parent or subsidiary of the Company as defined in Section&#8239;424(e)&#8239;or (f)&#8239;of
the Code (an &ldquo;<B>Eligible Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination
of Relationship with the Company</U>. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided
in paragraphs&#8239;(d)&#8239;and (e)&#8239;below, the right to exercise this option shall terminate three months after such cessation (but
in no event after the Final Exercise Date), <U>provided that</U> this option shall be exercisable only to the extent that the Participant
was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final
Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure
agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon
such violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
Period Upon Death or Disability</U>. If the Participant dies or becomes disabled (within the meaning of Section&#8239;22(e)(3)&#8239;of
the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship
for &ldquo;cause&rdquo; as specified in paragraph (e)&#8239;below, this option shall be exercisable, within the period of one year following
the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), <U>provided
that</U> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or
her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination
for Cause</U>. If, prior to the Final Exercise Date, the Participant&rsquo;s employment is terminated by the Company for Cause (as defined
below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment. If, prior
to the Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment by the Company
for Cause, and the effective date of such employment termination is subsequent to the date of delivery of such notice, the right to exercise
this option shall be suspended from the time of the delivery of such notice until the earlier of (i)&#8239;such time as it is determined
or otherwise agreed that the Participant&rsquo;s employment shall not be terminated for Cause as provided in such notice or (ii)&#8239;the
effective date of such termination of employment (in which case the right to exercise this option shall, pursuant to the preceding sentence,
terminate upon the effective date of such termination of employment). If the Participant is party to an employment or severance agreement
with the Company that contains a definition of &ldquo;cause&rdquo; for termination of employment, &ldquo;Cause&rdquo; shall have the meaning
ascribed to such term in such agreement. Otherwise, &ldquo;Cause&rdquo; shall mean willful misconduct by the Participant or willful failure
by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of
any provision of any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant
and the Company), as determined by the Company, which determination shall be conclusive. The Participant&rsquo;s employment shall be considered
to have been terminated for Cause if the Company determines, within 30 days after the Participant&rsquo;s resignation, that termination
for Cause was warranted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Company
Right of First Refusal</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
of Proposed Transfer</U>. If the Participant proposes to sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation
of law or otherwise (collectively, &ldquo;transfer&rdquo;) any Shares acquired upon exercise of this option, then the Participant shall
first give written notice of the proposed transfer (the &ldquo;<B>Transfer Notice</B>&rdquo;) to the Company. The Transfer Notice shall
name the proposed transferee and state the number of such Shares the Participant proposes to transfer (the &ldquo;<B>Offered Shares</B>&rdquo;),
the price per share and all other material terms and conditions of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Company
Right to Purchase</U>. For 30 days following its receipt of such Transfer Notice, the Company shall have the option to purchase all or
part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase
all or part of the Offered Shares, it shall give written notice of such election to the Participant within such 30-day period. Within
10 days after his or her receipt of such notice, the Participant shall tender to the Company at its principal offices the certificate
or certificates representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the Participant or with duly
endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company. Promptly following receipt
of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the purchase price for
such Offered Shares; <U>provided that</U> if the terms of payment set forth in the Transfer Notice were other than cash against delivery,
the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice; and <U>provided
further</U> that any delay in making such payment shall not invalidate the Company&rsquo;s exercise of its option to purchase the Offered
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shares
Not Purchased By Company</U>. If the Company does not elect to acquire all of the Offered Shares, the Participant may, within the 30-day
period following the expiration of the option granted to the Company under subsection (b)&#8239;above, transfer the Offered Shares which
the Company has not elected to acquire to the proposed transferee, <U>provided that</U> such transfer shall not be on terms and conditions
more favorable to the transferee than those contained in the Transfer Notice. Notwithstanding any of the above, all Offered Shares transferred
pursuant to this Section&#8239;4 shall remain subject to the right of first refusal set forth in this Section&#8239;4 and such transferee
shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by
all of the terms and conditions of this Section&#8239;4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Consequences
of Non-Delivery</U>. After the time at which the Offered Shares are required to be delivered to the Company for transfer to the Company
pursuant to subsection (b)&#8239;above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or
permit the Participant to exercise any of the privileges or rights of a stockholder with respect to such Offered Shares, but shall, insofar
as permitted by law, treat the Company as the owner of such Offered Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exempt
Transactions</U>. The following transactions shall be exempt from the provisions of this Section&#8239;4:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
transfer of Shares to or for the benefit of any spouse, child or grandchild of the Participant, or to a trust for their benefit;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
transfer pursuant to an effective registration statement filed by the Company under the Securities Act of 1933, as amended (the &ldquo;<B>Securities
Act</B>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
sale of all or substantially all of the outstanding shares of capital stock of the Company (including pursuant to a merger or consolidation);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided</U></FONT>,
<U>however</U>, that in the case of a transfer pursuant to clause (1)&#8239;above, such Shares shall remain subject to the right of first
refusal set forth in this Section&#8239;4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Assignment
of Company Right</U>. The Company may assign its rights to purchase Offered Shares in any particular transaction under this Section&#8239;4
to one or more persons or entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination</U>.
The provisions of this Section&#8239;4 shall terminate upon the earlier of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
closing of the sale of shares of Common Stock in an underwritten public offering pursuant to an effective registration statement filed
by the Company under the Securities Act; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger, consolidation,
sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who
were beneficial owners of the Company&rsquo;s voting securities immediately prior to such transaction beneficially own, directly or indirectly,
more than 75% (determined on an as-converted basis) of the outstanding securities entitled to vote generally in the election of directors
of the resulting, surviving or acquiring corporation in such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Obligation to Recognize Invalid Transfer</U>. The Company shall not be required (1)&#8239;to transfer on its books any of the Shares which
shall have been sold or transferred in violation of any of the provisions set forth in this Section&#8239;4, or (2)&#8239;to treat as owner
of such Shares or to pay dividends to any transferee to whom any such Shares shall have been so sold or transferred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legends</U>.
The certificate representing Shares shall bear a legend substantially in the following form (in addition to, or in combination with, any
legend required by applicable federal and state securities laws and agreements relating to the transfer of the Company securities):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;The shares represented by this
certificate are subject to a right of first refusal in favor of the Company, as provided in a certain stock option agreement with the
Company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Agreement
in Connection with Initial Public Offering</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Participant agrees, in connection with the
initial underwritten public offering of the Common Stock pursuant to a registration statement under the Securities Act, (i)&#8239;not to
(a)&#8239;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly,
any shares of Common Stock or any other securities of the Company or (b)&#8239;enter into any swap or other agreement that transfers, in
whole or in part, any of the economic consequences of ownership of shares of Common Stock or other securities of the Company, whether
any transaction described in clause (a)&#8239;or (b)&#8239;is to be settled by delivery of securities, in cash or otherwise, during the
period beginning on the date of the filing of such registration statement with the Securities and Exchange Commission and ending 180 days
after the date of the final prospectus relating to the offering (plus up to an additional 34 days to the extent requested by the managing
underwriters for such offering in order to address NASD Rule&#8239;2711(f)(4)&#8239;or NYSE Rule&#8239;472(f)(4)&#8239;or any similar successor
provision), and (ii)&#8239;to execute any agreement reflecting clause (i)&#8239;above as may be requested by the Company or the managing
underwriters at the time of such offering. The Company may impose stop-transfer instructions with respect to the shares of Common Stock
or other securities subject to the foregoing restriction until the end of the &ldquo;lock-up&rdquo; period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Tax
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Withholding</U>.
No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision
satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of
this option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disqualifying
Disposition</U>. If the Participant disposes of Shares acquired upon exercise of this option within two years from the Grant Date or one
year after such Shares were acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of such
disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Restrictions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation
of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable
only by the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Participant agrees that he or she will not transfer any Shares issued pursuant to the exercise of this option unless the transferee, as
a condition to such transfer, delivers to the Company a written instrument confirming that such transferee shall be bound by all of the
terms and conditions of Section&#8239;4 and Section&#8239;5; provided that such a written confirmation shall not be required with respect
to (1)&#8239;Section&#8239;4 after such provision has terminated in accordance with Section&#8239;4(g)&#8239;or (2)&#8239;Section&#8239;5 after
the completion of the lock-up period in connection with the Company&rsquo;s initial underwritten public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Provisions
of the Plan</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This option is subject to
the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant
with this option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of Page&#8239;Intentionally Left Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the day and year first above written. The Participant hereby accepts the foregoing option and
agrees to the terms and conditions thereof. The Participant hereby acknowledges receipt of a copy of the Company&rsquo;s 2017 Stock Incentive
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CARISMA THERAPEUTICS INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 5%">&#8239;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Name]</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 1in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SPOUSAL CONSENT:</B> <SUP>1</SUP></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 3%">&#8239;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 43%">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD STYLE="width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> If the Participant resides in a
community property state, it is desirable to have the Participant&rsquo;s spouse also accept the option. The following are community
property states: Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, and Washington. Although Wisconsin is not formally
a community property state, it has laws governing the division of marital property similar to community property states and it may be
desirable to have a Wisconsin Participant&rsquo;s spouse accept the option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE PAGE TO INCENTIVE STOCK OPTION AGREEMENT</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Exhibit&#8239;A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Notice
of Stock Option Exercise</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[DATE]<SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CARISMA Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3025 Market Street, Ste 140<BR>
Philadelphia, PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sir or Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I am the holder of an Incentive
Stock Option granted to me under the CARISMA Therapeutics Inc. (the &ldquo;<B>Company</B>&rdquo;) 2017 Stock Incentive Plan on [__________]<SUP>2
</SUP>for the purchase of [__________]<SUP>3</SUP> shares of Common Stock of the Company at a purchase price of $[__________]<SUP>4</SUP>
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby exercise my option
to purchase [_________]<SUP>5</SUP> shares of Common Stock (the &ldquo;<B>Shares</B>&rdquo;), for which I have enclosed [__________]<SUP>6
</SUP>in the amount of [________]<SUP>7</SUP>. Please register my stock certificate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name(s):</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid; width: 2in">&#8239;<SUP>8</SUP></TD>
    <TD>&#8239;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD>
    <TD>&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: justify">Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD>
    <TD>&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD>
    <TD>&#8239;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I represent, warrant and covenant
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter date of
exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter the date
of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter the total
number of shares of Common Stock for which the option was granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter the option
exercise price per share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter the number
of shares of Common Stock to be purchased upon exercise of all or part of the option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>6</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter &ldquo;cash&rdquo;,
 &ldquo;personal check&rdquo; or if permitted by the option or Plan, &ldquo;stock certificates No.&#8239;XXXX and XXXX&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>7</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter the dollar
amount (price per share of Common Stock times the number of shares of Common Stock to be purchased), or the number of shares tendered.
Fair market value of shares tendered, together with cash or check, must cover the purchase price of the shares issued upon exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>8</SUP>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Enter
name(s) to appear on stock certificate in one of the following formats: (a) your name only (i.e., John Doe); (b) your name and other
name (i.e., John Doe and Jane Doe, Joint Tenants with Right to Survivorship); or for Nonstatutory Stock Options only, (c) a child&rsquo;s
name, with you as custodian (i.e. Jane Doe, Custodian for Tommy Doe). Note: There may be income and/or gift tax consequences for registering
shares in a child&rsquo;s name.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution
of the Shares in violation of the Securities Act of 1933 (the &ldquo;<B>Securities Act</B>&rdquo;), or any rule&#8239;or regulation under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to
permit me to evaluate the merits and risks of my investment in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of
the Shares and to make an informed investment decision with respect to such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">I
understand that (i)&#8239;the Shares have not been registered under the Securities Act and are &ldquo;restricted securities&rdquo; within
the meaning of Rule&#8239;144 under the Securities Act, (ii)&#8239;the Shares cannot be sold, transferred or otherwise disposed of unless
they are subsequently registered under the Securities Act or an exemption from registration is then available; (iii)&#8239;in any event,
the exemption from registration under Rule&#8239;144 will not be available for at least one year and even then will not be available unless
a public market then exists for the Common Stock, adequate information concerning the Company is then available to the public, and other
terms and conditions of Rule&#8239;144 are complied with; and (iv)&#8239;there is now no registration statement on file with the Securities
and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the
Shares under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%">&#8239;</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT>Name</FONT>]</FONT></TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: NewSection Last; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>13
<FILENAME>tm238578d1_ex10-13.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.13</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARISMA THERAPEUTICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD><U>Purpose</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The purpose of this Amended and Restated 2014 Stock
Incentive Plan (the &#8220;<B><I>Plan</I></B>&#8221;) of Carisma Therapeutics Inc. (formerly known as Sesen Bio,&nbsp;Inc.), a Delaware
corporation (the &#8220;<B><I>Company</I></B>&#8221;), is to advance the interests of the Company&#8217;s stockholders by enhancing the
Company&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by
providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests
of such persons with those of the Company&#8217;s stockholders. The Plan amends and restates the 2014 Stock Incentive Plan (the &#8220;<B><I>Original
Plan</I></B>&#8221;) that was originally adopted by the board of directors of the Company (the &#8220;<B><I>Board</I></B>&#8221;) in December&nbsp;2013
and approved by the Company&#8217;s stockholders in January&nbsp;2014, was amended by the Board on April&nbsp;19, 2019 and approved by
the Company&#8217;s stockholders on June&nbsp;19, 2019, was amended by the Board on March&nbsp;12, 2021 and approved by the Company&#8217;s
stockholders on May&nbsp;3, 2021, was amended by the Board on November&nbsp;17, 2022 and approved by the Company&#8217;s stockholders
on March&nbsp;2, 2023. Except where the context otherwise requires, the term &#8220;<B><I>Company</I></B>&#8221; shall include any of
the Company&#8217;s present or future parent or subsidiary corporations as defined in Sections 424(e)&nbsp;or (f)&nbsp;of the Internal
Revenue Code of 1986, as amended, and any regulations thereunder (the &#8220;<B><I>Code</I></B>&#8221;) and any other business venture
(including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined
by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD><U>Eligibility</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of the Company&#8217;s employees, officers
and directors, as well as consultants and advisors to the Company (as such terms consultants and advisors are defined and interpreted
for purposes of Form&nbsp;S-8 under the Securities Act of 1933, as amended (the &#8220;<B><I>Securities Act</I></B>&#8221;) (or any successor
form)) are eligible to be granted Awards under the Plan. Each person who is granted an Award under the Plan is deemed a &#8220;<B><I>Participant</I></B><I>.</I>&#8221;
 &#8220;<B><I>Award</I></B>&#8221; means Options (as defined in Section&nbsp;5), SARs (as defined in Section&nbsp;6), Restricted Stock
(as defined in Section&nbsp;7), Restricted Stock Units (as defined in Section&nbsp;7) and Other Stock-Based Awards (as defined in Section&nbsp;8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD><U>Administration and Delegation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Administration
by Board of Directors</U>. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend
and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe
and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any
omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient and it shall
be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&#8217;s sole discretion and shall
be final and binding on all persons having or claiming any interest in the Plan or in any Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Appointment
of Committees</U>. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or
more committees or subcommittees of the Board (each, a &#8220;<B><I>Committee</I></B>&#8221;). All references in the Plan to the &#8220;<B><I>Board</I></B>&#8221;
shall mean the Board or a Committee of the Board or the Delegated Persons referred to in Section&nbsp;3(c)&nbsp;to the extent that the
Board&#8217;s powers or authority under the Plan have been delegated to such Committee or such Delegated Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delegation
to Delegated Persons</U>. Subject to any requirements of applicable law (including as applicable Sections 152(b)&nbsp;and 157(c)&nbsp;of
the General Corporation Law of the State of Delaware), the Board may, by resolution, delegate to one or more persons (including officers
of the Company) or bodies (such persons or bodies, the &#8220;<B><I>Delegated Persons</I></B>&#8221;) the power to grant Awards (subject
to any limitations under the Plan) to eligible service providers of the Company and to exercise such other powers under the Plan as the
Board may determine, provided that the Board shall fix: (i)&nbsp;the maximum number of Awards, and the maximum number of shares issuable
upon exercise thereof, that may be issued by such Delegated Persons, (ii)&nbsp;the time period during which such Awards, and during which
the shares issuable upon exercise thereof, may be issued, and (iii)&nbsp;the minimum amount of consideration (if any) for which such Awards
may be issued, and a minimum amount of consideration for the shares issuable upon exercise thereof; and provided further, that no Delegated
Person shall be authorized to grant Awards to itself; and provided further, that no Delegated Person shall be authorized to grant Awards
to any &#8220;executive officer&#8221; of the Company (as defined by Rule&nbsp;3b-7 under the Securities Exchange Act of 1934, as amended
(the &#8220;<B><I>Exchange Act</I></B>&#8221;)) or to any &#8220;officer&#8221; of the Company (as defined by Rule&nbsp;16a-1(f)&nbsp;under
the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD><U>Stock Available for Awards</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Number
of Shares; Share Counting</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Number of Shares</U>. Subject to adjustment under Section&nbsp;9, Awards may be made under the Plan for up to such number of shares of
common stock, $0.001 par value per share, of the Company (the &#8220;<B><I>Common Stock</I></B>&#8221;) as is equal to the sum of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
aggregate number of shares of Common Stock equal to 12.79% of the fully-diluted capitalization of the Company as of immediately following
the closing of the transactions contemplated by the Agreement and Plan of Merger and Reorganization between the Company, Seahawk Merger
Sub Inc. and Carisma Therapeutics Inc. (as it may be amended from time to time, the &#8220;<B><I>Merger Agreement</I></B>&#8221; minus
the number of shares of Common Stock that remain available for the grant of Awards as of the closing of the transactions contemplated
by the Merger Agreement); plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,265,664 shares of Common Stock; plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
additional number of shares of Common Stock as is equal to the sum of (x)&nbsp;the number of shares of Common Stock reserved for
issuance under the Company&#8217;s 2009 Stock Incentive Plan (the &#8220;<B><I>Prior Plan</I></B>&#8221;) that remained available
for grant under the Prior Plan immediately prior to the closing of the Company&#8217;s initial public offering and (y)&nbsp;the
number of shares of Common Stock (I)&nbsp;that were subject to awards granted under the Prior Plan and (II)&nbsp;that are subject to
stock options assumed by the Company pursuant to the Merger Agreement, as of the closing of the transactions contemplated by the
Merger Agreement (the awards described in the foregoing clauses (I)&nbsp;and (II)&nbsp;together, the &#8220;<B><I>Outstanding
Awards</I></B>&#8221;) in each case which Outstanding Awards expire, terminate or are otherwise surrendered, canceled, forfeited or
repurchased by the Company at their original issuance price pursuant to a contractual repurchase right (subject, however, in the
case of Incentive Stock Options to any limitations of the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to adjustment under Section&nbsp;9, up to 12,600,000 of the
shares of Common Stock available for issuance under the Plan may be issued as Incentive Stock Options (as defined in Section&nbsp;5(b))
under the Plan. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Share
Counting</U>. For purposes of counting the number of shares available for the grant of Awards under the Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
shares of Common Stock covered by SARs shall be counted against the number of shares available for the grant of Awards under the Plan;&nbsp;<I>provided</I>,&nbsp;<I>however</I>,
that (i)&nbsp;SARs that may be settled only in cash shall not be so counted and (ii)&nbsp;if the Company grants an SAR in tandem with
an Option for the same number of shares of Common Stock and provides that only one such Award may be exercised (a &#8220;<B><I>Tandem
SAR</I></B>&#8221;), only the shares covered by the Option, and not the shares covered by the Tandem SAR, shall be so counted, and the
expiration of one in connection with the other&#8217;s exercise will not restore shares to the Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
any Award (i)&nbsp;expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in
part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance
price pursuant to a contractual repurchase right) or (ii)&nbsp;results in any Common Stock not being issued (including as a result of
an SAR that was settleable either in cash or in stock actually being settled in cash), the unused Common Stock covered by such Award shall
again be available for the grant of Awards;&nbsp;<I>provided</I>,&nbsp;<I>however</I>, that (1)&nbsp;in the case of Incentive Stock Options,
the foregoing shall be subject to any limitations under the Code, (2)&nbsp;in the case of the exercise of an SAR, the number of shares
counted against the shares available under the Plan shall be the full number of shares subject to the SAR multiplied by the percentage
of the SAR actually exercised, regardless of the number of shares actually used to settle such SAR upon exercise and (3)&nbsp;the shares
covered by a Tandem SAR shall not again become available for grant upon the expiration or termination of such Tandem SAR; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of Common Stock delivered (either by actual delivery, attestation, or net exercise) to the Company by a Participant to (i)&nbsp;purchase
shares of Common Stock upon the exercise of an Award or (ii)&nbsp;satisfy tax withholding obligations (including shares retained from
the Award creating the tax obligation) shall not be added back to the number of shares available for the future grant of Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Substitute
Awards</U>. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or
stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such entity
or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding
any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section&nbsp;4(a),
except as may be required by reason of Section&nbsp;422 and related provisions of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD><U>Stock Options</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>.
The Board may grant options to purchase Common Stock (each, an &#8220;<B><I>Option</I></B>&#8221;) and determine the number of shares
of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise
of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive
Stock Options</U>. An Option that the Board intends to be an &#8220;incentive stock option&#8221; as defined in Section&nbsp;422 of the
Code (an &#8220;<B><I>Incentive Stock Option</I></B>&#8221;) shall only be granted to employees of Carisma Therapeutics Inc. (formerly
known as Sesen Bio,&nbsp;Inc.), any of Carisma Therapeutics Inc.&#8217;s present or future parent or subsidiary corporations as defined
in Sections 424(e)&nbsp;or (f)&nbsp;of the Code, and any other entities the employees of which are eligible to receive Incentive Stock
Options under the Code, and shall be subject to and shall be construed consistently with the requirements of Section&nbsp;422 of the Code.
An Option that is not intended to be an Incentive Stock Option shall be designated a &#8220;<B><I>Nonstatutory Stock Option.</I></B>&#8221;
The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is intended to be an
Incentive Stock Option is not an Incentive Stock Option or if the Company converts an Incentive Stock Option to a Nonstatutory Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable Option agreement.
The exercise price shall be not less than 100% of the fair market value per share of Common Stock, as determined by (or in a manner approved
by) the Board (&#8220;<B><I>Fair Market Value</I></B>&#8221;), on the date the Option is granted;&nbsp;<I>provided</I>&nbsp;that if the
Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not less than
100% of the Fair Market Value on such future date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Duration
of Options</U>. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the
applicable option agreement;&nbsp;<I>provided</I>,&nbsp;<I>however</I>, that no Option will be granted with a term in excess of 10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Options</U>. Options may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved
by the Company, together with payment in full (in a manner specified in Section&nbsp;5(f)) of the exercise price for the number of shares
for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable
following exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Upon Exercise</U>. Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
cash or by check, payable to the order of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
as may otherwise be provided in the applicable Option agreement or approved by the Board, in its sole discretion, by (i)&nbsp;delivery
of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the
exercise price and any required tax withholding or (ii)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional
instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any
required tax withholding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
the extent provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by delivery (either by actual
delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value,&nbsp;<I>provided</I>&nbsp;(i)&nbsp;such
method of payment is then permitted under applicable law, (ii)&nbsp;such Common Stock, if acquired directly from the Company, was owned
by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii)&nbsp;such Common
Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
the extent provided for in the applicable Nonstatutory Stock Option agreement or approved by the Board in its sole discretion, by delivery
of a notice of &#8220;net exercise&#8221; to the Company, as a result of which the Participant would receive (i)&nbsp;the number of shares
underlying the portion of the Option being exercised, less (ii)&nbsp;such number of shares as is equal to (A)&nbsp;the aggregate exercise
price for the portion of the Option being exercised divided by (B)&nbsp;the Fair Market Value on the date of exercise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
the extent permitted by applicable law and provided for in the applicable Option agreement or approved by the Board, in its sole discretion,
by payment of such other lawful consideration as the Board may determine; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
any combination of the above permitted forms of payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
on Repricing</U>. Unless such action is approved by the Company&#8217;s stockholders, the Company may not (except as provided for under
Section&nbsp;9): (1)&nbsp;amend any outstanding Option granted under the Plan to provide an exercise price per share that is lower than
the then-current exercise price per share of such outstanding Option, (2)&nbsp;cancel any outstanding option (whether or not granted under
the Plan) and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section&nbsp;4(b)) covering
the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price
per share of the cancelled option, (3)&nbsp;cancel in exchange for a cash payment any outstanding Option with an exercise price per share
above the then-current Fair Market Value, or (4)&nbsp;take any other action under the Plan that constitutes a &#8220;repricing&#8221;
within the meaning of the rules&nbsp;of the Nasdaq Stock Market (&#8220;<B><I>Nasdaq</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.</TD><TD><U>Stock Appreciation Rights</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>.
The Board may grant Awards consisting of stock appreciation rights (&#8220;<B><I>SARs</I></B>&#8221;) entitling the holder, upon exercise,
to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference
to appreciation, from and after the date of grant, in the Fair Market Value of a share of Common Stock over the measurement price established
pursuant to Section&nbsp;6(b). The date as of which such appreciation is determined shall be the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Measurement
Price</U>. The Board shall establish the measurement price of each SAR and specify it in the applicable SAR agreement. The measurement
price shall not be less than 100% of the Fair Market Value on the date the SAR is granted;&nbsp;<I>provided</I>&nbsp;that if the Board
approves the grant of an SAR effective as of a future date, the measurement price shall be not less than 100% of the Fair Market Value
on such future date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Duration
of SARs</U>. Each SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable
SAR agreement;&nbsp;<I>provided</I>,&nbsp;<I>however</I>, that no SAR will be granted with a term in excess of 10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of SARs</U>. SARs may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by
the Company, together with any other documents required by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
on Repricing</U>. Unless such action is approved by the Company&#8217;s stockholders, the Company may not (except as provided for under
Section&nbsp;9): (1)&nbsp;amend any outstanding SAR granted under the Plan to provide a measurement price per share that is lower than
the then-current measurement price per share of such outstanding SAR, (2)&nbsp;cancel any outstanding SAR (whether or not granted under
the Plan) and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section&nbsp;4(b)) covering
the same or a different number of shares of Common Stock and having an exercise or measurement price per share lower than the then-current
measurement price per share of the cancelled SAR, (3)&nbsp;cancel in exchange for a cash payment any outstanding SAR with a measurement
price per share above the then-current Fair Market Value, or (4)&nbsp;take any other action under the Plan that constitutes a &#8220;repricing&#8221;
within the meaning of the rules&nbsp;of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.</TD><TD><U>Restricted Stock; Restricted Stock Units</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>.
The Board may grant Awards entitling recipients to acquire shares of Common Stock (&#8220;<B><I>Restricted Stock</I></B>&#8221;),
subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price
(or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the
Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the
Board for such Award. The Board may also grant Awards entitling the recipient to receive shares of Common Stock or cash to be
delivered at the time such Award vests (&#8220;<B><I>Restricted Stock Units</I></B>&#8221;) (Restricted Stock and Restricted Stock
Units are each referred to herein as a &#8220;<B><I>Restricted Stock Award</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms
and Conditions for All Restricted Stock Awards</U>. The Board shall determine the terms and conditions of a Restricted Stock Award, including
the conditions for vesting and repurchase (or forfeiture) and the issue price, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Provisions Relating to Restricted Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Dividends</U>.
Unless otherwise provided in the applicable Award agreement, any dividends (whether paid in cash, stock or property) declared and paid
by the Company with respect to shares of Restricted Stock (&#8220;<B><I>Accrued Dividends</I></B>&#8221;) shall be paid to the Participant
only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such shares. Each payment
of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to stockholders of that class
of stock or, if later, the 15th day of the third month following the lapsing of the restrictions on transferability and the forfeitability
provisions applicable to the underlying shares of Restricted Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Certificates</U>. The Company may require that any stock certificates issued in respect of shares of Restricted Stock, as well as dividends
or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power endorsed
in blank, with the Company (or its designee). At the expiration of the applicable restriction periods, the Company (or such designee)
shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to his or her
Designated Beneficiary. &#8220;<B><I>Designated Beneficiary</I></B>&#8221; means (i)&nbsp;the beneficiary designated, in a manner determined
by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#8217;s death
or (ii)&nbsp;in the absence of an effective designation by a Participant, the Participant&#8217;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Provisions Relating to Restricted Stock Units</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement</U>.
Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted Stock Unit, the Participant
shall be entitled to receive from the Company such number of shares of Common Stock or (if so provided in the applicable Award agreement)
an amount of cash equal to the Fair Market Value of such number of shares of Common Stock as set forth in the applicable Award agreement.
The Board may, in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the
election of the Participant in a manner that complies with Section&nbsp;409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting
Rights</U>. A Participant shall have no voting rights with respect to any Restricted Stock Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Dividend
Equivalents</U>. The Award agreement for Restricted Stock Units may provide Participants with the right to receive an amount equal to
any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (&#8220;<B><I>Dividend
Equivalents</I></B>&#8221;). Dividend Equivalents may be paid currently or credited to an account for the Participants, may be settled
in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock
Units with respect to which paid, in each case to the extent provided in the applicable Award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.</TD><TD><U>Other Stock-Based Awards</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>.
Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on,
shares of Common Stock or other property, may be granted hereunder to Participants (&#8220;<B><I>Other Stock-Based-Awards</I></B>&#8221;).
Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or
as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common
Stock or cash, as the Board shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms
and Conditions</U>. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based
Award, including any purchase price applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.</TD><TD><U>Adjustments for Changes in Common Stock and Certain Other Events</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes
in Capitalization</U>. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares,
reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of
Common Stock other than an ordinary cash dividend, (i)&nbsp;the number and class of securities available under the Plan and the number
and class of securities available for issuance as Incentive Stock Options under the Plan, (ii)&nbsp;the share counting rules&nbsp;set
forth in Section&nbsp;4(a), (iii)&nbsp;the number and class of securities and exercise price per share of each outstanding Option, (iv)&nbsp;the
share and per-share provisions and the measurement price of each outstanding SAR, (v)&nbsp;the number of shares subject to and the repurchase
price per share subject to each outstanding Restricted Stock Award and (vi)&nbsp;the share and per-share-related provisions and the purchase
price, if any, of each outstanding Other Stock-Based Award, shall be equitably adjusted by the Company (or substituted Awards may be made,
if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the event the Company effects
a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding
Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an
optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive,
on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding
the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reorganization
Events</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definition</U>.
A &#8220;<B><I>Reorganization Event</I></B>&#8221; shall mean: (a)&nbsp;any merger or consolidation of the Company with or into another
entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities
or other property or is cancelled, (b)&nbsp;any transfer or disposition of all of the Common Stock of the Company for cash, securities
or other property pursuant to a share exchange or other transaction or (c)&nbsp;any liquidation or dissolution of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consequences
of a Reorganization Event on Awards Other than Restricted Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion of)
outstanding Awards other than Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise
in an applicable Award agreement or another agreement between the Company and the Participant): (i)&nbsp;provide that such Awards shall
be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof),
(ii)&nbsp;upon written notice to a Participant, provide that all of the Participant&#8217;s unvested and/or unexercised Awards will terminate
immediately prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable)
within a specified period following the date of such notice, (iii)&nbsp;provide that outstanding Awards shall become exercisable, realizable,
or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv)&nbsp;in
the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment
for each share surrendered in the Reorganization Event (the &#8220;<B><I>Acquisition Price</I></B>&#8221;), make or provide for a cash
payment to Participants with respect to each Award held by a Participant equal to (A)&nbsp;the number of shares of Common Stock subject
to the vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization
Event) multiplied by (B)&nbsp;the excess, if any, of (I)&nbsp;the Acquisition Price over (II)&nbsp;the exercise, measurement or purchase
price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (v)&nbsp;provide that, in connection
with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable,
net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (vi)&nbsp;any combination of the foregoing.
In taking any of the actions permitted under this Section&nbsp;9(b)(2), the Board shall not be obligated by the Plan to treat all Awards,
all Awards held by a Participant, or all Awards of the same type, identically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the terms of Section&nbsp;9(b)(2)(i), in the case of outstanding Restricted Stock Units that are subject to Section&nbsp;409A of the Code:
(i)&nbsp;if the applicable Restricted Stock Unit agreement provides that the Restricted Stock Units shall be settled upon a &#8220;change
in control event&#8221; within the meaning of Treasury Regulation Section&nbsp;1.409A-3(i)(5)(i), and the Reorganization Event constitutes
such a &#8220;change in control event&#8221;, then no assumption or substitution shall be permitted pursuant to Section&nbsp;9(b)(2)(i)(i)&nbsp;and
the Restricted Stock Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and
(ii)&nbsp;the Board may only undertake the actions set forth in clauses (iii), (iv)&nbsp;or (v)&nbsp;of Section&nbsp;9(b)(2)(i)&nbsp;if
the Reorganization Event constitutes a &#8220;change in control event&#8221; as defined under Treasury Regulation Section&nbsp;1.409A-3(i)(5)(i)&nbsp;and
such action is permitted or required by Section&nbsp;409A of the Code; if the Reorganization Event is not a &#8220;change in control event&#8221;
as so defined or such action is not permitted or required by Section&nbsp;409A of the Code, and the acquiring or succeeding corporation
does not assume or substitute the Restricted Stock Units pursuant to clause (i)&nbsp;of Section&nbsp;9(b)(2)(i), then the unvested Restricted
Stock Units shall terminate immediately prior to the consummation of the Reorganization Event without any payment in exchange therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of Section&nbsp;9(b)(2)(i)(i), an Award (other than Restricted Stock) shall be considered assumed if, following consummation
of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share
of Common Stock subject to the Award immediately prior to the consummation of the Reorganization Event, the consideration (whether cash,
securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock
held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type
of consideration chosen by the holders of a majority of the outstanding shares of Common Stock);&nbsp;<I>provided</I>,&nbsp;<I>however</I>,
that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding
corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the
consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares of common stock
of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as of the date
of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares
of Common Stock as a result of the Reorganization Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consequences
of a Reorganization Event on Restricted Stock</U>. Upon the occurrence of a Reorganization Event other than a liquidation or dissolution
of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit
of the Company&#8217;s successor and shall, unless the Board determines otherwise, apply to the cash, securities or other property which
the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as
they applied to such Restricted Stock;&nbsp;<I>provided</I>,&nbsp;<I>however</I>, that the Board may provide for termination or deemed
satisfaction of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a
Participant and the Company, either initially or by amendment. Upon the occurrence of a Reorganization Event involving the liquidation
or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted
Stock or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock then outstanding
shall automatically be deemed terminated or satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.</TD><TD><U>General Provisions Applicable to Awards</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability
of Awards</U>. Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are
granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the
case of an Incentive Stock Option, pursuant to a qualified domestic relations order, and, during the life of the Participant, shall
be exercisable only by the Participant;&nbsp;<I>provided</I>,&nbsp;<I>however</I>, that the Board may permit or provide in an Award
for the gratuitous transfer of the Award by the Participant to or for the benefit of any immediate family member, family trust or
other entity established for the benefit of the Participant and/or an immediate family member thereof if the Company would be
eligible to use a Form&nbsp;S-8 under the Securities Act for the registration of the sale of the Common Stock subject to such Award
to such proposed transferee;&nbsp;<I>provided</I>&nbsp;<I>further</I>, that the Company shall not be required to recognize any such
permitted transfer until such time as such permitted transferee shall, as a condition to such transfer, deliver to the Company a
written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the
terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall include references to
authorized transferees. For the avoidance of doubt, nothing contained in this Section&nbsp;10(a)&nbsp;shall be deemed to restrict a
transfer to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Documentation</U>.
Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms
and conditions in addition to those set forth in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
Discretion</U>. Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award.
The terms of each Award need not be identical, and the Board need not treat Participants uniformly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Status</U>. The Board shall determine the effect on an Award of the disability, death, termination or other cessation of employment,
authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period
during which, the Participant, or the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary, may exercise
rights under the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U>.
The Participant must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations before
the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may decide to
satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold
from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender
to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any
shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price unless
the Company determines otherwise. If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy
such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Common Stock, including shares
retained from the Award creating the tax obligation, valued at their Fair Market Value;&nbsp;<I>provided</I>,&nbsp;<I>however</I>, except
as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed
the Company&#8217;s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax
purposes, including payroll taxes, that are applicable to such supplemental taxable income), except that, to the extent that the Company
is able to retain shares of Common Stock having a fair market value (determined or approved by the Company) that exceeds the statutory
minimum applicable withholding tax without financial accounting implications or the Company is withholding in a jurisdiction that does
not have a statutory minimum withholding tax, the Company may retain such number of shares of Common Stock (up to the number of shares
having a fair market value equal to the maximum individual statutory rate of tax (determined or approved by, the Company)) as the Company
shall determine to be necessary to satisfy the tax liability associated with any Award. Shares used to satisfy tax withholding requirements
cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment
of Award</U>. Except as otherwise provided in Sections 5(g)&nbsp;and 6(e)&nbsp;with respect to repricings and
Section&nbsp;11(d)&nbsp;with respect to actions requiring stockholder approval, the Board may amend, modify or terminate any
outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the
date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant&#8217;s
consent to such action shall be required unless (i)&nbsp;the Board determines that the action, taking into account any related
action, does not materially and adversely affect the Participant&#8217;s rights under the Plan or (ii)&nbsp;the change is permitted
under Section&nbsp;9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
on Delivery of Stock</U>. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions
from shares previously issued or delivered under the Plan until (i)&nbsp;all conditions of the Award have been met or removed to the satisfaction
of the Company, (ii)&nbsp;in the opinion of the Company&#8217;s counsel, all other legal matters in connection with the issuance and delivery
of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock
market rules&nbsp;and regulations, and (iii)&nbsp;the Participant has executed and delivered to the Company such representations or agreements
as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules&nbsp;or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acceleration</U>.
The Board may at any time provide that any Award shall become immediately exercisable in whole or in part, free of some or all restrictions
or conditions, or otherwise realizable in whole or in part, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.</TD><TD><U>Miscellaneous</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Right To Employment or Other Status</U>. No person shall have any claim or right to be granted an Award by virtue of the adoption of the
Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship
with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant
free from any liability or claim under the Plan, except as expressly provided in the applicable Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights As Stockholder; Clawback</U>. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall
have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming
the record holder of such shares. In accepting an Award made under the Plan on and after the Closing Date (as defined in Section&nbsp;11(c)),
the Participant agrees to be bound by any clawback policy that the Company has in effect or may adopt in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date and Term of Plan</U>. The Original Plan became effective immediately prior to the closing of the Company&#8217;s initial public stock
offering of its Common Stock on a U.S.-based stock exchange whereby the Company&#8217;s shares of Common Stock are offered for sale to
the public. The Plan shall become effective on the closing of the transactions contemplated by the Merger Agreement (the &#8220;<B><I>Closing
Date</I></B>&#8221;). No Awards shall be granted under the Plan after the expiration of 10 years from the Closing Date, but Awards previously
granted may extend beyond that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment
of Plan</U>. The Board may amend, suspend or terminate the Plan or any portion thereof at any time provided that (i)&nbsp;to the extent
required by Section&nbsp;162(m)&nbsp;of the Code, no Award granted to a Participant that is intended to comply with Section&nbsp;162(m)&nbsp;of
the Code after the date of such amendment shall become exercisable, realizable or vested, as applicable to such Award, unless and until
the Company&#8217;s stockholders approve such amendment in the manner required by Section&nbsp;162(m)&nbsp;of the Code; and (ii)&nbsp;no
amendment that would require stockholder approval under the rules&nbsp;of the Nasdaq Stock Market may be made effective unless and until
the Company&#8217;s stockholders approve such amendment. In addition, if at any time the approval of the Company&#8217;s stockholders
is required as to any other modification or amendment under Section&nbsp;422 of the Code or any successor provision with respect to Incentive
Stock Options, the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment,
any amendment to the Plan adopted in accordance with this Section&nbsp;11(d)&nbsp;shall apply to, and be binding on the holders of, all
Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into
account any related action, does not materially and adversely affect the rights of Participants under the Plan. No Award shall be made
that is conditioned upon stockholder approval of any amendment to the Plan unless the Award provides that (i)&nbsp;it will terminate or
be forfeited if stockholder approval of such amendment is not obtained within no more than 12 months from the date of grant and (2)&nbsp;it
may not be exercised or settled (or otherwise result in the issuance of Common Stock) prior to such stockholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization
of Sub-Plans (including Grants to non-U.S. Employees)</U>. The Board may from time to time establish one or more sub-plans under the Plan
for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such sub-plans
by adopting supplements to the Plan containing (i)&nbsp;such limitations on the Board&#8217;s discretion under the Plan as the Board deems
necessary or desirable or (ii)&nbsp;such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem
necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only
to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants
in any jurisdiction which is not the subject of such supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Section&nbsp;409A of the Code</U>. Except as provided in individual Award agreements initially or by amendment, if and to the extent
(i)&nbsp;any portion of any payment, compensation or other benefit provided to a Participant pursuant to the Plan in connection with his
or her employment termination constitutes &#8220;nonqualified deferred compensation&#8221; within the meaning of Section&nbsp;409A of
the Code and (ii)&nbsp;the Participant is a specified employee as defined in Section&nbsp;409A(a)(2)(B)(i)&nbsp;of the Code, in each case
as determined by the Company in accordance with its procedures, by which determinations the Participant (through accepting the Award)
agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six
months plus one day after the date of &#8220;separation from service&#8221; (as determined under Section&nbsp;409A of the Code) (the &#8220;<B><I>New
Payment Date</I></B>&#8221;), except as Section&nbsp;409A of the Code may then permit. The aggregate of any payments that otherwise would
have been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid
to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company makes no representations or warranty and shall have no
liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under the Plan are determined
to constitute nonqualified deferred compensation subject to Section&nbsp;409A of the Code but do not to satisfy the conditions of that
section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitations
on Liability</U>. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, employee, or agent of
the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability,
or expense incurred in connection with the Plan, nor will such individual be personally liable with respect to the Plan because of any
contract or other instrument he or she executes in his or her capacity as a director, officer, employee, or agent of the Company. The
Company will indemnify and hold harmless each director, officer, employee, or agent of the Company to whom any duty or power relating
to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys&#8217;
fees) or liability (including any sum paid in settlement of a claim with the Board&#8217;s approval) arising out of any act or omission
to act concerning the Plan unless arising out of such person&#8217;s own fraud or bad faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of
the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a
jurisdiction other than the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>14
<FILENAME>tm238578d1_ex10-14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.14</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Carisma Therapeutics Inc.<BR>
<U>STOCK OPTION AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma Therapeutics Inc. (the &#8220;<U>Company</U>&#8221;)
hereby grants the following stock option pursuant to its Amended and Restated 2014 Stock Incentive Plan. The terms and conditions attached
hereto are also a part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Notice of Grant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of optionee (the &#8220;<U>Participant</U>&#8221;):</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 50%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    Date:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
    Stock Option or Nonstatutory Stock Option:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of shares of the Company&#8217;s Common Stock subject to this option (&#8220;<U>Shares</U>&#8221;):</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    exercise price per Share:<SUP> 1</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting
    Start Date:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final
Exercise Date: <SUP>2</SUP></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vesting Schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Vesting
    Date</U></FONT><FONT STYLE="font-size: 10pt">:</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 50%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Number
    of Options that Vest</U></FONT><FONT STYLE="font-size: 10pt">:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This option satisfies in full all commitments
that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Carisma Therapeutics Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Participant</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Street Address</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">City/State/Zip Code</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This must be at least 100% of the Grant Date Fair Market Value (as defined in
the Plan) of the Common Stock on the date of grant (110% in the case of a Participant that owns more than 10% of the total combined voting
power of all classes of stock of the Company or its parent or subsidiary (a &#8220;10% Shareholder&#8221;)) for the option to qualify
as an incentive stock option (an &#8220;ISO&#8221;) under Section 422 of the Internal Revenue Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Final Exercise Date must be no more than 10 years (5 years in the case of a 10% Shareholder) from the date of grant for the option to
qualify as an ISO. The correct approach to calculate the final exercise date is to use the day immediately prior to the date ten years
out from the date of the stock option award grant (5 years in the case of a 10% stockholder).</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Stock Option Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Incorporated Terms and Conditions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Grant
of Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This agreement evidences the grant by the Company,
on the grant date (the &#8220;<U>Grant Date</U>&#8221;) set forth in the Notice of Grant that forms part of this agreement (the &#8220;<U>Notice
of Grant</U>&#8221;), to the Participant of an option to purchase, in whole or in part, on the terms provided herein and in the Company&#8217;s
Amended and Restated 2014 Stock Incentive Plan (the &#8220;<U>Plan</U>&#8221;), the number of Shares set forth in the Notice of Grant
of common stock, $0.001 par value per share, of the Company (&#8220;<U>Common Stock</U>&#8221;), at the exercise price per Share set
forth in the Notice of Grant. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on the Final Exercise Date
set forth in the Notice of Grant (the &#8220;<U>Final Exercise Date</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The option evidenced by this agreement is
intended to be an incentive stock option as defined in Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, and any
regulations promulgated thereunder (the &#8220;<U>Code</U>&#8221;) to the maximum extent permitted by law, solely to the extent
designated as an incentive stock option in the Notice of Grant. To the extent not designated as an incentive stock option, or to the
extent that the option does not qualify as an incentive stock option, the option shall be a nonstatutory stock option. Except as
otherwise indicated by the context, the term &#8220;<U>Participant</U>&#8221;, as used in this option, shall be deemed to include
any person who acquires the right to exercise this option validly under its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Vesting
Schedule</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This option will become exercisable (&#8220;<U>vest</U>&#8221;)
in accordance with the vesting schedule set forth in the Notice of Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The right of exercise shall be cumulative so that
to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole
or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this
option under Section&nbsp;3 hereof or the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Form&nbsp;of
Exercise</U>. Each election to exercise this option shall be in writing, in the form of the Stock Option Exercise Notice attached as
<U>Annex A</U>, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, or in
such other form (which may be electronic) as is approved by the Company, together with payment in full in the manner provided in the
Plan. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may
be for any fractional share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Continuous
Relationship with the Company Required</U>. Except as otherwise provided in this Section&nbsp;3, this option may not be exercised unless
the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, director
or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors
of which are eligible to receive option grants under the Plan (an &#8220;<U>Eligible Participant</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination
of Relationship with the Company</U>. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided
in paragraphs&nbsp;(d)&nbsp;and (e)&nbsp;below, the right to exercise this option shall terminate three months after such cessation (but
in no event after the Final Exercise Date), <U>provided that</U> this option shall be exercisable only to the extent that the Participant
was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final
Exercise Date, violates the restrictive covenants (including, without limitation, the non-competition, non-solicitation, or confidentiality
provisions) of any employment contract, any non-competition, non-solicitation, confidentiality or assignment agreement to which the Participant
is a party, or any other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately
upon such violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Period Upon Death or Disability</U>. If the Participant dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3)&nbsp;of
the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship
for &#8220;cause&#8221; as specified in paragraph (e)&nbsp;below, this option shall be exercisable, within the period of one year following
the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), <U>provided
that</U> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or
her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination
for Cause</U>. If, prior to the Final Exercise Date, the Participant&#8217;s employment or other relationship with the Company is terminated
by the Company for Cause (as defined in below), the right to exercise this option shall terminate immediately upon the effective date
of such termination of employment or other service relationship. If, prior to the Final Exercise Date, the Participant is given notice
by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of
such employment or other termination is subsequent to the date of delivery of such notice, the right to exercise this option shall be
suspended from the time of the delivery of such notice until the earlier of (i)&nbsp;such time as it is determined or otherwise agreed
that the Participant&#8217;s employment or other relationship shall not be terminated for Cause as provided in such notice or (ii)&nbsp;the
effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant
to the preceding sentence, terminate immediately upon the effective date of such termination of employment or other relationship). If
the Participant is subject to an individual employment or consulting agreement with the Company or eligible to participate in a Company
severance plan or arrangement, in any case which agreement, plan or arrangement contains a definition of &#8220;cause&#8221; for termination
of employment or other relationship, &#8220;Cause&#8221; shall have the meaning ascribed to such term in such agreement, plan or arrangement.
Otherwise, &#8220;Cause&#8221; shall mean willful misconduct by the Participant or willful failure by the Participant to perform his
or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment,
consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), as determined
by the Company, which determination shall be conclusive. The Participant&#8217;s employment or other relationship shall be considered
to have been terminated for Cause if the Company determines, within 30 days after the Participant&#8217;s resignation, that termination
for Cause was warranted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Tax
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Withholding</U>.
No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision
satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of
this option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Disqualifying
Disposition</U>. If this option is an incentive stock option and the Participant disposes of Shares acquired upon exercise of this option
within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this option, the Participant
shall notify the Company in writing of such disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
Restrictions; Clawback.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
option may not be sold, assigned, transferred, pledged, encumbered or otherwise disposed of by the Participant, either voluntarily or
by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option
shall be exercisable only by the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
accepting this option, the Participant agrees to be bound by any clawback policy that the Company has in place or may adopt in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Provisions
of the Plan</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This option is subject to the provisions of the
Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>ANNEX A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carisma Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Stock Option Exercise Notice</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3675 Market Street, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philadelphia, PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sir or Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">(the
 &#8220;<U>Participant</U>&#8221;), hereby irrevocably exercise the right to purchase</FONT>&nbsp;<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">shares
of the Common Stock, $0.001 par value per share (the &#8220;<U>Shares</U>&#8221;), of Carisma Therapeutics Inc. (the &#8220;<U>Company</U>&#8221;)
at $</FONT><U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">per share pursuant to the Company&#8217;s Amended and
Restated 2014 Stock Incentive Plan and a stock option agreement with the Company dated</FONT>&nbsp;<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">(the
 &#8220;<U>Option Agreement</U>&#8221;). Enclosed herewith is a payment of $</FONT><U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">,
the aggregate purchase price for the Shares. The certificate for the Shares should be registered in my name as it appears below or, if
so indicated below, jointly in my name and the name of the person designated below, with right of survivorship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 4%">Dated:</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 46%">&nbsp;</TD>
<TD STYLE="width: 49%">&nbsp;</TD>
<TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="text-align: justify">Signature</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="text-align: justify">Print Name:</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="text-align: justify">Address:</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="4" STYLE="text-align: justify">Name and address of persons in whose name the Shares are to be jointly registered (if applicable):</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>15
<FILENAME>tm238578d1_ex10-15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Restricted
Stock Unit Agreement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Granted under the Amended and Restated 2014 Stock
Incentive Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma Therapeutics Inc. (the &#8220;<U>Company</U>&#8221;)
hereby grants the following restricted stock units pursuant to its Amended and Restated 2014 Stock Incentive Plan. The terms and conditions
attached hereto are also a part hereof and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Notice of Grant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of recipient (the &#8220;<U>Participant</U>&#8221;):</FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant Date:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of restricted stock units (&#8220;<U>RSUs</U>&#8221;) granted:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting Start Date:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vesting Schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Vesting Date:</U></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Number of RSUs that Vest:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This grant of RSUs satisfies in full all commitments
that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carisma Therapeutics Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Participant</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Street Address</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">City/State/Zip Code</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock </FONT>Unit Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Incorporated Terms and Conditions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For valuable consideration, receipt of which is
acknowledged, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Award
of Restricted Stock Units</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In consideration of services rendered and to be
rendered to the Company by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth
in this Restricted Stock Unit Agreement (this &#8220;<U>Agreement</U>&#8221;) and in the Company&#8217;s Amended and Restated 2014 Stock
Incentive Plan (the &#8220;<U>Plan</U>&#8221;), an award with respect to the number of restricted stock units (the &#8220;<U>RSUs</U>&#8221;)
set forth in the Notice of Grant that forms part of this Agreement (the &#8220;<U>Notice of Grant</U>&#8221;). Each RSU represents the
right to receive one share of common stock, $0.001 par value per share, of the Company (the &#8220;<U>Common Stock</U>&#8221;) upon vesting
of the RSU, subject to the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vesting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The RSUs shall vest in accordance with the Vesting
Schedule set forth in the Notice of Grant (the &#8220;<U>Vesting Schedule</U>&#8221;). Any fractional shares resulting from the application
of any percentages used in the Vesting Schedule shall be rounded down to the nearest whole number of RSUs. Upon the vesting of the RSU,
the Company will deliver to the Participant (or the Participant&#8217;s Designated Beneficiary, if applicable), for each RSU that becomes
vested, one share of Common Stock, subject to the payment of any taxes pursuant to Section&nbsp;7. The Common Stock will be delivered
to the Participant (or the Participant&#8217;s Designated Beneficiary, if applicable) as soon as practicable following each vesting date,
but in any event within 30 days of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Forfeiture
of Unvested RSUs Upon Cessation of Service</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event that the Participant ceases to be
an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors,
consultants, or advisors of which are eligible to receive awards under the Plan (an &#8220;<U>Eligible Participant</U>&#8221;) for any
reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately
and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation. The Participant
shall have no further rights with respect to the unvested RSUs or any Common Stock that may have been issuable with respect thereto. If
the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company
shall instead be deemed to refer to service with such subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Restrictions
on Transfer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Participant shall not sell, assign, transfer,
pledge, hypothecate, encumber or otherwise dispose of, by operation of law or otherwise (collectively &#8220;transfer&#8221;) any RSUs,
or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Common Stock to any transferee
to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Rights
as a Stockholder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Participant shall have no rights as a stockholder
of the Company with respect to any shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the shares
of Common Stock to the Participant following the vesting of the RSUs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Provisions
of the Plan</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Agreement is subject to the provisions of
the Plan, a copy of which is furnished to the Participant with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Tax
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Acknowledgments;
No Section&nbsp;83(b)&nbsp;Election</U>. The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant&#8217;s
own tax advisors with respect to the award of RSUs and the Participant is relying solely on such advisors and not on any statements or
representations of the Company or any of its agents with respect to the tax consequences relating to the RSUs. The Participant understands
that the Participant (and not the Company) shall be responsible for the Participant&#8217;s tax liability that may arise in connection
with the acquisition, vesting and/or disposition of the RSUs. The Participant acknowledges that no election under Section&nbsp;83(b)&nbsp;of
the Internal Revenue Code of 1986, as amended (the &#8220;<U>Code</U>&#8221;), is available with respect to RSUs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Withholding</U>.
The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant
any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting of the RSUs. To the extent
the Participant has not previously executed and delivered to the Company effective durable sell-to-cover instructions that by their terms
would cover any taxes required by law to be withheld with respect to the vesting of the RSUs, at such time as the Participant is not aware
of any material nonpublic information about the Company or the Common Stock and is not prohibited from doing so by the Company&#8217;s
insider trading policy or otherwise, the Participant shall execute the instructions set forth in <U>Schedule A</U> attached hereto (the
 &#8220;<U>Durable Automatic Sell-to-Cover Instruction</U>&#8221;) as the means of satisfying such tax obligation. If the Participant is
required to but does not execute the Durable Automatic Sell-to-Cover Instruction prior to an applicable vesting date, then the Participant
agrees that if under applicable law the Participant will owe taxes at such vesting date on the portion of the award then vested the Company
shall be entitled to immediate payment from the Participant of the amount of any tax required to be withheld by the Company. The Company
shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Right to Continued Service</U>. The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the RSUs is
contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued
service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with
the Company or any affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Section&nbsp;409A</U>.
The RSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section&nbsp;409A of the
Code and the Treasury Regulations issued thereunder (&#8220;<U>Section&nbsp;409A</U>&#8221;). The delivery of shares of Common Stock on
the vesting of the RSUs may not be accelerated or deferred unless permitted or required by Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Participant&#8217;s
Acknowledgments</U>. The Participant acknowledges that he or she: (i)&nbsp;has read this Agreement; (ii)&nbsp;has been represented in
the preparation, negotiation and execution of this Agreement by legal counsel of the Participant&#8217;s own choice or has voluntarily
declined to seek such counsel; (iii)&nbsp;understands the terms and consequences of this Agreement; (iv)&nbsp;is agreeing, in accepting
this award, to be bound by any clawback policy that the Company has in place or may adopt in the future; and (iv)&nbsp;is fully aware
of the legal and binding effect of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing
Law</U>. This Agreement shall be construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without
regard to any applicable conflicts of laws provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DURABLE AUTOMATIC SELL-TO-COVER INSTRUCTION<SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Durable Automatic Sell-to-Cover
Instruction (this &#8220;<U>Instruction</U>&#8221;), which is being delivered to Carisma Therapeutics Inc. (the &#8220;<U>Company</U>&#8221;)
by the undersigned on the date set forth below (the &#8220;<U>Adoption Date</U>&#8221;), relates to the Covered RSUs (as defined following
my signature below). This Instruction provides for &#8220;eligible sell-to-cover transactions&#8221; (as described in Rule&nbsp;10b5-1(c)(1)(ii)(D)(3)&nbsp;under
the Securities Exchange Act of 1934 (the &#8220;<U>Exchange Act</U>&#8221;)) and is intended to satisfy the affirmative defense conditions
of Rule&nbsp;10b5-1(c)(1)&nbsp;under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
acknowledge that upon vesting and settlement of any Covered RSUs in accordance with the applicable RSU&#8217;s terms, whether vesting
is based on the passage of time or the achievement of performance goals,&nbsp;I will have compensation income </FONT>equal to the fair
market value of the shares of the Company&#8217;s common stock subject to the RSUs that are settled on such settlement date and that the
Company is required to withhold income and employment taxes in respect of that compensation income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
desire to </FONT>establish a plan and process to satisfy such withholding obligation in respect of all Covered RSUs through an automatic
sale of the number of the shares of the Company&#8217;s common stock that would otherwise be issuable to me on each applicable settlement
date in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company
in satisfaction of the applicable withholding obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
understand that the Company has arranged for the administration and execution of its equity incentive programs </FONT>and the sale of
securities by participants thereunder pursuant to a platform administered by a third party (the &#8220;<U>Administrator</U>&#8221;) and
the Administrator&#8217;s designated brokerage partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Upon the settlement of any of
my Covered RSUs after the 30<SUP>th</SUP> day following the Adoption Date (or if I am an officer of the Company on the Adoption Date,
after the [120<SUP>th</SUP> day following the Adoption Date]) (the &#8220;<U>Cooling-Off Period</U>&#8221;),&nbsp;I hereby appoint the
Administrator (or any successor administrator) to automatically sell such number of shares of the Company&#8217;s common stock issuable
with respect to such RSUs that vested and settled as is sufficient to generate net proceeds sufficient to satisfy the Company&#8217;s
minimum<SUP></SUP> statutory withholding obligations with respect to the income recognized by me in connection with the vesting and
settlement of such RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes,
that are applicable to such income), and the Company shall receive such net proceeds in satisfaction of such tax withholding obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">I hereby appoint the [President
and Chief Executive Officer and Secretary of the Company], and any of them acting alone and with full power of substitution, to serve
as my attorneys-in-fact to arrange for the sale of shares of the Company&#8217;s common stock in accordance with this Instruction. I agree
to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the shares
of common stock pursuant to this Instruction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Unless the third and final
box in the definition of Covered RSUs below is checked, if I have previously adopted an automatic sale or sell-to-cover instruction relating
to Covered RSUs, this Instruction shall be void <I>ab initio</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>I hereby certify that,
as of the Adoption Date:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(i)&nbsp; I am not prohibited
from entering into this Instruction by the Company&#8217;s insider trading policy or otherwise;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(ii)&nbsp;I am not aware
of any material nonpublic information about the Company or its common stock; and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(iii)&nbsp;I am adopting
this Instruction in good faith and not as part of a plan or scheme to evade the prohibitions of Rule&nbsp;10b-5 under the Exchange Act.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="border-top: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 42%; text-align: left"></TD>
    <TD STYLE="width: 8%">&nbsp;</TD><TD STYLE="text-align: justify; width: 8%">Print Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%">&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Covered RSUs:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following restricted stock units (&#8220;RSUs&#8221;)
are covered by this Instruction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check all applicable boxes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
The first award of RSUs granted to me on or after ______________ [<I>insert date of grant of current RSUs the grant of which is
triggering the execution of this Instruction; if instruction is being executed in advance of a grant of RSUs, insert the Adoption
Date</I>] and any RSUs that may, from time to time following such date, be granted to me by the Company, other than any future
granted RSUs which by the terms of the applicable award agreement require the Company to withhold shares for tax withholding
obligations in connection with the vesting and settlement of such RSUs, and therefore do not permit sell-to-cover transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Any outstanding RSUs that were granted to me by the Company prior to the Adoption Date that (1)&nbsp;are <U>not</U> subject to any
prior automatic sale or sell-to-cover instruction and (2)&nbsp;for which the next vesting date is after the Cooling-Off Period,
other than any previously granted RSUs which by the terms of the applicable award agreement require the Company to withhold shares
for tax withholding obligations in connection with the vesting and settlement of such RSUs, and therefore do not permit
sell-to-cover transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
With respect to any RSUs, whether or not granted to me by the Company prior to the Adoption Date, that already are subject to an
automatic sale or sell-to-cover instruction (a &#8220;Prior Instruction&#8221;),&nbsp;I elect to have such sales effected pursuant
to this Instruction and confirm that doing so does not modify or change the amount, price, or timing of such sales from those
provided by the Prior Instruction (and, as a result the Cooling-Off Period is not applicable to sales pursuant to this Instruction
that were previously subject to the Prior Instruction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>16
<FILENAME>tm238578d1_ex10-16.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.16</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>CARISMA THERAPEUTICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE
PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The purpose of this Amended and Restated 2014 Employee
Stock Purchase Plan (this &#8220;Plan&#8221;) is to provide eligible employees of Carisma Therapeutics Inc. (formerly known as Sesen Bio,&nbsp;Inc.)
(the &#8220;Company&#8221;) and certain of its subsidiaries with opportunities to purchase shares of the Company&#8217;s common stock,
$0.001 par value (the &#8220;Common Stock&#8221;), commencing at such time as the Board of Directors of the Company (the &#8220;Board&#8221;)
shall determine. Subject to adjustment under Section&nbsp;15 hereof, the number of shares of Common Stock that have been approved for
this purpose is 328,432 shares of Common Stock. The Plan amends and restates the 2014 Employee Stock Purchase Plan (the &#8220;Original
Plan&#8221;) that was originally adopted by the Board on December&nbsp;19, 2013 and approved by the Company&#8217;s stockholders on January&nbsp;14,
2014, was amended by the Board on March&nbsp;12, 2021 and approved by the Company&#8217;s stockholders on May&nbsp;3, 2021, and was amended
by the Board on November&nbsp;17, 2022 and approved by the Company&#8217;s stockholders on March&nbsp;2, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Plan is intended to qualify as an &#8220;employee
stock purchase plan&#8221; as defined in Section&nbsp;423 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and
the regulations issued thereunder, and shall be interpreted consistent therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Administration</U>.
The Plan will be administered by the Board or by a Committee appointed by the Board (the &#8220;Committee&#8221;). The Board or the Committee
has authority to make rules&nbsp;and regulations for the administration of the Plan and its interpretation and decisions with regard thereto
shall be final and conclusive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Eligibility</U>.
All employees of the Company and all employees of any subsidiary of the Company (as defined in Section&nbsp;424(f)&nbsp;of the Code) designated
by the Board or the Committee from time to time (a &#8220;Designated Subsidiary&#8221;), are eligible to participate in any one or more
of the offerings of Options (as defined in Section&nbsp;9) to purchase Common Stock under the Plan provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">they
are customarily employed by the Company or a Designated Subsidiary for more than 20 hours a week and for more than five months in a calendar
year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">they
have been employed by the Company or a Designated Subsidiary for at least six (6)&nbsp;months prior to enrolling in the Plan; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">they
are employees of the Company or a Designated Subsidiary on the first day of the applicable Plan Period (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No employee may be granted an Option hereunder
if such employee, immediately after the Option is granted, owns 5% or more of the total combined voting power or value of the stock of
the Company or any subsidiary. For purposes of the preceding sentence, the attribution rules&nbsp;of Section&nbsp;424(d)&nbsp;of the Code
shall apply in determining the stock ownership of an employee, and all stock that the employee has a contractual right to purchase shall
be treated as stock owned by the employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company retains the discretion to determine
which eligible employees may participate in an offering pursuant to and consistent with Treasury Regulation Sections 1.423-2(e)&nbsp;and
(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Offerings</U>.
The Company will make one or more offerings (&#8220;Offerings&#8221;) to employees to purchase stock under this Plan. Offerings will begin
at such time as the Board shall determine. Each Offering will consist of a six-month period (a &#8220;Plan Period&#8221;) during which
payroll deductions will be made and held for the purchase of Common Stock at the end of the Plan Period. The Board or the Committee may,
at its discretion, choose a different Plan Period of not more than twelve (12) months for Offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Participation</U>.
An employee eligible on the first day of a Plan Period of any Offering may participate in such Offering by completing and forwarding either
a written or electronic payroll deduction authorization form to the employee&#8217;s appropriate payroll office at least 15 days prior
to the commencement of the applicable Plan Period. The form will authorize a regular payroll deduction from the Compensation received
by the employee during the Plan Period. Unless an employee files a new form or withdraws from the Plan, his or her deductions and purchases
will continue at the same rate for future Offerings under the Plan as long as the Plan remains in effect. The term &#8220;Compensation&#8221;
means the amount of money reportable on the employee&#8217;s Federal Income Tax Withholding Statement, excluding overtime, shift premium,
incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances for travel expenses, income or gains
associated with the grant or vesting of restricted stock, income or gains on the exercise of Company stock options or stock appreciation
rights, and similar items, whether or not shown or separately identified on the employee&#8217;s Federal Income Tax Withholding Statement,
but including, in the case of salespersons, sales commissions to the extent determined by the Board or the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Deductions</U>.
The Company will maintain payroll deduction accounts for all participating employees. With respect to any Offering made under this Plan,
an employee may authorize a payroll deduction in any percentage amount (in whole percentages) up to a maximum of 15% of the Compensation
he or she receives during the Plan Period or such shorter period during which deductions from payroll are made. The Board or the Committee
may, at its discretion, designate a lower maximum contribution rate. The minimum payroll deduction is such percentage of Compensation
as may be established from time to time by the Board or the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Deduction
Changes</U>. An employee may decrease or discontinue his or her payroll deduction once during any Plan Period, by filing either a written
or electronic new payroll deduction authorization form. However, an employee may not increase his or her payroll deduction during a Plan
Period. If an employee elects to discontinue his or her payroll deductions during a Plan Period, but does not elect to withdraw his or
her funds pursuant to Section&nbsp;8 hereof, funds deducted prior to his or her election to discontinue will be applied to the purchase
of Common Stock on the Exercise Date (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Interest</U>.
Interest will not be paid on any employee accounts, except to the extent that the Board or the Committee, in its sole discretion, elects
to credit employee accounts with interest at such rate as it may from time to time determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Withdrawal
of Funds</U>. An employee may at any time prior to the close of business on the fifteenth business day prior to the end of a Plan Period
and for any reason permanently draw out the balance accumulated in the employee&#8217;s account and thereby withdraw from participation
in an Offering. Partial withdrawals are not permitted. The employee may not begin participation again during the remainder of the Plan
Period during which the employee withdrew his or her balance. The employee may participate in any subsequent Offering in accordance with
terms and conditions established by the Board or the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Purchase
of Shares.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Number
of Shares</U>. On the first day of each Plan Period, the Company will grant to each eligible employee who is then a participant in the
Plan an option (an &#8220;Option&#8221;) to purchase on the last business day of such Plan Period (the &#8220;Exercise Date&#8221;) at
the applicable purchase price (the &#8220;Option Price&#8221;) up to that number of shares of Common Stock determined by multiplying $2,083
by the number of full months in the Plan Period and dividing the result by the closing price (as determined below) on the first day of
such Plan Period; provided, however, that no employee may be granted an Option which permits his or her rights to purchase Common Stock
under this Plan and any other employee stock purchase plan (as defined in Section&nbsp;423(b)&nbsp;of the Code) of the Company and its
subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such Common Stock (determined at the date such Option
is granted) for each calendar year in which the Option is outstanding at any time; and, provided, further, however, that the Committee
may, in its discretion, set a fixed maximum number of shares of Common Stock that each eligible employee may purchase per Plan Period
which number may not be greater than the number of shares of Common Stock determined by using the formula in the first clause of this
Section&nbsp;9(a)&nbsp;and which number shall be subject to the second clause of this Section&nbsp;9(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Option
Price</U>. The Board or the Committee shall determine the Option Price for each Plan Period, including whether such Option Price shall
be determined based on the lesser of the closing price of the Common Stock on (i)&nbsp;the first business day of the Plan Period or (ii)&nbsp;the
Exercise Date, or shall be based solely on the closing price of the Common Stock on the Exercise Date; provided, however, that such Option
Price shall be at least 85% of the applicable closing price. In the absence of a determination by the Board or the Committee, the Option
Price will be 85% of the lesser of the closing price of the Common Stock on (i)&nbsp;the first business day of the Plan Period or (ii)&nbsp;the
Exercise Date. The closing price shall be (a)&nbsp;the closing price (for the primary trading session) on any national securities exchange
on which the Common Stock is listed or (b)&nbsp;the average of the closing bid and asked prices in the over-the-counter-market, whichever
is applicable, as published in The Wall Street Journal or another source selected by the Board or the Committee. If no sales of Common
Stock were made on such a day, the price of the Common Stock shall be the reported price for the next preceding day on which sales were
made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Option</U>. Each employee who continues to be a participant in the Plan on the Exercise Date shall be deemed to have exercised his
Option at the Option Price on such date and shall be deemed to have purchased from the Company the number of whole shares of Common Stock
reserved for the purpose of the Plan that his accumulated payroll deductions on such date will pay for, but not in excess of the maximum
numbers determined in the manner set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Return
of Unused Payroll Deductions</U>. Any balance remaining in an employee&#8217;s payroll deduction account at the end of a Plan Period will
be automatically refunded to the employee, except that any balance that is less than the purchase price of one share of Common Stock will
be carried forward into the employee&#8217;s payroll deduction account for the following Offering, unless the employee elects not to participate
in the following Offering under the Plan, in which case the balance in the employee&#8217;s account shall be refunded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Issuance
of Certificates</U>. Certificates representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee,
in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or (in the Company&#8217;s sole
discretion) in the name of a brokerage firm, bank, or other nominee holder designated by the employee. The Company may, in its sole discretion
and in compliance with applicable laws, authorize the use of book entry registration of shares in lieu of issuing stock certificates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rights
on Retirement, Death or Termination of Employment</U>. If a participating employee&#8217;s employment ends before the last business day
of a Plan Period, no payroll deduction shall be taken from any pay then due and owing to the employee and the balance in the employee&#8217;s
account shall be paid to the employee. In the event of the employee&#8217;s death before the last business day of a Plan Period, the Company
shall, upon notification of such death, pay the balance of the employee&#8217;s account (a)&nbsp;to the executor or administrator of the
employee&#8217;s estate or (b)&nbsp;if no such executor or administrator has been appointed to the knowledge of the Company, to such other
person(s)&nbsp;as the Company may, in its discretion, designate. If, before the last business day of the Plan Period, the Designated Subsidiary
by which an employee is employed ceases to be a subsidiary of the Company, or if the employee is transferred to a subsidiary of the Company
that is not a Designated Subsidiary, the employee shall be deemed to have terminated employment for the purposes of this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Optionees
Not Stockholders</U>. Neither the granting of an Option to an employee nor the deductions from his or her pay shall make such employee
a stockholder of the shares of Common Stock covered by an Option under this Plan until he or she has purchased and received such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Options
Not Transferable</U>. Options under this Plan are not transferable by a participating employee other than by will or the laws of descent
and distribution, and are exercisable during the employee&#8217;s lifetime only by the employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Application
of Funds</U>. All funds received or held by the Company under this Plan may be combined with other corporate funds and may be used for
any corporate purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustment
for Changes in Common Stock and Certain Other Events.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Changes
in Capitalization</U>. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares,
reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of
Common Stock other than an ordinary cash dividend, (i)&nbsp;the number and class of securities available under this Plan, (ii)&nbsp;the
share limitations set forth in Section&nbsp;9, and (iii)&nbsp;the Option Price shall be equitably adjusted to the extent determined by
the Board or the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reorganization
Events</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definition</U>.
A &#8220;Reorganization Event&#8221; shall mean: (a)&nbsp;any merger or consolidation of the Company with or into another entity as a
result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other
property or is cancelled, (b)&nbsp;any transfer or disposition of all of the Common Stock of the Company for cash, securities or other
property pursuant to a share exchange or other transaction or (c)&nbsp;any liquidation or dissolution of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Consequences
of a Reorganization Event on Options</U>. In connection with a Reorganization Event, the Board or the Committee may take any one or
more of the following actions as to outstanding Options on such terms as the Board or the Committee determines: (i)&nbsp;provide
that Options shall be assumed, or substantially equivalent Options shall be substituted, by the acquiring or succeeding corporation
(or an affiliate thereof), (ii)&nbsp;upon written notice to employees, provide that all outstanding Options will be terminated
immediately prior to the consummation of such Reorganization Event and that all such outstanding Options will become exercisable to
the extent of accumulated payroll deductions as of a date specified by the Board or the Committee in such notice, which date shall
not be less than 10 days preceding the effective date of the Reorganization Event, (iii)&nbsp;upon written notice to employees,
provide that all outstanding Options will be cancelled as of a date prior to the effective date of the Reorganization Event and that
all accumulated payroll deductions will be returned to participating employees on such date, (iv)&nbsp;in the event of a
Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each
share surrendered in the Reorganization Event (the &#8220;Acquisition Price&#8221;), change the last day of the Plan Period to be
the date of the consummation of the Reorganization Event and make or provide for a cash payment to each employee equal to
(A)&nbsp;(1)&nbsp;the Acquisition Price times (2)&nbsp;the number of shares of Common Stock that the employee&#8217;s accumulated
payroll deductions as of immediately prior to the Reorganization Event could purchase at the Option Price, where the Acquisition
Price is treated as the fair market value of the Common Stock on the last day of the applicable Plan Period for purposes of
determining the Option Price under Section&nbsp;9(b)&nbsp;hereof, and where the number of shares that could be purchased is subject
to the limitations set forth in Section&nbsp;9(a), minus (B)&nbsp;the result of multiplying such number of shares by such Option
Price, (v)&nbsp;provide that, in connection with a liquidation or dissolution of the Company, Options shall convert into the right
to receive liquidation proceeds (net of the Option Price thereof) and (vi)&nbsp;any combination of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">For purposes of clause (i)&nbsp;above, an Option
shall be considered assumed if, following consummation of the Reorganization Event, the Option confers the right to purchase, for each
share of Common Stock subject to the Option immediately prior to the consummation of the Reorganization Event, the consideration (whether
cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common
Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the
type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration
received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate
thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon
the exercise of Options to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate
thereof) that the Board determines to be equivalent in value (as of the date of such determination or another date specified by the Board)
to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment
of the Plan</U>. The Board may at any time, and from time to time, amend or suspend this Plan or any portion thereof, except that (a)&nbsp;if
the approval of any such amendment by the shareholders of the Company is required by Section&nbsp;423 of the Code, such amendment shall
not be effected without such approval, and (b)&nbsp;in no event may any amendment be made that would cause the Plan to fail to comply
with Section&nbsp;423 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Insufficient
Shares</U>. If the total number of shares of Common Stock specified in elections to be purchased under any Offering plus the number of
shares purchased under previous Offerings under this Plan exceeds the maximum number of shares issuable under this Plan, the Board or
the Committee will allot the shares then available on a pro-rata basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination
of the Plan</U>. This Plan may be terminated at any time by the Board. Upon termination of this Plan all amounts in the accounts of participating
employees shall be promptly refunded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governmental
Regulations</U>. The Company&#8217;s obligation to sell and deliver Common Stock under this Plan is subject to listing on a national stock
exchange (to the extent the Common Stock is then so listed or quoted) and the approval of all governmental authorities required in connection
with the authorization, issuance or sale of such stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. The Plan shall be governed by Delaware law except to the extent that such law is preempted by federal law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Issuance
of Shares</U>. Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury
of the Company, or from any other proper source.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notification
upon Sale of Shares</U>. Each employee agrees, by entering the Plan, to promptly give the Company notice of any disposition of shares
purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares
were purchased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Grants
to Employees in Foreign Jurisdictions</U>. The Company may, to comply with the laws of a foreign jurisdiction, grant Options to
employees of the Company or a Designated Subsidiary who are citizens or residents of such foreign jurisdiction (without regard to
whether they are also citizens of the United States or resident aliens (within the meaning of Section&nbsp;7701(b)(1)(A)&nbsp;of the
Code)) with terms that are less favorable (but not more favorable) than the terms of Options granted under the Plan to employees of
the Company or a Designated Subsidiary who are resident in the United States. Notwithstanding the preceding provisions of this Plan,
employees of the Company or a Designated Subsidiary who are citizens or residents of a foreign jurisdiction (without regard to
whether they are also citizens of the United States or resident aliens (within the meaning of Section&nbsp;7701(b)(1)(A)&nbsp;of the
Code)) may be excluded from eligibility under the Plan if (a)&nbsp;the grant of an Option under the Plan to a citizen or resident of
the foreign jurisdiction is prohibited under the laws of such jurisdiction or (b)&nbsp;compliance with the laws of the foreign
jurisdiction would cause the Plan to violate the requirements of Section&nbsp;423 of the Code. The Company may add one or more
appendices to this Plan describing the operation of the Plan in those foreign jurisdictions in which employees are excluded from
participation or granted less favorable Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorization
of Sub-Plans</U>. The Board may from time to time establish one or more sub-plans under the Plan with respect to one or more Designated
Subsidiaries, provided that such sub-plan complies with Section&nbsp;423 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Withholding</U>.
If applicable tax laws impose a tax withholding obligation, each affected employee shall, no later than the date of the event creating
the tax liability, make provision satisfactory to the Board for payment of any taxes required by law to be withheld in connection with
any transaction related to Options granted to or shares acquired by such employee pursuant to the Plan. The Company may, to the extent
permitted by law, deduct any such taxes from any payment of any kind otherwise due to an employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Effective
Date and Approval of Shareholders</U>. The Original Plan took effect on December&nbsp;19, 2013 subject to approval by the shareholders
of the Company as required by Section&nbsp;423 of the Code, which approval occurred on January&nbsp;14, 2014. The first amendment to
the Original Plan took effect on May&nbsp;3, 2021. The second amendment to the Original Plan took effect as of the effective time of
the merger contemplated by the Agreement and Plan of Merger and Reorganization, dated as of September&nbsp;20, 2022, by and between the
Company, Seahawk Merger Sub Inc. and Carisma Therapeutics Inc.</FONT>&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>17
<FILENAME>tm238578d1_ex14-1.htm
<DESCRIPTION>EXHIBIT 14.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 14.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARISMA THERAPEUTICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CODE OF BUSINESS CONDUCT AND ETHICS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Code of Business Conduct and Ethics (the &ldquo;Code&rdquo;)
sets forth legal and ethical standards of conduct for employees, officers and directors of Carisma Therapeutics Inc. (the &ldquo;Company&rdquo;).
This Code is intended to deter wrongdoing and to promote the conduct of all Company business in accordance with high standards of integrity
and in compliance with all applicable laws and regulations. Except as otherwise required by applicable local law, this Code applies to
the Company and all of its subsidiaries and other business entities controlled by it worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you have any questions regarding this Code or
its application to you in any situation, you should contact your supervisor or the Company&rsquo;s General Counsel or the Principal Financial
Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Compliance with Laws, Rules and Regulations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company requires that all employees, officers
and directors comply with all laws, rules and regulations applicable to the Company wherever it does business. You are expected to use
good judgment and common sense in seeking to comply with all applicable laws, rules and regulations and to ask for advice when you are
uncertain about them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you become aware of the violation of any law,
rule or regulation by the Company, whether by its employees, officers, directors, or any third party doing business on behalf of the Company,
it is your responsibility to promptly report the matter to your supervisor or to the General Counsel or the Principal Financial Officer.
While it is the Company&rsquo;s desire to address matters internally, nothing in this Code prohibits you from reporting any illegal activity,
including any violation of the securities laws, antitrust laws, environmental laws or any other federal, state or foreign law, rule or
regulation, to the appropriate regulatory authority. Employees, officers and directors shall not discharge, demote, suspend, threaten,
harass or in any other manner discriminate or retaliate against an employee because he or she reports any such violation. However, if
the report was made with knowledge that it was false, the Company may take appropriate disciplinary action up to and including termination.
This Code should not be construed to prohibit you from engaging in concerted activity protected by the rules and regulations of the National
Labor Relations Board or from testifying, participating or otherwise assisting in any state or federal administrative, judicial or legislative
proceeding or investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Compliance with Company Policies</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Every employee, officer and director is expected
to comply with all Company policies and rules as in effect from time to time. You are expected to familiarize yourself with such policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Conflicts of Interest</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees, officers and directors must refrain
from engaging in any activity or having a personal interest that presents a &ldquo;conflict of interest&rdquo; and should seek to avoid
even the appearance of a conflict of interest. A conflict of interest occurs when your personal interest interferes with the business
interests of the Company. A conflict of interest can arise whenever you, as an employee, officer or director, take action or have an interest
that prevents you from performing your Company duties and responsibilities honestly, objectively and effectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>No employee, officer or director shall perform services as an employee, officer, director, consultant, advisor or in any other capacity
for a competitor of the Company, other than services performed at the request of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">No employee, officer or director shall have a financial interest in a competitor of the Company, other than a financial interest representing
less than one percent (1%) of the outstanding shares of a publicly-held company; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>No employee, officer or director shall use his or her position with the Company to influence a transaction with a supplier or customer
in which such person has any personal interest, other than a financial interest representing less than one percent (1%) of the outstanding
shares of a publicly-held company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It is your responsibility to disclose any material
transaction or relationship that reasonably could be expected to give rise to a conflict of interest to the General Counsel or the Principal
Financial Officer or, if you are an executive officer or director, to the Board of Directors, who shall be responsible for determining
whether such transaction or relationship constitutes a conflict of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insider Trading</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees, officers and directors who have material
non-public information about the Company or other companies, including our suppliers and customers, as a result of their relationship
with the Company are prohibited by law and Company policy from trading in securities of the Company or such other companies, as well as
from communicating such information to others who might trade on the basis of that information. To help ensure that you do not engage
in prohibited insider trading and avoid even the appearance of an improper transaction, the Company has adopted an Insider Trading Policy,
which is available from the General Counsel or the Principal Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you are uncertain about the constraints on your
purchase or sale of any Company securities or the securities of any other company that you are familiar with by virtue of your relationship
with the Company, you should consult with the General Counsel or the Principal Financial Officer before making any such purchase or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confidentiality</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All information and know-how, whether or not in
writing, of a private, secret or confidential nature concerning the Company&rsquo;s business or financial affairs (collectively, &ldquo;Proprietary
Information&rdquo;) is and shall be the exclusive property of the Company. By way of illustration, but not limitation, Proprietary Information
may include discoveries, inventions, products, product improvements, product enhancements, processes, methods, techniques, formulas, compositions,
compounds, negotiation strategies and positions, projects, developments, plans (including business and marketing plans), research data,
clinical data, financial data (including sales costs, profits, pricing methods), computer programs (including software used pursuant to
a license agreement), customer, prospect and supplier lists, and contacts at or knowledge of customers or prospective customers of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees, officers and directors must maintain
the confidentiality of Proprietary Information entrusted to them by the Company or other companies, including our suppliers and customers,
except when disclosure is authorized by a supervisor or legally permitted in connection with reporting illegal activity to the appropriate
regulatory authority. Unauthorized disclosure of any Proprietary Information is prohibited. Additionally, employees should take appropriate
precautions to ensure that confidential or sensitive business information, whether it is proprietary to the Company or another company,
is not communicated within the Company except to employees who have a need to know such information to perform their responsibilities
for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Third parties may ask you for information concerning
the Company. Subject to the exceptions noted in the preceding paragraph, employees, officers and directors (other than the Company&rsquo;s
authorized spokespersons) must not discuss Proprietary Information with, or disseminate Proprietary Information to, anyone outside the
Company, except as required in the performance of their Company duties and, if appropriate, after a confidentiality agreement is in place.
This prohibition applies particularly to inquiries concerning the Company from the media, market professionals (such as securities analysts,
institutional investors, investment advisers, brokers and dealers) and security holders. All responses to inquiries on behalf of the Company
must be made only by the Company&rsquo;s authorized spokespersons. If you receive any inquiries of this nature, you must decline to comment
and refer the inquirer to your supervisor or one of the Company&rsquo;s authorized spokespersons. The Company&rsquo;s policies with respect
to public disclosure of internal matters are described more fully in the Company&rsquo;s Disclosure Policy, which is available from the
Company&rsquo;s General Counsel or Principal Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You also must abide by any lawful obligations that
you have to your former employer. These obligations may include restrictions on the use and disclosure of Proprietary Information, restrictions
on the solicitation of former colleagues to work at the Company and non-competition obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Honest and Ethical Conduct and Fair Dealing</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees, officers and directors should endeavor
to deal honestly, ethically and fairly with the Company&rsquo;s suppliers, customers, competitors and employees. Statements regarding
the Company&rsquo;s products and services must not be untrue, misleading, deceptive or fraudulent. You must not take unfair advantage
of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair-dealing
practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protection and Proper Use of Corporate Assets</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees, officers and directors should seek to
protect the Company&rsquo;s assets, including Proprietary Information. Theft, carelessness and waste have a direct impact on the Company&rsquo;s
financial performance. Employees, officers and directors must use the Company&rsquo;s assets and services solely for legitimate business
purposes of the Company and not for any personal benefit or the personal benefit of anyone else.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees, officers and directors must advance
the Company&rsquo;s legitimate interests when the opportunity to do so arises. You must not take for yourself personal opportunities that
are discovered through your position with the Company or the use of property or information of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gifts and Gratuities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The use of Company funds or assets for gifts, gratuities
or other favors to government officials is prohibited, except to the extent such gifts, gratuities or other favors are in compliance with
applicable law, insignificant in amount and not given in consideration or expectation of any action by the recipient. The use of Company
funds or assets for gifts to any customer, supplier, or other person doing or seeking to do business with the Company is prohibited, except
to the extent such gifts are in compliance with the policies of both the Company and the recipient and are in compliance with applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees, officers and directors must not accept,
or permit any member of his or her immediate family to accept, any gifts, gratuities or other favors from any customer, supplier or other
person doing or seeking to do business with the Company, other than items of insignificant value. Any gifts that are not of insignificant
value should be returned immediately and reported to your supervisor. If immediate return is not practical, they should be given to the
Company for charitable disposition or such other disposition as the Company, in its sole discretion, believes appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Common sense and moderation should prevail in business
entertainment engaged in on behalf of the Company. Employees, officers and directors should provide, or accept, business entertainment
to or from anyone doing business with the Company only if the entertainment is infrequent, modest, intended to serve legitimate business
goals and in compliance with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Bribes and kickbacks are criminal acts, strictly
prohibited by law. You must not offer, give, solicit or receive any form of bribe or kickback anywhere in the world. The Foreign Corrupt
Practices Act prohibits giving anything of value, directly or indirectly, to officials of foreign governments or foreign political candidates
in order to obtain or retain business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accuracy of Books and Records and Public Reports</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees, officers and directors must honestly
and accurately report all business transactions. You are responsible for the accuracy of your records and reports. Accurate information
is essential to the Company&rsquo;s ability to meet legal and regulatory obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All Company books, records and accounts shall be
maintained in accordance with all applicable regulations and standards and accurately reflect the true nature of the transactions they
record. The financial statements of the Company shall conform to generally accepted accounting rules and the Company&rsquo;s accounting
policies. No undisclosed or unrecorded account or fund shall be established for any purpose. No false or misleading entries shall be made
in the Company&rsquo;s books or records for any reason, and no disbursement of corporate funds or other corporate property shall be made
without adequate supporting documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It is the policy of the Company to provide full,
fair, accurate, timely and understandable disclosure in reports and documents filed with, or submitted to, the Securities and Exchange
Commission (&ldquo;SEC&rdquo;) and in other public communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concerns Regarding Accounting or Auditing Matters</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees with concerns regarding questionable
accounting or auditing matters or complaints regarding accounting, internal accounting controls or auditing matters may confidentially,
and anonymously if they wish, report such concerns through the Secure Web Form at https://www.whistleblowerservices.com/carm. In addition,
the Company has established a Secure Hotline, accessible via a toll-free telephone number (866) 822-6485, where you can leave a recorded
message to report such concerns. See &ldquo;Reporting and Compliance Procedures.&rdquo; All such concerns and complaints will be forwarded
to the Audit Committee of the Board of Directors (the &ldquo;Audit Committee&rdquo;), unless they are determined to be without merit by
the General Counsel and/or the Principal Financial Officer. In any event, a record of all complaints and concerns received will be provided
to the Audit Committee each fiscal quarter. Any such concerns or complaints may also be communicated, confidentially and, if you desire,
anonymously, directly to any member of the Audit Committee of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Audit Committee will evaluate the merits of
any concerns or complaints received by it and authorize such follow-up actions, if any, as it deems necessary or appropriate to address
the substance of the concern or complaint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will not discipline, discriminate against
or retaliate against any employee who reports a complaint or concern, unless it is determined that the report was made with knowledge
that it was false.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dealings with Independent Auditors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No employee, officer or director shall, directly
or indirectly, make or cause to be made a materially false or misleading statement to an accountant in connection with (or omit to state,
or cause another person to omit to state, any material fact necessary in order to make statements made, in light of the circumstances
under which such statements were made, not misleading to, an accountant in connection with) any audit, review or examination of the Company&rsquo;s
financial statements or the preparation or filing of any document or report with the SEC. No employee, officer or director shall, directly
or indirectly, take any action to coerce, manipulate, mislead or fraudulently influence any independent public or certified public accountant
engaged in the performance of an audit or review of the Company&rsquo;s financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Waivers of this Code of Business Conduct and Ethics</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While some of the policies contained in this Code
must be strictly adhered to and no exceptions can be allowed, in other cases exceptions may be appropriate. Any employee or officer who
believes that a waiver of any of these policies is appropriate in his or her case should first contact his or her immediate supervisor.
If the supervisor agrees that a waiver is appropriate, the approval of the General Counsel or the Principal Financial Officer must be
obtained. The General Counsel or the Principal Financial Officer shall be responsible for maintaining a record of all requests by employees
or officers for waivers of any of these policies and the disposition of such requests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any executive officer or director who seeks a waiver
of any of these policies should contact the General Counsel or the Principal Financial Officer. Any waiver of this Code for executive
officers or directors or any change to this Code that applies to executive officers or directors may be made only by the Board of Directors
of the Company and will be disclosed as required by law or stock exchange regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reporting and Compliance Procedures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Every employee,
officer and director has the responsibility to ask questions, seek guidance, report suspected violations and express concerns regarding
compliance with this Code to his or her supervisor or to the General Counsel or the Principal Financial Officer, as described below. Any
employee, officer or director who knows or believes that any other employee or representative of the Company has engaged or is engaging
in Company-related conduct that violates applicable law or this Code should report such information to his or her supervisor or to the
General Counsel or Principal Financial Officer. You may report such conduct openly or anonymously without fear of retaliation. The Company
will not discipline, discriminate against or retaliate against any employee who reports such conduct, unless it is determined that the
report was made with knowledge that it was false, or who cooperates in any investigation or inquiry regarding such conduct. Any supervisor
who receives a report of a violation of this Code must immediately inform the General Counsel or the Principal Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may report violations of this Code, on a confidential
or anonymous basis, through the Secure Web Form at https://www.whistleblowerservices.com/carm. In addition, the Company has established
a Secure Hotline, accessible via a toll-free telephone number (866) 822-6485, where you can leave a recorded message about any violation
or suspected violation of this Code. While we prefer that you identify yourself when reporting violations so that we may follow up with
you, as necessary, for additional information, you may leave messages anonymously if you wish.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the General Counsel or the Principal Financial
Officer receives information regarding an alleged violation of this Code, he or she shall, as appropriate, (a)&nbsp;evaluate such information,
(b)&nbsp;if the alleged violation involves an executive officer or a director, inform the Chief Executive Officer and Board of Directors
of the alleged violation, (c)&nbsp;determine whether it is necessary to conduct an informal inquiry or a formal investigation and, if
so, initiate such inquiry or investigation and (d)&nbsp;report the results of any such inquiry or investigation, together with a recommendation
as to disposition of the matter, to the General Counsel or the Principal Financial Officer for action, or if the alleged violation involves
an executive officer or a director, report the results of any such inquiry or investigation to the Board of Directors or a committee thereof.
Employees, officers and directors are expected to cooperate fully with any inquiry or investigation by the Company regarding an alleged
violation of this Code. Failure to cooperate with any such inquiry or investigation may result in disciplinary action, up to and including
discharge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company shall determine whether violations
of this Code have occurred and, if so, shall determine the disciplinary measures to be taken against any employee who has violated this
Code. In the event that the alleged violation involves an executive officer or a director, the Chief Executive Officer and the Board of
Directors, respectively, shall determine whether a violation of this Code has occurred and, if so, shall determine the disciplinary measures
to be taken against such executive officer or director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Failure to comply with the standards outlined in
this Code will result in disciplinary action including, but not limited to, reprimands, warnings, probation or suspension without pay,
demotions, reductions in salary, discharge and restitution. Certain violations of this Code may require the Company to refer the matter
to the appropriate governmental or regulatory authorities for investigation or prosecution. Moreover, any supervisor who directs or approves
of any conduct in violation of this Code, or who has knowledge of such conduct and does not immediately report it, also will be subject
to disciplinary action, up to and including discharge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dissemination and Amendment</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Code shall be distributed to each new employee,
officer and director of the Company upon commencement of his or her employment or other relationship with the Company and shall also be
distributed annually to each employee, officer and director of the Company, and each employee, officer and director shall certify that
he or she has received, read and understood the Code and has complied with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company reserves the right to amend, alter
or terminate this Code at any time for any reason. The most current version of this Code can be obtained from the Company&rsquo;s General
Counsel or Principal Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This document is not an employment contract between
the Company and any of its employees, officers or directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Certification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">I, ______________________________ do
hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(Print Name Above)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have received and carefully read the Code of Business Conduct and Ethics of Carisma Therapeutics Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
understand the Code of Business Conduct and Ethics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have complied and will continue to comply with the terms of the Code of Business Conduct and Ethics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as noted below, I do not know or believe that any employee or representative of the Company has engaged or is engaging in Company-related
conduct that violates applicable law or the Code of Business Conduct and Ethics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Exceptions (describe,
or state &ldquo;None&rdquo;):</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-indent: 0in"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in"><FONT STYLE="font-size: 10pt">(Signature)</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>EACH EMPLOYEE, OFFICER AND DIRECTOR
IS REQUIRED TO SIGN, DATE AND RETURN THIS CERTIFICATION TO THE PRINCIPAL FINANCIAL OFFICER. FAILURE TO DO SO MAY RESULT IN DISCIPLINARY
ACTION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SUSPECTED VIOLATIONS
SHOULD BE REPORTED TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(866) 822-6485</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.1
<SEQUENCE>18
<FILENAME>tm238578d1_ex16-1.htm
<DESCRIPTION>EXHIBIT 16.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 16.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March&nbsp;7, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, District of Columbia 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have read item 4.01 on Form&nbsp;8-K dated March&nbsp;7, 2023
of Carisma Therapeutics Inc. (formerly known as Sesen Bio,&nbsp;Inc.) and are in agreement with the statements contained in the
paragraphs within section (a)&nbsp;therein. We have no basis to agree or disagree with other statements of the registrant contained
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ernst&nbsp;&amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>19
<FILENAME>tm238578d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm238578d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Carisma Therapeutics
Closes Merger with Sesen Bio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Shares of Carisma to commence trading on Nasdaq
under new ticker symbol &ldquo;CARM&rdquo; on March 8, 2023</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical
readouts across Carisma programs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">PHILADELPHIA &ndash; March 7, 2023 &ndash;
</FONT>Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies,
and Sesen Bio, Inc. (&ldquo;Sesen Bio&rdquo;), announced today the closing of their previously announced merger. The combined company
will operate under the name Carisma Therapeutics Inc. and shares of its common stock will commence trading under the ticker symbol &quot;CARM&rdquo;
on March 8, 2023 on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&quot;This merger represents a very exciting
opportunity for stockholders of each company, and we believe it gets us one step closer to our goal of revolutionizing the field of immunotherapy,&quot;
said Steven Kelly, President and Chief Executive Officer of Carisma. &quot;It will provide us with the financial strength to not only
continue to develop our lead candidate CT-0508 but also accelerate the growth of our platform and pipeline within and outside of oncology
and continue to develop additional strong strategic partnerships.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Dr. Thomas Cannell, President and Chief Executive
Officer of Sesen Bio, said, &ldquo;I want to thank the entire Sesen Bio team for their steadfast commitment to our mission to save and
improve lives. Patients, caregivers and investigators around the world have been important advocates of Sesen Bio and I want to thank
them for their support. I am confident in the potential of Carisma&rsquo;s promising technology and through the combined company, we can
continue to advance our shared mission of saving and improving the lives of patients with cancer. I know the future of Carisma is bright
and I am optimistic for their continued success.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Concurrent with the closing of the merger,
Carisma completed a $30 million financing from a syndicate of investors, including HealthCap, AbbVie, Wellington Partners, SymBiosis,
Penn Medicine, TPG Biotech, MRL Ventures Fund, the therapeutics-focused corporate venture arm of Merck &amp; Co., Agent Capital, Solasta,
Livzon, Pictet Alternative Advisors and 4Bio. The projected cash and cash equivalents as of the close of the business combination are
expected to be approximately $140 million, providing anticipated operating runway at least through the end of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In connection with the closing of the merger,
a one-time special cash dividend of $75 million, or approximately $0.36 per share, will be paid no later than March 10, 2023 to Sesen
Bio stockholders of record at the close of business on March 7, 2023. Under the terms of the merger, Sesen Bio stockholders also received
one Contingent Value Right, which entitles the holder to receive a cash payment related to any potential proceeds from the sale of Sesen
Bio&rsquo;s legacy assets, including Vicineum, and the potential $30 million milestone payment under the Roche Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The combined company will be headquartered
in Philadelphia, Pennsylvania, and will be led by Steven Kelly, President and Chief Executive Officer of Carisma. The board of directors
of the combined company will be composed of seven members, including Sanford Zweifach (Chair), Regina Hodits, Briggs Morrison, Bj&ouml;rn
Odlander, Chidozie Ugwumba, Steven Kelly (Carisma President &amp; Chief Executive Officer) and Michael Torok.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;The successful completion of this merger
marks an important milestone in Carisma&rsquo;s journey and significantly strengthens its cash resources to advance the company&rsquo;s
differentiated pipeline and platform,&rdquo; said Chairman of the Board Sanford Zweifach. &ldquo;The dedication of the Carisma team, as
well as the support and guidance of our advisors and stockholders, have been instrumental in bringing us to this moment. The Board and
I look forward to the opportunities that lie ahead.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">SVB Securities acted as the exclusive financial
advisor to Sesen Bio for the transaction, and Hogan Lovells US LLP served as Sesen Bio&rsquo;s legal counsel. Evercore served as lead
financial advisor to Carisma for the transaction, and BofA Securities, Inc. also served as financial advisor to Carisma for the transaction.
Wilmer Cutler Pickering Hale and Dorr LLP is serving as legal counsel to Carisma. BofA Securities, Inc. and Evercore served as co-placement
agents for Carisma's concurrent financing and Shearman &amp; Sterling LLP is serving as the placement agents' legal counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Carisma Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma Therapeutics Inc. is a biopharmaceutical company dedicated
to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role
in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University
of Pennsylvania*, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma is headquartered
in Philadelphia, PA. For more information, please visit www.carismatx.com *Carisma has licensed certain Penn-owned intellectual property
from the University of Pennsylvania, and Penn&rsquo;s Perelman School of Medicine receives sponsored research and clinical trial funding
from Carisma. Penn and certain of its faculty members are current equity holders in Carisma and have received and
may be entitled to receive future financial consideration from Carisma from the development and commercialization of products based on
licensed Penn intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note on Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any statements in this press release about Carisma&rsquo;s future expectations,
plans and prospects, strategy or future operations, and other statements containing the words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;contemplate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;target,&rdquo;
 &ldquo;potential,&rdquo; &ldquo;possible,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;continue,&rdquo;
and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
For example, statements concerning Carisma&rsquo;s business, strategy, future operations, cash runway, the advancement of Carisma&rsquo;s
product candidates and product pipeline, and clinical development of Carisma&rsquo;s product candidates, including expectations regarding
timing of initiation and results of clinical trials are forward-looking statements. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important factors, including without limitation: (i) risks associated with the
possible failure to realize certain anticipated benefits of the merger, including with respect to future financial and operating results;
(ii) the effect of the completion of the merger on Carisma&rsquo;s business relationships, operating results and business generally; (iii)
the outcome of any legal proceedings instituted against Sesen Bio, Carisma or any of their respective directors or officers related to
the merger agreement or the transactions contemplated thereby; (iv) the ability of Carisma to protect its intellectual property rights;
(v) competitive responses to the merger and changes in expected or existing competition; (vi) the success and timing of regulatory submissions
and pre-clinical and clinical trials; (vii) regulatory requirements or developments; (viii) changes to clinical trial designs and regulatory
pathways; (ix) changes in capital resource requirements; (x) risks related to the inability of Carisma to obtain sufficient additional
capital to continue to advance its product candidates and its preclinical programs; (xi) legislative, regulatory, political and economic
developments; and (xii) other factors discussed in the Company&rsquo;s reports filed with the Securities Exchange Commission. In addition,
the forward-looking statements included in this press release represent Carisma&rsquo;s views as of the date hereof. Carisma anticipates
that subsequent events and developments will cause its views to change. However, while Carisma may elect to update these forward-looking
statements at some point in the future, Carisma specifically disclaims any obligation to do so, except as required under applicable law.
These forward-looking statements should not be relied upon as representing Carisma&rsquo;s views as of any date subsequent to the date
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Julia Stern</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(763) 350-5223</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jstern@realchemistry.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">investors@carismatx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>20
<FILENAME>tm238578d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARISMA BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma Therapeutics Inc., or Carisma, is a clinical
stage cell therapy company focused on utilizing Carisma&rsquo;s proprietary macrophage and monocyte cell engineering platform to develop
transformative immunotherapies to treat cancer and other serious diseases. Carisma has created a comprehensive cell therapy platform to
enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Macrophages and monocytes are part of the innate immune system and can detect and degrade harmful substances through a process referred
to as phagocytosis, in which the harmful substance is engulfed and destroyed and in turn leads to the activation of a broad immune response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To harness the powerful immunologic functions of
macrophages against cancer, Carisma has developed a proprietary Chimeric Antigen Receptor Macrophage, or CAR-M, platform technology. Chimeric
antigen receptors, or CARs, are synthetically engineered receptors that are designed to bestow immune cells with the ability to target
specific antigens on the surface of cancer cells. By introducing CARs into macrophage and monocyte cells, Carisma aims to redirect their
potent innate immune functions against cancer. Carisma&rsquo;s CAR-M platform technology incorporates proprietary tumor targeting constructs,
vectors to deliver CARs to macrophages and monocytes and novel manufacturing processes. Carisma&rsquo;s CAR-M therapeutics are designed
to infiltrate the solid tumor microenvironment, kill cancer cells via targeted phagocytosis, and activate other immune cells, such as
T-cells, to initiate a robust anti-tumor immune response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s lead product candidate CT-0508,
the first CAR-M to be evaluated in a human clinical trial, is an&nbsp;<I>ex vivo</I>&nbsp;autologous cell therapy product candidate, wherein
immune cells from blood drawn from a patient are engineered outside of the body and reinfused into the same patient. CT-0508 is intended
to treat solid tumors that overexpress HER2, a protein that is overexpressed on the surface of a variety of solid tumors, including breast
cancer, gastric cancer, esophageal cancer, salivary gland cancer, and numerous others. Carisma has completed enrollment of the first group
of patients in a Phase 1 clinical trial of CT-0508, with nine patients having been successfully dosed. In November&nbsp;2022, Carisma
presented preliminary clinical results from the first group of patients. CT-0508 was successfully manufactured using macrophages obtained
from heavily pre-treated, advanced solid tumor patients and has shown high CAR expression, viability, and purity. In addition, CT-0508
has been generally well-tolerated after infusion with no dose-limiting toxicities reported to date from the nine patients enrolled in
the first group. While the results from this early clinical trial data are both preliminary and limited, Carisma believes the results
indicate that CT-0508 can be detected within the tumor microenvironment, or TME, lead to remodeling and activation of the TME, and potentially
induce anti-tumor adaptive immunity. Carisma anticipates providing multiple clinical data updates over the next 18 months. In the combination
setting, Carisma has observed the synergistic potential of CT-0508 with a PD1 blocking T-cell checkpoint inhibitor in pre-clinical models,
enabling a combination trial with pembrolizumab. Carisma submitted a clinical protocol amendment to the United States Food and Drug Administration,
or FDA, in September&nbsp;2022 to allow Carisma to treat patients with the co-administration of CT-0508 and pembrolizumab, and opened
the study for enrollment in December&nbsp;2022. The FDA has granted &ldquo;Fast Track&rdquo; status to CT-0508 for the treatment of patients
with HER2 overexpressing solid tumors and Carisma plans to prioritize development for this indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Beyond CT-0508, Carisma has a broad pipeline of
cell therapy assets in various stages of pre-clinical development. In addition to the development of&nbsp;<I>ex vivo</I>&nbsp;CAR-M cell
therapies, Carisma is also developing&nbsp;<I>in vivo</I>&nbsp;CAR-M gene therapies, wherein immune cells are directly engineered within
the patient&rsquo;s body. To advance its&nbsp;<I>in vivo</I>&nbsp;CAR-M therapeutics, Carisma established a strategic collaboration with
ModernaTX,&nbsp;Inc., or Moderna, focused on the development and potential commercialization of up to 12 product candidates, of which
four have already been nominated. In collaboration with Moderna, Carisma has established an approach that uses Moderna&rsquo;s myeloid
cell specific lipid nanoparticle/mRNA, or LNP/mRNA, technology, together with Carisma&rsquo;s CAR-M platform technology, to create novel&nbsp;<I>in
vivo</I>&nbsp;oncology gene therapies. Carisma believes this approach has the potential to enable a series of off-the-shelf product candidates
to target a patient&rsquo;s own myeloid cells against cancer cells directly within their body. As part of the agreement with Moderna,
Carisma received a $45.0 million up-front cash payment and an investment by Moderna in the form of a $35.0 million convertible note, in
addition to future research funding and the opportunity for milestone payments and royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Through its robust internal discovery engine, Carisma
is building upon its platform to enhance and expand the utility of macrophage cell and gene therapies, leading to the creation of multiple
product candidates with the potential to treat cancer and other serious diseases. By replacing the targeting domain of the CAR, Carisma
can reprogram the target antigen specificity of the CAR-M cell product and develop candidates against a range of cancer indications and
therapeutic areas beyond oncology. As a result, Carisma believes the flexibility of its macrophage and monocyte cell engineering platform
will allow Carisma to generate new product candidates suitable for clinical development in a cost-efficient manner to expand its pipeline.
In addition to acting as a first line of defense in the innate immune system, macrophages are found in all tissues in the body where they
serve key regulatory functions such as wound healing, termination of immune responses, and tissue regeneration. Using its macrophage and
monocyte&nbsp;<I>ex vivo</I>&nbsp;and&nbsp;<I>in vivo</I>&nbsp;engineering platform, Carisma is pursuing early research and development
of multiple assets for the potential treatment of diseases beyond oncology, including liver fibrosis, neurodegeneration, and other immunologic
and inflammatory diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">By investing in early platform research and accessing
key enabling technologies, Carisma is enhancing and expanding its platform capabilities and reinforcing its leadership position in the
engineered macrophage field. Carisma has developed proprietary CAR-M platform enhancements directed toward key product parameters that
are important for efficacy, safety, and patient access to its CAR-M therapies. Carisma plans to apply these technology enhancements to
future CAR-M product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma&rsquo;s Pipeline Programs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Using its proprietary CAR-M platform technology,
Carisma is developing a broad pipeline of product candidates, with a strong initial focus in oncology. Carisma&rsquo;s&nbsp;<I>ex vivo</I>&nbsp;autologous
CAR-M product candidates are summarized in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm238578d1_ex99-2img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is also advancing discovery-stage candidates
across a range of therapeutic areas, as summarized in the following table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm238578d1_ex99-2img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s lead product candidate, CT-0508,
is an&nbsp;<I>ex vivo</I>&nbsp;autologous cell therapy product candidate intended to treat solid tumors that overexpress HER2, a protein
that is overexpressed on the surface of a variety of solid tumors including breast cancer, gastric cancer, esophageal cancer, salivary
gland cancer and numerous others. CT-0508 is produced by engineering a patient&rsquo;s own monocyte-derived macrophages from blood drawn
from the patient with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2 CAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma has completed enrollment of the first group
of patients in a Phase 1 clinical trial, with nine patients successfully dosed. The second group is currently open for enrollment, with
nine additional patients to be dosed. In November&nbsp;2022, Carisma presented preliminary clinical results from the first group of patients.
CT-0508 was successfully manufactured using macrophages obtained from heavily pre-treated, advanced solid tumor patients and has shown
high CAR expression, viability, and purity. In addition, CT-0508 has been generally well-tolerated after infusion with no dose-limiting
toxicities reported to date from the nine patients enrolled in the first group. While the results from this early clinical trial data
are both preliminary and limited, Carisma believes the results indicate that CT-0508 can be detected within the TME, lead to remodeling
and activation of the TME, and potentially induce anti-tumor adaptive immunity. Carisma anticipates providing multiple clinical data updates
over the next 18 months. In the combination setting, Carisma has observed the synergistic potential of CT-0508 with a PD1 blocking T-cell
checkpoint inhibitor in pre-clinical models, enabling a combination trial with pembrolizumab. Carisma submitted a clinical protocol amendment
to the FDA in September&nbsp;2022 to allow it to treat patients with the co-administration of CT-0508 and pembrolizumab, and opened the
study for enrollment in December&nbsp;2022. The FDA has granted &ldquo;Fast Track&rdquo; status to CT-0508 for the treatment of patients
with HER2 overexpressing solid tumors and Carisma plans to prioritize development for this indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is currently in the pre-clinical stage
for another product candidate, CT-0525, which is also intended to treat solid tumors that overexpress HER2. By leveraging its discovery
engine and preliminary clinical data from its Phase 1 clinical trial of CT-0508, Carisma is building upon its CAR-M platform to generate
next-generation therapeutics that may increase potential efficacy and patient access. Notably, Carisma has developed a novel approach
to CAR-M therapy to accelerate the manufacturing process, increase the cell yield, and improve upon the potential anti-tumor effect by
engineering patients&rsquo; monocytes directly, without&nbsp;<I>ex vivo</I>&nbsp;differentiation into macrophages, as Carisma currently
does for CT-0508. Carisma refers to this CAR-Monocyte approach as CAR-Mono. By increasing the cell yield, the CAR-Mono approach enables
a larger potential dose, which may improve tumor control. The CAR-Mono approach reduces manufacturing time and leverages an automated,
closed-system manufacturing process. CT-0525 is Carisma&rsquo;s first CAR-Mono product candidate and is currently in the pre-clinical
process development stage. Carisma expects to submit an IND to the FDA for CT-0525 in the second half of 2023 and initiate clinical development
shortly thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is also expanding its pipeline to include
multiple tumor targets, encompassing diverse solid tumor indications with significant unmet medical needs, including the following product
candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>CT-1119:</I></B>&nbsp;CT-1119 is a mesothelin targeted CAR-M that Carisma plans to evaluate in patients with advanced mesothelin-positive
solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. Carisma anticipates nominating a lead
next generation CAR construct for CT-1119 in the first half of 2024 and expects to submit an IND to the FDA in 2025. In November&nbsp;2022,
Carisma presented preliminary and limited data demonstrating that CT-1119 can mediate phagocytosis, tumor cell killing, and pro-inflammatory
cytokine release and control tumor growth in pre-clinical lung cancer models.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>CT-0729:</I></B>&nbsp;CT-0729 is a prostate-specific membrane antigen, or PSMA, targeted CAR-M that Carisma plans to evaluate
in patients with advanced, PSMA positive metastatic castrate resistant prostate cancer. CT-0729 is in the discovery stage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s pipeline programs CT-1119 and CT-0729
may be developed using the next generation CAR-Mono approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s current CAR-M cell therapy pipeline
is informing the discovery and pre-clinical development of off-the-shelf engineered macrophage therapeutics. Carisma is developing&nbsp;<I>in
vivo</I>&nbsp;reprogrammed LNP/mRNA CAR-M therapies for cancer through its collaboration with Moderna. In addition, Carisma is establishing
an&nbsp;<I>ex vivo</I>&nbsp;allogeneic, induced pluripotent stem cell, or iPSC, derived macrophage and monocyte platform with the potential
to develop iPSC-derived CAR-M and other macrophage therapies for indications in oncology and beyond, including indications such as liver
fibrosis, neurodegeneration and auto-immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Carisma&rsquo;s Team</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma was founded in 2016 by leading cell therapy
experts from the University of Pennsylvania. Dr.&nbsp;Saar Gill is a co-inventor of the CAR-M technology and a co-founder of Carisma.
He is an Associate Professor of Medicine in the Division of Hematology-Oncology at the University of Pennsylvania. Dr.&nbsp;Michael Klichinsky,
Pharm.D., Ph.D., is a co-inventor of the CAR-M technology, a scientific co-founder of Carisma, and Carisma&rsquo;s current Chief Scientific
Officer. Dr.&nbsp;Carl June, a co-inventor of the CAR-M technology, is the Richard W. Vague Professor in Immunotherapy in the Department
of Pathology and Laboratory Medicine at the University of Pennsylvania. He also is currently Director of the Center for Cellular Immunotherapies
at the Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, and
Scientific Advisor to Carisma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s executive team has decades of experience
in business operations, discovery, development, and manufacturing of advanced therapeutics for the treatment of serious diseases. Steven
Kelly, Carisma&rsquo;s Chief Executive Officer, brings over 35 years of experience in the biopharmaceutical industry at all phases of
the business across multiple therapeutic categories. Carisma&rsquo;s Chief Technology and Development Officer, Daniel Cushing, Ph.D.,
brings over 30 years of experience in the biopharmaceutical industry and is responsible for product development at Carisma. Richard Morris,
Carisma&rsquo;s Chief Financial Officer, has more than 25 years of experience in building and growing successful biotechnology organizations,
with a focus on capital fundraising (including initial public offerings), financial strategy and operations execution, and business development
efforts. Carisma&rsquo;s Chief Business Officer, Tom Wilton, has over 25 years of biopharmaceutical industry experience, including corporate
strategy, business development, research and development operations, and marketing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Carisma&rsquo;s Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s vision is to become a leading cell
therapy company, developing and ultimately commercializing macrophage-based cell therapies that positively transform the treatment of
cancer and other serious diseases. To achieve its vision, Carisma has developed its macrophage engineering platform, a pipeline of assets
spanning numerous indications with unmet medical needs, a robust discovery engine, broad CAR-M intellectual property, robust manufacturing
capabilities, and a dedicated executive team with extensive experience in cell therapy and drug development, manufacturing and commercialization
and leading scientific expertise in the field. The key components of Carisma&rsquo;s strategy are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B>Advance Carisma&rsquo;s lead product candidate, CT-0508, through clinical development for the treatment of HER2 overexpressing
solid tumors.</B>&nbsp;CT-0508 is an&nbsp;<I>ex vivo</I>&nbsp;gene-modified autologous CAR-M cell therapy product candidate intended to
treat solid tumors that overexpress HER2. Carisma has completed enrollment of the first group of patients in a Phase 1 clinical trial,
with nine patients successfully dosed. The second group is currently open for enrollment, with nine additional patients to be dosed. In
November&nbsp;2022, Carisma presented preliminary clinical results from the first group of patients. CT-0508 was successfully manufactured
using macrophages obtained from heavily pre-treated, advanced solid tumor patients and has shown high CAR expression, viability, and purity.
In addition, CT-0508 has been generally well-tolerated after infusion with no dose-limiting toxicities reported to date from the nine
patients enrolled in the first group. While the results from this early clinical trial data are both preliminary and limited, Carisma
believes the results indicate that CT-0508 can be detected within the TME, leads to remodeling and activation of the TME, and potentially
induces anti-tumor adaptive immunity. Additionally, the FDA granted &ldquo;Fast Track&rdquo; status to CT-0508 for the treatment of patients
with HER2 overexpressing solid tumors and Carisma plans to prioritize development for this indication. Carisma has initiated a sub-study
to evaluate the combination of CT-0508 with pembrolizumab, a PD1 blocking T cell checkpoint inhibitor, for patients with advanced HER2
overexpressing solid tumors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B>Invest in Carisma&rsquo;s CAR-Mono platform technology to further extend its leadership position in macrophage and monocyte based
cellular therapy.</B>&nbsp;As part of its ongoing platform enhancement effort, Carisma has developed its CAR-Mono approach, which significantly
reduces manufacturing time and leverages an automated, closed-system manufacturing process. Carisma is currently in the pre-clinical process
development stage for CT-0525, Carisma&rsquo;s first anti-HER2 CAR-Mono product candidate, and expects to submit an IND in the second
half of 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B>Advance Carisma&rsquo;s pre-clinical CAR-M oncology pipeline candidates to clinical development stage.</B>&nbsp;Beyond its initial
HER2 target, Carisma is expanding its pipeline into multiple tumor targets and constructs. CT-1119 is a mesothelin targeted CAR-M that
Carisma plans to evaluate in patients with advanced mesothelin-positive solid tumors, with an IND expected to be submitted in 2025. In
November&nbsp;2022, Carisma presented preliminary and limited data demonstrating that CT-1119 can mediate phagocytosis, tumor cell killing,
and pro-inflammatory cytokine release and control tumor growth in pre-clinical lung cancer models. Carisma anticipates nominating a next
generation CAR construct for CT-1119 in the first half of 2024. Additionally, CT-0729 is a PSMA targeted CAR-M intended for use against
metastatic castrate resistant prostate cancer and is currently in the discovery stage. Carisma is also developing product candidates targeting
other cancer antigens.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B>Build next-generation technologies to expand the scope and capabilities of Carisma&rsquo;s platform.</B>&nbsp;Beyond its CAR-M
and CAR-Mono technologies, Carisma is pursuing multiple platform enhancements for its CAR constructs, editing technologies and therapeutic
delivery vehicles. Further, Carisma is actively developing a gene edited iPSC-derived macrophage platform and leveraging delivery technologies
for its mRNA-based&nbsp;<I>in vivo</I>&nbsp;CAR-M platform for oncology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B>Harness the potential of Carisma&rsquo;s platform to develop novel product candidates to address therapeutic areas beyond oncology.</B>&nbsp;While
Carisma has initially been an oncology focused company, Carisma believes the breadth of the myeloid engineering platform enables significant
opportunities outside of oncology. Based on early data related to Carisma&rsquo;s novel therapeutic approach, Carisma believes its platform
has significant potential across multiple therapeutic areas, including fibrosis, neurodegeneration, autoimmunity, and chronic inflammation,
which are currently in the discovery stage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B>Selectively enter into strategic partnerships and collaborations to maximize the potential of Carisma&rsquo;s platform.</B>&nbsp;Given
the breadth of opportunities enabled by Carisma&rsquo;s platform, Carisma may opportunistically enter into strategic collaborations intended
to advance and accelerate its development programs, expand into new therapeutic areas and enhance the capabilities of its platform. Carisma
currently has a broad strategic collaboration with Moderna focused on the development of&nbsp;<I>in vivo</I>&nbsp;CAR-M therapeutics for
up to 12 oncology targets, of which four have already been nominated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Background</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cellular Immunotherapy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cellular immunotherapy is a type of immuno-oncology
approach whereby human immune cells are utilized to recognize and destroy cancer cells in a targeted manner. To date, cellular immunotherapy
has focused on the transfer of T-cells or natural killer, or NK, cells. For example, T-cells with intrinsic tumor reactivity, such as
tumor infiltrating lymphocytes, have been utilized, as well as T-cells genetically engineered with tumor targeting T-cell receptors, or
TCRs, or CARs, have been tested in a variety of hematologic malignancies and solid tumors. The only FDA approved genetically modified
cellular immunotherapies for cancer are CAR T-cell therapies for B cell hematologic malignancies expressing CD19 or multiple myeloma expressing
B-cell maturation antigen, or BCMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Despite the incredible promise shown by cell therapies
for hematologic malignancies, the success has not been replicated in the solid tumor setting. There are numerous challenges impacting
T and NK cell immunotherapy in patients with solid tumors, such as the inability of cells to appropriately access the tumor microenvironment,
overcome immunosuppression in the tumor microenvironment and overcome target antigen heterogeneity. Importantly, there have been challenges
in targeting solid tumors with CAR T-cells without inducing toxicities against normal tissues or inducing severe systemic cytokine release
syndrome, or CRS. To date, no CAR therapies for the treatment of solid tumors have received marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Macrophages and Monocytes and the Tumor Microenvironment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Macrophages play a vital role in the innate immune
system, the body&rsquo;s first line of defense against foreign pathogens. Macrophages are highly plastic innate cells that mediate a multitude
of protective and homeostatic functions, including elimination of pathogens through phagocytosis, clearance of cellular debris, induction
or regulation of inflammation, antigen presentation, and tissue remodeling. Macrophages can arise from circulating bone marrow-derived
monocytes or embryonic precursors and are found in all tissues in the human body. Depending on the environmental cues, macrophages can
actively adopt distinct activation states, or phenotypes, to either initiate or terminate immune responses. While macrophage activation
states are complex, they can be categorized into two general subsets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Classically activated (M1):</I></B>&nbsp;M1 macrophages are pro-inflammatory and are associated with anti-tumoral functions.
They initiate or enhance immune responses by recruiting T-cells, upregulating antigen processing machinery and co-stimulatory ligands,
and secreting pro-inflammatory factors cytokines and chemokines, and ultimately promote T-cell responses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Alternatively activated (M2):</I></B>&nbsp;M2 macrophages are immunosuppressive and are associated with pro-tumoral functions.
They accelerate tumor invasion and metastasis and promote angiogenesis (or formation of new blood vessels) by secreting inhibitory cytokines
and upregulating immunosuppressive cell surface molecules, and ultimately inhibit T-cell responses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Macrophages are typically the most abundant immune
cell in the TME of most cancers, where they generally adopt an M2 phenotype and are therefore associated with poor prognostic outcomes
and increased intratumoral immunosuppression. For example, numerous studies have shown that patients with more M2 macrophages in their
tumors have reduced responses to immune checkpoint inhibitors such as pembrolizumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given the generally negative role of M2 macrophages
in the TME, there have been numerous therapeutic approaches focused on inhibiting tumor associated macrophage, or TAM, infiltration or
survival. Other approaches have sought to convert TAMs from an M2 to an M1 phenotype. While numerous studies have shown that TAM infiltration
is typically associated with poor prognostic outcome, macrophages have been shown to have potent anti-tumor capabilities if appropriately
activated and targeted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The Opportunity for Engineered Macrophages in Treating Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma believes macrophage and monocyte cell therapies
hold promise in addressing the limitations of other cell types and transforming the cell therapy treatment paradigm for solid tumors.
The inherent biology of macrophages and monocytes offers several potential advantages that directly apply to current barriers for cell
therapy efficacy in the solid tumor context.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Macrophages and monocytes are actively recruited
into solid tumors, while other immune cells such as T-cells are often actively excluded. Macrophages are professional phagocytic cells
capable of directly killing tumor cells through this unique mechanism. In addition to direct killing, macrophages can secrete pro-inflammatory
factors that convert the immunosuppressive TME into an environment that promotes immunity. Importantly, macrophages and monocytes are
professional antigen presenting cells, meaning they can directly present tumor-derived antigens to T-cells leading to anti-tumor T-cell
responses, a phenomenon known as epitope spreading. Epitope spreading enables activity against tumor cells which either lack or lose expression
of the initial antigen targeted by the CAR&thinsp;-&thinsp;a key challenge for cell therapies&thinsp;-&thinsp;and ultimately enables macrophages
and monocytes to overcome target antigen heterogeneity within the patient&rsquo;s cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma believes an approach which harnesses the
direct effector functions of macrophages or monocytes, optimizes their activation status toward an inflammatory M1 phenotype, and redirects
phagocytosis with molecular specificity would represent a major advance in cancer immunotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Carisma&rsquo;s Novel Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CAR-M have the potential to address the key challenges
involved in treating solid tumors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img03.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CAR-M have the ability to infiltrate solid tumors,
phagocytose and destroy tumor cells directly, and present tumor-derived antigens leading to activation of the adaptive immune system.
CAR-M mount anti-tumor immunity in numerous ways. First, CAR-M leverage the natural tumor-homing ability of macrophages and monocytes,
the naturally most abundant immune cells in the TME, to traffic to both primary tumors and metastases, enabling engineered macrophages
to act as a &ldquo;Trojan horse,&rdquo; tricking the tumor into recruiting engineered, anti-tumor CAR-M as if they were normal monocytes
or macrophages. Once within the tumor, CAR-M directly kill antigen-expressing tumor cells through phagocytosis and secretion of cytotoxic
factors. CAR-M secrete inflammatory cytokines and chemokines that promote a pro-inflammatory environment and lead to the recruitment of
T-cells and other leukocytes. Finally, CAR-M serve as professional antigen-presenting cells for T-cells, inducing epitope spreading, systemic
anti-tumor immunity, and immune memory against tumor antigens, expanding anti-tumor immunity to target negative tumor cells and potentially
preventing antigen negative relapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm238578d1_ex99-2img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Historically, macrophages have been challenging
to genetically engineer due to their inherent resistance to most commonly used genetic manipulation methods. Furthermore, controlling
the activation state of macrophages has been a long-standing challenge. Carisma believes that it has overcome these challenges with its
proprietary platform that efficiently engineers macrophage-based cell therapies and enables control of their activation state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s proprietary platform enables the
therapeutic use of engineered macrophages and monocytes for the treatment of cancer and other serious diseases and disorders. In its first
application, solid tumors that overexpress HER2, the CAR-M platform is designed to identify and eradicate HER2 overexpressing tumor cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, CAR-M are an individualized therapy
that begin with the isolation of monocytes, the pre-cursor cell to macrophages, from blood drawn from a patient through a process called
apheresis. The cells are purified, cultured, differentiated, and engineered with a CAR which bestows the macrophage with the ability to
identify and eradicate cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To enable its proprietary CAR-M therapy, Carisma
had to overcome several key technical challenges, which are summarized by its platform capabilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Gene Delivery</I></B>: Carisma has identified Ad5f35, a chimeric adenoviral vector, as a highly efficient vector for introducing
genes such as CARs into primary human macrophages and monocytes. Carisma has further developed additional proprietary technologies for&nbsp;<I>ex
vivo</I>&nbsp;and&nbsp;<I>in vivo</I>&nbsp;macrophage engineering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Activation State</I>:</B>&nbsp;Carisma demonstrated that Ad5f35 transduction leads to M1 polarization of human macrophages and
monocytes and renders them resistant to conversion to M2 by immunosuppressive environments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B>Tumor targeting:</B>&nbsp;Carisma demonstrated that macrophage function can be harnessed against tumors in a targeted fashion via
CARs. Carisma&rsquo;s CARs enable antigen specific activation of macrophages and monocytes, antigen specific cancer cell phagocytosis
and killing, and antigen specific release of pro-inflammatory cytokines and chemokines.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B>T-cell activation:</B>&nbsp;By appropriately engineering and polarizing CAR-M, Carisma has demonstrated that they are able to recruit
and activate T-cells&thinsp;-&thinsp;a key aspect to solid tumor immunotherapy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B>Cell manufacturing processes:</B>&nbsp;Carisma has developed manufacturing processes that enable the production of genetically
engineered macrophages or monocytes for therapeutic use.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the case of Carisma&rsquo;s lead product, CT-0508,
a chimeric adenoviral vector, or Ad5f35, is used to deliver an anti-HER2 CAR which enables the macrophages to detect, phagocytose, kill,
release inflammatory mediators, and initiate an immune reaction in response to HER2 overexpressing tumor cells. The resulting CAR-M, which
are adenovirally transduced and locked into a pro-inflammatory M1 phenotype during the&nbsp;manufacturing process, are cryopreserved and
shipped back to the patient for reinfusion. Reinfused CAR-M rapidly egress from peripheral blood and infiltrate tumor sites. Once in the
tumor, CAR-M are activated by tumor-associated antigen engagement with the CAR, signaling via an intracellular signaling domain to phagocytose
the tumor cell and release pro-inflammatory cytokines and chemokines that &ldquo;warm up&rdquo; the TME. They produce locally acting mediators
that reprogram the TME, drawing in T-cells and NK cells, activating nearby antigen presenting cells, or APCs, such as dendritic cells,
or DCs, and repolarizing immunosuppressive TAMs toward an M1 phenotype. In addition to direct phagocytosis of tumor cells, CAR-M present
a patient&rsquo;s unique array of tumor antigens to T-cells, leading to a broad adaptive immune response that has the potential to generate
broad anti-tumor immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Pre-clinical Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma evaluated its CAR-M platform in a variety
of pre-clinical&nbsp;<I>in vitro</I>&nbsp;and&nbsp;<I>in vivo</I>&nbsp;model systems and published its foundational data in Nature Biotechnology
in March&nbsp;2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">First, Carisma found that Ad5f35 led to the efficient
transduction of human macrophages and could be utilized to produce human CAR-M. CAR-M mediated potent antigen-specific phagocytosis and
tumor killing in a targeted fashion. CAR-M took on an activated M1 phenotype, expressed pro-inflammatory cytokines and chemokines, converted
bystander M2 macrophages toward an M1 phenotype, recruited T-cells, and increased antigen presentation to activate T-cells. Enhanced anti-tumor
T-cell responses mediated by CAR-M were noted in humanized murine models and the findings are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Human CAR-M Anti-Tumoral Function&nbsp;<I>In Vitro</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* SKOV3 = Human HER2+ ovarian cancer cell line<BR>
* UTD = Untransduced<BR>
* CAR = Anti-HER2 human CAR-M<BR>
* DeltaZ&nbsp;= CAR-M with a non-signaling control CAR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CAR-M were able to traffic to established tumors
and co-localized with metastatic foci in the lung after intravenous administration without a pre-conditioning regimen. CAR-M treatment
induced significant reduction in tumor burden and improved overall survival compared to mice treated with control macrophages in multiple
mouse tumor models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Transduction of macrophages with Ad5f35 led to
the induction of a durable M1 phenotype. Despite the purported plasticity of macrophage phenotype, Ad5f35 transduced macrophages did not
convert to M2 upon stimulation. CAR-M maintained a pro-inflammatory M1 state within the TME, while control macrophages were converted
to M2. Additionally, CAR-M induced a pro-inflammatory signature in the surrounding TME. Given that solid tumors are rich in TAMs, Carisma
evaluated the bidirectional interaction of CAR-M and M2 macrophages. While M2 macrophages failed to convert CAR-M from M1 to M2, CAR-M
converted M2 macrophages to M1. Additionally, the presence of M2 macrophages did not impact the tumor killing capacity of CAR-M, highlighting
their resistance to the immunosuppressive components of the TME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Finally, CAR-M were shown to interact with cells
of the adaptive immune system. CAR-M upregulated antigen presentation pathways and demonstrated heightened T-cell stimulation capacity
as compared to control macrophages. Notably, CAR-M were able to present antigens to T-cells following phagocytosis. In addition, CAR-M
were able to directly recruit various subtypes of T-cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To further its understanding of CAR-M, Carisma
sought to model their function in fully immunocompetent mouse models which have an intact TME and immune system, enabling recapitulation
of the complex immunological environment in human cancer patients. Toward that goal, Carisma developed a murine surrogate CAR-M to demonstrate
the mechanism of action of CAR-M&nbsp;<I>in vivo</I>&nbsp;in mice which have a fully intact immune system. First, Carisma validated comparability
between human and murine CAR-M. Carisma demonstrated that the same vector utilized in its clinical pipeline, Ad5f35, could be used to
engineer primary murine macrophages, and confirmed that T-cells were viable, expressed CAR, and were similarly polarized to an M1 phenotype.
Functional studies showed CAR-M mediated tumor killing of target cancer cells and enhanced the&nbsp;<I>in vitro</I>&nbsp;function of T-cells.
Furthermore, murine CAR-M released pro-inflammatory cytokines similarly to human CAR-M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pre-clinical immunocompetent solid tumor models
were established via subcutaneous, or SC, injection and engraftment of the murine colorectal cancer cell line, or CT26, engineered to
express human HER2. In this model, intratumoral, or IT, CAR-M monotherapy significantly reduced tumor growth and prolonged overall survival
compared to untransduced macrophages (macrophages not expressing a CAR). By rechallenging complete responders several months post tumor
clearance with the same tumor cells lacking HER2 expression, Carisma was able to demonstrate that CAR-M therapy leads to epitope spreading
and immune memory which confers protection against antigen-negative relapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CAR-M Control Tumor Progression,&nbsp;Improve Survival and Induce
Long-Term Protection against Antigen-negative Relapse</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img05.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">* UTD-M = Untransduced macrophage</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CT26-HER2+ tumors were implanted subcutaneously
in immunocompetent syngeneic mice. After 15 days, mice were treated with intratumoral CAR-M, UTD-M, or left untreated. CAR-M significantly
reduced tumor progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CAR-M significantly increased long term survival
compared to control groups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mice achieving complete responses, or CR, post
CAR-M therapy were re-challenged with HER2-negative CT26-Wt tumors to model antigen negative relapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Na&iuml;ve mice succumbed to disease within 35
days, while 100% of the mice from the CAR-M treatment group survived, indicating long-term tumor protection against antigen negative relapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">T-cell depletion reversed CAR-M induced protection
against antigen negative relapse, indicating that CAR-M treatment led to epitope spreading and anti-tumor T-cell memory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Analysis of the tumor microenvironment of mice
receiving CAR-M therapy demonstrated the ability of Carisma&rsquo;s therapy to recruit additional immune cells, including T-cells, into
the tumor. CAR-M led to immune activation in the TME associated with T-cell expansion, activation, and modulation of the overall T-cell
repertoire of tumor infiltrating lymphocytes&thinsp;-&thinsp;suggesting the induction of a broad anti-tumor immune response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CAR-M Reprogram the TME and Prime T-cells</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img07.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Immunohistochemistry assessment showed that CAR-M
treatment increased tumor CD8+ T-cell infiltration in the CT26-HER2+ model indicating activation of the TME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Flow cytometric analysis showed increased tumor
infiltration of T-cells, NK cells, activated CD86+ DCs and tumor associated antigen specific CD8 T-cells (gp70 Tet+) in CAR-M treated
mice, suggesting epitope spreading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Combined, these results demonstrate that CAR-M
have the potential to overcome some of the key challenges cell therapies encounter in the solid tumor setting and represent a novel immunotherapeutic
platform that can be broadly applied to diverse tumor antigen targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is applying its CAR-M platform to a broad
pipeline of product candidates, and Carisma intends to build a fully integrated immunotherapy company spanning autologous cell therapy,
allogeneic cell therapy, and&nbsp;<I>in vivo</I>&nbsp;macrophage gene therapy. Carisma currently owns all rights to its product candidates
and programs outside of its Moderna collaboration, which is limited to direct&nbsp;<I>in vivo</I>&nbsp;reprogrammed CAR-M in the field
of oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Macrophage and Monocyte Engineering Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img08.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Gene Delivery</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the core of Carisma&rsquo;s platform are its
proprietary viral and non-viral approaches for delivering different payloads into macrophages and monocytes and engineering them into
a variety of phenotypes depending on the disease which they are intended to treat.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For its initial solid tumor programs, Carisma&rsquo;s
adenoviral vector enables Carisma to generate an abundant supply of CAR-M cells and engineer the cells to be locked into an M1 phenotype.
Carisma selected Ad5f35 after testing commonly utilized viral and non-viral approaches and demonstrating Ad5f35&rsquo;s high efficiency
in transducing primary human monocytes and macrophages. Ad5f35 can transduce macrophages with high efficiency, viability and reproducibility
amongst donors. In addition to being highly efficient, transduction with Ad5f35 polarizes and locks macrophages into an M1 phenotype.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to Ad5f35, Carisma&rsquo;s platform
includes two other proprietary methods for delivering genes into macrophages. The first is a modified lentiviral vector, or Vpx-LV, which
carries viral protein X. Vpx-LV depletes SAMHD1 and permits lentiviral transduction of primary human monocytes, macrophages, and dendritic
cells. Vpx-LV was developed by Dr.&nbsp;Nathaniel Landau at New York University, and Carisma holds a global exclusive license to develop
this vector. Unlike Ad5f35, which induces a potent M1 phenotype upon transduction, Vpx-LV has minimal impact on macrophage phenotype and
can be utilized as a flexible tool to generate M0 (non-activated), M1 (pro-inflammatory), or M2 (anti-inflammatory) polarized myeloid
cell therapies with durable gene expression. Additionally, Carisma has developed a proprietary non-viral mRNA-based approach to transiently
engineered macrophage and a companion method to induce a durable pro-inflammatory M1 phenotype. Carisma has successfully generated M1-primed
non-viral CAR-M using a research manufacturing process consisting of mRNA transfection to deliver the CAR transgene followed by IFN&beta;
priming to polarize the cells to an M1 anti-tumoral phenotype. Non-viral CAR-M demonstrated high viability, high CAR expression, M1 polarization
and anti-tumoral function&nbsp;<I>ex vivo</I>&nbsp;similar to Ad5f35 engineered CAR-M. Additionally, in partnership with Moderna, Carisma
is developing a myeloid tropic LNP/mRNA platform to program CAR-M directly&nbsp;<I>in vivo</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approach to Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s proprietary technology and engineering
capabilities enabled it to pioneer the CAR-M field and conduct the first in human CAR-M clinical trial, establishing its leading position
in the engineered macrophage space. Carisma&rsquo;s goal is to advance&nbsp;<I>ex vivo</I>&nbsp;autologous cell therapies and off-the-shelf
therapies including allogeneic cell therapies and direct&nbsp;<I>in vivo</I>&nbsp;reprogramming approaches in oncology and other indications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Expansion: Building Upon the Learnings of Autologous
Cell Therapy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img09.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While the first iteration of its platform is the
CAR macrophage, Carisma has expanded its capabilities to include multiple myeloid cell types (monocytes, macrophages, and dendritic cells),
multiple gene delivery modalities (Ad5f35, Vpx-LV, and mRNA), various phenotypes (M1, M2, and subtypes thereof), and a broad variety of
payloads including CARs, immune ligands, secreted or tethered cytokines, transcription factors, and other genes that enhance efficacy.
Importantly, Carisma has expanded its platform to enable&nbsp;<I>in vivo</I>&nbsp;engineering of myeloid cells directly within the patient&rsquo;s
body. Additionally, Carisma has established a robust process to edit the genome of human myeloid cells by utilizing tools such as CRISPR/Cas9,
enabling gene edited macrophages with inhibitory pathways such as SIRP&alpha; genetically removed from the cell product. Carisma&rsquo;s
engineered macrophage platform enables fine tuning the activation state of the engineered macrophage or monocyte. Finally, Carisma has
established a novel Engineered Myeloid Microenvironment Converter, or EM-C, platform that utilizes proprietary synthetic cytokine switch
receptors to generate engineered macrophages that respond to M2 cytokines with M1 responses (for oncology applications) or to generate
engineered macrophages that respond to M1 cytokines with M2 responses, for auto-immune or chronic inflammatory diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Carisma&rsquo;s Pipeline of Product Candidates and Discovery Programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Using its proprietary CAR-M platform, Carisma is
developing a broad pipeline of product candidates, with an initial focus in oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><IMG SRC="tm238578d1_ex99-2img10.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lead Product Candidate: CT-0508</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CT-0508 is a cell product comprised of autologous,
peripheral blood monocyte-derived, pro inflammatory macrophages, transduced with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2
CAR. The anti-HER2 CAR is a first-generation CAR composed of a fully human single-chain variable fragment, or scFv, derived from the monoclonal
antibody trastuzumab, which is specific for human HER2. The anti-HER2 scFv is fused to a CAR backbone containing a cluster of differentiation
CD8 hinge, CD8 transmembrane domain, and a CD3&zeta; intracellular domain. The CAR is cloned into an adenoviral vector backbone and transduced
into monocyte-derived macrophages. Based on the pre-clinical data generated to date, CT-0508 CAR-M are able to specifically recognize
HER2 overexpressing tumor cells, which triggers both direct killing of tumor cells and phagocytosis. Additionally, CAR engagement by HER2
on tumor cells results in the secretion of a broad array of pro-inflammatory cytokines and chemokines, which contribute to the recruitment
and activation of additional immune cells to the TME, including effector T-cells and other antigen presenting cells. CT-0508 CAR-M are
antigen presenting cells, and after phagocytosing tumor cells they process tumor-derived antigens and present them to T-cells, leading
to T-cell immunity against tumor antigens. This additional activation of the adaptive immune system amplifies anti-tumor immune response
and can lead to long term immune memory not only against HER2, the primary target, but other tumor specific neoantigens as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Phase 1 clinical trial of CT-0508 is currently
ongoing. As of March&nbsp;7, 2022, seven clinical sites were open for screening and enrollment: (i)&nbsp;the University of Pennsylvania
Abramson Cancer Center, (ii)&nbsp;the University of North Carolina Lineberger Comprehensive Cancer Center, (iii)&nbsp;the City of Hope
National Medical Center, (iv)&nbsp;the MD Anderson Cancer Center, (v)&nbsp;the Sarah Cannon Cancer Research Institute, (vi)&nbsp;Oregon
Health&nbsp;&amp; Science University and (vii)&nbsp;Fred Hutchinson Cancer Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November&nbsp;2022, Carisma presented preliminary
clinical results from the first group of patients. CT-0508 was successfully manufactured using macrophages obtained from heavily pre-treated,
advanced solid tumor patients and has shown high CAR expression, viability, and purity. In addition, CT-0508 has been generally well-tolerated
after infusion with no dose-limiting toxicities reported to date from the nine patients enrolled in the first group. While the results
from this early clinical trial data are both preliminary and limited, Carisma believes the results indicate that CT-0508 can be detected
within the TME, lead to remodeling and activation of the TME, and potentially induce anti-tumor adaptive immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA has granted &ldquo;Fast Track&rdquo; status
to CT-0508 for the treatment of patients with HER2 overexpressing solid tumors. The components of CT-0508 cells are shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Components of First-Generation CAR Construct</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img11.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure Legend: CT-0508 is an autologous monocyte
derived macrophage cell product engineered with the adenoviral vector Ad5f35 to express an anti-HER2 CAR. The CAR is comprised of a single
chain variable fragment derived from a humanized anti-HER2 antibody which provides specificity against the target antigen. The scFv is
linked to a hinge domain derived from the human CD8 protein, which enables extension and flexibility from the cell membrane surface. The
hinge is linked to a CD8 transmembrane, or TM, domain which spans the cell membrane, linking the extracellular portion of the CAR to the
intracellular portion of the CAR, which is comprised of CD3&zeta;. CD3&zeta; signaling is activated when the CAR binds to the target antigen,
leading to macrophage activation, phagocytosis, tumor cell killing, and release of pro-inflammatory factors such as cytokines and chemokines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CT-0508 Therapy for HER2+ Solid Tumors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While therapies targeting solid tumors that overexpress
HER2 have led to improved survival in breast and gastric or gastro-esophageal junction cancers, there remains an unmet need in patients
with advanced HER2 positive, or HER2+, cancers and HER2 expressing cancers, including metastatic lung, ovarian, colon, bladder, and other
cancers for which there are no HER2 targeted agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Approximately 20% of breast cancers overexpress
HER2, a protein that is overexpressed on the surface of a variety of solid tumors. In addition to breast, gastric, and gastroesophageal
junction cancers, HER2 is also overexpressed in a number of solid tumor indications including but not limited to bladder cancer, ovarian
cancer, lung cancer and colon cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 3.5pt; padding-bottom: 2.25pt">HER2 Positivity Frequencies Across Tumor Types</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 8%">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid; width: 41%">Tumor type</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 2%"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; width: 41%; padding-top: 2.5pt; padding-bottom: 2.25pt">HER2 <BR>
positivity (%)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; width: 8%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Bladder cancer</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">8&thinsp;-&thinsp;70</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Breast cancer</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">11.0&thinsp;-&thinsp;25.0</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Cervical cancer</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">2.8&thinsp;-&thinsp;3.9</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Colorectal cancer</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">1.6&thinsp;-&thinsp;5.0</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Esophageal cancer</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">12.0&thinsp;-&thinsp;14.0</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Extrahepatic Cholangiocarcinoma</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">6.3&thinsp;-&thinsp;9.0</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Gallbladder cancer</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">9.8&thinsp;-&thinsp;12.8</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Gastric adenocarcinoma</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">7.0&thinsp;-&thinsp;34.0</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Ovarian cancer</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">26</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Salivary duct carcinoma</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">30&thinsp;-&thinsp;40</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Salivary mucoepidermoid carcinomas</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">17.6</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Testicular cancer</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">2.4</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2.5pt 3pt 2.25pt 0.5in; border-bottom: black 1pt solid">Uterine cancer</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.5in; padding-top: 2.5pt; padding-bottom: 2.25pt">3.0</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CT-0508 Clinical Study Design&thinsp;-&thinsp;Study 101</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ongoing Phase 1 clinical trial of CT-0508 is
a single-arm, open-label study of systemic intravenous administration of CT-0508. This study is intended to evaluate safety, tolerability,
cell trafficking, cell-manufacturing feasibility, and preliminary evidence of efficacy in approximately 18 subjects with locally advanced
or metastatic solid tumors overexpressing HER2 who have failed available therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A summary of the clinical trial design, dosing
regimen, sample collection regimen, and primary and secondary objectives are shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img12.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Filgrastim, or recombinant G-CSF, is administered
to patients for four days prior to apheresis to mobilize monocytes into the peripheral blood, increasing the available circulating monocyte
count prior to collection by apheresis. The CT-0508 cell product is then prepared, cryopreserved, and released following quality control
testing. The first three participants in the study were hospitalized for eight days after the first infusion of CT-0508 (Day 1 to Day
8) as part of the pre-determined study design. There is no preparative chemotherapy prior to the cell product infusion. The first group
of nine patients have been treated with a divided dose regimen consisting of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Day 1:</I></B>&nbsp;Up to 0.5 &times; 10<SUP>9</SUP>&nbsp;cells;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Day 3:</I></B>&nbsp;Up to 1.5 &times; 10<SUP>9</SUP>&nbsp;cells; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Day 5:</I></B>&nbsp;Up to 3.0 &times; 10<SUP>9</SUP>&nbsp;cells.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Adverse event reporting begins at the start of
mobilization and continues until any toxicities resolve or are deemed irreversible. Participants are continually reassessed for evidence
of acute and/or cumulative toxicity. Approximately nine participants in the second group of patients will receive up to 5.0 &times; 10<SUP>9</SUP>&nbsp;total
manufactured CT-0508 cells in a single infusion on Day 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">HER2 has several advantages as a target antigen
for CAR-M. In addition to being expressed in a variety of solid tumor types with significant unmet medical needs, HER2 is not shed or
internalized and is only expressed at low levels in non-tumor tissues. As HER2 expression is typically maintained over the course of disease,
CT-0508 may be developed for treatment of metastatic disease, for example, in the liver and lung, as well as primary tumors. Additionally,
HER2 is typically not lost after patients with metastatic cancer progress on available HER2 targeted therapies, rendering HER2 refractory
patients potentially eligible for CT-0508 therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Participants enrolled in Study 101 undergo one
pre-treatment and two on-treatment biopsies to assess CT-0508 trafficking, impact on the TME, induction of anti-tumor T-cell immunity,
and other biomarkers. Blood samples are also collected over a period of 52 weeks for evaluation of pharmacokinetics and biomarkers associated
with safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based upon clinical data, Carisma may seek Regenerative
Medicine Advanced Therapy, or RMAT, and PRIority MEdicine, or PRIME, designations for CT-0508, which provide an expedited developmental
and approval pathway, in the United States and the European Union, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CT-0508 Clinical Data&thinsp;-&thinsp;Study 101</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Enrollment of the first group of nine patients
in the Phase 1 clinical trial of CT-0508 has been completed and enrollment in the second group is currently ongoing. Carisma successfully
generated CT-0508 product for all participants enrolled in the first group of the study with an average cell viability of 89%, an average
purity of 85%, and an average CAR transduction of 81%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma has reported on the safety, clinical response,
and correlative studies for the first nine patients dosed in the first group of the clinical trial. Of such patients, two had HER2 overexpression
levels of 2+ by immunohistochemistry staining, or IHC, with additional fluorescent in-situ hybridization FISH confirmation; and seven
had levels of HER2 3+ by IHC. HER2 grading was performed based on the ASCO/CAP guidelines. Patients in
the trial had three median prior therapies with a range of two to 11. Patients had a median of two prior HER2 targeted therapies, with
a range of zero to nine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CT-0508 was well tolerated with no dose-limiting
toxicities. The majority (55.5%) of subjects with treatment-emergent adverse events, or TEAEs, by maximum severity were Grades 1 and 2.
One subject experienced an unrelated Grade 4 TEAE (related to progression of disease of the patient&rsquo;s cancer). For subjects with
TEAEs considered related to CT-0508, the majority (66.6%) were Grades 1 and 2, and none were Grades 4 or 5 severity. With respect to TEAEs
of special interest, six patients experienced CRS, and all of these were Grades 1 and 2. There were no episodes of immune cell therapy
associated neurotoxic syndrome, or ICANS, reported. No patients had severe CRS. No AEs, or SAEs, led to CT-0508 dose modification or discontinuation.
No major organ toxicity was observed. The majority of AEs, regardless of relatedness, were Grades 1 and 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 3.5pt; padding-bottom: 2.25pt">Overview of Subjects with Treatment-Emergent Adverse Events (Safety Population)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 8%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; width: 41%; padding-top: 2.5pt; padding-bottom: 2.25pt">Category</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 2%; padding-left: 0.75pt"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; width: 41%; padding-top: 2.5pt; padding-bottom: 2.25pt">n = 9 (%)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; width: 8%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">Treatment-Emergent Adverse Event (TEAE)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">9 (100.0)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">TEAE, Related to CT-0508</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">8 (88.9)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">TEAE, Serious AE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">4 (44.4)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">TEAE, Serious AE Related to CT-0508</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">2 (22.2)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">TEAE, AEs of Special Interest</TD>
    <TD STYLE="padding-bottom: 1pt; border-right: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">7 (77.8)</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; padding-top: 3pt; padding-bottom: 2.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#9702;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Grade 1</P></TD>
    <TD STYLE="padding-bottom: 1pt; border-right: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="padding-left: 0.375in; white-space: nowrap; padding-top: 3pt; padding-bottom: 2.25pt">3 (33.3)</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; padding-top: 3pt; padding-bottom: 2.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#9702;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Grade 2</P></TD>
    <TD STYLE="padding-bottom: 1pt; border-right: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="padding-left: 0.375in; white-space: nowrap; padding-top: 3pt; padding-bottom: 2.25pt">4 (44.4)</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; padding-top: 3pt; padding-bottom: 2.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#9702;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Grade 3</P></TD>
    <TD STYLE="padding-bottom: 1pt; border-right: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="padding-left: 0.375in; white-space: nowrap; padding-top: 3pt; padding-bottom: 2.25pt">0 (0.0)</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; padding-top: 3pt; padding-bottom: 2.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#9702;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Grade 4</P></TD>
    <TD STYLE="padding-bottom: 1pt; border-right: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="padding-left: 0.375in; white-space: nowrap; padding-top: 3pt; padding-bottom: 2.25pt">0 (0.0)</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 3pt; padding-bottom: 2.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#9702;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Grade 5</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; white-space: nowrap; padding-top: 3pt; padding-bottom: 2.25pt">0 (0.0)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">Discontinued CT-0508 due to TEAE</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 0.75pt"></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0.375in; padding-top: 2.5pt; padding-bottom: 2.25pt">0 (0.0)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Summary of AEs by Preferred Term and by Severity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img13.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The best overall response was stable disease per
RECIST 1.1 criteria. A best overall response of stable disease was observed in four out of nine patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Transient and low-grade fever was observed in seven
out of nine patients post CT-0508 infusion. All fevers resolved within 48 hours. In concordance with clinical observations, a transient
increase in serum IL-6, a pro-inflammatory cytokine, was observed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma evaluated the pharmacokinetics, or PK,
of CT-0508 in the peripheral blood and the tumor. Similar peripheral blood PK was observed for all nine participants with CT-0508 detectable
only on infusion days for four to eight hours post-infusion, consistent with rapid migration of CAR-M from the blood to tissues following
infusion. CT-0508 was detected within the TME of eight out of nine evaluable patients assessed to date using RNAscope&trade; technology
as shown below. These data suggest that CT-0508 rapidly egresses from the peripheral blood and successfully traffic to the biopsied tumor
mass.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CT-0508 Rapidly Migrates Out of the Blood and is Detected within
the TME of 8/9 Participants Evaluated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img14.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To evaluate the mechanism of action of CT-0508,
single cell RNA sequencing, or scRNAseq, analysis was performed on fresh tumor biopsy to investigate changes within the TME following
CT-0508 infusion. Analysis of screening (n=5), Day 8 post-infusion (n=5) and Week 4 post-infusion (n=3) biopsies revealed increases in
CD8 T-cells, macrophages, and neutrophils on treatment consistent with inflammation and activation of an immune response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These increases were also associated with reprogramming
of the infiltrating macrophages toward an M1 phenotype by Week 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Single Cell RNAseq Analysis Demonstrates Remodeling of the Tumor
Immune Landscape Following CT-0508 Infusion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img15.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To evaluate whether CT-0508 was able to initiate
anti-tumor adaptive immunity, TCR repertoire analysis was performed utilizing the Adaptive Biotechnologies&trade; TCR sequencing platform.
The analysis was performed on peripheral blood and tumor tissue. Peripheral blood TCR repertoire analysis revealed an expansion of T-cell
clones in the blood of participants post CT-0508 infusion, indicative of the initiation of an adaptive immune response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Early Expansion of T-cells in the Periphery Following CT-0508 Infusion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm238578d1_ex99-2img16.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on scRNAseq analysis, the frequency of effector
T-cells increased in all three participants with available screening and Week 4 biopsies (shown below). Furthermore, Carisma evaluated
T-cell subtypes and found that Participant 1 demonstrated an increase in proliferating and effector memory CD8 T-cells, Participant 2
demonstrated an increase of all subsets except for activated CD8 T-cells, and Participant 4 demonstrated an increase in activated CD4,
activated CD8 and effector memory CD8 T-cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Frequency of effector T-cells in TME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img17.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Differential gene expression analysis performed
on biopsies collected at Week 4 post-CT-0508 infusion demonstrated an increased expression of genes associated with cytotoxic CD8 T-cell
activation when compared to pre-treatment expression TME samples from six patients analyzed by RNA sequencing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Increased T-Cell Activation in the TME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img18.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TCR repertoire analysis of the TME revealed that
newly expanded peripheral clones accumulated over time within the TME, suggesting that these clones are tumor reactive. Expanding T-cell
clonotypes from patient 1, 2 and 4 at Week 4 post-infusion clustered with cells expressing high levels of CD8&alpha;, perforin, granzyme
B, Ki67,&nbsp;IFN&gamma;, and PD1 demonstrated their activated and/or proliferating CD8 cytotoxic T lymphocyte phenotype.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Peripherally Expanded T-cell Clones Accumulate in the TME and Adopt
a Cytotoxic Phenotype</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img19.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While preliminary, the clinical data to date confirmed
that CT-0508 is successfully manufactured from heavily pre-treated solid tumor patients, has been well tolerated, traffics to the tumor,
activates the TME, and may initiate anti-tumor adaptive immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional CT-0508 Studies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CT-0508 and Pembrolizumab combination sub study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This open-label sub study will assess the safety
and feasibility of co-administering CT-0508 in combination with the PD-1 inhibitor, pembrolizumab. The target population for this sub
study are subjects at least 18 years of age who meet inclusion criteria per the main protocol and have HER2 over-expressing solid tumors
and meet the sub study specific eligibility criteria. Carisma expects to report clinical data for this sub study in the second half of
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CT-0508 Intraperitoneal administration sub study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This sub study has been designed to assess the
safety and feasibility of CT-0508 via regional administration into the peritoneal cavity. The target population for this sub study are
subjects at least 18 years of age who meet inclusion criteria per the main protocol, that have HER2 over-expressing gynecological cancers
including but not limited to ovarian, fallopian tube, primary peritoneal, and endometrial cancers, who have disease spread mainly within
the peritoneal cavity that meet the sub study specific eligibility criteria. Subjects will be enrolled at select clinical sites participating
in Study 101 that have the capability to enroll and adequately treat subjects with intraperitoneal administration of CT-0508. Carisma
expects to report clinical data for this sub study in the second half of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CT-0508 Biodistribution sub study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This open-label sub study is designed to evaluate
the whole body biodistribution of CT-0508 after intravenous administration using radiolabeled CT-0508 and longitudinal PET/CT imaging.
This sub study includes&nbsp;<SUP>89</SUP>Zr-oxine radiolabeling a fraction of the CT-0508 cell product, followed by administration on
Day 1 and PET/CT imaging approximately on Day 1, 4, 8, 15, and 28 to assess trafficking and biodistribution of CT-0508. The target population
for this sub study are subjects at least 18 years of age that meet inclusion criteria per the main protocol. Subjects will be enrolled
at specific sites in Study 101 that have the capability to perform&nbsp;<SUP>89</SUP>Zr-oxine labeling, administration, and routine PET/CT
analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Synergistic Potential of CAR-M Therapy with T-Cell Checkpoint Inhibitors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Blocking the immune checkpoint molecule programmed
cell death 1, or PD-1, has revolutionized cancer treatment for patients with a multitude of solid tumor indications. Pembrolizumab is
a potent humanized immunoglobulin G4, or IgG4, monoclonal antibody, or mAb, with high specificity of binding to the PD-1 receptor, inhibiting
its interaction with programmed cell death ligand 1, or PD-L1, and programmed cell death ligand 2, or PD-L2. While pembrolizumab is currently
indicated for the treatment of patients across several solid tumor indications, the majority of patients have either primary or secondary
resistance to immune checkpoint blockade and may benefit from combinatorial therapy that could overcome immune cell exclusion, poor antigen
presentation, low T-cell infiltration, high TAM infiltration, a lack of productive co-stimulation, low mutational burden,&nbsp;IT immunosuppression,
and a low frequency of tumor reactive T-cell clones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on the data generated during pre-clinical
development, CT-0508 cell product is able to specifically recognize, cancer cells through the binding of the CAR to HER2 expressed on
the surface of these cells. This interaction triggers activation of the CAR-macrophages and results in direct anti-tumor effect by killing
and phagocytosis of the tumor cells. In addition, CT-0508 recruits T-cells, activates the TME, and as professional antigen presenting
cells, can process and present tumor associated antigen and/or neoantigens expressed by the tumor cells, leading to T-cell immunity against
these specific antigens. However, this indirect anti-tumor effect involves the engagement of T-cells that may be actively suppressed,
or exhausted, within the tumor micro-environment by a variety of factors including secreted immune-modulatory factors and inhibitory ligands
expressed on both immune and tumor cells. Additionally, several studies have demonstrated that patients with low mutational burden, low
MHC expression, defective antigen presentation, low CD8+ T-cell infiltration, or minimal Th1 cytokine signatures tend to be unresponsive
to PD-1 blockade. Therefore, based on the mechanism of action of CT-0508 and the limitations of PD-1 blockade, the combination of CAR-M
therapy with PD-1 blockade therapy may be beneficial by enhancing antigen presentation (innate immunity) to initiate a robust anti-tumor
T-cell response (adaptive immunity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CAR-M and PD-1 blockade combination therapy: Pre-clinical Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To model the combination of CT-0508 cell therapy
with anti-PD-1 inhibitors, Carisma used a murine colorectal cancer cell line engineered to overexpress human HER2. Tumors were established
in the flank of the immune competent mice and 14 days post tumor inoculation, mice were randomized and received either murine CAR-M alone
(IV), murine PD-1 blockade alone (IP) or a combination of both treatments. Using a regimen where CAR-M was injected first when the tumor
was well established, followed by the anti-PD-1 inhibitor a few days later, neither murine CAR-M (Anti-HER2 muCAR-Mac) nor murine anti-PD1
monotherapy had a significant effect on tumor growth and overall survival. However, when co-administered the combination of both therapies
resulted in significant tumor growth delay associated with prolonged survival of the mice (all mice in the combination group survived
until the end of the study). All mice treated with the combination of Anti-HER2 muCAR-Mac and anti-PD1 mAb completely cleared their tumors
(below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Assessment of Tumor Burden and overall survival in a Syngeneic Mouse
Model of Colon Carcinoma in response to treatment with IV CAR-M and Anti-PD-1 Therapy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img20.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">*Anti-HER2 muCAR-Mac are murine CAR-M and muUTD-Mac
are untransduced murine CAR-M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To determine the impact of Anti-HER2 muCAR-Mac
and anti-PD-1 mAb combination therapy on tumor burden, tumor volumes were recorded during the treatment period (depicted in the left panel
above) and mice were monitored for survival (depicted in the right panel above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the IV CAR-M alone and in combination
with anti-PD-1 therapy study described above, Carisma has performed studies with IT administered murine CAR-M. In this study, anti-PD-1
therapy was administered four times, at 3-day intervals starting 14 days post tumor inoculation (CAR-M therapy initiated on Day 15). IT
murine CAR-M and anti-PD-1 therapy improved tumor control and significantly improved survival probability. Cumulative survival for all
groups: 0% CR CTRL, 8.3% CR anti-PD-1, 38.9% CR CAR-M and 66.7% CR CAR-M and anti-PD-1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IT CAR-M and Anti-PD-1 Combination Therapy Improves Survival in
the CT26-HER2 Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img21.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Analysis of immune cell populations in the TME
showed that macrophages were more abundant in the CAR-M samples while other myeloid cells and DCs showed the greatest infiltration in
the combination group. A significant increase in total tumor infiltrating T-cells, and in particular helper T-cells, was noted in the
combination therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Profound TME Modulation in Response to IT CAR-M and CAR-M +Anti-PD-1
Combination Therapy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img22.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Analysis of the TCR repertoire demonstrated that
IT administration of CAR-M in combination with a PD-1 blocking monoclonal antibody led to increased frequency of T-cells in the periphery
and significantly modulated the TCR repertoire in the TME suggesting enhanced adaptive anti-tumor immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on these data, CAR-M and pembrolizumab represent
a potentially synergistic immunotherapeutic combination regimen that combines CAR-M to infiltrate the TME, degrade the tumor via phagocytosis,
and recruit and prime T-cells and pembrolizumab to prevent or reverse T-cell exhaustion. Patients with HER2 overexpressing tumors, such
as metastatic breast cancer, gastric cancer, ovarian cancer, esophageal cancer, and others are generally poor responders to pembrolizumab.
Carisma has initiated a Phase 1 clinical study to evaluate CT-0508 in combination with pembrolizumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Pipeline Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s additional pipeline candidates
are CAR-M therapies that incorporate all of the core elements of its macrophage cell engineering platform, along with certain new platform
enhancements that Carisma is currently developing. The CT-1119 product candidate targets the mesothelin tumor associated antigen that
is found on lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and numerous other solid tumors. The CT-0729 product candidate
targets the PSMA tumor associated antigen that is found on prostate cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CT-1119 (Anti-Mesothelin CAR-M)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mesothelin is a well validated tumor associated
antigen. Mesothelin has been shown to be aberrantly expressed on the surface of tumor cells and plays an important role in promoting cancer
invasion and proliferation. Mesothelin has been demonstrated to be expressed at high levels in mesothelioma, lung cancer, ovarian cancer,
pancreatic cancer, and other solid tumors with limited expression in normal tissue, though recent data suggests inflammation may induce
expression. There are no approved anti-mesothelin agents and no approved cell therapies targeting any of the solid tumor types that overexpress
mesothelin. Mesothelin positive solid tumors represent a significant unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While there are no mesothelin targeted approved
agents, numerous clinical trials have been conducted targeting mesothelin and safety has been established with a variety of modalities
including monoclonal antibodies, antibody drug conjugates, and CAR-T-cells. Targeting mesothelin enables a similar strategy to Carisma&rsquo;s
CT-0508 HER2 Phase 1 trial in that it enables (i)&nbsp;a basket trial design that includes patients with diverse tumor types and (ii)&nbsp;separate
arms for systemic and regional administration. There is a significant opportunity for regional administration of CT-1119, including intraperitoneal
administration for mesothelin positive ovarian cancer with peritoneal metastasis and intrapleural administration for patients with malignant
mesothelioma and lung tumors. There is also a significant opportunity for patients with mesothelin positive solid tumors with systemic
metastasis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To develop a mesothelin targeted CAR-M, Carisma
has screened anti-mesothelin scFv&rsquo;s using mRNA to identify humanized anti-mesothelin binders. Carisma obtained exclusive rights
to a humanized anti-mesothelin scFv from the University of Pennsylvania. Carisma demonstrated that human CAR-M engineered with an Ad5f35
vector show high viability and efficiently express an anti-mesothelin (meso) CAR. Similar to CT-0508, CT-1119 adopts an M1 macrophage
activation state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CT-1119 effectively phagocytose mesothelin positive
lung cancer (A549) and ovarian cancer (MesOV) cells as shown by two independent phagocytosis assays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To evaluate the effector function of CT-1119, Carisma
utilized mesothelin positive lung adenocarcinoma (A549) and ovarian cystadenocarcinoma (MesOV) cell lines.&nbsp;<I>In vitro</I>, CT-1119
shows robust killing of lung cancer cells expressing mesothelin and CAR engagement induces the release of the pro-inflammatory cytokine
TNF-&alpha; following stimulation with mesothelin expressing but not wild type (Wt) cell lines:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CT-1119 Kill and Produce Cytokine in Response to Biologically Relevant
Targets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img23.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to evaluate the direct anti-tumor activity
of CT-1119 in a relevant animal model, Carisma engrafted immunodeficient NSG-S mice with A549 lung adenocarcinoma cells expressing mesothelin
by intravenous administration, which creates a lung metastasis model. CT1119 demonstrated the ability to reduce tumor progression and
reduced the number of metastatic tumor nodules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img24.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These findings demonstrate that CT-1119, an autologous
human anti-mesothelin CAR-M, can effectively phagocytose and kill target tumor cells as well as initiate pro-inflammatory cytokine production
in response to mesothelin. Carisma believes that CAR-M is a feasible approach for the treatment of mesothelin expressing solid tumors
and is advancing the development of this program toward a clinical trial. CT-1119 is anticipated to be a CAR-Mono product encompassing
a next generation CAR to enhance function. Carisma anticipates nominating a next generation CAR construct for CT-1119 in the first half
of 2024. The IND is expected to be submitted in 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CT-0729 (PSMA CAR-M)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prostate-specific membrane antigen, or PSMA, is
highly specific to prostate cancer cells.&nbsp;<I>In vitro</I>&nbsp;studies have been conducted demonstrating that Carisma can:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Express anti-PSMA CARs on human macrophages</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Mediate phagocytosis of PSMA overexpressing tumor cells</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Induce killing of PSMA overexpressing tumor cells</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Initiate cytokine release in a PSMA specific manner</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Generate M1 polarized anti-PSMA CAR-M</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CT-0729 is in the discovery stage and a lead construct
has not yet been nominated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CAR-Mono: Pre-clinical Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, the CAR-M platform requires differentiation
of circulating monocytes into macrophage&nbsp;<I>ex vivo</I>&nbsp;prior to transduction with Ad5f35 to express the CAR.&nbsp;<I>Ex vivo</I>&nbsp;differentiation
takes approximately one week and is associated with the loss of a fraction of cells during the differentiation process. Carisma hypothesized
that monocytes could be directly engineered to express CARs, shortening the&nbsp;<I>ex vivo</I>&nbsp;manufacturing process from approximately
eight days to approximately one to two days. By bypassing&nbsp;<I>ex vivo</I>&nbsp;differentiation, CAR monocytes will be administered
to patients, wherein they will traffic to and enter tumor tissue, differentiating into macrophages&nbsp;<I>in vivo</I>&nbsp;rather than&nbsp;<I>ex
vivo.</I>&nbsp;CAR-Mono are a precursor to the CAR macrophage. Carisma further hypothesized that CAR-Mono may have improved tumor trafficking
potential, given their smaller size and increased chemokine receptor expression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To determine the feasibility of generating CAR
monocytes, or CAR-Mono, Carisma conducted&nbsp;<I>in vitro</I>&nbsp;time course studies to assess cell viability and CAR expression compared
to untransduced monocytes. Following transduction with Ad5f35, CAR expression and cell viability were tracked&nbsp;<I>in vitro</I>&nbsp;for
28 days. Viability was high (&gt;90%) and CAR expression was high (&gt;80%), and both stayed high for the entire 28 days of culture. Durable
CAR expression is critical to enable the cells to (a)&nbsp;retain CAR expression while trafficking to the tumor, (b)&nbsp;retain CAR expression
during differentiation into CAR macrophages, and (c)&nbsp;to enable sustained anti-tumor activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s first CAR-Mono program is CT-0525,
an autologous anti-HER2 CAR-Mono. CT-0525 is an advanced pre-clinical program, and Carisma plans to submit an IND for CT-0525 in the second
half of 2023, followed by initiation of a Phase 1 clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The M1 phenotype of Carisma&rsquo;s CAR-M platform
is an important aspect of the mechanism of action. As monocytes are the precursors to macrophages, differentiation and cell morphology
was evaluated after two days and seven days of culture. After seven days in culture, CAR-Mono showed a progressively increasing M1 phenotype
(high CD80 and CD86 expression) and expressed CAR. Compared to untransduced monocytes cultured for two or seven days&nbsp;<I>in vitro</I>,
Ad5f35 transduced CAR-Mono upregulated M1 markers CD80 and CD86, confirming that Ad5f35 transduction similarly induces an M1 macrophage
phenotype when added at the monocyte stage. Importantly, CAR-Mono-derived CAR-M had a similar morphology to CAR-M generated using the
standard method&thinsp;-&thinsp;confirming morphologically that CAR-Mono differentiate into CAR-M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To confirm that CAR-Mono differentiate into CAR-M
and take on an M1 phenotype&nbsp;<I>in vivo</I>, NSG-S mice were engrafted with NCI-H2444 (Non-Small Cell Lung Cancer). NSG-S mice are
highly immunodeficient mice that express human Interleukin (IL)-3, human GM-CSF, and human stem cell factor. These animals support enhanced
engraftment of myeloid cells compared to NOD/SCID Il2rg-/- (NSG) mice, they are ideal for studies investigating the adoptive transfer
of myeloid cells. Untransduced control or CAR-Mono were intratumorally injected (N=3 donors) and tumors were harvested seven days post
injection. Human immune cells were enriched using flow sorting and processed for scRNA sequencing. By comparing the gene expression of&nbsp;<I>in
vivo</I>&nbsp;and&nbsp;<I>in vitro</I>&nbsp;differentiated untransduced and CAR monocytes, Carisma&rsquo;s data suggest that the monocytes
have the potential to differentiate into macrophages and adopt an M1 like phenotype.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CAR-M are able to directly kill tumor cells via
phagocytosis and release of cytotoxic mediators such as TNF&alpha;. Carisma evaluated the direct tumor killing capacity of CAR-Mono at
Day 2 (monocyte phase) and Day 7 (macrophage phase). AU565, a HER2+ breast cancer cell line, was utilized as the target tumor cell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s data show that CAR-Mono mediated
effective killing at Day 2 and that fully differentiated CAR-Mono-derived CAR-M (Day 7) also efficiently cleared tumor cells. When comparing
CAR-Mono-derived CAR-M (Day 7) to CT-0508, Carisma found that CAR-Mono led to improved tumor killing and inflammatory cytokine production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CAR-Mono-derived CAR-M Show Robust Tumor Killing Activity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img25.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CAR-Mono-derived CAR-M Cocultures Show Robust Proinflammatory Cytokine
Production</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img26.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma previously demonstrated that CT-0508 CAR-M
are locked into an M1 phenotype by Ad5f35 transduction, and resist M2 conversion by immunosuppressive cytokines. Carisma evaluated whether
CAR-Mono similarly resisted M2 environments by culturing the cells for seven days in the presence of M-CSF (differentiation factor) or
M-CSF plus the immunosuppressive cytokines IL-10 and TGF-&beta; during differentiation. CAR-Mono showed resistance to polarization and
continued to express CD86 (M1) and not CD163 (M2) as demonstrated by flow cytometry and bulk RNA sequencing of untransduced and CAR-Mono-derived
CAR-M. Additionally, untransduced monocytes but not CAR-Mono significantly upregulated CD163 in response to IL-10 and TGF-&beta;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CAR-Mono Are Protected Against M2 Polarization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img27.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An important element to Carisma&rsquo;s cell therapies
is the long-term expression of its engineered CAR payloads by human myeloid cells. To evaluate persistence&nbsp;<I>in vivo</I>, monocytes
were engineered with a modified Ad5f35 vector that induces the co-expression of CAR and luciferase under a single promoter by using a
ribosomal skip site. This approach enables the ability to track luciferase using bioluminescent imaging and infer not only the viable
persistence but also the CAR expression of human monocytes in mice. Ad5f35 engineered CAR-Luciferase Mono was injected intravenously into
NSG or NSG-S mice and imaged for 180 days. While both NSG and NSG-S mice are immunodeficient, only NSG-S mice constitutively express human
cytokines that promote myeloid cell survival (GM-CSF,&nbsp;IL3, and SCF). Carisma found that human CAR-Mono persisted for at least 180
days&nbsp;<I>in vivo</I>, independent of cytokine support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CT-0525 Show Long Term Persistence&nbsp;<I>In Vivo</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img28.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To determine whether CAR-Mono are able to control
tumor growth in xenograft models, Carisma utilized a SKOV3 HER2+ ovarian cancer intraperitoneal carcinomatosis model. Anti-HER2 CAR-Mono
significantly suppressed tumor growth and prolonged survival up to 120 days post treatment, while mice that received untransduced control
monocytes or mice that were left untreated only survived for &lt;60 days. Carisma is currently evaluating CAR-Mono in immunocompetent
models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CT-0525 Suppress Tumor Growth&nbsp;<I>In Vivo</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img29.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In summary, CAR-Mono were successfully generated
with high efficiency and viability in a rapid, one-to-two day manufacturing process. CAR-Mono demonstrated stable CAR expression and viability&nbsp;<I>in
vitro</I>, and persisted for at least six months&nbsp;<I>in vivo.</I>&nbsp;CAR-Mono differentiated into CAR-M efficiently and adopted
an M1 macrophage phenotype, and resisted conversion to M2 in immunosuppressive environments. CAR-Mono were able to kill tumors cells in
the monocyte phase and the macrophage phase. CAR-Mono controlled tumor growth in a xenograft mouse model of cancer. Based on the pre-clinical
data to date, Carisma believes that CAR-Mono represents a potentially promising approach for cancer immunotherapy, while meaningfully
expanding Carisma&rsquo;s proprietary platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Next Generation Constructs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s discovery team is developing a
next generation CAR-M platform utilizing enhanced CAR constructs to increase potency and functionality of the engineered cells. This includes
optimization of each element of the CAR itself&thinsp;-&thinsp;the binder (which gives the CAR specificity to a target antigen), the hinge
(which connects the binder to the transmembrane domain and gives the CAR length and flexibility), the transmembrane domain (which spans
the cell membrane), and the intracellular signaling domains (which are responsible for activation of immune cell function). It is well
accepted in the immunology field that T-cells require multiple signals for activation&thinsp;-&thinsp;signal 1 deriving from the TCR,
and signal 2 deriving from co-stimulatory receptors such as CD28 or 4-1BB. Thus, all approved CAR-T products are second generation CARs,
incorporating CD3&zeta; as a primary signaling domain and either 4-1BB or CD28 as co-stimulatory domains. Third generation CARs, incorporating
three signaling domains, have also been evaluated in T-cells. Unlike T-cells, macrophages do&nbsp;<I>not</I>&nbsp;require co-stimulation
for activation and can be activated through a single signal, such as through an Fc receptor. However, multiple signaling pathways have
the ability to enhance the macrophage response and may improve target-cell killing, cytokine/chemokine release, and macrophage activation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Next Generation CAR-M Constructs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma has been routinely developing and evaluating
novel CAR-M constructs. Carisma&rsquo;s well-established CAR-M assays enable a distinct opportunity to identify improved constructs in
an efficient manner. Based on Carisma&rsquo;s early findings, CD3&zeta; is a potent activator of macrophage function and induces phagocytosis,
cytokine release, chemokine release, killing, and activation of pro-inflammatory genes. Given this finding, Carisma has been evaluating
the addition of other innate immune receptors such as Toll-like receptors, CD40, MyD88, Dectin-1, to CD3&zeta; to improve upon CAR-M functionality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img30.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Next Generation Construct: Pre-clinical Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s preliminary data assessing tumor
cell killing activity with CAR variants at a low &ldquo;stress test&rdquo; dose shows increased potency at low effector (macrophage) to
target (tumor cell) ratios. CD40 is an activating receptor found on antigen presenting cells including macrophages that is activated after
binding to CD40-Ligand, typically expressed on activated T-cells. CD40 signals through numerous second messengers leading to the activation
of NF-&varkappa;B and other transcription factors that induce a potent M1 phenotype and activate antigen presenting cells. MyD88
is expressed in macrophages and acts as an adaptor that plays a pivotal role in the signaling of Toll-like receptors. Carisma has found
that addition of MyD88 and CD40 to CD3&zeta; CAR-M, in a specific sequence with a specific hinge domain, leads to a significant improvement
to macrophage anti-tumor activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Addition of the MyD88/CD40 pathway significantly increases CAR-M
potency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img31.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further testing of the M88-CD40-CD3&zeta; CAR and
other novel CAR-M are ongoing. Leading second/third generation CAR candidates may be incorporated into
future autologous, allogeneic, or&nbsp;<I>in vivo</I>&nbsp;LNP programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Novel Modalities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is applying learnings from its autologous
CAR-M data, tools, and processes to establish off-the-shelf engineered macrophage therapeutics. To broaden the application of CAR myeloid
cell therapy, Carisma&nbsp;is actively seeking to develop a gene edited iPSC-derived macrophage platform. The goal is to establish a process
to generate allogeneic, iPSC-derived M1, M2, or CAR myeloid cells. One approach is using allogeneic iPSC myeloid cells manufactured using
the following summary process:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>iPSC-Derived Myeloid Cells: Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img32.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Initial&nbsp;<I>in vitro</I>&nbsp;studies show
that iPSCs can be converted to monocytes or macrophages, skewed to an M1 or M2 phenotype with cytokine culture, and can be engineered
with Carisma&rsquo;s proprietary vectors to express tumor targeting CARs. In addition to offering an allogeneic, universal donor platform,
iPSCs are expandable cells&thinsp;-&thinsp;unlike primary human monocytes or macrophages which are terminally differentiated. In the first
15 days of the process, Carisma noted &gt;1,000x expansion. It took approximately 15 days to generate iPSC-derived monocytes and approximately
20 days to generate iPSC-derived macrophages. The process is currently being performed in a non-GMP research environment at research scale
but has the potential to be developed into a commercial scale, GMP process in the future. The macrophages generated with this process
express canonical macrophage markers, appear macrophage-like with Giemsa staining and microscopic evaluation, and importantly demonstrate
cell-to-cell uniformity in morphology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>iCAR-M Production</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img34.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>iCAR-M Anti-Tumor Activity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to confirm that iPSC-derived macrophages
are effectively redirected against tumor associated antigens, Carisma introduced the anti-HER2 CAR into iPSC-derived macrophages using
Ad5f35. Engineered iPSC-derived macrophages efficiently expressed CAR, upregulated M1 markers, and demonstrated an acceptable viability.
To evaluate anti-tumor function, Carisma conducted an&nbsp;<I>in vitro</I>&nbsp;killing assay in which AU565 HER2+ breast cancer cells
were cultured alone, together with iPSC-derived control macrophages, or iPSC-derived CAR-M. As shown below, while the control iPSC macrophages
had minimal anti-tumor effect (orange), the iPSC-derived CAR-M cleared tumor cells over approximately 72 hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>iPSC-Derived CAR-M Exert Potent Anti-Tumor Activity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img35.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While iCAR-M appear to be able to exert direct
anti-tumor functionality, there are inherent complexities that will be critical to inform the ultimate allogeneic macrophage strategy.
CAR-M exert anti-tumor immunity through tumor infiltration, phagocytosis, cytokine/chemokine release, TME activation, T-cell recruitment,
and antigen presentation. To enable an allogeneic off-the-shelf iCAR-M program, the cells will inherently be either MHC mismatched or
MHC-edited (for example, MHC-I and MHC-II may be deleted using CRISPR/Cas9 editing to generate universally
accepted macrophages), and thus may have limited direct antigen presentation potential. However, iCAR-M are expected to maintain the other
mechanisms of action, as summarized below. Future studies will evaluate whether allogeneic CAR-M are capable of inducing epitope spreading,
as indirect mechanisms of antigen presentation have not been ruled out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Importantly, the iPSC-derived myeloid cell platform,
combined with Carisma&rsquo;s gene engineering capabilities, has the potential to be produced in multiple ways. First, iPSC-derived myeloid
cells can be expanded, qualified, and banked prior to being used as a master cell bank source for the production of engineered myeloid
cell therapies. In this example, iPSC-derived myeloid cells would be engineered with Carisma&rsquo;s proprietary methods (Ad5f35, Vpx-LV,
modified mRNA, or other) after differentiation into the desired myeloid cell subtype. Alternatively, Carisma is optimizing methods to
introduce the CAR (or other genetic payload) at the iPSC stage using targeted integration into desired genomic loci, isolating iPSC clones
with integrated genes and additional potential genetic edits, and differentiating these cells into monocytes or macrophages, and skewing
them to an M1 phenotype using Carisma&rsquo;s proprietary polarization processes. For this approach, care must be taken to ensure that
the CAR (or other payload) is not epigenetically downregulated or lost during the myeloid differentiation process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While the current focus of Carisma&rsquo;s discovery
efforts is to ultimately generate iCAR-M, the platform is expected to be readily adaptable to either develop (a)&nbsp;myeloid cells engineered
with other anti-tumor payloads, or (b)&nbsp;myeloid cells engineered with payloads designed to ameliorate disease outside of oncology.
Notably, Carisma has early non-oncology programs in liver fibrosis, neurodegeneration, and auto-immunity/chronic
inflammation which can be combined with the iPSC-derived myeloid cell platform. Currently, Carisma&rsquo;s pipeline is focused on autologous
approaches and direct&nbsp;<I>in vivo</I>&nbsp;reprogramming, and the allogeneic iPSC-derived platform is at the pre-clinical discovery
stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>LNP/mRNA Platform (Moderna Collaboration)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In collaboration with Moderna, Carisma is developing
an mRNA based&nbsp;<I>in vivo</I>&nbsp;CAR-M platform for oncology. This approach is highly differentiated in the cell therapy space&thinsp;-&thinsp;not
only because it relies on myeloid cells as the engineered effectors, but also because it utilizes direct&nbsp;<I>in vivo</I>&nbsp;reprogramming
of a patients&rsquo; own cells with a well-validated LNP/mRNA platform. By engineering a patients&rsquo; own cells directly within their
body,&nbsp;<I>ex vivo</I>&nbsp;autologous or allogeneic cell manufacturing is entirely bypassed&thinsp;-&thinsp;significantly increasing
the commercial potential of the therapy. Importantly, while this approach enables an off-the-shelf therapy, the engineered cells are autologous,
as it is the patients&rsquo; own cells being engineered into CAR-M&nbsp;<I>in vivo</I>, or directly within their body. This strategic
partnership enables Carisma to apply the learnings gleaned from autologous CAR-M development to expand its pipeline to up to 12 additional
oncology candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Studies with the myeloid tropic LNP have shown
mRNA delivery is specific for myeloid cells (monocytes, macrophages, dendritic cells). Based on clinical data using other (non-CAR) payloads,
Moderna has previously demonstrated that the LNP was well-tolerated after systemic administration and could furthermore be re-dosed. Preliminary
data have demonstrated that the LNP is efficient in transfecting myeloid cells&nbsp;<I>in vitro</I>&nbsp;and&nbsp;<I>in vivo</I>. In addition,
preliminary data confirms high CAR expression, viability, and CAR-M function. The platform summary for the&nbsp;<I>in vivo</I>&nbsp;CAR-M
approach is shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Myeloid Tropic LNP/mRNA Platform (Moderna Collaboration)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><IMG SRC="tm238578d1_ex99-2img36.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>LNP/mRNA Pre-clinical Data (Moderna Collaboration): Pre-clinical
Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>In vitro</I>&nbsp;pre-clinical studies with
the myeloid tropic LNP/mRNA platform have shown efficient transfection. Carisma has optimized conditions for&nbsp;<I>ex vivo</I>&nbsp;LNP/mRNA
delivery to human and murine monocytes/macrophages, as well as primary murine myeloid cells to establish various relevant murine tumor
models. Carisma&rsquo;s goal was to establish a platform with high viability (&gt;70%), high transfection efficiency (&gt;70%), and significantly
increased CAR-M killing activity compared to untransfected control macrophages. Key data for the anti-HER2 CAR constructs CTX_001 and
CTX_219 are shown in the figures below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LNP Transfection is Well Tolerated by Human Macrophages</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img37.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LNP Engineering leads to Dose Dependent CAR Expression</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img38.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to CAR expression and viability, Carisma
has shown that one day post transfection, CTX001 and CTX219 mediate potent killing activity against target AU565 cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LNP Engineered CAR-M Display Effective Killing Function</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img39.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Statistical analysis was determined using Two-way
ANOVA, * p&lt;0.5 **** p&lt;0.0001. The data were generated from N=3 donors (3 technical replicates per donor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LNP Transfection is Well Tolerated by Human Monocytes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img40.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LNP Engineering leads to Dose Dependent CAR Expression in Monocytes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img41.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to CAR expression and viability, Carisma
has shown that monocytes engineered with LNP/mRNA encoding the CARs CTX001 and CTX219 mediate potent killing activity against target AU565
breast cancer cells. These findings demonstrate similarity between LNP engineered macrophage and monocyte effector function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LNP Engineered CAR-Mono Display Effective Killing Function</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img42.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Statistical analysis was determined using Two-way
ANOVA, * p&lt;0.5 **** p&lt;0.0001. The data were generated from N=3 donors (three technical replicates per donor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To model direct reprogramming of TAMs to CAR-M,
Carisma generated tumor spheroids comprised of HER2+ breast cancer cells and human TAMs.&nbsp;Carisma confirmed that the macrophages embedded
within these spheroids adopted an M2, TAM-like phenotype. Carisma added LNPs (containing CAR mRNA and an M1 polarizing gene) directly
to the tumor spheroids and found that the reprogrammed TAMs mediated tumor spheroid shrinking over a 72-hour period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directly Reprogramming Myeloid Cells&nbsp;<I>within Tumors</I>&nbsp;with
LNP/mRNA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img43.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The first four indications have been nominated
by Moderna, spanning both solid tumors and hematologic malignancies. Pre-clinical platform optimization, as well as target discovery and
CAR development, are ongoing in parallel. Early&nbsp;<I>in vivo</I>&nbsp;proof of concept is expected in 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>EM-C: A novel platform for regulation of inflammation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cytokines in tissue microenvironments regulate
the balance between pro- and anti-inflammatory signaling. Dysregulated cytokine expression causes deleterious immunosuppression or inflammation,
underpinning the pathophysiology of numerous diseases. As examples, anti-inflammatory cytokines in solid tumors suppress immune activation
and safeguard the tumor, whereas pro-inflammatory cytokines in rheumatoid arthritis drive chronic inflammation. Rebalancing inflammation/immunosuppression
by targeting aberrant cytokine signaling offers a generalizable approach to treating many diseases, but systemic cytokine blockade carries
risks such as increased risk of serious infection. Cellular immunotherapies may offer a localized platform that could activate in response
to cytokines then proportionately remodel the microenvironment&rsquo;s inflammatory state as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Macrophages are tissue infiltrating homeostatic
regulators responsible for the initiation and resolution of inflammation. Carisma leveraged the ability of macrophages to regulate inflammation
by generating macrophages that express genetically engineered, synthetic cytokine switch receptors (SR). Carisma termed this platform
EM-C and evaluated its modular ability to convert immunosuppressive M2 signals into pro-inflammatory M1 responses for solid tumor microenvironment
conversion, or vice versa for the conversion of pro-inflammatory M1 signals into immunosuppressive M2 responses for auto-immune or inflammatory
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">EM-Cs were generated by expressing SRs in primary
human macrophages. First, Carisma generated SRs that convert immunosuppressive signals into inflammatory signals&thinsp;-&thinsp;focusing
on IL-10. To convert IL-10 (a cytokine well known to polarize macrophages toward an M2 phenotype) in the TME into a pro-inflammatory signal,
an IL-10 SR was designed by fusing the extracellular domain of the IL-10 receptor to an engineered portion of the IFN&lambda; receptor.
The&nbsp;<I>in vitro</I>&nbsp;response of IL-10 EM-Cs to IL-10 was monitored by the expression of M1 and M2 markers. While control untransduced
or CAR (a control irrelevant construct) expressing macrophages responded to IL-10 through the downregulation of M1 markers and upregulation
of M2 markers,&nbsp;IL10-SR EM-Cs upregulated M1 markers and downregulated M2 markers. These data and others demonstrate that Carisma&rsquo;s
IL10-SR EM-Cs can induce an inflammatory response when exposed to immunosuppressive conditions. Carisma has generated numerous additional
EM-Cs that respond to other immunosuppressive factors, such as TGF&beta;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Conversely, Carisma sought to develop EM-Cs that
can convert inflammatory cytokines into anti-inflammatory responses. As myeloid cells are recruited to sites of inflammation. This approach
would enable a myeloid cell therapy that accumulates at inflammatory sites and locally shuts down inflammation. This approach may have
broad utility in autoimmunity, chronic inflammation, fibrosis, transplant, and graft versus host disease. Carisma generated EM-Cs targeting
IFN-&gamma; and demonstrated that while control untransduced or CAR (an irrelevant payload) macrophages respond to IFN-&gamma; by upregulating
M1 markers and downregulating M2 markers,&nbsp;IFN-&gamma; SR EM-Cs responded to IFN-&gamma; by downregulating M1 markers and upregulating
M2 markers. These data demonstrate that Carisma&rsquo;s proprietary EM-C platform can be broadly utilized to generate engineered macrophages
with the ability to control the inflammatory nature of environments, and act as living converters, with broad potential applicability
to oncology, autoimmunity, chronic inflammation, and other indications. This platform offers broad opportunity for strategic partnership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Macrophages Expressing Cytokine Switch Receptors Can Invert</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pro- or Anti-Inflammatory Signals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img44.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indications Beyond Oncology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While Carisma is an oncology focused company, the
macrophage engineering platform Carisma has established offers broad opportunity to develop cell therapies for indications beyond oncology.
Carisma has numerous early-stage research programs designed to produce development candidates for liver fibrosis, neurodegenerative disease,
and autoimmunity/chronic inflammation. Carisma&rsquo;s new product candidates will incorporate all the core elements of its macrophage
cell engineering platform, plus certain indication specific modifications uniquely designed to address the pathology of each indication.
While autologous cell therapy may be utilized for proof of concept, these indications have the potential to be combined with Carisma&rsquo;s
allogeneic or off-the-shelf therapeutic approaches. Indications beyond oncology offer opportunities for strategic partnerships to accelerate
the development of these programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Manufacturing and Delivery</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma does not own or operate, and currently
has no plans to establish, any manufacturing facilities. Carisma currently relies on and expects to continue to rely on third-party contract
development manufacturing organizations, or CDMOs, for the manufacturing and release testing of viral vectors and cell drug products.
Carisma also currently relies on third parties for patient leukapheresis material logistics as well as to package, label, store, and distribute
the cell drug products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma has established and will continue to establish
arrangements with contract manufacturers to supply clinical materials and manufacturing capabilities for Carisma&rsquo;s clinical trials.
Carisma currently obtains its supplies from these manufacturers on a purchase order basis and does not have long-term supply arrangements
in place. Should any of these manufacturers become unavailable to Carisma for any reason, Carisma believes that there are several potential
replacements, although Carisma may incur some delay in identifying and qualifying such replacements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma also plans to continue to expand the scope
and number of its collaborations to further develop its manufacturing capabilities and to minimize manufacturing risk. As Carisma scales
to commercialization, it expects to increase its capacity with its current suppliers and evaluate other options to secure commercial scale
capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Manufacturing Process for CT-0508</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A CDMO is used to produce cGMP lots of viral vector.
The CT-0508 drug substance process begins by isolating the monocyte population from a single fresh patient leukopak mobilized by donor
pretreatment with filgrastim. The resulting monocytes are cultured in the presence of a cytokine and other factors to induce differentiation
into macrophages. The resulting macrophages are then transduced with the Ad5f35 vector encoding an anti-HER2 CAR. The resulting cells
are then harvested as drug substance. Macrophages derived from a single leukopak from one patient comprise one batch of CT-0508. Final
formulation is performed and transferred into freezing bags to generate drug product. The drug product is carefully frozen in a controlled
process and then placed into secured storage and maintained at a temperature of &le;-135&#8304; Celsius. Safety and specification tests
are performed and if found acceptable the product is released and shipped to clinical trial sites. The current process from receipt of
leukopak to drug product and cryopreservation is eight days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm238578d1_ex99-2img45.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma plans to continue to invest in process
improvements to reduce the overall manufacturing process time and improve costs for the viral vector and cell drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma strives to protect and enhance its proprietary
technology, inventions and improvements that Carisma believes are commercially important to the development of its business, including
through seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Carisma also intends
to rely on trade secrets related to its proprietary technology platform and its know-how, continuing technological innovation and in-licensing
opportunities to develop, strengthen and maintain its proprietary position in the fields of cancer and other indications including those
related to neurodegeneration, liver fibrosis and autoimmune disease, which may be important for the development of Carisma&rsquo;s business.
Carisma additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions,
where available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s commercial success may depend,
in part, on its ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions
and know-how related to its business, defend, and enforce its patents, preserve the confidentiality of its trade secrets and operate without
infringing the valid enforceable patents and proprietary rights of third parties. Carisma&rsquo;s ability to stop third parties from making,
using, selling, offering to sell or importing its products may depend on the extent to which it has rights under valid and enforceable
licenses, patents or trade secrets that cover these activities. With respect to both Carisma&rsquo;s owned and licensed intellectual property,
Carisma cannot be sure that patents will be granted with respect to any of its pending patent applications or with respect to any patent
applications filed by Carisma in the future, nor can it be sure that any of its existing patents or any patents that may be granted to
Carisma in the future will be commercially useful in protecting its commercial products and methods of manufacturing such products, as
well as being held valid if challenged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma currently controls over 15 granted patents
and over 43 patent applications pending in several jurisdictions, including the United States, Europe, Australia, Brazil, Canada, China,&nbsp;Israel,
Japan, Korea, Mexico, New Zealand, and Singapore. Intellectual property is a critical component of Carisma&rsquo;s business plan for maximizing
return on its investments. Carisma is actively developing intellectual property and will continue to maintain and defend United States
and international patent rights for its products, technology, and development and improvement of its discovery platforms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To maintain its competitive position in the market,
Carisma has spent considerable effort securing intellectual property rights, including several patent rights related to its proprietary
CAR technology and myeloid cell engineering technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Exclusively Licensed Intellectual Property&thinsp;-&thinsp;UPenn</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma has exclusive rights to three patent families,
and non-exclusive rights to related know-how by virtue of a license agreement with the University of Pennsylvania. These patent families
are directed to, among other things, methods of efficiently expressing CARs in myeloid cells, including monocytes, macrophages, and dendritic
cells and enhancing effector activity, as well as the modified cells and compositions including such modified cells for use in several
indications including various oncology targets. The applications will have an expiration date of no earlier than 2036. This licensed patent
portfolio includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>A patent family that includes nine issued U.S. patents and two pending U.S. patent applications relating to modified macrophages,
monocytes and dendric cells comprising CARs. These U.S. patents are expected to expire in 2036, absent any term adjustments or extensions.
Corresponding foreign applications have been filed and are pending in Australia (including one issued patent), Brazil (including one issued patent) Canada, China (including one issued patent), Europe, Israel
(including one issued patent), India, Japan (including one issued patent), Korea, Mexico (including one issued patent), New Zealand, Russia
(including one issued patent), Singapore, Thailand and South Africa.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>A patent family that includes one pending U.S. patent application relating to modified macrophages, monocytes and dendric cells in
protein aggregate-associated disorders. Patent applications in this family are expected to expire in 2039, absent any term adjustments
or extensions. Corresponding foreign applications have been filed and are pending in Australia, Canada, China, Europe,&nbsp;Israel, Japan,
Korea, New Zealand, and Singapore.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>A patent family that includes one pending U.S. patent application relating to activation of antigen presenting cells. Patent applications
in this family are expected to expire in 2040, absent any term adjustments or extensions. A corresponding foreign application has been
filed in Europe.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Exclusively Licensed Intellectual Property&thinsp;-&thinsp;NYU</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma has exclusive rights to one patent family,
and non-exclusive rights to related know-how by virtue of a license agreement with New York University, or NYU. The rights granted under
the NYU license are to all indications for human use. This licensed patent portfolio includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>A patent family that includes one U.S. patent relating to a chimeric HIV-1 vector with an SIV minimal Vpx packaging domain and method
of making virions with enhanced infectivity for macrophages and dendric cells. The U.S. patent is expected to expire in 2033, absent any
term adjustments or extensions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma Owned Intellectual Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma currently owns five U.S. patent families.
This owned patent portfolio includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>A patent family that includes one issued U.S. patent and two pending U.S. patent applications relating to macrophages, monocytes and
dendric cells comprising novel CAR constructs. Patent applications in this family are expected to expire in 2041, absent any term adjustments
or extensions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>A patent family that includes one pending Patent Cooperation Treaty, or PCT, application relating to mRNA transfection of macrophages,
monocytes and dendric cells comprising CARs. Patent applications in this family are expected to expire in 2041, absent any term adjustments
or extensions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>A patent family that includes one pending PCT application relating to modified immune cells for fibrosis and inflammation. Patent
applications in this family are expected to expire in 2041, absent any term adjustments or extensions.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>A patent family that includes one pending PCT application relating to in vivo delivery of CARs to a patient's own macrophages, monocytes,
dendritic cells, or stem cells. Patent applications in this family are expected to expire in 2042, absent any term adjustments or extensions.</TD></TR>
                                                                                                                </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>A patent family that includes one pending PCT application relating to self-polarizing immune cells. Patent applications in this family
are expected to expire in 2042, absent any term adjustments or extensions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Carisma will also seek to generate additional intellectual property that covers enhancements to all aspects of the platform, including
novel CARs, combinations, gene editing and manufacturing improvements. Where appropriate, Carisma will also look to in-license relevant
technology from third parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patent Term and Patent Term Extensions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term of individual patents depends upon the
legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is
20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&rsquo;s term may be lengthened
by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent or may
be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug, biological product
or medical device approved pursuant to a pre-market approval may also be eligible for patent term extension, or PTE, when FDA approval
is granted, provided statutory and regulatory requirements are met. The length of the PTE is related to the length of time the drug is
under regulatory review while the patent is in force. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman
Act, permits a patent term extension of up to five years beyond the expiration date set for the patent. Patent extension cannot extend
the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory
review period may be granted an extension and only those claims regarding the approved drug are extended. Similar provisions are available
in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Trademarks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s trademark portfolio currently includes
registered U.S. trademarks for Carisma in the United States, Europe, Great Britain and Japan. In order to supplement the protection of
its brand, Carisma also has a registered internet domain name. Going forward, Carisma will consider additional trademarks to enhance its
brand and support its products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Trade Secrets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma relies, in some circumstances, on trade
secrets to protect its unpatented technology. However, trade secrets can be difficult to protect in certain circumstances. Carisma seeks
to protect its trade secrets and proprietary technology and processes, including through confidentiality agreements with its employees,
consultants, scientific advisors and contractors. Carisma also seeks to preserve the integrity and confidentiality of its data and trade
secrets by maintaining physical security of its premises and physical and electronic security of its information technology systems. While
Carisma has confidence in these individuals, organizations and systems, agreements or security measures may be breached. Carisma may not
have adequate remedies for any breach and could lose its trade secrets through such a breach. In addition, Carisma&rsquo;s trade secrets
may otherwise become known or be independently discovered by competitors. To the extent that its consultants, contractors or collaborators
use intellectual property owned by others in their work for Carisma, disputes may arise as to the rights in related or resulting trade
secrets, know-how and inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Moderna Collaboration Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January&nbsp;2022, Carisma entered into a Collaboration
and License Agreement with Moderna providing for a broad strategic partnership to discover, develop and commercialize&nbsp;<I>in vivo</I>&nbsp;engineered
CAR-M therapeutics for up to 12 oncology programs. Carisma refers to this agreement as the Moderna Collaboration Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In collaboration with Moderna, Carisma has established
an approach that uses Moderna&rsquo;s LNP/mRNA technology, together with Carisma&rsquo;s CAR-M platform
technology, to create novel&nbsp;<I>in vivo</I>&nbsp;oncology medications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Moderna Collaboration Agreement, the
parties initiate research programs during a research term, focused on the discovery and research of products directed to biological targets.
Either party may nominate a target for inclusion in a research program, subject to certain exclusions. Carisma refers to a target included
in a research program pursuant to designated procedures as a research target. Moderna may replace research targets pursuant to designated
procedures. The first four research targets have been nominated and all programs are currently in the discovery phase at Carisma. Moderna
funds the cost of Carisma&rsquo;s activities in accordance with an agreed research budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moderna has the right to designate up to 12 research
targets as development targets during a specified development target nomination period upon payment of a development target designation
milestone payment. Moderna can replace development targets with research targets during a specified period of time. If Moderna exercises
its right to designate a development target, Moderna will have a worldwide, exclusive license under patents and know-how controlled by
Carisma to develop and commercialize products directed to the applicable development target, subject to certain diligence obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Commencing a specified time after the effective
date of the Moderna Collaboration Agreement, Moderna will have the right to nominate targets relating to diseases outside the field of
oncology for inclusion in research programs in specified circumstances. Such right is subject to the same exclusions as Moderna&rsquo;s
right to nominate other targets for inclusion in research programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the term of the Moderna Collaboration Agreement,
Carisma and its affiliates are subject to various exclusivity obligations under which Carisma is not permitted to research, develop or
commercialize particular products outside of the collaboration, including products for use as&nbsp;<I>in vivo</I>&nbsp;therapies in the
field of oncology, products directed to any target included in the collaboration, or products containing a polypeptide provided by Carisma
to Moderna in connection with a research program that are directed to any development target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Moderna Collaboration Agreement,
Carisma received a $45.0 million up-front cash payment. Assuming Moderna develops and commercializes 12 products, each directed to a different
development target, Carisma is also eligible to receive up to between $247.0 million and $253.0 million per product in development target
designation, development, regulatory and commercial milestone payments. In addition, Carisma is eligible to receive mid to high single
digit tiered royalties on net sales of any products that are commercialized under the agreement, which may be subject to reductions. Moderna
has also agreed to cover the cost of certain milestone payments and royalties Carisma owes to a licensor under one of its intellectual
property in-license agreements that Carisma is sublicensing to Moderna under the Moderna Collaboration Agreement, which royalties Moderna
may deduct in part from any royalties owed to Carisma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless earlier terminated, the Moderna Collaboration
Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the
Moderna Collaboration Agreement will expire on a country-by-country basis upon the later of (1)&nbsp;the expiration of the last-to-expire
valid patent claim of specified patents, (2)&nbsp;the expiration of regulatory-based exclusivity for such product in such country or (3)&nbsp;ten
years after the first commercial sale with respect to such product in such country. Moderna has the right to terminate the Moderna Collaboration
Agreement for convenience in its entirety or with respect to a specific product or target on ninety days&rsquo; prior notice. Either Carisma
or Moderna may terminate the Moderna Collaboration Agreement in its entirety if the other party is in material breach and such breach
is not cured within the specified cure period, except in the case of Moderna&rsquo;s breach of its diligence obligations, termination
by Carisma is limited to the applicable target and product. In addition, either Carisma or Moderna may terminate the Moderna Collaboration
Agreement in the event of specified insolvency events involving the other party. As an alternative to termination in the event of Carisma&rsquo;s
uncured material breach of certain sections of the agreement, Moderna has the option to continue the collaboration under the agreement
with reduced payment obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>University of Pennsylvania License Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November&nbsp;2017, Carisma entered into a license
agreement with the Trustees of the University of Pennsylvania, or Penn, which was amended in February&nbsp;2018, January&nbsp;2019, March&nbsp;2020
and June&nbsp;2021. Carisma refers to this agreement as the Penn License Agreement. Pursuant to the Penn License Agreement, Penn granted
Carisma (1)&nbsp;an exclusive, worldwide license, with specified rights to sublicense, under Penn&rsquo;s interest in specified patents
related to CAR macrophages, monocytes or dendritic cells, which Carisma refers to collectively as CAR-M, (2)&nbsp;an exclusive, worldwide
license, with specified rights to sublicense, under Penn&rsquo;s interest in specified patents related to CAR-M directed to mesothelin,
and (3)&nbsp;a nonexclusive, worldwide license under Penn&rsquo;s interest in specified know-how related to CAR-M, with limited rights
to sublicense only in combination with specified products or patents. These licensed patents and know-how arose primarily from research
conducted by Dr.&nbsp;Saar Gill and Dr.&nbsp;Michael Klichinsky at the University of Pennsylvania, co-founders of Carisma. The foregoing
licenses are subject to rights retained by Penn for specified non-commercial uses and rights retained by the United States government.
Under the Penn License agreement, Carisma is obligated to use commercially reasonable efforts to pursue development and commercialization
of at least one CAR-M product in oncology and non-oncology fields.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is responsible for paying Penn an annual
license maintenance fee in the low tens of thousands of dollars, payable until Carisma&rsquo;s first payment of a royalty. Carisma is
required to pay Penn up to $10.9 million per product in development and regulatory milestone payments, up to $30.0 million per product
in commercial milestone payments, and up to an additional $1.7 million in development and regulatory milestone payments for the first
CAR-M product directed to mesothelin. While the agreement remains in effect, Carisma is required to pay Penn low to mid-single digit percentage
tiered royalties on annual net sales of licensed products, which may be subject to reductions. Penn is guaranteed a minimum royalty payment
amount in the low hundreds of thousands of dollars for each year after the first commercial sale of a licensed product. Carisma must also
pay Penn a percentage in the mid-single digits to low double digits of certain types of income Carisma receives from sublicensees. In
addition, Carisma is required to pay Penn an annual alliance management fee in the low tens of thousands of dollars, ending after several
years, unless Carisma provides funding to Penn for research and development activities that extend beyond a specified date, in which case
Carisma will continue to owe the alliance management fee for each year in which Carisma continues to fund such activities. Carisma also
paid Penn an upfront fee in the low hundreds of thousands of dollars for the license to the patents related to the mesothelin binder that
is incorporated into the CAR design for Carisma&rsquo;s mesothelin product candidate. Carisma is responsible for a pro rata share of costs
relating to the prosecution and maintenance of the licensed patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The royalty period for each licensed product will
expire on a product-by-product basis upon the later of (1)&nbsp;the expiration of the last-to-expire valid patent claim of the licensed
patents covering such product in the country of sale or in the country of manufacture, or (2)&nbsp;the expiration of regulatory-based
exclusivity for such product in the country of sale. The license agreement remains in effect until the later of (1)&nbsp;expiration or
abandonment of the last licensed patent or (2)&nbsp;loss of regulatory exclusivity. Carisma may terminate the agreement for convenience
upon thirty days&rsquo; prior notice. Penn may terminate the agreement for Carisma&rsquo;s material breach, subject to a specified cure
period, except for certain breaches for which Penn may terminate immediately. Penn may also terminate if Carisma becomes the subject of
a specified insolvency event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>New York University License Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July&nbsp;2020, Carisma entered into a license
agreement with NYU. Carisma refers to this agreement as the NYU License Agreement. Pursuant to the NYU License Agreement, NYU granted
Carisma (1)&nbsp;an exclusive, worldwide license, with specified rights to sublicense, under NYU&rsquo;s interest in specified patents
related to the Vpx-LV and (2)&nbsp;a nonexclusive, worldwide license, with specified rights to sublicense, under NYU&rsquo;s interest
in specified know-how related to the Vpx-LV, in each case to develop, manufacture, use and sell products developed using the Vpx-LV, which
Carisma refers to as Licensed Products. The foregoing licenses are subject to rights retained by NYU to use, and to permit other non-commercial
entities to use, the licensed patents and licensed know-how for educational and research purposes, as well as rights retained by the United
States government. Under the NYU License Agreement, Carisma is obligated to use reasonable diligence to carry out a specified development
plan and to obtain regulatory approval for Licensed Products in the U.S. and each of the other countries in which Carisma or its sublicensees
intend to produce, use, and/or sell Licensed Products, as well as to begin the regular commercial production, use, and sale of the Licensed
Products in good faith in accordance with the development plan and to continue diligently thereafter to commercialize the Licensed Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is required to pay NYU an annual license
maintenance fee in the mid tens of thousands of dollars; up to $1,685,000 per Licensed Product in development and regulatory milestone
payments; and low single digit percentage tiered royalties on annual net sales of Licensed Products on a country-by-country basis until
the later of (1)&nbsp;12 years after first commercial sale of a Licensed Product in such country or (2)&nbsp;expiration of the last to
expire licensed patent. Carisma must also pay NYU a percentage in the low single digits to low double digits of certain types of income
Carisma receives from sublicensees or assignees of the agreement. Carisma is also responsible for all costs relating to the prosecution,
maintenance, and defense of the licensed patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The NYU License Agreement remains in effect until
the expiration of all royalty terms in all countries. Either party may terminate the NYU License Agreement for the other party&rsquo;s
uncured material breach or insolvency or bankruptcy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The biopharmaceutical industry, and in particular
the cell therapy field, is characterized by intense investment and competition aimed at rapidly advancing new technologies, intense competition,
and a strong emphasis on intellectual property and proprietary products. Carisma&rsquo;s platform and therapeutic product candidates are
expected to face substantial competition from multiple technologies, marketed products, and numerous other therapies being developed by
other biopharmaceutical companies, academic research institutions, governmental agencies, and public and private research institutions.
Many of Carisma&rsquo;s potential competitors have substantially greater financial, technical, and other resources, such as larger research
and development staff, established manufacturing capabilities and facilities, and experienced marketing organizations with well-established
sales forces, and any product candidates that Carisma successfully develops and commercializes will compete with existing therapies and
new therapies that may become available in the future. In addition, there is substantial patent infringement litigation in the biopharmaceutical
industry, and, in the future, Carisma may bring or defend such litigation against its competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The key competitive factors affecting the success
of Carisma&rsquo;s product candidates, if approved, are likely to be their efficacy, safety, convenience and price, the level of competition,
and the availability of coverage and adequate reimbursement from third-party payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unlike other cell therapy approaches, Carisma&rsquo;s
CAR-M platform is based on engineering macrophages and monocytes with proprietary vectors, constructs, and processes, enabling a differentiated
platform from other cell therapy competitors that primarily focus on T or NK cells. While Carisma believes that its scientific expertise,
novel technology, and intellectual property position offer competitive advantages, Carisma faces competition from multiple other cell
therapy technologies and companies. Other companies developing engineered myeloid cell therapies include, among others, Myeloid Therapeutics,
Shoreline Biosciences,&nbsp;Inceptor Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, Sirpant Therapeutics, and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Due to the broad promise of cell therapies, and
the potential of myeloid cell-based approaches to expand cell therapy efficacy into solid tumors, Carisma expects increasing competition
from new and existing companies across several fronts, which include, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Myeloid cell therapies:</I></B>&nbsp;Myeloid Therapeutics, Shoreline Biosciences,&nbsp;Inceptor Bio, Thunder Bio, CellOrigin,
Deverra</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Autologous T-cell therapies:</I></B>&nbsp;Adaptimmune Therapeutics, Autolus Therapeutics, Bluebird, Bristol Myers Squibb, Kite/Gilead,
Novartis, Gracell, TCR2, Poseida, Vor, TMunity, among others</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Allogeneic T-cell therapies:</I></B>&nbsp;Allogene, Atara, Century, Cellectis, Celyad, CRISPR, Fate, Gracell, Kite/Gilead,
Legend, Poseida, Precision Bio, Sana, Vor, among others</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>NK and other cell therapies:</I></B>&nbsp;Artiva, Celularity, Century, Editas, Fate, Fortress,&nbsp;ImmunityBio, Nkarta, NKGen,
Takeda, Adicet, Gamida Cell, among others</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><B><I>Direct in vivo reprogrammed cell therapies:</I></B>&nbsp;Umoja, Ensoma,&nbsp;Interius, Tidal/Sanofi, BioNTech</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to competition from other cell therapy
companies, any products that Carisma develops may also face competition from other types of therapies. Other companies developing non-cell
therapies, including gene therapies, include Gilead, ALX Oncology, Trillium, Five-Prime,&nbsp;Immune-Onc, Pionyr,&nbsp;Infinity, NextCure,
OncoResponse, Curis, Faron, Apexigen, Pfizer, Dren, and multiple biotechnology and pharmaceutical companies developing other directly
competitive technologies such as small molecules, immune agonists, antibodies, bi/tri specific antibodies, antibody drug conjugates, and
other solid tumor therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma also competes with third parties for retaining
qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well
as in acquiring technologies complementary to, or necessary for, its programs. Carisma may pursue the in-license or acquisition of rights
to complementary technologies and product candidates on an opportunistic basis. The acquisition and licensing of technologies and product
candidates is a competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies
and product candidates that Carisma may consider attractive. These established companies may have a competitive advantage over Carisma
due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive Carisma
to be a competitor may be unwilling to assign or license rights to Carisma. Carisma also may be unable to in-license or acquire the relevant
technology or product candidate on terms that would allow it to make an appropriate return on its investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s commercial opportunity could be
reduced or eliminated if its competitors develop and commercialize products that are safer, more effective, have fewer or less severe
side effects, are more convenient or are less expensive than any products that it may develop. Carisma&rsquo;s competitors also may obtain
FDA or other regulatory approval for their products more rapidly than it may obtain approval for Carisma&rsquo;s, which could result in
its competitors establishing a strong market position before it is able to enter the market. In addition, Carisma&rsquo;s ability to compete
may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Government authorities in the United States, at
the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among
other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage,
recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export
of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in
foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities,
require the expenditure of substantial time and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Licensure and Regulation of Biologics in the United States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, Carisma&rsquo;s product candidates
are regulated as biological products, or biologics, under the Public Health Service Act, or PHSA, and the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations and guidance. A company,
institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products,
and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable U.S.
requirements at any time during the product development process, including pre-clinical testing, clinical testing, the approval process,
or post-approval process, may subject a sponsor to delays in the conduct of the study, regulatory review, and approval, and/or administrative
or judicial sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A sponsor seeking approval to market and distribute
a new biologic in the United States generally must satisfactorily complete each of the following steps:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>pre-clinical laboratory tests, animal studies, and formulation studies all performed in accordance with the FDA&rsquo;s Good Laboratory Practices, or GLP, regulations
and standards and other applicable regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor intends to use in human
clinical trials along with required analytical and stability testing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>design of a clinical protocol and submission to the FDA of an Investigational New Drug application, or IND, for human clinical testing, which must become effective
before human clinical trials may begin;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>performance of adequate and well-controlled human clinical trials to establish the safety, potency, and purity of the product candidate
for each proposed indication, in accordance with current good clinical practices, or GCP;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>preparation and submission to the FDA of a biologics license application, or BLA, for a biologic product requesting marketing for one or more proposed indications, including
submission of detailed information on the manufacture and composition of the product in clinical development and proposed labelling;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>review of the product by an FDA advisory committee, where appropriate or if applicable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties,
at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities,
methods, and controls are adequate to preserve the product&rsquo;s identity, strength, quality, and purity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>satisfactory completion of any FDA audits of the pre-clinical studies and clinical trial sites to assure compliance with GLP, as applicable,
and GCP, and the integrity of clinical data in support of the BLA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>payment of user Prescription Drug User Fee Act, or PDUFA, securing FDA approval of the BLA and licensure of the new biologic product; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>compliance with any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy, or REMS, and any post-approval studies
or other post-marketing commitments required by the FDA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Pre-clinical Studies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before testing any biologic product candidate
in humans, the product candidate must undergo pre-clinical testing. Pre-clinical tests include laboratory evaluations of product
chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies.
These studies are generally referred to as IND-enabling studies. The conduct of the pre-clinical tests and formulation of the
compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United
States Department of Agriculture&rsquo;s Animal Welfare Act, if applicable. The results of the pre-clinical tests, together with
manufacturing information and analytical data, are submitted to the FDA as part of an IND application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Investigational New Drug Application</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An IND is an exemption from the FDCA that allows
an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA
authorization to administer such investigational product to humans. The IND automatically becomes effective 30 days after receipt by the
FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including
concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve
any outstanding FDA concerns before the clinical trials can begin or recommence. As a result, submission of the IND may result in the
FDA not allowing the trials to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the FDA raises concerns or questions either
during this initial 30-day period, or at any time during the IND process, it may choose to impose a partial or complete clinical hold.
Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments
in clinical, pre-clinical, and/or chemistry, manufacturing, and controls. This order issued by the FDA would delay either a proposed clinical
trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified
the company that investigations may proceed. This could cause significant delays or difficulties in completing Carisma&rsquo;s planned
clinical trial or future clinical trials in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the issuance of a clinical hold or partial
clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The
FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying
the FDA that the investigation can proceed or recommence. Occasionally, clinical holds are imposed due to manufacturing issues that may
present safety issues for the clinical study subjects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Expanded Access to an Investigational Drug for
Treatment Use</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Expanded access, sometimes called &ldquo;compassionate
use,&rdquo; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening
diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules&nbsp;and regulations related
to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies.
FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes
on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency
settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol
or treatment IND application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When considering an IND application for expanded
access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians
or investigators will determine suitability when all of the following criteria apply: patient(s)&nbsp;have a serious or immediately life-threatening
disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition;
the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context
or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere initiation,
conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential
development of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There is no obligation for a sponsor to make its
drug products available for expanded access; however, as required by the 21st Century Cures Act, or Cures Act, passed in 2016, if a sponsor
has a policy regarding how it evaluates and responds to expanded access requests, sponsors are required to make such policies publicly
available upon the earlier of initiation of a Phase 2 or Phase 3 clinical trial, or 15 days after the investigational drug or biologic
receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to and separate from expanded access,
on May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain
patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation
for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining
FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available
to eligible patients as a result of the Right to Try Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Human Clinical Trials in Support of a BLA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical trials involve the administration of the
investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision
of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among
other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part
of the IND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A sponsor who wishes to conduct a clinical trial
outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical
trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under
an IND, the sponsor must ensure that the trial complies with certain regulatory requirements, including GCP requirements, of the FDA in
order to use the trial as support for an IND or application for marketing approval. The GCP requirements encompass both ethical and data
integrity standards for clinical trials. The FDA&rsquo;s regulations are intended to help ensure the protection of human subjects enrolled
in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND
foreign trials are conducted in a manner comparable to that required for clinical trials in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, each clinical trial must be reviewed and
approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider,
among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability
of the institution. An IRB must operate in compliance with FDA regulations. The FDA,&nbsp;IRB, or the clinical trial sponsor may suspend
or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in
accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must
satisfy extensive GCP rules&nbsp;and the requirements for informed consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, some clinical trials are overseen
by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB.
This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check
points based on certain available data from the trial to which only the DSMB has access.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical trials typically are conducted in three
sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><I>Phase 1</I>&nbsp;clinical trials are initially conducted in a limited population to test the product candidate for safety, including
adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or, on occasion,
in patients, such as cancer patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><I>Phase 2</I>&nbsp;clinical trials are generally conducted in a limited patient population to identify possible adverse effects and
safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal
dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly
Phase 3 clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><I>Phase 3</I>&nbsp;clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate
is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population
to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse
patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may
be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately
label a biologic; such Phase 3 studies are referred to as &ldquo;pivotal.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In some cases, the FDA may approve a BLA for a
product but require the sponsor to conduct additional clinical trials to further assess the product&rsquo;s safety and effectiveness after
approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience
from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved
under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary
for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement
or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting Phase 4 clinical trials
could result in withdrawal of approval for products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A clinical trial may combine the elements of more
than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&rsquo;s
designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy
the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed
by the FDA. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and
reliable assessment of clinical benefit, particularly in an area of unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2022, with the passage of Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity
action plan for each Phase 3 clinical trial or any other &ldquo;pivotal study&rdquo; of a new drug or biological product. These plans
are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically,
actions plans must include the sponsor's goals for enrollment, the underlying rationale for those goals, and an explanation of how the
sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action
plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Finally, sponsors of clinical trials are required
to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National
Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, study sites
and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA
with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. Although the FDA has historically not enforced these reporting requirements due to the Department of Health and Human Services', or HHS,
long delay in issuing final implementing regulations, those regulations have now been issued and the FDA has issued several Notices of
Noncompliance to manufacturers since April 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Special Regulations and Guidance Governing Gene Therapy Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA has defined a gene therapy product as one
that mediates its effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome
and which is administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells&nbsp;<I>in
vivo</I>&nbsp;or transferred to cells&nbsp;<I>ex vivo</I>&nbsp;prior to administration to the recipient. Within the FDA, the Center for
Biologics Evaluation and Research, or CBER, regulates gene therapy products. Within CBER, the review of gene therapy and related products
is consolidated in the Office of Tissues and Advance Therapies, or OTAT, and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on
its reviews. In September&nbsp;2022, the FDA announced retitling of OTAT to the Office of Therapeutic Products, or OTP, and elevation
of OTP to a &quot;Super Office&quot; to meet its growing cell and gene therapy workload and new commitments under the Prescription Drug
User Fee Act agreement for fiscal years 2023-2027. CBER works closely with the Local Biosafety Board, a federal advisory committee, in
reviewing proposed and ongoing gene therapy protocols and engaging in a public discussion of scientific, safety, ethical, and societal
issues related to those protocols. The NIH and the Recombinant DNA Advisory Committee, or RAC, a federal advisory committee, also advise
the FDA on gene therapy issues and other issues related to emerging technologies. The FDA and the NIH have published guidance documents
with respect to the development and submission of gene therapy protocols.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA has issued various guidance documents regarding
gene therapies, including final guidance documents released in January&nbsp;2020 relating to chemistry, manufacturing and controls information
for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders, as well as draft guidance in January&nbsp;2021
for Human Gene Therapy for Neurodegenerative Diseases. Although the FDA has indicated that these and other guidance documents it previously
issued are not legally binding, Carisma believes that its compliance with them is likely necessary to gain approval for any gene therapy
product candidate Carisma may develop. The guidance documents provide additional factors that the FDA will consider at each of the above
stages of development and relate to, among other things, the proper pre-clinical assessment of gene therapies; the chemistry, manufacturing,
and control information that should be included in an IND application; the proper design of tests to measure product potency in support
of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene
therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene
therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by 10 years
of annual queries, either in person or by questionnaire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, to facilitate adverse event reporting
and dissemination of additional information about gene therapy trials, the FDA and the NIH established the Genetic Modification Clinical
Research Information System, or GeMCRIS. Investigators and sponsors of human gene transfer trials can utilize this web-based system to
report serious adverse events and to provide annual reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Finally, for a gene therapy product, the FDA also
will not approve the product if the manufacturer is not in compliance with good tissue practices, or GTP. These standards are found in
FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of human cells,
tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion,
or transfer into a human recipient. The primary intent of the GTP requirements is to ensure thatT-cell and tissue-based products are manufactured
in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue
establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Pediatric Studies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Pediatric Research Equity Act of 2003,
or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the
claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation
for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans
must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design,
any deferral or waiver requests, and other information required by regulation. The sponsor, the FDA, and the FDA&rsquo;s internal review
committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may
request an amendment to the plan at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA may, on its own initiative or at the request
of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or
full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that
the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are completed. The FDA is required
to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments under PREA, have failed to seek
or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. Unless otherwise required
by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has recently taken steps
to limit what it considers abuse of this statutory exemption in PREA. The FDA also maintains a list of diseases that are exempt from PREA
requirements due to low prevalence of disease in the pediatric population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Compliance with cGMP Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with its review of a BLA, the FDA
typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it
determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like
biologics whose attributes cannot be precisely defined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Manufacturers and others involved in the manufacture
and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign
manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing
process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded
under the FDCA. The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to
registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding,
or processing at a separate establishment outside of the United States prior to being imported or offered for import into the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with
cGMPs and other laws. Inspections must follow a &ldquo;risk-based schedule&rdquo; that may result in certain establishments being inspected
more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying,
denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing
process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval
before being implemented. The FDA&rsquo;s regulations also require, among other things, the investigation and correction of any deviations
from cGMP and the imposition of reporting and documentation requirements upon the sponsor and any third-party manufacturers involved in
producing the approved product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Submission and Filing of a BLA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The results of product candidate development, pre-clinical
testing, and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of
a BLA requesting license to market the product. The BLA must contain extensive manufacturing information and detailed information on the
composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs is subject
to an application user fee, which for federal fiscal year 2023 is $3,242,026 for an application requiring clinical data. The sponsor of
a licensed BLA is also subject to an annual program fee, which for federal fiscal year 2023 is $393,933. Certain exceptions and waivers
are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver
for certain small businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following submission of a BLA, the FDA has 60 days
to conduct a preliminary review of the application and it must inform the sponsor within that period of time whether the BLA is sufficiently
complete to permit substantive review. In the event that FDA determines that an application does not satisfy this standard, it will issue
a Refuse to File, or RTF, determination to the sponsor. The FDA may request additional information and studies, and the application must
be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once the submission has been accepted for filing,
the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has ten
months in which to complete its initial review of a standard application and respond to the sponsor, and six months for a priority review
of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be
significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may be
extended by three months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information
already provided in the submission within the last three months before the PDUFA goal date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity
of the clinical data submitted to the FDA. With passage of FDORA, Congress clarified the FDA's authority to conduct inspections by expressly
permitting inspection of facilities involved in the preparation, conduct, or analysis of clinical and non-clinical studies submitted to
FDA as well as other persons holding study records or involved in the study process. To ensure cGMP and GCP compliance by its employees
and third-party contractors, a sponsor may incur significant expenditure of time, money and effort in the areas of training, record keeping,
production and quality control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA may also refer the application to an advisory
committee for review, evaluation, and recommendation as to whether the application should be approved. In particular, the FDA may refer
applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee.
Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates,
and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the
recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The FDA&rsquo;s Decision on a BLA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the PHSA, the FDA may approve a BLA if it
determines that the product is safe, pure, and potent, and the facility where the product will be manufactured meets standards designed
to ensure that it continues to be safe, pure, and potent. Specifically, the FDA must determine that the expected benefits of the proposed
product outweigh its potential risks to patients. This &ldquo;benefit-risk&rdquo; assessment is informed by the extensive body of evidence
about the proposed product in the BLA. On the basis of the FDA&rsquo;s evaluation of the application and accompanying information, including
the results of the inspection of the manufacturing facilities and any FDA audits of pre-clinical and clinical trial sites to assure compliance
with GCPs, the FDA may issue a complete response letter, or CRL, or an approval letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the application is not approved, the FDA will
issue a CRL, which will contain the conditions that must be met in order to secure final approval of the application and will outline
recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a CRL may submit to the FDA information
that represents a complete response to the issues identified by the FDA, withdraw the application or request a hearing. The FDA will not
approve an application until issues identified in the CRL have been addressed. If a CRL is issued, the sponsor will have one year to respond
to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor
an additional six-month extension to respond. For those seeking to challenge the FDA's CRL decision, the FDA has indicated that sponsors may request a formal hearing on the CRL or
they may file a request for reconsideration or a request for a formal dispute resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An approval letter, on the other hand, authorizes
commercial marketing of the product with specific prescribing information for specific indications. The FDA may limit the approved indication(s)&nbsp;for
use of&nbsp;the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In
addition, the FDA may call for post-approval studies, including Phase 4 clinical trials, to further assess the product&rsquo;s efficacy
and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization,
or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that
the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals,
and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing
or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent
or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types
of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject
to further testing requirements and FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Expedited Review Programs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA is authorized to expedite the review of
applications in several ways. None of these expedited programs changes the standards for approval but each may help expedite the development
or approval process governing product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Fast Track designation. The sponsor of a product candidate may request the FDA to designate the product for a specific indication
as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if&nbsp;<I>they</I>&nbsp;are
intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition.
Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied.
In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections
of a Fast Track application before the application is complete, a process known as rolling review.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Breakthrough therapy designation. To qualify for the breakthrough therapy program, product candidates must be intended to treat a
serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate
substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor
of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement
of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Priority review. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be
a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA
aims to complete its review of priority review applications within six months as opposed to 10 months for standard review.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Accelerated approval. Drug or biologic products studied for their safety and effectiveness in treating serious or
                                                                                                                                                                                               life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated
                                                                                                                                                                                               approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical
                                                                                                                                                                                               trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical
                                                                                                                                                                                               benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other
                                                                                                                                                                                               clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of
                                                                                                                                                                                               alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate
                                                                                                                                                                                               receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently
                                                                                                                                                                                               requires as a condition for accelerated approval pre-approval of promotional materials. With passage of the FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products.
Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated
approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies
to the FDA every six months (until the study is completed); and use expedited procedures to withdraw accelerated approval of an NDA or
BLA after the confirmatory trial fails to verify the product's clinical benefit. Further, the FDORA requires the FDA to publish on its
website &ldquo;the rationale for why a post-approval study is not appropriate or necessary&rdquo; whenever it decides not to require such
a study upon granting accelerated approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>Regenerative advanced therapy. With passage of the Cures Act, Congress authorized the FDA to accelerate review and approval of products
designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that
is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates
that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative
advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough
therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Post-Approval Regulation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If regulatory approval for marketing of a product
or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory
requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be
required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply
with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are
required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections
by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including current good manufacturing process, or cGMP, regulations, which impose certain
procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue
to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other
regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A product may also be subject to official lot release,
meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution.
If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol
showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&rsquo;s tests performed on the lot,
to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution.
Finally, the FDA will conduct laboratory research related to the safety, purity, potency, and effectiveness of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once an approval is granted, the FDA may withdraw
the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches
the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency,
or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to
add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution
or other restrictions under a REMS program. Other potential consequences include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>fines, warning letters or holds on post-approval clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product
license approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>product seizure or detention, or refusal to permit the import or export of products; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>injunctions or the imposition of civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted
only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce
the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label
uses may be subject to significant liability. In September 2021, the FDA published final regulations which describe the types of evidence
that the FDA will consider in determining the intended use of a biologic product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication
regarding off-label information, such as distributing scientific or medical journal information. Moreover, with passage of the Pre-Approval
Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain
information about products in development to help expedite patient access upon product approval. Previously, such communications were
permitted under FDA guidance but the new legislation explicitly provides protection to sponsors who convey certain information about products
in development to payors, including unapproved uses of approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial
enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services,
as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including
civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Orphan Drug Designation and Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Orphan drug designation in the United States is
designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition
is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000
individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the
biologic for the disease or condition will be recovered from sales of the product in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Orphan drug designation qualifies a company for
tax credits and market exclusivity for seven years following the date of the product&rsquo;s marketing approval if granted by the FDA.
An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market
the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the
FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval
process like any other product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A sponsor may request orphan drug designation of
a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is
otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for
the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug.
More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor
seeking orphan drug designation must file a complete request for designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a product with orphan designation receives the
first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease
or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that
the FDA may not approve another sponsor&rsquo;s marketing application for the same product for the same indication for seven years, except
in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader
than what was designated in its orphan drug application, it may not be entitled to exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The period of exclusivity begins on the date that
the marketing application is approved by the FDA. Orphan drug exclusivity will not bar approval of another product under certain circumstances,
including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product
on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity
is not able to meet market demand. Under Omnibus legislation enacted in December&nbsp;2020, the requirement for a product to show clinical
superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDA Reauthorization Act of 2017, but have not yet been
approved or licensed by FDA. In addition, the FDA may approve a second application for the same product for a different use or a second
application for a clinically superior version of the product for the same use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA and Congress may further reevaluate the
Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the
11th&nbsp;Circuit in September&nbsp;2021 finding that, for the purpose of determining the scope of exclusivity, the term &ldquo;same disease
or condition&rdquo; means the designated &ldquo;rare disease or condition&rdquo; and could not be interpreted by the FDA to mean the &ldquo;indication
or use.&rdquo; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the
FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug
exclusivity to the uses or indications for which the orphan drug was approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Pediatric Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pediatric exclusivity is another type of non-patent
exclusivity in the United States and for biologics, if granted, provides for the attachment of an additional six months of regulatory
exclusivity to the term of any existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted
if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show
the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&rsquo;s
request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within
the statutory time limits, whatever statutory or regulatory periods of exclusivity that cover the product are extended by six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Biosimilars and Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 2010 Patient Protection and Affordable Care
Act, which was signed into law in March&nbsp;2010, included a subtitle called the BPCIA. The BPCIA established a regulatory scheme authorizing
the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an existing
FDA-licensed &ldquo;reference product.&rdquo; As of January&nbsp;1, 2021, the FDA has approved 29 biosimilar products for use in the United
States. To date, the FDA has approved a number of biosimilars, and the first interchangeable biosimilar product was approved on July&nbsp;30,
2021, and a second product previously approved as a biosimilar was designated as interchangeable in October&nbsp;2021. The FDA has also
issued numerous guidance documents outlining its approach to reviewing and licensing biosimilars and interchangeable biosimilars under
the PHSA, including a draft guidance issued in November&nbsp;2020 that seeks to provide additional clarity to manufacturers of interchangeable
biosimilars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the BPCIA, a manufacturer may submit an application
for licensure of a biologic product that is &ldquo;biosimilar to&rdquo; or &ldquo;interchangeable with&rdquo; a previously approved biological
product or &ldquo;reference product.&rdquo; In order for the FDA to approve a biosimilar product, it must find that there are no clinically
meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the
FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can
be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic
and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished
efficacy relative to exclusive use of the reference biologic. In December 2022, Congress clarified through the FDORA that the FDA may approve multiple first interchangeable biosimilar biological products
so long as the products are all approved on the first day on which such a product is approved as interchangeable with the reference product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the BPCIA, an application for a biosimilar
product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve
a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a
reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full
BLA for such product containing the sponsor&rsquo;s own pre-clinical data and data from adequate and well-controlled clinical trials to
demonstrate the safety, purity, and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved
as interchangeable products. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but
none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which
address pharmacy practices involving biosimilar products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Federal and State Data Privacy and Security
Laws</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under HIPAA, the U.S. Department of Health and
Human Services has issued regulations to protect the privacy and security of protected health information used or disclosed by covered
entities including certain healthcare providers, health plans, and healthcare clearinghouses. HIPAA also regulates standardization of
data content, codes, and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their regulations, including
the omnibus final rule&nbsp;published on January&nbsp;25, 2013, also imposes certain obligations on the business associates of covered
entities that obtain protected health information in providing services to or on behalf of covered entities. In addition to federal privacy
regulations, there are a number of state laws governing confidentiality and security of health information that are applicable to Carisma&rsquo;s
business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to
file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&rsquo;s fees and costs associated with
pursuing federal civil actions. Accordingly, state attorneys general (along with private plaintiffs) have brought civil actions seeking
injunctions and damages resulting from alleged violations of HIPAA&rsquo;s privacy and security rules. New laws and regulations governing
privacy and security may be adopted in the future as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, California recently enacted legislation
that has been dubbed the first &ldquo;GDPR-like&rdquo; law in the United States, the California Consumer Privacy Act, or CCPA. The CCPA creates new individual privacy rights
for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling
personal data of consumers or households. The CCPA went into effect on January&nbsp;1, 2020 and requires covered companies to provide
new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow
for a new cause of action for data breaches. The CCPA could impact Carisma&rsquo;s business activities depending on how it is interpreted
and exemplifies the vulnerability of Carisma&rsquo;s business to not only cyber threats but also the evolving regulatory environment related
to personal data and protected health information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect
on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use,
retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection
or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice
to residents regarding retention of information. The CPRA also created a new enforcement agency - the California Privacy Protection Agency
- whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply
to some of our business activities. In addition, other states, including Virginia, Colorado, Utah, and Connecticut, already have passed
state privacy laws. Virginia's privacy law also went into effect on January 1, 2023, and the laws in the other three states will go into
effect later in the year. Other states will be considering these laws in the future, and Congress has also been debating passing a federal
privacy law. These laws may impact our business activities, including our identification of research subjects, relationships with business
partners and ultimately the marketing and distribution of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because of the breadth of these laws and the narrowness
of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of Carisma&rsquo;s current
or future business activities, including certain clinical research, sales, and marketing practices and the provision of certain items
and services to Carisma&rsquo;s customers, could be subject to challenge under one or more of such privacy and data security laws. The
heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance
and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully
with one or more of these requirements. If Carisma&rsquo;s operations are found to be in violation of any of the privacy or data security
laws or regulations described above that are applicable to Carisma, or any other laws that apply to Carisma, Carisma may be subject to
penalties, including potentially significant criminal, civil, and administrative penalties, damages, fines, imprisonment, contractual
damages, reputational harm, diminished profits and future earnings, additional reporting requirements, and/or oversight if Carisma becomes
subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring
of Carisma&rsquo;s operations, any of which could adversely affect Carisma&rsquo;s ability to operate its business and its results of
operations. To the extent that any of Carisma&rsquo;s product candidates, once approved, are sold in a foreign country, Carisma may be
subject to similar foreign laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Patent Term Restoration and Extension</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, a patent claiming a new biologic
product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act,
which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming
grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the
time between the effective date of the IND clearing clinical studies and the submission date of the BLA, plus the time between the submission
date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a
total of 14 years from the product&rsquo;s approval date in the United States. Only one patent applicable to an approved product is eligible
for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is
sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals.
The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>FDA Approval of Companion Diagnostics</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In August&nbsp;2014, the FDA issued final guidance
clarifying the requirements that will apply to approval of therapeutic products and&nbsp;<I>in vitro</I>&nbsp;companion diagnostics. According
to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously
by the FDA for the use indicated in the therapeutic product&rsquo;s labeling. Approval or clearance of the companion diagnostic device
will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In
July&nbsp;2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and&nbsp;<I>in vitro</I>&nbsp;companion
diagnostic device on issues related to co-development of the products. The 2014 guidance also explains that a companion diagnostic device
used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device,
unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions,
such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&rsquo;s Investigational
Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations.
According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both
products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND
regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone,
or both an IND and an IDE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In April&nbsp;2020, the FDA issued additional guidance
which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple
biological oncology products, when appropriate. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending
that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling
for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific
group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the FDCA,&nbsp;<I>in vitro</I>&nbsp;diagnostics,
including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and
other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical
testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales
and distribution, export and import, and post market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance
or approval from the FDA prior to commercial distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA previously has required&nbsp;<I>in vitro</I>&nbsp;companion
diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval, or PMA, simultaneously
with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and pre-clinical data and the
submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the sponsor
must prepare and provide the FDA with reasonable assurance of the device&rsquo;s safety and effectiveness and information about the device
and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application
fee. For federal fiscal year 2023, the standard fee is $441,547 and the small business fee is $110,387.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Coverage, Pricing, and Reimbursement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Significant uncertainty exists as to the coverage
and reimbursement status of any product candidates for which Carisma may seek regulatory approval by the FDA or other government authorities.
In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing
the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are
unlikely to use any product candidates Carisma may develop unless coverage is provided and reimbursement is adequate to cover a significant
portion of the cost of such product candidates. Even if any product candidates Carisma may develop are approved, sales of such product
candidates will depend, in part, on the extent to which third-party payors, including government health programs in the United States
such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement
levels for, such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from
the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party
payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical
products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved
list, also known as a formulary, which might not include all of the approved products for a particular indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to secure coverage and reimbursement for
any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing
approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor
not to cover any product candidates Carisma may develop could reduce physician utilization of such product candidates once approved and
have a material adverse effect on Carisma&rsquo;s sales, results of operations and financial condition. Additionally, a payor&rsquo;s
decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&rsquo;s
determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the
product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage
may not be available to enable Carisma to maintain price levels sufficient to realize an appropriate return on Carisma&rsquo;s investment
in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage
and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement,
applicable to pharmaceutical or biological products, will apply to any companion diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The containment of healthcare costs also has become
a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have
shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements
for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies
in jurisdictions with existing controls and measures, could further limit a company&rsquo;s revenue generated from the sale of any approved
products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status
is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies
and reimbursement rates may be implemented in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Outside the United States, ensuring adequate coverage
and payment for any product candidates Carisma may develop will face challenges. Pricing of prescription pharmaceuticals is subject to
governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory
marketing approval for a product and may require Carisma to conduct a clinical trial that compares the cost effectiveness of any product
candidates Carisma may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays
in Carisma&rsquo;s commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the European Union, pricing and reimbursement
schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has
been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product
candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval.
For example, the European Union provides options for its member states to restrict the range of products for which their national health
insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may
approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company
placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription
volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount
of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially
in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare
costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to
the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations
may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade
(arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that
has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements
for any of Carisma&rsquo;s products, if approved in those countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Healthcare Law and Regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Healthcare providers and third-party payors play
a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with
providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims
laws, reporting of payments to physicians and teaching physicians and patient privacy laws and regulations and other healthcare laws and
regulations that may constrain Carisma&rsquo;s business and/or financial arrangements. Restrictions under applicable federal and state
healthcare laws and regulations, include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting,
offering, paying, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral
of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in
part, under a federal healthcare program such as Medicare and Medicaid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit
individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims
for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to made or used a false record or statement
to avoid, decrease, or conceal an obligation to pay money to the federal government;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>the Foreign Corrupt Practices Act, which prohibits companies and their intermediaries from making, or offering or promising to make
improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD>the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively
the ACA, which require certain manufacturers of drugs, devices, biologics and medical
supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within the U.S. Department of Health and Human Services, information related to payments and other
transfers of value made by that entity to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment
interests held by physicians and their immediate family members.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some state laws require pharmaceutical companies
to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by
the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and
other healthcare providers or marketing expenditures. In addition, certain state and local laws require drug manufacturers to register
pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information
in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma&rsquo;s operations are found to be in
violation of any of these laws or any other governmental regulations that may apply to Carisma, Carisma may be subject to significant
civil, criminal, and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such
as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of Carisma&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Healthcare Reform</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A primary trend in the U.S. healthcare industry
and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing
of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government
control and other changes to the healthcare system in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March&nbsp;2010, the United States
Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government
healthcare programs. Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For
example, in August&nbsp;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by
Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2
trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&rsquo;s automatic
reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per
fiscal year, which will remain in effect through 2031 pursuant to the Coronavirus Aid, Relief and Economic Security Act or CARES
Act. The American Taxpayer Relief Act of 2012, which was enacted in January&nbsp;2013, among other things, further reduced Medicare
payments to several providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. Under current legislation, the
actual reductions in Medicare payments may vary up to 4%. Further, with passage of the Inflation Reduction Act, or the IRA, in
August&nbsp;2022, Congress extended the expansion of ACA premium tax credits through 2025. Those subsidies were originally extended
through 2022 under the American Rescue Plan Act of 2021. These laws may result in additional reductions in Medicare and other
healthcare funding and otherwise affect the prices Carisma may obtain for any of Carisma&rsquo;s product candidates for which
Carisma may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since enactment of the ACA, there have been, and
continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment
of the Tax Cuts and&nbsp;Jobs Act&nbsp;of 2017, or the TCJA, which was signed by President Trump on December&nbsp;22, 2017, Congress repealed
the &ldquo;individual mandate.&rdquo; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance,
became effective in 2019 Further, on December&nbsp;14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that
the individual mandate portion of the PPACA is an essential and inseverable feature of the ACA and therefore because the mandate was repealed
as part of the Tax Act, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case on November&nbsp;10,
2020 and, on June&nbsp;17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality
of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although the previous administration took executive
actions to undermine or delay implementation of the ACA, those actions were rescinded with issuance of an Executive Order on January&nbsp;28,
2021, by President Biden which directs federal agencies to reconsider rules&nbsp;and other policies that limit Americans&rsquo; access
to health care, and consider actions that will protect and strengthen that access. Under this Executive Order, federal agencies are directed
to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19;
demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements;
policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to
enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The prices of prescription pharmaceuticals have
also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as
well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical
pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare
and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain
provisions in these orders have been incorporated into regulations. These regulations include an interim final rule&nbsp;implementing
a most favored nation model for prices that would tie Medicare Part&nbsp;B payments for certain physician-administered pharmaceuticals
to the lowest price paid in other economically advanced countries, effective January&nbsp;1, 2021. That rule, however, has been subject
to a nationwide preliminary injunction and, on December&nbsp;29, 2021, CMS issued a final rule&nbsp;to rescind it. With issuance of this
rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part&nbsp;B pharmaceuticals and improve
beneficiaries&rsquo; access to evidence-based care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, in October&nbsp;2020, HHS and the
FDA published a final rule&nbsp;allowing states and other entities to develop a Section&nbsp;804 Importation Program, or SIP, to import
certain prescription products from Canada into the United States. The final rule&nbsp;is currently the subject of ongoing litigation,
but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation
of products from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November&nbsp;20, 2020, HHS
finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&nbsp;D,
either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale
discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the
IRA has been delayed by Congress to January 1, 2032.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More recently, on August 16, 2022, the IRA was signed into law by President Biden. The new legislation has implications for Medicare Part
D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option
of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs
to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates
under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part
D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the HHS to implement
many of these provisions through guidance, as opposed to regulation, for the initial years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source
drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS
may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part
B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved
for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved
for a single rare disease or condition. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential
excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &ldquo;maximum
fair price&rdquo; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay
rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at
an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at 2,000 a year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July&nbsp;9, 2021, President Biden signed Executive
Order 14063, which focuses on, among other things, the price of pharmaceuticals. The Order directs HHS to create a plan within 45 days
to combat &ldquo;excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices
paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.&rdquo; On September&nbsp;9,
2021, HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a)&nbsp;make pharmaceutical prices
more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations
with manufacturers; (b)&nbsp;improve and promote competition throughout the prescription pharmaceutical industry by supporting market
changes that strengthen supply chains, promote biosimilars, and increase transparency; and (c)&nbsp;foster scientific innovation to promote
better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery
of valuable and accessible new treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the state level, individual states are increasingly
aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example,
require pharmaceutical manufacturers and other entities in the supply chain, including health carriers, pharmacy benefit managers, wholesale
distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare authorities and individual hospitals
are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other healthcare programs. These measures could reduce the ultimate demand for Carisma&rsquo;s products, once approved, or put
pressure on Carisma&rsquo;s product pricing. Carisma expects that additional state and federal healthcare reform measures will be adopted
in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services,
which could result in reduced demand for Carisma&rsquo;s product candidates or additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employees and Human Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March&nbsp;7, 2023, Carisma had 96 full-time
employees, including a total of 34 employees with M.D. or Ph.D. degrees. Of these full-time employees, 87 are engaged in research and
development activities. None of Carisma&rsquo;s employees are represented by labor unions or covered by collective bargaining agreements.
Carisma considers its relationship with its employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s human capital objectives are focused
on attracting, developing, and retaining talent. Cash compensation plans and equity grants are designed to attract, retain and to motivate
employees, directors, and select consultants to achieve our corporate objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s principal facilities consist of
office and laboratory space in Philadelphia, Pennsylvania. Carisma occupies approximately 4,369 square feet of office space under a lease
that is expected to expire in January&nbsp;2030 and approximately 3,600 square feet of laboratory space under a lease that expires in
October&nbsp;2023. Carisma believes that its facilities are sufficient to meet its current needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is currently not a party to any material
legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>21
<FILENAME>tm238578d1_ex99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;99.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Investing in Carisma Therapeutics Inc., or Carisma,
securities involves a high degree of risk. You should carefully consider the risk factors set forth below and under &ldquo;Risk Factors&rdquo;
in Carisma&rsquo;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2022 as updated by our subsequent filings under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, before deciding whether to purchase Carisma securities. The risks
and uncertainties we describe below and in the documents mentioned above are not the only ones we face. Additional risks and uncertainties
not presently known to us could adversely affect our business, operating results and financial condition, as well as adversely affect
the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary of Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma has incurred significant losses since its inception. Carisma expects to continue to incur significant expenses and operating
losses for the foreseeable future and may never achieve or maintain profitability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma has never generated revenue from product sales and may never achieve or maintain profitability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma is heavily dependent on the success of its lead product candidate, CT-0508, which will require significant clinical testing
before it can seek marketing approval and potentially launch commercial sales. If CT-0508 does not receive marketing approval or is not
successfully commercialized, or if there is significant delay in doing so, Carisma&rsquo;s business will be harmed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma will need substantial additional funding for its continuing operations. If Carisma is unable to raise capital when needed
or on acceptable terms, it could be forced to delay, reduce or eliminate its discovery or product development programs or commercialization
efforts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Cell therapy is a rapidly evolving area of science, and the approach Carisma is taking to discover and develop product candidates
by utilizing genetically modified macrophages is novel and may never lead to approved or marketable products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Even if any of Carisma&rsquo;s product candidates receives marketing approval, it may fail to achieve the degree of market acceptance
by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity
for any of its product candidates, if approved, may be smaller than it estimates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma relies, and expects to continue to rely, on third parties to conduct its clinical trials, and those third parties may not
perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay Carisma&rsquo;s
ability to seek or obtain marketing approval for or commercialize its product candidates or otherwise harm its business. If Carisma is
not able to maintain these third-party relationships or if these arrangements are terminated, it may have to alter its development and
commercialization plans and its business could be adversely affected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>If Carisma is unable to obtain, maintain and enforce patent protection for its technology and product candidates or if the scope of
the patent protection obtained is not sufficiently broad, its competitors could develop and commercialize technology and products similar
or identical to Carisma&rsquo;s, and its ability to successfully develop and commercialize its technology and product candidates may be
adversely affected and Carisma may not be able to compete effectively in its market.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>The market price of Carisma&rsquo;s common stock may be volatile, and the market price of Carisma&rsquo;s common stock may drop following
the merger of Carisma.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting
public companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Once Carisma is no longer a &ldquo;smaller reporting company&rdquo; or otherwise no longer qualifies for applicable exemptions, Carisma
will be subject to additional laws and regulations affecting public companies that will increase Carisma&rsquo;s costs and the demands
on management and could harm Carisma&rsquo;s operating results.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Provisions in Carisma&rsquo;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition
of Carisma, which may be beneficial to its stockholders, more difficult and may prevent attempts by its stockholders to replace or remove
its management.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>An active trading market for Carisma&rsquo;s common stock may not develop and its stockholders may not be able to resell their shares
of common stock for a profit, if at all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Carisma&rsquo;s Financial Position and Need for
Additional Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma has incurred significant losses since its inception.
Carisma expects to continue to incur significant expenses and operating losses for the foreseeable future and may never achieve or maintain
profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since inception, Carisma has incurred
significant operating losses. CTx Operations, Inc.'s (f/k/a CARISMA Therapeutics Inc.), or CTx, net losses were $40.8 million for
the year ended December&nbsp;31, 2021 and $28.3 million for the year ended December&nbsp;31, 2020. As of September&nbsp;30, 2022,
CTx had $70.6 million in cash, cash equivalents and marketable securities and an accumulated deficit of $141.5 million. To date,
Carisma has not yet commercialized any products or generated any revenue from product sales and has financed its operations
primarily with proceeds from sales of Carisma&rsquo;s preferred stock, proceeds from Carisma&rsquo;s collaboration with Moderna,
research tax credits and convertible debt financing. Carisma has devoted substantially all of its financial resources and efforts to
pursuing discovery, research and development of its product candidates. Carisma is still in the early stages of development of its
lead product candidate, CT-0508, and initiated its first clinical trial in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma expects to continue to incur significant
expenses and operating losses for the foreseeable future, including costs associated with operating as a public company. Carisma anticipates
that its expenses will increase substantially if and as it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>enhances the capabilities of its CAR-M platform;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>conducts its ongoing Phase 1 clinical trial of CT-0508;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>prepares for, initiates and conducts a planned clinical trial utilizing CT-0508 in combination with pembrolizumab;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>develops other CT-0508 combination studies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>advances CT-0508 for additional indications or any other product candidate into clinical development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>prepares for, initiates and conducts a planned clinical trial of CT-0525 for solid tumors that overexpress HER2;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>prepares for, initiates and conducts a planned clinical trial of CT-1119 for advanced mesothelin-positive solid tumors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>prepares for, initiates and conducts a planned clinical trial of CT-0729 for prostrate-specific membrane antigen positive
                                                                                                                                                                                                castrate resistant prostate cancer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>conducts discovery and pre-clinical testing of the development of&nbsp;<I>in vivo</I>&nbsp;CAR-M therapeutics for up to twelve oncology
targets, as well as multiple other targets and indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>conducts discovery and pre-clinical testing of its autologous cell therapy pipeline to gather information to apply to the development
of off-the-shelf engineered macrophage therapeutics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>develops iPSC-derived iCAR-M, or iCAR-M, and other macrophage therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>develops&nbsp;<I>in vivo</I>&nbsp;reprogrammed LNP/mRNA CAR-M therapies for cancer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>develops viral vectors to effectively engineer human monocytes and macrophages, including the Vpx lentiviral vector and Carisma&rsquo;s
Ad5f35 vector;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>conducts discovery and pre-clinical testing of other product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>seeks marketing approval for CT-0508 or any other product candidate if it successfully completes clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>scales up its external manufacturing capabilities and capabilities to support clinical trials of CT-0508 or any other product candidates
and for commercialization of any product candidate for which it may obtain marketing approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>establishes a sales, marketing and distribution infrastructure to commercialize any product candidate for which it may obtain marketing
approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>in-licenses or acquires additional technologies or product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>makes any payments under its existing or future strategic collaboration agreements, global exclusive rights licensing agreements or
sponsored research agreements, including with Moderna, University of Pennsylvania and New York University;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>maintains, expands, enforces and protects its intellectual property portfolio;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>hires additional clinical, regulatory, manufacturing, quality control, development and scientific personnel; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>adds operational, financial and management information systems and personnel, including personnel to support its discovery, product
development and planned future commercialization efforts and its operations as a public company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because of the numerous risks and uncertainties
associated with pharmaceutical product development, Carisma is unable to accurately predict the timing or amount of increased expenses
or when, or if, it will be able to achieve or maintain profitability. Carisma&rsquo;s expenses could increase beyond its expectations
if, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma is required by regulatory authorities in the United States, Europe or other jurisdictions to perform trials or studies in
addition to, or different than, those that it currently expects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>there are any delays in establishing appropriate manufacturing arrangements for or completing the development of any of Carisma&rsquo;s
product candidates; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>there are any third-party challenges to Carisma&rsquo;s intellectual property or Carisma needs to defend against any intellectual
property-related claim.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if Carisma obtains marketing approval for
and is successful in commercializing one or more of its product candidates, Carisma expects to incur substantial additional discovery
and product development and other expenditures to develop and market additional product candidates or to expand the approved indications
of any marketed product. Carisma may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that
may adversely affect its business. The size of Carisma&rsquo;s future net losses will depend, in part, on the rate of future growth of
its expenses and Carisma&rsquo;s ability to generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma has never generated revenue from product sales and may
never achieve or maintain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma only recently initiated clinical development
of its lead product candidate, CT-0508, and is in the pre-clinical testing stages for its other product candidates. Carisma expects that
it will be a number of years, if ever, before it has a product candidate ready for commercialization. To become and remain profitable,
Carisma must succeed in completing development of, obtaining marketing approval for and eventually commercializing, one or more products
that generate significant revenue. The ability to achieve this success will require Carisma to be effective in a range of challenging
activities, including completing clinical development of CT-0508, completing discovery, pre-clinical testing and clinical development
of CT-0508 in the combination setting and for additional indications, timely filing and receiving acceptance of its Investigational New
Drug applications, or INDs, in order to commence its planned or future clinical trials, including for CT-0525, CT-1119 and, CT-0729, successfully
enrolling subjects in, and completing, its ongoing and planned clinical trials, scaling up its manufacturing processes and capabilities
to support clinical trials of CT-0508 or of other product candidates, obtaining marketing approval for CT-0508 or any other product candidates,
manufacturing, marketing and selling any products for which Carisma may obtain marketing approval and maintaining a continued acceptable
safety profile of its products following approval. Carisma may never succeed in these activities and, even if it does, may never generate
revenues that are significant enough to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if Carisma does achieve profitability, it
may not be able to sustain or increase profitability on a quarterly or annual basis. Carisma&rsquo;s failure to become and remain profitable
would depress the value of its company and could impair its ability to raise capital, expand its business, maintain its discovery and
product development efforts, diversify its pipeline of product candidates or even continue its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma is heavily dependent on the success of its lead product
candidate, CT-0508, and its follow on HER2 product candidate, CT-0525, which will both require significant clinical testing before Carisma
can seek marketing approval and potentially launch commercial sales. If CT-0508 or CT-0525 do not receive marketing approval or are not
successfully commercialized, or if there is significant delay in doing so, Carisma&rsquo;s business will be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma only recently initiated its first clinical
trial, has no products that are approved for commercial sale and may never be able to develop marketable products. Carisma expects that
a substantial portion of its efforts and expenditures for the foreseeable future will be devoted to CT-0508 and related combination sub-studies
of the synergistic potential and utility of CT-0508. Carisma&rsquo;s business currently depends heavily on the successful development,
marketing approval and commercialization of CT-0508 and the success of related combination sub-studies. Carisma cannot be certain that
CT-0508 or any combination therapy will achieve success in ongoing or future clinical trials, receive marketing approval or be successfully
commercialized. Carisma is also currently in the pre-clinical stage for another product candidate, CT-0525, which is also intended to
treat solid tumors that overexpress HER2. By leveraging its discovery engine and preliminary clinical data from its Phase 1 clinical trial
of CT-0508, Carisma is building upon its CAR-M platform to generate next-generation therapeutics that may increase potential efficacy
and patient access.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma were required to discontinue development
of CT-0508 or CT-0525, or if CT-0508 or CT-0525 do not receive marketing approval for one or more of the indications Carisma pursues,
fail to achieve significant market acceptance, or fail to receive adequate reimbursement, Carisma may be delayed by many years in its
ability to achieve profitability, if ever, and may not be able to generate sufficient revenue to continue its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma will need substantial additional funding for its continuing
operations. If Carisma is unable to raise capital when needed or on acceptable terms, it could be forced to delay, reduce or eliminate
its discovery or product development programs or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma expects to devote substantial financial
resources to its ongoing and planned activities, particularly as it conducts its ongoing clinical trial of CT-0508 and pursues related
combination strategies, prepares for, initiates and conducts its planned clinical trials of CT-0525, CT-1119 and CT-0729 and advances
its discovery programs and continues its product development efforts. Carisma expects its expenses to increase substantially in connection
with its ongoing activities, particularly as it advances its pre-clinical activities and clinical trials. In addition, if Carisma obtains
marketing approval for CT-0508 or any other product candidate it is developing or develops in the future, it expects to incur significant
commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, Carisma will incur additional
costs associated with operating as a public company. Accordingly, Carisma will need to obtain substantial additional funding in connection
with its continuing operations. If Carisma is unable to raise capital or obtain adequate funds when needed or on acceptable terms, it
may be required to delay, limit, reduce or terminate its discovery and product development programs or any future commercialization efforts
or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself. In addition, attempting
to secure additional financing may divert the time and attention of Carisma management from day-to-day activities and distract from its
discovery and product development efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma&rsquo;s future capital requirements will depend on many factors, including:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the progress, costs and results of its ongoing clinical trial of CT-0508 and other planned and future clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the scope, progress, costs and results of pre-clinical testing and clinical trials of CT-0508 for additional combinations, targets
and indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the number of and development requirements for additional indications for CT-0508 or for any other product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the success of its collaborations with Moderna or others;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>its ability to scale up its manufacturing processes and capabilities to support clinical trials of CT-0508 and other product candidates
it is developing and develops in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the costs, timing and outcome of regulatory review of CT-0508 and other product candidates it is developing and may develop in the
future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>potential changes in the regulatory environment and enforcement rules;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>its ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the payment of license fees and other costs of its technology license arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for
CT-0508 and other product candidates it is developing and may develop in the future for which it may receive marketing approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>its ability to obtain and maintain acceptance of any approved products by patients, the medical community and third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the amount and timing of revenue, if any, received from commercial sales of CT-0508 and any other product candidates it is developing
or develops in the future for which it receives marketing approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>potential changes in pharmaceutical pricing and reimbursement infrastructure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the availability of raw materials for use in production of its product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property
and proprietary rights and defending any intellectual property-related claims; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the extent to which it in-licenses or acquires additional technologies or product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma management has concluded that there is
substantial doubt about Carisma&rsquo;s ability to continue as a going concern. As a result, Carisma management has included disclosures
in Note 2 of the consolidated financial statements and Carisma&rsquo;s independent auditor included an explanatory paragraph in its report
on Carisma&rsquo;s consolidated financial statements as of and for the year ended December&nbsp;31, 2021 with respect to this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of September&nbsp;30, 2022, CTx had
cash, cash equivalents and marketable securities of $70.6 million. Immediately prior to the consummation of the merger with Sesen
Bio, or the merger, certain investors  purchased shares of CTx common stock for an aggregate purchase price of
approximately $30.6 million, which was converted into the right to receive a number of shares of Carisma common stock equal to the exchange ratio in connection with
the merger. Carisma believes that it has cash, cash equivalents and marketable securities sufficient to sustain
its operating expenses and capital expenditure requirements at least through the end of 2024. However, Carisma has based this
estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown
to Carisma. In addition, changing circumstances could cause Carisma to consume capital significantly faster than it currently
anticipates, and Carisma may need to spend more than currently expected because of circumstances beyond its control. As a result,
Carisma could deplete its capital resources sooner than it currently expects. In addition, because the successful development of
CT-0508, CT-0525, CT-1119, CT-0729 and any combination studies or other product candidates that it pursues is highly uncertain, at
this time Carisma cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete
the development of any product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Identifying potential product candidates and conducting
pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and Carisma
may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, Carisma&rsquo;s
product candidates, if approved, may not achieve commercial success. Carisma will not generate commercial revenues unless and until it
can achieve sales of products, which it does not anticipate for a number of years, if at all. Accordingly, Carisma will need to obtain
substantial additional financing to achieve its business objectives. Adequate additional financing may not be available to Carisma on
acceptable terms, or at all, and may be impacted by the economic climate and market conditions. For example, market volatility resulting
from the COVID-19 pandemic, any other future infectious diseases, epidemics or pandemics or general U.S. or global economic or market
conditions could also adversely impact Carisma&rsquo;s ability to access capital as and when needed. Alternatively, Carisma may seek additional
capital due to favorable market conditions or strategic considerations, even if it believes it has sufficient funds for its current or
future operating plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma&rsquo;s limited operating history may make it difficult
for you to evaluate the success of Carisma&rsquo;s business to date and to assess Carisma&rsquo;s future viability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma was formed as Carma Therapeutics LLC,
a Pennsylvania limited liability company, in April&nbsp;2016 and converted to a Delaware corporation in May&nbsp;2017. In connection
with the merger, CARISMA Therapeutics Inc. merged with and into a wholly-owned subsidiary of Sesen Bio and was renamed &ldquo;CTx
Operations, Inc.&rdquo; Sesen Bio's name was changed to &ldquo;Carisma Therapeutics Inc.&rdquo; Following the completion of the
merger, the business conducted by the public company became primarily the business conducted by Carisma. Carisma is a clinical-stage
cell therapy company with a limited operating history. Cell therapy product development is a highly speculative undertaking and
involves a substantial degree of risk. Carisma&rsquo;s operations prior to the merger have been limited to organizing and staffing
its company, business planning, capital raising, establishing and maintaining its intellectual property portfolio, building its
pipeline of product candidates, conducting drug discovery activities, undertaking pre-clinical studies, manufacturing process
development studies, conducting early-stage clinical trials, and providing general and administrative support for these operations.
Carisma&rsquo;s prospects must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered
by companies in their early stages of operations. Carisma has not yet demonstrated its ability to successfully develop any product
candidate, obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on its behalf,
or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any
predictions you make about Carisma&rsquo;s future success or viability may not be as accurate as they could be if Carisma had a
longer operating history or a history of successfully developing, obtaining marketing approval for and commercializing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, as Carisma&rsquo;s business grows,
Carisma may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles. Carisma will need
to transition at some point from a company with a discovery and pre-clinical and clinical focus to a company capable of supporting commercial
activities. Carisma may not be successful in such a transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As Carisma continues to build its business, Carisma
expects its financial condition and operating results to fluctuate significantly from quarter to quarter and year to year due to a variety
of factors, many of which are beyond Carisma&rsquo;s control. Accordingly, you should not rely upon the results of any quarterly or annual
periods as indications of future operating performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The COVID-19 pandemic may affect Carisma&rsquo;s pre-clinical
studies and clinical trials, disrupt regulatory activities, disrupt Carisma&rsquo;s manufacturing and supply chain or have other adverse
effects on Carisma&rsquo;s business and operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The COVID-19 pandemic has caused many governments
to implement measures to slow the spread of the virus through quarantines, travel restrictions, heightened border scrutiny and other measures.
The pandemic and government measures taken in response have also had a significant impact, both directly and indirectly, on businesses
and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and
demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such
as travel, has fallen. The future progression of the pandemic and its effects on Carisma&rsquo;s business and operations are uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma and the third-party manufacturers and clinical
research organizations that it engages may face disruptions that could affect Carisma&rsquo;s ability to initiate and complete pre-clinical
studies or clinical trials, including disruptions in procuring items that are essential for Carisma&rsquo;s discovery and product development
activities, such as, for example, raw materials used in the manufacturing of its product candidates, laboratory supplies for its ongoing
and planned pre-clinical studies and clinical trials, or animals that are used for pre-clinical testing, in each case, for which there
may be shortages because of ongoing efforts to address the pandemic, or disruptions in Carisma&rsquo;s ability to obtain necessary site
approvals or other delays at clinical trial sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of the COVID-19 pandemic, Carisma may
experience further disruptions that could severely impact Carisma&rsquo;s business, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>disruptions related to Carisma&rsquo;s ongoing and planned clinical trials or future clinical trials arising from delays in completing
pre-clinical studies required to begin clinical development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>manufacturing disruptions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the inability to obtain necessary site approvals or other delays at clinical trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as Carisma&rsquo;s
clinical trial sites and hospital staff supporting the conduct of Carisma&rsquo;s clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or
recommended by foreign, federal or state governments, employers and others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study
endpoints;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>interruption or delays in the operations of the United States Food and Drug Administration, or the FDA, or other regulatory authorities,
which may impact review and approval timelines;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>limitations on employee resources that would otherwise be focused on the conduct of Carisma&rsquo;s pre-clinical studies and clinical
trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of
people;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>difficulties recruiting or retaining patients for Carisma&rsquo;s clinical trials if patients are affected by the virus or are fearful
of visiting or traveling to clinical trial sites because of the virus; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>risk that participants enrolled in its clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact
the results of the clinical trial, including by increasing the number of observed adverse events and refusal of the FDA, to accept data
from clinical trials in these affected geographies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The response to the COVID-19 pandemic may redirect
resources with respect to regulatory and intellectual property matters in a way that would adversely impact its ability to pursue marketing
approvals and protect its intellectual property. In addition, Carisma may face impediments to regulatory meetings and potential approvals
due to measures intended to limit in-person interactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, third parties, including manufacturers,
medical institutions, clinical investigators, contract research organizations and consultants with whom Carisma conducts business, are
similarly adjusting their operations and assessing their capacity in light of the COVID-19 pandemic. If these third parties continue to
experience shutdowns or business disruptions, Carisma&rsquo;s ability to conduct its business in the manner and on the timelines presently
planned could be materially and negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 30, 2023, the Biden Administration announced that it will end the public health emergency declarations related to COVID-19
on May 11, 2023. On January 31, 2023, the FDA indicated that it would soon issue a Federal Register notice describing how the termination
of the public health emergency will impact the FDA's COVID-19 related guidance, including the clinical trial guidance and updates thereto.
At this point, it is unclear how, if at all, these developments will impact Carisma's efforts to develop and commercialize its product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The COVID-19 pandemic continues to evolve and has
already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact Carisma&rsquo;s
ability to raise additional funds through public offerings and may also impact the volatility of Carisma&rsquo;s stock price and trading
in its stock. Moreover, it is possible the pandemic will further significantly impact economies worldwide, which could result in adverse
effects on Carisma&rsquo;s business and operations. Carisma cannot be certain what the overall impact of the COVID-19 pandemic will be
on its business, and it has the potential to materially and adversely affect Carisma&rsquo;s business, financial condition, results of
operations and prospects. To the extent the COVID-19 pandemic adversely affects Carisma&rsquo;s business, financial condition and results
of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &ldquo;Risk Factors&rdquo;
section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes in tax law may adversely affect Carisma or its investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The rules&nbsp;dealing with U.S. federal, state
and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury
Department. Changes to tax laws (which changes may have retroactive application) could adversely affect Carisma or holders of Carisma&rsquo;s
common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be
predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued,
which could result in an increase in Carisma&rsquo;s or its stockholders&rsquo; tax liability or require changes in the manner in which
Carisma operates in order to minimize or mitigate any adverse effects of changes in tax law. Prospective investors should consult their
tax advisors regarding the potential consequences of changes in tax law on Carisma&rsquo;s business and on the ownership and disposition
of Carisma common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma&rsquo;s ability to use its net operating loss carryforwards,
or NOLs, and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to the merger, Carisma has a history of
cumulative losses and anticipates that it will continue to incur significant losses in the foreseeable future. As a result, Carisma
does not know whether or when it will generate taxable income necessary to utilize its NOLs or research and development tax credit
carryforwards. As of December&nbsp;31, 2021, CTx had federal, state and local NOLs of $76.4 million, $76.4 million and $71.2
million, respectively, and federal research and development tax credit carryforwards totaling $3.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In general, under Section&nbsp;382 of the Code
and corresponding provisions of state law, a corporation that undergoes an &ldquo;ownership change,&rdquo; generally defined as a greater
than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three year period, is subject to limitations
on its ability to utilize its pre-change NOLs and research and development tax credit carryforwards to offset future taxable income. Carisma
has not conducted a study to assess whether any such ownership changes have occurred. Carisma may have experienced such ownership changes
in the past and may experience such ownership changes in the future (which may be outside its control). As a result, if and to the extent
Carisma earns net taxable income, its ability to use its pre-change NOLs and research and development tax credit carryforwards to offset
such taxable income may be subject to limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Carisma&rsquo;s Discovery Programs and Research
and Development of Carisma&rsquo;s Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cell therapy is a rapidly evolving area of science, and the approach
Carisma is taking to discover and develop product candidates by utilizing genetically modified macrophages is novel and may never lead
to approved or marketable products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cell therapy has yet to be broadly applied to solid
tumors, inflammatory disease, fibrotic disease or neurodegeneration. The discovery, research and development of engineered macrophages
to treat disease is an emerging field and Carisma&rsquo;s CAR-M platform, which is the first CAR-M to be evaluated in a human clinical
trial, is a relatively new technology. Carisma&rsquo;s future success depends on the successful development of this novel therapeutic
approach. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary
and limited. Carisma has only preliminary results from its Phase 1 clinical trial of CT-0508 and expects clinical updates in the next
18 months. As such, there may be adverse effects or limited favorable results from treatment with any of Carisma&rsquo;s current or future
product candidates that it cannot predict at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s success also depends on its successful
application of its proprietary macrophage engineering platform in the combination setting and to other indications by reprogramming the
target specificity of its CAR-M cell product and developing product candidates against a plethora of tumor associated antigens, including
in therapeutic areas beyond oncology. However, Carisma&rsquo;s macrophage engineering platform may not allow it to generate new INDs to
expand its pipeline on Carisma&rsquo;s anticipated timeline or in a cost-efficient manner or at all, which could cause the potential value
of Carisma&rsquo;s business to decline and materially harm Carisma&rsquo;s business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of these factors, it is more difficult
for Carisma to predict the time and cost of product candidate development, and Carisma cannot predict whether the application of macrophage
engineering platform will result in the development and marketing approval of any products. Any development problems Carisma experiences
in the future related to its macrophage engineering platform or any of its discovery programs may cause significant delays or unanticipated
costs or may prevent the development of a commercially viable product. Any of these factors may prevent Carisma from completing its clinical
trials or pre-clinical studies or commercializing any product candidates it may develop on a timely or profitable basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma is early in its development efforts. If Carisma is unable
to commercialize its product candidates or experiences significant delays in doing so, its business will be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is early in its development efforts. Carisma
initiated its first Phase 1 clinical trial of CT-0508 in 2021 and expects to evaluate a combination of CT-0508 with pembrolizumab in an
ongoing Phase 1 clinical trial. Carisma expects to submit INDs for CT-0525 in the second half of 2023 and for CT-1119 in 2025. CT-0729
is still in the discovery stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s ability to generate revenues from
product sales, which it does not expect will occur for a number of years, if ever, will depend heavily on the successful development,
marketing approval and eventual commercialization of CT-0508, including in the combination setting, or one or more of its other product
candidates, which may never occur. The success of CT-0508 and Carisma&rsquo;s other product candidates will depend on several factors,
including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>successfully completing pre-clinical studies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>successfully initiating future clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>successfully enrolling patients in and completing clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>scaling up manufacturing processes and capabilities to support clinical trials of CT-0508 and any other product candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>applying for and receiving marketing approvals from applicable regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>obtaining and maintaining intellectual property protection and regulatory exclusivity for CT-0508 and any other product candidates
it is developing or may develop in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>making arrangements with third-party manufacturers, or establishing commercial manufacturing capabilities, for both clinical and commercial
supplies of its product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>establishing sales, marketing and distribution capabilities and launching commercial sales of its products, if and when approved,
whether alone or in collaboration with others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>acceptance of CT-0508 and any other product candidates, if and when approved, by patients, the medical community and third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>effectively competing with other therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>maintaining, enforcing, defending and protecting its rights in its intellectual property portfolio;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>not infringing, misappropriating or otherwise violating others&rsquo; intellectual property or proprietary rights; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>maintaining a continued acceptable safety profile of its products following receipt of any marketing approvals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma does not achieve one or more of these
factors in a timely manner or at all, it could experience significant delays or an inability to successfully develop and commercialize
its product candidates, which would materially harm Carisma&rsquo;s business. As a company, Carisma has limited experience in clinical
development, having only recently advanced CT-0508 into an early-stage clinical trial. Any predictions about the future success or viability
of CT-0508 or any product candidates Carisma is developing or may develop in the future may not be as accurate as they could be if Carisma
had a history of conducting clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Drug development involves a lengthy and expensive process, with
an uncertain outcome. The results of pre-clinical studies and early clinical trials may not be predictive of future results. Carisma may
incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization
of CT-0508 or its other product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma only recently initiated its first clinical
trial of CT-0508 and its other product candidates are in pre-clinical development. The risk of failure for CT-0508 and Carisma&rsquo;s
other product candidates is high. It is impossible to predict when or if CT-0508 or any of Carisma&rsquo;s other product candidates will
prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities
for the sale of a product candidate, Carisma must complete pre-clinical development and then conduct extensive clinical trials to demonstrate
the safety and efficacy of such product candidate in humans. Clinical trials may fail to demonstrate that CT-0508 or any of Carisma&rsquo;s
other product candidates are safe for humans and effective for indicated uses. Even if the clinical trials are successful, changes in
marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations
or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an
application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before Carisma can commence clinical trials for
a product candidate, it must complete extensive pre-clinical testing and studies, manufacturing process development studies, and analytical
development studies that support its planned INDs and other applications to regulatory authorities in the United States or similar applications
in other jurisdictions. Carisma cannot be certain of the timely completion or outcome of its pre-clinical testing and studies and cannot
predict if the outcome of its pre-clinical testing and studies will ultimately support the further development of its current or future
product candidates or whether regulatory authorities will accept its proposed clinical programs. As a result, Carisma may not be able
to submit applications to initiate clinical development of product candidates on the timelines Carisma expects, if at all, and the submission
of these applications may not result in regulatory authorities allowing clinical trials to begin. Furthermore, product candidates are
subject to continued pre-clinical safety studies, which may be conducted concurrently with Carisma&rsquo;s clinical testing. The outcomes
of these safety studies may delay the launch of or enrollment in future clinical trials and could impact Carisma&rsquo;s ability to continue
to conduct its clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical testing is expensive, difficult to design
and implement, can take many years to complete and is uncertain as to the outcome. Carisma cannot guarantee that any of its clinical trials
will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing,
which may result from a multitude of factors, including, among other things, flaws in study design, dose selection issues, placebo effects,
patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moreover, pre-clinical and clinical data are often
susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily
in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure
of any of Carisma&rsquo;s product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception
of its other product candidates or cause regulatory authorities to require additional testing before approving any of its product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma may experience numerous unforeseen events
during, or as a result of, clinical trials that could delay or prevent its ability to receive marketing approval or commercialize any
product candidates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>regulators or institutional review boards, or IRBs, may not authorize Carisma or its investigators to commence a clinical trial or
conduct a clinical trial at a prospective trial site or at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols
with prospective trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>regulators may determine that the planned design of Carisma&rsquo;s clinical trials is flawed or inadequate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>clinical trials of Carisma&rsquo;s product candidates may produce negative or inconclusive results, and Carisma may decide, or regulators
may require Carisma, to conduct additional clinical trials or abandon product development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may be unable to establish clinical endpoints that applicable regulatory authorities consider clinically meaningful, or, if
Carisma seeks accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities consider likely to predict clinical
benefit;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>pre-clinical testing may produce results based on which Carisma may decide, or regulators may require Carisma, to conduct additional
pre-clinical studies before it proceeds with certain clinical trials, limits the scope of its clinical trials, halt ongoing clinical trials
or abandon product development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the number of patients required for clinical trials of Carisma&rsquo;s product candidates may be larger than it anticipates, enrollment
in these clinical trials may be slower than Carisma anticipates or participants may drop out of these clinical trials at a higher rate
than Carisma anticipates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to Carisma in a timely
manner, or at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may decide, or regulators or IRBs may require Carisma, to suspend or terminate clinical trials of its product candidates for
various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable
health risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>regulators or IRBs may require Carisma to perform additional or unanticipated clinical trials to obtain approval or Carisma may be
subject to additional post-marketing testing requirements to maintain marketing approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>regulators may revise the requirements for approving Carisma&rsquo;s product candidates, or such requirements may not be as it anticipates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the cost of clinical trials of Carisma&rsquo;s product candidates may be greater than it anticipates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the supply or quality of Carisma&rsquo;s product candidates or other materials necessary to conduct clinical trials of its product
candidates may be insufficient or inadequate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma&rsquo;s product candidates may have undesirable side effects or other unexpected characteristics, causing Carisma or its clinical
investigators, regulators or IRBs to suspend or terminate the trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>regulators may withdraw their approval of a product or impose restrictions on its distribution; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>business interruptions resulting from the COVID-19 pandemic may result in adverse effects on Carisma&rsquo;s business and operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma is required to conduct additional clinical
trials or other testing of its product candidates beyond those that it currently contemplates, if Carisma is unable to successfully complete
clinical trials of its product candidates or other testing, if the results of these trials or tests are not positive or are only modestly
positive, if there are safety concerns or if Carisma determines that the observed safety or efficacy profile would not be competitive
in the marketplace, it may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>incur unplanned costs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>be delayed in obtaining marketing approval for its product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>not obtain marketing approval at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>obtain marketing approval in some countries and not in others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>obtain approval for indications or patient populations that are not as broad as intended or desired;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>be subject to additional post-marketing testing requirements; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>have the product removed from the market after obtaining marketing approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s product development costs will
also increase if it experiences delays in pre-clinical studies or clinical trials or in obtaining marketing approvals. Carisma does not
know whether any of its pre-clinical studies or clinical trials will begin as planned, will need to be restructured or will be completed
on schedule, or at all. Carisma may also determine to change the design or protocol of one or more of its clinical trials, including to
add additional patients or arms, which could result in increased costs and expenses or delays. Significant pre-clinical study or clinical
trial delays also could shorten any periods during which Carisma may have the exclusive right to commercialize its product candidates
or allow its competitors to bring products to market before Carisma does and impair Carisma&rsquo;s ability to successfully commercialize
its product candidates and may harm Carisma&rsquo;s business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the FDA's and other regulatory authorities' policies with respect to clinical trials may change and additional government
regulations may be enacted. If Carisma is slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies governing clinical trials, Carisma's development plans may be impacted. For example, in December 2022, with the passage of
Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each phase 3
clinical trial or any other &ldquo;pivotal study&rdquo; of a new drug or biological product. These plans are meant to encourage the enrollment
of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, actions plans must include
the sponsor's goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them.
In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Similarly, the regulatory landscape related to clinical trials in the European Union recently evolved. The European Union Clinical Trials
Regulation, or CTR, which was adopted in April 2014 and repeals the European Union Clinical Trials Directive, became applicable on January
31, 2022. While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state,
to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only
requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to
both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment
procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment
by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state's decision
is communicated to the sponsor via the centralized European Union portal. Once the CTA is approved, clinical study development may proceed.
If Carisma is not able to adapt to these and other changes in existing requirements or the adoption of new requirements or policies governing
clinical trials, Carisma's development plans may be impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, cancer therapies are sometimes characterized
as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for second-line or third-line use.
When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy or a combination of these,
is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients
when prior therapy is not effective. For any of Carisma&rsquo;s products that prove to be sufficiently beneficial, Carisma would expect
to seek approval potentially as a first-line therapy, but any product candidates Carisma develops, even if approved, may not be approved
for first-line therapy, and, prior to any such approvals, Carisma may have to conduct additional clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The results of early-stage clinical trials and pre-clinical studies
may not be predictive of future results. Initial success in clinical trials may not be indicative of results obtained when these trials
are completed or in later stage trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The outcome of pre-clinical testing and early clinical
trials may not be predictive of the success of later clinical trials, and preliminary or interim results of a clinical trial do not necessarily
predict final results. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are
completed. In particular, the small number of patients in Carisma&rsquo;s ongoing early clinical trials may make the results of these
trials less predictive of the outcome of later clinical trials. For example, even if successful, the results of Carisma&rsquo;s Phase
1 clinical trial of CT-0508 may not be predictive of the results of further clinical trials of CT-0508 or any of Carisma&rsquo;s other
product candidates. Carisma&rsquo;s product candidates may also fail to show the desired safety and efficacy in clinical development despite
positive results in pre-clinical studies or having successfully advanced through initial clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moreover, pre-clinical and clinical data are often
susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily
in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Carisma&rsquo;s current
or future clinical trials may not ultimately be successful or support further clinical development of any of its product candidates and
Carisma cannot assure you that any clinical trials that it may conduct will demonstrate consistent or adequate efficacy and safety to
support marketing approval. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in
the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials even after achieving promising results
in pre-clinical testing and earlier-stage clinical trials, and Carisma cannot be certain that it will not face similar setbacks. Any such
setbacks in Carisma&rsquo;s clinical development could materially harm Carisma&rsquo;s business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Interim and preliminary results from Carisma&rsquo;s clinical
trials that it announces or publishes from time to time may change as more participant data become available and are subject to audit
and verification procedures, which could result in material changes in the final data.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, Carisma may announce or publish
interim or preliminary results from its clinical trials, including its Phase 1 clinical trial of CT-0508. Interim results from clinical
trials that Carisma may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant
enrollment continues and more participant data become available. Carisma also makes assumptions, estimations, calculations, and conclusions
as part of its analyses of data, and Carisma may not have received or had the opportunity to fully evaluate all data. Preliminary or interim
results also remain subject to audit and verification procedures that may result in the final data being materially different from the
preliminary data Carisma previously published. As a result, interim and preliminary data should be viewed with caution until the final
data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm
Carisma&rsquo;s reputation and business prospects and may cause the trading price of Carisma common stock to fluctuate significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma experiences delays or difficulties in the enrollment
of patients in its clinical trials for CT-0508 or any of its other product candidates, its receipt of necessary marketing approvals could
be delayed or prevented.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Identifying and qualifying patients to participate
in clinical trials for CT-0508 and any other product candidates in the future is critical to Carisma&rsquo;s success. Successful and timely
completion of clinical trials will require that Carisma enroll a sufficient number of patients who remain in the trial until its conclusion.
Carisma may not be able to initiate or continue clinical trials for its product candidates if it is unable to locate and enroll a sufficient
number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United
States. In particular, group 2 for Carisma&rsquo;s Phase 1 clinical trial of CT-0508 is currently open for enrollment with an additional
nine patients to be dosed in the study and Carisma is preparing to advance other products into clinical development. In addition, some
of Carisma&rsquo;s competitors have ongoing clinical trials for product candidates that treat the same indications as Carisma&rsquo;s
product candidates, and patients who would otherwise be eligible for Carisma&rsquo;s clinical trials may instead enroll in clinical trials
of Carisma&rsquo;s competitors&rsquo; product candidates. Carisma cannot predict how successful it will be at enrolling subjects in future
clinical trials. Patient enrollment is affected by a variety of other factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the prevalence and severity of the disease under investigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the eligibility criteria for the trial in question;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the perceived risks and benefits of the product candidate under trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the requirements of the trial protocols;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the availability of existing treatments for the indications for which Carisma is conducting clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the ability to recruit clinical trial investigators with the appropriate competencies and experience;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the efforts to facilitate timely enrollment in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the ability to identify specific patient populations based on specific genetic mutations or other factors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the patient referral practices of physicians;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the ability to monitor patients adequately during and after treatment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma&rsquo;s ability to obtain and maintain patient consents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the proximity and availability of clinical trial sites for prospective patients;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the conduct of clinical trials by competitors for product candidates that treat the same indications or address the same patient populations
as Carisma&rsquo;s product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the cost to, or lack of adequate compensation for, prospective patients; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the impact of the ongoing COVID-19 pandemic.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s inability to locate and enroll
a sufficient number of patients for its clinical trials would result in significant delays, could require it to abandon one or more clinical
trials altogether and could delay or prevent its receipt of necessary marketing approvals. Enrollment delays in Carisma&rsquo;s clinical
trials may result in increased development costs for its product candidates, which could cause the value of Carisma&rsquo;s business to
decline and limit its ability to obtain additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If serious adverse events, undesirable side effects or unexpected
characteristics are identified during the development of CT-0508 or any of Carisma&rsquo;s other product candidates, Carisma may need
to abandon or limit its further clinical development of those product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Enrollment in group 1 of Carisma&rsquo;s first
in human Phase 1 clinical trial of CT-0508 has been completed with nine patients successfully dosed and group 2 is currently open for
enrollment with nine additional patients to be dosed in the trial. If CT-0508 or any other product candidate is associated with serious
adverse events or undesirable side effects in clinical trials or have characteristics that are unexpected in clinical trials or pre-clinical
testing, Carisma may need to abandon development of such product candidate or limit development to more narrow uses or subpopulations
in which the serious adverse events, undesirable side effects or unexpected characteristics are less prevalent, less severe or more acceptable
from a risk-benefit perspective. In pharmaceutical development, many compounds that initially show promise in early-stage or clinical
testing are later found to cause side effects that delay or prevent further development of the compound. For example, while CT-0508 has
been generally well tolerated based on preliminary clinical results from Carisma&rsquo;s Phase 1 clinical trial, such results may not
be predictive or indicative of the successful development, marketing approval and eventual commercialization of CT-0508.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, if results of Carisma&rsquo;s clinical
trials reveal undesirable side effects, Carisma, regulatory authorities or the IRBs at the institutions in which Carisma&rsquo;s studies
are conducted could suspend or terminate its clinical trials, regulatory authorities could order Carisma to cease clinical trials or deny
approval of its product candidates for any or all targeted indications or Carisma could be forced to materially modify the design of its
clinical trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete
any of Carisma&rsquo;s clinical trials or result in potential liability claims. In addition, these side effects may not be appropriately
recognized or managed by the treating medical staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma elects or is forced to suspend or terminate
any clinical trial of its product candidates, the commercial prospects of such product candidate will be harmed, and Carisma&rsquo;s ability
to generate revenues from sales of such product candidate will be delayed or eliminated. Any of these occurrences could materially harm
Carisma&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If any of Carisma&rsquo;s product candidates receives marketing
approval and Carisma, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects
that were not previously identified, Carisma&rsquo;s ability to market the drug could be compromised.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma only recently initiated clinical development
of its lead product candidate, CT-0508, and is in the pre-clinical testing stages for its other product candidates. Clinical trials will
be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that
Carisma&rsquo;s clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive
effect, if any, or alternatively fail to identify undesirable side effects. If one or more of Carisma&rsquo;s product candidates receives
marketing approval, and Carisma, or others, later discover that they are less effective than previously believed, or cause undesirable
side effects, a number of potentially significant negative consequences could result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>withdrawal or limitation by regulatory authorities of approvals of such product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>seizure of the product by regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>recall of the product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>restrictions on the marketing of the product or the manufacturing process for any component thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>requirement by regulatory authorities of additional warnings on the label;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>requirement that Carisma implement a risk evaluation and mitigation strategy or create a medication guide outlining the risks of such
side effects for distribution to patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the product may become less competitive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>initiation of regulatory investigations and government enforcement actions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>initiation of legal action against Carisma to hold it liable for harm caused to patients; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>harm to Carisma&rsquo;s reputation and resulting harm to physician or patient acceptance of its products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these events could prevent Carisma from
achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm Carisma&rsquo;s
business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may expend its limited resources to pursue a particular
product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there
is a greater likelihood of success.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because Carisma has limited financial and managerial
resources, it focuses on discovery programs and product candidates that it identifies for specific indications. As a result, Carisma may
forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial
potential. Carisma&rsquo;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable
market opportunities. Carisma&rsquo;s spending on current and future discovery and product development programs and product candidates
for specific indications may not yield any commercially viable products. If Carisma does not accurately evaluate the commercial potential
or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration,
licensing or other royalty arrangements in cases in which it would have been more advantageous for Carisma to retain sole development
and commercialization rights to such product candidate. Failure to allocate resources or capitalize on strategies in a successful manner
will have an adverse impact on Carisma&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may develop CT-0508 in combination with other drugs.
If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, revoke their approval of such
drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs Carisma chooses to evaluate in combination with CT-0508,
Carisma may be unable to obtain approval of CT-0508 or market CT-0508.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September&nbsp;2022, Carisma submitted a clinical
protocol amendment to the CT-0508 IND for a CAR-M / anti-PD-1 (CT-0508 and pembrolizumab) combination strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma did not develop or obtain marketing approval
for, nor has Carisma manufactured or sold, any of the currently approved drugs that it may study in combination with CT-0508. If the FDA
or similar regulatory authorities outside of the United States revoke their approval of any drug or drugs in combination with which Carisma
determines to develop CT-0508, Carisma will not be able to market CT-0508 in combination with such revoked drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If safety or efficacy issues arise with any of
these drugs, Carisma could experience significant regulatory delays, and the FDA or similar regulatory authorities outside of the United
States may require Carisma to redesign or terminate the applicable clinical trials. If the drugs Carisma uses are replaced as the standard
of care for the indications it chooses for CT-0508, the FDA or similar regulatory authorities outside of the United States may require
Carisma to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs
with which Carisma determines to combine with CT-0508, it may not be able to complete clinical development of CT-0508 on its current timeline
or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if CT-0508 were to receive marketing approval
or be commercialized for use in combination with other existing drugs, Carisma would continue to be subject to the risks that the FDA
or similar regulatory authorities outside of the United States could revoke approval of the drug used in combination with CT-0508 or that
safety, efficacy, manufacturing or supply issues could arise with these existing drugs. Combination therapies are commonly used for the
treatment of cancer, and Carisma would be subject to similar risks if it develops any of its other product candidates for use in combination
with other drugs or for indications other than cancer. This could result in Carisma&rsquo;s own products being removed from the market
or being less successful commercially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may not be successful in its efforts to identify or discover
additional potential product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A key element of Carisma&rsquo;s strategy is to
apply its macrophage engineering platform to address a broad array of indications and targets to generate next-generation therapeutics,
including three programs for indications outside of oncology. The discovery efforts that Carisma is conducting may not be successful in
identifying product candidates that are useful in treating cancer or other diseases. Carisma&rsquo;s discovery engine may initially show
promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that
they are unlikely to be drugs that will receive marketing approval or achieve market acceptance; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>potential product candidates may not be effective in treating their targeted diseases.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Discovery programs to identify new product candidates
require substantial technical, financial and human resources. Carisma may choose to focus its efforts and resources on a potential product
candidate that ultimately proves to be unsuccessful. If Carisma is unable to identify additional suitable product candidates for pre-clinical
and clinical development, it will limit its potential to obtain revenues from sale of products in future periods, which likely would result
in significant harm to Carisma&rsquo;s financial position and adversely impact its stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Adverse public perception of genetic medicine, and gene therapy
in particular, may negatively impact regulatory approval of, or demand for, Carisma&rsquo;s potential products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The clinical and commercial success of Carisma&rsquo;s
potential products will depend in part on public acceptance of the use of gene therapy for the prevention or treatment of human diseases.
Public attitudes may be influenced by claims that gene therapy is unsafe, unethical, or immoral, and, consequently, Carisma&rsquo;s products
may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact Carisma&rsquo;s ability
to enroll clinical trials. Moreover, Carisma&rsquo;s success will depend upon physicians prescribing, and their patients being willing
to receive, treatments that involve the use of product candidates that Carisma may develop in lieu of, or in addition to, existing treatments
with which they are already familiar and for which greater clinical data may be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Risks Related to the Commercialization of Carisma&rsquo;s
Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even if any of Carisma&rsquo;s product candidates receives marketing
approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical
community necessary for commercial success, and the market opportunity for any of its product candidates, if approved, may be smaller
than it estimates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any of Carisma&rsquo;s product candidates receives
marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others
in the medical community. For example, current cancer treatments, such as chemotherapy and radiation therapy, are well established in
the medical community and doctors may continue to rely on these and similar treatments. Efforts to educate the medical community and third-party
payors on the benefits of Carisma&rsquo;s product candidates may require significant resources and may not be successful. If Carisma&rsquo;s
product candidates do not achieve an adequate level of acceptance, Carisma may not generate significant revenues from product sales and
it may not become profitable. The degree of market acceptance of Carisma&rsquo;s product candidates, if approved for commercial sale,
will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the efficacy and potential advantages of Carisma&rsquo;s product candidates compared to the advantages and relative risks of alternative
treatments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the effectiveness of sales and marketing efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma&rsquo;s ability to offer its products, if approved, for sale at competitive prices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the clinical indications for which the product is approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the cost of treatment in relation to alternative treatments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the convenience and ease of administration compared to alternative treatments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the strength of marketing and distribution support;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the timing of market introduction of competitive products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the availability of third-party coverage and adequate reimbursement, and patients&rsquo; willingness to pay out of pocket for required
co-payments or in the absence of third-party coverage or adequate reimbursement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>product labeling or product insert requirements of the FDA, the European Medical Agency, or the EMA, or other regulatory
                                                                                                                                                                                                authorities, including any limitations or warnings contained in a product&rsquo;s approved labeling;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the prevalence and severity of any side effects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>support from patient advocacy groups; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>any restrictions on the use of Carisma&rsquo;s products, if approved, together with other medications.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s assessment of the potential market
opportunity for its product candidates is based on industry and market data that it obtained from industry publications, research, surveys
and studies conducted by third parties and Carisma&rsquo;s analysis of these data, research, surveys and studies. Industry publications
and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be
reliable, although they do not guarantee the accuracy or completeness of such information. While Carisma believes these industry publications
and third-party research, surveys and studies are reliable, it has not independently verified such data. Carisma&rsquo;s estimates of
the potential market opportunities for its product candidates include a number of key assumptions based on its industry knowledge, industry
publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market
opportunities. While Carisma believes that its internal assumptions are reasonable, no independent source has verified such assumptions.
If any of Carisma&rsquo;s assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the
actual market for any of its product candidates may be smaller than it expects, and as a result Carisma&rsquo;s revenues from product
sales may be limited and it may be more difficult for Carisma to achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma is unable to establish sales, marketing and distribution
capabilities or enter into sales, marketing and distribution agreements with third parties, it may not be successful in commercializing
its product candidates if and when they are approved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma does not have a sales or marketing infrastructure
and has no experience as a company in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial success
for any product for which Carisma may obtain marketing approval, it will need to establish a sales, marketing and distribution organization,
either itself or through collaborations or other arrangements with third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma currently expects that it would build its
own focused, specialized sales and marketing organization to support the commercialization in the United States of product candidates
for which it receives marketing approval and that can be commercialized with such capabilities. There are risks involved with Carisma
establishing its own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and
time-consuming and could delay any product launch. If the commercial launch of a product candidate for which Carisma recruit a sales force
and establish marketing capabilities is delayed or does not occur for any reason, Carisma would have prematurely or unnecessarily incurred
these commercialization expenses. These efforts may be costly, and Carisma&rsquo;s investment would be lost if it cannot retain or reposition
its sales and marketing personnel. In general, the cost of establishing and maintaining a sales and marketing organization may exceed
the cost-effectiveness of doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Factors that may inhibit Carisma&rsquo;s efforts
to commercialize its products on its own include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>its inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service,
medical affairs and other support personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>its inability to equip sales personnel with effective materials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>its inability to effectively manage a geographically dispersed sales and marketing team;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future
products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by
payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the inability to price its products at a sufficient price point to ensure an adequate and attractive level of profitability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>restricted or closed distribution channels that make it difficult to distribute its products to segments of the patient population;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the lack of complementary products to be offered by sales personnel, which may put Carisma at a competitive disadvantage relative
to companies with more extensive product lines; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>unforeseen costs and expenses associated with creating an independent sales and marketing organization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma is unable to establish its own sales,
marketing and distribution capabilities and it enters into arrangements with third parties to perform these services, Carisma&rsquo;s
revenues from product sales and its profitability, if any, are likely to be lower than if it were to market, sell and distribute any products
that it develops itself. In addition, Carisma may not be successful in entering into arrangements with third parties to sell, market and
distribute its product candidates or may be unable to do so on terms that are acceptable to Carisma. Carisma likely will have little control
over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market its products effectively.
If Carisma does not establish sales, marketing and distribution capabilities successfully, either on its own or in collaboration with
third parties, it will not be successful in commercializing its product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma faces substantial competition, which may result in others
discovering, developing or commercializing products before or more successfully than it does, thus rendering Carisma&rsquo;s products
non-competitive, obsolete or reducing the size of its market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The biopharmaceutical industry, and in particular
the cell therapy field, is characterized by intense investment and competition aimed at rapidly advancing new technologies. Carisma&rsquo;s
platform and therapeutic product candidates are expected to face substantial competition from multiple technologies, marketed products
and numerous other therapies being developed by third parties that use protein degradation, antibody therapy, inhibitory nucleic acid,
gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small
molecule inhibitors. The competition is likely to come from multiple sources, including biopharmaceutical companies, academic research
institutions, governmental agencies and private research institutions that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization. The competition is likely to come from multiple sources,
including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public
and private research institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is aware of a number of companies generally
pursuing the development of myeloid cell therapies, including, among others Myeloid Therapeutics, Shoreline Biosciences,&nbsp;Inceptor
Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, Sirpant Therapeutics, and others. Carisma is also facing competition from companies
pursuing autologous T-cell therapies, allogenic T-cell therapies, NK and other cell therapies, direct&nbsp;<I>in vivo</I>&nbsp;reprogrammed
cell therapies and other macrophage-targeted oncology therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many of the companies against which Carisma is
competing or against which it may compete in the future have significantly greater financial resources and expertise in research and development,
manufacturing, pre-clinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than Carisma
does. These competitors also compete with Carisma in recruiting and retaining qualified scientific and management personnel and establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary
for, its development programs. Carisma&rsquo;s commercial opportunity could be reduced or eliminated if its competitors develop and commercialize
products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products
that Carisma may develop. Carisma&rsquo;s competitors also may obtain FDA or other marketing approval for their products more rapidly
than Carisma may obtain approval for its products, which could result in Carisma&rsquo;s competitors establishing a strong market position
before Carisma is able to enter the market. In addition, Carisma&rsquo;s ability to compete may be affected in many cases by insurers
or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain
of the indications that Carisma is pursuing, and additional products are expected to become available on a generic basis over the coming
years. If Carisma&rsquo;s product candidates are approved, it expects that they will be priced at a significant premium over competitive
generic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Technology in the biopharmaceutical industry has
undergone rapid and significant change, and Carisma expects that it will continue to do so. Any products or processes that Carisma develops
may become obsolete or uneconomical before it recovers any expenses incurred in connection with their development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mergers and acquisitions in the biopharmaceutical
industry may result in even more resources being concentrated among a smaller number of Carisma&rsquo;s competitors. Smaller and other
early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These third parties compete with Carisma in recruiting and retaining qualified scientific and management personnel, establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary
for, Carisma&rsquo;s programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma has pursued and may in the future pursue
the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. However, Carisma
may be unable to in-license or acquire any additional technologies or product candidates from third parties. The acquisition and licensing
of technologies and product candidates is a competitive area, and a number of more established companies also have similar strategies
to in-license or acquire technologies and product candidates that Carisma may consider attractive. These established companies may have
a competitive advantage over Carisma due to their size, cash resources and greater development and commercialization capabilities. In
addition, companies that perceive Carisma to be a competitor may be unwilling to assign or license rights to Carisma. Carisma also may
be unable to in-license or acquire the relevant technology or product candidate on terms that would allow Carisma to make an appropriate
return on its investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even if Carisma is able to commercialize any product candidates,
the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform
initiatives, which could harm its business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The regulations that govern marketing approvals,
pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly
change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require
approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or
product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, Carisma may be required to conduct
a clinical trial that compares the cost effectiveness of its product candidate to other available therapies. In some foreign markets,
prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result,
Carisma might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay its
commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, Carisma is able to generate
from the sale of the product in that country. Adverse pricing limitations may hinder Carisma&rsquo;s ability to recoup its investment
in one or more product candidates, even if its product candidates obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s ability to commercialize any product
candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related
treatments will be available from government health administration authorities, private health insurers and other organizations. The availability
of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and
other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products, including
Carisma&rsquo;s product candidates. Government authorities and third-party payors, such as private health insurers and health maintenance
organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry
and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage
and the amount of reimbursement for particular medications. Increasingly, government authorities and third-party payors are requiring
that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.
Coverage and reimbursement may not be available for any product that Carisma commercializes and, even if these are available, the level
of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which it
obtains marketing approval. Obtaining and maintaining adequate reimbursement for Carisma&rsquo;s products may be difficult. Carisma may
be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative
to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, Carisma
may not be able to successfully commercialize any product candidate for which it obtains marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There may be significant delays in obtaining coverage
and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA
or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that
a drug will be paid for in all cases or at a rate that covers its costs, including research, development, intellectual property, manufacture,
sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover Carisma&rsquo;s
costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it
is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other
services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices
than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement
policies. Carisma&rsquo;s inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private
payors for any approved products that it develops could have a material adverse effect on its operating results, its ability to raise
capital needed to commercialize products and its overall financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No uniform policy for coverage and reimbursement
for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly
from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require Carisma
to provide scientific and clinical support for the use of its product candidates to each payor separately, with no assurance that coverage
and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&nbsp;and regulations regarding
reimbursement change frequently, in some cases on short notice, and Carisma believes that changes in these rules&nbsp;and regulations
are likely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There can be no assurance that Carisma&rsquo;s
product candidates, even if they are approved for sale in the United States, in the European Union or in other countries, will be considered
medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate
level of reimbursement will be available or that third-party payors&rsquo; reimbursement policies will not adversely affect Carisma&rsquo;s
ability to sell its product candidates profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Clinical trial and product liability lawsuits against Carisma
could divert its resources and could cause Carisma to incur substantial liabilities and to limit commercialization of any products that
it may develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma faces an inherent risk of clinical trial
and product liability exposure related to the testing of its product candidates in human clinical trials and will face an even greater
risk if it commercially sells any products that it may develop. While Carisma currently has no products that have been approved for commercial
sale, the ongoing, planned and future use of product candidates by Carisma in clinical trials, and the sale of any approved products in
the future, may expose Carisma to liability claims. These claims might be made by patients that use the product, healthcare providers,
pharmaceutical companies or others selling such products. On occasion, large judgments have been awarded in class action lawsuits based
on products that had unanticipated adverse effects. If Carisma cannot successfully defend itself against claims that its product candidates
or products caused injuries, it will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result
in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>decreased demand for any product candidates or products that it may develop;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>termination of clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>withdrawal of marketing approval, recall, restriction on the approval or a &ldquo;black box&rdquo; warning or contraindication for
an approved drug;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>withdrawal of clinical trial participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>significant costs to defend any related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>substantial monetary awards to trial participants or patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>loss of revenue;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>injury to Carisma&rsquo;s reputation and significant negative media attention;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>reduced resources of Carisma management to pursue its business strategy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>distraction of management&rsquo;s attention from Carisma&rsquo;s primary business; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the inability to commercialize any products that Carisma may develop.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma currently holds $10.0 million in product
liability insurance coverage in the aggregate, with a per incident limit of $10.0 million, which may not be adequate to cover all liabilities
that it may incur. Carisma may need to increase its insurance coverage as it expands its clinical trials or if it commences commercialization
of its product candidates. Insurance coverage is increasingly expensive. Carisma may not be able to maintain insurance coverage at a reasonable
cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series
of claims is brought against Carisma for uninsured liabilities or in excess of insured liabilities, its assets may not be sufficient to
cover such claims and its business operations could be impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Risks Related to Carisma&rsquo;s Dependence
on Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma relies, and expects to continue to rely, on third parties
to conduct its clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion
of such trials, which may prevent or delay Carisma&rsquo;s ability to seek or obtain marketing approval for or commercialize its product
candidates or otherwise harm its business. If Carisma is not able to maintain these third-party relationships or if these arrangements
are terminated, it may have to alter its development and commercialization plans and its business could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma relies, and expects to continue to rely,
on third-party clinical research organizations, in addition to other third parties such as research collaboratives, clinical data management
organizations, medical institutions and clinical investigators, to conduct its ongoing Phase 1 clinical trial of CT-0508 and related combinations
studies, its planned clinical trials of CT-0525, CT-1119 and CT-0729 and any other clinical trials it conducts. Carisma does not plan
to independently conduct clinical trials of its product candidates or any other product candidates that it may develop. These contract
research organizations and other third parties play a significant role in the conduct and timing of these trials and subsequent collection
and analysis of data. These third-party arrangements might terminate for a variety of reasons, including a failure to perform by the third
parties. If Carisma needs to enter into alternative arrangements, its product development activities might be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s reliance on these third parties
for discovery and product development activities reduces its control over these activities but does not relieve Carisma of its responsibilities.
For example, Carisma will remain responsible for ensuring that each of its clinical trials is conducted in accordance with the general
investigational plan and protocols for the trial. Moreover, the FDA requires Carisma to comply with standards, commonly referred to as
good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported
results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities
in Europe and other jurisdictions have similar requirements. Regulatory authorities enforce these GCPs through periodic inspections of
trial sponsors, principal investigators and trial sites. If Carisma or any of its contract research organizations or trial sites fail
to comply with applicable GCPs, the clinical data generated in its clinical trials may be deemed unreliable, and the FDA or comparable
foreign regulatory authorities may require Carisma to perform additional clinical trials before approving its marketing applications.
Carisma is also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored
database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal
sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If these third parties do not successfully carry
out their contractual duties, meet expected deadlines or conduct Carisma&rsquo;s clinical trials in accordance with regulatory requirements
or Carisma&rsquo;s stated protocols, Carisma will not be able to obtain, or may be delayed in obtaining, marketing approvals for its product
candidates and will not be able to, or may be delayed in its efforts to, successfully develop and commercialize its product candidates.
Furthermore, these third parties may also have relationships with other entities, some of which may be Carisma&rsquo;s competitors. In
addition, principal investigators for Carisma&rsquo;s clinical trials may serve as scientific advisors or consultants to Carisma from
time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation
result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation
of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical
trial itself may be jeopardized, which could result in the delay or rejection of any marketing application Carisma submits to the FDA.
Any such delay or rejection could prevent Carisma from commercializing its product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any of Carisma&rsquo;s relationships with these
third parties terminate, it may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable
terms. Switching or adding additional contract research organizations, investigators and other third parties involves additional cost
and requires management time and focus. In addition, there is a natural transition period when a new contract research organization commences
work. As a result, delays can occur, which could materially impact Carisma&rsquo;s ability to meet its desired clinical development timelines.
The COVID-19 pandemic and government measures taken in response have also had a significant impact on many contract research organizations.
Although Carisma plans to carefully manage its relationships with its contract research organizations, investigators and other third parties,
it may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on Carisma&rsquo;s business,
financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma relies on third-party contract manufacturing organizations
for the manufacture of both drug substance and finished drug product of its product candidates for pre-clinical and clinical testing and
expect to continue to do so for commercialization. This reliance on third parties increases the risk that Carisma will not have sufficient
quantities of its product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair
Carisma&rsquo;s development or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma does not own or operate, and currently
has no plans to establish, any manufacturing facilities. Carisma relies, and expects to continue to rely, on third-party contract manufacturing
organizations for both drug substance and finished drug product, as well as for commercial manufacture if any of its product candidates
receive marketing approval. Carisma also currently relies on these third parties for the manufacture of plasmid and viral vectors, patient
leukapheresis material logistics, as well as packaging, labeling, sterilization, storage, distribution and other production logistics.
This reliance on third parties increases the risk that Carisma will not have sufficient quantities of its product candidates or products
or such quantities at an acceptable cost or quality, which could delay, prevent or impair Carisma&rsquo;s development or commercialization
efforts. Carisma may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if Carisma
is able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>reliance on the third party for regulatory compliance and quality assurance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the possible breach of the manufacturing agreement by the third party;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the potential failure to manufacture Carisma&rsquo;s product candidate or product according to its specifications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the potential failure to manufacture Carisma&rsquo;s product candidate or product according to its schedule or at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the possible misappropriation of Carisma&rsquo;s proprietary information, including its trade secrets and know-how; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for Carisma.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma or its third-party manufacturers may encounter
shortages in the raw materials or active pharmaceutical ingredients necessary to produce Carisma&rsquo;s product candidates in the quantities
needed for its clinical trials or, if its product candidates are approved, in sufficient quantities for commercialization or to meet an
increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or active pharmaceutical
ingredients, including shortages caused by the purchase of such raw materials or active pharmaceutical ingredients by its competitors
or others. The failure of Carisma or its third-party manufacturers to obtain the raw materials or active pharmaceutical ingredients necessary
to manufacture sufficient quantities of its product candidates, may have a material adverse effect on Carisma&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s third-party manufacturers are subject
to inspection and approval by regulatory authorities before Carisma can commence the manufacture and sale of any of its product candidates,
and thereafter subject to ongoing inspection from time to time. Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations
or similar regulatory requirements outside of the United States. Carisma&rsquo;s failure, or the failure of its third-party manufacturers,
to comply with applicable regulations could result in sanctions being imposed on Carisma, including clinical holds, fines, injunctions,
civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products,
operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Carisma&rsquo;s products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s product candidates and any products
that it may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, Carisma
may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under
cGMP regulations and that might be capable of manufacturing for Carisma. Any performance failure on the part of Carisma&rsquo;s existing
or future manufacturers could delay clinical development or marketing approval. Carisma does not currently have arrangements in place
for redundant supply or a second source for bulk drug substance. If any of Carisma&rsquo;s current contract manufacturers cannot perform
as agreed, it may be required to replace such manufacturers. Although Carisma believes that there are several potential alternative manufacturers
who could manufacture its product candidates, it may incur added costs and delays in identifying and qualifying any such replacement or
be unable to reach agreement with an alternative manufacturer. In addition, the COVID-19 pandemic may impact Carisma&rsquo;s ability to
procure sufficient supplies for the development of its product candidates. The extent of this impact will depend on the severity and duration
of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s current and anticipated future
dependence upon others for the manufacture of its product candidates or products may adversely affect its future profit margins and its
ability to commercialize any products that receive marketing approval on a timely and competitive basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma expects to depend on collaborations with third parties
for the research, development and commercialization of certain of its product candidates. If Carisma&rsquo;s collaborations are not successful,
it may not be able to capitalize on the market potential of these product candidates and its business could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma anticipates seeking third-party collaborators
for the research, development and commercialization of certain of its product candidates. For example, Carisma entered into a strategic
collaboration with Moderna in January&nbsp;2022 focused on the development of&nbsp;<I>in vivo</I>&nbsp;CAR-M therapeutics for up to twelve
product candidates. In collaboration with Moderna, Carisma has established a myeloid tropic LNP/mRNA&nbsp;<I>in vivo</I>&nbsp;CAR-M platform
for oncology targets, which enables an off-the-shelf approach wherein the patient&rsquo;s own myeloid cells are engineered directly within
their body via the administration of a myeloid-tropic LNP encapsulating macrophage reprogramming mRNA CAR constructs, removing the requirement
for&nbsp;<I>ex vivo</I>&nbsp;cell manufacturing entirely. As part of the collaboration, Carisma received a $45.0 million up-front cash
payment from Moderna, in addition to future research funding, milestone payments and royalties. Concurrent with entering into the collaboration
agreement, Moderna made an investment in Carisma in the form of a $35.0 million convertible note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s likely collaborators for any other
collaboration arrangements include large and mid-size pharmaceutical companies and biotechnology companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any such arrangements with third parties will likely
limit Carisma&rsquo;s control over the amount and timing of resources that its collaborators dedicate to the development or commercialization
of its product candidates Carisma may seek to develop with them. Carisma&rsquo;s ability to generate revenues from these arrangements
will depend on its collaborators&rsquo; abilities and efforts to successfully perform the functions assigned to them in these arrangements.
Carisma cannot predict the success of any collaboration that it enters into.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Collaborations involving Carisma&rsquo;s discovery
programs or any product candidates it may develop, including its collaboration with Moderna, pose the following risks to Carisma:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these
collaborations; for example, Carisma&rsquo;s collaboration with Moderna is managed by a joint steering committee, which is comprised of
representatives from Carisma and Moderna, with Moderna having final decision-making authority, subject to specified limitations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaborators may not perform their obligations as expected;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaborators may not pursue development of Carisma&rsquo;s product candidates or may elect not to continue or renew development programs
based on results of clinical trials or other studies, changes in the collaborators&rsquo; strategic focus or available funding, or external
factors, such as an acquisition or business combination, that divert resources or create competing priorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaborators may not pursue development and commercialization of any product candidates that achieve marketing approval or may elect
not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&rsquo;
strategic focus or available funding, or external factors, such as an acquisition or business combination, that may divert resources or
create competing priorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon
a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed
or commercialized under a collaboration and, consequently, may have limited ability to inform its stockholders about the status of such
product candidates on a discretionary basis; for example, data, results and know-how generated in the performance of the Moderna collaboration
is deemed the confidential information of Moderna, which Carisma may not disclose except under limited circumstances;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Carisma&rsquo;s
product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed
or can be commercialized under terms that are more economically attractive than Carisma&rsquo;s;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>product candidates discovered in collaboration with Carisma may be viewed by Carisma&rsquo;s collaborators as competitive with their
own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of Carisma&rsquo;s
product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or
marketing of a product candidate or product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>a collaborator may seek to renegotiate or terminate their relationship with Carisma due to unsatisfactory clinical results, manufacturing
issues, a change in business strategy, a change of control or other reasons;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>a collaborator with marketing and distribution rights to one or more of Carisma&rsquo;s product candidates that achieve marketing
approval may not commit sufficient resources to the marketing and distribution of such product or products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation
or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product
candidates, might lead to additional responsibilities for Carisma with respect to product candidates, or might result in litigation or
arbitration, any of which would be time-consuming and expensive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may lose certain valuable rights under circumstances identified in its collaborations, including if it undergoes a change
of control;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaborators may not properly obtain, maintain, enforce, defend or protect Carisma&rsquo;s intellectual property or proprietary rights
or may use its proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or
invalidate its intellectual property or proprietary information or expose Carisma to potential litigation; for example, Moderna has the
first right to prosecute, enforce or defend certain patent rights under its agreement with Carisma, and although Carisma may have the
right to assume the prosecution, enforcement or defense of such patent rights if Moderna does not, Carisma&rsquo;s ability to do so may
be compromised by Moderna&rsquo;s actions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>disputes may arise with respect to the ownership of intellectual property developed pursuant to Carisma&rsquo;s collaborations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties,
which may expose Carisma to litigation and potential liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaborations may be terminated, and, if terminated, Carisma could be required to raise additional capital to pursue further development
or commercialization of the applicable product candidates; for example, Moderna has the right to terminate its agreement with Carisma
for convenience in its entirety or with respect to a specific product or target on ninety days&rsquo; prior notice, in connection with
a material breach of the agreement by Carisma that remains uncured for a specified period of time or in the event of specified insolvency
events involving Carisma; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at
all. If a present or future collaborator of Carisma&rsquo;s were to be involved in a business combination, the continued pursuit and emphasis
on its product development or commercialization program under such collaboration could be delayed, diminished or terminated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any collaborations that Carisma enters into
do not result in the successful development and commercialization of products or if one of Carisma&rsquo;s collaborators terminates its
agreement with it, Carisma may not receive any future research funding or milestone or royalty payments under the collaboration. If Carisma
does not receive the funding it expects under these agreements, its development of its product candidates could be delayed and it may
need additional resources to develop its product candidates. All of the risks relating to product development, marketing approval and
commercialization described herein also apply to the activities of Carisma&rsquo;s collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma may in the future decide to collaborate
with biopharmaceutical companies for the development and potential commercialization of any product candidates it may develop. These relationships,
or those like them, may require Carisma to incur non-recurring and other charges, increase Carisma&rsquo;s near- and long-term expenditures,
issue securities that dilute Carisma&rsquo;s existing stockholders, or disrupt Carisma&rsquo;s management and business. In addition, Carisma
could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Carisma&rsquo;s
ability to reach a definitive collaboration agreement will depend, among other things, upon its assessment of the collaborator&rsquo;s
resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&rsquo;s evaluation of several
factors. If Carisma licenses rights to any product candidates it or its collaborators may develop, Carisma may not be able to realize
the benefit of such transactions if it is unable to successfully integrate them with its existing operations and company culture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may seek to establish additional collaborations. If Carisma
is not able to establish or maintain additional collaborations, on commercially reasonable terms, it may have to alter its development
and commercialization plans and its business could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To realize the full potential of Carisma&rsquo;s
macrophage engineering platform and accelerate the development of additional macrophage engineering programs, Carisma plans to continue
to selectively pursue collaborations with leading biopharmaceutical companies with particular experience, including development and commercial
expertise and capabilities. Carisma faces significant competition in attracting appropriate collaborators, and a number of more established
companies may also be pursuing strategies to license or acquire third-party intellectual property rights that it considers attractive.
These established companies may have a competitive advantage over Carisma due to their size, financial resources and greater clinical
development and commercialization capabilities. In addition, companies that perceive Carisma to be a competitor may be unwilling to assign
or license rights to Carisma. Whether Carisma reaches a definitive agreement for a collaboration will depend, among other things, upon
its assessment of the collaborator&rsquo;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed
collaborator&rsquo;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood
of approval by the FDA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities
of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty
with respect to Carisma&rsquo;s ownership of technology, which can exist if there is a challenge to such ownership without regard to the
merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator
may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether
such a collaboration could be more attractive than the one with Carisma for its product candidate. Carisma may also be restricted under
future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and
time-consuming to negotiate, document and execute. In addition, there have been a significant number of recent business combinations among
large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration Carisma
may enter into may limit its ability to enter into future agreements on particular terms or covering similar target indications with other
potential collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma is unable to reach agreements with suitable
collaborators on a timely basis, on acceptable terms or at all, it may have to curtail the development of a product candidate, reduce
or delay its development program or one or more of Carisma&rsquo;s other development programs, delay its potential commercialization or
reduce the scope of any sales or marketing activities, or increase its expenditures and undertake development or commercialization activities
at its own expense. If Carisma elects to fund and undertake development or commercialization activities on its own, it may need to obtain
additional expertise and additional capital, which may not be available to Carisma on acceptable terms or at all. If Carisma fails to
enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization
activities, it may not be able to further develop its product candidates or bring them to market and generate revenue from product sales,
which could have an adverse effect on its business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma has a number of academic collaborations to supplement
its internal discovery and product development program. If any such collaborator decides to discontinue or devote less resources to such
research, Carisma&rsquo;s discovery programs could be diminished.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s discovery engine is supplemented
by academic collaborations to expand its platform, which Carisma relies upon to advance its development and commercialization plans for
its product candidates. In August&nbsp;2020, Carisma entered into a scientific research and licensing agreement with Nathaniel R. Landau,
Ph.D. and NYU Langone Health through which it obtained exclusive rights to develop their Vpx lentiviral vector globally for all indications.
Carisma also has an ongoing discovery program in neurodegeneration being pursued through a sponsored research agreement with Dr.&nbsp;Saar
Gill, Associate Professor of Medicine at the University of Pennsylvania and co-founder of Carisma, to develop CAR macrophages and microglia
targeted against protein aggregates associated with neurodegenerative disease pathology. In addition, Carisma from time to time may enter
into academic research collaborations to explore the development of new technologies and indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While these academic institutions have contractual
obligations to Carisma, they are independent entities and are not under Carisma&rsquo;s control or the control of Carisma&rsquo;s officers
or directors. Carisma&rsquo;s research and licensing agreements with academic collaborators generally provide academic collaborators with
license maintenance fees, development and regulatory milestone payments, royalties on net sales of products and a portion of sublicense
income that Carisma receives. Upon the scheduled expiration of any academic collaboration, Carisma may not be able to renew the related
agreement or any renewal could be on terms less favorable to Carisma than those contained in the existing agreement. Furthermore, either
Carisma or the academic institution generally may terminate the sponsored research agreement for convenience following a specified notice
period. If any of these academic institutions decides to not renew or to terminate the related agreement or decides to devote fewer resources
to such activities, Carisma&rsquo;s discovery efforts would be diminished, while its royalty obligations, if any, would continue unmodified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Any acquisitions or in-license transactions that Carisma completes
could disrupt its business, cause dilution to its stockholders or reduce its financial resources.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma has licensed three patent families from
the University of Pennsylvania and one patent family from New York University and may enter into transactions to in-license or acquire
other businesses, intellectual property, technologies, product candidates or products. If Carisma determines to pursue a particular transaction,
it may not be able to complete the transaction on favorable terms, or at all. Any in-licenses or acquisitions Carisma completes may not
strengthen its competitive position, and these transactions may be viewed negatively by customers or investors. Carisma may decide to
incur debt in connection with an in-license or acquisition or issue its common stock or other equity securities to the stockholders of
the target company, which would reduce the percentage ownership of its existing stockholders. Carisma could incur losses resulting from
undiscovered liabilities that are not covered by the indemnification it may obtain from the seller. In addition, Carisma may not be able
to successfully integrate the acquired personnel, technologies and operations into its existing business in an effective, timely and nondisruptive
manner. In-license and acquisition transactions may also divert management attention from day-to-day responsibilities, increase its expenses
and reduce its cash available for operations and other uses. Carisma cannot predict the number, timing or size of additional future in-licenses
or acquisitions or the effect that any such transactions might have on its operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The FDA, European Medicines Agency, or EMA, or other comparable
foreign regulatory authorities could require the clearance or approval of a companion diagnostic device as a condition of approval for
any product candidate that requires or would commercially benefit from such tests. Failure to successfully validate, develop and obtain
regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm Carisma's product development strategy
and Carisma may not realize the commercial potential of any such product candidate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If safe and effective use of any of Carisma's other product candidates depends on an in vitro diagnostic, then the FDA generally will
require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves Carisma's product
candidates. The process of obtaining or creating such diagnostic is time consuming and costly. Companion diagnostics, which provide information
that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA, EMA and
other comparable foreign regulatory authorities as medical devices and require separate regulatory approval from therapeutic approval
prior to commercialization. The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond
to a product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic candidate. The PMA process,
including the gathering of preclinical and clinical data and the submission and review by the FDA, can take several years or longer. It
involves a rigorous pre-market review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device's
safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing,
and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements
governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse
event reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given Carisma's limited experience in developing and commercializing diagnostics, Carisma does not plan to develop companion diagnostics
internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining
approval for these companion diagnostics. Carisma may not be able to enter into arrangements with a provider to develop a companion diagnostic
for use in connection with a registrational trial for Carisma's product candidates or for commercialization of Carisma's product candidates,
or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of Carisma's
product candidates. Carisma and its future collaborators may encounter difficulties in developing and obtaining approval for the companion
diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any
delay or failure by Carisma's collaborators to develop or obtain regulatory approval of the companion diagnostics could delay or prevent
approval of Carisma's product candidates. In addition, Carisma, its collaborators or third parties may encounter production difficulties
that could constrain the supply of the companion diagnostics, and both they and Carisma may have difficulties gaining acceptance of the
use of the companion diagnostics by physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any companion diagnostic collaborator or third party with whom Carisma contracts may decide not to commercialize or to discontinue selling
or manufacturing the companion diagnostic that Carisma anticipates using in connection with development and commercialization of its product
candidates, or Carisma's relationship with such collaborator or third party may otherwise terminate. Carisma may not be able to enter
into arrangements with another provider to obtain supplies of an alternative diagnostic test for use in connection with the development
and commercialization of its product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the
development or commercialization of its product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Risks Related to Carisma&rsquo;s Intellectual
Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma is unable to obtain, maintain and enforce patent protection
for its technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, its competitors
could develop and commercialize technology and products similar or identical to Carisma&rsquo;s, and its ability to successfully develop
and commercialize its technology and product candidates may be adversely affected and Carisma may not be able to compete effectively in
its market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s commercial success depends in part
on its ability to obtain, maintain and enforce protection of the intellectual property it may own solely and jointly with others or may
license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product
candidates. Carisma seeks to protect its proprietary position by filing patent applications in the United States and abroad related to
its technologies and product candidates that are important to its business and by in-licensing intellectual property related to such technologies
and product candidates. If Carisma is unable to obtain, maintain or enforce patent protection with respect to any proprietary technology
or product candidate, its business, financial condition, results of operations and prospects could be materially harmed. Any disclosure
to or misappropriation by third parties of Carisma&rsquo;s confidential proprietary information could enable competitors to quickly duplicate
or surpass Carisma&rsquo;s technological achievements, thus eroding Carisma&rsquo;s competitive position in its market. Moreover, the
patent applications Carisma owns, co-owns or licenses may fail to result in issued patents in the United States or in other foreign countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The patent prosecution process is expensive, time-consuming
and complex, and Carisma may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications
at a reasonable cost or in a timely manner. It is also possible that Carisma will fail to identify patentable aspects of its research
and development output before it is too late to obtain patent protection. Moreover, in some circumstances, Carisma does not have the right
to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology
that Carisma licenses from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted,
maintained, defended and enforced in a manner consistent with the best interests of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The patent position of biopharmaceutical companies
generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation.
In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect Carisma&rsquo;s
rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability
of methods of treatment of the human body more than United States law does. With respect to both owned and in-licensed patent rights,
Carisma cannot predict whether the patent applications Carisma and its licensors are currently pursuing will issue as patents in any particular
jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, Carisma may not
be aware of all third-party intellectual property rights potentially relating to its product candidates. In addition, publications of
discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other
jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither Carisma
nor its licensors can know with certainty whether either Carisma or its licensors were the first to make the inventions claimed in the
patents and patent applications Carisma owns or in-licenses now or in the future, or that either Carisma or its licensors were the first
to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of its
patent rights are highly uncertain. Moreover, its owned or in-licensed pending and future patent applications may not result in patents
being issued which protects its technology and product candidates, in whole or in part, or which effectively prevent others from commercializing
competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and
other countries may diminish the value of its patents and its ability to obtain, protect, maintain, defend and enforce its patent rights,
narrow the scope of its patent protection and, more generally, could affect the value or narrow the scope of its patent rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moreover, Carisma or its licensors may be
subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or the USPTO, or become
involved in opposition, derivation, revocation, reexamination, <I>inter partes</I> review, post-grant review or interference
proceedings challenging its patent rights or the patent rights of others. An adverse determination in any such submission,
proceeding or litigation could reduce the scope of, or invalidate, its patent rights, allow third parties to commercialize its
technology or product candidates and compete directly with it, without payment to it, or result in its inability to manufacture or
commercialize products without infringing third-party patent rights. If the breadth or strength of protection provided by its
patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with it to
license, develop or commercialize current or future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s owned or licensed patent estate
includes patent applications, many of which are at an early stage of prosecution. The coverage claimed in a patent application can be
significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if its owned or in-licensed
patent applications issue as patents, they may not issue in a form that will provide it with any meaningful protection, prevent competitors
from competing with it or otherwise provide it with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship,
scope, validity or enforceability, and its owned and in-licensed patents may be challenged in the courts or patent offices in the United
States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated
or held unenforceable, in whole or in part, which could limit its ability to stop others from using or commercializing similar or identical
technology and products, or limit the duration of the patent protection of its technology and product candidates. Such proceedings also
may result in substantial cost and require significant time from its management and employees, even if the eventual outcome is favorable
to Carisma. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting
such candidates might expire before or shortly after such candidates are commercialized. Furthermore, its competitors may be able to circumvent
its owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result,
its patent portfolio may not provide it with sufficient rights to exclude others from commercializing technology and products similar
or identical to any of its technology and product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patent terms may be inadequate to protect Carisma&rsquo;s competitive
position with respect to its current or future product candidates for an adequate amount of time.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Patents have a limited lifespan. In the United
States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional
filing date. Various extensions may be available, but there is no assurance that any such extensions will be obtained, and the life of
a patent, and the protection it affords, is limited. Even if patents covering Carisma&rsquo;s current or future product candidates are
obtained, once the patent life has expired, it may be open to competition from competitive products, including generics or biosimilars.
Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such
candidates might expire before or shortly after such candidates are commercialized. As a result, its patent portfolio may not provide
it with sufficient rights to exclude others from commercializing products similar or identical to Carisma&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, patent term can also be adjusted
due to delays that occur during examination of patent applications, which may extend the term of a patent beyond 20 years. There is a
risk that Carisma may take action that detracts from any accrued patent term adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It is necessary to pay certain maintenance fees,
also referred to as annuities or renewal fees in some countries, throughout the lifetime of a patent at regular intervals. Failure to
pay these fees can cause a granted patent to prematurely expire, without an opportunity for revival. There is a risk that Carisma may
be unable to maintain patent protection for certain patents in all markets due to finite availability of resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma is unable to obtain licenses from third parties on
commercially reasonable terms or fail to comply with its obligations under such agreements, its business could be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">It may be necessary for it to use the patented
or proprietary technology of third parties to commercialize its products, in which case Carisma would be required to obtain a license
from these third parties. If Carisma is unable to license such technology, or if Carisma is forced to license such technology on unfavorable
terms, its business could be materially harmed. If Carisma is unable to obtain a necessary license, Carisma may be unable to develop or
commercialize the affected product candidate(s), which could materially harm its business and the third parties owning such intellectual
property rights could seek either an injunction prohibiting its sales or an obligation on its part to pay royalties and/or other forms
of compensation. Even if Carisma is able to obtain a license, it may be non-exclusive, thereby giving its competitors access to the same
technologies licensed to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma is unable to obtain rights to required
third-party intellectual property rights or maintain the existing intellectual property rights Carisma has, Carisma may be required to
expend significant time and resources to redesign its technology, product candidates, or the methods for manufacturing them or to develop
or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Carisma is unable to do so,
Carisma may be unable to develop or commercialize the affected technology and product candidates, which could harm its business, financial
condition, results of operations and prospects significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, if Carisma fails to comply with its
obligations under any license agreements, its counterparties may have the right to terminate these agreements, in which event Carisma
might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that
is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect
the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination
of its rights under these agreements, or restrictions on its ability to freely assign or sublicense its rights under such agreements when
it is in the interest of its business to do so, may result in it having to negotiate new or restated agreements with less favorable terms,
cause it to lose its rights under these agreements, including its rights to important intellectual property or technology or impede, or
delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma does not obtain patent term extension for any product
candidates it may develop, its business may be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, the term of a patent that
covers an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Drug Price Competition and Patent
Term Restoration Act of 1984, or the Hatch-Waxman Act, as compensation for the loss of a patent term during the FDA regulatory review
process for a drug product subject to the provisions of the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of
up to five years, but patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product
approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it,
or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-United States jurisdictions
to extend the term of a patent that covers an approved drug. While, in the future, if and when its product candidates receive FDA approval,
Carisma expects to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable
authorities, including the FDA, will agree with its assessment of whether such extensions should be granted, and even if granted, the
length of such extensions. Carisma may not be granted patent term extension either in the United States or in any foreign country because
of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable
deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover,
the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could
be less than requests. If Carisma is unable to obtain any patent term extension or the term of any such extension is less than it requests,
its competitors may obtain approval of competing products following the expiration of its patent rights, and its business, financial condition,
results of operations and prospects could be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes to patent laws in the United States and other jurisdictions
could diminish the value of patents in general, thereby impairing its ability to protect its products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Changes in either the patent laws or interpretation
of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith
Act, could increase the uncertainties and costs surrounding the prosecution of its owned or in-licensed patent applications and the maintenance,
enforcement or defense of its owned or in-licensed issued patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the patent positions of companies
in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed
the scope of patent protection available in certain circumstances and wakened the rights of patent owners in certain situations. This
combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future
actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable
ways that could have a material adverse effect on Carisma&rsquo;s patent rights and its ability to protect, defend and enforce its patent
rights in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental
bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken Carisma&rsquo;s
ability to obtain new patents or to enforce patents that Carisma owns or has licensed or that Carisma may obtain in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The federal government retains certain rights in
inventions created using its financial assistance under the Bayh-Dole Act. The federal government retains a &ldquo;nonexclusive, nontransferable,
irrevocable, paid-up license&rdquo; for its own benefit. The Bayh-Dole Act also provides federal agencies with &ldquo;march-in rights&rdquo;.
March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant
a &ldquo;nonexclusive, partially exclusive, or exclusive license&rdquo; to a &ldquo;responsible applicant or applicants.&rdquo; If the
patent owner refuses to do so, the government may grant the license itself. Carisma collaborates with a number of universities with respect
to certain of its research and development. Carisma cannot be sure that any co-developed intellectual property will be free from government
rights pursuant to the Bayh-Dole Act. If, in the future, Carisma co-owns or in-licenses technology which is critical to its business that
is developed in whole or in part with federal funds subject to the Bayh-Dole Act, its ability to enforce or otherwise exploit patents
covering such technology may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Although Carisma or its licensors are not currently involved
in any litigation, Carisma may become involved in lawsuits to protect or enforce its patent, the patents of its licensors or other intellectual
property rights, which could be expensive, time-consuming and unsuccessful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Competitors and other third parties may infringe,
misappropriate or otherwise violate Carisma&rsquo;s or its licensor&rsquo;s issued patents, the patents of its licensors or other intellectual
property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may
be difficult or impossible to obtain evidence of infringement in a competitor&rsquo;s product. To counter infringement or misappropriation,
Carisma or its licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive
and time-consuming and can distract its management and scientific personnel. There can be no assurance that Carisma will have sufficient
financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any
claims Carisma asserts against perceived infringers could provoke such parties to assert counterclaims against it, alleging that it infringes,
misappropriates or otherwise violates their intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, in a patent infringement proceeding,
such parties could counterclaim that the patents Carisma or its licensors have asserted are invalid or unenforceable. In patent litigation
in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness, enablement, or written
description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld
relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before
administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination,
post-grant review, <I>inter partes</I> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign
jurisdictions, such as opposition proceedings. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
Similarly, if Carisma or its licensors assert trademark infringement claims, a court may determine that the marks Carisma or its licensors
have asserted are invalid or unenforceable, or that the party against whom Carisma or its licensors have asserted trademark infringement
has superior rights to the marks in question. In this case, Carisma could ultimately be forced to cease use of such trademarks, which
could materially harm its business and negatively affect its position in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An adverse result in any such proceeding could
put one or more of its owned or in-licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put
any of its owned or in-licensed patent applications at risk of not yielding an issued patent, and could limit its or its licensor&rsquo;s
ability to assert those patents against those parties, or other competitors, and curtail or preclude its ability to exclude third parties
from developing and commercializing similar or competitive products. A court may also refuse to stop the third party from using the technology
at issue in a proceeding on the grounds that its owned or in-licensed patents do not cover such technology. Even if Carisma establishes
infringement, a court may not order the third party to stop using the technology at issue and instead award only monetary damages to Carisma,
which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of its confidential information or trade secrets could be compromised by disclosure during
this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or
developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the
price of its common stock. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and
products and have a material adverse impact on its business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Interference or derivation proceedings provoked
by third parties or brought by Carisma or declared by the USPTO may be necessary to determine the priority of inventions with respect
to its patents or patent applications. An unfavorable outcome could require it to cease using the related technology or to attempt to
license rights to it from the prevailing party. Carisma&rsquo;s business could be harmed if the prevailing party does not offer it a license
on commercially reasonable terms or at all, or if a non-exclusive license is offered and its competitors gain access to the same technology.
Its defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs
and distract its management, technical personnel and other employees. In addition, the uncertainties associated with litigation could
have a material adverse effect on its ability to raise the funds necessary to continue its clinical trials, continue its research programs,
license necessary technology from third parties, or enter into development partnerships that would help it bring its product candidates
to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any such litigation or proceedings could substantially
increase Carisma&rsquo;s operating losses and reduce the resources available for development activities or any future sales, marketing
or distribution activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma may not have sufficient financial or other
resources to conduct such litigation or proceedings adequately. Some of Carisma&rsquo;s competitors may be able to sustain the costs of
such litigation or proceedings more effectively than Carisma can because of their greater financial resources in one or more aspects,
or for other reasons. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise
Carisma&rsquo;s ability to compete in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may need to license intellectual property from third
parties, and such licenses may not be available or may not be available on commercially reasonable terms.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A third party may hold intellectual property, including
patent rights, that are important or necessary to the development of Carisma&rsquo;s products. It may be necessary for it to use the patented
or proprietary technology of a third party to commercialize its own technology or products, in which case it would be required to obtain
a license from such third party. A license to such intellectual property may not be available or may not be available on commercially
reasonable terms, which could have a material adverse effect on Carisma&rsquo;s business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The licensing and acquisition of third-party intellectual
property rights is a competitive practice, and companies that may be more established, or have greater resources than Carisma, may also
be pursuing strategies to license or acquire third-party intellectual property rights that it may consider necessary or attractive in
order to commercialize its product candidates. More established companies may have a competitive advantage over Carisma due to their larger
size and cash resources or greater clinical development and commercialization capabilities. Carisma may not be able to successfully complete
such negotiations and ultimately acquire the rights to the intellect al property surrounding the additional product candidates that it
may seek to acquire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Third parties may initiate legal proceedings alleging that Carisma
is infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and
could have a material adverse effect on the success of its business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s commercial success depends upon
its ability and the ability of its collaborators to develop, manufacture, market and sell its product candidates and use its proprietary
technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties.
There is considerable patent and other intellectual property litigation in the biopharmaceutical industry. Carisma may become party to,
or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to its technology and product
candidates, including interference proceedings, post grant review,&nbsp;<I>inter partes</I>&nbsp;review, and derivation proceedings before
the USPTO and similar proceedings in foreign jurisdictions, such as opposition proceedings before the European Patent Office. Numerous
U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which Carisma
is pursuing development candidates. As the biopharmaceutical industry expands and more patents are issued, the risk increases that its
technologies or product candidates that Carisma may identify may be subject to claims of infringement of the patent rights of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The legal threshold for initiating litigation or
contested proceedings is low, so even lawsuits or proceedings with a low probability of success might be initiated and require significant
resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and its adversaries in these proceedings
may have the ability to dedicate substantially greater resources to prosecuting these legal actions than Carisma can. The risks of being
involved in such litigation and proceedings may increase if and as its product candidates near commercialization and as Carisma gains
the greater visibility associated with being a public company. Third parties may assert infringement claims against it based on existing
patents or patents that may be granted in the future, regardless of merit. Even if Carisma diligently searches third-party patents for
potential infringement by its products or product candidates, it may not successfully find patents its products or product candidates
may infringe. Carisma may not be aware of all such intellectual property rights potentially relating to its technology and product candidates
and their uses, or Carisma may incorrectly conclude that third-party intellectual property is invalid or that its activities and product
candidates do not infringe such intellectual property. Thus, Carisma does not know with certainty that its technology and product candidates,
or its development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&rsquo;s
intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Third parties may assert that Carisma is employing
its proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations
or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates
that Carisma may identify or related to its technologies. Because patent applications can take many years to issue, there may be currently
pending patent applications which may later result in issued patents that the product candidates that Carisma may identify may infringe.
In addition, third parties may obtain patents in the future and claim that use of its technologies infringe upon these patents. Moreover,
as noted above, there may be existing patents that Carisma is not aware of or that Carisma has incorrectly concluded are invalid or not
infringed by its activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing
process of the product candidates that Carisma may identify, any molecules formed during the manufacturing process or any final product
itself, the holders of any such patents may be able to block its ability to commercialize such product candidate unless Carisma obtained
a license under the applicable patents, or until such patents expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Parties making claims against it may obtain
injunctive or other equitable relief, which could effectively block its ability to further develop and commercialize the product
candidates that Carisma may identify. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee resources from its business. In the event of a successful claim of
infringement against Carisma, it may have to pay substantial damages, including treble damages and attorneys&rsquo; fees for willful
infringement, pay royalties, redesign its infringing products or obtain one or more licenses from third parties, which may be
impossible or require substantial time and monetary expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma may choose to take a license or, if it
is found to infringe, misappropriate or otherwise violate a third party&rsquo;s intellectual property rights, it could also be required
to obtain a license from such third party to continue developing, manufacturing and marketing its technology and product candidates. However,
it may not be able to obtain any required license on commercially reasonable terms or at all. Even if it is able to obtain a license,
it could be non-exclusive, thereby giving its competitors and other third parties access to the same technologies licensed to it and could
require it to make substantial licensing and royalty payments. Carisma could be forced, including by court order, to cease developing,
manufacturing and commercializing the infringing technology or product. In addition, Carisma could be found liable for significant monetary
damages, including treble damages and attorneys&rsquo; fees, if Carisma is found to have willfully infringed a patent or other intellectual
property right, it could be forced to indemnify its customers or collaborators. A finding of infringement could prevent it from commercializing
its product candidates or force it to cease some of its business operations, which could materially harm its business. In addition, Carisma
may be forced to redesign its product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements.
Claims that Carisma has misappropriated the confidential information or trade secrets of third parties could have a similar material adverse
effect on its business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If its trademarks and trade names are not adequately protected,
then Carisma may not be able to build name recognition in its markets of interest and its business may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While Carisma seeks to protect the trademarks and
trade names it uses in the United States and in other countries, it may be unsuccessful in obtaining registrations or otherwise protecting
these trademarks and trade names, which it needs to build name recognition in its markets of interest and among potential partners or
customers. Carisma relies on both registration and common law protection for its trademarks. Its registered or unregistered trademarks
or trade names may be challenged, infringed, diluted or declared generic, or determined to be infringing on other marks. At times, competitors
may adopt trademarks and trade names similar to ours, or collaborators may fail to use Carisma&rsquo;s trade names or trademarks, thereby
impeding its ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark
infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of its registered or unregistered
trademarks. If Carisma is unable to protect its rights to trademarks and trade names, Carisma may be prevented from using such marks and
names unless Carisma enters into appropriate royalty, license or coexistence agreements, which may not be available or may not be available
on commercially reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During trademark registration proceedings, Carisma
may receive rejections. Although Carisma would be given an opportunity to respond to those rejections, it may be unable to overcome such
rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity
to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed
against its trademarks, and its trademarks may not survive such proceedings. Effective trademark protection may not be available or may
not be sought in every country in which its products are made available. Any name Carisma proposes to use for its products in the United
States must be approved by the FDA, regardless of whether Carisma has registered it, or applied to register it, as a trademark. The FDA
typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If
the FDA objects to any of its proposed product names, Carisma may be required to expend significant additional resources in an effort
to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties
and be acceptable to the FDA. If Carisma is unable to establish name recognition based on its trademarks and trade names, Carisma may
not be able to compete effectively and its business may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma may license its trademarks and trade
names to third parties, such as distributors and collaborators. Though these license agreements may provide guidelines for how
Carisma's trademarks and trade names may be used, a breach of these agreements or misuse of or failure to use its trademarks and
trade names by its licensees may jeopardize its rights in or diminish the goodwill associated with its trademarks and trade names.
Carisma's efforts to enforce or protect its proprietary rights related to trademarks, trade names, trade secrets, know-how, domain
names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources
and could adversely affect Carisma&rsquo;s business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Intellectual property litigation or other legal proceedings relating
to intellectual property could cause it to spend substantial resources and distract its personnel from their normal responsibilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if resolved in its favor, litigation or other
legal proceedings relating to intellectual property claims may cause it to incur significant expenses and could distract its technical
and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings,
motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it
could have a substantial adverse effect on the price of its common stock. Such litigation or proceedings could substantially increase
its operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.
Carisma may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of its competitors
may be able to sustain the costs of such litigation or proceedings more effectively than Carisma can because of their greater financial
resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios.
Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise
its ability to compete in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Obtaining and maintaining patent protection depends on compliance
with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and its patent
protection could be reduced or eliminated for non-compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Periodic maintenance, renewal and annuity fees
and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies
in several stages or annually over the lifetime of its patents and patent applications. The USPTO and various foreign governmental patent
agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application
process. In certain circumstances, Carisma relies on its licensing partners to pay these fees to, or comply with the procedural and documentary
rules&nbsp;of, the relevant patent agency. With respect to its patents, Carisma relies on an annuity service, outside firms and outside
counsel to remind it of the due dates and to make payment after Carisma instructs them to do so. While an inadvertent lapse can in many
cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure
to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents.
In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If Carisma
or its licensors fail to maintain the patents and patent applications covering its product candidates, it would have a material adverse
effect on its business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma fails to comply with its obligations in its current
and future intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to its business
relationships with its licensors, Carisma could lose intellectual property rights that are important to its business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is party to a number license and research
agreements. Some of these agreements provide Carisma with the intellectual property rights required for the development of its product
candidates, including the license agreement with the University of Pennsylvania. These licenses and research agreements and similar agreements
in the future may impose diligence, development and commercialization timelines, and milestone payment, royalty, insurance and other obligations
on Carisma. If Carisma fails to comply with such obligations, the parties to these agreements may decide to terminate the agreements or
require Carisma to grant them certain rights, in which Carisma may not be able to develop, manufacture, or market any products without
the rights granted to it by these agreements and may face other penalties. Any such occurrences could adversely affect the value of any
product candidate being developed, including CT-0508.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For a variety of purposes, Carisma will likely
enter into additional licensing and funding arrangements with third parties that may impose similar obligations on Carisma. Termination
of these agreements or reduction or elimination of its rights under these agreements may result in it having to negotiate new or restated
agreements with less favorable terms, or cause it to lose its rights under these agreements, including its rights to important intellectual
property or technology, which would have a material adverse effect on its business, financial condition, results of operations and prospects.
While Carisma still faces all of the risks described herein with respect to such agreements, Carisma cannot prevent third parties from
also accessing those technologies. In addition, its licenses may place restrictions on its future business opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the above risks, intellectual property
rights that Carisma licenses in the future may include sublicenses under intellectual property owned by third parties, in some cases through
multiple tiers. The actions of its licensors may therefore affect its rights to use its sublicensed intellectual property, even if Carisma
is in compliance with all of the obligations under its license agreements. Should its licensors or any of the upstream licensors fail
to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to Carisma, or should
such agreements be terminated or amended, its ability to develop and commercialize its product candidates may be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Disputes may arise regarding intellectual property subject to a licensing agreement, including:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the scope of rights granted under the license agreement and other interpretation related issues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the extent to which its technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the sublicensing of patent and other rights under its collaborative development relationships;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>its diligence obligations under the license agreement and what activities satisfy those diligence obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by its
licensors and it and its partners; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the payment obligations with respect to licensed technology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the agreements under which Carisma
currently licenses intellectual property or technology from third parties are complex, and certain provisions in such agreements may be
susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what Carisma
believes to be the scope of its rights to the relevant intellectual property or technology or increase what Carisma believes to be its
financial or other obligations under the relevant agreement, either of which could have a material adverse effect on its business, financial
condition, results of operations and prospects. Moreover, if disputes over intellectual property that Carisma has licensed prevent or
impair its ability to maintain its current licensing arrangements on commercially acceptable terms, Carisma may be unable to successfully
develop and commercialize the affected technology and product candidates, which could have a material adverse effect on its business,
financial conditions, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, licensors could retain the right to prosecute
and defend the intellectual property rights licensed to Carisma, in which case Carisma would depend on its licensors to control the prosecution,
maintenance and enforcement of all of its licensed and sublicensed intellectual property, and even when it does have such rights, Carisma
may require the cooperation of its licensors and upstream licensors, which may not be forthcoming. Licensors may determine not to pursue
litigation against other companies or may pursue such litigation less aggressively than Carisma would. Its business could be adversely
affected if Carisma or its licensors are unable to prosecute, maintain and enforce its licensed and sublicensed intellectual property
effectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s current or future licensors may
have relied on third-party consultants or collaborators or on funds from third parties such that its licensors are not the sole and exclusive
owners of the patents and patent applications Carisma in-licenses. If other third parties have ownership rights to patents or patent applications
Carisma in-licenses, they may be able to license such patents to its competitors, and its competitors could market competing products
and technology. This could have a material adverse effect on its competitive position, business, financial conditions, results of operations
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In spite of its best efforts, its licensors might
conclude that Carisma has materially breached its license agreements and might therefore terminate the license agreements, thereby removing
its ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are
terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to
seek regulatory approval of, and to market, products and technologies identical to its. This could have a material adverse effect on its
competitive position, business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may not be able to protect its intellectual property
and proprietary rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Filing, prosecuting and defending patents on product
candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect its
rights to the same extent as the laws of the United States. In addition, the laws of some foreign countries do not protect intellectual
property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available,
judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, Carisma may not be able to prevent
third parties from practicing its inventions in all countries outside the United States, or from selling or importing products made using
its inventions in and into the United States or other jurisdictions. Competitors may use its technologies in jurisdictions where Carisma
has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories
where Carisma has patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete
with its products, and its patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many companies have encountered significant problems
in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly
those relating to biotechnology products, which could make it difficult for it to stop the infringement of its patents or marketing of
competing products in violation of its intellectual property and proprietary rights generally. In addition, certain jurisdictions do not
protect to the same extent or at all inventions that constitute new methods of treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Proceedings to enforce its intellectual property
and proprietary rights in foreign jurisdictions could result in substantial costs and divert its efforts and attention from other aspects
of its business, could put its patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put its patent
applications at risk of not issuing, and could provoke third parties to assert claims against Carisma. Carisma may not prevail in any
lawsuits that Carisma initiates, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, its
efforts to enforce its intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that Carisma develops or licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many countries have compulsory licensing laws under
which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents
against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially
diminish the value of such patent. If Carisma or any of its licensors are forced to grant a license to third parties with respect to any
patents relevant to its business, its competitive position may be impaired, and its business, financial condition, results of operations
and prospects may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may be subject to claims challenging the inventorship
or ownership of its patents and other intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma or its licensors may be subject to
claims that former employees, collaborators or other third parties have an interest in its owned or in-licensed patents, trade
secrets or other intellectual property as an inventor or co-inventor. For example, Carisma or its licensors may have inventorship
disputes arise from conflicting obligations of employees, consultants or others who are involved in developing its product
candidates. Although it is Carisma&rsquo;s policy to require its employees and contractors who may be involved in the conception or
development of intellectual property to execute agreements assigning such intellectual property to Carisma, it may be unsuccessful
in executing such an agreement with each party who, in fact, conceives or develops intellectual property that Carisma regards as its
own, and Carisma cannot be certain that its agreements with such parties will be upheld in the face of a potential challenge, or
that they will not be breached, for which Carisma may not have an adequate remedy. The assignment of intellectual property rights
may not be self-executing or the assignment agreements may be breached, and litigation may be necessary to defend against these and
other claims challenging inventorship or its or its licensors&rsquo; ownership of its owned or in-licensed patents, trade secrets or
other intellectual property. If Carisma or its licensors fail in defending any such claims, in addition to paying monetary damages,
Carisma may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that
is important to its product candidates. Even if Carisma is successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect
on its business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may be subject to claims by third parties asserting that
its employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, including of their
current or former employers or claims asserting Carisma has misappropriated their intellectual property, or is claiming ownership of what
Carisma regards as its own intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many of Carisma&rsquo;s employees, consultants
and contractors have been previously employed at universities or other biopharmaceutical companies, including its competitors or potential
competitors. Although Carisma tries to ensure that its employees, consultants and contractors do not use the proprietary information or
know-how of others in their work for Carisma, Carisma may be subject to claims that these individuals or Carisma have used or disclosed
intellectual property, including trade secrets or other proprietary information, of any such individual&rsquo;s current or former employer.
Litigation may be necessary to defend against these claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma fails in prosecuting or defending any
such claims, in addition to paying monetary damages, Carisma may lose valuable intellectual property rights or personnel, which could
have a material adverse effect on its competitive business position and prospects. Such intellectual property rights could be awarded
to a third party, and Carisma could be required to obtain a license from such third party to commercialize its technology or products,
which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if Carisma
is successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to its
management and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma is unable to protect the confidentiality of its trade
secrets, its business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to seeking patents for some of its
technology and product candidates, Carisma also relies on trade secrets and confidentiality agreements to protect its unpatented know-how,
technology and other proprietary information, to maintain its competitive position. Carisma seeks to protect its trade secrets and other
proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them,
such as its employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers,
consultants, advisors and other third parties. Carisma may have also entered into confidentiality and invention or patent assignment agreements
with its employees and consultants, but Carisma cannot guarantee that it has entered into such agreements with each party that may have
or has had access to its trade secrets or proprietary technology. To the extent Carisma becomes involved in litigation that may require
discovery of its trade secrets, know-how and other proprietary technology, Carisma will seek to secure protective orders from the court
that bind the parties with access to the discovered information. Despite these efforts, any of these parties may breach the agreements
and disclose its proprietary information, including its trade secrets, and Carisma may not be able to obtain adequate remedies for such
breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated
a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside
of the United States are less willing or unwilling to protect trade secrets. In addition, Carisma cannot be certain that proprietary technical
information and related confidential documents that Carisma has shared with its collaborators and/or submitted to governmental agencies,
including regulatory agencies for evaluation and supervision of pharmaceutical products, will be kept confidential. If any of its trade
secrets were to be lawfully obtained or independently developed by a competitor or other third party, Carisma would have no right to prevent
them, or those to whom they communicate it, from using that technology or information to compete with Carisma. If any of its trade secrets
were to be disclosed to or independently developed by a competitor or other third party, its competitive position would be materially
and adversely harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Intellectual property rights do not necessarily address all potential
threats to Carisma.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The degree of future protection afforded by Carisma&rsquo;s
intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect its business
or permit it to maintain its competitive advantage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>others may be able to make product candidates that are similar to Carisma&rsquo;s but that are not covered by the claims of the patents
that it owns or licenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma, or its license partners or current or future collaborators, might not have been the first to make the inventions covered
by the issued patent or pending patent applications that it licenses or may own in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma, or its license partners or current or future collaborators, might not have been the first to file patent applications covering
its inventions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>others may independently develop similar or alternative technologies or duplicate any of its technologies without infringing its owned
or in-licensed intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>it is possible that its owned or in-licensed pending patent applications or those Carisma may own or in-license in the future will
not lead to issued patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>claims of issued patents that Carisma holds rights to may be held invalid or unenforceable, including as a result of legal challenges
by its competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>its competitors might conduct research, development, testing or commercialization activities in countries where Carisma does not have
patent rights and then use the information learned from such activities to develop competitive products for sale in its major commercial
markets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma cannot ensure that any of its patents, or any of its pending patent applications, if issued, or those of its licensors, will
include claims having a scope sufficient to protect its product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma cannot ensure that any patents issued to it or its licensors will provide a basis for an exclusive market for its commercially
viable product candidates or will provide it with any competitive advantages;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the U.S. Supreme Court, other federal courts, Congress, the USPTO or similar foreign authorities may change the standards of patentability
and any such changes could narrow or invalidate, or change the scope of, Carisma&rsquo;s or its licensors&rsquo; patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>patent terms may be inadequate to protect its competitive position on its product candidates for an adequate amount of time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma cannot ensure that its commercial activities or product candidates will not infringe upon the patents of others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma cannot ensure that it will be able to successfully commercialize its product candidates on a substantial scale, if approved,
before the relevant patents that it owns or licenses expire;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may not develop additional proprietary technologies that are patentable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the patents of others may harm its business; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently
file a patent covering such intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Should any of these events occur, they could have
a material adverse effect on its business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Risks Related to Regulatory Approval and Other
Legal Compliance Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The regulatory approval process of the FDA is lengthy, time-consuming
and inherently unpredictable, and if Carisma is ultimately unable to obtain marketing approval for its product candidates, its business
will be substantially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The time required to obtain approval by the FDA
is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including
the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical
data necessary to gain approval may change during the course of a product candidate&rsquo;s clinical development and may vary among jurisdictions.
Carisma has not obtained marketing approval for any product candidate and it is possible that none of its existing product candidates,
or any product candidates it may seek to develop in the future will ever obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s product candidates could fail to
receive marketing approval for many reasons, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the FDA may disagree with the design or implementation of Carisma&rsquo;s clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed
indication;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may be unable to demonstrate that a product candidate&rsquo;s clinical and other benefits outweigh its safety risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the FDA may disagree with Carisma&rsquo;s interpretation of data from pre-clinical studies or clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>data collected from clinical trials of Carisma&rsquo;s product candidates may not be sufficient to support the submission of a
                                                                                                                                                                                               new drug application, or NDA, to the FDA or other submission or to obtain marketing approval in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with
which Carisma contracts for clinical and commercial supplies; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the approval policies or regulations of the FDA may significantly change in a manner rendering Carisma&rsquo;s clinical data insufficient
for approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This lengthy approval process as well as the unpredictability
of future clinical trial results may result in Carisma failing to obtain marketing approval to market any of its product candidates, which
would significantly harm its business, results of operations and prospects. The FDA has substantial discretion in the approval process
and determining when or whether marketing approval will be obtained for any of Carisma&rsquo;s product candidates. Even if Carisma believes
the data collected from clinical trials of its product candidates are promising, such data may not be sufficient to support approval by
the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, even if Carisma were to obtain approval,
regulatory authorities may approve any of Carisma&rsquo;s product candidates for fewer or more limited indications than it requests, may
not approve the price it intends to charge for its products, may grant approval contingent on the performance of costly post-marketing
clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for
the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects
for Carisma&rsquo;s product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even if Carisma completes the necessary pre-clinical studies
and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent Carisma from obtaining
approvals for the commercialization of some or all of its product candidates. If Carisma is not able to obtain, or if there are delays
in obtaining, required regulatory approvals, it will not be able to commercialize, or will be delayed in commercializing, its product
candidates, and its ability to generate revenue will be materially impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s product candidates and the activities
associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping,
labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject to comprehensive regulation
by the FDA and other regulatory authorities in the United States and by the EMA and other regulatory authorities outside of the United
States. Failure to obtain marketing approval for a product candidate will prevent Carisma from commercializing the product candidate.
Carisma has not submitted an application for or received marketing approval for any of its product candidates in the United States or
in any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma has only limited experience in filing and
supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical research organizations or
other third-party consultants or vendors to assist it in this process. Securing marketing approval requires the submission of extensive
pre-clinical and clinical data and supporting information, including manufacturing information, to the various regulatory authorities
for each therapeutic indication to establish the product candidate&rsquo;s safety and efficacy. Carisma&rsquo;s product candidates may
not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics
that may preclude Carisma obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are indicated only
for patient populations that have not responded to an existing therapy or have relapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The process of obtaining marketing approvals, both
in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained
at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates
involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or
regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of
an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or
may decide that Carisma&rsquo;s data is insufficient for approval and require additional pre-clinical, clinical or other studies. In addition,
varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent marketing approval of
a product candidate. Any marketing approval Carisma ultimately obtain may be limited or subject to restrictions or post-approval commitments
that render the approved product not commercially viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma experiences delays in obtaining approval
or if it fails to obtain approval of its product candidates, the commercial prospects for its product candidates may be harmed and its
ability to generate revenues will be materially impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Failure to obtain marketing approval in foreign jurisdictions
would prevent Carisma&rsquo;s product candidates from being marketed in such jurisdictions, which, in turn, would materially impair Carisma&rsquo;s
ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to market and sell its products in the
European Union and many other foreign jurisdictions, Carisma and its collaborators must obtain separate marketing approvals and comply
with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The
time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside
the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the
United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country.
Carisma or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at
all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory
authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.
The failure to obtain approval in one jurisdiction may negatively impact Carisma&rsquo;s ability to obtain approval elsewhere. Carisma
may not be able to file for marketing approvals and may not receive necessary approvals to commercialize its products in any jurisdiction,
which would materially impair its ability to generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, Carisma could face heightened
risks with respect to seeking marketing approval in the United Kingdom as a result of the withdrawal of the United Kingdom from the
European Union, commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and European
Union Customs Union. As of January&nbsp;1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became
responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic
law, whereas Northern Ireland will continue to be subject to European Union rules&nbsp;under the Northern Ireland Protocol. The MHRA
will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines.
The HMR has been incorporated into the domestic law of the body of European Union law instruments governing medicinal products that
pre-existed prior to the United Kingdom&rsquo;s withdrawal from the European Union. The MHRA may rely on a decision taken by the
European Commission on the approval of a new marketing authorization via the centralized procedure until December 31, 2023. Any
delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force Carisma to
restrict or delay efforts to seek regulatory approval in the United Kingdom for its product candidates, which could significantly
and materially harm Carisma&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma expects that it will be subject to additional
risks in commercializing any of its product candidates that receive marketing approval outside the United States, including tariffs, trade
barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies
and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations,
which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;
and workforce uncertainty in countries where labor unrest is more common than in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Inadequate funding for the FDA, the Securities and Exchange Commission,
or the SEC, and other government agencies, including from government shutdowns, or other disruptions to these agencies&rsquo; operations,
could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed
or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation
of Carisma&rsquo;s business may rely, which could negatively impact its business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ability of the FDA to review and approve new
products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel
and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the FDA have fluctuated
in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to
be reviewed and/or approved by necessary government agencies, which would adversely affect Carisma&rsquo;s business. In addition, government
funding of the SEC and other government agencies on which Carisma&rsquo;s operations may rely, including those that fund research and
development activities, is subject to the political process, which is inherently fluid and unpredictable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For example, over the last several years the U.S. government has shut down several times and certain
regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical
activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process
Carisma&rsquo;s regulatory submissions, which could have a material adverse effect on Carisma&rsquo;s business. Further, future government
shutdowns could impact Carisma&rsquo;s ability to access the public markets and obtain necessary capital in order to properly capitalize
and continue Carisma&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Separately, in response to the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA's
inability to complete required inspections for their applications. As of early 2022, the FDA has resumed inspections of domestic and foreign
facilities to ensure timely reviews of applications for medical products. However, the FDA may not be able to continue its current pace
and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required. Moreover,
on January 30, 2023, the Biden administration announced that it will end the public health emergency declarations related to COVID-19
on May 11, 2023. On January 31, 2023, the FDA indicated that it would soon issue a Federal Register notice describing how the termination
of the public health emergency will impact the FDA's COVID-19 related guidance. At this point, it is unclear how, if at all, these
developments will impact Carisma's efforts to develop and commercialize its product candidates. Regulatory authorities outside the United
States have adopted or may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience
delays in their regulatory activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a prolonged government shutdown or other disruption
occurs, it could significantly impact the ability of the FDA to timely review and process Carisma&rsquo;s regulatory submissions, which
could have a material adverse effect on its business. Future shutdowns or other disruptions could also affect other government agencies
such as the SEC, which may also impact Carisma&rsquo;s business by delaying review of its public filings, to the extent such review is
necessary, and Carisma&rsquo;s ability to access the public markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Regulatory requirements governing gene therapy products are periodically
updated and may continue to change in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA has established the Office of Tissues and
Advanced Therapies, or the OTAT, within the Center for Biologics Evaluation and Research, or the CBER, to consolidate the review of gene
therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.
In September&nbsp;2022, the FDA announced retitling of OTAT to the Office of Therapeutic Products, or OTP, and elevation of OTP to a &quot;Super
Office&quot; to meet its growing cell and gene therapy workload and new commitments under the Prescription Drug User Fee Act agreement
for fiscal years 2023-2027. Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from
the U.S. National Institutes of Health, or the NIH, also are potentially subject to review by the Office of Biotechnology Activities&rsquo;
Recombinant DNA Advisory Committee, or the RAC; however, the NIH announced that the RAC will only publicly review clinical trials if the
trials cannot be evaluated by standard oversight bodies and pose unusual risks. Although the FDA decides whether individual gene therapy
protocols may proceed, the RAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has
reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND on a clinical hold even if the RAC
has provided a favorable review or an exemption from in-depth, public review. If Carisma were to engage an NIH-funded institution to conduct
a clinical trial, that institution&rsquo;s institutional biosafety committee, or IBC, as well as its IRB would need to review the proposed
clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted
by others may cause the FDA or other oversight bodies to change the requirements for approval of Carisma&rsquo;s product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA has issued various guidance documents regarding
gene therapies, including final guidance documents released in January&nbsp;2020 relating to chemistry, manufacturing and controls information
for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders. Although the FDA has indicated that
these and other guidance documents it previously issued are not legally binding, Carisma believes that its compliance with them is likely
necessary to gain approval for any gene therapy product candidate that Carisma may develop. The guidance documents provide additional
factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper pre-clinical
assessment of gene therapies; the chemistry, manufacturing, and control information that should be included in an IND application; the
proper design of tests to measure product potency in support of an IND or biologics license application, or BLA; and measures to observe delayed adverse effects
in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends
that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of
five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, for a gene therapy product, the FDA also
will not approve the product if the manufacturer is not in compliance with good tissue practices, or GTP. These standards are found in
FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of human cells,
tissues, and cellular and tissue based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion,
or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue based products are manufactured
in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue
establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Finally, ethical, social and legal concerns about
gene therapy, genetic testing and genetic research could result in additional regulations or prohibiting the processes that Carisma may
use. Federal and state agencies, congressional committees and foreign governments have expressed their intentions to further regulate
biotechnology. More restrictive regulations or claims that Carisma&rsquo;s product candidates are unsafe or pose a hazard could prevent
Carisma from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval
of Carisma&rsquo;s product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations,
policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As Carisma advances its product candidates through
clinical development, it will be required to consult with these regulatory and advisory groups, and comply with applicable guidelines.
These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process,
require Carisma to perform additional studies, increase Carisma&rsquo;s development costs, lead to changes in regulatory positions and
interpretations, delay or prevent approval and commercialization of Carisma&rsquo;s product candidates or lead to significant post-approval
limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring
a potential product to market could decrease Carisma&rsquo;s ability to generate sufficient product revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even if Carisma, or any collaborators, obtains marketing approvals
for its product candidates, the terms of approvals and ongoing regulation of its products may limit how Carisma, or any collaborators,
manufacture and market its products, which could materially impair Carisma&rsquo;s ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once marketing approval has been granted, an approved
product and its manufacturer and marketer are subject to ongoing review and extensive regulation. Carisma, and any collaborators, must
therefore comply with requirements concerning advertising and promotion for any of its product candidates for which Carisma or they obtain
marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions
and must be consistent with the information in the product&rsquo;s approved labeling. Thus, Carisma, and any collaborators will not be
able to promote any products developed for indications or uses for which they are not approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, manufacturers of approved products
and those manufacturers&rsquo; facilities are required to comply with extensive FDA requirements, including ensuring that quality control
and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as
the corresponding maintenance of records and documentation and reporting requirements. Carisma, its third-party manufacturers, any collaborators
and their third-party manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with
cGMPs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, assuming Carisma, or any collaborators,
receive marketing approval for one or more of their product candidates, Carisma, and any collaborators, and Carisma and any collaborators&rsquo;
respective third-party manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing,
production, product surveillance and quality control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma and such collaborators are not able
to comply with post-approval regulatory requirements, Carisma and such collaborators could have the marketing approvals for their products
withdrawn by regulatory authorities and Carisma or such collaborators&rsquo;, ability to market any future products could be limited,
which could adversely affect Carisma&rsquo;s ability to achieve or sustain profitability. Further, the cost of compliance with post-approval
regulations may have a negative effect on Carisma&rsquo;s business, operating results, financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may seek certain designations for its product candidates,
including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, but it might not receive such designations,
and even if it does, such designations may not lead to a faster development or regulatory review or approval process.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma may seek certain designations for one or
more of its product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product
that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence
indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints,
such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies,
interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development
while minimizing the number of patients placed in ineffective control regimens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA may also designate a product for Fast Track
review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening
disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track
products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&rsquo;s
application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation
of clinical data submitted by the sponsor, that a Fast Track product may be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma may also seek a priority review designation
for one or more of its product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides
a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation
means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These designations are within the discretion of
the FDA. Accordingly, even if Carisma believes that one of its product candidates meets the criteria for these designations, the FDA may
disagree and instead determine not to make such designation. Further, even if Carisma receives a designation, the receipt of such designation
for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered
for approval under conventional FDA procedures and does not assure ultimate approval by the FDA, including the Fast Track designation
Carisma received for CT-0508. In addition, even if one or more of Carisma&rsquo;s product candidates qualifies for these designations,
the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for
FDA review or approval will not be shortened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma, or its collaborators, may seek approval from the FDA
or comparable foreign regulatory authorities to use accelerated development pathways for its product candidates. If Carisma, or its collaborators,
are not able to use such pathways, Carisma, or they, may be required to conduct additional clinical trials beyond those that are contemplated,
which would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if Carisma, or they, receive them
at all. In addition, even if an accelerated approval pathway is available to Carisma, or its collaborators, it may not lead to expedited
approval of Carisma&rsquo;s product candidates, or approval at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Federal Food, Drug, and Cosmetic Act
and implementing regulations, the FDA may grant accelerated approval to a product candidate to treat a serious or life-threatening condition
that provides meaningful therapeutic benefit over available therapies, upon a determination that the product has an effect on a surrogate
endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit
to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or
mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic
image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An
intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality
that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit measurement of a therapeutic
effect that is considered reasonably likely to predict the clinical benefit of a drug. The accelerated approval pathway may be used in
cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important
improvement from a patient and public health perspective. Prior to seeking such accelerated approval, Carisma, or its collaborators, will
continue to seek feedback from the FDA or comparable foreign regulatory agencies and otherwise evaluate Carisma&rsquo;s, or their, ability
to seek and receive such accelerated approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With passage of the FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products.
Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated
approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies
to the FDA every six months (until the study is completed; and use expedited procedures to withdraw accelerated approval of an NDA or
BLA after the confirmatory trial fails to verify the product's clinical benefit. Further, the FDORA requires the FDA to publish on its
website &ldquo;the rationale for why a post-approval study is not appropriate or necessary&rdquo; whenever it decides not to require such
a study upon granting accelerated approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There can be no assurance that the FDA or foreign
regulatory agencies will agree with Carisma&rsquo;s, or its collaborators&rsquo;, surrogate endpoints or intermediate clinical endpoints
in any of Carisma&rsquo;s, or their, clinical trials, or that Carisma, or its collaborators, will decide to pursue or submit any additional
application for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance
that, after feedback from the FDA or comparable foreign regulatory agencies, Carisma, or its collaborators, will continue to pursue or
apply for accelerated approval or any other form of expedited development, review or approval. Furthermore, for any submission of an application
for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission
or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A failure to obtain accelerated approval or any
other form of expedited development, review or approval for Carisma&rsquo;s product candidates, or withdrawal of a product candidate,
would result in a longer time period until commercialization of such product candidate, could increase the cost of development of such
product candidate and could harm Carisma&rsquo;s competitive position in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may not be able to obtain orphan drug exclusivity for
any product candidates it may develop, and even if it does, that exclusivity may not prevent the FDA or the EMA from approving other competing
products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Orphan Drug Act, the FDA may designate
a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs
approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently
receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing
exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic
indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity
period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular
if the product is sufficiently profitable so that market exclusivity is no longer justified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order for the FDA to grant orphan drug exclusivity
to one of Carisma&rsquo;s products, the FDA must find that the product is indicated for the treatment of a condition or disease with
a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease
for which Carisma seeks orphan drug exclusivity does not meet this standard. Even if Carisma obtains orphan drug exclusivity for a product,
that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition.
In addition, even after an orphan drug is approved, the FDA and comparable foreign regulatory authorities such as the EMA can subsequently
approve the same product for the same condition if the FDA or such other authorities conclude that the later product is clinically superior
in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost
if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
quantity of the product to meet the needs of the patients with the rare disease or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2017, the Congress passed the FDA Reauthorization
Act of 2017, or the FDARA. The FDARA, among other things, codified the FDA&rsquo;s pre-existing regulatory interpretation, to require
that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for
the same rare disease in order to receive orphan drug exclusivity. Under omnibus legislation signed by former President Trump in December&nbsp;2020,
the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before
enactment of FDARA in 2017, but have not yet been approved or licensed by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA and Congress may further reevaluate
the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals
for the&nbsp;11th Circuit in September&nbsp;2021 finding that, for the purpose of determining the scope of exclusivity, the term
 &ldquo;same disease or condition&rdquo; means the designated &ldquo;rare disease or condition&rdquo; and could not be interpreted by
the FDA to mean the &ldquo;indication or use.&rdquo; Thus, the court concluded, orphan drug exclusivity applies to the entire
designated disease or condition rather than the &ldquo;indication or use.&rdquo; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the
FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug
exclusivity to the uses or indications for which the orphan drug was approved. Carisma does not know if, when, or how the FDA or
Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect
Carisma&rsquo;s business. Depending on what changes the FDA may make to its orphan drug regulations and policies, Carisma&rsquo;s
business could be adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma is unable to successfully develop companion diagnostics
for its product candidates and secure clearance or approval of such devices by the FDA and other regulatory authorities, or Carisma experiences
significant delays in doing so, Carisma may not realize the full commercial potential of its therapeutics.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma believes that its success will depend,
in part, on its ability to develop companion diagnostics, which are assays or tests to identify an appropriate patient population for
these product candidates. Carisma has little experience in the development of diagnostics and may not be successful in developing appropriate
diagnostics to pair with any of its therapeutic product candidates that receive marketing approval. Companion diagnostics are subject
to regulation by the FDA and similar regulatory authorities outside the United States as medical devices and require separate regulatory
approval prior to commercialization. Given Carisma&rsquo;s limited experience in developing diagnostics, it relies and expects to continue
to rely in part or in whole on third parties for their design and manufacture. Carisma also may in the future depend on other third parties
for the development of other companion diagnostics for its therapeutic product candidates. If Carisma or its collaborators are unable
to successfully develop companion diagnostics for Carisma&rsquo;s therapeutic product candidates, or experience delays in doing so:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the development of Carisma&rsquo;s therapeutic product candidates may be adversely affected if Carisma is unable to appropriately
select patients for enrollment in its clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma&rsquo;s therapeutic product candidates may not receive marketing approval if safe and effective use of a therapeutic product
candidate depends on an in vitro diagnostic; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>Carisma may not realize the full commercial potential of any therapeutics that receive marketing approval if, among other reasons,
Carisma is unable to appropriately select patients who are likely to benefit from therapy with its medicines.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of any of these events, Carisma&rsquo;s
business would be harmed, possibly materially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Any product candidate for which Carisma, or any collaborators,
obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and Carisma, or any collaborators,
may be subject to substantial penalties if Carisma, or any collaborators, fail to comply with regulatory requirements or if Carisma, or
any collaborators, experience unanticipated problems with its products when and if any of them are approved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any product candidate for which Carisma, or any
collaborators, obtain marketing approval, as well as the manufacturing processes, post-approval clinical data, labeling, advertising and
promotional activities for such product, will be subject to continual requirements of and review by the FDA, EMA and other regulatory
authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing
requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records
and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product
candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the
conditions of approval, including the requirement to implement a risk evaluation and mitigation strategy. New cancer drugs frequently
are indicated only for patient populations that have not responded to an existing therapy or have relapsed. If any of Carisma&rsquo;s
product candidates receives marketing approval, the accompanying label may limit the approved use of its drug in this way, which could
limit sales of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA may also impose requirements for costly
post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product, including the adoption and
implementation of risk evaluation and mitigation strategies. The FDA and other regulatory agencies, including the Department of Justice,
or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed
only for the approved indications and in accordance with the provisions of the approved labeling. The FDA, DOJ and other regulatory agencies
impose stringent restrictions on manufacturers&rsquo; communications regarding off-label use, and if Carisma does not market its products
for their approved indications, it may be subject to enforcement action for off-label marketing by the FDA and other federal and state
enforcement agencies. Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating
to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal
and state healthcare fraud and abuse laws, as well as state consumer protection laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, later discovery of previously unknown
side effects or other problems with Carisma&rsquo;s products or its manufacturers or manufacturing processes, or failure to comply with
regulatory requirements, may yield various results, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>restrictions on such products, manufacturers or manufacturing processes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>restrictions and warnings on the labeling or marketing of a product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>restrictions on product distribution or use;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>requirements to conduct post-marketing studies or clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>receipt of warning letters or untitled letters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>withdrawal of the products from the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>refusal to approve pending applications or supplements to approved applications that Carisma submits;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>recall of products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>fines, restitution or disgorgement of profits or revenues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>suspension or withdrawal of marketing approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>suspension of any ongoing clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>damage to relationships with any potential collaborators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>unfavorable press coverage and damage to Carisma&rsquo;s reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>refusal to permit the import or export of Carisma&rsquo;s products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>product seizure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>injunctions or the imposition of civil or criminal penalties; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>litigation involving patients using Carisma&rsquo;s products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, manufacturers of approved products
and those manufacturers&rsquo; facilities are required to comply with extensive FDA requirements, including ensuring that quality control
and manufacturing procedures conform to cGMPs applicable to drug manufacturers or quality assurance standards applicable to medical device
manufacturers, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of
records and documentation and reporting requirements. Carisma, any contract manufacturers it may engage in the future, its collaborators
and their contract manufacturers will also be subject to other regulatory requirements, including submissions of safety and other post-marketing
information and reports, registration and listing requirements, requirements regarding the distribution of samples to clinicians, recordkeeping,
and costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product such as the requirement
to implement a risk evaluation and mitigation strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma&rsquo;s relationships with healthcare providers, physicians
and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could
expose Carisma to civil, criminal and administrative sanctions, contractual damages, reputational harm and diminished future profits and
earnings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Healthcare providers, physicians and third-party
payors will play a primary role in the recommendation and prescription of any drugs for which Carisma obtains marketing approval. Carisma&rsquo;s
future arrangements with third-party payors, healthcare providers and physicians may expose it to broadly applicable state and federal
fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which Carisma markets, sells and distributes any drugs for which it obtains marketing approval. These include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><I>Anti-Kickback Statute,</I>&nbsp;which prohibits, among other things, persons and entities from knowingly and willfully soliciting,
offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an
individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good
or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><I>False Claims Act -</I>&nbsp;the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary
Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the
federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement
material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government, or knowingly
concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><I>HIPAA -</I>&nbsp;the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements
relating to healthcare matters, and apply regardless of the payor (e.g., public or private);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><I>HIPAA and HITECH -</I>&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH,
and their implementing regulations, which impose obligations on HIPAA covered entities and their business associates, including mandatory
contractual terms and required implementation of administrative, physical and technical safeguards to maintain the privacy and security
of individually identifiable health information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><I>Transparency Requirements -</I>&nbsp;the federal physician transparency requirements known as the Physician Payments Sunshine Act,
under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the Affordable Care
Act, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&rsquo;s
Health Insurance Program to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, within the United States
Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians,
other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate
family members; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><I>Analogous State, Local and Foreign Laws -</I>&nbsp;analogous state, local and foreign fraud and abuse laws and regulations, such
as state anti-kickback and false claims laws, which may be broader than similar federal laws, can apply to claims involving healthcare
items or services regardless of payor, and are enforced by many different federal and state agencies as well as through private actions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some state laws require pharmaceutical companies
to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by
the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians
and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information
in some circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating
compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Efforts to ensure that Carisma&rsquo;s business
arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible
that governmental authorities will conclude that Carisma&rsquo;s business practices may not comply with current or future statutes, regulations
or case law involving applicable fraud and abuse or other healthcare laws and regulations. If Carisma&rsquo;s operations are found to
be in violation of any of these laws or any other governmental regulations that may apply to Carisma, it may be subject to significant
civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion from government funded
healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens, diminished profits
and future earnings, additional reporting obligations and oversight if Carisma becomes subject to a corporate integrity agreement or similar
agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of its operations. If any of the
physicians or other healthcare providers or entities with whom Carisma expects to do business is found to be not in compliance with applicable
laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The provision of benefits or advantages to physicians
to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited
in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European
Union Member States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Compliance with global privacy and data security requirements
could result in additional costs and liabilities to Carisma or inhibit its ability to collect and process data globally, and the failure
to comply with such requirements could subject Carisma to significant fines and penalties, which may have a material adverse effect on
its business, financial condition or results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The regulatory framework for the collection, use,
safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for
the foreseeable future. Globally, virtually every jurisdiction in which Carisma operates has established its own data security and privacy
frameworks with which it must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding
individuals in the European Union, including personal health data, is subject to the E.U. General Data Protection Regulation, or the GDPR,
which took effect across all member states of the European Economic Area, or EEA, in May&nbsp;2018. The GDPR is wide-ranging in scope
and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other
sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding
data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification
of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases Carisma&rsquo;s obligations with
respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes
to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes
strict rules&nbsp;on the transfer of personal data to countries outside the European Union, including the United States and, as a result,
increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries
that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities
to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR,
which can be up to four percent of global revenues or 20.0 million Euros, whichever is greater, and it also confers a private right of
action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain
compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make
their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Similar actions are either in place or under way
in the United States. There are a broad variety of data protection laws that are applicable to Carisma&rsquo;s activities, and a wide
range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based
on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy
and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the
California Consumer Privacy Act, or CCPA, which went into effect on January&nbsp;1, 2020, is creating similar risks and obligations as
those created by the GDPR, though CCPA does exempt certain information collected as part of a clinical trial subject to the Federal Policy
for the Protection of Human Subjects (the Common Rule). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect
on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use,
retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection
or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice
to residents regarding retention of information. The CPRA also created a new enforcement agency - the California Privacy Protection Agency
- whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply
to some of Carisma's business activities. In addition, other states, including Virginia, Colorado, Utah, and Connecticut, already have
passed state privacy laws. Virginia's privacy law also went into effect on January 1, 2023, and the laws in the other three states will
go into effect later in the year. Other states will be considering these laws in the future, and Congress has also been debating passing
a federal privacy law. These laws may impact Carisma's business activities, including its identification of research subjects, relationships
with business partners and ultimately the marketing and distribution of Carisma's products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given the breadth and depth of changes in data
protection obligations, preparing for and complying with such requirements is rigorous and time intensive and requires significant resources
and a review of Carisma&rsquo;s technologies, systems and practices, as well as those of any third-party collaborators, service providers,
contractors or consultants that process or transfer personal data. The GDPR and other changes in laws or regulations associated with the
enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from Carisma&rsquo;s clinical
trials, could require Carisma to change its business practices and put in place additional compliance mechanisms, may interrupt or delay
its development, regulatory and commercialization activities and increase its cost of doing business, and could lead to government enforcement
actions, private litigation and significant fines and penalties against Carisma and could have a material adverse effect on its business,
financial condition or results of operations. Similarly, failure to comply with federal and state laws regarding privacy and security
of personal information could expose Carisma to fines and penalties under such laws. Even if Carisma is not determined to have violated
these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative
publicity, which could harm Carisma&rsquo;s reputation and business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Current and future legislation may increase the difficulty and
cost for Carisma and any collaborators to obtain marketing approval of and commercialize product candidates and affect the prices Carisma,
or any collaborators, may obtain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States and some foreign jurisdictions,
there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among
other things, prevent or delay marketing approval of Carisma&rsquo;s product candidates, restrict or regulate post-approval activities,
impact pricing and reimbursement and affect Carisma&rsquo;s ability, or the ability of any collaborators, to profitably sell or commercialize
any product candidates for which Carisma, or any collaborators, obtain marketing approval. The pharmaceutical industry has been a particular
focus of these efforts and has been significantly affected by legislative initiatives. In particular, there have been and continue to
be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.
Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria
and in additional downward pressure on the price that Carisma, or any collaborators, may receive for any FDA approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, the Medicare Prescription
Drug,&nbsp;Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products.
The legislation expanded Medicare coverage for prescription drugs purchased through a pharmacy by the elderly and disabled and introduced
a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this statute provides authority
for limiting the number of drugs that will be covered in any therapeutic class, subject to certain exceptions. Cost reduction initiatives
and other provisions of this statute could decrease the coverage and price that Carisma receives for any approved products. While the
MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar
reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March&nbsp;2010, then-President Obama
signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability
Reconciliation Act, or collectively the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was
enacted. In August&nbsp;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by
Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2
trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&rsquo;s automatic
reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2%
per fiscal year, which went into effect in April&nbsp;2013 and will remain in effect through 2031 under the Coronavirus Aid, Relief,
and Economic Security Act, or the CARES Act. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments
to several providers and increased the statute of limitations period for the government to recover overpayments to providers from
three to five years. Under current legislation, the actual reductions in Medicare payments may vary up to 4%. Further, with passage
of the Inflation Reduction Act, or IRA, in August&nbsp;2022, Congress extended the expansion of the Patient Protection and Affordable Care
Act premium tax credits through 2025. Those subsidies were originally extended through 2022 under the American Rescue Plan Act of
2021. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices
Carisma may obtain for any of its product candidates for which it may obtain regulatory approval or the frequency with which any
such product candidate is prescribed or used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since enactment of the ACA, there have been and
continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment
of the Tax Cuts for&nbsp;Jobs Act, or TCJA, in 2017, Congress repealed the &ldquo;individual mandate.&rdquo; The repeal of this provision,
which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December&nbsp;14, 2018,
a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and
inseverable feature of the ACA and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA
are invalid as well. The U.S. Supreme Court heard this case on November&nbsp;10, 2020 and on June&nbsp;17, 2021, dismissed this action
after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over
the ACA are likely to continue, with unpredictable and uncertain results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trump Administration also took executive actions
to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the
ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory
burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January&nbsp;28,
2021, however, President Biden rescinded those orders and issued a new Executive Order which directs federal agencies to reconsider rules&nbsp;and
other policies that limit Americans&rsquo; access to health care, and consider actions that will protect and strengthen that access. Under
this Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions,
including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine
the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance;
policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial
assistance, including for dependents. This Executive Order also directs the U.S. Department of Health and Human Services to create a special
enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma expects that these healthcare reforms,
as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other
healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that Carisma
receives for any approved product and/or the level of reimbursement physicians receive for administering any approved product it might
bring to market. Reductions in reimbursement levels may negatively impact the prices Carisma receives or the frequency with which its
products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar
reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue
from product candidates that Carisma may successfully develop and for which it may obtain marketing approval and may affect Carisma&rsquo;s
overall financial condition and ability to develop or commercialize product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The prices of prescription pharmaceuticals in the United States
and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices Carisma obtains for
its drug products, if and when approved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The prices of prescription pharmaceuticals have
also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as
well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical
pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare
and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain
provisions in these orders have been incorporated into regulations. These regulations include an interim final rule&nbsp;implementing
a most favored nation model for prices that would tie Medicare Part&nbsp;B payments for certain physician-administered pharmaceuticals
to the lowest price paid in other economically advanced countries, effective January&nbsp;1, 2021. That rule, however, has been subject
to a nationwide preliminary injunction and, on December&nbsp;29, 2021, CMS issued a final rule&nbsp;to rescind it. With issuance of this
rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part&nbsp;B pharmaceuticals and improve
beneficiaries&rsquo; access to evidence-based care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, in October&nbsp;2020, the
Department of Health and Human Services, or HHS, and the FDA published a final rule&nbsp;allowing states and other entities to
develop a Section&nbsp;804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The
final rule&nbsp;is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New
Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for
review and approval by the FDA. Further, on November&nbsp;20, 2020, HHS finalized a regulation removing safe harbor protection for
price reductions from pharmaceutical manufacturers to plan sponsors under Part&nbsp;D, either directly or through pharmacy benefit
managers, unless the price reduction is required by law. The final rule would eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale
discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the
IRA has been delayed by Congress to January 1, 2032.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More recently, on August 16, 2022, the IRA was signed into law by President Biden. The new legislation has implications for Medicare Part
D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option
of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs
to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates
under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part
D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of
HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source
drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS
may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part
B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved
for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved
for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these products in price negotiations,
Carisma would be fully at risk of government action if its products are the subject of Medicare price negotiations. Moreover, given the
risk that could be the case, these provisions of the IRA may also further heighten the risk that Carisma would not be able to achieve
the expected return on its drug products or full value of its patents protecting its products if prices are set after such products have
been on the market for nine years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with
the legislation by offering a price that is not equal to or less than the negotiated &ldquo;maximum fair price&rdquo; under the law or
for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part
D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024
and, thereafter beginning in 2025, at 2,000 a year. In addition, the IRA potentially raises legal risks with respect to individuals participating
in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual
coverage limit before they reached the higher threshold, or &ldquo;catastrophic period&rdquo; of the plan. Individuals requiring services
exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until
they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals
by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket
expenses, each of which could have potential pricing and reporting implications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accordingly, while it is currently unclear how the IRA will be effectuated, Carisma cannot predict with certainty what impact any federal
or state health reforms will have on it, but such changes could impose new or more stringent regulatory requirements on Carisma's activities
or result in reduced reimbursement for its products, any of which could adversely affect Carisma's business, results of operations and
financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the state level, individual states are increasingly
aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, health care organizations
and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will
be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for Carisma&rsquo;s
products, once approved, or put pressure on its product pricing. Carisma expects that additional state and federal healthcare reform measures
will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products
and services, which could result in reduced demand for its product candidates or additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In other countries, particularly the countries
of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations
with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or
pricing approval in some countries, Carisma, or its collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness
of its drug to other available therapies. If reimbursement of Carisma&rsquo;s drugs is unavailable or limited in scope or amount, or if
pricing is set at unsatisfactory levels, its business could be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma is subject to anti-corruption laws, as well as export
control laws, customs laws, sanctions laws and other laws governing its operations. If Carisma fails to comply with these laws, it could
be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect its business, results
of operations and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s operations are subject to
anti-corruption laws, including the Foreign Corrupt Practices Act, or, FCPA, the Bribery Act, and other anticorruption laws that
apply in countries where Carisma does business and may do business in the future. The FCPA, the Bribery Act, and these other laws
generally prohibit Carisma, its officers and its employees and intermediaries from bribing, being bribed or making other prohibited
payments to government officials or other persons to obtain or retain business or gain some other business advantage. Carisma may in
the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and it may participate in
collaborations and relationships with third parties whose actions could potentially subject Carisma to liability under the FCPA, the
Bribery Act, or local anti-corruption laws. In addition, Carisma cannot predict the nature, scope or effect of future regulatory
requirements to which its international operations might be subject or the manner in which existing laws might be administered or
interpreted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is also subject to other laws and regulations
governing its international operations, including regulations administered by the governments of the United States, United Kingdom, and
authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs
requirements and currency exchange regulations, which is collectively referred to as Trade Control Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There is no assurance that Carisma will be completely
effective in ensuring its compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements,
including Trade Control Laws. If Carisma is not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade
Control Laws, it may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses,
which could have an adverse impact on its business, financial condition, results of operations and liquidity. The SEC also may suspend
or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&rsquo;s accounting provisions. Likewise, any investigation
of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by the United States, the United
Kingdom or other authorities could also have an adverse impact on Carisma&rsquo;s reputation, business, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma is subject to stringent privacy laws, information security
laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies,
contractual obligations and failure to comply with such requirements could subject Carisma to significant fines and penalties, which may
have a material adverse effect on Carisma&rsquo;s business, financial condition or results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is subject to data privacy and protection
laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other
things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive
regulatory systems in the United States, the European Union and the United Kingdom. The legislative and regulatory landscape for privacy
and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection
issues with the potential to affect Carisma&rsquo;s business. Failure to comply with any of these laws and regulations could result in
an enforcement action against Carisma, including fines, imprisonment of company officials and public censure, claims for damages by affected
individuals, damage to Carisma&rsquo;s reputation and loss of goodwill, any of which could have a material adverse effect on Carisma&rsquo;s
business, financial condition, results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are numerous U.S. federal and state laws
and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA
establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected
health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of
protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining
whether protected health information has been handled in compliance with applicable privacy standards and Carisma&rsquo;s contractual
obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of Carisma&rsquo;s
business activities now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma is unable to properly protect the privacy
and security of protected health information, it could be found to have breached its contracts. Further, if Carisma fails to comply with
applicable privacy laws, including applicable HIPAA privacy and security standards, it could face civil and criminal penalties. HHS enforcement
activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal
resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response
to violations that threaten the privacy of state residents. Carisma cannot be sure how these regulations will be interpreted, enforced
or applied to its operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, Carisma&rsquo;s
ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications
to its policies, procedures and systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2018, California passed into law the California
Consumer Privacy Act, or the CCPA, which took effect on January&nbsp;1, 2020 and imposed many requirements on businesses that process
the personal information of California residents. Many of the CCPA&rsquo;s requirements are similar to those found in the General Data
Protection Regulation, or the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected
about them and how such information is used and shared, and providing data subjects the right to request access to such personal information
and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out
of &ldquo;sales&rdquo; of their personal information. The CCPA contains significant penalties for companies that violate its requirements.
In November&nbsp;2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which will significantly
expand the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information
of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections
for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information.
Most CPRA provisions  took effect on January&nbsp;1, 2023, though the obligations  apply to any personal information collected
after January&nbsp;1, 2022. These provisions may apply to some of Carisma&rsquo;s business activities. In addition, other states, including
Virginia and Colorado, already have passed state privacy laws. Other states will be considering these laws in the future. These laws may
impact Carisma&rsquo;s business activities, including Carisma&rsquo;s identification of research subjects, relationships with business
partners and ultimately the marketing and distribution of its products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Similar to the laws in the United States, there
are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or
other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area,
or EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May&nbsp;2018
and which imposes obligations on companies that operate in Carisma&rsquo;s industry with respect to the processing of personal data and
the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors
to maintain a record of their data processing and policies. If Carisma&rsquo;s or its partners&rsquo; or service providers&rsquo; privacy
or data security measures fail to comply with the GDPR requirements, Carisma may be subject to litigation, regulatory investigations,
enforcement notices requiring it to change the way it uses personal data and/or fines of up to 20.0 million Euros or up to 4% of the total
worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals,
negative publicity, reputational harm and a potential loss of business and goodwill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The GDPR places restrictions on the cross-border
transfer of personal data from the European Union to countries that have not been found by the European Commission to offer adequate data
protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data
from the European Union to other countries. In July&nbsp;2020, the Court of Justice of the European Union, or the CJEU invalidated the
European Union-United States Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the
United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard
contractual clauses, for transfers of personal data from the EEA to the United States. While Carisma is not self-certified under the Privacy
Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States, generally, and increase
Carisma&rsquo;s costs of compliance with data privacy legislation as well as its costs of negotiating appropriate privacy and security
agreements with its vendors and business partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the withdrawal of the United Kingdom
from the European Union, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom
and includes parallel obligations to those set forth by GDPR. As with other issues related to Brexit, there are open questions about how
personal data will be protected in the United Kingdom and whether personal information can transfer from the European Union to the United
Kingdom. Following the withdrawal of the United Kingdom from the European Union, the UK Data Protection Act 2018 applies to the processing
of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the Data Protection
Act of 2018 in the United Kingdom that &ldquo;implements&rdquo; and complements the GDPR, has achieved Royal Assent on May&nbsp;23, 2018
and is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain
lawful under GDPR. The U.K. government has already determined that it considers all European Union and EEA member states to be adequate
for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union/EEA remain unaffected. In
addition, a recent decision from the EC appears to deem the United Kingdom as being &ldquo;essentially adequate&rdquo; for purposes of
data transfer from the European Union to the United Kingdom, although this decision may be re-evaluated in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Beyond GDPR, there are privacy and data security
laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting
provisions. These laws will impact Carisma&rsquo;s ability to conduct its business activities, including both its clinical trials and
any eventual sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential
enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While Carisma continues to address the implications
of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level,
with new regulations coming into effect and continued legal challenges, and Carisma&rsquo;s efforts to comply with the evolving data protection
rules&nbsp;may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with Carisma&rsquo;s
practices. Carisma must devote significant resources to understanding and complying with this changing landscape. Failure to comply with
laws regarding data protection would expose Carisma to risk of enforcement actions taken by data protection authorities in the EEA and
elsewhere and carries with it the potential for significant penalties if Carisma is found to be non-compliant. Similarly, failure to comply
with federal and state laws in the United States regarding privacy and security of personal information could expose Carisma to penalties
under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring
that Carisma change its practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation
and significant costs for remediation, any of which could adversely affect Carisma&rsquo;s business. Even if Carisma is not determined
to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and
generate negative publicity, which could harm Carisma&rsquo;s business, financial condition, results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma employees, independent contractors, consultants, collaborators
and vendors engage in misconduct or other improper activities, including non-compliance with regulatory standards and/or requirements
and insider trading, Carisma could sustain significant liability and harm to its reputation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is exposed to the risk of fraud or other
misconduct by its employees, independent contractors, consultants, collaborators and vendors. Misconduct by these partners could include
intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate
information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state
healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory
authorities, report financial information or data accurately or disclose unauthorized activities to Carisma. Employee misconduct could
also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and
serious harm to Carisma&rsquo;s reputation. This could include violations of HIPAA, other U.S. federal and state laws, and requirements
of foreign jurisdictions, including the GDPR. Carisma is also exposed to risks in connection with any insider trading violations by employees
or others affiliated with Carisma. It is not always possible to identify and deter employee or third-party misconduct, and the precautions
that Carisma takes to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or
in protecting Carisma from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such
laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against Carisma, and Carisma is not successful
in defending itself or asserting its rights, those actions could have a significant impact on its business and results of operations,
including the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If Carisma or any third-party manufacturer it engages now or
in the future fails to comply with environmental, health and safety laws and regulations, Carisma could become subject to fines or penalties
or incur costs or liabilities that could significantly harm its business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma and third-party manufacturers it engages
now are, and any third-party manufacturer it may engage in the future will be, subject to numerous environmental, health and safety laws
and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials
and wastes. From time to time and in the future, Carisma&rsquo;s operations may involve the use of hazardous and flammable materials,
including chemicals and biological materials, and may also produce hazardous waste products. Although Carisma contracts with third parties
for the disposal of these materials and waste products, it cannot completely eliminate the risk of contamination or injury resulting from
these materials. In the event of contamination or injury resulting from the use or disposal of Carisma&rsquo;s hazardous materials, Carisma
could be held liable for any resulting damages, and any liability could exceed its resources. Carisma also could incur significant costs
associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma maintains general liability insurance as
well as workers&rsquo; compensation insurance to cover costs and expenses it may incur due to injuries to its employees resulting from
the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. Carisma does not maintain
insurance for environmental liability or toxic tort claims that may be asserted against it. In addition, Carisma may incur substantial
costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental
laws and regulations may impair Carisma&rsquo;s research, development or production efforts, which could adversely affect its business,
financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in
substantial fines, penalties or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Employee Matters and Managing Growth</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma&rsquo;s future success depends on its ability to retain
key executives and experienced scientists and to attract, retain and motivate qualified personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is highly dependent on the research and
development, clinical, financial, operational and other business expertise of its executive officers, as well as the other principal members
of its management, scientific and clinical teams. Although Carisma has entered into employment agreements with certain of its executive
officers, each of them may terminate their employment with Carisma at any time. Carisma does not maintain &ldquo;key person&rdquo; insurance
for any of its executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal
and sales and marketing personnel will also be critical to Carisma&rsquo;s success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The loss of the services of Carisma&rsquo;s executive
officers or other key employees, including temporary loss due to illness, could impede the achievement of its discovery programs, development
and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing
executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals
in Carisma&rsquo;s industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and
commercialize products. Competition to hire from this limited pool is intense, and Carisma may be unable to hire, train, retain or motivate
these key personnel on acceptable terms given the competition among numerous biopharmaceutical companies for similar personnel. Carisma
also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition,
Carisma relies on consultants and advisors, including scientific and clinical advisors, to assist it in formulating its discovery, research
and development and commercialization strategy. Carisma&rsquo;s consultants and advisors may be employed by employers other than Carisma
and may have commitments under consulting or advisory contracts with other entities that may limit their availability to Carisma. Failure
to succeed in clinical trials may make it even more challenging to recruit and retain qualified scientific personnel. Carisma&rsquo;s
success as a public company also depends on implementing and maintaining internal controls and the accuracy and timeliness of its financial
reporting. If Carisma is unable to continue to attract and retain high quality personnel, its ability to pursue its growth strategy will
be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma expects to expand its development and regulatory capabilities
and potentially implement sales, marketing and distribution capabilities, and as a result, it may encounter difficulties in managing its
growth, which could disrupt its operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma expects to experience significant growth
in the number of its employees and the scope of its operations, particularly as it functions as a public company and in the areas of product
development, clinical, regulatory affairs, manufacturing and quality control and, if any of its product candidates receives marketing
approval, sales, marketing and distribution. To manage Carisma&rsquo;s anticipated future growth, it must continue to implement and improve
its managerial, operational and financial systems, expand its facilities and continue to recruit and train additional qualified personnel.
Future growth will impose significant added responsibilities on members of management, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>identifying, recruiting, integrating, maintaining and motivating additional employees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>managing its internal development efforts effectively, including the clinical and regulatory review process for CT-0508 and other
product candidates Carisma is developing or may develop in the future, while complying with its contractual obligations to contractors
and other third parties; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>improving its operational, financial and management controls, reporting systems and procedures.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s future financial performance and
its ability to advance development of and, if approved, commercialize CT-0508 and any other product candidate Carisma is developing or
may develop in the future will depend, in part, on Carisma&rsquo;s ability to effectively manage any future growth. Due to Carisma&rsquo;s
limited financial resources and the limited experience of its management team in managing a company with such anticipated growth, Carisma
may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel. If Carisma
does not effectively manage the expansion of its operations, Carisma could experience weaknesses in its infrastructure, operational mistakes,
loss of business opportunities, loss of employees and reduced productivity among remaining employees. The expansion of Carisma&rsquo;s
operations also could lead to significant costs and may divert Carisma&rsquo;s management and business development resources. Any inability
to manage growth could delay the execution of Carisma&rsquo;s business plans or disrupt its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many of the biopharmaceutical companies, and in
particular cell therapy companies, that Carisma competes against for qualified personnel and consultants have greater financial and other
resources, different risk profiles and a longer history in the industry than Carisma does. They also may provide more diverse opportunities
and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what Carisma
has to offer. If Carisma is unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which
Carisma can develop product candidates and operate its business will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma&rsquo;s internal computer systems, or those of its collaborators,
vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of Carisma&rsquo;s
product development programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s internal computer systems and those
of any collaborators, vendors, suppliers, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access,
natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions
or to security breaches from inadvertent or intentional actions by Carisma&rsquo;s employees, third-party vendors and/or business partners,
or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have
become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service
attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the
confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or email fraud to cause
payments or information to be transmitted to an unintended recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Carisma experiences any material system failure,
accident, cyber-attack or security that causes interruptions in its operations, it could result in a material disruption of Carisma&rsquo;s
development programs and its business operations, whether due to a loss of its trade secrets or other proprietary information or other
similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in Carisma&rsquo;s
marketing approval efforts and significantly increase its costs to recover or reproduce the data. To the extent that any disruption or
security breach were to result in a loss of, or damage to, Carisma&rsquo;s data or applications, or inappropriate disclosure of confidential
or proprietary information, Carisma could incur liability, its competitive position could be harmed and the further development and commercialization
of its product candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma&rsquo;s employees, independent contractors, including
principal investigators, consultants and vendors and any third parties it may engage in connection with discovery programs, research,
development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization may engage in misconduct
or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could cause
significant liability for Carisma and harm its reputation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma is exposed to the risk of fraud or other
misconduct by its employees, independent contractors, including principal investigators, consultants and vendors and any other third parties
it engages. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that include
failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide complete and accurate
information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state
data privacy, security, fraud and other healthcare fraud and abuse laws and regulations and similar laws and regulations established and
enforced by comparable foreign regulatory authorities, report complete financial information or data accurately or disclose unauthorized
activities to Carisma. Misconduct by employees and other third parties could also involve the improper use of information obtained in
the course of clinical trials, which could result in regulatory sanctions and serious harm to Carisma&rsquo;s reputation. This could include
violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection
Directive. Carisma is also exposed to risks in connection with any insider trading violations by employees or others affiliated with Carisma.
It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions Carisma takes to
detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Carisma from
governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations,
guidance or codes of conduct. Additionally, Carisma is subject to the risk that a person could allege such fraud or other misconduct,
even if none occurred. If any such actions are instituted against Carisma, and it is not successful in defending itself or asserting its
rights, those actions could have a significant impact on Carisma&rsquo;s business and results of operations, including the imposition
of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation
in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting
obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm,
diminished profits and future earnings, and curtailment of Carisma&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to the Ownership of Carisma&rsquo;s Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The market price of Carisma&rsquo;s common stock may be volatile,
and the market price of Carisma&rsquo;s common stock may drop following the merger.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market price of Carisma&rsquo;s common stock
following the merger could be subject to significant fluctuations. Some of the factors that may cause the market price of Carisma&rsquo;s
common stock to fluctuate include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>results of clinical trials and pre-clinical studies of Carisma&rsquo;s product candidates, or those of Carisma&rsquo;s competitors
or Carisma&rsquo;s existing or future collaborators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>failure to meet or exceed financial and development projections Carisma may provide to the public;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>failure to meet or exceed the financial and development projections of the investment community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>if Carisma does not achieve the perceived benefits of the merger as rapidly or to the extent anticipated by financial or industry
analysts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by Carisma or its competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>actions taken by regulatory agencies with respect to Carisma&rsquo;s product candidates, clinical studies, manufacturing process or
sales and marketing terms;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>disputes or other developments relating to proprietary rights, including patents, litigation matters, and Carisma&rsquo;s ability
to obtain patent protection for its technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>additions or departures of qualified scientific and management personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>significant lawsuits, including patent or stockholder litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>if securities or industry analysts do not publish research or reports about Carisma&rsquo;s business, or if they issue adverse or
misleading opinions regarding its business and stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>changes in the market valuations of similar companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>general market or macroeconomic conditions or market conditions in the biopharmaceutical sector;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>sales of securities by Carisma or its stockholders in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>if Carisma fails to raise an adequate amount of capital to fund its operations and continued development of its product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>trading volume of Carisma&rsquo;s common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships
or capital commitments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>adverse publicity relating to product candidates, including with respect to other products in such markets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>the introduction of technological innovations or new therapies that compete with the products and services of Carisma; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>period-to-period fluctuations in Carisma&rsquo;s financial results.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moreover, the stock markets in general have experienced
substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations
may also adversely affect the trading price of Carisma&rsquo;s common stock. In addition, a recession, depression or other sustained adverse
market event could materially and adversely affect Carisma&rsquo;s business and the value of its common stock. In the past, following
periods of volatility in the market price of a company&rsquo;s securities, stockholders have often instituted class action securities
litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if Carisma experiences a
market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with Carisma&rsquo;s
strategic direction or seek changes in the composition of its board of directors could have an adverse effect on Carisma&rsquo;s operating
results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma will incur additional costs and increased demands upon
management as a result of complying with the laws and regulations affecting public companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma will incur significant legal, accounting
and other expenses as a public company that Carisma did not incur as a private company, including costs associated with public company
reporting obligations under the&nbsp;Exchange Act. Carisma&rsquo;s management team consists of the executive officers of Carisma prior
to the merger, some of whom have not previously managed and operated a public company. These executive officers and other personnel will
need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws
and regulations to ensure that Carisma complies with all of these requirements. Any changes Carisma makes to comply with these obligations
may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements,
rules&nbsp;and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also
make it more difficult for Carisma to attract and retain qualified persons to serve on the board of directors or on board committees or
to serve as executive officers, or to obtain certain types of insurance, including directors&rsquo; and officers&rsquo; insurance, on
acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Once Carisma is no longer a &ldquo;smaller reporting company&rdquo;
or otherwise no longer qualifies for applicable exemptions, Carisma will be subject to additional laws and regulations affecting public
companies that will increase Carisma&rsquo;s costs and the demands on management and could harm Carisma&rsquo;s operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma will be subject to the reporting requirements
of the&nbsp;Exchange Act, which requires, among other things, that Carisma file with the SEC annual, quarterly and current reports with
respect to Carisma&rsquo;s business and financial condition as well as other disclosure and corporate governance requirements. However,
as a &ldquo;smaller reporting company,&rdquo; as defined in Item&nbsp;10(f)(1)&nbsp;of&nbsp;Regulation S-K, Carisma may take advantage
of certain exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act of 2022 and reduced disclosure obligations regarding executive compensation in Carisma&rsquo;s
periodic reports and proxy statements. Once Carisma no longer qualifies as a smaller reporting company or otherwise no longer qualifies
for these exemptions, Carisma will be required to comply with these additional legal and regulatory requirements applicable to public
companies and will incur significant legal, accounting and other expenses to do so. If Carisma is not able to comply with the requirements
in a timely manner or at all, Carisma&rsquo;s financial condition or the market price of Carisma&rsquo;s common stock may be harmed. For
example, if Carisma or its independent auditor identifies deficiencies in Carisma&rsquo;s internal control over financial reporting that
are deemed to be material weaknesses, then Carisma could face additional costs to remedy those deficiencies, the market price of Carisma&rsquo;s
stock could decline or Carisma could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would
require additional financial and management resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Provisions in Carisma&rsquo;s certificate of incorporation and
bylaws and provisions under Delaware law could make an acquisition of Carisma, which may be beneficial to its stockholders, more difficult
and may prevent attempts by its stockholders to replace or remove its management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Provisions in Carisma&rsquo;s certificate of incorporation
and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of Carisma that stockholders may consider
favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions
could also limit the price that investors might be willing to pay in the future for shares of Carisma&rsquo;s common stock, thereby depressing
the market price of its common stock. In addition, because Carisma&rsquo;s board of directors will be responsible for appointing the members
of Carisma&rsquo;s management team, these provisions may frustrate or prevent any attempts by Carisma&rsquo;s stockholders to replace
or remove its current management by making it more difficult for stockholders to replace members of Carisma&rsquo;s board of directors.
Among other things, these provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>establish a classified board of directors such that only one of three classes of directors is elected each year;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>allow the authorized number of Carisma&rsquo;s directors to be changed only by resolution of its board of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>limit the manner in which stockholders can remove directors from Carisma&rsquo;s board of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and for nominations to
Carisma&rsquo;s board of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>limit who may call stockholder meetings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>prohibit actions by Carisma&rsquo;s stockholders by written consent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>require that stockholder actions be effected at a duly called stockholders meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>authorize Carisma&rsquo;s board of directors to issue preferred stock without stockholder approval, which could be used to institute
a &ldquo;poison pill&rdquo; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions
that have not been approved by Carisma&rsquo;s board of directors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD>require the approval of the holders of at least 75% of the votes that all Carisma stockholders would be entitled to cast to amend
or repeal certain provisions of Carisma&rsquo;s certificate of incorporation or bylaws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moreover, because Carisma is incorporated in Delaware,
it is governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law which prohibits a person who owns 15% or
more of Carisma&rsquo;s outstanding voting stock from merging or combining with Carisma for a period of three years after the date of
the transaction in which the person acquired 15% or more of Carisma&rsquo;s outstanding voting stock, unless the merger or combination
is approved in a manner prescribed by the statute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>An active trading market for Carisma&rsquo;s common stock may
not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to the merger, there had been no public market
for shares of Carisma capital stock. An active trading market for Carisma&rsquo;s shares of common stock may never develop or be sustained.
If an active market for the Carisma&rsquo;s common stock does not develop or is not sustained, it may be difficult for its stockholders
to sell their shares at an attractive price or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma&rsquo;s executive officers, directors and principal stockholders
may have the ability to control or significantly influence all matters submitted to Carisma&rsquo;s stockholders for approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma&rsquo;s executive officers, directors and
principal stockholders, in the aggregate, beneficially own approximately 53.95% of the Carisma&rsquo;s outstanding shares of common
stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all
matters submitted to Carisma&rsquo;s stockholders for approval, as well as Carisma&rsquo;s management and affairs. For example, these
persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger,
consolidation or sale of all or substantially all of Carisma&rsquo;s assets. This concentration of voting power could delay or prevent
an acquisition of Carisma on terms that other stockholders may desire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If equity research analysts do not publish research or reports,
or publish unfavorable research or reports, about Carisma, its business or its market, its stock price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The trading market for Carisma&rsquo;s common stock
will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts
may elect not to provide research coverage of Carisma&rsquo;s common stock after the completion of the merger, and such lack of research
coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, Carisma
will not have any control over the analysts or the content and opinions included in their reports. The price of Carisma&rsquo;s common
stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If
one or more equity research analysts ceases coverage of Carisma or fails to publish reports on it regularly, demand for its common stock
could decrease, which in turn could cause its stock price or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma will have broad discretion in the use of the cash and
cash equivalents of Carisma as well as the proceeds from the Carisma pre-closing financing and may invest or spend the proceeds in ways
with which you do not agree and in ways that may not increase the value of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Carisma will have broad discretion over the use
of the cash and cash equivalents of Carisma and the proceeds from the Carisma pre-closing financing, pursuant to which, immediately prior
to the consummation of the merger, certain  investors purchased shares of CTx common stock for an aggregate purchase price
of approximately $30.6 million, which was converted into the right to receive a number of shares of Carisma common stock equal to the exchange ratio. You may not agree with Carisma&rsquo;s decisions, and its use of the proceeds may not yield any return
on your investment. Carisma&rsquo;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy
and Carisma might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity
to influence Carisma&rsquo;s decisions on how to use its cash resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Carisma may be responsible for unwinding contractual relationships
related to a strategic transaction with respect to Vicineum, which may adversely impact the business, financial condition and results
of operations of Carisma.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July&nbsp;15, 2022, Sesen Bio made the strategic
decision to voluntarily pause further development of Vicineum in the U.S. and Carisma does not expect to pursue further development of
Vicineum for the treatment of non-muscle invasive bladder cancer. Sesen Bio previously entered into various agreements and licenses with
licensees, licensors and other counterparties related to the development and/or commercialization of Vicineum. Prior to the consummation
of the merger of Carisma and Sesen Bio, Sesen Bio began the process of winding down its operations relating to Vicineum. In connection
with a strategic transaction with respect to Vicineum, Carisma may be responsible for unwinding contractual relationships related to Vicineum,
which could divert the attention of the management teams and employees of Carisma from day-to-day business, result in liability, impose
additional costs and otherwise adversely affect the business and financial condition of Carisma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>carm-20230307.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaaBqbOdzZR+mYkxtmB1benq/ykhvaZ1UCvg8G4W0cIA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:CARM="http://carismatx.com/20230307" elementFormDefault="qualified" targetNamespace="http://carismatx.com/20230307">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://carismatx.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="carm-20230307_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="carm-20230307_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="carm-20230307_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>carm-20230307_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://carismatx.com/role/Cover" xlink:href="carm-20230307.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://carismatx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="loc_deiDocumentInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_FormerAddressMember" xlink:label="loc_deiFormerAddressMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiFormerAddressMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>carm-20230307_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_FormerAddressMember" xlink:to="dei_FormerAddressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_FormerAddressMember_lbl" xml:lang="en-US">Former Address [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>carm-20230307_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://carismatx.com/role/Cover" xlink:href="carm-20230307.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://carismatx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="loc_deiDocumentInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiDocumentInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_FormerAddressMember" xlink:label="loc_deiFormerAddressMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiFormerAddressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tm238578d1_ex99-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ R # 2(  A$! Q$!_\0
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M_KG/_P"@5C6PD*<>9-G;@LWK8BHXRBEHWUZ(Z0>,O#^/^0G%^M+_ ,)EX?\
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M%*5F[M^5O^&.6('RX8?-TYI&8)@L0/J:Z*RF@O9-?N 6D5K$LAD10PY3G"\
M]>E6]/BO&TFR;1+>VGW,WVTR!&._)X?=T3;W_P#K4>WT00P?,U=Z:]-=[?\
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MZ-%,GD1?.$P) 68AB/7&.M4?%,4T4UOYL-W&NYPOGQ1H#SVV=OK1&NI-(=7
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M#'>@E=^"PS]>:T]?C">(M15% 5;A^ . ,_R_*MR+4+/3M'TP7*&6.6UDW0)
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M_"MM(_Y[77_?8_PKD^NTN[/9628MJZM]YY7@48%>J?\ "MM(_P">UU_WV/\
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M]U_WW_\ 6H^NTOEZ!_8>+\OO/+%X PH H7ALA>O6O4_^%;:1_P ]KK_OY_\
M6I?^%;:1_P ][O\ [['^%'UVE_2%_8>+\OO/*S@MDCKP>*,#C@?)TQV^E>I_
M\*VTC_GO=?\ ?8_PH_X5MI'_ #VNO^^Q_A1]=I?TA_V'B^R^\\LQ@YX!/)(&
M*0*H^XJKZX&,UZI_PK;2/^>UU_WW_P#6H_X5MI'_ #VNO^^Q_A1]=I)W[>0O
M[$QGE]YY654G=M7>.^.]!Q)]\ _45ZI_PK;2/^>UU_W\'^%'_"MM(_Y[77_?
M8_PH^NT?/[@_L/%^7WGE@4;=F 5],<4$\;2N1Z&O4_\ A6VD?\]KK_OX/\*7
M_A6VD?\ />Z_[[_^M1]=I?TA_P!AXOLOO/+.0,')'?/>F!%7_5QJI]A_D_K7
MJW_"M])/_+>[_P"_@_PI/^%;:0/^6]U_WW_]:CZ[2_I!_8>,\OO/*PH5]P S
MZ^]*.C#CGKQ7J?\ PK;2?^>UU_W\'^%'_"MM(_Y[77_??_UJ/KM+^D)Y'BWO
M;[SRM55/NHH'; IQ)/:O4O\ A6VD?\][O_OL?X4O_"M])_Y[W?\ W\'^%'UZ
ME:R_('D>+?;[SRK HP*]4_X5MI'_ #VNO^^Q_A1_PK72/^>UU_WV/\*?UZEW
M?W!_8>,\OO/*\"NL^'1 \4-U/^BO_P"A+74?\*VTC_GM=?\ ?8_PK0T?P;8:
M'?&\M9)FD\LQX=LC!(/I[5E6Q=.=-Q3>IU8/*<51Q$*DK63[GG7C3'_"8ZGG
M^]'_ .BUK P,UZ]J7@;3M5U&:^GDG668@L$? X 'I[55_P"%;:1_SVNO^^Q_
MA3IXNG&"3O?0C$9/BJE:<XVLV^IY7@48%>J?\*VTC_GM=?\ ?8_PH_X5MI'_
M #VNO^^Q_A6GUZEW?W&']AXSR^\\KP*,"O5/^%;:1_SVNO\ OL?X4?\ "MM(
M_P">UU_WV/\ "CZ]2[O[@_L/&>7WGE>!2@CTKU/_ (5MI'_/:Z_[['^%+_PK
M?2?^>UU_W\'^%'UVEW8?V'B_+[SRIL,.1044G)09^E>J_P#"M])_Y[77_?P?
MX4?\*VTC_GO=_P#?P?X4OKM+S'_8F,\OO/*MHY^4?-UXZTFT*1@+P<].]>K?
M\*VTC_GO=_\ ?S_ZU)_PK72/^>UU_P!]C_"A8VEO^@?V)B_+[SRMU20Y95/U
M )]J<<L5)^\OW3W%>I?\*UTC_GM=?]]__6H_X5OI.<^==?\ ?P?X4?7*7](7
M]AXS;3[SRL* K *,'J,41HL9^2-1WP!7JG_"MM(_Y[77_??_ -:E_P"%;:1_
MSWN_^^Q_A1]=I?TA_P!B8Q]M?,\JQEMQ W>I%&!@C  /4 =:]4/PVTD_\MKK
M_OX/\*/^%:Z1_P ]KK_OO_ZU"QM+^D)Y'B^R^\\L"*BD*J_-UP.M"\ @*/\
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M\_\ K4?7:7](?]AXOLOO/*@BQG@*/H!^-+@'/"Y^E>J?\*UTC_GM=?\ ??\
M]:C_ (5MI'_/:Z_[^#_"CZ[1M9?D+^P\7Y?>>5@*%"CH.@]*.,UZI_PK;2/^
M>UU_WV/\*KW_ ,/=*M=.NKA);DO%$SJ&?C(!/I36-I;78GDF+6KM]YU6C_\
M(&L?^O>/_P!!%7Q5#1_^0-9?]>\?_H(J^*\5[L^VI_!'T7Y(=1112- HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MI"V#TI"_H,TKV =12!L@'%+3 **;O%,CN$ESL(;:<'!Z&CI<3:3L2T4W?CJ*
M V3TH&.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9KH.M]1>.3[/>#8_ W'O]?\ 'I5>ZE$WB2UA&W;;J7D)/ SQC]5K'O=>BNM
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M_P#K4L911-&A!EV';\P&,\XY/+8/7N.?I36ZB+L C-(Q.8UD )QW)^ZH]S^
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M@8W"*C45-_"U=?Y'RM:WLEO=W,4BMF*1E>+ 91AB.#[=!6W,D!@FN -I90K
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M[ENDK6?;_A]?E8S$M[J*^%U!(C .!+%ORR_[)!Y.,G!'//O6H]Z\%S/RCQ7
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MX%5K^&6YL+B&&4Q2O&RI(/X&((!_ U:--/2IDKIH$[.Z/()M.ETZZ$#PI&P
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M;XB(!!+::=-&H^6YN)P5<=B"GS'ZD5%5M1LFE\['7A(1YFY1;VZ)G<V\$-M
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M=2IQUY]*GFW75#:L2[@>]!( J"VD:2VC=\;ROS[>FX<']<U%J-\FGV9N'4L
MRK@=RS!1^IH<DES/8%%M\JW.-\56X&H2NI!)PQ&:Q[20[@H/6M!_#FJ0W\TM
MPNZ,.S&X\S=Y@)/;.?P/3WK,>)H)V&=N.17P>80DY.;C:[/K,/R*FH1E?0VX
ML*N<U9$F['I6+%=,_4U?BE)7/:O"E39,X6- D8RM-4KSD_3-1HZ&/)/--1QN
M^;I6:NE8QY299 ,YJ1[V);)XRN6VD8Q522>.-_:J;3&68*H)9B%4#J2>U=&'
MJ5(-\G738/9*6KT([&RUF35(Y[43A/-&V0,1&%!Y!'3UKT@'C%9VCVDUK8".
M?_6,2V,YV].*TL8K]#RO#NAAU>]W9N_1GCXW$>VGLM--.HZBBBO5.(*I:Q_R
M!+__ *]I/_035VJ6L?\ ($O_ /KVD_\ 0336Y$_A?HQFC_\ (&LO^O>/_P!!
M%7A5'1_^0/9?]>\?_H(J\*'NQ4_@CZ+\D.HHHI&@E(<CFG4AZ4 9>HZ)9:B,
MRP@/CAE&/SKEM+\*W%XL[W 2%HY61<'.<=:[MN*JV ,:S[@1NF=A[C->?7P-
M"K43E'N==+%U:<'%/L9-EX2M("&E)<^G:MEU^S0$0PYVCY47C-6-PSWJO>7)
MMH3*MO+.5_@B&6Q]*Z:&&IT=*2L<U:M*:;G(R#HLNHW0N-3*L%Y$*G(QZ'V_
MG7#^(+*&;49HX(EC02AL'C'K@>H!/7BNZEUF6>-D@T_4-[ @9A*X_$\5SFL:
M5?211R-:[<,2$1BS?5B/_P!5>M1DXOW_ )'S..A3E#]RFW>[=GZ=3CYFMX2&
M38WE= K'/^?Y4A-K''N=O,9PKE60,QYX;;_>'J!FIM2TU[*_6.Y@;=C.\$%>
M0<8/3\*R3+)$W^J=6+#,L?0 '^+O^5=;\CRE%];IF;>P1?:HEC5)#(?DB9#@
M\G.">O//Z]<U:EFECC_?P2QALJWEC>?]Y<D_E@U?OXGCAB,*B5B<A_[ORGD-
MV/)YP1UZ5CQ -<"WED\GCAY9 P) Z9X )[4&RU1<>]DTR*!E E,ZY6=003PN
M#UYR"./;MTJ.UU:_>.9&C#L&;:W!(R/7CK@\>_X59GL3_9HANMT7D2,R2QJ&
M9LY.T+R<Y;N/Y50O].DTY;:6U/[^1#SG@].2!QWI!'E:&Z7#%<)\]V(96'",
M-P P,<=JIR^>I\B2Y+VZ2AMZKC=R?NCZ5-?S)]EBN)%"2A@)9!'@GMR.V??%
M,FECNKT(D@:&- N%/)]<>_.*=FV:VMJ2W&FO,BK"\;V\A#OGG8.N5/\ GK7H
MOA#P'%%=7L&KV,%S9O%&8FE@#!P03E7SE6]1]*X2ULKV>!I[73K^>'=M\R&!
MW4#N/E!'Y'CBO1_"7C+1+&Q73M3U2YL[A3\D>JKY91?0.0 1]<&HQ"DJ?N:O
M\3MP<$ZG[Q:=#J[/PKH-E&([?2+/:.A:(.W_ 'TV36O#!% FR*)(U_NH !^E
M,M+B&ZB6:WFCFB<962-PRL/8CK5BO);EU9[\8Q6R$Z4M!H%(H*3!I:* *&JZ
MC:Z/I\U]=L5AC&6P,D^@ [FO ?&OB]?$6KPW]CI(LIK5OENF.Z20C 7(^[QG
M()R0:];^)$$DOADR)G;%,CO[#U_#->,Q0*TY\IE964B0 =>O;_/6NNA2C)<S
M/(QN*E3GR=+&5=:UXAU*W\FXUN^N80!NAEN&PPQU(XS^-9&UH$9#%)M]!R.?
M8_GBNG:TA+G:A^1MJ[03R.H!'6JMU91S2+)&[0L?E?Y?R'3K_A71[-'"J]W:
M1A6L:SL2F">>#@,*E2R^T/&A&&=P-O3C-7K6Q$4XED1G=.>&&<>Y_2K$"%M0
M^UV\)WQ\A6YXP01CO^%/D*E4UT'PV266HP1A&W'ACT QV^E6[RUE&H;RX$3D
M*J@9[COVZ5+)&+ELM?0^9WVG!&>F1U'Y57%]-87JV\J>8 0 ^1^'7MTK1*QR
MMMZFFT4MU$UH\I9V(QNY]#UZXK-DB_TEHW7&WJ,8QSC(QVZ5T.AZ3>>*+MK>
MQ$$#0KYK22L>#P /7TZ59TVXD\,>*WAU73EN9=X610F3MZ[T!ZC&3Z>N*?,M
M5NUT'2I324GHF]&;W@O1_#6OPK<W$6;Q(UC:S:7Y3M Q( ,$[@!U)'7BO3((
M8XD6*% D2* J*, #V%>8Z3H]E!\5VVD"!E-W:!#M#!E!&/4 A^/:O5$]J\ZO
M+WE9Z-'T.%7+%I;W%[T XH)Q2!P>><>XKG.OJ/S29I-PQU_*D# G'?K0(7/-
M4ET^V6Y:X,8>4G/F/R5]AZ5;)!-9+Z/*SN4U6]52<[05./;D5<?6QC5Z>[?Y
MK]3'\6 W0VAF"0#+[N%+>@]37!7+,J*(X(@%[.O0_P!.WZUZG_PCUH58RO+/
M(01OE;=C/?'2L74/!EN;&4)(ZNN7\P LS+W7:.OX5UTJL(KEN>'B\%6J3=6W
MXGGB2SQ*R!!N;:PC8\)D^@Q[^W%49[)KF*4QW !*X#/$H (_O<<CI[U8N45_
ME._S%3'7!_ ^O&/PIJ71M[-HF1B74A7) 8-C!!-=C/+6FJ.=GTR ($*2B8*#
M(4Y7<PR0.Q _6LE=#FN/-A3<[["4Z9^E=4UO!<Q$VWFH%Y]._;G'^?RG6>W2
MV^T7=H\;Q#@HI3(]\]/Z\UFX)[G8J\X;'!0:5(X)".X49<+P<'ZUT%C:_9E:
M73F1F5?FC9C\IQU]C^':MB'4K>X2ZBF6(/*,1;I%   ^Z /TYS4-O8QPB5@Y
M4!3YG0CUR33C&PYUY27O#;J[2^MC<R*H2/@!5_UC$XYQVXI;29O(,<D&Y6SM
MVCM[?E5*SAO9[<0[4V*^Y-WOVR*W/#^G'5M7MH9TNUL9)3 9[9"RH^.!NQCK
MQ[5HERKFD9J',^2)U/@>#2;J6&SEBG@N8+GS[2>)>"0H#(6P0>G0^O%>L*0#
MBN!M?A]J>C3>;HOB>> ]TN(!(C?4 CM70:6?%27WDZM!I<MJ1Q<VTCJV?="#
M^AKS<0XU'>+^1]!A(2I0Y9+YG0 Y&12\TB=*=7*=P4444P&>O6D^I/YTN.3U
M_&L;6?$,>CLB-97ERS#.8(MRCZFJ492=D9U*D:<>:;LC5W J <\]F%<+X_6T
MA@M4$ $A.X.&R0H/( /3DBB?Q_._[NWTAT/3,NYOT45';:1>:W.=6\1%K6RC
MP=DJ["RYS@C^%<X]Z[*=%TGSU-$>1B<1'%0]E25V^MM$NNZ//) &O R2;4;:
M9$VGE6Z8]Q5G5'>W;RK&,,F#YA 7GZ9'WE(#<CG''-5=1F1#,PRL#Y*EAECS
MQ^E4+2\87,@F>0*09,)\PX&/H<\=NWU%=CO;4\J,%+5>NO7O_F/T^V>XCGV3
MSHJDK*'DSYA[D^ISDYZYS5JP5SI.K?/NN)8O+5"F2Y*LH./^!'/TJ#RWM;YI
MHI+4QJW(20 KR>#V'/KSVI+KQ,TCLEC;F*3=@%&PYYY&=N1^ KEI4JT*DY5)
MWB_A7;N>AB*U"O2I0HT^6:^)WW_K_@&%-:2"TGS:R[%8B42*0X8'IR<$C)Y]
MZOWEM(=.CEMI=T&[<X9%("[0,'OVK8U:2*XTBTM[,. Z+NF/.<="<$_>Z\XZ
M&LO389](6Z>=)67&X>8<ANN<9/\ GZ$UI&*U:.:4FTE+1KIOY%K3=*MKBR:Y
MTRZ1YC@2*['$A(!^\><\]?2J%EKALH765-DT9/EHC;U.3C'MSW]Z9IX7['+=
M3RC[,6QMC8\G YY[U76X628.EO$L7F!_*[D#G&3C'2LZU&%>')-778Z,/5JX
M>K[2G*S7WK[^Y++*TTEQ/*P4LP9L=$^4#^I_.M_PU;QW>JPW,UI+=6T!Q-%
MQ\PKM(#<<XR1T]*H:C9-*&:T42B0&)^,=#P?08_J*M:!IVM6&MJNGDIJ=M&T
ML<)8;I, $H.S$J<[>X!KIC2C2ARQ5DEHO0YYUI5I\]1MR;U\_P#/T.]M?"6F
MZS<27.C:M>6<R?ZV&:(K(N?4C:2.V>_J:UH/!.M(1GQ+<HHZ;))3^A>KOA?Q
MEIGB1%7<MOJ&,/ XPQ(ZA2>OTZC]3U0=0!R:XIUZT79_C9_C8]FGA:$US1Z]
MFU^%]#C+CP+<WT\#ZAK4MVD7RX> !BN>5W9S^>378P01VT,<,,82*-0JJ.@
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M''0Y[5PU:CESTX+6W2W4ZZ,8)PJ2:M?SZ6?]>9YY8&R_LY \Z"Z?+ELG<%!
MQGITSQ[+6A&;8<,-O."1)G.63!Z<\%C^!KFVB>POF@GA>*97PP((/KT_*MA+
MJW>2-I?*1=B[AY9QN(_B(Y R!G )QTKY2I'WK2BD]%^A]GB*3OS1;:>O]6-
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M1T?_ ) ]E_U[Q_\ H(J\*'NQ4_@CZ+\D.HHHI&@4444 %)CWI:* $Q2XHHH
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ML\.IN2F]'TU\SII8B5)QE!*\7>_]?/[]#PRWF:WE:)T:.5<JZGC#=#5W[0@
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M[&F+K\#R1(B2'?*8V8@ )\A?)/3H/7UZ8-'L];VU0O:PMN:V *!UK,37;65
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M!+G';MBNC'-,$48P B#  & .W2I!4MI[*QI3C*.[N+5+6/\ D"7_ /U[2?\
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M%=_]!.;_ +]1_P#Q-%D%WV+M%4OL5W_T$YO^_4?_ ,31]BN_^@G-_P!^H_\
MXFBR"[[%VBJ7V*[_ .@G-_WZC_\ B:/L5W_T$YO^_4?_ ,319!=]B[15+[%=
M_P#03F_[]1__ !-'V*[_ .@G-_WZC_\ B:+(+OL7:*I?8KO_ *"<W_?J/_XF
MC[%=_P#03F_[]1__ !-%D%WV+M%4OL5W_P!!.;_OU'_\31]BN_\ H)S?]^H_
M_B:+(+OL7:*I?8KO_H)S?]^H_P#XFC[%=_\ 03F_[]1__$T607?8NT52^Q7?
M_03F_P"_4?\ \31]BN_^@G-_WZC_ /B:+(.9]B[15+[%=_\ 03F_[]1__$T?
M8KO_ *"<W_?J/_XFBR"[[%VBJ7V*[_Z"<W_?J/\ ^)H^Q7?_ $$YO^_4?_Q-
M%D%WV+M%4OL5W_T$YO\ OU'_ /$T?8KO_H)S?]^H_P#XFBR"[[%VBJ7V*[_Z
M"<W_ 'ZC_P#B:/L5W_T$YO\ OU'_ /$T607?8NT52^Q7?_03F_[]1_\ Q-'V
M*[_Z"<W_ 'ZC_P#B:+(+OL7:*I?8KO\ Z"<W_?J/_P")H^Q7?_03F_[]1_\
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M*[_Z"<W_ 'ZC_P#B:/L5W_T$YO\ OU'_ /$T607?8NT52^Q7?_03F_[]1_\
MQ-'V*[_Z"<W_ 'ZC_P#B:+(+OL7:I:O_ ,@6_P#^O>3_ -!-'V*[_P"@G-_W
AZC_^)J.?3+FXMY8'U.;9(A1OW<?0C!_AIJUR97::L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tm238578d1_ex99-2img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $\ N0# 2(  A$! Q$!_\0
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M6+XQ_P"@O#_X I_C1_PL7QC_ -!>'_P!3_&N8HH]G#L@]I/N=/\ \+%\8_\
M07A_\ 4_QH_X6+XQ_P"@O#_X I_C7,44>SAV0>TGW.G_ .%B^,?^@O#_ . *
M?XT?\+%\8_\ 07A_\ 4_QKF**/9P[(/:3[G3_P#"Q?&/_07A_P# %/\ &C_A
M8OC'_H+P_P#@"G^-<Q11[.'9![2?<Z?_ (6+XQ_Z"\/_ ( I_C1_PL7QC_T%
MX?\ P!3_ !KF**/9P[(/:3[G3_\ "Q?&/_07A_\  %/\:/\ A8OC'_H+P_\
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M_A8OC'_H+P_^ *?XT?\ "Q?&/_07A_\  %/\:YBBCV<.R#VD^YT__"Q?&/\
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M*]?R/^)G)Q_TS3_"B\@]TQE((X(-%.>1I9&=R6=V+,?4TE4)L****!!1110
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M!_*DR,XR/Q.*!"T44=\?G[46&%% ^8X7D^@YI,^X'UXIV8"T4F1@GDX]!FE
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M*\)G69T8=#N7MCM51JQ;LA2I22NSFMP]:=[5V]U;Q2>$=2M9M @M+RRABE7
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MF[$3<6ER]SZ?M_\ CVB_W!_*BBW_ ./:+_<'\J*\Y[GIK8^8OB'_ ,E"UO\
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M^Q/UW#?SHZ[R(?\ GC'_ -\BCR(?^>*?]\BN0/Q"ME/.EW?YK_C36^(UJ/\
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MXKU+[5<1PEK>';O;&<;JL-K>EY_Y"%O_ -]ULMCA4HIN[ZO\_4NGDTTBJ?\
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M^Z.>OO2Y-.% #/*0#&!CTI?+7TIU% #&AC8$%00>H(H\F/*G8N5^Z<#(I]%
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MFU<?7G/]* )!TI:!THH **** "BBB@ J.5F7;M&3FI*CEWY79Z\T /%+110
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M#<![BG17$<R!X94D0\!D8$?SK@ULK*?7V:31YUEMH9$9T@(>\8H-^Z3J1Q@
MGFK7A*U^S3:F4M);6RFU!)+;9#Y(<^2JL#&.%5=H'N0319"4GL=IY@+E0P+#
MJO&12&5 VTR(&]">?;BN*U2QU%_$MR]H+F"*XEMD>># 8Q\[N<'':L,V.MW<
M5H^H17TC0F LP1=[$22<MQR<;?:J4+DN;70]26170,C!E/(8<@T1R+(@9&#
M]".17F_F:_'+HD*17\9C%NT^U0(YD9\."H& 0,9Z?SK1@M]1L? 6G011W5N4
MD_TA;=?WRQ[V^Z/7I0XV!3;Z'<YQ]*"QZ<9KS]WUUM1M/+DU; \G[,KHH#IN
M_>&;CKMY[54AM_$ZV\,S7FJF4P^<R97&\3D!<8_N'IW_  H]FNX>T?8]*5PX
MRK!AGJ#3;C_CVD_W3_(UYM%%XAM;N_331?1R&6Y=T=!Y.P@;"GJV?>NC\,O?
M-I]Z;F2]DM\?N'O0!(?D^;. .,YI.%NHU._0O^#O^1*T3_KRB_\ 0111X.X\
M%:)_UY1?^@BBDQK8^=?B,1_PL36\_P#/8=?I6??>%M9T^*&=K)[BUN$$D5S:
M9FB8=_F /([YQBK_ ,1^?B)K?'/G#\>*Z6T?6W=M'TS7-+\.P011JMK9ID7$
MCH3M=R-Q? /4\5ZBG*,(V/,Y5*<KG*> A_Q7VB<?\O(YKZL'6OE/P%N_X6!H
MN[[_ -JP?KDYKZL[_C7+B_B1U832+'4445QG8%%%% !1110 AKF_!1QX5A/_
M $UE_P#1AKI#7-^"L_\ "*PX./WLO/\ P-J!$8TJ6^FE2Z3]T-2>:<N"/,C5
M#Y07U ^3_OFH+CP[/$&^SV=K/ UTTODO=-&"NP!/FVGON_/O27USJ=YJ-^MA
M-J*B*18;<PK%Y"L "S.6!)PQ.0/3'>I(/%%Y*DTHL$$;#-N&DP6RV &S_0<=
M*!DO_"/_ &UE^V6\=O&MN8HUAG9S$[$Y8-A?]G\NE(;#4V%G:O961L8HT$RQ
MW)0L^>21Y?(SR!D9)JO)XAU-;>=IX;2(""=HY(I6)#KA5.",8+-CGTS4L>N:
MA"B6K1VTEU&V)) YV%%C5F(P.6YQP,9- &A?V]_%JB7]C#;3L(C"RSS&/9DY
MW A6_+CZU2O=%U344837L2R)&%C"*I5VR"2002OIQ4<NNWK0>4_D122+&\;0
M.6*!CT;<.N 34L&L7X93MMFMUB,TY=V,B#L.!C/MZ4 )<>'FNWO+J:.+[:\J
MO&/,)4HH "MQT/S#I4NJ:->ZA%Y'VM'B#%UBD50$('R@;1R <=:C;Q!>.5B@
MM8&G=84VM*0%E?)8$@=%0;CWYJ*'Q%J+PL[V=JQ>,-"L3L=Q+8!.1P#U]: (
MW\/:A]FN,&*>6<QB53,4W@#YANVG!STX/ IUGH&H6ODK)#9W"[ "TLC-Y!#%
MCM&W+]0,Y%1MXCOY8[:X2."(QI))/%(QPP#;1MX)R><#]:WM,N)9[R_61F:-
M)5";@ 5R@)7\#0!A_P#"/7<4%N$@LI9&CD$[RN1LD=MS2#@[O3!Q]:AAT34K
MF.>1(8HG*R[+B21A*Q*E%W+CA0.>IS@5VI&1TH QR>M ''W7ANZ1)$LHH##Y
MT06$3F+Y$B(&6"MR&).,<C'-4/[+NQ>6^E&S,NW[.)+ED?$:I\S;6P5()_V@
M<Y^7H:]!Q32,F@#F_#^B7>GW<D]VJA^5WBX>0R9.2V" %^G/UJG'X8O#?V[S
MM ULLLGFJKG=Y0=)(D Q_?7<WL2.<UV"J  ,4N!Z"@#D(/#EZTD?VR.TE!$;
MS2>8278%V88V]"S9Z_A6]HEF]AID%M($#IN+;#D DD\=/6M+ ]*  .@H ***
M* "BBB@ /2F'O3C24 <Y%_R-FI<C_CW@ZG_>J\<#C(_.N>O=/LK[QGJ2WEE:
MW02U@*BX@64+RV<;@<5:3P_HA_Y@>E_^ $7_ ,36O,CE5.5VU;=]^YK' _B7
M\_\ Z]-R/[R_G_\ 7JDOAW0^^AZ7_P" ,7^%2KX;T'_H!:7_ . 4?^%+G0>Q
MEY?B2Y'JOY__ %Z;D?WE_P"^A_C0/#&@$_\ (!TK_P  H_\ "G+X6\/_ /0!
MTO\ \ H_\*?.A>QGY?B1G']Y?^^A_C33CU7_ +Z'^-6/^$5\/_\ 0!TO_P
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MR'L!1110 AJ,!O.8D_)M7 ]^<_TJ0U&JGSW8G@JH ].M $O:BD'2EH ****
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MHJY8N0HQDGJ?J:ACTRRA=VBM+>,NXD;;&!N8=">.OO5H')IU(93.FV91D-K
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MZE>AS559CO7/2FP;?)3R_N]J?G .?2FPE3"I087M6)Z!)1110 4444 %%%%
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MYN(-._X1FX?2Y+4.^N"[DRGR9,F_.P 'C;BN^HO<@>?!^_(X_P  X'C_ $0
M''VD  GZU]52 E6"G!['TKY5\!?\C_HH'(%T,'U_SBOJSO\ C6.+^*)OA?AD
MCS"+1?$2WM_<C39X1(0QCCD0+(5DS\OSDDE>[$>G%)/X=U^ZE:_BL)H-0DM-
M2BBD>==T+22(T0)#'&5#@$9VD_C7J.!Z"C'M7/SLZ/9^9YG)X>UOR\Z993V4
M2_:?LL4TRE[=6C48)#'&Y@<8)QG/%9FKVTNEVB->VD]MIKR3-:Z:]X@F1_*
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M"1T.:D==:EM2%FU&,118B_OR,SX0L<?PJ,M]>:[,#T%'X4 <;)-JQGN9H6U
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MI>HM_P S!<#_ +<X/_B:=_8^HG_F8KC_ , X/_B*TUZU*G?BCF97LH^?WO\
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MH5G3P09_U$7X1BM:;UK-GZDUM!,\ZO%+I^",F>W@Y_<1?]^UK/FAA_YX1?\
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MU%':B@ HHHH **** "HI6"E3C/.*EJ*5BNTA<Y.* )!2T@I: "BBB@ HHHH
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M9UC_ ,^5O_WZ%']G6/\ SY6__?H460797_X270O^@UIO_@6G^-'_  DNA?\
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M;_\ ?L?X4ATZQS_QYV__ '[%%D*[*H\2:#WUO3?_  *3_&E_X230?^@YIO\
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M .!:?XU8_LZQ_P"?*W_[]"C^SK'_ )\K?_OT*+(+LK?\))H7;6]-_P# I/\
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K'_/,?X4:!J9W@[!\%Z)R/^/*+_T$45L1JL<:HBA44850,  =J*5Q\I__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tm238578d1_ex99-2img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'D R # 2(  A$! Q$!_\0
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M&E_^.T?\+9\5_P#/'1O_  &E_P#CM<511[&GV#VU3N=K_P +9\5_\\=&_P#
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M2_\ QVC_ (6SXK_YXZ-_X#2__':XJBCV-/L'MJG<[7_A;/BO_GCHW_@-+_\
M':/^%L^*_P#GCHW_ (#2_P#QVN*HH]C3[![:IW.U_P"%L^*_^>.C?^ TO_QV
MC_A;/BO_ )XZ-_X#2_\ QVN*HH]C3[![:IW.U_X6SXK_ .>.C?\ @-+_ /':
M/^%L^*_^>.C?^ TO_P =KBJ*/8T^P>VJ=SM?^%L^*_\ GCHW_@-+_P#':/\
MA;/BO_GCHW_@-+_\=KBJ*/8T^P>VJ=SM?^%L^*_^>.C?^ TO_P =H_X6SXK_
M .>.C?\ @-+_ /':XJBCV-/L'MJG<[7_ (6SXK_YXZ-_X#2__':/^%L^*_\
MGCHW_@-+_P#':XJBCV-/L'MJG<[7_A;/BO\ YXZ-_P" TO\ \=H_X6SXK_YX
MZ-_X#2__ !VN*HH]C3[![:IW.U_X6SXK_P">.C?^ TO_ ,=H_P"%L^*_^>.C
M?^ TO_QVN*HH]C3[![:IW.U_X6SXK_YXZ-_X#2__ !VC_A;/BO\ YXZ-_P"
MTO\ \=KBJ*/8T^P>VJ=SM?\ A;/BO_GCHW_@-+_\=H_X6SXK_P">.C?^ TO_
M ,=KBJ*/8T^P>VJ=SLA\7?%9E,?DZ+PH.?LLO_QVG_\ "V?%?_/'1O\ P%E_
M^.UPB_\ 'V_^XO\ ,U-1[&GV#VU3N=K_ ,+9\5_\\=&_\!I?_CM'_"V?%?\
MSQT;_P !I?\ X[7%44>QI]@]M4[G:_\ "V?%?_/'1O\ P&E_^.T?\+9\5_\
M/'1O_ :7_P".UQ5%'L:?8/;5.YVO_"V?%?\ SQT;_P !I?\ X[1_PMGQ7_SQ
MT;_P&E_^.UQ5%'L:?8/;5.YVO_"V?%?_ #QT;_P&E_\ CM'_  MGQ7_SQT;_
M ,!I?_CM<511[&GV#VU3N=K_ ,+9\5_\\=&_\!I?_CM!^+/BO/\ J=&_\!9?
M_CM<52G[QH]C3[![:IW.T_X6SXK_ .>.C?\ @-+_ /':/^%L^*_^>.C?^ TO
M_P =KBJ*/8T^P>VJ=SM?^%L^*_\ GCHW_@-+_P#':/\ A;/BO_GCHW_@-+_\
M=KBJ*/8T^P>VJ=SM?^%L^*_^>.C?^ TO_P =H_X6SXK_ .>.C?\ @-+_ /':
MXJBCV-/L'MJG<[7_ (6SXK_YXZ-_X#2__':/^%L^*_\ GCHW_@-+_P#':XJB
MCV-/L'MJG<[7_A;/BO\ YXZ-_P" TO\ \=IR_%?Q65=O*T8;1G_CUEYY _YZ
M^]<13X_]7-_NC_T(4>QI]@]M4[G9?\+9\5_\\=&_\!I?_CM'_"V?%?\ SQT;
M_P !I?\ X[7$]J6CV-/L'MJG<[7_ (6SXK_YXZ-_X#2__':/^%L^*_\ GCHW
M_@-+_P#':XJBCV-/L'MJG<[7_A;/BO\ YXZ-_P" TO\ \=H_X6SXK_YXZ-_X
M#2__ !VN*HH]C3[![:IW.U_X6SXK_P">.C?^ TO_ ,=H_P"%L^*_^>.C?^ T
MO_QVN*HH]C3[![:IW.U_X6SXK_YXZ-_X#2__ !VC_A;/BO\ YXZ-_P" TO\
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MUJS%&U14OG_],H?^_8I//_Z90_\ ?L5D;71'14GG_P#3*'_OV*//_P"F4/\
MW[% 71'14GG_ /3*'_OV*//_ .F4/_?L4!=$=%2>?_TRA_[]BCS_ /IE#_W[
M% 71'Q4*_P#'W)_N+_,U;\\_\\H?^_8J!9C]LD/EQ?<7C8,=33#0=14GG_\
M3*'_ +]BCS_^F4/_ '[%(+HCHJ3S_P#IE#_W[%'G_P#3*'_OV* NB.BI//\
M^F4/_?L4>?\ ],H?^_8H"Z(Z*D\__IE#_P!^Q1Y__3*'_OV* NB.BI//_P"F
M4/\ W[%'G_\ 3*'_ +]B@+HCHJ3S_P#IE#_W[%'G_P#3*'_OV* NB.BI//\
M^F4/_?L4>?\ ],H?^_8H"Z(Z*D\__IE#_P!^Q1Y__3*'_OV* NB.BI//_P"F
M4/\ W[%'G_\ 3*'_ +]B@+HCHJ3S_P#IE#_W[%'G_P#3*'_OV* NB.BI//\
M^F4/_?L4>?\ ],H?^_8H"Z(Z*D\__IE#_P!^Q1Y__3*'_OV* NB.BI//_P"F
M4/\ W[%'G_\ 3*'_ +]B@+HCHJ3S_P#IE#_W[%'G_P#3*'_OV* NB.BI//\
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MA_[]B@+HCHJ3S_\ IE#_ -^Q1Y__ $RA_P"_8H"Z(Z*D\_\ Z90_]^Q1Y_\
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MQ6C_ &S)_P! _3/_  $6C^V9/^@?IG_@(M%Y=@LNYG<4<5H_VS)_T#],_P#
M1:/[9D_Z!^F?^ BT7EV"R[F=Q7J?P=^YK'^]%_[-7GO]LO\ ] _3/_ 1:]+^
M%%XUVFJ[H+:+:8_]1$$S][KCK6%=OD>AK12YUJ<3\;?^1YM?^P;%_P"C9:\Y
MKT;XV_\ (\VO_8-B_P#1LM><UT4/X:,,1_%84J??7_>'\Z2E3[Z_[P_G6K,.
MIOT445F;A1110 4444 %%%% !4*_\?<G^XO\S4U0K_Q]R?[B_P S0!-1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!"O\ Q]O_ -<U_F:FJ%?^/M_^N:_S-34 %%%% !11
M10 4444 %%%% !2G[QIIZ4IZF@ HHHH **** "BBB@ HHHH *?'_ *N;_='_
M *$*93X_]7-_NC_T(4 1]J6D'2EH **** "BBB@ HHHH **** '/]R+_ '/Z
MFFTY_N1?[G]33: "BBB@ HHHH **** "BBB@!5^\/Q_E24J_>'X_RI* "BBB
M@ HHHH **** "BBB@ KU/X._<U?ZQ?\ LU>65ZG\'?N:Q]8OY-6%?^&S:A_$
M1R7QM_Y'FU_[!L7_ *-EKSFO1OC;_P CS:_]@V+_ -&RUYS6V'_AHQQ'\1A2
MI]]?]X?SI*5/OK_O#^=:LP1O]Z/QHKIO ]KIUSJEZ=5MDN+:*U+E6_A^=!D?
M0$UC*7*KG3&/,[',_C1^->@7?A"&U\-#3A;QG6VO8T\YNH225T0?0A,_0UC+
MX0ANYA'I>J?:"EZME<>; 8]C'/S+R=R\'T/%9JM%ENE);',?C2?C77MH&ESZ
M+:I97$LSR:HUNUS]E/F*HCR5" G/(R/KSBI(_"UM87$WFLUS%-I-S<Q"9 KQ
MNG R%9AD'GK1[:(>RD<;1^-=K/H.E1Z;J]Q='9+;V-I+$;>$@*9 .<%^23P?
MQ/M65JGAD:7:7UT]YO@C>%;5Q'@7(D7?GKQA>O6FJL6)TVCG_P :A7_C[D_W
M%_F:E%1+_P ?<G^XO\S6IF34444 %%%% !1110 4444 %'XT&N\T+3]._P"$
M=TBZN;/2&2:>5;N:^F\M]BL/N<C) )]>U1.?*KEQCS,X/\:*Z9O#=A<V\5S9
MZA)F_O9+:Q@:'.X!P 6;/ P0>F:</"$5Y*(M+U,W)2]6RN/-@\O8S9^9>3N7
M@^AXJ?:Q'[.1R]%=K:>%]+U&PM+6RO'>2?57MFNWM]K*%B+%=N[D$C/7O^%9
M.G>&#J-OILJW@07;W D)3B)(0"6Z\Y!Z<4>UB#I2,#\:/QKJ=(T?P_='4G_M
M"XN88M.>X4_9RCQ," 21NP2,C !(.?:LC2[>(V.K7D\2R+!;;(]PX$KL%4_4
M#<?PIJHG<'!HS?QHKL/#-A;R^%[J\-GI<URMZD0?49-B!"F2 <CG/]:BU71=
M"?\ M75+74#!I]O<K!"D41E#N8]Q"DD<;@>?2E[57:#V;M<Y2C\:Z:Z\(+ +
MRUBU R:I90)/<6YAVH VWA7SR1N'8>U.NO"5K!#J?E:J\MQIDL,-PAM]JEI'
M"_*V[D#GJ.U'M8A[.1R_XT?C74OX4L1K5WIT>I7<QM#MF:*SZ-NQC)<*!CDD
MD>V:F'@F&*>2*[U5T(U,::GEV^[>Y0,K<L,#DY^G>CVT0]E(Y#\:*VM7T&#3
MM/6[M[YKD+=R6DH:'9B1 "2O)R.>O%8M:1DI*Z(::=F%%%%,04444 %%%% !
M1110!"/^/M_]Q?YFIJA'_'V_^XO\S4M "T5VEK!I,2>&;*XT:"<ZI$HFG#.L
MH9I"@(P<<<=NU0+X42<V5FMQ!$SW=W#YQ7YW$1&!RP!)[#CJ:R]JNIJZ3Z')
M?E1^5=)+X3%O?7B7-W-!:6=NL\TLMJPD7<=H4)GDY[@X]ZBA\/V+0W5[+K2+
MIL,R0)<I;LQD=ANQMX(P.OZ9H]I$GV<C _*C\JZG_A";LW?V5;J-Y4OOLL^U
M>(D*;UD//W2H)[=*1/!CRZ4+V.\),D4D\ ,#!&1"<;GSA68#('-'M8]P]G(Y
M?\J/QKIV\)6_F16B:N'U":S^UQV_V<X(\O>%W9QDX-8^J:;_ &6UI&\V^::V
M2>1 N/*WC(7W.,'\:I3BW9 X22NR@:#U/UHH/4U9 ?C172^#]/@OO[6:6TMK
MJ2"T\R%+I]D>[<!R<C'!]:NWV@:5?WY\BZM;#[+I_P!IOA;,9XD<, 0ISUP0
M< GFLG52E9FBIMJZ.-_&CI74'P8QTHWL=ZS;X'N80;<A'C4G +YPKD#(7GTS
M56]T"TTUHH;G4T.HCR7DM#"P!#X.T/T) //2CVD0]G(P*7\:[B]\+075[):6
MH@MDEUV2RC<(Q9%$>X#[V"OMC.>]4].\,6[WVF2P7D5[;W4D\+":!D"O&A)X
MW9([@YH]K&UQ^RE<Y/%%;,^AVMGI4$]WJ:PWES:BZAMC"Q#(20HWCHQP>WU-
M:/\ PB*06MI?FYDFC^TV\<T4MLT099"/NDG)'49P/:AU(D^SD<K^-/C_ -7-
M_NC_ -"%7-=MXK7Q#J5O @2&*ZD1%'\*AB *IQ_ZN;_='_H0J[W5R;69'V%+
M2#I2U0@I*]&CT?1HM/TQ[ZRTZ.RGTQ9KBZ>X*7 D*MRB[N>0.W<UDR^&K*]T
MO2OL]PMO?R:4UVT7E$B9E+%B6S\I(&!QVK!5HFSI.VAR%'Y5T?\ PB>[P^^J
M)>N#'''*ZS6[1IM=@ORL3SC/)QBK-[X%GM[ZQM(;MY&NYA$)'MRL1&,[U<$A
MA@'C@^U5[6'<CV<CD_RH_&MG7M .C1V\R3O+%.74>;"875E/.5)/!R"#WJS<
MV6E?\(+'>V<<K7@OEAFGEP"<QEBJ@?P@_B<9JN=6374.1W:9SM%%%60.?[L7
M^Y_4TVG.?EB_W/ZFFT 'XT?C6]X-L;;4?%-K:W<*30LLA,;G )",1G\1726F
MD:-=ZIHMO=6>G17LTTHFMK*X,L9B$9*LV"<'</6LI5%%V-(TW)7//:*Z%?"\
M,ITR2VU!Y[6^$H#I:.7#1]0$!).>,'CWQ5U? Y;5GLQ?,P%I'=1JD(\YU8D8
M"%@,C!SS1[6/</9R.1_&C\:ZJS\%2W3W1DNY8XHKH6B,+1RQ8C.YU."B@$9)
M]:Q[*&.RUUK:\L3?O&[Q+;HQQ))T7IR1GG ZT_:)WL+D:W,VBMOQ3;65IJD4
M-K%%#,L"?:X8'+1QS<[E4DGH,9Y/-8E5%W5R6K.P+][_ #Z44J_>'X_RI*H0
M4E+7:^'=+M)?#-M>/I^FW$CW[Q327UP8ML853\IW#GD^M1.?*KLJ,7)V.*H_
M&NV?P_H%Y9$6EV8(Y=9>UMKCRS(74JNU>H^4$GGTJCI_@Q[X7$9NY$N(I)HP
M!;,8LQYR#(2!DXX S4JK'<ITI(Y?_/2BNCF\*/'X<BU9+EYO,B60"*#?&"V/
MD+@G:PSSN 'O2ZYX0ET6PFN&NC(]O(D<ZM"R+EAUC8_? /!XIJI$7LY'-T?C
M73^&+?3-4MI].EL(I+SR99%D:5O.D8*2BQ 87C!)SUKEUZ"J4KMH3C9)BUZG
M\'?N:Q_O1?R:O+*]3^#OW-8_WHOY-65?X&:4/XB.2^-O_(\VO_8-B_\ 1LM>
M<UZ-\;?^1YM?^P;%_P"C9:\YK;#_ ,-&&(_B,*5/OK_O#^=)2I]]?]X?SK5F
M*-^K%I?7%DERMNX47,)@ER,Y0D'\.@JO1635]S>]MC8O/%.L7LDLDUT"\KQ.
MS*H!#1YV$8Z8R:6Z\5:M=/$YGBA:.<7&8(ECWRC^-L#YC]?4UC45/)'L5SR[
MF[_PF&L"2)XY+:+RI6F58K=%7<RE6) '.03G-02>)=2D"@&WC5+>2U1(H%15
MCDY90!6311R1[#YY=S5'B34B+E6>)TN;=+:56B4@H@PO![CUJ?7M<BU#3]+T
MRT-PUII\157N,;W8GJ0.,   >U8=%'(KW%SRM:X5"O\ Q]R?[B_S-35"O_'W
M)_N+_,U9)-1110 4444 %%%% !1110 58FO[B>PMK&1U-O;,[1+CD%L%N>_2
MJ]%*P79;_M.\%I:6RS;4M)6E@*@!D=B"3GZ@5=NO%.K7;1,9XHFCG%SF"%8]
MTHZ.V!\Q^M8]%)Q3W17,T;<GBW5WD@=9+>$P7'VE!# J 28(+' YSDYS3&\4
MZJ9[2:.2&$VCN\*PP*BJ7^^, 8(.._K6/12Y(]@YY=S9_P"$JU077G!K8*(&
MMA MNHB$;')&SIR>:S$NYDL9;-640RR+(XQR2H('/I\QXJ&BFHI;"YFRR-0N
M%TM]-#K]E>83LN.=X& <_2FB]N!ICZ<&7[,\PG9=HSO"E0<_0U!13L@NS6N/
M$VJ75FUK-+'M=%CDD6)5ED1<85G R1P*V]6\8V]UH]U;6WVIY[MX&=[B.(;/
M+;=DL@!<D@<D=!7'45#IQ?0I3DC53Q'J*3W\S&WE-^XDN$EA5T9@<@@$8!!/
M%/E\4:M-()))XRXO%OL^6/\ 7!=H;\ATK'HJN2/87/+N7+C5+NZM6MIG4Q-<
MO=$!0/WC#!/_ -:J=%%-*PFV]PHHHIB"BBB@ HHHH **** (1_Q]O_US'\S4
MM1#_ (^W_P!Q?YFIJ -NV\6:G:6MM#"MGNM8S'!,UNK2QC.>&/3K5:#7KZWA
MMX@898[=I'59H@X8R8W;L]<X_"LVBHY(]BN>7<V?^$JU+[3YI%JT7V<6WV9H
M08C$#G:5/OSGK2IXJU(37+R+9S)<,C/!+;JT0*#"E5Z# K%HH]G'L'/+N:L7
MB75H9M2F6ZS)J*%+EBH.X'T]#C(IJ:_>IIB6!2UD2.-HHY9(%:2-&.2JL>G-
M9E%/DCV#FEW-O3M;4^(K/4]3FF7[(L80VR*6(CP%4Y(X(&":S]6U"35M8N]0
ME&UIY"X7.=H[#\  *J44**3N@<FU80TIZF@TIZFJ)+%KJ%Q96]Y!"4"7<7DR
MY&<KD'CTZ4EI?W%C'=QP% MU"8)<C.4)!X]#D57HI<J'=FF/$%Z=,6P=+:1$
MB:".62!6E2,G)4,>@J6;Q/J4]F+=_LV=L:/.(%\UU0Y4,_4@8%8]%3R1[#YY
M=S:'BS51.)Q)#Y@O6OQ^[X\XKM)^F.U0V?B+4;%+98'B MY9)H]R X:1=K9]
M>*RZ*.2/8.>7<U5\1Z@NF"Q_T=E6$VZ3-"IE2(G)0/U J>Y\7:I=B7S!:[I9
M(I976$!G>,C:Q/KQBL.BCV<>P<\NY-=W4M]>SW<Y!EGD:1R!@;B<GBF1_P"K
MF_W1_P"A"F4^/_5R_P"Z/_0A5;+01'VI:0=*6F(M7VHW&HBU%R4(M8%MXMJX
MPBYQGU/)YJU'XAU"*2V=7BS;VK6D>4_Y9MG(/OR>:RZ*GE5K6*YGN;,GBG4I
M;1[=A;8DAC@DD$(WNJ8VY/M@4K^+-4_=>0;:V\N<7/\ H\"IOD P&8=#].!S
M6+12]G'L/VDNY=U'5)=2\L20VL*QYVI;PK&,DY)..IJ/^T+@:2=,W+]E,XN,
M8YW[=O7TQ5:BGRI*Q-WN%%%%4(<^-D7^Y_4TVG./DB_W/ZFFT 6M-U*XTF^2
M\M&43(&4%ER,,I!X^A-)I>H7&CW\5[:%%GBSL++N R".GT)JM12:3'=FM9>)
M-1L+>WMX6A,$"RHJ21A@RR8WAO4'%.;Q-?22J\L%C(JPK L;6Z[0BDE<#L1G
MJ,5CT5/)'L/GEW-S_A+M5>>YEN#;7/GRK,4G@5U20#:&4'H0 !]*I:7K-YI&
MJ?VC:&+[3\V&>,$#/4@=JH44^2/8.:7<MZCJ,FISK-+#:Q,%VXMX1&#R3D@=
M^>M5***:22LA-WU8J_>'X_RI*5?O#\?Y4E,059>_N'TN+36*FVBF:=1MYW$
M'GZ 56HI-7'<O6^LWEK:VUM$R".WNA=Q@KDB0 #/N..E7XO&&JQ%&Q:M(CRN
MDCP LGFDEP#V!R:PJ*EPB]T-2DNIJKXBODT][.-;:,/"+=YHX565XQV+#K]>
MOO3=1U^\U6%DNH[3>[!I9D@59)2!@%F')K,HHY(]@YY=S7L/$NI:;9+;6Q@
MCW^3*T0:2'>,-L;JN:QQ@4M%4HI.Z$VV%>I_!W[FL?6+^35Y97J?P=^YK'^]
M%_)JQK_ S6A_$1R7QM_Y'FU_[!L7_HV6O.*]'^-G_(]VO_8,B_\ 1LM><9K:
MA_#1CB/XK"G)]]?]X?SIN:<GWU_WA_.M68(W\T44F?>LS86BDS[T9]Z N+12
M9]Z,^] 7%HI,^]&?>@+BU"O_ !]R?[B_S-2YJ)?^/N3_ '%_F:!DV:,TF11D
M4 +FC-)D49% "YHS29%&10 N:,TF11D4 +FC-)D49% "YHS29%&10 N:,TF1
M1D4 +FC-)D49% "YHS29%&10 N:,TF11D4 +FC-)D49% "YHS29%&10 N:,T
MF11D4 +FC-)D49% "YHS29%&10 N:*3(HR* (A_Q]O\ [B_S-35"#_I;_P"X
M/YFI: %HHI,T"N+129I<T!<***,T#"BDS10 M!ZFD-*3S0%PHI,^]&?>@5Q:
M*3/O1GWH"XM%)GWHS[T!<6BDS[T9]Z N+3X_]7-_NC_T(5'GWJ2/_5S?[H_]
M"%#&1]J6D[49]Z!7%HI,^]&?>@+BT4F?>C/O0%Q:*3/O1GWH"XM%)GWHH&/<
M_+%_N?U--IS_ '(_]S^IIF?>@!:*3/O1GWH%<6BDS[T9]Z N+129]Z,^] 7%
MHI,^]&: N.7[P_'^5)2K]X4W/O0,6BDS[T9]Z!7%HI,^]&?>@+BT4F?>C/O0
M%Q:*3/O1GWH"XM>I_!W[FL?[T7\FKRO/O7JGP<^YJ_UB_DU88CX&;T/XB./^
M-Y/_  G=K_V#(O\ T;+7F^3ZUZ1\;_\ D>K7_L&1_P#HV6O-ZUH_PT*M_$89
M-7-)19]:L(9!NCDN8E8>H+@$53J]HG_(?TW_ *^XO_0Q6CV,XI7/I?\ X5_X
M6_Z \/\ WV_^-'_"O_"W_0'A_P"^W_QKI:*\;GEW/6Y(]CFO^%?^%O\ H#P_
M]]O_ (T?\*_\+?\ 0'A_[[?_ !KI:*.>7<.2/8YK_A7_ (6_Z \/_?;_ .-'
M_"O_  M_T!X?^^W_ ,:Z6BCGEW#DCV.:_P"%?^%O^@/#_P!]O_C1_P *_P#"
MW_0'A_[[?_&NEHHYY=PY(]CF?^%?^%O^@/%_WV_^-<U<>%M#M?%U[;1:; (1
M90.$8%@&+R GGZ#\J]+KB[__ )'B^_[!]M_Z'+6=6<N1ZFE&$?:)6*7_  C>
MB?\ 0+M?^^*/^$:T3_H%VO\ WQ4EWJ,T-_'9VUDUS(T1E.)53 ! []3S447B
M"QD@6=Y!%&R*V'^^&+,NW:,G(*-TST/I7!S5;7N_O/4Y:-[67W"_\(UHO_0+
MMO\ OBC_ (1K1?\ H%VW_?%3_P!LZ;YT,7VV+?,JM&,\$-T.>@SVSUI+?6=-
MNV58+V)RSB-0">6()&/J <'H<4N>KW?XE>SH]E^!#_PC6B_] NV_[XH_X1K1
M?^@7;?\ ?%3C6-.,T<(O(O,D.%&>^2O7MD@@9ZD<4R'7-+N$E>&]B=84,DA&
M<*HZGIT%'-5[O\1<E'LOP(_^$:T7_H%VW_?%'_"-:+_T"[;_ +XJS=ZK8V.S
M[5<I%O&Y=V>GJ?0<CD\4T:QIQNI+7[9$)H]V]2<;=O+9/3@<_2CGJ]W^(_9T
M>R_ @_X1K1/^@7;?]\4?\(UHG_0+MO\ OBG6FN6M^;W[*3(EHJLSCC=E2V #
M]/UJ*UUWS3;&[M&M([F$S12M*K*5"AB"1]T[3GGT/I3O5[O[R>6CV7W#_P#A
M&M%_Z!=M_P!\4?\ "-:)_P! NU_[XJQ;ZM87140W4;,VX!>03@9/!'H0?IS4
M3Z[IP5O+NHY'$1E5%/WAMW  ],D<XZXYI<U7N_Q'R4>R_ 9_PC6B?] NU_[X
MH_X1K1?^@7;?]\4^'7-.E:*,W,:321+)Y3'E05W8)Z9QSCK2+K^DM;F=;Z(Q
MAE7//5@2N..<X.,=<&CFJ]W^(<E'LON0W_A&M%_Z!=M_WQ1_PC6B?] NU_[X
MJ2/7M*F21X[^%EC0.Q!Z*3@'WYP.._'6B37=+ABCEDOH523)4DGL<'/'&#P<
M].]'-5[O\0Y*/9?@1_\ "-:)_P! NV_[XH_X1K1/^@7;?]\4IURV:RU.ZC5W
M&GLZR+C&XJ,G!J-->CBN'AU"'[&RPK,"9 ZE2VT=.<Y[8YS3O6[O[Q<M&^R^
MX?\ \(UHG_0+M?\ OBC_ (1K1?\ H%VO_?%,NO$VDVEH;AKM7_=M*J("68+D
M'CMR".>A%68]:TV6Y^SK>1^=@G8<C&%W'.>AV\XZXI<U;N_Q#EH]E]R(?^$:
MT7_H%VW_ 'Q1_P (UHG_ $"[7_OBG_V]I7D>>;Z(1[PF><Y() QC/(!(]<5%
M/XCTR*,R+<I(JRI&Y7^'<VW=[C/IFCFJ]W^(.-'LOP'?\(UHG_0+M?\ OBC_
M (1K1/\ H%VW_?%._MW3P!(;F(0&,.)-WJQ7&.N<C'UXZU=MKJ"\@6>WD62)
MLX9?8X/ZTG.JMV_O&J=)[)?<4/\ A&M%_P"@7;?]\4?\(UHO_0+MO^^*U:*7
MM9_S/[R_8T_Y5]QE?\(UHO\ T"[;_OBC_A&M%_Z!=M_WQ6K11[6?\S^\/8T_
MY5]QE?\ "-:+_P! NV_[XH_X1K1?^@7;?]\5JT4>UG_,_O#V-/\ E7W&5_PC
M6B_] NV_[XH_X1K1?^@7:_\ ?%:M!Z4>UG_,_O#V-/\ E7W',VWA_2&\4WD+
M:;;&);.%E79P"7D!/Z"M@>&-")_Y!-I_W[J&T_Y&^^_Z\8/_ $.2ML=:].$Y
M<JUZ'C5(1YWIU,P>%]"_Z!-I_P!^Z>/"V@Y_Y!%I_P!^ZTUZU(.M7SR[D<L>
MQF+X5T#_ * ]I_W[J1?"?A_'_(&L_P#OW6FM2KTHYY=PY8]C-7PCX=(R=&L_
M^_=/'A#PY_T!;+_OW6LGW:E']*.>7<.6/8R!X.\-GKHEE_W[IP\&>&_^@)9?
M]^Q6RO:I1THYI=PY8]C!/@SPW@_\26R_[]U73P#X99 9-'@WD9;#,.>_>NE;
M[IIL2E844G)"@$^M'-+N'+'L<[_PK_PM_P! >'_OM_\ &C_A7_A;_H#P_P#?
M;_XUTM%'/+N')'L<U_PK_P +?] >'_OM_P#&C_A7_A;_ * \/_?;_P"-=+11
MSR[AR1['-?\ "O\ PM_T!X?^^W_QH_X5_P"%O^@/#_WV_P#C72T4<\NX<D>Q
MS7_"O_"W_0'A_P"^W_QH_P"%?^%O^@/#_P!]O_C72T4<\NX<D>QS7_"O_"W_
M $!X?^^W_P :0^ O#*X":1#M;AQN;D?GZXKIJCD4EHR#C#9/OP:.>7<.2/8Y
M[_A7_A8C_D#P_P#?;_XT?\*_\+?] >'_ +[?_&NE'2BCGEW#DCV.:_X5_P"%
MO^@/#_WV_P#C1_PK_P +?] >'_OM_P#&NEHHYY=PY(]CFO\ A7_A;_H#P_\
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M'I[9I-/T*Z"Z=<7MPAGMD@ 1(\ "-6X/)R<OUZ<<5T5%+VT[;A[&%]CGI_#
MFM;6(W6&MD(0[#@MYHD!(!!QQC@CKUIR>&]MK<1&>,/<6\T+F.,@ R$<\DDX
MVCJ>:WZ*/;3[C]C#L9!T9SIVJV9N%*7Q<J=G,>Y ISSST]J)M"@2R-OIR06)
M+HSM#'L\P*>AVD'!]C6O14^UE>Y7LHVL<Y;^%S#9WL#78)N;:2#<L9&W?([Y
MY)_OXQGMUJS<:";RW>*XN 3+/)-*T:;<[X3$0,DXZY[],5M44W6FW>Y/L(6M
M8P+/PZUO=07$D\+20RH^8XBNX*CKR69CGYR?0=J;;^&Y89E=KQ?+2:.411QE
M4)5]^2I8@,>GR@#OBNAHI^VGW#V,+6L<W>:#<I+]HM9E:5KA7 :/A1]H,I)Y
M&<;L5L:=9M9P.LDHDEDE>:1@NT%F.3@9.!5RDI2J2DK,<:<8NZ%HHHK(U"BB
MB@ HHHH *#12&@#,M/\ D;[[_KQA_P#0Y*VQUK#M/^1OOO\ KQA_]#DK<7[U
M>M3^!>G^9XE7XY>H]>M2#K4:]:D'6K,R1:E2HEJ5* )UZ5*/Z5$O2I1_2@"1
M>U2BHE[5** $;[IIL*A844'("@9]:<WW3380HA0*<K@8/J* 'T444 %%%% !
M1110 4444 %1R %XR3C#9 ]>#4E1R!2\9)Y#?+[G!H D'2B@=** "BBB@ HH
MHH **** "D/2EI#TH 9$ -^"#EB3[5)4<04;]IS\QS]:DH **** "BBB@ HH
MHH **** (IU#1$%MH/<U+4<X5HR'.%[G\:DH **** "BBB@ HHHH ****  ]
M*Y^/_DH,_P#V"HO_ $:]= >E<_'_ ,E!G_[!47_HUZ:ZDOH>._&__D>K7_L&
M1_\ HV6O-Z](^-__ "/5K_V#(_\ T;+7F]>M1_AH\VK\;"KVB<Z_IG_7W%_Z
M&*HU>T3_ )#^F_\ 7W%_Z&M:2V9$=SZ\HHHKQ#UPHHHH **** "BBB@ KB]0
M_P"1XOO^P?;_ /H<M=I7(7$/G>.M0^8C&GVW_H<U9U%>#-*+M43&F%#.LW.]
M5*@CT.,_R%-DM8'388U"[E<A1C)!R,_E6E]A_P!L_E1]A']\_E7G<DT>HYP*
M01538%4+_= X_*D$:*P(100, @<@>E7OL(_OG\J/L0_OG\J.20_:1*6T$@X&
M1WIJ11H241%)ZE5Q5_["/^>A_*C["/[Y_*CDD'M(E#R8^/W:<9Q\HJ*YLHKI
M55V=5&>$;&<]<UJ?81_?/Y4?81_?/Y4<DA<\"@(HUV[44%1M4@<@>E(T$;+@
M*%(! 90 5SZ'MU-:'V$?\]#^5'V$?\]#^5/EF/VD"C'&L42QH J*,*!V%/JW
M]A'_ #T/Y4?81_ST/Y4N20>TB5**M_81_?/Y4?81_?/Y4O9R'[6)4HJW]A']
M\_E1]A']\_E1[.0>UB5**M_81_?/Y4?81_?/Y4>SD'M8E2BK?V$?WS^5'V$?
MWS^5'LY![6)4HJW]A']\_E1]A']\_E1[.0>UB5**M_81_?/Y4?81_?/Y4_9R
M#VL2I15O["/[Y_*C["/[Y_*E[.0>UB5**M_81_?/Y4?81_?/Y4>SD'M8E2BK
M?V$?WS^5'V$?WS^5'LY![6)4HJW]A']\_E1]A'_/0_E1[.0>UB<_:_\ (WWW
M_7C#_P"C)*W!UK(CB\KQE>KG/^@0'_Q^2M<=:]2"M%7['D5'>;:[CUZU(.M1
MKUJ0=:H@D6I5Z5$M2I0!.G2I1_2HE^[4H_I0!(O:I142]JE% "-]TTV';Y*;
M?N[1CZ4YONFFPE3"A484J,#VH ?1110 4444 %%%% !1110 5')MWQYZ[OE^
MN#_]>I*CD*AXP1DEN/;@T 2#I10.E% !1110 453O/M_R_8C;#^]YV[],53A
MOK^/4(+2^A@'GJY22"0D97&000/7UIV,W42=FF;%%-&<TZD:!0>E%% $<6WY
M]N?O'/UJ2HXBIW[1C#'/UJ2@ HHHH **** "BBB@ HHHH CFV>6=_P!WOBI*
MBG*B,EAD>GXU(* %HHHH **** "BBB@ HHHH #TKGX_^2@S_ /8*B_\ 1KUT
M!Z5S\?\ R4&?_L%1?^C7IKJ2^AX[\;_^1ZM?^P9'_P"C9:\WKTCXW_\ (]6O
M_8,C_P#1LM>;UZU'^&CS:OQL*O:)_P C!IG_ %]Q?^ABJ-7M$_Y#^F_]?<7_
M *&*TELR([GUY1117B'KA1110 4444 %%%%  :Y5A_Q76H_]@^V_]#FKJJY9
MO^1[U(?]0^V_]#FJ9?"RH?$C3HJCJ6I+IEMY[VT\T8(#&+;\N2 /O$=20.,T
M^/48#+%!,1;74N2EM+(GF$#T )S^%<MCMNBW15(ZOIH.#J%H#G;S,O7&<=?2
MEEU6P@\\2W<"M!'YDJ>8-R+ZD=:+!=%RBL^YUJQM-+749I2+=T#H5&XMD9P
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ML!D^E2"@ HHHH **** "BBB@ HHHH #TKGX_^2@S_P#8*B_]&O70'I7/Q_\
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M(Y*'PI,B0H!96PCB6%_LX;,Z[E+;R?93^)ZU8E\.W4ULL#2VX6$NR$*<S%I
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MSD]NJBJNB_\ (P:9_P!?<7_H8J[WC<FUI6/KRBBBO&/5"BBB@ HHHH ****
M$/2N7;_D>M1_[!]M_P"AS5U!Z5R[?\CUJ7_8/MO_ $.:E+X65'XD:=%%%<AW
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '.-_R.MY_P!@^#_T.2M0=:RS_P CK>?]@^#_ -&2
M5J#K78MD<$MV/7K4@ZU&.M/% B5:E2HDJ5* )U/RU*/Z5$O2I1_2@"1>U2CI
M42]JE% "-]TTV)66)%8Y8* 33FY4TV%=L*+G.% SZT /HHHH **** "BBB@
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M$'W?O$@\?3G)I+CQ/*(+IX;,X2.7RF;=RR<9.5Q@GI@GMTS5R\T"*\OH)GD
MAB$8$7EC.$.0 WIG'!S[8R:M'1M.;SMUI&?/R).O.3DXYXR>>,<\T]!6D0WK
M7B:8G[UTN4CWS+;!6D? Y";\#KCDC^=2Z?=3/IL%S=F(H;9)6E0\,2N6.,<#
MI^M376G6MZ$%S LFS(&20<'J,CJ#W'>G_8[?RIHO*'ES B1<G!&,8]N!CBEH
M.S./CUC5HK:&::2ZCDN;:1T6X2/8SD#8(]O/!9?O=JV&\0M!%'+):[H9@RV[
M"0>9(RL$&5Q@!B1W.,\U?AT/3("#'9H"-N"221@@C!).!D X]A3AH^G#S?\
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M2_=J4?TKG/2)%[5**B7M4HH 1ONGUIL081('^]@9^M.;[IIL(*PH&.2% )H
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M5X%&!6?_ &_H_P#T%;'_ ,"$_P :/[>TC_H*V/\ X$)_C2LQW1H;11M%9_\
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M&C16=_;VD?\ 05L?_ A/\:/[>TC_ *"MC_X$)_C19A=&C16=_;VD?]!6Q_\
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M1HK._M[2/^@K8_\ @0G^-']O:1_T%;'_ ,"$_P :+,+HT:*SO[>TC_H*V/\
MX$)_C1_;VD?]!6Q_\"$_QHLPNC1HK._M[2/^@K8_^!"?XT?V]I'_ $%;'_P(
M3_&BS"Z-&HY%RT9SC!S]>#5+^WM(_P"@K8_^!"?XTQ]<T<LA.K6(P<C_ $A.
M>#[T[,+HU!THK._M[2/^@K8_^!"?XT?V]I'_ $%;'_P(3_&BS"Z-&BL[^WM(
M_P"@K8_^!"?XT?V]I'_05L?_  (3_&E9A=&C16=_;VD?]!6Q_P# A/\ &C^W
MM(_Z"MC_ .!"?XT6871HT5G?V]I'_05L?_ A/\:/[>TC_H*V/_@0G^-%F%T:
M-!Z5G?V]I'_05L?_  (3_&C^WM(_Z"MC_P"!"?XT[,+HNQ+MW\@Y8GZ5)67'
MKFC+OQJUB<L2?](3_&G_ -O:1_T%;'_P(3_&BS"Z-&BL[^WM(_Z"MC_X$)_C
M1_;VD?\ 05L?_ A/\:5F%T:-%9W]O:1_T%;'_P "$_QH_M[2/^@K8_\ @0G^
M-%F%T:-%9W]O:1_T%;'_ ,"$_P :/[>TC_H*V/\ X$)_C19A=&C16=_;VD?]
M!6Q_\"$_QH_M[2/^@K8_^!"?XT[,+HNSKOB*Y SW-/'2LR77-'>,J=6L0#W^
MT)_C3_[?TC_H*V/_ ($)_C19A=&C16=_;VD?]!6Q_P# A/\ &C^WM(_Z"MC_
M .!"?XTK,+HT:*SO[>TC_H*V/_@0G^-']O:1_P!!6Q_\"$_QHLPNC1HK._M[
M2/\ H*V/_@0G^-']O:1_T%;'_P "$_QHLPNC1HK._M[2/^@K8_\ @0G^-']O
M:1_T%;'_ ,"$_P :+,+HT3TKGX_^2@S_ /8*B_\ 1KU?_M[2/^@K8_\ @0G^
M-9-E>6UYX^N7M;B&=%TN(%HI P!\U^.*:6XFSR3XW_\ (]6O_8,C_P#1LM>;
MUZ1\;_\ D>K7_L&1_P#HV6N+\/V$&J:Q'8SPWLHF4JGV) \B-V;:>JCN,CCO
M7JTG:FF>=45ZC1EU=T8!M>TU6 *FZB!!&0?G%7=>\._V%(R_VMIE[B4Q[;2?
M<X]V7''3'7K5/1/^1@TS_K[B_P#0Q6ETXW1%K2LSZN_L?3/^@=9_]^%_PH_L
M;3/^@=9_]^%_PJ]17BW/6L4?[&TS_H'6?_?A?\*/[&TS_H'6?_?A?\*FN[^S
ML$5[RZ@MT8[5::0("?0$]Z=;7=O>0K-;7$4\3?=DB<,I]<$4]1:%?^QM,_Z!
MUG_WX7_"C^QM,_Z!UG_WX7_"KN1ZTQ)8Y<F-U8!BIVG."."/K2N!5_L;3/\
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M^%_PJ]11<+%'^QM,_P"@=9_]^%_PH_L;3/\ H'6?_?A?\*O447"Q1_L;3/\
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MO^%']CZ9_P! ZS_[\+_A5Z@T7"QG1Z/I1W;=.M/O<Y@7K^5/_L;3/^@=9_\
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M5ZBBX6*/]C:9_P! ZS_[\+_A1_8VF?\ 0.L_^_"_X5>HHN%BB=&TS_H'6?\
MWX7_  K(M+:"U\?7"6\$4*G2XR1&@4$^:_I72GI7/Q_\E!G_ .P5%_Z->A=2
M6MCQWXW_ /(]6O\ V#(__1LM<MX0M?M>K7,?^DN193LMO;2F-[DA<^6".>>N
M!UQBNI^-_P#R/5K_ -@R/_T;+7*>$;&.]UMC)'/,;:WENH[>W<I).Z#(16'(
MSUXYP#BO3A_!7H>?/^*R]KVEZ?!X5L[RWTBXTZY26*W9YRX-V?)#2L$<\;9
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M0=^M=VE<^)Y'+W=SMRV-:-+][MT)E^[4H_I42_=J4?TKF/3)%[5**B7M4HH
M1ONFFPD-"A P"H('I3FX4TV%MT*,1@E0<>E #Z*** "BBB@ HHHH **** "H
MY" \8(SEN/;@U)4<C$,@ SDX^G!H DHH'2B@ HHHH **** "BBB@ I#TI:*
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MN)4!B\HJJ(V!DD%2P)4Y/)'4 >E=!17E)VV/2:N<S/X0@N&G62]NC!(+@)"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "@T44 <1JMC:77CBY%Q:PS8TZ CS(PV#YDGK]*D&BZ4?\ F&67
M_?A?\*?>_P#(\77_ &#H/_1DM6QUJFV9J$7NBHNB:5_T#++_ +\+_A3UT72@
M?^099<?],%_PJVM/'6ES,?)'LB5:E7I42U*O2D63K]VI1_2HE^[4H_I0!(O:
MI142]JE% "-]TTV(L8D+##$#(]Z<WW3CK38MWE+O^]@9^M #Z*** "BBB@ H
MHHH **** "F2%@R8Z$X/Y4^F2;MR;>F?F^F#_7% #QTHH'2B@ HHHH ****
M"BBB@ HHH- $<18[]W9B!QVJ2HXMWS[O[W'TJ2@ HHHH **** "BBB@ HHHH
M CF+",E!D]ABI*CFW^6=GWNU24 %%%% !1110 4444 %%%%  >E<_'_R4&?_
M +!47_HUZZ ]*Y^/_DH,_P#V"HO_ $:]-=27T/'?C?\ \CU:_P#8,C_]&RUR
M/A6:QAUEOMK6L9>WE2WDNTW0I,5PC./3/<CC@UUWQO\ ^1ZM?^P9'_Z-EKD_
M",JP^(H&?5ETM""K7!@\XX_NA<'D]N*]2'\%>AY\_P"*RQJ]K::9X7M=/EN=
M+N=16Z+QO8.)"D)4[A(XX.6Q@=1@UDZ)_P C!IG_ %]Q?^ABNP^(FIFY@M;.
M.]LI+>%\I$L#K</P?WDC-&@QUX48Y[XS7'Z)_P C!IG_ %]Q?^ABG!WA<4U:
M=CZ\HHI,BO)/3,C6=:.F7%I;10)-<7.\JKS")0J@9)8_4#'O3K76[=E1+QX;
M>Z<H/)6429WDA,$#G.T]/0^E5M7T2XU#5X;Z&YLU\J!H1'=69G'S,"6'SK@_
M*!41\-O+JEIJ$]W&7MXS L44'EQB-DPX W$@EL$'/ & .22]"-;FS<:C:6S2
MI-<1QM%&LKACRJDD _B015>WURQEAED-Q$JQR^62'SU<HOXDC&/7BJ+>&+8:
MC93Q2NEO;(08')?S2&WH69CG"L6./7'3%00^$8T>V\R\=HH;-8&14V[Y!O E
M)SU_>.0/4@]J-!^\;=GJMC?R,EK<)*RC<0O<9QD>HR#R.*NUAZ/HDFGSI/<W
M*3R16RVD.R+RU2-3GD9.6.!D]..!6WD4GY#5^H'K6%:?\CSJO_7A:_\ H<U;
MO>L*T_Y'C5?^O"U_]#FIKJ#Z&]FC-8GB#7'T:*!HK?[0[LSN@.-L*#=(_3L.
M@[D@58.MV0>5!(S&*2*)MJY!:3&S![@[AS2LPNC3S17.6OB^RFL8+B>*X@,D
M:RR*8BPA5F*@N1P 2#^1/04^3Q78VX*SF4LN2YAA=U5?-:-23CNRD?\ UN:=
MF+F1T%%<_+XNTR&-GD-P-@D,B_9V)B", Y88X )'Y\58A\16,TIAS-'*OF9C
MDB*L-BJQR#_LNI'KFBS#F1L45AQ>*=-FF1$>8*VT>:T+"-2T8D += =IS^G6
MK&F:[9ZL[);.^Y460+(A4LC9VL,]0<&BS'=&I1112&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!P^J7+P^-+N1+.ZN$%C!
M&3!'NP=\AYY]#3O[5<'G2M4_\!__ *]:2?\ (RZK_P!<K?\ D]3O6RBGN<;G
M--V?X&-_;6WDZ7J?_@/_ /7J-_$]M""7L=17'_3O_P#7K4EX4USVH=ZUA2C(
MY*V*JTU=?D=/9W4%[;1W-M(LD,@RK+WJVE>966MR>';YY@"]E(<W$(_]#7_:
M]N_UKTN&198DD3.UU##((.#['I6-6DZ;\CKPF+AB8W6ZW+*]*E']*B7I4H_I
M61V$B]JE%1+VJ44 (WW338@PB0,<M@9/O3F^Z:;"I6%%)SA0,T /HHHH ***
M* "BBB@ HHHH *9("60@\ \\]L&GU'(N7CY P<_7@T 2#I10.E% !1110 44
M44 %%%% !0:*0]* &1!AOW'JQ(^E25'$-N_G.6)J2@ HHHH **** "BBB@ H
MHHH CF#&,A#ANQJ2HYEWQE<X)[U)0 4444 %%%% !1110 4444 !Z5S\?_)0
M9_\ L%1?^C7KH#TKGX_^2@S_ /8*B_\ 1KTUU)?0\=^-_P#R/5K_ -@R/_T;
M+7)^$K^WT_6FEGN1:.]M+%!=E"PMY67"N0 3QTR.F<UUGQO_ .1ZM?\ L&1_
M^C9:XC0K*#4=6BM+B&_F60$*EA&KRENW!(&/6O4A;V*OV//G_%=CH/$]S+'X
M;M+#4=<36;Y[G[3!,A=Q%"5(($C@%MS8.!D#97-Z)_R,&F?]?<7_ *&*Z/QM
M8:;816%O!J=Y=WUO&(&AEC3;;QC)"%TX+ GH">IYKG=$_P"0_IO_ %]Q?^AK
M3IVY-!3OSGUY6+XAU.33+6%H719)IQ$NY-V<@DXRRC.%[D#ZGBMJHYH(;B,Q
MS1)(AZJZ@@_@:\E'I-71YRGB&]N[NUORSL=L+&"%\+(5-V"  2,MY:]SR!R<
M5J)XGOC+# ;W376=8&-XB'RH-X<E6&_D_( .1][FNR%O"&#") 0<@A1UY_Q/
MYFJEWI-M=6Q@4&!6D\TF#"$MZGC!SWR#FKNNQ'*^YQL?C35)-F(K1]J[BZE5
M2;]^\?REI 0,(.@?EAQTS9G\4ZK::<UZT=M,LBW'EQ)&5*&.=8P22V",-N/W
M>G7O756FE6=G;V\$<"LL!+1M)\[!B<ELGG))))JV(8@,"-,<C&T=^OYT<R[#
M47W.'?Q/?HCSO# 9(/.17WC;C]S\SJCLHV[R3R>%[9-=3I-T]S%-ON[:Z:*4
MIYENI53P#@\GGGL2/Y5=CM;>&-8XH(T100JJ@  /4 4Z&&*WB6*&-(XUX5$4
M #Z 5+8TFAU85I_R/&J?]>%K_P"AS5NGK6':?\CSJO\ UX6O_H<U$>HWT+-U
MH5C?:E]LO84N2(?)2*9%=$&<D@$=3QGZ"LVV\'P6KQ"+4+P0HT+M$=A#F(CR
M\G;G@!1P>=H[YKIJ*+L+(YI?!T"0&!;^Z$#QB&=,)^^C5F*J3MXQN(R,$@\^
MM6#X8M2DZ>=-B8*&Z<;9FF&./[SD?2MVBB[%RHP9O"UI.M^&GG'VU)4?!'RB
M0@G''^R,47GAF*ZNY;J.]N;:>1V9FC"GY6C2-E^8'J$4YZ@BMZBB['9&'#X7
MLX;3[*9)GB+QN0Q'.V(18X'0JOYT[1/#L&B;_*F:3*+&N8XTVJO3[JC)]2>N
M*VJ*5V+E04444%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <C<:E8V/B?4UN[R" O% 5$L@7/W^F:'\0:-_P!!6R_[_K_C
M3;WCQQ=?]@Z#_P!&2U;!.>M:\R5CF=*3OJ9TNO:05.-4LS_VV7_&L&^U?3FW
M%;ZW;Z2 UV2D^IJ0$YZFM(U^79'/5P3J*S9RN@>'C<3QZGJ,1"J=UM;N/R=Q
MZ^@[=3[=F*B6I4K&=1S=V=5"A"A#E@B=.E2C^E1+TJ4?TJ#<D7M4HJ)>U2CI
M0 C?=--A 6%%!R   ?6G-]TYIL(40H%.5"C!]J 'T444 %%%% !1110 4444
M %1R %HR3C!R/?@U)4<@4M'D\Y^7ZX/_ ->@"0=**!THH **** "BBB@ HHH
MH ***0]* &1*%+X.<L2?8U)4<04%]ISECGZU)0 4444 %%%% !1110 4444
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MAS(ZRBL[2=0EOTNEFCC62VG:!C&Q96( .1GZX/H0:T:10AZUAVG_ "/.J_\
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MN?E5_O<G>175Z+8G3K22W\M8XQ<2M&B]%1G)4#TX/3M2:&FV:5%%%(H****
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M,D7M4HJ)>U2B@!&X4TV%@T*,!@$ X]*<WW338B6B0D8) )% #Z*** "BBB@
MHHHH **** "HY&P\8QG)Q].#4E1R,0\8 R"<'VX- $E% Z44 %%%% !1110
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MT:+,+HZ*BN=_X3OPO_T&[3_OHT?\)WX7_P"@W:?]]&BS"Z.BHKG?^$[\+_\
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tm238578d1_ex99-2img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Y S0# 2(  A$! Q$!_\0
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MG5_\+-\:?]!^;_OQ%_\ $4?\+-\:?]!^;_OQ%_\ $5RG-'-'LX=@YY=SJ_\
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MF9 <\)\QP?8"B+G?4<E&VASPI:0=*6MS$**** "BBB@ HHS10 4444 %%%%
M!1110 4449H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<Q11172<X4444 %%%% !1110 4444 %%%% !6]HNB65SI-YK.KWDUMIUM*D
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M/0''Y5<.;6^Y$E'2QL>(/!":+<Z3'%?&Y2YG%I=NJ_ZBX!7<@]>&X^AJ76/
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M>%]H4)G(/.3G(XZ'O5?O.5]R?W?-Y&]'\/K0Z[<6;7>H20)I2ZDD<5L/M/+
M>6T>?O>U4/\ A#[6XUV*Q@;5K&W2UDN[N74[01.D2=610?F]/K5N+QKI!UK4
M-3EL]0MY-3T[[/>?9'4%9B03)&2> <=.QJC!XGTW3=92[M!J]];36TMI>1:E
M.A=HGQPC+T[GGO4KV@W[,2S\/^'M9U;2;;2=8NR+RY^SS0W, 6:,8R'&"5(/
M3KFIM3\)Z?:3VEO''XBA>>]CMO-OK%8HL,V"5;/)[CUJ.RU_PWHNJZ1/I.F7
MS)9W7VB:YNG3SY!C C 4[0HZ\_I3;S7M%>\MKRWF\0S20WD=R8KV>-X\!LD
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M4?B* %HI/Q%'XB@!:*/Q%'XT@"C%)^(H_$4P%Q1BD_$4?B*0"XHQ2?B*/Q%
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ME#7(>-U>-3T)4C.#]*2U\:Z!>"<PWKE8(6GD9[>10J+U.2HS1>KYA:GV0O\
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MWD8%02I/"\<@]:.:H]+L'&FNB)/^$(\*_P#0O:;_ -^!1_P@_A7_ *%[3?\
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MC5G_ (2'2C>6%H+Z)IM0C,MIMR1*H&<ANE%ZG=BM3\BI_P (1X5_Z%[3?^_
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M9R,?6C(H 6BDSSCO4<D\<31*YP96V)[G!/\ 2@"6BD!JO/?06PD\QB#'&96
M&3M'% %FBD)'/M36<*4&&;>< @9 X)Y]N* 'T4@(/2EH **** "BBB@ HHHH
M **** "N4\"?ZKQ!_P!ANY_FM=77*>!/]5X@_P"PW<_S6M%\#^1F_C7S.KKB
MO$TS:5XWT+7)[>YDTZ&">WFE@A:4Q,V-I*J"<'UQ7:U6DOX(+Z"T<L)9@2G'
M''O2@^5W')71Y]:VEY)\-O%\WV.YC.HSW=Q;PO&1*R,!M^3KDXZ5JZM;W#MX
M$VP2MY-U&9<(3Y8\@CYO3GUKK([Z&2_ELU),T2AWXX /3FK 88R.E7[5ID>S
M7<X#P%KEO8:)::-=6FI17AN)1@V,NP;I&()?;C&".<US%G?WB^$=!\,7-KJE
MGI[0M)J,\5G*SLAD;$*[02,]R>Q]Z]FWY[\'WHW^_3KSTIJJDV["=.Z2N>6Z
MVB7]\TVDZ?=)8CPS=6\*&T=-K!\!-I&<^@ZGK3-+T/4]'\4^&K)(96TAEDNH
M9"I/V:1[<B1&/8;L$9]:]1GN4MX3*^=H8 XYY) '\ZDW#!YX[T_;.UD@=)/J
M>0"ZU32?!</AFWL;E-8MI75[9M+^TQ7N7+!PY&T#OGKGZ5V7CFVN+WP0(&@>
M69YK7S8XTR?]8F[@=AS77;L+UX^M)G'/2I=75.Q2IZ--GC>EZ1JD7B+3);VU
MG\O2=4CTZ%_+;F!/-8OT^[\R#-226?B2623QI'I*;AJ/VU S/]J\A?W7E>7M
MZ%.>N:]@SSCO]:7('/ZU;Q#;O8CV"2M<\WM]2_X1^3Q):WNB7M_+J=X]U:1I
M:M(EW'(!M0M@A<="&Z4R^TK7[KQAJDNC32Z3<#1[<1JL:M$[#/[G<1@8Z9%>
ME;L#V^M-EE6&%Y'SM12Q_ 9J55L[I#=*ZLV>7:4L>CR>&=:72M273;6TGM;E
M&A:2:UG9LL[*!D@G/('0_A5;6;2^U>V\0:Q9V-Y!;7]]8+;![=A(_EMAI=G7
M'.>>PKUJ.598DE7.U@&&?0]*=N&>M-5FG>PG2NK7/-_%OA2[MO#/B'49[ZXU
M?5;R&&#*VX3"+(IPJ)^>?:GW=E?>'_&&G:C->:GJT<&FW;YEB#;& 7"#8HY8
M]CSQ7HN>>.OUH#=A4JL[693I+<\FT+3/$/AW4]$U^]TZ,K<RNE^]NSO,XN&W
M R)MX"-CUQ3?M&IZ%X6N_#GV6Z&K"[F<+_9ANHM15F)4[B-H[9)Y&.E>MY]/
MTH#<<'@U7M[N[1/L;+1GE%R;RT\737%]<ZUICRZ9:*[Z99&0/(%^93A& P>P
MJUKTD/V^TOQ+XALI7TY4BU2"W:0W1!/[J:'9PV>><=>U>E"X0W#0!OWBJ'(]
M 21_0T_=QNSQZYH]MMH/V6^I@^&KB[MO!=E<:K9BVN8K<O+!%#MQC)X0="0
M<#N:\^T^Q\2:==Z=XON=,7,MZT]WY;.UP89R%*-'MX"@ CG(Q7L&1U%)NZ\\
M]^>E1&KRWTW*E3O;78\4U+0=5L_#>I:CI]K<.-0N[BVOK;RVW,OGEHI@N.W3
MZ,*Z2;41I7B7Q='/INHW)OX8$MT@LWD64B':1D#:.2.M>C[N^?UI<GWJW7;W
M7]:?Y$*C;9G'0:7>Z=\(7TRY1GO8M)DC:-1N(8HV%&.N,@?A7G-UH&J?9)K
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MCGKS_DK-K_V!)?\ T<E=)7-WG_)6;7_L!R_^CDKI*SJ[KT-*>S]1:Q(89X=
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MXROS@ANG.?FR.O2D?2Y1I\44=N@?^SWA<# RYV8!_$-6[BEHN%C%O-,WF_\
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M DO_ *.2NDK.KNO0TI[/U%HHHK(U"BBB@ HHHH **** "BBB@ HHHH ****
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M=[4E%'(@YY=Q=WM1N]J**.1!SR[AN]J-WM111R(.>7<-WM6'XS/_ !1&N_\
M7A-_Z":W*PO&?_(D:[_UX3?^@FJC!<R)E.7*]3;\/_\ (MZ7_P!>D7_H HH\
M/_\ (MZ7_P!>D7_H HI/<I;'/7O_ "5FU_[ DG_HY:Z.N<O?^2LVO_8#E_\
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M;5_VN "<YQ6Z+2 6CVWEYA<-N4DG.[.>>O<T1VD,22*D?RR'+@DG=P!W]@*
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M>]EM]/<&X!\O34E1FQ][#?GT I7NKUC/(EUL$4D**AC!!WA<Y[]R:U?L=MA
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M%<"(0V*SA5C7!;+>W3CM6]"(54I"$"(2N$  ![BCR(@"HC0 KM("CD>GTYH
MRI+B\BFE@^U;F+0%7*+\N]B",>G'%$<]XDN7NV=8[P6^UD4;E..3@=>>WI6M
MY49;<44GCG [<C\J/*CZ[%^]N/'?U^OO0!D1ZE,UO8'S5,DHF+C R=JL1^H%
M,>^O;2$.UP)3):";+H $;<H)&.V&SSZ5K)#:F20I%#Y@/SE4&<D=_P #4GE1
MY'R+PNWIV]/I0!C7,DJSBU>X-PJRV\@<A<J3)C'''.,B@:A=);P7?G"5IRX-
ML%&%PK' [\;<'-:\=M!$FR.&-%SNPJ #/K]:!;0K(\BQ(DKC#2*H#'\: ,2:
M[G6!LWJW DL9)BI1<*W&.G;GH:N+<RM-+*]X(4BN/)\DH""./QR<Y&/UJ6VT
MJ.&5I)'$K%"@!C51@]<X').!5LV\)F$QBC\T<!]HW?G0!S\E]<20,'ED>*YM
M)G&]44$!<@J!R!SWJT+DV<T]P7 MUG03<?PF% #^!Q^=:BV=JN=MO",YSA .
MO6F75DMS%Y6[9&[ RA5'S@8X/Y"@9 UU<PZ&]VXS/Y9DVD?=SR!^ _E4$L\T
M$D5L-1$AF= 9"B[HP0W/''.,#(_.M<C(P>E1+:6RQ-$MO$(VY9 @P?J*!&++
M>3I)DMY[VLDP1L#Y\1;L''<$X.*GM _]M1,]W]H+69;.%&,L/3M6JL,2*JI&
MBA/N@*!CZ4D5M!"Q:*"*,GNB 4QDM%%%(04444 '>N4\"_ZKQ!_V&[G^:UU?
M<5RG@7_5>(/^PU<_S%4MF2]T=76/JES-;W,AA*JXMLJQ4$@^8!^7/2MBF/%&
MY)=%8XQR,\>E248E\L[,]I+=,ZI<0$,47)#'H1C!QC/3\Z19Y8\V\$LB-YMP
MY$:IG D(R2W 'MUK<,:,2612<@Y('4=/RIC6UN^-\$;8)8;D!P3U- 7,3^T+
MV:P>Z6Y$9BLTGP$!#-\W7/;CM4TUQ>0326XNBS&2##E%RH<D$ 8]N*U#';J1
M#LB&]2 F -P';'IS^M/,4;-N**3QS@=NGY4 9*3WD4H:2[,B)>?9RIC4;E/<
MX'7GMCI4"WUS,T:F>0QW,$K LJ#HN05 R0/K6X5A5E5@@9FRH(&2V,Y'O@4B
M6MO&VY((E;.<J@!H Q8+FX%EM6]\H6UG'(N54^82I//L,8X_.IA<7\T=W<QR
ME/)VE;?8.?D5V!.,YY(K3^QVN$'V:'"?='EC"_3TH>/S(I5AD$;L>74 D'W]
M\4 16-P]X)IPW[AG*PX_NCC/XG-9%H\D4"117$OF2/-(VQ(PQ"R$9+-QC\SS
MV%;T$"6UM'!&"$C4*OT%(UK;NJAX(F"DD!D!P3U- &1;W]Q=VZ.UZMMLM5F+
M!00Y)8$G/8;>WK212S)=31K=%1/>[#)M7Y1Y888!'?&.:UC!:NRQF*%C$,A2
M@.S.>@[=_P J<UM _F%X8V\S&_* [L=,^M,9E17-W/=Q6JW9"K)*IE5%)D"[
M2/;N0<>E/T^\N'NTCN)F;S49EP$,;8(Y4CD=>AK36**,+MC10@PN !M'?'I2
M100(QEBBB5GY+(H&[\12$8VIJYO+_$Q_U-OA2 0/WAY_SZU++=7,$L]J;J1W
M\V-8V$:[SN!) Z*/NGDUK/!%(^]XD9P,!BH)QG.,_6FRPP2 B6.-@Y&=Z@[C
MVZT@,6">>YN[+S+A\QW4L?\ #\V$S@XX)[<5H7<TIODMUN?LR>2TN_ ^8@XQ
MSV'4U82"UD13'%"RAMR[5& PXR/?M4=W:"]",LX4 '^!74^XSW]Z8&0NI7TT
M",LI4K:).678 S'.2V[^'CM4\EY>8NKC[1L6"2("(*"IW*A8$]>K&M-+"V6"
M&$PHZPJ%0R*&(Q4IAC;=E%.\@ME>I'K^0H R4O;QKS=N(C^U&#RV*!=H./\
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M>*:TV-C<[Y_"-B/U J[L0$$*,@8!QR!2D ]0* ,%/M+(F;^Y^>P^T$Y ^?\
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MC@M[Z25&E*[\AMN8V/#=^<'VJ!]0O'LI9D9D\D)!(>@#[OG;H>@QS[UO!$4
M*J@#D #I2X'I^E &=I4TLK7"M*LD:,H0B3S",CD;L '_ .O6?#((IFA:[>*)
M[R;S7WX*]U&?X<]??%= JJBX50H'8#%!C1L@HIW=>.M D9]I<2OI,TAD+E/,
M$<IZNHSM:JJNR&VCN=0FCBDM_-,K.%+.<9&<= .<5MX&,8XQTI"B,H4JI Z
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M 8#W%TUG+.+J5'BMX'4#&-S#DGCGZ5--+-;W3VS7<JV_GH&E9N4!0G&[' )
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M(P>.H]*4*% "@ #H .E "UA>-/\ D2-=_P"O";_T$UNUA>-/^1(UW_KPF_\
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ME'/3'- !11SZ4R.02H'4-@DCE2#0 ^BCGTJ&XN8[5%:3=\S!5"J6))[ #Z4
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MRP1W0#2+*SQD%#T)YQG&<YP:;'-YC(UW+.EHTDY#99>=PV@D<XQG%=#S1S2
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MG;[[YG6)VD>SE2-E!^_V&>QZU6N6DNWD:%)_+,$2YV,O/F#./PK?+*,Y-!<
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M6.598]_FR>6%#9]6ZOD\_P"%6KZ'-]YLUH]U"8"B(J[MK9_3(QS[5>%[:.5
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MC5%;Z?<)<1+(DS>7<-+YF] F"2<]-Q/.,'\ZW** ,Z[AD%\EPMM]I3R6CV9
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MF>.6/,:H/,9.<9[( .,]<U5:&2XN+Z*.V&6NXV\_(^4!4/USUQCUK;H  S@
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M _Y%O2_^O2+_ - %%:/=F:V1SUY_R5FU_P"P)+_Z.2NDKF[S_DK-K_V!)?\
MT<E=)6=7=>AI3V?J9^M6EU=Z>R6>I3:?*A\SS845B0 ?EPP(P<_I7(^']9O[
M+P!)XKU?5[B]WVC2"W>-%5'#$  J 3D@#FN]==\;(>C @X]ZYT^"[!O#>G:
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M".P.ZS@NI0R0GH#@ ;B!T)Z5*E!7*E&;.*T[Q3KD]U!]FUF[O=0;4V@?339
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MM=77*>!/]5X@_P"PW<_S6M%\#^1#^-?,ZNLS4+N:*;RH'(98C(56+<>O!))
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MH3P3]:+H5F94=_>B&*:26)A(LPVB/&"@.#G/?;R*674;RUB0O)%*TMOYH(7
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MH"JI)"@$G)P.IHN/4=1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6'XS_Y$C7?^O";_ -!-;E8?C/\
MY$C7?^O";_T$U4/B1,_A9L>'_P#D6]+_ .O2+_T 44>'_P#D6]+_ .O2+_T
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MDSQTILLJ0Q/+(=J*,DXSQ0 ^BD!R,CD>M+0 4444 %%%% !129YIJ2I([HK
MM&0&'H< _P B* 'T45#-<PV_^MD"?*S\^@ZG]: )J*0'(R** %HI*BFN8;<H
M)'P9&VH "23^% $U%)FB@!:**8DJ2%PC E&VMCL>#C]10 ^BDHH 6BFNZQHS
ML<*H))]!0CB1%=3E6&0?44 .HHIJ2*Y<*<E#M;V.,_U% #J*0T4 +129HS0
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M#;/GS8F"-TY((%6N::B!%"J %'  [4!8RK>]MVM;2V6W9YEV*8"A'E$=2<C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC\3_ /0A7_\ X,(/\:/^$C\3_P#0A7__ (,(/\:[>BE:/8=Y=SB/^$C\3_\
M0A7_ /X,(/\ &C_A(_$__0A7_P#X,(/\:[>BBT>P7EW.(_X2/Q/_ -"%?_\
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M2/Q/_P!"%?\ _@P@_P :/^$C\3_]"%?_ /@P@_QKMZ*+1[!>7<XC_A(_$_\
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'%%7:*0S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tm238578d1_ex99-2img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #L U(# 2(  A$! Q$!_\0
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MA+,1/+)</+L<IA@NYB%&?3%;OVC5?^@=;_\ @4?_ (BCS]5_Z!UO_P"!1_\
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M^T:K_P! ZW_\"C_\118/:KL_N9IY]JAN8([JVEMYEW12H4=?52,&J7VC5?\
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M5#E0X)"_WL>GO0!+BC%,AN(KB)989$DC;HZ,&!^A%2T -Q1BG44 -Q1BG44
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MAMM/:]N)%A@2/S'=S@*N,DFBI2G3^-6",E+8L45E6&OV>H321)YT,B()=ES
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M$;PN%P"&R""!G  P!7$_$'PY#9ZIHNLK?:C)+<:]:@V\MR6@3)/W4Z#I^IH
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MKO*\M\0^'-.TCXJ>$M0M(Y5N-0O;E[@O,S GR\\ G"]3TKU*@ HHHH ****
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ML/\ .*MVUJ0CSD@;N!CJ1_CVK#U!YH[^[CR2SA><8P/_ *U!I3C>3-*14B#
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M!CBN ^#'_)-[7_KYN/\ T8U 'H%%%% !1110 4444 %%%% !1110 4AI:0T
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M4@[A*%^0'&3AQR,$'H0#L+:$6UO'""6"J!G &?P  'X5-N]C7%_$2'[5I5M
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MHH **** "BBB@ HHHH **** "D:EI&H ^??&G_(Z:M_UW_H*U/AA_P CFO\
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MLY[*VBMK:2/='#%M*H/0;?E_*LWQY.+?PM)*2%Q/"!)NVF,^8OS [TP1U!+
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M #L.*/;1B[TE?U.%UJE6/[G74Y3Q/X;O-:N(+C1]+U"XBV'?=7;?/.>S88Y
M]. /05V=IX'TZ^T2S35HKB6[$2&1Y)B70A>4!Z!1D\"NP &.E.P/2LG=[NYL
ML+'F<I:W[[&=I&D6NB6"V5FK+ I+ ,<G)//-: I<44'4DHJR"BBB@84444 %
M%%% !1110 4444 %%%% !1110 4$9HHH C\B/<S;1EAACZBH7TRQD(+VD+D
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M#@LV1G#$!B-U>@XH 10 !2T44 %%%% !1110 4444 %%%% !1110 4F*6B@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/AO3;O6(=3E@_?QL'PIVJ[K]UG ^\R]B>E:]% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>tm238578d1_ex99-2img05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %L U(# 2(  A$! Q$!_\0
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M (A0!Z-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %<SJG_)0O#W_7G>_P#M&NFKF=4_Y*%X>_Z\[W_VC0!TU%%% !1110 4444
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MIMS<2F6>6UC>1R -S%02<#CK6G0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5PLCPLL,GER$':Y7=
MM/KCO7*6WAN^M]4:[AMM+@E9WD-TDL[$LV<MY1.W)S_>-=>>M>>:1)<R^,W4
M232P_:G8WB_:&23;YH*$%/+&-RK]['[L8Y- '7ZGK$.CBR2>.>5KJ=+=3'&2
M S$+N8]%&2/Z5B2_$+38FD7[+>/("3&BJF9D'F[I%^;H/)DX.#P..172WMA#
MJ$4<<X8K'-',NUL?,C!E_4"L&;P#HLWG$BZ5I7+!UG(,0._*)Z*?-DR/]H^U
M #XO'&CM<7"3RM:V\,;2?:[@JD3A656P<Y&&=1R!UXK-\':E8ZMXT\77NG7<
M-W:NUF%FA<,I(B(."/>MRT\*:39W\]W' 6,R%/*D;?&@)4L%4\#)52?<5E>&
M8(K?QYXPCAB2*,&SPB*% _='L* .QHHHH **** "BBB@ HHHH ***S=1N+Z&
MYM$M6M@DTGEOYJL2/E9LC!']W'XT 1^(;J&RTY+J=PD,,\3NQZ !@:S/"=I+
M.EQK]ZA6[U,AU1NL4(_U:?ER?<UE>.+?4?%&HV?AO2;F*'R66^O7E4LA53\D
M9Q_>.3CVKJ=5FO;:Q22R>WC<2(C":%I!AF"\89<8S^E(SLI2OV_,?KNJ0:+H
MMWJ,XRD$9;;W<] H]R<#\:YKX<^!K7PAIK7"K(+^_1'N0S96/J0BCT&<<Y-2
MZIOU_P 6:?HCD/;:<%OK\JN%:3_EDG4]\MCG@"NQ K1JT4NK+6XM%%%0,*3(
MI'4LA4,5)&,KU%9^C><UF[SW,L[>=(H,@48"N5'W0.PH TJ*** "D/2EI#TH
M ::3..3TJIJ=B^H6;6\=W<6C$@^;;D!QCT)KSC3?A5JMGXRNM9D\37'DS-(5
M\HD3#=TR3\OUXI,J,4UJ['JBG(JI#JNFW(F,-];2B 9EV2J?+'/+<\#@_E2F
MT=M*:S^T2ES"8O/8_/G&-WU[US4NDZU=6$.G_8]/L42)+5[A3YC&,$%MHP/D
M(7&T\_-VQRR3H[C6-+M!&;C4;2$2KOC\R95WKZC)Y'O5A[FWCEBB>:-9)B1&
MC, 7(&3@=^.>*X[_ (175S:7%J=0"!+5[:&2-5 E0ON574@E1@[/E(.!D&K-
M_H>K3FRNH&MS-9AI+:%QM6%ODQ'N'WA@,N[WZ4 =5#/#.&,,J2!6*,48'# X
M(..X]*DK&\-:2^BV,]JQ!S</*&!R6W8)8^Y.2?K6E>_:A93_ &'R?M7EGR?/
MSLWXXW8YQGKB@#E?'WW_  M_V,%K_)Z[ ^U<'=Z+XVUN^T@ZM+X?2TL;^*\;
M[)YPD;9G@;N.YKO* .?N;7Q0VIR/;:A8)9F>(I&\)+B(#YP3ZDXQ70"EHH *
M*** "BBB@ JIJ8MCIMR+Q6:V\IO-5 Q)7'. O/Y<U;I"* /,?!OER>,#=0V/
ME_:5N'8-9W,1@ 8;?GD)5]PYZ+CMZ5Z?7F/A>VCC\=^>+FZ82_:MDMQ;RJ+E
M@^&V,SD848_A&<''!KTZ@ KF=4_Y*%X>_P"O.]_]HUTV1ZUS.J?\E"\._P#7
MG>_^T: .FHHHH **** "BBB@ I#2T4 <_J_AV?4-6AU*UU6XL)XX3!F)$;*D
MY_B!]!6=9C5=.\96VG7.M7%];S64LQ66-%PRLH'W0/4UV!'%<;KM_%I/CC3K
MZXCG-N+"6,M%"TF&+K@?*#Z&I:MJ<U2,8^_Y^9-X2_Y&#Q=_V$E_]%)76#I7
MFOA_Q=IEAK/B.:87>RZOA+'LM)&.WRU'( X.0>#7::)XCT_7Q<?8'E8V[!)1
M)$T94D9'##TK>HFWS)::?D;0DI+0U\44@I:R+$/ -<!X8\4Z-I.DM:7MVT4Z
MW$Q*>2YQER1T%>@$9%,\M?2I:;::-Z=2,8.$E=.W6VU_\SG/^$\\.?\ 00;_
M +\2?_$T?\)YX<_Z")_[\2?_ !-=)L7T%&Q?2E:?<?-0_E?WK_(YO_A//#G_
M $$&_P"_$G_Q-!\>>',?\A _]^)/_B:Z-E ' _2L73_$-MJ5S!;I9WD;3I(P
M,L!50$;:<GL3U'J*+2[AS4/Y7]Z_R-2SO(;ZUBN;=]\,JAD;!&1^-6!R*0(%
MZ4IR!5'.]]!<"DQ6!J.I^([>^DCL/#T-W;#&R9KY8RW'/RE3CFETW4_$5Q?)
M%J'A^*SMB#NF6^60KQQ\H SD\5IR.U[_ (B-J6**:,Q2QI(C?>5U!!_"D2*%
M%VI&BC 7"J!QV'TK*UN^:PU#1Y'N!!:/<NEP[-M3'E.5#'M\P'XUC0"?57T^
MZ&J7Z175_<QCR9MJ/"IF*$<=,*N#W&*@9UPA@5!&L:!0=P4*, ^N*<8XBVXH
MI8'.2O/I_C7"Z3JLPELY8]3NKZ\EN[E+FQ$BR;8U,F"%.-A&U #D9S[U#J>N
M:O%-KT4<T\/VI2EB&4%K5TA5WZ9'W6+=3RM 'H2*JJ%0!5 P !@ 4ZJVGNTN
MG6TCL6=H49B>Y(%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH 0UP>AS);>)C:2O(9GN[AE87MRJ-
MEG; A*"+('H<=\DUW%P91"Y@5&EVG8KL54GMD@' _ UPVG7EW>>*;=;\3- E
MQ)Y4GVB1K?S0&!5/W*AB/F R<<'J10!WHZ4M(O2EH *Y'P]_R4'QC];/_P!%
M&NNKD?#W_)0?&/UL_P#T4: .N[44=J* "BBB@ HHHH **#TJC)J4,5_'9,)_
M.D&5Q"Y7'&3N QQD=^] $FH7C6-C-<BWDG\I2Q2,J"0.3]X@5CZMK,5KIEEJ
MUY$]M%'(92CLI;'E28'RDC)X[]ZD>>\GTO6?M+PL(EEB411E3PF<G+'U_2N4
MUN'5/%6KZ3IVD26PL]'>&YOOM&=DSX&(N >B[B?<CTI,B3MIU.F\):=/;V$N
MH7ZXU'47^T7'^QG[J?11@?G4GB[5[+1- EO;Z=(HDEC(#, 7(=6VKGJ2 >/:
MKNI7=U9K"UM;13>9(L9\R8Q[2Q '13FN+\5Z+;_$;7(]!D9TL-*/FW=S"?F$
MS+@1*3QT))XXXZ545^ 1CRJQT'@S3YX-(?4KT?\ $PU20W=QSG;N^XGT5<#\
MZZ8=*KV=I'8V4%I"I$,$:QH"<D*HP.?PJQ0VV[LM*P52OM4@T\PB9)V,S;$\
MJ(OENPXZ5=K)UL#=IG'_ "_1_P FI :JG<H.",^M4='_ ./!O^OB;_T:U6;F
MYAM+66XF?9%"C2.V.B@9)_*L#P;XCTGQ#IEQ)I5V+A(;F02$(RXW.S#J!V(-
M '2T444 %%%% "8HP?6EHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY_YB _\ 1:TWPS_R-WB[_KZA_P#10I_A?G7/%/\ V$!_Z+6F7'A&_P#[9O\
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MC66RM;E98G-R[16^I3S)$V_)W1,H1,DGH>N<5Z70 5S.J?\ )0O#W_7G>_\
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MW;NREL\X*CTKNQTH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_@!%4=QI/B5+:5HO%$CR*A*+]@B^8XX% SI!S3JH:,]Y)HMB^HKLOFMT-PN
M,2;1N'''7-7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M0C@US&BZU:7OB;4K>'35MY7+YN@1NN?)?RFW#&1@D <G(]*Z@]*SK31-/L=1
MN;^WMA'<W/\ K7#'G)R<#.!D\G&,GDT :-%%% &'KU_ DMGIEWIIN[34G:"9
MG"F)5V,V&!Y;.T\ 5'X7\1KK]M(19FU,:Q.B;P^8I$#1MP!@XZCL1U-;%Q9P
M7+P/-&':"3S8B2?E?!7/Y,1^-5]*T6PT6*2+3[80I(V]AN)YQ@ 9)P    .
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1[Q/_P!#E+_X+X_\:/\ A'O$_P#T.<O_ (+X_P#&B_D1SR_E_(ZO=1NKE/\
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MFM?]_!4MM/1&\*=.4;RG9]K,Z_S%P3T ZYJI;ZSIMU'-);W]M*D )E9)5(C
M[DYX'O3-1L'O="N[!)2LD]L\(E/8E<9-8M[I^JZM;BU;3K.PC=8X99 PD;RU
M;<RJ!C,?&W!P3N/ QS1@;5SKVD69B%UJ5I"9D\R+S)E&]?[PYY'O5J2]MH3
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M7!GO?!4B?N5B^TL^%VG"J@.,YQ@8]?SJ6VO9=Z>3X,N(TAD+1IO96+$A<DD
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M+_<'\JFJCK6P4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_-[MFFE8)2ON17-_/; '[$[ G _>HN2>@Y-8>IZGJD[VWV?0)GFMY1.@-Y"
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MNO\ #7/A;2/^O*'_ - %2:]_R+NI_P#7I+_Z :C\-?\ (JZ1_P!>4/\ Z *
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MVOOM2RD@9??M4 GT Q744 %<OX,_UWB;_L-S_P#H$==17+^#/]=XF_[#<_\
MZ!'0!U%%%% !1110 4444 %%%% !1110 4444 <M\1/^1#U7_<7_ -#%;^GG
M_B6VO_7%/Y"L'XA*7\"ZH%!)*+P/]X5E6WQ.T&WLH8Y$OP8XU5C]F.,@8]:G
M1,YI3C"J^9VT_4[P'-+4-M,MS;Q3IG9(@=<]<'FIJHZ4%%%% !1110 4444
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M=?R'Y#TK)\*:OIFJ&]?3K.6U,KK>/YF,S"0$+*,$XSY9&./N]* )?^$NL/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 9GA[3I-(\.Z?ITT@DDMK=(V9>A('./;TK3HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *#S110 P1J"2% )ZG'6J=SH]E>7-I<3PAWM',D')"JV,;MH."0.F1QVJ_
M10 T1JK%@ &/4@<FG444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$>E+10!R,/P\
MTF&Q-FUUJ,L0@DMX!)<?\>Z/][9@#!.!R<\<=,U7F^'UM]KTM87'V.UOFOYC
M(?WDDF  @  4(2JL1C^$8KMJ* ,+2_"MCI6M7FK0O.]U=*5<R," "V[' !//
M=B2!P*W:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>tm238578d1_ex99-2img07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img07.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )' R # 2(  A$! Q$!_\0
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M]2?2O'I+[Q+?^'?"4L-W?:A%)IYDN[.RU$07DKY.),GYG  Z#N*S]?ND\0^
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MT%J8O_"6^'O^@S9?]_A1_P );X>_Z#-E_P!_A6U11H&IB_\ "6^'O^@S9?\
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M;?'D()0GE8&/E*D$<>E11V_P\BTJWTR.73%L[>X6ZBC6?&)1T<G.2?K72?\
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M6I7!@L=0MKB4*7*1R!C@8&?U'YUHT4:!J+1110,**** "BBB@ HHHH ****
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MYLL;3R-A'$>X8/.UA^7/M1<)'DA[2+:I!<E2Q)#9_#G\,4K@26*117P.[9
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M<_RJ_I5C;6.G06EO=+MC/,A(+,6Y/ID=OI5>62ZT[1Y_L[K*8D5MLLP0,?\
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M/CVL0Q"MT+#CG'2EFO(W'E26Y,JG;EFP003U^@QS35VP9 ]LQ<^7Y>Y06P4
M)]1SU'4YJ)XYE*+@@*X96S]T#O2[7%P@(5E+%%;.1@C.,=?SH5+IX5N70#+,
MOR$G"YX)!/?-5JA$\96.'>C.A902[$=NG'H?>NM\%AC9W;L'&Z?C<,<8]*Y
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MW)947J>#P<#I3L%[DUM:O#$;2)I9@TCDL_49'.?KZ<8]*@A$4,5QM0KY;!B
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M5VTL3?6Y8MIVMYW B6*$*1L+\Q@?Q8SP<9K.-ZT8:6VMY)]/F))D$)&0V,8
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MOG74PG11(P0$ Y  Y0GMTS4LGR*DCM(>DB!QDA<?=..W _.FIJ$5PC11S11
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M(_,4-$WZE6>VN[RVMH9A!(PD$LF5W"0XSG'& ,>WXU=N/.B:2)PBV_FH$#L
M#\O)P.@Y[^E4HTF2*ZO[F,&9?D3Y]P;C +#MWS]:;*LTD,&U.9/D$L4?&<=@
M?_UU20MRHSQ:E;3QV;6_VJ%7,95MWE@GDAL<'(X'O5A;(:=<VT8\X_:,I)/Q
M(=VT?,WXCWZ^]1KISPF&'393"%RDJ& '(;U)/)_.KL=HGVZ,27<P-NNT-O)5
M^N0?<>U)*VMBG8KWD-Y<L(XQ:RVQA*-(8_GC;LQ'Y<=>:J&P:-HK> M$7607
M,L3%EY&XD!L]2 /;)K2<RS%DMS&2Y+/MR6W<?*<<#@TY(%M[R/9(@)#;48DD
M$'OCCJ>].R>MQ*36A5@>>&UM+EX)8$AB*[$8.J9. -J]1T.:LW86[FE<LX4X
M  8(1@\#IQQVI8E\SS47RX)&8;5/.<<X7!SC..?>A%\J,),%CN9NAW$')ZXY
MX(ZTXI(3=R1+%482K'BY$!@:1FSQQU&?8>_-9]Z))M&BC,,BR %%\M7+%\]<
MD<=.IJ\Z+YRB23;D[FRP<Y!X.,<^U4;*[2U?4)!J,SJ)&\S:I^]QQSUZ]AQF
MI:&F:4=V\FG>0\20;X Z&/G;)CG..?SJDL_F202+!#,JHZM/$^Y-YZ=3R>V?
M8BKMO'&6$^X(ZA1&H8X(!^[GO5!;FP759(XUS=]Y(E)&,< GIGGK2?9 BRFJ
M%[6*+RX!-.?*C4LV'8'G;],'@UG3:=>OJ%HPF:>%6D#QS8P3TV9X[9_2M62-
MCJ0,L!;8&8*<9Z8ZGIG/6LF[MK&6SCGM2QF:X600R2&(EQC=N]< 9QZT22V'
M$W-%B$/C2.(Q)NC\L(R*R@1GGZ'G(^E>ICI7EGAN9(];M(K)//7SOGD+8V(>
MHST//\/&*]3%9R)EN+1112)"BBB@ HHHH **** "BBB@#/UN4Q:-=868EXV0
M>3&792PP#@ GC/H:Y'X=0BVBFMVEMFDBAC1ECOYYG&.[1RJ-@],"NMUV\2QT
M6YF>66'*%%DBA:5D9N P502<$@UQ_P /1=/=WDUU?7%Q*\*"42QS@;@Q V^:
MHX"A1QU).>@R =Q]OMOM_P!A\^/[5Y9E\G=\VS.-V/3)J*VUC3[V]N+*UO(9
MKFV.)HT;)C/3GTK.GT2:/Q(^M6,=JLS63P,'!4R.60J6('0!<?E6?9^$[E-2
MU0S3_9;&[#86QN95=W:3?YA)/R-CY?E/.3TX% %O0_\ D;O%'_76V_\ 1*UT
ME<CX1L$TSQ#XFM8YKB95F@.^YF,KG,(/+'DUUU !1110 4444 %%%% !1110
M!$V=I(Z^E<EX5U#Q/=ZQJ$>M6GE6J']R2FWG/0'^(8[UV7%)M'I4M-M.YK"H
MHPE'E3OU?3T$7J>*=1BBJ,@HHHH **** "BBB@ I#2TAH \[F@59')PTYD)(
M!)(YX(([#FFWQM_-D4(Z.2/,8Q@[AV('?!(%-*JMW-M,BS1[^_;G#$#K221_
M:(/FAED544[WR6&< [1^9K9#*R37,UT[12[VCC\L1;20QYRV1T/'!JVB>7/#
M$\3,T+ 2-UW!^GOVJE*K27)*':@Y;>_WQT P.G/%:-OFXFBN(&W(%Y=FSY;%
MN5_#D>U4P*-Z;>&Y6P,4H:8$?W1][/+#U[5=6TCM('D \W:I*(_\/8\GCJ*K
MW,SR72"7R&7<3D/_ *LYY)]ZO3O;37)2!BQASYF#E@<8P%/^\#FD[H"DB2O?
M-<RR/$JH6/&<C'3/O_2DC1FMT"!%$H\M@F-X/8Y]33=/AF+JDB"1(_W1VG:&
M/J1V_P#UTL<Z3WTL+R(&\X%TB8AA@8'3L:=PL3+9.9O*GF_UZG(A!X(QG<?P
MP*99S.@(C@D*#)<1PY?KD #GDXZ&II1"G,4O[HX5C$<LFT>OIFG6.H300H'C
M*Q@$R. ,L!WXYSBE=M 5YGG\QWA!0L50AQM;!YYSTXZ^]1%$4QL(S&%!;DC.
MX=N?SQ[U8U6Y^T1VI$FUFY'&0YS@=NO3\ZJ7!CM]0BMXE!D<>6[@?*A"ELD]
MCD'D=^M-.RU 6UCFEN09(%E9L*[$G( 'O^-,BDM;:Z$+8^TFW,H1D)0=N3ZY
M/ZU>1YA:HY?:Q4$O(.7'3MSGTSZU7U*[9518XG%LN(R N2.G) YX)'7WHNV
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M?"#$V=PN"464;6]<C)_7C\*FI\('25'<?ZB3_=/\JD'2H;HA;65CT",3^58
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M,9#]Y6/0J,@BJ=TA(>\[2RV[-/YD+2$8C3:< <9_$?K5>Z2-9%C!())+,K$
M >HZ]^WI4QN;D8BF@*Q(-T@] >PX]O7C-,&);-(=YC(+.)'/(4\ 8[=<8]J:
M5AW(HXTFMR_.U&55W':I)))W4_$R3/%N,:IU,BC ..V/8<5<C>&.S F1)%89
M0,I)*=/\2:B5$:VN(S<A8U&\^4!\RXX/3@8_G34A#)9(U4Q6\XCB*8W$9W,
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M!Z$4Y7\F]WO'&WE+AB#P!G/?FD5DDG55(!'+;1P<@?GV%-D**3)+L"N,$1\
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MLO+-GN?7BHS);J[(,CRHQY<P)*D\Y/UZ#-!D5I+<$;3*?WBDD8[[@3TY/:F
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M+S1L6,8P?^6B@+DCG;WS[5#&K-*RHYQC$B(/D_#// ]*DF1K@+&@D)W#&?E
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M'A>G.1GOFO3ATKS+0 $UJU!V)")@%&-S%L>_ QZBO316<MR6+1114B"BBB@
MHHHH **** "BBB@ HHH/2@!,BC.>*X8>)KV'X@SZ?<7<:6,;NCP.JKY42P(X
MF+'G!=BN>G0=12:)XDU>[U?58@G]H/$LC"T4I&8&6=HU3<?5 &^;TXZT :^A
M?\C=XH_ZZVW_ *)6I_%?B ^&-!FU06;79C=$$2R!,[F"]2.,9S6)I\_B:SUG
M5K]O"LC+?/$RJ+^'*[(PO//M5;Q:OBCQ%X?ETV'PNT+221L7>_A( # GH>N
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MPD$;/ ^SY\%0>G?(ST':M^W\)74<DC2?9VWD'(8\<\C%1CPA?QQXBDMU.02
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M1U0JJQQC+.[,%51[EB!^-7ZI:KIEOK&G2V5SO\N3:=T;;65E(964]B" 1]*
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MZ079SIUMO8Q%CY8R3%_J_P#OGMZ5H@8I3DI;(<(N.[%HHHJ#0**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&L$_8OW@/F?NV7G^[R1UH&:^H_$#2;&WTEX(KS49M5C\VTMK.'?*Z8R6()&
M*H?#[Q+>>(]3\4-//*]M;7PCM8YH]C1)@Y4C&<@CO6';^%/$FA-X1UFQT^*^
MO=,T\V-W8F=4.&S\RN>.":Z#P#H>LZ5J/B2\UJWAADU*\%PBPR[U QR,]>,X
MYH$7-?\ 'EIH-]-:'2]6OFMHA/<R6EMN2%#W+$@'CGBDU#X@:59V6ESV\5WJ
M$VJIYEG:VD.^61<9)P2, 5S'BOPYXIU?Q!J\9M&U#3;JV"6&=1,$-JVW#%XQ
M]XYY[U%;^%O$FBIX2UJRTZ*[O]+L'LKNP:X5"0V>5?IF@99\1_%,PZ)I5[HM
MG=LUUJ M;A9K8[X=I^>/&?\ 6'MU!Y]*T&\9BR\1ZY-/+J4EO9:9#>-IOV9
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M'V#Q%_T&+'_P /\ \<K<HHN'*8?V'Q$?^8Q8_P#@ ?\ XY1]A\1?]!BQ_P#
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M?W;S_P #IO\ XNMNBB["R,3_ (1;3/[MY_X'3?\ Q='_  BVF?W;S_P.F_\
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M*YBU2RDS>:E&D%J;='8^;)QE%QN)7YCC&?EH [7(I0<UY%I_BO5Y)O#^GKJ
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M'PQABMK> ZD2D188\@'8K-&?W9))5OW?WLDX8CTQ8D^'D<L)MVU$FV:/#(8
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MW_0PZ[_X%C_XF@ \*:1K.E6UTFLZO_:,DD[/$VW&Q"3Q_7VZ5T5<[_PBC?\
M0PZ]_P"!8_\ B:7_ (11O^AAUW_P+'_Q- '0T5SW_"*-_P!##KO_ (%C_P")
MI/\ A%&_Z&'7?_ L?_$T =%16+8^'VL;M+C^V=6N=N?W5Q<!D.1W&!6R.E "
MT444 %%%% !1110 4444 %%%% "'I7!ZOIR:IXOU9;2?4[:ZM]/B>1K?4/LZ
M3-E]BXVGCALMT&>E=[7 ^/)/#EU*+*[ACEUE5C,)%F\S;2^=GR@Y+*KX4^A.
M* .A\&M9MX.T=K".6.T-JGE)*VYU&.A/?Z]ZW",@U3TNZL[W2[6YT\J;.2)6
MAVKM 3' QVQTQ5S(- '%Z]X/O_$&IW4L^H6\5NUK+;PM%"?-VN!A7R<%0PW<
M8)Z53N/ 6I72RS2:A:+=7K3K>[8FV".4QD^7SD$>4.OJ:] P*7 H XRP\$!+
MZ[&H31W&GLDT4$*!D?;+-YS;V!Z@@ 8["I? 5O'9PZ[:0AA!!J\T<2LY;:H"
M8&22:Z[ KEO!G^M\2?\ 8:G_ /04H ZFBBB@!,>]+CWHHH ,>]&/>BB@ Q[T
M8]Z** #'O1CWHHH ,>]'XT4USA: %(S2U@6VMW4_BBZTEM-G2VAB#K=G.UR<
M<#C'?U[&M\=*2:>Q<X2A92ZJ_P!X4444R HHHH **** "BBB@ HHHH ****
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M8TN^1H=1M[.PEC C9L%_-4-P04/R$E,GMCU-=I7+>(]"OM=O((0NF/81KO\
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ML/J*F,N;4UJTG2:3ZI/[R>BBBJ,@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "J6JVT5YIL]O/GRG0AL/L/J/F[<XYJ[5/5
M+9+S3;BVDM8[I)8RC02-M5P>Q/.* .7\"V<R:->QSV1LF=Q'^[E!) C"Y&"<
M'CKU)YHB^'EC;M$8KV[Q#EH]X5MK;F*GIR!O;COWKH=&@AM[<Q0Z6-/52,H
MF'XZY4\_4\UIT <C9^ -*@MY+6X>XN+=PH"&0QE2"23N0@G))XZ#I4_P]R?
MVG;F9B/-4%F+' D<#D\G@5T]<Q\//^1'T_\ WIO_ $:] '3T444 %%%% !11
M10 A (P>E9P\/:*.FD6'_@,G^%:5% &=_P (_HW_ $";#_P&3_"C_A']&_Z!
M%A_X#)_A6C10!FGP_HV/^038?^ R?X5AZ1=6DMSJ[6OAQ;6?3RRQ,(%0S\'A
M3CC./U%=:>E-QS2=RXRBD[JYE^']2NM6TB*[O+%[*9B087SD8/!YYYK67I0
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MW(/% '(6\?B=?$U[*MEX?^TFUAWMYLO3=)CG9G/'/T%:V_QF!Q;:!_X$3?\
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M +\U17Q#)_PE$DG]@ZSS9*NWR$W??;G[_2MK4_#6F:OJ=AJ-Y"SW%@^Z!@Y
M!R#R._(K,#ZM_P +)=,6W]F_V>N3G]Y]XX_\>S^%4HIK05RX/$[DD+H&M$CJ
M/(3C_P ?K:MIC<6T<QBDB+J&\N489<]B/6LC1?"]IH>J:G?V\]S))J,GF2+*
M^54Y)X_.MT#%)VOH,*HZO;7-WI5S;V=R;:XD0K',!G8?6KU!&:EJXTVG=',O
MX774O#-KI6NW$EY)%AGF5MI9@3C]#BNBBB6*-(T&%10H^@IVW-.HLD7.K.?Q
M/35_?N%%%%,S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'O@ >_BGQ*FL1:6?"MM]ID@:X4?VJ,;%95//E]<L*M_VOXN_Z%.U_P#!L/\
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M8V^5+O<K/ZYVC:5QGH:9J'@.:^TNTM%U9H&MYWG41Q 1H7,FX(.H&)"N"2,
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BDMXI0
M\:.!T#*#[]_H/RJ6B@!  H '04M%% !1110 4444 %%%!Z4 %%,,J XW+D\
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MO_OJ#_XU0!O5@^)$\1.++_A'Y+1")LW/VC."GH.*/^$<NO\ H9];_P"^H/\
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M<SJNE>);G7VN=/UQ;73S:M&(#&&(E[-R/7!_#WJY_P (Q:_\_P!K'_@SG_\
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M!I/_ (Y0!:T2ZO+W2+6YO[?[-=2)NEAP?D;TYK0K%\KQ*/\ EZTG_P !I/\
MXY2^7XE_Y^M)_P# :3_XY0!LT5C>7XE_Y^M)_P# :3_XY1Y?B7_GZTG_ ,!I
M/_CE &S16+Y?B3_GZTG_ ,!I/_CE; )P,XS[4 .HHHH **** "BBB@ HHHH
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MW&)^JU>(H  ' I%<T>6UM;[CATI:04M,D**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH KWSS1V,\EN8A,J,R&7.S('?
M'./I7.>"=7EUBRN;B:6U)W)B&V5PD8*CIN ZG)Q6SK\5Q-HETEM=?99=H83\
M_( 02>/8&LWPE):7FAO<:?>":":1B'2U6#:W0_*H&3WS0!T/F>U<[XQ.;'2S
M_P!1:S_]&BN=A\ ZS'#!&^IV[&)'7< P)RK#!P!D.3EB>> .<9J76="O=.M-
M"DFU>Y=(M1M$:R4)Y&?-Z@E=_&?7MTH ]"HHHH **** "BBB@ HHHH ****
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MO3/4\XQ7;4 <OT^*"_\ 8%/_ *.KJ*Y@_P#)41_V!3_Z.KIZ "BBB@ HHHH
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ML;FQ^)LBW.IW%^7T@LK3JBE!YWW1M X^M=M0 49I"<"JQOK4)._GQD0 F7#
M[,#)SZ4";L6LT50TK5['6[)+S3YQ/;L2H< CD=1@U?'2@$[ZH*CFE2"%Y9&"
M1H"S,QX '4FEEC,D3('9"P(W+U'N/>L:3PZ\D31R:WJSHP*LK21D$'L?DH&<
MWJ'B)[O4O[7\,1QZK*-+D$,:Y 8^?&&XX/ R<<5VUA+<3V%O+=0B"X>-6EB!
MSL;'(S[5Q=EX3M])\5V^GZ??W]M;C3I' C= 03*F?X>]=)_8$I'_ "'=7_[^
MI_\ $53:V0&T.E%1P1F&!(S(\A50-[G+-[GWJ2I 0]*3%.HH !1110 4444
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M<C'8F0X_*EH9**3T?F=,.E%5+;4K&[?R[:\MYW R5BE5B!ZX!JW3-1.*S]=
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M'-:MI5W=>-]&U"&PAFMH8V\RX9\%.N.,\]>..YK6M?$-A=Z[=:-$[F[ME#2
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M_P#O@5(D21KM154>BC JFT]D)#ATI:**D84444 %%%% !1110 4444 %%%%
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M-']IV'_/];?]_5_QK-_X0OPM_P!"WI'_ (!1_P"%9\^A>"8-1CT^30=)^TN
MP4:<K  YQN8+A<X.,D9Q2 Z'^T]/_P"?ZV_[_+_C2_VG8?\ /];?]_5_QK@+
MC3_ $VK:1?Q6VE+:E)E\I--RDQ+I&&8A<+M?C+?WJV'TWP"FJ'3&T?1A>B5(
M3#]@4G>R%U'W<<JI.>G% '3_ -IV'_/];?\ ?U?\:%U*Q9@JWMN6)P )5)/Z
MUF#P7X6_Z%O2/_ */_"GQ^#_  U#*DL7A_2HY$8,CI9Q@J1R"#C@T ;0.:*
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M[PWX8LO"]E+:6,DS122&0^85X/M@"BB@#:HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>tm238578d1_ex99-2img08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img08.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &_ R # 2(  A$! Q$!_\0
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M>2.]8VJNNJZ3IL4E^NI1OJ\<3NEOY6T$$$8'U//O7H\D0? **V/49IGD*/\
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M;/NJ![  5/M+H/JC4F^;3TUT=]QR#"U)3 #DY]:?61Z(4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$[7LUH87@T>?X6PO5[B:,9]6C 'ZUG_#W1-4T[7+E[RTD@CAB,;%^[$@\>O
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M !4RE"S1I2IUE.+?XLWQRHI:;GTI<U@>G<6BD!]:"30 M%%% !1110 4444
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M//7IZ4.BTKLJ.,C.2C'O8]#4DGFG4R/H/I3ZQ.\**** "BBB@ HHHH ****
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M'3K4JMD<]:J0R;@%;J*G4X-0T;1>A/12*<TM2:(**** "BBB@ HHHH ****
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M#IMH+J2W\YUDNMJJ=V-H;'-0C0=7ET;0[2X: SV%TK.P?AHUR%/UQCBG>(M
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MM/\ P';_ .+HYY#]C3O>VI>6G5G>5JH_Y>[0?]N[?_%T>7JO_/Y:8[_N&_\
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M*** "BBB@ I&ZBEHH S-"CDBTBVCE0HX#94]CN-:=%% !1110 4444 %%%%
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M&%'TI:P/4"BBB@ HHHH **** &E<]Z-I_O&G44 -V^]+M]Z6B@!-M&WWI:*
M&[?<T;3ZTZB@!NT^M&WWIU% #2F1C/%*!BEHH :4R>OZ4N/<TM%*P"8]Z,>]
M+119 )@^M&/>EHHL@$Q[T8]Z6BBR 3'O1@^M+13 0+@GFEHHH **** "HY&V
MCCK4E-==R\T 9\BL[,<<GO\ Y_SS4L%L%VLP 8>G;_/'Y"K"PJ"214FT4[D\
MH!<4M%%(H**** "BBB@ HHHH **** &LN1414CZ5/2$9IBL5RH(P13/*/56_
M U9*"F%33N2T0;7'4 _2C)]#^53$$=124[BL1;CZ?I2_,>BU*,^]%%PL1[&;
MJ0/I2J@7GJ?4\T\(<Y IX3UI7&D1\FI%C[FGA0*6E<I(,4444AA1110 4444
M %%%% !29I:C?.#CKVS0 _-&:Y"[\1:K8R>3<1VRR#'.W"MPN2,N#C);GV'>
MG:?XN#3 7[6\<9'^L#JH3[Q);+G  0UI[.5KHYOK5._*SKJ*B5]V.>#^M25F
M= M,D;"T^H7ZT#*UPV4\OIN'-8!C:"0HZD8Z'VK;<[Y6)^E+@,<-M/L<4YQ3
M1-*KRNQQ_B#56TG2FN8T#2LP2,'IN/\ G-<&^H:O<S_:I-3O#,#D,LQ4#\!Q
M7I7C?19M5T$"T3=/;.)EC4\L.A'UQTKRQ;Y(U:.3]VPX*OP5/N.M>%CW5IRM
M#8^SR54:V'<K+FNT[]/O/2O OB2ZU59['4'\VYMP&$G=U]_<'^==GCT%>??#
MC1KE)[C6;F.2*.1!'"&7&X$Y)QZ=.:]$4C:>1CUKUL*Y^R3GN?.9K"BL5.-+
M;R_$\A\?>8WC-Q,3Y:P)Y:MTP<YQ^/\ 2L*<1B/KSBO7_$?A:S\1P()F:*>+
M_5S)C*_XBN6M/A>1< WVIF6W!SLCB*%O8DD_I7EXG U:E;GB?18'-\-3P\8U
M'9Q5K=S8\!>:W@ZT\S. T@3_ '=QQ71$<8(IT%M%:V\=O!&(XHU"(J]% I6&
M*]NFN6*B?'8B:JU95([,?$Y*<]0>:M*<K5&,XDQZU;C/!ILF+*FJ_=M/^OJ+
M^=73T-4=5^[:?]?<7\ZND<$5)9S2>*S<74\%OI%]<+!<- TJ!2NY3@GK5JR\
M26=]K-YI:[DNK8X(?HX'4K7)0:1<P:M?27&B:I*9+^25)+>Y")M+ @D!OZ5=
M;PY?3W&L7D436]_'?&XL9&Z.-HR#_LGD5T\L#R8UL0TG:^KOIT5_S-6+Q6MQ
MI5KJ5MI5[-#.K-E0OR;3CYN:+;QE;3VUE=-:7$5M=S&!9GQM5N@SST/8USIL
M-<@\(:7HR:7<^4Q?[6(F7>$WG"C)[CFNC>V;4_"5W9G2)+4I"T<-M(5R2!E<
M8/'-2XQ23?<J%6M--K>W;KO;]!;KQ?:6J:C(+>:6.Q98Y)8\;6<]5'KCO2:A
MXQL-/T.UU1TE>.YY1$QOX&3Q[5FS:+=Q_#JWL8;-S>,(I)H>-Q?<"V3WK+U'
MPGJ7V?6$CMY)8DAVV$61U=@SX^F,548TWUZBG5Q*V6Z739O7\%I]QU-SXI6+
M4Y]/@TN]NY841W,(!QN&1U-%QXK6&Y6UBTV]GN1$LLL48&Z('H&YZ_2N>U/1
M[I_$UY<RZ1J-S!)%$(VM)Q'R%YS\PJ75=-EGDB8>'M0WK"JPW-M=*)0<?=?G
MMZG-)PA=6$JU?E?KVZ';6-TM]9PW2))&LR!PDB[64'U'8U:V\=:RO#T5]%H-
MFFI,&O5C_>X.><GC/J!@?A6MVK!Z,].#;BFP P *6BBD6%%%% !1110 444A
MZ&@!,G-&[WJEJEXUAIEU=JH9H8V<*3@' KFK/Q5J7GZ9_:5A;Q6^HD+$\,I+
M*<9&5(_E5Q@VKHYZF(ITY*,GJ_\ .QV6ZDWXKAX?&FIG3H-3GTVV_L^6;RMT
M<_[P?-M^Z1@_@:T)O$&J7=]<6^BZ?#<16K;)9IY=@9^NU??ZTW3DMR(XJG+1
M/^O0ZDMB@,37'/XON+FQL7L;)/M-S<-:R0W#E?*D&<@D?2HY_&-];6M['-8P
M)J%K-%$8Q,3&PD/!#=>WI1[*1/UZCO?\_P SM<FC<<UQ[>*M0M)KZUO[&".Z
M@M3<QB&8NC =B< BF2^+-1>[MK>TM;'?+9K<DW%P8P,]@<&G[*94L722?]=;
M'9;C1N.>U<AJ7B'7=.LH+L6&GR1.%5FCN2WSLQ  XY'3FI=3\1ZII>GVHFT^
MWDU2X=@EM%*67:H+,V<>@_6E[.6@Y8F";O?379]3JMS>W^%&XUS%[XHE71]*
MO=/@BG;4'1$61RJJ6!.,CW&*JGQ7JB)J$3:7$]]8!998892X>,YSM/\ >&.A
MI>SD.6)II\M_ZW.R!.*-QKG+'Q(-7U<6^FJLUDD(DFN<GY2WW5'OZ^E-U/7-
M3@UQ=+TZSMIG^S>>3/*4P,X[4>SE>P_K-.W-?K8Z4,32YKBY_&<Z:5/,+!8[
M^WN4MIK>5_E4MT.X=O>GW/B?4['2+R^NK;3V,+1A%M[DN#N8*=W QUH]E)+4
MA8ND^OF=@20.U(&)..*R-?U=](T]+F.-9"T\<15R1@,P&?UJI9^(R3K"7T20
M2:82SX/#)@D-^.*7*[&LJT(RY6_ZM?\ (Z/=SCO1DUPZ^+-5==,5+&S2>]@:
M?$\YC5 #QDX[BK5QXCU>.33;6*TL);R\$APMP3&-OHP'I[=:ITI&2Q=.UU?I
MT[V_S.NW'-!)KC%\87BVT\\UA&!970AO1')OV*>CJ1U [BM72M=EUC5+M;6)
M6TZWP@N,G,DG<+[#CFDX-;EQQ$)-)=3?!S2TQ"><T^H.@**** "HY'V]ZDIC
MH&&.] $2S<D$BI@<C@U0E5E9AQ@#KZTZ"ZP5C<@GU!_+_/UIV(YM;,OT4@)I
M:184444 %%%% !1110 4444 %%%% !1BBB@!,4;12T4 )@48%+10 8HHHH *
M*** "BBB@!"<5&9E R6%/;H?I5"8?(< DX/0'T;T!H0F6FNHEZN ?I2?;(>G
MF#.<=/I_B*HS9RV%)Y/\+>I_V:@#$,N5;.X'[K?WD_V?\_J*2,W-HTAJ-L5S
MYJX]<'V_Q%1G5;)<DSJ,9SP?<_T-8:[O(0;'SM ^XW/RQ_['^?Y59BV)!Y<G
MW6'W&_N2_P"Q[']/H6HHS=62V1TK:Q9JQ4W"Y!((VGL2/Z&HSK=CN ^TKR0
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MQ/"I5I?OD8QS[U?'2L7HSOC9I.PH%+112*"BBB@ HHHH ,4444 &!Z48%%%
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MZ25BS%NI)-<>,Q+H15MSU\IRZ&,G*51^ZOU/8=&\3:7KN4LYV\U>3%("K?\
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M+4;K4FDU&82LLD0QP"VPG=CT)%2P7<>&C1=BE@Y"@@,>O^16:Z7!:2-Y/M
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MI8X#??\ 0<M_]:JLNLL8R85C!S@*QRWUP*KZ?8"[+RS.2JM@\\L?<UIL+6S
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ME=.W2N2^(<7F>%)7 SY4J/\ KC^M:4OC5SEQ;:H2:[,XS0=1>X\1Z:ADW 3
M 5ZZV ..U>/>!;7[3XK@./E@#2'\.!7L(&/KFNC%I*IH<&4-SH.4N_Z'AHU.
M3[)Y7F?*0<BO9=&N!=:+9S@YWPJ?TKQ/5[7[#J]_:X_U4SA?]W.1^A%>U>'X
M/LWA^PA_N0*/TJ\4HJ,6CGRF<W6J1ET_S-,=*6BBN ^A"BBB@ HHHH ****
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M84$D')ZGFM$:6IT4Z7YC^6;<P>9QNP5QGZTN>*1;P]5R;NUH^IRUKJ6KZO\
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M16L*10TJ30%(&*?10 P)B@J2:?10 W::39SFGT4 -VFC:2:=10 S::7!IU%
M#-I-+MYIU% #-IQQQ1M.*?10 P)SG H"D'I3Z* "@]*** &,.*XR*Z-MJ>JK
M_:T-GFZ)"20[L_*.<YKM",C%1O;QN"2BY]2H)IIV,JE/FL^QR&M02:CJ<KV,
M+LEJ@2\P2OVA<Y\D>N.N?P[UIRV?]N:3.JW0^QW,.V%!#M:(_P )SGJ"/2MW
MRQC@*,\].]*L87@8 ^E4YD*@M;O<Y+3YYM;FEU"XB,9L[5H"A&,7!!\S'L,
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ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>tm238578d1_ex99-2img09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img09.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %M U(# 2(  A$! Q$!_\0
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MO1_PF]O_ - C5_\ P&_^O1[&?8/KV'_F_/\ R.KHKE/^$WM_^@1J_P#X#?\
MUZ/^$WM_^@1J_P#X#?\ UZ/8S[!]>P_\WY_Y'5T5RG_";V__ $"-7_\  ;_Z
M]'_";V__ $"-7_\  ;_Z]'L9]@^O8?\ F_/_ ".KHKE/^$WM_P#H$:O_ . W
M_P!>C_A-[?\ Z!&K_P#@-_\ 7H]C/L'U[#_S?G_D=717*?\ ";V__0(U?_P&
M_P#KT?\ ";V__0(U?_P&_P#KT>QGV#Z]A_YOS_R.KHKE/^$WM_\ H$:O_P"
MW_UZ/^$WM_\ H$:O_P" W_UZ/8S[!]>P_P#-^?\ D=717*?\)O;_ /0(U?\
M\!O_ *]'_";V_P#T"-7_ / ;_P"O1[&?8/KV'_F_/_(ZNBN4_P"$WM_^@1J_
M_@-_]>C_ (3>W_Z!&K_^ W_UZ/8S[!]>P_\ -^?^1U=(:Y7_ (3>W_Z!&K_^
M W_UZ/\ A-[?_H$:O_X#?_7H]E/L'U[#_P WY_Y'1W7^H;\*H5D3>-+>2,J-
M(U?)_P"G;_Z]5O\ A*XO^@5JO_@/_P#7JHTIVV(EC:%_B_/_ ".@S7%^/]-U
M'Q =*T.UAF6SN+@27ETJY6)%Z9]3U./85J?\)9%_T"M5_P# ?_Z]'_"60_\
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MBCQ6L.B7=['K"[K:>$J$4E2,.2>,9_2NG_X2R'_H%:K_ . __P!>C_A+(?\
MH%:K_P" _P#]>ERS[?U]X_K-#^;\'_D</_PCMV/ OAZUOM OIWMFE\U[279=
M6NYR057HP/%=+X MM=MX]0&J/>_8/,46*7Y!G"\[MV.@Z<>U:?\ PED/_0*U
M7_P'_P#KT?\ "60_] K5?_ ?_P"O0XS:M;^OO&L5AT[\WX/_ ".@R:,US_\
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MW]?>'UVA_-^#_P CH,T9KG_^$LB_Z!6J_P#@/_\ 7H_X2R+_ *!6J_\ @/\
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M *]6!XVMP!_Q*-7X_P"G8?XU<*%1=#.>/P[^U^?^1U=%<I_PF]O_ - C5_\
MP&_^O1_PF]O_ - C5_\ P&_^O6GL9]C+Z]A_YOS_ ,CJZ*Y3_A-[?_H$:O\
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M-/'2F4\=*:)8M%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUO9-Z=/3^M#O*6JMA-YML,G++\I_I5JN-GKIW5PHHHI#"BBB@ HHHH ****
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MKSB6;M%%\S'_  J)U(P5Y.Q<*<ZCY8*[-9F5022 !U/I7!^(O$']J,UE9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &2_ZLU6JS+_ *LU6IHF04444R0HHHH *,444 %)
M2T4 )BEQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %)BEHH 3%%+10.XE+BBB@04444 %%%% !1110 5)#]X_2HZDA^\?I28
MUN6.U,;K3^U,;K4LT0F11D4E%(H7(HR*2B@!<BC(I** #(HR*** #(HXHHH
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MH **** "BBB@ HHHH ***K7-Y';C'WI/[O\ C32N)M+<L$@55EU""/@,7/\
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MI;,,#RRY=BN?J/S->M#I651).R-:;;5V+1114&@4444 %%%% !1110 4444
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M\RW(#?>CXY!&* ->WU2ZE$?G:1=6[/-Y>'>,[1@G?PQXXQZU)I.K0:O9)<Q
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M,ADCB.-G;HHS7*ZG>-%"\N?WLAPM;VIR8@6,?QGGZ"N&UZ62XN4M8<F1RL*
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M;Y]PO^FW0#RDCE1V7\*Z6FA:=7-*3D^9GH4J4:4%".R"BBBI-0HHHH ****
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M444 %%%% !1110 4444 %%%% !1110 R7_5FJU69?]6:K4T3(****9(4444
M59[&&8[L;6]5JE+IDP!V[9!6O15*31$H)G,R:2A.7L^?4+_A4!TBVS_Q[M^;
M5UG>BK51F3P\&<Q'I$6?DL\GU*D_SJ]#IDV -BQK_GL*V:6DZC92H113ATZ%
M,%\NWOT_*K>,# ' I:*ANYJDEL%%%%(84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% $,UM%./WB9/KWJC)I;C)B<'V;@UJ452;1+@GN<Y-I98YEM
M Q]0N?Y56;2;;O;,/^^A75TM6JCL9/#P9RB:3!GY;0M]035V#2Y%XC@6,>N
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M1BEHH ,4\=*93QTIH3%HHHIDA1110 4444 1W#.EO(T:%W"DA1W-<F/$WB#
M_P"*6N/^^S_A7845<9);JYSU:4YM<LW'TM^IQ_\ PDOB#_H5I_\ OX?\*/\
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M'_??_P!:NTHH]I'^5?B'U6K_ ,_7]T?\CB_[?U__ *%>X_[[_P#K4?V_K_\
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M_P"$D\0?]"M<?]_#_P#$T?\ "2>(/^A6N/\ OX?_ (FNQHHYX?RK\0^KUO\
MG\_NC_D<=_PDGB#_ *%:X_[^'_XFC_A)/$'_ $*UQ_W\/_Q-=C11SP_E7XA]
M7K?\_G]T?\CCO^$D\0?]"M<?]_#_ /$T?\))X@_Z%:X_[^'_ .)KL:*.>'\J
M_$/J];_G\_NC_D<=_P ))X@_Z%:X_P"_A_\ B:/^$D\0?]"M<?\ ?P__ !-=
MC11SP_E7XA]7K?\ /Y_='_(X[_A)/$'_ $*UQ_W\/_Q-'_"2>(/^A6N/^_A_
M^)KL:*.>'\J_$/J];_G\_NC_ )''?\))X@_Z%:X_[^'_ .)H_P"$D\0?]"M<
M?]_#_P#$UV-%'/#^5?B'U>M_S^?W1_R.._X23Q!_T*UQ_P!_#_\ $T?\))X@
M_P"A6N/^_A_^)KL:*.>'\J_$/J];_G\_NC_D<=_PDGB#_H5KC_OX?_B:/^$D
M\0?]"M<?]_#_ /$UV-%'/#^5?B'U>M_S^?W1_P CCO\ A)/$'_0K7'_?P_\
MQ-+_ ,)+X@_Z%:X_[^'_  KL**.>'\J_$/JU;_GZ_NC_ )''_P#"3>(/^A6G
M_P"_A_PH_P"$F\0?]"M/_P!_#_A7844<\?Y5^(OJU7_G\_NC_D<?_P )-X@_
MZ%:?_OL_X5KZ%J>HZBTXOM*DL1'MV%VSOSG/8=,#\ZV:*4I1:TC8TIT*D97E
-4;7:R_1!11169U'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>tm238578d1_ex99-2img10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %6 R # 2(  A$! Q$!_\0
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M\:H\WPW_ ,^6K_\ @9%_\:HN^P<OF9%*KM&ZNC;74AE/H1TK6\WPW_SY:O\
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MM(H$,RJ<,AY+$-SGUQ7,^;X;_P"?+5__  ,B_P#C5'F^&_\ GRU?_P #(O\
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M_E4U0Q?\?$_U7^5 $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ZS\'/\
MCQU;_KK'_P"@FO)J]9^#G_'CJW_76/\ ]!-85_X;-\/_ !$>7?$3_DH&L?\
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MWFJPK=32W33;PDV?E4\+DG\OPQY[15R@I.[(C4<59'L]I?F^\7>(+:4;KFQ
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M_P E UC_ *[?T%<Q73_$3_DH&L?]=OZ"N8KII_ CFJ?&_41ONGZ5O1_ZM/\
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M\4D]A+"MK<^8-Z_WE_.C>O\ >7\Z^G_[/LO^?.W_ ._2_P"%']GV7_/G;_\
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MQ5R\\3N#=FSC8+$((U\^UE#F21R#\A 8@*,X R:2;6]0@L!+YB2R2W"01_\
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MS(GW2[F0,)(R"RC)&T-O'0\E0..O(S//KUI;7OV219?-\Y(3@# W*"&Z_=Y
MSZF@#3HKG9?$KO+;_8[:259C%\A10P5RQW9+C^!"<8[J3W%6-%UTZF_E2V\D
M3L'DC8J KQA]H(Y)].H&>U &U1110 4444 %%%% !7&-8SW/BC6I(+^6UPT(
M8)&C;OD//S UV=<S:?\ (QZY_OP?^@&M(=3"MT]?T9&--OUZ:Y<?^ \/_P 3
M3OL&HC_F.W'_ (#0_P#Q-:1I#WJS&WF_O?\ F9WV34Q_S';C_P !H?\ XFC[
M/J@_YCMQ_P" T/\ \35\TT]:9+7F_O?^91\G5O\ H.W'_@-#_P#$T>7JP_YC
MUQ_X#0__ !-7.]-/2F3;S?WO_,J;=6_Z#MQ_X#P__$TA&KC_ )CL_P#X#P__
M !-6CUI#3T[$N_=_>RF%U8$L-<GR>O\ H\/_ ,303J__ $'9_P#P'A_^)JSV
M%--.R["U[O[V5&FU@?\ ,<F_\!XO_B:B:[UH?\QN7_P'B_\ B:LO59^]6HKL
M82E);-_>R%M0UM?^8U+_ . \7_Q-1-JNN#_F,R?^ \7_ ,33I*K/6BA'L<TZ
MU1?:?WBMK>O ?\A=_P#P'B_^)J)O$&OC_F+'_P !X_\ XFH9.E5WK14X=CEG
MB:R^V_O++>)O$ _YBI_\!X_\*@/BGQ K%AJ?)Z_Z/'_A5-^E5GK14:?\J.66
M+Q"^V_O-%O&'B,?\Q,?^ \?^%=EX2\7)K2?8[PK'J,8R0.!,/[R_U%>9O59I
M'AD2:.1HY8V#1NGWE;MCWHJ8:$XV2LPP^:5Z-1.;<EV_R/H"BLOP_/J5SHMO
M+JT"PW;+\RJ>H[$CL3Z<UJ5XS5G8^VC+FBI=PHHHI%!1110 Q5 F=@V2<9'I
M3Z8J@2NP;).,CTI] !1110 4444 %%%% !4:J!,[!@2<9'I4E1JH$SL&R3C(
M]* )**** "BBB@ HHHH **** .>T_P#Y'K7/^O.R_G/4=YXHN].O3'=Z,T<#
MK,;>07 9W\M2QW*!\H(!P<GMG&:DT_\ Y'K7/^O.R_G/4#>'-5FO=1FN=2L9
M5O(I(0WV-Q+%&1\J*WFE0!P3A1N(Y[8UTOKV1EK;3NQ^G^---U2_TNTLYK:>
M6]@:5UAN5=H,*&PP'/?';I5C4M=O-.OX4?2BUB\\<!N// 8L_0JF.0#UY!Z\
M'%)!X<\B[T2<7"?\2RW:!@(\>;E N<YXZ9QS3;G1=5G\0QZ@+^Q:VB(\J":T
M=FC'\15A*!N/]XJ<4O=N'OVU*]GXNEO9I8X=*=R\4DMCMF&;@(^PYR $Y*GJ
M>#^%(WBR\2UO?-TJ&&YLIQ%<>;>JEO&"@<,92OHRC&W.3Z<U%;>$+^Q:1K35
MXHVB@D@L";7/D+(^]B_S_.> !C;TY!JU9Z'K-AIBVUMJ6G12I*7R+%V24$<^
M8&E+LQ8[MV\$GKFF^3H)<_4U=+U6/4[*TN%AFA:XMDN1'*A!16&0"<8S[9S6
M6/&>F0_:/MQ>V,=W+;(JH\K2>6 68!5) P<^P%7=!T>30M+M--6Y$UO;PA-S
M)AV?));(. .>% X]:RQX/<7[7/VY?FN+J?;Y/_/:,)C.[MC/O[4ERW=RGSV5
MA]UXUL;:\B@4+.LTD:(\1=@ Z%PS83 &!V)_"KD/BC3F2R\Z4H]V%*%(Y'C!
M;[H,FT 9[9Q6);^ Y[:. 1ZI&7B^S\M;$@^7$T9X#]]V>O'O37\ W$DE@&U6
M)XK-8?+62V+%&C.24^?"[N_!/3FJM3[D7J=C?L?$5M<^'SK%T/LMNI8/N.[&
M&V]ASD]@.],D\8:%%9QW3WQ$<A<8$,A==GWRR[=RA>Y8 #O4"^%F7PM_8XO!
MYJR^='/Y7"N)-ZY7/(SP1GGVJK>^%=6O<3R:W!]M>":UFD^Q?N_*D(.$3?E2
M,<$LWN#4VA<J\[&C<>+]"MKMK62^S,KB,JD,CC<4WA054@DJ<@#D]!DU6D\<
M:-%=6ZO/_HMQ:BYCN0K$;=VT[@%RH'=FP!T.*AA\%B"X5X[W]VNHP7JJT63B
M*!8MA.>IVYSC\*I?\('>1VT<%OK$2*;"6PF+6FXLDDA<LOS_ "MS@9R.^#32
MI]Q-U.QT@\1:4=6_LL78-WG;MV-MW;=VW?C;NQSMSG':J?\ S4!/^P6W_HU:
MJVW@][74D:._']G)=B]6W,.9/-"!,>9NQMX!QMS[XXJT?^2@)_V"V_\ 1JTK
M+IV'>77N?/7Q*_Y*'K'_ %V_H*N6/P^?Q!H%KJFA71&56.YBU >2!+CYC&^-
MKKD'OD<9JG\2O^2AZQ_UV_H*T)4TZXGTJT\2ZCJMQ9PZ+;RQ0P;5Q([1[4B4
M@@@1ODGJ2A^E>G=J$;'F63G*YQ=[:26%]<6<Q0RV\K1.4;*[E)!P>XR*^O\
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MAUB'_GTU3_P67'_Q%;BU*.E/VGD+V+_F_#_@G._VO#_SZ:I_X++C_P"(IO\
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M[,>YK0HHKG;;=V>G&*BE&*LD%1KL\Z3'W^-W]*DJ--GG28SOXW?TI%$E%%%
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M_017QS7V-IG_ ""K/_K@G_H(KEQFT3KP6\BU1117GGHA1110 4444 %5[_\
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M;3/^059_]<$_]!%?'-?8VF?\@JS_ .N"?^@BN/&;([<%O(M4445YYZ(4444
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M\2O^2AZQ_P!=OZ"N4KJ_B5_R4/6/^NW]!7*5[5/X$>'4^-^H5]C:9_R"K/\
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M&PN<A3[_ .%=-3(X8H=WE1HF]BS;5 W,>I/O0 ^BBB@ HHHH **** "BBB@
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M #3&AZHIQ[4NQ<YVC/3.*6B@!-JXQ@8],4;5QC _*EHH ;L3=NVC/KBG444
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M-6!F=<8(QD^M24 %%%% !1110 4444 %1JP,SJ%P0!D^M25&K S.N.1C)]:
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M<?=QSZ\5)69TA1110 4444 %%%% !4:.#-(F "H'/KFI*C1\S2)@?*!SZYH
MDHHHH **** "BBB@ HHHH C5\S.N!\N.?6I*8KYF=<#Y<<T^@ HHHH ****
M"BBB@ J-7S,ZX'RXY]:DJ-7S,Z8^[CF@"2BBB@ HHHH **** "BBB@#G]/\
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MM_Z-6JCU)ET*>I_#7PKJ^HS7]]IK2W,[;I'^T2#)^@; JI_PJ3P7_P! EO\
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M]UG_ ,&US_\ %T?\(C8?\_NL_P#@VN?_ (NBBCGEW#DCV#_A$;#_ )_=9_\
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MS_X-KG_XNC_A$;#_ )_=9_\ !M<__%T44<\NX<D>P?\ "(V'_/[K/_@WN?\
MXNC_ (1&P_Y_=9_\&US_ /%T44<\NX<D>P?\(C8?\_NL_P#@VN?_ (NC_A$;
M#_G]UG_P;7/_ ,7111SR[AR1[!_PB-A_S^ZS_P"#:Y_^+H_X1&P_Y_=9_P#!
MM<__ !=%%'/+N')'L'_"(V'_ #^ZS_X-KG_XNC_A$;#_ )_=9_\ !M<__%T4
M4<\NX<D>P?\ "(V'_/[K/_@VN?\ XNC_ (1&P_Y_=9_\&US_ /%T44<\NX<D
M>P?\(C8?\_NL_P#@VN?_ (NC_A$;#_G]UG_P;7/_ ,7111SR[AR1[!_PB-A_
MS^ZS_P"#:Y_^+H_X1&P_Y_=9_P#!M<__ !=%%'/+N')'L'_"(V'_ #^ZS_X-
MKG_XNC_A$;#_ )_=9_\ !M<__%T44<\NX<D>P?\ "(V'_/[K/_@VN?\ XNC_
M (1&P_Y_=9_\&US_ /%T44<\NX<D>Q$O@K2TN))UN-6$LBJKN-4N 6"YP"=^
M3C<?S-2_\(C8?\_NL_\ @VN?_BZ**.>7<.2/8/\ A$;#_G]UG_P;7/\ \71_
MPB-A_P _NL_^#:Y_^+HHHYY=PY(]@_X1&P_Y_=9_\&US_P#%T?\ "(V'_/[K
M/_@VN?\ XNBBCGEW#DCV#_A$;#_G]UG_ ,&US_\ %T?\(C8?\_NL_P#@VN?_
M (NBBCGEW#DCV#_A$;#_ )_=9_\ !M<__%T?\(C8?\_NL_\ @VN?_BZ**.>7
M<.2/8/\ A$;#_G]UG_P;7/\ \71_PB-A_P _NL_^#:Y_^+HHHYY=PY(]@_X1
M&P_Y_=9_\&US_P#%T?\ "(V'_/[K/_@VN?\ XNBBCGEW#DCV#_A$;#_G]UG_
M ,&US_\ %U8T[P[8Z9?->PO>23M%Y1>YNY)\+G.!O8XY':BBES2?4.6/8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>tm238578d1_ex99-2img11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #' 9 # 2(  A$! Q$!_\0
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MHH **** "FDG/%.IC4F!1_MFQ^U/;_:4,B Y SVZ_E2VFL65_(8[6X65@,D
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M&UH5?85E/4^Q[BGOJ]C$RJ]W"I<!ERW4'H:J/I-Y)Y4SWP:ZCD,BLT64&1C
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MF#=$?I7MNE?\@FR_ZX)_Z"*VQ-*,&N4=M+EW%%%%<H@Q1BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>tm238578d1_ex99-2img12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] R # 2(  A$! Q$!_\0
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M_BT?\+.MO^@9-_W\6O-Z*/J=+L']M8S^9?<CTC_A9UM_T#)O^_BT?\+.MO\
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M\+.MO^@9-_W\6C_A9UM_T#)O^_BUYO11]3I=@_MK&?S?@CTC_A9UM_T#)O\
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MX6=;?] R;_OXM'_"SK;_ *!DW_?Q:\WHH^ITNP?VUC/YE]R/2/\ A9UM_P!
MR;_OXM'_  LZV_Z!DW_?Q:\WHH^ITNP?VUC/YE]R/2/^%G6W_0,F_P"_BT?\
M+.MO^@9-_P!_%KS>BCZG2[!_;6,_F_!'I'_"SK;_ *!DW_?Q:/\ A9UM_P!
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M ?G]!34BLTM=&B^Q(TMYM,LS.V?]:5P!G X&#3]LME_6_P#D)8.6[=OO\O\
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MT4MC9P_:[Y;566.SMYTMBS; TF,D\Y(&3W[TZ.SL-IO9+(!6TXW7V<.P4.)
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M8K%+,\Q^SBYWJ'CV_=0C&&!]>N!55[>UET+S+2*$RPQJUUO+"56+8W#G:5Y
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M5(_X%5T:5:6VH6@,9VWE\IM\.01!@'KG_: S[&IE72;5M36G@IRBIWT?]?\
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MU9TVRAN=<MK*5Q+#),L;/$QPPSU!(K0N=*ME6S9[2XL99KL0&"5\EXSCYQD
MCT]*3G"+M8I4:U6+G?;3?^N_<R8K^\AF$T5S(DJH(PP/\(& OTI)+ZZFEEED
MN)'DE39(S-DLOI].!6U=:*K:O'I\>FW%DKW!C6XE=F#*,Y(!'H,U1!TJZN8K
M>WM+B/=.J+*T^XNI;!W#'!QZ4E.#U2*E1JQT<NOGO]Q5TZ\_L_4K>[V[_);=
MM!QFB75+^X>%YKR:1X3F-F?E3ZCWXZUKQZ5:*M^Z6<UZ]O=O$8(Y=K1Q#H_
M)/IZ<5!8QZ9+I][++82N]K&KY%R1ORX'(QQUHYX-WL-4:L8J'-9.[Z]/1>11
MEU2_FDCDENY6>)M\9)^Z?45%:WES92-);3O$[ JQ4]1Z4^&U:_NI$M55,(\J
MQLQ)PHS@'')QFG1VL<26MS>%OL\^XHL7WV .._ !/&>?I5^XM#!*M)\R?S_
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MQR0C8Y]?8_2HH[J>&*6.*5T28;95!X<>]6K;2Y+J;R1/;13F0Q+!)(0[,.W
M('/'.,U?TVPMITTDR0@F9KD29)^;:N5_(TY3@F*G1KRMK;M^1F6^IWUK#Y,%
MW+'%R=JG@9ZX]*KM-(PC5I&(B&(^?N\YX_'FG6T(G?:TT,*A<EY6P!^0))]L
M5<_L:<7#(9;?RE@%QY^\^7Y9. W3/7C&,U3<(O4RC&M-:7:V&/K.I2,C27LS
M,AW*=W(.,9^N#UI=.U6:PGC?=(Z1+((U#8V%U()'IU!_"F'3)]L+Q-%,LTYM
MT:-B07X]NX(-68]!N9=H^TVBAIWMX]TI'F.IP0..^>O3Z5#=*UC6$<3SW5[_
M ->94DU.^FGCN);N5YHP0CD\KGKBFVM]=V(86MQ)%O W!3PV.F15F71KF%48
MR0.3.+=Q&^?*D/0-Q]>F>E.FT.>$.7N;4B*413[)"3"2<#=QTX[9I\U.UA>R
MQ/-?6Y FK:@@D"7DP$K%G^;J3P33'U&\>S%HUQ*;<  1[N,#H/H*OWNA>3J]
MW9V]S"\5N"SRNQ C4''S\=<D<#/6H5T.Z>X2))+=EDA:=)A)B-D7J<D<8P>#
M24J6XW2Q*=M>V_\ P2&+5;^">6:&[E228YD8'[_UJ!KF=Q,'FD83,&ER<[R.
MA/ZUI#P[<L8O+N;-Q.I:WVRG]]C.0H(R#QWQ56TTU[V,>3<VWG,K,L!D.]@.
M3QC /!X)%-2I[HETL1I%W^__ ()5FFDG;=*[.VT+EO0# 'Y5H7VN7EW&(5FE
MCMO*2,P[\@[5 _(XSBK4.APO#I4PO+5VNR=T+R,N[#8"@A3CT/O5(:3*\;3/
M-;6R-*\<0FE(+E>H'';IDXI<]-[]"E2Q$(NW7?[K_J1+J=\MI]E%W*+?:5\O
M=QM/4?2JSRO+MWN6VJ$7/91T%7-,LXKEKB:YWBVM8C+((S\S<@!0>V21S5W3
MH=)U'4XT:UF@A2*6295FWY"KD8R,YIN48WLMB8TJE11O+?1)LQY)9)4C621F
M6-=J _PCK@?B:MQ:UJ<);RKZ=-V,X;T&!^G%6YM&BMH-0,LA_<30+%*.ACDW
M'=COP :-;L(+"3RH;":--_[JY,V])TQU'&,G@\&DIPDTK%NC6IQ<[VMZ^?\
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M/KS5*'Q#JGVS5T?3V,=M 954L&,;A<["5ZYZ^HKJ4D61 Z$,I&00<@BEVCG
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M=V.<FQN&Y3_<;_']:FA\;6$3B/5(;G39NZSQ''X$=:Z@]*CDACE7;)&KJ>S
M&M>=/XD<GU>5/^#*R[/5?+JOO,Q?%.A,N1JUGCWE JC=^.= M0=M[Y[?W84+
M9_'I6JVAZ4[;FTVT)]3"O^%3QV=K"NV*UA1?18P*%[/LP:Q+6\5\F>9ZU\0;
MV_1H;!/L<)X+YS(?QZ#\*Y MDDDDDG))/6O?A;P_\\8_^^12_9H/^>,?_?(K
MJIXJ%-6C$\C$916Q$N:K5O\ (^?\CUHR*^@/LT'_ #QC_P"^11]F@_YXQ_\
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M%&17O_V>'_GC'_WR*/L\/_/&/_OD4?7_ .Z+_5U_\_/P/ ,BC(KW_P"SP?\
M/*/_ +Y%'V>#_GE'_P!\BCZ__=#_ %=?_/S\#P#(HR*]_P#L\'_/*/\ [Y%'
MV>#_ )Y1_P#?(H^O_P!T/]77_P _/P/ ,BC(KW_[/!_SRC_[Y%'V>#_GE'_W
MR*/K_P#=#_5U_P#/S\#P#(HR*]_^SP_\\8_^^11]G@_YY1_]\BCZ_P#W0_U=
M?_/S\#P#(HR*]_\ L\'_ #RC_P"^11]G@_YY1_\ ?(H^O_W0_P!77_S\_ \
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MH;=HE\IT7)4HV,D@8)!.>O%6= N7O+*.62\N9Y'BC9Q-!Y:J2,_+\JY&?<T
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M^K?A0!/1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.]4+DM)I_B"U:5Q##:QS+&MZT^UCNSEO? RO2NTBM;>!&CA@BC1_O*B!0WU
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M\:WG2<::D>=1Q<*F(G22=U^AN44@Z4M8'HA1110 5%<?ZL?6I:CF4LF ,G-
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M.!GUIDT?G0219QO0KGTR,5$%))\SN7-Q;]U6.:T?7+F'P_<O?N9[NWC256(
M,JR*#'T_VCM_"K&D7VHQ:/.USB\N8KN2%W>18E4 ]23T%2KX;B\_2I6N&)L(
MEC90O$VWE<_1LFB7P_OC^6X0NMZ]VHEBWH2V1M9<C.,\'UJR!4\1"6SM98;)
MY9KBX>V$22*<.H8GYNA7CKZ5)#K@D$*R6KQS/>&SDCW@['"[LY[C&/SIMIH(
MM1:@W.\P7<ET3Y87<65AC X'WJ6;0V<2O%=>7.;W[;$Y3(1MH7:1GD8!].M
M%37=4N&L+V&TA</%=16[NLNPD-M/![9W8]NM6+G5VT>.)9K(K NQ2SW:M)R0
M. >7P3UZTHT%VMKJ.>],LES<QW#2>4%P4*_* #T^6H[_ ,.&]NKN074:)=.C
MMN@#NI7& K9X7C.,>OK0!;75)IK^:"VL7FA@E\F682JN'P"< ]0,C)JC8Z]>
M&PGN;VS50MZ;92D@/679C\,]>]74TRXM]0GFMKX1VUQ-Y\L)A#-NX!VMG@'
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M4?VEB._X!_9&%[/[SO?^%AP?] Z7_OX*/^%AP?\ 0.E_[^"N"HH_M+$=_P
M_LC"]G]YWO\ PL.#_H'2_P#?P4A^(<&/^0=+_P!_!7!T4?VGB._X!_9&%[/[
MSI->\1:=KT,"7&GS+Y,H<,'&2O\ $OXBM=?']LJA5TZ4 #  D'^%<)15/-,2
MTE?;R,UDF#4G)1U>^IW@^(< _P"8=+_W\%+_ ,+#@_Z!TO\ W\%<%14_VEB.
M_P"!I_9&%[/[SO?^%AP?] Z7_OX*/^%AP?\ 0.E_[^"N"HH_M+$=_P  _LC"
M]G]YWO\ PL.#_H'2_P#?P4?\+#@_Z!TO_?P5P5%']I8CO^ ?V1A>S^\[S_A8
M=O\ ] Z7_OX*/^%AV_\ T#I?^_@K@Z*/[2Q'?\ _LC"]G]YWG_"P[?\ Z!TO
M_?P4?\+#M_\ H'2_]_!7!T4?VEB._P" ?V1A>S^\[S_A8=O_ - Z7_OX*/\
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M46YN5&(,D!F/.<XP?]KVK3V<FKHR=:"DXOH045?-A#NC*SN8A;^?*VT @9P
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MUIEG=_8]02Z2($(Q(3=C@YXS^-2'3+DG"JNXNJF/>"R;ON[OK_G%0_9)#<M
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MR?#*E?#5AN&-T9<#T#,6'Z$5K4 %%%% !1110 4444 %3V_5OPJ"I[?JWX4
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M8DY4KUSGH3SUYKUO[#9_\^D/_?L4OV&S_P"?2'_OV*IY;5?_ "\_ G^U*/\
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M'ZUZW]AM/^?2'_OV*/L-I_SZ0_\ ?L4?V94_Y^?@/^UJ3WI?B>4-J$(TYHP
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M!+"+PW[VIN/*^7:J;]VW/4@@8S5G0%G6ZUD7+QO,+T!GC7:&_<QX..W'ZYH
MVMPR0",]QFC<N<;AGTS7%QV#7EY??9=/87JZJS#4,JHB4.I(SG)XR,8[U;TV
MVCDU[4)CHT=P5U!L7;,F8L*O0'GB@#J<C) (R.H]*6N8TRU31]4@M;VPC-S,
M\@@U*,Y,QY8A^X;&?4<5T] !3)8DGA>&5=T;J593W!X(I]% "*JHJJJA54
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M: *5MHME:W*7$:3-)&"(_,G>01@]=H8D+QQQ6A3/+&,_-CZFCRQ_M?\ ?1H
M?13/+'J?^^C1Y8]3_P!]&@!]%,\L?[7_ 'T:/+'^U_WT: 'T4SRQ_M?]]&CR
MQ_M?]]&@!]%,\L?[7_?1H\L?[7_?1H ?13/+'^U_WT:/+'^U_P!]&@!]3V_5
MOPJKY8]_^^C5BU7:7Z]NISZT 6:0G%!.*YCQ;XPC\/+!:6MNU]K-Y\MI91]6
M/]YO11Z__7(23;LA-I;F[?:C9Z9:/=7UU#;0)]Z25PH'YUQTGQ0L;N5X= TG
M5-;=>-]K;D1?]]'I]<4S3/ $NJ72:KXUN?[4OSREIG_1K<?W0O1OJ?UZUW4-
MO%;Q+%"B1QJ,*B*% 'L!5^ZO,GWGY'##Q=XU<;T\ 2A?1[] ?Y4R?XD:EID#
M2ZSX*UBU5>KP[9D'U;@"O0,48HYE_*'*^C/+/^%ZZ'_T"M1_\A__ !5+_P +
MTT3_ *!6I?\ D/\ ^*KHO%/PWT#Q,DDCP"SOFR1=6ZA23_M#HWX\^]> ^)_"
MNI^$]2^R:A&"KY,,Z?<E'J/?U'45TTX49Z=3GJ2JPUZ'KG_"]-$_Z!6I?^0_
M_BJ/^%Z:)_T"M2_\A_\ Q5>$T8^E;_5J9A]8F>[?\+TT3_H%:E_Y#_\ BJ/^
M%Z:)_P! K4O_ "'_ /%5X3CZ48^E'U:F'UB9[M_PO31/^@5J7_D/_P"*H_X7
MIHG_ $"M2_\ (?\ \57A-2K;2O:R7"@&.-@K'/.3TH^JTQ/$S6[/<?\ A>FB
M?] K4O\ R'_\51_PO31/^@5J7_D/_P"*KPFBCZM3']8J'NW_  O31/\ H%:E
M_P"0_P#XJC_A>FB?] K4O_(?_P 57A-%'U:F'UBH>[?\+TT3_H%:E_Y#_P#B
MJ/\ A>FB?] K4O\ R'_\57A-%'U:F'UBH>[?\+TT3_H%:E_Y#_\ BJ3_ (7I
MHA_YA6I?^0__ (JO"J*/JU,/K%0]NN/C-X;NI())M&U%V@?S(R?+X;&,_>J?
M_A>>A_\ 0*U+_P A_P#Q5>(6UI)<B8H5'E1F1MQ["H!S2^JTM[!];F]+['NW
M_"]-$_Z!6I?^0_\ XJE_X7IHG_0*U+_R'_\ %5X313^K4P^L5#W;_A>FB?\
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MTT3_ *!6I?\ D/\ ^*KPFBCZM3']8J'NW_"]-$_Z!6I?^0__ (JC_A>FB?\
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M7KC^TUL-(L$OYOLPNI&>X$2K&QPH!P<L<'T''6L:?7]?.H>(K<:;$UK9P(P
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MY(/'%<CJ6EV7B?XHRZ9K$7VJQLM+6:*W=B$\QG(+$ \G'%1:OX9UBQUW1O\
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M_#_(T?L6F?\ 03/_ 'Y-'V+3/^@F?^_)K.HHN'LI?SO\/\C1^Q:9_P!!,_\
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MCF2XNKCS<;R+./:J;5R S,SC'(JK!\/)I7N=^JP+ DZV\4P7*LS1^9\_S?(
M" >N":PF\4ZW)>0W4E\TDL-M]D7>BLOD_P!PJ1AA]0:;'XCU2)9T62#RIW#M
M$UK$8PP&T,JE<*0.,@"LE&JNIHY4WT-;Q!X:AL/#^G:Q&5@CFM;=!&@+F:9@
MS.Q.<*, ?7MWJC'8Z;+X%N=02"8:A;WL4+RM+E2KASA5QQ]T<G)SZ51EUS4Y
MK)K*2Z9[9HXXC&54C;&24[<$9//7GG-.CUW48M'?24DB%BYRT?D1DD\\[MN<
MC)P<Y%4HRLE<ERC?8SJ***V,@HHHH **** .P\->'=+U72[*_NE=8;6\F&IL
MK'_4+%YB_3[K"KUSX C1IK16>.=)[JX\[[Y^QQE%3"Y&XLSCG/K7&VFK7]C8
MWME:W+16U\@2YC &) ,X![CJ>GK5Q_%6N27D-U)?M)+%;?9%\R-64P_W&4C#
M#Z@USN%2]TS92A;5&Y#\.YI9;D/JMNL*3K!%,%W*S&,2?.=WR  @'K@FJWB'
MPS#8:!IVL(R0136MN@C7+F:=@S.Q.?E& /KV%9,?B/5(UG198/+F<2-$UK$4
M#@;0RJ5PIQQD 5%)KFIS6+64ETS6S11PF(J,;8R2G;J,GGKS34:E[MB<H6LD
M=):>#XAX O\ 5+FSNI+\VZ7=O(H;RXXS*%QZ,2NYCZ#'K7%5<@U2_MK.YLX;
MJ5;>Y18YH\Y#*""!STY':JE:1BTW<F332L%%%%60%%%% !1110 5);M"EU"U
MRA> 2*95!P2F>1GMQFHZ0C(Q28'I%Q\/[3R;ZVM_,^WMJ.;(;LAK/S(TS[G]
MZ#G_ &365J7@J%K6\U.PO$BM6,TUG"XR'A20H/G)^\V"0,'([UCQ^+_$$5Y!
M=)J<HG@M?LD;[5^6+^[TYZ#GKQ50:U?C2UTXRQO;(&$8>%&:,,<L%<C<H)YX
M-8*-1=3=SIOH=C9^ (K#Q!:6U_<17:F26">W(\L^8('<%3NRR KC/'(Z<UA6
MGAN&W\<V.@7TDMR/-CCN_LZ$%6(RP4]P.[>F2*IR>*-8FNH[MKI/M2;OWXMX
MQ(Q*E"68+ECM)'.:KC7-474;74!>/]LM46.&; W!5& #Q\W''.>.*:C4ZL3E
M#HC3\8:59:9=V'V&.)8[BV\UGMYS- [;V&8W/) P <]\USM7-1U6]U5XFO)%
M80IY<2)&L:1KG)"JH '/-4ZT@FHV9G)INZ"BBBK)"BBB@ HHHH [OPUX:T74
M['2=2ODD6Q1;B/4BLA_U@=!'],^:G_?-!\ K]F2WED-O=6L<DU]( &)5IS%"
MJJS*.=CMG(X]<BN0AU;4+?2[C3(;J1+*X=9)81C#,N,'/7L/RJX_BK7)=1FO
MYK]IKB>(0RF6-&61!T4J1M(!YZ=:YW"I>Z9NI0MJC8/@%ULKJ>35[4!)+B.!
MUVF.7RAG)8L,;L@# ;GK47B[PY;Z3;6VHQ%8HKJ.!88$0MD^1&\C,V?E^9^!
MU.2>E8P\0:H+::V-PK0S.SLC01D*S##%<K\F1Q\N.E,NM;U.]M7M;F[>6!S&
MS1LJXS&FQ".."% &1U[YIJ-3F3;$Y0LTD;\VG:-+X1AO=/M+:ZFM8X7U)UO)
M!-&S.01Y9&W!X&03C/2JOBVQTRQ72Q:61L+^6W,E[9>>TODY/[O);D,5Y([9
M%4!XEUE;*&S2]*00M&RJD2+DH04W$#+8P,;LU'JNO:IKC(^I7(G9"2&\E$.3
MU)*@9Z#K3C&2:=Q.4;6,ZO8O@/\ ?U[Z0?\ L]>.U[%\!_OZ]_VP_P#9Z6(_
MAL=#^(CUV;_6?A4=23?ZS\*CKRSTPI",\52BU:RGU*33XY2;F,99=IQ^?XU9
MN!,T#BW>-)L?*TBEE!]P",U,9*6S*E&4=)*Q2M]"TVUG6:"W*%&+(GF,40GN
MJ$[0?H*N16L,$T\T:!9)V#2G)^8@8'TX%8MG?ZO(FHS3R61BLI)8RJ0N&<JF
M002QP,D4[2_$#7'AZ:_OHU2>V7,J1Y .5#(1G^\"*HDU+W3[;4(T6YC+>6V]
M&5RC(?4,I!%0G1;#[+%;K')''$2R>5,Z-D]26!!.>^<UCKK^H'2+::;[';W,
ME^UI(T@/EQ@;N>H],=:WM/DEFME>:YMK@LQQ);*0A'MR>>O>@")]%T][*.T^
MSA88FWQ['965N?F# YR<G)SS2'1-/-G':^05CC<R(RR,'#GJVX'.3DY.><UD
M6.OWLTMDTK64J75R\'D0@B6, M\QY.1\O/ ZUKIK5E)=K;JTN6D,2RF)O+9Q
MU4-TSP?R- %BSLK>PB:.WCVJS%V)8LS,>I))R3]:?;VT-HC) FQ6D:0C).68
MEF//J2:S#XFTQ7VM),!YC1;_ "'VEQGY <<MQP*G77+%K*2Z+R(L<GDLC1,)
M!)QA=N,Y.1Q0!-_9EGY)A\G]V9_M!&X_ZS=NW=?7GTJ,Z/8F\:Z$3K*SAV"3
M.JLP_B*@X)_"F+KM@;6XN'>2(6Y"RQRQ,KJ3]T;>ISGC'6JMOKT4E_J)D=XK
M2U@A<K+$4='8N""",G.%P/>@#1?3;-X9H6A!CFE\Z1=Q^9\@YZ^P]JBFT33[
MBZ:YE@+.[!G42,$=AT+*#@GIU%5+[7%_LJ]EM/,BNK<(3'/$48!F !VGJ",U
M8EU>"SEOFN[A1#!-'$ L390LH(!/\62>U %K[!;?VB+_ &,+G:$+*[ ,!TRH
M.#C)QD5E1Z"\>@:G9*85N+YII'90=BLYX'X# JXNNV+6TTQ,R>2ZQO%)"RR;
MF^Z I&23GCUJ6PU.#46F6!9U:%MD@EB9"&].?P_.@!MGHUC8ES%"-[QB-BSL
M_P G]T;B<+[#BG6>DV=@^ZW21<+M56F=E5?15)( X["KM% !1110 4444 %3
MV_5OPJ"I[?JWX4 <7\2K:XM+?3?%%DA:XT2X$TBJ.7@; D'Y8_#-=C8WL&HV
M4%Y:R"2WGC62-QW4C(J6:&.:*2*5%>-U*NK#(8$8(->;Z9=R?#36?[$U%F/A
MJ\E+:?>-TMG)R8G/8>A_'UQ2]Z-NJ,W[KOT9:U35+/PO\49=4UF4VUA>Z6L,
M5P4+)YBODJ2 <''-1V/B;X7Z;JT^JV5Y8P7\^[S9UCDW-N.3GCN:] 9(KB,!
MU22,\@$!@:9_9]G_ ,^EO_WZ7_"ES+J.SZ' W_B;X8:IJD&IWUY8SWL&WRIG
MCDW+M.1V['FMG_A9_@O_ *#T'_?M_P#XFNF_L^S_ .?2#_OTO^%']G6?_/I!
M_P!^E_PHO%]PM+R/.?%WB_1/%6F6VBZ%>B_O[B]MRD44;\*L@9F)(&  .M>F
MYY-11VMO Q:*".,D=40#/Y5P/Q(^(47ARR?3=.E5]7F7'RG/V93_ !-_M>@_
M'ZTESM1BA-\MW(\[^+WB)-9\5K86[[K;35,1(/!E)^?\L ?@:\_HR6)8DEB<
MDGJ3[T5ZL(*$5%'F3DY.["NF\,^$&\1637 NY8B;M;11';&4*64MO<@C:G')
MYKF:Z+P_XK_L*Q^S-8&YVWB7L;"Y>+$BJ0,A?O+SR#UI5.:WNCARW]XEM/!S
MW-M8W+:C%';S07-S/+L+"&.!]A(Y^?)Q@<=:EMO!MO?-9W-IJSOIMS!<R^<;
M7$B- NYT,>[KC&,'FHXO'%P#;K-I]O-$L5W#<19*K.EQ)O8<?=P<8QZ40^-7
ML)+9=+TY;.UM;>XB@B6=F</,,-(7/)88&.G2LW[4T7LRR_@,0Q75Q)J,SVT,
M,$RFWLS)+LE4D,\>X% ,<GGK5"X\*?9] _MS^T$:P>WC>&01\R3LQ4PXSP5V
ML2?0#UIF@^*GT?4FU2>VEOM2#AX[F2[D4@XQAP/OK[&J-QK4MSH-OI31J$AN
MI;K>"?F9P!C'08Q^M->TOJQ-T[&=1116YB%%%% !1BBB@ HHHH **** "BBB
M@ K3TG0+W6H[B2U:V1("BN]Q.L0RYPH!/<GBLRNH\(^(K;0[/4X9IYK>6Y:!
MHIHK5)]OEL6(*N0.<\'M43<E&\2X)-V9GIX4UJ26.%+3,KWLEB(]XR)4 9@>
M>  <YZ<5./!NK/<6<5NUE=)=RM#%/;W2/$)%&YE9@?E..>:WHO'.DQ7@D2QN
M$@?4[JXDB0C(AFA$9P<_>SEL=*AT?Q/H?ALZ;:V;7EW;17KWEQ--"J$GRFC5
M%0,?7).:QYJG8TY:?<QSX-U8,Q=K)+80K/\ ;#=I]G*%M@(D!P?FXQ4!\+ZJ
M(A,(X6@-M+=><LRF/9&VU_F'&0V!COD>M:VC^,'74EN-1O7M((HE@2UL["-[
M=XMQ9HVC) &2>O/)JM<^)H)/#6JZ3:12VT-WJ8N8+<8*1PX)*9Z]1&<=/EIJ
M5383C3W.9I:**Z#$**** "BBB@#J/#7@YO$5A]I6[FB+7@M%$=J954E=V]R"
M-J>_--M?!TEQ:V-T^H1QVTUM<W5Q+Y9801P2;"1@_-DXP..HIGA_Q9_85@+4
MV!N"EXM[$XN7BPZK@!@OWE]JEB\<7(^SI-802PK#=07$6XJLZ7$GF,./NX.,
M8]!7._:7=C9.%E<DMO!UO>R64]KJS2:;=07,HF:V(D0P+N=#'NZXQC![U*W@
M/RTN9WU":2UBMX+A/L]FTDI24$AGCW H!M.3D]15>'QJ]A<6G]F:<MG:V=O<
M101+.S,KS##2%SR6Z8^E5="\4MI&IG5+BVFO]2#AX[B2\D0Y QAP/OKTX/I2
M_>CO3'W/A7[-H!US[>KZ>]O$\$@C.99F8@PXSP5VL2?0#CFN=K1N=9EN]"MM
M+>)52"ZEN=X.-S28R,=!C'ZUG5M#F^T9RMT"BBBK("BBB@ HHHH U?#VC?V]
MJ4EH9GB6.WEN"R1>8Q"+N("Y&2>W-;J> LW>H1M?SO'9VUO<@06323,)C@*8
MMP*L.XS7/:+K,VAWD]S FZ26UEMP0Q4IO7;N!'<=:VX_&^7O6O-,$SWUM;PW
M3I<O$TKQ$D2;E&06&,^N/>L9^TOIL:PY+:E*7P_96>C17]_JS6[78E:SA^RE
MF=4)7,F#\F2,8YK2N? ?V)=4DGU"5X[!H48V]H96S)")0SJ&RJ#.W=SSVK,D
M\16EUHT>GWNC1W'V42K9R_:'4PJY+;6Q]_!.1G%:$/CH1:[<:V-)7^T'5%C<
M73JJA8ECVLHX=?EW8/<U+]IT*7LRA?:'IMKX:M=7AU:>5KIWCBA:TV_.FW>"
MV\X'S<''.*HC0=2V"5H D/V5;PRLXVB$MM#G'OQCK[4V?57N-!L=*,2JMI--
M*) >6,FW(Q[;?UJ]_P )1,?"<>@/:QM&D@)GW$.T0<OY7TW$G-7[]B/<*_B#
M15T2ZM8HKQ;R.XM8[E)4C* AL\ 'GM[4[5=#73='TK4([^.Z2_60XC1@(RA
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M/^@'IG_@)'_A1_PC.@?] /3/_ 2/_"CZXNP?5?,^2\CU%&1ZC\Z^M/\ A&=
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M/^$9T#_H!Z9_X"1_X4?7%V#ZKYGR7N'J/SKV+X#L-VO<]H/_ &>O4O\ A&=
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8@ HHHH **** "I[?JWX5!4]OU;\* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>tm238578d1_ex99-2img13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %] U(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ,T5G7LTD6IZ9&CD)+*ZN/4"-B
M/U K1H **9*2$)':GT %%(:;&25Y]3_.@!]%%,4DNP]A0 ^BBF,2'7T)H ?1
M0*1^%)]J %HI%^Z/I2T %%,0DEOJ:?0 44S_ ):X]J?0 44Q^,>YI] !12-]
MVA.5!]J %HHHH **** "BBL/4_$L6E:LEI<0E(#%YKW+R!% PQ. ?O8"DD#D
M C@\X -RBN<C\<:#+;&X%Z1$%W$M$PX&[/;_ &"/KCU&8I_'>D1VANH//N8@
M"6\J%O[C/@9&"<*>,\=Z .HHK-T_6;34YIHK5V9X>) R%2AW,N#GOE&X_P :
MTJ "BBB@ HHJ"\)%LV#CD?SH GHI!TI: "BBB@ HHHH **** "BBB@ S16=;
M32/K=_"SDQQQPE%QT)WY_D*T: "BBB@ HI#TIJ'.?J: 'T444 %%%(: %HID
M9)0$]<4^@ HHHH **9(<(3[4^@ HHHH ***8Q(8>YH ?1110 4444 %%,)(D
M4=CFGT %%%% !113%)+L.V!0 ^BBB@ HHH- !13$/+?7%/H **** "BD--C)
M* F@!]%%% !1110 4444 %%%% !1110!#<W4%G T]S*L42XR[' &3@?J13S-
M&N=SJN.N3BJ>LZ8NL:5/8O*\*R@?O(\;E(8,",\=0*Y?5O#UG!)=ZAKNH&2V
M=8$'[D,SR!P22BKRS[8UPHZ)[T =D;F$#)E3'/?TZTV"\M[F&*:&9'CE :-E
M/#@C/'KQ7G\/A70+=-/O8M7C33D"["P0,9&\@+@X^7/EKGH27/8U/%X1\.6M
MQ:0IJ; H28T0IC*")6VD#Y6RJ9P03O([T =S+>VL$$D\MQ$D,8+/(S@*H'4D
M_@?RIZSQ,NY9%( R2#T&,UPA\*:1/%%$VHP"PCLGBD7$<;$R#:C,H  *AGP2
M,DOS5Z'PMHVF6VJ6CZ@(SJ*AI2[HK ;B1@="N6P 1C''2@#K?/B/21>@/7L>
MAJ.:^M;:(RS7$4<8QEF< #) 'ZD#\:XS_A&-"O)Y)4U4I+%F,[%BBV-$5!XV
MCY 4'R_=SD]Z1O!F@>40^I@ND*[I':(DI\FTMQC;E ?3DT =K)>VT,Z023HL
MKAF5">2!U/T%/,\2D@R*,8ZGUZ5R.L^%-(U'5)[F[U#R9;J/[A,8) "#C(R5
M^0?+TY/K4:>$M"AN5+7T;>6\<YC<Q$_N@%&6(W;1MZ$X!S0!V0GB.!YBY.<<
M]<=?RH$\1 (D4@C(.>WK]*X"R\+>&I;*U:WUK=;P.Y&YT <G,9+9]<8ST)^M
M2Q^"=!#^4=69Y(K=K?:9(\HH+,>.P&X@@\$#G- &SJ.JPC4]'N5(>R\V7%PC
M;@6\MQMQU['FK_\ PD.G_P#/5_\ O@UR^JVMOI6GZ'9Q2"2P2>1DG3:22RR-
M@*,+CGL?PJMY]C_SUN/^_(_^*KQ\;6QT*EL/%./G_P .;TYX1+]]*S.OD\0:
M>R$>8_(_N&G?\)%I_P#SU?\ [X-<=Y]E_P ]I_\ OR/_ (JCS[''^NG_ ._(
M_P#BJXOK.:_\^X_U\S3VF7?\_/Z^X['_ (2'3_\ GH__ 'P::GB#3PN#*_4_
MP'UKD//L<?ZZ?_OR/_BJYO4_'N@:3J4]A<#46EA(#%+9"IR >,R#UJHULWEI
M&FG_ %ZEQEE\MI_U]QZK_P )#I__ #U?_O@TT>(-/#$^:_('\!KR'_A9WAK^
MYJG_ (#)_P#'*/\ A9WAH_P:I_X#)_\ '*TYLZ_Y]+^OF5RX+^=_U\CV#_A(
M=/\ ^>K_ /?!II\0:>6!\Q^#_<->0_\ "SO#7]S5?_ 9/_CE'_"SO#7]S5/_
M  &3_P".4<V=?\^E_7S#EP7\[_KY'L'_  D.G_\ /5_^^#2'7[!_E65\MP/D
M->0?\+.\-?W-4_\  9/_ (Y2K\3_  TKJVS5/E(/_'LG_P <IJ6<W5Z2M_7F
M#C@K:3?]?(]9_P"$HTI/E,TF1P?W9H_X2K2O^>TG_?L_X5XXWQ$\-LQ;_B:#
M)SC[*G_QRC_A87AS_J*?^ J?_'*][V=:WPGS[JXCLCTG4?BCX5T>]>TO+V=)
M@ Y"VSMP1D<@55_X7-X+_P"@A<?^ DG^%</+X/T/Q9IDWC6ZU6^@TTQB-8$M
MU67<C>7W8CD]/KUJQ%\$+'5=-M;W2]:O+99069;V!7..WW"!Z\Y(/:MTJ:5I
M/4ZTYV5SK_\ A<G@K=N_M"XZ8_X])/\ "C_A<W@K_H(7'_@))_A7'?\ "@)]
MV/\ A)8NG_/D?_BZ7_AG^X_Z&6/_ , C_P#%U7+1[CO/L=@?C)X*8#_B87'7
M_GTD_P *7_A<O@O_ *"%Q_X"2?X5QI^ %P/^9EB_\ C_ /%TO_"@+C_H98O_
M  "/_P 71RT>X7GV.P;XR^"]I_XF%Q_X"2?X5U&H>)=+TBVM)KVX:-+E=T9$
M;-A0 2S8'RJ 1DG@9KR9OV?[C:?^*EBZ?\^1_P#BZ]-UKPC:^(=(LM/O)2(K
M=0&*QH2XV[2 6!*_4'-95%!? RHWZG2@YHIJC P.@IU9E!1110 'FLN^T#3-
M2NA<7EJ)G"[2K,VQA@@;ESM8C<<$C(R:U*\?^)WQ.UCPYXC71]'6&+RH5EFF
MECWEBW0 'C&.]5&+D[(3:2NST?\ X1?2#$L;6?F!86MP9)'=@C$,1N)SU .<
MY&.*&\,Z4\!ADM"Z'.=\KDG,9CR23DG:2,_CUKF/#WC^ZU;P)::P]E%]OFO%
ML"A<I$968*&)P2%Y![\\5H6/C>-XV6ZM]T\8N&F:W;$:+$5!),NPJ3O7 QWZ
M]Z35G9C3N;VEZ1%I9NVC+-)=3F>1VQDG 4#\%51GJ>IY-:5<4_Q#LYX8)+*S
MN7+21+/YH4"!6G,1W8/)RKXVY'R\XK3TSQ9!KNBW6H:7:7$IA&4BDVH9,@,I
M!SC!!^HYR,T@.BHK.T'47U?0-.U&2-8WNK=)F13D*64' /?K6C0 57O?^/9O
MJ/YBK%5[W_CV;ZC^8H L#I10.E% !1110 4444 %%%% !0>E%% &-IKR/XAU
M7S8O+(2$+\P;</GP?;Z5LUY-X[^(UWX(\92VUMIT%T+FSAE+22%=I#2# P*Y
M_P#X7[JG_0!L_P#P(;_"M8TIR5TB7)(]YHKP;_A?NJ?] &S_ / AO\*/^%^Z
MI_T ;/\ \"&_PI^PJ=A<Z/>#T-,C[_4_SKPH_'W5/^@#9_\ @0W^%(/CYJ@Z
M:!9_^!#_ .%'L*G8.='O5%>#?\+]U3_H V?_ ($-_A1_POW5/^@#9_\ @0W^
M%'L*G8.='O-(>U>#_P#"_=4_Z -G_P"!#?X4'X^ZI_T ;/\ \"&_PH]A4[#Y
MT>[1?ZM?I3Z\%7X^:HHP- L\#_IX?_"E_P"%^ZI_T ;/_P "&_PH]A4["YT>
M\T5X-_POW5/^@#9_^!#?X4?\+]U3_H V?_@0W^%'L*G8?.CW67[C?0U)7@K?
M'S5",'0+/'_7P_\ A2_\+]U3_H V?_@0W^%'L*G8.='O-%>#?\+]U3_H V?_
M ($-_A1_POW5/^@#9_\ @0W^%'L*G8.='O-,?JOUKPG_ (7[JG_0!L__  (;
M_"D/Q\U0D9T"SX_Z>'_PH]A4[!SH]ZHKP;_A?NJ?] &S_P# AO\ "C_A?NJ?
M] &S_P# AO\ "CV%3L'.CWFBO!O^%^ZI_P! &S_\"&_PH_X7[JG_ $ ;/_P(
M;_"CV%3L'.CW8_ZU?QI]>"_\+\U3(/\ 8%GG_KX?_"E_X7[JG_0!L_\ P(;_
M  H]A4["YT>\T5X-_P +]U3_ * -G_X$-_A1_P +]U3_ * -G_X$-_A1["IV
M'SH]YIBX\QL>@_K7A/\ POW5?^@#9_\ @0W^%(/CYJ@)/]@6?_@0_P#A1["I
MV#G1[U17@W_"_=4_Z -G_P"!#?X4?\+]U3_H V?_ ($-_A1["IV#G1[S0:\&
M_P"%^ZI_T ;/_P "&_PH_P"%^ZI_T ;/_P "&_PH]A4[!SH]V3DO]?Z4^O!1
M\?-4&<:!9\_]/#_X4O\ POW5/^@#9_\ @0W^%'L*G87.CWFBO!O^%^ZI_P!
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M_GVUO_OB+_XJN6U6^\$ZOJEQ?ROXCC>8@E4B@P, #NWM77_\*K\-?]!#6O\
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MV#XO_0Y*\UQ7I7QR_P"1_@_[!T7_ *')7FPZ5Z5'^&CFGN)BEHHK8D**,T4
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M^,=(@G$,[W$4AVC;) PPS;?DZ?>PZDCT.:KW'CK2(XM\0N9V(4JJ0D;MS*,
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MM?\ H7Y?_ X?_&Z[GQ-8Z;KGAS1$:S>/2S=R[;(DQLKJ)1N+ Y'(/'O7-?\
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M\!F_^*KT&EH^M5>X?69G+6OP,U.[M8[B/7+/9(H89@?/\ZF_X4'JW_0=LO\
MOR_^->OV6I6>E^&K2YO9T@A$:C>YXR>@]S6O',D\22Q,KQNH964Y# C@@UK[
M>IW/7C%.*9X0/@)JS#(UVR_[\O\ XTO_  H/5O\ H.V7_?E_\:]WB^X/I3Z/
M;U.Y7(CP7_A0>K?]!VR_[\O_ (T?\*#U;_H.V7_?E_\ &O>J*/;U.X<B/!#\
M!-6 ).NV/_?E_P#&C_A0>K?]!VR_[\O_ (U[O+]QOH:DH]O4[AR(\$_X4'JW
M_0=LO^_+_P"-+_PH/5O^@[9?]^7_ ,:]ZHH]O4[AR(\$_P"%!ZO_ -!VR_[\
MO_C1_P *$U88']NV/_?E_P#&O>Z8_P!Y?K1[>IW#D1X1_P *#U;_ *#ME_WY
M?_&D_P"%!ZO_ -!VR_[\O_C7O=%'MZG<.1'@G_"@]7_Z#ME_WY?_ !H_X4'J
M_P#T';+_ +\O_C7O=%'MZG<.1'@A^ FK9 _MVRR?^F+_ .-'_"@]7_Z#ME_W
MY?\ QKW?_EHOX_TJ2CV]3N'(CP7_ (4'JW_0=LO^_+_XT?\ "@]6_P"@[9?]
M^7_QKWJBCV]3N'(CP3_A06K?]!VR_P"_+_XT?\*$U8G']NV7'_3%_P#&O>Z8
MO^M;Z#^M'MZG<.1'A'_"@]6_Z#ME_P!^7_QI/^%!ZM_T';+_ +\O_C7O=%'M
MZG<.1'@O_"@]7_Z#ME_WY?\ QH_X4'JW_0=LO^_+_P"->]4AZ4>WJ=PY(G@H
M^ FK$G_B>V/'_3%_\:7_ (4'JW_0=LO^_+_XU[NG5OK_ $I]'MZG<.1'@O\
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M.!TZ"F:/%)!I-K%*I5UC 93V-73VKH1[\/A0V+_5K]*?3(O]6OTI]!84444
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M_EM^%/IG_+;\*?0 R3JOU%/IC]5^HI] "-]TTB?<7Z4K?=-(GW!]* '4444
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MDD:0W-O1!,NAV"W,TL\X@022S1E'=L#)93T)/:K:_P"L;Z#^M/7! (Z4Q?\
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MK2%&,U=NQQUJ$9RNSV$V+;6_>VGW3_R\Q^A_VJ\>3X<^(@@'V&SX'_/]!_\
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MEE4 E$9L'H<#-8GA75;W5K)Y[QXV;*[?+A$8 (SVD?/UX^E;%^RBSE#?Q*4
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M;TS@T 4?%<MOX=T30X-4O"+.&8J;X19#.8WPHC7GIW]JYK_A+_"'_0?;_P
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M'Q?^AR5YM7I/QR_Y*!!_V#XO_0Y*\VKTZ/P(YI[A2"EHK4D#0**3- "T444
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MFQ?=_$_SKK-Q]1K_ *QOH/ZU)48^^WT']: )*C;[Z_6I*C?[Z?7^E #Q2/\
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M%% $9_UR_C_2I*C/^M7\:DH **** "F+_K6^@_K3STIB_P"L;Z#^M #Z***
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M XYC]#PU '+_ !1U>&?P+H^L6MO&8I;W:+6ZB5XU.V0$E?[V0>:\B_X21_\
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M &1]6^O]*?3$ZM]:?0 4444 !ID?W!3C38_N"@!]%%% !1110 4444 %%%%
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M%_JQ]*?0 4444 1R_<;Z&I*CE^XWT-24 %%%% !3'ZK]:?3'^\OUH ?1110
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M9P?W/R^_M0 FKW-[<Z?H=]):M:ZH\SJZQH1(%"2#_> . <54^TZU_P ]+_\
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M_>_I4E !1110 &F1_<%.--C^X* 'T444 %%%% !1110 4444 %%%% !1110
M4$XHI#TH Q_$E@^M:'=:;!.D<LX4;B>@W GCZ USLGA?6;2W73+'4PVDB#8/
MM$F'WXDR,!<;<LIX(P%QBK&H^"[JY\47.NVU[%'/(NV)63[G[DINW+ALY.<
MXYZ9 -5F\&:W,8#<ZWYYAC94+LYVDB1>F<'AU^8C/RXZ4 2/H_BR,NZZVA#
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M7Z4^F1?ZL?2GT %%%% $<OW&^AJ2F2_ZMOH:?0 4444 %,?[R_6GTQ_O+]:
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MMY*X;YW6, D$J , ?>!..E2:1K>NZI9:K<2:9';2V\*?9K5U8.TK0))@L>"
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M-75)4#J)$*L 1GD'D'VIW;U9[=-W@FR>D/:EI#06-B_U:_2GTR+_ %8^E/H
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M^C7>I^*;Q[;R]J6\ .]L=WJ#_A$]4](/^^__ *U8R3N>/7HU)5&TC%I*W/\
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MF;Q'HZPN6U"%0!R3D"G_ /"1:3_S_1?K_A2E*4MV"26QIGI38_N?B?YUG?\
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MY5)_PD6D?\_T?Y'_  H T'ZK]:?61)XBTCY<W\(^8=<T_P#X2+2?^?Z+]?\
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MK._X2+2,?\?T?Z_X4P>(M(\Q@+^'. <<Y'7VH UZ*RQXBTG_ )_HOU_PI?\
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M\&,2Q \)L&>G R<#CU/UK0E<QQLX!.T$X'?BG1QI%&L:*%11A548 'M2D9H
MY'P!XCE\1Z?=7$\,,,OF+(8XD*X#J&&<DY/OQTY KKCT.*BM[6"U#B"&*(.Q
M=A&@7<QZDXZFIJ .=BNK^3QM/:B2T>U@M0\N(2)8]YPB[]V#G:['@8P/6NAI
MBPQK(\BHHD< ,P7EL=,GO4E '(^,?$4VB76F1QQ02)*YDD\U2=H5XUSP1M'S
MGGYCD#@Y)'6COUJ*:TM[AHVG@BE,;;D+H&VGU&>AJ4#% &1XGU"XTOP_<75J
MD32J44"7[H#.%)P2-Q )(7(R>,\TWPGJCZUX7T^_DMUMVFBYC7H,$KQ['&1U
MZ]36M-!%<PO#-&DD3C#(ZAE8>A!ZTZ.-(T5$4*JC 51@ ?2@!U%%% !1110
M8HHHH **** "BBB@ HHHH *KWO\ Q[-]1_,58JO>_P#'LWU'\Z + Z44#I10
M 4444 %%%% !1110 4444 <KXQUJ7PW:I=V26JW%P7#RW .TB**20+P1R=NT
M>F<X/2NDM9C<6D,Y0H9$5]IZKD9P:+BU@NX_+N(8Y4R&VR(&&1T.#WJ4# Q0
M M%%% $<\@AMY)#T12W7'2N9\#ZS<:QIER]VL"7,<W[U;= (P719.&#N'^_G
M((Z]!74D9&*BM[2WM(_+MH(H4R3LC0*,GJ<"@":BBB@ K$\2:G?:38V\]I##
M(&NX(96E<C8CR*A( ZGYO;U]CMTR6*.9-DB*ZY!PPR,@Y!_ \T <IX7\03W^
MKWNF&&WCM[96\E(00T*I-)#L?)/)\L,.G7';-==4,=K!#++)%#&CRD-(R( 7
M([D]_P :EYH 6D/3BEHH YK7]6N;35[#3WM+>33[R*X\YI7^9BD98*!T XY)
M/X=Z/!>O7>O:7-+?F'[7#*(Y5A4!%)1' 5@[AN&Z@_@,5T,D$4KH[QHS)G:S
M*"5R,'![<4VWM+>TB$5M#'#&"3LC0*,GKP* )L44=J3-  >!UKA-7\4:A;ZQ
M>6T9TV:&WDA19"K8M)))(XU,AW#<=LCL0,;0%R?FKNR,U3.CZ:9993I]H99E
M*RN8%W2 ]0QQR#@=: *_AO4Y=9\/66H3*BR3QY81_=R"1E?8XR/8UJTR.-8D
M5$5511A548 'H!3Z "D/%+2$9H \XU#Q=JT7VZYB72KC[+<^3#<IC"<2-*@#
MR+YC*L:Y((RQ88^4UZ!87*WNG6UTI)6:)) 2I7((!Z=NO2H!HFEJLBC3;,"4
MAI +=/G(.03QR:O 8&* %HHHH KWTYM;&XG$D,9BC9]\[;8UP,Y8]AZUY[;^
M.-0%S:%X].:9IQ!<L@.9U^T+$HCPQ&0)2_5A].<>D,H<$, 0>"".M5H],L8A
M"([.W00$F$+$H\LGJ5XX_"@"W1BBB@ JAK-U+9:7-/!-;0R@ ))='$8)( SR
M/7@9&3@9%7ZCFACN(FBFC22-QAD=00P]"#UH X+0_&-W>ZOI4;QVD4&H1J9_
M) =FN"LF1]_<J@1#YMK#C&>]>@XJLEA:1RQRI:P+)&GEQNL8!1?[H/8>U6:
M"BBB@#EO'7BF3PIH1NX(1)<.<1[U8QK@98L1TXZ>I(J#PUXAFO?$-YI2Q6R6
M<2RM"L((>()*8\/D]6^\.!QZUULL,<\;1RHKQL,,CC((]P:9%:P0S231PQK+
M+CS'5 &?'3)ZF@":BBB@ H Q110 4444 %%%% !1110 4444 %%%% !1110
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MDA6)MY0HK[P,>C8P?PXK6 R* ,4 +1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>tm238578d1_ex99-2img14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Q R # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WYF"J2>@&
M:YB#QYH<\L:>9<(KR>4LLD#+'NSC&[I72S?ZE^?X3_*O+O#GA_4/$/AA;:74
MDBTEKIW>!8,R';(3][/&<4 >HAL\_P"35?4+^/3M/GO)4D=(4+%8UW,?H!UK
MRS4)[I_%M^MSJ,=E?+?*+3SC-N,0/RA%4%6!'6K$]KG0_&&IF>X%U#-+!'B9
M@J [2<*#QS0!ZC%(LL22J"%90P#=1FJ-KK%O=:W>Z6B2":S1'=B/E(;IC\J\
MPU:YL5U353?WEQ%,-.MFL@LK ^;Y8QC'!:GWEHUVWB.YO7F2\M],MY0R.5(D
MV>W4_P"-.P'KV:3</6O']:N[JYOXCJ6H):A]-@:TEG>107* N4\O@ONR"#6Y
MI]NT_B;4KN\FNIYK"Q@G18791(_EMD[>Y/OW- '?7=TEI:37,@)2%"[!>3@#
M-9W_  D-H/"W_"0&.7[-Y'G[<?/M^E>9:/J$<UV!:W($=QIEP9HEFDE(;;D"
M0MUD&>@Z5U#Y/P5; Y_LLC'4]/YTK =;<ZK!:Z(^JR(YA2 3%0/FVD9Q]:LV
M=TEY9PW2 A)D#J&X.",UY1YUH4OX]'N)I[7^Q3]O5F8A)L#:/FZ-[#M3]0N+
M8-(FLW5Q!$NE0G2Q&S*K2[>=N.K;L<4 >M9JO?7:6-C<W<BL4@B:5@.I"@G^
ME>77]VS2*?%%U=VTITF)[(*67=.1EL;>KYQQ]:9J%PTID7Q'/<QSMHRFRC)9
M1),5.X8'4],@T >FVFK6UUHT&JY,5K+")\R<;5(SS69:>,]&O9'C@EF+B-Y4
M5H64RJHR=F1\WX5D26L][\'X(+96DF;3HR%4<M@ D"I=.\1:'J]]HUI9VQO;
MJ),[T0C[%A,'=D#'IB@"]%X[T>>Z^RI'?F;(!7[(^1GIGC@5O7E[;Z?9S75U
M*(H(E+.[= *Y?2S_ ,7-U\\_\>D _2JWBVPUZ7PCK*74UO<QE4:*.W@97"AP
M6SR<_+Z#M0!N6GBW2;RUNKF.651:1^;-')&5=5/.<$9Q18>+=,OTF=/M,,4,
M)F>6>!HT"#OD]:Y*XO+'Q!K>MZC:FYN=,_LE8)9;2/<V[<257/!8#J.U4)KB
M;4M,UW3-$U"\U33AI0<&4%C'*&'R#CKMSE: .\T_Q;I&I).T-PZ>3%YSB6,I
M^[_OC(Y'O4FC^*=+UNX:"SF?S53S DD90LG3<,]1[BN'FOK?6M1GN]+A^WV]
MMH+0RH@(&\](S_M#T%2>"YXY?$]MY-ZVJJNF;'F,9'V0@C]U^/H>>*8'IA8?
MEUK.AUJ";7KK2%CD%Q;Q),S$?*0W3!_.N \53Z<GBW6!J5W-$%T^-K8)(ZYE
MYQ@+WJLUF^HW>K2:D9Q>0:!'/E9"C"0(3DXZGB@#UH'';VHW5XYKNJB>SM_.
ME:.\32(98Y99I!YCD9_=JO&X=R:W--@75/$%]=W5S.S6VG6\Z 2E5+F,Y+ =
M: /1]U!;%>2:+IL5Q#X2\R:Z(U&VE%W_ *0_SA1D#KP,TV+4(_[#TFTOY#Y?
MVJX19KJ>185"L0H;;RQ] 30!Z[N]>*-U>065\EQI7AX:]>SQZ1Y=RKR^8R_O
M WR!B.<@= :N7-SI_P!HL5UC4-071?[/9K2:XW1N\N[C..K8Z ]:0'H;ZQ;I
MK\6CE)//E@,X;'R[0<'\:=_:47]J_P!G>7-YGE>=YFP^7C.,;NF?:O*+A]>G
MATA\RB^.CN9P<B1H1(3@?[13'O6AJ5Y;2&\?3)Y/L?\ PC;M"OF$D'<.O?=G
MKWIV ]5W'TJ.XN(K:WDGG8)%&I=W8\* ,DFO,$6ZTZ[B&ERW!GNO#_VAE,A<
MM)@<C/?Z51TJ);^RU&.*_BG4Z9(T]K$TSOYJC(9MPP&S_".M(#U!-9M9;RS@
MA$LHNXS+%,B$H5'JW;K6CN^M>4Z9<@)X;71IBS?V7<$HDA(\\(-P^H8'^E/T
M>?3&TZ1K'5-4&I'39/MHB1Y1')C[SJ>0P/0#M0!ZFSA!EB !U)-*IR,UY5X=
MN=+\K4X+V4SV"6*-<7%I-))"_('S*>5E/<"O3;+RC:0F#/D[!LSG[N..O/2@
M"S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %&:*0T 07=W!96\ES<2".&)2[LW0
M 5AVGC/2;QW2,72RB%YHTD@96F11D^7G[WT%'CFRN;_PG>PVJ-)( K[%ZL P
M) ]>!TJEIOB32M9U/3+:QLWNIHHV+SF(I]CPN,'(ZGIB@"Q;^.M.N;O[)'::
MCYX(#*;9@4STW>G6MS4=0M=)T^>]O)/+MX5W.^/PKG-&W?\ "Q/$K$$ Q6^#
MCC[@_.J?BNPUMO"NI"\NXKY \4B106VQ@JR MGDYX_E0*Z-N#Q=IDUC?77[^
M/["@>>*6(I(JD9!P>N:+7Q9875O<W$D5Y;6]O#YSR7,!12OMGK^%<K<7%GKV
MJ>(M3@2ZNM)?3XH'>V0AW;=DA0P&<#K6?</<:KI/B"RT:YOM1TL6,;(9@Q(E
M#J2BY .=H/'KBF%T=W9>+M*O8+F3?-;_ &:+SI5N(C&PC[-@]14FC^)].UNY
M>WMC.DZH)?+FB,99#P&&>HKBKZ]CU[4=4U+2[=KVUBT46[CRV :0L3LQC.0.
M<"I_!<B2^)R;>ZGU*$:<D<EU-&5-NP(_=\@?UI!='>:IJ4>E:7<WTJ,Z01F0
MHA&Y@/2GVMY'=64-R!L29 ZJW7!&:\T\7FW.M^($U3[3YIM$_LM%#[6XPV O
M&<]<]JH:QYWVQ4O[D6T)T^$6,CI*0&VC/EA/X\]C3L%T>KQZG92:E+IZ3*;N
M) [Q#J%/2K8<$G';@UY<]O)9>*;TJ'.J3Z0CVTA1E,D^WYR/0G'0U1T4WAMK
MUM)O,WRZ9*LMM''-O,GJQ;Y1(,]NO:BPSUB\OK>RM);JXE5((1ND<G[HJK'K
M$,VHV]I%%*ZSP>>DZK^[VYZ$^M><1V^C7_A^_CTK^T9YUTP-<H58Q"8<G.>?
M,SG@5-%(\ES9-H1<D^'YQ!LSCSL].>^<_P!*0KGJ/F*-QR,#KR.*42*3@<_C
M7D5I+;&./^Q)+IQ_94IU3?OXEV\;MW\>[/2M?PY:BP\2^'V@\Y!=:6TESO=F
MW.,8SG@'_"@+H[K^TT_MAM.,$P*P^<9BO[O&<8SZU;#@CCG'7!KSKQ>T@U[6
MPAD(_L+Y=N<!O,/ZU8\.VB:=XTMHK8RB"?2%EE#,S!GW+R<]^M,+HZN]UZQL
MWO(C)ON+2#[1) A^;9^/TJSIFHQZGIMM>QHR+/&L@1R-R@^N*\^UZWM+7QIJ
MY>)DEN-)9H#@_/)R&(QWP/Y55T^TGTZXT<Z6LZW%WHLQ8;F(:0+E<@\ YQB@
M+H]6# YQVZ\]*Y[5O&&GZ+>&WO+>^SN5 Z0%D9F' !'!-<;X&!DUFR>*^ F6
MW87MN(YM[-ZR%OE#9STKI/B!EM-TD+EB-5MR=O. "<F@+HNGQEIBSV$4R75O
M)>NR1":$KT('.>@Y%6KSQ)866O6FC2L_VRZ'R +D#KU/;H:YCQM8/JGB?3K>
M,'>;*X:-QT5UP5Y^HK'LGN=0\3>'M<NX7CFO;V1=A!^2../:,^GS9/XT!='8
MV/CC3M1DC6UM-0D21]@E%L=F<X^]Z5TD<BR<HP90<9!SS7E7@?4;6TAM+:XU
MN_@E\]Q]@%NQC/S'JVWC/7K7H/ATZ:=//]EPO#;^=)\CHR$MGYC@\]:3&:Y&
M1[TS8,8QQZ5)10 PH,YP-WKCFD*<8Q[>QI^X>N*7- &3!HD%OK5WJH:4SW2(
MCJQ!10G0@>M:0"X//7N:K:G?PZ9837=PP6.,9R3CGL,URUOXKO)[.&Y5;4[4
M5YPF3NW3>6%4YZCKWR: .Q**<9 ..G I0@SG'/?%<LNOW\DZ0A;<-<N1"2A_
M=@3&/YAGGU[=Z;;^);N66$F*%8UEABE7G<QD)&5YX QT/OZ4 =5L4=  .>,"
MEV C! VXQC'&*P?#^K7>I0M]I6%6:UAND,0. ) QV\GG&WK]:W5#E1RO3TH
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MG'C8QE0FI=C#^'=C)!?ZC--^[D55B,3###/.3[5Z-GBN/U0'1/%%GJ:X6VO
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MZV??@X '0#/WL]/2H+S5M;8Z9?1.E]=0/=B&50&(3RUR6"X!9<DX&,XKO?\
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MTS0M8_MG2XKO[/-"6 W+)&R<X_AR.5]#WHYF'LX=B;^SQ_ST_2C^SQ_ST_\
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M5>M60.HHHH **** $-)FE:L5G;>WS'J>]5%7(G/E-G/THR*QM[_WC^='F/\
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M/B1$]G:Z7XDA4F72+M9'V]XF(5Q].AKI]3D^TZ)+) HD#QAU]U/?\JJ:N_\
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MT5!?J/\ E'>CY:8(T]!2^6G]T4 .^6CY:9Y:^@I?+3^Z*8#OE]:,+[4W8O3
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M)+8S1NK#GIT/OD'U%7="VI9I#'%*(HQ\LDD?E[B>3A>PK5P>U+CG- "T444
M(3BF>8@)!9<YQC-.89%<E>Z)J4FN27<*YADO87="XP44 [QZ$'(([@T =5YB
M2(61E8>H.:<A^1?I7,^&=+O+& &YMC:JMG%"T6\,7D4?,_!('8>]=(L:[%X[
M4 29I"?SIOEKZ4>6O7;0!Q7BK4(M0>UMT'[J*[#,['&XC((4=R.M==8^7]C@
M,1!CV@@^OO7&ZQH\L%]:(2K++=@0L&QACD_,/QKL;.T6VLXH>6V*!N]:SC>]
MV;U5!)*!;S1FF>6OI0$3T%:& _-)DTWRU]*/+7T% #\T9IAC3'2CRU]* '9K
M)\2K8/X:U-=4D6.P:V=9W89"J5(SCUYK4\M?[HK*\2Z%'XB\.7VD.QB%U'L$
M@_A(((/Y@4+=7$[VT//?AK\2K"?3M+\.:B9DO8H_(2X?&R7'"Y/4';CKZ5ZA
M]JM\C,T7_?P5XMH'P6U1=:C?79K7^SXFW,MO(Q:7VZ#:/6N]_P"%5^$\<6$^
M?^OE_P#&MJBA>\3&#G9W1.UY'I>NSO;+YL4BC>$8  ]1^/\ C71V=_!=VRS1
MN K=0W!!]#7-?\(FVEHMMI,2_8QDK')(<J3R>3G()YK6LO#\$5N!<#S)F.YF
M4D#-<<4TVEL>E5=.4$[ZCM;>+[ 9-Z[XV#1X.3N]*33M;BNY5AE1HI2O!8C#
M>H'H:;>Z!"\/^C#9*IW*6)(_&J=EX?G:X#WJH(E.0JL26/UJ'!JKS);[A%47
M3=WJ6O$.BV?B#3VMIV <<Q2 C*-_ATS7"P#4K?3H=-O-I6"_5M_FCYP 1@#O
MZCZ5Z*-%LQ_RR;_OLURNLZ+):WFGHI!B>]58#GD,0QP?;'<5M)RM9&%.E1=1
M5);H[.P:)K.!H"#%L&T^HJSDU4T^R%G8PVY)<QK@MC&23DG\ZL[%]*I;$/5C
M\T9IGEKZ"D\M?[M,0_=2YJ/RT]*7RU_N_P Z 'YI ::8U':CRU_NT /S1FH_
M+7^[2^6OI0 ,<@UYQXL!M-5N#93E)9%#.X;;Y3G@\^^,_C7HQC7& #S7#>--
M$E2"\U)2K6Y0&5<_,O;CU[5M0Y>=2D<^)YG"T#H_#<MM_8-MY+8P,.&^\'ZM
MGWR:UQ,G]Y?SK!TSPY#;6FR['F3LQ9RI( ]OR JX=#L!_P L6_[Z-<=2=7G?
M(DUZ_P# .FFH\BYKKY?\$TO.3^^OYT><G]Y?SK,_L.P_YY'_ +[-+_8=C_SQ
M;_OHUGS8C^1??_P"[0[O[O\ @FEYL?\ >7\Z/.3^^OYUF_V'8_\ /)O^^C1_
M85C_ ,\6_P"^C1S8C^5??_P M3[O[O\ @FEYR?WU_.CSD_O+^=9O]AV/_/%O
M^^C1_85C_P \6_[Z-/GQ'\J^_P#X 6AW?W?\$T6FCVGYU_.N/L_$%K9:Q>DA
MS;32[A(H'RG&"<=<5O'0;$J086Y&/O&N;/@^^%V8UDC^SD_ZS)SM^F.M=N$=
M^;VRMZ,XL4I)Q=+6S.R\Z)DRLJ'/((/ZUYMJ%XO@3QO=SV:"?3-6C^T36D;
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MV@O]P_G5U>N?6DTT4I)[#J***"@HHHH **** "BBB@ HHHH *:?\^U.II'-
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M4*J.S,6VC/WLD@G)ZC%;I!QUI:* .:UCPS-JMYYOVJ$PDY\BY@\U4;&-R?,
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MZ7>[=IB%V^QHP1$PX_U8/(6B[%RKL=/]D@_YYBC['!_SS%3T478[(@^R0?\
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MJ;,_BS9;7UBL[M''Y/F()"HY8$$$GCL#T^G/90Q1Q1JD2A47A0.@% $E%%%
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M&<"4H<'#JRXZYY# UVMNH2%%"[%"@!?0>E9EYX=L]1NFEO6FF4D%8BY"+CT
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A'2BBB@H0]:6BB@04444#"FGH:**8A4^[0.U%%:#D?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>tm238578d1_ex99-2img15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J R # 2(  A$! Q$!_\0
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MF=#17/?\)3X=_P"?^+\F_P */^$I\._\_P#%^3?X4>RJ?RO[@^MX?^=?>O\
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MI ,4SR(O[OZT>1%_=_6@"2BH_(B_N_K1Y$7]W]: )**C\B+^[^M'D1?W?UH
MDHJ/R(O[OZT>1%_=_6@"2BH_(B_N_K1Y$7]W]: )**IF)/.D&W@8_E2^6G]T
M4 6Z*C@_U"?2I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ ZTF,4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCMI;.X;S(EVE=.C@PN0-S$2'(]L4Q'90?ZA/I4E1P?ZA/I4E(84444 %%%%
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M]]K_ /$UR/\ PFOB#_H('_OTG^%'_":^(/\ H('_ +])_A1]9K_SL/[-P?\
MS[1UW_"N=*_Y^;W_ +[7_P")H_X5SI7_ #\WO_?:_P#Q-<C_ ,)KX@_Z"!_[
M])_A1_PFOB#_ *"!_P"_2?X4?6:_\[#^S<'_ ,^T==_PKG2O^?F]_P"^U_\
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M?^_B?XU=HH I?:[O_H'2_P#?Q/\ &HY[V_6(F+3&+Y'WY4 QGGOZ9K1IDO\
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M)K>!_P 36Z_[^5V8?"RKIM.UCR\=F=/!N*G%N_8]EW3>B?F:-TWHGYFO&O\
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M]_#1_P ))K?_ $%+K_OX:/[,J?S+\0_UCH?R/\#V7=-Z)^9I<S>D?YFO&?\
MA)-;_P"@I=?]_#1_PDFM_P#05N_^_E']EU/YE^(O]8Z'\C_ ]FS-Z)^9I?W_
M *1_F?\ "LGPM<377AJRGN)6EE=26=CDGYB/Z5MCI7F2BXR<7T/HJ515(*:Z
MJ_WD7[_TC_,_X4?O_2/\S_A4M%2:$7[_ -(_S/\ A1^_](_S/^%2T4 1?O\
MTC_,_P"%'[_TC_,_X5+10!%^_P#2/\S_ (4?O_2/\S_A4M% $7[_ -(_S/\
MA1^_](_S/^%2T4 1?O\ TC_,_P"%'[_TC_,_X5+10!%^_P#2/\S_ (4?O_2/
M\S_A4M% $7[_ -(_S/\ A1^_](_S/^%2T4 1?O\ TC_,_P"%'[_TC_,_X5+1
M0!%^_P#2/\S_ (4?O_2/\S_A4M% $7[_ -(_S/\ A1^^](_S-2T4 4CYGGR9
MVYX]?2G?/_L_K3+N=;6*[N'!*Q(9"!U("YK'@\1-)>VUN;-=KF..:1)@PCD=
M2RJ./FP!R>V13 Z*#_4)]*DJ.#_4)]*DI %%%% !1110!1U>%YM-FV>:752R
MI$Y4L<=..H]JRO"W^C:,V4E6&,Y7*..,9.%;+=<_6M'6Y=FF2H=NV7]V291&
M<$'IG@GV[U3\,0K#8N ) 2^#NM_)'  &T9((]P?Y4 7M)N(Y=-AD7?M?<PRA
M!P6/4$9%73*O;/\ WR:KZ;S8IG^\_P#Z$:M8H P=7U:XCNQ9VFQ&$8DDDD0M
M@$D  9']TY_#UJ[I.HR7EJQN%59HWV/Y8.T\ @CTX/3M3M1TN"^VR2-(DJ<+
M)&V&P>WN/K4]G906-N((%*H"2<G))/4D]S62C/G;;T-&X\J26I-YJ^__ 'R:
M/-7W_P"^33\48K4S(S*N,\_]\FLX:@_G;BHV],8YQ6ICWJJ+.$7&[:?[V,\9
MK*HINW*RHVZDXE7_ &O^^32^:OO_ -\FG8I<5J2,\U??_ODUDZYJTMA!$MLJ
MF:5BH:13M4 9)QQGMQFMG%4]0TZWU&W\JX#84[E93AE;U!_&IFFXM1W*BTI)
MRV,O0M9N+N26UN]ADC0.LD:D J21@CG!!'XYK=\U?]K_ +Y-4=+TJVTV-C#O
M:20 O)(V6;T'L!Z"M#%*FI**4GJ.HXN3<5H-\U??_ODTAE7_ &O^^34F*3%6
M08-SJEZ]W(+3R%C@<IB56+2,!SSD;1SZ'UK5L[V.[LX+E0P65 X!!XR*K7>C
MVES<>8_FJ9.) DA42 #N!^7%:*(J*%4 *HP .@%9P4TWS/0IN-E83S5]_P#O
MDT>:OO\ ]\FGXHQ6A)5NKQ+:VDF(9MBYQ@C-9.DZ])=WAAEB5=V64KGCZUNO
M&LB%' 96&"#W%4[+2[2SD>2&/#$D9)S@5E*,W)-/3J:P<%!J2UZ%P2K_ +7_
M 'R:/-7W_P"^33L4N*U,AAE7W_[Y-9&HZC<"Z^RVGEHP02.\J%AR3@  CT/.
M:V<52O\ 38+O;*YD25.!)&Y5L$\CW%1-2<;1W'&U]1NFZ@;RW9I%VR1R-&X4
M$C([CVZ5=\U??_ODTRVM8K2!88%VQKG SDGU))ZGWJ;%4KVU$,\U??\ [Y--
M>950L=V ,GY34N*0KGO3 YF'6KXM'=N(?L\FTF$*=RJ>GS9Y(SZ8-=)YJ^__
M 'R:S(]"LX[I6'FF-"'2$O\ (ISQQ[=AT%:H&*RIJ:OSNY<W%_"-\U??_ODU
M6TTYMF/_ $VF_P#1C5;JIIW_ ![-_P!=YO\ T8U:D%RJ6HV<EY"L<=PT!#9W
M+GG@CL1TSD>X%7:* (IU+0.HW9*D?*<'IV-<Y'H6L,RSS:Q+YA9':,9V@XY4
M 'IG./K7444 (O3IBEHHH **** .6\501R36TDD+2[(I0L<ELTT+DX^4[>5?
MCAOK45O>:@+E(W-]:[4C$-KY'FJ4\K+;W(SD-D9SV'!S778I* .)N+WQ!#;Z
M9LFF+36HE>22+K,2/D8+&>,9XX[\\47&H^(EN-3PS(8DGV1"(MP!^[9?DQD\
M=6.<GCBNV H(HN*QQLTVJK>/$YFG^SW+&&62!=P!MF;@A0/O\?I0M[K442)+
M<7;1N+5YI_(4O&'5O,V@+CJ%['&379?6HKJT@O(##<1"2,D'!]1WIW"QSL=W
M-?>!+JXGE:61HYQO90I(#L!D #' ':O)A]T5[9J5FD?AZYL[2%47R3''&@ '
M/ %>8#P;X@P/^)<W_?Q/\:]?+JD(1ES.Q\KGU"K5G!TXMZ/9&'16Y_PAOB#_
M *!S?]_4_P :/^$-\0?] YO^_J?XUZGUBE_,OO/F_J.)_P"?;^YF'16Y_P (
M;X@_Z!S?]_4_QH_X0WQ!_P! YO\ OZG^-'UBE_,OO#ZCB?\ GV_N9AT5N?\
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MI)KN_P S]&PL7&A!/>R_(6BBBLSI"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#/OW>.VO7BC$DBQ$JA&0QV\#'>N?\,P(656B(\E
M?,1&TLVPB=N&*D]2>E:VMW45M:W*3.\2SJ8A*L981DJ<%L<@5S6@6^GRZDDL
MBP*T2(J)#+.^Z3/WSN QZ8YZ\TT)G=P?ZA/I4E1V_P#J$^E24AA1110 4444
M 4]0LC?6XB#1+\P;,D0DQ] 3P?>BPT\6$31BXGF!;=F9]V/8>@]JN44 5--_
MX\4_WG_]"-6ZJ:;_ ,>*?[S_ /H1JW0 R7_5G\/YT\4R7_5G\/YT\4 %%%%
M!3/^6W_ :?3/^6W_  &@!]%%% !2'H:6@]#0 R/_ %:_04^F1_ZM?H*?0 44
M44 ,?[\?U/\ *GTQ_OQ_4_RI] !1110 4Q/XO]XT^F)_%_O&@!]%%% !3)?]
M6?J/YT^F2_ZL_4?SH ?1110 4444 ,_Y;'Z#^M/IG_+8_0?UI] !5/3O^/9O
M^NTW_HQJN53T[_CV;_KM-_Z,:@"Y12'@&L>7Q)9PW0MC'<F9I'CC41Y\TI]_
M;SV'KCVS0!L$XI!(I9E# LO4 \CZU5L+S[?:+<")HP68!6()X8KGCZ5YUX'^
M&VM>&?'6H:W?:NEQ;3+( $9B\^YL@R C Q]3S[4 >FS3Q6\3RS2+'$@W,[L
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M7\,_\^,'_?QO\:/^$7\,_P#/C!_W\;_&CF#E/(:*]>_X1?PS_P ^,'_?QO\
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M8LQJ8&0#Y6!Z?>KMUTJT!@(1QY&3&!(V!D@],\\@'GTKG?"\#V5MJ#Q)ODV
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M(9)KM9(R'VF[653@]\*,9S^(Z'BF([*#_4)]*DJ.W_U"?2I*0PHHHH ****
M&2Q1S1M'+&KHW564$'\*2.&.)G9(T0N=S;1C<>F3ZU)10!4TW_CQ3_>?_P!"
M-6ZS]/N8$LU5IXP0SY!<?WC5K[7;?\_$7_?8H ?+_JS^'\Z>*KR75N8SBXB[
M?QBG?:[;_GXB_P"^Q0!-14/VNV_Y^(O^^Q1]KMO^?B+_ +[% $U,_P"6W_ :
M9]KMO^?B+_OL4S[5;^=G[1%]W^^* +-%0_:[;_GXB_[[%'VNV_Y^(O\ OL4
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M3_OLT>?/_P ]I/\ OLTRB@+#_/G_ .>TG_?9H\^?_GM)_P!]FF44!8?Y\_\
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M_I0!9HJ'RG_Y[R?^._X4>2__ #WD_P#'?\* )J*A\E_^>\G_ ([_ (4>4_\
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MOJ6L)I:S7DU_#*L(\LI#@%_.=3YGR\?($QG'4]ZLBXUYI[[S)9XV42@*D#.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>tm238578d1_ex99-2img16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &? S0# 2(  A$! Q$!_\0
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MUPR&U9FX4IC#;6SUK0\6?&"W\)>,)M!N-'FN=ENKQR0R9>21A\J!<=_7/X4
M>G,>*YF\\<:-8^,;7PK/+.-4NE#1J(B4(()&6[?=-<-H/QEOI?%\'A_Q1X<D
MT:2[=5MV=F!4M]W<& X)XR._:N6^)&M1^'?C]I>KS02SK;6T;>3$/F<D. !^
M)%(#Z)HKR'P_\8]0N/&4'A[Q)X:DT>2[8+;EBP92WW=P8#(/3(KH/&GQ'/AS
M5[3P_I&ER:OKUVNZ.U1]JH.Q8_@3]!R13 [ZBO,_#?Q,U&?Q;'X5\5:"='U6
M==\!24/'(,$@>W0\@GIVJEX@^,_]C>*M5\.0Z#-=WUN5CM!%(6-Q*P!P5"Y
MP??I0!ZSFBO,KCXD>(K70-);_A"KZ?7=0$V;) RK#Y;;<L2,@'(/]:I:%\6M
M6'BRS\.^+?#+Z3=7I MY%<D$G@9![$\9!_"@#M+OQQHUCXRM?"LTDXU2Z0/&
MHB)3!!(RW_ 3729KP[Q'_P G0^'_ /KW3_T"2O<1TI <WX<\=:+XIU34=.TR
M69KC3VVSB2(J,[BO![\@UTC-@5\O^"/%UUX6\:>+$TS1;C5]2O;ETM[>$''R
MR,26QDX&:]8^'7Q3_P"$RU&ZT?4M-.FZO;*6:+<2' .&X(R""1D&FP.DT'QQ
MHWB/6M3TC3Y9VN].8K<!XBHR&*\'OR*Z7->&?"$A?BOX\)( $LF2>W[YJU+O
MXQ:OJNK7=EX)\+2ZQ#:-B6Z9B%;MP!T![9.3Z4#9[!17!?#[XF6OC@7=K+9/
MIVJ6?^OMI&R,9P2#@=#P01Q7/7_QAU74]9N]/\%>%Y=92S;;-<LQ"GG' ';(
M.,GGTH$>O4=JX'X?_$NW\;27EC/82:;JUE_K[:1L\9P2#@'@\$$<5S%]\;;Z
MX\175CX8\+SZQ9V)/VF:,L690<%E"@X'H3UH [[1O'.BZ]XDU'0;&6=K[3]W
MGAXBJ\-M.#WYKIATKY^^"^HQZO\ %GQ1J4,;QQW<,DRI)]Y0TJG!]Z^@ATH
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MX')_$Y->,Z)X?NO$G[06HZY-I,]IIUA(9$>6!D65T 12">I)RW'85[LO HZ
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M<#I'^M %FBJWF7'I'^M'FS^D?ZT 6:*K>9<>D?ZT>9/Z1_K0!9H(R*K>9/\
M],_UH\R?TC_6@"P![FEJMYD_I'^M(9IPX7$?.?6@"U15;S)_2/\ 6CS)_2/]
M: +-&*K>9/Z1_K1YEQZ1_K0!8Q2U6WW'I'^M'F3^D?ZT 6:*K>9/Z1_K1YDY
M[1_K0!9HJMYEQZ1_K1YD_P#TS_6@"S15;S+CTC_6FI-.Z!@(\$9[T 6Z*K>9
M<>D?ZT>9/_TS_6@"S15;S)_^F?ZTN^X](_UH L456\R?_IG^M'F3_P#3/]:
M+-%5O,GSC]W^M'F3^D?ZT 6:*K>9/Z1_K1YD_P#TS_6@"S150S3APN(^03WI
MWF7'I'^M %FBJWF3_P#3/]:/,G](_P!: +-%5O,N/2/]:/,N/2/]: +-%5O,
MG](_UH\R?L(_UH LT56\R?\ Z9_K1YD__3/]: +-%5M\_P#TS_6@R3XZ1_K0
M!9HJHDT[H&Q&,C(ZT[S)_P#IG^M %FBJWF3^D?ZT>9/Z1_K0!9HJMON,?=C_
M %H\R?\ Z9C\Z +-%5O,G_Z9_K1YEP.HC_6@"S15;S)_2/\ 6CS)_P#IG^M
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MR]N[TWE[=[1))Y810JC  4=.M;%( HHHH C;_CX3_=/]*DJ-O]>G^Z?Z4_-
M"T444 <EX]ECBLM+\^>6&V:^03/$[*=F&STYK-TNZ=-4N1X9GNKW3ULV9_MC
MOY:S \;689SC-=7K&DG5)-/83^5]DNTN/NYW8SQUXZUI./,1E8]01P:8'/\
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M39[R[NKPW=[>,K2R[ BX48 "]A6Q2 **** &'_7C_=/\Q3ZC/^N'^Z?YBI*
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M7_GI)_WU2VO_ ![)]*FH @^RK_STD_[ZH^RK_P ])/\ OJIZ* (/LR_WY?\
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M9?[\O_?5!MACB24?\"JQ2&@"I;P!K=#YDG3^]4OV9?[\O_?5+:_\>T?^[4U
M$'V5?^>DG_?5'V5?[\G_ 'U4]% $'V8?WY?^^J/LP_OR_P#?53T4 0?9E_YZ
M2?\ ?5!ME_YZ2?\ ?53T4 5_LR_WY?\ OJE^S+_?E_[ZJ>B@"O\ 9E_OR_\
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MH **** "BBB@ [5#:_\ 'LGTJ8]*AM?^/9/I0!-1110 4444 %%%% !1110
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M HHHH A?_CZ3_<;^8J:H6_X^E_W&_F*FH **** "BBB@ HHHH **** "FO\
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M3J0=*6O(/4"D-+2&@"*U_P"/:/\ W:FJ&U_X]H_]VIJ "BBB@ HHHH ****
M"BBB@ J)O^/J/_=;^E2U$W_'S'_NM_2@"6BBB@ HHHH **** "BBB@ HHHH
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M6HG_ ./B+\?Y4 2T444 %%%% !1110 4444 %%%% !VJ&U_X]D^E3=JAM?\
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M_"Q?$/\ ?L__  %6N*G3<H)G54J)2:N>K;F_O-^=='X5)(N\DG[O4_6O!?\
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M4]>6>F%%%% !1110 4444 %%%% !43?\?,?^ZW]*EJ)O^/E/]UOZ4 2T444
M%%%% !1110 4444 %%%% "'H:CM?^/6+_=%2-]TU';?\>T?^Z* ):*** $-<
MOK;,-28!B/D'0UU!ZUR^N?\ (4;_ '!29E5^$SM[_P!YOSHWM_>;\Z3%&*@Y
M=3I- )-E(22?WAZ_05K UC:$XBTZ5V^ZKDGZ8%6!K=E_ST;_ +Y-6=<9)15S
M2HS6;_;=E_ST;_ODT#6[)B%#L23@?*:+E<T>Y;;_ (^E_P!QOYBIZ@/_ !\H
M?]AOYBIZ904444 5;_\ X]F^HK*[5JW_ /Q['ZBLNLY;G31V"IK/_CZ3\:AJ
M:S_X^T_&I1I/X66+N>2*4!&P,57^US_\]/T%27_^O7_=JK3;U(A%.*)OM<W_
M #T_05;LY7EC<N<XK-J_I_\ JI*<6[BJ12CH6X/^/>/_ '111!_Q[Q_[HHK0
MYB4]*YGQ!I6K3ZK9:CI%Q96\MNCH[W 8[E;^'CMQ735QOB6"WU'Q5I>GZK(X
MTZ2%RD8<HLL^0 I(]N@H >/^$P4J9-3T+8"-V%;.*ZU>E>/R:;H%KX7CN@(Q
MK=K<[6MVE8M*PDQL*9],=*]@7I0P'5#=+*]O(L#JDQ0A&89"MC@D=ZFI#TH
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M[Y$OG"'S6\H/UW;,XSFM^B@#"O\ PGI6I7KW5Q#)OEQYJI*RK+CIN4'!K:1
MB!0  !@ =J?0: (;7_CVC^E35#:_\>T?TJ:@ HHHH ;FE_&L/5[RXM[Q4BE*
MJ4!P /4UG_VI??\ /PWY"K4&T82KQB[,ZS- KD_[4OO^?AOR%:^D74T]M,\S
MERK>G;%#@TAPK*3LC6HK*&O6N/NR_D/\:/[>M?[LOY#_ !I<K*]I#N:M1/\
M\?$7X_RK/.O6O]V3\A_C5\G,T)]0?Y4FFBHSC+9DU%%%(H#7/^,1_P 4Q=?\
M!_\ 0A705@>,/^18NOJO\Q7/B?X,O0Z,+_'AZK\SRSBCBC%&*^,/T$TO#O\
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MNM\;#M7L7P'ZZ]_VP_\ 9Z\=KV+X#]=>_P"V'_L]+$?PV%#^(CV&U_X]HO\
M=J>H;7_CVC_W:FKRSTPI*6D/2@#B_%'_ "%Q_P!<5_F:QLUL>*.=8'_7%?YF
ML:NV'PHZ8[(,UU_A3_D'3?\ 74_R%<A77^$_^0?-_P!=3_(5%7X2:FQT%)D5
M0U?5%TBP>[>">=5Q\D";F_\ U>]<TNMZKK-[8PVUU96=O=%QNMW%Q*H5<\G[
MJG\#7*8':@YJ)O\ CZC_ -UOZ4L"E(E0LSE5 W-U/N?>D;_CZ3_=;^E $M%%
M% !112$XH 6BDS1F@!:*3- .: %HHHH 0]#45K_QZQ?[HJ4]#45K_P >L7^Z
M* )J***  UXW\1?^1OD_ZX1_UKV,UXY\1?\ D;Y/^N$?]:RJ_">9FG\#YHY2
MBBCI7,?,GI'@O_DGVL?[TW_HL5YLOW17I/@S_DGVL?[TW_HL5YL.@K2>R._%
M?PJ7H+4UI_Q^V_\ UU7^8J&IK3_C]M_^NJ_S%0MSBCNCZ!/_ !\)_N'^8JQV
MJ _\?"?[A_F*G[5VGVR"BBB@9E:__P @MO\ >7^=<K75:_\ \@QO]]?YURE<
M5;XCVL#_  OF+5_1O^0K#^/\C5"K^C?\A6'\?Y&LX?$CIK_PI>A/XB_X_P"/
M_KG_ %-9-:WB+B_C_P"N?]36355/B9&&_A1$[UT/AS_CWN/J/Y5SW>NA\.?\
M>]S_ +P_E3H_&9XW^"S:@_X]X_\ =%%$'_'O'_NBBNX\,EHHHH **** "BBB
M@ I#2TAH XB_U?7)YM=O+"\B@MM(?8+=H0WGD*&;+=NO:NNT^Z%[IUM=JNT3
MQ+(!Z9&:Y34-!UM)=:MM/6V>TU=M[2RR%6@)7:W&.>G%=98VRV5A;VJ$E88U
MC!/< 8_I0 ^U_P"/:/Z5-4-J?]&C^E2Y% "T4F103Q0!SVMH[WRE49@$'(&>
MYK-\F7_GE)_WR:YWXC.Z^(H0'8#[,O ./XC7(>;)_P ]'_[Z->G2PSE!2N?+
M8O-%2KR@XWL>H^3-_P \I/\ ODULZ,K)9W(=67GN,=J\6$LG_/1_^^C7H?P]
M=QH6IMN.Y7)!)SCY:FOAW"'-<TP&91K5N3EMHRP#P*7-<./$^L #_2Q_WZ3_
M  H_X2?6/^?M?^_2?X5HL+.Q@\VH)VL_P.X/;I78]98?H?Y5XO\ \)/K!ZW8
M_P"_2?X5[,OW[<GNI_E7)B*4J=KGK9=BX8CFY+Z%FBC(HS7*>L!K \8?\BS=
M?5?_ $(5O$BL#QC_ ,BS<_5?_0A7/B?X,O0WPO\ 'AZH\NHYI*6OC#]"-'P[
M_P C'I__ %V%>MM-'&0'=5]-Q KR3P[_ ,C'8?\ 785T_C74;JROK5;>4(&C
M)/R@YY]Q7N8"LJ.&E-]SYK,J#KXN%./5'9_:H/\ GM'_ -]"C[7!_P ]H_\
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M65TCBD$@B\LJ74DHP]1_6NC*C.['.,4G!--,<9.+370X[_A +7_G\F_(4?\
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M3_\ G_N?R7_"C_A5FGG_ )B%S^2_X4^WU^_U26WL4U/[#.D<\MW*;;)78V%
M##&-ISGVKIO#E[<:AH<%U=8:5]WSA=HD4$@-CMD8/XT[@4-)\,IH5A/IT%PT
MD=VS;V<<KE<<8^E8H^%>G@ ?;[G\E_PKO2H)!(Z=/:L_6FU1--=M'6%[Q2"J
M3?=8=QVYI7 Y+_A5EA_T$+G\E_PI5^%M@K!OM]QD'/0?X4_3=8U^_P#$=O:M
M>6B,L+/<6S6[H4 90003][!X(XKNARM,"DS3A6EW)F(E<8/-*;>]+$B]V@]
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M ]E-, N%8LJ\]?\ ZU4_#-_J%T+J'4'$LD/ED2B/R\ET#%2/5<X_&M_8-V[
MSC&:%)IW0G%-69R__"&0?\_3_D*7_A#+?_GZD_(58\0:T^C7EJS'%L\4Q?\
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MTA0$@#.W(^N* /2%.:=35[TZ@ -<%K&J1-XAO8+S7X].%L4$*?9%D)!4$G+
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M JCJ.NP:5=;+JUNU@*AC=)"7C'LQ'(_*KMCJ=EJ</G6-U%<1_P!Z-PV/KZ4
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MMW"L>.AR#Q7#:4ME'JKZ@EQK<1EE@#2R.G^D*[$(6 'W25QZ\T >CBEI!2T
M!-<!J6JQ/KU]%>>(8]/-M($AC%FLAV[0<[B#SDG\J[FZB>:WECCF:%V4A9%
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MO)HV6WFAN6EC;:H!&#T;:!SCD"@#K;:!;6WC@3<4C0(NXY. ,<GO4U%(W H
MX[QT;5X(XI+2>:98I)2T-QY)2(;0^3SN!R/EQ6MX:6VAM[NVMXY%:"Z=)7DD
M\QI'P#N+=R01].G:L'Q3/EGCUBPT^YM4<F$QWWE3JIXZ'J2.H!K=\)SV4^C
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M49E_T='"D\]<Y&,=:Y_2]'\2VMQ#]DECTZP5@6M9IOM!V]P/E&/SKML"DP*
M!1@4M%% !7 :U#I]QXCO#J>DZHZIL\N6Q27;,-G._!P<9Q].*[^N.U-+V+4M
M5!TR]O4O8EB@D@F"K&-O*G)&T[LG/O0@.HT\QM80&&)HHB@V1LNTH,< CM5F
MJFF)<0Z;;1W;^9<K$JROZMCFK= &7J^AQZO]G+W=W:R0,622UD"-R,$9(/:J
M=MX4CM]0MKV35M5NWMV+QI<W = 2".FWT)KH**  =*0]*6B@#B-4T:YN=;N+
MG2]&DM[LMSJ!O!&'X_NX;(_"NAT*WU>WLRFLWD5U<;OE>)-N%]#TR??%:V!1
M@4 %%%% &)XL8KH$V+(WF60&!59BPW#.-O.0.0:S?"T.E6]Y,MA8:I%*Z%FE
MOHW'&<X!;W.<5K>)+>YN]$FAL]QE8KE$?8SKD%E![$C(JCI!NKG7)+O[!=V-
MH+983'<.#O<'@A03C SSWS[4 =**0C/2@4M ',Q^#$A4I!KNM0Q[BPCCN@JK
MDD\#;[UL:1I46C:>MG#++*BLS;Y6!8EB2<D =S5ZB@ K'\26L5WI30RZ6^I*
MSK_HZ.$)/KDD8Q6Q1B@#BM*T?Q):W4)MYH[#3U8;[66;[0=O< [1CCW-=H.E
M+CG-% !2-TI:1NE ' :M#IUQXBOCJ6D:JVQU\N6RCEV3+L .[!P3U'';BNXL
MC&;.$Q1M%$4&R-EVE1C@8[8KE=3COH[[5T.FWMZ+U0EO-!.%2)0HPIRPV$-D
MY[YKJ=/2>+3[>.Y??<+$JR-_>8#D_G0!9K*UC0H]8DMY&O+RUDMRQ22UD"-\
MPP><&M6B@# M/"L=MJ-O>R:KJEW);EC&EU.'4$@@\;?0UO\ :BB@ /2N'U'1
MKJXUJYN-*T:2UNBW-^UX(Q)[[<-D?45W%&* ,K0[;5K:RV:Q>175QNX>)-H"
MXZ'U/O6K110 5A>+"1H<G^AO>*70-"BL6(W#)7;R".H/M6[6/XEM[FZT>2*T
M#M(60M'')L:1 P+*&[$C- &7X5@TJWN9EL+'4XI2F6EOXW&5SG:&;W.<"NL'
M2N;T8W=SK<]XUC=6-J;=8C'<2 EW!X(4$XPO&>^:Z0=* $(R,5S,7@Q($$<&
MNZW#$"2L<=T JY.>!MKIZ* *6EZ9'I.GQV<,DLB(6.^5LLQ))))P.Y-7:**
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MODNG/S2\'H#CYC[FO2:3% $%@DT6G6T=PVZ=(E60YSE@!G]:L4#BB@ HHHH
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MC_A<WP_QG_A(H_\ P'F_^(H [NBHK>XCNK>*XA;=%*@=&]5(R#^52T %%%%
M!1110 4444 %%%% !1110 4444 %%(3@9KD-3^*7@O1M3N--U#6T@N[=MDL9
M@E.T]<9"D4 =A17"?\+E^'__ $,4?_@/-_\ $4?\+E^'_P#T,4?_ (#S?_$4
M =W17':;\5/!6KZE;Z?8:Y'-=7#B.*,02C<QZ#)4"NQH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+F^A:XDVBYP71MG.&'8^E '?CFEI!TI:$ 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XI\7!_Q<+P]_UXS_\
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MOKS3H+&VLIF9HS<"1SE<9R.,>U=EM'I1@4  Z4M'2B@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>tm238578d1_ex99-2img17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+ ?0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH ***:_W&^E "Y%+FJ:1J8U)>7) _Y:M_C2^6G]Z7_OZW^- %O-&:J^4O\
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MT)["K%07<'VFVE@\QXO,4KOC.&7/<>] '+S^)KZTL[YYUM,VUW';&[ ;RAN
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MO$QF/JT:KA%*W]>9]!@<LI8B@JDF[Z_UL>H?\)MH/_/U)_X#R?X4?\)MH/\
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M\9^GI6O37^XWT- #+?\ U$?^X/Y5+45O_J(_]P?RJ6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *.U%':@"%O^/B/_ '6_I4PZ5"W_ !\1_P"ZW]*E
M'2@!:*** "BBB@ HHHH *#THH/2@#B_B)_QX6'_7=O\ T$UP)KO?B)_R#[#_
M *[M_P"@FN"-?*YE_O#^7Y'VF4?[JO5_F+1117G'JA1110 5O>"_^1HM_P#<
M?_T&L&M[P7_R--O_ +C_ /H-=.$_CP]3CQW^[3]&>H+U-,M?^/=/\]Z>O4TR
MU_X]D^E?8H^!1-1113&%%%% !1110 4'I10>E "&OF#XE_\ )1M:_P"NJ_\
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M/^N[?^@FN"KY7,O]X?HC[3*/]U7J_P Q:***\X]4**** "M[P7_R-,'^X_\
MZ#6#6]X+_P"1I@_ZYO\ ^@UTX3^/#U./'?[M/T9Z@O4TRU_X]DIZ_>-,M?\
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M5Z)P!1110 4444 ?37PP_P"2<Z/_ -<V_P#0C76-_K8_Q_E7)_##_DG.C_\
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M6R"2N2>=M '0T444 5Y+.WEC\N6WA>/<7V.@(W9SG'KR?SI4MX;: QP11Q(
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M_P"^J\C^UJ7\K/<625VK\R_$]>WBC>*\A_X2'6?^@G<?]]4?\)#K/_02N/\
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M!O\ R-NH_P#7A_[46O,:].^!O_(W:C_UX?\ M1:PK_PV:T?XB/>A7S#\2_\
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M)<Z1IXM)I$\MW21FRN0<?,2.H%14Q$9Q:2+IT)1E=F]7S!\2^/B-K7_75?\
MT!:^F520NV7?;@8Z?CVK U#X?>%]6OYKZ_TE)[J8@R2-*X+'&.@('0"L*-14
MY79M5IN:LCY;S1FOIK_A5_@K/_(#C_[_ $G_ ,51_P *O\%_] ./_O\ 2?\
MQ5=7UN/8YOJLNY\RYHS7TU_PJ[P6/^8''_W_ )/_ (J@?"_P6?\ F!Q_]_Y/
M_BJ/K<>P?59=SYES1UXKZ:_X5=X+_P"@'%_W^D_^*I?^%7>"_P#H!Q_]_I/_
M (JCZW'L'U67<7X8_P#).M(_ZYM_Z$:ZMO\ 6Q_C_*J>GZ5:Z/IT5CIT;06T
M((CC5B0O?J<GK5J)&PC.6+ =#V-<$G=MG;%621-1112*"BBB@ HHHH ****
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M^67G12O!YXYS21>)M<AL7O"\5V98;YHK<0[2C02E1R#ELCJ,=J[WR8QC$:\
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-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>tm238578d1_ex99-2img18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Z NX# 2(  A$! Q$!_\0
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M" Z^*=%'UOX__BJ .AHKGO\ A.O"/_0TZ+_X'Q?_ !5'_"=>$/\ H:=%_P#
M^+_XJ@#H:*Y[_A.O"/\ T-.B_P#@?%_\51_PG7A'_H:=%_\  ^+_ .*H Z&B
MN>_X3KPC_P!#3HO_ ('Q?_%4?\)UX1_Z&G1?_ ^/_P"*H Z&BN>_X3KPC_T-
M.B_^!\7_ ,51_P )UX1_Z&G1?_ ^+_XJ@#H:*Y[_ (3KPCC/_"4Z+_X'Q?\
MQ5:VGZE8ZK:BZT^\M[RW)*B6WE$BDCJ,CO0!;HK D\;^%(9GBE\3:/'(C%61
MKZ,%2.H(W=:;_P )UX1_Z&G1?_ ^+_XJ@#H:*Y[_ (3OPA_T-6B?^!\7_P 5
M1_PG7A#_ *&G1/\ P/B_^*H Z&BN>_X3KPC_ -#3HO\ X'Q?_%4?\)UX1_Z&
MG1?_  /B_P#BJ .AHKGO^$[\(?\ 0TZ)_P"!\7_Q5'_"=>$1_P S3HO_ ('Q
M?_%4 =#17/?\)UX1_P"AIT7_ ,#XO_BJ3_A//"'_ $-.B_\ @?%_\50!T5%<
M]_PG?A'_ *&G1O\ P/C_ /BJ/^$Z\(_]#3HO_@?%_P#%4 =#17/?\)UX1_Z&
MG1?_  /B_P#BJO:;XBT76)'CTO5[&^= "ZVUPDI4'H3M)Q0!IT444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '(?$8 ^'K0,H8'4;8$'_KH*D:UMMQ
M_P!%M_\ ORO^%,^(O_(OV?\ V$K7_P!&"K#=3_G% $/V6UX_T6WY_P"F*?X4
M?9;7_GUM_P#ORG^%9,\^JWM_>V^FW-M:BS"C$T'F><[#(W'(VITY'/\ *JX\
M1SVEY>I?6A^QPW4=O]IB<8C+0H^,'E_F8C.!V]Z -[[):_\ /K;?]^4_PH^R
MVO\ SZVW_?E/\*YJU\=6E\N+:U,TKO$L4<%S&Y(D;"LQ!PI'4J3Q[U,OB_\
M=AY])N80_FQ1JLR2%IHWV/&,8XW9PQZX/ Q0!O\ V6U/2TMO^_"_X4?9;7_G
MUM_^_*?X5S5YXN:RU*VMKFT:"8M)#+9[U=GEPGE!'Z<[NIQBK$GB2YM[NXMU
MTR6ZGBDEW(DR(L:QHC,,D?-]\@9&3CI0!N_9+;_GUM_^_*?X4?9;7_GUM_\
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M!Y;1.@41[<9!89)8_P! 3^%;A8K=8+.#]U9V\12*?R2)4^\0<,,C/!8$'G-
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M4>__ .P9%_Z&U ';#I2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA=H9E'4XI^GZ-;:=-),DEQ-,Z",R3R;V"#HN?09[Y-9'_"P= _O:A_X+Y?\
MXFC_ (6#X?[-J'_@OE_^)H O>,/^1*UW_KPF_P#036UXH_Y$G_P'_P#0TK@_
M$OCC1+WPKJ]K"U]YLUG+&F^QE5<E3U)7@5W'BZ98/ 4DLFX)&L#-M&XX#*>
M.M $I^\:*Y=OB#H&>NH\_P#4/E_^)I/^%@^'_P"]J'_@!-_\30!U!KF?&$,L
MZ:6MNS"=+HRQ;21EE0L ?4'&/QIH^(.@>NH_^"^7_P")I#X_\/GJ=0)'0_V?
M+Q_X[0!C?VI/)K]QJ\4[V\.HV4($K*2((!.8P^T\<@,?;=3I]9OX9YKBWF^T
M!(Q#'=;0JM$9<&3^[QTW=*USX^\.X/\ Q_8QC_D'2]/3&W]*3_A/O#H&!]O
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MI8ES"SAMT?IGY0?459\2R-9Z_I>H;I#]@MIKAP,_.H:,,"!U)!/^13O^$_\
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ML'0!QNU#_P %\O\ \30!U-5OA\/^)5JO_8:O?_1QKG_^%A>'P>6U'_P7S?\
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M-2%ORZU#:NK1?*RM@G[IS0!8HI,^E!.!0!$A)N)1GCY<5-4"<7$O']VI@<T
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M'I52'3+U]3L[Z[DM]T)EW)$#PK*  "1ECQR3BLR#P>4A:TD6U,/ES(EP"YF
M=67.TG:#\W)YSZ4 ; \2Z9]GDF::1$0*Q+PNI96. R@C)!)ZBD.O6TPA^S2A
M2UV+9TFC96#;2V,$9!QR">,5EP^%IQ;[&2QBE C7S(R[%PK!CG=PHXZ =>]7
M;G09Y]4-VLT:I]OANL<YVI%L(^N: +5MXDTRY_U=PP!C:0/)$R*RK]X@D '%
M266O66H7'V>W>3S?+\[;)$R93.-PR.1FLF3PY(-)M;628$06UQ#(8P=S!P?N
MU%H#7M[X@^U7"*(8+ 6^](WC!;>#T8#G Z#.* (?'U]:FPL+3[1#]I&IVC>3
MYB[\>8.=N<XK6UZ6>>XL=*M9VA>]=_-E3[R0H,N0>Q)**#VW9K"\?:-IGEV.
MK?V?;?VB=1M8_M7E#S-OF 8W=<5MZ\C6%W8ZS'$SI:-(EPL:Y;R9 -S =]I5
M#CT4T 7K31--L[;R(;&!8_X@4#%OJ3R?QK*FM(_#NJ6L]D/+T^[F6WGMA]Q'
M;A)%'\/S<$=#G/:MZUO+>[MA/:SQ30L,AT8$8K#OKF/7-6M-/M'6:&UN$N;R
M53E4*?,B ]V+;21V /X@%S7[^6RTLFS*?:YI4M[<L,JLCL%!(]!DM^%/TSP_
M8:='E(A-.P_>W,P#R2GU+'^72HM?L);G2@]E&K75M+'<PH3@2,C;MN>VX9 /
MJ:N:9JUIJUHL]H^<\/&PP\;=U9>H(/!^E &-KUA'I%M/KVFQB&ZM$,TR1#:M
MS$O+HP'!.T'!Z@XKHTE1U5D=2I&0<]0>E8/B:]6YLYM"M'5]0OXF@"*<^4C?
M*TCXZ!021ZG [UN1VT42(BH J !1Z =* .>M+7_A)I9+R]EE_L\2,EM;1N45
MU7C>^.3D@X'84M]I1T*V?4M&:2,P+OEM3(S1RH/O#!/!QR"*2POHO#C2:9J3
M&&W$C-:7+C]W(C'.PGLP)(P>O6G:IK,6IV\FEZ/(MU=7"F)WCY2%#PS,W3IG
M'J: &^-)TG^'6O2(PVR:9,R\]C&:?XB_Y$^/_>MO_0TJ+QG:QV_PXUV)5&(]
M,F0''4",BI?$(!\'Q@],VW_H:4 6O$-[/'#:V5C*$O-0N!;Q2#DQ#:S.^/4*
MK8]\4ZV\-:/!%L_L^"9CRTMP@ED?W+-DU'XAM)E2SU*R@\VXTZX$_E*/FD0H
MR.H]]KDCU( J[9ZO8WMOY]O=PR1MR#N (]B#R#]: ,E[0>&]3M&L\IIEY+Y$
MUODE89&'R.G]T$C:1T^8'L:DU*-=6\16VER_-:V\?VN=.TC;L(I]0""<?2H[
MJZ37]7L[*S;S+2RG%S=SH?EW*#LC![G=@GT"X/45)>LFD^);6\?"6]W%]D+'
MHL@.Y<GWY% '0*O?O45Q;0W,+PS1K)$ZE75AD,#U!J53Q^-,ED5%9G9551DL
MQP /6@#&\.2O!%?:7/*7_LVY\B)W.2T117CR>Y"N%SWVYJ&3[5KFJ75LEW+:
M:?:MY3F [9)I._S=E&0..2<T[PXHO?[2U9H\1ZC<^; &&"8518T8Y_O;2P]F
M%,>9_#VIWDDT,TFFW3B831(7\B0@!@P'.TXR#]: &7EK<>'(?MUE=7,]I"<W
M%K/)ORAZE2>01UQTKI%FC90RNI!&0<]17,:AJ2^(K9M+TI9)([CY;BZ*,(XH
M\\X) RQ'  ]?:NE2WB5558U 4 #Z"@#"O//UG6I=,2XD@LK:-'N6B;:\KMG:
M@;L  2<>HJ27PGI\:^98--8W*\I/#*Q.?]H$D,/4&H[F4Z%KLU])&YTZ\C19
M9$4GR)$R S ?PL#C/;:/6K%SXHTJ*$-#=+=2N/W<%M^\DD/H /Z\4 3:%J,M
M_IX-TJ)=Q2-!<*OW?,0X)'L>&'L:Q/!7_(E7'_7S>?\ HUZV-!T^6TL"UZJ"
M]N)GN9U4Y".YSM![[1@9[XS6/X+'_%%7'_7S>?\ HUZ $\)7L>G?"S2;N3YA
M!IJ2;0>3A>!^=7]/T"&Y5;S642]OI5#L9!N2//.U%/  X]ZSO"E@FI?"K2;0
MX4S::B!C_"2O!_.M?2-;BG@6UO2MKJ,"A)[>1L$$<97/53U!% %/5M+AT*&3
M5]*06Y@^>XMXSMCFB'W_ )>@8#D$>E="LL31JXD7! 8'-8.OZC'J%O)HM@ZS
MW=VIC?RSD0QGAF8]N,@#U(K<CMHDA6,(NQ5"CCVQ0!@:5IT.O9UC4E%RLC'[
M+#(,QQQ@D*=IX+'&<GU%7K[PW8W*E[:)+.\49BN;= CJW;..H]0>#530;R/2
MD&@W;+!/:DK!O.%FBS\I4GT!P1[5I:IK5II<!DE8/*>(X(SNDE8]%5>^: $T
M/4&OM+CEGVI<*6CF4< 2*<-_C^-9]XKZWK<^G":2/3[1$-SY3[6FD89$>1R%
M"X8^N]1V-7-!TY[328UNT4W,C---CL[')'X<#\*I7$J^']>N;V=<:9J"IYLR
M@GR)T&T%L=%9=HSV*<_>H L2>%-(,7[BV-K*,%9[9BCJ?7(//XYJ30;^XGM;
MFWOV4WEE<-;3.!M$F &5P.VY&5B.Q)%/N_$&EV=MYTE]$5/W5B;>S$]@J\DU
M#H%K<>3=WM_"([F^N&N&A.#Y2[51$)]=B*3[DT )K=U<M-9Z;83"*XO&;=-C
M/E1*!N8?[664#ZY[4@\(Z0(_FAF:;_GX-P_FY]=V:36[>6WNK'5K6W:<V9<2
MPH,L\3@!BH[L"%..X!J4>*-%:U\_^TK?9W!;#?3;US[4 1Z-<7-O?W>D7LQF
M>V"2PSOPTD39 SZL"K GZ>M;9D7LP)],U@Z-'-J&I7FLW$31Q3(D%M'(N&\I
M<G<P[;F8G'H!6YY,8.?+7(H YY+S6=:+7.F-9V]DKD0O<1L[3E3C=P1M4D<=
M^]:6D:F]]#,+F)8+JVE,,\8;(##!!!]"""/_ *U9<$.JZ"GV.UT^._L]Q-NX
MG6-H@3D*^[J!D\C)]JT-(TR6V6XFOC#+>74IEE,8^5>  JYYP !U]Z +U[>P
MVEE/<R./+AC,C8] ,FL/3M!34[>/4-<0W%W.N_R'8^7;@\A O3(& 2<Y.:V;
M_3X+VPN+1U"I<1-$Q'4!AC^M9>D:W'%!'8:K*EMJ4*!)%E.T2X&-Z$X!4]?;
MIVH KZA8KX9*ZKIQ:.T5U%Y:ER4,9(!=0?NLN<\=1D>E6/%#?Z)8C()&HVXX
M_P!ZH-8OHM?_ .))ISB<3./M<R<I#$"-P)Z%F&5 'N>U3^*$46EB0H!.HVY_
M\>H J^+_ /D->$C_ -1?_P!H2U/+ NN>()K>Y DT^P"$PG[LLS#.6'<*,<'O
M4'BX?\3KPE_V%O\ VA+5@3)H_B:=9]L=KJ6UHI#PHE48*'T)&"/7F@#H%7"
M>E<[?VT>BZU:ZC; 107DPM[R)>%8L"$DQV;=A2>X;GI71*_ R/TK U69=4U>
MSTFW;?Y$RW5V5((C5.54^Y;''H#0!J:GJ":=IEQ=MA_)C+;<XW'L/Q.*R8/#
MKWT2SZS=7,MTX#&.*9HXXN^U0I[>IK3U734U#2KBS4*IE0A6(X#=0?SK-M_$
M]I#$L.L,;"]C&V5)E(#'U5NA!]J "TDN-'UJ#39[F2YL[I6^S22G+QNHR4+=
MP5R0>O!K8OKZ"RL+F\F;]U;Q/*^.NU02?T%8EL[:_K=O?+#(FG62OY+R*5,\
MC J6 /(4#//?/'2MC4--@U#3+NQD4!+F%X6(Z@,I4_SH R-,T*._@CU#7(5N
MKV=1(T4OS1P \B-5/' XSU/6F:KI2:%;RZQH\?D/;+YD]M'Q'/&/O#;T#!<D
M$=P.U6-'UI&@6SU*1+?5+=0DZ2':'(XWH3U5L9'IG':HM=U-+^UET33)4GO;
MN,QLT9W+;QMPTC$<# S@=S@=Z -N6ZAAM9+DNIB1#)D'^$#-8^@::+B*/6K^
M,2:E<+O!<9^SJ>51,]  1R.2<YK5EL+>33Y+-45(VB,(X^ZN,#\A6=X<U#?:
MC3;H^7J-FHCFB)P2!P'7/56 !!_"@"_J6E6>JV_E7L*N!]Q^CQGU5NH/TJIX
M?NYY;2>UO9 ]W8W#6LKD8\S #*WU*,A/OFK]]?6^GVKW-W,L4*#EF/\ +U/M
M69X?M9#;W=_=P-'/J%RUR8G^]&NU40'WV(N1V)(H BT>V75KZ77+E1(PE>*S
M5N1$BDJ6 _O$@\^E;\D2RQ-&ZAT8896&01W!%86@3KI\UQH=P0DT,KRV^>/-
MB=BP(]P201["MTR8!- &#IL0T;7I-)C)%C-#]HMD//E$'#H/]GD$#MFJW@7_
M (\M:_[#E]_Z/:K%G(-:\1RWT1#V-I$;>)^TDA.7(]@ !GUJOX%_X\M9_P"P
MY?\ _H]J +OA%U_X1JU&1G?+W_Z:-5+3;+_A)HEU;4GE-I,2UG:I(500]%=L
M?>9A\W)X! JWX2B1O#5L2H)WR]O^FC54TG4(?#MNFBZJPM_LO[NTN&&(YX0?
MDYZ!@N%8'N,]"* "_LQX8B.J:?)*+.%E^UVK.77RLX+KG[I7[WN :Z@R+R"R
M_G7,:K?P^(HGT;2Y3<+<$)=SI_JX82?G!/=F *@#INST%=+Y49))09ZT <['
M;'Q'J5T]U)(--M9C!%;HQ42LOWW<CDC/ '3BK%UX7M(XS-I(^P7J#,4D3$*3
MV#CH0>]5[6[3P]J%U9WI\FSN9VGM;AA\F7.6C8]F#9QZ@^Q NW_B2RM8PEO*
MMW>2#]Q;P,':0]NG0>I/2@"?1-475-(MKP@1O(OSIG[K X/Z@U5U:\N;B^MM
M*L9O(DN$:66X4!C%&N!\O^T2<>U3Z)I0TW1K>TF*O*BDR,.A<G)_6JVK6\MC
MJEOK5O \ZQ1M#<11#+&,D'<H[D$=!R: &GPQ%&OFVNH7\-V,8F:X+\_[2G@C
MVJYHFI27U@3=!([N"1H)U4_+O4\D>Q&#^-5'\6:4T6+626ZN3PMM#$3*3Z;2
M./J>E6-"TZ2VL7-ZJ&[N97N)@IR%9C]T'O@ #/?&: *^MS2WFH6.BV\[0_:E
MDGN94/S+"A4%5/9F9T&?3=5F/PUHL<'DC2[1EQ@EX@S-[ECR3[U4UM&TS5++
M7(XB\,$<EM=*BY*QN4(<#OM9!D>C$]JU8=2LIK<3Q74#0L,AUD&,?6@#(M(V
MT'78M.65VTV[C=[=9&+&WD3!9 3SM*G('8@^M5[0Y^*%^?\ J%0_^C&J>WG7
M7_$$-W -^G:<CA)L<3SN-IV^JJN03T);_9J"S4+\4+\#H-*A_P#1C4 =6*1J
M4&L[7+B:TT'4+JW8+/#;22QL0" RJ2.#[BAAN[%&7PCH5Q;6MN]D/+M8_)B"
MNRGR^Z'!^9?8U@^(O \NMWEQ&'LH["YB2%OD99(T7 ( 4[6XZ;AQFO,)O'WC
M*<(7UR5<#_EE#&N?R6HO^$W\8#!_X2"[ZYP5C_\ B:Q]M$]!9?5[H]Q7P?HZ
MZE/J,<,\=Q/.+B5DN' =^.2 <'H..E,;5="\.2_V=O:#S)/-DVQ.RQF1L!G8
M#"!F/&2*Y_X9>(M9U]-3.KW2W!@:,18B1-H(.?N@>E:?B%M1NM22P&B7-QI3
M;'N)K=H\S,&!V'<P(08!;C) Q6B=U='%4ING-P9J77A/1;Z]:[GL\R.P:11(
MP20^K*#ACTZBME(U0848 X QP*$]^N:DJB Q28%+10 FT9HVBEHH 3:,48I:
M* $P*-H]Z6B@#D_B!_R!M/\ ^PI:?^C!75E0PYKE/B!_R!M/_P"PI:?^C!76
M4 8MSX;T>6X\QK",-(27V94-]0" :TK:SMK2!8;:%(8EZ)&N *?+_K(_J?Y5
M** $VC&*R=1T'2[QWN)[-#,0 TBY5F&>Y&,_C6O4-Q_JF_#^= $%CI-AIR%;
M2UCBW<L5'+?4]3^-7:0=!2T 1O#&Z%74,IZ@\@U':Q1QVT8C144CH@ %6#TJ
M*W_U$?\ NT 87CP8^'_B'_L'3_\ H!IOB'_D3X_K;?\ H:4_QY_R3_Q#_P!@
MZ?\ ] -,\0_\B?'];;_T-* .CP#U]:RK_0M)N[A)KC3K>25FPSE!D_4]ZU>]
M13_>B_WJ "&VAMXEB@B2*->%1%"@?@*;>6=O>VLEM<Q++#(,.C]"*G%+0!SH
MT[5],AV:?JL<ENOW4OXC(5'8!U92?QI7T.[U$K_;5^+F(')M+>/RH6] P)+,
M/8G%;5QQ$S#@XZ]ZE4?*/I0 B( HP,8XQTI2HY/M3J1NA^E $, W0+G)Z_SJ
M>H;?_CW7\?YU-0 W:,?6JT%M!%+*8X(D);!*( 3^(JT>E1Q_ZR3_ 'OZ4 2!
M0#FN0\%?\B5<?]?-Y_Z->NPKC_!?_(E7'_7S>?\ HUZ +?@  _#[0!_TXQ_R
MK7U'3;*^@_TNUAGV_=\Q <?2LCX??\D_T#_KQC_E70S_ .H?Z4 16=C:V4/E
MVMO% AY(C4+DU8P*%Z4M %:[T^TOH?*N[:.=.H$BYQ]/2J>F:+IMB!-:V44<
MI!!D"Y;'ID\UJGI45M_Q[K^/\Z )%&!2,BD$$9!ZCUIU% %"VT^RMYY)(+.W
MB?=]Z.)5/3U J[L'I4:??D_WOZ5-0 W8*K-:VYOUD,$1DVYWE!N_/K5NH3_Q
M]#_=- $FP9SWIU%% $$P&8_]\5, ,U#-UC_ZZ5-WH " 1S5:]MH)[=A-!'*!
MR!(@;'YU:J*Y_P!0_P!* """*&)4BC2-!T5% 'Y"L7Q2,6=AC_H(6_\ Z%6\
MOW1]*PO%7_'G8?\ 80M__0J *7B[_D->$O\ L+?^T):Z2YL[>]MW@N84EA?A
MD<9!KG/%W_(;\)?]A;_VA+754 <\WAF!)5A34=4C@VG$*WC!0/0=\5JV.F6>
MGV_DVD"Q)G)QU8^I/4GZU.W_ !\)_NG^E2T )@5#.H^3C^,5/4,_\'^^* )
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MQE(/LHPH^F*L6&H7UCJ,.F:C,;F.X!^RW>T*S$#)1P.-V.01U IM =+4,_\
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MF=EY^SWVUTD]MP *GWY'M6II6I)JFGQW48="V5>-_O1NIPRM[@C% &C44?\
MK9?J*YV[O[[5;^>RL+EK6TMF\N>Z0!I'?&=B9X&,C+8/TJ'^Q9(\/:ZQJT4X
MY\Q[DRAC[JPVD?3'ZT[ =97*^!?^/+6O^PY??^CVK0T/5+BZDGLM05%O[;!<
MQ_<E0_=D4=L]QV-9_@7'V+6L?]!R_P#_ $>U("]X0_Y%FV_WY?\ T8U;,O\
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MJ,ZW)>>VNU78+FV?8^WKM/4,.^"#4.G>'+:"YBOIYKF]NEYCDNG#>5QSM4
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MD>@SQ=_R&_"7_86_]H2UK:QK,&DB(-%+<7$[%8+:'[\A[]2  .Y/ K(\7?\
M(:\)9_Z"W_M"6H(G^U>)=8NI ?,A9;6//\,87<<>F2<_A5/0SBKNQ*=3\2O(
MLR6FCQ*!_J&GE9OH7"X'_?)Y[UI:3KJZA.]I<VSV5_&-S0.P;<O]Y&'WE_4=
MP*@[8].*S-7/V=M/OER)K>]A52.I61UC=?H0V<>P]*E2=S64$E<[3< .3BL3
M4/$VD6=S]FFOH_.1LNB N4'^U@''XT>)=0FLO#UY- 'CFV[5?'W"2!G\,U6L
MK*'2[5+2U79&G7'!9N['U)]3UIMV,HQYC<LM1M-2MQ<65S'/"3C?&V1GT^M6
M217'JHT_Q/97-O\ +]N+07"#_EKA"ROZ%A@\]Q6MXCU&6P\,ZI=VZLLT-K(\
M;$?=;:<'\#S3OH#5G8@U#Q3907$MG;P7-_<)Q(MI&&$9]&9B%!]LYJ33?$]G
M?7B64D=Q97;+E(;I-ID Z[&!*MCO@FL:SLXK"TBM( ?+C'WCU<]V)[DGD^YJ
M#5K9;K2IT+F.1 9H9%X,<B\JX_V@0/Y5"GJ:^R]VYW>X;>*Q+SQ"5OGL--L9
M+^ZCP)=CJD<)/.'<\;N^T9.#TI4UF23PF-66$B5K 76T#(#&/=@?C4.B6J6>
MC6L,9W9C#NV>7=N68GN2<\__ %JMF*0PZ_>Z:F[5-':.U!R]Q:SBX6/W8;58
M#W (%=#%-'-$LD;JZ, 593D$'N/;FJ!XR00*S?#;+9G5M/C5C!9WNV!0/N(\
M:2A/P,A ]!@4(<E8LZKX@%I=BPLK5KV^VAFC#A$B'8R.?NCZ D^E9ZZMXCA8
MR/I^FW*'DPPW$B2#Z%UVG\=O:JN@?O-.:];F:[FDFE8CDG<0!^  %:A'XC^=
M2Y,T4%8T=)UBVU>T,UOO1D;;+#(NUXF'56'K_.L;P)_QY:U_V'+_ /\ 1S5'
M:G[)XPMWCSB\M7691W,94J?K\Q&:D\"?\>.L\?\ ,<O_ /T>U4C*2LR]X1./
M#-MG^]+_ .C&J#6O%^DZ1.;&5IKB\"Y:"UC,CH.V[LOXU6TB_?3O <MW'$SO
M;PW,R@C@E6=A_*N L(S#9)ND,LLO[V:4GF61AEF/U_D!["HE+E-J-+VC/2=$
M\7:3J\ZV<336]YMR+>ZB\IV ZE>S8]LUT6X5XGJ*LUC)(C^5- IF@E[Q2H,J
MP^AQ^&1T)KUW3K\WVFV=TT3JT\,<I7'W2R@X_6G"7,%:E[-Z#-3URQTH1BZD
M)EE_U4$2&223_=0<FJ%GXHL/,CM[F*\L'D.(_MMNT2N3T 8C&?;.:SM)(NKG
M4-4E7_2)[AXLGJD:$JJ?0<G'J:OSVT5W ]K.F^*8;70C.1_C3<M253NKG1!A
M3)KB&"%Y9I4CC099W. H]R:P_"]Y+-X>A$Q:5X6DA\P#.X(Q4'\A575P-1\1
MVEA<)NM88&N3"XR)7W!5R.X'6G<SMK8NV_BK0Y[UHH]4MRTF F6P&/L3P:W
MP[_RK$GBCN[=[>>-)X)1L>-QN5@>,8_S^E0^&+ATL[JSD:29;.Z>"-S\Q,>
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MVLHGMI&^[N (*M_LLI*GTW9[5SC:L;;:E_I][;3CK$+=I%)_V67(8>]=TPW
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M\/FZF U:V+ +E03D?48XJ?\ X2W0O^@G!^O^%<UIZW-EK5SXA,5N_P#;$EK
M4C)82@# :/\ N[03N##^$]*[L(F<;5_*@#)_X2S0O^@E!^O^%1-XMT#[1&#J
MMN&*G"Y.3].*W#&G]U?RJA-HUO/K5IJC;A-;1O&BC&TA\9R/PH K#Q;H6/\
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MV<CQO(OS.V?E4'/ SR:WF.!7)^+KZSL/+EOUL[BW523:2R*DI/\ ?1B>?<4
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MBY61?-:XG,Q==OR,">V.W;FD!OUB>)[I[6RML73VL<URD4LZ)N*(02<9!QG
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M;)K$\/$1VMQ;^68V@G9&C\PR*O0_*3_#@YQVZ5MF@#"\1;8H(+PO+";:0O\
M:8U#>0,8+,IZKV/YU7\/2_;;Z6^^T27BF,1I=[!'$P!Y6-<G(]3[59UT13W.
MFV<MN;CSKC_5O(4C 5269AT; Z*>IY[4W3D6T\1WELMOY DC$RK'(2C#(!)3
M'RMGTZCZ4P-^BBB@!KYP,>M<K<0RW-_J,-I8FYA:1#-YDP3;* "&C/)SC'M7
M5/T_&N7;3X[S4=4>V&H(\;#<8K]X4EEVCY0H/'&.>]+J!I>&$BCT"U2"29XP
MIYF^_G<20WN#D5L5D>'/L_\ 8EM]F21(\'Y)7W.K9.X%N_S9Y[UKFF!R'B8V
M2ZLK3M=!1:AKWR5!7[.),C=GD<[NG49K4T!7:*YNG6<M<2E]\RA2PQ@87^$
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M)JDNHR^9\\DD>P(<?=4$ D>_>MZD ]J6@ IK8[TZF,<4 <?JAUA+J-]0,_\
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M4LFQB 2N<X]JDHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI" 32T4 -P!2@"EHH *S[[2;6_D6642+(@*AXI"C8],CJ*T** *EG8V]C;B&
MWCVIDL<DDL?4D\D^]6S110!3OK"WOX!%<(2%8.I5BK*PZ$$<@TVPTNUTYG:!
M7,CX#22.78@=!D]O:KU% !1110 UQD5E76B03W+W"W%U!))@2^1+L$F..?\
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MB@ I" 1@]*6B@"-X8I  Z*X4@@, <$=#4F,444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 (1SFEHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>tm238578d1_ex99-2img19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #O S0# 2(  A$! Q$!_\0
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M;5YX_),\_E8>0+M7"G=\V"?OH,8[DC(&2 =312 TM !1110 4444 %%%&10
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M (FM*B@#-_L^^_Z#-Q_WYB_^)H_L^^_Z#-Q_WYB_^)K2HH S?[/OO^@S<?\
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M&1ECV%589K_4M2O(EENM/CM]JJK1Q-YF=WS@_-P<#'0^U;N*S;=@NLWYP?\
M5P]!_OT ']GWW_09N/\ OS%_\31_9]]_T&;C_OS%_P#$UI44 9;6%\JD_P!L
MW/ SQ#%_\356307O9H;N749VE0 HS01@KR&'&WU -;QZ5%")LOYI7&?EV^E
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M@C+;0SGJ<$_R!/L 34EM>07BLUO*LJHY1BIR PZBJ,RQ6=;?\AN^_P"N</\
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MU[G.[VB!X/\ OG@=L]G+:7.L$2:BAALNJ66>7]#*1_Z ./4GH-A4"@   #@
M"GL+<K6>G06,'DVX*KDL3N)+,>K,3R2?4U8\K_:?\ZDHI#(_+_VG_.CRN/OO
M^=244 -5-O<GZFG444 %%%% !1110 4444 %%%% !6+X@_UFD?\ 81B_]!:M
MJL7Q!_K-(_[",7\FH UR*Q])\/II>HW]XMU-*;M]Q1SPO)/'YULGH:Q]+U&^
MO-0O8+FP:WAA?$<AS\XR?_U\4G4Y?=[B]BI^_P#RDVI:-!J=S"]PSF*-'1HE
M8@.&*\''4?+T]Z@LM!CM$TE0ZDZ<C(A$8&X%=OX>M&L3ZLEU:0Z6BG>KLY=0
M5R"N Q)&!R>G/'%4[35]1EFT>.9D2:YCW7$7V=P!US\Q/RG( "_7M3&=/12#
MI2T %%%% !5:2\CCN8[=@YDD4LNU"1@8SD]!U'4U9I-HH 7M1110 4444 %%
M%% #6&1@UQ>LZ/%HT,1TF,PR/=!T;?\ )&6(!R"?NXX 'X5VU07$(D4?*#@Y
M -5&7*S.I!3C9E#1M5&H1R1N%2Z@;9/$&SM..OT-:U<E>M'I/B2QNY,QQ2 6
MSG<>"<D;N<8!'7MS75*P8 @Y!Y%$EU74FE)ZQ>Z_I&!X4"'P3IPEV^7]G^?=
MTQSG-16=OIDYM-1T-5>2(I:M*-VX09!*G=R1@*03SC&#BI/"\8E\#:?&REE>
MVVE0<$@YXS65X0CGAUB\CFBO+,"-2MK=RR2L^ J[MQPAP%5?ES]:DV.V*[D*
MD @\$&L'5X(K:Z\/Q0QI'&-1X5%  _<R]A70"L37O^/_ $'_ +"/_M&6@#;J
M.2$2'.Y@>Q!Z5)10 #I4+19DWDY 7  ]:FHQ0!@W"LK&<>8L8&WYCW[_ .?>
MJX99 RJQX)!XQ@UT11-I3:,'M6%<0RP714H3&YVI@9/7J3F@9$6564,1N/ R
M>3_G%3P7$L#94@>H[&LF3SK:X9V,A"@+NE4$-SUXY&.E7\_+RQX&3@4KC<2[
M-?-,FPHJ@]3UJGXHE$O@N];(SM0'Z[UJOY\DN7MMK@':-W )SSS[?S&*?XCM
MF@\'Z@7/S,J9 Z#YUIB:L;>K_8CID_\ :)46HP7+9XY&,8YSG&,<YQBJ-C;6
MXU)-1TN-/(OE9[J1.!(P "$@]#RV??.:M:]!]HT6YC%M/<,,.D5O((Y&96#+
MM8D8((!_"L?P3YWV2[6=ID<3M_HTS2,T0R>27 )W?>X '- CII8([B(Q3(KQ
MMU5AD&JCH(]8LD4 *MO, !P ,QUH"J,W_(;M/^O>;_T*.@"]4#VP>5)/,D4J
MV["GAN,8/M4]% !5.Y BBEF97?VC7+8Z5<I" 1@C(H PY$=,L0P1NF3U':HJ
MW)(XWB,9'RXZ#M7*3//;SI#*)(YWR_R)N5E7KU/3!!_ TAI7+]3074EOPO*_
MW353>\D):,;7(^7>.,]L^U,:<[&P"&!P"RG!QU]\>]%PL7Y;HS,K;%0J=P('
M/YTS7'#W?AYE.0=2'_HB6LXSO]KBMTW,9,>7QD$]\G_ZW:K>IP-;R^'D=@S_
M -I@G'3/D2]*8-6-#69]-M8[:XU*18UBE#0N<Y#[3TQS]W=GMC.>*BTC3H]+
MO)X+*!8=.9%EC5/N^8S.7([CC9QT]*K>+[5KC3(VCLKJZDCDRHMIC&R JRDD
MC+%<,00 3STJ3PFTC^';1I9FDD*Y=7W;HCWC.[G*].?R%"$;$UM#<[?.BCD"
MMN7>H;!'<9JI;?\ (;OO^N</_L]:-9UK_P AN^_ZY0_^ST :)YJ(0A7#!F]Q
MGK4M% "8XJI/&L<!+!B2>2HZ\\5<I&4,,, 1[T <_.LT0"LK9)Z>GO321FMJ
M[A$T#  [ARI'K6 %<S;3 X$:[C*Z\DGC [CO0-$I8*,G@58MM0>-2H&Y5)7#
M<8Q5.4DJ-C8)/'_U_:F%R01N;YAG((^7V% )7-%;HM=Q2$*BJ2, =CZTDISX
MSLB.G]G7'_HR&L^RE-_=/#;D$POMDW'MCK[U=,8B\7V" D[=-N!D_P#72&@&
MK&[1110(**** "BBB@ HHHH **#TKE[?7M2-ZT45B=4MP6_TFVC,.W';Y_E8
M_P"ZU '445!:727EK%<QA@DJ!U#+@@'U'8U6U'6K/2Y$2Y9P64N=D;-L0$ L
MV!PHR.30!H452O\ 5;73(EENG959@HVH6R3]![BF/J\*:G]@$5P\P"EC'$61
M V<;FZ#H: +C?\?"_P"Z?YBI*B)S.O\ NG^8J3- "T49I,T +129%&: %I":
M,BHKB>.WMY)Y7"1QJ69CV ZF@#Q;5_C7JEKXBN([2PM6TZ"5H]DF[S) #C.[
M/RGCTKU31[9;R.WU>YE^T7$T0DC8KA8D89VHO;@\GJ?7M7*1_"W0M9U$ZYJ,
M$\4MS*9VLT?;'@G(##&<]VP<9)%>AHJQJ%4 *!@ #  K6HX62BC*"E=N0X#%
M+29HS61J+129%&10 M%)FC(H 6BDS2%L4 .HJ-)XY,['1L'!VMG!I^1ZT"3N
M+110#F@84444 %%%% !6+X@_UFD?]A&+^35M5B^(/]9I'_81B_\ 06H V.U5
M+;4K"\N+BWM;N"::W;;-'&X9HSZ$#I5S&16)I'A+2=#U/4-1L(6CN=0??.Q<
ML"<D\ ]!DDT]!.Y=OM3L].*?:I2FX%@1&S *,9)(!P!D<G YIL6L:=.MD8KI
M'%\";;&?WN 2<?@*DNM*M+VZ@N+F%)7@#",.H8#)&3@]_E'-5(O#=C%/83JU
MQYEBNV$F9L8PPPPZ'ACVSTI#-<4M(!BEH **** "BBB@ HHI"P4$D@ >M "T
M5#'=12N51P6]*ES0 M%%% !2'I2TAH Y#QQ;&YTBX&%9(U$DJOTVC/ZUTFG2
MI/8P2Q$&-D4J1TQBJ/B&2W&G2V]QL"3C9\P)#=R/EYZ U=TN)8-.@ACR$C7:
MN3DX' JV_<29A&+]LY+LC)\+\^![ % P^S'Y3GGKQQ7-^ H/)UJ8_9!8@VYV
MVNYW(^89(>0!V'3V&1[5U'A%-_@W3%W%<P 9'4=:M66AI:78NI+V\NYE0QHU
MS(&V D$X  '.T?E4&Y;NKZWLRJS3*KL#L0GYGQV [FN>U'5[6]U+P["'V7+7
MY?R&X<!8I0<CM@UU+('5E8 JPP0>A%8&JVT5I<^'XH4"1C4N@]?)EH Z L!C
MGK2CFF!<DYP0.G%*N53YCD]STH =032 YI: ,V\U&"%@2Q5P>,C&?89^E7E5
M=O P.N*9+:0SNKR(&9>A(Z5-B@#E=5CF746F5Q)M;*Y^7;QC:>1G)/>L!M6D
MBO?)DPJHQVC)50^>Y].2#6_XBD:*20!-YD(6-5Y))'.0>WTKCKUXVD/EY5N=
MS,0-JYS@?IP/2LINQUT8\RU1T&@W$T^MP6VW]WM::4EADGV'IFM[QC_R*=__
M +J_^AK6-X!LL+=WYVD.1$A Y(')/\JV?&?_ "*=_P#[J_\ H:U4-C&M;GLB
M;Q0JOX9OU:S%X#'_ ,>YD>/S.1QN0%A]0,UA_#Z(PVU\K 1MYBGR=N#&,=#D
M!S]6Z]JZVZ@-U;20B:6 L,>9$0&7Z$@U6T[2(]/DFE%Q<7$\VT/-</N8A<X'
M   &3V[FK,AUYJEO9EH\F6< $01\R$$XX'6J4.J6E_KUM';SH\J6DDCH.2H8
MQD>U:L]M'<Q&*90\9ZJ:J-$L6K64: *BVTP4#@ 9CH T-PS@D4M5XUE*MYQ3
MS,MM*#H,\=>^,5-G:!DB@!U-8[1D]!3J* ,HS0/J 92^9/W4@8$!O3K]3TK0
M\I!&%"X"C"X_AX[5&UC"UVET5/FH" =QQSZCH>E3GH12&<I<R0Z>IG>5FC5@
MF9),;BS 9.XXZUA/K%J\;3QN+AD7!15; .[/?\OJ:N:G?K;SW%H+92PD+EB
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M -&0U=TJW>VTVWBDQY@4;\'//>J4W/C2R_[!UQ_Z,AIK8SEN;5%%%,04444
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MDA(6*(=9')PJ_B?R&33=+L38V01V$D[L9)Y!_'(?O'Z=AZ  4UW$]="V(_\
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M9MO#MOH%Q8W5F\I\L+;-%@!&WLH,A '#X49(P#U/- '55B^(/]9I'_81B_\
M06K:K%\0?ZS2/^PC%_)J -D=!2T@Z"EH :R!B"1R.E.[444 1/*%(!Q[Y/2J
MDJR7 FS$5V-A<,#O'K[=35R124.T GT/0T]0!V% &3/8E%+*W"C^(_I5"X::
M%?W<!D?<H*;@N 2 3SZ#G'?%=&4&XL1STK.O8  &&-Y))'J/6@"@,GH*9%,L
MP<H&^5V0[E*\@X.,CD>_0U,+>UF:,R1"2:,[HF* [&P02,^Q/-64B;>0SEU<
M?-M'(]* ,F\BM))(1=0+(S[HH]T9;&Y?F&<< @=ZG9HX(BS,L<<:Y))P% 'Z
M"KOV1K6+S-[,&;=MD.2#[>WM5>>(-"4*@N0=RORI'N/3UH$4;.^-W*Y15>W9
M1+;W$1W)(A'K_>SG@9XP:FNDD>W<110R2C#(LWW-PY!. ?Y5CV%]<3Z.UND5
MY'>6\8W<([%@1QEB0"1T#'.T@UL1I!96NU (H8P6^9N%&<G)-4U9B6HV>*=Y
M[=X;CRUC<F2,KD2*1C'L0>0:==6\=W;O;REPCCGRW*-U[$'(Z43W4-LJM-((
MT;_EH>%'3&6Z#.1CUHALK6VD,D-O%&Y!!95 ."Q8\_4DTAW$A:X62]C66ZB5
MR-CEU(&5 ^0=L'U'6M".^G1%4OOV@#+#D_6J;0[YXY=[KY8;Y%;"MD8Y'?':
MH[G,6+DRR".%&9XDCW&3T[9R,< =<TAEC4-=%DL,TTD$4?F@-YF22,'.P#)+
M>WIDUNVTOG0AR ,]A7,A(A=).QE\R50$5\E5P"<@?PG!()_"NAT\8LT]\G]:
M;$C,\&_\BAI?_7 ?S-;M87@W_D4-+_ZX#^9K=I#*4VEV<R%&@15+;FV#;N."
M.<=>":P]9T^'3I-(O(;*>X:WOB\LL<)FE"M'(#T&<9(XZ=*ZFB@##_X2BVQ_
MR#M9_P#!;-_\342>+[&666)++5F>(A9%&G394D9 /R^A!KH&!*G!P:QOLNH+
MK,$Y=3'C$OE_(AZ\D9R6^Z!U&,]* &_\)1;_ /0.UG_P6S?_ !-1S>+[&V0/
M/9:M&I=4!;3I@"S$ #[O4D@?C6_G K*UV"ZNK2-+0,6#[B%<*<A3M.3Z-M/X
M4 0_\)1;_P#0.UC_ ,%LW_Q-(?$]L>#INL<_]0V;_P")K91B$&[DXYIVZ@#F
M;;Q+I;SR/;6.JLT3&*0)ILORL "0?EX."*N?\)1;?] W6?\ P6S?_$U/I-O<
MP7%\9L[)9=Z%F!)))ST.,8VXZ'UK5[4 <_+XOLH3&);+5D,CB- VG3#<QYP/
MEZ\&L_Q%K(U70KFRM=,U<SS;50-I\JC[P/)*X%;&KVMY/+&]NSLBK\R*X4YW
M+RI/1MN\ YXS[U=TU)TT^!;HDSA ').3GZ]Z +0[T,H=2K $'J#WI:* *$^D
MVDRHHC,00?)Y/R;3N5LC'?*BLVYCM-"U"RN(M/G=?(>%GM;5I7XV;0Q4$XPI
MZUT-% &%_P )1;X_Y!VL?^"R;_XFF0^+[*XC+PV6K2(&9-RZ=,1E201]WL01
M^%;LPD,1$14/V+#(_*LJQM;V'5IWE;,#C( .$#<<JN>,G<3GGGK0!'_PE%O_
M - [6?\ P6S?_$U%)XPL8I8HGL]6668D1H=.F!<@9./EYXKH"<5D:A;WDVI6
M<L.?*C.2P8 +\PW9'?*Y'XT 1_\ "46__0.UG_P6S?\ Q-0W&OV-U$T4^E:M
M)&W56TR8@_\ CM= &QUS3)MYAD$>0Y4[?KB@#E=,UG1XY)K^QL-7=+L*0R:=
M*5V@8 7Y>G>M+_A)[;_H':S_ ."V;_XFK6B03VNGK!<!@R$[=S9;;VS@D9^G
M%:1Z4#;ON8#>+[);A8#9:L)64NJ?V=-DJ, D#;VW#\ZJWFI_VMJFBQV]AJ2^
M3?>;(\UE)&JJ(I!DLPQU8?G5G5;/4Y+V22U>0H54)MD"E3M?..G&[82.^.^,
M5OI]T9ZT"'4R6*.:,QRHKH>JL,@_A3Z* ,VYT2SN6W.K+P!B-MHP 1MP.V#6
M<UU;Z)K%YC3;O9<)&^ZSLG=6;YMQ)08W=.M='10!@OXKM8XV=[#5U102S'39
M@ !_P&DB\66<T22Q6.KO&ZAE9=.F(8'D$?+6Q<+,T>V(Q#)P?,4L"/H"*HZ/
M!=6XG2XSM+YCW-G ]  2 HXP./I0!!_PE%O_ - [6?\ P6S?_$U%_P )A8_:
M3;?8]6\\()#'_9TVX*20#C;TR#70%@#BL@6]Y_PD)N<-]G*;=VX8VX&%QUSN
MR<^_6@"/_A*+?_H':S_X+9O_ (FH;KQ3IZ6\DMUI^JK#&I=V?39<*H')/R^E
M= ']C5/589+K3IH8BX+@*=A ;&>0,\=,]: ,NW\0V<$>U-.UDJ3G_D&S?_$U
M-_PE%M_T#M8_\%LW_P 36G8+,EC MQCS@@#@,2 <<\FK#=* .?3Q?9//)"ME
MJQEC +H-.FRH.<9^7O@_E3;2\.I>*X+B*SOHH8K&9&>YM7B&YI(B -P&3A3^
M5.2SU1-7\TN[1&8D-Y@'R9SAAW&,@#G'MUKH!TH #7SEXULI!XRU:1XG59+I
MRK,I ;IT/>OHT]*\!\60E_%VJDG/^DM^%85OA/1R]VJ/T+WPFLY8_%S3F)Q$
M;20!]IVD[E[]*]=TJ\M;R2\%M 86CF(DRJJ7/3=@'.#CJ>N*\N^&,>SQ8V#_
M ,NLG&?=:]6L(+*">Z%J5,F\"8!RQ4XW ').T8;('3GWJJ7PF>-=ZK^1?HHH
MK4X@HHHH 0UQ.DZ=J4EV)X@K6TLD4C7HNF)DV.Y8[",@L&"E>@Y]JZO44O'M
M_P#09(XYU96'F [6 /*G'(!'<5SNEZ%>0W%O<7.CZ+'()-\DL;-Y@)/) VXS
M^- '6KTK U[1KR_N)'M'@ N+-[.7S21L5CG<, Y(YX./K6^OW12T 8^IV-UJ
M&DW-F/*1F=/*.XD%%93D\<'@]/:JMSHUY-K+RH\ LY;F&Y<DGS%:,8V@8P0<
M+SGCGBNBQ1B@"N8S]H'S-RI[^XJ3RS_??\Z&_P"/A?\ =/\ ,5)0!'Y9Q]]_
MSH,9Q]Y_SJ2FDCU% $4FV)&DDE*HHW,Q;A0.I-9FD0M=M)JLH</< "!23E(1
MROT+9W'Z@=J-2/\ :-\FE(08@!->8_N9^5/^!$<_[*GU%; %/86XWRS_ 'F_
M.CRSC[[_ )U)2$TAC/+)_C?\Z#'C^)_^^J?GWJO-,Q;RHL&0C/LH]30"&RNP
M;RHV9I#SR>%'J:?';B-2=[%CRS$]33HHEB7.26)RS'J35:[NW$BVUL ]RXR,
MCA%_O-[>@[G\<)*X2DDC*\26']M6+:3"Y\]BLFXGY8\'@M]>F/\ "LCPKX)N
MM)U0W]]/$712L:0DGD]220.W:NPL[1;6,J"S.QW.[=7;U-6@!6RJRC%P6S..
M6$ISJQK37O+88(S_ 'F_.CRCC[[?G4E%9'8,52,Y)/U-<9\2-8N],TJVM[.1
MH3=NRO*APP4#. >Q.>OL:[:LO7=#LM?T]K.\#;<[D=.&1O4?G0!XQH.NW^D:
MM!/!<2LK2*LL3.2L@)P00>_/!KU+7]5U"UUA;6SFD4?9&F5([0SF1PV IQ]T
M'UXJEHWPYT_2M0CO)[J:[>)MT2.@50>Q('4C\O:NN^R0?;/M>P>>(_*WY_AS
MG'YTP,O2]3U&]?4(KFUAMY+8JBGS-PW&,,0WT)_+\Z30;^]N+J^M;Z42/;LF
MUO),3'(.3MR?ER.#WY]*TETZT6>YG$0WW*A9LDD. ,#(Z=.*9I^E6.EJRV</
ME[\;CN+$X& ,DDX'8=J0%ZBBB@"*Y&ZVE4/L)4@-_=XZUQ7@69UEN+2VGANK
M!%1S-#;M$N\JJ\%G);=M+$@8R3S7;3\0N<L, G*]1]/>O/O!1DG\0W%R?MT@
M,!!GO;;R)G.X8#!%"-]20?:@#T6L7Q!_K-(_[",7\FK:K%\0?ZS2/^PC'_Z"
MU &R.E+2#I2T %%%% !1110 4C $8(I:0XQSTH P[V)X9'\A5&,%3)]W\:OP
MS(ZA4YESD@K5AH(W&?J0>O6HA;^5)NC4;1T ."/\: !296V85DYR3D]S61J-
MK<7#R6\4<<,#0L#-)R=V<?<Z$8SWK96W'E$_,KMR2#SFL^ZL&GN4>:5]H',8
M.$9LJ0V<9R,8QTY-"$SGK>X6"PM(9=.GL6N?W/EVR%A >BY91\O &">F.O%6
M8HXI+2Y^SDN\H*?Z5N9691LY5NW'..O7O5/6]1O;/7X+>&%'@CB$\B+*XD="
M=K879M8+D'&X?E266H76J:A.GV40VR!OLMV5RT@. &7(Q@_-]1@]ZTL2W8UH
M@7A19HT5]H+Q@[@#[>W''TIC3SK(P-J[*)%565U.X'&6(XP 3TZU4NI$L[5K
MFZFM+.[EQ'YX3.[!.Q<'EN#T]S5^$*P\WRC&\@!=6'S?CBIL._0G4J6 8<9S
MQ44]G%=P^7,I:+<KX#E<$$$=#Z@<5'=7D=L(_,*Y8XP" 0O=OH,C-648KTV_
M,.I[5-NH[INQ3,EG:"ZN$P<R SF,%VWX Y SSC%;^E1>1IT,1EDE*#!>0Y9C
MGN>]93?9HF C"Q22L6VC W-W/N< 5M6;;K6,CTQ0P,KP;_R*&E_]<!_,UNUA
M>#?^10TO_K@/YFMV@84444 %&*** $-</-IFN7%M96RBZ1[0XDE\[ D82!U8
M<\C"\Y]<5W-13S06T9DGECBCZ%G8*/S-(#C#8^(FU":XBC*HER+Q4EG/SDH@
M,:X/0 2+@X&6!JYH]JVAI]MU2\$!E,BM&Q;YB7+ L2Q!8 <8 X)_#HQ>6GFB
M(7,'F%=P3S!DKC.<>F*6"[M;E=\%S%*N=NZ-PPSZ<4P*.G+*VK7MT)7DLYXH
M3"Q;*Y^?=M';JM:U(*6@!,"EQ110 4444 %%%% !28%+10!2U>">ZT>]M[9M
ML\L#I&V[&&*D Y[<US<]MK,^NP:E;P7,44><122A<_*JG<N[!'+D?3Z5V-1-
M-"A96E0%%W,"PX'J?;@T <,FE>(HK:3R]Y2*&>U2-YR9'5MY$F<XSDQ\DY 4
M^M;>FBW\/Q>3>W\:O/M98OF"K@8.,ECR>O/7M6]YT/R_O4^8_+\PYYQQ^-1-
M?V:%5:[@4LQ509!R0<$#GKGB@"KHD%S;QWBW+2,6NY&C:1MQ*'&WZ#VK4I *
M6@!,"EQBBB@ HHHH **** #&:3 ':EHH S=9CG>UB:V5V>*>*5D0X9E5@6 Z
M9XSQWKE7TO79;K4I0+E8KRW>)%,^#&&>5A@9X8#8O'3</2N[('4U!]JM=A?[
M3#M!V[O,&,^GUH XR33/$4\<@F4&.\>',9E),*I(GWAN'!3=D*>?QK?L7M=/
MA72)-1#W1+;5!(*AB2 N<X ' R3TK7,L0;:9%#8S@MS@=Z$FAD4-'*CH3C<K
M C-("EH$-S;Z!80WF_[2D"++O;<=V.<GO6E2#VI:8"8%+110 &O%?%"O+XEU
M ,Q*K.VT>E>TGI7D_B&)7U^]Q&JGSFRP)RWZUE55T=F$=ILE^'OF+XA,>\^6
M+=SM[=5KT'2=(CTN:]DCGEE-U+YK"0@D' '4 9Z=ZXSP2BIK; 1*&\E_FR<G
MD>^*Z[1]-EL+J_ED,06XD#JD><#KR<\Y/&1STZ]@Z>Q&*=ZAL4445H<P4444
M (:X_1[VYNY;>2:XUN1GD.YD@46S<GH=N=GOFNP-<5'#<Z7?6S.I6V-TL85-
M7=P-S8'[O9@C)Z9_E0!VJ_=%+2#H*H:CK5EI;HET[@LI<[(V?:@(!9L#A1D<
MF@#0HJCJ&KVNF)&UR9,R$[%CC+L<#). .@')-1KKEI)>);0K/,SHDF^*%F15
M?.TE@,#.#0!>;_CX7_=/\Q4E1$YN%_W3_,5+F@!*\M^+GB_6/#SZ?9Z5*UM]
MI5WDN H)."!M&>G7)_"O4B:S-:T'2_$%J+;5;.*ZA!W*'R"I]01R/P-7!I2N
MR)IN+2.+^$6O7VO:-J$FH9DN([KYKHC!ERHX/;*@ ?3%>D51TS2['1K)+/3K
M6*VMTR0D8P,^I]3[U;>5(UW,P ]2:4I)R;0X)I68_--)ZU7,TDO$,?']]^!^
M74T"W+\S.9/]GHOY?XU%R[=SFIM<OC</)&ZI&K$+&4'('J>N:Z6S"FVCE4-^
M\4.=W4Y&>:\_U'Q=X?AUZ2%M.GDA20K+,CX4L#@X3N/Q&<=#78W&O6HB466Z
M[FD&8DA0L&'KGH ,C-3",K^\:UJE-Q7(K=RW>7C1LL$"B2YD^XIZ =V;T _7
MI3K.T6V1B6+RN=TDC=7/]/8=JH6JWL:ETLP9Y#F26XE"Y/L%W8 ["K?V?4)<
M>9?)$.ZP1#/YMG^5:-]$<R3;NQ-:U>WT/2Y;^YW&-, *G5F)P *PO#'CJW\0
MWS63VK6MQM+H"^\.!UYP,&M#5_#%MK&G26L]S<EFP5E:4ML8="%^[^E97A?P
M)'H&H&^FO/M,P4I&%3:J@]3U.3BD6=F.112#@49H 6O.OBYXHU#P[H5K#ILC
M03WLK(;A?O(H&3M]"<CGZUZ(36#XK\*V'BW2#I]_N3#;XIH_O1/TR/SY'>J@
MTI)O8F:;BTCY]\*>-M<T77[63^T+JYMY9E2>">5I%D4D#@,3AN>"*]ZU[6;V
MQU5;6VDC4?96F53:O,TCAL!?E/RY]:Y?PY\&]/T76(=1O=0?4# V^*(PB- P
MY!;DYQ^%>BBSA^W"]*_OQ%Y6[/\ #G.,?6M:\X2=XF5*,XKWC.TO69[MK_[;
M:"S6T*[F:0'&4#'/IC-1^'=<EUF:_+B)8XY%\A4.6\ME!!;WY_#IVK3CTVWB
MN;F=4.ZY $H+$JV!@':>,XXI+/2[.PGGFM;>.)YR#)L& <# X[5@;EVBBB@!
MLB[HV QR.XR*Y_2_#DECJBWLAT^,I$T82PL_(#[B#E_F.[&WCZFNBHH *Q?$
M'^LTC_L(Q?R:M::>.!2TCJH )Y/I7.ZGJEI?C0VBD"M+J",D;D!V #9.,YH
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MH=G: Y@"S^8!'[$'D'^( YJ[86,\*V<5SIL[10SB5U$&XL5C"J<G'5@'QVP
M.E=W@48% &8-7P,?V=J'_?C_ .O1_:__ %#M1_[\?_7K3I"<4 9O]KG_ *!^
MH?\ ?C_Z]-&MPBZMK>:VO(&N9/*B,L.%+;2V,]N%/Y5J9SVK$U__ )"7AW_L
M)'_TGFH W**** (9[F&VV>:X3>VU<]SZ56N-5BM[DV_D7,LBJ&;R86< '..1
M]#2ZEIJZE&B.Y0*V<A03TQP2.#SU'-5--LK>RUO4Q;Q!/-6*5\$G<QWY/- $
M_P#;*?\ /CJ'_@*U']LI_P ^.H?^ K5I44 9<FKHT;*++4,D$?\ 'JU<5:Z*
M^GPZ/,-,N;VXM55+B.6VV(0(F4;<)@X9B<D9([UZ01D&HX71P51MVS@F@#@(
MM/NH=-N;)].ENGFB(2ZEMW#0GR@@1?E)P#TY'!/XVDMY9$,C:7<VQ\ZU=8(X
M&*KY3Y9N  6(XZ=A7=8HQ0!F#6$'_+CJ'_@*U+_;*?\ /CJ'_@*U:5)F@#._
MME/^?'4/_ 5J=;ZQ;W%Z+,17$4YC:4+-"R94$ D$^[#\ZOFL:;_D=;/_ +!T
M_P#Z,AH VC7G&MP(VL7;+N)\TY!%>CUQ.IVX.IW+ @YD.1CI435T;4968WPI
M"D>K$Y;?Y39XXZCO6]H;WLD]^;H72QB;$2W*J#CG)&WC![#L .Y(&=X?B":B
M6R,^61C'N*W-/NI;BXOHY8U3[//Y:[23N78K GW^:B.B%5=Y7+]%%%69!111
M0!FZ[<SV>DSSVW$BA?FV[MBE@&?'?:"3CVKEK80#4K:_L5M C7*V\ 6TC#78
MP/-FW 9&,L<CCY?>NZ*YIOEKQ[<4 .7[HKG]?T>\O[B1[1H,7%F]G+YI(V*Q
MSN& <D<\<?6NA P** .?U/3M1NIH+BW6U\RW$L2+)(P#1NH&XD*<,".G3WJH
MGAJYBNM/\I;4"V6!6NP668B,8*[>A#=.HP">#75XHH KE,W ^9AE3W]Q4GE_
M[3_G0W_'PO\ NG^8J2@"/R\?Q/\ G6#KVH7-K<16]O*T>Y2[/@$GG&!G]:Z(
MU3O=.M;]5%Q'N*G*L&*E?H14R3:LC2G*,9)R5T8>E:Q<7,<L<[7),9 \Q;=B
M2#]!C-::7-F&WG[3O_O/#)G]5JW:65O90^5;Q[$SD\DDGU)/6K&!325M2)MN
M3<=$4/[1L@?FNBO^]E?YBJ]SK=C#MCANXIIW^XGG ?BQ[#W_ "S2W^JK$Y@@
M=?-SM9R"P0^@ Y9O]D?CBH[:QGF0AB]O$YW2$D&>4^K-T7Z#\Q3NC)N1XEJ/
MEMJMU(F1!YS':HQD9.<>F><?A7L^C7.E1V4,@OHEDDB3[\@4JN/E4 ] !_CW
MK!N_A?87.I/.E[-%:R/N>W S]0&SP/\ &NZCMXDA2%441HH55QP . *-5U./
M#0Q'/)UGZ#(Y+>4#RK@/_NN#4I0?WW_.H'TVQ?E[.W8^IB4_TJ(Z/89RL)C/
M_3*1D_D10=VI//)#:PO-//Y<2#+.[X 'O5/3=9TS5V=;"_6<I]X*QR/?![5E
M^*O#TVH>'Y[:PEG:;*L(Y)V97P<X^8]?ZUS'@3PSJ]EKWV^]MY+2&*-DPY&9
M">,8]!US]*EMWM8YIUJJJQ@HZ/J>F>7WWM^='E_[3_G3QTI:HZQ@7:.I/U-<
MAX_\07>BZ;;Q6+F.>Z<KYH'**!SCWY'ZUV)K&\1^'K;Q'IWV6=S&Z-OBE49*
M-TZ=Q@\BIDFUH8UXSE3DH/4\JT3Q;J^G:K"\E]<7,#R*)HIY"X()QD9Z'Z>E
M>DZ[KUSIFI+;0O;(#:M.!-&[F1@V B[3QGZ&L31OAM'9:E%=7]ZMRD+!TB2+
M:&8="V2?RKMOL4/]H?;<-YXB\G.>-N<]/K2@FEJ<V!I5J<&JK,_3];GO1?B7
M3Y+=K0+\KNOS$H'P?3KW_P 0(O#.N7&LQS&=(E*"-@8U9?O+G:0W/'3/0]JT
METNV6>\DPQ%X )D+94X&W..Q(X_"F:;HUII1<P>:S.JH6ED+D*H^503V&35G
M>:-%%% !1110!#/;0W&/-C5]N<$CD?0]JPM6L+>T?2#''E_[20^8_P SDE6S
MR>><"NCK%\0?ZS2/^PC%_P"@M0!LCI2T@Z"EH **** "HIHS(I X)XSZ5+10
M!S5OX-TJRU+[=%!-)+YC2('E.R%BNWY4R%'&>V>3711((T"J  /2GT4VV]P"
MBBBD 53O2^QL'";3VZU<-4=2C=K5VBV^8HRH;[OXT"9P6OIJSB.6" J+;<)I
MPP=9X64!U$7S')SQD?P]<&O+[^TUS1TN?/T^9K0?*B7<0D"!CD9ZJ#@ <' X
M]*]QA C22X8SKO\ WC)(=Q3  P .G3.![URNKZ9=,C:>Z1S6OD^;YWD.8]Q<
M;P(E#;G.21W&3BNFE/ETL<U6',EJ>+S--;#;%,@4D878%;(Z-CI^.:OV]S=B
M6"""2W6<H5;+ K@9^\1_%D$X]ZZ+7="@U/6W6"QETY!=B%A(&VJ& *@<87@$
M@<]<>@I;31+*2$W6EF1[2Y=()9/+)<1N<'&.,Y53MZXSUKO530\NI1B[IJY8
MTF^N$E1V#1W"$[%B8_O#_>!&#^'O79C4&U#2;N(W<#SE5>8_:64+\H.4&, C
M@'MGK531]/O]/LY]6MC!$)<+]F:!8TSD*).<8 &#CC.#ZBM*;3-NH2Z9!/#&
M;F)F1 P7S'8X8;%Z#: ,D=2.]<TW%SN52IU(TK='?3;?Y_<;_@^P>&P6YF\S
MS6RN&=B,9]#]/?J<'!KJ:J6%L+*R@M@Q81($R0!G'TJW7%-\TFSUZ,.2"B87
M@W_D4-+_ .N _F:W:PO!O_(H:7_UP'\S6[4FH5G:C_Q]:;_U]?\ M-ZT"0!D
M]!6;?2))/I;HRLINLAE.0?W4E &BJ[1W_&G444 %(5&0<<CO06 8*3R>@I'8
MJI(!/L* '"HY&D!4(FX$X8YQ@>M/!HS0 HIL@W(1DC(QD=J;Y\?F^7O&_P!*
M>3F@#!T22YM[V[L+@NRJQ>)F;)QGIG]:7QA_R+4W_7:W_P#1R5#J!,/B[3I-
MZ@.C KG!(Z9_45-XPY\-3?\ 7:W_ /1R4D5+N;U%(*6F2%4+A=VL6ZY(!MIA
MD''\4=7))$B4L[!5'4L< 54D.=:M3_T[3?\ H45 %Q1M4+DD 8R>M.HHH *0
M* <]Z3<-Q4$9'44,V,8!.3CCM0 ZFY;S -ORX^]FG4F: %JEJMH]]IL]O'*\
M3NN Z-@@]>M65FC=V17!9>H!IYZ4 G8PO#%W<363VUUDS6S;"S')8=L_J*=K
M_P#R$O#O_82/_I/-2P(D/B6<HZ@R1C<@]>N?TI->/_$R\._]A(_^D\U);%3U
M=S<HHHIDA6;"-VMWXR1^YAZ?5ZT'=4QN8#)P,G&3Z50M_P#D.7W_ %QA_P#9
MZ -&BB@T %(% )P!S0K!LX.<'!I-QW 8.#WH =3 7+L"N .ASUI](3B@!:I:
MBDC6I:-G#(=V%.-V.U6DFCD!V,&QP<4X\B@"M8W/VJV#X(8':V?45GS?\CK9
M?]@Z?_T9#4NFOB[N8LCD[Q^>*BF_Y'6R_P"P=/\ ^C(: 9M5SMY9R->2MY;D
M%B0<5T5)B@:=C%TNUDBNBYC91L(R1]*GTG5TU1YPL#Q>605+$'>I) /'3E3Q
M6F1FH+:RMK1I6MX(XC*V^0HN-S>IH!NY8HHHH$%%%% !1110 445G:CK-GI<
MB)<R."RE_DC9]J@@%FP/E4$CDT :-%4-0U:UTQ(VN6?,A.U8XV=C@9)PH)P!
MR340U_3S>16HF+/+LVLJ,4RPRH+8P"1R : -!O\ CX7_ '3_ #%25$3^_7_=
M/\Q4F10 M(3VH) KS;XG:M=V]S8V$-P\,,L;2.$<J7(. #[4F[*YC6JJE!S:
MN>C.ZQHSN0JJ,DDX %8TUU>:OB/2V$-J?OWI'WAZ1CO_ +W3TS7'^ _-\06<
M\6IW<MQ;64B[87<E3D9^;U QT/\ +BO0&U"RB^3[1#D<;58$C\!2YE8=.3JQ
M4DK)C;#2;;3T'E M)C!D?EC_ (?A5WH*I?VBK'$4%S)](B!^;8%!GO7_ -79
MHH]99<?H :.9&W(T2M>VR7*V[7$2SMR(RX#'\.M60:\?U'2]5.M3QR6T\EU)
M*65U0G=SP0WI_*O3;>UOA;QK/J#>8%&[9&O7'/)!KEH8B564DXVL=F(PL:,8
MM33N:E(:I"SD)^:^N3^*C^0H-@I^]<71_P"VS#^6*ZKOL<=EW%U'4;?2[*2[
MN6(B3T&23T  ]:S-&\56.M7+6\<<L,P4LJ2 ?,/8@T[5_#L&I:=);I+(LIP5
M=Y&?!'J">E97AOPC<:7J/VV]FC9D4K&D1)'/!)) [5RSE75:*BO=ZG73AAO8
M2<I/GZ'9+TI:0' HR*[#C UCZ[J$UE#%' =LDI/S]=H'7'OR*V,YJAJFFKJ,
M"KNV2(=R/C./K[5,KVT-*3BIIRV.;MM5O+6=7>>26/<-Z2'=D>WI5[7O$4ND
MZ@MLC62C[,TX^TR%3(0V-BX[FG6GAV47"/=RQF-&#;(P?FQTR3VK9^P1'4A?
MG<9A#Y/7C;NW=/7-134DO>-L3*E*2]F9UCKS7D>H,=/N8C9JK%9 ,N2@?:/?
MG'Y4SP[KQUDS(_V<O$L<FZWDWKAP2 3V88((K2@T^.WO;JZC>3=<E6D0D;=P
M&,CC.< #KVI+'3(;!IGC:1Y9FW222$$MCH.,  >@%:G*7J*** "BBB@ K%\0
M?ZS2/^PC'_Z"U;58OB#_ %FD?]A&/_T%J -D=*6@=** "BBB@ HHHH ****
M"BBB@ JEJDHBLG9C@#DX&21]!5PG%9FI2[E 4Y"Y) ZYH S4 BE\Y%0*W,K'
M(.,<?TK#O;VZ-LKV<#2V,L,V3,"CHRYVL7) VGMGMT]*TY;5YW%RA\F9H?+!
M9?F0$@D9!Z_UJG?21W5H]O<6L%Z\<Z1M%Y9D4O@,I( ^7L>> /K6B,'H<4]K
M<W%Q]HM1;F.XE;SV@&4+8ZNQVX8A@WL>G2M2TTR>">'3HG\RWM)_EB$;;49E
M)/F.O1LECG!' YJY(%;3YK^_MM0G:T.8HX]P(; &U>FXY8\CL .HQ6EI45M>
M73B-GANHMA=8)202.&#9QDY!!R#73*I[IY\:3Y]OZ_KUN9TR/IEH8Y)&;4$0
MP1[7 )B^\2,\(3USS]VM[P9I]Y:Q[I4@^SL"ZRK)YC2EL'(/8#OZFIK/23?Z
ME#?7=@(I8&;,AVD2#H!CDXP2?J*ZA%50  !CH!6,Y^[RHWI4&ZOM&]%M_P $
M<!2T45@>@<YX765O U@L#A)C;8C9AD!N<$_C3;!=8TZ^M1J-X+BTDC$8!(,@
MG;!P2% *C:^&X^]C'&:3PYYY\ V?V7'VC[(?*STW\[?UQ5?POJ,U_+/87RM/
M):R>8DKSQ3%.!\K&/@,"6Z]B* .FO;;[993V^[;YL;)NQG&1C-8C:5]CO-*D
M:XD+BZ?,:,5B^99&^YTXSC-=&*SM1_X^M,_Z^O\ VE)0!HC@"HI6D5LJN0/3
MJ:EHH 0<\U 2X<QKG&,DGK^%6*0C(QZT 9KW\L7[MD!8#J35>6]FE1TR!N_(
M5=?3T\DC^/LU8S3QI.\+,=Z+N*A22!DC^E [7$8G>I<#/(!W=>.M:5GJ0&R*
MX(R?NL.<_6LN8>9A2Q574@8R#G^G%1HS^8T)(+*JLP"XW=NM*Y5KHT-4MK>X
MO(;H7)\V/!6-1D, <D?CQ^5,\52++X5DD7[K2VY'_?Y*JDIN^?Y<X<C/0C'!
MJ/6IGD\*7"D$HL]OM<_]=DX_"A">QT&KQ7DVFRI83"*X)7#YQQN&X D'!(R
M<'!JCI1U*UU.>TU*Z6Y21=UHZC!*)@,7   8EATX.,\=*LZ\;P:1,;(L)@R$
ME75&V;AOPS< [<X)JAX5U!M6L$FG0/<6V8?M D202 ]<,GRD\#..XH$:VI63
M7UJ(E9 0ZN/,7<IP<X(STJA9:8-.U:T47-Q*?L31XDD)4;3$,JO1<]\5N51E
M_P"0W:_]>TW_ *%%3$7NE0.\BR#Y"5)QQ_/Z5/1B@!I7.>V>]5V:4K($S\O
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ME%\B/-*^[;P0H ^F,]:ZE+>-!A!L'^SQ4<#K<Q++!=B6-NCH58'\14OE2?\
M/9O^^1_A1""@K(<YN;NQ?*_VF_.D\OC&YOSH\I_^>S?]\C_"C8X_Y;-_WR/\
M*L@/*']YOSI?+_VF_.J:WL$ERL":A"TAW#8'0MD=1CV[U;\N3_GLW_?(_P *
M %\K_;;\Z/+_ -IOSI/*D_Y[-_WR/\*/*?\ Y[-_WR/\* %\O_:?\Z/+_P!M
MOSJ.3,0W/<;5]6V@5';3"Y#&*[63:Q5C&5;!]#0!8\O_ &F_.@1_[;?G2>5)
M_P ]F_[Y'^%'E2?\]F_[Y'^% #U7'<GZFEQ341E/+EOJ!3Z $Q2T44 %%%%
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M#&C-INIO)!IT]G;-!L?[2(-[/N&W:8NP&[.3UQBD!UV<"L_43FYTPC_GZ_\
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M(!V[6*C=C>>ASSSFNKKC<"Z\7R)%/8RP2N5FB C+,JH,@DC<3GL#QBNR'2@
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MF(*HR_\ (;M?^O:;_P!"BJ[D52E.=;MO^O:;_P!"CH O4U@3T/>G44 %%%%
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M#<HKGKCPS90V[R"ZU9BBEL-JUP!QZG?Q63!I5N)+:2:;6_*OMK*K:G< 6X(
M )#\EB<\XZXH [>BL+_A%+'_ )^]7_\ !K<?_%TO_"*6/_/YJ_\ X-+C_P"+
MH W**Y;4=%TW385EDGUIU)()759^,*6[R>U9T-A:6UO$+FXUN25IY%D/]JS#
MRP) HZ/AL;U'OC/6@#=\&_\ (H:7_P!<!_,UNGI573[&#3;&"SM5*00H$12Q
M8@#W/)JU0!C:C;ZI+$OD3J) 7_U>4&"C 9R3D[MO\ZIK!J,5UI7G3J+<7+CR
M9%+R_=E*YDW8X7'&#]:Z6J>HZ9!JD"PW#3*JN'5H9FB8$ CAE(/0F@"V.E+6
M"WA:P123>:N .<_VK<?_ !=9-OI%B=6-O]NUB6"<[HI/[2N%6/Y?]6/F^8_(
MS<^M ':45A_\(I8_\_FK_P#@UN/_ (NLO6M$M+&&!H[S6=QDW-MU.<Y106<<
MOW4'WH ["J>IVAO]/GMA(8S(N X_A/8UG#PK8D?\?>K_ /@UN/\ XNC_ (16
MQ'_+WJ__ (-;C_XN@%H96G>&KV/4%AO9/-M@IE=T'#.3]WGGWKJX+:&  11(
MF!CY5Q7+:/H%M=->+/>ZUN2=B@?4KA2(R3MXW].#@]ZU/^$4L?\ G\U?_P &
MMQ_\722L5*;EN;E87C#_ )%J;_KM;_\ HY*R=5T2VMKJUBANM:W;MY U.;$P
MR$V9+_+\SJ<_[/O5VU\-:5J-G;W!DU22)PDPCFU&=UR"&&07(/('Y4R3IN]-
MD#;#L(#8X)&1FG44 8>H6NI2LA65G&S$B0.8L_.IXR<@[<\Y_G26,6H1:M:?
M;KF*7_0F 58R&5@8MQ+9(;)] /QK=K/U+1[;5'B>>2Z1H@P5K>YDA.#C.2A&
M>@ZT :%%<_+X9TZ",R27NK*@ZG^U+CC_ ,?K-TW1;.6ZFM)+S69"A9TG.IW"
MB52<_*-^,*&5<^WO0!V5%8?_  BEC_S]ZO\ ^#6X_P#BZR;[1+2#5K.%+W61
M&>9E&ISX;<0J<E\\-Z4 =E4%W ;B+8&VG.0:R1X5L<?\?>KC_N*W'_Q=,F\,
M6$43R&ZU@A5+8&J7&3C_ ('0!=M;#$K&89"_=]#6BJJOW5 ^@KE-#\/6UUI,
M)N+[6&N%&R4MJ=PK;AUR-_!]JT/^$5L0,_:]7_\ !K<?_%T ;M8>O_\ (2\.
M_P#82/\ Z3S5AW^G6=EJ97[1KC1Q1G?$-4F ?(W;P?,S\H1ACONK>@\,:?#=
MV]T)+^66W<O%]HOII55BI7.UF(SAB/QH VJCF$AB80E!)V+@D?D"*DHH YW4
M;36'F8P32,"5*B.38 VUAG!_A#8)'.?>K>G+<KK>I?:98I,K$8_*C*;4R^ <
MDY/OQ]*USTK*O= M;^[^TR3WT4A0(?LUY)"& )(R%8 ]30!JT5SEWX=L(8&+
MZIJ\1;Y5<ZG.<'''\=5-(T2WNH6BFOM;\Z#".SZE.ID_V]N[@-@D4 ==16'_
M ,(K:?\ /_K/_@TG_P#BZRAHMO\ \)"UL=0UKR#$$"_VE-@2 ;B<[\\J1[<4
M =C5.]M#=*H# $9ZCK6>/"UGC_C^UC_P:7'_ ,75'5O#L-OI=R]O>ZX9]FV+
MR]1G8ACP"!NYP3G\* -JRL@J[Y4^8' !Z"KZ@*, 8^E<Y9^'K&[LXITO]8VR
M(&XU6?O_ ,"JP?"UIC_C^UG_ ,&D_P#\70!N5BS?\CK9_P#8.G_]&0U@0V%H
MVK2PF\UTQF01;#J4H\H@E=V=^3N./IBNCL- M+"]^V1RWDL_EF(-<W<DV%)!
M( 9CCE1^5 &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8FI:
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D99C;1>:K%@^P9!/4YJS110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>tm238578d1_ex99-2img20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *H U(# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%9.L^(]+T!K-=2NU@:]F6WMU(+&1ST  '
MZ]!F@#6HK)UWQ+I'AFUCNM9O4M()'\M'96.6P3C@'L#5;2?&?A[7;*\O--U6
M":VLAFYE(*+$,$Y)8#C /Y4 ;]%<YH/CGPYXGNI;71]5AN9XAN:/#*V,XR P
M&1[CU%1W'Q"\+6FO_P!B3ZU;IJ&_88SG"M_=+8V@^Q/M0!T]%(#QS2T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR03%V&!DX^8CN.M>EHBJ@50  , #@"O/?'_'CSX?_P#7_+_Z"M 'HHZ4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ.\^%OA"XLY88-%M[.1UPL]LNUT/J#4.G_"_1%,TVN^9KUY*P)N+_P"8@ 8
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M+M*="?G_ $]\T ?0%>=_$#_D?/A__P!A"7_T%:WKSQUX?T?3M-NM8U".Q-_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KS;QOI?B73_%UMXL\.6$>ID6+6-U:,<,$
MW%@R\C/)[9/MSQZ37D'Q+T^'4O'FDVNO:W<:5X?ELG$4D<FQ6N QW!B>!\I7
MDCM0!0\&>'/%NJ7WA>/6=)_LS2O#F]XWDXDN)#T&.H'3L!C/4XKVZO(O#/@S
MP1IWB;3[S3O&K7M[%+NBMSJ$+^:V",;5Y/!/2O7: $/2N!^)NBZEK \-C3;.
M2Y^RZO#/-LQ^[C'5CDCBN_I,4 >=^.]'U>'QAX?\7Z1ISZD=.WPW-I$P$A1@
M0&7/7[S?I[US]OX!UO7?!OC&>_M?L6IZ_="ZM[1W!,8C8LBL>@)R1_/%>RXI
M,<4 >3:'IWB/Q)XT\.:CJ^@S:3:>'[1HV,T@)GF*[?E [=_PZGBN?E\*^*[#
MPSJGP_L]!>:TO=0\Z#5!*HA2#<I^;N"-@XZ]?;/O.,48% &?!HMBNGV=I-;0
MW*VL*Q1M-$K$  #N..@KA/&]C:67CSP#]EM8(-U_+N\J,+GY5ZXKTRO._B!_
MR/GP_P#^PA+_ .@K0!Z)1110 4444 %%%% !1110 4444 %%%% !1129YH 0
MBN>CTK38O%%RXL+1/+M(9 1"HVG?)D].OO70EJXSQAJ!TRUU^Z!VM_9D4:'_
M &G>11_.J@KNQ,G9'EGB.>5O 6O:O(V)-8N-P'J@F4 ?F&_#%>[Z'916&AV-
MI%&L:16Z*%48 ^49KQ#XB6\-KX<\.>'HKB,W(6&*6)'!99&8'E1TY8]:]^&!
MP, "B<N:I)]+_P# _0WFDH0]/U8ZBBBI,@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J&IZG#I<"S3B0HS;1L7<<_Y%7Z:
M5J9)M/E>HU:^J.+U?Q891 -.EG@)?]XSPYX]@>M5K3Q/=P:E&+J]EN+8JQ8"
MVVG/;CJ:ZK5M&CU981)--$86WJT9P<U6LO#<=G?I>&]NIY44J/.;=P:\F=#%
MNK=2T_KI<].%?"JERN.O]=;$VG^(+34[@P0+.KA=WSQE1BM9#E:0)@=>/2G
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M+_$T^&8/B;I<_BOS9].?32GD1,X,3[VPYVD$@Y(X/51Q7M%><^/5\0G6K?\
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ME=KL\P8([G!'/.,XXS7N- !1110 4444 %%%% !7G?Q _P"1\^'_ /V$)?\
MT%:]$KSOX@?\CY\/_P#L(2_^@K0!Z)1110 4444 %%%% !1110 4444 %%%%
M !7/^-!_Q2MV?]N'_P!&I705S/CFZMX?#5S'+/$CLT156< D"5.E 6N6O%6M
MIX>T"YU X,BC;"A_CD/W1^?)]@:X!;"?PYHDEF07UG5XHQ*QY<O([EA^ P/K
MDUM7LB^+_'D5I$RRZ5H@\^5ARLDY^Z/0X_HU<-8W\T_B*R:2\>6=;A "TF6
MW=.N?6IQ%3V<%!;O5_H>GE>&5:<JLGI!?>]U^*.BO;2UM?BSX5TV"1"NFZ7<
M$X/1V1EP?<Y)Q[UZ;IW_ "#K7_KBG\A7BEIX>O-7\;ZQ:62VT@T[6!=7.JL2
M)5!&[RASST(]CFO;-/YTVV_ZXI_(4FK2^1P2;DFY;MEJBBBK,PHHHH ****
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MSM_QY&W6!W;GL.&/!Z$UWU !1110 4444 %%%% !7G?Q _Y'SX?_ /80E_\
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M"#S6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:/D1 IMPWH<D#';(]:XR'4+6R^"FJ^$[F55U_P#M00_8O^6A;>AR!Z<'GUH
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MI+=ZLYWQ1:1QO'! I!GV@#<<$E^O7VKLT4(H4#@# KF-?0S>)]&B'(+;B/\
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M[<#'/W#G\*YN\\#ZI?75];326W]EZAKJZA=J'):2W2-<1XQU+J,\]![XKT3
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M>Y%>OUX@7\-?\+=\,?\ ""_9Q)^]&H_81^Y\K ZX^7INSCOM[XKV^@ HHHH
MJWNG66I6YM[^TM[J$G)CGB5US]",4ZVL;6SM5M;6WA@MU&%BBC"H!Z;1Q5BB
M@"A9:-INF&0Z?I]G:&4YD-O L>\^^T#-(VBZ8^HKJ+Z=9M?+TN6@0RCZ-C-:
M%% "*, "O._B!_R/GP__ .PA+_Z"M>BUYW\0/^1\^'__ &$)?_05H ]$HHHH
M **** "BBB@ HHHH ***9+(D,3R2.J(@+,S' 4#J2>PH >>E<Q;ZK9Z'I6NZ
MEJ$PAM;>^F>1S^& /4DX %7+OQ3I4.BZAJ=K>6]]'90F61;699#T.!P3C.._
MO7E5A'>^.O%FGZ;KBQ6VDR*^M?8H9?,%SNP$#L#P!Z'W]: .7\17&K>)-6CU
MS5XGB6_BW6%FQ/[JWW':2/4X)SWZ^F/6?#-K"_PXM#+!#YB';D(/^>N#U]JQ
M=1A'BCQY?;4C^P::(;/>J#.XOC /U9ORK?N9CHEG+H5G;&:&W196F:0*0"V[
MICUXK'%UU3AR35DEOYM?Y'=1I0G#]V_>;6G1):7^;:.DU2.*WT2\2)4B3R7P
M% 4#@^E><-) U@/+@Q*H >0W/S$Y[)GI74VDMQXQF)EQ;Z? 1OB1\F1O<\<5
MO-X?THQ[/[/MQVR$&:\NM1EC/?IZ*WWG11JQP?N5$W*]_3R9P*R:I.GV\S76
M;>%F28KP.<8!_&O2[-B]E ['+-&I)]3BL3_A#=+*[/\ 2=OIYQQ6_%$L,21K
MG:BA1GT%;X+#5*+?.]_.YAC<13K)<BV\K$HZ44#I17IG %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445C:Y9ZS=K"-(U.
M.Q92?,+PB3>.W7I30T;!.!FFJ^]0PZ'D$'.:\^UVV\;V.G,4UA[\R'RS%;6*
M[L'.3D#@8J#PU:^-+C31 -2DTU+8+$D5U8@DKCC!(R?2M/9Z7NB_9Z7NCTNB
ML/0[+7+268ZOJL=\C*/+"0"/:>^<=:V\\5D]R'H97B/6TT#19;]H6N'5ECAM
MT.&FD=@JH/J3_,T>'M;@\0:%::K;HR)<)DQM]Z-P2&0^X8$?A7(^,+V_U'QM
MHVDZ9IO]I#2Q_:EW!]H6$;N4A!8@XP2S8[X![5GZ%>7FEWOBS0=3L#IQN[>7
M5K*W-P)0 ZE955A@<.-V.VZ@1ZCYJ[MN1NQG&><5CMX@$W]M1:?9RW=YI6$:
M#(3S9#&'"JQXZ,!DUYI_85AIOPV\+^(K:-UUGS-.D:],K>:WF/&K(6S]S:Q&
MWH!BK.I:;86EA\5;FWMHHKA(W570890ULCM^;9/UH ]8B9W@1W0QNR@LA.=I
M]*RM$UY-:O-9MDMS$=,O#:,Q?=YA"*V[V^]C'M69%JWB.%[*VM/#0N[$Q0C[
M8=01#@JNX["">.>_.*YSP_I.JZAXC\8R6'B.ZTN-=896BAMX9 Y\J,[LNI(.
M./3B@#I-0\:1V'_"4;K%W&@0QS/B3'G!T+X''&,>]5(O%GBZ>VCFB\ 3-&Z!
MT/\ :UN,@C(ZFN1U"UN;*P^*4%Y?RW\ZV-ONN)41&?,+8!"@ 8Z=*ZO2] \6
M'2[)U\;.L1AC(C_LJ$X7 XS].,T 7=7\6:E9>(8=$TWP\^HW3V7VQP+Q(0B[
M]I'S<'G'0T_3/%UQ+KL&C:SH=SI-Y<Q-):EYDFCFV_>4,AX8#G!QQ6'K-IJE
MY\6XXM*U5--G&A%FE:V6?<OG\KM)&.2.?:H?#\-W_P +'DM?%=_)=ZU9V[OI
M;K&L5O+ ^ [HH_Y:#[K DX'MS0!I'XB,;"36H= O9O#D3,'U))4R4#;3(L6=
MS("#SUP"<8KMHY5EB61&#(P#!AT(/>N#U&2;QT9_#^CH;?P[&_E7^H(,"?!^
M:"#L>1AGZ#D#)KK]118=!O(XU"HEJZJJ]@$. * +WF#=MR-V,XSSBD$JMD@@
M@<$@]Z\63P[8P_#[P3JD7GIJ=[=6$,]\DSB9HYB%=-V<[=IP!VP*T/$&F6GA
M_4O%UAI$ M+2;PE-</#$2%,H+J'QG[V.,]Z /6]WJ*Y6^\7W3ZO<Z7X?T275
M[FS(%W)YZP0PL1D(78'+8QP <9YQ6/KUPHT7X?JLOS2:I9$ -RX\IL_4<BK?
MPZ*VS^)M-G(&H0ZU<33J3\SK)M9),=<%2 #_ +- &SX=\3QZZUY:RV<^GZG8
MNJ7=G.06B+#*D,.&4X.&'7%5;#QK:7WC.[\.K;R)Y(=8KLM\D\D80RQJ/5=Z
MY_'TINI^,]*TZ/Q')"I>?1[=7N'"C8TC [(]V<EL@#';(]:\^EM?$^B>$])U
M&;PVT=SI%TVJW-ZMZCO*'):<&,#.&5B,=MH]* /0-9\5ZC8^)UT+2_#[:G<F
MS%XS"\2$*F\I_$.>?YT_2_%UQ-KT.BZSHEQI-]<1-+;[YDFCF"_> =#]X#G!
M[5SE\M]K/Q5AFT'6(['S?#R3"=K83AXS-P-I(QG(.?:E\/QW@^(5S!XHO9+W
M7[&V9]+(58;>6W?AF11SOR-K9)Q0!W'B/5QH'AZ^U9H3.MI"93$K;2^.V>U0
M>&?$$/B;P[:ZO'$T"S!@\3MDQ,K%64GV(-<GXJU37[_P%XB35_#BZ7"NGNRR
MB^2?<W'& !CN<^U9ES<RZ(-<\.0$1R:\+>;30.SW.(IV'^X09#_O4 =AX-\9
MP^,4U*6WLY(([.Z,"L[Y\U<9#@8& 1@_C73+*K9VL&QUVG.*\AC_ +/TFQ\:
M6$@OEMCJUM9006,@CEE)BB58PY^Z&P 3QP35G3[.71_B-H"0^'[+03=072O;
M6E[YC7"J@(,BA0O! P<DG)]* /5O,7?LXW$9 SSCUIP/&:\GT#2= OOAW:^*
M=:NY(-2EQ=7.LJY$\,OF8*AN=H!^39C&">.37IFH0WMSITL=A=K9W+ >7.\/
MF!.1U0D9XR.O>@"6"^MKF:>&&>.26W8),BMDQL1D ^AP0?QJ<G%>;>%=)\3)
MXK\0.^O1"--0B-SG3 /M0\I,[3O^3CY>,\C-=?XLUQ?#GA?4-3/S201'R4 R
M7E/"*!WRQ% %#2?&UIJWBW4-"2VDC^S!O)N68;+DH0LH7C^%B!^M=.TJJ,L0
M!ZDUXO<6_B'PGH'A_4)_#AA'A^8SWEX+Y)6F27(G)0#/S%MW7C;[5TJZ-I?B
M7XGZR-0C2^LH]-LY(HG<M"Q8R?/M'!.!P?<XH [/5-:MM):R%R)";RZ2TB"
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MUVS;6[S2'TP/_I"PJ-Y7!Z?+ZXKTB@ HHHH **** "BBB@ KSOX@?\CY\/\
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MI[Q26L6YL1M$<H0<Y.,=ZFDT;3YM2DU"2U5[J2V^RO(V3NBSG81TQD^E7Z*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ]&HI66X'G?_  D7Q*_Z$*U_\&D7_P 51_PD?Q+_ .A"M?\ P:1?_%5Z)13
M\[_X2/XE_P#0A6O_ (-(O_BJ7_A(_B7_ -"%:_\ @TB_^*KT.D) ZT >5:)\
M0_''B.R>\TKP7;7$"2M"S_VBBX=<9&&(/>M/_A(_B7_T(5M_X-(O_BJG^%&B
MZEH/A>[M=4M'M9WU":548@Y0[<'@GTKO* ///^$C^)?_ $(5M_X-(O\ XJC_
M (2/XE_]"%;?^#2+_P"*KT.B@#SS_A(_B7_T(5K_ .#2+_XJD_X2/XE_]"%:
M_P#@TB_^*KT2B@#RK6)_'VNV8M;[P#$80X?":O&N2/7YJQAX5\23PR0GP(EH
MYY6Y_M5)60^@&\=1FO;J3%7&I*.Q<9RCL>)+HOQ)TN&*+2[*Z\M<_NQJ,2JO
MT&_'K3VN/B$;BWDOK.]%S:N7155)54D8^\@PW!_6O:L>U&*OVSO=I%JJ[W:/
M%-2\1^,XKBQ74XI+:=9U>W1HU_>N0<#Y203@GY>OJ*LZEXR\7Q_9HKVTBMFW
M)<ILC.Z1<\!@K' /<'!KKO'.CZAJFK^$IK*U:>.RU>.XN&4@>7&!@L<G^5=F
M/F&0:KVR_E0_:K^5' 6OB;QG<6*W@T"R>U9/,$OVA4&W&<D%R1^(K)T;X@ZU
M?:K<0PV4%T\YWPPF8((PJ\@$\'IFO5&C#@AL,#P01P:B%E:H05MH01W$8%0J
MD=;Q)4XZW1YCI?Q#UB]UZ:&"SM[AKC"PVYG"A"HYPQX.>:;:_$/5[CQ$T45E
M;R&4"".U\\!0X)Y#]"3DC\J]/6RME(*VT(8="(P/Z4?8;8$%;>$$<@B,<57M
M(?RC]I'^4\Q7XAZP?$ODBRM]Q'V;[+YXV^9N^]OZ9SQZ5M:KXM\3:18/=7OA
M^WMXA\H=KM6^8\#@')__ %UVGV&U!R+:#/7/EBI'@CE7;)&CKZ,H(I.<;KW1
M.<;_  GENB^-_&E];"#2_#MMJ_V=0LMPUZD3D\XRK$>G45J?\)'\2_\ H0K;
M_P &D7_Q5=[';0PDF**-,]=B@9_*IATK.33=TC.33>B/._\ A)/B7_T(5M_X
M-(O_ (JL_2OB!XYUP79T[P7:SBTN&MI_^)BB[9%ZCDC/7J,BO4ZXGX=:/J.C
MQ^(EU"U:W-SK,]Q#N(.^-L888/M4B*?_  D?Q+_Z$*V_\&D7_P 51_PD?Q+_
M .A"MO\ P:1?_%5Z%2T >>?\)'\2_P#H0K;_ ,&D7_Q5'_"1_$O_ *$*V_\
M!I%_\57H=% 'GG_"1_$O_H0K;_P:1?\ Q5'_  D?Q+_Z$*V_\&D7_P 57H=%
M 'GG_"1_$O\ Z$*V_P#!I%_\51_PD?Q+_P"A"MO_  :1?_%5Z'10!YY_PD?Q
M+_Z$*V_\&D7_ ,55*^\?^,]%N-/&M^$+:SMKR\CM!*+]9"&<^BDGIDUZA7"_
M$K1M1UJVT!--M'N&MM8@N)MI V1KG+')% '<CO2T@.:6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4<0JQ=GD;<\CGJS'N3@>@K9HHH **** "BBB@ HHHH P_%'A73?%NF"QU)9
M$<2130OMDA<?Q*>>?J"*H>'/ 6F^';R\OOM5]J5_>((YKK4)A)(4'\/  QT]
M^*ZNB@#@M.^$^@Z9K%M?17&HR06DQN+6PEN-UO;R$YW(N,]>>2?QQ7>T44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6)O]'4 XRS9(.<=#@YQ0(]R!R*6D7I2T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3719%
MPZAAZ$9IU% $:01(<I$BGU50*'ACD1D=%96&&!&01[U)10!"+:&.-$2&-53[
MBJH&WZ>E>>IX#U_5O&]GK7B?6;:[L]-E:2QM;>';WRN_@<CY?7.T>]>D44 ,
M,:LK*RAE88(/((ID-K;VRE8((XE)R1&@4'\JFHH  ,4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%)F@!:*,T9% !117!>-?B?IWA2\@TZV6/4-4DF1)+99-HA0XY<@'!Y&!WH
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M;USXCZ5>_#]]$6PU:.X\M%WRVFU!A@>N:BFFL5&?2WZFDG^X:6]_T.^\"?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6'X@\+:9XE:P.I1R/\ 8;@7,.R0KM<="?6MRD/2@#P*\M?AA=>,-4M?$=EJ
M6E:BUW(6EGE80RY<_.".BD\C(Q[UZ?X,\'>&O#4<]WX;8R17BJ'D%QYRL%R1
M@]/XC7(Z]JOBCQU>WFCZ/X3T\V%K<26[:AJJATW*=I* CCIV#'Z5O_#CX>-X
M$AO'EU(W<]X$WHB;8TVY^[W)YZG'0<4 =]1110 4444 %%%% 'FV@?\ )=_%
MW_7C;?\ H"5Z0.E>;Z!_R7?Q=_UXVW_H"5Z0.E "T444 %%%% !1110 4444
M %&*** #%9'B311XAT.XTMIV@6;;F15W$88'IGVK7I#0FT[H+7/-/A7;26>O
M>-;:6X>XDBU%4:9_O.0IY->EGI7GGPZ_Y&[Q]_V%A_(UZ&W0T-WU!'.:</\
MBLM3_P"N,?\ 2NDKF]/_ .1RU/\ ZXQ_TKI*Y<-M+U?YG1B-X_X8_D%%%%=1
MSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1G%%97B%=;?29!X>>R34=R[&O=WE;<C=G:"<XSB@#5J"VO;6\1GM;B
M*=%8HS1.& 8=0<=_:N"\CXN?\_?A3\IO_B:Q_#WA/XF^&+2XMM/N_#/EW%R]
MT_FF5CO?&<'8..* /6\TM<;H,/Q"75HSXAN-!?3=K;Q9"3S-V/EQN&,9ZUV(
MZ T 9>IZ[;:5J6E6,\<S2ZG.T$)C *JP4L2V2,# [9HUS7;;0([&2Z29UO+V
M&RC$2@XDD;:I.2/ESU[^U<_XU(C\4>"9G.(QJC(6/]YH7"C\3Q3?B0P-OX8C
MS\[^(K':/HY)_04 =J#SCO5*;5;6#5[73)';[5=1O)$@4\JF-Q)[?>%<-I^@
MQ>)_$_BY=3OM2:&VOUCMHH;V2)828(R6&TCGZY ].:Q?#$7]O:QX!U/4I;B:
M\FTJ=Y)/M$B[FC9 I(# >N?[W?- 'L /UI2P'7BO%U:[T[X>:MXOBO[^;5X[
MB>UMV>Y8QPQM<^7PF=ORAB02.#[#C4L]/U?2-;T>:PT?5[)7NDAOGU'68YTN
MHVR&)4R'YQ]X; .AXH ]4W<9P:H'5[3^VQI D8WAMC=; IQY>X+G/3J>E>0Z
MW(+SPYK.O:=#XAOYXOM$T.N&^^RV\>PG'E1>9\R+C;]SYL'GFNB@M8I/B9#J
MLB7$MT?#BWI5;B0!I0X&-N[&,?PXQGG&>: /2PPQFC.>E>'V U_4?"$/B*WL
M-7.M3Q_:DU9M7C2W#$YVF)I HC_AP5SCWKJ]+TW_ (3#6O$%YJUY?6\UA=BT
MM(K>\>);4")&W@*0&)9R<MD$ <4 =IH.L0:_HUOJEJDJ03@E5E ###%3G!(Z
MCUK2KD?AB,?#K1P7#GRW^<?Q?O&Y_&NNH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *0]J6D/2@#Q#3[GQGX.\2^(CH_@RXO+&^OGF5I3\Q.3R&'53U
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M_#LX\7>/O^PL/Y&O0B_:O(=+\):AJWBSQ;/8>*=1TD?VB2Z6H&')!()R:D\
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M]X <=CCC.*Z.B@"AHVD6FA:7!IM@A2U@!$:,<E023U^IJ_110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 55O[^TTVSDN[ZYAMK>(9>69PJK]2:M5Y5\
M:MCVOAJ"^=TT>75%6^8' "X[D=.-YH R?$_AC1K=6U^]^(VIVEEJ<K36Z1.S
M*P8[L(H.2 #Z5U7PO\/>'M-TZ[U/1-8EUB2]<+/=RM\WR]$*]5/.>>>?I7&0
MVVB^+/B_%:PBVN/#/A[3@J@ON@ 4>I."-SCD]=G<"M?X6_8E\?\ C5-$V_V(
M)(O)\O\ U8;G[O;&=V/8"@#UVBBB@"AJ^BZ;KMD;+5+..[MBP8Q2#(R.AJU+
M#'/&\<J+)&X*LK#(8'J"/2I:* ,#2/!7AO0;Y[W2M&M;6Y?(,D:<@'J!G[H^
MF*W@,4M% 'FV@?\ )=_%W_7C;?\ H"5Z0.E>;Z!_R7?Q=_UXVW_H"5Z0.E "
MT444 %%%% !1110 4444 %%%% !2'K2T4 <1/X&O%U2_OK'Q+>V(O)C-)%#&
M,9_/FN.^%_AS4]3\$PW%IXEO=/A^T3+Y,* KD.>>O>O9FX!^E>>_!7_DG,/_
M %]3_P#H9K3VL^Y/*B]_PANN?]#MJG_?L?XT[X?W5]/%K4%_?3WK6FH/ DDQ
MYVJ /P]?QKLZXGX?_P#'SXG_ .PQ-6G.Y4Y7\B>5*2L=MVI&ZTHZ4AKFZ%LY
M_P '_P#(.NO^ON3^E=%7.^#_ /D'77_7W)_2NBKGPG\"/I_F=6*_C2]?\@HH
MHKI.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C
M-(>E4]0BNYK1DLITAGR,.RY&,\\5,G97L-*[L6RU16]U!<JS02I(%8J2C9P1
MU%87V+Q+C']KVW_?@?X56L]"UVPB=+;5+9%=RY!BSDGKU%<KKU.96INWR_S.
MA4(<K;FK_/\ R.L!I:Q+&TUJ*[5[W489H,'*+$%.>W.*V1G-=%.?,KVL83CR
MNR=_07-)NKAO'-A%JGB[P?87#RBVGGNA,D<C)YBB'.TE2#@XY'<9'>L32?"&
MB7OBSQCH]Q:%]+L?L[6EGYC^5;M+#N=D7/!) P1T[8S6A)ZKFLCQ/KR>&?#E
M]K,D#SQVB!S$A +#('!/UKSWPG>7%UJ/PZDN9GED?2;X,SL26(,8&?4X%1>*
MM]W9?%..)B^R*T.T'.W;$&8?H: /3]2U,:;HMWJ;1F1+:W>X* X)"J6QG\*Y
MR]\:ZG;Z5;ZK:^%KJ\L);!+YYTNHE$8*;RI!.20.XJYXGU"V'PWU6\,JBWDT
MN1EDSPVZ/Y<'W) _&JPB>+X/"*12KIX?VL#V(M\&@".P\<:C=:-<:Q<^%[NT
MTZ/3WOHYWN8V$BJNX* #D%AGM4$7C_51IL>J7/@O54TYXA.9X9HIB(R,[M@;
M<>.:<O\ R0O_ +EL_P#I/6SX=NH++P'I%U=2K#;PZ9 \DCG 51&N2: -73]0
MMM4L(+ZSF2:VN(Q)%(G1E/0U@7/C:VM?']OX3DM)1)/ )5NMPV;B'(0^Y$;8
MKFO ]]KVD_#S0TT_PY)J*2I+,/\ 2T@,2-*Q08;KE2#5/Q+;W5YXEU^^B@\O
M4=/TK3M2BBW;BLD4DKLF1URNY?QH [+Q=XTMO")TQ)[>2YEU"Y$$:1L!M&0"
MYSV!91^(KJ,XKQSQ5=Q>)(;WQ!"PDL8;G3;*R<'^]-'+,1]2T:_\ -:FJ65E
MXA\3ZVT7AV77C!(MK-<:A>+!;6A" E(A@L,9RS 9R>N,4 >GYHSSBO&O#;R>
M(M.\":1J\LL^G3VEW/(CR-BZDB?:B,>K!5).#UQSG%>A>&M/TC2-0U;3M)NY
M-J21RRV!;,=F67@(,?*& SMR1Z8H Z2BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *H:MI-AK>GR6&I6D=U:ORT<@XXZ$=P?<5?K@_B1;>)%71-3\.0S74EA>>;/
M:12E#,A'0@$;AD<CWZ=: -JP\%>']*T6]TG3M.2VM;U&2<(Q+N",<L22>,X]
M*M^'O#>E>%],6PTFT6W@!W$ DL[8QN8GDGBO(/#?Q!\?,^K>3X;GU8B^?>K2
M$_9#@?N1CL/ZUZ-X,\1^)=;EO5U_PVVD+$J&%B2?-))R.?3 _.@#L**** "B
MBB@ HHHH \VT#_DN_B[_ *\;;_T!*]('2O-] _Y+OXN_Z\;;_P! 2O2!TH 6
MBBB@ HHHH **** "BBB@ HHHH **** &2'Y#]*\-^'7Q*T/PIX2CTO48=1-P
MD\KGR;4L,,Q(YXKW0C-&..IH Y7PK\0-%\87MS::8MVLMLBR2">'9P3@8YJG
M\/\ _CY\3_\ 88EJAH'_ "7'Q=_UXVO_ *"*O_#_ /X^?$__ &%YJUC_  Y?
M+\R7\2.V'2D- -#=:QZ#9S_@_P#Y!UU_U]R?TKHJYWP?_P @ZZ_Z^Y/Z5T5<
M^$_@1]/\SJQ7\:7K_D%%%%=)S!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4F!Z4M% ";1Z4;1Z4M% "8%+110!2N]*L[V_LKZ>
M/<V3.UO)N(\LLNUN <'(XYS3;?1[*UU"_OX8 EU?[/M4@8_O-B[5XS@8''&*
MOT4 <]<>"M N=*LM->Q*V]@2UIY<SH\!.<[7!W#KZU8TKPOH^B1W*:=810K=
M "X&682X!'S;B<GDY/?/.:V:* .1@^&GA.">.1-)&R.3S8[=IY&@1^NX1%MH
M//I73W5I#>V<]K<)OAGC:.1,D;E88(R.>AJ>B@"@-'LAH?\ 8PMQ_9_V?[+Y
M.X_ZK;MVYSGIQG.:YZ/X7>#8VC/]B)*(L%$GGEE08Z?*S$?I7844 -5 J@
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M6T:\56D;DYA)))]223^- &O:>,-0M]9LM.\1Z"=*:^8QVMQ%="XADD )\MF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M * E>D#I7F^@?\EW\7?]>-M_Z E>D#I0 M%%% !1110 4444 %%%% !1110
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MDKT5J>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*.&3/0 _C71W6@PV/Q/\.7&FZ0EO:K:7@GEMK;8@8^7M#,HQD\XS[UR?@_\
ML'3/"UI::YX%U*XU&-I?.D;PX\I;,CE?G*<_*10!T'B*YO;-/".G6WBJZ$-]
M=2QSZFC0[Y4$;.#G:4Z@#(%0:C?7WAS5=$^Q>,9]9>\OX[:33KGR7:2-N&93
M&H*[1SGIZU-K-C:^(;GP4+;0)AI$=[,)K2XT\QK$@B<#?&5PJ[L8R #Q1J?A
MZ+P7XDL_$?AW1T^QS,+;4[&RMLL$8X$T:JN05)^8#J* ->^T[7[V_P!3NKKQ
M!-HNG6X_T,6@B;*A<M+,74Y&<_+QP.O-7O!&L7NO>#-,U2_C"75Q&2^U=H?#
M%0X'8, &_&N-\0ZS-K?B*YTO5-*\0KX=LW"^39Z7/)_:+@\EW4?ZH$8VC[W4
MG'%>AZ/>07VE07%O:W%K"052"XMV@>,*2N"C %>G'MB@#GKSXD:/9O?#[+J<
MT6GS/#>S0VC-';E3@EF]._&3CM5JQ\<Z9?ZM::>EO?Q"]W?8[J>V9(;G:NX[
M&/\ L@D9 R!Q7.'3KW_A!/B%!]AN?/NKS4&@C\EMTP9 %*#&6![$=:TM5L[J
M1O 7EVL[?9KU&GVQ,?* MI!EN/EY('- &TGB[37\+7/B)3-]@MA*9/W?S_NV
M*M@9]5-8M[J>I^)?%3:'I.H2Z;96EI%<WMU$BF9S+G9&FX$+\H))P3TKE)KB
M_L_AKKOA-="U>;5R;M56.S=HW1Y&8.L@&TC:> #DG@#-= R7GA/Q-_;O]G7E
MYIFHV$%O=BTA:66UEB!VL8Q\Q4AB#@9!% &UI6F>(-&UY8GU2;5M$EB8E[UD
M\^WE'3!51O4@GJ..*YWQ!XIU6U\5W&I6ETP\/:'-;VNI1!01(TN=[9QG]V'B
M/'OZ5IQ^*]4U+4FO=.TF^CT.QM99;AKFS=)KR7'R1PH1NXYR<')X^N7H?P[F
MO_"6-8UK6(+C55:YU"UCD18S)+RP*E"1@8&,]NU &OX\O;R"X\.6MIJTNFQW
MVHF&>XA* [/*=NK@CJ!61JE]?>&]0T8V/C.;69+K4(;:33[GR)&DC<X9E\M0
M1M'.>GK5%++4M<TCP98:YI%Q/+INK-:WZW-HS1R)'$ZK*<C!1AL^;H2>M:NK
M>'(O!GB"R\2^'-%0VSL+;4[&RM=S&-C@2QJHR"I/(4?,.O3- 'HF/DQG\:\X
M^%'B35=6LI[77+MKJZ>*.]MYG !:%RR%<  ?*\;#\1736OAN6'6SJI\0ZU+&
MTCR?8Y9@8,-GY=NW.!G@9["O.[/3]?T/P/X7U;2]+NSJ\=M<:=/;F%ED5)BQ
M1W&,A4D5&.>S$T ;GAOQ5J-_\1-::ZO=N@BR>XLXS@(L<<OE&3.,\E)#UZ$5
MN6WQ#TRXDL2;'58+._E2*UOI[0I!*S_<P<Y&[L2!FL+^Q-0T#Q)/!HE@]PEG
MX46UM'EB/E2S+(Q"EONECU(SWK!NH[K4+'1+A?\ A+=1OK;4+.XODN;62&&W
M"RJ7VQ!55B.P7=@ G.!F@#T'4O'6GZ=?7EJEGJ-Z;$ WDEE;&1+?(S\QR.<<
MD#) KH+._MK^Q@O;69);:>,2QRJ?E92,@_E7!V&H3>$+[Q)9WFE:E=O>:A+?
M63VMH\R7(D Q'N4$*5(P=V..>E=KIJ3SZ);+J%G#;S20 3VJ'<D9(Y3IR!TH
M SCXJM?^$N&AYAV&P-Y]I\\8SY@39C\<YS^%;P<,NX$$=01WKBC\--!_X2P7
M_P#8>B_V7]@,!M/L28\[S-WF;<8^[QGK73ZA.NCZ-<7$%J\HM8"8[>WB+,VT
M?*BJH^@P* .$UOQ5J=MXMGU.WN2OAS1KJWL=0C"@J[2Y\QR>O[LO%T]ZZ_7/
M%6G^'I;*&\%P\MZ76VC@B,C2LH!V@#N<C%<?HWPWEO/"/DZKK>L07&IQM<:A
M;1RH(_.E^9P5*$]3@\]NM1Z)_;-[?>!O[4TZ\%UI<E[:WDKV[A04BV)(6(QA
MQ@ANA.<4 :VL^/X_^$4\07>GVE_!JFF0$O;7-KAX69"4=ES@IQG()Z5H6NM+
M>:]H2O/J%K+=6<\GV&6!5$FTJ"S]U(SD =0U<]X@TO4+O4/B&L%C</\ ;-%B
MBMB(SB9_+E&U#T8Y(X%6@)]=\4>&KV"UU*UMVTF\@DF>V>%X'/EJ,[A\IR"1
MGKC(S0!L?$74+S2? >J7VGW#6]W$J>7*H!*YD4'KQT)KG?$UOK?A/PY=:Y!X
MVO;F6V42+;7T4#1S\C]WA5!R<XX-/\7^%+VR^'VNP0ZGKFMS7,42I!<OY[#$
MBD[550<XZ^PKH;+X?^%+2XBNH- LA/&0R,Z%]A]0&S@T 85PVLZ]\0;G38=?
MO])MHM*M[KR;98S\[LX.=ZGT%7]+O=9T+QE#X=U;4CJ=K?VSSV=U+&J2J\9&
M^-MH (P<@X'2J-]J,F@_%/4=0N-*U>YM9]*MX4ELK"6==XD<D$H" <$?G4EG
M#J'B[QA#K4EA?Z3IEA936]LUU'Y-Q)++@,X0Y*A0.,]3@XH [B]F>VLYIHX)
M+AXT++#'C=(0/NC)QD^]<?X/U;7[_P 7>(K775A@-O%:206<+[UMPXD)!;'S
M-P,GIQQ6YH7AV7199G?7-6U(2*!MOYA($P>JX48-9VB6UQ%\1_%=Q);S)!-!
M8B*5HR$D*K)N"MT.,C..F: -;Q#XCT_PS:076I/(D,TZVZF.,N=[ D<#GL>F
M>U8J_$73S<R61TK6UU%5#K8-8GSI$.?G SC;Q@DD8.!WI?']K<7B>&A;6TT_
ME:_9RRB*,OL16.6; X4=R>!3Q;3CXLM>?9Y1;?V&(O/\L^7O\\G;NQC..<4
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MQM4>I8@8Y&17=>$M,FT7PCI&F7+!I[6TCBD(.1N"@$ ]QGB@#9HHHH ****
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M"C HR*,B@ P*XRU_Y*Y??]@I?_0UKM*XRU_Y*Y??]@I?_0UK.?3U.S"[5?\
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MC3'C>UE<[C&6'*9''&.@XRI/&:SU\*^&_B1XDUNXN+2\T35+*Z-O/Y%PH:X
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M:JP^Q3'D ?[%;NG_ ! \-ZI:+=6E\[PL2 QMY%Z>Q6M>UL[4Z7"3;0Y\@?\
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M 'R*!#$K;EC53ZA:3IUY6O)?)?\ !#GHK:+^_P#X!(AR*=34[TZNPY4%%%%
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M]&&LWNRD>B44F:,T +129%&10 M%)D49% "T4F11D4 +129%&10 M%)FC(H
M6BDR*,B@!:*3(HR* %HI,BC(H 6BDR*6@ HHHH **** "BBB@ HHHH ****
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MBA)_X*H_\:/^$5^('_10D_\ !5'_ (UZ#10!Y]_PBOQ _P"BA)_X*H_\:/\
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M\3:QK&GR:[>6DD.G:9;7*LUI$5/8');!.?3)SR<#B_[0M#\ XM"$T9U0ZMY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>tm238578d1_ex99-2img21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img21.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $E E@# 2(  A$! Q$!_\0
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MIL5P95C7S-JEST,F=^2.,%?2L#5/%7B*6PUSQE;ZS<V]OI&I"VATU0#!)$K
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M77[>)-(E*1QJV5.0,=ZUK=AY$8!S\H_E63X@@NY[ 16@# D%ACG%1QIKZQ(
MUF, <,IR/K7#[1TZ[M!VMT2[OS.;H= "*52#WK""^(2W+V./]TU+HEY<7L5P
MUSL\R*9HOD''!Q75&O%S4.5J_D(VJ*:#Q2@UU7$+11FBF 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*#C(SV&X<T 345#YRKU('KDCC]:=YN<8QSZ<T 245&SD<XS]*1)-PSD$>HH
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M;C_KD_\ *@#A_@S_ ,DXM/\ KO-_Z&:]!'05Y]\&?^2<6G_7>;_T,UZ".@H
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MYL74_P#305!X[\-R>(_#T,=M;M-?0LK6Q^URPB)FPIE^1@&*KNP#D\D C)R
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MMFM?] V/_O[2?;=:_P"@;'_W]H^MQ_EE_P" L+&T6YH+'VZ5B?;-:_Z!D?\
MW]JG<ZEK27UNGV0+N/\ JP<AAWY[4I8R,4G9Z^06.J%+35ZFG'I7<(#32*#4
M;%L'K0)L?@4H(-5%NHWO);19 9XD25X^ZJQ8*?H2CC_@-60<'D$?6C0?6PXC
M'TI-HQG%9FO:U!H.D7&HW(=XXAPB=78G 4>Y-<X^O^+K*"+4+S0H);1F7S+6
MUD+W$2DC+ 8PQ (R* .VQQTHP#U%<AXT\73^&;&![.T6\NW26Y>)WV8MX5WR
MM]<<#W-2^(_%$UAI6E7>CQP7O]ISQQ0,[X1E<;E;(]1@T =5L![>](5],?C7
M%2^)=?T74]*B\06%DMIJ5X+))K24LR2LN4RIZ@[6!QTXK=\3ZO)H'A;4]62,
M2O9VSS*C'&X@=Z -K:*0*,US&F>*&N/!DFLW<(ANK<2Q75LK9V3QL4= ?]X<
M>QJ?P3K]QXG\+6>L7-N+::<R!H0<[=KLH_E0!T>!2$"D?@=ZYO6?&VEZ!J'V
M.]34&E*"3-O922K@^Z@\T =)M%&T5Q?_  M'P^?^6.L?^"J?_P")H_X6AX>_
MYY:S_P""N?\ ^)H [3:*7:.XKBO^%H>'O^>6L_\ @KG_ /B:/^%H>'O^>6L_
M^"N?_P")H [0J.G2@+BN+_X6AX>_YY:S_P""N?\ ^)H_X6AX>_YY:S_X*Y__
M (F@#MJ*XG_A:'A[_GEK/_@KG_\ B:/^%H>'O^>6L_\ @KG_ /B: )_B1_R)
M5W_UTA_]&"NJC&8X_P#='\J\P\7^-]+UWPY-IUC;:LUQ+)%L#Z;,HX<$Y)7%
M>F0$E4]E (_ 4 3;?:BG44 -/0XKR[QGH-O:06\NK^,O$F)+WS+.&V2)Y5E"
ML?W>V/> %+=^G6O4F.%)KD?%>DWD^JZ%KMAY#W.D3REH9Y#&DD,J;'PV" PX
M()]"* .*\/7^E:IXXT:X_P"$A\4:C=_O!;1WUK&(,!2&/W  ?]H8;MGFO7X1
MA /08_+BO+M$T_6I?$.EV$45C)I&EZA-=+JD%^C^8CJP$7E@[@<MSV^6O4HF
M#J&!SD9H DHHHH #TJM?_P#'C<?]<G_E5FJU_P#\>-Q_UR?^1H X?X,_\DXM
M/^N\W_H9KT$=!7GWP9_Y)Q:?]=YO_0S7H(Z"@ HHHH **** "BBB@ HHHH 0
M]:B;E6^AJ4U#(?E;Z4"?4X[X;_\ (#O?^O\ G_F:[4=OI7$?#@YT2]7C/V^;
MIS_$:[4-0MC'#OFIHEII YI0>*.U!N<+\1YXD\&7$;,%:5T" ]2<@FHK3XBZ
M(MM$-EX<1J-RVS$=/7OR*J_%NU5? LU^X!N+9H_+?/ )(!X^E=9HFF6VGZ-:
MV]O$BQ+$I /S8R!G!-9N$^>Z.^-;#+"QA.+<DWULMEU^78Q?^%D:(?E\N_R1
MQ_HK?X5L:#XAL/$=M)<63.4C?RV$B;2&ZUI"*/(_=IUQ]T?C7&?#<A8-=XP1
MJLXVCM\[?_J_"G[T79LF4:,Z4I1BU:V[[NQWJ]^E/S4(D QW]:D# GI6APIW
M'&DQDTX45+5QC".*-HI]%,=QNT4G'I3Z*5@N-HIU%%A#:*=12L VBG446 ;1
M3J*+ -HIU%%@&'K01[4^BG8 I#TI:*8##T-<QXB\*0^(;B&674=1M6B# "UG
M* Y]1WKJ:9L/>C?0J$Y0=X'D$'PUULZOYL]_*+5F\N29;QO/\H=/FQSWXKO?
M#_AN'P['-Y-[?W/FD%C=S;]O^[QBNB*TFPD=JF-.,=4=&)QM?$I1FU9=$DD<
MQX]TRZU/PM,+.$S7%O+'<I"IYEV,"0/<BL^Z^(%I-8Q#1+6>]U><JD5@T;(5
M8GDN<84#G)KN&7.!CI3!$ Y<(H8\;@.?S%4<IYY';Z_K'C/4M8TZ73[:.S0:
M?&-0M9)@1C<Y3:R\$\9[X%<['I][9Z58>$;XW,K:/K<4<<\#O&6MG!="K@[E
M"Y*\-D8QTKV8)CH!^5)Y8SRJ@^N,G_/6@#S:^T*W\+^-M-U>ZCO=6TZX8VT4
MU]=2W3Z5,W1DW,?W;8P3]Y2/O8.*N>,;;Q&G@CQ0-2O].N;0Z;+Y45K:/'(#
MCC)+MD8KOC'N7Y@I]NN:3R_EQA2.X(X/M0!YU?V-RGQ!N-#2&4Z=JMS#JDCJ
M,HIC 613Z;BB'\*W?ALDD?@JW25&C?[1<?*PP1^^?'Z5U)3Z \@<4L:E3T ]
MAV_SS0 \]#]*P==\30Z!/#'-8ZC<B4$@VEN9 OUKH*9AL^U '(6OQ#TZZU*R
MLGT_5;9[R801/<6A12Y!.,GV!_*NGNKVWL;8W%W/'!$" 9)'VJ,^]<UXWS]N
M\'Y_Z#\7_HB>N;^*6@:]KQCT_1EU"8W<1WQ,4%EB+YP')^8.6"@9PI)Y. :
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M4_\ 013-BW4#+ECP/RJQ32M G<XFX^'FF76N-JDTUS).\OF,&D^4X.0,8Z8
M'X5T$>A:6J\Z=:^N3&*U=H]*-HQC Q4*$4;.M6:2<G9:;]C-_L/2O^@;:?\
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M-&:A+8[$T&3 R>!T))Z4UJ(GHI,TM QI.!7.Z]XIM=!GBBN;:]D,H)#6\!D
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MR?WA^E>F1]2<_A0!)1110 'I5:__ ./&X_ZY/_*K)Z56O_\ CQN/^N3_ ,J
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MN#FEK0X0I#2T4 (!1BEHH 0BDVCTIU% #2@-+M&,=J6B@! H%&!2T4 %%%%
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MW_H9KT$=!7GWP9_Y)Q:?]=YO_0S7H(Z"@ HHHH **** "BBB@ HHHH ****
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M^N3_ ,J .'^#/_).+3_KO-_Z&:]!'05Y]\&?^2<6G_7>;_T,UZ".@H ****
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M\TU8_P#<67_XW0/&7CW_ *)J?_!JO_Q% 'HG-'->=_\ "9^/?^B:G_P:K_\
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M \?3UK:@^(FCQ>"-'U'7+V.TFU:R=T!!PSJ ' QTY84 -^#7'PWM#_TVF_\
M0S7H(Z5XO\,_B%X6T'P/;6&IZM%;7*RR,8V!S@L2*[#_ (6YX&_Z&"W_ "-
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M ]A_X#+_ (5JT4 97_"-:'_T![#_ ,!E_P */^$:T/\ Z ]A_P" R_X5JT4
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MXSC)H UO!_A*7PQK'B&Z::U:WU.[^T016Z%?+7L,=/RKL!("<?UKR*#6]?\
M#7B"2PN]<_MNXBTJ2]U.#:NVUD"Y3!&,!LC@X.,'O5GPIK6OV^O^%_[3U5KZ
MW\3V,UPT3H!]FEC57^3_ &=K 8H ]6S2TQ*?0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &L
M#Q;X?7Q/X;N]):=H'FVO'*!G8ZL&4X[@,!D5OTA4'K0!R/A/PO>:1?ZEJNK7
M\5[J>H%%EDAB\N-4084 5UR],4;1Z4N* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHIK-M!/\Z  ]:X/Q5X'O=8U66_TK5([!KVS^P7X>+?YD.>J\
M\,!D<UVXGC9@!(ISZ'-.4@J,CMS]: /.M7^'%Y-+<QZ-JL5I9:E81:?J*30[
MV9(AA70CHVW(.>.?:N_T^SBL+"WLX1B&")8D'LHP*G&WK@9IP(SF@!U%(6 I
M0<T %%%% !1110 4444 %%%% !1110 4444 %%%% #6'-<K%X:O++5?$FI6=
M[$MUJ:+]F,D61!(JE58CN,G./:NK(!I, 'I0!YMX:^'NL:-;7.G7NK6-WIMZ
M)#>'[*?M-R[CEWE)))R2>?6K/AKP'?Z7K6G7FJ:K'>PZ-:M::9''&5*J_#/)
MDG+;<+Q@<5Z"5&*0+CC%  HP*=1BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*\2Y_P"$9U7!P?LDN#G&
M/E-:M4=5M#?Z9=68<(;B%HMQ&=N1C- 'A>F>#[*7X,'Q/;75[;ZU#9272W N
MGP2F3C&<<@8QZXKL+GX@:M!X0T+5T_L>W6[LO.N+C4;@1*\RC!2-!RVX@D$=
MB*K0?#+Q*/#4?AJY\9(NA!=LD%M8*DCH#DKO//\ C6UJW@:[;6[*^T/4H-/C
MM=/.F>5+ 9?*BZ#RCD8;&!S0!!IWQ#O+QO!]W/8)%INOAXG<;CY$ZYVKNQC#
M=1W^4U4O?B=>V^CZAJ:6$*6J:LNFV]Q+N\M!G#2RXZ*#63XNT=?#OPNL?![/
M/?:R',NFS6EN01(LJ_-D?=($F,YY!-=A9^$[_3O!6E:;I.JMIUY:;99&>,2I
M.QY=)5ZLIR<X(- %GP7XDOO$"W1NFTR:.$J([C3YRP;/4,C ,A'^T!77*<KG
M-<+X.\"MX>UF\U>Z?3ENKF)(?L^F6@MK=%7OMR<L3SFN[7I0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F*,4
M44 ,,:D@D#(Z''2G;0 *** % %+110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>tm238578d1_ex99-2img22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img22.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'I HH# 2(  A$! Q$!_\0
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M(<C(X/?VKR336MX=/GA=Y_/C;RY(G@'E-)G! 8?>SVI][X<M-21?L[QVDRH
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M(AYJ*RH>&/\ >_\ K5[[&/E^IK@Q[DYIM6T/7RA1]G)IWU'T445YY[(4444
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M_9W3?EL_N$MI9DN&D%[)':JFY(B/E##.>/0URVIWBZQ=K=P174TB$.24Q$S
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MN5" #S3XDV +]T$[F#'/-=4*%2+_ ';UN[_Y/NO)'GU<13:7M8Z6=E?KWO\
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M4'.8\$9!&,UF1BUCP4!9H8PO')53_6M:_NUO)FMQ)(T>\"24Y <]F JA%&Z
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MMKJ: S(WDY+'=T']:18BD,<WVB1I9@3*A&!$0> #W&.:9(%BG@;RXFF)P'R
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MG;2_3IU^XL:A%! \)MI%EM9,[]YPRCL"/4U4B\P-*)!A <1ELAF7W'MT![@
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MZW\NJ\P$DL<10R.!G>5'."!P?Z4L:DLN^9HX7.[<S$ GN/3K395:WNH-LR/
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M?2O0P].C))P?=+H]-U;\4>5B93;][=I._9O6_P"&MRV\UT\EK=7#O*(VPIW
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M.]6GTU:=0CW0HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY:FRA3DIU5>25E;S?GT^XR)KB&WL#)Y@DB1?DW-G/ITIL=S&T<*%XDNFCW&
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M:%[*6IZD3Z4W/->8'XN'*9T;AESC[0<[OP7ITI+CXOBWC+OHK8P<*)\LQ[
M+GFE]6JVO87UVAS*/-KV/4Q2UY-%\8;O[8UM+X7E0B,R!_M093QG&=OU'X5
MOQJO#;/-)X92(I$92DE\ V!CMMXZUC9]3LN>P8%%>9:'\5)M8U>.Q_L9(XS*
MD4ETET'C4N,JHXY;VKTM.E2,=1113 **** "BBB@ HHK(UWQ)H_AR."36-1A
MLDF8K&TI/S$<D=/2@#7I#7)1?$SP9*Z1IXBLV=C@*">?;I4__">^%_-EA_MR
MU\V+'F+S\N>G:BS>PG9;G29Y[TO%<V?'/AH.B'6;?>Z[E'/('4CBGKXV\.,"
M1J\& >^X?EQS3::W$I)NR9T/'I0<8KF1X\\,,Q4:U;DAMA'S<-UQT]*(O'WA
M:>:2"/6[5I(_OH"<K^E'*UT%S1ORWU.DS\M&?PKGV\:^'%"YU> !AD<$9_2H
M'^('A1&16URWRV<<,>G!Z"BSM>V@<R<N5/7L=1WZT ^_>L)/%N@RQ^9'JD!3
M!)(S@ #.>E1KXS\.,N5UBV(X((SW[]*17I\CH..>:4=:PI/&&@)$DC:G"$D8
M*&PW)_*FIXT\.RJY35X,1J&;(8 #..XHNF.S730Z#-'>N?7QIX<:ZAMAK%J9
MI\B)-W+8_"BX\:^'+1_+GUFV5S_""2?R S4W2=A\K.@S2$^U8#>,_#R1^8VK
MVX7^]SQ^E-_X37PX8PYUFUVMT///Z51+T5VCH<\]*4<BN;G\<^%[>+SI=:ME
MC! W?,?Z4S_A8/A-)FA.O6@E49*$GCC/IZ4P>GS.H P*6N0/Q,\&K$)3XBL_
M+8D!OFP2.O:K">/?"SV,EZFN6K6T8!>0,2%'0$\4F,Z>DKDW^)/@Y+<7!\0V
M8B.<-D\D=>,5MZ1K.GZ[9K>:;=)<P$[0Z9 S^(%" T>]+24M !1110 4444
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M]&A4<VEA[;NZ6E]M?O\ \MB>RM/*N!9WUW ]O+$6#D@,C'H0P&>N!],UG"U
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M<'//%5[-QBN;J9PJ1G>VQZ:*6FJ?:G4C0**** "BBB@ HHHH **** "BBB@
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M6OX+MZF-JFKRZ7IWV&-A'<6+ E)\*26.0 ._%6;NY!MK8):"_,R[9H-P1MP
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MNM%N]O7MJD<JI4Z/*YR?-KILEV;6MU^)):^(9+R6\TS3+:XM3(AFD60AR77
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M^H"ZBEDUM+AKE717RV>ZY4'@XS6E.)E49[%\/M1FU/PNES-J5SJ),TBK<W$
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M7[7Q%:6=U,T%TC::O#AAEMQZ'V%&FZ='<Z\^ID3-*8BOEQ,-C#L2#WQC'O7
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M2*Y%*[O;2_KO\]$9$=K?QL\UK(Z1D$*SG!95YQ^0J/55G,D%R;AGW+N4D;&
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M]*R=3\0:D+R%=7M"CC[J6 ^\@^\!SQELYP*?INJ7BKJ#,%E$RF6VL?-[X'(
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M /IG-51<7)\FBUT,ZL)1J-SW?]?([T4M(*6NLS"BBB@ HHHH **** "BBB@
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M/WJKG[I]1TJ["\-UYLMP8WF9Q*L>\".-#@'MC.!S]!6==)-=.K,TL,<2DH"
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MTP V0#T' Z]*\/UN;3M;L3'IMC!";-@(Y=S@LA.<$,3NXSR<5Z[\!0%\"3X
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MP79"HGWHO7(X.?TKUZV%3I7DUHK+K?1[]C2#G3C-S3Z^BN[.RV=BPZPMX?\
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M _&LY4U)J/-K>[.NES4E*48]+1_X/GZ=+7"5+W5/)GOH)TME0&XE&U TH'R
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M^7&'VI'&F1NP<;CGI5&\T^[AGB,Q\I!R64[E?/8?GVKV&X\ Z'=&$RK<GR5
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MK,1PQ-I,R1+EHPQE.3SDG*CD=*6SN]2OKO1)]6"#4&T:]6;8P*L00-WRDCG
M)QT)KK+_ ,(:5?W9N66ZMIFC$+M974EOYB#A5;8PR!VJQ%X:TJ VODVGE+:V
MK6D*1LRJD38RN._3KUJE)(+-G VW]K'0O#7D#4;C3$TP>;;:9<K%.LA8;78=
M63&1QWZUW7A"]6^\.V\BW\]Z4+1/+<1>7+N4X*NO9AT-02>#-'>.R6-+NVDL
MH3;P36UY+%(L7'R%U(++G!YSSBM?2M*M-'LDL[&+RX$)(!)8DDY))))))YS2
ME),<4T7QVI:2EJ2@HHHH *3N:6D/2@1YC\3-6U+3=6L8[&_N+9&@9F6)L G=
M7$?\)1K^?^0U>_\ ?VO8/$/@[3O$UU#<7TMTCQ(8U$,@48)SSE361_PJC0/^
M?G4O^_R__$UC*$F[HZZ=6G&*4D>:MXI\0!21K5]T_P">OUKT;QC)='3/"4UN
MB7%X=0A9$F?:LC&)N"W:I/\ A5.@<C[1J7/_ $V7_P")K<U?PO!K&GV%H;V]
MM&L)5EMY[5T$BLJE1RRD=#Z5=-.+U,\1.$U[IR\<FI)X^T.ZU_2[732R2V]L
M]C*)!+(PR4D. 0  2/?TKH_%^J7VGVNF6NG2+%=ZGJ$=DD[+N$(96=FQT)VQ
MG ]2*BL?!L%MJEOJ-[JVJZK<V^3;_;YE9(2>"55%49]SFM+7=$MM=L$M+AI8
M]DBS13P-MEAD7[KHW.".G0Y!Q6EU=',D[,YG6-1U_P +:5>2/J:ZCYKPPV;R
M0@31.[;6+*N P'4>IXJK::MJQNI[1Y]1O[&>RG,DMY9>08)%7(P1@%3TQVQU
MK=;P597,-\-2OK_4;F]18Y+J=T1XU4Y7RQ&JJA!^;A>2.:DM_"2I<&YO=9U7
M49_L[VT374D8$*,,,0J(JEC@98@FG="LSD/#C740T&2Q2-[Q/"CF!9#A6D#+
MM!]LXK0\+Z]J$VM6=KJ.L7*W,T+&XT_4+(1'?C/[EUX(!SP2<BMV#P7IL$-O
M"TEU+%#IS:7LDD \R%L9W%5!W=LC'6DL/!Z6E[87%UJ^IZBNG@BTCNVC*PY&
M,Y5 S$#@%B31=#LSJ$^A'U-/IB=^*?4EA1110 4444 %%%% !1110 4&BD-
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MNX4NX8HN M%-WBC>/I]: '44@-&X4 !&:,4TNHYS^5*'!'I]: '8I,49HS0
MM%-+ =<4N: %HINX4[(H **;N'K2@YH 6BBB@ HHHH **** "BDR*,\T +28
MI-P]*-PH 7%+2;J-U "XHI-PI<T (1F@#%+D49H 0C-&*7-(6 H 6C%&:,T
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M@M])=4F:59;EV4,%AWA?U9@/SJ]K6BMJWBVT2XMW?3IM*N[2X<< >84&W/N
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MWNON,TS_ (3K2OL*W?DZAB6<P6T/V*3S;H[=VZ-.K+M.=W ]<5S>L6.I:_\
MV_J<.EW$,4FFI9013J!+.PDW%MN> .G/O6WKMM>6FL^']:AL9KN+3XIH)X(0
M"ZB54 =1WP4QQV)HL.[*VO\ C6(^#K_4M,EDM+FSG@CN8[N$QR6X:10V]&'
MVDG(SGMFM(^,+.ZCOK:!+VTOH[:2>".^M7@,JJI^= P&X XR.H[BN5UG2M8U
MBUU_5+?29 ]W+91VMI-A7E$,H)9QT"GI["M/4([_ ,2ZW#>0:7>6EO8V5TI-
MRH5I9)$VA% )SZY^E%D*[N7;#QE%;^']'>]2[OM3O;-;C[/8VQED8<;FP,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>tm238578d1_ex99-2img23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img23.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %^ KP# 2(  A$! Q$!_\0
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M,#\!47A_PMXNU+QM!XG\674-L+2(QV]C8R':V<\O@\C))YSDX[#%>F8%!&:
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MIN=SS\Y/&!P!FMZ7PCJVHZW:ZMJNMPRRV]O/;+!!:[(E65=I."Q);(4G)Q@
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M6_Z'72__  7K_P#$UM>&=,\;66I._B/Q#9:C:-$0D4%J(V#Y'.0!QC-=?10
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MZ5P8ZU-:_P#'U#_UU7^8K*>&I6;L=5+,\5=1Y]+H]^4]*?35IU>$?H 4444
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M5A:-XNT#Q!IMQ?Z9JD$]K;\3N<IY6!GY@P! P.IJ/0/&?AWQ3-/#HNJ0W<L
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M5)VKUT[GA>1Y_P"$/^2M_$'_ +A__HIJ]"KSWPA_R5OX@_\ </\ _135Z%3
M**** "BBB@ HHHH **** "BBB@ HHHH :U<UXQU&[TW3X9;.8PNTNTL%!R,>
MXKI6Z5R/C[_D$VW_ %V_I7)C).-"4H[V.O P4\1",MFSE?\ A*M<(_X_^/\
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M^%^AK2^)>J_,]_6G4U>@IU?-'Z@@HHHH&%%%% !1110 4444 %%%% !1110
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M(//3%>FUY]X$_P"1\\>?]?\ '_Z+%>@T %%%% !1110 4444 %%%% !1110
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M9Z!_R7_Q9_V#X/Y1T >F"D:G"FM0!XUXV_Y'"_\ JG_H KGZZ#QM_P CA?\
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MNZ'\3;S4M2TE[W1!9Z1K3O'IMU]H#,S+G[ZX^7=@XKT8$GM^E>%>'X;W5(O
MOALZ;?07>@W3RZ@TL)5(PN[&&/#9R.E=[JOPJT'6=6N=1N+O5TFN7\QUBO61
M 3Z#M0!!X$_Y'SQX#U^WQ_\ HL5Z#7F/PMTR#1O$OC+3;9YG@MKR-$:9R[D;
M,\GO7IU !1110 4444 %%%% !1110 4444 %(>E+2'I0!@^+O^1:N_\ @/\
MZ$*\L%>I^+O^1:N_^ _^A"O+!7S>;?Q8^A];D?\  EZ_H+2K_K$_WA_.DI5_
MUB?[P_G7DQW1[;V9[5#_ *I/]T5)VJ.'_5)_NBI.U?<+9'YP]SS_ ,(?\E;^
M(/\ W#__ $4U>A5Y[X0_Y*W\0?\ N'_^BFKT*J$%%%% !1110 4444 %%%%
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M#_DO_BS_ +!\'\HZ /3136IPIK4 >->-O^1PO_JG_H KGZZ#QM_R.%_]4_\
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M-3T %%%% !1110 4444 >?>!/^1\\>?]?\?_ *+%>@UY]X$_Y'SQY_U_Q_\
MHL5Z#0 4444 %%%% !1110 4444 %%%% !2'I2TAZ4 8/B[_ )%J[_X#_P"A
M"O+!7J?B[_D6KO\ X#_Z$*\L%?-YM_%CZ'UN1_P)>OZ"TJ_ZQ/\ >'\Z2E7_
M %B?[P_G7DQW1[<MF>U0_P"IC_W14E1P_P"IC_W14E?<+9'YOU//_"'_ "5O
MX@_]P_\ ]%-7H5>>^$/^2M_$'_N'_P#HIJ]"J@"BBB@ HHHH **** "BBB@
MHHI#B@ )P:3--8\\>E<]K6E3"VU"^BU?4XG2)Y%CCF 12%)&!MZ9%-6);MLC
MHB<UR/C_ /Y!5K_UV_I5K1-*E>SL+^75]4E=HTD:-Y@48E0>0%JIX]_Y!-M_
MUW_I7%C_ /=Y^G^1WY8V\53OW_S//Z6@=**^0/NUL7=$_P"0]8?]=Q7L8KQS
M1/\ D/6'_7<5[&*^ARGX)>OZ'RV>_P 6'I^HM%%%>T> %<AK.N6]WXJ7P-<V
MLQ35-,ED>YCD"[4(92 ,=<=ZZ\]*\A\<>&7\4?&#2;-YKZUMCI+EKJURI5@S
MG;NQCGTH O+\"?!R$;GU211U1[O@^QP :]%TZQMM+L+>QLHA#:V\8CBC'15'
M '\J\W_X4I:=O%.O_P#?^O0]$TQ='T6RTU)YIUMHA&)9CEWQW8^M !K6K6FB
M:5<ZE?2&.UMUW.P4L>N. .3R0*Y3P#XWO/&&K>((Y[$6=M821"VC=2LVUPQS
M)SC.%!  XSWKMY8TD0I(JLI[,,CV_6O.OA]_R43XA_\ 7]!_Z"U 'HQ9<=1^
M=>:>'_\ DOWBO_L'P?RCK3U+X5Z%J>IW-]/=ZLLMQ(9'$=ZZJ"?0#I7.> ]'
MMO#_ ,9_$NF6CSO!#I\.UIY#(YSL)RQ^M 'KHI&I12-0!XUXV_Y'"_\ JG_H
M KGZZ#QM_P CA?\ U3_T 5S]?0T?X<?0_-<=_O-3U84445L<8#K4UM_Q]P_]
M=5_F*A'6IK;_ (^X?^NJ_P Q4R^%^AK2^)?+\SW]>@IU-7H*=7S1^H+8P?&'
M_(KWOT7_ -"%>5YX%>J>,/\ D5[WZ+_Z$*\K["OFLV_BKT/K<C_@2]?T"EI/
MQ_2C\:\D]T"*!2?C^E** .Y^'G_'MJ'_ %T3_P!!-=O7$?#S_CVU#_KHG_H)
MKMZ^LR__ '>/]=6?"YG_ +U/^NB'4445WG %%%% !1110 4444 %%%% &1XH
MW?\ "*ZOMN?LS?89]L_/[L^6WS<<\=>.>*\&T63X.?V%:#5]/U$WWD+]I+?:
M3E\?,<H<8ST]J]_UV^72]"U#47C\Q+6VDG9,9W!5)Q^.*\CEE\;6/A5/'$^I
M:3-9F%;J32EM%V"$X^4/_> .* /:+79]DA\H$1[!LSGICCKS4M064ZW5C!<(
MI598U< CH",XJ>@ HHHH *;D54U*:[MM-GFL;3[7=(A,4.\)YC=AD]*\]\%>
M(->;4O&S>()UFDTUD86\1S'#\CL53VX ^M 'IP(]:6O%O#_B'Q';?\(?KU]K
M4]Y#XBN)(;BQ=5$<.<[?+P.,8KLM3^*W@[1M3N=-O]5:*ZMG,<J"!SM8>X%
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M*\<T3_D/6'_7<5[&*^ARGX)>OZ'RV>_Q8>GZBT445[1X 4T Y[TZB@ HHHH
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M&&>M8-S_ ,CUIY_Z<)__ $..O'UNKC8O^D39_P"NA_QI?M$Y8/YTA?& V\Y
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MY%RH!9<;D(.0PSW!%<[X:\ 7&E>($UO6-=EUB]M[06=H6@6)88A[#JW7GW-
M$>I>,/%UIJ=U;6G@2ZN[>*0K'<+=(HE7U -<C87?C:R\?ZMXH_X02\?[?;1P
M?9_M$8V;=O.<_P"S7M04#FC:* /.O^$X\;]OAS>'_M[CI#XW\;'_ )IS>?\
M@9'7HV/K^=&WZT >$ZW%XSUC5Y]0_P"$)O(C-M^3[1&<84#KGVK/.D>-,_\
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MI TN&$0V2P^0D<? 5,;<#\*@\/:#8>&-&ATG3%D6UA)*AW+D9.3R:UJ,#TH
M\[B^"O@Z&/REAU Q=X_MTFUOJ,UW%C8VVF6<%G9PI#;PJ$CB08"@=A5RB@!#
MTK"\3>$M'\66D<&K6QD\EBT4L;E)(B>NUATZ"MZC H Y7PUX!T'PM<S75A#/
M)>3+M>XN9C+(1Z GI^%7[CPUIUSXIM/$<BR?VA:0-!$PD(4(V<Y7H?O&MNC&
M.E # .3S61K_ (9TWQ(+$:BLK?8KA;F'RY"F''3..H]JVL"B@"EJ=A!JVF7>
MG708V]U"\,H4E2592#@]N#3-'TFUT/2+72[%76VMD\N,.VX@>Y/6M"C ]* ,
M32/#&FZ)-J<MG')NU.X:YN?,<N&<YSUZ#GI6'I?PM\,:3JT5_;V]PQ@D,MO;
MRSN\,#G^)$/ -=O1B@!!@ 8Z4M%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !2$4M% #=H]:,#UIU% #=HI=HZU1UF]GT[2I[NVL9K^
M:-05MH2 \F2!@$\=\_A7 1?%;49]6GTJ'P/JTFH0());<3Q[D4]">: /2G7=
MD<=#UYS5'2-(M-#T\6-@K);*[.J,Y8)N.2!GH,GI4ZW<2PPM<LEN\J@B.5P&
M!QT]S4KRQ1G;)*BG:3\S <=S0!2L]&LK#4M0U""-A=:@Z/<2,Q).U=JJ,] !
MT ]36F.@J W$ 6-C+'B7A,N,-GL/6G":-D9Q(I5,[B&R%QUS0!(0*3 ]:IW6
MJ6EGID^HRSI]EA0R/(IW  #)Z=:@T'6K;Q#HEKJMF6$%R@=%;[P!]?0T :>T
M<4%0>M1O/%&Z(\J*[_=5F +?3UI99HH4WRRI&N<9=@!G\: '[01@\_6@@8]J
MY_Q3XIA\,0Z;));27 OKR.S7RW VES@-SVI-%\5Q:QXHU[0TM9(Y-(:-7E9@
M1)O7(P.U &E-H]G-K5OJ[1L+VWB>!)%8C*,02I ZC(!YZ&KW2F3SPP)OFDCC
M3^\[!1^9H:6)55VD0*WW6+#!SZ4 5-+T:RT@77V2-E:ZN&N9G=BS/(W4DG\!
M^%:(&*K_ &B']X1-&1'Q)AA\GU]*Y>'QW;ZCX;.M:-8W.H1BZ^SB)65'/."_
M)X% '845 9DC\M9'5&D("J[ $G'0>M*)HRC/YJ%%SN8,,+CKF@"0J#1@>M1K
M<1/#YPE0Q<G>&&W\Z!/$91&)D,F-VP,,X]<>E $@4#I2[11D>M0I<PR1LZ31
MLJ$AF5P0,>I[4 2X'J:KWUC;ZA87%E=1++;W$;12HW1E(P13S<PB(2F:,1GH
MQ<8_.D:Z@CW;YXE"D!B7 VYZ T ,LK./3K""S@+^5 BQIYC%C@# R3UJ'1M&
MLM#MI;>QC9$EGDN)&=BS22.VYF8GDG/\JN-(B,H:1%+= 3U^E1_:[=8!,9XA
M$W1RXVG\>E %FD(ICR(B&1W5$ R68X I(I4FC$D<BNAZ,K9'YT /V@@CUHVC
M.>]0QW$,Y;R9HY-O#;'!P??%4- U>?6-/EN;G3YM/9)GC\J9U8D*?O9'&#_2
M@#5P,YYHVBHXIXIHS)%,DB9QN1@1[\BD%S"6C GC+2<H-X^8>WK0!+@>M9T.
MCV=MK-WJL,;+=W4:1S$.=KA.A*],C/7TK2'(%+0 R2,2(RDD;@1D'!Y]#VJE
MH^DV>AZ;#IUA%Y5M",*I)).23DD]23DGZUH48H **** "BBB@ HHHH ****
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M,&N#T2?Q#X0T9- D\/7>JBR!BLKRWD39-%D[-^2"A P#U''%>A4FWG/%=J.
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..M3J "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>tm238578d1_ex99-2img24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img24.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Z <(# 2(  A$! Q$!_\0
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MKLU.[$PCP3]WY1C.:Z:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHH)Q0 44W-&?>@!U%%% !1110 4444 %%%% !1110 U@""",
M@TWRUP.![>U244 ,V#.2.>Q]*=@#M2T4 -9 PP0"/2D* C!''H:?10 @7%!
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MYV[ 5G:'I<\ERVL:K@W\P^6+M;IV4>^,9-8U)MODCN_Z_P"&-J<%;GGM^?\
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MCOS5[^UM:U88TS3VM8#_ ,O-X-N1ZJO4USOA/0;N758+^XA,=K"2PW_QMC
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M>\9P010 ZBHI;B*"-I)9%CC499W(4 >Y/2FR7EO##YTDT:1<?O&<!>>G)XH
MGHJG?:G::=827UU.D5K&NYI2<C';IUSQ3-*U>RUFR2\L+@30.2 P!&"#@@@\
M@CT- '!?&O\ Y%O0_P#L.VO\GKTL=_K7F?QK_P"1;T/_ +#MK_)Z],'?ZT +
M1110 4444 !Z5SVLQZ"VOZ$VIR(NIK-*=,5G8%GVC?@#@_+ZUT)Z5EWMX]OJ
M-A FFS7"W#NK7$8&VWP.K'KSP.* -,=!2T@Z"EH **** "D;[IQ2TC?=/TH
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MBO"Y]*CO/$.MP>"/A[H%W:V-VT5Y-J0SOF'WDA7(" 8(XX]A0!W_ ,)O[/\
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M0!A1RZ/_ ,)B\0M?^)Q]C5C<>2W,.XX7?C'7/R]:W1UK,6ZU)M>>T;34&G"
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M]+L%_P!&L((V]=F3^=<WN+K<]/FKRVBEZZO^OF>8^*M=FU?5&\MY1:(!Y4;
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M5O%03DTNWI1SMJURU0@JGM$E?T$VG'6E"TM+4&XF*0@^M.HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHS1VH \R^-?_(N:'_V';7^3UZ8.
M_P!:\S^-?_(MZ'_V';7^3UZ8".: %HI-P]:K7.HV=F5%U=P0%CA1+(%S^= %
MJBFJP)R#D'N*=D4 %8^HW44.L:9"^ERW<DKN$N4B#+:X'WF8_=ST!'7!K7+
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M %@]E#]JEN%GQ\YB<;<^P(/^16?_ ,(!XO\ ^BFZGQ_TYI_\52?\*_\ %_\
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M\76MY:Z9<^'=&BC87EE)?_:([F0YP44=!TY/- 'LU%(/NBEH **** "BBB@
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MB..&/6--@O4A;?&LRY"FM>B@".&)(8UCC14C4 *BC 4 8  ["I*** "BBB@
MHHHS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>]O$L;.
M:ZE5V2)"["-=S$#T'>N%\2>/Q'IFW2H[F&Y=MHEGMRH0=\;A@FO0<"LW6]$L
M]>TYK*\5O+)RKH<,I]0?6@#ROP]XWU:QU2-;^\N+VTD;#QN S GNO&?PZ5Z9
MI/B:SU>Y>"W@O$=5WDS0%!^9K(\/_#ZQT6_%[+=2WDT?^JWJ%5?? ZG]/:NQ
M ')QUH !R*\>UFROX_B;XG\1:/N?4='@L7, /%S;NDGG1$=R0JL#V*"O81QF
ML*PT#[#XKUC6_M/F?VG#;QF$QX\OR@PSNSSG=TP,8H XJT\26?\ PDOBSQ':
M2JUM_85G<1GJ3_K< ^^>"*=XE\-6>F_!:_\ M-E;OJ$>F%I)WA7S!(?F8[L9
M')-7HOA=8V^H:S);7KPV.JW%K--:"+A5BD,C1JP885V/IQSUS75>)M%_X2/P
MSJ.C&X-O]MA,7G!-VS/?&1G\Z )-$TRPL]/MWM+*VMV>&,N88E0MP.N!S6J!
M@5#:1>1:0PYW>6BINQC.!C-34 %%%% "$XK'L/%&D:GK%[I-G>QS7]B<7,*Y
MS'S@Y_&M@]:\6^&X_P"+Y>//]Y__ $:* /:ATHKGM4\:>'M&N&@U#6+:"5&\
MMXR<LAP#\P'08(YZ<U-JOBO1=$M;>YU#4X(8KCF%OO>8.N5 R2,'K0!K7,OD
M6\DQ!(C1FP.^!G%<[X'\96OCG0VU:SMI[>(2F+9,03D8YX^M:)U*SU;09[NQ
MNH[FV>!RLL9RI^4UYY^SW_R3J3_K]D_D* /611110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 444=* "DXQ2%A56_U&UT^T>XNI1'$O<@G\A2DU%78T
MFW9(MY%+7/:9XITS5)OL\$DBS$9598]N[Z5NJP&?6HA4C-7B[E3ISIRY9JQ)
M2<49XKG=-URYO?&FO:*\40@TZ"UDC=<[F,H<L&.<?PC&!ZYK0@Z+Y?:CBN.E
MUW7KSQ-K^A:2FFI/806DL$EVLA5O,+;]VTYZ+QC'/6LO1];\>ZMJ^JV /AE3
MI=RD$Q\JX_>;E#$J=W'![]Q0!Z-Q1D5YUI6N^.O$,-Y>:4GAN.UBO)K>..Z6
M<2$1N5^9E) )]@:Z7PKXB'B32&NGM7M+N"9[>[MF;<8ID.&7/1AW![B@#?R/
M6ER*X*W\<7C?%&[\+W%I NGHH2"Y4-O,NP/M8YQTSCCM3M0\;W=O\3K#PQ;V
ML$EI*H%S.X.Y)"K.J+@XSM&3QW% '=&O%OAO_P ER\>_[S_^C17L^<=:\K\"
M>'M7TSXN>,M4O=/F@L;QF-O.P^63,F1C\* -#3[*)]>^)$LMJ&>5HD#,F=ZB
MV& /7DM7.G[/9^'?!]U/J.H:'?)ICQ0ZHEJ)X%^Z3#+&0>3C(^[TZFO9=F0?
ME'/7CK1Y8_NC'IB@#B_!=S=77@B\DNK>"+YIQ%+!;&W6Y3G$OEG[I;TKGOV>
M_P#DG4G_ %^R?R%>G:@,:;=\?\L7_P#037F'[/C!?AS*2<#[9)_(4 >M45@7
M_BS2-/UBPTR:Y)N;^5H81&F\;UZAB/NX]\5LV]S#<PK)#*DL;?==&#*?H10!
M-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !2$9I:* *UW \]I+$DS0LZD"
M1.JGU%<7XB\-ZE_9_F1WMS?F-MS1..0/4 =37>4UE!%85J,:L;2-Z->5&7-$
M\DT'2+[4-3B$*RPJC;FGV$;/S[^U>BZ;I-U8W#23:I<70*XV2@8!]>*U-H]*
MD Q6&&P<:*WNSHQ6.J8B5VDD %>>W&K6/A#XEZI>:W<"TL=:L[86UW*I$0DA
M\P-&S= V&##. 1[UZ'4;0HZE74,IZAAD5W' <)X-NX=;\<^)_$-@6ETNXCM;
M:WN=A59GC5]Y7/)4;E&[&#G@FK'@W*^,?&Y92 =1BP2.O[E:[78  !P ,#VH
M* ]: /)_!GCGPYX=TS4=/U34?(O1JET_V?R)&?!D)& JG.1Z5I^&-$\2S:5>
M:E;WIT2;5-0FO3;W%HLKK&V @8$_*V "1[UZ-CWI @% 'C6H6=ZFM>+-1&^>
M^T>XT^^\Q4V>=Y<0\W:/]I-W'X5-I\$TNO>#M9GCD6?6M2N]2=6^8QQO%B%2
M0.T0C'US7K^P>]&Q?2@!#TKE=#\<Z=KWBS5_#MM:W:76E$B:255"-AMORX)/
MY@5U9'2O%_AO_P EQ\>_[[_^C: /:1TI:P]>\5:7X:L);W49\0PM&L@B&]T+
MG"Y4<@'U]JT[:]@N]WD31R;#APK E#@'##L<'.#0 FI?\@RZ_P"N+_\ H)KR
M[]G[_DG$O_7Y)_(5ZCJ/_(,N_P#KB_\ Z":\O_9[&?AU)_U^R?R% 'G_ (Y^
M'VOW?C^#R;>STM=6NY5MS;R2.N>3YLA .TOGM^5>Y^ ]*N=&\(V%C>:;;:=<
M1*0]M;2;T!S][/J>I^M=+L&.]*%Q0 M%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%(: "FDX&:K7MTME9S73J[)$NY@B[F/T%<5K_CAET[;IT%U#/(<"
M6> KM'MGO5PIRF[)'-7Q-.A'FF=X&'6GJ:\@T#Q=J=GJ$?VNYN+RV<X='^=A
M[K[UZ)I7B.WU6Y:"&VO(V52V9H"@//J:TJT)TW[QSX7,*.)5XZ/L;E4M1U;3
M](M?M.I7]K96^X)YMS,L:[O3)/7@\5<'2N!TN&+6?BUXDFU"%)WT:"T@T\2#
M(@$JL[NH/&YB -W7 QTK ]$Z<^*-!338]3?7=,73Y'\M+IKM!$S\_*'S@G@\
M9SQ4<'C+PQ=W,=O;>)-'FGE8+'%'?1,SL>@ #9)JK#X4\/Q^(+RY\BV>:^1)
M);)T0QDIE?.$>.&^8J6]_>L3P%H^G.NN3#3;(30ZU<"&7[,FZ/!&"#CC';%
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M 2S1,% [D@UY_P#!;0-6\.>"'LM7LI+2Y-T[B.0@G:0.>#0!Z11110 4444
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>tm238578d1_ex99-2img25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img25.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %A KP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!KT&L_5M1&EZ7<7C-"/+''G2>6A8D  M@XR2!67X5\3_ /"26LTIBMXGC/\
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ME^,6M:E:>&K[2;?0Y[JQNK0^??J^%MCN Y&.?S[U$ASX!^'1_P"HA;?^BI:
M+/C_ (\%W_/\47_HU:[A7_XGBQ[[/_CTR$V_O_O=<Y^Y[>M</X__ .1*O_\
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M1I)$X>-U#*R]&!YR/S%3:[N3.$6U)K8X/Q=K>N:1:6]I(VRZG9OL]W9R!%;
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M,,$=./2N:BTW.L?8?[.*>(AJ;W#:D(XSB,W+'?@OG!7'R=<<8[UZXJA5
MZ =JH?V)I2WQOETNR%WN+_:!;IYF[UW8SF@#FO$.AZD=%:>X\2W5P+>:"Y,<
M\44<+".9'(;9'O\ X>QJAX=L;;Q?>76JZA&0OEI +>"ZGCP59C\X&P-G((R#
MQ7HA&31B@#SKQ#X>&B7<5UX;M[VVEG$<,Z6-G'*K1B3YV8OSN"L^/7%=5H6C
M6%CH]I#':J62, O-"JR$]<M@<'/6MO%&* //K+PO>1>)!%):WO\ 8<,BR01O
M?(Z+('=BQ3;DJ=R8&>,&MOQ%H.E3Z49W%M826\B3+>);*S1E6!!QBNGQ2$4
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MN=59]@"@<9.<YSP.V: .CI,TWIVKA-/UF^MV\?W)N'E;3KIC;),Q9(U%NC8
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M'FR1[QRP&,>^<9]Z +RYYSZTZD7O]:6@ HHHH *:W3\:=37Z?C0!1T:X^TV
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M. LJ+"H#@= ?6JTWAC3W>U6%%MK>"X6Y>"&-0LSIC86.,\$ \'M6YU%&!Z4
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M"S>=OE3,Z;2%7KV;!_"O3?"OB&+Q+ITEW%:R6OE3-"8Y&#'('7CCO7B6D_\
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M 'E/(_*K,%W!=*6MYXI5!VDQN& /IQWK,"Q12#IUI:0!1113 **** "C%%%
M#"@(YH* #]*?10!F:GH]OJJQK<27*K&RNHAF9!N!#*3CJ00"*MI$(D1 SL
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MJ7PL_P"1?OO^PA+_ "%>6Z3_ ,@JW_W3_,UZA\+3CP[?G_J(2_R%<V&_BO\
MKJ>-EW^\3_KJ=Y5#5XC/8[!:O<GS$/EI*(SPPYR2.G7'?&*SK_Q99Z?JT6F2
MV]\US+_J_+MF=7P 3@CTR,U>U6(W-@4-K]K_ 'B'RUE"=&!SGCIC./;%>A<^
M@NF:"=_K3J1>_P!:6F,**** "FOT'UIU-;H/K0!2TB(P6/EFU>U(=CY3RB0\
ML><Y/7KCM5^J&CP^18B,6AM1O8^49/,ZL3G/OU]LU?H **** "BBB@ HHHH
MXCXD"(:/8S7#VYMHKP&:&YOVM(YAL8 %U&202&Q[<U?\#2VLWAF)[.WMH(?,
M?Y+:Z:Y3(/.'89//Y56\>6]O<V6GPR6%W>SRW+Q0PVS(A;?%(K[F?@#86YZY
M QS5WP=8W5AH2Q7JW2W3S22RBY:,N2QZ_N_E ]A_.@#@87L3\3+M)O["-R-5
M 7[9/,;O^'&P#Y/]T=N]>P)WKS6/5+ZQ\;W%O%J;2:9-J81VDTUW2*1MH\D3
M;OE).,<8!.*]*3O0!@>++.>\M(1%;/<JI?=$F.6*,$;GT8@^W7M5+78+N70[
M:S;3)KVY0+&TV RH?+^:0+N&\CD 'N<UU4L\4"[II$C7(&78 9/UI6=4&68*
M!U)- 'G7Q$T^X'_"+W2ZC=+;1ZM8Q&S<*5=C(,.S8W;A]<5Z17$_$HC^SM _
M[#]C_P"C*[:@ HHHH **** $/>LK6XB+0WL3JD]GF5&8X7 'S*?8C(_(UK5!
M=VT5Y:S6TZ;XI5*.OJ",&IEL-:&;I/B"TU=RD/G1R!0QCE7:=I[UL5S%MX;F
MTJ?[98W;S3JNW9<!=KKU*Y R#[_I6I!K%JZOY\@M)8<>;%<$*4ST.3U!['I6
M-*4^2U71FE2,.;]UJC3-,\M=^[:-W8XYH5PZ@J0P/((.<TX=3TK<QN87B;PY
M:Z]ILT)BB6\*$0W)&'C;_>'..U<OX9\->(M!NI[R*#38RT:Q&S\TXEP<[@P&
M%/89!_#BO1A1C-6IR4>4#C=5\;SZ28[>;1+H7TF2(FD41E1C)$GI^&:W="UN
MVU[2X[VU8C=D/$Q!:)@2&5L=P0?YTFL^'M-U^.--0@=S$Q,;QRO$ZYZX9"#@
M],9JN?!^@""*&/2X8?*4+')!F*50.F)%(?\ 6G>#CY@;/VB$7 @,R><1N$>X
M;B/7'7%2YXSFO+Y/ >L)XJ%S;21B,72W$>HSRM+-&HP=AR=S< IR<8)KI-8O
M_%&D:->78ATZ[\J,LIB#HP]]G.0!DXSDXIN"NE%WN,ZP'-+7G7A'QIJ-ZU\+
MM)M6MX@A2ZL;8?*S;LHP!Y(PIXSC/-:FK>/K2PD@AM["\N+J0%C#)&T!51@9
M)<#/)P,9H=.2ERA<[&BL71O$NE:W90S6E[ 7D7<T#2KYD9[JRYR"#Q4:^+-'
M;7#HXO0;S>8\;3M\SKLW8QN]L_K46=VK ;U%1RRQPQ/+*ZI&BEF=S@*!U))Z
M"JUAJECJEO\ :;"\@NH02I>&0, 1VX[TNEP+M%-W>I_.C/-*Z =129&*,@4P
M%I,"BC-*X"$#%&T4N1FC(]J   "EH%%, HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K.UR33X-&O)M52-[".)GG61-Z[ .<KWXK1K.U[[
M,= OQ>W#V]J;=_.E0X9$VG)'O0 NF0Z>]A:SV-O"MNT2M 4B"X0@%<<<<8K0
M&,<5X-X;MM!M;NT=;[QG96T%[;P11W-SB,^8"T;.@ VHVT#W)KW=>E #J\\\
M6^%M9U7Q1;7UBB%!]EV2F?8L)CG$C&2/_EJ,#Y0<X/(QUKT.B@#S'XP^%--U
M+PO?^(+C[1]NT^T(@"2D)C=GYE[]:A3_ )$'X=_]A"V_]%2UTGQ4_P"27^(?
M^O4_S%<VG_(@_#O_ +"%M_Z*EH8%GQ]_R)5__O1?^C5KN5@_XG<=Q]DC_P"/
M79]J\SY_O [-N.G?-<-X_P#^1+O_ />B_P#1JUW*P#^VEN/L<.?LHC^U;AYG
MWL[,8^[WSGK2 Y/PE_R+D/\ UWN?_1[UH^$/^0QXE_Z_T_\ 1"5G>$^/#<7_
M %WN?_1\E:/A#_D,>)?^O]/_ $2E84_B9S0W1Y!I7_(*M_\ =/\ ,UZ5\.O^
M1/U?'_/W/_Z"*\UTG_D%6_\ NG^9KTKX<_\ (GZO_P!?<_\ Z"*YL/\ Q7\_
MS/&R_P#WB?S_ #/%(=QAB8NY(48)<YKV?X?PFZ^&UNC6J79^UN?+EDVCB7.<
M^W7'M7C%O_Q[Q_[HKV;X?VXN?AK;QFSAN_\ 2W;RIFVKQ+G.<'D=1[BNJG\3
M-LOG*5:5V>C#OBEI 1CK2Y'K6Y[@4444 %-?[O)QS3J:W0?6@"CH\'V>Q$?V
M2.U^=SY4<F\<L3G/OU]LUH50TB 6U@(A:0VF'<^5"V5&6)SGU/4^YJ_0 444
M4 %%%% !1110!P&LZ9HFO>/WL=6TO391!8++YUTQ$DC%CM"C(&U<'/?)'2KG
M@.6,^#BEE8V430330B.SD/D32*2-R,<G:3]<5N:OX9T;Q B+K&F6E\(SE//C
M#%?H>HJ:XL%AT2:RL8(8T$#1PP+\D8XP!QC ^E 'E]E+<ZEX^C@_L*:4K=I=
M7T=IJQEL[648Q)(NT+YG<*#DD XXKU].]>5:5X1U+1DMFLO!T<,UN1(BIXAD
M\KS!SG9C!!/7UKTS3?M9T^!K](TNS&OG+$<J&[X/IF@#,\3:9/J5O$((8YRG
MF QR-@'=&R@\^A(--O\ 29K[0$TZ6-)9(/(*22-D.R%26QVZ'ZUK7VH6FFQ"
M6]N8;>-F"AY7"@D]LFF7FJ66GPK->W4-O"Q 5Y7"@YZ8)H XGXF::&E\.:@;
MJ[!CUJRB^SB8B%LRCYBG0M[UZ'7$_$GYM.T#'_0?L?\ T97:[AG&: %HI-P]
M12!QZB@!U%)N'J*-P]: %HI-PSC(HW+ZC\Z $(XZ5SOB70Y]4-K-;"%Y8"WR
M2\!@<<Y]1C]371;U]:3(QU'YUG.G&I'EEL5";IRYX[G.Z7:ZIH5A' 88KN)2
M3LB;:Z9.=JYX('X4P^+[9;\0M:W"1A_+>63 V-G!R.O!QGZBNC.#QD5E3>'-
M,GOS>2Q%G9M[(6^1F]2O0UE*$XQ2I?B:QG!R;J_@:H<;<@@CU!S3+>\M[I6:
MWN(IE4[6,;A@#Z''>LF^\.6%Q:31VT8M9'4@&%F1?Q4'!'MBLW1?#5_932S/
M=QVC% @6V 8$#N<C\JJ4ZBFH\MUW)C&#@Y<VO8Z[-)N'K7(^(;#5W2'RYY[R
M $[T@'EOGL3@C(J_I<6O0:?"D[VKNJXVRLV\#/ + XSTYQ25;WW%Q>G4;IKD
M4K[]#?SD4A.0*X>35-?7Q"(MKF03!5M57]TT?<[B/3)SZC%;E_JFJVFGSS_V
M6BE$R&6X#X]\8!..M*&(C)-J^GD.="47%76IMHJIPH ]@,?RK*USPYIOB$0_
M;HY2T.[9)%*T; -C<N0>AP,CZ5DZ#K^H7+W"2V\E\D80^;;!%VDYR#E@#T!X
M]>:DU?Q)>6TT,-O8O;NZLQ>\4 $#' VD^OK36*@H>UNTO0/JU3VGL]+^IK#P
M_HS6,-F^E64EM"@2..2!7"J!T^8&N97X;62ZKYHNG73A.;A;&- FQB=V%<8(
M4$Y &/2M[3_$*W-C#.]C?+YB!ODMF=?P('(K-'B]CJ7EFS(M#.80=K>;D$C.
MW'KVZU?UJ,$FY;DJC.3:2V)-:\%6NHZ1<6EM=7T4D@!3SKZ>6(D$, R,Y!4D
M8(QTS5#P[X-O]/ENKBZU::VN9]HV6! 3"]"=ZG)Y_ <5OWWB.VM+*2=8+MG'
M"H]I+&"Q( &YE ')'-5=-\50W(F6\B:!XR/N*TBL#[@<'V-5]947[*^KU)5&
M;@YI:(YOQAX0UC4;FUD21]:@1&C\F[:-#"Y.?,& %/'&<9&..IKH=,TOQ)8Z
M;:6\FKVDS11JK"6W9CQVW;N?KC-.U#Q;!;S+%9Q&Y?&Y\DH%'XCK5R#Q+I=Q
M;QRFZ6,L,E'!RI]*?UF,_P!VFM!NC445)QW.$M)O&H\6[66]><3MYT4@9;$P
M\XVMC'3&,?-GK73:[K?B/2M!N+LZ5;(Z 9ECG,@C!."Q7:"0,_I4R>,K9KP1
MM;NEFSE%N6/4COMQP"0>?:KEUXFTNWMFE2ZCGD!PL4;?,Q)P!^='UJG+WM+(
M'1J1:36K.:\)>+M5U&.ZWV<FKQ1,H2[LA$J\C)4Y8 D>H]:=K_CN^T^^2TM-
M+\AUA\^3^T"%RN<87:2,>ISQ6[IWB?3[F-TN6BL9(S]R65=I![@]#5'7M4T*
M[EACETZVUEH_W@X1Q&,XX)[GT[XH^LT7^\=N4/8U.;DMKV+ECXQL+K3[>Y>U
MU2$S1+)M_LVX<#(SU5"#UZUEZ3\0DU'78+3[ 8[.[E,-M.7^<L Q!9,< A3]
M.]=#!X@TB6)'CU*R7>NX*TZ*1]1GBN?TQ_#/_"3_ &FTTUH[F5V6*ZSF-G.<
ME5SA20.N!FG[:BOB>^VHE3F[V6VYW"]Z6F(0<XI]"("BBBF 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% "'I7)^.?$F@:1IW]F:]]I\C4HI8\00
M-)E0 &R0./O"NM-9VNV,FI:%?6,=RUL]S \2S+U0D8S0!X5H-YX<N_$5E!/X
MQU34K>>XM]EJVF[//:+Y8@[@<A>OOU-?0J]*\@MX_$VJ-HNB:E>^&+.RT^YB
MD^T6=X&ED\L\!$[$]#]37KZC H 6DR*6N#\1^,[K2/%$.G0^1!:1)!)<SSPN
MR!99-F"Z\1CKAFXSC.!DT 6_BI_R2_Q#_P!>I_F*YQ/^1!^'?_80MO\ T5+3
M_C'XIAT_PU?:"]A>2RW]F2MQ''F*/#8^=NW2F)_R(/P[_P"PA;?^BI:&!9\?
M_P#(EW_^]%_Z-6NX$*_VZD_V>V#?9-GGY_?8W9VXQ]SOUZ_6N'\?_P#(EW_^
M]%_Z-6NY6+_B>)+Y5IG[($\W_EO][.W_ '._UI,#D_"G_(MQ]OW]S_Z/DK1\
M(?\ (8\2_P#7^G_HE*S?"9_XIR+_ *[W/_H]ZTO"'_(8\2_]?Z?^B4K"G\3.
M>&Z/(-)_Y!5O_NG^9KTKX=?\B?J__7W/_P"@BO-=*XTJW_W3_,UZ5\.O^1/U
M?_K[G_\ 017+A_XK^?YGC9?_ +Q/Y_F>*6__ ![Q_P"Z*]E\ P+<?#2W1K:U
MN!]K<^7='"<39SWY'4>^*\:M_P#CWC_W17LWP_C\WX:6Z^3:3?Z6YVW?^KXE
MSGZ^GOBNNGN7EO\ &E_74ZCQ)JXTW3Y1;ZGIUK?B,O$MZX^8#K\N03G&/K5+
MP;XA?6-'M9=0U+2I;ZYC69(+1@&C5E!VE2Q.02<UDZU96=]\3F6[M(+A%T1"
MHFC#X_?MZBHFTRPL?&_AIK.PM+=FDN S00+&6_=]\"NY4UR7/;YO>L>B@G%.
MI .*6N=%A36Z4ZFOT'..?6F!0T6!;>P"+;VMN-[GR[4Y3EB<]N3U/OFM&L_1
MHQ#8!/)M(?G<[+3_ %?+'GIU/?WS6A0 4444 %%%% !1110 4444 -VTH&*6
MB@#&\0:;<ZC#%]D>%9$\Q2)20"'1D[#J,Y]^G%4[[1+R6SM8+9[=C:1M#%YS
M-AU:+RR6QW!R<=QZ5TA&:-OUH Y?5? .A:^EG_:D,L[6D*PQL)F3@=\ ]?>L
M2;X1^'Y-3M)XFNH[.-7$]M]IE)E)QM.[=QC!X[YKT3%<IJE_>0^([>&*>1!N
MMQ# H^6</)MESQSM3)]L4 4_^%4>$QS]ENO_  -E_P#BJI:=\(-!@:[^VR7-
MTLD[/ !<2IY49 PGWOFQ@\^]>A,<*>,USWAO4K^_O]5^W6]U $E0PQ31!1&I
M4?*""<GC)/O0!S^J_"+P_<Z;/!IYNK.[=<17!N99/+/KMW#-64^%'A0(H:VN
MV8  G[9*-Q]?O5O^*;FYMM(#6LACD::--^[:%4L,Y;!VC'\6#CTJ?0IYKO0+
M&:Y+-.\*F0L-I8XY/XT <=-\(M ;5[:>)KI+*..19K;[3*3*QQM;=NXVX/YU
M=_X51X3_ .?6[_\  V7_ .*J75=1N;)-5^V:C.@6[C2W\E1'G=$"%W'.U<\E
MCZ'V%;DAO6\,!TO$:]-J&^U11;E9]HRZK[\D#W% '(:=\(M MQ<F^>ZNS)</
M)"1<2IY<1/RI][G [\4NK?"/P_<Z9/!I[75E=N ([AKF601G(_AW#/&1U[UH
M6.J:D_B+3X9S+Y4L,0*"3&=T)9G*;>1N&,[A@X%6=>U&6#Q!9VUK?/'=.%<0
MM@1;0W(.>69_N@#I][C'(!07X4^%-H5K:\)Z$_;9>3C_ 'JJR?"'0&UB&Y22
MY6P6!XY+3[1*2\A(*ONW<8 (QCG/M6_X6O+F\@N?-N'N(U,9223KN,8+KQZ,
M2,=NG:L"77M1^P:K)IES=WL8*QK(L:O+"PWEWV<;5;"JHZ\%L8/(!<_X53X2
M!_X];KU/^F2__%51TKX0Z%:VLD>HRW-[,9G=9!<R)M0G*IC<>@P,]ZZG6[]+
M7P^MW-/<6P;R_P#5 "1B<83)X7)X)/2L32=2U1]?LX+B]%Q&T,:.86R'/DAC
M(%VCY-Q_UF1DY&T8S0!0UCX0Z%=Z9+!IDMU87;$%+AIY)-O.3\NX=1[U?_X5
M5X2R?]$NQD]/MDO_ ,55_6]1FL]:M/)OGC4\31#D(A5SY@7'S $ DYX"]#FI
M_"MZ;ZPEN%O)+B!I/W/G$-*JX'W\="3DX[ C.#D NP.=/PCT,ZTEP);L:?\
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MYU/A_P /:?X;LI+334D2"20RD22M(=Q '5B3C@<5KTR/H:?6A 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5C^*;>2[\*ZK;Q"<R26DB(
M+<9D)*G&T=S6N:Y?Q9H$VMR69B\3WVB^2KY%JZKYN<=<^F/UH \Y\-6^DV\N
ME12_"/5(+M&C5KQK?A'&,N2<=^:]N7I7D6IVFJ^";W2+ZU\;WVJ_:+^*VDL+
MID<2HYP< =QUS7KJ]* %K U;PAI6M7\=Y>I*TBJJNBR%4F57#JLB_P 0# '!
MK?HH XWXIY'PO\0<G_CU/\Q7.I_R(/P[_P"PA;?^BI:Z/XJ#_BUWB'_KU/\
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M<9LUQ']X^YY]??-:% !1110 4444 %%%% !1110 4444 %%%% !2!0.U+10
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M\B5?_P"]%_Z-6NX5_P#B>)'YMI_QZ;O+V'S_ +V,[L_<]L=:X?Q]_P B5?\
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MJ8>$S)L+JL$2%@/3<K5U8Z"D I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LSQ#<7MIX>U
M"YTZ+S;V*WD>!,9RX4XX[UIUF>((;FX\/:A%8O,EV]NZPF!PD@?'&UCT.>]
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MCYOTKC^KU%3]IT*YE>QTNKS?:/"BR?:H;G-Y&/,AC,:\3 8QD\CIGO4^M?\
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M!+<301RJTT./,0')7/3/UJ59%89!!'8@YS0 ^BF[QWX_&D:554LQ"@=23TH
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M_D=?#'_72X_]%UZ4?@^1Z[^-'/\ C+_DHMY_V#H/_0Y*9X0_Y*%IO_7I<?\
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M+E2[,/<=:Z>DP*32:LP6ASLEI+-:BV?PZOD 8\L7*@8QC'';%(UE(\K2MX=
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MEM"\JPB23A=S' !/;Z]*N;AT[UQ4FHV/B6PFEUW3%33K&X,%U93HTLBW(;:
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M!DG.3SUSD\]R#WH*+.F36XDLPNH-<$P^0OWB'9>I)/ /RMUY.*M3?\C)8_\
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M<<>4>/Q[_AR?2I5UBT,YA,I5@,_.I4?3G'-/GB]F/EEV-'-&:SEUFP:-I!<
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MG[AFWYCDC?A@P ^9A]_N* -*#PSX>\47\'BG_2+E9Q%/;H[/&D;H1B0+P0_
M!SV%=AMYS2!<&G4 %%%% #2BD8(J!+*VM4?[-;Q0E@!F- OTZ59HH R;*WU.
M.9#<W,<B"':0O4OG[W(';-8EMX<O+22.S36X)$5'?9+81M)\S[L@Y^[DGCW%
M=@0*B^SQ?:/M&P>;MV[O;TH Y<:->&&Z?^V;']T6&?[.CPF%!P_N,G.,<$5'
M)IMS';6\LFNZ>@;#%VTZ/#+C)*\\?CGBNH6QMDCGC6%0L[%I0/XB0 2?R%,F
MTRTG@C@DA#1QC"#.,#&/Y4 <]_94XOQ;?VW8AV7B'^SXO,SZ_D/2H5LI6MKB
M5=>TX^62 _\ 9\6U/[N[GL?3'X5U1T^U>[6[:!#<+]V3N*KQZ)I\=N\*6RK&
M^TN,GYL8QGUZ"@#GY]/>W6 R:]I\:N2&+Z?%ANQV\C^+'K_430V%Y!J#I%KU
MJCJFW8EA$),]6!.>F-IQ[9YK6GTW2,003Q6ZA<B*)FP.N3@?6K/]GVHNS>>6
M!.009,GI]* ,)/[6DM))$\5VK,IQO%HFQ<_=W?-Z8J1DU4+;N/%$ C?EBUHG
MS#I\O/\ >(]:U(M*TM[5HX[>%H'(8A>02">?KS2W&F:<T<7VBWB*1C:A?^')
M![^^* ,HIJJ7DD,GBB$!5_U8M(PX(&6)YQC#*>G%0[]4-C)(/%MKYF?ED-FG
MEC/*9&<_=QWYYZ5OKIEDMR]R+>,3/G<X')S@'\P!^5,&CV MWM_LRF&0@LA)
M(.!C^5 &.[7XDM]OBN )*-RAK6/+@\*5Y]?;\J<@U)IIU_X2F$I$"2!:Q[EV
M_>W<]N*UFT;3W,)>UC;R?]7G/R\Y_G3AH^GK++*+2(22JR2-CEE;J#]: ,!7
MU1K'S1XMM"^_RQ(+-#'N/(&-V<XQWKH=,$PM!Y]X+MB=RRB,)E3TX%-ATJR@
M@:"*W5(W;<54XR>F:M00I!$L48PB*%4>@% #RH;K5=;&UCF,R6T*RDD[P@#9
M/7GKS5FB@#*:WU+[:&6>,6XE+%.<E,=.E9DNE:A::K/<6VO+;B^G#/%):HW1
M,!4/'HO)_K73X%12VT4SQO(@9HVW(?0T 8:VFN-=O%_PD285%.P6:;AR>3ST
M/;Z&H1'K1L'E_P"$HM]V\QK)]C0H&+;0#SDG.!CUKH1:P)</<+$HF=0K/CD@
M<@5'_9UI]F:W\E?*9]Y7_:SG/USS0!A.=37[.Q\50+')DDM:)\Z\ ;>?[S(.
M_7M2JNIM=S1'Q1$=@_U8M(]ZD9W9YZ8V_KU[;$FDV,L4,4ENC)",1@\[>0?Y
MJ/RH_LJR\V27R!YDN[>^3D[NO\_PH PB=36P,[>*[4%6 :3[&GE@D!@.O'RD
M'KW'6GE+]IK5E\46Y$B[T)LXRSAONE2.Q_7BM.73-)M[5HI8X8H6<,=[;0S;
M0HSSR<#%3#2[!X[8K"I6!5$!4G"@=,8H P%TR:>]NA)KMC(Y'[P?V?%YF%&#
MO)//Y5DR^";>[\-KIIU33EMUD7"QV2J@;=D=&!Z>_P#A7:II^G/-<.L43R2
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M3T6M8:79+>_;5MXQ<G_EIWZ8_E4L%G!;/(\2;6DQNYSG P*J-*$=B)5)2W+
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M4?.D)4J86;.UHCGH1TX]Z ,3P_X,DU4))KJ7#1QEA-%/.['[1@9FMIE8$12
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H%% !1110 4444 %%%%  >E(.M%% "T444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>tm238578d1_ex99-2img26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img26.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $\ KP# 2(  A$! Q$!_\0
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M_P"$OUKA0?\ 56?KZ?9ZZ.LC5]0GTZ-I[>S>[< _ND)S@!F/_H.![D4 5_\
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M9I$.5G8ZJ$ O(" <.1S^%3[%_NC\J@MQ^\EX(_>'MBK-66-*@ X J*W^_/\
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M[_P8O71T4 <O+X4B$D(_MG7CN<C/]HOQ\I.?T_6I?^$2B_Z#>O?^#%ZVI_\
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M3)MA+8PY!3[R]J[8]*@NN(1_OK_Z$* .&^UQ?9_)_M7Q9D60LR_]GS;MP/\
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M0LC?*< J>#C)Q]30!J^%_P#D5=*_Z]8__016M61X6&/"NE 8Q]ECQC_=%:]
M!5:V&-_^^W8CO5FJML,%^@_>-V/K0!5\1?\ (OW_ /UQ-96H?\>UQ^/\ZU?$
M7_(OW_\ UQ-96H_\>UQ^/\ZPJ?$C*?Q'00#$LO&,N>V/2K-5H/\ 6R\8_>'L
M1Z59K<U$;I4%N,-,<8R^>F,_**G;I5>W'SS]/]9_[** +-%%% !37Z<4ZFN:
M ..L[#3[CQE<.CSRW-N^7D:P0!7VJ=IGVY;Y67C/MGBC6? $&LW-Y/\ :VM_
MM;[WV(,J3&J$@]C\HY],BJ&CM#/\2]0N450SJR;S %9BJH#']5()+9R<@$#
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MNX8 ABDC'Y3QT&>^:JW.I^-H[JX6"W>6(3.(V^RX!3#;N",Y3"E3DAV)'(%
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M_,U-_%5:,JUUO7:P,8^8<YY]:L=Q1N!P<).X_P#75_\ T(UU7AS_ )%S3O\
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M4$AQ<1#/)S_*IZ@D/^D1#_>[^U $]%!X%4KZ_P#L(C+032[V"#R@#@GIG)%
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MGPU_R$;[_KA#_P"A2U6U[_D9I?\ KRA_]#EJSX:_Y"5]_P!<(?\ T*6O1?\
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M3SF=\D[R@7()X&!Z#C\*3BGN7=K8X[^R?$[2O$UOHZHNU@_VF3YSG)&-F1C
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MHR9[B23H3V<G'X5K-:0M(TABC+L &8J"2!TR>]/AAC@C6.)%1%&%51@ >PH
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M0>&'YUUDTZ6]O)-(V(XT+NV,X &3_*DBM887<QPQH7QN*J!NP,#/X5,0".E
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M';K'D(1A@&4<9Z?2H/$GA:_\K5[RSB2[N;VULXGV#:\TL<^YF(YP-I'0\8-
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MH *@D'^D1?CZ475Y;V,+374\4$*XW22N%4?B:S'\1Z$9XV.LZ?QG_EY3C]:
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MSGB_4IM*TV&>%[:-6G"2/<!3@;6(VAB 3D#OTR>U;UN0T$;Y!RH.1T/%<?\
M$.X-MI]H\FU8#(R^89EC*/M.,'<&.1N!"YX)SQ74Q.(]/BD5"P$0(1!DGCHM
M %S-86J?\C/H/UN/_0*S4^(&CR2!!'>!C(8]OEJ?G4!F (8@@*RMN&5((P3F
MHX/$&GZ[K^@R6KLIS.RQR@*Y0Q(RN!G[I5T.?]H X.10!V8Z44#I10!7O#B)
M>O\ K$Z$#^(5,O2H;P9B7_KHGI_>'K4ZC H 6H+HX@8@@<CG/N*GJ"Y.(2?<
M?S% $O:L?5]1DMF-JD(<RQ$[F;&W/%:_\)KG==YU*+_KC_6N;$SE"FW'<VH0
MC.HE+8GL]2DNXIK=HA&8HE(*MG()([_2MP=ZY?2O]?>^GD)Z?WF]:ZA?P'TI
MX:;G24F%:*A-Q1D:[JB62"V-O-,]Q%(5\O;@8P#G)']\4S1]9CO9%L_LT\4L
M<*N?, P1T[$]ZJ>)?^0C8?\ 7"?_ -"BJ#P]_P A^7_KT_\ 9Z[>1>SN8G6C
MI2GI12&L@.5_M*^7QX+!IW^P-$-J*GR!]I.TMM^]@9 #= >*ZH\+7G\"E/BF
M//D4S;&6-BC,2A5F"EO*"@C!XWYP*[]N5H Y;7=-B@>VNC),9IM7M9&.\C^(
M*%P.J@=CWYZUU2]ZX2^T.ZTZ_:\EO]\-UK5I*L2CG_68PQ/89&,?W??CNQ0
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MA31LX_'"R*=2(,7E/YAWIY>_8=Y(!W;"V/+QR!G<!Q0!U?A+_D4=(_Z](_\
MT$5LUC>$O^11TC_KTC_]!%;- !5:V'W^ /WC>E6:K6_\?_71OYT 6:0TM!H
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M.#U^IH WZ0TM!H K1?\ ']-QQY:?3J]6:JPX^W3#OY2?S>K5 !4 _P"/MO\
M<_K4]0*?]*8_[']: )/\*XI?NGZG^9KM?\*XI?NGZG^9KS,PVC\ST,#\4CH-
M#/\ H=OQ_P L!_Z$:UQ61H?_ !YV_P#UP_\ 9C6N*]&'PKT.&7Q/U%HHHJB0
MKA/$5P5\<Z1 ;5&1FBVF4P@,?-SN7,ROE?38V3CCN.[KB_$CW$7C#1I(&C1
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M,AG%PR7+_$9U>./RTC&"%=\*4Z[O)VHQ/\/F=!T-=H>%KAW0?\+2BE,MN#Y
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M>?\ EZ/?_IFM>;0_WIGI55_LT3B;5C]F@4<_*J]^/T)S^!Z\ _+NTX.8HO\
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M,^'K_P!?)-9&I_\ 'G<GM@_SK*<FGH9R;N=#;D^;,"<XD..<^E1:Q_R![O\
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M[@]05/63T)'TXJWIVJZ=J5W,]HEPLPC4.TUE+"2H)P,NHSU/ K6'W1BDHI;
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M$JY'EW00,W<D;685H4 %%%% !1110 4444 -89K#NG\0&YF%LMND2,-F<$R
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M:* .32R\9"9-^HZ>8=ZE_E.2OR[A]STSC_Z_'6)]VC:#3AP* "BBB@ HHHH
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=:=2J^7Y*D8/.<_*..G^16U30H!XIU !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>tm238578d1_ex99-2img27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img27.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $W R # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %%%%  >E<IIH)\3^)\ _\ 'W#_ .D\==6>E<GIO'B?Q/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%!.* "BDW>QHW4 +12;A2CD4 %%%% !1110 4444 %%%%
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M]NS@2./3 XSVSGM74TUE# @\@\$>M 'E6J:K80:M';V_C"^735TN>:WN$O\
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M$DAAZ'O4U8.ASE9F@)^5QN'U'7]*WJ\V<>631NG=!1114#"E'0_2DI1T/TH
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MIIV=QIV=SEQT%)6C>Z:8@9;=2T9.2@ZK]/45YOKE_JT>OLD$LZ ,OD(F=KC
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MF^7!;(&#G/%=90 4T]:=33UH R+3_D9]3_Z][?\ G)6P*Q[3_D9]3_Z][?\
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MT'_KPA_] %;U !1110 4444 %%%% !1110 4444 %%%% !2&EHH \GURSO\
M5KS4_$-Y#HEYI^G;[;9.+@^6(G)9E XSS@D==HQTKT+7+)-3\-WUGF$K<6S)
MF5RJ8([D<@5Q&LMX'.MWL=Y>ZW$7GS>65O%=BVGDR,EE5-K9P,D'!KT:6W@N
M[1[>>&.6"5-KQNN593V(/:@#A]%E_L[Q/8V5SI?AD2W:2B*?21B2,JN3N!7.
MTCC(/7%=]VKA_#E_HD.L11Z?X6CTR*],L5K?1QPJ+CR\[@0IW*/E)&1V[5W-
M '-6?_)1]6_[!EI_Z,FKI:YJS_Y*/JW_ &#+3_T9-72T %-/6G4T]: ,BT_Y
M&?4_^O>W_G)6P*Q[3_D9M3_Z][?^<E;%1#8J>_R0M133QV\322N$11DL>@I+
MBYBMH6EE<*J]3_3ZU2BMY;R5;J[0JJG,,!_A_P!IO5OY?6FWT0DA(X9-0D6>
MY0I IW10-U)[,X]?0=OKTT1PO-+BE(II6%>XSY2<8%/ YK+@TMXM4DNS(I5B
MQX7YSG'#'/(&..*U!20V+1115""BBB@ HHHH **** "BBD;I0!R&J:7?77BN
MWEM[$36JRQR3O,WE(,8R596RY^5?E9=I*CD8KL!7!QW.LZCX@55?48["TN0K
M-LPY!?HP5@&7Y2,D$A6!*\[AW8H B^S1"<W BC\[;M\S:-V/3/7%<SIO_(S^
M)_\ K[A_])XZZP]*Y/3?^1G\3_\ 7W#_ .D\= &Q112$X&3TH =_RR_X%24"
M1#'@.I.[UHH 2EHHH 2G+U_"DI5Z_@: &TM%% !1110 4Z3[Y_#^5-I\GWS^
M'\A0 RBBB@ HHHH 4_<'X_TI*4_<'X_TI* "BBB@ IT?WC_NFFTZ/[Q_W30
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M?_)1M6_[!EI_Z,FKI,T +33UI<U"]Q$LRPF5!(W*H6&3]!1>P&;:?\C-J?\
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MYJ0M;75ONB",N[!^7!!]".QI3$T?,!(_V"?E/^%-M(9D\^695629P=B'(
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M#R,CG'O2VEU%>VXG@8M&20#C'()!_458 Q13C);RN.<HO:-A:***U,PHHHH
M\J\3W>JV6L7*:;XCU"XCEC_<+%>V82&?<V5D#@,J ;<8R>O.17J4>?+&<9QS
M@\5YCXPTC=KCOIFDI)OAW6_V+3K:99KD,V\3EUW <ITQU)SG%>G1Y\M=P ;
MR!TS0!YWX6L(8_$Y>XT[7+>XCDF\M)F5K.+E@&3^/E2< YQN(KIO%6C7>LV-
MK%9I9F:"\AN0]T2-OEN'^4@$Y.,?0FN(\,:?ID7CRUN[:&[B$IN1'<SV(7[7
M(I<-B3>6 P>ZC)0'CI7K% '&V>FH?'^O1F>Z_P!(L;25B+ALJ?,EX4YRJ\=!
MQR?6NF^P+YHD\V?(F,V/.;&2NW&,_=[[>F>:QK/_ )*/JW_8,M/_ $9-72T
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MK$A2KU_"DI5Z_@: $HHHH **** $-/D^^?P_E3:?)]\_A_(4 ,HHHH ****
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MS^)_^ON'_P!)XZZD2HS,BNI9?O 'D?7TKEM-.?$_B?\ Z^X?_2>.@#8HHHH
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M'!% '3?;[/\ Y^X/^_@_QH^WV?\ S]P?]_!_C69_PAWAC_H7=)_\ H_\*/\
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MH@WV:1@75I6(R%/0,OYUL_\ "?>&O^?^3_P$F_\ B*Z10%4 < = *6@#FO\
MA/O#7_/_ "?^ DW_ ,11_P )]X:_Y_Y/_ 2;_P"(K1\0Z]9^&M'EU2_$QMXV
M12(4+L2S!1@=^35;_A+=);7=.T>.5Y+K4+<W,)1,IY>"02W;(!P/:@"J/B%X
M7,AC&IL74 E1;2Y .<$C;WP?RIW_  GWAK_G_D_\!)O_ (BI;G7M-L_$3V4=
MG<W-^T<7VJ6UM]_DQDML\UAT&2Q YQDG&*K+X[TY]'_M6.SU%[1YXX+=E@YN
M2[;5,?/()]<'VY% $G_"?>&O^?\ D_\  2;_ .(H_P"$^\-?\_\ )_X"3?\
MQ%;UI<&[M(IS#+ 9%#>5,NUT]F&3@U/0!S7_  GWAK_G_D_\!)O_ (BC_A/O
M#7_/_)_X"3?_ !%:'B'7[+PSH\FJ7XF-O&RJ1"F]B6( P._)JO\ \)9I;:]8
M:,DDDEU?P?:(61,ILP6!+=B0K$#VH JCXA>%V=D&I,74 LHMI<@'ID;:=_PG
MWAK_ )_Y/_ 2;_XBI+G7]-L/$#V45E<W%\Z1FZDM+8OY*$D(96';[V!R<9.,
M57'CS37TH:E'::C):R7"6]LRP#_26=BJF/GD9!ZX/MS0!)_PGWAK_G_D_P#
M2;_XBC_A/O#?_/\ R?\ @)-_\16]:7!NK6*<PRPF10WES+AUSV([&IZ ,S2-
M?TW7/-_L^X:;RL;\Q.F,]/O 9Z=JTZ0"EH **** "BBB@ HHHH #TK'U33+B
M[LYX5E$ZS_*T<^T*B'KM(0G..A.:V** ,73=*FM-0DN'$00K(H*Y+/N?=\W'
M\/0=:R-"A^RZ_P")HA))-B\B.^9M[<V\9ZUV)Z5R>F_\C/XG_P"ON'_TGCH
MV=W^ROY4N[_97\J;10 _=^[SM7KZ4F[_ &5_*C_EE_P*FT .W?[*_E1N_P!E
M?RIM% #MW^ROY4JMS]U>GI3*5>OX&@ W?[*_E2[O]E?RIM% #MW^ROY4;O\
M97\J;10 N[C[J_E3Y&P_W5_+VJ.GR??/X?R% ";O]E?RHW?[*_E3:* ';O\
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M7JB@H/FYR?2@#T&BBB@ HHHH **** "BBB@ HHHH #TKD]-_Y&?Q/_U]P_\
MI/'76'I7)Z;_ ,C/XG_Z^X?_ $GCH V**** '?\ ++_@5-IW_+/_ (%3: "B
MBB@ I5Z_@:2E7K^% "4444 %%%% !3Y/OG\/Y"F4Z3[Y_#^5 #:*** "BBB@
M!3]P?C_2DI3]P?C_ $I* "BDI: "G1_>/^Z:;3DZGZ&@!M%%)0 M%%% !2GJ
M:2@]30 4444 %%%% "M_JE^II*5O]6OU-)0 4444 %*.A^E)2CH?I0 E%%%
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MJBB@ ^7_ &J,K_M444 ..-HZ]ZBEFCBZ[BQZ*.IJ0_<'U/\ 2L/4[J2UAED
M!E,@0$]!D\$_A51CS.Q25V7VN7;[H"#\S5:._BFE,27@=QGY5<?TK/TZ\GNV
MGMYV4D("'5=N,Y'2JUII5U%=0&18TCA;.Y6^]CL!VK?D2W-.5+<WCD_QR?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M >E<GIO_ ",_B?\ Z^X?_2>.NK/2N%76++2?%7B)+YY83-<PO'^XD8,OD1C(
M(4CJ"* .GHK$_P"$NT/_ )^Y/_ 67_XFC_A+M#_Y_)/_  %E_P#B: -W_EE_
MP*FUB?\ "8Z#C9]N;?\ >V_9I<X]<;>E'_"7:'_S]R?^ LO_ ,30!MT5B?\
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M (+YMR\LOV:7(STS\OU_*C_A+M#_ .?N3_P%E_\ B: -NBL3_A+M#_Y^Y/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **P/&:+)X8N(W&Y'E@1E/<&9 1^(
MJ&\\*>%;*TFN9M$LA%$I=L0@G I-V5P.EHKB;/1/#TUY%;W7A6TM3."86(5\
MD#)4X^Z<<_AUK1N?"WA2T\KS=%LAYLBQ)^YSECT%3"<9J\6-JQTM%<$\7@9-
MQ.@QE!$9O,%I\I4-M_\ 0N/K5F;3?!%MI<FHSZ1:QV\4HAEW6QW1N6"X9<9'
M+#\#GI5B.THKD8-%\%7,VH1QZ58YT]MMRS0X5#MW=>AP.N*JW=KX"L1?FXTV
MR46,2338MR?E?[I7CYL\=/44 =Q17'W>C>#;*=89-$MF<Q^<PCMB^R/IO;'0
M5':Z9X-O)K:*'08"US$9D)MP (^S$^AH [2BN/&C^"6NX+9-*L7DN%1HBL.5
M8,'*G/N(V_*J[V?@9 2='M^)'C;_ $0@KL*AF((X4;EY]Z .XHKC[K1/"%K+
M#&-!MYVEF, \BW#@. 25/IP"?P-0&P\%^2LJZ!&T;R+'$PM.)2V2"N>HPIY_
MQ% ';T5R&G:)X0U.>>&#0K4&$\EH0 ?F9>/Q1NM:/_"%>&?^@'9?]^A0!K"S
M@5YW$29N,>;D9WX&.?PXK,_X1'1/LGV7[$?(WK($\Z3@K]W'S< =AT':F?\
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M"U:47"N8EV[@$!P?QKKQTH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_LGQ=_T--C_X*/\ [;110 ?V3XN_Z&FQ_P#!1_\ ;:/[)\7?]#38_P#@H_\
MMM%% !_9/B[_ *&FQ_\ !1_]MH_LGQ=_T--C_P""C_[;110 ?V1XN_Z&FQ_\
M%'_VVC^R?%W_ $--C_X*/_MM%% !_9/B[_H:;'_P4?\ VVD_LCQ<.GBFQ_\
M!1_]MHHH 7^R?%__ $-5C_X*/_MM']D^+O\ H:;'_P %'_VVBB@ _LGQ=_T-
M-C_X*/\ [;1_9/B[_H:;'_P4?_;:** #^R?%W_0TV/\ X*/_ +;1_9/B[_H:
M;'_P4?\ VVBB@ _LCQ=_T--C_P""C_[;1_9/B[_H:;'_ ,%'_P!MHHH /[)\
M7?\ 0TV/_@H_^VT?V3XN_P"AIL?_  4?_;:** #^R?%W_0TV/_@H_P#MM']D
M^+O^AIL?_!1_]MHHH /[)\7?]#58_P#@H_\ MM']D^+O^AIL?_!1_P#;:**
M#^R?%W_0U6/_ (*/_MM']D^+O^AIL?\ P4?_ &VBB@ _LGQ=_P!#38_^"C_[
M;1_9/B[_ *&FQ_\ !1_]MHHH /[)\7?]#38_^"C_ .VT?V3XN_Z&FQ_\%'_V
MVBB@ _LGQ=_T--C_ ."C_P"VT?V3XN_Z&FQ_\%'_ -MHHH =9Z!K7]M6E_JF
INV]XEJL@CBBL/)Y<8R6WMV[8KI*** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>tm238578d1_ex99-2img28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img28.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &- KP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0T[14NVEU;30UQ+YGE6\H$<? &%!/XT[ZZG2JTO:J[5M>J.P7%.K,_M[2?\
MH)V?_?Y?\:?%K6FS2K%%J%K([<!4E!)_ 4[HZE4AW7WHT**:'4C(/Z4NX>M,
MT%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML?J:IANU/>;>J#'W1@?G0!9M'VWL#>DB_P ZCE.Z20]3N/\ ,U%'($E1ST#
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M:-=FT6[@:Y +&$2*7P."=O7C(_.LCP__ &E9P6NE7T;S/:V47G7CNS>;-_$
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ME=KM:%71%X?_ .297F>TUOD?\ DKD?!V@QZQK<T,D>V%%!+XX!/'^-=CH?\
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MI8/"]A;BWV+*3!#/"&,F2PF*M(S>I)0'/UH HS^-+= TT-C=3V<,$4]U<(5
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M(C$HR[.BK]37IFG^#M2DMI;0_8/+9LM,V2ZCT Q7 02K;^-+>X>)I5BF21U
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M61V"-EAN/2NI^#RX\66QR3NE7J<]C4RVL<F+?[OYK\ST75<?\)5>]#G45_\
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M8\T\$:9YWC!$VQ 66]R9/N*4. 2?0=:[7Q+;V_BCP)>ZA L9FT\EG+1A2/\
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M\AM&O6LX6AMOM;@I(06,P.)3QV+=/I7;54W[P(****D HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *\
M]I;W,D;S01R-&<H70':?4>E2[<]J?10 T+BG444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5:^_X\KG_KDW\C5FJU]_QY7'_7)OY&FMT*6S/C[6CC
M5Y_PJK%*(Y%;T/Y]JZ6XT.]N[TW,-KYBE< [XQW'/+9]1T[TG_".:GLV"P.W
M).=\6<'^'._H.M;5_P")+U,J/\./H<YN';\*>9-S;CU  KHU\/:H'!:P#8?=
MPT7*\<??[X.:7_A']1W%CI2L-Z-M$L8X&<@'=]/K61J<_!*L=S$YY56!/YU$
M6&2 :Z23P[J<C$_V: I4_+YL8/WR1SNXXP,T?\(_JI9O^):%C9'&WS8FPQC*
MC'S#OS0!SKS;XT7LHX_'FDAF$<\<AZ*V:WV\.:J]J\3:;N?  D$\0QCVS]:I
MMX2US_GR7_O_ !__ !5 C#<DDG&,G-.BDVNISTQ6L_A+7<<62^_^D1__ !5:
M*^'-2!5O[.Y7.5,D6"#VQOH YO?DD^I-3K(/L83OYF[]*W4\-ZH"I-AE>AR\
M7]W&1\W6I8_#^HKY>[2\E9 Q/F1<C=G&-_0#(]Z!G,AAVS3S+F.-2?N=/QKH
M/^$=U,VIA&E['VN _G1G<25P?O<=#2GP[JI?'V *H8LNUHNA'0_-Z_E2>P&U
MHY_XMUJ!_P"GBW_] DKSF)P'5LC@BO3K"UFA\%:E:NN)1=6Z;<CKLDXR#BN9
M3P]J(VO_ &:21D%3)%M(/3C?V]:UK?Q7Z+\CS<)_%J?+]3FPV><\FI8Y0H?/
M\:E?Y5T)\.ZEN!&GY7&&&^+KMQD?-W//M3QX?U(K&O\ 9GSJVYG\R(Y&>!C=
MV&1[\5F>D<R6&.OM3GE!(/H *WO^$:U0PB,:;LPN-WFQ-DY'/+#'>I8_#VI+
M,K2:8LJ!LLOF1+N''&0W?'/'>@#G4D"A\]6  _.F;\#CM72R^'=4>1W33]@(
M?:F^+')X!^;GK^E0W'AC5WB(2RY9\X:2(8&,8'S47N!STC[HT4'[I/ZXKM?A
M-_R.-M_UU7^M<^?".N9_X\E_[_Q__%5UWPVTB_TGQC9&]@$7F3+MQ(K9P#Z$
MU,]CDQG\/YK\T=SJR[]>OER1G4 ,@X(^9>]>C-IL+F R"64P%F1F;)^88.?7
MJ:\ZU9UBUN_D;.U;\$X&>CK7J44BRQK(N=KC<,C!P?:JE&UB<+\53U_0AL;.
M*P@\B"/;&#D#.?UJW114G<%%%% !1110 4444 %4]4U*UT?3YK^]D:.WA +L
MJ%B!G'0<]ZN4UD#=>1Z4 <)\*)$F\)W$T<A=)-1N'4D8.&?(X[9Z_C7>9KS?
MX>2ZE%X>NQIMK!<1'4KO>TTI1@_FG(Q@Y ]:ZW[7XC_Z!MC_ .!)_P * -O-
M&:Q/M?B/_H&V/_@2?\*/M?B/_H&V/_@2?\* -O-&:Q/M?B/_ *!MC_X$G_"C
M[7XC_P"@;8_^!)_PH V\T9K$^U^(_P#H&V/_ ($G_"C[7XC_ .@;8_\ @2?\
M* -O-&:Q/M?B/_H&V/\ X$G_  H^U^(_^@;8_P#@2?\ "@#;S1FL3[7XC_Z!
MMC_X$G_"C[7XC_Z!MC_X$G_"@#;S1FL3[7XC_P"@;8_^!)_PH^U^(_\ H&V/
M_@2?\* -O-&:Q/M?B/\ Z!MC_P"!)_PH^U^(_P#H&V/_ ($G_"@#;S1FL3[7
MXC_Z!MC_ .!)_P */M?B/_H&V/\ X$G_  H V\T9K$^U^(_^@;8_^!)_PH^U
M^(_^@;8_^!)_PH V\T9K$^U^(_\ H&V/_@2?\*/M?B/_ *!MC_X$G_"@#;S1
MFL3[7XC_ .@;8_\ @2?\*/M?B/\ Z!MC_P"!)_PH V\T9K$^U^(_^@;8_P#@
M2?\ "C[7XC_Z!MC_ .!)_P * -O-&:Q/M?B/_H&V/_@2?\*/M?B/_H&V/_@2
M?\* -O-&:Q/M?B/_ *!MC_X$G_"C[7XC_P"@;8_^!)_PH V\T9K$^U^(_P#H
M&V/_ ($G_"C[7XC_ .@;8_\ @2?\* -O-&:Q/M?B/_H&V/\ X$G_  I\%SKK
M7,:W&GV:1$C>RW!) ]0,<T ;-% Z44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !5:]&;.X_P"N;?R-6:K7I_T.X/\ TS;^1IQW0I;,^-==3R]9N9?*
MW@X)Y J+R)!I(U#[.IB,IBQGN!GT]ZOZRGF:K*@X+$ ?6O0)/!T,/@+^SY+D
M*NPS^<%R3*P& ?;@"MJW\67J94?X<?0\HAN?.D6-+8;F P,^OX5/=&2RNC;S
M6JAQU!;_ .M6EX-TN"[\56ZW,WDQ6V'D9NAQTS72?$;1(OM<.J6S-CR]LRXP
MN.=K*?YUG8T1QMFKWEM<3);H/)C$C#/4''M[U1^VDR#%O& QP/FX'Z5ZUX%\
M& ^&$NIYO+_M 8<$C*Q 8'T/?->9S:))#KATH[O/6X\E<_S^F.:0PU.VETV"
M"1XT821[^AXZ_P"%)I%K)K&HQV<<2*SG QR<XS7I_C#PC;7W@T/:W"R7%@N(
MRA_UBXY4_GFL7X::+!YEWJC2D76WRX(ASCIN;^0H$C@)XI!/)"4B&QBI^7GB
MIK""2]NEMH;;+X)_(?\ UJWO&>C+I'B29(R6CG E3)[GK_*M?X>Z7$E_+J<S
M,<@K#&%!#=0WUZT <$UT$DV&U7@_WO>K1$WV+[4+5=F<<GI^E:7B?0X;3Q!+
M#93-+%=,C1;AC82V"OX$&O0[WP7;0>"1IJ7"M/\ 9]XF"@;Y.N,^F>*!GDT-
MP9IHHEME+2@8^;GG\*??EK.\:U:!"5;;N5N/Y5K>!M*AU/Q1:F9Y%@MPLC[!
MGD= ?09ZUT7Q.\.06LT&K1M()78"9"H"'L"N!^'Y4 BUH+>9\,KY]H&Z:W.W
M_@$E>=Z;;/?WJVD<"B0YP<^@)_I7HN@IM^&E\H)XGMQ_XY)69X T/=<RZR90
MI1Q'$K#@Y!W']:NM_%?HOR1YN$_BS^7ZG"-=A79?LP^7_:'KCTJV8KA;!;T6
M@\IFV@EO_K5;\5:/'IOB6\M8)?-1Y49&QCAN?ZUZ&/#^GS^ QI8O-TD<.3(%
M&X29R >^,U!Z)Y7!=>=-'&MJA:3&WYO7IVJ34@]A>S69@0O&Y3);&?TK3\':
M=;3^)H1>2/'%;*9)"G))7_Z]=%\0]!M6DAUZWG=_/<)*"J[#S@$8 Q1YC./T
M\/?P7$J6Z*L,7F-SVR/;WJA)>DKN%N@5<<;NY_"O1/AKHL%WINHR/+@28@,;
M8.Y3UQ[^]<WXE\)C1O$$FF02M-%,RM Y^]@] ?<4 5'TJ8>&UU@(GEF<PD;>
M!@ Y_7]*ZSX0 _\ "76Y(09D7&T?6N@N] LE\"II:22R*L.Y60[LR\9/Z5A_
M"-2OB^V!ZB50?UJ9[')C/X?S7YH],U(?\3R^//\ R$1W_P!M:]1KRK5F8:Y?
M;-I?^T/EW=,[EZUZG%O,:F3:),?-MZ9[XKHKQLH>AE@G>57_ !$M%%%<YZ(4
M444 %%%% !12$XJI/J5I;WMO9RW427-QN\F$L-\F!DD#J0!0!<H[FLK_ (2'
M2C)=1+?P-+:HSS(K9957 8X[X) ..A(!P:NV5TE[:QW,6=D@R,D'C\"1^M '
M&_"K_D6;_C_F+WO_ *--=U7"_"G_ )%B_P#^PO>_^C37=4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %(1FEHH !P**** "BBB@ HHHH **** "BBB@ HHHH **0UQM]X\:S
MOM6C71+RXM-*D5+JYB=3LRH;(7.2 #VH [.BN5N_&MI!JFC6D5G=S1:KL\JZ
M";8AN7<.3U.!T%5KSQ[#::M/;KIUS+86MVEE<WRLNR*5\8&WJ0,C)H [.JU[
M_P >4_\ UR;^1KE;;Q]%<:M;P'3+I-/N;U[&"^)&UYE)&-O4 D$ UU5[_P >
M4W_7-OY4UNA/9GR)J3;=;\S&2LBD"NCM[V_CF5(I93(9,B$DL&)]5K.LM-?5
MO&UM9(N=\@9N>BJ"Q_E7O&E6%F";J." 2H-OF>6 ?SKO]O&G4FG&]SGIQYH1
M]#Y]T:PNCJNN>1"X2(#SE ^Z-QXQ6SJT6K/X+NYF,ATP,(_GZ;@.V>>*[SP]
MHKB+Q@]HP6ZGO#"&!QL"H/U.:;XCM[N?X0&&X1C=Q1C:".6)) S[]*R6(M3<
M+&O+K<R/#4VLR:7+86UK)+%_9B/$C\C=M7)7/4'D8KE-0CNQXQ-[+9-:RI K
MB-USR1@=?K7K=K91:9'H5H8E\ZSM8OF.<H=@S_DU,+.)_BE]I\I'C;30RC:"
M">F?PJ'4AHN78;C=6N>76.HK8:9J,<UJ\Q\II$=6*F$@<G'<'I5/P_+J5GX>
ML-0@0I;Q2.B2JO\ &W4'UR*]H\1:2E_H6H6J0Q?:9X9(PWE@,0!D#-<SX-L[
MNT\!:9%;Q RBY5I5XX7.#_2M7B4ZOM%$E0M&USS#Q7:W\4>E27X8*T;^5O\
MO;<@\_G6IHMIJ=KH6GZC"K&-=XC"C=MW$CH/7U]JZ7XNZ<SZ+9ZG'P([@QR
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M1Y-U??:?-,C78GQ,V4"$%L="JJ,>P/6MR:]M;9E6>XBB9ONB1PI/TS4HD!H
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MSC*KC [<X P#UQFKL?ANTBU@:B&G+"5KA83*?*64H4+A?[Q#$>G)K8WBC>*
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M10 4444 %%%% !2'I2T$9&* /,/&)T!?BCI9\3?8?[._L:X.+T*4+^8G3/\
M%C.,<USEOKUYH_@^PMK?5=2L$F?4)M/'[E-UO&P,>]YU)P,\*O+!NV!7MDMI
M;SNKRP1R,OW2Z!B/IFB6U@GV>;$DFP[EWJ#M.,9'I0!Y'=>,/$J0Z2B7+-)X
MFTVV^PND28MKK<HF(XZ%&WX.>0:W-!U^]/Q%O]*OM7>[5VG-K%:M$T$<49 V
MR*%$B2 YR2<-VKK[OP_97NKZ9J,OF>9IHD^SQJP$8+@ DKCD@#CTR:T([2"*
M5Y4B197^^ZJ S?4]30!X]K?AJ[\4?$'Q796-K9K,&L3_ &C-(1-9X0$F, $D
MD ]P*N7_ (NUB/Q)<&+7-MY#KT>GQ:"(X\2V[%07/&_)!+;LX&*]9$,:NS*J
MAF^\0 "?K49L[<W N##&9@,"4J"P'UZT >0:QK>IWUEXUTJ;6[B>XCL+FY@^
MQF%X%A23 3Y5WH^ 58,3U)'05K>(9EE^ UY(-7_M)38I_I/R?-ROR_* ..GK
MZ\UZ3'9VT3R/'!$C2G,A5 "Y]_6@6=N(/($,8AZ>6%&W\NE 'D%]XD\1V]SK
MMQ:ZV\-KHUSI\<5H+>-ED654#!F*EL=2,=R?PFU/Q%J.F2:M%;3K9PW'BA[2
M:ZA$431Q_9XV'SN-H8MQN?/IZ5ZR;2 A_P!S&=Y!;Y1\Q'0GUQQ^59FC>&+#
M1K.[MT,]U]LN7N;A[N3S6D=@!SD8P J@#'0"@#SH^*=8\O0K35O%4&EP30W<
MDFJP>3()VCDVQH6P8\A?O #DC K(UF[N+#_A9!?6O.EC>WEBM;B&%E=&$9#[
M&4\ ':.,=,\\U[<UA:/"D+6T1BCQLC*#:N.F!VI6M+=Y#(T,;2,NUF9 21G.
M"?2@#RG6/%VL0Z]J+0ZWY5]:ZO!8VF@^4A%U"S+ECD;R2"S;@0!BEC\1>((]
M9M;PZXTMF_BA]'^PF"/8826YW ;BPP,'/US7JQM+=K@7!AC,P&!)M&X#TSUH
M^RP'K$A^;?RH^]Z_7WH D7K3J0 "EH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G-G/\ ]<V_E5FJUYQ9W'_7
M-OY4X[H4MF?(6J+;MJKL[KRI./, RV<?RS^55]EJ(MAD7<6YVRC&.W;K6M?>
M+]=TJ_EM+?5YX+5#\D:JK 9'/4$U$?'WB01B4Z[<["=H8QIU[_P^];5OXDO4
MRH_PX^AGK'9!E#2$?.5.91CMDCZ<U,\&G[1Y<X8D'K(!R.@_$9-6H_B%XAE.
M%UV<DG  C3GT_AJ2;Q_XB@=HY-<N5E4X*F),C_QVLC4SF:T6!A&Q.Y=Y!D'4
M.1C_ +YQ3O)T_P U UQL0O@DOGC K03Q]XA<%DUNZ8 9.(D_^)J/_A8GB$G_
M )#MT,_],DY_\=H H3)8K"[)=*7QF-2W) QG\^:H&5<??'/O70S^.O$UNJE]
M:NU5EW#]TG(/_ ?:BV\=^*+N011:W=M(<X'EI]3_  ^E '-M,FTC>!^-75AL
M_,&Z10G1B)>3[XK1D^('B?E1KEWD#_GE'_\ $TZ'QWXEE<)'KER[X/'EI]3_
M  T 9BI:%AE\ ^DH.#CH?QJ=$T]H&#3X8;BJB0?,0?EY[9%6?^%A^(,8_P"$
M@N#Q@GRT_P#B:L'Q[XB6(2MKEQL)QN\I/R^[0!E.EH(I2) 6$;.F)1SR,#^?
MY5(D=B6E628A8SA!Y@^85=3XB:^V!_;MQG/ $2'/O]VED^('B.&0QG6KH.#@
M@Q)P?^^:3V ZG2C&?A]J0B)$?VBWQD]MDG>N!CALE=&,R+%SN(F^88[XQ_G%
M>AZ7J-S?>!-1U"6=I;AKFWD,I R3MDYQTKCXO'WB25L1Z]=,^"?]6G;O]WV_
M2M:W\5^B_(\["?Q9_+]3-:*RW &7*D=1*."%YS]#D>]3(E@(&?SAYK _NS*.
M>>.??K5G_A8GB ,H.O7'XQI_\34Y\>>(T@69]<N!$Q*AO+3J.O\ #[UF>B8[
MQVJ[@CAB!\I\P8(W8_"I'6P1LELJHR?WW4@'(''M6BOQ#\02?\QRYYX'[I/I
M_=I9?B#XCB<H=:N0PX*F)/\ XF@#.MS:K-$_F,J%#O)D&1VSC\:9=+9Q6ZO'
M+^\(4D>8#@G.1_+GWK5C\?\ B"0,5URZ88R<1)R/7[M1M\1/$"]-<N1@\_ND
M_P#B: L8)E3. P_.N\^$KAO&%N0<XE7^M8S>.O%"VRW']MW8C<E0WEIR1_P&
MNH^&_B#5->\867]HWTMT(I08_,51M)SGH!43V.3%K]W\U^9;\1*K_%*Z5AD-
MJ<8(/U6OH*-5C0(@PJ@ #T%?/?B([?BI=$*21J<>% Y/*]*^A(V+1ABI4D D
M'J*[\7\-/T+H?%/U_0DHHHKA.D**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JM>?\>5S_US;^56:K7G_'E<_P#7-OY4X[H4MF?'FNQM)J<R(,NV  .I/'%=
M!?\ A*ZL? T1DMY#>*[7,N>D:$ !?<\9K/D=8_%<3OP%D!_2NMN/$\]U9M:S
M*2CY1Y,\[3QTZ5V2HSJ3DX=&SGI2M3C?L>>^%]#NM6UI+:)-Z1[7E(/ 4<UJ
M_$'1I+#Q&9!%Y45W$)E!;OT-.\)W=QI5QJ$D;8/F1HX X(P<BMSXE2VDUBZ0
M_:/M$+J<R\KM=0<+Z5BZ4E'GZ&UU>PWP7X2?5/#,LTL _P!)+) [>PZ_3(K@
MWT>^CUE--DA*7GGK%Y9[DX7BO9/!LMVVGM8PP2M';Z>LT)(*?/M!(S[]JXR[
M C^(37@,Y\JW$QW+A]Q3C([')YI.G)-(+JUR3QQX2O;;1(+L1H$M%\B?:<X&
M2 P]LG%5_AMX=GN[JZU658_LD$;*I9L;W88&/I76?VG)JWABY34)YMS^8FY4
M^0D+E0WUK"^'US<_8M,@@MYI3YKB0#[K@]!_]>J]C+GY&',K7.0UO3WTS7KN
MV<C(?*E>F#TK8\&:!<W5])J$MN[6B9C'.-S$'I] ?UI_C:*X;4;.YNK.2UFE
MC<.67 ?#8!'X5T7@[61IVAP6QE+&Y9Y3@9V%> /QQ4JFV^5+4=['FVL:7<:;
MK5U9/&RO'.$"8Y(SD8^HQ7;ZAX/OK/P$%EM6^UQ8O).?N@@#;CU JEXAO8[_
M ,8Z)=M(Q>0()GD3[K!B ??J*]%35K74-#,MQ+,@2Y^RM)$I8L,?*Q7T/<=J
M/9R[!<\?\&Z'/K'BBTM44/'&/,F)/&T<_KQ6EX^\/3Z5KL=T(Q':W.6C(.1N
MYR/UK6\ V%PD.M7%K;S2WMJ4"1QC/S9X^N.N/:NJ^)>FR-X.CN)HI([B*2%S
M'V0L0#G\S4\KM<I&#X>4I\,KU3VFM_\ T&2L'P+H9U#4+JXF0&UC38#NQEF!
M'%=#H0_XMO?_ /7Q!G_OF2CX;0?:XWA$#2?NI6;"_>8=!FKJ1<JOR7Y(\S!O
M][/Y?J>;ZSI-SI>KS6$Z_O%D54 .=P.2",?6N]U#P=>6_P .U#VX-W ?MD@W
M#(#@<?@!53QG%!%XM\/3)9W%K%)&I>*5?G7#D?CZUZ!I$2:UHNH;X+F)+:1D
M3!R=I7@-Z^_UJ>233?8]&]G8\>\'Z,VK>(;>$A/*CQ)([G"@ <#/N:T/B#H4
MFFZ\)XT46MRNZ-@<@$YR"?QJQX0\ZVT#5[F.V+(TR1&8](^,_G^E;_Q'2"7P
MSX?F$6ZYG*&60'()"]#Z&FZ;4%4Z"OJ9/@+PG<ZSI%RYAW12'R$<=<X_Q KC
M-5T>]TS4KK3KN,1W,,FUU_SZUZUX#OIC96&B6\689;9YP44AC)@GD]NA&:Y7
MQ=+;?\)W87""8Q/!"9(Y%._.<8]_K2=.25^X[FEJ'@V\A^'P0Q)]H@47+ 8S
MSCCZX_E47PC_ .1NM1_TT7^M=[<VM[<PZ9%<V-Q+'=0%IY0"I@?H ?;'8UQ?
MPTMOL7Q ^S9SY5UM!QU'.*BK%QCK_6IRXM_N_FOS-'Q!S\5KG_L*1_S6OH3U
MKY[\1J3\4[H*VTG4X\'&<'*U] PAUC57;>XX9L8R?7%=>*^&GZ%T5[T_4FHH
MHKB.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *3(]:#UKS.^N-:N+WQC?6VO7-J='E!M
MX2%,) B#D,I'?US0!Z9D4N:\YO-;UJXNO!6I1WYM[35'B6:RCBQEC&6;+$DD
M= !QTS5.Z\5SGQ?J#W\VL6^F:??QV:-9(GD*3CF8DY.XMC@$ 8H ]1S5>\_X
M\KC_ *YM_*O/-+U74++QK]G\07>N6YNM0GBL4:-/L<R9)1<CYLX_E7H5X?\
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M&"">O*U] KL10B@!1P !P!7=BO@I^AT05FR2BF^8OK2@@UQF@M%%% !1110
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M !;O4/\ KXM__09*X6TP6?\ W&_E6M57K/T7Y'FX7^+/Y?J,&!CC_&M"$_\
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M 4444 %%%% !1110 4444 %%%% !1110 56O<_8[C_KFW\C5FJU]_P >4_\
MUS;^5..Z$]F?'^L-C5I?PJ*VE"Q77^U%C_QX5/JMNSZO(=P"E-V<$\ X_F:A
M2V9(G+. 6RFTJ=V1@]/2MJ^E27J94/X<?0A+?-^(J>\8?;9P/[V::MFSL,31
M\MMSSP3C&?3K4DMJQG8LX4L<@%3SSC^?Z5E<UU$B8?9KC(_N\Y]Z@+9Q5I+1
MQ:S;2KJ5\S<,XPI.?Y4TZ?(K[6D3(SC'<]A^//Y4W),$ADS9@M^?X3G\Z?9.
M$ND;T#?^@FF-;2FU:48:*(#YE!YS@_ID54$I4Y7'_P"L47N%F/9\J.?PJ>P?
M9=!L_P +']*HEN./2KT%JXD*JXW,K+DJ=H/&<GZ4KA9D ;(J96(LWP>KC^5,
M6V)  E3&,@D$9&,_G5C[&_V-R'# /\Q522-IVGZ\GCUQ330695W?*<\U8O&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "H;F,R6\D8.-RE<^F:FHH \D;X,12R
M%VU=223SY!'X?>H_X4I#_P!!89'_ $P/_P 57K=%;_6*E[_HO\CG^KP_IO\
MS/)?^%*0_P#06'4G_4'_ .*I/^%)VY7']JKC_K@?_BJ];HH^L3\ON7^0_J\/
M/[W_ )GD1^"%J0 =47 4J!Y!X'I]ZGGX*0,23JHY)/\ J#U/_ J]:HH^L3\O
MN7^0?5X>?WO_ #/(W^"-NYRVJ@X&!^Y/3_OJF?\ "B[+_H(Q_P#@.?\ XJO7
MZ*/K$_+[E_D'U>'G][_S/(/^%%6/_01C_P"_'_V52_\ "DX,8_M8$>\)_P#B
MJ]:HH^L3\ON7^0?5X>?WO_,\D_X4I""/^)JO!R/W!_\ BJ!\%( =W]K#=P<^
M2?\ XJO6Z*/K$_+[E_D'U>'G][_S/(_^%(VQSG4TY&T_N#R#V^]2?\*1M]JC
M^U5PARH\@\?^/5Z[11]8J>7W+_(7U>'G][_S/-;7X7"UT2YTT:H"DTT<@;R<
M;0@88QGONJ@?@O P*G4P5]#$?_BJ]9HK&;<W>1#P=)N^OWO_ #/)O^%*V^01
MJ0XSC,1XS_P*D'P4@4AAJ0!XY\H__%5ZU14\J#ZG3[O_ ,"?^9Y'_P *1M<,
M/[03YAM/[D\CTZTX?!2W P-27'IY1_\ BJ]:HI<J#ZG3[O\ \"?^9Y(?@E:D
M+_Q,$^7./W)[]?XJ0_!"U:,1MJ"E!T4PG _\>]Z]<HHY4'U.GW?_ ($_\SR#
M_A1NGKUO8^?^F)_^*K5\/_"J#P]K%O?V]ZI$;AF40XW8_P"!>]>E44<J#ZG2
AO?7[W_F1HHQFGX]S2T51UB8%)LYS3J* $ Q2T44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>tm238578d1_ex99-2img29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img29.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $5 KP# 2(  A$! Q$!_\0
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MMWXDL+./4Y)!<XTY0]P%MW)P03E1CYA\IY''!YK9##\: %HI,BE!!H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH)Q2
M@T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !103BJ?\ :=E_:0TX7<)O6C,HMPX+[ 0"VWKC)'- %RBLJ#Q)HUU<
MSV\&J6<DL"LTJB4?*%X8_0=_3O4NF:UINL)(^G7L-RL;!7\ILE21D9';(YH
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M/3'Y5*OQ)T6. /=PW]JR6*W]P)+9L01MG 8]B2" ._% %K_A$[__ *&[7/\
MOJ+_ .(H_P"$3OO^ANUS_ON+_P"(JK+\2M#BT>74S%?F&"5HKA%M\O 54,=_
M. -I!ZG-0CXEZ7'=ZO'<6MW'#8300Q3*A8732J"@3IR=PP,].>!0!H?\(G??
M]#=KG_?<7_Q%(/"E\?\ F;M<_P"^HO\ XBL/7OBKIEOX<EO-'2>ZO#;M,B-;
M.R0XD\O]]C[OS CKV]*]!A;>BMZJ#0!S?_")7_\ T-VN?]]1?_$4?\(E?_\
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MLG_(F-_V#S_Z+IWA7_D4=%_Z\(/_ $6M &O1BBB@!-HSGO1M%+10!SVC@?\
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MS4-2EV>8#)F%2RNH4J5$80< 8(4-G//)J6X^&VC737):XOU$_P!G;"RKB.6
M!8Y5!4_/@ '.5([5Y+!<>(_^$!DT,3ZAMNM.;6OMA=RZJL3;X=W7)E53CT8U
MW?\ PF>NQ^+5T^.>/Y+L6ITTV;;_ +/Y&\W1ES_>[8QVZT ;M_\ #+2M2B6.
M?4=5&;8VMP8IDC^TINWC>%0#AN1M ].1Q79HFP 9/  KR"+QOXNMM&CFO;BV
M8W=K87+70L"JZ>DTA61F7=\^T#/;D^G%=[X'U>^UO0#=7TBSLMQ+%%<I"8A<
M1JV%D"GID?A0!TM%%% !6=K;3QZ+>RVUPUO-%"\B2*JM@J">C CM6C6?KO\
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MW:VDDD*R1A_F"DCCT[XH I:;\1?".KZC#I^GZ];7%W.VV.)=V6.,X'%=0?F
MKQG0=9U>U\;Z5IM[K4%W++< -;0Z8D;- T!D68.!@(&^4\Y_+%>R9VB@"-+:
M&*626.&-))/ONJ %OJ>].B@B@0K%&D:EBV$4 9/4\5SDOC V-ZT&J:/=V*B"
M6Y$IEBD!CCP"<(Q(R64#/4FKNE^(1?7%Q:W=C/IUS#$DYBN&0YB8G:P96(ZJ
M01V(_&@#E_AS_P C9X]_["_]#7HE>=?#=U?Q5X\=&#*=7X*G(/!KT6@ HHHH
M YKXA?\ )//$'_7C+_Z#5GP9_P B1H7_ %X0_P#H JM\0C_Q;SQ!_P!>,O\
MZ#5CP7_R)&A_]>$/_H H W:*** "BBB@!"0!R<5Y[XB(_P"%S^#3GC[)>_\
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M-(2.3^M;MA_:9U:^^U#_ $0,!;\+TXZ$<GOG/>M:@#F3XINSU\*:[_W[B_\
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M7.?[P]J];!/UKB[3XE>&]3U/2K#3+I;Z[OGV-'!\QMQM+%G] ,!>.YKL^G-
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M8,Z/9#_IA'_Z"*M[:JZ7_P @BR_ZX)_Z"*MT )BC%+10 F*,4M% "8HQ2T4
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M]#:N]K@M,_Y+=K__ &"+;_T-J[V@ HHHH **** "BBB@ K+\1MJ$?AO4WTE
M^HBUD-LI&<R;3M&._/:M3M65XFM7OO#&J6L<T<+S6LB"61RBH2I^8LO( Z\4
M ><Z!JUA<^)=!C\,Z%/:WA+#67ETP0!8]GS;F(&&W[<!>.N:]7V*ZE6'RD8Q
M7F7@[7_$EU)I44WB'POJ&F%S:%[<3>=,R(6*J2 I;'.>X!KTX$B@#F)_ 6B2
M7,DD<4D,;V3V?E1N0JJS!MPST(P,=JT-)T)K"ZGO+J^FO[N6-(/-E15Q&I)"
M@* .K$D]S6FEQ%+(Z1RH[(<.%8$K]<=*(KF*928I4D )&48,,_A0!P7PY'_%
M6>/?^PO_ $->B5YW\.?^1L\>_P#87_H:]$H **** &MVKSVX/_%^[7/'_%/'
M_P!'/7=W[RQV4SP)OF6-FC7U8#('YU\R27]X]R^L-=SC4^7-SN/F*_\ ='/0
M'(V_A652HJ=FSOP6!GB^;E:7*KZGU"H^4>U>?_!C_D1)?^PA<_\ H==MI<T]
MQI5E-=)LN)($>5/[KE02/SS7$?!C_D1)?^PA<_\ H=:G >B4444 %%%% "$9
MI @%.HH ***3- 'G_P -O^0]XY_[#;?^@+7H->>_#;_D/>./^PVW_H"UZ%0
M4444 %%%% !1110 4444 >6VVE^,I/%7BF70M4L]-M7OU.+RS,AD/E)\RGCC
MMWZ&NS\-VGB.UCN!XBU.SOI&<&)K:W,00=P?7FM['.:6@!.N*,"EHH , 4F!
MC&*6B@!,#TKB/B]_R2G7_P#KBG_HQ:[BN'^+_P#R2G7_ /KBG_HQ: .MTO\
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M\LC3W%PZA3+*WWC@=!P !V  [50UC1]<U&XA%M>Z;!:V]Q'/ KVKLX*CH2'
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MBMK=9"0GF2.%4MCG:,Y..<#'>MFJ&J:7;:OITMA=*QAE R48JRD$%64CD,"
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MMH4 1(-.N8I9)VY9YE^<*!V49 /<\U,YJ"NSHP^&JXFHJ=)7;/:<UY[\&/\
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M'@N=4LH94^]').JLN1D9!/H0?QJU;7MO>PB:TGBGB)($D3AE..O(I@6**0G
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M/1****"0HHHH **** "BBB@ HHHH **** "BBJUW?6]A:S75W,D,$*-)([G
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MS>*M"M6*RZM:9ST24.?R7-<.#P5'"1:HK1N^_4J4W,UI9HK="TLB1H,99V
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M[>__ $ 5#\&/^1$D_P"PA<_^AUD^+?%FD1_$C0;H3R26^D-.MY)%$SK&64
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MS$#O@BF5G0 XY4'(Q4E]I=CJ<:QW]G!=(IRJS1AP#ZC(XHDKZ U=6/.;"_\
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MI5G82*5\D6T_FAQSG/IV_.MV-U= R,&5N00<@CZT^@ '2BBB@ HHHH ****
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MSU)]*6]U"UTVSDO+ZXAM;:+F2:=PBISCDG@<D5X5JSZ?JW@K3+R>*:UM;#Q
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MIRWL$L,S,GEL#DY*_?7GM@FNBN/!,5_HEWI>IZSJFH17+1,6GE4E/+;<-N
M,G&?7%69O"&FSZMJ6HRF5I-1L5L)TW?+Y8STXZ\]: $\%7NJWWA/3[K6!;FY
MEA1P\+EO,0HI#-P,,<DD#BNCK&\.Z$GAW2(],CO+NZABXC:Z<,R)@ (".P &
M*V1TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ Q48@A60R+$@D/5@HS^=%%  T$3NCO&C.ARC,N2I]O2LC6/#5GK<^E/=
M/(L6FW2W44,9"H[K]W<.X!YQ110!K&WA>59FAC:5/NN5!8?0UEZ]X>M/$(T]
M+IY4%C>1WT?EMC+ID 'V^8T44 :D<$*1>6D2+&<_(% '/7BA;:W2$PK!$L1Z
MH$ 4_A110 ?9H/(\CR(_)QM\O:-N/3'2GF-"NTJ-N,8QQBBB@!L=O!$%$<,:
M;1A=J@8'7 I&MH'F69H8VE485RH+#Z&BB@ -M 9&D,,>]@ S;1DXZ9/M2M;P
MNY=H8V=EV%BH)*^F?3VHHH 40Q!E81H&4;00O('I]*:UK;M#Y+01&+_GF4&W
M\J** '"&(%"(T!083Y1\H]O2FFV@:-HVAC*,264J,$GKD=Z** )%544*H  &
M !T%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !@>E)@>E%%  % Z 4N!110 F!Z4N!Z444 &!2
M8%%% "XHP!VHHH ,"DP/2BB@!<48%%% !BC%%% !@4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>tm238578d1_ex99-2img30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img30.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Y ?0# 2(  A$! Q$!_\0
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MJFIWJZ=IT]VR[O+7(4?Q-T _$D#\:@L=62?2_MMULMO+W+<*S<1,IPP)^HH
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M-21S_P (A:R:<'<<23.Y4./7]PB?]_#7ISVJ+%*MLL<$C[B)%C'#$?>QW/\
M/%9WAW01H-I-&UW+>75S.UQ=7<H ::0@#. ,     = !0!L 8%+110 4444
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M1110 4444 %%%% !15:[OK6QC\R[N8;>/^]+($'ZTEGJ%G?H9+.[@N$'5H9
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M 4444 %<O\0_^1#U7_<7_P!#6NHKE_B'_P B'JO^XO\ Z&M73^-$5/A8_P
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M**#0 45RDGQ TN.1XS9:H2K%3BT)Z%A_[*?\YI/^%@:7G LM4/..+0^H']:
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M% 'FOB33OB#XDT9M-GTO0H8VFBEWI>2$YCD5P.5[E<?C6M]N^(V?^0)X?_\
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MO_\ D&W?_7%__033_!G_ ")NC_\ 7G'_ .@TH[BJ_P /Y_H;U%%%:'*%%%%
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MV%F=($V[VZL2<D_B23^-%1JUKBA=RO8T:***R-@HHHH **** "BBB@ HHHH
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M -!-2^#,CP9HV?\ GSC_ )5S6CZ7K?BS0+:YU#6DBLKQ,R06UMM=ER05WDG
M..PKO+:".V@C@B4)'&@1%'0*!@"A)IZCJ3BXI1=^I-1115'.%%%% !1110 4
M444 --<1<_\ )8++_L'-_P"S5V[=ZX>X_P"2P67_ &#F_P#9JB70WH?:]&=%
MXJ_Y%'6/^O.7_P!!-5O _P#R)>D?]>X_K5CQ41_PB.L?]><O_H!JMX(_Y$K2
M/^O<?S-;?8^9G]CYF;X[_P"0IX8_["*_TKG+7_DBFK_]=9O_ $;7:>)]%NM7
MO=%EMC&%L[L32[S@[>.GJ>*XNU/_ !935_\ KK-_Z-K6EM\T<M7?Y,V?!/\
MR-NO_P#7&V_] K8^('_(CZK_ -<U_P#0UJ#PKHMW8ZOJ&I2F/[/>PP>5M;YN
M$YR.U3_$#_D1]5_ZYK_Z&M91^->OZG13WC\C2\/_ /(MZ9_UZ1?^@"N:TO\
MY*WK7_7HG\HZZ7P]_P BWIG_ %Z1?^@"N:TK_DK>M?\ 7HG\HZE[G12VJ>C_
M #1W-%%&:1S"$XK)U#5+VWUG3[&UTFXNDN"6GN0P2*W0=R3U8DC"CJ,^E5&N
M9_$9UG2&M-3T^UBQ NH*PB:5C]XQ=\#CYL8.3BM?3=.MM*TVVL+2,I;V\8CC
M4L6(4=.3R: *FD>'K+19KZ>V\YI[Z8S7$TTID=SS@9/0 '  Z"M:BB@ HHHH
M *3'-+10 A% I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA/'MC
M?3ZII5U)8:CJ>@P)*+NRTZ9DE\PXV2;593(!AAM!SSG!KNZYW6_#=Q?ZQ;ZQ
MIFJRZ;J,,)MRXB6:.6(G=M=#CH>0001SUH XN#Q?IWA?P]OTK5UN8+W4S;6D
M6JM)$-,^7+I,SDOA<$@'GY@!QS5FS^)ES>6=Q:VT>FWVK#48=/MI;2X)M)3*
MI<2$\L H5]R\G*\'FM7_ (5YFVDF?6+AM;?4!J(U(1(-LH3RP!'TV;/E*D\^
MM6KGPA>:AIGE:AK\\M_%=I>6MW%;QQBVD087;'SE<$@AB<Y/2@"I?^*?$>B6
M<L&I:59R:C-=P6FFRP2LMO<O+GKG++LVL6]>,=:JZIXWUKP]:ZY;ZI96,FI6
M%@NH6SVS/Y,\1?800WS*P;W.00>*TKCP7<ZE8SIJGB"\N+]YXKFWND18TM)(
ML[#'%R!U.[.=V?IB"\^'\NJV6L?VMK4MUJ.I6BV7VI;=8T@A#;MJ1@]V))))
MSQTQ0!%+XQU;0M0N8O$EI8I"-*FU.(V,CLRB(KNB;<.3\PPPP#SQ66]SXAO?
M&G@2YURUTZ%9Y+F6)+1W9HB;=CL?<,$X(Y'<'CO77:OX2MM:U:.[NY2T TZ?
M3I( OWTEVY.[L1M_6LRQ\#ZA#J>C7>H>)+B_CT<.MM$ULD9*M&8_G<')8 CY
MN.G3G- &98_$2^?Q'IMC>'1F2^NVM#:V=T9;BU.&*EV&4;[N& Q@GO3;?QUX
MC_X167Q1=:?IHTJ&Z,3I$\AE\I9S%))Z# &<<]"?87-/^'=W8_V+;MXCFFT[
M1;H3V=H;2-> &&'8<L0&(SQW)![7)-)M?"GP^N=)N+>\U>W?SU,-M;%Y)?.=
MVV[1G'W\9Z=^* -31-;GU?7M=MEBB&GZ=-';13*26EEV!Y,]L+N4?G6_7,>
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M+FE_]></_H K6&QE+XB\_P#JW_W35/P%_P B/I/_ %Q_]F-7'_U;_P"Z:I^
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M$;2?^N/_ +,:NO\ ZM_]TU2\!?\ (CZ3_P!<?_9C3G\(1^,Z2BBBL38****
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M1=!LM.,GF-;Q!&<#&X]S^>:T<>U**)3;T",+.XM%%%26%%%% !1110 4444
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M^R+"ZM9_+9CO:5D*E<@<#8<YQ0!WE%%% !1110 4444 %%%% !1110 4444
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M;?#[PQ:17D<.FX%[;FUN2UQ*S2QDY(9BQ)^N<@< XKHX84MX4AC&V-%"J/0
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M:?\ PC-K]MT*[\V;?HL3Q0#(PX= AW<>@'3% &Y1110 4444 %%%% !1110
M4444 %%%% !1110 48HHH *0C-+10!6L+"UTNRBLK&!(+:$;8XD& HZ\59HH
MH **** "BFN"4(#;21P?2N4O/[7T_1+B2]NW#/=Q;6M^6"-(-P''7!(Q^5 '
M6T5S]A)MDF:UEU6YF6(E8KT-&C'MR5&#3[?Q"UY;W%Q;6,KQ01_,'8(?-[Q\
M\?+W.>/>@#=HKF?^$J*17I>"WDDM4C?%K<^:K!FVXS@88>F*?/KNH6YO%DTJ
M+?9Q"XEQ=97RCG&#MY;Y6XP!QUH Z.BL&?7+H3W:VM@LT5K$DLCF?:S*R[L*
M,')P.Y ]ZJGQ"MM-?3E_-BDE@2U5W"*-\0;EC]T=230!U%%8NG:VVH+<)'##
M)<02(LBP7 ="K?Q!L#.!GC /%3:Y<SP64,=L_ES7$\<"R8SLW'EL>N,X]Z -
M2BLF'3)[2\BEAU"YDA((FCN7,F[CAE/\)SZ<8[5BP)?)X3CUE-5O#=);?:"D
MKAHW(&2I&.AQB@#L**YG5M6N9?LXL7,<4<\'VB0=R[+^['X')_#UIM_/>3#6
M[N&\E@_LX8AB3&UBJ!SOR.<YQ]* .HHJ."3S8(Y,8#J&Q]17/ZK:31ZO8)'J
M=^B7<[JZ+* % 1F^7CCD4 =)16-8--%K]W9M<2RPPVL#+YAR<EI,GZG _*LS
M5+WR_$=U%<7FHPVT5K'(!:*2 <MDG"G'04 =917-:<FH7VEAC?SQ6IN&=)Y
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MT!4;2QSS_O5?HH HWVFQW>G_ &./$"!T8;%&!M8-C'X5(!=_VENWC[)Y)!3
MSOSUS],U:I!UH R;S29Y+][RSNEMY)8Q'*'A$@8#." 2,$9/J/:HYO#XN'Q)
M<N\+V?V28,H+..<,&[')STK;HH R8M.U)?,>752\OE>7$5A"JO/WBN2&;\A[
?5JC.!GK2T4 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>tm238578d1_ex99-2img31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img31.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &/ KP# 2(  A$! Q$!_\0
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M]4TZVU;3+G3[Q-]O<QM%(OJI&/SKRU/A5XJM-.DT&P\:&+0)'+>48/WB@G)
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M\_6O4*,"@#S[X<Z%?Q+XBU/6--%DNM7AF2PEPQ2/G[PZ<YZ>U=7_ ,(SH/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR:O2J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGD>U(S.@LO&WAC4;X6-EKMC/=,=JQI,"6/H/7\*DU#Q?X<TF\:SU#6[&UN5
M)BFG56 /3@U7USP9H>MZ%)I4EE!!&5Q%)!$JO PZ,A X(I-8T:S3PO>&Y@AN
M[F*P=3<SPJTCE8R-Q..O&: )+;QOX6O;I+:UU_3IIY,A(X[A69L#/ SZ UJ6
M&IV6J6:7=A=175N^0LL+!E.#@\BN7^'&F6'_  @/AZZ^Q6WVC[%&WF^4N_..
MN<9S7(>*K^Z^&GB">/19K1+3Q%N:.WG<*MG=$@&;']PYR?<4 >KV^J6-W=W-
MK;W44MQ:D+/&C M$3T# =#5NL3PMX<MO#.B1V,+F65F,MS</]Z>5N6=C[G],
M5M&@#,U/Q)HFBSQ0:GJMG9RR_P"K2>94+>^">E79;VV@M6NIIXX[=%WM*[ (
M%]<],5P?@6QL_$#>)]6U*UAN9[S5)[9O.0-B&/"*@SVQG\ZY33<WMIX:\+73
M-+IT7B&[MVC<Y$D4&6C1O51D<'TH ]=TO7M)UR)Y-*U&VO40X<P2!]I]\=*L
MW-_:V;0+<SQQ&>40Q!VQO<YPH]3P?RKB-=MX-%^)7A2\L88X&U#[1970C0*)
M4";DR!W5AUK+\4:%=6OC+POJVH:K->SRZVL4$6 D5O$5<A54=3P,L>3B@#U.
MBBB@ HHHH **** $)P*\1U'P;KDOBAM'N(+2/1)=;.K37S3JK2(>D94G.1R!
M]:]N/2O 7L_ 5SXS\2_\)MJKR7RWS>2XED$?E8X4;.Z]"#Z<4 >D?#RROX_[
M=U7488;>?5-0:<6\4@<1J%"C)'<XS3_B)XEO]!MM,L]*BMFU'5+D6T$MW_JH
MO5C^E.^'MMX1M=+NE\'S^=9F?,S>8[X?:.[\],5N>(O#FE^*-+;3M6MA/;D[
MU^8JR,.C*1T/- ' OHGQ4B1KC_A*]"DP-WE-;*$/MGRZZGX>^)IO%7A9+ZYM
MXX;J.9[>80_ZMG7JR^QR*YI?@9X7WY:]U=X_^>1N1C'I]VO0M'TFQT/2X=-T
MZW6"U@&$1>?<DGN3ZT 7J**CFFC@ADFE=4CC4L[,<!0.230!)15#1]9T_7M.
M2_TRZ6YM7)595! )!P>M7Z /-?A'][Q;_P!AR:O2J\U^$?WO%O\ V')J]*H
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MVQC^T:K<R2JF(P,K$N>K,<9]OQKU&N<U;P+X:UJ[GO+[1;.>\E7#3R)EB0,
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M_P!AR:O2J\U^$?WO%O\ V')J]*H **** "BBB@ HHHH **** "BBB@ HHHH
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M[N&. #USBN@O6O&\$W3:BL2WK:<YG6+[HD\L[@,]LUJQVEO%(98[>))&ZLJ
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M5&_\1:5I>?ME]"C?\\P=S_\ ?(R:\2O/$VM2:C=R1:UJ(A>:0QJ+AU"KN.T
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M_$L5Q-Y\Z:O(LDI&/,8  MCMDY->HT %%%% !1110 444F1ZT +129%(3WH
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MUH.\)->FAS7A#PD/"EA<VPOGNS/+YI=XPF/E Q@'VK4UC1K77=)GTV]#FVG
M#A&VG@@\'ZBM&BES.]S*4G*3DWJSS[_A37A(C_5WO_@0?\*[JTM8[.SAM8L^
M7#&L:9Y.%&!_*IZ*J4Y2^)W).-\;^ 8O&DMD\NH26GV57 "Q!]V['J1_=K'\
M/?"*W\/Z_9ZJFLS3-;,6$9@"ALJ1US[UZ515*K-1Y4]!\S$VUS5Y\/O"VH7D
MUY=Z1%+<3.7D<LP+,>IX-=-16:;CJA&5HGAO2?#L<T>E6:6R3,&D"DG<1TZD
MUJD<444GJ[L!,48I:* "C%%% !28I:* $Q2T44 %%%% !1110 4444 %%%%
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MQMI+FZFCA@B7=))(P55'J2>E $]%<M9_$;PC?WL=I;ZY;M-*P6/<&57)[*Q
M!_.K^M>+=!\.20QZQJ<-F\REHUDS\P'7H* -JBL'2/&OAK7KK[+I>LVMS<8S
MY2MAB.^ <$_A6W)*D4;22,%1069F.  .I- #Z*HV.LZ=J>EKJ=G=Q36+*S"<
M'"87.3D]A@UGZ5XS\.:Y>FRTS6+:YN0I81HW+ =2N?O#W&: -ZBBB@ HHHH
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M#TI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:*
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M_0$'_@1)_P#%5L^%?"<?A8ZJ8[M[C^T+U[MMR!=A;^$8ZUT= '!_\*;\"?\
M0$'_ ($2?_%4?\*;\"?] 0?^!$G_ ,57>44 <'_PIOP)_P! 0?\ @1)_\51_
MPIOP)_T!!_X$2?\ Q5=Y10!P?_"F_ G_ $!!_P"!$G_Q5+_PISP+_P! 0?\
M@1)_\57=T4 >&>"/AYX7UCQ/XOL[[3!+!I]\(K9?-<;%^;C(//0=:[?_ (4W
MX$_Z @_\")/_ (JMCPYX3C\/:SKNHI=O.VKW(N&1D $9YX![_>_2NDH X/\
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M(D_^*H_X4WX$_P"@(/\ P(D_^*KO** .#_X4WX$_Z @_\")/_BJ/^%-^!/\
MH"#_ ,")/_BJ[R@T >&+\//"_P#PN5M _LP?V:-+^T"'S7_UF[&<YS7;_P#"
MF_ G_0$'_@1)_P#%5L#PG&/'Q\5?:W\PV?V3[/L&W&<[MW7-=)0!P?\ PIOP
M)_T!!_X$2?\ Q5'_  IOP)_T!!_X$2?_ !5=Y10!P?\ PIOP)_T!!_X$2?\
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M"]<*,=ASS0!Z%1110 4444 (>G%>;ZIX]\3OJ6LIH'AR&>PT;/VB>\D:)I<
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M,84L!T!K6HH **** "BBB@ KG)O /A.XFDFF\/:>\LC%V=H02Q)R23ZUT=%
M%33]-L]*LH[*PM8[:VCSLBB7:JY.3@?4TVRTFPT^XNI[2SA@ENY/-N'C7!E?
MU;U/)J[10 4444 %%%% !6+J_A'P_KUS'<:IH]I=S1C"R21@MCTSW'UK:HH
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M!R.*RK;P+X5L[J*ZMM L(IXG#QR)" 58<@CWKH:* $'2EHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>tm238578d1_ex99-2img32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img32.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (+ KP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHH/2@!I8#O1N'J*Y#Q&-4M?$=KJFG6]Q<"&T:
M%X8^0XD<#./52%;Z!JP[-O$&C6NFV4(O7:.5S)NB:039G(;G!Z+SDLO!&,]*
M /2]P]11O'J./>O.DN/$$TD3O-?R-!>(>("B/N23Y"I4$ $)D<CD?-Z6]%G\
M1WEQ9+=74ZQ-*&N5%NRF,["60LR@;=V ,9^M '=;@>A%&17!ZII>HZGXCDC6
MTB:!9I-KSJWEX\F/!^4@YSG'T(JE-IFI6FHO%:?;+O4?),*7,R.A5A;[1()
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M2+J0\9NV+H1G5>." 4]O5<5Z<O2G)6&U8=1112$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4'I12$T ,;@9/ KDFUN]CFOK^2]MX[.TNY+=K-D^=U13T;
MJ7)Y Z8KK'D1?O,JCW.*H?V3I<U^U]]EMI+IA@R[02>,?GCC/I1<#D+CQI?W
M"P26]L]F"KY$JEA(/W14@D ]'(/'7UJ[KNN:I9>)C;6SG[+$EL7_ '"LH\R1
ME8LV<KP,C -;D>BZ) HBCM+50&)"X'!.,_\ H*_D*FN-(TRYO$U"XM87N4 5
M)G ) !R/R)S2N.S.?3QN9[W[)!IA>:298X#Y^$<%G&XG'^QGC(YZ]J71/%YU
M;6TLE@8+/;1W*JS "%2O(S_&=W&!]:VK?1-%AN3/;65JLV_?N0#.[).?S8_F
M:L1:+IT#0M#9PH82#&57[N!@8]."13%L7E'()ZT^D'&*6@ HHHH **** &D\
M5AZM?-;:]HEMY:LMU+*C$GH/+)Z?A6S(ZQH7<@ #))KDM;O7FU_01;!P!-*3
M(5']P],T75RHQ<MCK0RKQP,#M3E<'IR/:L%V>1=LDKLOHQX/UQ3[>>:T)6,(
MZ$YVDX(/L:R51-V-'1=KF]FDJM;727,6]<@@X93U!]*L9R*TN8^1C^*+MK'P
MYJ%TB!FCB. 3@'M_6M&V<26\<VT*9%$A ]2,US_B^^5_#.I11*TC^7@X' Y&
M:GBEN'M8?,FD!,:Y PHSCVI.2436-.4D;ZLI. <_2GUST1:V<20E0Q&"&Y!'
MO6G:7XF?RY$V28R!NR&'J*F,TQ2IN)>IK#-&<U7NKN*V \PDEN@49)JV[&:U
M,O1=0.H7^L1/$B_9;PPJ1R2-HYK;W*.IQFN,T2>X;4==.6B!OCA=H!QCUK4>
M,2$F1V8XX+-R*B51)V-E1;.AS2UD1:E)'C[0JE,\R)QCW(K45L@$=",U2DGL
M9RBX[CZ***HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFZE;:M:M<6;EXA+)"6VD?,C%&'/H0:O4 %%%% !1110 4444 %%%% !1110
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M&DC-Y=;)&))=3.^"2>N1@_C77U"NQ/E7:.>@P.M2@YH 6BBB@ HHHH ****
M"BBB@ HHHH **** $;M]:\FBN]6TOP?I_A^RCNTURQ9+=K)M/,L5R!*,R>85
MV[=N6SN'->LXI-I]<?2@#R=M+N9/&$XNYI+?4#JXFMY5TV261H0P*[9@=HC*
M9# ].>"<4_2=#-K:>'K^VL7AU*35[@33;2',;+-PQ_N\)UXZ5ZKL]*0*>YH
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M=?QHHI#LBS%?NC 3_,O]\=1]15^WFFLYQ>:>X5SRR_P3#T(_K6,15JPE*2F
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M8?X3P,>U[16["3N8X7D5&<JI8(O5L#H*XW_A-]6X/_"#Z[TSTC_^*KMB,T@
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MK\LH/) (XW$5WV!Z44 ,CZ?U]:?110 4444 %%%% !1110 4444 %(W2EHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 F*-M+10 F*7%%% "$ GFN;T36KO4/%?B;39Q&(=-E@2$
MJN&(>(.<GOS72'K7&^&ACXB>.!ZRV1_\@"@#LQTI-M+10 F*7%%% !BBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHI": %HI,GTHR?2@!:*3)]*,GTH
M 6BDR?2C)]* %HI,GTHR?2@!:*3)]*,GTH 6BDR?2C)]* %HI,GTHR?2@!:*
M3)]*,GTH 6BDR?2C)]* %HI,GTHR?2@!:*3)]*,GTH 6BDR?2C)]* %HI,GT
MHR?2@!:*3)]*,GTH 6BDR?2C)]* %HI,GTHR?2@!:*3)]*,GTH 6BDR?2C)]
M* %HI,GTHR?2@!:*3)]*,GTH 6BDR?2C)]* %HI,GTHR?2@!:*3)]*,GTH 6
MBDR?2C)]* %HI,GTHR?2@!:*3)]*,GTH 6BDR?2C)]* %HI,GTHR?2@!:*3)
M]*,GTH 6BDR?2C)]* %HI,GTHR?2@!:*3)]*,GTH 6BDR?2C)]* %KC/#A_X
MN3XU'O9'_P @UU%_?6VFV4MY>SI;VT2[I)9" %%<IX#674;K6_%,D31)K-PA
MM8W&#]GB0(C'_>Y/T(H [:B@=** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 0FN 6YUCQU?70T[4Y=+\/6TS0"YM@/.O'4X;:Q^Z@/ /4]J[J
MY8K!*PX*HQ!]\5RGPN15^&N@[1C=;;C[DL23^= $7_"MM.8Y;6O$1;N3JDE+
M_P *TTW_ *#'B+_P:25VM% '%?\ "M-,_P"@QXB_\&DG^-'_  K73/\ H,>(
MO_!I)_C7:T4 <5_PK33/^@SXB_\ !I)1_P *TTS_ *#/B+_P:25VM% '%?\
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M4?\ "M-,_P"@SXB_\&DE=K10!Q7_  K33?\ H,>(O_!I)1_PK73?^@QXB_\
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M?\*UTW_H,^(O_!I)7:T4 <;;_#3P]%=QW-TM[J3Q'=&-0NWG53Z[6.*Z]5
MX&!P.*?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#=
M?\>D_P#N-_*N7^&'_)-/#_\ UZ#^9KI[H_Z+./\ 8;^5<O\ # @?#3P__P!>
M@_F: .OHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X_XB
M:UK/AWPM/JFD6]K<>2?](2Y5S^[/!*[6'(R*YSX*ZOK&I>&1!<V]M%I=@!;V
MKHK"24C))8EL=^PKTRZM8;RVEMKB,20S(4D1NC*1@BJ'A[0K/PWHEKI-BK+;
MVR;5+=6/<GWH U0>*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1C
MB@ )]Z,UPOB3Q/)%XB_LJ$SQ>7"3YD9QF4KN7/\ LX!_/VK1T3Q=%J^M3Z:M
MN\?E E921\^, \=NM5R2M<KE=KG548%-%.J20HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "D:EI&Z4,#R/Q40/B',?9#^'E58\#?\CQ=_[DG_H5=E?Z
M?:W?B> 2Q(QDT^=2Y49QN0=?H?U-7=,T6'3IIYU_>SSD>9,RJK$ 8 X'_P"N
MMG4]VQIS:6-4=*6DYI:Q,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**3- "YHJE/J=C;2RI->01M$JO('< H&)"D^@)! JSYJ=R.>G- $E%1>>F,A
ME_.F07<%U"DL$R21R#*,IR&'M0!8HJ+SX]I;<, 9SGM4-IJ5I?0B:UN8YHB<
M;T;(I7 MT5!+=P0)OEF1%. "S8SGI2QW,4J*Z2*4;&&SP<]*8$U%("#TI: "
MBBC- !1110 4444 %%%% !1110 449HS0 449HH **,T9H **,T9H **** "
MBBB@ HHHH **** "BBB@ I.U+4%S,88&<#F@"6E%8AGE+Y\UO7BM*SG,\9W?
M>'4U3C8A23=BU1114EA32:4FLJYNI'D*HQ55)''>FE<ER2W-3O2UEVES()51
MV+!O7M6H*&K FF+1125-RA<TF156[N# @ ^\W2J*W<ZMNWY]JM1N0YI.QLT5
M'#()8E<=",T_-26+129I: "BBB@ HHHH **** "BBB@ HHHH *1AFBD8X% '
M 7M]=K\5K6W$[B$1J@0=-K+DC\P#^%=^O2O/=2-I%\5;:66Z*$1*6!3@,%P!
MGW'>NP76K7&0)B.Q\IN:JHTK>A;3=K&GFD# UC3:O-,"MK R'_GK,O ^B]34
M45[<V<R/<3^= Y"NS* 4)Z$8[5BYJX_9RM<W\TM1AL_2GYZ"M#,6BBB@ HHH
MH **** "BBB@ HS13'Z'I^- #MP%&:XJ274KK6;Z/^VKR&..Y\I4MUB"A=BG
M^)&.>?6G7$.HQ2!5\0:I@^OD?_&JAS1#J)'9YI":X^Z@U&$)M\0ZISUSY'_Q
MJB>#4(X59?$&J;B1_P \/_C='.A>T0>(? =MX@UF349;ZXA+QQ1M'&@*D(68
M9SU^8J?;;[U2C^&^U9M^MW$GFM*?FA7Y-X097G@_)U[Y-7)(K^.R$Y\0ZF/4
MGR<?^BZIRWDL5F[/XKODGVDJC/;CG\8ZEU8K<I3N,N/APQO4>WU1H[<R%F0I
MDHO)&WGE@3@,>@ X-.E^&R>5&MOK%S$L8SM10N6\O83GL3U)P?I6>]_K$=S-
M'_PD>J[8XPX8PP@'IZQ>]/CU#4KAD1?$UW'NB\P$O!^7,58?7*5KFO(S0\.^
M Y].O(M1OM1S<B.5&MX,^2H?.-N<= ><CD\\42_#B)[*ULX=6N(H88(XI%"Y
M\TH&&[)/RYW'(&>@]*HVMUJUT;<KXFOCY['Y1Y .,^GE4XRZ]]G,Q\1Z@H\[
MRL[8".N,_P"JK/\ M&EY_<'LV76^',1#@:DQ&]9(S);JQ0A@<9S]W ( [9SF
MFQ?#6)2-^L74@4?*&0=<-ACSRP+<'L !4?VJ]AFDCG\3:B1')M+ 0=#TZ1U/
M/+=K)MC\0ZMP,D%8<@<?],O>MXXFE))I[F<GRZ';I\J@$Y]Z?FN-N(-0BC5Q
MK^JKGL?)_P#C5+);Z@ML)!X@U3)QU\C_ .-UMSHCVB.QW4;AC-<<+?4#:>9_
MPD&J;O\ MA_\;JG?/JEKH-]?IK^I-+;PO(JMY.TD+D XC!Q]"*.=#51'>@YZ
M4M-'!Z]Z=5EA1110 4444 %!Z44'I0 W-&:Q]7U2:SE6*(+EEW989K-&N7PY
MW1_]\?\ UZQE6C%V.B&&J3CS1.JS1G'>LO2=1DOEDW@90CIWJ'5=5GM)_*A"
M9*[LL,U3J)1YB%2FY\G4VLT9KE/[<ON[1_\ ?-;&DZC)?1OO50R8Y X-*-6,
MG9%3P\X+F9J4A-8FJ:M/:W'D0*@.,DD50&MWXY+(?^ ?_7I2K1CN5'"U)1YD
M=6#2UF:5?27T3LZ@%"!Q6D":UB^97,)1<79BT444R0HHHH **** "BBD)H 6
MH+B+SH64'D]*E+ *2>E94M[)(3L.U>V.M-(B32W(C;S!]OEFM&TA,,9W8W'D
MU0^T3=/-:@74RMGS"?K6C39"<5L;&:7-8M]K/V6W0HH:9_X>P]_UK.@\272R
M@SK&T>>=JX(%2J<F-U8IV9U1K*N;=UE9E7*L<\5//>X1?*/+*&W>QJJ;J;_G
MH?PHBF.331+:6SF57=2H7D9K3]ZQ_M4_7S":=+JC06DDCJ"RCY<=S0XL2DD:
MV30#7#OJE[)(9#<.K'H%X'Y5T&DZJUS:2-/@O$0"?[P/0TY4Y)7)C5C)V+E]
M T@#J,E>U9XC=F"A&S]*L/?3$\$*/3%-^V7 _C'Y46EL$K-W-*WC\J%4[CK4
MF>*S([Z8, V&7V'-8VI:U<R3O'!(8HU)&5X)I*#;&ZD8HZS<,X[TZN6T;5YV
MNTM[A_,5SA6/4&NH!I2BXZ,N$U)70M%)GVI:DL**** "BBB@ HHHH *#THH/
M2@!I.*S;G6(8Y&BB1YY$ZK&.![$]*FU2X^SV$K@_.1M0>K'@5E01&*)8DYV#
MG_&LIS:T1K2I\VK.,O7DN?B; UPBAFV$)]X!=N._6NVY]:XZZN9Q\1[>(2L(
M]BIM'3!7)_45V"G)((Q@TJ[;47Y'7%6V%I&5#&,D-D892.,>E#+NP,D8-+[D
M#FN=#=V0I#)"/]'NKB+T4/N'Y-FM#3]2=YOLMU@3XRC#I(/;W]JJYQ_A4<L7
MFIMW%6!#*PZJ1T-5&33,YTTUYG1!L]Z=6'%J\\)47< *?Q21'/XD=A6TK9 .
M<UUJ2>QQN+CN.HHHIB"BBB@ HHHH *8Y/89I],?!4\9]O6@#C;;?_;NI;P#B
M]Y5>G^K2K5^K+*,(V0F?KS7/7<4J:EK$D=JV%O0,!@,?NTXR3WJ:>-Q->!=-
MV/$ T9>7(0Y'/O7E5,7:;A;R(=#2]Q;G5KB698UV.%3YF5,!7_N<GD\TCZS>
M20PB2!(P2/,)Q^ZX)&>>,CUJU/HL4-HD!NKIAYWGL=R_ZP$'(X[D9J6]TJ)[
M><M<77^E%!+^\'.!@ <<<5LZ4D_B,W42OH9DNHW]SIAC8+;A5W$[274#.& Y
MZD8I+.UMIHX&D5F>X'F2,UN3AAVW'[O.>,ULI9+%']K^T3O(8EC.]P1@$D=O
M<_G5F(;M/D7)PV0<''%5[)/66K)=1WTV,BRMT,-H[>86EE,4F9&.Y1N.TDGH
M,#\JKB!)8YVD8R&"\AMHSP"L9:/(RN,Y#$'/6M6STR$Q1B.6XC$,F]%64D;L
M=\Y/>H['38I'N%GGFF62838W[<,,8/R\_P (_*G[*%[\J)4GIJ4+BTAWZHWE
MG-O"9(26)\MMI.5R>.E-N=-9;E[&S:41C;<"(.6W'/(.XD8ZG\*OIIB37%XG
MGW"?:%9'((.%Z< CC@TNV:#66G=ED@6+8Q"EG.,G.%'O3=.,E9H(SDK-,P[@
M,(;LA(6:Y:.6!7AV.4!&2"N0.^>G2KK7/E7=T?)BBC:W 9U;<N2%].GXTZ&X
MB^VZ%&[!)/)<>7*-C= /NM@_I4U]&!'9J,KYD[1N%)&Y26)! ZC@5P3P*MH^
MG^1T1Q+6XV2YCL8H)+F15$D092FYBW7J/IBM9YHY+-521&) ( /-8ZK+83M^
M\#01[X1$SX*_("2">/XNGM5*2;30+<W*O;.)-\\LD97]V<X.>AZ=JF-6K13@
MXW'*%.>M['4*3_9_&<?_ %ZSM7!/@[6.#Q:2_P#H)K.6(&T#)<2KNNO+1=__
M "S)."!W&"*@UZ(P:!KL?[R01H L@;  .,\9JECX\RBXZL%A[ZIWL>GC[WXT
MZFC[U.KVB@HHHH **** "D/2EH/2@#F=?1VO(V"DJ$QG'N:QW<(K.QP ,].E
M=%KCO&BF.81G/0GD]:YR^O+AK&8&<D%#7!7M&39Z^%E*4$EL+I7B:WL7F4P2
MN&(PPP!Q3;_7K>^O0XC>-2H +<USL&3'SD_4TDQ*R)AL'(_G7%[>?*H]#U'@
MZ49NHMSI))!%&SOP%Y/%+I?BBWL#*C02L"1@\"F:C<SMITZF8D;,8KGX#\F,
MG^E5*JX37*90P\:T&JAT-[KUO?7^_P MXP0%&<<FEDE$43.Y.U>O%<ZS%9XR
MK$$.#G\:W]3NYVTV96F8@CH!]*:J.2;EN.5)4W&,";2_%,%D)4,$C;FSNR *
MVK3Q;9W4RQ%)(RQ !."*X&W)*#D_G5FT_P"/^US_ ,]5_G3IXFHFH]"*^ I-
M.;['JJDFG5&#@FE+'W_"O8/FQ]%%% !1110 4AI:0T 077_'M)]*RU4&!V[A
M@,UJW?%K)]*RU_X]I/\ ?%7$RGN1"I85#F3(SA":CI1.ENDLDAPNPCZ]*T?D
M9IZF7JMO(P6=5)4#:Q';TK,1'FD6.-=SL< #FM5-=EBW".%"K==W-*FO21ME
M+2W4^H&*T7,E9(Q:@W=LTH(/+>*%N2H"G/T%(1\QP.YK(G\1&WCENY81F-2X
MV=,@<5YQ=ZG?7]RUQ<7,ID8YP'("^P [40IRD$ZL8K0]=[<T7MJLX>W7"[L;
M?K7)^#]:GO8YK.[=I&A7>DC')*]P?I6M>:M+-<%H'\M,_*1UI.$E*Q7M(N*9
M ^GWD<FQK>3<./E7(/XULV=@]C9$S</*XR!Z#I_.L@:KJ'_/W)^E!U.].-]P
MS '.&IM29,7!.YNN@$43*.6!)_.FX^M>>^)_$5W>7*V43O#! NU@AP78\DY]
M.16?HFMW>FW\69Y'@9@LB.Q(P>_/YU2I2Y;B==<UCU4*/LY8CY@V*PKO3YXV
M,BQLT3<@J,XJ_>ZC]FB\B, N3DD]%%9ZZK?J,+<NH] !_A6<;K8J;B]RYHNF
MSR7L=Q)&T<<9W<C&XXKJZXK^V-0+#_2G./50?Z5#K7B^\L]&94 %W(P2.0#I
MZGZU,H2DRJ=6$59'=[N:4&O UU*_%Q]H%]<^;G=O\TUZ]X0UB36]"CN)L>>C
MF*0CN5QS^1%*I1E!79I2KJH['044"BL3H"BBB@ HHHH *0\"EI&Z4 <]>,\V
MK2)*QVP[6BC)XZ?>]^<_2EQTXYQCCBG7\BS:LNSI!$0[=\M@@?I^M(*Y).TC
MNI_"8<OA_P [Q1'K N %C"YBV$G@8ZUN$X')]^O2D)Q69JEP=XMU.!C+^_M4
MN3:2?0T2)Y-4@C)5-\I!ZJ./SI@U6$X#QR(/7 (_2LO%+4E<IT,,R2 21,K#
MV/\ G%.9MSDG&3V]*YZ*9[>7S(^/[PSPPK?C9)465.C#K3):MJ17*F7RH <>
M=*J'Z=3_ "KI%Q@"N=G7S(SM;:Z'<K>C#D5LV=S]HL(KEE(WH&88Z<5M2.6N
MGH7!THKCO^%CZ2I*G3]=R"0?^)5-V/\ NTG_  LG2/\ H'Z[_P""J;_XFN@Y
MSLJ*XW_A9.D?] _7?_!5-_\ $T?\+(TC_H'Z[_X*IO\ XF@#LB<45Y=XP^*:
M6&@-<Z/9Z@EVDT?_ !_:?+'$5)PP+, .F<5I^ OB5;^--T']G75M>1KF0A"\
M'X2#@?0\T =XU<Y;ZS=W7B2YLXE0VD7!WQLKC &2#T/)X'/X5T+<CGI7+6"B
M/QG>)]Z382. /D(7'/UW#U&.: ,E+2:;Q)J3QQDVQN65HY'8$MY:8)[8_P :
M>^G7\;6:L$+!LW#"1_W@[?7&>];&E\:EJ0WM)_IQ^8]_W:5I77^M7GL*\RHX
MW;Y>H*DWU,^^C;:@VMW[>U+=HWV5,*<Y';VK2O.0@^M%T/\ 1T^O]*J5;5Z$
M_5T^IF.C?V>N5;MV]Z2%&%DYPV>>U:C#_0Q^%$7_ !ZM^-/VSO8/JZWN9EE&
MWEM\I_+VI+%&WOE2?P]ZU+3_ %;?6FV?WV_#^=$:S=O,/JZ778R[9&%X_P I
M[]J4(W]HY*MR?3VK2A_X^6_&E_Y?_P :7MW;;J'U=;7,NZB,EV@*YSC.15*^
MT>)?LZ6Z-;(DGF;8DX+>^?J:Z&8XND_"B['SI]*'6:3\@^K+N<U?PW MIVF@
M"*]RCIAMQ(PHZ=NGZTNJ(_\ 9NK#:Q_T1..O\+UOZE:P7=O&D\2R(#D!NF:A
MN=)LI+24F'!F4)(ZL067ICK5^WLY/T#ZNNYSZZ3:O=Q;8##(]KN+0_*Q.X?,
M<?X5B:C//'X2U&.Y+RM=6HD67&6)&"<^WOV[UW<&GF*>*Y2X;RTB\D(PSQG/
MWNO:L+4O^1%<=O[-N/\ T 5C4M6:BRHTN1WN=V/O&G4WUK UGQ?8Z%>K:W5K
MJ<KLF\&UL9)E ]"5!YKTT!T-%<;_ ,+)TC_H'Z[_ ."J;_XFC_A9&D?] _7O
M_!5-_P#$TP.RHKC?^%D:1_T#]=_\%4W_ ,31_P +(TC_ *!^O?\ @JF_^)H
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M7&<1LWY"H<UF:KK<NE+Y=MM\^6-@6/(53W^M*S>PM%N5=4\/W=Y.]U8Q>;D
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MQ^A_G6)K/_(M7O\ UZ7/_H IQI)23)E2M%L]%QS^-&#ZTO>EKM.$3!HYI:*
M$YH(-+10!A+X2T;^WYM=DL(Y=2EVYFE^<K@8&W/ K: QUI](>AH J3_Z_P#
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M:'I>K^7_ &CIUK=^7]SSX@^WZ9Z52_X0KPQ_T+VF?^ R?X5NCI2UZI\\8/\
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M9/\ 5OYTX?\ (8'^]_2@'O\ (6\_Y"<7_ ?YT:KS/%_NG^=%Y_R$X_\ @/\
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M)&UK)(VFP-#?1W133[(0H0BLN..2<MG)Z4NI>$;G4/$$=^UW;>5'<1SQR&V
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MMP>+H;N2Q2!+BUE?4?L4]M<6X\Q6V%]IPV%R "&R1@UFZ'XRN7M;W4=4AO\
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M$>GZ.Z6W]FV6IF]6]$F7D42-(J[,<-EL$^@-3:3X9U&SMO#$4HBW:=?7,]P
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M3-(T317KA"LBG# 9QN''4=J ./BT.^DD6\CM]19Y-5LY)OM-M%!A(PV7"IV
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M+,9G>,%AA]BDX7=WP*N:?X+T33)Q-;6TNY8&ME$MQ)(J0G'[L!B0%X& .F*
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M[%E+?5C75UB:%I,UE+J%[>2+)>W\_FRE/NHJ@*B+[!1^9-;= !1110 4444
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( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>tm238578d1_ex99-2img34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img34.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #K HH# 2(  A$! Q$!_\0
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MU9V%HI,T;A[_ )4A"TA4$8(XI0<C-% ";11M'''3I2T4 -V*>HI<#TI:* .
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MQ8=2<\U$U@)01( RD<BL(U4G<E22=R3X<H4\**I//VB0_K765FZ%9PV.FK#
MNU-['&<\DUI<U,GS2;.>3O)E#6-9M]$LEN[I)C 95C9HXR^S<<!B!SBO.+&3
M1;ZPM=(3Q=?OH<JQHNG3:?ERA(Q"9O+^Y_#CKCC=7JS# R.O:N1A^(OA 7<>
MG6VI[G\P6\:P6DS1AL[0H94VXSQG.*@@Z\=*",T#H*6@#.DT2PE;4#);(_\
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MH%OI=E'CN(%S^)QDU?I<4N9FJ2&HBQ@"-50>BC%+SGK2T4ACHO\ 7)_O"NX
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M8HF]@.%SC)],UQ'_  E>KR>&)+E;:UBU276&TR!&)>*,^?Y8+$8+84$\8R:
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M@M?W6!#Y/E>5OSLVD_Q[LG.:W?#^AKHNGR0/</=S3W$EU//(H!>1SDD#L!T
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M CFM"^'V@Z-IWV::RMM1E9R[SW=LC-GT (.T>U:O_"+>'O\ H :5_P" <?\
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M'3IWKK-,FCFMF,,<D:J1PPQN! (8>Q%6I)%B4L^>F:P]LXMJ)',UL/ "@ #
M  'X4=,5$LX+["N#C.>HJ45S=3/J8]RKJS*X;&?F(ZGZ&L+5=(;40I64HZC
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M;^)_M2A(=.>R^S[#DDR;]V[/X8Q71B@#@O\ A)OB'_T3V'_P<14G_"3?$/\
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MGD\[[.6C@=D$F,["P&,X]ZV.HXI"YF9AT=3_ ,MF_(5EZCX+M-17#SR(<8!
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M&=P)!!!Y!!R*YZZ\&Z?>"=9[G4&CN41+N,73!;G: HW_ %4 '&,CK71*.30
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M6P#L90>W2IKZQ^Q:=H2WM_;+=W-O/?SVVL2/'9RRRD.X$JGY9$SM4$'Y<]Z
M/9J*YSP+<_:_!.D3[;E0UN,"YE,KX!(Y<@%AQP<<C%='0 4444 %%%% !111
M0 48HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &E W7FC9[FG44 96LZ#;ZY'!#=7%PMO'*LDD$; )/M((63C)7('
M (K39 PP:=10 @&!C.:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>tm238578d1_ex99-2img35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img35.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &  B8# 2(  A$! Q$!_\0
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M JCH!],5+W% 'D_P5GOFE\46E[J%Q>_9+U(4>=R3P&!(R3C..E>LUY-\&?\
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M]J]!" # Z4,!WH \E^&=IK5WK\:ZU;2I%X9M'TRW>52!)(9"#(N>O[M$&?\
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M%,]QJ$UVIB! 57Q@<]^*ZH=*6B@ HHHH **** "BBB@ HHHH **** "BBB@
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M^6.Y#8\:QJF>S1_^@UJYXXKC[?Q5IT5_>SMYNR8J5POH,5M2Z]9HBB M<3.
MRQ0C<V#Z^E<M'$4I1?+(Z:M"K%KFBU_PR,S7?%#:;?26(MM_[K(?=CK57P_X
ME,DEEIGV7"D;-^[T%9'B)+RXU=YI+*2,F-<* 6P/?'>F>&X9O[=L7:&0+N.6
MVG'0]Z\6>*K_ %OECM>VW2Y[$<)0^J<TK7M??K9GIT?3GK3Z:@ZTZOISYY!1
M110 4444 %%%% #6^Z:\SOK'QCHGQ"UO6/#WAR&_M-2CMQ*T]ZD>YHTV@ISE
M1@D$,#DC.><#TQ_NFN-UOP"VMZQ-J/\ PDNN60EV_N+6<+&N %X!'&<9/N30
M S3-;\>SZI;Q:AX-M+6S=P)IUU1)#&O<A<<_2NU4CTKRBY\/2>#/%/ARYG\1
MZUJ-G>7ZVA@N+CE9""4; QN7( (([YSQ7JX'- #JBFC$B%"Q&01E>"/I4M0W
M2/) Z(Y1F4@.!RIQUH \'^(_AO2?"?A9M T[1;FX:YE6ZGUR[3S/LX+Y.75<
M]L$8^ZQZG@S>-PMS<_#70/MZW^F2+ 7E4?+<[2B[L>A&>O3-:%Y;_%27PWJ7
MA:XTJ+4?M9DB&KR7<8'E-P<KG@X]N]6O$?PWU6'PWX4DT8)>:MX>*-Y9<(L^
M&#L QQQD<9Z@T 54MX_#7[0HMM-7[/:WNG>;+!& L9(C?^$8'6,'ZDGO6#X9
MT6PU?X4^.]:O[=+C47DN9%N91ND4QQAUPQY'S$G\:[+PQX9\0:I\1[OQGXEL
M!INV 06MEYZ28&TJ<E2>/O'ZM[5S_P#PB/CKP]I/B/POI.E0ZCI>KR,T5[]H
M2(Q*XVME2V?NX'% '3^"_%KZ=\';#5[NTO;TVO\ HYCMU#R. ^T$ D=B/RH'
MQHL">/"OB<_]NB?_ !==?X0T$>&_"NFZ3N#-;1;78?Q,>3^I-;N/>@#R'X'7
M N[GQ==+')&LU^L@6089<[N".QKU^O)?@Q_R%?&O/_,3'_L]>M4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(
M3B@"M?W4-C9SW=PX2""-I)&]%49)KSWP]JMI;V&I:GJ+3)J>O'[8T9C+>3"R
MXMX\X[1X)]V:MCQI(VKWFF^%H)@IOG\^]QVM(R"P/^\<+^=8GBL*OB6=0N/D
M3@=AM K@Q^(E0I<T;:M;G=@,/&O5Y)=+O0ZC1/$.GS0V.GI([3^6J<QG&<>N
M/:E\0>&EU:2*]L;@V&M6O-K>H.G^Q(/XXSW7^1KD?#/_ ",%E@8 8_\ H)KT
M[ QT_P :SR[$RQ%*\NG8K,</'#UN6/57U]3PS4/CUJEO<K:VVB6)EA_=7+O.
MQ1Y%)#&,@?<XX)YYKM="^*]EXATR%M/T?4KO5&&V6R@A^6)_]J5L(%/4$G.,
M\<$5XEXB^'/B;1]9GMH=&O;VV:1C;SVL+3(Z9XW;<[#ZAL5[3\(O!^H^%/#U
MTVK)Y5]?3"5K<.&\I0N%#$<;NI./;O7I];'G]+BZ]X9\6^-=#N['6;W3])MY
M0&AL[1/.9F4AE\V5@,88+]P#ZD<5Y"GP<\;FZ6 Z=; $_P"N:Z3RUYZY!SC\
M,^U?3-[!-/;-';W#6\A(Q*J@D<\\5@?9]5&L)9?VO)AH3(6\I<\'&*PJ57%K
MW6S2%/FZEWPCH">&/"NG:+')YIM8MKR%<;V)+,<=@68X'85=OM/^VM&/M5U!
MMSCR)-N>G7CG_P"O4]G#-!:)'<3&>4#YI& !;\JE?J,#FM+*2U(NXNZ.9TG3
MGNXI)I-3U &.=T 6;C /?BNG' XYK%\.D?8KGIC[5)_.M@-V([UAAHJ,$TC2
MO-NHTS/U_P#Y 5YS_P LS5VW?_1XQC'R#O[5Y[KVKZA_:-]9_:G$ <ILXZ5/
MH.NZE)J(BD\Z[40MMA0#).1@Y[5PK,*;Q#A9WV.[^SJRH>TTMO\ D=O?7)M-
M/N;@*&:&)G"L>#@$_P!*X67Q?=37=O.;2$&'. &/.1BNAOVUJ[TR[5[>&VC,
M+C8#YLDG!^48P.:X#[/<?+FWF#-T'EG)KGS/$U(\OLG9>AT99AZ,U)U-7Z^3
M.[TOQ9%=V<LUX$BD238L<09RPP#G _$?A6;XKU!K[3(&%I<0Q><"))1LSP>@
MZ_F!5WP3 T>GW1DB:-C<<;TP2-J_US717EA;7R".YA65%.0&&<&NR,*N(PR4
MG9M')*=+#XN\%I%_H>1'E#QC/XUZKH]K!#IEL8(4C+1*Q*KC.1U-9MGHFFR:
MIJ,;6D11&0*".F5YKH8XUB18T 5% 50.P%8Y?@94&Y2UZ?<:X_'+$*,8JUB&
MX3%O+SGY"/YU3T1=VAV1Z?NA5^Y_X]Y?]P_RJGH7_("LO^N0KTW;VR]/U/-7
M\-KS_1FFG>G4U.].K<@**** "BBB@ HHHH J:A?VVFV,UY>W$=O;0KODED.%
M0>IKRS5-0\'^(7U;Q#!X\U:""W57N(+.Z:-8QA4&U"!G) ^I-=#\6%6;PO96
MTG,%QJEK'*">&4N,@^U9_CG3=*'BSP,\=O:+C4FB;:B@%-I8 ^H#*",]Q0!E
M> 8_!NK>*XKA+[7;S7+6,R6\6M,VY$QC>BG@\$X_R:]@%>?^.&B3QEX%NH&C
M^TG4VA,B8W>6T3!ESUQR?SKT$"@!:0C-+10 FT=Z H I:* $V@4;12T4 )BE
M[T4G>@#R?X,_\A;QM_V$Q_[/7K->3?!G_D+>-O\ L)C_ -GKUF@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDA"
MC)(  ))/84KN$&YB H&22< "N%\6^(K+6K%/#6C:A#=7NKS?8I#;R!C;PD'S
M9#CIA P'N10!/X.5M7OM3\5SH ;Z0P6+#_GTC)"L/9CN;Z8J:\L+/5M4U&Z>
M',5K$8V;)_>R!?K_  @ 5IWCQ:/HT-K8Q[<(EM:QKVP,+^ %5Q9ZE:V'V"UA
MMY(O+*F:24AF)'S$C'7))KCKVG[K5TM?F;TFXZIV;T^74K6?AZV;3+2\L@+?
M4 BNLV2><<@@]C6OIVI"]1XW0Q74?RRQ'JI]1['M4&GIJD$=M;3V]MY,:;"Z
MREFX''&WVIVI6$KL+VS(BO81QS\LB]U;U'OVI17)#F@K6W7^0Y2YI6F[WV93
MU&&_M6M/+U:Y/GSB(@JG .<]JV+.VEME<27<MR2<@R #;[<"N5U#Q597:V;"
M.96AG620%>.,]#WKH=*UJVU=9GMMX$1 ;>N,YZ5G1K4)56HR[=?(NK1K1I)R
MBUOT\S3+'FLELCQ7&<'_ (\V[?[0JAXMO[?^Q9H([J/SBZ?(K_-]X>E<$7?.
M[>Q(!YW'./KUKFQF/5&:ARWM9[^IU8++Y8B#FI6Z;'L()7@X^HKF?%NJWNG-
M:&TF\OS ^[Y<YQMQ_.H] 75[C1K;R;J"*W^8!V5GD/S$=S@5!KWAN_N7MWMI
MIKMP&\PSR  =,8';O^E;8BK5J8=RI1:;,</3I4\1RU9)K4P;3Q!J=H0D-Q\K
MR[R@0?,2>:[8?VS>C*[+!"<'@.Y'\A7%6?A_4[HB:*$%8Y-K'>."IYKTX $'
MCJ:Y\MA6E&7M6[:6.O,Y45->Q2OK<\ZUCP]J45Q>7; 20*Q?S6<9(]36EX9T
M/4+'55NIXD6(PL =^>3CM]!71:\,:#>?]<_\*OPC]S'_ +H_E6M/ 4HU^=-W
MW_%G/+'UIT/9NUMOP0_RQCKBLV^&-8TX9_YZ=?I6KVK+OO\ D,Z;_P!M/Y5Z
M-977W?F<%))/[_R-#;A@<T^D;J*,UI<S1EV'_(9U3_>C_P#0:U>V:RK#_D,Z
MI@'[\>?^^:U#R*RI-<K]7^9K5^+Y+\D0W/\ Q[2?[I_E5/0\_P!A6?\ UR%-
MOWU,N8[6WMWA*XWO*5;/TQ4&EQZK:006L\%MY,:[6=9B6Q]-M3=^V6C_ $"R
M5)JZ^_R9N(<YI],CZ<]:?70C,****8!1110 4444 8WB#P[IOB?31I^K0--;
MAUD"+*T9RO0Y4@US/_"G/!#')TRY)!R/^)A/Q_X_[UWK_=->;R_$*S\._$/7
M=-\2:U;V]CLMVT]!A]A*?O ^T%E.<$;L9!XH UM/^%?A+2M2MM1L["=;FUD$
MD+/>2N%8=\,Q'Z5V0ZURMA\2/!^J7\%A8Z_:SW4[A(HUW99O3D5U8QF@!:**
M* "BBB@ HHHH *3O2TG>@#R?X,_\A;QM_P!A,?\ L]>LUY-\&?\ D+>-O^PF
M/_9Z]9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S
M=5US3-$MQ/JNH6ME"QP'N)0@8^@SU/M0!I4UC@=:J6.HVFJ6:W=A=P75L_W)
MH) Z'\1Q7+^(/%]C<1W^@Z/]HU76'MY(O(T\!O)9E(R\A(1,''5L^U &1J7Q
MO\*:=JDED%U&[$3[)+BUA5H@1UP2P)QZ@&NULO$>E7ND6^J1:A!]BGC#I-(X
M0$=\Y/!'<'H:^.;JTN--N'L+V![>[A^1X9%PP8=L?RQ7T!\*_ >FOX4MK_7=
M&2:]DE>: 7BEBD1.5.T\#/7ISUH'8H_&'QY;WOAU-+T"^,\<TVV]GMT8H$ R
M%$@^7YCV!R<8[\^(V%W=:9?07FGR-#>0NK0M$>=P(QTZYZ8[]*^N?$FF:1J.
MDC3-4DCBL)!@PEQ&KXP0/;! -><6_@+P?I-[)=64DCWB7*"S:2XW+$<@B0CT
M4\Y/I6%2O"EK+\S2G2=1=?Z_R/0M,:76+M+^90J01*@C["4@%_R)Q^=="JCT
M%5;"".WLXHHFW(JC#9^]QU_'K5P#BJIQM&[W9$WS.RV0@4#M37 "MQV-24C
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MY=R^II$7RH)RI!(PV1^% &#8>)-73Q1I>F:GX&L=*^V2D1W)N$/*C)VX7EL
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MV@"D*PM%%%,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;/NM[B-9(V]5(S5O/- 'D_P9_P"0MXV_["8_]GKUFO)?@R?^)MXU_P"PF/\
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M /$UZL ,=*7 ]* /*/L'QG_Z#.B_]^U_^)I/L'QG_P"@SHO_ '[7_P")KUC
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MX/(Z<9-25X:L.K?#CQ7X6>37]1O[?6CMOX+J3>N\[<E<],%L_1:]P&=V,]*
M'4444 %%%% !1110 4444 %!Z44AZ4 -WY.*:0"<$#/H>]<-XVT#Q/XEUO3=
M/T_49=/T JS7\UM,$F9N2 .Y' '!QR<YP*YWP)=7F@?$#7?##:S<ZIHEA:B8
MRW+[S W4C//J<CIQ0!ZX/E'0\=Z<K9X[U\\VR>(/$_A+6/B"?$FHVM[93R&T
MMHGVQI&I!V;>G?'([<YKVKP9JLFN^#]*U64J9;JV223 Q\^/FX^M &]1110
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M^AX]>?=AU]JK6VG65G([VMI! S_?,<84M]<5;H **** "BBB@ HHHH ****
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M9OO&*,*6^N!0!9 HI>@HH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2O&/'
MUC;:G\<O"=G>1"6WD12Z'&&VEV .>V5&1W%>T'D5SFH^#M,U+Q5I_B.?SOM]
M@,0[7PO?J._WC0!POB>RMK/X[^#'MX(H6FBE\SRU"AL*X&<=>N*S_#<%K?\
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$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>tm238578d1_ex99-2img36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img36.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,- <(# 2(  A$! Q$!_\0
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MBJUI<Q75M%/"VZ.5 Z'&,@\BEN+F*VMWFFD6..-=S,W0#UI6'=6N2YHW#-<
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M'YBNLTV]34-/@NHSE)4#C\:)4Y12DT*GB*=2HZ<7JMRZ.E+2*>*6H.@****
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MQR\PBXE.,=,\=C4PK13@UI9ZE5,)5:JI^\VDDWVTT.:FCF\#:[%=P9_L>_C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML"?NC/'?%89M],U75F33M0>V2X;=Y<L/!/?83_(UTT6AC3X(XK?,RID\N8Y
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MZ*.[@EXCFC<_[+ U)N!.:X6/X9:9!! B%':%8AND@7+[(O+Y*XZG#G'>H9-
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M]_6JY4WN5RKN=[N.#UX]J:WW2<$?2N$M?!NLR&-M1UFXF(=2_P#I<AW 2/N
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M+3&'RFD]A,\FNX)+2]NH;VVD-RTA8$J<R9Z$>M=KH&DO!HMNMZ9%;;DQ[MH
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M';S>491YL1SE)!W!'MQR.>:<LI^UQ-,%$L3^1-CH0>5/TS_,TVZB:RD7R\[
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MR!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFJ-C?PWUK'<0'*2*' 8%6 /3(/(JXIJ35--70ZBDS2T#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@]*0G% "$F
MJ]U>06<!FN)DAB7[TDAVJ/QJOJ6I+8"$F&>7SI!$/)C+[2>YQT'O6?;:7<7D
MJW.M-')(8FADMHSNMV^;(;!YW8Q3MW,W)[(1YK_6I3##%):62O)#<>>A5Y5*
M_*\1';WK4L-.@L8$CB7<RH$,K'+N!TW-U-6$5%  X&.,5)Q0WV",%>[U8!13
MJRM5URRT>)6NI<,W"1IR[_05G6?C;2[JX6%VEMF<[4,RX#'TSVK"5:FI<KDK
M]CIC1J2CSJ+L=-D^E&:SM0U6UTNV\^\G$29P.Y8^@'K6-;^.=+EF"2"XA4G
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MG@/X9C##C[2O_H+5W)KB/B<C-X8C"(S'[0IPJD_PMZ55&WM(W)QR;P\[=O\
M(Q_&%FUG8Z%KMLG[R"..-R.OW0R']&'XBMGQCKR?\(2DUN^&U%51/93@O_XZ
M&'U-:T^G+JOA%;&3@RVBA?9@H(/Y@5YMHUO?:SJVDZ1=QR"VLW<R J<*B_,>
MH]0%_P"!5T0M))O[+?W'FUN>E)P@OXB7R>S_  U/1O!ND#2/#MO$5VRRCS9
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MR03"AY_B(JAWQ2'))8G);FD).,Y'3J>E;I61Q2ES.[&S2QV\;S3.J1(,L['
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MM[.E9;LH#@#]*DAB$TZ1G^)@I^G>F58L/^/Z'_>_H:]-['S22N;:*JH%50%
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MK(1Z8K%ZBM?4#BS?W('ZUD=!6L-KG-5^)&=KUR;30KVX5L$1$+]3Q_6O*%&
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M10 4444 %%%% !1110 4444 %%%% !1110 4TCBG4=J ,?5 UNT5^@RT#'S
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M$BR9SV!R:]\B<. ZD%6 *GVQ7EXV-IJ7<^GR2I>E*'9_F3T4@-+7">\%%%%
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MBB@ HHHH **** "BBB@ HHHH **,TF: %HI,XZTN<T %%&:* "BBB@ HHHH
M**** "D(S2T4 <QXBT>:X26XMMS2$8:/KN &.!^)KDFNP9C_ *0AS*Q_UV<_
M,W/7FO474D=<5S6N:)+*PNK-Y0P;+1+(XSV&T*0 >I)K>G4MHSS<3AF_>CN<
MBMVO7[0HSN.?-_VF]Z?:R2W!2&"022%%"HDF2< ]!FDMS<W$R0Q2S/(V0%2=
M\GYFY&&]*[K1-(;3[53/,\UP0 S,[,!@G&W=DC@X-;3FHHX\/0E5EKL+HNE_
MV=$Y>1GFD"[SNR/ER!C\*V%IH7G\*>.!7&W?4]R,5%604444B@HHHH ****
M"BBB@ I"P'6@US7BKQ+;:+"EJXD>YN5(18^"H_O$]O:G&+D[(#I"^.?6F&>,
M.(RZ;SR%W#)_"L'1[NUE-K)9^8+6Z#+Y<A)*2+SW_'\J\UOKF>?Q=J,LLKF1
M+AE1MQRH!XQZ8QTK2G2<VUV&E<]K!R*=4-NS/!&S')902?PJ7-9"%HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI*  GBC)IK,!Q49<F
MFA-DA<#K3#(2>*:?>FEE4\L!3L2V/+,:3)]3^=0FXC'<GZ"D^TC_ )YM^)I\
MHN9$^3ZFC+>M5Q<@G&P_G2BY0GHP_"BP<R+ =A3@X/6H1*C=&_.G]>A_&E8:
M9,&R*7-0 D&GA_6E8JY(#FEIJFG9I#"BBB@ HHII8CTH 4FF,H..:1I, DD8
M R?:LZXU[3K>*.5[N,QNVU63YLD=>E3*:BKMCBG)Z*Y/'IMM#=/.J'>^,@G*
MC'H#TZ]JN 5A_P#"4:<#.#*P,#%6^0_,0<?+Z\U>M=5M+I83'<QYF7=&A.&(
M^G^>E0JT).RE<;I2@M8V-&BF*^>].S6I(M%%% !1124 +0332V!S4;.3T% F
MR0N!3#)Z4S/K2$@?>('UJK"N.W'UKS#XDG/B;3?>U(_\?->E&>/GG)]J\Q^(
M\H;Q'IK <"V).?\ ?-=&'7[Q!!W9TGA@;-*L&'!%^WZH1_6N$D(_X2S5 0.;
MF3^M=QX>G!T6T8#A+\$G\"/\*\ZU2=K7Q7J092)#=$A#U.X\8^N:UI+WYEW2
MDSW2!BL$7_7-?Y"I ]5X94,,:EL,$4$8Z<"I1ZYXKBMJ1?4G# TZJ^>:>),4
MFAIDM%-#9IU(84444 %%%% !1110 4444 %%%% !1110 444AH ,\5&[\XI6
M;C%1<G_$TTA7%ZTQY%C^]G/H*CDGY*IVZFJXSU)YJTC%R)'G9\@#:.V.M1X[
MGGZTN*4#BJ(U8T5'<.4MI7!PRH2#]!4Y*JI8\ <D^@K"OM8@N[;[-8DS23@J
M2O11T-5%7V,ZDU!:LT[&5KBP@E?[S("?K5C IMK +:UBAZA%"Y]:EV^U)O70
M<$[*^Y'BG!V3[IQ0Q"#<W ]3TI!M90P8$'H1TI%>A.ER&X<8/M4XY Z$'TJD
M12QR-&3CD>E)HT4WU+H.*D4YY%0(XD&5IRDKS4-&B98%%-4Y&:6I+ G!%9^I
M7RV-I/<."WEHSB-<;GP,X'O5QV(R?0>M</.)=<UXF8&!8&VQLO0X;(4D]V(Z
MBN;$5>2-EN_ZN;4::F[MV2)%N+[6IUO"WE6!S#-&DI(QCG''/KGMS5B/0;.&
MT:V8/,R3!D=B 6R,=N.F*TXXVF?;$NS<-K&/!4'L<5-:?8IYIX$=9)H&43(N
M0%; (('H?\]*Y(X9SUE[S[LWE7:TA[J,V:PLG2[5;=";E@>!SQR<?0U7N=(M
MFN3=6KM$;>(+ JXP6&0#TSUW=/2NI%O$1]Q<Y)R!W/6JMQ8<9APH&U<'D!1[
M5<\,K;+\C-5Y)Z,Y_3M7O-*NH],U)'FFE(D$F_<45N /]KE6)] 1UKKHG$@!
M5@5/<'-<[<6PN[62!B(GE&3.^-RY]/;C\>>U0>%KR6&XETQXSY:;F21N#G/3
M!['J,44:KA)0D[I_U8N<%4BYQT:W_P SK1TI:8IXI]>B<8F:8SXSZT,V*CSS
MDT$W \G--=PG+''\Z9+,%X7EOY56.6)+')K11,W-+8D:X8GY1M'K49&>223[
MF@4H!)JM$9N[&X]*XOQWX?OM3EM;^P5)3 GE21%MIP3D$'ZUVGF1;V3>NY!N
M89Y4>I]J\]\1^*;LZM':0,BVH!W!3_K.<#GTX!K:CS\UX]!*:4DD][FSX7L+
MB+P_<6TS+]H$V\8/ 9<$ >O3'XUKFPCN]3BNY]/C26%<!W"ERW;GT%0>$W:3
M0\ORPE921SGTK3GU&RMY_(FN(TEQT)_K43;<V#?)I-DQY.>M*"5Y4D57;4;)
M1DW,>/4<_I3K6Z6ZW%8941>CN,!OIWJ6B5.+>CN7$N"#AP/J/ZU.K!AD'(JF
M5YXI5+1L2OY5+1LFT7 V#4RMFJL<JO[&I,XJ&:*18%%,1@13JG8L6BBB@ HH
MHH **** "BBB@ HHI#0 $XICMCFG$X!S4!.<TTA,7WJO-+D[$/'=J?/)L7:/
MO&JP S5I&,I=$,9DB7<[*J#J6.!3QR,TDD"31M'*@=&X*D9!K,,3Z-,K([M9
MNV"K<^6?;VJ[7,)2<=;:&OC^59]YK%I8EUE8F2,X9 /F'&03[56UCQ':Z; -
MC+-,3PBM]WZUPFJ:P+Z\\V9V$I7#';@*.P%:TZ4I/78XL5C8TTXTW=G43ZO-
M_P (Y)<"<M-+<[-HZQKZ?CC/XUR<-\]E<$K-Y,G488?_ *^]4'D$RD.[*"QV
M%6SD XZ=Q_A3_+$FT#;(I!,;DY'T/?UXS77"FH['CU:KJM2?0ZB3QQ>1PI"(
M83,P \UVV')Z84]33M-UNVD&Z[U*[BE<Y/EY9<>I]*Y$P/&6DR79L*Z@DXZX
M(XX[BGVNYT>4-;,N BF,\$G@ \=0,FDZ4>A?UJH[-RO;N>FVHTR]E"?VD+M^
MNQINOX=ZUUC1%"(FQ1P !P*\957BD4HQ#YW(R@@_6MG3_$-_'<+$U[)N+;L,
M2=]8O#OHSMIYC&*]Z)Z<0",TW K TK^U]0M7F%XD222L<E-Q'L,\8':MRWMV
MMXO+>:29\Y+N>3_A7-*-G8]6G4]HKJ+LQZDHV5//\ZMQL'7(_$>E5L8H1S&V
M>QZU+-D[%M6P>M39R*AR"/KTIRDYP:S9LF9/B:Y2WT299/,_??N@8^H)]_P-
M9ND*D6E1K%<>:LGSE&7#+GT%6?%QD325VW*PJ9 &4CF3T X/IGIT!IT,ADM(
M=T\5QA 2T8VC'KN/2O+JN]?T2.Z*M07FW^!J6<*I!O*X=AU*;2!Z&J=[H]IJ
M,_VA)9(+F/*>?;R;6'LV.OXUJ1E1 IR,8ZYR/SK$N=&@DN)+FRU*:QFF.9#
MZ[7;'4J<@GWKT::26AQMZZB?V3J\66@U^9CDE%FA5AC)P#@9Z8&?:K6D:C<7
M3W-I>Q+'>6CA90A^1PP)5E^H[52?19'8E_$>H9!)PDJ  '..WI@?A4^E_;K.
M]EMKNX2YMBH>&Y8J'))/RM@_-@8P<5H]1MHL7T8BF$HV$OU# DL?\,5S>MM!
M;WUI?RW,DC @>7$,8V_-P3C']<>U=;J))M_EW]1G81FN:\03.FFQK'=6R?O?
MNN K# [9';(R?2O*Q44D[=-?F=>&=YI=]/D=9;S+-#'(N=KJ&&1V/2I7; JI
M8>8+.#SF5I=@WLG0G'4>U2MR2:]*&J3.*3LV%0RR[247[W<^E.ED")GN>@JI
MUY)YK5(RFR.61H8G<1O)MYVIRQ%1V=];WH/DR?,OWD889?8BK0! S6=J-H$_
MT^!=L\?)V\;U]ZM,YJCG'WNAIXX]/>L76=;.ER",J,R)E'[!LG((],8JAJOB
ML1VA6Q5O.;C>5Z'O@5QEUJ5S=@<&5R=S.>2?;_\ 56].@V[R.#$XY?#2W-]/
M$$"V^IR7+XFN$P&"GY<=O;K7&7TZMJ,,JOO^3&1]>E3+<K(7EQE2RQ[&_O8.
M?SROY4Z.*QO+B*&4;9%;:5W=1CKGT^M=<8J)RX.O)5XW5[%P:S<0?N[*ZDC:
M0CY8C@G SWXSQ5C3]7GM9?,>$7!D.UA."R@D<Y(!_,<=>:S4M8$C\M  O+#S
M!RK#TIL$8\]7DD;:GS%D<$,!S@#KGM0XQ9AB*TI5I23MJ=G!XQL(6 ETP>8.
MIC4?IFNFM-;TN]$;0WD66'"L<-7E$I"D/('+OR%!Y;/;';&<4F\V_P P^;NR
MAA\WKC-92P\6:T\PJQT>I[&EQ QC59HR903& P.X#KC^?XT-+$) C2H'/09Y
M_*N"\.I#JNHI;^:0(HV+*K89>G ^I_2NWM=*L[(EH( '(Y<G<WYFN24%#2YZ
MV'K3K+F4;?,L9VXQD&K,4HD'N.HJ BD!*L&&>*SL=FQ<!*G/:IE.:@5@RY!I
MZ-@XJ&;)DU% Z45)04444 %%%% !1110 444AH CD/:HR0JD]A2L<L:AN&^5
M5'\1JDC.3*Y)=B3WIP'-(O6G =:T1B&<$=O3-9NOW$4.D2AW57D7$8]6]JN7
MMF+VSDA+LC$;DD7JC#H1]#7F^JZE/>W"O/(6=A@ <8^G;%:T8<TKG#C<3[&%
MNYG7<K'8NP@D_=QQ]0:KV3K/;Y,:.C;B0>RD]/SR/PQ0]FP21@JJ,[=IZD>O
M_P!:JHF9+N,W"L8I0/+B." 1Q_3%>@?/+;0=(8X0X7(V';@\!,\GGTYZ_6FJ
MC^2IVNRX_=/QACZ+GT[?4U#?N9P6FB,4*2!=S\C YZ=,\U%:WDDKM';^=,K
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M4&H4444 %%%% !1110 4444 &*A=<&IJ1AD4(3*[*&4@U68B(.TC!54$DDX
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MAC?4K4.#@J90""*N1NKQJ48%3R"#D'\:\F2ZTFUEUIM2T9KLM=.%F1<+'G(
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M2(NO6C!]#4H1?2EHN.Q&$S4@4+Q3J*D=@Q1110,**** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>tm238578d1_ex99-2img37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img37.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y HH# 2(  A$! Q$!_\0
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M9>(?^@W;'_MS_P#LJY[3?B0M]>6D%QX>U.SCGO#I\EQ*T12*Y&?D^5LL./O
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M+:SAL&U$7#2Q/NA#;5^1&)#,W&T_CB@#IOL7B 9_XG=MQ_TYC_XJE^Q>(?\
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M '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK,E_J^KV$EJ(6T^5$#"0-Y@9-P..WTH V:*!10 4444 %%%% !1110 4444
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M3#!R748*@'@D=A6=/X-U^33["T72K8/'9_V<2DZ!(-LRN+@=_G"G('S GTH
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M4X.."0>.A-9^J^!--U2Y>83W%J2(5"0!/+58@P5=C*5(PQZ@XX(P1768I"*
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MFMH9S$94#F&0/&2/NL!C(_,U8;[IKGM:UF]TN_@ MH'M'*+M,A\Z4DG?L X
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M MP+ELN)$ [DXX _O'ZYK=BACAB6.)%2-!A448"CT % &1??\C/H_P#NS_\
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M%/.D)?[2&(W<#C'K76+6]*M"M'GIR37D1*+B[-6'#ZTN!116Q(4444 %%%%
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M0!/130P[FEW"@!:*3< .M(6QGD8H =14?F#.,\TX,".#0 ZBH_,^903R:DH
M**** *5U86M]&$NH$E4'< PS@U4'AS1_^@;;_P#?%:U':G9$.FMVC*_X1S1O
M^@9;_P#?%'_".:/_ - RW_[XK3I1UI6,^6G_ "HS/^$=T;_H&0?]\4?\([HW
M_0,@_P"^*U**+#]G3_E1E_\ ".Z-_P! R#_OBC_A'=&_Z!D'_?%:E%%@]G3_
M )49?_".Z-_T#(/^^*0^'-'_ .@;;_\ ?%:M!Z46&H0OHC.MM&T^SG$UM9PQ
M2#@,J\BM%.F**5>E!HDEL+1110,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** &OTZ5R%[INLOXA:Z@WFWGG5)5,I 1(URC =L
MMD'VKL:B_B% '(7^GZW<VMK:7 >XG-RKM.FU52,$9&1@@\$]#Z4W6;;7[G5V
MFMTG"6;236VS;L)*",<=6;$LK8/&46NQ;[X^I_E31U'^?[U ')F+Q7@20R/^
M[_U<<A3+@[C^\([@!1QZTV%/$YBD=Y[I8E\V2$%4,A^2)55AZ;S,P&?NA177
M?P'\?Y4K?ZP_0?R- '-3?;6?3$NK:>3R[22:2-3N8R\+UX&0&8U7AT[5H?#]
MA"OVE+C[:T\JQN%(7<Q52.0J_=!4=*Z_N/\ >/\ 6D;_ %?X4 <A /$Q:V-R
M;AA*LLD@0(OER_*%0\G]V?G/K]WTI+73O$5O!;6JWDVR$Y9SM)D^YD?3)<UV
M/\9_"FG[GX4 <>A\2) Q:"X63:C[8-FW$CEI1S_&N[:/]W/>I+:S\0C3+MI)
M7CU"988$F;:S1J7^=\="55B??;75K_K?P/\ Z%3G_P!6?Q_D: .+NI?$44DJ
M^9>$R70BACBC5CY0R=P8\9( R3CK2K:>(K>:69ED9I/FF:+:7ZPQC8#QD(DC
M>F7KL)?]5)]#_*GCH/K_ $H XR6W\2W<TL,KWT-N)%1FB= Q3S!AD/LH.3WS
M4EL/$YBCEN/.\^2Z'FVT8"I&FYLA7S]T*5YQSMZ#-=:O\'X?RIQ_U5 ''7=S
MXCN+W4WT_P [R8RT40=%*$9124&068#S&YX) '>K]O#KL<%Y,]P\LB0!;6%P
MH#O@G<V.O) Z]JZ#LOU_]EIR_P"K'^Z/Y4 <+;VWB>&=YE%T#<S-*/-9"05$
M2(K]@I59&P.["IKF/Q<+:=(Y9GFE0^6R;!Y<I3Y0?2,,1GO\IKLQV^E-_P"6
M!^M '/V\%_)X@M3<2RMLGN)RI "QQ<QQJ,=<_>YYKJ*C7H?]\U)0 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>tm238578d1_ex99-2img38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img38.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #S HH# 2(  A$! Q$!_\0
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M9*R@R*49!RQ"Y!8'D]O6L[2/"^H6[16U];I)L@=)KM9?]:&B"",?Q?*1U(Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOQ8V<4LGF0D*3MD'RCO@>HH ]>WC. >:7<N<9&:XJ;4]6DT'PDS:A''=:C+
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MU6- 75M-\<W&CWVNW6J6YTP7*FYC12K^9M_A [4 =S10.@HH **** "BBB@
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ML:M0?J*R]1T2+4KVTN))I4-NQ90AX/.>:U5&.U--W#4=1115#"BBB@ HHHH
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MX.L+^R2^^U1^3 [1B&,KMY5 ';&X]3_7BNHQ18/8Q\_O?^9A?V1K/_0R7/\
MX#1?X4U])UG_ *&.X/\ V[1?X5OX--84![*/G][,7P]->.=0AN[HW+6]R8UD
M9 I(V@]!]:W%Z5A:#_Q\ZU_U^G_T!:WEZ4+5#H_ A>U%':B@U"BBB@ HHHH
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M/@_]1)O_ (B@#L<T9KS_ %OQ9XST#29=2O?#>E>1$5#>7J!)^9@H_@]2*O\
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M #9YV/B?=_9@/[%B-QC[XN<19['&W./;]:Y_1]-OO&7B*265MZO*);VXQA5
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M6O\ K^/_ * M;R]*2V,J/P+^NXM%':BF;!1110 4444 %%%% !1110 4444
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MM9G=U3>0T97C.,\^]:JYXIIW5Q$=S:07ENT%S"DT+8W(XR#@Y'ZU(J 4ZBJ
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MTS6WFML+;L9QGT)KTB.-50*% 51@ =AZ?H*=G%G7.:FK'GXL;F&R+PZ/?OB
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MBB@UZ"]J***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>tm238578d1_ex99-2img39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img39.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $5 HH# 2(  A$! Q$!_\0
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M+2^2(7F4/OP#MQG(.&7_ +Z% #/[5UC_ *%NX_\  N'_ .*H_M76/^A;N/\
MP+A_^*J[?ZOINE(C:A>V]HKDA3.X4,1U )ZU5MO%6@7L]M!:ZQ8SS72[X(XY
MU+2#U !YZ&@!G]JZQ_T+=Q_X%0__ !5']JZQ_P!"W<?^!</_ ,54MGXFT34=
M0EL;+5+2YNX@2\,4H9P <'@>AZU%'XO\.2K.T>N6#K;L$F87"X1B< $Y]10
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MACMGC8>8TDK!2>.%YSN]!5?0[V?P3X=U2RO[2]U"_M+D2FZCA=_M_F_ZN7<
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M\C!IW_7.7^0K4QQ69<_\C!IO_7.7^0K4['Z5C!ZR_KL7+:/]=S@M<&/C)X9
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MRH [AU&YL<G':I?[0L_^?NW_ ._HH H?\(OH?_0(L_\ OT*/^$7T/_H$6?\
MWZ%7_P"T+/\ Y^[?_OZ*/[0L_P#G[M_^_HH H?\ "+Z'_P! BS_[]"C_ (1?
M0_\ H$6?_?H5?_M"S_Y^[?\ [^BC^T+/_G[M_P#OZ* *'_"+Z'_T"+/_ +]"
MC_A%]#_Z!%G_ -^A5_[?9]KN#_OX*DBGCF!,<J2*#C*,",^G'^>: ,S_ (1?
M0_\ H$6?_?H5432['3O$]C]BM(K?S+>;?Y2[=V"N,XKHZR+O_D:-._Z]Y_\
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MV\\=S$DL+AXW7<K@\$'TH B.F6&#_H-M_P!^E_PJKI4,4-WJJ11I&@NEPJ*
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M/_@0W_Q%'GZ]_P ^=C_X$-_\16KM-&TT_9O^9AS_ -U?U\S*\_7O^?.Q_P#
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MN<<X$7_Q%._L^X/_ #%;[\HO_B*O#&:=0!G_ -GW/_05OORB_P#B*/[.N/\
MH*WOMQ%_\16A29% %#^S[C_H*WWY1?\ Q%']GW/_ $%;W\HO_B*OY'K2Y% &
M-/%<VES8G^T+F59;@(ZR+'@C:Q[(#VK8%9VI_P"OTWVNQ_Z ]:(H HZW_P @
M._\ ^O=_Y&I-,_Y!=G_UP3_T$5'K?_(#O_\ KW?^1J33/^079_\ 7!/_ $$4
M 6STK/TC_47/_7W-_P"AFM ]*S](_P!1<_\ 7W-_Z&: -"LY?^1CD_Z]5_\
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MBA_N]<5ARZ[Y.JFR$!,2.D3SAL;7<$J,=^G7WIC^)H8=4N8)T$5I!*8'NGD
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ME17 67C+Q;J-Q>P6WA"U,EG-Y$P.JJ,/M#<'9SP15W^W/''_ $)EG_X-U_\
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M1Z%-?6*Y6:[M@.A5Y5Y^N34#:YI$(PVIV: =O.7_ !K@A\)9<\ZM;D^]K_\
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M"NA&1A?&'SL;?EVYZ;O[W?'I7$:IX.UA[%I+*.)KN>]EBNHVEVB:T:;S$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!,4FP444 )L!8GFAE&:** %V^Y%(4&._KUHHH 1845V8*
M SX+'N<<<T[8,8]>M%% "$#D=O2EV ]>:** #8/4_G1L'O110 QH8S(DA4%T
M&%8CD?YQ3M@QWZ8HHH  H)^M!4?6BB@!J6T48<1KLWL6;;QDGJ3[T_:*** #
@8/4TBH/4_G110 AA0NKE067.TGMGKBE* G.3110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>tm238578d1_ex99-2img40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img40.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %+ R # 2(  A$! Q$!_\0
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M_C]U;_KZ_P#9%K6K)TG_ (_=6_Z^O_9%K6J*7P_>:5?C?]=$%%%%:&84444
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MBA9 W(/.78#]:S/!$5]9^$]/T_4-/FL[BS@2!A(Z,'(49*E&/'UQ0!T=%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>]LK?4+62U
MNHQ)!( &0DC.#D=.>HJQ10!D?\(SI7_/*?\ \"Y?_BJ/^$9TK_GE/_X%R_\
MQ5:]% &1_P (SI7_ #RG_P# N7_XJC_A&=*_YY3_ /@7+_\ %5KT4 9'_",Z
M5_SRG_\  N7_ .*H_P"$9TK_ )Y3_P#@7+_\56O10!D?\(SI7_/*?_P+E_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8=V
M,^+=._Z]Y?YBL/QKX-DU:3^U-,5?MZKMEB)P)U'3GLPZ#/4<'M6[=_\ (VZ=
M_P!>TO\ ,5L]:RH2<)R:[_HC>;:4&NWZL\!6_P!2\/RR0K>7VE.6R\3$Q@GU
MPPP?J/SJ6SLM6\2WN^W2ZU"=L*;F9B44>[G@#O@?E7>?&%1_PKZ?C/\ I$77
MZUV=AM72[4G  A3D_P"Z*])U_=4TE=F?M==C*\-^&+?0M&>S<K<2W&6N9&7B
M0D8QC^Z!P!_B:T8-&T^VD$L-G"DBMO#!>0VTKGZX)&:F_M"S\D3?:X/*)VB3
MS5VY],YZT\W,"JC--&%D.$)<88^@]:XVVW=D-W94N-"TNZ8&>PMY"'9\L@^\
MQ!8^^2!GUQ3;CP[I%VD27&G6TBQ%S&&C&%W'+8],GDUH&1!((]PWD9"YY(]<
M?C21W$4I(CE1R.NU@<?YP:5V*Q5NM'T^]6);FSAF6$8C#KG:../IP./:F?V'
MI?VB2X^P6_FRL&=]@RQ#!L_F ?J!6CFDR*+A8BFLX+EX7GACD:%_,B++G8V"
M,CT.":F[TM(>M)C,K2?^/W5O^OK_ -D6M:LG2?\ C]U;_KZ_]D6M:HI?#]_Y
MFE7XW_71!1116AF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8
M=W_R-FG?]>\O\Q6W6)=_\C9IW_7O+_,5M5C2WEZ_HC:KM'T_5G!?&'_DGT__
M %WB_G6[JUM-=^$[>.&(S8$#O"IYE164LGX@$8[]*YSXP7=N_@J>S6>(W7G1
M,(0XWXSUV]:[31KRUO-,MS;7$4P2-%8QN&VG:.#CO76]*:]6<NCDT<K?10SW
MME>P>'+E+..]5Y1]F^:3]S(N?*[ %E&>^?:L?4M$U":.1H]-N8;6;[2UI D
M=D+^7B-ATB#%6;<,$9ZBO4J*CF'RG,ZAIVHW?B73I[>XELA'8RI)-'&L@#%X
MSL^8'T)_"L31-*UJ-[>TF-Y;P;XQ+)& C,H%P6R1TRQC/'J*]!HHYA\J/-AJ
MFM1S6-O=7%X-2:2UC6,,OEX*#>)!_>+!B>.F,<9K=\'-K;//_:K7!7RH\B>,
MJ1-SOVDGD=.GR],=ZZ9K6W:Y6Y,$1G5=HE*#<!Z9ZXJ8"ARZ D+2'K2TAZU#
M*,K2?^/W5O\ KZ_]D6M:LG2?^/W5O^OK_P!D6M:HI?#]_P"9I5^-_P!=$%%%
M%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!AW?_ "-FG?\
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M8S"-V+O'LQ@G)(#;NG:K\&E7]EK_ (@U6 VSF^A@6V1W8 /&C#Y\#@9(Z9H
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M RP;P%<QR)(A1XV'564\@\@_0BKU !1110 449HH **** "BBDS0 M%(*#0
MM&!29I: #%%)F@&@!:*0G% - "T44F>* %HH%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4454U'4+?2[&:\NF*PQ+EMJEB?0
M #DD],4 6Z*PIO%-E$L#^7</%);QW+R*G$$3G"L_/&3GIG&">@J6R\0VE[J
MLXTF4N91#*Z ),8VVOM.<\'U SU&10!L449HH ***:[I&I9V55'4L<"@!U%
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M+Q'5<P3W)MT?Y@>9!RO3/X8[UE_"H8^&NC@  !9  #G'[UZ .QI#T-+2'H:
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MR >N*-6L9+^Q:"-@K%@<GV-+I-B]A8+!(0S DDCW-9Z\VQ&O-L7C6!<0V_\
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M!F,I53&<'*K\P/2@#U,]*\HC@F9KV01,3)&[7\,,#K+&IND9DE;_ ):-Y9<
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MX,CX93GY5/9>U>E4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 F!Z4M%% &9JFG27KV\D,D:2P,67S$WJ<C!R,C\ZFTNR_
MLZPBM=^_8#EL8R2<G [#GI5S%+2LKW)Y5?F"BBBF4<IK-C;:AXSTN"[A2:+[
M),=CC(SE:T1X5T+_ *!5I_W[JO>?\CWI?_7G/_-:Z#O4)*[.2G3A*4W)7U_1
M&-)X8T")&=]+LU51EF9  !ZFLP0^"#;FXQH_DAMID+KM!QG!.?0'\JV?$-A-
MJ6@W=I  99$&%8X#X(.TGT.,?C67<Q7VK:?K&-$^QO-8-!&963S97(;"_*2
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M.*T/A4<_#71SG.5D.2,9_>OV[4 =C1110 4444 %%%% !1110 4444 %%%%
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M?^BTK=K"T'_D):[_ -?H_P#1:5NU*V,J/P??^;"BBBF;!1110 4444 %%%%
M!32%'44ZL;Q1<36NA220S&!FDBB:9>L:/(JLPST(4GGMUH /%!<>&[TPOJ22
M;5PVF(&N!\P^X#P??VS6/\*\_P#"M='SN^[)][K_ *U^OO6??W6IR:;J>D6^
MG:IJ\"WKVZW%I>K#-$BI$XS(Q!)W,RYZX7!K:^'FF7FC^!=,L-0@:"ZA5P\;
M,&*Y=B,D<="* .GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!-H]*0X[4ZN!T_4K]+VWN())KZ^N!?&XL3/A<Q/B-0#Q'@X7/&=V3F
M@"KX/65?BCXD$BZFI-I$1_:#AF(\Q^4QTC_NBO2*\]\$Z'JMGXRUG5[W2+C3
MH+R"-52>^6Y)<.S-@@_*.1@=!7H5 !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <[>?\CWI?_7G/_-:
MZ#O7/WG_ "/>E_\ 7G/_ #6N@'6H6[.>C\4_7]$-EXAD_P!T_P J\\^"W_(B
MO_U^S?TKT.;_ %,G^Z?Y5YW\%_\ D17_ .OZ;^E5U.Z/\*7JCJQXHLMS'R;S
M[.-^VZ\D^4Y0$D _\!/) !QP:;'XMLFC)EMKZ!S$)HXY8/FF4D#Y,$Y.67CW
M%5X]"U6*P.E1WUNFG*DB(1$3*RL& 5LG  W#D<G':HGT'7GMXI!?645[:VIM
M[5HXF*J6VAG;)Y.$X&,9/.:NR.:[+C^,-.C16>.Z# N)8_)^: (0&+\\ ;AT
MSUK5;4(5U&.Q);SI(6F7CC:I4'GURPKD;CP7>75I!'(UB'CCDC!(D?RV9@WG
M*3R9<CDGVK=OO#MMJ>KVMW?0P7,,%N\0CFC#'<S*=WIT4_G0[#U)K3Q'IUU:
MBY:=8(2JL'N&5 =P) Y/7 -7#J-F)T@-W )I "D?F+N8'H0,Y-<OIG@M[&XL
M7FE@ECMC&2GEG!VPR1\9_P!\'\*R8_"]_;W5II2Q-)$)(I);OR<% L)C)1\\
M#IA<9R3VHLNX7?8]!M[RVNE9K>>*8*VUC&X8 ^AQWJ8USOACP]/H?FF>6*1F
MBBA4QES\J X)W'C.>@Z>IKHC4L:,+0/^0EKO_7Z/_1:5O5@Z!_R$M=_Z_1_Z
M+2MZDMC*C\'W_FPHHHIFP4444 %%%% !1110 4R6))XVCE17C<%65AD,#V([
MT^B@""VM(+*!(+6&."%.%CC4*H^@%3T44 %%5[[[6+*8V(A-WL/DB<D)N[;L
M<X^E<OO^(_\ SQ\+_P#?R?\ PH ["BO/'U[Q\GB6+0C;>&_M,EF]X'WS[ BN
MJ$>N<L*T]_Q&_P">/A?_ +^3_P"% '845QSR_$5$9C#X7P!G[\_^%9V@:YX_
M\0Z%9:O:6WAM(+N,2(LCS[@#ZXXH ]"HKC]_Q'_YX^%_^_D_^%9=_P"(/'NG
MZUI6ERVWAMI]2:18F5Y]J[%W'=^'I0!Z)17'[_B/_P \?"__ '\G_P *-_Q&
MSS#X7_[^7'^% '845YYH>O>/=?L'O+6V\-HB3RP$2//G<C%3T[9%:>_XC_\
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M_P * .PHKS_7-9\?Z#H=[JMS;^&GAM(C*ZQO/N('IFKL,_Q$FACE6'POAU#
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M4-U:6]["8;J".>(D$I(@9<@Y!P?0\U-10 "BBB@"&.T@BN);A(8UFE"B214
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M7-VDB80NJ,"$)!(&]<XI<L>R%_9V%_D1SW_"J'_Z#?\ Y+?_ &5+_P *I?\
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M3P8N.>0:[?K10!RLWA22^M]96[NU%QJ+0RK+ A4V\T<:*'7)/1D##VXJ#3/
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOQ=-' NC2S2)'&FJP%G<X
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M&74@D$>O )_"@#0HK+MM=LKV^AMK25+A9H9)4FB<,AV,JD9'?YQ6I0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %9VJ:3%JK0K<,3!&) T6.'WH4Z]N&;\ZT:* .=T_PI!965G#
M)=7,\UL"?.9\>8Q8L691QDDFGZ?X=DM;C4;FXND>XOHUB=K> 0J -WS;<G+_
M #'+$]AZ5OT4 <E;^#[NV2VD354-W;>6L4AM1Y:HD31@;-W4;V;.>I].*=%X
M)MH;86\=S*$#@JP W!5@,*C/J"S/GU-=710!S=EX7>"[M[NXNUFG@VA-L 1
M$C9$PN3C&]SUZMV IK>'+J/PW=Z='<K(\THD"A2D:#<I**I+;5.T\9/+'H.*
MZ:B@#%CT24^(_P"U[BXB9D1XXEB@\MMK$<2-N._&!C@>M49_"3SRJ[74+;;F
M><+) 64B7&00'&2,8!Z8."#7444 <\GAN0,8GO%:S%\+U8!  <ABX5FSR VW
M' P%%0V_A".$)_I;,5>!V)C'S>7(TOKWD?<?H*Z>B@#E5\(S165Y91:D!!=0
M(CYMP7WJH7<3NY4[<E<?Q'GFKNEZ!)87[WUQ>&ZN)#*7;RP@)<IT&3@!8T4#
MT%;M% '+_P#"'H/[-!G25;2)XY4GAW+-O=7=L!@ 21WR.>E0:?X3O#%%-J5X
MGGK(91'%$ $+S+-("V?G)**N<#@=*Z^B@#E$\'R16]U;0ZAB&ZM5@E#0!F+#
M=\P.[@$L25QU)Y&:>?"D\LOG3ZD7F<SF5Q"%SYL:I\HS\NT( .O&?K7444 <
MM%X1>.VLHEN8(6MIEE,T%N4D.T  *Q<D?*"ISD$-C Q3I_#MYJ&N7MU<W2Q6
MDDD6R.- 9'6-<K\^> '9CC'8<\FNGHH YS2O"R:?]A\R2&1K-MRM'!L+XCV+
MDEF.0"W?^+@"DO?"SWVK3W37S);S.LC0K&-VY8RB_/GH,[@,=>]=)10!RUIX
M1D@DMIIK\23VZHB%8 J!8XW2/Y<G!4R,V<\D]@*CC\%F* VL>H,MJ%4H@B&\
M2+ (58MGD #=MP.>]=;10!CV6DM!K'VDHJ06UJEG:HIZ)P7..V2%&/\ 9]ZV
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>tm238578d1_ex99-2img41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img41.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Z R # 2(  A$! Q$!_\0
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MC,DA!.!G'09)Y(H MT5D:;XHT;5[IK2SO URJ[S!)&\4FWIG:X!(]\5K;A0
MM%)N!K/UC7=+T"R-YJM[%:0#^*0\GV ')/TH T:*0,& (Z'FEH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*U'08=1NX[
MK[9>VTT<9C#6LQCRI(.#Z\BJW_"+C_H.:W_X&'_"MZB@#!_X1<?]!S6__ S_
M .M1_P (N/\ H.:W_P"!G_UJWJ* ,'_A%Q_T'-;_ / S_P"M1_PBX_Z#FM_^
M!G_UJWJ* ,'_ (1<?]!S6_\ P,_^M1_PBX_Z#FM_^!G_ -:MZB@#!_X1<?\
M0<UO_P #/_K4?\(N/^@YK?\ X&?_ %JWJ* ,'_A%Q_T'-;_\#/\ ZU'_  BX
M_P"@YK?_ (&?_6K>HH P?^$7'_0<UO\ \#/_ *U'_",#_H.:W_X&?_6K>HH
MP?\ A%Q_T'-;_P# P_X4?\(P/^@YK?\ X&?_ %JWJ* ,'_A%Q_T'-;_\#/\
MZU'_  BX_P"@YK?_ (&?_6K>HH P?^$7'_0<UO\ \#/_ *U'_"+C_H.:W_X&
M?_6K>HH P?\ A%Q_T'-;_P# P_X5>TO2(M*6?R[BYG>>3S))+F7>Q. HY],
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MGI0!8MI$D@C:-U==HY4Y%356L=/L],MQ;V-K#;0 DB.% BY/4X%6: "BBB@
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M5L+JXEN-UQ%/*[N\D;C)W*JLO(/!"+[C'!ILWA*QEMH;<2W44<-PUROER_\
M+1NYR#G&>,]*W\T4KL5D96H:'%J5A':7$]P50$%@XRX(P=V00<CV^E5'\)6#
MPRV_F7:VLJ%6MUG(3)386]<X]3C/.,UT'-%*["R,_5='M=9LUM;U6>)9%D&&
MP<CW]#R#Z@D5?QBG8I#VH R8/^1HO/\ KVB_FU:]9$'_ "-%Y_U[1?S:M>LJ
M6S]6:U-UZ+\@HHHK4S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L[6]7@T/2I;^X2214*HL<8!:1V8*JC/<D@5HUGZSI%MK>E36%T9%CD
M*L'C;#(RD,K*?4$ T 8>H^+;W2]%NM2O/#EY']D?$T9FCQMP"'5LX8<XP.0<
MTM[XP?3KZRT^\T:[COKY1]DA5U<2-NPZ[AP-HPQ)_A/KQ4\OA3[9H6HZ;?ZK
M?W;:@1YMQ(5#*!C 10H51QV'.2:35_!UKK.J#4KB\NTNX506;QLH^R%6W%D&
M,9;HV<Y'% "KXJ1=5N;"YTR^A,4$EQ&=H=ID1PA(126&21MR.1]*SY?B'90Z
M=I]\]C=^5=6_VJ094&"+S%CR<GYCN8<#M^NGI'AEM)UJ_P!3_M2[NI+YB\J3
MI'@?W0&"AL*. N<#)JC=> ;"[TO3=-EN;AK6Q4IL*1DRKN#<DKE3D#E<'!(H
M Z\=**0=*6@ HHHH **** "BBB@ HHHH **** "BBB@#)G_Y&:S_ .O67_T)
M*U#TK+G_ .1FL_\ KUE_]"2M0]*QI[R]?T1I4VCZ?JSC+S2+7Q+>:K!JIGGM
MXKI42'SF6, (I'R@XSECS5BPO(]"N]3CFN+F2S@AMVC21VE8,Y9=JYYY(4 >
MM1KJ=CI>K:PE_=16S/=AU\T[=RF-!D?B#3(;>/Q!?:J;.Y 39:M%<*NY1+&[
M./KSC(ST-=C^$X4WSFK+XG2'8DNEZBMP\RPK;F--[%E9@0=VTC"-_%QBHYO&
M6GP6WFO;W@=3)YT'ECS(?+ 9RPSC@,IX)R#QFF76D:Y>26UU)>V7GV]RLT<(
MC;RE 1U//WB3OSZ<"L^_\%7-^9+B>XM)[FX:1IDFB;RE+JB!T&<AE5  3UR>
ME1:)O=F]JVOQ:1;0W#V=W<PRLJA[=5."Q"J#N8'DL*BB\56#W&H6\R3VTVGP
M+<3I,H&%*YXP2"1QGZBI=2TB2_T:"P%P=\4D#F609+^6ZL<^YV_K69?^$GO=
M:EOOM2K'-.K2Q[3\\0108R?=D4_3(I*W4;OT.@TW4(M4TVVOX%<0W,2RH'&&
MP1D9'K5NL_1-/?2]$LM/>02-;P)$7 P&P,9Q6A4C04AZBEI#U% S)@_Y&B\_
MZ]HOYM6O61!_R-%Y_P!>T7\VK7K*EL_5FE3=>B_(****U,PHHHH **** "BB
MB@ HHHH **** "BBB@!#TKRVZN[34_B3 SO&)(;I(D07D;%61OO!<;@2%QCL
M"WJ:]2;I7 ZR\P\?V\JZE)'!'+;0RQ#=E6<DJ% 8*0Q7#$J2-W?' !VUS?6]
ME&CW,T<2O(L:%VQN9C@*/4DU7;7M,2>YA:]A$ELA>8%ON 8SS[9&<=,BFZSI
MQU&TB5(XS+'<12*SCE0LBLV#VR%-<U>>%M2NF\I1 L=M<7%S!(7_ -<TDRRA
M&&/E'!!//8T =A97UOJ%L+BUE66(DC</4'!!!Y!![&K%<)K6C:E'H=[J"SZM
M#=FXEN1::1<HA8-M4!BPP<!-QZ=6ZUM>!KJYO_ ^BW=W.\]Q+:(\DCG+,Q'4
MT =#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5E>(-?M/#FGK>7BR-&S^6JQ@$EMI(')
M'7&/J16K7%?$ 7<-M:745PT<2L4,:2RJSN?F& G!P%)R>F* .ITK48]6TNVO
MXD=$G3<$?&5]0<$@\]P<5<K(\.2^;X7L'23S3Y(&[+<D<?Q<]L<UDCQ!JLD$
M42P6D-ZS79<,6>-5@;;MSP<G*\_4X[4 =;17'6WB^5HXK^:#_B7S-*BQQ1L\
MZF--^<#.[.&& ,_=ZYXUM!\4Z=XCDNHK$72R6A03)<V[PLNX$KPP!Y H VZ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#)G_ .1FL_\ KUE_]"2M3M67/_R,UG_UZR_^A)6H>E8T]Y>O
MZ(TJ;1]/U9Y_\8^?A_-_U\1?S-=Q8\6%M_UR3^0KF+BSAU[5M2&I+]HMK6<0
M0VS$[!A%8L1W)+=3TQ5WP\7M=4U#2Q([VT*12PB1BQ0/N!7)Y(!7(],XK?VE
MTH@Z-ES7.C'(I:3-&:DS%I*7-%, Q1110 4AZBEI#U% &3!_R-%Y_P!>T7\V
MK7K(@_Y&B\_Z]HOYM6O65+9^K-*FZ]%^04445J9A1110 4444 %%%% !1110
M 4444 %%%% "'I7&ZGK%E;^.K*RET.">[94$-XR9E 8X)0[#\J@DD[AT/X]D
MWW37#WWVG_A-K2]>WU2SMRZ0F2'RTCF.YE E)E^93P0 F[D<]J .X'2H#>6P
MEEC^T0[XEW2+O&4'J1V'UJ8_=KSR[\/ZM-J-XZV<A'FS2,I9!$Z--&X6,YW%
MG6/#!^ <@8'4 W/&\MI<^"+Z1I-+EMV52&OIBL!^88RR]\]/? I_P[_Y)UX?
M_P"O*/\ E6#K=CJL7AO4+V*[O-,@>YFG>R@T^.[D='V@94@[>0S';TW'/2M[
MX=_\D[T#_KRC_E0!TU%%% !1110 4444 %%%% !1110 4444 %%%)F@!:0]*
M V:I7NK:?8.L=Y>00,PRHD<+D4 70:1FQ7$:%KZIJUX=0U(+;G/E><^%^]V_
M"NG;47ECCELK4WL$BY$L4J!?3N:PH5E6ASKS_ VK472GR2*VC^(HM8N[BWC@
M>,P=2Q!SSCM6T*Y?2=;MKJZN$T[17$R?ZW:8T)YQUSSS72P.\D2M)&8W(R4)
M!*^V1Q3HMN%V[BK149V2MY$E%%%;&04444 %%%% !1110 4444 %%%% !6%X
MJL+C4=+2&"Q@OU6=7FM)BH$R '@%@0#G!SZ \C-;M<C\1B4\*O)]H,*I,C,0
M1@C!X(+INYP0 <D@<'I0!N:!:W5EH%C:WOE?:(H5201 !01V& !QTX 'L*+K
M0M-O(/)GM@8_,>3 =E)9\[^00<-DY'0YZ4WPWM_X1O3REQ-<*8582S1LC,#S
MDJWS#Z'FJ/BK7I]#AA>UACFE9)9"K!F)5%W$87D9.!N/"Y&>U &G%H]A!J!O
MHK<+<$8W!C@9 !(7. 2% ) R<5QG@ 2#QAXQ\T3AO-MC^_N1.V-KX^8=O0=A
MQ6Q_PEGDW#7-VL,>DF2:)95+,ZF)=Q8@9!4X;&/0=<\<_P##&>UNO$GBV>R:
MR:"26W939PM%&<JW.UN=WJ>YS0!Z51110 4444 %%%% !1110 4444 %%%%
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M!&=OE[4&"OS[B 1QD<"NE^'?_).] _Z\H_Y4 =-1110 4444 %%%% !1110
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MH_Y4 =/1110 4444 %%%% !1110 4444 %5;O4+:R*B=V7=TQ&S?R!JSFC%
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M** "BBB@ HHHH 3%*.*** "BBB@ HHHH Q=5U2^M]4MK"PLX;B6:)Y299C&
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MRV)$TGF?\M$'3:"0#]#R.,OD?</9O^=_A_D7/M?B?_H$6'_@:W_Q%'VOQ/\
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M#$Y=X3")$F/\.X$C(!YQT)QGI4OAUXY/#M@\(D$;0J5\R4RL1ZESRQ/7-:=
M'/?\(O!+=,;R07-FSR2?99(AL+R+M<GU!RW'^T>O&.7^&B6\7B;Q?':)9) D
MUNJK96IMXUPK#&P]_4]">:[2+7[2;5&L DP(=XUF91Y;N@!90<YR >X'0XSB
MN3\!>=_PF/C#SQ?!_-MN+YE:3&UL<KQM].^,9H ]!HHI"<"@!:*YZU\8Z==Z
MZ=*CANP3+)!'=-#B"65 2Z*V>2,'MCY3CI70T %%9>IZ_9:3.D-QO+NN[Y #
M@9QD\\5I*X=0RD%2,@@\&@!U%4M0U*WTRV-Q<OM3( ]23Z4[3]0M]2M%N+9M
MT;$CW!]Z5U>PKJ]BW1FHY25C8JNX@' SC)KE_"-Q=S7%R+F,A0%()/?)J7*T
MDNY+G:27<ZRL&31;F36QJ(NX0 P(C\@DX'&,[NOOBMZL:1]4_MM50-]AR,G:
MN.GKUZT2MU"5NIL+TI<4B]*6K+ #%%%% !1110 4444 %%%% !1110 4444
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M?_'* .OP*,"O.[>?QY/XEO=&_MS25-K;Q3^<=,;#[RPQCS.VW]:UO[,\>_\
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MK!M?^1UO_P#KSA_]">MZH1G2V?JPHHHIFP4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 )@9SWI:*,T )@ Y[TM%% !@9SCFBC-&:
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M4O\ OA/_ (JC_B:?] #4O^^$_P#BJ]'P*,"I>08%_9?WL?UZOW_ \X_XF?\
MT -3_P"^$_\ BJZ'PA!=1IJ,MU9S6IFG5D28 ,0$49X)[BNEP/2EP!VKJPF6
M8;"3<Z2=VK;F=7$5*JM(****](YPHHHH **** "BBB@ HHHH **** "BBB@
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M%!.XA03A03S@8J^>E+2'I2&85K_R.M__ -></_H3UO5@VO\ R.M__P!></\
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M3UO5,3&CL_5A1115&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4ASCBEHH R+30+6V;4%9GN+>^G-Q);W"H\:N>N
MT;<X.!U)Z5=M]-L;3;]FLK>':25\J)5P3UQ@=\#\JM44 0&RM27)MH<NXD?Y
M!\S#HQ]2,#GVJ"XTNWN-5M-1D#&>T218AN^4;\!CCUP,9]SZU>HH A:UMW\T
MO!&QE4+)E =ZC/!]1R>OK1)9VTI8R6\3ED\MMR Y7^Z?;VJ:B@"&2TMIB3+;
MQ2$H8R70'Y3U7Z'TI9+6WF*&2"-R@(0L@.W(P<>F1Q4M% $+6MN]O]G:"(P
M!1$4!7 Z#'3BJ>F:1'IMS?W"SSS2WTPGE:8KP0H4 ;0. % ]?>M*B@ HHHH
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M9UEK5I?VJW,3E86 97E&P$$D#!/KC/T(]:FN-2M+2*:6XNH8DA&Z0LX^0>]
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MB#[;%IH;3F,@643C?M4'YRN,!25QU)Y'%10>)+]EM1-I*^9>VQGM5AN0P<@
M[&)5=IPV<\C@UI9G+<Z6BN;@\86?]FO>WBO'&DSPE[9'GC)4@9#*O0DX&0.:
MZ-3D9HLT%Q:***0PI#TI:0]* ,*U_P"1UO\ _KSA_P#0GK>K!M?^1UO_ /KS
MA_\ 0GK>J8F-'9^K"BBBJ-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>tm238578d1_ex99-2img42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img42.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $O KP# 2(  A$! Q$!_\0
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M!:*,T9H **,BC- !129I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK3JRQXAT<?\ ,2M_^^Z7_A(M'_Z"5O\ ]]T :9K"\'?\BEI_^ZW_ *$:L_\
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M!=QZL0.35*P_Y&+6/I!_Z":QG\4?7]&:0VEZ?JC9'2B@=**U("BBB@ HHHH
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M6'_(Q:Q](/\ T$UE/XH^OZ,N.TO3]4;(Z44#I16I 4444 %%%% !3'<("QZ
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MH **** "BBB@ HHHH ****  U!<W45K%YLS%4R!D GD^PYJ<UEZQ_P >L?\
MUWC_ /0A03)V5R4ZK;>EQ_X#2?\ Q-']J6W_ $\?^ TG_P 35O\ &LS5?$.D
MZ)Y8U*^2!I,[$.XLV.I"@$X]Z!6F^OX?\$L?VK;?]-__  &D_P#B:/[4MO\
MIO\ ^ TG_P 361/XY\+VSQK+K, ,@!C(#$.",C! YR/2K]OX@TBZ@N)H;^(Q
MVT0FF8Y7RT(R&.>@P"<^QIBM/O\ A_P2Q_:EM_TW_P# :3_XFC^U+;_IX_\
M :3_ .)K/N/%OA^TGMX+C5(8I+A4>,/D</\ =)/1<]LXS5VXU;3[74+;3Y[R
M*.\NB1# 6^9\#)P/I2"T^_X?\$?_ &I;?]/'_@-)_P#$T?VK:C_GO_X#2?\
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MU"Z);+0M.LEM?*M8]]M'Y<4C#+@?7\3^9K1 Q0*6D,:_2LBP_P"1BUCZ0?\
MH)K7?I618?\ (Q:Q](/_ $$UE/XH^OZ,N.TO3]4;(Z44#I16I 4444 %%%%
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M,6L?2#_T$UKOTK(L/^1BUCZ0?^@FLI_%'U_1EQVEZ?JC9'2B@=**U("BBB@
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M(F7??Z88Q?L[ 6[9-KCA1SP^<\_2NE&0*Y[_ (07PZ?^7!O_  )E_P#BJ/\
MA!?#O_/@_P#X$R__ !5 '19HS7.?\()X<_Z![_\ @3+_ /%4?\()X<_Z![_^
M!,O_ ,50!T>3Z4$GTKG/^$$\._\ 0/;_ ,"9?_BJR]:\-Z5HTFDW5A;/#/\
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M]E!,WBK5 7C5B-D/4C/]R@#J<CUI,CUKG?\ A'-3_P"AJU3_ +XA_P#B*/\
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MI&[@,X'GI_$><\D_C7>5R7Q*/_%!:A_UTM__ $?'76T 8&B?\A_Q#_U]1_\
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MDW&99/NB-3QMQS@\C@'M4^[^-'EKG..?6E  &!0!6N;*&[9#*&.PY7!Q5G'
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M3?\ KRF_]"6NB[TCE@G.4KM[V_!>1A_\5/\ W](_[YE_QH_XJ?\ OZ1^4O\
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MK+^'X_XM]X?'_3A%_P"@BNDVBLJD'*UF-.P"G"DQ2UH(****8!1110 4444
M%%%% !1110 4444 )BC;2T4 -*Y[TN*6BE8!,4M%%, HHHH **** "BBB@ K
M)\2)</H5S]FDCC=5W%I)"B[1RP)"L<8SV-:U4M78IH]ZP )6!R 5W G:>W>@
M#DOAQ/'=0:G.)EEEDG0R/AP6^0 9W11D\#&>>G6HM-\5:M=:/JLDKVJ7<04P
M-*A1(W).^-^OW."3C^(58^'ABETZ[F"*)99$:4B6%\ML'_/(# ]CSUKM-@(Y
M)H \N\7:[K%_\/T+:+*]K.MNTU^\R($83K_RS^\0<#! Y# UZI7)?$D8\!ZA
MS_RTM_\ T?'76T %%%% !1110 4444 %%%% !1110 4444 %%%% "-TIF<>U
M/;I6'KUGJEWY/]FSB+:6W_.5STQT%3)V5R9.RN;.<5S6H^*](COKG2M1!CAV
ME)7DP4(('!QZ@XKHH598U#G+  $^^*SM6N+?2+:34?LBR2K@$J &.>/O8I2O
M9-$S;2O>Q5T[Q7I5]J$>GV+L^5Q&Z+\A ';Z=*Z$'(%9.E"UU*"'5_L:13SK
MNR0"P[=?H!6A/+Y,$DI&0BEB!WQS3BWU"#;5WJ39I:P_#_B&+Q!!++% \(C8
M*0Y!SQ[5MCFFFFKHJ,E)7B+1113*.;NO^1[TW_KRF_\ 0EKH<9/-<]=?\CYI
MO_7E-_Z$M=".M);LYZ/Q3]?T1RGQ*4?\*WU[_KU;^8JQHM_'IO@72[F56=5M
M(0%3DL2H  ]R:A^)7_).->_Z]6_F*GT2QBU'P+IEK*65'M(OF0X*D $$>X(%
M&G,=C_@KU_0EDU^\BDA@;1+D74LI18S*@4@)NW!LX/ QCUIL?BE9$M9!87(A
MFD\EG8*#')O9"FW.6(*MG;G'6AO#EP\D5P^MWK7L;EQ<%(R "I7:$V[0,$GI
MDFHH_"2Q7EM+'JEV(X59?*=48,S,S2/N*Y#.6.2/PQ5:&.I)I_BR#4M,OKZ*
M"0+:0^<R;E8L-I8#@\-\I!!Y!QFEC\7:?-<6\,,D4OFI&Y9)EPF\XP??K19>
M%H+.PO+7[5-*+BV^R[V55*1!2H "@ D9ZD9/%/N/"]G/+;2AY(S;K&H"!1NV
M9QGCKS1H/4>/%6CO;BX2_C\LXP=K9((W9 QG&WG-6;?7-/NKI;:&Z1Y6&5 S
M\W /!QC.#G%8%_X3FBCMWTN=Q=10+;"1Y A$8CV?W2#G )X[<8J[H_A.#2KN
M&X2<N8HP-AB0#>4"EMV-V,#IG'-&@M3H\US^E?\ (V^(/I;?^@-6_C%8&E?\
MC;X@^EM_Z U21/XH^OZ,Z$=*6D'2EIFH4444 %%%% !1110 4444 %%%% !1
M110 PYW=:X7P*]TEU>6LBWBPHN5CGEE<6QWD>4=X +8YROR^G&,]=JUO+=Z7
M=V\,<$DDD954N"?+8XZ-CG'TKFO!7A:^\/M>2:A'9&XN0-\MK,Y4X_A6,J%1
M0.!C)/<DT =GFJ>K_P#(&OO^O>3_ -!-<U!J&O)XIU2.1;E[/!6!6A'EJQ"^
M7M(&3DE]Q)(&!TK/L)O&M_X;\J."WN))=T<DFJ,8) "BYP$3! 8N!P. * -W
MX?\ _)/] _Z\8_Y"NEK@-$M?'NB:'9:7#8:#*EI"L*N]Y*"P QDX2FGQ+XV'
MB1-!_LK0OMCV;7H(O)=NP2!"/N=<L* /0:*X_P"U_$+_ *!7A[_P-E_^(JAJ
MGB+QSI"VAN=)T$_:KE+6/;>2\._3/R=.* ._HKD/M?Q!_P"@5X?_ / V7_XB
MJ]]JWCRPT^YO9M*T#RK>)Y7VWDN=J@DX^3VH [>BN&T[6?'FJ:9::A;Z3H*P
MW4*3(KWDNX!@" ?DZ\U9-W\0O^@5X>_\#)?_ (B@#L**\_TGQ)XXU@7IMM(T
M(?8[N2TDWWDOWTQG'R=.:T?M?Q!_Z!7A[_P-E_\ B* .OHKS[_A)/'!\1G0O
M[(T+[7]D%WN^V2[=F[9C[G7(K1^V?$''_(*\/?\ @;+_ /$4 =A17GVJ^)/&
M^CO8"YTG0C]NNTM(MMY+P[9P3\G3BM+[9\0?^@3X?_\  V7_ .(H Z^BN&U'
M6?'FF:9=7]QI.@&&VB:9PM[+DA1DX^3TI]EJWCV^L;>\ATK0/*N(EE3=>RYP
MPR/X/>@#MJ*X_P"U_$'_ *!7A_\ \#9?_B*S](\2^-];ANI;32M"46UW+:.'
MO)/OQMM;HG3- 'H%%<A]K^(/_0*\/?\ @;+_ /$5G)XD\;R>()M$72="^U0V
MZW+$WDNW:S%1_!G/% 'H%%<?]K^(7_0*\/?^!LO_ ,16?JGB3QOI$NG1W.DZ
M$3J%XMG%LO)>'968$_)TPA_2@#T"BN/^U_$$8_XE?A[_ ,#)?_B*W]&DU633
MU;68;6&\W'*6LC.FWMRP!H T:*** "BBB@ JGJHSI=V/+DDS _R1'#M\IX7W
MJY6/XGM+J_T&YM;*"VGN7 \M+F1TCSD<DISQZ"@#$^']W<W&G7*7+32>5(BI
M*[AE(* [01'&<CHV0>>_IV(/%<KX(T*\T+3)K>_B43R2AVD6[:82''4!@-@[
M;1^9K*T^_P#$_P#8^I"\^W?:"8]C>0NZ,[OWPCP "H7&W.<G/6@#4^)7_(A7
M_P#UTM__ $?'76UYQJ>G^-/$?A"#3FBTX>?%$TTUW(T<P99-PRBJ5&0JYZ=3
MZ5M?:/'Q_P"8=X>_\#)O_B* .MHK@M/\1>-M2O\ 4K.'3-!$FG3"&4M=RX+%
M0W'R=,$5H?:?'W_0/\._^!DW_P 10!UM%<$_B'QJGB&+1#IFA?:I;1[L-]KE
MVA%=4(/R9SEA6A]I\?8_Y!WAW_P,F_\ B* .MHK@=6\1^-='>P2XTS06:^N5
MM8BEW+@.P)!/R=.*T?M/C[_H'>'O_ R;_P"(H ZVBN%U?7/&^BZ-?:I<Z9H+
M06<#W$BQWDNXJHR<93KP:M17OCR:&.1=/\/;74,,W<V<$9_N4 =A17)?:?'W
M_0/\._\ @9-_\16=H7B/QKX@TJ/4K33-!6&1W0+)=RY!1BIZ)Z@T =]17)?:
M?'W_ $#O#O\ X&3?_$5G6?B'QM?:MJ>FQ:9H(FTYHUE)NY<-YB!QM^3T/YT
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M4RB-1(0%+[>2/3/I4FX4;E)QGF@!:BEACE9#)&K[&W+N&=IZ9'H>3^=2YHH
M04M%% !1110 4444 %&*** $(%'%+10 F!1BEHH C2)$=F5%4L<L0,;CZGUI
MY%+10!&8D,@DV+Y@& V.0*>!2T4 1O$CE2\:OM.1N&<'U%/Q2Y%% #)(UD1D
M=0RL""I&01Z&E50H  P!QQ3J* $(IL<21)L1%1>N%&!3\TF10 $"F")%=W5%
M#/C<0,%NW)I^X?Y%&10 8J/R8_-$GEKY@! ;'(!.2,U)D>M&1ZT &!3'BCD
M#HKX.1N&<'UI^11N7UH   *:\:R*5=0RD8((R"/>G;A1D4 -5550H& !@ #&
M!3L4;AZTM $<<21+MC14!.<*,<^M28HHH **** .;N?^1\TW_KRF_P#0EKH3
M7/77_(^:;_UY3?\ H2UT!I+=G/1WGZ_HCC?B586<O@?6+R2UA>Y@M6\F<QC?
M'R.AZBM/P;I]E9^&=/DM;2"!Y[:-Y6B0*9#MSEL=>I_.J^L0+K&MS:9=EFL8
M;9)'@!PLK.6'S>H 7I[U-H"G3]4NM*BD9K2.WBFAC<D^5DNI4'T^4$>E/F5K
M'9[-\M[G2#ITI:;N]J-WM09BT4;J6@ HHHH 1JY[2O\ D;?$'TMO_0#70M7/
M:5_R-OB#Z6W_ * :74RJ?%'U_1G0CI2T@Z4M,U"BBB@ HHHH **** "BBB@
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M.C_*_O7^1GOXHU<_<L+)/9YG;^0%1-XAU]R<#3D'M&[?UK5_X0[1QT2Y_P#
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MCO\ -7H*_7- "XHQ110 4444 %%%% !1110!RNI74%GXVTV6YGCAC^QS#<[
M#EE]:U3KVDL?^0G9_P#?Y?\ &KLMI!.09H8Y".F]0:C_ +-LO^?.W_[]"E8P
MC"<6VGN[_@9.H3>'-36/[5J%H6C)*2)<A'3/7# Y%.T^[\/:7 8[2_LT#G<[
M&X#,Y]2Q.36I_9ME_P ^=O\ ]^Q1_9ME_P ^=O\ ]^A2U+O6M:_YE?\ M_2?
M^@G9_P#?Y?\ &C^W])_Z"=G_ -_E_P :L?V;9?\ /G;_ /?H4?V;9?\ /G;_
M /?H4]2;5?+\?\RO_;^D_P#03L_^_P O^-']OZ3_ -!.S_[_ "_XU8_LVR_Y
M\[?_ +]"C^S;+_GSM_\ OT*-0M5\OQ_S*_\ ;^D_]!.S_P"_R_XT?V_I/_03
ML_\ O\O^-6/[-LO^?.W_ ._0H_LVR_Y\[?\ []"B\@M5\OQ_S*QU_2?^@G9_
M]_E_QK.T*Y@NO$^O2V\R2QD6P#HP(/R'TK:_LRR_Y\[?_OT*FAMH;?(AACC!
MZ[% H#EFVG+H2KTI:!THIFP4444 %%%% !1110 4444 %%%% !1110 4444
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M5XB+F(.T,7F7+*0BPJD<9D;ON^9R ,?PFM>+PKHT5Y-=?V=;/-*-A9XP2J;
MFP<<+M7I[MZFK#Z#I4DL4LFG6CR1%RC-$"5W\O\ GW]: .?'C&66\CB&EF+9
M(&NWEF7]S"8O,+<#[P4KD>XY-6K3Q8\YLC-H]W9K>3")'N@8U&0",Y'#'. #
MC)! )K3M_#>CVL<4<&F6D:1,70+$.&*[2?J1QGTHM_#FCVLEO);Z9:Q-;9,)
M2, H3Z?R_&@#'U+QK:Z9>7$,UC,T,)>,2H0V^154[ O7DNJY]6 [U=T_Q#)J
M%^+-M+N+=EA\Z=IF $2EF5..I+%&.,#CK4T'A31H?MI-A;RO>EC<O)&&:4,<
MD$]QT_(5>M=-M+($6MM%#E50E%P2J] 3WQD]: .73Q?<3:N(H=/_ ')A0Q1M
M(H>5G,A5B>B*$@E8@\_=IZ>/+=R7_LZY$ VKO+#+2&%9=@7KT=03TR16P?"N
MA>0]O_8]AY,D@E=/(7#.,X)X[;C^9'>K4FC:=-')%)8VSQR!@ZM&,-N !S]0
M /H!Z4 8/_"7F9[JU2R>*YMTN&G8RJR0B)5.[C[W+J,#H0P/2N@TBXN+O1K&
MYNH?)N9K>.26+^XY4$C\#D56D\.Z:U@;*.TB@@9/*80*$S'NW%..Q.<^N3ZF
1M4#  _E0 M%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>tm238578d1_ex99-2img43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img43.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  HH# 2(  A$! Q$!_\0
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M1_5O^AHO_P#OS'_A1_PCVK?]#3?_ /?J/_"NCHH YS_A'M6_Z&F__P"_4?\
MA1_PCVK?]#3?_P#?J/\ PKHZ* .<_P"$>U;_ *&F_P#^_4?^%'_"/:M_T--_
M_P!^H_\ "NCHH YS_A'M6_Z&F_\ ^_4?^%'_  CVK?\ 0TW_ /WZC_PKHZ*
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M'M6_Z&F__P"_4?\ A71T4 <Y_P (]JW_ $--_P#]^H_\*/\ A'M6_P"AIO\
M_OU'_A71T4 <Y_PCVK?]#3?_ /?J/_"C_A'M6_Z&F_\ ^_4?^%='10!SG_"/
M:M_T--__ -^H_P#"C_A'M6_Z&F__ ._4?^%='10!SG_"/:M_T--__P!^H_\
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M%(.E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG1N'J* '44W</44;QZC\Z '44T,">"*=0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2$9I:0]* .,\4,%U1?D9SY2\#ZFN?#70;YK6,H2,;).
M1]:Z;Q*,ZB.#Q&.?Q-89XR1^%-"$*KQP/Q%.51QA1@U#Y39!2=D<\[6^9?\
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M7#!@)+26,L< @!A^..E6'P-H$>[)P2 .*3)9&V@XQGWJK)+<VZLZ[98U^\&
M#;?;'&?KB@"Q*L94B08!X)/!-!0([$J2" /O'&/I35D#Q@D @@-QSQZXIADV
M3[0C'.,MGB@"5>A+*FP_=Q41$<8Y Y]*';YF* G X [U$2TD0=E*D#)4D=:
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M \S@+ACGGCU]*X=)BJ^8H4[>F.WX5LZ3<0R2F.X!,S$;'SR3[F@#=FGB2!9
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MXH UO"__ "$G_P"N1_G77UR/A?\ Y"3_ /7,_P ZZZI&%%%% !1110 4444
M%5[V[@L+26[N94AMX4+R2.<*JCJ2:L5S?C[1[O7_  -JVEV.#=7$.(U)P&(8
M-MS[XQ^- $>D>/=!UO48K"TN+A9YHS+;BXM9(1<)W:,N &'TKI@>*X:T\1:E
MKLT-K8^&;NS:.TD\VYOHA']EEVX5(\_>^;N., 5Q^A:5J*76G&QTG5[6^CL;
MM=?EN2VVZD,9V $DAV\SD$=!^5 'LTLJ11/+(P5$4LS'H .IJ.QOK;4K&"]M
M)1+;3H)(I%Z,I&017CVE>$KV"#04^P7C27GA^XBU'S6;YY=J^6KY/!!X%-\+
M^%1?7_A"WNM*OXM/MM(E%U','1/M*R G=SSELL/7CM0![7GVK*TO7[#6-);5
M+*5GM5:169HV4@QL5;Y3SU4UY=IFE:JGB'3V_L_54\2)K)EO]1=F\E[+<V5W
M$[2"NT!0.#Z5UO@/3[NT^'EQ;7-K+#.9KTK%(I#8:1RO'N"* .GLM;L-0T)-
M:MI6:Q>$S*Y0@E ,DX//05GVOC30[S3-,U&WO#);:G.MM;,(R=TAS\I'53P>
MM<IX4U66+P+:^')=&UB*^6PDA9Y+0B/<%8_>]^@^M<YIOA36=&E\&+:6,W]F
M7-Q:W5[!M.;2X1,,W^R&!Y]Q0!Z!#\2_#$]T(/M5S&#<&V$\MG*L)E!V[?,*
M[>H]:ZX'.:\H\*^!+O5='EBUB_U"WT]=6GG_ ++\M423$I96W8W8)P>N*]8Y
MY)]* .5\2_\ '^/^N8_F:YV<O'&9$&2A.5QU'M[UT?B2,/J (Z^6/YFN><8(
M^7.#C)--"&1S"X19(FWQD<^H/O43R-&"9'0[,AE4Y'3H:2XMF8AX,QLQPWHW
MI52"W54>$DOYQ.3[CU-,"C>:HRZ:Z%0&DX#+_=ST ]:Y=-R%AO/)Z8J]?QFW
MN&#2"3:>2IR,5G!E8\N<#! H E(/W ><]*< <EL8*CBFP,@''(SQFI"1),""
M<Y'(Z4 2)'O&8\A@,L#U_"I(V9'#J2=O. >:A5AM)7CL0>]31@,JNS%&SCY3
MDT =!I4[76Z43'S6.'#C@#_]5:<CLJK)&I>/;S\W..>GYUQ\>]'1;<[6+#!S
MWKKXRB2JJN3E<8 X'M^>: )XRCHJ1L.@(!Y(&*>N>I[^II@9SG*@+GC!YQWI
MT3%@1E2%) QTQ0!(>E3Z<!_:$?\ NO\ ^@-5<U/8$C4H^.JO_P"@-0 Q5RH
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MA4H6(+8QY8[9I))8XTWR#"C\S3W&9)(P 2P^8,,@BJ+V_P!F783O@8;?+/\
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M>JZ(QO'D+ X1?E4X.?\ ]53_ "XPI*E3@9[T .1@P^4Y%6=.P-1CY.2K]?\
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M0 R4$KRW [4_3GV:@C 9PDAQZ_(U-="W0\5-ID3)J43<8 <_^.-0!0BM+R^
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MI:VZ7*NMV6(#<"$C^%J ,M>HJ5LE,L>G09J18K/ /VYNG_/ THBLUX%\<?\
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MH06R.3ZT :B.KY(Z"EQ],54CD*# '%*9ST'6D ^54Y.>:2T/^E*.GROS_P
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M'-.'"T *?QJ>9S'IEL0"297'3ITJ#BK$K$:;;@=Y'_I0!1D99&9L8;'7G/\
M^JJYF6-44!BYX '>I,LLAP<@GYO3%-!193(KY#< ]EH J26Z+"B1N8D'#!QD
MG-3Q1!85CC4X7(X///<T_:'<-A3R0K @].M.52$'EQEGWC*@X(R1S^')H B-
MK!O3>J H5*@+D@]Z?<Q322HN"RC<&#@'D]*GVQ[#MD4D9^8-G#4[RPT>2^58
MY8KCF@")W\E2X5C&%&T 9;/T J*XCB@*DA1W$Q^ZK#U-69(UFAP3C+#&"3WX
MIEQ&CDB6$RAWVIZ#O^% #(F:2-+B21"[@HI8_)WX&,9_GTIP:12/,B7>/EP#
M\I^G?'M4=S9I<0',4Q:)BPPO&XC((P>G _.EAU".YE"#*W."6@9"""!R,^M
M$BH?OA7PPR!G[O/. >U.10CEDD)&!\F<\^M1JCQOA1A50*&Y)+'DFGHHWY('
M+810,8]<_C0!-N(!SCKCBC@KDGCI4#*\@&UR@&03CD^XJ7;N50<Y'H>M #[=
M<7EO[2+C\Q1>RHMW=;B>)G/3I\QI8F N[?WE3^8J.^.;V\PNX+(_W><\GB@"
M.1V9!M8#UW&JTA,N H*L&Z_X5(9/+BW/&P&.0>H_"HX)%D0LN0#R"1TH C@6
M1279LJ&X [59C3;RP4+V]:0'/#+C//'3'K2Q.&CW,/D)(7OQ_2@ 7_CXVA1R
M@+'.<&HH[8?:GNB[F5L K@%0/0#MU%2M&Y?B(GDDD';M/;ZBI68PDLX #D ,
MQQG'0<9H J[E,"Q7<C0[B5/&3^!^E-VYN3:Q+(A\O')P@!]<'[W?TYJT[J8Q
MYBR8)^;*X'?UJ(S1W,\J03HDG#O@#Y@">"/\F@"M:/$L#1Q[99HC^\VJ<!N>
M<GJ.M6A"L<:@>8$0?WN3^-(%83R;H-J2':?*&<\=?4Y!XXJ&*4SPB$%OF& &
MZ@=]Q/(YH ?-;JR+G?M/S-SR._'M5P.K ?/NXS@55M(I(8@K,7"C ]:E211C
M&.&Z>WO0!-DX&%Q]:0*P'S$?@*%#@C+'&#]X 4\Y/.3UYXH UO"B[=7DR<GR
MC_.NTKC/"Q_XG#_]<C_,5V=2,R/^$=TG[+J5L;&-K?4I&EO(SDB9F !)S[ =
M*HS^!?#-W);27&D0RM;1I$F]F(*I]T,,X<#MNSBNEHH XR'X>Z1)X@U#5]4M
MH+Z>XNUN8=RD>7M4 *0#AL$9Y!K>CT'2XH-0MQ8Q&'497ENXV&Y9V8!6+ \<
M@"M6B@#DY/ FD6GA[5-,T6TMK![^+8\LD?GYQT#!R<J!QCMGBLOPW\-K33A>
MG4XK&5+J.*+[-9QO'$HC;<#RQ8MNYR3VKT"B@#G]5\'>']<NOM6I:9%/,8O)
M9BS*'3G"L 0&QDXST[4^7PGH<]K=VTVG1/#=B,3H6;$@CQLSSVP/RK=HH QK
MCPSHUU<7,\^GQR2W4T4\SDMEY(@!&QYZKBD?PSH[F4M81GS+U=0?YFYN%QMD
MZ]1M'M[5M44 8$7@[P_!K;:U%I< U$NTGF\X#GAF"YVACW(&345EX'\-:;J:
M:A9:1!!=)(TB2*6^0MG.T9PH.3D# Z5TE% %#4-+L]42!+ZW69()TN(PQ(VR
M(<JPQW!I+/2+&QN;VXMK9(YKU_,N7!),K8QDY/IQBM"B@#FAX&\-"UEMO[(A
M,$MO]F="S$&/>9-O7IN.1CH34MQX/T"[AGBGTN!DG\HOU!S&,1D$'*E1P",&
MN@HH P;?PCH5K:P6T.G1B*"Z^V1@LS-YW_/0L3EF^IK;7K3Z#0!Q/BAO^)Q@
MKD>2IY.>Y[5A[L%VYZYP2?PZUN^*6*ZL"%/^I7+ =.36  \I!&U!CY2>3[TT
M(K7EMYQ7;(RN.>N:YG5LV\KC=N;/'>NKE8<(I)=0&R#R<5RGB&,K=M(H*JXR
M1UY[TP,HR%I0226]13I3)*Y;<6+<,:KJNUQAN_3O5E6R,E<<<C."/\: %@<\
MJ<+CH/ZU8#NY9V9MV,_A4((612![#( S3F;,H"':: +*3 X5T.0Q!^;MBM+2
MYG$IA7/E.<D-SGW.>E8YP6S$I#$X S6A%Y<6WS26#KEBAYQV'YT =&D2ACN"
M;V.[!/)]\_TJ_;Q $9#$YR..!GTK$MS+89\Z$2P-W_+_ /7700("PP&PWS$;
MMIYZ8SUX]: +<##Y07CRP8J2,DD=?R]*NQ1XRS29)/3&!6?"5B4.+==X)"(@
MR?KFKN4^1&+ GGD9_#/K2 O !0.![@4J@[VR?EV/C_ODTX<>E!X#^OEN?_'3
M0,Y,'Y02!G'6HI!YB%2HY]1VI91B$)$Q'/'\Z:5&,ORX7 .:!#0-N2/X>!Z_
MG7%ZA/<RW)^U/D[L 9Z 5V@R,,Q YP">AKAM9W'4F7R]HSFF V!\$N>>V3V'
MK[TB@Y# %AT ([>M-A+(KCC''2IUSY0;:2W:@"56)5]N"&X.0.*<85WY*EF]
MCS3(3$B .00#C&.AZT^)TQN8[N,9'!H DM93;W4,C LRMDAN0>:ZQXX+X12C
M#;2&"D!@#ZD=O4^U<M%!YAW9V*@X8C^G>KNFK*7\VWE"F/F17S]WG)Q_GI0!
MN!W8*') 8 CCD<=S4R'*G:3@=#GTID,HNH"\"E8SG!92,^W7I3&PH5-Y5@,D
M8R#ZXYZ4 21$M&"X*DDY&:D3E1C/'K4:9,C!1N;.3D=JDC)<$J<<D?-0 [I4
MUR"=+MR&8'S) ,?A4(&/>IKDXTRW4X +OS^5 %!CAU(V[F.1SP!BJ\,2[G4,
M'4GF,],=>:E19-I+D8'3W%,64*ZE(Q\QY!(_SZ4 / ),FY\IRP_V1Z#O27D3
M264D,))=@"A.>&QP?Z5* %9P<;5X'8CI_GFL[Q#JBZ9I<VTLD\F4BR.IQR?P
MYH XQ=2N;.Y=+69EEW'<0?O'/6K4/B'6-NTR"0'J&C!QV%8UARXF)Y+'IWK:
M4;3O Y)YI 2VGB/5H+D-(?,C'_+,\ ?3'0UH+XD='#6L8A9SF0$Y!)/)QVK.
MD/EE=VQP_. .15>Y4@97\"*8'H/5!*!YIP&0MAL'!Y!QD BFS R12QJ8Q(%W
MH=H;;QR1D<YQ67X8NWGLA!*7)09B)X!4=1^>*UR_RAFVQHW& N[;Z<^E "8V
M#YY,LJA6(Y+XQS375BR*K8!^;/7.#G&.W ZTNU _GLP=201M3MU!]:9$4#,L
M0#..3UR5/UH E8@R $K@]CUIV%0*JJ!VP/2H'C+(LA3:O)=,?-^!['VJ<(OR
M' RH^6@!\2YN[;VE7^8IM\RK=W1P/]?(/_'JEMSBZ@]Y$Z?457O%!OKE<<>=
M(1]=QH KS.%4[@Q!''UIJKLA0+C* YYQ3L)A6!)(Z"FAV<$LH521G)ZG- "#
MYY(I "C8R3QD#ZU,HCC!,>2Q!^Z3VYJ$+\VUB6[JPP ><8_2I<)@I@1@'YL=
MAWQ0 ^18W*EP"Q<G)7)'T]*YO6_%\=D\UK:1AYMYW.W*X  X'>JGB?Q(L<$F
MGVCG<QP\@Z?A7$_-(YSDLQI :TFM:C<X)N;C9S@+(5 _"KWANX-WK,'G@2;F
M.=_S<X]^]8K.8U50GS= !72>$+,M?M.HVB/\L_Y]*!G;22CRB5'S@'Y,<Y__
M %@4S[)"9?WB9*-D>8<D'/)_E4Z/OW2/E,?*X(&.O4'N.M1C8BJ=^YF;!=5Z
M]>E,1%+*I(1CN)^4#&<'W_+BDVL SRL2Q*]&(P!Z 5(5&))$R2>"3P>/TZU#
M;B5+D^8V"^-PSD?A0!<!!8C<V6IP^Z5!/'K_ (U7Y,V0X+*"#[U9&<9)!Z<B
M@#4\)@C69"?^>1_G7;5QGA<_\3EO^N1_F*[.I&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4&BD/2D!Q7BR18=3$LCI''Y2@,W<Y/ ]36"[>6A
M<@*FW(#C!%;7BF(?\)$LNW>WD *3T7KT'K[UAONP#QCC(/.#5(1 D^ZV!)"A
M3Q[@5@:_)%(J.)-\FWY=O(Q6^\*NA0G:K9)P>HK U'39$M/-CB9L\LN?N^F*
M8'.AF&W"#!Y!'>K*E1'G)W'I3F6/[.!O99HQT]>>U1+(S_*ZC'J: +")Y@V@
M'!& /3'>@0 $@8)'\1IPRS9CRH;H,TY2-X W%_XJ '11'#$+D8R#Z>]6=C@Q
MO(2%) &T<U""&9?+3D_>.>M3*S2.NT%?X0!R2WK0!TT%L+S3XXA*V,+DG.#S
MSQZUHPVY^QA#*6=,@,6VD#TX[?X5EZ&EP&7-P1". A/>MH(0GEQN0$P6)P?P
MP: )H$(1)/.9E3EMIW9X[^E6XY-ZAX\-&?F5OKUJ R(^P@.4*X90QX/]#]*E
MB R950JV-H+'[P]^:0%V&4@$.2>>#[5(DF9"H.[*.!]=IJH<+US4<<WF2F,C
MY621<#O\AS]* ,%65Y&2-U<H K%>BD#D$^M,$D<RMM/S*W/:I\*D:Q1JD:(,
M*B\!16>+80SR2PJ_3+ '@TP+0!;Y6C^7L *X[7]@U.7Y@[\9'IQ73W NKF+$
M+JCD<A:YK4M/GLS'*X# ]6!Z\^O^>E %&,JQ9=N">,#K4@$>_P"4MZ$;N,_3
M\*21HO,+PDLAZJ>H_&G)LPQ; <CI0 \P[\-G /8CKBG+ <%<]/;%/+JL9#9*
MCHW<9%(CD_.PSGC!Z4 6HSDJJCH.>.]6]%0S>=EQD)AXCP&XR/U%9LK2HH"Q
M<RC/R'M6MH%A/;W'VB5"L?3'0MF@"Y86GV-5B5_,24C).0%/MZU=^0LTN5()
MVLWZ4QE#K'O8#[O'3IC%2Y*Y(7KG Z8% "Y\M6&?GSP3Q@4]#C.,=>U5U1-S
M-&!F7D^F?:K& G'KP* 'U)=L%TRW+8"^8X.[ISC%1=,4^[C1M/M&89997"DG
M[O3D#UH I3 J"YPVP\ 4S)<--&-ZD#KTQWJJ\M\+X1F!/LY8YYZ^AJPKQR/(
MBXW@<XZ'V]J )0&5#D$[3M!)ZUR/C=C++:0@D':S;CZ$]/PQ78+B5"" <\@D
M#IVKF/$]A<:I=VZPARR+@L3E<]3TZ8H Q[.W5(88U4-W)J8L68\8&<51L9W#
MF.=\%>,^M:(V  H58MU'H* &!.69HQ\O>J,UP7D")U)Z=JTY7"*P YD'(JEH
M]G]OUD1 $JOSMC^Z.M '=:/;/9Z7#&&#RB,%E/( /(^E)J-XL-M<^2Q,JE$)
MVY"CU(]*NOMVAEW1PQ@%4!PJX_#G.1GZ"F"XW+-,BIG 5F QO';&1SUH @@E
MN1"8+G"7$0 9\';R. /4\59"'RU0L<% =Q&,MG/]*2,LL"/(A#[!DD@D9YZ^
MASG\:"55T 90%<X0C[XQC\,9- #)LD#:Y4(WS ]ZFC.4&&! [CO46))X4^8H
M2<L>I-/C5,O*&)WGYAZ4 6+4?Z7!N.1YJ_S%5]0DC74;L;]S+(X?:>$.[O[U
M8MB1=6YP,^:O\Q5.>2VN;F\MXH@L*3R+M QSN/)[F@""(QRK\K?(QX9>HH)4
MX*\X/(8<U2CMY;:.1;9N2X(';'>KGF-$5\PC.,@'UH EC60G?L(()PHXJOJ=
MP\&DWDX&UHXMV">G;^M2QL#F0@G)]..G%/*!]\4D2NC8!!].IX'TH \?;)E.
M3@D\U?AM# GG.5;(X'O6CXDT!--87%K)NC=O]7R2M8ZWLGE&.0 KV]:0R(9D
MN>AX.:])\/6+6VEIYBNAE^8G&,#'!SZ=:XKPSIKZAJ:OLW0Q?.Y/(^E>D"..
M*-45BBX'1.HQT(/Y4P)'!B\LK"7R,8SG;^/TJC_:B?;_ +.W,)0A9,]6]/PZ
M5><L0K*_S;AQP0H]%].U5'R[03"),C <LOS ]>M B1_,EN;8I$ZA2<D'Z9_
MU,9.=B@@].G2G2L [= N[:S,W./7]359Y-DR^7N?) 7!Z4 68XHXVD<1$$L2
M?5B:D3.5!&WCH.E59HY(Y5E,CL@X*@9Y/>K9./ER=Q'Y4 ;/A48U>3/_ #R/
M\Z[.N,\*MG5W'4B(\_B*[.I&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4&BBD!Q/BK/\ ;"X8 "(9![]:P (XDW<A1SZUO>*^=93[O^I7D]N3
M6$0I0@C.>#_C5(1'#*K1^88R$/0,PS^55R7A#M.Y9';:% & .U66"EAC)*]
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MW#)C/0J>^>M0*#,78L6(;<'')C[XQZ4 2;1%-\HW#NQ;/)(Q0'P5(!8XY '
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M8\PT7 \XG9XEE5(\J%!!5R#R:9 9"YE==BN""IR2,5Z/_P (?I6T#9+C&/\
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D Q/")SJ[G/\ RR/\Q7;UF6&A6>FW!FMQ('(VG<V>*TZ3&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>tm238578d1_ex99-2img44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img44.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %V R # 2(  A$! Q$!_\0
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M_%TOE:S_ -!B/_P"'_Q='*PYD;M%87E:S_T&(_\ P"'_ ,71Y6L_]!B/_P
M1_\ %TK,.9&[16%Y6L_]!F+_ , A_P#%U%--JUG):O)J44\;W$<3Q_90F0S
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M&"=)'M"L@+3;#CD?PY[47'B>>VBE$FF[98;EH'S./+7 !Y;L3G'IGO0!V?\
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MS0M4M]/OFE62:)IBZKE8T7NW.>W0 FN@K/O-%TR_NX+J\LH)YX 1&\B!BN:
M.?N/B-HD4*S0"]NHGMTN(I(K<@2HV[[N_&<!&)^GKQ5B'QMIT5E+=:JYL(1<
M2112.DFV5%P=^2HP,,.O&0?2M.[\-:+?PF*ZTRUEC*!-K1C 4$G&![D_F?6J
M?C==GP_\1*O &F7  '&!Y;4 = #FO.+:'Q+X5NO$%C8>'7U7^TK][RTN_-C6
M$>8 "LV6# *1V!R*]'QS1M!H \UN(O$6F^(/$KP^&KG4/[4MX8XI8)HDA#B,
MJV=[!@N3Z'BIY_!]W:>'/!]I':1W-]IUW:BZF3;E8D#%N3@E03TKT/:*"N:
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M0 4444 %%%% !29H-<C%=WT^LR"*:[>X2]V%5'[@0C&<^^/QS0!U]%(.M+0
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MCH.!3J* "BC-% !1110 4444 8OB[_D4]2_ZXG^=;58OB[_D4]2_ZXG^=;5
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M[+,"/_KTD7A.!)BLC>9:AFD6-OO;VC1"Q/K\K'ZM2U-+4NYLZ?J$.I6IGA#
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M51@ 41QI&BJBA548"@8 'I3Z "BBB@ K&UO_ )"6@_\ 7^?_ $1+6S6-K?\
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M1HI-PCPAC(SW.UB.: -JBDW#&>U&: %HIGF)YA3>N\#)7/./7%.S0!C>+O\
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MT;* SLX<N4YW @AOKQUI778+/N<F/$VL3VTUO ;87^GPR)?%QM7SO-$<>,G
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M_.E ^8<@_C0!H"EI!2T %9^NZ8NM:%?Z6TK1+>6TEN9%&2@=2N<=\9Z5H44
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M,+6LDF54%@Q*M]X'('?TIU[X"TN\OENS)<1L)XIF5",.$51M.1T/EID]>.M
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M"*Q?^$4M/^?[5_\ P8S?_%5-HFAKHBWZ1W$TZW5R;C,SEV7**N"Q))^[G\:
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MF@!:*3-&: %HI,T9H " 001D&LT:%I9'_(-M?^_0K2INUO4?E0!0_L/2\?\
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M]H,VP%?E+,V<KNW'!X&10!U^AZ&FBS:F\<N]+VZ-R%(.4R ",DG/2MG->7W
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M129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC-
M"T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS
M0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T444
M 1O"KMN)?/LQ%-^S)_>?_OLU-10!#]F3^\__ 'V:/LR?WG_[[-344 0_9D_O
M/_WV:/LR?WG_ .^S4U% $/V9/[S_ /?9H^S)_>?_ +[-344 0_9D_O/_ -]F
MC[,G]Y_^^S4U% $/V9/[S_\ ?9H^S)_>?_OLU-10!#]F3^\__?9H^S)_>?\
M[[-344 0_9D_O/\ ]]FC[,G]Y_\ OLU-10!#]F7^\_\ WV:/LR_WI/\ OLU-
M10!#]F7^])_WV:/LR_WI/^^S4U% $/V9?[TG_?9H^S+_ 'I/^^S4U(S!1DD
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M9E_O2?\ ?9H^S+_>D_[[-.\Z/^^OYT>='_?7\Z &_9D_O/\ ]]FD^RI_>?\
M[[-/\Z/^^OYT>='_ 'U_.@!GV5/5_P#OHT?94_O2?]]FG^='_?7\Z/.C_OK^
M= #/LR?WG_[[-'V9/[TG_?9I_G1_WU_.CSH_[Z_G0 W[,G]Z3_OLT?9E_O2?
M]]FG>='_ 'U_.CSH_P"^OYT -^S+_>D_[[-'V9?[TG_?9IWG1_WU_.CSH_[Z
M_G0 W[,O]Z3_ +[-'V9?[TG_ 'V:E5@PR""/:EH A^S)_>?_ +[-'V9/[S_]
M]FIJ* (?LR?WG_[[-'V9/[S_ /?9J:B@"'[,G]Y_^^S1]F3^\_\ WV:FHH A
M^S)_>?\ [[-'V9/[S_\ ?9J:B@"'[,G]Y_\ OLT?9D_O/_WV:FHH A^S)_>?
M_OLT?9D_O/\ ]]FIJ* (?LR?WG_[[-'V9/[S_P#?9J:B@"'[,G]Y_P#OLT?9
MD_O/_P!]FIJ* (?LR?WG_P"^S1]F3^\__?9J:B@"'[,G]Y_^^S1]F3^\_P#W
MV:FHH A^S)_>?_OLT?9D_O/_ -]FIJ* (?LR?WG_ .^S1]F3^\__ 'V:FHH
MA^S)_>?_ +[-'V9/[S_]]FIJ* (?LR?WG_[[-'V9/[S_ /?9J:B@"'[,G]Y_
M^^S1]F3^\_\ WV:FHH A^S)_>?\ [[-'V9/[S_\ ?9J:B@"'[,G]Y_\ OLT?
M9D_O/_WV:FHH A^S)_>?_OLT?9D_O/\ ]]FIJ* (?LR?WG_[[-'V9/[S_P#?
M9J:B@"'[,G]Y_P#OLT?9D_O/_P!]FIJ* (?LR?WG_P"^S1]F3U?_ +[-344
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M:AX[_L_3+JYEL0DT-\UH(7F ) YWY]^P]2!79GFJ[V5O)GS((7R<G=&#SZT
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M_P _;_\ @-+_ /$T?\)7H_\ S]/_ . TG_Q-;0''6C'O0!B_\)7H_P#S]/\
M^ TG_P 31_PE>C_\_3_^ TG_ ,36U^-&/>@#%_X2O1_^?I__  &D_P#B:/\
MA*]'_P"?I_\ P&D_^)K:Q[T8]Z ,7_A*]'_Y^G_\!I/_ (FC_A*]'_Y^G_\
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M7QK;S>((-.M8#/!*0OVA6/4^@QR/>FDV9RJ1CNSK****1H%8VM_\A+0?^O\
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MM"^_=&K;UVMD9W#T/M3S( <$C/IFCS,9R,8H"Y6BTVVCDN7V;C<$>9NY! &
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M(]BCLU#^_;_]\FC9J']^W_[Y-7J*111V:A_?M_\ ODT;=1_YZ6__ 'R:O44
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M![ _2K]% &>^CV;64=IL98XFWH5<AE;))(/7.2:=;Z5:6DD<D,6UHT,:G.<
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M4@NH#"9EGC,2]9 XVC\>E<1'X9G@TZQ6/3W61M-N8;H12!'9V*%1N[GAL?\
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M7,?6N+T&Y\32_$'7+34+>R33;=$99X[?:\P.?+&[O@9S]*ZC[-JO_04@_P#
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M%!'X*TY 6(4.H+')XD;J>YKI:YKP$S-X+TXLFQB)"5SG:?,;C/>NEH ****
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M>'_^@3;?]\T?\(CX?_Z!-M_WS0!K?:(?^>J?]]"CSX?^>J?]]"LG_A$O#_\
MT";;_OFLBX\):1_PD=G,FGV8L4MYA*"P'S97!QGM@\]J .M^T0_\]4_[Z%'V
MB'_GJG_?0K('A/P\PR-*MB#_ +-+_P (CX?_ .@3;?\ ?- &PLB,,JP8>QS3
MJJ6.F66F0M%96Z01LVXJ@P"?6K= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ&D4<<TZB@!,"C I:
M* $P*,4M% "8%&*6B@!,"D=<J<>E.HH 04M%% !1110 4444 %(1D4M% &5H
M^BQ:1+J30ME;Z\:[*XQM)15(_P#'<_C6K17$?$6/Q1+%8IX:-R&(F$Q@8+@E
M1LSR#USTH [>D(#*0>0>M>9/!XYTOQ'&JS2W&CK)!YSF0ML #L[ L2Q3H".O
M(JW>:[XHGT#1[Y+:.&\NC)(L$(.UCM_=JV3WY.,^E &EIO@*#3?$%EJD5VVV
MUC=%AV#^(D]>P^;IW-=@.E>2ZCXO\9V>I0Z-+;)]MGS'$(X!F4'S!YGWOEQA
M3W'7-6;V\^(ZZ;=P16Y8FWEBB9(P) VRX5&#;NH,<#?]M: /4LU7O;2.^LI[
M64 QS1LC ^A&*YS2]7OK[Q5"A@O;>U;3"\T-T@5DE610C<$CY@9._.RNKH \
MYF^%44F[&IN!LC4 Q _=&#GU]O2O0H8A#"D0)(10H)ZG Q4E% !1110 4444
M %%%% !1110 5C_V*!XJ_MI9<$VGV9X\GGYL@^E;%&* $'2ES6+XJFU&#06D
MTH2&[^T6P C3<VPSH)./]PM^%>=M=?$>R\/Z?>HMS<W4MI<37-OMW,/E14 !
M4;'!9F"\YV$4 >O=:XC4? DEWKKZA;W_ )227:7+1G<>B@''/!X^G6H[SQ+K
M)T+6)1%' +*:.V%TAW%B=A=\=MH;!]P?2L?5_B!XET- ]_IEM!$_S12/"_S\
MD"/&[)8CG<.F>E 'J0XS2UYK;^)/&RO&W]CB2!R)");=RX5MC%000!@.P''\
M'-6M"\0ZM/+X7M;T7D=[+)/%J$=S:M&& B=PX) !PRH,CCY_>@#OV&X8/2O-
M[OX8W$N5M]5$<068*K*QQO9F"YSROS\^N!7I Z"EQ0!1TBQ;3=)M;)Y3*T$0
M0N?XB*O444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4A&:** $VBC8*** #8,Y[^M+M%%% ";!FG444 %%%%
M !1110 4444 %%%% !1110 4444 !&:3:/>BB@!OE1E2I4%3U&.#2/!')@2(
MK[3D;@#@^M%% #]H]Z0QJ6#$?,,@'N,T44 .Z4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>tm238578d1_ex99-2img45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-2img45.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A R # 2(  A$! Q$!_\0
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MBF1MW  /.?3'7- $]%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HJ*:800M*^=JC\ZS8M5N99/+73I02Q"EW"Y &?\ '\J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **** "BBB@ HHHH **** "LKQ"?^)9M]9%_0Y_I6K63X@_Y!Z_\
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M6>W:WF)NI%SP7E[$]P <^HH ]BHID:>7&J!F;:,98Y)^II] %+4S_HA7&=S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIN<T .HH'2B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH Q_"\GF^'X7]9)O_1K5L5SG@23S
M?"-L_K-<?^CY*Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)Q0 M%9]_K%IITUM#
M<R;'N'V1_*2,\=?0<BKNX^HH&TTKCZPK*"9/%6I2-=S/'Y,1$+-\B[B>@_X!
M^IK6N;N&SA,UQ*D<8ZLQQ7*VGBK3CKUW*YDCAG2.-)67C*;LY[@?-Q]#TJ92
M2T;-*=.I.+<%<[$=**CCE22-7C=75AD,IR"*9<7*6UO)/*P6.-2[''0#K5&7
MD3T54T_4+?4[1+JU??$V<$C!R.H(JW0#5M&%%%% !1110 4444 %%%% !111
M0 4444 <C\,I/-\!6;^MQ=C_ ,F9174?:[<K*?/BQ%Q(=X^3C/S>GXUR?PL_
MY)[9?]?-Y_Z4RUQU[X=UM]7\16\.G7']GZ]?2QW;!2,1Q!9%<>HD!DBSW.*
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MR*=5M)JS)/0=,U.VU2R6YMF)0G#*PPR-W5AV-7J\TLK^?2+TWMN"ZG N(?\
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M\=&7!Y8XR*FU&UU.]\+^#;O5=/N;]K22&?5;3R0\C-Y+*6,?\160@D#ZXXH
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M33PI_P!#-HW_ ('1?_%5<'AS1,<Z/I__ ("I_A1_PCFB?] ?3_\ P%3_  H
MI?\ ":>%/^AFT;_P/C_^*I?^$T\*?]#-HW_@?'_\55S_ (1S1/\ H#Z?_P"
MJ?X4?\(YHG_0'T__ ,!4_P * *8\:>%1_P S-HW_ ('Q_P#Q5)_PF?A3_H9M
M&_\  ^/_ .*J[_PCFB?] ?3_ /P%3_"C_A'-$_Z ^G_^ J?X4 4_^$T\*_\
M0S:-_P"!\?\ \51_PFGA0_\ ,S:-_P"!T?\ \55S_A'-$_Z ^G_^ J?X4?\
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MIH5N7W9;#.%61C,Z&)@J@$.>C?2I*MRZ/K,#E)=&N\CO$%D!_%33HM#UR?\
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M1='31K=X4E,N]MQ8PQ1]@.D:J.WIWK3H **** "BBB@ HHHH **** "BBB@
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>70
<FILENAME>tm238578d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm238578d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -(# 2(  A$! Q$!_\0
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M)HXMLC*V>!S@=#S0HR;33M8RJU(QBXN-[Z(;H,=I/HL?B'5F$UQM9FFF&1&
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M,_G&,;ADDXSUXZ4_4;*2[2'RI5C>*42*63<#C/&,CUJ_247>X<D;<I6M8[I
MWVF6%\]/+C*X_,FLY]&N5%U!;7BQVMRS,RM%N9"WWMISW]P>M;5%%V+DBU9C
M(HEBB6-.%48 ] *JZ9I_]GVSQ>;YFZ627.,8W,3C\,U>%)2N79;E&VT_[/?W
MMSYF[[4R-MQ]W:N/Z54BTN^ME:WM=05+8D[ T.YXQ_=4YQCTR#6R:2G=DN"*
M=W;73E&MKI8RH(97CW*^?7D'/T-&E:>-.MY4WAGEE:5RHVJ&..@[#BKE.%%W
,L'*N;FZA1112+/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139932716567248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  07,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Carisma Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">491-6422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CARM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former Address [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Sesen Bio,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">245 First Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite&#160;1800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>tm238578d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="carm-20230307.xsd" xlink:type="simple"/>
    <context id="From2023-03-07to2023-03-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="From2023-03-072023-03-07_dei_FormerAddressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-03-07to2023-03-07">0001485003</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-03-07to2023-03-07">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-03-07to2023-03-07">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2023-03-07to2023-03-07">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-03-07to2023-03-07">2023-03-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-03-07to2023-03-07">Carisma Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-03-07to2023-03-07">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-03-07to2023-03-07">001-36296</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-03-07to2023-03-07">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-03-07to2023-03-07">3675 Market Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-03-07to2023-03-07">Suite&#160;200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-03-07to2023-03-07">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-03-07to2023-03-07">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-03-07to2023-03-07">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-03-07to2023-03-07">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-03-07to2023-03-07">491-6422</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-03-072023-03-07_dei_FormerAddressMember">Sesen Bio,&#160;Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-03-072023-03-07_dei_FormerAddressMember">245 First Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2023-03-072023-03-07_dei_FormerAddressMember">Suite&#160;1800</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2023-03-072023-03-07_dei_FormerAddressMember">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-03-072023-03-07_dei_FormerAddressMember">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-03-072023-03-07_dei_FormerAddressMember">02142</dei:EntityAddressPostalZipCode>
    <dei:WrittenCommunications contextRef="From2023-03-07to2023-03-07">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-03-07to2023-03-07">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-03-07to2023-03-07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-03-07to2023-03-07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-03-07to2023-03-07">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-03-07to2023-03-07">CARM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-03-07to2023-03-07">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-03-07to2023-03-07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8.9_
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  &F&=6EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (  :8
M9U:JQ"(6,P$  "("   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P
M%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!Z)1\
M>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6V
MG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*
M0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/
MJ!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#
MK+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPY
MZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    "  &F&=6)!Z;HJT
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M2P$"% ,4    "  &F&=6!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  :89U8+VAX9[    "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M  :89U:97)PC$ 8  )PG   3              "  <H!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ !IAG5N8F,XTH!0  _!8  !@
M     ("!"P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M  :89U:?H!OPL0(  .(,   -              "  6D-  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ !IAG5I>*NQS     $P(   L              ( !
M11   %]R96QS+RYR96QS4$L! A0#%     @ !IAG5JK$(A8S 0  (@(   \
M             ( !+A$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  :8
M9U8D'INBK0   /@!   :              "  8X2  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  :89U9ED'F2&0$  ,\#   3
M          "  7,3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(  +T4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm238578d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm238578d1_8k.htm">tm238578d1_8k.htm</File>
    <File>carm-20230307.xsd</File>
    <File>carm-20230307_def.xml</File>
    <File>carm-20230307_lab.xml</File>
    <File>carm-20230307_pre.xml</File>
    <File>tm238578d1_ex10-10.htm</File>
    <File>tm238578d1_ex10-11.htm</File>
    <File>tm238578d1_ex10-12.htm</File>
    <File>tm238578d1_ex10-13.htm</File>
    <File>tm238578d1_ex10-14.htm</File>
    <File>tm238578d1_ex10-15.htm</File>
    <File>tm238578d1_ex10-16.htm</File>
    <File>tm238578d1_ex10-4.htm</File>
    <File>tm238578d1_ex10-5.htm</File>
    <File>tm238578d1_ex10-6.htm</File>
    <File>tm238578d1_ex10-7.htm</File>
    <File>tm238578d1_ex10-8.htm</File>
    <File>tm238578d1_ex10-9.htm</File>
    <File>tm238578d1_ex14-1.htm</File>
    <File>tm238578d1_ex16-1.htm</File>
    <File>tm238578d1_ex3-1.htm</File>
    <File>tm238578d1_ex3-2.htm</File>
    <File>tm238578d1_ex99-1.htm</File>
    <File>tm238578d1_ex99-2.htm</File>
    <File>tm238578d1_ex99-3.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm238578d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 30
   },
   "contextCount": 2,
   "dts": {
    "definitionLink": {
     "local": [
      "carm-20230307_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tm238578d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "carm-20230307_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "carm-20230307_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "carm-20230307.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 64,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 25,
   "memberCustom": 0,
   "memberStandard": 1,
   "nsprefix": "CARM",
   "nsuri": "http://carismatx.com/20230307",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm238578d1_8k.htm",
      "contextRef": "From2023-03-07to2023-03-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://carismatx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm238578d1_8k.htm",
      "contextRef": "From2023-03-07to2023-03-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 1,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r14",
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r13",
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r20": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r21": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001104659-23-029687-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-029687-xbrl.zip
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M/"6?),NQ\\XL_]]LMRDY*]T0_<OSCN8H_V/:-Y'UK5&W4DTU_ ]02P,$%
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M77/MY23[[5'P )@"EI%('=+"8*UO[BK04J[R!ZMDR_Q2X#;9)J&MB8@&IS&
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MZSWMS:\NQ2?QM?E*_+7"!1'?_!=02P,$%     @ !IAG5DLZDPSV!P  CF,
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MI\A76,:"+'3<-5KO(7V.&?]5<@-5C^/'/9X1?9^KP]%I,=9?N@<42Q&@%_T
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M99>JL4?W;1B@.-2R$%+U9ZMB<.ZL?413-?FHCE9'] _]QQ/4-_\"4$L#!!0
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M!;6(" 3[V/D3Y/K$\TG'^*D;.QM[R(=]DPA);KM@N)L.;/?:TD$T&/A)DNT
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MZO6=7N F2:5O?NJ1S=K>P^\D=A'(95S5Q630C8+U*9$&B]]-=T^EH0A)K51
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MD,^2!+_N8MDUI.P@K"&1CCTLY,TD'<<%X6B0*#EK_SH6;*4$$NZ<!2[%<9P
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M\;_=O2.LOL*([SHJC 0H%F@1/F7%:=1JV&;A93>OH#G,WSL#Q2G61$SO)<%
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M 0L*_<%HD!EJ)!2Y [0-2 @%4@W+[P,IA/$JP32S[J"-PO"REELH"$[S6\D
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M+^YME]5VNGM906&FZ7;9*IGZT_"N_OX3&SS;Y0;/U96OL]#.7EN9531;'.E
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M^3VXU-% AS5R9E>)V=&0VCR=6&@.1<@A)4R675 T7&)N,87$7O8MW,K02FN
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MH08OQES'*\4,&"-.#I./B=9+L(ZPP"B'/Z:3FN,2G"6]:,B-:XP['L9 KWU
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MG7?.+U'H7ZLO3T 1=D7@[&-CL;=B##J/^NDMUH*&'YQW8B+S4$&TB7WAO&\
MP1K%7C2F6L38_L?+:BTS+>.T5:DFZ"U(.A=F)9XF*GR R_2PE5-IZ#RXRX'8
MTMJ@B@>C3,O=ER:V)B_SS$PG2+Z[4%X3B89"%N.O.<,(Q%X_9W58:IUBGEB!
MYS]B!9Y$;O]7D@C#[%TT<;,&CUY9&QU1;P#9 (N_LQZ4H.#N#$@C3;3PD^&U
MRB:2N$V(B>770!GPTU&*^$LJ$=6I)7*5^'=&;KTGT=K2EQ#G(Y)3+E*:_QU0
M,M!Q43(-7:!::#0%*M8GXO0J]J^O$^<D H*4H+;)-.O5G__^K_;F]LL8^)T7
MN*@^RI]65^2;!WW?B_X&*O;Q>CP:=+GURX6+DIWG_&<L_"LN]!9RI3BUZMRB
M#2K""P>13]'2RRB.;I::8I2=*>VX^OSD0W37+DLDJ,T!Z!P$;B*CT8^/C[-K
MIG-)5(8,M[53#3GR!)CL:;*IWT (5HFM\V3^D[^[&<OYXL5L%A9#4&(!9BD(
M<CO#/#CEUNGD3^V+U[F56V>C ,G #;EL0S8UC=5W_=@B TL-L$@49;N?(@97
MT8@RQ)8Y'=EYJ+*$MEVS5@%NUE$6SC$W2*.*2LT%(X:H0L(]*@:9W=4BX,7L
M[Y)7B@V:>'6K*VIYL[97/FYC-M$HNXCB=F5?WHA*MJO$O@.EL3IO*/&.F.)\
MQW!Z\&;J[F>QBEG'88W?*(5!XYCS=*+\MB] \K1VJ(7]TBT6'B]NLW19,W96
M&';9:4.9EU5:1K(@BPN44#QG7Z7JJS-GX<@H7*>T#YW4+^.+T MDLZ1ROP9+
M"D+[\_CJ0 4?@GC-AH!81G,55;?5E</&I\9)@_* 7HMN/')C596T4Q;@96;;
MYGK5R9)WW/-A2':HRK[RG[)G+_C9BO*F?,*O8M<+0'D#5?#<]:*K*WK3/A[=
MLEQ?"H!85A<OW\A<E0)WWL31:#BS.QZ^;+_B9/WQ;B-.6O:M6/*R"KS8E,V]
MC33LPV8X@8=J-:G&W%4Y-EHX-CP?=F5&SLI3Q6VI@ -_SQX1-UANW?)#JO-B
M\P4_*\]B*BC5'"MV  1^TUX5<WR@RNU.G*Y(Q]@/J0S/0C$.)@8=LXMW4:U2
M&,KHD43N*L/RP-WE HJ/; #G"2O+Y59/U4=2*C]S'USYMZZK;]:+I!Z&&:B@
M^23KRM 51ERL>=H<0D?^D@I/R5+#T"L_NH[=81^-K98)/2N8?67XY+%&BWG"
M/C6DH3P[H")47WJIM[O [B# X4GE6%TAG8,MG!1B7,/:ZL[6\YH1%YAWD9ZA
M^<Q3F G"K+ARCK2_0-J#&5<0AEG?UQ@@64I7>2:\S#.1^"@=V,RIW6SM-!P=
MY_@G( H2 :W<GRB61SLQ5UVQ+ICR#%&'<V5U.04LP=[U@;SW^F$41-<3JL#!
M>CB9(/>'L1_H-6WB8K+"WO#-EMHQBSV5D].DO=@/14VJ:6&O(6<? D\9 "\?
MD0-!E:X -D4K>#L*A9Z. D'V1]<C%=@"W[4;^>/HL;=('4RBPN*+IT\UQ.(4
ML #CQA*6U!)CB<XZIQ6_ *)[?OG^66$N70C?=5ZAU5<;;C]RNQXJ>'OE?,"L
M5LD&0Y!97S7VY;,@DZ.H8CQO%^T %,6JYTENXM45*Z^5[$PQ6Z_RP,<24U=0
M$!5^B1XURHI+\)9NPF@<".\Z3ZZS<C#XO#Q3)XX"H:)(-4K(*B7EUT^E#<:X
M1?@7AT)YCF+2L8Y[X?J!Y,/MQA/9TS"4,3!4PC'VOZ,D#UG>(7175RQ]PZ!;
M!N+/3W$<)C@67@&QT5(T3T:LV!S^!*^"+)!G;IR&2.M2YS=N7)0"D,AOB:1@
MI,*("I9SH0 *.?))O)3U@1C)T3& ;2L!CY"=H\V4UJ_)4<T!^!:.0DR""<^_
MQD%75ZC^3TUN!S;1-"@FAG#4"GO*]J/V@/B?!O#%)UZR+/C?;C:)UO&H%^@N
MFD932*^TB,J'<(SG?@)+!* NGJY!-DXH!\70=U"XHX""OA@02AR%</!"Q$H.
M=*7BB1YG'[L@#'S"&%SZZLHEGAZ]9Y.@3W"&(9S7/J*7[U90F?Q"OYC*4)8H
MWQQ5:C/*[+)L&[O,U'*[J!FD*<-Y5GJJF(7JVJ:*L)IWD]#E<$6:*>\O-U&9
MPR>U\\,G]41\4@ME$7FS(QO$%L8C,E&OW32HF#9RVEQ""P0@O/TB7(]CH1*!
MX:^$H(= 8X)HJ*(O+B:AY]X!-3-QDFM\39<-G7*AN=U^Z?15)*)*CUQ=F2*7
M3EF!4Q0_M\J.8"IG2'+"/AW($/URE_FJ9EK4=,[/+G]_5@/F&HMQ%%Q->_27
M#[^]AT?W@>Z%;JG@ZNR??SKE\*;RS6('4O/YB]/#WY^5;33C62%;72MDW0-I
M/X33ENR*)&.?<C.0J_.+;T047XLT&H>F[,OEJJK9DE[-/1F3QS7G;-$WB_<*
M %IE1XJ,Z=18QD# JV!>LE:K'K"4 3F:_ZA@;$J@\&_1$/]D6=)"B9CV'JRN
ME#H]%D3/BO3"@',U,?5Y03VX?A5Q.2@8":A9D/8/W"'2)=XI?ET0=.&%Q)!T
MKZD8%8NWEB2+5G&TE\&JD812E_),QM;B*2U[=:6UN[M=ME)3BE0.$A8-"</>
MN:"M^6%R@YTA933!++'//(4B?I%/N!S!2$!#])J),EK#RSU1*O=AN54Z3IE7
M),OLX6'6Y6%B;TNXY.\'7:1C $@E>08,Y"CP(E<UMM/ K-5J[D$KXS'@F-\>
M'>C*;IDR]_[]08W"]/4E*";,-\Z!LHFNP BD'$VZ5(N0A?(W JA;QK-!M=IA
MLDG0+O3<Q\=8SCWJ27=&]<3F2'F5#[6.@CGLM<X 4)P?;:7'JO(TB"63$&X#
MF*NI:0%71&1/4 F+0DS:1P/K7R.?Q9=,2=4'HO,&W![;H:FVV[X; +*DR+D)
M[E%96=\_N0#.O/_^U3-L@H%=M"E%C2PM(!T0^=-N+;IEN2EL?@MD#B0;1Q7"
MY_1%.(>>&*.9O \_BH,(P_ 2RDT!K'4&5)N7+,4NUMF.K@2UH\64#V9::)=/
MQU%\@Q>"&GO2R*_A?H:U]WY7\/FBX"&S7PP1975EG2N)PGBG^Q>'^[^^<-Y?
M_'&*OE;8G-=SF8BBZX>Z.^ V,; J\TIX%':<$*0R4-BY/TSB?Q%F34-YD-/U
M][-^E$993#]+2'JUEQ>_@P+VRX=G.OF1G)2P"(#T$>:QD"F!K16RR1Q^QA!K
M+#H<LK$-?6,]NH PD5M:74DF"95*P81&X5)A"'1_X4F.5'5R>?$U9:QH;>/C
M)ZYA/98!&Y-!UP^HBE<4C!A8E'2=1%?I&"51!;Y746^4%1%!C%9-YA3%SB;<
M(DLP;#9GLLX!3-XZ"M#+R"BD9,C&#_-[FN%5E/#Q4\OC*J&0\"TWX]>(A5.%
M0;Z=KQ'UOD/!3L7\K*[(H)\%"7(%+&\:H*?BBVS=M&B_)/5O@'9_O]IJ:2!%
M3@Y!OXGE2N&EV=Z)=LO@4,9L^<5R Z&\K54G+AC]R>M*L<:/_#O]>@S !7\>
M9^R2W?CPY&_'EZ7\U+2NARE2"1U/X,FX[]] [(6M'Z'7%> XH91Q20-VV$+:
M;LGP3EK1F03V V!_LAS.<7@5NYS9QM3,'6 3="UD\$+Q!EA<U@B3+144,186
M<A0H1W34S=^/3QT$PG)+9:KPP?O3TV?%\='1;*K"TYPY6@/>)^IW!@(Y$WT5
M%L1NMD$?_?2:X,WP .EU?)T/R'3$V(2./R)GE9!><-)DJ$!T$8?#D#*,R=#R
MO?8L?3\$3P;FK:ZHR+P9!(_]9F98X"S2=PK';)&^E@&@.AXPHWVDLN'(KPT%
M('-FHZPC,#69A!W5P4%CI.4<5LG/66&8<FK<VBU9$H8<C'1SFKD\UJ>C6\%2
MB[19Y7S'5<;!$L,=(D?^Y&"9JRO%H[N'/8]*6"2)*Y>7L\T=G1W__DS&70Z&
MHVM0\=^GGDE>WAQ9Y"4[*DMNVB_:SG(&-Z0 0'E\%P-#@2F(ZTC)5U+J^F4$
M  S+G"1S#7/HWOI)E=A5/+)*,E0,C*[V0QL42.J2!;J#,JGA'?Y>K&WTORT_
M?$DEJNL^%7EXX=15PN1/_EX!?YY$<\JC:4DW)66E:F;J3):G8&825(61SA^^
M(PLR &P4TH%KSCF:7M"Q2V;HBLF4QZ%@=ZC)B:G%'7<N,&>^C%GABVO&(K+R
M!5'I(HU2$N8#VD;T#G"@CT; 28W)E!E*KLCO1>:FU4NE6+(,F3EK D/J8JO:
MVO*G.UR2I=7E"$EIN^4<1F!GH.1AXXV(7.N3BHC%U95\R&)V_EDST_N$/!;?
MOT?L(QG;<L&/SO<0^SB/'WSWAQ_\B?C![Q?)6N=(5HTN/P)952"K(C*FJM&M
M.EL_,4B#*ELGLSTX8CAK@=(7W&!%9A7H^@"JH>/W<=R79I-3)-)V7DCH8')"
M-.&@?1V^3]:37*QH+DF$OSS*WB[-$"FIOEE63JR8TI&;G'KG:,'\BT6D!C<.
M*MVSU:[;GEY/XJ9U6HDY  ?%RMS++K66<P,W)F[\KZUM;LQJ/A*%(RX^AYZ-
MU,4P MFH$QTT\ 0<PM;6?RL=PQBR$(SJ2OLX-K9SL80),.54:R#Y(^)5"U D
M1"BN_!1]$V'B@&I'IH^)[L228&M4ZBE$HBWI(XD/ .C&P03 *QV18T2-E[#%
MIQHBN..</F"R?/M2@\H>AT_<Q9 M>/E"9+G^Z'B T2@%O8_T,;,8%CS9]P<,
MQ&^B"!/?J'[%.I%EN]Y5.G7AF&Z$#2EX*3V\"1Q5]9O@ZIA=C',-N<@.!C^"
M.);VT2N.[)+M4=R=,(6KN]6_<T=2U^$B3&8-IO6*):ZNE*ZQD/-9&/",%FKC
M);P3EF)95[ ]-1"RW2TI\S550XRR,PV/@XP+#Z,P%K>1420.I50L(X ?N$5]
M(<'*S%OK95H%MS6'I5#G*P-"(E")KV4)$%D\/'#'#A>\H\:\L<_:5P]X0>@6
M:9HQ:\W1<J3K!*,!4.W1 -!HHN*[UN_DSP*+T&&,@[PY^,W$<S(AKD]T);8"
M,K>VFAJ;);XS$;#J&%+H,(,_'N%Z!%H,(<EU'Q6:PLMF"]&A--++-BMY (#K
MU@4=2_::+;2Y@(52X+TF)3.7[)2O&*E%759J=XWF %EC;,^=)"I>3E(B](CI
MFHH@.P#>N0 CM&I?%9KI&W2&8+77&Z'!@42/(N,UF6E-%_7OR=,\^/#J?!]%
MC0" 2[8'S<3 T1 WJ,!G=45A/H#[NB='H#,'-1B0)<Z0!X"_V-?TE@N>4K)B
MG4_%'9/5*,--LCO('V4<3SEU-O+POH \%\I$?CEUQH8++L5^YB@M'@!ZG$L!
M1-*TKZ)CCD7&9,'(;T+'G(R,41FE+Z1C-H/)D2G =JJ\AHX.;K^+S MW8+VE
M2\:MKB0CM*%DJ/* 5*0V'=\YQ&%.A'?FP7>.,+@7'O,Y*2R>*?/( NEH%K&Z
M>[9WFF^< *0IW"N 'L:1U;+EYD#93\J@F$,<KC&:A(EA!@)H2L8,TQ"E2A0Q
MZJE[IUB2K)$EKTRB.MJ63 )""?/8/]G!-['":<*%;NPFI;N[NSH7&J.18HS&
MP:8?V"#Y(/((85J[.]M3NQK#<[9<8K2CIC:K TR&CU41(8T Q2/-FHQYLF:'
MAE92P_4)@*0,<N H%=DY(%11O>YRHH'4,,L2CK$'"O]>PNRC$,[# R0"& RP
MA2@E3!LKP"BKLION"B =PJ+E][L&VOGW8T60QFR5/%!(B-W<G9806Q5;5TPO
MLX(@JG-9>15F)$35%.BT=),$UXCE_FVO("ICH,=Q'"KVH,TY!C_TTLCR N9B
MISB>@73M3/O]A'ZF,@6Y=''(8;&9J)UJRQ$8T[(:L) EORK76G!9/J>L>RL%
M=]<X7/UV[E#G"(FD#+'4%66Y$+K0:>GZ\SG#*E$X?]#;3%/Z(O"H*%K,H6^^
M7:,YHAX%R&%;;5G5&_#]DQ]'F9-U[O5DK8QXV_N9L\1TO-BW6S-.APM5X5S7
M %+8USTD>3!_OB6!;ME<,I/Y EMQ.&^!" W[&HMRD2)&,/C!V;[$I190J.6F
M2G/8Y5O-'X;Y)V*8?R#;Z1?8325VY40>^>T]+*= ^$@ OJ?E5$XTVW1:0519
MPBW;)_;O*S.6\HQRW/L;2S>WGU<;2YU26RDQE,WF-S"6.@5;*1NXYS263H&"
MQ:CC5L?=15I+IZS\64&'9VLIAA3,I[^;,'M?!7ZV'1)XZ\,K\//8(:W+F=\0
M.56_)XUGFA6R0BTG)^1BS9 5-KVI]H/5E0<P0SI?8(4DB__BS9!S627N985<
M7?D"\X6S<!LDD+VYC9!+3_468H14JN #4;'[62%E*/Q#4+'[6"%!,?XR,Z2S
M8"OD5'(WPPRY<'R778J^'(]GH]6]S)!$^\K%R&I#I+-X.R2)=?<W1$K;WU>8
M$(U1V*WWC4R(3MZ"R(2MTH0H+^F'#?$+<Y&GQ)D6#(N=SFS#8C$D5258F27I
M9'JGSF\&@%,9% "XE!EIIQOD#'D1-H=)D#K',@:>7RZU%%+"DSU]2]6_NV!#
MECV\K/<A"Z#DA\^/5!C<K$Z0':]I:SJ,5/:VM-I-RHIRT#(N5 TMS$+J@V[E
MB6#8]]U\12DYD)$E8 _&&2-AF$R"6S?TW>\$U+_6DF'<7SX,+/OE$6+!LLGF
MM6H4$3%OUH"US(H!T]-^>2#89GM*()BV;<!:<KS@F]@VOC80;#I,+'LTV/35
M3P\)FSM.(0?)7Z(EK*Y\\V %4TM Q\4"@ZZ^V-9!LN-"3 A?9>LP9,?'";F:
M9>M H^TCA5Q-UWV NCQTR-5];!W<%/4! J[N306!L#Q:U-4,>T=%(.$#4K,I
M-@^ZH6]ON2TVDWNHT*NI-H_5E4<-O:K"^]651P^]LFP>&<R5AT5_??Q5!M1S
MV3Z X'_+(*R"[8/S[+[<^+&X\"FB:U]C_)@1/I5=U%3[!RSC'V$ F2=<H?4C
M7.&)A"L@+</SN(ZHI!TU1Q\R?Y(061UC6G.4JZ%<P@ DGB6%>!'U406EFWH"
M<?HM,5*1RC)7@+)9?036<_R8\#P6H')*&>1J%*#HC8%C<Z^[0C":O6S=E@G6
M=N4CM<$L:6;Z&/C6][L^=G]M-1O/:W KC1T:%?[8K5E-9IG2?<-NV N@!U1"
MP6K\C)%>3Z*$PGXZLVJ"O* IC5#S'84RF3 !(4EX5F4:C$*D\^'$+#0!J)]D
MLR=3#4"Y6+"86+$$;LZHXJ#+9\D_AZ(N3)&.Z+*X]Y3J-*6Q@'+H>XAE6*ZM
M_!F 4<8#DA?M?5!Y)8'*1=@KQEUG"]RG4O_Z!!/38K?4<)^5WS#5<LZJFP54
M%IR X*:T)!6ECK>&RH#JV@5+2$28"]?E]G'RZ7/U-,6/7M!]'>O[HY,&VMIC
MA8I@P,T6->2?6>F2EZ1NTXS"Y1(]-$/IW&73RKMD0$21["H@R4B?D%H$AN['
MB>!!5E<N0)4J=(;;_[<[&+X\YR7@Z+9]-U,WJ74:&?E#N$ZJ?XE6?%K?!P9C
MF^#;#YY+18SKH^!+6)G5>$7I,]>QRU)I)'FFNCE^6R+.*,1F$%EJ>&$;["J@
M=53 3Z[3>M;0+M^Z+AMS&F9)"=OWOPCR5E=HEB-EQN4C.AO% %\)7[N9=%&;
M#7K._)!GS[JZ8DU;@#;:B:3ALF(MZ^5DB])M%1,FM?#*NK5NZVB/+L[.G@QY
MFBW7%9@%[Q=Q("%]LII(U\K!V![ J09%S9;P2$ME0 Y#_Q(AT#%EP!E[=&9L
M$5C[8O8XG\"( F*K20)CJ\7_M&LD16*_3?QGD__94N(DI@7\(^7)0^SS0!4O
MX9"?4E6N#V&I5U'<MU@7EH_+-V1U5#_6,J?:?#6Z3B+L;N2\CN*N:GLZ(QQ[
M=:6BRA97(8]OG O .O]6H49^N#?LU8/O1V$B@AE5O+(FRQ<":V61LS'F+K:>
M=-O*&C:V!7:Y87IAGO3C$"ECH<4PT$++T'EEV/"-3EX:D$X2^0T# M^E>DK=
M)U$KTYX&QXXF39E_1,%]V@:'(TAW;L)6?2H'"8RYQDY.9$!=DWAG=*LT!"!I
M()3J7NNY2CS V(#<2ATIJ5[(D-V11/K,/N8FA/[D.GUXX.>U?IH.DQ<;&^/Q
MN)&(7N,ZNMW8!UR&)28;PH,9-SPW=3=:FSM;S69GH]ELMEK-S>VMW7:GV=P"
M7K*1#MKM]O.=G>?UUO//F^W-;J?13P=K>\,XN@-)G\017.<&?$';'\'9$)VV
MZH&W=IEP_+3A9L$_BUEGN[VSO8OK[&QO-9_7.^8J,=$#VS,'M$8VQ><:/V]G
M"U-,#:/S3(YCLAK26X- 7?8R%XJD]MW5:KYI_;$\F5,%=:OHHE)*L)4S#(%4
M#LY%UY9GH16;>:,WD'QBJHTSX+M($N5Z-@= D54)\=*;)YUY7 3,L":4ZB5<
M?GK(GAAM^2=#O7) UF1;!NFS9!PF44LJ$273TSC&Y!0L4,]$.-.B4$A1.OWU
MXH.EKG#:HQ3R[-[*BAV8Z8HSZ1V'O18(7HT=!$H7(NL]G 2+<>3),XFLN!,Q
MV?8S?QH=.1E#< LX /N/VJTF.[%L%QM59/7AS.!8-#6JI.-HDI$A,+)TJUF'
ML1#JL-28-I<3H?W#B? H3H24G,. W<$0N6UX_?-:<XT^ ^/IJ<_WGG3L>VG_
M!?F$[1-JEIP01\2FL9J&6I/TW* .!.,:5@XOKNWA6CWUA!R>@"GU]HJ_J *_
M5+9SJ]'LR%!:?AA_V3?4_PA;&?L]RI^^,M*D"0UCY]4D<,?)2R,DX;6?8/KY
M'\*-C8$WTAC_!T]T>9&/-"QMM3O H\9"]JDH;/TI:%R7%M/2E5R!6^B;QWT!
MY1_PW#OU=\R6#8&2I&H4;IF[T9OM1I,CE.E31XZ38E3!@6SH?"[(9(%BDCE\
M021ZFDKXJTG]/4#]4P""?#'L+[#)V[E;I091M-&46K[E217LU5.>M2R)%%(B
MGV;A)/]X3=999@D  SZODYIC>PXRX$JJ=!VTO9J&<F6/5ZK=:.A1[S'E#3@$
M$8/Z'&5J?$8785TUTXC<"URXFXFL.=@G*9I$ISCJ"6^$KP\$&H+1HBO[.V$Q
MU1%%91#>,C6N*B3M>K<T:!BE*/^H<67 -,F4_2A Z0"'D]%SH'?X-+-(^=",
MYW ($.RP4@=E.A@CA)&*>M-]WGHHR]+YJ,0I_U9N?>#>H-^:" J*=VSNEB(J
MA[?QX>"/\I"7F@+,MA_/Q4#XG-(,NLOQ9B%A )G2*8'?- <S.,^U9F>>)==@
M>4.?I86Y;+N=ABR-TVFTE\QH^YT(@%LS!$ &D&OL.>>&:68/E;7$CH#H8B4B
M( 2_N9C0PT&B9ZCU)D9-?_OY)R8;'H=.B7EQFC&#'*<]N>?N*,&B40F)4]CU
MD7D!G419[359[PF?M/3]^YK+5<\G:T30L;&+HR">6L8,Q9W/31+SRW=*5F\T
M051[EP8);N)0N@)W. Q\YL9HU-&FBQJ:B:0=F^90&2Q/R:I]25*W>81H)P*"
M!<2M+\DFLSHBV"5PM;HB;6MH7&;F::&0.D8C<$ V&.+XUF&,!K*>Y+.FR*'$
M. 0 G#>SKY ;7MO$=.1,#C3H =41AR  ,Z84>.AY*7AY$"&/0BF)?C1>\)-D
MI%*,!NZ$XU.IL)7,@,-^I3')!!'U^U:UP870*P%RH\!&?X?< P-J*>O*%S*D
MV1^@!4Z0E$K21LH-72*G'XT)!#TOQA56+0^=I<NMER#(R6X@$@?SH ("&HD2
ML-%1D#JRUX>X SSL^6A#HS!<_C#.R#B"2I&0VS Q#Y5 QP>'M5@V8EIMCD>0
MI5@NFZE'J;R59RMZHQ$VG9TN-%FMI6!I"!FE$I-.>"]ZT.UIL68<"#Z33.R!
M.2JE'NDSV&31YVFKQ&7DG;)-*)&FRP;B+'LA#SQCT4W\%#-/X;7QN-'CR(3T
MK@$W9K<LI %! I%9E'2^OFRQ<S7B1K9*<$'RD(%Q&9R4KV=U12Y(90]>1:,X
M@VPR5LL!/7(SX'5%5[Q0-)5,T=/47F77H'2J=P@Y\QP&%=CFP(6-N91?ZO!J
M2.LCU$44>%#2]3V(R,\;S59!1#8:'+T^I'1_5MB?F%Q;$99AB@K$#5&@'1*3
M5)FL;A@"P^Z1#PL?Q_UGDH.6/_<U662+ASD$DLA1'/HD%562R=U=(),R"NT?
M02VMSCDA&TXUH&E3JHWGZ]J+M[I2.)UG3M)',1II"G;I0G>LIS0*8D(J_@\)
M@R0*1*6L=)O6CKHF^'H4DP0%5R$C%/<Y)+6UV]FL4>7#BM+1Y@MV:*7RTXW1
M.9A+J@I\5PEMO A@![*#4 WV%<L=^N8&34!872EXUY$K,(/((DR-C>US0S2*
M1#.67,/,) &7A3EU=P2OU+238ENQ)]2$+6=8N<":C]R;[NH*SRD%%X9NC19D
M_LXN'X$7QRNY/(PR\0: >F1WT6JXZMHF2V;@'FE>8]0?Q/ZKB/U.&;'_0);*
MHUL*OWE:!/ZR1 YYI<09"_V5=2__]+F?W*RNO'8YML!^9;II#VA3FT@V_-%9
M,MO>(_GJ.S]\]4\DX0_0'%@N!BO7WT?1#=+L"Q65EBR[F^]R'EU!(;A0^.FF
MJ=M3LA=ZMJ2O%UD='40@#T*'YR5F496!<$-#XCN3[9 -'OL>_N&L?EB42B)I
M[>YN,8/WP]L(\\=!%D"[4DJEVH':R#@DD"[9^X9C@22)E87T0FK:XT<1I'I]
MG&4/I(HL.5<N<G3+A3V76B6/:G6EZJS,L"IC=BO\LD!)$Z[YCB7M65V-AK+8
M1:*_RHK6@Y#FL_S#/V$'&NKBP=8UE)XP4QZT:_Y"ADW6N&H0G \)6/XM2U0
M0X" .J\'^V+3^P!(-R#<7,?1..W7V%E3>?NR3]\X0@.@%/DRA;RFI$SYB^SM
MG?^:M.3!,"AY0Y89*/E^%'CY+[&HQ\ 8!&B.^H4VEW_^.G*#)/\E9K^$A:$'
M[J3P%7:+RG\9C5(\I/S7> '%5<D[*SP<H<T +KSP0XR])@K/<_V(XB@@*H(<
MDO\>+3'%I8S+SK/TD).^]:TB(:% M ;4I?IMVAB'19<(-C+WKBQ+I61IA'7
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M&N?AC9$PT7$S,Q3D^YC$8B%##>P(" XAIFZ%^&(M+S=D 3E<]XG (2OWR<F
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M[FP_WTA$$M;1]-/<[33OQ%VKZ77X<-6ZZC!R'2@CIB"_4/;Y11X]EA7^O]\
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MS<S9_S,DW<V:GHW:WOV-1*J\@KLI4;1*Z-W[;CP:!&(I_^Y-MPVK=W2G HV
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M/Q1E);!,N^J_*RO./IEY.'%_Y=5J4YZY2.IL$HF;(BZ*^%$N%T/0,4P@RBA
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MV,89=QMB*Y_SXPN,&2.-,#?&SH7PS557$70;!0/S,/CMXN"@BPG)E!P7I?9
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M<UW#/A*@.AG0:W&#[+EKU$!0!4-,@F7#+=9/4DEE!9Q)\! W(LN6-6N!&ST
M6#,I=GE;0E/6?$'3 2U*M"#*,U.IMVF!CM9M6BW ]@HEJX_Z8@8K(''DW)2>
M"4)07$D_/-FGM%!XT^*'1JQ.HONANB2Z9/645;)!]<+;FI#A6UY%1Q4[5!QQ
MXWO]R6<OZPZ/1M]!P3*E-J="/^BV)2D<ZI;JQ73HK]TW^1)7D,4+W"HP8J:-
MR^8&7Q:!P;Z<XSZE*PH_8,&!O#=T?[8W8$.K3)C%(<4PP6M.M<TB1.OC_J/
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MU-_::_7U*UTZDHK2V%>Z-M,'*)4J3>7SUY+JGNN"2+4_[WW:DQ"3,=5NGQW
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M10SH%C=56^&.@D^C-(9W!M43/44]OM1 8T '$Y#S5<H  DSA!0UG1)/6@7P
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MUNSL'_YFY^215O)D H]L3'([]LH@R?-D_$:\Q,\&20KRQWWV+I) R.LP>9:
MA08 G%3'(\C\A>X\ASE;IA^D2GY>&2C8!(!Q0C#[(+UL@0C!_-HI/<0\1\PP
M,A9Q-^^'$0_NE1'OL4:6%%FW<ZJ,]V.D)ZQX^>SK5)'W(#1,NL7/4>5"P FJ
M2E.OP1Z,KZ=4+ ORYK%A4^6KK)"BBTZ0!04LHGPQJWI$=,:,&/@<# ],!=Y&
M89'3UF3H5Z+12G]QS27,C#D%3:+B$.[AO%5WL0PO=(9:8-*K(,LP/<*-0"]6
MSK+ SI&Y2> G.T7F.Z.SGC=^1DH-*[O(.Q60*&G6(*>,N+%X)1=D9K16*PO
M6(T]0^G OC[%B;WXC/=^CFIPKT>U7]HH1 [7'E<^I8?#NHHB B7IP"3&R]I&
M"TYH@XC(\$3!(/"O<F>^U ;84)- =9-1QIN\%"[S#W@&EY3YA5PDO7;78XMB
MY_SX\!UH0NS[R(0<YAA)*. <H%?$A) &14Z0@%:"WM[</#;%Z%ONH6+GF!7J
M,XBM=NW2]TTD<735L)(-9_*PU^U< HKHT$?LCVU=IW$]45P!=K.ZIE7477%/
M,^ %(?I2C**JSA/X#7A<8V=11]/$BLJ%EZJU87,7.@&B,2[@.(E74/-4N6:(
MB+L-T4./FAWR+,)21AYQBFM=&0Y&NBA:\ZC5]1JOX<[#Z*'.@BC)BA2,,NG\
M_,A+B2^6'PU4?HF,NDZL.(Y'U+<A'ST>JU##3^C,GN#1(4PS(A#33[RNE=>%
M]\KK2F/^A)U,'V'KQ+Z2P.6 ?O;Q1&HDM:E\+M3H+DR-\SB#W^D0 T?"8V7-
M)P56%QPNM'M\765C _C6TN9R::(R%89JN>64U7Q*(*8C7TL!VIS&9VOT31H+
M*D5E%)/Y0NJQ^FX'N;,1YH$L,F4]F_ R^LGT4+,.YAAS"Q>^GM6QW\T@R;CY
MT-T5*XI]UGW0EH>%=G]"MS_6^59A5$W+62RQTX^B8S+S1D.3'C2X(A\E*= (
MX L4G&P(9FF-D;-E^JV<W/-.(Q/WWFD!NL;"Z>64' AMJ&"E=(A><]]D;TQ<
MB8-6?./72;4G/M;.Q]3BZ&QX;O?PP%JFU2:R14UBUVC.YG_X<M@)U/1: TYG
M'E_I=FK>*0=<2V!K'G*7S]IPB&SVPIT9(XUK[O>;UG9+W"$&SF%R5!3),5A%
M@0M?U:#A8RW(DKL)Z=.0VG.LOH$"YO#ER&1U\M ^( !$5@PR<BJY6(T=@GX&
MH_!"<02/AN1%SKYWP&VR @0(96Y@.HM)3T";^_HYVF,N2]H('=YB' 8HBV,U
MH>*UP4QVM>1"()70RQMIH?QNY\9=J'!03Y:6-.[9,"AV_+7 ,TO:@CY]QQHQ
MHQNA6J( %YKP).%FW)8>NFRS0I:;/D&+GVR"##-38]AC+^]IQH,G;G/NEELU
M+0 8?<$H4-%7[8WB_!FD8X$V!-892.] >:I_@TW1WJ-I(358'9)9D;8@MND]
MN*W5E=Q,(RYNO.>/Q(0SDA>JHA[*+$CU@&TYAS='-VXMJ^+8$G+K\,#LRM@S
M!K^'!?P"-A)82D60MVH8J7MP*'4$EE3;4YAEJ%(*8WC,"J.FL%A-VH=FF[_"
M[I8X3XCL2=R&I,A%I,<ZE^Q'0P]Q,&H%BVU!9QTVC4-_ZWO6C04J4,4J[-5-
M4(_W90!()&]A)')^H\=@JCRY9\Z@?4!6.2! #3C!=(M5RKJ_G>SUA\N R:1,
M.T18Y)&L,:4V6M3#ZFZY%65..]]<P]3#S%,,VZ %.@"-R^PI<U9OY25/1(7W
M4J:<N[[XZN1LL9>-;1/UR][@N,;*VQ:_85HJ?/U]0C.S+[%9>%"-RJRU $/*
MYHI523UD6#1LB_[5!%:[FX(I$FR+(SE6C*JC!!&P40G2V+?P&S/HRE,@::$2
M+K86(>'"<:93FV?T,^6BG:IAD<GH*?EB49,O."V"S)V3-,'$NE#TC5=EJC]M
MPD^2%I$IU$MEAG*EYQPRH*E&*CP'J3ZZFJ!0#$R&5:G>@^C'02B6!F(Y :VE
MC&=$\K+Z]%*01!&KK=&5TZCL=&6Z)R@>-G^2,YQ#5GRG9"9P.*.Q0),;Q_F4
M:":*RU3G>6DM&AMH8E%F :DGA5M4FO23>BV*)]0Y1:/VO 4D!B;=/J%2I/-@
M)8^J96^00FJ0<=T.3H/]>#@D9:59YF&2U<'H#KQR#DYY!5V'E: Q0)1B4@B7
ML^"7J-SJW$80R* T<S\QA\5,"*AP=:"5$Y,RQ*P!TW&MWNG<P)381('H2>[(
ML$;7U0!YS=)JEDLQ5:7=#MJ6EG2JY&FS I@FD=B<O<OTERD*98*!:5S+-9"
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MR]P],2AR&R*$LYH,94IE[0R/J3:/)&;[I$I6K1O)^GQR&7MN@^KXBW\49PL
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MB(FQ)X,8Y5,,/ G/E56I%&AB<+I0%RK)UNUM8%VK.TT"=:WAH%7L3#=#'?H
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MN2M !$0)?1^@4M0B](M@Y'):G$*;(4]PNM1%YDT7(=2 L;[F8AJ["1E$%,#
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M7FPNH!<5\?E&8HWXLI4,%OC'+ WF  POJG/4\\\YQ^PS>/F=V]BG-[:QV"R
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M;Q+,)85HT1LI:N\\6V=SUW9PUZWH83BH4;?*-(2#N2H1J(]\!UU#P';J%?>
MRJ@1[N>_R%6CHD3!CH$:Z^K2H4PHO%X)"@8S?GQE'^JU:.HUIO=H?9$HBH%K
M4E[L!I$-79 "A&&-LPPIRJ>AHL)';N>5-R<#R5.7YJH1-\1XM$0_#O[:<]I)
MB-)%E82T"DPY"FK#9@)!<6<H]'!8-]L4F&C.X<_.E6^RAP$!,N2 XJ0+/)I
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M$$W29 ,!M<BE^1*_0&T:ELV,_1UBL!RA)EC5;H?67*/(KIN,TL1:68+'&%U
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M ^/*FB*'&ZF TZ7*4B7(2(Q QC(/<XGY3?WA54SU:WT#BLQH9]NO!US,2%G
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M)&KHFHUW9T=_4&S_R_#7T_W_ E!+ P04    "  &F&=6N#=/Y50@  !8I0
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MZR+=$Z-962U4E5^)BZ)<%4+6L,!:%>*E+A/>-WQO9S@ ")0%X%6Y6,KBRL&
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M.2UZ[L/[P6F,M@L/%XO9E:T="QT#[\XT3*RF=EM43.:::-[0V0+:>H)]O%K
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MS3M @P[NS0KM#XSV 04*J"U7.L[A/);37/."PZC[9I(QDD39-(LRC]*"UZ#
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M#Z8_STF@(C<V9N:3#W,E#&!2UYP9 ^K;)0P@:N^<&0,-XVI/&*BJ  $M(ON
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M7R- GVLX&$.T.S*X/+]U#S4MFZAYG7PG$^P3D%U0]$H5LIAQFIL91]BL961
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M\_=+U]Y]#"/)*4%T?6VH2_07I&64-+B$R)XG&*4K60_K@VV1BNB#C$DZ]?4
MBU2"BKH<!$?LQRNHUA2D%SH!C7^P-8AA\FN;&]57G]W!$3@  0$[YENM]N26
M@MU%6#0MQ0:1PKVBC4,O!J9DF(H!TX<*!Y#EEU$:_R?B7US1N 1"0J#EZRRY
M-FX<6>8]3QLR2<43G$LYQ:$@SE62438][*<9;KV\OAK8CX##IQ$H-$.MK$M4
MNDW2JI.7+;^6HLU!EN*EU'-\3X5-=G+M-!WSBFEJG(@4H+DUNK.7:]+JR(:G
M6WA7R9O4:4.N"7<&N))&!>RDIX23,OI(P_:R@;P.=-SYG5$+@E)F6#_,;"0G
M/JFH-4@(ISX:I5$.5%U7)$.)U)Y:^N(<10;H"F08@NOLHV;VP;-TH\M0SHG6
M"QI9@OK]SNXF7($=BGA.>P@_,/0'@%P,"=#E4=87EO,[#<0'?ATB'."ASVY2
MAW(@I; FYY,)W'$%FWU)2U]95;OZSC2 ?PX_B9;K^R96?HF'KUL\K]?$(;E@
M0UL6G<QLF<MR+ZR,JA:)-.1(>A>P+Z!%;-8D)GEA3$F*9=)^<J]0D_'DP\G)
MD=B>FB/,VEZC</4$)DKTL><<,8X281O81 '/E6;3GRL>#40!G?P9K*/F?L%6
M73*6)Z:3]3!8E$YS!K1_<C$57$J@%)859K>T), ?O&G-4?OA2<1V"5X5W7MA
M D%%;[I" 6[CET$PSG]%\1E;;_$ ="OK4S',=8AK2<X"/=!.WS/;Z=O_6VJ_
MJ5.S$#<Q.JX9%;^'F9 IZAIQFB?*S[9(_M-*314\,DZ$*_J9('X/GN8]F 5,
MX(H$3(E2BX@BR3C,HQO\/<XQHT,<<4TZ7$=I+++CMMD96$NW(@B] 6K!Y[1Y
MAX*-F8'>%)?\&B>MT5\Y9$^!_Q18D,8JA4;TRFJO;1JVF5?:MGPV5G7GMG(?
M\+GWM:U4810.#!6T0J2BTS^J*MK0ADY)GP%17D^VJ0^D[TI;VYQLI%Z$FZ_\
MO:_5?M:( 57@;W8XO@<Q?]^QH857.UA_?RTXA,$'GU2IFK)@J]AJC1OLIJ2*
M,,[\CJUYT:E:RE8V5!(=B ]YQN7Z6L5_+/2\:4J-4#$-\LO;DV7J$"VD/4Q!
MB1F$2 I<^^GWR]%H&(\H?:&X4AO>H.)VY76S(5V^$\19.L[534YWOWI5'+9.
M9GE:\?K:A4DP],P2_V[V\[9Y;[T:U#3TV%8VI'$&SH$K"EB0)U0]XT^9.?EY
M'U[?GA:TBN;(#BQ=S6U-JL9G><R;DACJAJ7M/X>*CN6<-=W5:6]]C)25[;E*
M3R6ISU-'ZV&Y!AE\<Z6)VK)<<!YNO:FSA.9YRZ3=^6U;R/9%L=+<IW #1&V@
MN#?M0-NDKBT<9ZSJRAEOR#9[&)CJ!3KF?_T1'/._KASSRYZ0LEB\?SCV%QZ"
M/W(NYRW\7O3"94]+Z8XZZVLS#1 'K--@>* /G2$A;"M+/9>X]^ < WN%DF,9
M!)^\CT$3"!J&$>I%IJ+A=5P$OA^":L&^]<:3ZUE"!&8UQU1M9FRH1!@$6<Y0
M]-SQXK<(8N0L<#VHF(W"IF^PI5H8V=Z0#&S,651]6E)Y/3C9.'69KZWNZRW$
M:^(:B&N;N\/JD'AY7:) ,-,PV?3+U _?/D^'%%/!O&]4<AO>0=O'"32RO'31
M-. E)F>:QEIXN"G5A\TQWM+?*H$_(07N4TD^"^-IYZSB+;7O$F#@[)"U)'>%
MAR .H(3+JSR;7E[5)V,2?,KLDG5!:[W,:/OAZ/89V-F79&=OKJ^15H#DD%7/
M#F?QCTV*MTTJIT83]HU-%&LIU;J1_.=NJ4H$5I&5R1JFM1U:?01B/XB'L>GU
M?,CMQU9&9"%)R9* N7W43"JCB".B)M@6>4DI!DFIUH.2+0T[GE*GLSTP59X4
M)$E58(Y:S9^&@*<_ L>\N*K)M4,2D=$(J]1J;:VO28*Z;T_5SH(]NE68J#NR
M=_S4N+L'U$'/MNE)W):L=2\H4\VY? (P!0>H&6'*DG,-9\J"3.$2S8,S=7?X
M4-I'?]X4&D#"V\SEAOT5QQ](Y.F 2G(8"8OL][*"B8[=5T=QCJ I:0D'"@,4
MQD%B2UT"%K'2\QX\3:8-4<-ZQERN0E5P!(UY&Y-8HDE<4EL =-'-TK!V+7TW
MA:@K^1T^9'\(3BEOGD>VUPG>A5#6U\Q!8=V*PT\.;K+""2,+SD2:2U^7-[J2
MQV R:#PY5E@NC<*&TDYX4/^+BT3-XB5*Y-\DK!@UB RK-.-B !P?%W&HV7>E
ME?78_ZTS4)F&L-OT'*E^-7.P.QPJFM;M6V:X=\QH* ^[\.HH'5.^BX&'H")!
M"E$+&[(#P\9I>N@W@ZZ,0YY Y<J^[RJ<T:8+HC8OI1<@;5S0F,$J0>K@):X!
M1LN"MN:QM-"Q2%?GBT9J8 !6IWV$SFEO ^[4O#M>4_=@_D9)\#QT7TE:-EW?
MS,424_!B]SR:I1P[S >9WRU<]?UZSN5!E)(;LI6PO V:R_N,@JV=2EL5(>(D
M%2$_KZZBL#;]RW05<98'[Z6V(&TZ2_$52DM=RR^O0I3 %$M[&0Q8/,1>TXC/
MF5]5&W7\JZJ?J$;UQ&<0[FLJ_C4\I,HWYM)H'%4%N1&?-3FCY<Z>75\GV8W)
M=+%U,D^W_[%I3HW/LU7(*EL)> NK'&S0UAYA9Z+1B)I,- E!\WP'F*:6IR00
M)T)97 UD^F&&I&,S=]@MDP(Q7<63#MM@"%64Q%$_ILY$ Q.5(I!QSKB,#6"S
MN;FCQAJG31*G)![K?C+?V$M\.<2">'^$.3]P?*L5/!TZ/&3W4V(!,\ZN23I1
M;TC34^_YT0$Z4WT #:/EM(A@?%PJB^E^6!-KNPTA5TOU*'8)>)6638AQ6%!&
MLV5*0[3M#9/$3-;T,K$E/>&.6#AT\W8@ 05+'3$!6OV0$$&"),O&QYFGV:'T
MH\+H2)3\8BN@OH#'$2.1V=9)^X[I!=CG1-I89JX745B\P.#3;S]"\.FW5?!I
MN<W=!6>UOD&< C]!J<W7_U4I@O&(NY-C-OHT$7:-U1SY("Y,KJDTOG"(\6PS
M<V\0/[NBYME%T1M)]M=(WQBE9A2/?+W@^0R]8#ZWHU?!JFL*]^SR1)>"ASH4
MJ+53*:W@F[X'S\]]!V$7VXJ:4 &2Z);TO7KJU[$I?/(S92@-QB9U]DNLLD'7
MO]8?%>5$_3U-!X(T@X^+21LTE3#DOZ9V,1(,J"0:ULJHO$9QA20]N=-T2WU5
M<HP6%F(MCVEH44Y^\DHM"(>$X*!-0-6*#(1U/)XDVN'C((YV(SKU8BI&EY!F
MGR^:9H]<V3!0;DHH0"3TRQ!4V\,@J?9@\//"JQBXC?['3H!.U]B=H]8E)\"&
MJK?XO,[HATEVP_QX'E=$$,*[]<)VUF=[Y6Q]TZH.L\RD-L<8)@%2@3]A.D25
MLCC3TL)H^E<V M+P!C^3SEJTH0U:3Z7#?YQA+B6#D;,]N)54TWF^TUA I Q$
MQB^FJ,YR6A\_3MH$>+$X8G!7$7O$,C)@IRGN6-U15\N:=EV9T$MB7>+S"5G*
M7 #>>$5K[%X6.!/0M70SSPYD-C61>G.-)2N_PFKKI&"B1'>^HB7QG0Z2%S[U
MFN=,L"H0NR<T;)</SF?'P+[(:Q A6=Y,HS:9XY9I ;[#VEJ41_MC!@K$B9^Q
MP0[&NCS-!0B(/7@GGSN/DDZ'U;)Z0(8X+_[N;D?M;N]N=WAP?CN<*E*;N-8P
M3P$FQ-W'2DX/@+NGMIU:,'J?!:VO;:#[#A50K[414)?IV?#*3B9HT+F23379
M],NB9=.YY Z;(R:)/ZURZ;P]T\:D)H6<,@^S6NYVF')/ZIE5=S4U1XZN2X2N
M@]JB]C> U\ @_O@."&_94_482M/#AVK7<)"_W1=L+XK1ZPBN%OP_B7=([S@)
MY31E7KG>!7?"_M::Q'T&ZB^PTE;87ZQCK%#NO?GF[IE^YW/V_?XC./M^7SG[
M%IUIONSI+<23,&(&-LW3?(@%9"F"SQ;<374&JUPVE6I!&*//%HXQ>N*0>JR9
M?<H:]LHMT[Q%"P<8;=HCL8U8U_WS2J>8Q]B([NW4D]GM+U&6!Q#07HY+S7/3
MH?PI+&VCQ/)ID8CQ%H(+9@4!&*_TV(?78Z6_'N?P$P"C33^GUHYSHG4V-'T*
M^SS56_UUU#"&=<6'.82,];4O@L@07$N#D%%M-GE7$\".^JCU9-ZVP1Y^EDE'
M></()82[;^L5O%:1]$US9\00D;,V]#;L!C[)C<:DUQ*E J3DP[_6W*,MF^?E
M>)4631W.N5NQEFVJP(QY.%#3B0&H: ?4172+>"3F;XY8&V6<L.9@RCIH18)&
M[TV^P@98#[)O--PP+WA495<&"=&HVS4V!F=-R,S>YF50.<M0ZCC\Q2&3$K;-
M(<)Y !;BK,CU" ,]!56XA_N,!]E/_,-'ADWA'$B:W>3-BL>O(QW-))6CXK:<
M&83<6_'T!]>_[^#I#,B'+ELJ_O3SBD$RET\\KNI=Q$@E$XG=%5Z[^V8X:N.=
M-=[L*2@ITX*IIIK[/OM!MDL+W .<$XV("O)=DZ,$77?BV-,"E\?,P_2C9(\\
M!@\:"R%GAM=A;I_)_[R#;+4QXQ:D=,AZ'1EG&ZP.U,,GL!CDD/4UA/ 8<<*J
MAR/EH* ]V'@!(.(\\%8]*BZ4GY[>]Y6:UN*-]35''R+M,7,\HR8[*+$H:]-J
M 5<P5)U*]8B%\:XFR]! .Y4SJV8=66H(WC@IEA %5Z^4^53[0**L? B4)M8#
M4M!P' M3*2F.1C"-_C6559(@D\1Y*/P:L =J9459\N;%A;F8<2CC(M'1D(MM
M5&(B B3F@PY1E+6NQ=/?L;IL2\MJ.LIAS^I0GTZ'!NFVTHBG4'.BL7M<F-2H
MG%#N#:=V#:>\36QBH47F*C3FW._9@%^,J&FJA&3??96U?>.]??^<75>?L>ET
M=+]PUU<LN($%#Q?+@H$NJ1WA70B+7A(%<SE*0I(61C8=H\PFHAXX;7A:(.:.
MV&LZL-5LV[]F6PP.=2<$:.1<?WI!;/J3=4SV%H[(PZKS<]?Y%CF5-O1GCG^B
MQAF^<$6/#?2H%TN/PL1M&[MJR1$#?DUM><(@FTCV3^2Q6U_WQN\U9G.DR,W\
M:R)/1S#XDX&VVV%5WRLT,CWH"I/&YX,3>I+%MN?PU&5@O%@"$EG<A'H3=_BR
MV5WPS4ES@>&]G>T?(;ZWL[T*\"TWYQL]@"3F_JUW2F,/YWR(-=:),9X^W^9F
MAZ?'XOQR0I#B_62JGQ0?;U42W;AJLK_ADF(8#RHEEWW=P 0==[T+)$+5 **E
MRK*A<-[..@.F[)H!,'2W=#RZ!#4C!_$NB:VD#F-W -98X,U4\2R)G%P1RD5Q
M\)1@AAT+%A'4&&-Q)LQW>.LW!#)O,%X\_T&,O_V)ZO"=\3!;"*VTDH:S>;G8
MLQE+MS)6?46SK*#6!!BLG3##>8@^*@(AHBX$+L HQZ\5QHAJCJ<%>JWQ*1;1
MB)!<QYW9F$;FL)I!K2BI@9*N'B^7YY"=K59O"23-R>?9T$]BXL?(B8"KTC51
MX*G5IH=)1EU>2(,N;N$FKCJ0<OSZY>26#J_?B.F<;.+;V%MG$O+\H ?9</5N
MT0POF\J %Z+^+B?]Q@MWV:*XQDJ$TG1$CFQ'9$-[.8??DF2.Z.>L4BEDG%*T
M$:F#BU[WU-3]R?.;>FD'P"*N:Q\YTC">Z4%QSX%>O&*:#43W]T/%"<@3&6;J
MQBE7=61IBYK9":6U)R ]#$;V7.*%OE7NTV9#.X%*6(X8%QAC>:IOR7_,G88B
M;C;$VC6?%:S;BTWUO]$]@^AR7L/.K,\*CM<H3J,4A0A[*O@=N49H:KAB@CW:
M4GRAZ^UE/1@=<[SHJEH%%?\LD.<->%C2Q*WH2*/U#/_D'BZ:H.ZXO>E03S21
MH;<:$N2D6AH&'74XHVWF@]/081DX<<&N5L>N>L=["\9J8!271HORVG<24(WQ
M;^-&(9RA 1W%+J<F%(6% =' IG)4 %'O"F52-#5%M D8QP17.J=BIN%4FQR=
M@:X$!<BMCEK=BN\T\)V/#QR?;$ CZGAU"K4VT6G0@;AC*]@QCGF#ZLTL$JJU
MRS']B*3M8#5B)2@G)N*$I"K^3T$*GNME:#I_>WUK&8DO62SQ$5F)?M.R:9RN
M5_C=(6VDLYUB7=B%?=2N]5+=_T+Q3V*D'JW-;&>9>S1(Z#LK4JJ3TOA1YEEX
M^,*4)/C-LBZH=W5C5DZ8^SS,F(>J EY4R+@MNG:A7'=P&+E7+_7K;GNE%P45
MO10-<NPP=PZS!O+0WUC1//UH4U-<OZI)5DH<W: >?\K_G%&=G1\BJK.SBNI\
M4]:+(+Z@CP]C!XH78ECHE-H&<S86<BAT I3T3@%"J%8)._9$KC+1B1IZ9K6"
M2;0R$P]/AF6QIZ)UR-<+UFE,-XMO; +T/#!SL8 4%;%KC2QK6E&HP"*\J,@]
M+\\N\V@L0_1XX';_^9,=6[_BMR;>>KRLY@$:QCQ;?)>ZI@(C$3O?2Q'8LI?O
M=$$O<%BX3N>0GJPZM< M?C"GBN]1[R$\P]EY!RI,@"YB,4_J(*1^8SF>@<F+
M]+M'9,% ;7)7I$RG-'G9K<"G_!^T%& ":12;!'@/T,6VSPX].9<(JHR.M1(&
M.NK,JH8Q<"FQE^'.;7<(2+2\XB*.4*.:Z?Q%'2\NJOXDH\W-*,R[J[^*I[JI
M'F6$!JNM/\'OI51:N72AN5(_):?([Z=>]X=MJ7V$F8X0NP+L]8V=;=D&$P-'
M^)?;0K"=9*<9^!>QV,G=J8>F*;3Q>]]=RM4()V5-3&=:AC0+2OX@CQE]H5<3
ML#Z]A X4VJI"ZF7<CO"2A_1MI&BM9U%(Y4"U=MW\;LXV=> +5BVL;&M9NA4_
M?_C2G</(.Z@47><(:X;>;]S,:CLBSY/B^&<;:;&K7*K?),?C;BZ [8A-!U?*
M;(]LBHCMV-YN:KN:00,47FDIRL<SUC5<?*_E18R9]11GD$D)(KA!/$$-MH6]
MNI/9/, 5U3]\?4TCU9/A1#4LY*:>V'P6<5;;XEM#,L*K*]4ND@LS"X+IF6V.
MW1%1+4.AS@OV?%&)#8(+3O5\+I/@I?.8>U4UP=>E_!)8&1[F=5&#JUK?.J=A
M>0-EXRRZQ!QTT!:Q ]^6.O2$(C 0B?W9'8"397+;4(F;== :>LT2:D02T1*]
M]LIV02&D7NCEE2FM]9Q\SE\5=@_&P;NHOA>F<MG\!5?[P9,YF%%IE\QMLH%_
M@24ZN?H.#OZ] XT\7SC0B.ETW *)NT^:ZER=DN,42#%OKE[R#U[1$;%54)4<
MYV<"[8F=.XM1<%?IK+7NWDOFAW&'O:7YG1TO$U;>J49PV/90H4,GH4%+9-M%
MHL3X1+X*_TV/@'/=AY%*D1,5&$QA'1);;"K'9H\=R94*]I;QLYEA4[SP93R.
MX&T=<G6S$,9F)?_]?+NSO;U-44.L@:^.I%H:L>&#+ :&X0'?Z8,L=FHMKBD;
M((JK/&_>6OY&\Z":M#N);FT'#4M^7%Q?A?;#Y%P]Y*8AE]-YL/ZDO6+P&%N'
M43#:&J'K2GDSM_T.*_UKV+>? ^E0:]ZS$9O,-R(0+HJNU+.(DR&2'&QMSZT/
M&NNWFFAN,%%%8KW1N6E57^W&TMSR?+/C-0USG3]I_L*\YEP&$G.4A9WE(QV7
M4MCBP+;3RB;-;%<K@:'9#*]C^XO10G->=4"Y1@B[-'/"M2]=/#ZK=(2/DDY
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M:X>?X&^OX2!5N\[$[0]25924U,H$980"9X"?O-3FU&7_NU) !-AG2 ^I36V
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M2:TF\I63^"JM]+T>][^WJ-'3%1#I2OEXQ,K'2EMX3+*M5M!Q^K:"$661*#Z
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M)$__0R\,6<2Q6==F-34E[\2C!W"#@5$\BK;@>Q PJV0330W<> .[.X^*,JJ
M?#)Z'_R]*(M55,-YP?WA_ZZ;LFH2F Q^  N#N:[H0I6F6,119ZTRSV$F-![Y
M0YXOT]DR<J<0G:=9%JWP;_AGO>3KG\O+[1VGK[Q/8!7E67J6 AO#3W6S*CBD
MJIE6Z3Q-R@WN#Q//$QSVR[H5K7.RM\(>A%X<(#K8%OQTCL^NR^(LG1L]WF61
MS8&OXE:5!LAZ[C;MV[+"$ZR VE<@,**J+F;OX,5)&9TE66.B_WJP\^#!PPB8
M4<2,N4]&C$>[_/-C_'F/B%JMS!RY?+:!N:5 H#*SO<7"S.H4+@SN'%,>*5#X
M ,S5X%<S4]9)FL,4\QJ( 9<+C'$)D]S@'L!^PYMI>YB.D;J 0/Z"D?4]\--Y
MBA>KBI#(TSQ9P+/1W%2S,IV:^:V1'1?2S>'K/V H))Z7KX_V8-MIS^"B&&5C
M<.ZX'2!BS&F!%POW2C:H:E8KYJ;R%$FC9,;;5IJ%*4LFKV1:G!E+>CJ$+XN9
M%F-\$7T'! F\%$<"(AB/IB8W"V!<\*($.,-O0I_(SL+C6:2YF6^3N%\465:<
M5[_<W)-J270<Y=XB6:79YI</C4//5NE_#+]6CK=?'7BX\^W__=.CQS\_N?K_
MB*KQ8N_E_N'^R?[KP^,G<-7WCDXF^X?1T=N#O>/H]4O4>(]/CM[NX@,W]W0^
MXAY]JF.$D=["<3U\>O_ML^L^,WCS"[P^S/5P!CMP=,DZK6$'_H/WF'AE4\$_
MITT=Y05<1]0 SM/*Z,V3V\CRF_0:O,PK WI*?@J,5KBG<-D5,AQ/4GM2JLDS
M4X&=\GY=PG^SS7A4F1JY TA\]U9^VTXTD7G1<&GE#\3<"SD!J06TAG!V[EN=
MYPUF&1]!E*$Y./MWDY9%V1*UX]%2#"-9>^2V&383:.+8$#\7>W/G\5:R3;3Q
MA6Y11>1_MTL7[!*J5"J!_]E&/8:-FM-&?8'[I'Z*SA:A#A.]@<T#Q0FW"?7/
M#3,U_;A>)G4T3T&?K4$!!I4(WB1_(4<KB^84V&!N\*L5J&9H&P%G0Y6Y3'$E
MJ/F615:1LT?^R)!QP^]QN&H\:F#RI6KQ\@A95#'HPF"-\51VT.8EMJD&GCPJ
MRXFVTGR6-7.UN9C!AH_RB_4'J/W)]S2%\:AG#M;OPQM$&F%152 *V-8=V!K1
M0]?%N2&+@;_!IV8)" CZDC_SM%:@@.24I,5XA)-;%UDZ@UV,O(,"6W-)CB2[
M^_C+XCQ'[U.ZQD?/BIH)?M:4P$3P%*8;7E3"<[!RZTMD"P.6_@<X G[QIC3)
M:IK=Y%WYQC&H_^O>O>AE:K+Y+V#.G)HG\/R_&Y//4(.+[MV3Z,;3%_N_ZSMY
MI'MUL89''J&N+I],B[HN0%7_ 3^;@I5M2OO9\RR9O8L>PLLK(,<Y3.!-.![-
MS%_HT_OPSI[73V%[W]V;&C3A?@$3&.?L3^F'GAGA-#_VE=[&W,>=X<VXB:?Y
MMVF\0MI]D5; BE(VC]^4Q<R8>5L.,MMB!U4!NO*\60-/$4<=<GORMX,2&EC;
MQ'#@RW<I&<@@ H!YKY.4U&7U=Q+W5D\',728!=O51<F29(&>\L@*H I>7RI_
MWOW]*#I!;@Z7#S3K-;''!3D<VZL#V4'S81' SAV9H6-RT98PQO%H;J8T![@/
M:;W9MAP/+(7\'OM?P*@W94U<$3:];HAC=EX<Z:ZB PDV:8KF!0H6LC \RS[:
MFFPS;=0Z0Q*OWO30G\#>17)6XM[!6DU5)],LK98PWKJ!?\V00M[!-.P;815)
MIMZ@LR)K5B8Z-^BQP#F<P9&=&I$@*8B7#.:.%@2/LB[3F0$9J]Z,!7JEMK[7
MR98)R<MYLL%(C)6=\'?H[$*7+KY#_%;P,9T_'3X0,@IS=_1XYJ7)S!FZ_R8N
M2@*D-AYM/6]O5!3N$Y$;F41Y<<'VJ.O&#A$2,(U"'U4UR<^0 ,8CI8#8;33M
M3P)[**_@H<6U+/[L3[09.TQKX]&'B TD&5TZM'%9OR&/%#\'*A:=-5YL5A'X
MM;O+)&>:V&5-Y@8+-/Y?Y'&]S+#+^.!;TU5E[\PBW:+G1<)>\A>D7A8]II%3
M9:?Z\%P?=O[U+W9OC@QH,DVO=2U6$'".]4:O>VD?WZJ$=Z%;/UVD)/7H&>!?
MI:DIIH.B#Y@%,AZ\\NZ;+2N&9A@D*H&QX1U= (,NM]VV$^M"@@8..#4F!YD)
MYD4R+]:U>U_WD%F0DP$6+1I@'T#],T.?&HI42*3!<B\RK9(UQEN2C(.+<Y.!
M>"BM5VP\NI5!ZH^@AP;X)WKW7B3M:*BE!5 R4!P68G/AX4;'2=V4\"G,!BS'
M9.,T#/HC%T$_3?)W%1X(KN+/HGP7VW_1424-*&4EN31Q !!OIXD<\D%RCH<P
MA3- B?ZEA'DN$8:^A)UV9&;H"ZZ^T#T9RCWY,BS8O[TS8"^\88WKGTG_1SO?
M?;G2W]NE\6BR*IK.;OD6H36\@-68!#@6.U-C$F'T8V=]P)[Q&K=23X,' 8+V
M)(JRDP+NI+X\XG?'$09/0.M/]4?>#Y+9K&S0AD'14\P:R?EX@_95C?]Z8>8-
MQW IC#I+LEF3$8>$8X5?%\"#\YDD9OPZF;Q!?QQF#Q +W9IZ\ZQQ<N-1WF N
M"FG&OQ]5:D3DT:K)ZA0FYB0L_2!J/;\T&3U LI/W"B=6FD4&NXAL/+>V[9$Y
M!14 'M@JBX:26^;%.7Q=C$?X2&[@@E<U2(HB,Y17M?V%DJ-NQ#^]M8_A0+_@
M6WN< !V053BDL/ONFH0>C"/0,4]3NDR<ER1_QI%UACO?3Y;"O1+7SQJN$>6?
M\#_T'LME>Y<7Y_>6Q7F,B11S56\K]DJSHH-^_@RI'MF#=:=0 DQ%*6!);"^U
MNIO4,\L7#]YG\@JW,LW/X-,"=&2PE.E^ [_Y/9V!;M:LGAZ_??/LY-73^_A?
M&"2KX ;A!%'+CGY__MV]G[[[/A:-J]?_9#.NR)5^GK.ZM4SF,ETRX-F\OV2V
MSQ=*@NB.N\!8A"-."^!_<)]SNK"^1:%>$K0WV)$DWP*? [Y*/-2*$/9$Y4 Y
MGKSJ2"0\PJ-BAFI-*-'H+</..CI,)V=BF#$YN7SKQI-V?<*D1V>(D/>028@Q
M*Y<4"31B)8V7$/WX(65$__AEDLI%/@6Y5+!5FASE)\0-),)U\CK;B1@BJ_V4
MBAN\M9<+TSQZ$KU>$\O]!<<5BGL2_8Z.1_CZ>J(X_0E<0<)W&*=YT/-.3AGR
MUJJK?!*=;-8P]*1,INGL2728K SOQ&&!ZWL4A&OT5_C-72CI.BZSQT ON--5
M@GQ4)';,Z94+-!3F'O^U3I!5D9LZ_0\R77-&/)*#-2TUA[(\B1%C=F!D[8HP
M2#0>490(K[^S(I!E^TF>48HKM"ZY5H(PBII\EH*X2>9G:46!F"(Z3S#F<0JG
M.O><^Z&@=UF@30GKY*".O&NC2:B4(4J.^"1:%ZA.X:M\R>3/U$;0=J*7F Z0
M@5Z"88@D^(6-2YFJ-R1V@WG?WZ;$D]T!"L2HWPM#2T<E,:BO45T/3+(9F)I\
M7*"L%E_@#KT$._(?)CK]N//S%VI#L;(QZ-&7?";,"%W"18YRD$/P,;(DBF*S
MC:J9FRT3/JFCEK.C_C*M@ ]4RWS=OMG!VJRO>UM><PA+I>UXM,O1L5DWY3"R
M\37W2$017>MWFRU3LXC,>S-K2 I+@"R.,/V:)&\LSSBI;I]!07 &__0>9F^;
MS?\K8ZD/,4G5E&B6EF$ KZ64V+ <?8[F![H.,(:7K!,XT@VJ#AQ*R_UY?(7!
MM-Z:VZ\[9A'D8Y#N* D90_>""@U+RIHE.TT\9U.-4\Z*U13(/E2WJW25@A89
MZL/Y69%1_6&8BN+[PF!")18D)IG1<B:JOYQ2Y!HN%L:=\4/6C-GE2/H6[,Y?
M!:JM^AUG6OEI/%YMHY3T2299.T<%"_ XW9;37OQ,%[Y8X<(6*HU1!-M =J!A
M8T)LGJ$W<96D1'0V\4L6H8Y\K0,K#?.)-ZJ^9ZAFLI%#\IXMEI;*KFG&/;ZH
M9*@.Y /)/>ABW=S&/)Y_>D4H\WH\ZJO"C+YFZ=H7#;O 4'<E1+.BXMMJWJ_%
MS]Z3!$J%BYP%<E%V21!/P"OH>5?IWD@M[0O#^5DTK%9B#916;6_?\NJFAWA8
MZ-.^KOHX8 W '[R(:_+>KWI SM'DI4E7TZ9$YN,]RKF,R5R+[('G \$D[[>C
M=(6.#1NZ[(OBLI<CV=!(EFNR^.A-\Q7G/8RO.2XUA:XNR$.&910KTQ5JL$93
M=5_N0CSC4?OE*&7.BP8X/#)6ET@%KVBH#KAGE/8*L*Y0?3]]6]*2:C%GV(J7
MB*2?1JOQ9&1QO):>:0BFB#^!,"MZ:!JQ^CZ6\H[QB%]BI<R,$TJ &*@NN50F
M0JO#'^? 3#%ZQS/-"M0RDK+<P/?GP 8J=R1(;DE=E^F4W%(>Y>$WH#_/80U>
M)AL12"< M\41N""ZQJQAVW/#[4H:\PNT$.A$*6'J+ &B(/N[D(J9]^FJ60&/
MHRCFVC)+V-N,4ZA *:=,6]JD4RS&YYVHDW=\-$BLLYG0^8:CI)5>AZ9*IG D
MK.FP.F)WP&.*$=<PA35E/SVRJRGF%)(=CZQE$7/B0%(5.2QHX^>5(PI.Q$H>
M*2((?'":<^4K'H'X,+>0:I1&J^0=9T&S;N*3!/XHH B;1C$>Z74<VHPN<9AA
M@@"[!I]L7[ .!<C^NU,&N4%)B4R0K5'M%BK4AI0_>6^C, #]O#TRT0\5X5?-
M"O_F_4HKO:I,6WY*"U MZHYI;5;X[M,2;X1RIT7[Q@8+2ZMA%KJE)Y6<%2E'
M&C'MMFBFM3<]FHT= ^LI@D%2XMET 42H@H8X]Y3MWOW.BPB/6[(726F5038F
M*:6^@]7/2A 52N0]!<=QR0<O$Q$4&N>(YU26J^(@_58+4S*?DA@*5\O(^J=Q
M$2,S[].*IO&!M +1B9 VWNX<[T0+@Q4,F7=SG4RAU \GT<%(JPUG9&3%K/\W
MGS*@^5DBI(^_KF#HX[M@Z#5K[]-KUMZMQ#?MM$<0P_>*Q;TUV+_ R-1H^RBE
M-=09\4M@APC"HN(F=$6@SFKA*'H0C43<VQFP%9!>:BH7C=RJ6V*7QX$Y1:')
M*3SX):6"T0 %%U>C4RR7@FE*TK%2N[]FT FI,!P<<U*1C0[S&A1@*"UU#W&Z
M;D7RN&;I$[ 0*WWD@* TI3 I*+7O=S A[12GCKJ@*4Y? "(87[#9-5^P@Y05
M=EM*>([%EDDE2%QT\ZP(+FQHKT6A03:AIZ5SEF5T6A1S+!6$P[1Z.VK89'2B
MP8DX488<MS(!L$1C>!:-+X6U$S?/(=#M;E(M+8S!)3PG<=]U\-5>IF4%78N5
MU,1,8E ':PFJ9>-OW;E="I)KDVG2=31CGZ3,;.^]_'V$5\*[$.TI@ZF!V\ 6
M%%%X)5FC9/OPOMQ@=66@.#%T;8.BW>>NLZ875B8+!;0/Q&R83GP<(Y]82"U7
MCP*?F1+.I2CFB_:,JJ=^,/BO^4J:R/^+2T6%O9R;!+&<L(!6,D)!P!$R4\%Y
MSJ!JSV!&-LUSBH9'59>-E/]B[(]P3Z*S]*P@B4(_HMSG$IA231DK:>X*P*7^
MH#1<Y05RM:J8+!A@;B:V6[/6)%N=)(<O83P#:AZR5YJ2GSZ)Y8M-B4)HCMKJ
MUER>62487X#)BY7$9(1N$M^)&,:>"-=%C!K,FQ)_05AL/<",YFFEE9.8._;O
MQHW)>(<VDL7I81YJ:<QN&(-9XNJ F:D'8)V4M84[49L.PS8U'I)Q*6)\:3B*
MZ^HWX(MI4;R[![_ L^EX'/,"V3FE?JUBOGV)_9"VUQY1QL KB'K,6"Q*" R
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MVCXMJ*9>MGO)=AL9.FH!0WM!&09IT/<(I(8TGQ%64+F6-)6'8H-N@U0Z7P>
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M;I=35]EKBWRGY"2O/LY"LDM>AEJ9J/FBSU^@+'] Y921>@SGM+(9)TZ%AJ6
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MH //;(FZE)6PTB7B<FVI"7UCKN$F=8D 5G^#V?'7$5<[9!ANF^>2BZCM^MR
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M\$"H]]*AJ;^IO;5;"+35-VJAD2XNT-^B0'WKUFBU-;G6P=S=T,^,4GQ)W6"
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MB6' 4X, \]$6!T$L#!*V6D4EO2S@O!2M(%&6K^-L.XC3[W]Y\"!:[ZQV>$)
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MV8NQ1*"TE_-T@VV,,224ASVR.8;8BRK=DVSPX\[#"".17O,\"]=]J=S+1U]
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M<'=+CO,DT^*,' "FXH13L##GE$9V_&VR6C]Y$VT=G$0'Q0S&WJ^J!EZV"\H
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M/"FIE!?-$U8T-]CTG' 7V=4U'HEB>86,RV&Y^]CM;6SWOPV9_.#!?]M;V(6
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M,PP09HZ2:&K5$6T/&!Z%;3JOXWQVPQII/K5T^5.NGI&^/T'5Y9!8G#J-!,&
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M&@JQ(ZIYP-?'<%",'1%&G^/K'@S&]1]AYGA\[%)7*>7?V1'D#:^ VR'[##N
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MK(-%Q<,( $><2D/-C%S0C<<A&5AVS]S?EA #K@@NZ'6G3"U!OQU^)[-X^%B
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MOJ@K 7GNI#FSZ11-UDE"CB(=']]I>=6I%]J2$/J2VZA*$@95B+71-(FTPA@
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MJV+[JR.MQ*=\ULWLFLA8Z#7HDOHVJU.!2PD3W0!R;^>6V(F)H%TR3"97E0U
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M]WDI=R1"16$C"F^Q1)E@J4$)KHU\(G)M_Y D6(4_2?1%4>N!&<V:+ .[NZF
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M3(^;RIN?C0:WR!<=#&F.X[ !0?. EYX7H$3C)L">H%44$!G04@HW!'1!GZ#
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MI[:2?UGD&=4TF0)YRJLSQ2+64L(G_9IO&R;G@J7$:*I#54ZF^MZ!7#K(@$1
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M(_F5%">NI"%$N[H8>[HZBYUED_5%L#9L? ])X'MPSAX%YEZ6DO!KYUKLDJC
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MI/*W;CO%<$O-YG,+)V6*]^V#??BZGKWU47[N:+YF0C#0OL=V=SJI: ([T4Y
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M 0<##N@7:_;IL*+3B_+8XQB3@&$( R2(M,%D"5*M-5>T&JHU<=JPVI$0'5P
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MP9>\*J@F@"Q$X!^@OA?E)WK(I7*6E% *AU:EM=Z-?%_-Q.7=,YQ947+P<8,
M MK4^%KTO8 VC@\D<)2P'*H;FG@E"ZG@EXD10)AYR,"HI&>A7=(IMI_ IJ(2
MW)N8DB%%F3A@_O)3P&_A)C":5."4"JJ"+%\SUAO_F*WJ=OAMPOXR>3RH&;EF
MM491]A5K;),'[B2'>G(CS4=<947>K^YLS(R8J;#5:AQPZ/C&\'Y7/..9!WBB
MJ>FI%KA[GGO^G8Z_;D*>EKPR@*N5J.;&^2/.*KPQL0!EL'Q6&6AMR<K#FIA2
MA2@ZL- 7PU>:TK?SQ# @?E1RC>3WQI$\:R@J:^*N_D+1:8-6?DFY;C6SRRG=
M8X3BU[!?L];5#^*WWJ,N5BN(&L;3B+=4'--8]55+-\GV=^Q'$* 7]$!.R-FM
MF/75Y,Z%#9BFG$K0=MMX@0V7<4#9'"6C+ /WIYWZ'3BML$KT7*TZCD?/R>J]
M$1D+OVD\^A<5^C8>*>&YVM3$$%;9\70X&9^M@P0S*"N5AFU6%RK-E"#L=) L
MN"<"?8WP&K& NQ)AHLB1) H.$X1+JIZC9TXKQI&M^]Q)Y,;#V .\^IP2^_'Q
M19&O(E<7@-N%0]A6 #,\XV:Z+$ !=9$)+B_@;:S@W=Q<03,T1&MI6'$#;)UJ
M+6QPF&,0!K"&W<I4<IWI"_2()47<<.&_7)B2,H,* L5%1S.ACIB0_K( BX'<
MWW)^E+M'O9 D8ND=HJFEM5TKL#.2YU+$8B.3Z>=7'YK*BIFZ*$J.J84K?8X
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M G>C^"[7-P^U$,78Y6E>%/34LDS9N[:VI^@^+;5U:0/P"D$U[GUZ//*:Z70
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MH3\W_)PX K5+WGRB6VYQA[G%30IA_TDU=(BI=EQ50Y7Z O41YF89K&#R"5F
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M)=H9%?I8S%#"0,!<R<P49F+:I^U'-!Z)W)BE)0*56T_;</: P??CBB)3H,D
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M$@9PPS.5"%7"R2)3)=?:TK[*[OWFAK=S=F?HTGG[=PO:V0WG+7SGYO9_[>R
M[J#S]$<P\T_U,WC^ORV:7/#:9]&_5=[BWZ*='4G.>?[R];_-Z/S.G:9<P",'
MB\:,LC,IFZ:<_Q@]P<\F8%OIRG[V(E?)QV@?O5-P@5.8RC56TP^UVK%I-GL#
MD^&,"F^]9J7/HI/E E9Y6*E)ECR+WJBYYMUX4^+"]_T?/3"_PF]P%Y\_@!T9
MV)P)Z/8?=R8:V<6/T8+VUI_BDX$IXB;Z&^(=FD\#P9#^W'#.?%3?H$U@THIN
M-/O&)"BAK#(92E_YY;YU2^D16TK('751*V>1'XI^GWC?D(9B;.\,Y4B%$<,A
M0]=:)9[B3'^"59*S3&=/#(@9,L;8![[*&C.O(4U$9+L9PAO3=V&NO8QWX]?>
M4J*? AF]4#5HQL<*U/^E\4 .V:V))E4ZFL#S44V/QSVGY/^C"B_,S%%F-"#9
M3BS@RQRF 38<4A,\_W\_>O)]O+>W1[X]8*CBW<,Y13PEZ]:+?A956YV566J4
M\[1L)TAO3%:P::AMN\F#O8"F:Y-+6";EX I87=XR?,= 5J:;&\:*&%J-C>9V
M7:'L.%<?65/E&%#9%JP:+=32^OO]D2DU#1-8O"@SKV5SPZV"#49S=8)Q8W:U
MVO<;M9]>;!3FK )3 QZIX)[Y\8(!#_);O.+GH&S%PQK[YH9W-L[-LE 9>7)!
M-BO4+>L&ON 9!?[=U08/:'XMO!/,$S!VP*[-ZAF<F9FT;Y.<!)MC7^#/RQD_
M9YD^Y_0(C-42 :*V. >E  QO4B4:/!$@E%"I=988F?E(:F!&)6 _AQEZ+_!K
M0Z2B*->^%@V6>G%JSR+-ZJ32OE%$+U@[%.^(\4T<XSLD:MC<>&F/!$GG15FT
M]1 ?M(%\F# 9<7"VEBM:VDJ#E_F>A F^& _]T=[?5AK$X?4* AZP=V"MT?2\
MU!QX.C7!&2%%H5M5@\54^TZY 3>F-S^;,!/2/Y!T@U$B^R*:!PQZ6H(5AIL
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M8G!*>N%T!"[+=AX81W?Z4T9!.,=R28@/4,2V"/4S3Z;G&6Q':H4RR%:0X^U
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M;I.+Z,5./< F/SB[)NF;)^G]/:;I-P1)RB1\""<A_0XD,]Z#TQK ;Z.R-?@
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MOQGYFB%$R-9#TZ6=H>D(4( ;ZP[V )=6V[8[N7CTJ=N,<>EOF5P.S*HL&TZ
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MY9=WAR]?OG[SC__Y;N\[^O?QN\,C\^_#7U[_X\W_?/?^]3_^>?+=^#4)<T[
MFE.+&F9D_O8,5(RTF?T8/7WZM^^(R3P_>3_^_6?8 RI1N;F=S.*^,USKY.7X
M5\J\'L*T7F#UU,G+_MLNECE\!*-&>_0]#/>@?A =-^B:C_ZWSO/E\-BCW_UX
M[V^.!N"-\)_W\%KX RE@2 Y\MZ:2J^XM3(OD^5W1"0ZXII%[12./=O'03C ,
M?W=D0F,>S3(]]<S=M]3CM/H::.8&".H62 B+B[XF&@KV]V;>(J?TM:PPI*97
M_]^KHW^=O/[WJQ47Y:9H]&M9_?T]WYMB6:SUO,\P:2)%9!Q0L._?;EQ];G>P
M4N&_*YBLL^\OY\,7>6_VU]X;]M[LW_.DXS&T,9S'ZV7?1B[Y]B("^\I=!D,D
M=,/YRL__!<+NGZ]?O#Z1Y-GG#_[U$V[<U^\$N;=[[M(^CR46TI2=ZN2]IX?K
MU/$[BR;O2_#^\_][;"#F3 H?WJ]/A/+GW:]8 &X1*Q%Y]&  FC*$!, :\RE,
MU%D/M"N _6/D7>K39;(E;-W2RBKT6F-%-3%,RGRKN2^X+=CR,@>#H)6 N4AK
MKB1IJUHR,3G) P<-,FFOT+^ <SB\:M@VU[5?5<ZQ^VYY?IK57-KME4A>O+,(
MCD0EW[%#?>1P[LI(O_;#D\K/9%T7Z'XQ@*//_^_KAE+>78((7CG*-26D\SR?
M>V"+EUQ72T07W5,_ UA%<OMLCOLBJ/KDWD!^A7E/1)BI$:(QMJ%[CPZYEDL;
MHZTAR 7\F<F<WX5=SVP&MTD5*[K@1@:&QU:LNT:12:)S!J@OL1Y@*J_RTPP%
MHF0VO&N27A9FS>+=)NC_ %93VH%*0G4/SP/6=0^#'_?]+DYN[BY.L;S "QXV
M%_3BN)KXLLG<-MV]EW6#R8JV?%GH#DF-Q9)VDO *Q<9(@MN2HW]-)A+D)R)V
ML-T+::K) !)^\@@^D&M*I;$9.NN+\,5@0>[K1>A?@JAS!S8W1EZ">Z@:W9+#
MW_/J7]4#=!-N0A@"?82?X[?>IVM"?KW/>,O>[L%-W[=LVY[==2=WR]DT"'S/
MSJ^K_F^\O%AE%Z(B&W=A'<=,Q6:;KI8]ID$78:?C4/!'DE5).^<^+G4L-0:Y
MX*&= T\8-XMAGK>"V8D=&ML"+X];U3.8\@ZN@+74"@LJQLQ$BFM\!!/>]S[S
M6Z7L]Z<@,QR_)Q[SO0*"(,YJ9Q]A4!Z9ZDY6MPWLF,&C'[DAU.8*$^17[(37
M)<H<R144FO&[X24!PRL#MH"Q"!>'6(N@M0BZ632GM0RZ6 89$RO5=5)E$[2L
MQDWF0B=JR.= !?>JEL690P"0<:0F-4\)P4C;B;06B\?-9DBN9)^BK2?;.W/8
M^)D1$F')V!5T]G'3N(J"'^* T*PM#HA7VHR[P2O@;:-EU..F@UN- +F4[>LJ
M_%8)Z:V2V\UH5>49=P(>VJ,4).=L>^0!20-3\3=YE.P5@'<J\JEI(T'9$^ +
M:!!SE*((']!6Y@AAC\9-I$<2U 0.3P'UI"AOYPN8XSRH;/0/A,\AV%I+5+>I
M09FR);HB&#]N@ETTH*LQ;]=(A<$LOP-->!4E<["ZQU10CYR&A? 8J!ZTJ![N
M^@0%@QWF.,0.1S*X &,BU,?, N$_77I&.G%%2NZ&4X^JZ+J,!1M74ZDBC9EB
M<PC< =,@@*O,K>[:11B<+ 4EQ^)4NM9+X^:Q0JOU%=FGVQ[&Q%8 !>1(&]=#
M\3"%M5BF>?!RW&167)7MW>@P) CA,8Q_N+1U9^S@QI_S\9B5C9O%593[8$],
M4S4BC**,D*?AA)0X#!5\347V(P]F%3])J%FYH'Q0P4<H!8.O,A\PZB;$H)A^
MN_==][\;E,;]@W7*%*=,'=SSE*F_+"&O<1K_NLDV!S>6;$,@$"&(%[L9N>H>
M)-*YP<NZN@[<,Z5F&(M)I#%&"" B?:[5YL:<&Y5B_7U6D_:&RBV7H&.K!^OZ
M\EH#AWZO>(0K;P;JQW&9(^2-GR- :38A_K%5;5>8T!:(6F"&!OOI(@2 KFJ<
M,:GLY[/.%MDV"[1^$ IHZ"MJB0TR7^)(U:"?</^1C2'C7N&_DP%<\G4VXAW>
MT(<W=D,/$= "++CY!-0S#SP")./'#*_&N.P9@U[NXV\,V9-BY(MQ-A"AM.AC
MOJDEC5&"R1)$:F>NZ$:H+TC<# $L"*#)Y8O%O0DBE!&,'B#N!;.(!%I4?T)K
MBU#%A!MY/HH^@P,S1#=PT 03+T]*& +[#%JT,'K&2WT0UY;=_FT?\8\,.]O5
MQ,Y( WU2*&!*.3K^Y.W("38&3T'])QL $QO)OF9(##Z+SMLX ZJS%X4'K!*\
MDJ;ISS/\(:4BN8G*8+;SKT&:"L$DT4Y"W%R+WQ4N(K1Q^K:-&23SSBP$/@S2
MJ7JGCAM4>QFE*"_*Z10GF6= 0:DRO:/!S&3XVVD 0R0T^PWF@WP1QOGH9E4;
M(UX1((X0WBHM[<7LN9^KJE)%L_1B;92FAR9_9F J>VFMZ)LH_::C)-U-2Z5>
M8V^;ONM8LM>K:[5ZL<WX;"Z'& ;U@(Y3TR(J\"-=Q%DW-["KN[BG^'; C^KI
MDJ[V)\UZ%:EPL>F&CIZ)K!$WGW@-Q?^_OA9W<RT>W^RU<%08Y.Z61$>2(1XS
M(Q>B$(JX)$*-KZK@@E'(GK0*U%^_Q6X?MUT#\_M[0L@"38]8"[I0>"'<WIXZ
M%,)!YGK:1)-<%1]W/WQ[AW!%9][#M3./G7D/U\Z\KY.0U\Z\OP33QGWV*T5?
M/#_^U[N?]I\_P#_6%:.WNO''"C0;4'V.G=,259?W.M>J#B!+OT7*O^'-_OTU
MV.P56-PO5:,_>%OJ6/M7/6V4C!_6E/"Y,WRI%:BG;F,CNZ_WL+#A7MJ-KPMJ
MC-1#0.X$?)9E6WEUQ/S<[P*1&/40$C\$?87"R >U@\0C]QBMY0+QY@8,13X-
MZT;TFEG!;TR>Y MQ%7^ :=BN5*9IV-!CE%8N*9(]1. ?;)\1N\;-#0?I;($X
M#;8S3;+3M2&EG+;_G_\7-E9R&V?%B-V-C'8WJN'4!1>Z:2M)RN2B,W\FV.)$
M8R(0[N![?O0EU;<6J:IGS[Y_<+#_X-%C =;'.)LI;O):<7OO=@5ML)$4-G#]
MQ"89 4^;1<O1A*O&0_NP&[U8T@+("VW78#U7W:&BWV'VT@X,6\V4'_%1HC$L
M=UU0;0/3 ^V-<2#3"R@K3MQMG,J&;_)<4+W2O:*=3S!>YEJ;UUQ=[T41)&3
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M>\R8YH(]WW_Z_<.!/?C>_[77@7;,3-YB6DNTOW_PZ(GW#OOQ_J-]<SP@H8]
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MH8/K 1H<O0O;223<Y9FN,RI_4K+ *33A5M7/,.JH%;?@'AW1ZT>I,)Z)23S
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MB;WUQXI-0$\*9,0%F\BP>*,&Y[F8+6N4/:,=?=ZYF_'$ $6;ABLO5$IURHZ
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M,C,X-3<X9#%?97@Q,"TY+FAT;>U]>6\;Q[;G_P3X'7K\YMV1 $J6Y"5V[&=
MMI4;STMLCZ7$<Q$$@V)W4>RXV<W;BV3FT\_9:NN%HA3;D6P%@261W;6>.G76
MWWGZX\G//ST;CY[^>'3X$GY&^-_3DU<G/QT]>WJ7?\*W=^7KI\_?O/Q7='SR
MKY^._NO.K,CK[Z/]O64=G:0+746O]7GTKEBH?,(?3*)C7::S._ BO/KVLN\]
MB1:J/$WS[R-\=.])5.N/]8[*TE/X*-9YK<L[SYX^?_:/?%HMGSR]^QQ&_/9S
M]%6FI_.:NCKZ.$^G:0T-[C[^[-W^75/4<5.G11Z]*):KKV1Z7E]'/[_]Z<V_
M?CYZ?1(=_O/=T1'^]DE[OF.G\UFF\D=3U>EL)1^F>:*QT;W=!VE^Y]G)CZ^.
MH[X9CD=;]5Q'_\B2?S?%D\/34NL%O/B/DO[>GD1I!9TF.E)55,RBGU49SZ/O
M)M'!WL&]R'_U:#;3<9V>Z>BEJK5[?[J*5)Y$4UV?:PVTH\JT6JCH9*Y+M=1
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M.$2YW9+Q*)U%*9ROHLF2:"O=9OXRI6F=I45FM2ELD#JOK'H57+!V]$ZW,(;
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M,,FRR($[S-),!_W!"[EF Y9>J#3;CM V7C73/^ =W$M4*RI<4N'=K.C ^$0
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M%:<'[PQ=O!-RH/<P@HD[SE_)5B3;L G<_UN4-+!9-,9OMA=T5*'SC^FB(3T
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M)A'K>#=\FR; S/:F\9D+7%.'G0,01*/*K8?F-XD&M=FA0.&&8K<49E+-*+&
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MR[1N$DXMPM=F(+U>Z\,Q<"BLHA+:E]H,P$D[%69D;/NI15X:$-X2>,SH#Q-
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MQX Y)-5L%2[#_;W'ARX"&%&50/1\AR:.!H>4$-WM/W[TT(=IG[0*#R2V?H!
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M?HUCN#>S2#_\%BS2#V\MTK<6Z4]1W/&=KN %Y@NH0@'KH"O\K4C>E4$+F7@
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MJC.59L0KM_K<MT185AW:%E^HT3F\^&'+]I.TPIIDK-@[A*/^JZ]GR^,^)4?
MOGG\L5NQ33 X'2%M'6YOI7W-4\W3]0K]UX:H\?A;,$@^OC5(WAHDKRRAF&))
MAX[=NCQZS (R]3&LM2AI>FQ7_?4L>WD,<;B8)%D&U* $&HX-Q>Q^S=Y4YJ'F
M)FU7)]U&*?Q"_<7'BWU;4'PGW.(MB\UV&!Q#%X8K=)=0;)H33V=&4.C1&A)0
M3]X;7IUBMMW6/5/SB)/"*7V(*T_T5M21PC6VUD^/56Y+'&=T:>&8R=\$F[*-
M2[]^18(\,"Y%MW:O>@I\NCTA:1XCFF>KMH%Q2Y1.V5VJ^P@WL.C11IT G3%E
MO 0D,-,NAUAO.PN(%)SL;)^/M^OFS="Y'5*8./-'KT6%L<CNV2[9-XF/7J3A
M$?Z+5Q"&"8 B.OHHP&;].QQ1RMSL5ND,E]0L/M<&4P9WPK[8A_3L&2/>R>..
MYFLF! ,R?6A7IQ-V*8@I0]7JPYWK%*I<(N$*$AF;31CDZ_EPAR!=^7TR/HO?
M2;?>87>IG#?$ \P-*,DW -NXE) );<!D)B%&=H>RI.#BGU<@+0IK\&GK5:\#
MQ^,><,C8G6[H)/>^-300<8R!5RY+8F028DV3ODU&X!+&G0UWV]H-0-A5&<(M
ML0&\"PK',(,7,&P,J;.#8<=[33BRM!5'GJ':OG*1+<<54W;W6Z<"#"'XFL8%
MB-^O5!O$F-O@?5M@GB3%[\-R24"8<]OCI%6GIE8?)73")'%X2+:*X%'R[C-A
MY4Z_1A)FPE#5I?%("O($T!\I8II@,)V6JEFVTAR?,/_BMS<^[YK-.F<K)\Y;
M8=AV144&*5W$H);[Z%H@<9U"?U+M2DB8XHF,CN&,FI-UGB:R)<%9'+*0$LFU
MSC_'DZ>MVF6."?8=G4LQN;Y[<8&0413-T;VINL9AJ]*MP:]Q,I6]-%K,OI/N
M:6=HT!E-ME7/H(@;,JX BA$BUH42D%<7@5G#X&4<>C#$HMV1=%9$4"BL=/<-
MRS/T;ERT;M]:=\5F6X=Y (3;+)66\"ZVQ1*Q(&7_Z@\N=_NR;J>8\>)@C-0I
M%E\#-@U#U;.9P:""R[S(S@P265JA!79W/'HU"SXQ\%CRM$V:IV<>[NVX(H^3
M\#U704W7)$[:9'@)JB^G:6T*ACEAMQM&L.\J)'@!:!V_]R3ZS.0]&8_XN+75
MD)H@TGO(4WF0&C7%B')=:K-$?K7#86 !)[]:(9R(VHD/1/WMP\=51 9.8/1I
M#J!GPM_X!)Z0$)Z9.H0#S"ML=X.=127)K[1']&H16P,:_RITZ),P?'(@%H$Y
M+47^)>)'PA@8$\E-+B]8Y]ZKV-DO.Q3?FXX2))LH_V/$3AZ/_ S9L#E.'&!-
M\R)I[:;MWIUG!XQ%=P3S@KVPZR4ASG[J(.>'>I6EY%+ZF>H)^$D@>=*WUB&[
M"2$.*2$XDU+!@LD38YXN>S#M/7;B0,XGG0P!OY85R4X\I_[ZK3[D1=5@6K!.
M7,9=I@AP$XF/$)J]27")3Y-2ASXF&(E184PF%EJ+*&_#MRY@MR90=Z'JVJ1"
MA<%KUD7>#P=/8Z<QV7?Z"VR0:UWL]7VU54WZJ^"MMU$%R1HBRT)M7%C&EK>6
M0[0)U!%S$B,*$>8J!YS6LS8J[V%TW7-/-[.R[\-Q^Q7C0^#7+V=PWVPZ7]02
MO[]W:XK__$S\U>OH_:N3UT?'Q]'['X_>';WY81(P.:EK3RYSDQG:89\^H#!?
MOES_W![6ZW\T!W$$/]^@3PZ?_W04O3CZZ:>WAR]?OGK]S_^ZLW>'_CY^>_C"
M_&T(FH]S#+*@6E9 T^:WRSABSM.DGN.C>_]YYQF.X)UI_@RQ6V.5&?J 0Q(2
M3*9G]1VB^J<G+\U;TMX#:.TYQA^?O&P_L9X+V1'=QR;N5G>CXQK-<=%_ZRQ;
M];5G>L0)F.6$I^"?=W]E0L^(^5Q^ G>>#0WXDX[N!/T65QK>BWFJ9Y[ ](8
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MG<D*=3$+S!4YR"R[O>@35O)U.W],-5"&Y[-.GB:JA#43JR5)@<OBJ;"E4&3
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M6S.8''VJ&ZK(M5QG\A(A0IAG@U5"9L\89&4,=BNF!CG0?2%+H*B!!W@6&$S
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ME=6;D J_T0G$ YX?E"PD8='!)2W.^;V6.4U0 6MO6B51#(O/<HR\HV6 +2Z
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M:_]JXHQQ'#X>B4R!K:3//T@%Q%ZETM8DX3=4#3E^OI )34'&*#>0+_&G)%[
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MJR!U!/TQ0TIU^;BD;]GPP]%A9/*":3Q";PH509N33%0%P3/' @+GGN[B:ST
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M5NERB7R#=L0R^%*[MZA7Q(T:8Q#?+'4B]J2$L&,$I\E L#M/'9/3$W4&KPL
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M+EM!'GIHV_WV4%Z 6,_-D=;=RL)L_]_'$?O-5E/88B+>!&U-W.XJ$VKM<".
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MOYLV^6%/G%"WD>J-^(0 Y*LHEV]+N#Y[?_+AG[2K/Y[_].G=_P-02P,$%
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M7"]8D_F0(Y3(377"LL_UQ#T;P[@!\TE2ZMD/T7;2.=NXHNE\<LZ*!2-3)"*
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M(\VP>;U\AC.T&G:J+<0M/-7/V')WKNM$UXANUH-FS@T@VIZB>^]/4\5^1(T
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MWF/R^R'XN,^OZ^-^,X?S&SS4?+1QW[]_^_'=O][@/_YQ]NO[-_\?4$L#!!0
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M^4"=M$E%J^U6VX+8[$[12!4&,$9.:<BST=?_:GGPJL.::5Z?8OYY1",5(>M
M@TV'JI0MX)-*9SPP00IQRUJ"(X)M'5T\'/>VW<,:)>-LF,@A]30BU 5JXZ0_
MB/Q-ZGLT$3]#8D'8H:F*%S(B8TG#&26 =3J(U6HUR:+4<#V!S\6?FT46A%@@
M>I;G70ITAA;!=L=N9=E$ 7X"XZUC:UWB$=BD[:T[0XDM.T5TID_:0G".;1C"
MI7?9PCD3)VEQ2M>T^4 G<J>C<*'C*IY$\ RL.54-%<7(#$G%1U>L20NQ//GC
MQ]-6TL$B:$UMH&,BX.S!!CMIL(:OFKE%Q^!8$!.39HP1:4:!:)VJ9EZ1]X<4
M:9S<E1M@--'L%%]]9;OY1 K(HNE)^,RSHM?UIY9YP?9YG6$K4QD3:SAH_<:[
MWNFINP/O.\?HWS<R>/S_(X-_N9OH)A2?VA+>_^)H6&\)=HADC\_ N+F/#4!H
M"N&[+:)?8#]'ECJO1MMXHJ7IU(JFGP H!D[9YP@M@*7TCM/T6%]&PP%*B_5-
M8:1Q+[7KZ?!U39/=YI"I3#C@(S;R87=?%3I1 F@UIU@K!+1O>K%N&-^V=.F;
M= X_:N\]-%^0.%50X;OQ3MS!]J<$(3;?_A1PM_T1[?C&9Q5!^0V9( ES%6XJ
MUXY3;\AQWNNIN:$R355N?.9J<T/?;->'?K'[T7B$UZD7FW3T\[(B-U-,1(<1
MD /O:T1_ZB_')H5^SX/I\#Z.QZ5-1P/$3,XKO20.TVO,SC0?YQ+ 7RBF34<9
M\X']9\^>H@.ARJZN)0TB1EMA@O+&PK<#M)GB=_$WVA5]<=# !SGQ^"O-&1I"
MLB46(1ZK3W?5H8UW_K@9/8PV2W6_L.T^)]X2VA^,]9,,:3F'Q;G@TTEL-*NF
MECX=<EFF"ZCQ3/@VR4(L][=[;4)VIZK92* "'VFOH-,8DF'63;VF\Q)M6[H\
M7=/8:/&YH)#$O:-L4FX),Q!M[,9'8"?;QYX42(1 !KN-1G@N'NB' A:DX9/W
M+HM\O*&L\%%*'(C3ACS.O(1(A&KI4/](;ZJLFNEPXSQG4PDFV' $2;O!;AC%
MNI/!:#YDT0,-57G< "/&F&XF6/VA6K,FU9/;(CD>]% 0T.65T<WE6(GV:=!O
M? ]W'<!<T((O-M!%&JS-<RCJ=F)_FPZ*(,KST(F3&Q1O+NFO_J60AK'1(9U=
M=S?EDFF(^+5C87K(Q=FI[QU213W2=F5S!B1N3AYB%4BPS2=/E9KR;I;1I'*J
M3:+;O9NWV$P@2VNN:#N88+R"SLZ!(/($',&J-QV4;P9FC9:4R@MIJ6U!Z+1'
MR(Q*=!F";J\V<IR%BLOD]31'C4=G;;HBAVM#MU<H8Z;I&H>/D N@';=)>Y/N
M>Q9.X=_)J(BW5RG%H%,/;-+C>+[1G^XF;S80N:)9K$_(T4A%%LFP "R2"'W]
ML&^ +-T7; :T&QK@\>LF.WM'D[%YW>TR-^64]#5%BV;RWU[A&@Z:U?A6]<T+
M,>3G6T Y?J7:_38W>TE%F 3!K[WA*PBCWL[1,H(FA]8!"JNZ0F?#P:9AZ3O(
M@:!(7Q)V\0W6VOO85?.8>'-<3?</ 7<TBC,]V.K7PU?7T=KT:@J/B3BUK5E&
M,8D^@[01NAH=;I"Z]@KD#;19:K7J7ZO@VWR4>FXVZ;6##7AZTD0&BF//K0JZ
MR&7$^N[R;L,(Z!:KK'WT65R(G,I;G8C7;H7'*SX$-]UPG4J0,@EWZS)/-PC]
MC>T/!_U*0\U.06?5NKNK%5&[0S&^D$!G$%34R&U&ZL)'9)N:AI'0&,A!VHA&
MQ@K,6?HFX/-TQIW&+%1RC%R!L%SN4K#OG\C"^%[EE-P!X@IA)15PWWEG%['I
M.X@'5F20GOE3KM''PT%RW)TW(5^BM:(!B.2;$4BDYW?<.]VAJ/^L#?2D4;+]
M]U3PP8\_/'DHGCS=&S]]3/]DY-]1QP^>[/=78F790M&-PFI-\[@_1*2>INMY
M?X!@;6\2_G5C[/D',//O&(D].1!O2Z:*S\49W<#[%TW(_D@SK"\M\!']@]'X
M+TCI'YK^+U!+ P04    "  &F&=60;$@"PDA 0!RTP4 %0   '1M,C,X-3<X
M9#%?97@Y.2TR+FAT;>R]:W/;UK(M^IU5_ \XN2<I>2^*UL//O*IDR4YT8SDJ
M2TG./E]N@21(8AD$N %0-O/K;X_NGB\0E!3'SB(MG:JS5RR2P'ST[-F/T:._
M__GR[/6/W<[W/[\\.J'_C?#_OK\\O7S]\L?O'\K_TJ</]>/O7_QZ\M_1Q>5_
MOW[YPU?C(J^_C?;WYG5TF<Z2*GJ3O(_>%K,X[\D?>M%%4J;CK^B']-/SO_J[
M[Z)97$[2_-L(7]W[+JJ3#_5NG*43^E.93J;U5S]^_^+'EQ^FZ2"MO\D'U?R[
MY\_[!]\_?$%C/_\T;_WJ1WGP)WM@.(UADM=)R?,X/GI[>G%V%+WX[>+TS<N+
MB\V>!@_YUZNDO$J3]YL]5%WQ-!\E^/U>_W&:?_7C<5RFU2R.+J=)&<^319T.
MJ^@T'_9[45%&^FDO2JLHCH99FJ?#..MVJCJ>)+1K61;5_,-E-"QF\SA?1N-B
MN*B2453D$3TL2_],\XEYSC=E]3^+XKLJFI?%O$R3.BZ7-,@A_6N*!\;Y*)H5
M>3%<UOKT)*<))#0;>L@\B^MQ4<ZBNHA&R562%?-NIR[CO,)?XSJ]2J)T-EOD
MA8PII:6AK]9E$M?1,,Z'2<EOX(^CBAY:+*IHE%9)7"55WPPRFL95-,2/:!8Q
MSZM,IDE>X?G!E+T!=3M)'@^R!)_IY[R6$:U%5(SM/.B1;KY5,&':MO?3=#B-
M!C0SFBX-/8ZJQ6!2%HLYGD&?TK(,LJ(8\3AHE'&6X8E+^D6J?^QW.V?KWA#%
M91+-X[+&XS#2-,]IFK)J250MJSJ9\4]HN6B-ZV18\S]'R:2,1PDM33D;+S(,
MBT2 5I16>$KCFTQIK+2I](<J*I-Q4M),:7-H"K39-!*\OZA2FF.:ZS3Q_I7G
M0=!HK1;9&(O/;Z[JLECJO^C']:+,HRR)1[*Y])!X2%M/VT\21].*HT%9Q",S
MIS*IYD5>)?UM.YB7!58GQX)BDO/B?5)BJ43"LV)"PC5>Y$/,NZ*)=SN!8$WB
M-*^,V/<"V=:SP]+M'\3C*8VQI,<>Y74Z2?+H;3),YC6I 2=0HA6.WNZ>]3SQ
M3X93'M*R;Q_2[<3ZE%*?4IG?TG] #JME3A.KH5"RI7] [ ]HXG1R\5V2 KHG
MZ#/:\@%)1/'>[*\<A/=I+0(5#TCEU$L6#5KCI"9=-4^&Z9BFI0.JH)KPW6I1
MCN,A'T_5#G* HA=+$C22NM%BR,J+AHP_%->JJLHM<IS.6#AI,FF)(T1O2\MN
M9U[4M,.-0^?V,-RS_HK2Y&5O6W5ZXK HYT49XXS[6UHO9K3FLA*8RI#>4Y>+
M85WUNITK&AJO,M1I1MI-=B<*)KJB0>A?>4$"1-_)%[1^=!Y9.<OA]_1H8]RU
M?\'X>\IJ(LW':59C K(U14;Z3$8_2VDL27Z5ED4^H_7K1>]24L+^ED57::RS
M)!D)]0T&K!HB4=7OBTZ/Q("445QU.Y>[^A<>3UJG^$4<E<5@4=4L/;LRHFU7
M+<T-@C;%!I*\L_2-TA&F?GRYN_=X[QE)"K9DG):T"KJ7.(51<A5G"[XE22V3
M:EG0:*R-0-=N&F=B..0ZJ],?DP^T55?%]P]/=:;QHH8(XR(.K];F:' YDG9(
M\VXG./GCLICIG3@JX_>Y_($4&UT(.&R0-$^W%(NZ2D>)N?\&Q6C)$H(GC]EN
MX8/.,AC/$O.8OED,S(>^D=""BN"*=>')JVHM.B)E\H$L!]+?/[]\>] 395LG
MN,+P!7J0]QTQF!I:*8ZN8ISD)?[AOP*WZ#!;C'#P!C2 BM2<T?03^A>4N/EW
M4LE!CC/[IXJL[BNHATFF=SW_F8_V@K0W=H-/2M,H(E,HXR.6Y&6193B-9B5%
M/-A6Z7;H;[IPE<C&.?T\B?8;TH'?&B$3%9[3/KF?3N,KGF%"MPB=4N@7N@'I
MLA@5M&!],E.C-[2&LT%2BC0=[!T<6#5,^I96%HX%A)L4W"S-,6D[!OITD=4J
M0HTY1-X4W.:_IT4(!N)T(+UD46&TONHL!C6I=$@*OV.:T(0R"'>R6XN!2:L^
MNL+ZCP*=9Y< >X*EKZ8%R?:4O#T<P4BEAJZ-'G2?7'JR@W/2Q_62%R<>C=*:
MOZ,3Z';P+%Y/N@CII&$.[^D<[=(I3$JQ>,<U5"1. RPJV9:"EWP7:\CW2%U\
M2(?TGPFL/;IX:KF:66W8Y0PW4T2&#YBO4'BU^]$?TU2-Y\:NP!Z,RVS9%!UZ
M5<R'>T"2&NPO%H$'BM4UXDLV=4IF3^6_@C0)*9>AW#ET(LTNP_8=)&K^TH"Q
M!*D<SG4W$OWQ\NQE3S0IW_RS G<J+95W_ZB%B@?QMWF[V"9(L1,\GL4P\:^:
M>!3/G6/#&VNM#/K6,)V;._\J974PHYFE=$K=>O%*+>8C_B)4CFP.W0O1_C/<
M[/6T8G'!G^F(#V@9,52RG)(:NQU:C\6 /*<K[/>4;;B$KIL*GHZ=B7>L17SH
M_)_L0TD/WV&(<L]&PVDR?#<O4K:(.':!JS7GTV$'S\L(8X7=*UY/?XPJ#/R6
M.2D"$K'T3[J'!FZ9R+4@65!?SCP6FK@8%EE$.CX?L1Y3K?];#L&)+FI>KE>X
M5[!-)^5B$AV-2,1HLB6_FP9% WYU<L0^S069K U-Q!Y<EI&M:L9B[PM[*JSA
M.BQVX^#Q_BJRH/C3$]DA&U[L)^Q$O1C!^2Y]W4SC.B%C.AQ6'[X^QLW;27X=
M:\AOLA&,@5=T>T2793Q\]TW)?Z 'Q_6"C4(S&KR$#P.F8NX ,Z-NAZ>$*\^_
MW[!SP26)\9ME(9,VYS>0W5J0]DK_3(R3PH^7%_+-R^>55F?K;*X7R;+ E,UU
MYQ\IX[+.TSET1L+>7& .Q60AR%T*BP#W,T=@*EYY_[QXRQ9< 4:\_64MQNOM
M,K'S, 86+XFFN%'#JLLJ&X:AW;6/PAA;'H7[)O*>I-9<Z,:Q6\ N4^@1B@86
M05=!L\8K3#@2Z<)<I%%:5S<-QO=%W*3(KX2.J::L*_@<)O"R24]D\:#08XFQ
M=#MGI)?*/+[\/SUYKHV8Z0<]/P[67/A [T.=D<TUI/],_[0GGRP0VK']@U5#
M&&[T6$(H9%84BQ)F$MT9&9U&T@!\N><%[L):;:35\;M1^F(8S)]$9T[OCCE0
M0QJ+YE*9G]FUU\"3"JMUM+-T3@<]C_,"L:9TF"4/9V_?'/'ZO'YSKO]P_BL\
M+G+=X)KQZ&[M^+*K)J$Z<4J]C2?_-MCY@GQD=I9#2>RWF0@0;S-[K(P$8,R&
MT3LUV!=S%%&.83$>[]+W=FGYLG'+MHFWP#ZJ<T_L%&'=!6&\1C1 _V@/A[-)
MTE*/P%$5A/;B29DD+&[!CG<[9KX(LZ17+.O_^]'C_AZ9-5D&"5G,=\GXRO'J
MBJ[5>&F%EJ0BS6F)1.L/EN:ID9I'O#WLN/SO0_^)PX)^19* -<L+.'/8'U\W
MC1>PH6&9D;5'JSY>Y"-C/>')Q1Q6)EM ?!W0DQ$&8@.3QR<W2EDLXPQFZ0;?
M#U^Y','_VMV-7J5)-OHV.B=U_AU]_W\6">TW/?:[Z-<YQX6^Q7,O$@X2?1?]
M3CXW/HYV=S5/]?W)Z>]F2/(BLN;G])6#>6U>O4M6<EW,OHV>X&^D"VC;[-]>
M9'3=1_MS=6-I?,$4=RNZCV6>;4D;^PI^Z5[+.^EO]$QOKF:6WT67RSD]^J@D
M#V;X7?2&K#%9B3<%YK?O_^BA^14^P0I^_Y FWK(&<(C?[0X2$A-ZVIS7U1_B
MDY8A8JW\>7L;YN]_\$I_;!BS[,BG%9"-$]XUL6K- =#5:\)E")*09LB07QG"
M$#07NN>?DYH=+-*,#_IB3HH O_>S/$D^Y2L=1YL,2:,,.*\D41$O(LMW$+[2
M-#7@E(G3*I8V[@N]9HVWA%A!4V$[VSQ0_;=.)[U8PC>FL\7OAKULP[ C6N?4
M^H)TO7F+ N^3?E<69)G/O-^9\+6]9G4%] EJK=F+1W(G;'/X<S*W"JG_.)_X
ML6]G6[,J-6:?9+%B!)GHAF0;UMRD?.7$ZDVO<;7'6?(A'=CMP@;_Y7P?7 IL
M;=.5DA &KGX2W9;]JQ9IS=<T+HPV"UEB4\.BJG>3,584?Z,3D,-'+HS$L5"J
M9=[O=AI&-5Q[W%-8"8EHJ 5/+QHG>968N[$MU=8+ ^TEAKJ0-%<,ZS^MJD52
MF2=PL)+M9OQS"?^<'/'H70)!FRQHM0HZ92Z?H('MZ#T_<YK$&3OS="YGQGW&
MEH3!;(V8RZOQ7%EDN%S1;^S&K>YAMV,V\9I ;SY:;Y6W[7K@;,P7)>TF?2JQ
M(&LF>%*.#>7(HXV J--DW%7O%/N.JSFP3>GV8ZR2'!FGY*9Q3B%/%B1NWMKT
M/$W@)>B0!,-NCK-X-I/ML?IAVW0\)\5@^[$,Y+H35EL'6Q)SB)2^V.U .FWL
MQEKN36=2%+TQ^.3@&5FSKQC&<XETIIJ'XJ!]40[--Z'HD[*:IG/:[$J.J)P=
MQ(]:$O"TI71_]]=D1X/<:.B"Z,4DAJ<8Y1P!?1^7(SZ01AV114Y&#1TY20N0
M0)30 3!F8XULL.J)ATO$Y<>)#>.:_ 4O):>DZC"5%C@O-H1"?@MM"WV#-(^7
M(0P&#+B"&MPZKQ7EN<'BR9 ;TB)-+_'<1$_.Y>ZLH%^V$9+CU.PU$N@YP<ZE
M2RLO(M,65FH-)VB,%C@+/MHI*TF.7^#XN.N^L>*WR>K1V-9(F&  %J072_(O
M1N:2DQL;$)CW_X0,MODS?_4E-WD^IV<_11=OC^EELX/#9X^?/AOM_W_)A^?/
M=P_2V61OO__O^>2KZ.CUY0]?_5,HNXT]$+?SC0_NEAM\<%?=X'\4 &E"VA)&
M9B_->*Z["G?T8GDP(:K*=Z-6W*5>Q-GBIH(;%_!CV!J"JMO@BW:-\KA>G1T$
MZFSC)_=1R)B>!XWY5/@6BRJ)/@Y4 G_];Z)*5D ET4=@2KH='U2R!E/BL#2R
M#C3.P3+P_==$R-7-W"6]S:%KWWUN(H$4=.'EC(RE,S1 1W(7\N(J+6D> H;K
M14>CQ^/#QSV$K('=$)=$,O*<TR1S9O./[!H5]SDP/*W G3:P#I+.53*$BRT(
M&]K]X:(LZ0?T):2R&]GKGJ;:^-$FY(+<O7F+H-!NA06*/A44B.S9OXD%BCX)
M%*C;^;M8H.C30(&0UOH[6*#F:G\D%$@<ZX_' D5_&0JT!N\C(9_; 7ZBSX[W
MH6-\>\!/]%GQ/MW.7P'\1)\;[R/I6 7"W(3?2>O/ ]V1T-0]=&<[KL_@PE(M
M$,@NNPD 9<#ND6#P.MOQX+&I]C%^Q\?8?YQDRFBYRWAB8D;6:S$Q3Q'!MEN/
M-04K5_SP%AA=;R56$W?- )5+T- =CF5UX?*P&("G-HNYC %VIQ^J-\'1EIAH
MGRY\N%#+]=4M4JA@H!Q\Y/T(ZE(2.*2=$EMYT%K5T'-#XP,/2WX)GU<.<SJ#
M/DYD*<)4@Z?::2JH!1DL73":7Z&G3PU=K]3"@#W$$"H6]7HW8Y32PTM^IT:]
MPR(.]D7-*EDA[G9&12()$MUBIT:YB$M+K%+=7).IL]B8V'V@53.\2B;AZ:^3
M35/2=]T#!$<#?SK*D.4LO:6#F6$."4N'KK*L)NQS4I:B$5<?3#;8 M5IX7;6
M=/3%)I SPWF$"#[:C"TPNJ,RF).[6@G7*@Q]<X)Q#)H.HU<E@?&LNGDL+S<H
M$LY&<]C?5Z6L7=P&D1X@Z> =DBL/4SE]<Q)Y]YK=60Q6'4$QP:=Q!LA21+?*
MH5;6:<%+6Z*4[J@I&7:26* =AEVXP6K\=E'$P[L513R\JU'$S973VP4D&]E0
MD\SA(C7$:^AZM4Z 7^_'1C1798L--T(2NPIKZWS0!QM_*,D#N 3)R44^2^AB
M3D:L#NB^&@6%1V$P4S4=XU<T2OKMYUOYRZ,7KU]&QR]?OSX_.CDY??/3#U_M
M?<7_OC@_.C;__N/TY/+G'[[:W]O[^JN/'<%-)_'RK7DR(QQII<R)IA^"\N'[
MRQ/SC??IJ)[:??[^X>7)CVV?'LC'KWY]<QFHCG$\2[/EM]>/^[H?7BQG@R*3
M!)>GB&AU9^EH5-2TOOCMC_9_9( FWWJYN[^___Q;DU950+7\50@":!@P>S/<
M-:8:TQA<\*J;3H.I(&0O,/"K;"C$/7)7<OI7\)C6U,)E"]2X:D32_K( @0&=
M(0%^N2AF@3@H2A:]^K=FV9OO="NJ6IQ2>/YBUT:>78MXC*VQ-=>OK(\?Z?!N
MWT<&\7#C94Y/H.\_7A?J<EG@]EB7%PH1PW^4S'BD,B,3]N#!(NR!<X^M":MI
MU?B"88<J7(X6B']1[/HX%](#])-W*2.+,K:<.2HL5IL^9E(6[VFOFR$ ;Q<U
M'- 747QX^1;_!V?_7J]\27IE[^E!BU[!7T6OD'0AEI'LVA*#&4(J<9X85"37
M%IQ?G*&NX*]H'M3<K5$]/7Y>9+0.O;*.,0K6(%(=@NAA6C&2QPS15>^[">C9
M=TA8,>7_*:'^9U)EUC!1Z&IEM4FL=4^T&B"I6$I$U7CI"^LNMBC3T*O;8)?C
M=FND7I^/U[4)05T^SB@RK&UFUL7)C49R6LN]5FM0VB%O?NBE'[4BAZZIHK'(
M9+H>;"U/$Y8F@%M1X+4'#5]?B-1,47C(0%.4I+'U:U*M9(I">M)A3P/KM%@9
MN>Y*N\$>/=:<=45Z?G'<BU;SB"$FV4:S5K'@'$TR"&L\S28E934<('1E\<T2
M^=:W![3BGPH:U3=N_&\;:"\#4[N=:Y"I@L=<U'0]FXS"YIXB(0!K')K+))YM
M(XS/"#$2A0SKEGS7P=[^$V2[356"KP6Z'1B"I9^(_"UGMTWQ\^=)GE?+C"ZH
ME,[,2=F7F5S$<1G]!)"\\'3!%KNBL9",!14"'B"4Q0+?E*'Q%W7$_6[GYT2(
M.Z*CJBJ&; >>E\4XH7_Q-\_@%$+9Z]5VDEZEE68^?DY@ N(EN[]:B:YO/YFS
M=#B-DRSZ):/_2//J'1".YV"*ZI_TZ5*>\O_<=J* 2%2,[&>[H77"/3^EL:JL
MIVDRCB[L,[J=7Q&4QAUOQTR_S:+_=X'JEEN.*I7TXUM,MAQ%?_2CW^/)PE]F
M6MI3C\W,1@I/$I3Y6;C[>5Q/W9:^%OT*I+G=HULL_L^))B'\R.0)QY^]27"(
M2KP:$MI%1D)W&O*MD8:6EYW3M9.!#^9B."V*+) 9KJ=O//L\+M_1LT_)(4GK
M12TU&\=RA82K<.-L>E*2X#8L.AJ1=!9<TV%$?$N5B17.Y$,R7+!96I-ZU,3'
M,!Y)+2IKD13Q/;9O!["Q$$XF@TMN!7JWM2IZOA4A1R&,>P,S9-SQ(''3FDU<
M+82ZJ.GY9$G\0D+CDC6NNI?/UTL[(3U=O6B MRMEQ>'C:)G$96-VMC(FQ?U:
MTD7+(R/#" 8 V>@L+BBEF4^YQ@.%]?P#LR**XW,!- _%!SC I"C35DXK'O1E
MJ$]//&O,SN*$9)*TV?&"31BCO[J=8'9['SL[R29H\4YJBIU,VB$H.K=>4-]J
MG;.BI+^XT$%C>J_2'%!(>J&=#02-7'>&2=!=MG97;'HP%KP/QP@=7 9S\BZC
MHIS0*OVIHJEYZ%@AZ*@?)N52 Y-.FKN,4_88=GS+2"#K\P59BD-8P9Q:JQ[T
MHK&=@M;S+TWZ70^".4FFAL=*1I#^2,:TK/5:.7AA?F37Z9*N[S_2K,9C&46!
M;?:7ZYI-=2OIFW^6X0V  9E*KW6TO;7E4<'YEW-.6A?AGPW6A[=+YCRZ6\F<
M1W<UF?-/.!P7>KRVV.FP<U&S/%6TY+!  CSP/4RAKV7P[04U1*0E<#<B/YXM
M ZZ2$."X.X@!-_:\&:;?1?#-1-"0/C9LO2MV@R&PN[:D&BPOY!,D5\SRHI-;
M!_]HU*FVUYC&07645(R",C3.&?IKH<LKB;+6Y)@EBUPM>I=2+/$# /7),K)_
M%P)-@\M'RZZ_#8PO+(NK>E0V2YJD@!5'33N0AT9BH6S%X9T<,@KA:@"I57!S
MA(:?1.P;[#0"<#02Y+E6XKJFKN)9BRL!T$!)),2KR#G.ZEPO*ZCN>B;==)\X
M_&("_$?*RO17*RMLX+ UUMGJ>;0 %\-483],+V@)PG4Q1<31=F?%B 0\D3":
M%G.T17"O*^D 4?EM,7T? =?W89S7HO75MOYL</WHMFC];N>?@.O?CKFSV_G<
M</V_PMP94$Q\:KC^[9D[NYW/"->_/7,G.<J?%JY?_6U^SNH&P/Z1E7Z$.TSZ
M?EO1VH$Z,BC!D;0FV&7H.F="+)2C6530+ YH@N$;M0+16F[0GH0VVF$B6 8I
M=EBS#O<0@B_5PCAE5A+HIE;>0(;AMG#F,^E<R8X&&\RCZRA$UN4'V>D1^D,.
MAZLMX!D:'BL?GE_DDR+H9>(1<T029;K.GUE)B1N M(?;@Z+Z./AS=#OT\VW+
M(?07W<X*BMD')J\&A.5Z"4HNUZ"I>]>#IP+(,[BO'>;Y7AU\J>I@G<,1B*:8
M[S;A;F, 'CT)F$7;7 ^#W3$'7(E]T]K<CEFWPV(K.*00S- .Y95JC58,KT'-
M:=>.?O07\)8>(O#O 2X;O0?D^W+$Y.R9QBQ>\9V'5OP84_^SH14E?-&$*T:?
M%*UX,WH44*=NY^\!1YN&9H"88^A:0R:L.XK'HR^5D@%V.W\)VK:VA*6);[N&
M+;J-#\C2(Y(=Q]>R?9VT[;E7V5^JRGZ!9&&T4B/HD<5Y=(Q\HP_)(M(^91XG
M7$M8T=A9[0J;SX5H!&MDK.6HLQR$5E.WT\$QLDL>[O=;BI*1>N#^O'1&)N<,
M6XDQ7<OH*IF".9NTR2LQ4T/V]:%&U .^+V8^Q7N@@'U(FF>_VD%[AB"7AY@7
M^^.38E:.I+]]<R0Q_IO(U>T+\%-+'G9_>+_0P_MST*3.IP18<Q2]]HU:H-MV
M&8"(:53J@V_@H75GFX-1SNYQ(0N$RSAZ%GLX2T/1;Q-?K0P1R)K2^IO(D&%I
M;^U,J?6LOCM&MYGE+F<EY3I0.6:]%[%R]4C$C"T>LD1BM:R:2RG+%BR,]0=7
MYN!S:$H#(+_(RRM5O@8*HX16#HUP/1<J>90F'"8NVG!:%F0N.2I4Z9\BOBMB
M@3<:$]L"EK\=7.'QW8(K/+Z'*]Q?3O^)R^DB09I=+"5!K[*O[7J[(#:72\#/
M^-I>C8+VPOQ CNB?R>UO..]"^BEEZ&/C'@EO!+DTF )MW1.=6D?]C/UYY;JG
MMLRM,96@;:%IEF/8FI4!@PE$O&"'J>7I63)TO )\ZZNW,H?BE+"?DP -T]R_
MA_HNO>,TO]\*Z;KN.[;KR#4M=KS>1K?H 013M=NQ/7>L@6 +J4W'G>C&ACM;
M=$^1XT7W!=)X^6BSL4Z6\KD-=K[<5IYG.YLTA/GC%-1TGUIV_F+72"3YJH;A
MA!L!D,J0MJLK;;2D]WJB[&3#@BR^/Q._HW;86(@Q S9>)#T0&&\E8?9AZU#%
MFFR<0H%X27V%=M1%O16=C@5X%A&'X^+K,GKS2\]T7'X%*,&'&%B'GOT5GW4T
M8D[SBA2!1.'HT$&ALV5I._<:,@/M(<REX,O9?&KZJO.!Y8-JEH4)<=YSQY#*
MOA V;$L_:JG]:G12UB:&07/K;N?R^*W?YMJ]EX9A&^5Z])M34RN#DE:^@(%6
MUKA D+YD0$:1T\B03&8I@&/O#]G@5+Q\5!J69_B%>;&POYN)A-]Y(4'3M</S
MDJS')_O/,6/K-["#) 0U%H7S0EXR8R'0LC17M_OB^.QH@Q'([:?W)*GFJ>:[
MF?=HQ/![VI<9,' "^Z#S&:ZN!%36K6M/N5J%\Q^'BS9/! BM9!3S9]):'NI$
MF?M82FA?L;<6NCB<DG20.,,5)#]W*"'62Q:Q-[_(^-)FH5&8' CC_Z;X4&8>
MN^XN<HIJS4[.RU1 HZ:%P?K^J9*Y9W"JC*1:S U,QA+#M_Y4X*+FQXU..5,T
M7I":4&;!-&T7%)9!B^0.J%LE+IEQ!ST 4TA[.GMJ*L/,)06G#7R-Z;63D\$3
MNVXN4O@IWZX0?S/=8&#L--(0W4ZUS$<D4HEHE;<7GE+.F<VL<7)7ZW'\\?-\
M;>,W"_]7?1)G&WP*C0UPUFA-?Q:TIF?L#DO*64-2MM5*\.=+YO,2%P@7PY1%
MUMY<"$(CW85J[1K42*TW.Q09086C3;H(AW]:<,HE.FOT)P*.3=J^, >HOE</
M/O/X:2(NE@NA9GXB:3Q1BRLFR#@2Z4)33K9CD1]@TE2@@1#9(5E<:)CI&])Q
M*=GU4#W$U]\H&:"^2<Z;@)?9A.!F2:;_D1^2LJI#LY*Q*PRR'9$,<BQ<'"0A
MX=(HBFZ8ED-^"<BTT::0=KHLWIN O.N8Q/H D*@E!\CHO>0050:X=5-+*#'^
MI/_C23)/)+FLEI@G_"#J7D#N9N&0062O[G$\*N8,7*<QHW^8@\1Q\D_,FODT
MH6N";-.*6V^27N6.1X8[#OI'NTLE*XVE#%30Q]+8EZ"HR78%$=#K!Y;?I0'U
MF6H\H=('+\Y[PS"9(>\,Y/X]</S+"=W W<M 72;&K8H*;?[.V?Z#!EG,V7[4
M;*2VDN$WQRDV%>TC V0P6$XI,!15U"<+"<+GB[8);C0%&U8>'=MRD7J> :W.
M8FXT#<-,C6(IM#<6ACPE3:QC&Q:[=/1FIHT;[2C]M5*\0D6/EYMZ95Y :$%=
M&--!PUAD8LH_>\T:'EBHI(N=!V/.YWV*[LL]2D<9M^,TNMX[3 <KA^E@Y3 U
MC'*]P]M.$\1S[6'RJ7;58[^**T-2HB"4*JT,HQB+:4R..-OP^&"G8/Z!F;V]
M$8J4G@]7Z'>150]P&MUQL>AA!_&IY$@%IW-U@M+16KMFS,C4HNN\Y3#I\_]S
MA^GS&YW89KKR50]S"K0 /G- 9@DRB,;H%$?2HNVYO6IAFXA4/:]UI5?#(&8'
M7?$D=M:ZL.+%7AK,TE5!*Z3.?4+;!B.2G#"X@)5IN2ATS6PJD,"I1*XXEXW(
MD_69@6N'1\7^DKCR4LH8N,5<"-\X+J8IMP:EK,LE?$3NS@!]I\;L6K#NCN$G
M9+G?-N>%TQ\L$6['\V3">D@<&!"#!"LH[K<IP6BZZ7:'VI+?21",U,5DIUQ*
M-9P(N?>Q67MY=-;SPH=0+;2!=/JO4CC%T:]LYGJO$;F '\*= ;2_.9ZCY2\B
MT B%T'_L.\DV1O"-DD:/"D;$O&#N&-[R.(0&OUM&?5$A?U*"+*^J)<C=I.,P
MH*-.@Y2!P#/2L/$&2^?MLO)/[E96_LG=SLI_IO@4XO2_VORN]/5XZ9()9^%=
M<<F<M BC\RVYK4&J%=#1M4V^O6CXM,A&-F:>Y@;T9:@/&0*N^6ODS047S,]
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M[6=;DGKA?6FP<6WRPJ^)#M0*F2E;:Y6M4N/6G4V"4*E0AD "JZ__\AOHE:9
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MBGAPC0@)0L@M0;2>Z;B8DMHY.X"CSL7Z!1=H-[IR7CG 4-5F*+Z?)L@@.F/
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M&F.ZC(!7B$E+TR='9>ZX>+Y(*8CPY09H+2DS9$?>6B2+(2L."J)XD**XR-F
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MEA5#0RG8X!_,01M,OVPU\OWTJEKL+T&&!UW8')BA89($M%=J?V;E50T @\(
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M;[L]DN#HNT<C,EN^J]ZV5ZH]DLJF%X*N,;X1D?KM=T02CVT/P3Z\!0.?)AR
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ML*;!&81O 7]P:GS$R"7*+W6:0?,[;Y1PM4]@H01&5#G3G]'VFL$;;36V9U>
M*,)&3O\;4#8J9[#H$8;!C#DIC-3D^+!><.&,L"YJKJ#S)J/L8,:6G=9N*;HE
M5Y!VQ7ANPP>@#JEV)#$$V#/>F'2=O+*Z+6Z GG3'U0@C7*Y7^A9*$E&6G3G0
MBJ>L%]&SID"Z<63F:W:4X)Q2%30"F/M^$KQHIF $"-Z\HQ$NSFS5[N.A$);T
MG\O%.MA-N=WIR>EI.NR9_C7"SMYS"W!7H<UI$L1NVDQ)X*:.!'<2M#X&U1!(
MA:6[8!3YF+6W,U(G]T0NKYW&99(:8V/_T0NOX*!MG[S+H]/4T1F5%8IT/,Z4
M_IP5BX0LUN;3]RR">[R&=ZZ C!8[>X&C7>(M5#Y-*O P2FN<+OJ[:!5_>/GJ
M,\&].'Z,57,A-&]#HAR%O+LD1IS_L@!+=K#M3)WN7@SQ!4LNX[Z;E^%7\Q-3
M#W=8="K$8\11JEL]J'6CF@[I3P@\1U'91_FA$C6)"E_+=U.PWODN<I]'LA;I
MPX-GM;"#E3AHY(1&)@NY=?V6ROD0]M\H?W!_R) :'?]=V9;,6]16@4SK-.W;
M>'F-R::,RK<OG>6S1,Z&1Q<]QBD]#@V5;*IXV>/X-H2=CJ3&_2]U.RZNI,B\
MNF2)9M!1!AEQNWV-U&EF<Z?=9O-Y>J5"K)WBT-X+7%(=(1$^QN$?'LS62!1+
M$K@;9.M)Q%U\.Y-)B#T9UQEDG>;1K9#Q>HHINK\[[8YUV,\_LCKLYQ]K'?;^
MKM3A,\%LSZ6Z(_2\,QN3O!S;E>$,58-"A?)$3&4?QU-!V=.KZ<#7S ;!5&NJ
ME36F9;DQ5JMRZ&<V,/J,5R%@[%:2VN7/DC5%IL"LZ= @C7HO-Y$#0]?!:38_
MA&VS>(_J'1S)#FDZQ% #DS?T"*/X>T?S@1!I/KT)L>[(M;I9:56J!IZ_(<8\
MB2$_!%XI>':B=UM.[_"INTHD),B,#XU[X.R<UG/T@T)T(?AR%WOJ&CW!] A?
MC'_U+-^4LY6Z34(E4T.GVHH-=_*FME]WMM6B(V.+T(.CE!DWQ.'K%9*DB:*7
M65FGI=CS?;:=M7KA'JV7(7M#21^.J.[\>Z8 3C#OSDG"MN\YYH<'VT^C)$#Z
M3.\?W]XMFJ=B*WRYY2[+P7$3*P=T.4/!NC19$S?[1AGDR8;=/E.[(/5EQVB(
MRIH4]71OVV2G2!C**SVC '=_LM9ZE-@'6W3Z:%EDYQ.@\0?&AE1VNX.II+]9
M*Z3 UK-3SQXT403PY<YXPAUD0VO<0\!"&EMXL6SFP759KO!4L0Z<>%69'+8W
MB$1RLUAH$41\U&VW7WA6<R(LCG3;@N[=$D\A(U9X]_.7..5*4&<LB]]]_L7Q
M21%.[#F^O%X>S=J&<J@4"M+3^ZSKUE<4G]=;Z"1VVZ=8!Y\D,68R%9N]@B3N
MD\L7VFGF*4"13H\( VX8CEN=GW&UND'8]+O3S__@G@%#^MWI%X_=1\LJ+CPL
MG^W;8BC1@1GY+XP\*B!_VF++S^F&T\?LLQUXC*N:4W)9(PM-9: PCO"U,*J:
M*;FVV93SE6HHHGC706I,"!\V:2O%M9Z]">UX%P\B'7L9E[LS:I284*7[&#RR
MC(BWH"$@E2N4\CG&D^9T;$^')!;B0]AT-#>5QO#B2<$Z<:CX;:Q*I%0VXVDE
MH4W -E=(R+0.Y*2,9/R%,QWKN^=:9)K2V..4",^V+2689Q5W@AY@>E\W,EL6
MC^^?B9F#OS?2V0E B3B=G=-W>. 3Q&!6%<"W@=0\) 5+.'Q#)BP_/2F;R#>E
M- [Z'?7X<9;1JMB&3C(2\?4>'KSG_6;C:T32"IBWS=%X<Z3_5)G).'J4/"@R
M^,FC3^.1V7LF^5ZW"I'QD5S]\$#HL!7P03 *ONDB&6.T_^1TYW63#3H:4Z[*
MNQ[4'G;,W'0IU\2VR8.$OW_RV*X-WA7!Z"076M)37D(@V)DM&O3;[I$BO*V8
M-:Z=NZT<411 N:BV B,+M(M5F,W59I"?/>E8V_ :\W%I.>L%?@F%+76-P_?J
M\)7@D=4 <FD6,WH;X4\^_7>')W!+JS_@6I9%XQ*E@B*+8K>N8LDYE?\F.@X^
MHTBHX:'5JW+QPEI$S\+&8( :7*CH>E$O=;:5K->;17KJ@4!Q%)^8[\;SVX,$
MY:H>CDUUPK4>+YIRV7%89=-<_/Q9]NM$'[.ZUK1$FI0ZG"CS\/%D(W\EQWCX
MQ,("]R8HY(D,YUQIP*\KOV0=KW6\SY:\^'HA+ZC_.MW)V%4*!U,346Y'H;9M
M1-TSEXCJ.])#!_OA@>X*$3R,^9J]"/]9>-U-=+M=@-S3*NQ+P/G'56MEV$=_
MV%F&52_G\&" $OB\77>KJHK+:??,"?@V?& .S0T<NBL"';&ROZW&K:\+/_KC
MJ%\J?O156*0(K6+M^$2JPG]>+ZKXV:.[UU8QG.TW>ER\<K64W=\;R><*_$PA
M33R4RT7*U(U2_LXF="33F*Q%XJ&*7F/XDNPPW"H:3B+H5*AMZ_3.A)9 7K&#
M^Z)IBZV>TSQ1D*8/>[XR%812:Z;.3=CQI%&]Y5=ZU")_TJ,767P7-@7LZ[Q>
M*.M7]#R(][_MU=Q])$/R03H[?&0[H^2!F3U(3RS88&818C-.?Z92JB7F=XTG
MMT<"ULO[EBW 1L&[" :AGF],'=12],&FX[J2W'C:'LO,O"G+MOB.33SA6O'C
M%V%9E-6\^$NX)4CCWFX*416_=<-/FB.*GE(\?98*@BQ#-L&1;-B59 H__=Q6
M%%10B=8P3FXX.IEQ?M"YX=S%M6'.!GZ]A7\M+A!!+KCI#P]2+B/;[^Z$=+Z'
MGF;RPI'0RG1N1(W=J4L("@]FI=J2ZMB2ZB;95@E5Y!)A;8A$%:.0'-Z8UC4V
MNY3GI3K;_3YA[U(1_>(CJXA^\5 1O6\K]79<,]MZP"[:N:ZC#7O983ZHX[U@
MRLBL/8&SU8* AEEE@-5B'HPU&D;$AVK67;D0,80I/.V6RF<;VI(0W];S+="$
MA,Q96503%5[%"&X!>Y9$_[U48RKYR]\].CG^ZBXYREX;U':>;617?'PRG/4D
M..;6S*5P$,MERH7'_/_NT?$?XC5_[LABRQ'GRS![,74SZ#@HY#B/;[0/B8&S
M5/RRDV%PFOF.&Z19CU1X7;*K86)@6L*."J[!0*95EE"><$W'?LQMWR63RG&@
MRRVXU/!8F7,G_>/Z*F6V9+*"OW2%;(I?HI?A) _7V[E,4SH,.9WWIG0\GZJ+
MTB/$.L05S/<"9J:36+KIBB)/O1GE08OA3IOU.'WH(N!5L,.=-+,2)-VK1&C#
M6'+2*J;2PXP,Y=('7W;<^D@LUMSNP=2$04M6Z>?L?&7'D,F,\B%,FL%=9F8T
M*CI+M2H\P%I^%<84':98E=H2"TN0*^:NM4<L-M0YB 8[O6/7+K(Z*>C94CUK
M;G3;[)B"?+7$JT;*2+T4WR<>2,'Q3MG1MSI@E=33./WKI=2.>G-]IR7,+ZO%
MUOAO(-S@VHMVHAC7ZCR6*R;+L+;:)9(D%D?C!XC&I+KCL>[1D+OKF5F:A!'6
MF/CCXI9SA^^^:-&RT5VRD7HF:ML:"^IBT*8M-#K$SE!_)EG6N!=6W&-?<G?'
M^JY4?=_B<.$>'OC\N_X%^7?[TB^2?R^&T^]^RK&,9:FQMM47NLQ[Z!EQB2UM
M!_Z2&!PJYEY^1DX?\W%[4G]@%-K^O,60O75:JALS/)%^8&TPNN.P2)N%>38V
MJ5O\U_[YYDW7Y4_E:Q1Y%T^>Z2UWI?X/#_3=U^VMV7O:G_===VO;Y]G:#$55
M]C+L88'D*78.5$\V;502,R;F=&! ]14PZN%?\XT;,$NK[DLQ7-=>(DF8V<B
M+"IOR7/?8Y/!!.\ 8?L'D]G]\WJ>FFM.?G96EYSU=TV@@KW^#OG3P:^-^/%O
MDST-=_H'DJ<8^E^7[XY^^"N/RI3M?%_Z\)\>&X.DVY.,:7#TR7BXL="6@)VC
M_ P@[ J.5#5W*LNN9MU96<JN2QOBL3JQY:%+(A.OK*\ZS^L5/R.MAX4@:32)
M_>!,$YVF!;(\QQ=.I\5*/5;]T9#;DLMYQRFD)Q &7&I,F36<+-?!:6/OKI,
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M?]ETM3K ,^;7TEZBT[$2S*Z- 0=X=\NIG9Z;3A$?W)_DT=7A@7M<_*A9/?W
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MF["45-2#3;%<,X(2[K@,8--&19ZTME&A[AP[D>++@?R6K%]SZU)YR"Y?B"!
M[ROY-R0)+EUZ#1G#N%R2V(JZ8@E59 /;.Y/W?':WA5N1<AU]GXI"IK9A30?@
M\<G1M#2%/3J_.W#+>',)IRP-:)/+IA&Q(O2(H"XB.3H$>&W"K<;%<]G,I\&-
M>.+_6_P(^;WWDY%C7J"#+[$ Z].I2J]T24NM4%'DTD1FBRLL.821<@K.:BYP
MJ>JY6D<G4K8ZHE%V_D8XLW.\LL,WS_K!4H$A''"!,-QNW7L>MN 19:UO1&0*
M<WMQ>"!K&G<M87V[=<>&1$L)A14NTDQJ6$2'#WA/OX_C0F!?Y+BJ%C$?23+T
M*8A]"(M+EN$R. 30P,,N44)V ?QKWZ.WU()+XGJHIOK@TF.HHPX!*AKB0>FI
MP'+,>PU7<SVW[B]+=X4!#Y"D+Q881^^<0:Z8C,U;)@G'%%<M8-3X<;MW&_K;
MQALW+*%85L\W$;N39:>Y&<)?1OZKV2N3EM'%7(SO%4SEI!I\^9E]C&GO[8NY
MUZ\V7 XM"ICA9]/*Q!VT/NF=556ZW3+(DZ9M'?/TM I+IA:>>.S.Z[I9=T#%
M$T!O0?@-F%4EE;KA(6O/M6/X.+]T^/T3[,=).$3IC,PWHWS:<UNE;?0]=QS[
M/O&='QXH/,L,E?[=&F&R1&YLS+C/K1%W!%]]]9&!K[[Z6,%7]W>E[HP3GY$W
M.>S@,Y+:JT1]/WIDY#B#?NTYF# 8ZO_45?L80,8'+B?BOW4-&@)Q6013X0^_
MGT]Q[O+ I\/.E!?4^'[?\B_LGTNM]#O"MHY."/@6?+4H.?(KS*3Y;DJRT\'U
M7-,_<*JVQ;R>54>K2Y*0".'.--AX\@%HV%6K$$;P$]5'A'5>2)]>V3)*0J^6
M+["%F"FX1:60=,77VBRE(4T2,B#G,O72O/]7E3O)6E+E<RHG SL4)%@+IP2B
M;_LS"4AVS)GS9_$XQEVR"">?JA3T?YKHVN3<S=)7Y".YPVVE/4-3/WH(F\>G
MQQ.GB.V(EYL.[7OB?*>9,ZW-PP,1T OOA^IY< %$.B]\_S^(:@J'_5KD.^1!
M/Q'MN2/SY'L)J*YW)\A/757M!<6<NFJ%84EV#JQT\4^'!_:W3[^6K(8N*9X-
M,6Q8-LO8FR05*%%U<9_'_(>&KKLR%3J-?E*TOX U@O3QOF?8_H:-9MQ$DC'O
M/Y/DDW5G'!Z4WK[NFK_8CJ9KB?-MZZZ,;XS@NHNV62^9$]=5-,I<1T8S6TM6
M:C7I]J *H:-J[BF"K#HV!-&>,)[J=UI.VIH*8WSBS7_8(#[I5+%1*9A^KD'+
M[%FLO$O(^S.LF6E%-"',*B\6#1)!2NS H%=L+UWJ@?M^W1<@L'DW._3W=<?H
MH.N7W)" LKE*B]T"R_X7Q42O\EQ6ZCG&NN/KB@,SR1C.V_3K>.%H?V_9HE,]
MPI6X@QF1:NI&R66 X=!2S#CIL35]Q%1=!BU*V(SA&$L=?XF$#1RQS6K1!]ME
M40SNHU(1V02&]>(@FOD5]LZ6G+L%KN+)9CZRIG02:M7(TOC>P,[I1WF+HZ?>
MUR%8NT'JB,6P?@WV]%&W,LICL(6&)S'(@OLON$&2&C\]>?2E5&YL8(<'ER0-
M6(889$+2F+)EUN52B,"LUF9E)_QLZA0[DM.@:Q(>F5Q:-HC7Y^4,"-\!;L<H
MF)P0X!Q-T[!>:N:S*MMY+71VCF6!*817E]CUIP1G\)^/M]+4X4^/OO!I])W;
MRA%6D)A&]%^EWTZK49@C1CC!ZC7KBTNS4:-B1B7;%L&<1^^UE=03:=!@.2<P
MSB+=5YE6WGT6;[P3V2_KBP(^K\2]ZRV+$;VI%^5&1O?X9(1%^$<YZUZ#]PZ7
M.0_+]PSG)PJ]T->=BN;+O+P11S;\(^/>CC1&FGG!Z[%:Z:P- >U-T[X5IDG1
M^X7RLCIK&+8L6=,"WNE62E4#1Z$E@*=Q[3T:*AM%:C>MG4M5TUU=>CL\?LC4
MV6TPD[J=K*^DDS@\8!4,"A6$X_B1[P%I0V;[(5X==NL"W2ERTZV8A5TL^L7(
M4R0^-\7MI;B1Z%KPA_XF5^(2OI3=1L_!]C/+MWNBX^:7>&3KF<LNRX4/+9Z]
MVTHA>O^>!;-80SB/V=\W"8Q8 EFVCY'ZDZVD]C4*=4+SXDA5'"IBEU^=57NE
M6K@IPM76P=51)KT\$-_E&N8>F%OLP<$!'U''+<I93YRXRQ A3.IEYB!)M:W?
MAO7=DQQV?5ST)Z%L(VHDWM]BK$Y[8:0:LXNTK6%:E2=4]%136;8S[$3USO[+
M7'W%^I0PCZB0ZURLU3=PQ&G6M!;]4ZM++ZB;&&,'N8"Y"%/P*L5^]-C"-E1<
M7VP\?5GJ80^3-A6TF;:7WXKVX(O:UX)G(N!!EN0&-+A:'Y8B?-F;N/"PFH[:
MYMRY*L/+&@>SOD -(,0 (^/3%,AU#[=@M]@NAF=Y%"@.(GPL(C-=KZXG9<QL
M*<LO1XPY<6_$U%D?@KW7L 0-P7!3AI4UW7FW(MX,P4WOAH2'\(X^=N9-%(0;
MBR9R&4%G&BFVG;D9%]0.9%5O:T?N#^D/0: WE=-NK=&.KO<N!D\\'"7/T+1;
MJ8;MT$I<G_Z-R0?*U&8Q;B!:&XR#48&@/@PK:CCW!/T:(-V6RWOBG"SUULL!
M7E;S99I31FLK:8G!1 CR(P(^Q ]!VB1,+G):>.;A%]ME*#]<V9@D3:;RPC?+
MB@] .>?PK'R$33%;MS23^1C#>]=;)W+%02O,:JN467V&@@:G7*4(9F .!SFP
M[K$MNEO%ZXN3CZOB]<7)QUKQ^FV@ +(]1\/,'7H@2.NFP#B"53>\G_1N/G_]
MC>%,L!@$I4L7S'+Q0(*LY :.:J3(FNMZ=S946C0$"L\+]U)I<$D/HY5H(/+L
M74VR!:.8:Q1X *GM%QV)<LU0JRKUR/$#;)O0D<LZAL ,]FA>:UHW^CWN28/O
M)=/$^82<+[QEPZ6X=H1>B24> J9* R*6?D%?F[#L="7K(I \4Z8W@Y^-;&>]
M6%=;7DN&P(+]O"XEH2P9T^R$+0W8E,[L81]@7"DL*-IOIN<S3UP>TYV:'OY!
MN D\>H:6;:57=/!$ 9U.H.'91RAZG][@]J1&#Q,/S7KB-A(3LYS?>1W.4KAQ
M<#.NY7S!W.-39(='JWDA 9N@++N=@FA%OZ&KJO#.MEF"8DTD!5\B9=T9+6O*
M?0ZOSE'Q=M'<:,*.K7VZPUQXDVB'GKYY\0U[ <+*DGL+H%,0- *'"^O:!ZG)
MK5-85[ $E^7B0CG U<ETJ79HDPS\?A7SBWCEE]7D[>'!LJFQ&J)VN;FG*37*
M)XI@Z0@9%1M'0!0^QV,1!259F[U;2?V@.9'=;CEN*$)!%T%"219[D)WK)![B
M9N=_"V(L++UYN62^ERF]<;U@V!I7;FP(40!FXMQC!CEZY@\4I1]&LQY:P"2;
MBPR;O(HAHZ408S+89F$#M$#P'ZG8SK@!C0/#G56D?-;\B@/2D_6^<]H>4T$C
MS\-!'@ZUX Z,@W5;*OE]%4ZEX$)W5WU:_.K=I*U2[56)[9OI9A$F2FC,+7TF
M+0D%*ZK!."E2D(38KB1M@F\3C")EV7ZSSK^'[? OV0ZGMV^'U"JW:SML85,(
MWR$[Q&R3?-K>LA?G7T]L%ME'>;=?[._;Q9TE^\N$!E= PJQR*B))E$2X1+[/
MA/T7(MPL4C=="+>.BQ>FKFA5QV%B2S<9/1SPJK&$7(X:KN5O[#ZA:H1"=]@"
M(,(^'049AVN<#]OP ]^&CW=O0T-\U[(1=JW,:14<7VD(U^*DK/@6+NLM#'3!
M(8YHC;#-4V<:EB9=2U8_+#[2+1LN-*O1#;ICO:;2*"05%@S5I"4O%AJW+0=+
M@I;BB]9 ]F8L &>*)!4^T6Z#. (S'4HTKM=;68N?8=KST0@#/FU4K"![HP9D
MO!J'4;"**(XN+]57#2<S-!.W&NB$S03%DAZGH,@#43)0VI";,8)YF\O(= J6
M78T>)%J=5O-:NXLD0M"\Y9"NB^0VUM+J- UV,LS=S:7TY(9I0'R-^%?R+YPK
M:_5E0F9$8(A]0PBS8*#(K.8HX[X6S\'&[ONL>]W5"M==UM?-*GC6BM'=;V:!
MYPN-?R44B?V*I:EX5%+6E9( &BN4J6P=T\W]\R/6A5*L,@!*MF6MO%!N<\<D
MO^LRR^IZ$N)8Z@W5AS>"U/&,$6X;[U0@D7?^^6"YH==RO]9TRP6CW/1D#/K1
M* ,NS!3M1HQS DU: CZ5*I(\L#OUC?]JVDS62J(1AV>H0$/NE0+"2TR)MO8/
M#[3(%>S>G FV)!>2Y]1<-Z/^N),&.4&)7M9STXE$<@SFU#KAMMXIQ1DK11I&
MJ5.!D3BMDG@QZQS4"H85H[+$0;>=F0%*HZI6 A9M73/]9L?[] DL 0<WL66Z
MU)2(3:D]N(E\Y=(TQ))!)K&KV(<TK>>0N;9,GD#2W!; -.U88T Y9N* O,2T
M+6\$J)C)"^Z!=-ZNTO$ ^[5F,\1+GEO24W1@@8=EMZ5F0[)6R29L^X6]355H
MC%_/SY[P#FX'@I;;KH036S(3!/1G@M;E'8$QNR8I6;DFT[5K"-7*\#4/;+L!
MPC*VU:]=Q5?ZT"S-WZUGTGW' T[SM*FY+D\6S^0J<KMQ)8V@;#;.^P##8TI&
M.DS(M-(&5BN/1EY^;K[4O9IA&@16*;4/ID1U0,?%=Q9D!2='#D=O?K,WD])=
MT0"80VAU2A6J$ T!AYKK\QHS FLK%!M@I'B.F-'MF\R1>S5S\YT@1TQNK05J
M_$0^AE\ F;!W&RT<XT_#&J.D\NG)Z>G( ?S#S)3B04.BC*^1758_7BWJX+85
MKU$6O'(R93^^/AL53X*=;PTMR\1B!,O2'4O:L;)(X*[3_639IY1Z.Q+/"5\S
M[&H388#F%[H#N8\E&\.:H;C%V%S>@\(F_)4=W;BQJL!=5:5LI%R=5 K_MEYH
M2]1]'FI7P8J9LY^%RL[],PES^_3L* G.)>7%-QKA<WO8Q$A*7C$FQD7DW*A_
M[XJ+!A?FW,61BG_&HWV^H6Z<PL\JQ=LC7N(/C4<+_DFX4[1?=(F!7QN0=^&I
M&OYXE4G)*IJIJWJ8$HQD#K%TC2^F=5L)$%5;@!OINN4+,SV[@E_455+(7 2?
M$G/QRVVYX1WRV]2/:ZLIV5X9Z,CS6'-&C*(YK\D4U"CG>(\19=NK+.;<TZ7B
MTDVX?E-\8C]09_:BN?XTC#V\Z!(U!$OX0#NO>*GKY_#@N19H!:LGPH<T!R^?
M?\_UD.SG*!N#=N<9Z"T"R[<WT4@/J7XCX\C:L.N5Z;7G;4-.YXKDMA%.N%UT
MY=FF,^*8EJ2,>=&'<?8NL.7LJ66[Y0W U]N:[JP!@AJ(]#8NZS$SCF5L7Y.]
M\N3L\(#6^CJ8,S4WIA4(%MO8RS.IKVO*QE:KX%@7RRJ\.0;*.,.6^.[O'IV,
M3DY.DLD%RPCN$B]MA4*&]7- K"^B+!G=^^ YH/@H\1(\A@J/JXT M (J4YO[
M(4G=OD?2I1J:>(>"(58US>[?N;R^__Y-L(J4CA*2#F0>@]T@53%VTTZAS)':
M.P\%H^>R"#:.WHNR@?39-O1C"I6'Z[]L*#P0QGIX\+)9.!1"1C, &&I7X^.S
M9?#C<,H^NL=NPAWA4X\^,OC4HX\5/G6O5RK5C>DHA?WXND<*^)WY#J)G3H1K
M<.K9UX'6RU?J:NVKQO&Y,TV@75FP<P=UJ]A=:J$JLR\2(TN\0DPUVE6L*H7#
MO0W>5&0)5BXE?NB('?&?F@K#G9"""B=:9;AW_&2\44QKN9(V'37OP>BN\*/F
MJI+#6B =..4BRYQ(+B_6DWF%@WA2@ZO]NF[7G2J\Z$TE8[\(4U3Q1U?UI&T$
M/]-=)=ERZ;S1<-$R<5?-% 6Z28@*%; 4%A$ 5M<A=DC5"'OXE/C+?U&]*_(?
MQ%I7K_-#'S]XN?42GLUQ\3>I">C9(B[Q$YHP8;!(FMS/<@;<UU'-'NV/WSQ[
M'64^JV[PS7?Q9O)M&8@I2&2_D"@]CT)8) %8"]:XC'B4JO@1B09Z9.=*D8.?
MGTGKG^ZP6E_9C^=GYZ.MPS1J""F!T9,PN>(DRA5E"Z?]"G?ES+0MGIBVA4SW
M-?)J>, "44%-)E\\HS#MO:F6*P:X\IHDRHVYR\6B6;-=$:""U5PS,ABSO3CW
MK"[Q:M9#'U$YV*MY=:T5'5[E%0=8_#Z$H:NOWZ !1R\GG\3H"6.^:+5OG4#Q
MQ31_/>CVFS>E>"4(C3QQL1,@[S-]'QYXJN^B#+&Y<"S#U9N%F"%LW$U85!T<
MD\='X?_\X5CF$G<,;Q\QA9?1_J'!3\(2U2S[-P(U2\V)0PHDV%[R3D0M6VG4
MZ*!K6KB_?+5?B+.ZN"@OM.4OQBV(=]:1K;!CV@OQ\BAB3Q2-*F^F:\(W5HA8
M=,%F\0?\P7A/,1\A?HF+]G4EN4<D!)Z^/!M8B$)$??;D?1-!'*6LV)28"X^0
M/;W;4A*^; ^9#!H$DE:3RP7-1960KG'@> CZMIPT;K884ENAH-,H IW/&CI(
M'BU7&,K9(8??UCWV:]]_AJI[;_#=[7E*K>.'!^[Y>RHH$GP,_GI>E=J)]N<0
M'H10+%JD$WFW?*'-3@+#7+7$A9-2*\G>R?.73[M1D0^3>[XMV]@XV/7M3/P2
M$M^ ?&,!A]6<M[!,VW*V2H\X\#R/9$02N&5>%SY^6:V#]?3=XT]U/#MB2TU]
M5].8^=8,OVR/@<FN5XY]3O?\--)9S,.+)"NMH+%'QF=8H'A371LC'*QR'UR.
M/!=\EGG]%F8QEJM2C<\78)"?]*\EU4$3G,?N#3=%-YULY('',BB *R0JUC[5
M!"*SGZ'[8]N )B_*<0,R668D.]$GR[>ZV)GP1,,-Z9JN6;*OT_%?YYGT?%5]
M+6F37<R<XA#JTLX3)7BL[I(U+\J?,N<YU4Q\C]#F:S^V)"8L/.4\:TMV3ME+
M4,E"IXTBG;&Q@XV*%_[ZA"W)53K!/(E2$',06&$]M%?M6L;0!9E*) Z*W^\)
MQM3Q=- =:9Q9HHJ TPYEZW@+Y%XN+H^+V(1BJV#=K;5ZK6AO724IR:BCCT-D
MT3#FC?PX-D=V^FP]ZG4$^)?%HR^.X$U$AEK?^P"O^&I]A0>88=.+V\'Y7JQ9
M$B^MZM0ICX^D'1^=R'?UY?#+(0!O:7FU:0:0SC"<AA3'X3?&I[LHZ[;:NW,I
MO<K&!*RHTNFG/&749/<$6]U5B;YSYHU$1CM/8NSLL+ *VVK ?>@[ZM]IV/<"
M891A#PS.?GA@(4KPO-,MWVQ"<'<E$IW5BR>OG[\Y=@1^EJKUN6]I%9)!:A3F
MR:R#"SX'01CKE3?5^$@:"CK>)TP:O$T6<8W=J;=8%2L1S:FL*?G-_GDQL7H@
M>W H$'3O-GB@\/B42LG .A[$4/?UW^B"*O/2UHE(0=:5!&T].=;S5PD2$Q4:
M6A2=U@MI:MJBPULX#Y7&ZH+9&QF0J+=9/W\**I/&6^XB\8NS1DVBE]J,2XQ!
M?3A_Y %,&4Z#4;D!_Z(K;.G#ON^?G'_VJC.Y^#*)PN.:;,>268G('39!7:%L
MM=(*!A<W/V!U9*T =9=\D 1*&9GG8Q9!<ASU%9P/WB%6+,*\YTGV6NB,4MOP
M^5&,,@<?CP_CYDO:G&,+L4?FP<TBXD @2G*!]&P:,V@0%KX<0EC4ML*!M%Z(
MLH9YH\?]SCV)EB):C ,]/(@&Z<JX;K(Z6/@+!U/;^TFAJYJVD9+&)26U3')E
MVBS$GQ(6I!!.5V2 D]E2;9C[:R+NF, __<@2^*<?:P+_-].98EJY#9[!'HM,
M_902:?%QHD?S+-BAE;!X!0MV>G+R6"SUJ]?/SD:*=@7,.D02JF.&0[A:-29Z
MQ$JZ@R_W=4<=I'4GA+6'9U>Z1-#*E_55KPVD%F;,EEE)E-3C,P6'WX%41N8/
M&?1MVG1F\'K)["3;/GPMB?NWU%YQ N&1\@<"R$5=/LX0S;W6SMWU6>07W$O,
ML3..3?&F,64T"<*3S3FP?FMD=WU#@,1?_1OA#9H0E\,GR_T31-.'-OK#Q%HD
M_3?LEA?1EBGQPX)9(AE,Z\@$79XOPT<D(L1T)LJQ'SN!8PG!I=>34NV"?*-S
MS893D4O3YIR<U251D:P&R.F=[AX!?".F$0 UY3$J>02)3;@\D$\6.L-24U^8
MJ92)U$9[UUD/WUQ!M(O$AQ1Q($!^N9;Z>WS2WIY2)&,11!0 .[E91'K'ZTIE
M6U:7D>4TTAW$%WO1BA:'+!N)KO,,+-'W#15VW!JF<5&1D:R?=\APF%S4%))F
M\&C#[ETG=#09)+A8N]20W;M53@5VEA:Z%MWX'.KY&G#BO<0(2FZ;Z%97KO"2
M$F<U.1:FDE/,TF[9@YDP4AIY1I&CI(=IQ=8)@T.455=1+ M6OGC9+(Z>I/@G
M_'(EC$@Q=HU)'L"!JJE# XE/FD:1S)<5<.0@Z?^ZJMZ*?*6TUY69,8G_5C8&
MR7_T+A'W6Y::3!8FC<GI^(&TD>15B>LV34MFDT;O6QCA/+%8<[[1N%O"#-J4
MIET"C.T0TZB3:!K84L#@+%VL\'.V505W?]GQ]; ?,TP[\[4QYPG]KT@UC,,G
M!%QKD6N,BFQA,C'CKFI"D@M%O'7L]>QXUL=T>3RVY2JR+7 1,6I]5!.HW1$?
ME7/KU3+&/FL;B).6CM"]LWC!^7LRI,[^VLW(/CJ#SPEZ6R@%&)\KU98C;V4\
MA,-JC/U"3*^$-20%M92AH'OALA4WY!CM.4H^[DZ+<RMC4RXR@C6EFJM7Z#W0
MUE]7%<@+22H-IJZ*3Y^0":#@,=!/]/"E9LM<',3,@17M\K )NQ7;9I8Q(= _
M@;0STL'$%?#L6'M>??_FK @[+5B $#F*1P9!GW9E4DOY<UD%P3>_L%033%8$
M5=S032Q70BI 50UK<5@BO\)ZMR)J]FXSOLB A]&UC-RD$<+A5EG,'T>:!2=D
MZWWSF&B1LZR7B>GG62(2690JRPN1A3HNO@&IWQ1ZD#C02]&/!7E=7RVU=P,5
M0W3)GH%Z6 ]E&VLARKA=MU%,+W(DV6FPM4^X?,DO4YPM$IS*;U"XYY+5"XL2
MC@Y.A#+M=^57ENRIC;V2'!1]?N/MPV&N4T+H[Q0X#2";NG&K @TY^%=WR.MG
M?WWV\KQXA>^0 (/]&!*!@6RZ6I1&7M#K] @A8VL: >4J#H1-$K>^!]6H5: Q
MCCZ'D+8<W!;2%VE"(6;OMV$8E32*S]K=Z::8*G_DWQ8L> C<2@. F\:PU!!E
MT^-]T:=<4=U!F;NS1_"Z-YC.G&O4D180=&*O%C[8;%:U*9&+6#GBVWXE@L1_
M85?"L][V$Y?>0\Q9Y>,+3$ J/?:8@0B;0_+W4EMV/=HI']T[9D*8&LX9CWZ9
MEX+D2I>E(9 *(=!5TOJ#XJC5@2:75?#]*VL ,GTWUS5IMJFWM/65R[VPY]C@
M,VN%?&F^.2YR \M^9YA&NMRII,303_UN,)R'J[7-(LP4UBBE3A@(@='-X4H&
M[>IQV+?S<B-+/+P?_DO<7OZ+< U4#M+ L0^=EB4&.4?BG86$V(G-1U4S(SS'
M#)BD[?>X>**<7[J\APWCJ'=L*Q4U6T9:@L?PBK4NI^RP6TK'M"?P@E?S&%<8
M.LRW;NK.]-3R( I@=!?WJJ3>G.<TS/WJ*@N[40ZY"J&4ED3NT/0]"=D0U89.
M&[GI)ED^ANJ#M7T_]4#PP%581Y;OT7C0]"&\5HYH>];M] @GUZ;78^#.=_.Z
M3)2Q/^%[Y]0 Y9V2'YB+;VN#:NXM>?SY928GOPT,<K"<7.DV1!I2AM)J99]M
M..55%M5%2CE=C>N+M3!3RET=I$M6*;(&47GW#DKTP7%DUEL-'>E]ZA"G=]H#
M@P9J[_/+GL0OLNQL8I+LJ7-ZU()0&DE.H]?+)@GP)MMJ/M)03U'RO=:AGSU]
MN3'84HGD4?#*JLI4*PS.28$.[LDL#W<%6'MX)%99]6QD8J(?G^EES3<C_M;T
M/!(.ES!<7.IWCT>GGY^.3DZ_='8S7DVL14:G$-FBH]&0%Z1O9,IYK[N89;=#
M'%<6_(-*7_R\47[U>/35X\?AN+ #]1TH<V(Q7Q.(TE*;ZP!)!G.F<+YP4T?&
M5KH+I>1C1BA>57F8MR.7)*93QR'EB1B77"%Y.L;1R6#X'MO%.U9U'W]D5=W'
M#U7=WT3@.C=Y>=Z+T>V7)Y2AHN%+^@Y+L"P DD;5 4N;]7<R&W=7UM-.3@'O
M^MQ8MPS8*AAP\"*@6[88>J6G"BVP<6  ]QM%[2580:8XLFA=6RL,NT1P"0.R
MA!OAN?IIM)X)GB)>151OA,B6:";0:81'DC2@P%9*\"4H*57P7K1CX/S;48]O
M0P]:??J4_Y/P11/Y.Y!]@-A([3)5!/V0A<!Y+'Z'G>PQ;3-\5959=3_P5QPX
M3_1%JU\>G08RJ1&8+9TG\_L-HQG>$3^:"+O;$)>D<JF,+$ZS _* H]3D00;$
M3NB@CZ;ABY>[MX2Y'OA8^!SHPIBB'(NN$K.E(,_U #W]Z=O>]ER!C#H$.:M+
MH@*T/M_$\I=*5TE>S">X;3EO;5C5R>LM5X5YU>\*O9E4FABW(1MFE>BA1[:%
M'O=5.;^!LEULD.)S<3[@ZVBG0AH@G3R]#_PQ6[A\& U7A2.9,>48$/AP3#%V
M966);JA*W!M?#I'C?(CA+4>]#*;1)MENR6YJ6['W )I0.3SP-R;;L\U>G4BV
MXF"0><J*Q:Y ETAO[C9:EWG(NDG*N116]7HQ9^Q6_4WJ89Q3'M"/V^W]WC/O
MW8[OU08W657'1^?@D@+ @9RF VR(67TD+ZRPBP'MCGT=G)A%,(V8N',RKW\P
M3)/.SXS%IT?08_G?B!SY]RZFZ#:>D*^7T:O>+?%[G*]RIJYZJ2< _%-)J5]X
MR+*YGD>^#,MU Q%JSWU2JF1T_,# .?Z9!4?L CI)Y4A#0%=<-G.'T[&L&TEL
M\J$IU,AR_N<I1VDY';PB]_K0ZXS4=OB@V53&0N*3-*Q(F1Q&F2E,A#!]W1;.
M!I$4$#)NBE"&CT-5X"HBP23C+,83. IMRJ;0X4@?K7A;54LY?%SU#1<PW2$M
MDWT026KO'VE6;Z8'H3^S--#5EDR/A9)^-QCLR,0< <NQ<T8/ODZD")+7Z6^1
MNI0LX;9%@.,SLAPGR2AS$?5%^.4\U49B?.L+)KE\)[8C47 U?%\DN*W[A>O#
M!%C:Q"V=ST9J4(52A!6Q1\-?45J:<E'-A9$G:5NHD(5/0,FVA:RW2^BG9MWT
M$^5S9=MV8L3NM#/,L;G]DZ^$PQ!?Z4;$GU4WL<L00*P'LTM!7"R*YKK[:M_2
M8(\O>.HR* J3&OW?3TID[0D6  [OJGPKZ?@)%1KO<RYB9XZVGW!_J@\C?%-[
MFJ9UD.#OWYSE6SAGN@UNV2[T10\&.RJ6+&R*5[]B@K?7R[(9P(88SV-6?X9[
MW+G^&NO-$)E9IQ0G2U(XG+3>,SR6'O=<>F($Z(E6/CX<]K!0P@MGH@<I,^>:
MNEZ;]>JFJB\$2-,7FT>,7JKX0D'!&JWLZ76/\#4KZ3GP;VV]T(FD+&64Q\V4
M5/I&F!WL"?O?<@RPO9Z%I1*.BQ_EW^-2/9(^NC8=%;MR&A!L(BMHS[_.5#%6
M>15 O#WO26V#=WK=3B@+B0CFM+92@N_*W:H0W.*/*A5 \')ZG,[*R9$"1HG_
M.L- "B/)ZQ_4D4M00_GSWEFSY]NO5$^%1!-N\X-MJ2WF888X"0J_T"YL)IOI
MM<?#1DO23BJT1GBF^II=-<%[$3QU'\';7V:\BZ+;W3$EA'%Z+P? %DUIR%4G
MR89;;N$P^GI$4SM>'K00H32!MZ8"419+ZJ_41^D&UY#^5FDN5$.C3MN9$'?C
M.=Z:A*9-B3%HO[21?]GCYJ+BWC9P#FCI[7OK.\-CIJ[M$%@C]J%K-]-)J(T[
M(I=HY8WY2X2&K)HP.\:\":TSO@V<&=PA)G9V/'F2^$/2TV9YPCI'M5T9L8E:
M4/FF%@@ZZ%),-T? Y6ZLU)AU.8.N?G?$4-[!BM/8CXMO(VDHT,F1M2(<%]7B
M(HXPA).8'G-I\HQ4C](AXJ>S-"?QR&$\^E*UUL>K8M K(P.>"=NX_4X\>O._
MXB+)OQ O#A&#M:S&9K[>2P3NV9;!'=E<B<=]R;9'DTFN.HE_P$A.J+X170\@
M-)/2S%*HA<;]RFPF1^/:C_+4M<"T,S1"^NXGW:<R3Z2_$MRV?) 5CY^O?)1G
M&@+BQ#,(CO<.UJ(DY9LTZ@+66:XU@9&32/CG3>3MSY$$T_V0'X3PB90FP:L&
MQ+1["GUV$+B/[BAB8+$: Z#/DGQ'3Z:-DTQHY69@<DR]D?P][7453!+S%EKI
M%5(,D0W,*^:\25HC*JTM&#MB6FQEI2/-/WN&)0WKAN >PP?)#\EE$99[&#N]
MN*L*C/J@;_,7>OWLQ9O1MCBS]8@,>)RYG\D/<S_SF!>E^30&9:'PYF#1?([W
M&!N4^:ET?^&UB[88@C=*P53,AI9S"U0C+WWRKMCW%M8T5^*S\[,W/QW+__-#
MD*@Q\M.HQA086#JE-[0L3Z$%[)3$E2IXW)RF6+J$X496*/U;]!,E^HTTP74[
M65]U!%1WZ79)3#*%)MI0$9QTH9\@ZC/CG<(*U(9P#D-V?0)U.D/C@&@F!MGS
MA;G#%$1B63^V00TLY./B+-L7))C90,&C$MJ028YFZT.B'/)@JLB9FR(S*#V@
MN5Y.$/#QX(S@$K9C)A!-!(5X49XMA"R!3<SULWS :__Z<HR_$33A\X\,FO#Y
MQPI-N+\K=6?BZMD[-&+!XKZ6K?=*S<H^)JQ<%C,Z?,(9J$^I=E:+O+T,-&!1
MVJ>)ZNLQ6AX=2JN*,Q5=B&A9+SW-2]:3B;.-G<,X'^0D]V-Q0$>>&O%W5D"]
MB R^6RC)7S-1^B )^%M* GZ+,O)Y"WONX'M]1..0 $\6-)JS3K$1E9_.?$,)
M_@8BEK 3D)YPXXAW:E"J:^'U*,I0/60F;",4&?_U_.73X^))'%E&J!-<@XO:
MT(_#CUO4L\@PC/ VT0N7Z--*&F"-B(6QQ44HKNANS:HC5.+AH9F"?.WPLUXI
MT3O&I-%E9F- U*8SEHETN>/#@QWCIS%)?I;RI@ZA<M/K,_]RX)T4B4ZB9J97
M</[B#DZ/H3^1*8Y(;&%A0?+JZ/.-M25+NS4N.$\B9=):KLPWL?52H-+ [PF4
M.ZV*"S&=?Z4^'^/0$+U\HF7"1K*J:>NBN#O$6\1%)$CM00?U0S1ZW\#?,ZJI
ME7*VY>:OD;+];!.WX7CH1WH>CP:.R)AG'C ?$);?;3^L7;UI>Z;$(SN3_JB)
MDBJ44S)\FN"CTN+ T,AZ&NU2&(Y3.:VO&*4)-G\Q"+&9;W($Q6*Z;&H*G(%D
MI7JGG8@K(]/L)8:1O\RXT5Q.E'MZUUSW3)BFQ85T12I/7KL(</:HS<;V1\^Y
M&E]=^K$B4]0E@J59U(2-(%^BC;U)0A*PSW(V4UV?MBG)0X,D1@B30\141EW;
M2=MTW1&2P76P1!Z82[C#@\GY\$W.JQR,"=:6[?4<#J?,6^DA.*76+3:D<SY(
M9B1ZJKK 0RL: VAHOVO]/C<HE@>M;/-?1:54I+?*BT7#*FUKR:>Z$9[*4J4;
M)(N4Z:N1L0%)FBT<;#K?^T^=14J*@'1@5\"QEI'5]]&)!\%&G.K#WOJ ]];9
M@&[NL:@F#L*WU(^UD[UN=Q._85]@T=/]C4>VI'/V^'];+D<XE1>)FD3Q;<+R
M $7&\)79>JXGL3!"F;IQ[\0W"V$U1:U;IS>T]W.75MC0NN-T6>O*CJ#9 ^.:
M'N E$KL09% IE$$U5%,KZK]Z$O[)_RD76&RY-PZR':'JI?8F<FN*OQ4<Q^"_
MD6-"G4_%6W7*=!8NO#&] "',#8ZQU^?>^TF,8KE(T?2743Y;*5BPR;*V^W+!
MTDY]+<QF=8NCO.WH@@27?UQ/E3_I"O0_1J;$7^_]!&[+#J\$#RKDSY-)LS;$
M!B:EAKQ-6](UT6C,<8QEF9K4!R:]MY&%BH43I'__U<_^3_ZOG)/E4G2QH\T/
M)E&@1C8-3AJ]#\-V0((RSS1N$=5L&82]GSXY%PD2&#I#0H3)ALQ;#P-7J,TZ
MTE79U*L"I[G7A"JZ2/[5<_!/_B\*RY?YDF.B>7!2V^K(0^["OZX:K2";FEZW
MW;\C,_?CZ[,!+J?8U$-U.[B45M^G\T1(N2NC# X+](18\'C%6Z[J\>'!-BH8
M17*OY>SK33$-_Q]QBZ7=92E84=A9S&J B1J?2Q*D*J$*-W14F$/-O+<X<%2Z
M;D)LA2AS^UY9S<#X2 <G('%U,B,C(N:4A# BUT'03\3RX7EAGC<^*/Q$\(6I
MO<CE?:>?BJ+,NE]9FU134YB)L,==[RR<FR])M'MX0+F:6)C()E;F$YR@O"H.
MD=G&.SG_WFV=0EN2,EA[<;6[0HNJB^DL'1[<5&-@C V_S7IC*0N\THS^!B]E
M:S8W&<HVA-\P.>B),9DE@W^C9P)3C:P" (93[1E=)? 3,HY,-/"Z9-3AV]^U
M_A]"\@\R)'_M=<9*4:B<6B9WV,@^X=XCCUZTJX.FS:VC(=".9U%$7XA6(Z<B
M\[U[6$Q3IZQ</Q='GH&\9JC%L3*_+(MXM=?Y(7"N[K8+ 2.5184!%:4<I/S7
M8DA_^0*!U08ZQ8?O#K9^=IV2A8:A84GFWR,&\^D"XC-?'?DD*U:P*MOY9G?-
M, -:; NK29MA'$0BQ$%#CBLU./FOD7M^60?BPP^E9;7M9/N<B!B[%*TV6OE4
M/>!4.OG-#.%OA#S[XB-#GGWQL2+/?C.I$_@M9[:UDN[X/J+%GL^,%Q%>8L80
M/PS7)4(K1\<:05G,O;J32SJ,!GMCQHE1/M9@5&A89$LNJ,&5>XEIL#W*==?]
M#^1O_U?NFYE2IH0A5ZI'')GM'$@XX=!R+)(^0QR&4NV3%-:"+Y.="WMKDCC1
M7%=^^&>P_E<1+T/4B>6[UTL1W<YK M+!W>?]D=F+4K[N<0%>LK!O2C\OBKOX
MP#-"EW-)AVT^:7LVF:2:NA2.Y: @4"F?DU^ -5J.MO9GT<]2I^ .ER8G7(^3
MPV2IW>;P$Y/UN"LTC$)X@SSK3(R"0R+JM6N3B@";I)]"!Z?4JB'^T^;-]]&$
M9C2@+ 4TI'2Q(-V3E-1<_KLH1",I(WJ$I7^8A!2>B&)T&Q/%[7034H@5=85=
MY/*Y$J F=W>\@WN,B=_1IN48Q+53)^=3;H@1P68D63CUHD>'!UKW*@;(_$69
MT>\VR]C96A?QV_!&",#%A7LX/$VMU%JQ4)'JF321Q"X>0.WRWR6ZRYU#WQXL
MEY@F6;H261 N'!L;6GTNA,I!S@&[%.Y*C?'#@^Y2..E0>;FB^J$^4 B+N$8R
M58 8U&%<E@MW328X:;:ZK*LVMF')].FDIBH9QNKS/GD+3.U B?WWD6=E[.6$
MZW51U2>6A_75R!P8FR^_.O!ZH@JH63QK/[;>-N" 9 ^IH)G3DT^0"_(!L,"@
MZLBC@6(T]OIE&9YBPA*L')&2)]RW34E*-]^Q'M:U9@GS0H$EXJ3S+'U]MF7+
M=M@KY><SA+QFNLPB"L%\/4LN03,!/U#*Y]G&@S-Q*:%SI4[:<?$#H:P =C7,
M0 H-@ J@AP-28*7QVKJ[8O>3DV+*E7+#=7"ZJE "G!$M0%')1'C1PQJA5\B+
M[A :&8GR23TGS"[W]G:>L3EE.QY'$MG])J[HNX **NP\^J?J-3E'Z>L>'?>.
M!K->_<(I\[G+LI7P:Y-^2-?TFU)DFZ3;T?= 2@->*7V("OX[+G[D%U.LC_YE
MC=VZU":X357^'P\-$!]&IC+ODS4YDAB#M;VME1_CHX1A,T,U(/IF1,JZZ!-]
M,NJ X?3HOGY(@G^(2PM:1JDI7CD":.S C<?5E@?,/1OXL"P^R&5!W9!D)JRH
MH3PIY"*$1^!1KXT7N.W<US.*6#GNN[4TGAM'RW5CC"VSE$TRP0!;>@]K[<-<
M:W;0=%7]/PS+6G*)+0058B(V4N-1JFZL2559 @[\G?PKU=3@?CTLE@]QL=2+
MOZ\7B3'$%D)RLR?U=4V8X*1EE1%(I?!_08JV-^6KV]NWMP21NN0,CF+$,]J=
MT\TT_*)PZ7)>3E(:PZ+'5U'K3T#!<A& ;,@88HUG ]0]$M769#]OVFD*@M7O
MM) M2ZE;R.:D5R,Y:$KX,MT 7FY$<."F8_:CO.FTEIIRA>&:E_6XMDZO? Z:
MV>R(=P/,1HGQA81,!)4$JCLCV6?$):$A)5BA^29.1;H.&8J&Y-!\2\N\5JPE
MX6]O0 QO<*U'*:^@P!GDV^I%JFY(59G)X:GPNDAK&NE,<C;#K)AA&1_R7N&E
M&%NC34RL^RN52[D%]/H@.(&5* H+&8_?$40\TKA; %J*91L5B[)MFYN,QT@Z
MQ+.\)5L$+U"N#+.Z:!:N<C(B/W6X"R36I.G:40<Q>ZT<ZVDE9FR0UJ.<4@=H
M\4@<N8C\%.;P]V;=;NDSO&C:"DD?H<CK@UE>M56L5:)=.I6-GKT3Z@8@708@
MA9&2;<N.<(N(8FKEY-R$_*>)^S;-@^AOE!M<+98YL@H6.3GC7;AR$W0BTC\9
MKD)I0@EUZ+0,$JFK8E/$JYC_TCG.7@S*A:A4*85Y9:S V$>Q=7.L3*%]H&,8
M";085O/(D4\CM%+:SKX@>%A<U]4FIH!W/SEFI?_H,F\^1;=>Q#FG)6I2F]VO
MD(?]5^[CF;/46T9ZVS*KA:]M^T^03?=25YK;I-F=2/X[GF'E%(92=$RU6_;O
MZRF+&H<'>@;QG7AJ1OSC*?CL5R8@]N<U)%R%[0M__1&%D;@;5<4R_.T[ H]B
M[)5?Y'NRC'$,WZ_#W&'.KNN)\&&G0K?6,9.LIO+F3MAG:0_N#COH/[;<\]C4
MYC$52J*''W%F\^Y,1Q48SL4R2Q<?'H@G)KW%ZHHQVR!S"J425W4W=#/=&O%P
MK/2RD!-+3KTT9'W)= .C@0S_2:3RGB[V.^*6OOS(<$M?/N"6?EW<TH\BCL=V
MU*<]A;S@#,S77=C+J\T^PICTT91:P:,V:5]R@><ZHG&5&&L1;%^+=QI/;;('
M\1CV7HDZS^2713"E,-,NPYEV44\LN^N(IC?]*/L-0;FPYFMP+B;Y^7Y+B81Q
M+,6&T["ZL<:YTY.3T<G)">.RX(VL4;8:?'0>2NX:5\),DRX!#^0]UU#!=N,D
M)DT]BYFIW]%(X<LT:NE(Z'B\Z=1:R*K:!PX,"\&%&)E8]#F(-4Y(,A8^38&]
M*Q59D"$6!I[FEZQ7?RB;1OAF&(/'<YC,O*OR73CE*_+,RXMC&:E*MD,@V)1Z
M!^-UIRK=%G\2UIV_E8BT2*4N7UNWAIWD=!T?'ISE#-X$0WA[QAY=E0)UL'+1
M3IA6HJ1<7YF@M):3$Y%7N7U]WR0D(Y5\A(7-#J\O?J<? Q4^ZDB>WD69TO[,
MQP)=\AKU)<4,S5./*5_)5J&^G"&\18:.^XA8DZF1WYJ"&*<@R<6YZGO*UTAF
M)L*5UD*LMB@N,%61#&>HZ2%*@[/EF5.M:DQ[*CY]EHDV&<W<KC<HFKL9]&)+
M[UP!M'J);1RMR:_U64MZG90[6MPTHW5XD'3A!-V3D$6Z0^P^B0+ /12I_<&.
MQ-2<Z 3L7+9JH<'=1+<M1K1J-^S^.P] [6&9<,.*FE&)7.5:^K\O-TL\#5K*
M5<NDR[!TXYP0:DUDJ-O8;2>T2\%VO(@G'NBD\E<K%!'O?4H_D]F'.Q]OE"@P
M([V44>?ONATWG3+;.\F$Q&#O:<+V;5,]]RMVEW)S-)<T<O(6F2SV*/6=GD'&
M'(A6(ND,\GNU-3+(:EY-5GXGAH^1(G4JA_[=$MBSXTXW96K.,@A9[#Z5F)^X
M)R+<MQ><.TN/BQ^'_^"8/9*^*%:PTR<)VU;%MF2]#1^SV1%W^]KNF2EWQH]4
MJIO)*\MQ&85Y1B^NHAEV_;PCKLSMRWH>3NCPM_DFK8,!%T%-IAO=N&W" 4>K
MPZ.W[+\3D\3P=W-S$?-'DN$L<'RNYD:AF][.OFTY'NA1/]DO)Y6FU9K0U#C[
M/,"POU[0;&BGAG/-=JY84V$);DJ;]4?:,K4U<1LY/1:8Y4!KJM-NGS>Q]L1%
MRW%DR]B=.!WDX6X6JH5UR_G1/\!1%>,?(LF)48G&]HRHUZ#Z$\@1"VCYJOR[
M&(\DD)"$KZ@*-W(:K^9^9R:R-[D,'KGUM9&0BKGJFT^KL%JF)BC\X]4BW+3+
M<]F+<J*[PBH LAY/3TY/1NKF151F5/159Z/A)#HJ&YL\<I,D,E@,NLNH!7)!
MH>G.<U!!T!RFY4?-Z+VNK"]7OHM*1OCSZ<FC/\B1&TL5FTK*%5$&:"K]K 2?
MF.3O#JJ*7.JM@[+,]&[6LZ0F8\7VD+4<4':!C'=;OSRT!LF!L\V>F]TR7'HO
MS9%5?A-[!<1\5"*AK4P%4LY_G[W">[9^EG[3B,ED:R[<"H&EJ7""A:E=LY W
MIQB64+V85F$,P9XT:X&;G"V7%9(A.N6'!X\>K2YECI[ /M7,+,02;]P\CY (
MGUKCQBB^LN6Z%0&5V59]MILTRZIGGF4=XGO&IR"F;<@5,7H$<Q J?^SIKW<Z
MJ5%:C^UD* ;H"<@VX>"6YW&X6)I2+*%>VY-IBPMU;%<]FX>-:B2JE9/4BK;H
MVA3Y%'2-?$Z[9CJ(#>].1FK3JT$F&Q9^-R]O*-_WYW*Q1GO(Z>,12IJ/1RE8
M3NUB\FIJM%$))G)<;1KCH[:W8?41 I&F5;O=8\&6*47#S544V+HA_0)=;9++
M?P13!_7O=$SJ@;/6G**'6609M\Q8PKN)BK/[9@;03LL&]+:>['L2.CV(?Z=P
ME=3) 7X#ZPF  5'1R5__K>G6>&Z.7%XL-HLFDO:PCD.<:2?EEK";\=(TOO%W
M<!72Y/ 2FZW%C&Q19J.29Z9+,PMD:(F]JIR+9<0^Z_,$7V:F<JH6FDNW&'JP
M;':I><X].2OK5FJ)RT8JPV5QTZ*<OTBALAET[-?$$!&N(4DN7FW:T)B 1L)\
MFBR_ITYB[(**TF%Q4,MFJ;O<6#V_!ND-V7/,F<O)C6C4JBNYX_:3Z) M<).>
MVO! 8GS<2W7 @]2[Q% KLA?-;#;@Q,8A6\^+MM4F"7FCD5CV++Z$PYK/T6J%
M9E(9[[&E-2Q:$/.DOQ/;F7*,#$&Z?@RB)O:ZU^M$V81W6G<9>V*E>VSI[EC?
M_<-'5M_]PT-]]]<]2+^IFRYLPWFIG?I[?IS".(=([B2L(0F.7R5#A\<[0Q/Z
ME$'O$Y(.D+%)I7>1[Y,"K_F$,-DOT/=J#OJC$SNVD(""!62BAQ*/2O/TS:LG
MS[6WE_],Y 7\B3-KW>0RF/)($Q6UG7L]%>/>*Z)K+3 \/HC[.TI*Z3^%WLE\
M@-1P&P&LER&6H1B"?)U6/![;]'J/8K1KD4#%T'22JEC16:=]5@=:YNO1J(==
MO71N9W'ZE1]K+)G/-(^:.3:'!UIZA;8%LDW_M[UO[6TC.[;]+D#_@1@DN39
M:239\W",,X L>6+G>,:"K4EP/S;)IM0QR2:Z2=DZO_[NM:IJ[]K=3=ES<)(K
M'>?+C"61W?M9SU6K=CRS&*VVQ".&H;AU<:W2&1'>O80I*.0?&T[/7[<+G=63
MH_'^GLQ+<,'JW=LW72(GC4MWPM[2B2X6;6](8?IOIYLZ<PX3]IF37K2U]I">
M8=IE \:MB$,T#HA6&STS K;122&K0)H-Y.(LIRY[C9]^QY&3Z)L<7.EV[^J"
M@[-1S#=I3#K8,+=?P=V?A8WD5"+#(6W=E=#$&2W3A=#7,IWJ22C"9G=&2"A
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M";E8D.=X;EZ[I/>4K;Q;B89*Y0?X6&92"XA+&T8_B_7H^*VZ@22#H:Q6MB)
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MDB=(!15M?@F%B[D<(R0"S5!%TS6)M9<)[01UC3\CT&*IELLP4Y:-Q9,8.Z8
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MGVR.9@(R"9KCPFV,7Y@IRBR)FF)6F;"[31G!@4M#ZEB=F2U><+XWP!IMZHV
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M53 Q_LL,:%-<TRBOJ(.,2RUM5;:)^WL++",/^WCWMER*$<*6,](6H^^5%K)
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M& 77]?3=R_?@-17Q/#I=HD(C^*>7Q:<P^G"L]"GIV)W$,:;#C#'F#;VEF??
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MUN<FUH.#U=+E\:F:%MQQX8/AECVD>7DT7"*< I*M/=B")**][RO<78[8P$M
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M:<\JY8>N8%2+%^@OI(@G%&$DU'&&=XZJME.P&(VF=.2ST, :H8O!2R)VN('
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M1+&O!'@/(WV7(^A!XR:+>M4N&!(8&4J&# K9E00CM)ARAD_YO5P#,#,ZGZ6
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M772LCF;Y&,^QD:&J,/#+RU/;7=UT3@@^A,'1$SR.BU;\+K7F<TX(X'V)OJ>
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M)8;]IZ]*\]^99M:0;N.V@1(K:35GDT-'/K.!YTQ4GZ] $" 9]F R#2*&Z-U
MM_)NH+99ASF=F"C:^FA<0Q4A;>.2OY6!2-E:E^BW0WU*Q2&A0BSV>-:MT<3P
M>(WRN,%M1A<1])KAH*,YH N1W(V[E6Z!TIH3==PN*=^6" 7_UA.0=;Q'$+C
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MV)C)4V(&<0/Z&_+'(U@!68NR3(' 7ZA$Z#624@K&PVENG6/56BLY&CC(6KC
M@O:YXGX'B5[ 1$(>MUJY=IR%YU*6$SSOV>N)Z6IM8%Q<% H\!B^1ECU8\<GD
M>S".V8-3!.&K$!>$QZ3\*9Y7*; 1C&E86]]*&,-PG&G,8W[[0>@EHH\89/,R
M1GPUO%8<LN$,'[WXDDF#NB%X@I,(?25E;NL$ 2%O@;;<6EX]OD;AD6WKM,AF
M"@R-2?'M#71 !HOTQH$B+P$ \YR3* P&EO=Q 5AX6ZMR+MVF>ZB*_^+SMT7[
MH<W>!BS$\!A\I>U4N*ZP$K1O]D;(:AXWCF38NP"4R-:^PM.F^>)X)\740/!Q
M1#KBY-&>1%* -:$7#/-0CXBK3/RL-4I4R58(5M J"M _0Q'T>^< %<[7W.#(
MXRN%X\BK&&G,H<^/.BZQ(\S;74KD[RA^9EYSCY(\5;H_Z,^0M"9)JJ0-+7$+
MKMXQNTB6]JMA8-E0FW6!_$N1:E*(1EMP5QQ, 5LM82 7$SRDY9N47-(X@KBX
MMV1R@P'U[#2Y#\ P$]K JX A'(Z5P=,&53UT:[ *2'AI;"=X8N9![7$1*%D#
MZT6Z2:S*V=\B(9&C>_B'D)S%3MVHT-D*7!-2_P2T+!0)" XSS'*PKQ4/E;W9
MP4QX/CKA2(#?7SW[]-GOX^I\2-!2TYPDB%J%*:>0X:I&AH3>Z<6G"_SC^?/G
M?Q!@,'WXNQ=_"!UV!)$Z^'7AFQ1$9.N^] G/5'XNWPJ+:R/E/2>&<KK74!C#
M*1:O(5C-**\K=KX EYZ2BXAH()6% U16ROC:U ',:R_!^K;8*UY/M48 XR%&
M+(!LEB6AG50@>9671V:RW; X)82#*M0);:%@S+QJ47#O#<VZL_:PL+22\K"<
MU7DOC:A,]VMQ'#\(-2-*]Q9I11BJ;6 VECY24%Q5/J)37"2KEB@U (O%6O+X
M.#X*'IO1\B.8.Z"GV-BMD[,B'-1<I:6-AHX)9O?$%$G\R,K\A$3 2(YQR(0K
MP4_C-]G_S][;-D=N7%G"WQG!_U QL<]Z)@)L2_*\:]81+;5D]SZ6U"&UQ[$?
MP2H4"7454 ,42'%^_>8]]R5O)A)%MFQY29KS8:SNKD(!B<S[>NXY R/W[=7)
M*0J[_4!8<4/ G9]]37BWGVKRW9$Y1H8N]LQ9)-^1\7H(O/+D4SA?&)J0J\_L
MP*@'@K&%/(>']5&*5=6=(!"=6CZA@=[5G2[0L0_')$8:N+R?P)2A3AT3&3U$
M$V')'?\@-68VU(D!"]X>\]Q#LVT&&6(GDMNKOG?VT-C+ 'G_W9?OPG\P7E5Y
M^@$:D/%"MKHT=:(L!S(258"7"(<>#B$8%\AWQ L0W%*_C,FT<(NM0OG#0DZ#
M*NLJ-[7P[_&4Y]5 ,13'#]T6*2U%$&P1"CTH@9P>.5P@7&1A(A:L/3R9X PD
M02['#8,EQI20T3.$+5TT[*>PH!BNH U-2VQLK<Q^Q#HNAT9^H=\2WPR83VE?
M,M?K0(G[(7>@O#Z1)36Q9NH^MO%LU4Y6)W,(M/4<W2K93Y,"U>T51UUEIR0S
MI7C!RL.$\U Z,\JZT#2D1S5UL"@8GE7<LK#G,[<7)]!*Q+4PR,Q8U62"RAM^
MS\^6W8UPJ'&\K0)Q21R^,PZ22+BENBJ>'X(Y::%AQS%,":1^H$) ?FPXK2@%
M*:!_CZ./LAWHY-!:$V8Y6#3YTGM\YU7X.-=[: J*!V :N.IF.]1[VB%?1\_(
MPH4T"!2ID+<4;%<&<V;I(#MKP1;S),9Z@-X#T.S=^K&+!ST,(_S9)R\8X2?,
MV/!V6PI):)//0/GK$,D1A18SWK6#64?"Q&\FKF*A#&#Z#+$>$+WCG/8[#Q#F
M,8$S8=Y[ .Z?7VX\UB)_QP%"%K]D)4FN(E1.HE2BSH2KHBJ4&<9<3R0I*]AT
M3?I["S_4LFPHAM[I0]DPQ((.S%+!-H1O?D*T]'Z-<P&>.2U78,79BU. ( IZ
MH-3?NIK-93-_DY[ />477O+%);*ADO<C=@,4N_U@[^:F'3&YC\U%QKCN$JYA
M],B"1PZG C ;^E]E6 @!&AB.0:E,$6S85T=1@.I&+JH4% "0]T>N!3L_Z1K6
M&;;+7U5#.#0GA&=YPU3'.$H4FP7W<912<7"/8;V,&(H</?'KAZ1-LUF>$8XZ
M5/%&8C7)U&*X=10N>B#B>2O,601=V2<X6E1&C#1.D5]UL4V!?UZW27 5(_T0
M5;@T7@GF8N<NK]_6($XF?^0"/S;]@2:9_YNN4-;L81HMRL-!8?%C8SU4>@W%
MX,0V24B\]RWO&UGA<(1(>@+ONG!5_G$M6OJ]EAS0)ZF=N^@F)"PN)+>Y[<"!
MR"2'8RW"JIR9)?;E@YD"@R\HI->EU%FEI)-!1=]+ AGXJ]4/X5KK:]5_VW!V
MYGF(3T;[52&-*%6#A.%XS"F.E>=(LE$/\U"[!&W33!'JJ/R#]2HL0,CPZ(C5
MG?#L"QWQ[378$XADY_13Q";@^=EM/WS(R!J$IXFBVY[2R?2X*>='I)H]4:='
M),"UZQ'Q?LQY7%&#'AT10CAR1-?YY7?_^?;-Q:?_MJ)^)M0ZP7$?^6?VX;5.
M8"^N/S3=*I8B1*9/O-HFJ\?)_?;&\7SR5=/YWX54B=)-/=Y<8*?D+J3%[)GY
M%4H-978,'I! /G!+538/W1%V]+IA3;8.0_]4:A4613D.QK7E1U53$O6,PJ6+
M(YIQH?)WJSV%<#<%[A6MRB E?\P&KMQ@6^4M GUQJ=1M\O:X<,=J9\:51382
M]#O@D!+<[UJ.-U';7LN,A[F%Y5HV<[ X1<BD*Z"SWZ"3Y9 [;W^P9=QFS;!:
M]7G;O#:9FC$&'HQ21AH_I% 2BVZYN&-]ZO.S_YIJB1M/U^F]LA-<K?LBP0&0
M!S2'(\<7 @> 2 [QD_D-C2U?^38B=[SG_+:)<FUA630,?_+-,2OZ$@D5-3D!
M"Y"*D8%FSL]T'E^MF_'H5A(Y^>U/FK@Z)?VS&]0G3UC6'</>_:CCE,@8I3L_
M.:;MUA?Z2J/DFB"42%43"9,(0?*V9)YT+5B+L/3C7H33;EKR[S?-6M6JCGRD
M=LWTH3Y0)$!=(#/<)%@SBI1Q?.I@P#_45TA;=S6Q]=!_49FMU5U.?^P)=E.E
M?'[1_\B"8-Y??P0N^A>Q&:N/-1G,U/B+V(R9W[O/9 3C*S8C%V6(FC:1G1K$
M$E=#XZ-;?RS<YN#,ULQXGSR;A+29Z OX" L_^M ?K.8OMWA?Q(G>[I(0E]ZV
M[R?^@NP'+VC3OS):/>E?NC//K%&N.H>Z?&L66@Y>),MZ0:P_M\T!JAI6*FE6
M5'6/2B9I[& V*,$4\#9ZV1;/<UL<5<4BML]\\'.O^(2'YR9\O10A*%4=1XHO
M6^AE"WW\%EJ']&%BND&*'G>[EVWT/+>1.*A].T:Y1VD0%+;0@7!R-$;5$@QE
M+SE3A,JA6S 0?=M(5$+"3ORAZV\OKOO;EYFK9[^/$I*@@<JR0],UMU%\\%2T
MP[,NW)0$&G54CF,,BJS[+B1U;2;%\DS&M:1EOIQ9@E)1*]OG9Z AKB/!\&JH
M;ZW^,4K7U G+1(WZ*\+&(>6-'+=')9Y\@..P7XP5AO,S82G7SO]\U*HZH4WG
M&7^9<;E8 "F6:Z42@*8*(:7C6%@G)&8H 6DG!QBI^E"ON:7=C2 =.OK^ &-.
MA^F0R+]SL<M*50];;;H=6VYO)^/;$RY&.0R':5@#K:XC(3_CK5[>28?%, <H
M"C'U)6N_:<S0)_B^T_O/,"%_]FX#$M#'*A]9[ZI<]WYU@FY_J4_SN'LP#X&6
M??H"+7O"T+)\7RZ?N7HP\529 5%@+[<F=;#K\FX)S"J05,<I:XWN6<D=LQ:.
MYG?Y )KZ7GCCT)EU"J^*6'7WRB*J#FN4RHS,_5R&@/"H8>DIK  \3PLI*?I\
M_;MOWE4IRWY9Q"@19CZM8I2_.;&CAD%R=O6D,:U.@:&]4D&.YC%X;%@>+/*>
M.)8WSMIY+V->&!/@E:)QB8-%+A-NA%&XAZ:K=XQH8S=(6+L1L\OL8U.>MJB^
M'?7LFYM^K4V4IOUO8!%0!"62P'&!?=JU+F@<S8NC**7@F$"$T4IOUI/ !&2?
M^OY%(L3A6_B1\9[$+G9MPBXR4_1[Q%[B86:E%&@)^BYVBPI37_AOCAX:CWE<
MN)XUJS%*M68IDCX[FKX_FN!J9F* $F/$"W'#,%Z @>PA$>T!P[NL,?ZE90I1
M<>&0TJ3/NFE_26#Z;1[3T--+ WA%4D AL":[D9Q!FQJQ^2L*("_93F:/Z=*2
M%0'E9&@ =7\S#J+"5@_'TOY3+2N8*V%O3^_:M>G*V*'>*Z_/>[/6 ??D\]E
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M'PCQ"03QI=!2@OYQ&G6PH-3N9'!$+!A +HLP$5DV3Y1WE7D\/^"5$O:B^>@
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M?^%8818J>$J=Q5C!;W@+%]XC]I4_2BC/O(5L>&C)>5!V:6:='P*S1>UUWV\
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M?L:L(*H2][T/'RZHL6H 1]\1X:\PW'-"R][A#TU]?7?QPY[BB-=[0AO5J[<
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M2D8''/YZ[[5Y,NA2EI@-Y2?AU)C038V!C^*"SOG]>P,@KXFW;U<^SZ]6WT7
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M5&$G.YU[SLRSL?KXJIVL%5Z=)S'/5T3W6W!#<47B>2.K\.<NQB(RP4)5C[D
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M>LE+:8VSH(I)T#),>2(_ZUZ*#JA5Q7B.J/\3>U5%+2,L\1#6,H(G+$!3#]$
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MSQ _=]B;O"5-)ZG3C>C,H^$%2R&S-])>2P7DC-F&:<<=<[L3!6!T"YDR)(.
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MAH8;[8<](> CJ%D"M.K#O-J(K_T,G@V9$,&EF2GR+4$N-T;&T[T#^XO&/<3
M,J<W,MRGNAE[VXW#G3C[VT6]JCC<#,N.RU"(*AO&35!;E"%S?7.V_#7,1E=7
M+O@1)DON F+JPI&UMJ&2@"YB6@HT&=K] 4Q7M=6YD7)VNG0Z5W.#T\),;GZ(
MLQ_0V&@H9!*>>.O4>I81U9]<S=J]Z+?I^]YADW:[NO>7CW7O?[^Z]TN +(-U
M-YCE"9UJS=%K+4G,?CPKU\%A@+-&YH^P3U?_9/(+_"P28.@%R"<^/)C@P]!:
MSJ6F>$^?G8X6!+PWJ8%']!DM)B%W79RK$&]+C2-<-)R^/7)Q)=Q3NL/I[CQX
MOS9H3]@5^'JW.*^V2*43_;X=[/A\C.U**S?FYE&)275FS?+TU,&J"?KCV>GL
M^S9,0YAE@N!3_7R[K<A?>TX&>3M[HS\.3U;V[S6IF/!CEN&C+CPPSD_Y6;1V
M"$2VQ)*YG?W'D^.GE/YCU)96)U%WZ/%Z7YA?\/3D:7C7,%RS7:-(!@)[1JZ@
M\Y:2B.2Y8R$$)_7<"A3>48FQTBYLS_"GN;?&J! !,I;V\UJCC]0C8LZ5 )D+
M1@^<$X L#F^XEIU/9N(YYM)&J:4@W)[^XO!@@U;8NH>;A2&8K-^' ^,TG!$K
M6R9?T!(CAT*@[G 1- &A(_C%DUFDEWD6'/BFO*R[X,6?HH_N315.YZ6P0QER
M^JU"'9*Z\.F;%V_Q%P[@3D.PB%AK]JX,'N ^W("OY=;IT_%URG'/8CA(7*B3
M:4CY3#3)LS#<!%P89 KB(8\48=TN;$&YB:1U0[X"]>J-SPI.8:)EKBK.(5[*
MHCP.CCI&4%M-W:KBG2J-B&X- &T^6 /P"BY1M./)__4OCF??<(63.6>H*A:L
M/N4[<=V7S5*\;-N -B4OWS"H/;4=3Y\6L?9&.B9:A2<_75NC;F]MB1((7ORZ
MW@7_IOP ,[.HM[W?I%]B22CFLR9EB*N*R&CK<_1S$2+ GL5^]M2M3%M.;T*\
M$*+MUZM28YG# ]B!04UPM =I8@I&>^31V*>9%OKPJ@8;>)[! _1&N;DU56<.
ML'1/7ILHD5Y<^:6O+5A&B<=@V;'WM/?=(.$NX;3<,;UJ>A-JN.;XZBQB<^^P
MYS@%EJ,F?9R'RJPD)^5H1H8+:I*2"7\M8F<&FF-7L-+A)+<DH6X'Z>F+1KJK
M-I4D:<)_4@TI#Y<JKD8G:"R6"-*GM;T:S.#LV8YC&AZV[]NSB*QY]^Q[WJ_!
M+O[6[5%^"-FC_[E:X(QRG=5,FE<=_V='GY#EE>?6>,Z>V4#4D;D+,:+N+ :B
MEQT6W@S![EKQ9@F9@S!L%>A?#AZ6'"B"CPL/_WMGM,A#F!,N23!EOP8<X<GO
M<*!P*NQY+5G09VWX%4#/49[GSRU=IXE?"@_R+@QT3VT#BXCX&8[(3( Y;K50
MLV@X ?M>Y%)IL80WHA.%>KV"@R2U%OV-P"8XXJ-WWDDPK#>"^V&SY,!J-.DT
MJUN:E+6TXPS74+@/N!GP&F&WUPO-U?%!2L/T=@<36\DHA<GH%CR[1%G01OR7
MC/,)@_?8=C6S[W>-D)MA<;';M @VJ^[YR*Q[6?CA.99;<CBT^T1&F('K]7+9
MHSL;=3#:=*0P)>U)MJ\D5]"8:+GE)\UM_B&M6/J$$0Y@;L.C\4=%QUKV=&?+
M+MLU&QPV\ZW(E"Q<,Y_$W??.VF'*WW6[]69VZOK2,4Y R7#'&]/67AK9$SE&
M=%:B+AF+$T.B3#.<$0O#S/H$P-"TM.)YN;7>T7*P+70PK5@XI8P.9@P]926Q
M<"XJZC,DI)M@/:V#OHA/21MX2.G)]878KJTK@M-DE)R23I)2_>/6"V\='C";
MPXRTGA2C93UKXQ(B16+HZ ]$D),Q'*;I3R;12=D.CV<_9GC:I[!ZO/4NVBO8
MG&(6P]ZO\7\8VWDM;A !2KKHX:)0K+"[%[8"?J0>>>7-Z0C1.IA'<6\9G.5;
MKL@"JMP8RL6:_">W.1X-*I!7S@F)8JS&,^9HU-X7NKR=H);.U-X^+G<$%_D<
M,;] T>F*XD%CVP=31.]4#%^#<"7TCEQ[!]-/.'7#DO]#]OAQ+^20RDW5AI4F
M[C1=0,32#+_0<T>8[(Y(&H0K.#CELQ__^O+YT9/??Q5F?,UR+Y'P@S9 IUO#
MJ"05@V?+F/U4*O-8IE)Q_WA\MH.1]20^%[53>U345Y-#X)(?D2#S%=7=K-.
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MV@>:?)3Z :UC"I13Q1!=#G_<86H&T_PY*R!47ASPY/ADMA:51&P9&C35CM,
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M[&PWU2S(!P,/R.@7K._*%#\9"(WIN?;=$MZ00DB?G;U,0*A2*M<!98DP@8+
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MCKS(AW6P($V5L(-F?E(DGXC-%%@$.YAI8.XIM*3+E-XG/JO&^O#@.2NW@K-
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M6FCD]+.^U3(;J$P5EEJ99TNCH!P]!&)!IT0?AK"6PN.;#,X]T&NY+&M61?7
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M<.P])QQ]U893.LPO4S\HYI[,)EY?<Q74Y^-$]U+]10'Y&ZG&!1';@T/GK*K
M1=.EO1$2?+"2F-&9)OI,,?]%5'<]E)C:4@O+R30QR29U\PVT*W$W]6UOA;3/
M9"I+8LCO>_K'HMIT_-].8'+72Q^FW%OY+$0CF"'Z2A2RVJOD3OJ8UW9*X1V0
M(W04;-GSDODJ^VT1NR0.#WA!DP5S\Y.F'FU(C-<T"K99LJ%(<PNT%'AV7=/9
M?%7VO32'N=^"B]7JNMJ81F>SF]]$+$R3HO&120U(*#F5_B-8Z(NRJZ1TPQV+
M_7I63U#%V*18KE5Z\_B'\'DA[83V1L9[==5R)0V/,N@X;] $.N>Y.)Z=RF^#
MBP(%UO/&#I8F>"M;H5!;!M\F50IT:D&&\%EP@RHOK+ZJWL^R5#%&2UD\Y('.
MVK(CZ3/^,3QUWY/76/F!>S?'&O)L'Q)3)4']4TT%RSK>]18LI]C"N@S$B>(8
M<B-_:UQ"BRI<.^R0W08]?9Z\->JL:"^_(S8GCIS11G9NDH6I\:H?=77O*0?]
MH";55>A$>NE(3^5NNM1C0B@) VOP\&G7R:S1USM6:Y7O>^=?IC+3($^O[]2O
M$N)Y5B8+C\>C]^(#[S-LYJ%26DX$#5(+,A8"]QP1,XRG"]X A3\Y\A@:"HHZ
M3J]<7;1KWJDLH%U=BO:B]E [MM'%8/CT3)R04Y1P*%'I/#QH*CZ!%]5ENZV\
MRC6K)X:/SI5$V51>W<F=S6 <X $]2]YV+31(Z*O%QN%%XG<.6+$;XD$:,/.N
M#+@6CL_(2>OOR4S*:C$CP/_]D,"#?^Q61,+0#3[2F@ C1+J%HQ2-T^BJ"]_N
METR1XM?3V-+&2<?*;/O961E6#)6&<=JL5CIQXX-7A&6[6U4]+\YLD$@*=+/2
M]<XQD))A-8G"NIVXQ&Z 8<UWRUG%;.;IHZO:*'PI# PKY@FGL') >@:=<5K>
MG#NY5Q[.2D6)1\XN>%2-?,!IGRWS*;"X'_VZ')<;9I"U@,%4Y'>[WW#X9L*Z
MWH;8?66S\[:1*^K?W"]Q0.0:F'?[3+Q-8]FO'QO+[G)CV3_+,_H1AMA1532M
M\HV7JD<=/EFMJL[9)8L'Z/-(['6%4R%>0?<Z<XD[0Q\VZGJ3"0@H4;9K5W8N
MVJU\*FH_%@E9.BO4,V%#. SM3!:>.&G9X6L;?[;SB<6><[>>=I)=Q/\ G+ET
M&E@I?NQ,(N*-48=)>87DV\#KDA:#4=(0TT-RH(.G-QY?;U\\"X/?[.!"AG74
M!<,@ 3*QG9!8 D.O\!.*4::0ZTG /!*_>$EZP2M'[D5> !U4N(-?Q&PTI=-V
M%B?CN_:J0J8DG 3]+79.H<KN)00@EL+5-'NYK=8\ED].?KG\U2^?_(K_U2[Y
M_]_8XI^]/?I3D?0KLOXUB/JW8?'2S.AQ%[<;$Y:XUTL\C(2";RM^@->PSKRE
M61F^O"7_!5$M/UC&TG1X\):C5WZ#7Y_\6CWDMV5W5H9Y.?KQPZK:8]'@DZ<G
M3Y\F@AZ>!],Y5Q$?%T]]2MLV/3_'&)LHISV"3V.P/=8'^K!GKBF9S,0FCIDS
MFN/)R9W=9 [!V-")NWF=*;QFZ%'/=]81H=90Y<M[WM'XFK?NS25^>]LX;C82
MQB%T")Y8F\LU4'^<"3:DJR>U)+7SC(,):YBQE3WC(8GJV#86W>]/82)ASE/B
MNX4.O1#>NHR1 &D\[:$N?B'EPBAB*R-$F(O*ZC6D_"S$2<2T/FVL2PF6,=@2
M.-=5M>8E %D-)16.ZCJ4G&U<6(3#:EG.JV&&@]A_PL7V0J_@'[>X';\'CYJ*
MSZ#"2UQ8Z=TSTA'CCR-P;<+@Q?2-9.PM:SK%T,<'RA7N '-/:\>_XZ1 6%35
MN;N'LKICK]%UWD\5&&#0:5MN)2.N)Y/0]A\>G.W-4]K$2W%FXWD(UT&J#V?*
M<L_O.1T8NPO=M.N8RR;ACE8:861;,UQ9D<6"40)>">2,R%[H1)/,,:W-S:ID
M;K6P3-O+*E/<NK>^U:=/J@CS\*2RN%0/+L<P(H6(/Q$7M RP99*2^=2-)=Y9
M).GS&2ERQ9(9(>:?EJD-P7IZV1*39D+#!FD![2ZL&UDN>1G"+DCL9/%D%'UA
M2NA5ZWJW%KLCAV/=<1[?BCQQ0>/D,E),4M:1*FT]KY2M%7:FM;N>L=2< @A*
M*W:HB%ZK=[OIR"@8O7*VMY(/,IMCQG.T'!/+1V<5\RH-W-5A_B,Z!"(<S(2F
M.-71[AN9GTA#F'R_&_*5A=+FQJ5)XCO=C@L/R;*"-K7;N_FE)_8QA85N(ZO?
M[IZ$5$S><Y/#6"IIRD(XL>2;1^_X\.!T-/9(W_^1F.J!E.V-$1B%2U0>.=TX
MLJVHUDCFHFW Q] (!5I75?Q+M@;Q!R#/1ND/TI!0 =A7Y2.D_J&M'T[M<WAK
M;.#-#A9GS.#$U<$N.I^R"UY2U&O?MRM39APOSCZNH0>VAJ)/(J&L.4?)D091
M03DAXS*B%,W-Q]KCFGE@:\:=6Z+3W+3;.LLTYFX1,2BT/5@71;*H(3EA.J,0
M%"9./7%<P?WA5"C CRT8DK70:G*7C^ONWV?=L:VZNF"QV#DJZ6-+YG'>']B\
M!\MQ49_5V^MD*Y/3*GQ^U:'T3@F$/IBCQS7QP-:$IE7S;%!<(PH9!/ (&:?%
M;L5&HUIDV1ZV&X]+Y($M$0N*;I.X0IZ8Z"XV7;6LH%(A=1<4@<"8D:PQ4?A+
M-6G"BMN)"(M!B@\/K,2Z:2%-,-O4JY765+GT3S^^:CNB(5_4(02K'(R]]0S\
MI0-(7;0]*.DY@]HAEVKR)BM+95,1S!'R(?]'T':![!&RG5^'J1QOX58]=I \
MO+T2S6D5]2NE_*UV$NL/1=:RW\Y^^^4O]&/ ,,6GAT>F:?K$Q%[I!L&2W*ZD
M4(P+ 3P3XH6%Y& W%6J @@9P*=^Q5/=U)29(5%,MXL$TMF1)>&3XXBLS*$/+
M9@6)T(4O, B$-[8TA[D!3> .3T^^T FUZMNWTC;SS WL#^65&#WUROJH#037
M/-BK?O8$RP-\06TW6MD.!I64B[A9>\L*;K!VE%) ;4B(\>?M^HS!O+[Y@$L*
M,VEVLDPHDIS 6FT9' T!M(J '=(_HQ6@F.,0(EP\NYC1A3S[[&,?'2+?I-GG
M*'3M!:1$5O?1UHKT+N5<4)V9=_59G"F /,(Y<+?KP+<!9W[Y",[\=P!GGC;<
MA13[U+3%;43Y(L>U'![ %1'*#E.4'I1X!=ZN(!V0FX7SQM=?I<TE7ESL!&DX
M$4I&\.OWMSY?1RYN+:%3E3>X= OVYAKK<> I8 S7H&1L[ 12\?VH&9P8;IHE
MH MM,G$.5[&]$+*!2X9QT*W<+?!&URX48S%WUS8Q.+E^H3+$9WF!-E]1@L?/
M%Q!I:FLW *FO<8V\BROGKJZ8SZ;DH$=Z#6+<P_@;U;]-1P@#29$">84B/4SP
M. %E= -9\^6*##]Y@D* "X05]4$LQB"OR2X7I !YG_=VCW[T^'L)[A2G),B/
M\OP<(-)M53AD$\K 5Q*[?:C7+/'ZY1?'OX^>^76N2[Z#!3 7[$#L&BR$";*O
M,F]>).7G%RW >7#A"4!W7L$4%4P>:2Y_!%7>9M5@U?V495-XC/0UT!)J8%XN
MR[KK"4PY,RPEO3 A<'L6+A0VS*FWY1>]Q=M1L]VJ,JZ'=!/ZJ LX%K'N ! U
MY.Y88 ,F-?K6BF\7.^" .U^MQKQ60 2VO0G=-O"1-%1:JA^[::],CBV'; '?
M-0&^HW8HM!()0H$[RO/3>U'UX7WO@?T,!Q2"86)R$?K4C^!7+2B0U2_L&D.C
MC7XY96,M4@95.;7XC"SB"29G$K6#I(17"=KUWAK0=Q<?[44>'BCPS+:;A5)N
M%A<&IZ>5.CG-.GT\._76?%*=F^/9BXG?\JE)VYR6"I, D3Z3?7>.L!QN_4V8
M[QC*BMJWLL0X[X]X7E@0&-G"I=T&ED/N0\P28Z02MP("DMTB?%T8"?+"F$=C
M? 3L[0P*+Y.#T9"F_GT**Z<S3L>^U1=NMFJGC6I8E!D7<C#6MI$(>'D3D'X<
M$Q[,>\O0<(KXK]GZ5\UY6)65VXCD@2)IS#;/[W8B!FM(+H#V.U\.30?!0-SF
M?G-T@O5C:X4$ Y4Q,9HB7MC(;FP%F=Y!W)F[Q<P'3G>-#07UG6DZ&Z.[ZU3J
MF=-.N?5IN]SX4$^V6IZ[:G%&:19H53(Q"U#+7:5)(BQ$$:VG-5GV%^RPT7]A
MZL*!K1HX>DGG?TC.#2I=@I9Q;ID(3[8]27]S2X"TK*P)]7LI_!L]^CC2:R&!
M5>Y[[*SMA<S:OMWI^52>(QW&-!'TQ:B0*@0%W&>8<+*$WVO7P[W&L-]B:LWJ
M[/I*.P-M=F?73FX^$[>;U2+LTZ[?E=R23_,5#O1@(18U.^XIS0)<OMUZ78[9
M>TV..^!XN/;\(M+)\ ._^S"2"FEB+&&_X@U-PY &$__QQ<GQ;V9K@-&! I>N
MEI+\1U1"R Z;4#RPZY254:A\!"*.Y![\DX'I=14%Q@3\3][I\>S_A56MZY:7
M]1@+#2P/)[8+.ZO=QK79TBOMD5R;,?\#3!UL\F ##%NYH@0?NM3V1N(@73M)
M 4Z,9SBWPPJIQ8*Z()H6!/_UO&NOMA<JE;7G5@KKF*21S7)?\OQ)]QN_"6>Y
M0() )T'OQ?Z,=J*A,Y_'A(<X/:&9W0H'"FD#TKJ,<<SDV..6%T"DMC,],F@O
MW:>V)M^H.M+'L&NNZD;X6Z*8?$;]Z=A&2B> YBL0.?7C7T-,WU2[M6]DBAY;
MO=Z4XK%%H8;1_F!R<:F_FS:TXT>.N^_>6O8?F]GWN]5>^HZ_+*@%%Q?HJV;V
M=0U8V$)+YS+HAP>Z.C'*\%3@D]6PN.36+)FT*^>+UNE0)^ OQV^/O8Y33$:B
MKY2G4#;T^!4/#^R2FNS<AC/8]F73-D?K73]?D3IGV<.$GJW*!= &<T LNV/W
MGHYHAVH=:HDOP].%/[.AC$0VJV#?J?>5&]#EGQA[_D]-04CS%9IGJPY"1&@.
MS4CO_&N%WWS.)2[AP*W_84>6ON[Q+,E9^Y/-3EZMEJ7'K+VNG^&S<'8UT:;W
MM*YU2\)%SVG!/1MK?*:7! QK.!<C7M3';]6?;BO\Z-IUP_,X5,FBQEG+,=*6
ML!_.)TA;I7@6JQ IMOLJ/7"YF[[<@R-R@<<U,R($86&AKVHYGN":;%JX1J/4
M8[$O;C2FO)'$(+%$=]4"W;*\^9NO9C]R4_P?9C\ SW#?JYW_NM+CYU__^/S_
M 3WS^7?O7OT0_N/_ U!+ 0(4 Q0    (  :89U9I:A)53@,  .<,   1
M          "  0    !C87)M+3(P,C,P,S W+GAS9%!+ 0(4 Q0    (  :8
M9U8]%L-%H0@  -)H   5              "  7T#  !C87)M+3(P,C,P,S W
M7V1E9BYX;6Q02P$"% ,4    "  &F&=6MV3'@W@+  !)C@  %0
M    @ %1#   8V%R;2TR,#(S,#,P-U]L86(N>&UL4$L! A0#%     @ !IAG
M5DLZDPSV!P  CF,  !4              ( !_!<  &-A<FTM,C R,S S,#=?
M<')E+GAM;%!+ 0(4 Q0    (  :89U:C883@OF   '$@ @ 1
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M+FAT;5!+ 0(4 Q0    (  :89U8;5N ('3H  !\I 0 6              "
M >P1 0!T;3(S.#4W.&0Q7V5X,3 M,3,N:'1M4$L! A0#%     @ !IAG5L.V
M1445%0  EX0  !8              ( !/4P! '1M,C,X-3<X9#%?97@Q,"TQ
M-"YH=&U02P$"% ,4    "  &F&=6BBNB=Z$8   RD@  %@
M@ &&80$ =&TR,S@U-SAD,5]E>#$P+3$U+FAT;5!+ 0(4 Q0    (  :89U:X
M-T_E5"   %BE   6              "  5MZ 0!T;3(S.#4W.&0Q7V5X,3 M
M,38N:'1M4$L! A0#%     @ !IAG5HAYA,:05   CS4" !4
M ( !XYH! '1M,C,X-3<X9#%?97@Q,"TT+FAT;5!+ 0(4 Q0    (  :89U8@
MR6I6"UL  ,X, @ 5              "  :;O 0!T;3(S.#4W.&0Q7V5X,3 M
M-2YH=&U02P$"% ,4    "  &F&=6E7P(%XI)  #TG0$ %0
M@ 'D2@( =&TR,S@U-SAD,5]E>#$P+38N:'1M4$L! A0#%     @ !IAG5N5.
MP^^N6P  5^\! !4              ( !H90" '1M,C,X-3<X9#%?97@Q,"TW
M+FAT;5!+ 0(4 Q0    (  :89U;&4)2WJE\  "1Z @ 5              "
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M2P$"% ,4    "  &F&=6JC)P48T0  !O.@  %0              @ $L0@0
M=&TR,S@U-SAD,5]E>#DY+3$N:'1M4$L! A0#%     @ !IAG5D&Q( L)(0$
M<M,% !4              ( ![%($ '1M,C,X-3<X9#%?97@Y.2TR+FAT;5!+
M 0(4 Q0    (  :89U;V3)@DFVX! (X3"  5              "  2AT!0!T
J;3(S.#4W.&0Q7V5X.3DM,RYH=&U02P4&     !D &0"(!@  ]N(&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
